Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Clinical Packet
August 9, 2017

Table of Contents

Helpful Hints/Reference Document 2

External Criteria
Antilipemic Agents 4
Cardiac Agents 5
Oral Anticoagulents 5
Platelet-Aggregation Inhibitors 7

Agenda 8

Pharmacotherapy Class Reviews
Pharmacotherapy Review of Anticoagulants, Oral 9
Pharmacotherapy Review of Platelet-Aggregation Inhibitors 116
Pharmacotherapy Review of Antiarrhythmic Agents 242
Pharmacotherapy Review of Cardiotonic Agents 307
Pharmacotherapy Review of Cardiac Drugs, Miscellaneous 358
Pharmacotherapy Review of Bile Acid Sequestrants 390
Pharmacotherapy Review of Cholesterol Absorption Inhibitors 443
Pharmacotherapy Review of Fibric Acid Derivatives 533
Pharmacotherapy Review of HMG-CoA Reductase Inhibitors 607
Pharmacotherapy Review of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors 853
Pharmacotherapy Review of Antilipemic Agents, Miscellaneous 883
Pharmacotherapy Review of Nitrates and Nitrites 968
Pharmacotherapy Review of Renin-Angiotensin-Aldosterone System Inhibitors, Misc 1003

New Drug Review
New Drug Review: Adzenys XR-ODT™ 1014

Pharmacy and Therapeutics (P&T) Committee
Helpful Hints/Reference Document

P&T Charge

As defined by §22-6-122

The Medicaid Pharmacy and Therapeutics (P&T) Committee shall review and recommend classes of drugs to the Medicaid Commissioner for inclusion in the Medicaid Preferred Drug Plan. Class means a therapeutic group of pharmaceutical agents approved by the FDA as defined by the American Hospital Formulary Service.

The P&T Committee shall develop its preferred drug list recommendations by considering the clinical efficacy, safety and cost effectiveness of a product. Within each covered class, the Committee shall review and recommend drugs to the Medicaid Commissioner for inclusion on a preferred drug list. Medicaid should strive to insure any restriction on pharmaceutical use does not increase overall health care costs to Medicaid.

The recommendations of the P&T Committee regarding any limitations to be imposed on any drug or its use for a specific indication shall be based on sound clinical evidence found in labeling, drug compendia and peer reviewed clinical literature pertaining to use of the drug. Recommendations shall be based upon use in the general population. Medicaid shall make provisions in the prior approval criteria for approval of non-preferred drugs that address needs of sub-populations among Medicaid beneficiaries. The clinical basis for recommendations regarding the PDL shall be made available through a written report that is publicly available. If the recommendation of the P&T Committee is contrary to prevailing clinical evidence found in labeling, drug compendia and/or peer-reviewed literature, such recommendation shall be justified in writing.

Preferred Drug List/Program Definitions

Preferred Drug: Listed on the Agency's Preferred Drug Lists and will not require a prior authorization (PA).

Preferred with Clinical Criteria: Listed on the Agency's Preferred Drug Lists but will require a prior authorization. Clinical criteria must be met in order to be approved. For a non-preferred product to be approved, failure with a designated number of preferred agents and clinical criteria must be met.

Non Preferred Drug: Covered by the Agency, if it is determined and supported by medical records to be medically necessary, but will require a PA.

Non Covered Drug: In accordance with Medicaid Drug Amendments contained in the Omnibus Budget Reconciliation Act of 1990 (OBRA 90 federal legislation), the Agency has the option to not cover (or pay for) some drugs. Alabama Medicaid does not cover/pay for the following:

- Drugs used for anorexia, weight loss or weight gain, with the exception of those specified by the Alabama Medicaid Agency
- Drugs used to promote fertility with the exception of those specified by the Alabama Medicaid Agency
- Drugs used for cosmetic purposes or hair growth
- Over-the-counter/non prescription drugs, with the exception of those specified by the Alabama Medicaid Agency
- Covered outpatient drugs when the manufacturer requires as a condition of sale that associated test and/or monitoring services be purchased exclusively from the manufacturer or designee
- DESI (Drug Efficacy Study Implementation [less than effective drugs identified by the FDA]) and IRS (Identical, Related and Similar [drugs removed from the market]) drugs which may be restricted in accordance with Section 1927(d) (2) of the Social Security Act
- Agents when used for the symptomatic relief of cough and colds except for those specified by the Alabama Medicaid Agency
- Prescription vitamin and mineral products, except prenatal vitamins and fluoride preparations and others as specified by the Alabama Medicaid Agency
- Agents when used for the treatment of sexual or erectile dysfunction, unless authorized for pulmonary hypertension.

(From Alabama Medicaid Agency Administrative Code, Chapter 16 and Alabama Medicaid Agency Provider Billing Manual, Chapter 27.)

Prior Authorization (PA): Process that allows drugs that require approval prior to payment to be reimbursed for an individual patient. Drugs may require PA if they are in Non-preferred status or if they required PA prior to the PDL

Medicaid may require prior authorization for generic drugs only in instances when the cost of the generic product is significantly greater than the net cost of the brand product in the same AHFS therapeutic class or when there is a clinical concern regarding safety, overuse or abuse of the product.

Although a product may require PA, the product is considered a covered product and Medicaid will pay for the product only once the PA has been approved.

Override: Process where drugs require approval prior to payment to be reimbursed for an individual patient if the claim falls outside a predetermined limit or criteria. Overrides differ from PA in that drugs or drug classes that require an override will automatically allow payment of the drug unless something on the claim hits a predetermined limit or criteria. The different types of overrides include:

Maximum Unit Limitations
Early Refill
Brand Limit Switchover
Therapeutic Duplication

Electronic PA (EPA): The EPA system checks patient-specific claims history to determine if pharmacy and medical PA requirements are met at the Point-of-Sale claim submission for a non-preferred drug. If it is determined that all criteria are met and the request is approved, the claim will pay and no manual PA request will be required. Electronic PA results in a reduction in workload for providers because the claim is electronically approved within a matter of seconds with no manual PA required.

Prior Authorization Criteria Definitions

Appropriate Diagnosis: Diagnosis(es) that justifies the need for the drug requested. Diagnosis(es) **or** ICD-9 code(s) may be used. Use of ICD-9 codes provides specificity and legibility and will usually expedite review.

Prior Treatment Trials: Prior authorization requires that two (2) prescribed generic, OTC or brand name drugs have been utilized unsuccessfully relative to efficacy and/or safety within six (6) months prior to requesting the PA. The PA request must indicate that two (2) generic, OTC or other brand drugs have been utilized for a period of at least thirty (30) days each (14 days for Triptans, 3 days for EENT Vasoconstrictor Agents), **unless** there is an adverse/allergic response or contraindication. If the prescribing practitioner feels there is a medical reason for which the patient should not be on a generic, OTC or brand drug or drug trial, medical justification may be submitted in lieu of previous drug therapy. One prior therapy is acceptable in those instances when a class has only one preferred agent, either generic, OTC, or brand.

Stable Therapy: Allows for approval of a PA for patients who have been determined to be stable on a medication (same drug, same strength) for a specified timeframe and who continue to require therapy. Medications provided through a government or state sponsored drug assistance program for uninsured patients may be counted toward the stable therapy requirement. Medications paid for through insurance, private pay or Medicaid are also counted toward the requirement. Providers will be required to document this information on the PA request form and note the program or method through which the medication was dispensed.

Medical Justification: An explanation of the reason the drug is required and any additional information necessary. Medical justification is documentation to support the physician's choice of the requested course of treatment. Documentation from the patient record (history and physical, tests, past or current medication/treatments, patient's response to treatment, etc) illustrates and supports the physician's request for the drug specified. For example, if a recommended therapy trial is contraindicated by the patient's condition or a history of allergy to a first-line drug, and the physician wants to order a non-preferred drug, documentation from the patient record would support that decision. In addition, medical justification may include peer reviewed literature to support the use of a non-preferred medication.

External Criteria

Antilipemic Agents

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least two prescribed and preferred lipid lowering agents, either generic, OTC or brand, within the past 6 months, or have a documented allergy or contraindication to all preferred agents in this class.

- For Zetia®, if prior usage requirements have not been met, approval may be obtained for adjunctive therapy to a current lipid lowering drug.

- For Praluent® and Repatha™, 12 weeks of prior therapy with at least two maximally tolerated doses of statins is required. If prior usage requirements for these agents have not been met, approval may be obtained for adjunctive therapy to a maximally tolerated statin (or a statin or ezetimibe for patients with a diagnosis of homozygous familial hypercholesterolemia).

Stable Therapy

- Approval may be given for children age 18 years and under who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 6 months for initial request and up to 12 months for renewal requests.

Electronic Prior Authorization (PA)

- Antilipemic agents are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Cardiac Agents

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least two prescribed and preferred cardiac agents in this class, either generic, OTC or brand, within the past 6 months or have a documented allergy or contraindication to all preferred agents in this class.

- To meet these prior usage requirements, drugs within this specific classification must be judged against others in the same class (AHFS specific).

  - For example, to qualify for a non-preferred cardiotonic, the patient must have met prior usage requirements of 30-day treatment trials with two other preferred cardiotonic agents, either generic, OTC or brand.

  - For Ranexa®, in lieu of prior usage requirements, approval may be obtained for adjunctive therapy to a current antianginal drug.

  - For Corlanor®, previous beta-blocker usage or contraindication to beta-blocker therapy is required.

  - For Entresto®, one (1) prior therapy with either an angiotensin receptor blocker or ace inhibitor is acceptable.

Stable Therapy

- Approval may be given for those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer-reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Cardiac agents are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Oral Anticoagulants

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least one prescribed and preferred oral anticoagulant in this class, either generic, OTC, or brand, within the past six months, or have a documented allergy or contraindication to all preferred agents in this class.

Stable Therapy

- Approval may be given to those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (EPA)

- Oral anticoagulants are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

Platelet-Aggregation Inhibitors

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

The patient must also have failed 30-day treatment trials with at least 2 prescribed and preferred platelet-aggregation inhibitors in this class, either generic, OTC, or brand, within the past 6 months or have a documented allergy or contraindication to all preferred agents in this class.

Stable Therapy

- Approval may be given to those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Acceptable medical justification consists of specific clinical diagnoses for 1st line treatment by certain branded products in lieu of prior usage, allergy, contraindication or intolerance to the use of aspirin, cilostazol, ticlopidine and dipyridamole.

- Clinical literature and guidelines support the use of Aggrenox®, Brilinta®, and Effient® for specific 1st line indications; these indications include acute coronary syndrome, acute myocardial infarction (NSTEMI and STEMI), peripheral arterial occlusive disease (PAD, PVD), transient ischemia or ischemic stroke due to thrombosis/embolism, and percutaneous coronary interventions (balloon angioplasty, laser angioplasty, intra-coronary stents, other catheter devices treating coronary atherosclerosis).

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Platelet-aggregation inhibitors are included in the electronic PA program.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

AGENDA

ALABAMA MEDICAID AGENCY
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

August 9, 2017
9:00 a.m. – 12:00 noon

---

1. Opening remarks……..…….Chair
2. Approval of May 10, 2017 P&T Committee Meeting minutes……..…….…….Chair
3. Pharmacy program update.....Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers' representatives
   (prior to each respective class review)
5. Pharmacotherapy class reviews……University of Massachusetts Clinical Pharmacy Services
   - Anticoagulants, oral – AHFS 201204
   - Platelet-aggregation Inhibitors – AHFS 201218
   - Antiarrhythmic Agents – AHFS 240404
   - Cardiotonic Agents – AHFS 240408
   - Cardiac Drugs, Miscellaneous – AHFS 240492
   - Bile Acid Sequestrants – AHFS 240604
   - Cholesterol Absorption Inhibitors – AHFS 240605
   - Fibric Acid Derivatives – AHFS 240606
   - HMG-CoA Reductase Inhibitors – AHFS 240608
   - Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors – AHFS 240624
   - Antilipemic Agents, Miscellaneous – AHFS 240692
   - Nitrites and Nitrates – AHFS 241208
   - Renin-Angiotensin-Aldosterone System Inhibitors, Misc – AHFS 243292
6. New Drug Review – Adzenys XR ODT™…University of Massachusetts Clinical Pharmacy Services
7. Results of voting announced……...…….....…….…….…….Chair
8. Next meeting dates
   - November 8, 2017
   - February 7, 2018
   - May 9, 2018
   - August 8, 2018
   - November 7, 2018
9. Adjourn

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Anticoagulants, Oral
AHFS Class 201204
August 9, 2017

I. Overview

Apixaban (Eliquis®), dabigatran etexilate mesylate (Pradaxa®), edoxaban (Savaysa®), rivaroxaban (Xarelto®), and warfarin (Coumadin®) are oral anticoagulants approved by the Food and Drug Administration (FDA) for the various cardiovascular indications outlined in Table 3.[1-5] Warfarin has been the principle oral anticoagulant for more than 60 years and has extensive, well established data demonstrating its safety and efficacy in all of its FDA-approved indications.[6-8] Apixaban and rivaroxaban are selective factor Xa inhibitors while dabigatran etexilate mesylate is a direct thrombin inhibitor (DTI). All are novel oral anticoagulants that are approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) and for treatment and reduction in the risk of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have previously been treated.[1-4] Rivaroxaban, apixaban, and dabigatran are also indicated for the prophylaxis of DVT which may lead to PE in patients undergoing knee and/or hip replacement surgery.[1,4]

Warfarin is a vitamin K antagonist (VKA) that works by interfering with the synthesis of vitamin K dependent clotting factors and anticoagulant proteins C and S. Specifically, warfarin inhibits the vitamin K epoxide reductase enzyme complex, resulting in the blockade of the regeneration of vitamin K1 epoxide.[5-8] Conversely, the new oral anticoagulants target a single enzyme involved in the coagulation cascade. Dabigatran etexilate mesylate is a prodrug that is converted to dabigatran, a potent, competitive inhibitor of thrombin. As a DTI, dabigatran inhibits the conversion of fibrinogen into fibrin; thereby inhibiting the development of a thrombus. Both free and fibrin-bound thrombin and thrombin-induced platelet aggregation are inhibited by dabigatran etexilate mesylate.[2,7,8] Apixaban, edoxaban, and rivaroxaban selectively inhibit factor Xa, thereby preventing the generation of thrombin and ultimately preventing platelet activation and the formation of fibrin clots.[1,3,4,7,8]

The oral anticoagulants included in this review are listed in Table 1. This review encompasses only oral dosage forms and strengths within the AHFS class. Warfarin is the only product available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Oral Anticoagulants Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Apixaban	tablet	Eliquis®	none
Dabigatran	capsule	Pradaxa®	none
Edoxaban	tablet	Savaysa®	none
Rivaroxaban	tablet	Xarelto®	none
Warfarin	tablet	Coumadin®*	Coumadin®*, warfarin

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the oral anticoagulants are summarized in Table 2.

Table 2. Treatment Guidelines Using the Oral Anticoagulants

Clinical Guideline	Recommendations
American College of Chest Physicians: **Antithrombotic Therapy and Prevention of Thrombosis, 9th edition**	Management of anticoagulant therapy • For outpatients, vitamin K antagonist (VKA) therapy with warfarin 10 mg/day for the first two days, followed by dosing based on international normalized ratio (INR) measurements rather than starting with the estimated maintenance dose is suggested. • Routine use of pharmacogenetic testing for guiding doses of VKA therapy is

Clinical Guideline	Recommendations
(2012)[6]	not recommended. • For acute venous thromboembolism (VTE), it is suggested that VKA therapy be started on day one or two of low molecular weight heparin (LMWH) or low dose unfractionated heparin (UFH) therapy rather than waiting for several days to start. • For VKA therapy with stable INRs, INR testing frequency of up to 12 weeks is suggested rather than every four weeks. • For patients receiving previously stable VKA therapy who present with a single out-of-range INR ≤0.5 below or above therapeutic, it is suggested to continue the current dose and test the INR within one to two weeks. • For patients receiving stable VKA therapy presenting with a single subtherapeutic INR value, routine administering of bridging heparin is not recommended. • Routine use of vitamin K supplementation is suggested against with VKA therapy. • For patients receiving VKA therapy who are motivated and can demonstrate competency in self-management strategies, it is suggested that patient self-management be utilized rather than usual outpatient INR monitoring. • For maintenance VKA dosing, it is suggested that validated decision support tools be utilized rather than no decision support. • Concomitant use of nonsteroidal anti-inflammatory drugs and certain antibiotics should be avoided in patients receiving VKA therapy. • Concomitant use of platelet inhibitors should be avoided in patients receiving VKA therapy, except in situations where benefit is known or is highly likely to be greater than harm from bleeding. • With VKA therapy, a therapeutic INR range of 2.0 to 3.0 (target, 2.5) is recommended rather than a lower (<2.0) or higher (range, 3.0 to 5.0) range. • In patients with antiphospholipid syndrome with previous arterial or VTE, VKA therapy should be titrated to a moderate intensity INR (range, 2.0 to 3.0) rather than higher intensity (range, 3.0 to 4.5). • For discontinuations of VKA therapy, it is suggested that discontinuation be done abruptly rather than gradual tapering of the dose. • For initiation of intravenous (IV) UFH, the initial bolus and rate of continuous infusion should be weight adjusted or fixed-dose rather than alternative regimens. • In outpatients with VTE receiving subcutaneous (SC) UFH, dosing should be weight-based without monitoring rather than fixed or weight-adjusted dosing with monitoring. • A reduction in therapeutic LMWH dose is suggested in patients with severe renal insufficiency rather than using standard doses. • In patients with VTE and body weight >100 kg, the treatment dose of fondaparinux should be increased from 7.5 to 10 mg/day SC. • For INRs between 4.5 and 10.0 with VKA therapy and no evidence of bleeding, routine use of vitamin K is not recommended. • For INRs >10.0 with VKA therapy and no evidence of bleeding, it is suggested that oral vitamin K be administered. • In patients initiating VKA therapy, routine use of clinical prediction rules for bleeding as the sole criterion to withhold VKA therapy is not recommended. • For VKA-associated major bleeding, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate is suggested over plasma. Additional use of vitamin K 5 to 10 mg administered by slow IV injection is recommended rather than reversal with coagulation factors alone. <u>Prevention of VTE in nonsurgical patients</u> • Acutely ill hospitalized medical patients at increased risk of thrombosis:

Clinical Guideline	Recommendations
	anticoagulant thromboprophylaxis with LMWH, low dose UFH (two or three times daily), or fondaparinux is recommended. Choice should be based on patient preference, compliance, and ease of administration, as well as on local factors affecting acquisition costs. • Acutely ill hospitalized patients at low risk of thrombosis: pharmacologic or mechanical prophylaxis is not recommended. • Acutely ill hospitalized medical patients who are bleeding or at high risk for bleeding: anticoagulant thromboprophylaxis is not recommended. • Acutely ill hospitalized medical patients at increased risk for thrombosis who are bleeding or at high risk of major bleeding: optimal use of mechanical thromboprophylaxis is suggested rather than no mechanical thromboprophylaxis. When bleeding risk decreases, and if VTE risk persists, it is suggested that pharmacologic thromboprophylaxis be substituted for mechanical thromboprophylaxis. • Acutely ill hospitalized medical patients who receive an initial course of thromboprophylaxis: extending the duration of thromboprophylaxis beyond the period of patient immobilization or acute hospital stay is suggested against. • Critically ill patients: routine ultrasound screening for deep vein thrombosis (DVT) is suggested against. • Critically ill patients: use of LMWH or low dose UFH thromboprophylaxis is suggested over no prophylaxis. • Critically ill patients who are bleeding or are at high risk for major bleeding: use of mechanical thromboprophylaxis until the bleeding risk decreases is suggested rather than no mechanical thromboprophylaxis. When bleeding risk decreases, pharmacologic thromboprophylaxis is suggested to be substituted for mechanical thromboprophylaxis. • Outpatients with cancer who have no additional risk factors for VTE: routine prophylaxis with LMWH or low dose UFH is suggested against, and prophylactic use of VKAs is not recommended. • Outpatients with solid tumors who have additional risk factors for VTE with low risk of bleeding: prophylaxis with LMWH or low dose UFH is suggested over no prophylaxis. • Outpatients with cancer and indwelling central venous catheters: routine prophylaxis with LMWH or low dose UFH is suggested against, and prophylactic use of VKAs is suggested against. • Chronically immobilized patients residing at home or at a nursing home: routine thromboprophylaxis is suggested against. • Long distance travelers at increased risk of VTE: frequent ambulation, calf muscle exercise, or sitting in an aisle seat if feasible is suggested. • Long distance travelers at increased risk of VTE: use of properly fitted, below-knee graduated compression stockings during travel is suggested. For all other long distance travelers, use of graduated compression stockings is suggested against. • Long distance travelers: use of aspirin or anticoagulants to prevent VTE is suggested against. • Patients with asymptomatic thrombophilia: long term daily use of mechanical or pharmacologic thromboprophylaxis to prevent VTE is not recommended. <u>Prevention of VTE in nonorthopedic surgical patients</u> • General and abdominal-pelvic surgery patients at very low risk for VTE: no specific pharmacologic or mechanical prophylaxis is recommended for use other than early ambulation. • General and abdominal-pelvic surgery patients at low risk for VTE: mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients at moderate risk for VTE who

Clinical Guideline	Recommendations
	are not at high risk major bleeding complications: LMWH, low dose UFH, or mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients at moderate risk for VTE who are at high risk for major bleeding complication or those in whom the consequences of bleeding are thought to be particularly severe: mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients at high risk for VTE who are not at high risk for major bleeding complications: LMWH or low dose UFH is recommended over no prophylaxis. It is suggested that mechanical prophylaxis be added to pharmacologic prophylaxis. • High-VTE-risk patients undergoing abdominal or pelvic surgery for cancer who are not otherwise at high risk for major bleeding complications: extended duration (four weeks) of LMWH prophylaxis is recommended over limited duration prophylaxis. • High-VTE-risk general and abdominal-pelvic surgery patients who are at high risk for major bleeding complications or those in whom the consequences of bleeding are thought to be particularly severe: mechanical prophylaxis is suggested over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated. • General and abdominal-pelvic surgery patients at high risk for VTE in whom both LMWH and UFH are contraindicated or unavailable and who are not at high risk for major bleeding complications: low dose aspirin, fondaparinux, or mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients: it is suggested that an inferior vena cava filter not be used for primary VTE prevention. • General and abdominal-pelvic surgery patients: it is suggested that periodic surveillance with venous compression ultrasound not be performed. • Cardiac surgery patients with an uncomplicated postoperative course: mechanical prophylaxis is suggested over either no prophylaxis or pharmacologic prophylaxis. • Cardiac surgery patients whose hospital course is prolonged by one or more nonhemorrhagic surgical complications: adding pharmacologic prophylaxis with low dose UFH or LMWH to mechanical prophylaxis is suggested. • Thoracic surgery patients at moderate risk for VTE who are not at high risk for perioperative bleeding: low dose UFH, LMWH, or mechanical prophylaxis is suggested over no prophylaxis. • Thoracic surgery patients at high risk for VTE who are not at high risk for perioperative bleeding: low dose UFH or LWMH is suggested over no prophylaxis. It is suggested that mechanical prophylaxis be added to pharmacologic prophylaxis. • Thoracic surgery patients who are at high risk for major bleeding: mechanical prophylaxis over no prophylaxis is suggested until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated. • Craniotomy patients: mechanical prophylaxis is suggested over no prophylaxis or pharmacologic prophylaxis. • Craniotomy patients at very high risk for VTE: it is suggested that pharmacologic prophylaxis be added to mechanical prophylaxis once adequate hemostasis is established and the risk of bleeding decreases. • Patients undergoing spinal surgery: mechanical prophylaxis is suggested over no prophylaxis, UFH, or LMWH. • Patients undergoing spinal surgery at high risk of VTE: it is suggested that pharmacologic prophylaxis be added to mechanical prophylaxis once adequate hemostasis is established and the risk of bleeding decreases. • Major trauma patients: low dose UFH, LMWH, or mechanical prophylaxis is suggested over no prophylaxis.

Clinical Guideline	Recommendations
	• Major trauma patients at high risk for VTE: it is suggested that mechanical prophylaxis be added to pharmacologic prophylaxis when not contraindicated by lower extremity injury. • Major trauma patients in whom LMWH and low dose UFH are contraindicated: mechanical prophylaxis is suggested over no prophylaxis when not contraindicated by lower extremity injury. It is suggested that either LMWH or low dose UFH be added when the risk of bleeding diminishes or the contraindication to heparin resolves. • Major trauma patients: it is suggested that an interior vena cava filter not be used for primary VTE prevention. • Major trauma patients: it is suggested that periodic surveillance with venous compression ultrasound not be performed. <u>Prevention of VTE in orthopedic surgery patients</u> • Total hip arthroplasty or total knee arthroplasty: use of one of the following for a minimum of 10 to 14 days rather than no antithrombotic prophylaxis is recommended: LMWH, fondaparinux, apixaban, dabigatran, rivaroxaban, low dose UFH, adjusted-dose VKA, aspirin, or an intermittent pneumatic compression device. • Hip fracture surgery: use of one of the following for a minimum of 10 to 14 days rather than no antithrombotic prophylaxis is recommended: LMWH, fondaparinux, low dose UFH, adjusted-dose VKA, aspirin, or intermittent pneumatic compression device. • Patients undergoing major orthopedic surgery (total hip arthroplasty, total knee arthroplasty, hip fracture surgery) and receiving LMWH as thromboprophylaxis: it is recommended to start either 12 hours or more preoperatively or postoperatively rather than within four hours or less preoperatively or postoperatively. • Total hip or knee arthroplasty, irrespective of the concomitant use of an intermittent pneumatic compression device or length of treatment: LMWH is suggested in preference to other agents recommended as alternatives: fondaparinux, apixaban, dabigatran, rivaroxaban, low dose UFH, adjusted-dose VKA, or aspirin. • Hip replacement surgery, irrespective of the concomitant use of an intermittent pneumatic compression device or length of treatment: LMWH is suggested in preference to other agents recommended as alternatives: fondaparinux, low dose UFH, adjusted-dose VKA, or aspirin. • Major orthopedic surgery: it is suggested to extend thromboprophylaxis in the outpatient period for up to 35 days from the day of surgery rather than for only 10 to 14 days. • Major orthopedic surgery: it is suggested to use dual prophylaxis with an antithrombotic agent and an intermittent pneumatic compression device during the hospital stay. • Major orthopedic surgery in patients at an increased risk of bleeding: intermittent pneumatic compression device or no prophylaxis is suggested over pharmacologic prophylaxis. • Major orthopedic surgery in patients who decline or are uncooperative with injections or intermittent pneumatic compression device: apixaban or dabigatran etexilate mesylate (alternatively rivaroxaban or adjusted-dose VKA if apixaban or dabigatran etexilate mesylate are unavailable) is recommended over alternative forms of prophylaxis. • Major orthopedic surgery in patients with an increased bleeding risk or contraindications to both pharmacologic and mechanical prophylaxis: inferior vena cava filter placement for primary prevention of VTE is suggested against over no thromboprophylaxis.

Clinical Guideline	Recommendations
	• Asymptomatic patients following major orthopedic surgery: Doppler ultrasound screening before hospital discharge is not recommended. • Patients with lower leg injuries requiring leg immobilization: no prophylaxis is suggested rather than pharmacologic thromboprophylaxis. • Knee arthroscopy in patients without a history of prior VTE: no thromboprophylaxis is suggested rather than prophylaxis. <u>Antithrombotic therapy for VTE disease</u> • Acute DVT of the leg or pulmonary embolism (PE) treated with VKA therapy: initial treatment with parenteral anticoagulation (LMWH, fondaparinux, or IV or SC UFH) is recommended over no such initial treatment. • High clinical suspicion of acute VTE or PE: treatment with parenteral anticoagulation is suggested over no treatment while awaiting the results of diagnostic tests. • Intermediate clinical suspicion of acute VTE or PE: treatment with parenteral anticoagulation is suggested over no treatment if the results of diagnostic tests are expected to be delayed for more than four hours. • Low clinical suspicion of acute VTE or PE: it is suggested to not treat with parenteral anticoagulants while awaiting the results of diagnostic tests, provided test results are expected within 24 hours. • Acute isolated distal DVT of the leg without severe symptoms or risk factors for extension: serial imaging of the deep veins for two weeks is suggested over initial anticoagulation. • Acute isolated distal DVT of the leg and severe symptoms or risk factors for extension: initial anticoagulation is suggested over serial imaging of the deep veins. • Acute isolated distal DVT of the leg in patients managed with initial anticoagulation: using the same approach as for patients with acute proximal DVT is recommended. • Acute isolated distal DVT of the leg who are managed with serial imaging: no anticoagulation if the thrombus does not extend is recommended; anticoagulation is suggested if the thrombus extends but remains confined to the distal veins; and anticoagulation is recommended if the thrombus extends into the proximal veins. • Acute DVT of the leg or PE: early initiation of VKA therapy is recommended over delayed initiation, and continuation of parenteral anticoagulation for a minimum on five days and until the INR is 2.0 or above for at least 24 hours. • Acute DVT of the leg or PE: LMWH or fondaparinux is suggested over IV or SC UFH. • Patients with acute DVT of the leg or PE receiving LMWH: once daily LMWH administration is suggested over twice daily administration. • Acute DVT of the leg and home circumstances are adequate: initial treatment at home is recommended over treatment in hospital. • Low risk PE and home circumstances are adequate: early discharge is suggested over standard discharge. • Acute proximal DVT of the leg: anticoagulation therapy alone is suggested over catheter-directed thrombolysis. • Acute proximal DVT of the leg: anticoagulation therapy alone is suggested over systemic thrombolysis. • Acute proximal DVT of the leg: anticoagulation therapy alone is suggested over venous thrombectomy. • Acute DVT of the leg in patients who undergo thrombosis removal: the same intensity and duration of anticoagulant therapy as in comparable patients who do not undergo thrombosis removal is recommended. • Acute DVT of the leg: use of an inferior vena cava filter in addition to

Clinical Guideline	Recommendations
	anticoagulants is not recommended. • Acute proximal DVT of the leg in patients with contraindication to anticoagulation: use of an inferior vena cava filter is recommended. • Acute proximal DVT of the leg in patients with an inferior vena cava filter inserted as an alternative to anticoagulation: a conventional course of anticoagulant therapy is suggested if the risk of bleeding resolves. • Acute DVT of the leg: early ambulation is suggested over initial bed rest. • Acute VTE in patients receiving anticoagulant therapy: long term therapy is recommended over stopping anticoagulant therapy after about one week of initial therapy. • Acute symptomatic DVT of the leg: compression stockings are suggested. • Acute PE associated with hypotension in patients who do not have a high bleeding risk: systemically administered thrombolytic therapy is suggested over no such therapy. • In most patients with acute PE not associated with hypotension: systemically administered thrombolytic therapy is not recommended. • In selected patients with acute PE not associated with hypotension and with a low bleeding risk who initial clinical presentation or clinical course after starting anticoagulant therapy, suggests a high risk of developing hypotension: administration of thrombolytic therapy is suggested. • Proximal DVT of the leg or PE provoked by surgery: treatment with anticoagulation for three months is recommended over treatment for a shorter period, treatment of a longer time limited period, or extended therapy. • Proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor: treatment with anticoagulation for three months is recommended over treatment for a shorter period, treatment for a longer time limited period, extended therapy if there is high bleeding risk. Anticoagulation treatment for three months is suggested over extended therapy if there is a low or moderate bleeding risk. • Isolated distal DVT of the leg provoked by surgery or by a nonsurgical transient risk factor: treatment with anticoagulation for three months is suggested over treatment for a shorter period, and anticoagulation treatment for three months is recommended over treatment of longer time limited period or extended therapy. • Unprovoked DVT of the leg or PE: treatment with anticoagulation for three months is recommended over treatment of a shorter duration. After three months, patients should be evaluated for the risk-benefit ratio of extended therapy. • First VTE that is an unprovoked proximal DVT of the leg or PE in patients who have a low or moderate bleeding risk: extended anticoagulant therapy is suggested over three months of therapy. • First VTE that is an unprovoked proximal DVT of the leg or PE in patients who have a high bleeding risk: three months of anticoagulant therapy is recommended over extended therapy. • First VTE that is an unprovoked isolated distal DVT of the leg: three months of anticoagulation therapy is suggested over extended therapy in those with a low or moderate bleeding risk, and three months of anticoagulant treatment is recommended in those with a high bleeding risk. • Second unprovoked VTE or PE: extended anticoagulant therapy is recommended over three months of therapy in those who have a low bleeding risk, and extended anticoagulant therapy is suggested in patients with a moderate bleeding risk. • Second unprovoked VTE or PE in patients with a high bleeding risk: three months of anticoagulant therapy is suggested over extended therapy. • DVT of the leg or PE and active cancer: if the risk of bleeding is not high,

Clinical Guideline	Recommendations
	extended anticoagulation therapy is recommended over three months of therapy, and if there is a high bleeding risk, extended anticoagulant therapy is suggested. • DVT of the leg or PE in patients treated with VKA: a therapeutic INR range of 2.0 to 3.0 (target, 2.5) is recommended over a lower (<2.0) or higher (range, 3.0 to 5.0) range for all treatment durations. • DVT of the leg or PE in patients with no cancer: VKA therapy is suggested over LMWH for long-term therapy. For patients with DVT or PE and no cancer who are not treated with VKA therapy, LMWH is suggested over dabigatran etexilate mesylate or rivaroxaban for long term therapy. • DVT of the leg or PE and cancer: LMWH is suggested over VKA therapy. In patients with DVT of the leg or PE and cancer who are not treated with LMWH, VKA is suggested over dabigatran etexilate mesylate or rivaroxaban for long-term therapy. • DVT of the leg or PE in patients who receive extended therapy: treatment with the same anticoagulant chosen for the first three months is suggested. • Patients incidentally found to have asymptomatic DVT of the leg or PE: treatment with the same anticoagulant is suggested as for comparable patients with symptomatic DVT or PE. • In patients with chronic thromboembolic pulmonary hypertension, extended anticoagulation is recommended over stopping therapy. • Superficial vein thrombosis of the lower limb of at least 5 cm in length: use of a prophylactic dose of fondaparinux or LMWH for 45 days is suggested over no anticoagulation. • Superficial vein thrombosis in patients treated with anticoagulation: fondaparinux 2.5 mg/day is suggested over a prophylactic dose of LMWH. • Upper-extremity DVT that involves the axillary or more proximal veins: acute treatment with parenteral anticoagulation (LMWH, fondaparinux, or IV or SC UFH) over no such acute treatment. • Acute upper-extremity DVT that involves the axillary or more proximal veins: LMWH or fondaparinux is suggested over IV or SC UFH, and anticoagulation therapy alone is suggested over thrombolysis. • Upper-extremity DVT in patients undergoing thrombolysis: the same intensity and duration of anticoagulant therapy as in similar patients who do not undergo thrombolysis is recommended. • In most patients with upper-extremity DVT that is associated with a central venous catheter: it is suggested that the catheter not be removed if it is functional and there is an ongoing need for the catheter. • Upper-extremity DVT that involves the axillary or more proximal veins: a minimum duration of anticoagulation of three months is suggested over a shorter duration. • Upper-extremity DVT that is associated with a central venous catheter that is removed: three months of anticoagulation is recommended over a longer duration of therapy in patients with no cancer, and this is suggested in patients with cancer. • Upper-extremity DVT that is associated with a central venous catheter that is not removed: it is recommended that anticoagulation is continued as long as the central venous catheter remains over stopping after three months of treatment in patients with cancer, and this is suggested in patients with no cancer. • Upper-extremity DVT that is not associated with a central venous catheter or with cancer: three months of anticoagulation is recommended over a longer duration of therapy. • Acute symptomatic upper-extremity DVT: use of compression sleeves or venoactive medications is suggested against.

Clinical Guideline	Recommendations
	• Symptomatic splanchnic vein thrombosis: anticoagulation is recommended over no anticoagulation. • Symptomatic hepatic vein thrombosis: anticoagulation is suggested over no anticoagulation. • In patients with incidentally detected splanchnic vein thrombosis or hepatic vein thrombosis: no anticoagulation is suggested over anticoagulation. <u>Antithrombotic therapy for atrial fibrillation (AF)</u> • Patients with AF, including those with paroxysmal AF, who are at low risk of stroke: no therapy is suggested over antithrombotic therapy. For patients who choose antithrombotic therapy, aspirin is suggested over oral anticoagulation or combination therapy with aspirin and clopidogrel. • Patients with AF, including those with paroxysmal AF, who are at intermediate risk of stroke: oral anticoagulation is recommended over no therapy. Oral anticoagulation is suggested over aspirin or combination therapy with aspirin and clopidogrel. For patients who are unsuitable for or choose not to take an oral anticoagulant, combination therapy with aspirin and clopidogrel are suggested over aspirin. • Patients with AF, including those with paroxysmal AF, who are at high risk of stroke: oral anticoagulation is recommended over no therapy, aspirin, or combination therapy with aspirin and clopidogrel. For patients who are unsuitable for or choose not to take an oral anticoagulant, combination therapy with aspirin and clopidogrel is recommended over aspirin. • Patients with AF, including those with paroxysmal AF: for recommendations in favor of oral anticoagulation, dabigatran etexilate mesylate 150 mg twice daily is suggested over adjusted-dose VKA therapy (target INR range, 2.0 to 3.0). • Patients with AF and mitral stenosis: adjusted-dose VKA therapy is recommended over no therapy, aspirin, or combination therapy with aspirin and clopidogrel. For patients who are unsuitable for or choose not to take adjusted-dose VKA therapy, combination therapy with aspirin and clopidogrel is recommended over aspirin alone. • Patients with AF and stable coronary artery disease and who choose oral anticoagulation: adjusted-dose VKA therapy alone is suggested over the combination of adjusted-dose VKA therapy and aspirin. • Patients with AF at high risk of stroke during the first month after placement of a bare-metal stent or the first three to six months after placement of a drug-eluting stent: triple therapy (e.g., VKA therapy, aspirin, and clopidogrel) is suggested over dual antiplatelet therapy (e.g., aspirin and clopidogrel). After this initial period, a VKA plus a single antiplatelet agent is suggested over a VKA alone. At 12 months after stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease. • Patients with AF at intermediate risk of stroke during the first 12 months after placement of a stent: dual antiplatelet therapy is suggested over triple therapy. At 12 months after stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease. • Patients with AF at intermediate to high risk of stroke who experience an acute coronary syndrome (ACS) and do not undergo stent placement, for the first 12 months: adjusted-dose VKA therapy plus single antiplatelet therapy is suggested over dual antiplatelet therapy or triple therapy. After the first 12 months, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease. • Patients with AF at low risk of stroke: dual antiplatelet therapy is suggested over adjusted-dose VKA therapy plus single antiplatelet therapy or triple therapy. After the first 12 months, antithrombotic therapy is suggested as for

Clinical Guideline	Recommendations

	patients with AF and stable coronary artery disease.
	• Patients with AF being managed with a rhythm control strategy: it is suggested that antithrombotic therapy decisions follow the general risk-based recommendations for patients with nonrheumatic AF, regardless of the apparent persistence of normal sinus rhythm.
	• Patients with atrial flutter: it is suggested that antithrombotic therapy decisions follow the same risk-based recommendations as for AF.
	
	<u>Antithrombotic therapy for ischemic stroke</u>
	• In patients with acute ischemic stroke or transient ischemic attack (TIA), early (within 48 hours) aspirin 160 to 325 mg is recommended over therapeutic parenteral anticoagulation.
	• In patients with a history of noncardioembolic ischemic stroke or TIA, aspirin (75 to 100 mg daily), clopidogrel (75 mg daily), aspirin-dipyridamole extended-release (ER) (25 mg-200 mg twice daily) or cilostazol (100 mg twice daily) is recommended over oral anticoagulants, the combination of clopidogrel plus aspirin or triflusal.
	  o Clopidogrel or aspirin-dipyridamole ER is recommended over aspirin or cilostazol.
	• In patients with a history of ischemic stroke or TIA and AF, oral anticoagulation with dabigatran 150 mg twice daily is recommended over VKA therapy.
	  o In patients who are unable to or choose not to take an oral anticoagulant, the combination of aspirin plus clopidogrel is recommended over aspirin alone.
	
	<u>Primary and secondary prevention of cardiovascular disease</u>
	• Patients ≥50 years of age without symptomatic cardiovascular disease: low dose aspirin (75 to 100 mg/day) is suggested over no aspirin therapy.
	• Patients with established coronary artery disease: long term single antiplatelet therapy with aspirin (75 to 100 mg/day) or clopidogrel (75 mg/day) is recommended over no antiplatelet therapy, and single antiplatelet therapy is suggested over dual antiplatelet therapy.
	• Patients in the first year after ACS who have not undergone percutaneous coronary intervention (PCI): dual antiplatelet therapy (ticagrelor 90 mg twice daily plus low dose aspirin 75 to 100 mg/day or clopidogrel 75 mg/day plus low dose aspirin 75 to 100 mg/day) is recommended over single antiplatelet therapy. Ticagrelor 90 mg twice daily plus low dose aspirin is suggested over clopidogrel 75 mg/day plus low dose aspirin.
	• Patients in the first year after an ACS who have undergone PCI with stent placement: dual antiplatelet therapy (ticagrelor 90 mg twice daily plus low dose aspirin 75 to 100 mg/day, clopidogrel 75 mg/day plus low dose aspirin, or prasugrel 10 mg/day plus low dose aspirin) is recommended over single antiplatelet therapy. Ticagrelor 90 mg twice daily plus low dose aspirin is suggested over clopidogrel 75 mg/day plus low dose aspirin.
	• Patients with anterior myocardial infarction (MI) and left ventricular thrombus, or at high risk for left ventricular thrombus, who do not undergo stenting: warfarin plus low dose aspirin (75 to 100 mg/day) is recommended over single antiplatelet therapy or dual antiplatelet therapy for the first three months. Thereafter, it is recommended that warfarin be discontinued and dual antiplatelet therapy should be continued for up to 12 months. After 12 months, single antiplatelet therapy is recommended as per the established coronary artery disease recommendations.
	• Patients with anterior MI and left ventricular thrombus, or at high risk for left ventricular thrombus, who undergo bare-metal stent placement: triple therapy (warfarin, low dose aspirin, clopidogrel 75 mg/day) for one month is suggested

Clinical Guideline	Recommendations
	over dual antiplatelet therapy. Warfarin and single antiplatelet therapy for the second and third month post-bare-metal stent is suggested over alternative regimens and alternative time frames for warfarin use. Thereafter, it is recommended that warfarin be discontinued and dual antiplatelet therapy should be continued for up to 12 months. After 12 months, antiplatelet therapy is recommended as per the established coronary artery disease recommendations. • Patients with anterior MI and left ventricular thrombus, or at high risk for left ventricular thrombus who undergo drug-eluting stent placement: triple therapy (warfarin, low dose aspirin, clopidogrel 75 mg/day) for up to three to six months is suggested over alternative regimens and alternative durations of warfarin therapy. Thereafter, it is recommended that warfarin be discontinued and dual antiplatelet therapy should be continued for up to 12 months. After 12 months, antiplatelet therapy is recommended as per the established coronary artery disease recommendations. • Patients who have undergone elective PCI with placement of bare-metal stent: dual antiplatelet therapy with aspirin 75 to 325 mg/day and clopidogrel 75 mg/day for one month is recommended over single antiplatelet therapy. For the subsequent 11 months, dual antiplatelet therapy with combination low dose aspirin 75 to 100 mg/day and clopidogrel 75 mg/day is suggested over single antiplatelet therapy. After 12 months, single antiplatelet therapy is recommended over continuation of dual antiplatelet therapy. • Patients who have undergone elective PCI with placement of drug-eluting stent: dual antiplatelet therapy with aspirin 75 to 325 mg/day and clopidogrel 75 mg/day for three to six months is recommended over single antiplatelet therapy. After three to six months, continuation of dual antiplatelet therapy with low dose aspirin 75 to 100 mg/day and clopidogrel 75 mg/day is suggested to be continued until 12 months over antiplatelet therapy. After 12 months, single antiplatelet therapy is recommended over continuation of dual antiplatelet therapy. Single antiplatelet therapy thereafter is recommended as per the established coronary artery disease recommendations. • Patients who have undergone elective bare-metal stent or drug-eluting stent placement: low dose aspirin 75 to 100 mg/day and clopidogrel 75 mg/day is recommended over cilostazol in addition to these drugs. Aspirin 75 to 100 mg/day or clopidogrel 75 mg/day as part of dual antiplatelet therapy is suggested over the use of either drug with cilostazol. Cilostazol 100 mg twice daily as a substitute for either low dose aspirin or clopidogrel as part of a dual antiplatelet regimen in patients with an allergy or intolerance of either drug class is suggested. • Patients with coronary artery disease undergoing elective PCI but no stent placement: for the first month dual antiplatelet therapy with aspirin 75 to 325 mg/day and clopidogrel 75 mg/day is suggested over single antiplatelet therapy. Single antiplatelet therapy thereafter is recommended as per the established coronary artery disease recommendations. • Patients with systolic left ventricular dysfunction without established coronary artery disease and no left ventricular thrombus: it is suggested that antiplatelet therapy and warfarin not be used. • Patients with systolic left ventricular dysfunction without established coronary artery disease with identified acute left thrombus: moderate intensity warfarin for at least three months is suggested. • Patients with systolic left ventricular dysfunction and established coronary artery disease: recommendations are as per the established coronary artery disease recommendations. <u>Antithrombotic therapy in peripheral artery disease (PAD)</u> • In patients with asymptomatic PAD, aspirin 75 to 100 mg daily is

Clinical Guideline	Recommendations

	recommended.
	• In patients with symptomatic PAD, long-term therapy with aspirin (75 to 100 mg daily) or clopidogrel (75 mg daily) is recommended for secondary prevention of cardiovascular events. Dual antiplatelet therapy or the combination of an antiplatelet agent with moderate-intensity warfarin is not recommended.
	• Use of cilostazol in addition to aspirin or clopidogrel is recommended in patients with intermittent claudication refractory to exercise therapy and smoking cessation.
	• Use of prostanoids in addition to aspirin or clopidogrel is recommended in patients with symptomatic PAD and critical leg ischemia who are not candidates for vascular intervention.
	• In patients undergoing peripheral artery percutaneous transluminal angioplasty with or without stenting, long-term therapy with aspirin or clopidogrel is recommended over dual antiplatelet therapy.
	• Following peripheral artery bypass graft surgery, long-term therapy with aspirin or clopidogrel is recommended over the combination of antiplatelet agent plus warfarin. Clopidogrel plus aspirin for one year is recommended in patients undergoing below-knee bypass graft surgery with prosthetic grafts.
	• In patients with asymptomatic carotid stenosis, aspirin 75 to 100 mg daily is recommended.
	• In patients with symptomatic carotid stenosis, long-term therapy with clopidogrel (75 mg daily) or aspirin/dipyridamole ER (25 mg/200 mg twice daily) is recommended over aspirin (75 to 100 mg daily).
	
	<u>Antithrombotic and thrombolytic therapy for valvular disease</u>
	• Antithrombotic therapy in the first three months after surgery:
	  o In patients with aortic bioprosthetic valves, who are in sinus rhythm and have no other indication for VKA therapy, aspirin (50 to 100 mg/day) over VKA therapy is suggested in the first three months.
	  o In patients with transcatheter aortic bioprosthetic valves, aspirin (50 to 100 mg/day) plus clopidogrel (75 mg/day) is suggested over VKA therapy and over no antiplatelet therapy in the first three months.
	  o In patients with a bioprosthetic valve in the mitral position, VKA therapy over no VKA therapy for the first three months after valve insertion is suggested.
	• Long-term antithrombotic therapy for patients with bioprosthetic valves:
	  o In patients with bioprosthetic valves in normal sinus rhythm, aspirin therapy over no aspirin therapy after three months postoperative is suggested.
	• Early postoperative bridging to intermediate/long-term therapy (postoperative day 0 to 5):
	  o In patients with mechanical heart valves, bridging with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) over intravenous (IV) therapeutic UFH until stable on VKA therapy.
	• Long-term antithrombotic therapy for patients with mechanical valves:
	  o VKA therapy is recommended over no VKA therapy for long-term management.
	• Intensity of VKA therapy for patients with mechanical aortic valve prostheses:
	  o VKA therapy at a target of 2.5 over lower targets is suggested. A target of 2.5 is recommended over higher targets.
	• Intensity of VKA therapy for patients with mechanical mitral valve prostheses:
	  o VKA therapy with a target of 3.0 over lower INR targets is suggested.
	• Intensity of VKA therapy in patients with double mechanical valve or with additional risk factors:

Clinical Guideline	Recommendations
	○ VKA therapy with a target of 3.0 is suggested over target INR 2.5. • Antiplatelet agent in addition to VKA therapy for patients with mechanical aortic or mitral valve prostheses: ○ Patients who are at low risk of bleeding, adding over not adding an antiplatelet agent such as low-dose (50 to 100 mg/day) to VKA therapy is suggested. • For patients with mechanical aortic or mitral valves VKA therapy over antiplatelet agents is recommended. • In patients undergoing mitral valve repair with a prosthetic band in normal sinus rhythm, the use of antiplatelet therapy for the first three months is suggested over VKA therapy. • In patients undergoing aortic valve repair, aspirin (50 to 100 mg/day) is suggested over VKA therapy.
American College of Chest Physicians: **Antithrombotic Therapy for VTE Disease (2016)**[9]	Choice of long-term (first three months) and extended (no scheduled stop date) anticoagulant • In patients with proximal deep vein thrombosis (DVT) or pulmonary embolism (PE), long-term (three months) anticoagulant therapy is recommended over no such therapy. • In patients with DVT of the leg or PE and no cancer, as long-term (first three months) anticoagulant therapy, dabigatran, rivaroxaban, apixaban, or edoxaban is recommended over vitamin K antagonist (VKA) therapy. • No non-vitamin K oral anticoagulant is preferred over another. • Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. • In patients with DVT of the leg or PE and cancer ("cancer-associated thrombosis"), as long-term anticoagulant therapy, LMWH is recommended over VKA therapy, dabigatran, rivaroxaban, apixaban, or edoxaban. • In patients with DVT of the leg or PE who receive extended therapy, there is no need to change the choice of anticoagulant after the first three months. Duration of anticoagulant therapy • In patients with a proximal DVT of the leg or PE provoked by surgery, treatment with anticoagulation for three months is recommended over (i) treatment of a shorter period, (ii) treatment of a longer time-limited period (e.g., six, 12, or 24 months), or (iii) extended therapy (no scheduled stop date). • In patients with a proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor, treatment with anticoagulation for three months is recommended over (i) treatment of a shorter period and (ii) treatment of a longer time-limited period (e.g., six, 12, or 24 months). Treatment with anticoagulation for three months is suggested over extended therapy if there is a low or moderate bleeding risk, and treatment for three months is recommended over extended therapy if there is a high risk of bleeding. • In patients with an isolated distal DVT of the leg provoked by surgery or by a nonsurgical transient risk factor, treatment with anticoagulation for three months is suggested over treatment of a shorter period, treatment with anticoagulation for three months is recommended over treatment of a longer time-limited period (e.g., six, 12, or 24 months), and treatment with anticoagulation for three months is recommended over extended therapy (no scheduled stop date). • In patients with an unprovoked DVT of the leg (isolated distal or proximal) or PE, treatment with anticoagulation for at least three months is recommended over treatment of a shorter duration), and treatment with anticoagulation for three months is recommended over treatment of a longer time-limited period (e.g., six, 12, or 24 months).

Clinical Guideline	Recommendations
	• In patients with a first VTE that is an unprovoked proximal DVT of the leg or PE and who have a (i) low or moderate bleeding risk, extended anticoagulant therapy (no scheduled stop date) is suggested over three months of therapy, and (ii) high bleeding risk, three months of anticoagulant therapy is recommended over extended therapy (no scheduled stop date). • In patients with a second unprovoked VTE and who have a (i) low bleeding risk, extended anticoagulant therapy (no scheduled stop date) is recommended over three months; (ii) moderate bleeding risk, extended anticoagulant therapy is suggested over three months of therapy; or (iii) high bleeding risk, three months of anticoagulant therapy is suggested over extended therapy (no scheduled stop date). • In patients with "cancer-associated thrombosis" and who (i) do not have a high bleeding risk, extended anticoagulant therapy (no scheduled stop date) is recommended over three months of therapy, or (ii) have a high bleeding risk, extended anticoagulant therapy (no scheduled stop date) is suggested over three months of therapy. <u>Aspirin for extended treatment of VTE</u> • In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, aspirin is suggested over no aspirin to prevent recurrent VTE. <u>Whether to anticoagulate subsegmental PE</u> • In patients with subsegmental PE (no involvement of more proximal pulmonary arteries) and no proximal DVT in the legs who have a (i) low risk for recurrent VTE, clinical surveillance is suggested over anticoagulation or (ii) high risk for recurrent VTE, anticoagulation is suggested over clinical surveillance. <u>Treatment of acute PE out of the hospital</u> • In patients with low-risk PE and whose home circumstances are adequate, treatment at home or early discharge is suggested over standard discharge (e.g., after the first five days of treatment). <u>Systemic thrombolytic therapy for PE</u> • In patients with acute PE associated with hypotension (e.g., systolic BP <90 mm Hg) who do not have a high bleeding risk, systemically administered thrombolytic therapy is suggested over no such therapy. • In most patients with acute PE not associated with hypotension, systemically administered thrombolytic therapyis NOT recommended. • In selected patients with acute PE who deteriorate after starting anticoagulant therapy but have yet to develop hypotension and who have a low bleeding risk, systemically administered thrombolytic therapy is suggested over no such therapy. <u>Thrombolytic therapy in patients with upper extremity DVT</u> • In patients with acute upper extremity DVT (UEDVT) that involves the axillary or more proximal veins, anticoagulant therapy alone is suggested over thrombolysis. • In patients with UEDVT who undergo thrombolysis, the same intensity and duration of anticoagulant therapy as in patients with UEDVT who do not undergo thrombolysis is recommended. <u>Management of recurrent VTE on anticoagulant therapy</u> • In patients who have recurrent VTE on VKA therapy (in the therapeutic range)

Clinical Guideline	Recommendations
	or on dabigatran, rivaroxaban, apixaban, or edoxaban (and are believed to be compliant), switching to treatment with LMWH at least temporarily is suggested. • In patients who have recurrent VTE on long-term LMWH (and are believed to be compliant), increasing the dose of LMWH by about one-quarter to one-third is suggested. • Recurrent VTE while on therapeutic-dose anticoagulant therapy is unusual and should prompt the following assessments: (1) reevaluation of whether there truly was a recurrent VTE; (2) evaluation of compliance with anticoagulant therapy; and (3) consideration of an underlying malignancy. A temporary switch to LMWH will usually be for at least one month.
American Heart Association/American Stroke Association: **Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals (2012)[10]**	Prevention of stroke in nonvalvular AF • Apixaban, dabigatran etexilate mesylate, rivaroxaban and warfarin are all indicated for the prevention of first and recurrent stroke in patients with nonvalvular AF. • The choice of antithrombotic treatment should be individualized based on risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in INR therapeutic range if the patient has been taking warfarin. • Dabigatran etexilate mesylate 150 mg twice daily is an efficacious alternative to warfarin for the prevention of first and recurrent stroke in patients with nonvalvular AF who have at least one additional risk factor and a creatinine clearance (CrCl) >30 mL/min. • The use of dabigatran etexilate mesylate 75 mg twice daily in patients with AF and at least one additional risk factor who have a low CrCl (15 to 30 mL/min) may be considered, but its safety and efficacy have not been established. The use of dabigatran etexilate mesylate in patients with more severe renal failure is not recommended in patients with a CrCl <15 mL/min. • Apixaban 5 mg twice daily is an effective alternative to aspirin in patients with nonvalvular AF deemed unsuitable for VKA therapy with one or more additional risk factor and no more than one of the following characteristics: age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL. • Although safety and efficacy have not been established, apixaban 2.5 mg twice daily may be considered as an alternative to aspirin in patients with nonvalvular AF deemed unsuitable for VKA therapy who have one or more additional risk factor and two or more of the following criteria: age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL. • Apixaban 5 mg twice daily is a relatively safe and efficacious alternative to warfarin in patients with nonvalvular AF deemed appropriate for VKA therapy that have one or more risk factors and no more than one of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. • Apixaban should not be used if the CrCl is <25 mL/min. • In patients with nonvalvular AF who are at moderate to high risk of stroke (prior history of transient ischemic attack [TIA], stroke, or systemic embolization or have two additional risk factors), rivaroxaban 20 mg daily is a reasonable alternative to warfarin. • In patients with renal impairment and nonvalvular AF who are at moderate to high risk of stroke (prior history of TIA, stroke, or systemic embolization or two or more additional risk factors), with a CrCl 15 to 50 mL/min, rivaroxaban 15 mg daily may be considered; however, its safety and efficacy have not been established. • Rivaroxaban should not be used if the CrCl is <15 mL/min. • The safety and efficacy of combining dabigatran, rivaroxaban, or apixaban with an antiplatelet agent have not been established.
American Heart	Recommendations for risk-based antithrombotic therapy:

Clinical Guideline	Recommendations
Association/American College of Cardiology/ Heart Rhythm Society: **Guideline for the Management of Patients with Atrial Fibrillation (2014)**[11]	Class I • In patients with atrial fibrillation (AF), antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke, bleeding and the patient's values and preferences (Level of Evidence: C). • Selection of antithrombotic therapy should be based on the risk of thromboembolism irrespective of whether the AF patter is paroxysmal, persistent, or permanent (Level of Evidence: B). • In patients with nonvalvular AF, the CHA_2DS_2-VASc score is recommended for assessment of stroke risk (Level of Evidence: B). • For patients with AF who have mechanical heart valves, warfarin is recommended and the target international normalized ratio (INR) should be based on type and location of the prosthesis (Level of Evidence: B). • For patients with nonvalvular AF with prior stroke, TIA, or a CHA_2DS_2-VASc score ≥2, oral anticoagulants are recommended. Options include warfarin (INR 2.0 to 3.0) (Level of Evidence: A), dabigatran, rivaroxaban, or apixaban (Level of Evidence: B). • For patients treated with warfarin, the INR should be determined at least weekly during initiation of antithrombotic therapy and at least monthly when anticoagulation (INR in range) is stable (Level of Evidence: A) • For patients with nonvalvular AF unable to maintain a therapeutic INR level with warfarin, use of a direct thrombin or factor Xa inhibitor is recommended (Level of Evidence: C). • Re-evaluation of the need for and choice of antithrombotic therapy at periodic intervals is recommended to reassess stroke and bleeding risks (Level of Evidence: C). • Bridging therapy with UFH or LMWH is recommended for patients with AF and a mechanical heart valve undergoing procedures that require interruption of warfarin. Decisions regarding bridging therapy should balance the risks of stroke and bleeding (Level of Evidence: C). • For patients with AF without mechanical heart valves who require interruption of warfarin or newer anticoagulants for procedures, decisions about bridging therapy (LMWH or UFH) should balance the risks of stroke and bleeding and the duration of time a patient will not be anticoagulated (Level of Evidence: C). • Renal function should be evaluated prior to initiation of direct thrombin or factor Xa inhibitors and should be re-evaluated when clinically indicated and at least annually (Level of Evidence: B). • For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF (Level of Evidence: C). Class IIa • For patients with nonvalvular AF and a CHA_2DS_2-VASc score of 0, it is reasonable to omit antithrombotic therapy (Level of Evidence: B). • For patients with nonvalvular AF with a CHA_2DS_2-VASc score of ≥2 and who have end-stage chronic kidney disease (creatine clearance <15 mL/min) or who are on hemodialysis, it is reasonable to prescribe warfarin (INR 2.0 to 3.0) for oral anticoagulation (Level of Evidence: B). Class IIb • For patients with nonvalvular AF and a CHA_2DS_2-VASc score of 1, no antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered (Level of Evidence: C). • For patients with nonvalvular AF and moderate-to-severe chronic kidney disease with a CHA_2DS_2-VASc score of ≥2, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (e.g., dabigatran, rivaroxaban, or apixaban), but safety and efficacy have not been established

Clinical Guideline	Recommendations
	(Level of Evidence: C). • In patients with AF undergoing PCI, bare-metal stents may be considered to minimize the required duration of dual antiplatelet therapy. Anticoagulation may be interrupted at the time of the procedure to reduce the risk of bleeding ant the site of peripheral arterial puncture (Level of Evidence: C). • Following coronary revascularization (percutaneous or surgical) in patients with AF and a CHA_2DS_2-VASc score of ≥2, it may be reasonable to use clopidogrel (75 mg once daily) concurrently with oral anticoagulants but without aspirin (Level of Evidence: B). Class III: No Benefit • The direct thrombin inhibitor, dabigatran, and the factor Xa inhibitor, rivaroxaban, are not recommended in patients with AF and end-stage chronic kidney disease or on hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits (Level of Evidence: C). Class III: Harm • The direct thrombin inhibitor, dabigatran, should not be used in patients with AF and a mechanical heart valve (Level of Evidence: B). <u>Recommendations for rate control:</u> Class I • Control of the ventricular rate using a beta blocker or nondihydropyridine (non-DHP) calcium channel blocker (CCB) is recommended for patients with paroxysmal, persistent, or permanent AF (Level of Evidence: B). • Intravenous administration of a beta blocker or non-DHP CCB is recommended to slow the ventricular heart rate in the acute setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated (Level of Evidence: B). • In patients who experience AF-related symptoms during activity, the adequacy of heart rate control should be assessed during exertion, adjusting pharmacological treatment as necessary to keep the ventricular rate within the physiological range (Level of Evidence: C). Class IIa • A heart rate control (resting heart rate <80 beats per minute [bpm]) strategy is reasonable for symptomatic management of AF (Level of Evidence: B). • Intravenous amiodarone can be useful for rate control in critically ill patients without pre-excitation (Level of Evidence: B). • Atrioventricular (AV) nodal ablation with permanent ventricular pacing is reasonable to control heart rate when pharmacological therapy is inadequate and rhythm control is not achievable (Level of Evidence: B). Class IIb • A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable as long as patients remain asymptomatic and left ventricular systolic function is preserved (Level of Evidence: B). • Oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated (Level of Evidence: C). Class III: Harm • AV nodal ablation with permanent ventricular pacing should not be performed to improve rate control without prior attempts to achieve rate control with medications (Level of Evidence: C). • Non-DHP CCBs should not be used in patients with decompensated HF as these may lead to further hemodynamic compromise (Level of Evidence: C). • In patients with pre-excitation and AF, digoxin, non-DHP CCBs, or intravenous amiodarone should not be administered as they may increase the ventricular response and may result in ventricular fibrillation. (Level of

Clinical Guideline	Recommendations
	Evidence: B). • Dronedarone should not be used to control the ventricular rate in patients with permanent AF as it increases the risk of the combined endpoint of stroke, myocardial infarction, systemic embolism, or cardiovascular death (Level of Evidence: B). <u>Recommendations for Thromboembolism Prevention</u>: Class I • For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with warfarin (INR 2.0 to 3.0) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the CHA_2DS_2-VASc score and the method used to restore sinus rhythm (Level of Evidence: B). • For patients with AF or atrial flutter of more than 48 hours duration that requires immediate cardioversion for hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least four weeks after cardioversion unless contraindicated (Level of Evidence: C). • For patients with AF or atrial flutter of less than 48-hour duration and with high risk stroke, intravenous heparin or LMWH, or administration of a factor Xa or direct thrombin inhibitor, is recommended as soon as possible before or immediately after cardioversion, followed by long-term anticoagulation therapy (Level of Evidence: C). • Following cardioversion for AF of any duration, the decision regarding long-term anticoagulation therapy should be based on the thromboembolic risk profile (Level of Evidence: C). Class IIa • For patients with AF or atrial flutter of 48-hour duration or longer or of unknown duration who have not been anticoagulated for the preceding three weeks, it is reasonable to perform a TEE prior to cardioversion and proceed with cardioversion if no LA thrombus is identified, including in the LAA, provided that anticoagulation is achieved before TEE and maintained after cardioversion for at least four weeks (Level of Evidence: B). • For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for at least three weeks prior to and four weeks after cardioversion (Level of Evidence: C). Class IIb • For patients with AF or atrial flutter of less than 48-hour duration who are at low thromboembolic risk, anticoagulation (heparin, LMWH, or a new oral anticoagulant) or no antithrombotic therapy may be considered for cardioversion, without the need for post cardioversion oral anticoagulation (Level of Evidence: C). <u>Recommendations for pharmacological cardioversion</u> Class I • Flecainide, dofetilide, propafenone, and intravenous ibutilide are useful for pharmacological cardioversion of AF or atrial flutter, provided contraindications to the selected drug are absent (Level of Evidence: A). Class IIa • Administration of oral amiodarone is a reasonable option for pharmacological cardioversion of AF (Level of Evidence: A). • Propafenone or flecainide ("pill-in-the-pocket") in addition to a beta blocker or non-DHP CCB is reasonable to terminate AF outside the hospital once this treatment has been observed to be safe in a monitored setting for selected patients (Level of Evidence: B). Class III: Harm

Clinical Guideline	Recommendations

	• Dofetilide therapy should not be initiated out of hospital because of the risk of excessive QT prolongation that can cause torsades de pointes (Level of Evidence: B).
	
	<u>Recommendations for antiarrhythmic drugs to maintain sinus rhythm</u>
	Class I
	• Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level of Evidence: C).
	• The following antiarrhythmic drugs are recommended in patients with AF to maintain sinus rhythm, depending on underlying heart disease and comorbidities (Level of Evidence: A):
	  ○ Amiodarone
	  ○ Dofetilide
	  ○ Dronedarone
	  ○ Flecainide
	  ○ Propafenone
	  ○ Sotalol
	• The risks of the antiarrhythmic drug, including proarrhythmia, should be considered before initiating therapy with each drug (Level of Evidence: C).
	• Because of its potential toxicities, amiodarone should only be used after consideration of risks and when other agents have failed or are contraindicated (Level of Evidence: C).
	Class IIa
	• A rhythm-control strategy with pharmacological therapy can be useful in patients with AF for the treatment of tachycardia-induced cardiomyopathy (Level of Evidence: C).
	Class IIb
	• It may be reasonable to continue current antiarrhythmic drug therapy in the setting of infrequent, well-tolerated recurrences of AF when the drug has reduced the frequency or symptoms of AF (Level of Evidence: C).
	Class III: Harm
	• Antiarrhythmic drugs for rhythm control should not be continued when AF becomes permanent (Level of Evidence: C), including dronedarone (Level of Evidence: B).
	• Dronedarone should not be used for treatment of AF in patients with New York Heart Association class III and IV HF or patients who have had an episode of decompensated HF in the past 4 weeks. (Level of Evidence: B).
	
	<u>Upstream therapy</u>
	Class IIa
	• An angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced left ventricular ejection fraction (Level of Evidence: B).
	Class IIb
	• Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension (Level of Evidence: B).
	• Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery (Level of Evidence: A).
	Class III: No Benefit
	• Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease (Level of Evidence: B).

National Institute for	<u>Interventions to prevent stroke</u>

Clinical Guideline	Recommendations

Health and Clinical Excellence:
Atrial Fibrillation: The Management of Atrial Fibrillation (2014)[12]
	• Do not offer stroke prevention to people aged <65 years with atrial fibrillation (AF) and no risk factors other than their sex (that is, very low risk of stroke equating to CHA_2DS_2-VASc score of 0 for men or 1 for women).
	• Consider anticoagulation for men with a CHA_2DS_2-VASc score of 1. Take the bleeding risk into account.
	• Offer anticoagulation to people with a CHA_2DS_2-VASc score of 2 or above, taking bleeding risk into account.
	• Discuss the options for anticoagulation with the person and base the choice on their clinical features and preferences.
	• Apixaban
	  o Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorization, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as:
	  ▪ Prior stroke of transient ischemic attack (TIA).
	  ▪ Age 75 years or older.
	  ▪ Hypertension.
	  ▪ Diabetes mellitus.
	  ▪ Symptomatic heart failure.
	• Dabigatran etexilate
	  o Dabigatran etexilate is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more of the following risk factors:
	  ▪ Previous stroke, TIA, or systemic embolism.
	  ▪ Left ventricular ejection fraction (LVEF) <40%.
	  ▪ Symptomatic heart failure (HF) of New York Heart Association (NYHA) class 2 or above.
	  ▪ Age 75 years or older.
	  ▪ Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease, or hypertension.
	• Rivaroxaban
	  o Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular AF with one or more risk factors such as:
	  ▪ Congestive heart failure.
	  ▪ Hypertension.
	  ▪ Age 75 years or older.
	  ▪ Diabetes mellitus.
	  ▪ Prior stroke or TIA.
	• The decision about whether to start treatment with a new oral anticoagulant should be made after an informed discussion between the clinician and the person about the risks and benefits of the agent compared with the alternatives, including warfarin. For people who are taking warfarin, the potential risks and benefits of switching to a different oral agent should be considered in light of their level of international normalized ratio (INR) control.
	
	<u>Assessing anticoagulation control with vitamin K antagonists</u>
	• Calculate the person's time in therapeutic range (TTR) at each visit. When calculating TTR:
	  o Use a validated method of measurement such as the Rosendaal method for computer-assisted dosing or proportion of tests in range for manual dosing.
	  o Exclude measurements taken during the first six weeks of treatment.
	  o Calculate TTR over a maintenance period of at least six months.
	• Reassess anticoagulation for a person with poor anticoagulation control shown by any of the following:

Clinical Guideline	Recommendations
	○ Two INR values higher than 5 or one INR value higher than 8 within the past six months. ○ Two INR values less than 1.5 within the past six months. ○ TTR <65%. • When assessing anticoagulation, take into account and if possible address the following factors that may contribute to poor anticoagulation control: Cognitive function, adherence, illness, drug interactions, and lifestyle factors including diet and alcohol consumption. • If poor anticoagulation control cannot be improved, evaluate the risks and benefits of alternative stroke prevention strategies and discuss these with the person. <u>When to offer rate and rhythm control</u> • Offer rate control as the first-line strategy to people with AF, except in people whose AF has a reversible cause, who have HF thought to be primarily caused by AF, with new-onset AF, with atrial flutter whose condition is considered suitable for an ablation strategy to restore sinus rhythm, and for whom a rhythm control strategy would be more suitable based on clinical judgement. <u>Rate control</u> • Offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium channel blocker (CCB) as initial monotherapy to people with AF who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities, and preferences when considering drug treatment. • Consider digoxin monotherapy for people with non-paroxysmal AF only if they are sedentary. • If monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any two of the following: a beta-blocker, diltiazem, and digoxin. • Do not offer amiodarone for long-term rate control. <u>Rhythm control</u> • Consider pharmacological and/or electrical rhythm control for people with AF whose symptoms continue after heart rate has been controlled or for whom a rate-control strategy has not been successful. <u>Drug treatment for long-term rhythm control</u> • Assess the need for drug treatment for long-term rhythm control, taking into account the person's preferences, associated comorbidities, risks of treatment, and likelihood of recurrence of AF. • If drug treatment for long-term rhythm control is needed, consider a standard beta-blocker as first-line treatment unless there are contraindications. • If beta-blockers are contraindicated or unsuccessful, assess the suitability of alternative drugs for rhythm control, taking comorbidities into account. • Dronedarone is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial fibrillation: ○ Whose AF is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option and after alternative options have been considered AND ○ Who have at least one of the following cardiovascular risk factors: ▪ Hypertension requiring drugs of at least two different classes. ▪ Diabetes mellitus. ▪ Previous TIA, stroke, or systemic embolism.

Clinical Guideline	Recommendations
	▪ Left atrial diameter of 50 mm or greater, OR ▪ Age ≥70 years, AND ○ Who do not have left ventricular systolic dysfunction, AND ○ Who do not have a history of, or current, HF. • People who do not meet the criteria above who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop. • Consider amiodarone for people with left ventricular impairment or HF. • Do not offer class 1c antiarrhythmic drugs such as flecainide or propafenone to people with known ischemic or structural heart disease. • Where people have infrequent paroxysms and few symptoms, or where symptoms are induced by known precipitants (such as alcohol, caffeine), a 'no drug treatment' strategy or a 'pill-in-the-pocket' strategy should be considered and discussed with the person.
American Association for Thoracic Surgery: **2014 AATS Guidelines for the Prevention and Management of Peri-Operative Atrial Fibrillation and Flutter (POAF) for Thoracic Surgical Procedures (2014)**[13]	Recommended prevention strategies for all postoperative atrial fibrillation (POAF) patients • Patients taking β-blockers prior to thoracic surgery should continue them in the postoperative period to avoid β-blockade withdrawal. • Intravenous magnesium supplementation may be considered to prevent postoperative AF when serum magnesium level is low or it is suspected that total body magnesium is depleted. • Digoxin should not be used for prophylaxis against AF. Recommended prevention strategies for intermediate to high-risk POAF patients • It is reasonable to administer diltiazem to those patients with preserved cardiac function who are not taking β-blockers preoperatively in order to prevent POAF. • It is reasonable to consider the postoperative administration of amiodarone to reduce the incidence of POAF for intermediate and high risk patients undergoing pulmonary resection. • Postoperative administration of intravenous amiodarone may be considered to prevent POAF in patients undergoing esophagectomy. • Atorvastatin may be considered to prevent POAF for statin naïve patients scheduled for intermediate and high risk thoracic surgical procedures. Rate control recommendations for patients with new onset POAF • Intravenous administration of beta-blockers (e.g., esmolol or metoprolol) or nondihydropyridine calcium channel blockers (diltiazem or verapamil) is recommended to achieve rate control (heart rate ≤110 bpm) for patients who develop POAF with rapid ventricular response. • Caution should be used with patients with hypotension, left ventricular (LV) dysfunction, or heart failure. • Combination use of atrioventricular (AV) nodal blocking agents, such as beta-blockers (e.g., esmolol or metoprolol), nondihydropyridine calcium channel antagonists (e.g., diltiazem or verapamil), or digoxin, can be useful to control heart rates when a single agent fails to control rates of POAF. The choice should be individualized and doses modified to avoid bradycardia. • For patients with hypotension, heart failure or LV dysfunction, or when other measures are unsuccessful or contraindicated, intravenous amiodarone can be useful for control of heart rate. Amiodarone could result in conversion to sinus rhythm, and if it is initiated after 48 hours of AF, both a transesophageal echocardiography (TEE) when possible, to rule out left atrial/LA appendage (LA/LAA) thrombus, and full anticoagulation should be considered. • For patients with heart failure, LV dysfunction or hypotension, intravenous digoxin may be considered for rate control of POAF.

Clinical Guideline	Recommendations
	• For patients with ventricular preexcitation (i.e., Wolff-Parkinson-White syndrome) and POAF, use of AV nodal blocking agents, such as beta-blockers (e.g., esmolol or metoprolol), intravenous amiodarone, nondihydropyridine calcium channel antagonists (e.g., diltiazem or verapamil), or digoxin, should be avoided. Recommendations for the use of antiarrhythmic drugs for pharmacologic cardioversion of POAF • Restoration of sinus rhythm with pharmacologic cardioversion is reasonable in patients with symptomatic, hemodynamically stable POAF. Intravenous amiodarone can be useful for pharmacologic cardioversion of POAF. • It is reasonable to administer antiarrhythmic medications in an attempt to maintain sinus rhythm for patients with recurrent or refractory POAF. • Amiodarone, sotalol, flecainide, propafenone, or dofetilide can be useful to maintain sinus rhythm in patients with POAF, depending on underlying heart disease, renal status and other comorbidities. • Flecainide or propafenone may be considered for pharmacologic cardioversion of POAF and maintenance of sinus rhythm if the patient has had no prior history of myocardial infarction, coronary artery disease, impaired LV function, significant LV hypertrophy, or valvular heart disease that is considered moderate or greater. These agents may need to be combined with an AV nodal blocking agent. • Intravenous ibutilide or procainamide may be considered for pharmacologic conversion of POAF for patients with structural heart disease and new onset POAF, but no hypotension or manifestations of congestive heart failure. Serum electrolytes and QTc interval must be within a normal range and patients must be closely monitored during and for at least six hours after the infusion if either ibutilide or procainamide. • Intravenous ibutilide or procainamide may be considered for patients with POAF and an accessory pathway. • Flecainide and propafenone should not be used to treat POAF in patients with a history of a prior myocardial infarction, coronary artery disease, and/or severe structural heart disease, including severe left ventricular hypertrophy, or significantly reduced left ventricular ejection fraction. • Dronedarone should not be used for treatment of POAF in patients with heart failure. Recommendations for prevention of thromboembolism for patients with stable atrial fibrillation/flutter undergoing direct current cardioversion • For stable patients with POAF of 48-hours duration or longer, anticoagulation (with warfarin for INR 2.0 to 3.0, a novel oral anti-coagulant [NOAC] or LMWH) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the method (electrical or pharmacological) used to restore sinus rhythm. • During the first 48 hours after the onset of POAF, the need for anticoagulation before and after direct current (DC) cardioversion may be based on the patient's risk of thromboembolism (CHA2DS2-VASc score) balanced by the risk of postoperative bleeding. • For POAF lasting longer than 48 hours, as an alternative to three weeks of therapeutic anticoagulation prior to cardioversion of POAF, it is reasonable to perform TEE in search of thrombus in the LA or LA appendage, preferably with full anticoagulation at the time of TEE in anticipation of DC cardioversion after the TEE. • For POAF lasting longer than 48 hours in patients who are not candidates for TEE (e.g., post-esophageal surgery), an initial rate control strategy combined

Clinical Guideline	Recommendations
	with therapeutic anticoagulation using warfarin (aiming for INR 2.0 to 3.0), a direct thrombin inhibitor (e.g. dabigatran), factor Xa inhibitor (e.g. rivaroxaban, apixaban), or LMWH is recommended for at least three weeks prior to and four weeks after cardioversion. • Anticoagulation recommendations for cardioversion of atrial flutter are similar to those for atrial fibrillation. • For patients with an identified thrombus, cardioversion should not be performed until a longer period of anticoagulation is achieved (usually at least three weeks) and in accordance with established AF guidelines. <u>Management of anticoagulation for new onset POAF</u> • For the prevention of strokes for patients who develop POAF lasting longer than 48 hours, it is recommended to administer antithrombotic medications similarly to non-surgical patients. Anticoagulation within the first 48-hours of POAF should be considered based on the CHA2DS2-VASc risk score of the patient for stroke weighed against the risk of postoperative bleeding. • New oral anticoagulants (dabigatran, rivaroxaban, apixaban) are reasonable as an alternative to warfarin for patients who do not have a prosthetic heart valve, hemodynamically significant valve disease, and/or severe renal impairment or risk of GI bleeding. • It is reasonable to continue anticoagulation therapy for four weeks after the return of sinus rhythm because of the possibility of slowly resolving impairment of atrial contraction with an associated ongoing risk for thrombus formation and for delayed embolic events. • New oral anticoagulants should be avoided for patients at risk for serious bleeding (including GI bleeding) as they cannot be readily reversed. However, their use may be recommended in situations where achievement of a therapeutic INR with warfarin has proved to be difficult.
The American Heart Association: **Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association (2011)[14]**	<u>Recommendations for initial anticoagulation for acute PE</u> • Therapeutic anticoagulation with SC LMWH, IV or SC UFH with monitoring, unmonitored weight-based SC UFH, or SC fondaparinux should be given to patients with objectively confirmed PE and no contraindications to anticoagulation. • Therapeutic anticoagulation during the diagnostic workup should be given to patients with intermediate or high clinical probability of PE and no contraindications to anticoagulation. Fibrinolysis is not recommended for undifferentiated cardiac arrest. <u>Recommendations for initial anticoagulation for patients with iliofemoral DVT</u> • In the absence of suspected or proven heparin induced thrombocytopenia, patients with iliofemoral DVT should receive therapeutic anticoagulation with IV UFH, SC UFH, a LMWH agent, or fondaparinux. • Patients with iliofemoral DVT who have suspected or proven heparin-induced thrombocytopenia should receive a direct thrombin inhibitor. <u>Recommendations for long-term anticoagulation therapy for patients with iliofemoral DVT</u> • Adult patients with iliofemoral DVT who receive oral warfarin as first-line long-term anticoagulation therapy should have warfarin overlapped with initial anticoagulation therapy for a minimum of five days and until the INR is >2.0 for at least 24 hours, and then targeted to an INR 2.0 to 3.0. • Patients with first episode iliofemoral DVT related to a major reversible risk factor should have anticoagulation stopped after three months. • Patients with recurrent or unprovoked iliofemoral DVT should have at least six months of anticoagulation and be considered for indefinite anticoagulation

Clinical Guideline	Recommendations
	with periodic reassessment of the risks and benefits of continued anticoagulation. • Cancer patients with iliofemoral DVT should receive LMWH monotherapy for at least three to six months, or as long as the cancer or its treatment (e.g., chemotherapy) is ongoing. • In children with DVT, the use of LMWH monotherapy may be reasonable.
American College of Cardiology Foundation/ American Heart Association: **Guideline for the Management of ST-Elevation Myocardial Infarction (2013)**[15]	<u>Antiplatelet therapy to support primary PCI for STEMI</u> • Aspirin 162 to 325 mg should be given before primary PCI. • After PCI, aspirin should be continued indefinitely. • A loading dose of a $P2Y_{12}$ receptor inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI. Options include clopidogrel 600 mg, prasugrel 60 mg or ticagrelor 180 mg. • $P2Y_{12}$ inhibitor therapy should be given for one year to patients with STEMI who receive a stent (bare-metal or drug-eluting) during primary PCI using clopidogrel 75 mg/day, prasugrel 10 mg/day or ticagrelor 90 mg twice daily. • It is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses after primary PCI. • It is reasonable to start treatment with an IV GP IIb/IIIa receptor antagonist such as abciximab, high bolus-dose tirofiban or double-bolus eptifibatide at the time of primary PCI (with or without stenting or clopidogrel pre-treatment) in selected patients with STEMI who are receiving UFH. • It may be reasonable to administer IV GP IIb/IIIa receptor antagonist in the precatheterization laboratory setting (e.g., ambulance, emergency department) to patients with STEMI for whom primary PCI is intended. • It may be reasonable to administer intracoronary abciximab to patients with STEMI undergoing primary PCI. • Continuation of a $P2Y_{12}$ inhibitor beyond one year may be considered in patients undergoing drug-eluting stent placement. • Prasugrel should not be administered to patients with a history of prior stroke or TIA. <u>Anticoagulant therapy to support primary PCI</u> • For patients with STEMI undergoing primary PCI, the following supportive anticoagulant regimens are recommended: UFH, with additional boluses administered as needed to maintain therapeutic activated clotting time levels, taking into account whether a GP IIb/IIIa receptor antagonist has been administered or bivalirudin with or without prior treatment with UFH. • In patients with STEMI undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist. • Fondaparinux should not be used as the sole anticoagulant to support primary PCI because of the risk of catheter thrombosis. <u>Adjunctive antiplatelet therapy with fibrinolysis</u> • Aspirin (162- to 325-mg loading dose) and clopidogrel (300 mg loading dose for ≤75 year of age, 75-mg dose for patients >75 years of age) should be administered to patients with STEMI who receive fibrinolytic therapy. • Aspirin should be continued indefinitely and clopidogrel (75 mg daily) should be continued for at least 14 days and up to one year in patients with STEMI who receive fibrinolytic therapy. • It is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses after fibrinolytic therapy. <u>Adjunctive anticoagulant therapy with fibrinolysis</u> • Patients with STEMI undergoing reperfusion with fibrinolytic therapy should

Clinical Guideline	Recommendations
	receive anticoagulant therapy for a minimum of 48 hours, and preferably for the duration of the hospitalization, up to eight days or until revascularization if performed. • Recommended regimens include UFH administered as a weight-adjusted IV bolus and infusion to obtain an activated partial thromboplastin time of 1.5 to 2.0 times control, for 48 hours or until revascularization; enoxaparin administered according to age, weight, and creatinine clearance, given as an IV bolus, followed in 15 minutes by subcutaneous injection for the duration of the index hospitalization, up to eight days or until revascularization; or fondaparinux administered with initial IV dose, followed in 24 hours by daily subcutaneous injections if the estimated creatinine clearance is greater than 30 mL/min, for the duration of the index hospitalization, up to eight days or until revascularization. <u>Antiplatelet therapy to support PCI after fibrinolytic therapy</u> • After PCI, aspirin should be continued indefinitely. • Clopidogrel should be provided as a 300 mg loading dose given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI within 24 hours of receiving fibrinolytic therapy; a 600 mg loading dose given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI more than 24 hours after receiving fibrinolytic therapy; and a dose of 75 mg daily should be given after PCI. • After PCI, it is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses. • Prasugrel, in a 60 mg loading dose, is reasonable once the coronary anatomy is known in patients who did not receive a previous loading dose of clopidogrel at the time of administration of a fibrinolytic agent, but prasugrel should not be given sooner than 24 hours after administration of a fibrin-specific agent or 48 hours after administration of a non–fibrin-specific agent. • Prasugrel, in a 10 mg daily maintenance dose, is reasonable after PCI. • Prasugrel should not be administered to patients with a history of prior stroke or TIA. <u>Anticoagulant therapy to support PCI after fibrinolytic therapy</u> • For patients with STEMI undergoing PCI after receiving fibrinolytic therapy with IV UFH, additional boluses of IV UFH should be administered as needed to support the procedure, taking into account whether GP IIb/IIIa receptor antagonists have been administered. • For patients with STEMI undergoing PCI after receiving fibrinolytic therapy with enoxaparin, if the last subcutaneous dose was administered within the prior eight hours, no additional enoxaparin should be given; if the last subcutaneous dose was administered between eight and 12 hours earlier, enoxaparin 0.3 mg/kg IV should be given.

American College of Cardiology Foundation/American Heart Association: **2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary**	<u>Early hospital care- standard medical therapies</u>
	• Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia.
	• Anti-ischemic and analgesic medications
	  ○ Nitrates
	  ▪ Patients with NSTE-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin.
	  ▪ Intravenous nitroglycerin is indicated for patients with NSTE-ACS

Clinical Guideline	Recommendations
Syndromes (2014)[16]	for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. o Analgesic therapy ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTE-ACE if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use o Beta-adrenergic blockers ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTE-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. o Calcium channel blockers (CCBs) ▪ In patients with NSTE-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTE-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-clockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTE-ACS in the absence of beta-blocker therapy. o Other anti-ischemic interventions ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTE-ACS patients due to a reduction in recurrent ischemia. o Cholesterol management ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTE-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary

Clinical Guideline	Recommendations
	heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTE-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system o ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. o ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. o Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS treated with an initial invasive or ischemia-guided strategy o Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTE-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. o In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. o A $P2Y_{12}$ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for $P2Y_{12}$ treatment in patients with NSTE-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTE-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatide or tirofiban. <u>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</u> • Antiplatelet agents o Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI o Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. o After PCI, aspirin should be continued indefinitely. o A loading dose of a $P2Y_{12}$ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. o In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. o In patients receiving a stent (bare metal or drug eluting) during PCI, $P2Y_{12}$ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice

Clinical Guideline	Recommendations

	daily.
	• Anticoagulant therapy
	  o An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation.
	  o Intravenous unfractionated heparin (UFH) is useful in patients with NSTE-ACS undergoing PCI.
	  o Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH.
	  o An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTE-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI.
	  o If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time).
	  o Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue.
	• Timing of CABG in relation to use of antiplatelet agents
	  o Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG.
	  o In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery.
	  o In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding.
	  o In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion.
	
	<u>Late hospital care, hospital discharge, and posthospital discharge care</u>
	• Medications at discharge
	  o Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required.
	  o All patients who are post–NSTE-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use.
	  o Before hospital discharge, patients with NSTE-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms.
	  o Before hospital discharge, patients who are post–NSTE-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use.
	  o For patients who are post–NSTE-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services.
	  o If the pattern or severity of angina changes, suggesting worsening

Clinical Guideline	Recommendations
	myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. • Late hospital and post-hospital oral antiplatelet therapy ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a $P2Y_{12}$ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given for at least 12 months. • Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTE-ACS ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor.
European Society of Cardiology: **Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation (2015)**[17]	Pharmacological treatment of ischemia • Early initiation of beta-blocker treatment is recommended in patients with ongoing ischaemic symptoms and without contraindications. • Sublingual or intravenous nitrates are recommended to relieve angina; intravenous treatment is recommended in patients with recurrent angina, uncontrolled hypertension, or signs of heart failure. • In patients with suspected/confirmed vasospastic angina, calcium channel blockers, and nitrates should be considered and beta-blockers avoided. Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes • Aspirin is recommended for all patients without contraindications at an initial oral loading dose of 150 to 300 mg (in aspirin-naïve patients) and a maintenance dose of 75 to 100 mg/day long-term regardless of treatment strategy. • A $P2Y_{12}$ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risks of bleeds. ○ Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindication, for all patients at moderate-to-high risk of ischemic events (e.g., elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). ○ Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no contraindication. ○ Clopidogrel (300 to 600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation. • $P2Y_{12}$ inhibitor administration for a shorter duration of three to six months after DES implantation may be considered in patients deemed at high bleeding

Clinical Guideline	Recommendations
	risk. • It is not recommended to administer prasugrel in patients whom coronary anatomy is not known. • GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications. • Cangrelor may be considered in $P2Y_{12}$ inhibitor-naïve patients undergoing PCI. • It is not recommended to administer GPIIb/IIIa inhibitors in patients whom coronary anatomy is not known. • $P2Y_{12}$ inhibitor administration in addition to aspirin beyond one year may be considered after careful assessment of the ischemic and bleeding risks of the patient. <u>Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes</u> • Parenteral anticoagulation is recommended at the time of diagnosis according to both ischemic and bleeding risks. • Fondaparinux is recommended as having the most favorable efficacy-safety profile regardless of the management strategy. • Bivalirudin is recommended as an alternative to UFH plus GPIIb/IIIa inhibitors during PCI. • UFH is recommended in patients undergoing PCI who did not receive any anticoagulant. • In patients on fondaparinux undergoing PCI, a single intravenous bolus of UFH is recommended during the procedure. • Enoxaparin or UFH are recommended when fondaparinux is not available. • Enoxaparin should be considered as an anticoagulant for PCI in patients pretreated for PCI with subcutaneous enoxaparin. • Additional activated clotting time-guided intravenous boluses of UFH during PCI may be considered following initial UFH treatment. • Discontinuation of anticoagulation should be considered after PCI, unless otherwise indicated. • Crossover between UFH and LMWH is not recommended. • In NSTEMI patients with no prior stroke/TIA and at high ischemic risk as well as low bleeding risk receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily for approximately one year) may be considered after discontinuation of parenteral anticoagulation. <u>Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation</u> • In patients with a firm indication for oral anticoagulation (e.g., atrial fibrillation with a CHADS2-VASc score ≥2, recent VTE, mechanical valve prosthesis), oral anticoagulation is recommended in addition to antiplatelet therapy. • An early invasive coronary angiography (within 24 hours) should be considered in moderate- to high-risk patients, irrespective of oral anticoagulant exposure, to expedite treatment allocation (medical vs PCI vs CABG) and to determine optimal antithrombotic regimen. • Initial dual antiplatelet therapy with aspirin plus a $P2Y_{12}$ inhibitor in addition to oral anticoagulation before coronary angiography is not recommended. • During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all non-vitamin K antagonist oral anticoagulants (NOACs) and if INR is <2.5 in VKA-treated patients. • Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase.

Clinical Guideline	Recommendations
	• Following coronary stenting, dual (oral) antiplatelet therapy (DAPT) including new $P2Y_{12}$ inhibitors should be considered as an alternative to triple therapy for patients with non-ST-elevation acute coronary syndromes and atrial fibrillation with a CHADS2-VASc score of 1 (in males) or 2 (in females). • If at low bleeding risk (HAS-BLED ≤2), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for six months, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months. • If at high bleeding risk (HAS-BLED ≥3), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for one month, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months irrespective of the stent type. • Dual therapy with oral anticoagulant and clopidogrel may be considered as an alternative to triple antithrombotic therapy in selected patients (HAS-BLED ≥3 and low risk of stent thrombosis). • The use of ticagrelor or prasugrel as part of triple therapy is not recommended. • In medically managed patients, one antiplatelet agent in addition to oral anticoagulant should be considered for up to one year.
American College of Cardiology/ American Heart Association: **2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007)**[18]	• Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients unless contraindicated. • The use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely.
The American College of Cardiology/ American Heart Association: **Practice Guidelines for the Management of Patients with Peripheral Artery Disease (2013)**[19]	Exercise and lower extremity peripheral artery disease (PAD) rehabilitation • A program of supervised exercise training is recommended as an initial treatment modality for patients with intermittent claudication. • Supervised exercise training should be performed for a minimum of 30 to 45 minutes, in sessions performed at least three times/week for a minimum of 12 weeks. • The usefulness of unsupervised exercise programs is not well established as an effective initial treatment modality for patients with intermittent claudication. Smoking cessation • Patients who are smokers or former smokers should be asked about status of tobacco use at every visit. Patients with lower extremity PAD who use tobacco should be advised to stop smoking. • Patients should be provided with counseling and assistance with developing a plan for smoking cessation. • One or more of the following pharmacological therapies should be offered if not contraindicated: varenicline, bupropion and nicotine replacement therapy. Antiplatelet and antithrombotic drugs • Antiplatelet therapy is indicated to reduce the risk of MI, stroke and vascular death in patients with symptomatic atherosclerotic lower extremity PAD and in asymptomatic patients with ankle brachial index ≤0.90. The usefulness of antiplatelet therapy is not well established in asymptomatic patients with ankle brachial index between 0.91 and 0.99. • Aspirin (75 to 325 mg/day) is recommended to reduce the risk of cardiovascular events. Clopidogrel (75 mg/day) is recommended as an alternative to aspirin. • Combination of aspirin and clopidogrel may be considered to reduce the risk of

Clinical Guideline	Recommendations
	cardiovascular events in patients with symptomatic atherosclerotic lower extremity PAD who are at high cardiovascular risk and not at increased risk of bleeding. • The addition of warfarin to antiplatelet therapy is of no proven benefit and is potentially harmful due to increased risk of major bleeding. Medical and pharmacological treatment for claudication • Cilostazol (100 mg orally twice daily) is indicated as an effective therapy to improve symptoms and increase walking distance in patients with lower extremity PAD and intermittent claudication (in the absence of heart failure). • A therapeutic trial of cilostazol should be considered in all patients with lifestyle-limiting claudication (in the absence of heart failure). • Pentoxifylline (400 mg three times daily) may be considered as second-line alternative therapy to cilostazol to improve walking distance in patients with intermittent claudication. • The clinical effectiveness of pentoxifylline as therapy for intermittent claudication is marginal and not well established. • The effectiveness of L-arginine for patients with intermittent claudication is not well established. • The effectiveness of propionyl L-carnitine as a therapy to improve walking distance in patients with intermittent claudication is not well established. • The effectiveness of ginkgo biloba as a therapy to improve walking distance in patients with intermittent claudication is not well established. • Oral vasodilator prostaglandins such as beraprost* and iloprost are not effective medications to improve walking distance in patients with intermittent claudication. • Vitamin E is not recommended as a treatment for patients with intermittent claudication. • Chelation (e.g. ethylenediaminetetraacetic acid) is not indicated for treatment of intermittent claudication and may have harmful adverse effects.

American Heart Association/American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (2014)**[20]	Recommendations for Nonvalvular Atrial Fibrillation:
	• For patients who have experienced an acute ischemic stroke or TIA with no other apparent cause, prolonged rhythm monitoring (~30 days) for AF is reasonable within six months of the index event (Level of Evidence: C).
	• VKA therapy (Level of Evidence: A), apixaban, dabigatran and rivaroxaban (Level of Evidence: B) are all indicated for the prevention of recurrent stroke in patients with nonvalvular AF, whether paroxysmal or permanent.
	  ○ Selection of agent should be individualized based on risk factors, cost, tolerability, patient preference, drug interactions and other characteristics including renal function and time in INR therapeutic range if the patient has been taking VKA therapy.
	• Target INR for patients with ischemic stroke or TIA with paroxysmal (intermittent), persistent or permanent AF on VKA therapy is 2.5 (range 2.0 to 3.0) (Level of Evidence: A).
	• Combination oral anticoagulation (warfarin or a newer agent) with antiplatelet therapy is not recommended for all patients after ischemic stroke or TIA.
	  ○ Combination therapy is reasonable in patients with clinically apparent coronary artery disease particularly an acute coronary syndrome or stent placement (Level of Evidence: C).
	• For patients with ischemic stroke or TIA and AF who unable to take oral anticoagulants, aspirin alone is recommended (Level of Evidence: A).
	  ○ Adding clopidogrel to aspirin therapy, compared with aspirin therapy alone, might be reasonable (Level of Evidence: B).
	• For most patients with a stroke or TIA in the setting of AF, it is reasonable to initiate oral anticoagulation within 14 days after the onset of neurological

Clinical Guideline	Recommendations
	symptoms (Level of Evidence: B). • In the presence of high risk for hemorrhagic conversion, it is reasonable to delay initiation of oral anticoagulation beyond 14 days (Level of Evidence: B). • For patients with AF and a history of stroke or TIA who require temporary interruption of oral anticoagulation, bridging therapy with an LMWH (or equivalent) is reasonable, depending on perceived risk for thromboembolism and bleeding (Level of Evidence: C). • The usefulness of closure of the left atrial appendage with the WATCHMAN device in patients with ischemic stroke or TIA and AF is uncertain (Level of Evidence: B). <u>Recommendations for Acute MI and LV Thrombus:</u> • Treatment with VKA therapy (target INR, 2.5; range, 2.0 to 3.0) for three months is recommended in most patients with ischemic stroke or TIA in this setting (Level of Evidence: C). o Additional antiplatelet therapy for cardiac protection may be guided by recommendations such as those from the American College of Chest Physicians. • Treatment with VKA therapy (target INR, 2.5; range, 2.0 to 3.0) for three months may be considered in patients with ischemic stroke or TIA in the setting of acute anterior STEMI without demonstrable LV mural thrombus formation but with anterior apical akinesis or dyskinesis identified by echocardiography or other imaging (Level of Evidence: C). • In patients with ischemic stroke or TIA in the setting of acute MI complicated by LV mural thrombus formation or anterior or apical wall-motion abnormalities with an LV ejection fraction <40% who are intolerant to VKA therapy because of nonhemorrhagic adverse events, treatment with an LMWH, dabigatran, rivaroxaban, or apixaban for three months may be considered as an alternative to VKA therapy for prevention of recurrent stroke or TIA (Level of Evidence: C). <u>Recommendations for Cardiomyopathy:</u> • In patients with ischemic stroke or TIA in sinus rhythm who have left atrial or LV thrombus, anticoagulant therapy with a VKA is recommended for ≥3 months (Level of Evidence: C). • In patients with ischemic stroke or TIA in the setting of a mechanical LVAD, treatment with VKA therapy (target INR, 2.5; range, 2.0 to 3.0) is reasonable in the absence of major contraindications (Level of Evidence: C). • In patients with ischemic stroke or TIA in sinus rhythm with either dilated cardiomyopathy (LV ejection fraction ≤35%) or restrictive cardiomyopathy without evidence of left atrial or LV thrombus, the effectiveness of anticoagulation compared with antiplatelet therapy is uncertain, and the choice should be individualized (Level of Evidence: B). • In patients with ischemic stroke or TIA in sinus rhythm with dilated cardiomyopathy (LV ejection fraction ≤35%), restrictive cardiomyopathy, or a mechanical LVAD who are intolerant to VKA therapy because of nonhemorrhagic adverse events, the effectiveness of treatment with dabigatran, rivaroxaban, or apixaban is uncertain compared with VKA therapy for prevention of recurrent stroke (Level of Evidence: C). <u>Recommendations for Mitral Stenosis, Mitral Regurgitation, Mitral Prolapse, Mitral Annular Calcification, and Aortic Valve Disease</u>: • For patients with ischemic stroke or TIA who have rheumatic mitral valve disease and AF, long-term VKA therapy with INR target of 2.5 (range, 2.0 to 3.0) is recommended (Level of Evidence: A).

Clinical Guideline	Recommendations
	• For patients with ischemic stroke or TIA who have rheumatic mitral valve disease without AF or another likely cause for their symptoms (e.g., carotid stenosis), long-term VKA therapy with an INR target of 2.5 (range, 2.0 to 3.0) may be considered instead of antiplatelet therapy (Level of Evidence: C). • For patients with rheumatic mitral valve disease who are prescribed VKA therapy after an ischemic stroke or TIA, antiplatelet therapy should not be routinely added (Level of Evidence: C). • For patients with rheumatic mitral valve disease who have an ischemic stroke or TIA while being treated with adequate VKA therapy, the addition of aspirin might be considered (Level of Evidence: C). • For patients with ischemic stroke or TIA and native aortic or nonrheumatic mitral valve disease who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended (Level of Evidence: C). • For patients with ischemic stroke or TIA and mitral annular calcification who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended as it would be without the mitral annular calcification (Level of Evidence: C). • For patients with mitral valve prolapse who have ischemic stroke or TIAs and who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended as it would be without mitral valve prolapse (Level of Evidence: C). <u>Recommendations for Prosthetic Heart Valves:</u> • For patients with a mechanical aortic valve and a history of ischemic stroke or TIA before its insertion, VKA therapy is recommended with an INR target of 2.5 (range, 2.0 to 3.0) (Level of Evidence: B). • For patients with a mechanical mitral valve and a history of ischemic stroke or TIA before its insertion, VKA therapy is recommended with an INR target of 3.0 (range, 2.5 to 3.5) (Level of Evidence: B). • For patients with a mechanical aortic or mitral valve and a history of ischemic stroke or TIA before its insertion and who are at low risk for bleeding, the addition of aspirin 75 to 100 mg/day to VKA therapy is recommended (Level of Evidence: B). • For patients with a mechanical heart valve who have an ischemic stroke or systemic embolism despite adequate antithrombotic therapy, it is reasonable to intensify therapy by increasing the dose of aspirin to 325 mg/day or increasing the target INR, depending on bleeding risk (Level of Evidence: C). • For patients with a bioprosthetic aortic or mitral valve and a history of ischemic stroke or TIA before its insertion and no other indication for anticoagulation therapy beyond three to six months form the valve placement, long-term therapy with aspirin 75 to 100 mg/day is recommended in preference to long-term anticoagulation (Level of Evidence: C). • For patients with a bioprosthetic aortic or mitral valve who have a TIA, ischemic stroke, or systemic embolism despite antiplatelet therapy, the addition of VKA therapy with an INR target of 2.5 (range, 2.0 to 3.0) may be considered (Level of Evidence: C). <u>Recommendations for Noncardioembolic Stroke or TIA</u>: • For patients with noncardioembolic ischemic stroke or TIA, the use of antiplatelet agents rather than oral anticoagulation is recommended to reduce the risk of recurrent stroke and other cardiovascular events (Level of Evidence: A). • Aspirin (50 to 325 mg/day) monotherapy (Level of Evidence: A) or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg twice daily (Level of Evidence: B) is indicated as initial therapy after TIA or

Clinical Guideline	Recommendations
	ischemic stroke for prevention of future stroke. • Clopidogrel (75 mg) monotherapy is a reasonable option for secondary prevention of stroke in place of aspirin or combination aspirin/dipyridamole (Level of Evidence: B). This recommendation also applies to patients who are allergic to aspirin. • The selection of an antiplatelet agent should be individualized on the basis of patient risk facto profiles, cost, tolerance, relative known efficacy of the agents, and other clinical characteristics (Level of Evidence: C). • The combination of aspirin and clopidogrel might be considered for initiation within 24 hours of a minor ischemic stork or TIA and for continuation for 90 days (Level of Evidence: B). • The combination of aspirin and clopidogrel, when initiated days to years after a minor stroke or TIA and continued for two to three years, increases the risk of hemorrhage relative to either agent alone and is not recommended for routine long-term secondary prevention after ischemic stroke or TIA (Level of Evidence: A). • For patients who have an ischemic stroke or TIA while taking aspirin, there is no evidence that increasing the dose of aspirin provides additional benefit. Although alternative antiplatelet agents are often considered, no single agent or combination has been adequately studied in patients who have had an event while receiving aspirin (Level of Evidence: C). • For patients with a history of ischemic stroke or TIA, AF and coronary artery disease, the usefulness of adding antiplatelet therapy to VKA therapy is uncertain for purposes of reducing the risk of ischemic cardiovascular and cerebrovascular events (Level of Evidence: C). Unstable angina and coronary artery stenting represent special circumstances in which management may warrant dual antiplatelet or VKA therapy. • For patients with noncardioembolic ischemic stroke or TIA, the use of antiplatelet agents rather than oral anticoagulation is recommended to reduce the risk of recurrent stroke and other cardiovascular events (Level of Evidence: A).

National Institute for Health and Clinical Excellence: **Myocardial Infarction: cardiac rehabilitation and prevention of further cardiovascular disease (2013)**[21]	Drug therapy
	• Offer all people who have had an acute MI treatment with the following drugs:
	  ○ ACE inhibitor
	  ○ Dual antiplatelet therapy (aspirin plus a second antiplatelet agent)
	  ○ Beta-blocker
	  ○ Statin
	
	Antiplatelet therapy
	• Offer aspirin to all people after an MI and continue indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation.
	• Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely.
	• For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment.
	• Special considerations should be made for people with dyspepsia.
	• After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for Helicobacter pylori should be considered for treatment in line with dyspepsia.
	• Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI).
	• Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent.
	• Offer clopidogrel as a treatment option for at least one month and consider

Clinical Guideline	Recommendations
	continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and stopped dual antiplatelet therapy or had an MI more than 12 months ago). <u>Antiplatelet therapy in people with an indication for anticoagulation</u> • Take bleeding risk, thromboembolic risk, and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes. • Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. • Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban, or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the oral anticoagulants are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Oral Anticoagulants[1-5]

Indication	Apixaban	Dabigatran	Edoxaban§	Rivaroxaban	Warfarin
Prophylaxis and treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement					✔
Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism					✔
Prophylaxis of deep vein thrombosis and pulmonary embolism in patients		✔			

Indication	Apixaban	Dabigatran	Edoxaban§	Rivaroxaban	Warfarin
who have undergone hip replacement surgery					
Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery	✔			✔	
Reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction					✔
Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation	✔	✔	✔	✔ *	
Treatment of deep vein thrombosis and pulmonary embolism	✔	✔ †	✔ †	✔	
Reduce the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial therapy	✔	✔		✔ ‡	

*There is limited data on the relative effectiveness of rivaroxaban and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
†Indicated for treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for five to 10 days.
‡Indicated to reduce the risk of recurrent DVT or PE following initial six months of treatment for DVT/PE.
§ Edoxaban should not be used in patients with CrCl >95 mL/min because of an increased risk of ischemic stroke compared to warfarin.

IV. Pharmacokinetics

The pharmacokinetic parameters of the oral anticoagulants are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Oral Anticoagulants[1-5,8]

Generic Name	Bioavailability (%)	Renal Excretion (%)	Active Metabolites	Half-Life (hours)
Apixaban	50	27	None	6.8 to 12
Dabigatran	3 to 7	80*	Dabigatran (major); 1-, 2-, 3-, 4-O-acylglucuronide (all minor)	12 to 17
Edoxaban	62	50	M-4 (<10% exposure of edoxaban)	10 to 14
Rivaroxaban	66 to 100, dose-dependent	66	None	5 to 11.7
Warfarin	~100	92	Warfarin alcohols	168

*Intravenous administration.

V. Drug Interactions

Major drug interactions with the oral anticoagulants are listed in Table 5.

Table 5. Major Drug Interactions with the Oral Anticoagulants[8]

Generic Name(s)	Interaction	Mechanism
Anticoagulants (Apixaban, Dabigatran, Edoxaban, Rivaroxaban, Warfarin)	NSAIDs	The risk of bleeding may be increased. Increased anticoagulant activity and risk of bleeding gastric irritation and decreased platelet function contribute.

Generic Name(s)	Interaction	Mechanism
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	Azole antifungals	Effect of anticoagulant may be increased.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	Macrolide antibiotics	The anticoagulant effect of oral anticoagulants may be increased. Inhibition of metabolism (CYP3A4) and P-gp by certain macrolide and related antibiotics may increase exposure.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Edoxaban, Warfarin)	Rifamycins	Increased elimination of anticoagulants due to induction of metabolism (CYP3A4) and P-gp transport by rifamycins.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	St. John's Wort	Increased elimination of anticoagulants due to induction of metabolism (CYP3A4) and P-gp transport by St. John's Wort.
Anticoagulants (Apixaban, Dabigatran, Edoxaban, Rivaroxaban, Warfarin)	Antiplatelet agents	Concurrent use may result in increased risk of bleeding.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	Fibric acids	Concurrent use of fenofibrate and anticoagulants may result in enhanced anticoagulant effect.
Anticoagulants (Apixaban, Dabigatran, Edoxaban, Rivaroxaban, Warfarin)	Serotonin reuptake inhibitors	Concurrent use may result in an increased risk of bleeding.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	Nintedanib	Concurrent use of nintedanib and anticoagulants may result in increased risk of bleeding.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban)	Hydantoins	Increased elimination of apixaban due to induction of metabolism (CYP3A4) and P-gp transport by certain hydantoins.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	Protease Inhibitors	Inhibition of metabolism (CYP3A4) and P-gp by certain protease inhibitors increases apixaban exposure.
Anticoagulants (Apixaban, Dabigatran, Rivaroxaban, Warfarin)	Carbamazepine	Increased elimination of apixaban due to induction of metabolism (CYP3A4) and P-gp transport by carbamazepine.

Generic Name(s)	Interaction	Mechanism
Warfarin	Androgens (17-alkyl)	The hypoprothrombinemic effect of oral anticoagulants is potentiated by 17-alkyl androgens.
Warfarin	Antineoplastic Agents (Capecitabine, carboplatin, cisplatin, cyclophosphamide, etoposide, fluorouracil, gemcitabine, paclitaxel)	The anticoagulant effect of warfarin may be increased due to possible protein displacement, inhibition of warfarin metabolism, or inhibition of clotting-factor synthesis.
Warfarin	Barbiturates	Barbiturates reduce the effects of anticoagulants due to increased metabolic clearance of anticoagulants, likely caused by induction of hepatic microsomal enzymes.
Warfarin	Cephalosporins	The anticoagulant effect of warfarin is increased.
Warfarin	Quinine derivatives	Quinine derivatives may inhibit the hepatically synthesized clotting factors. Anticoagulation may be potentiated.
Warfarin	Quinolones	Increased anticoagulant effect of warfarin.
Warfarin	Sulfonamides	The anticoagulant effect of warfarin may be enhanced.
Warfarin	Tetracyclines	The action of warfarin may be increased.
Warfarin	Thioamines (Methimazole, Propylthiouracil)	The action of oral anticoagulants may be changed during coadministration of thioamines.
Warfarin	Alteplase	Risk of serious bleeding may be increased due to additive or synergistic effects.
Warfarin	Amiodarone	Amiodarone inhibits the metabolism (CYP1A2, CYP2C9) of the R- and S-enantiomers of warfarin. Hypoprothrombinemic effect of oral anticoagulants is augmented by concomitant amiodarone therapy.
Warfarin	Cimetidine	Stereoselective inhibition of the hepatic metabolism of the less potent (R)-warfarin enantiomer increase in warfarin effects; possible hemorrhage.
Warfarin	Dextrothyroxine	Dextrothyroxine increases the hypoprothrombinemic effect of oral anticoagulants.
Warfarin	Metronidazole	Liver metabolism of the S- enantiomorph of racemic warfarin may be decreased by metronidazole.
Warfarin	Tamoxifen	The hypoprothrombinemic effect of oral anticoagulants may be increased, possibly with bleeding.
Warfarin	Vitamin E	Vitamin E may interfere with vitamin K–dependent clotting factors, thereby adding to the effects of oral anticoagulants.
Warfarin	Corticosteroids	Corticosteroids may reduce anticoagulant dose requirements and occasionally induce hypercoagulation that could oppose anticoagulant action.
Warfarin	HMG-CoA Reductase Inhibitors (fluvastatin, lovastatin, rosuvastatin, simvastatin)	The anticoagulant effect of warfarin may increase. Decreased S- and R-warfarin clearance by inhibition of CYP2C9 and CYP3A4 metabolism, respectively.
Warfarin	Hydantoins	Increased hydantoin serum concentrations with possible toxicity. Increased PT and an increased risk of bleeding may occur.
Warfarin	Penicillins	Large IV doses of penicillins can increase the bleeding risks of anticoagulants by prolonging bleeding time. Conversely, nafcillin and dicloxacillin have been associated with warfarin resistance, which may persist for three weeks or more following discontinuation of the antibiotic.

Generic Name(s)	Interaction	Mechanism
Warfarin	Thiopurines (Azathioprine, Mercaptopurine)	Thiopurines have been reported to increase the synthesis or activation of prothrombin, as well as reduce plasma warfarin concentrations.
Warfarin	Acetaminophen	Acetaminophen (APAP) appears to increase the antithrombotic effect of oral anticoagulants in a dose-dependent manner. The interaction may not be clinically important with low-dose, infrequent use of APAP.
Warfarin	Aminoglutethimide	Increased warfarin metabolic clearance, probably because of liver microsomal enzyme induction. Warfarin's action to decrease prothrombin levels may be reduced.
Warfarin	Argatroban	Both warfarin and argatroban increase the INR, increasing the risk of bleeding.
Warfarin	Bosentan	The effects of warfarin may be decreased. Induction of warfarin metabolism (CYP2C9 and CYP3A4) by bosentan is suspected.
Warfarin	Chloramphenicol	Anticoagulation action of oral anticoagulants may be enhanced by chloramphenicol due to possible inhibition of hepatic metabolism of oral anticoagulants.
Warfarin	Cholestyramine	The anticoagulant effect of oral anticoagulants may be decreased by cholestyramine due to reduced oral anticoagulant absorption and possibly increased elimination.
Warfarin	Clopidogrel	The risk of nonfatal and fatal bleeding may be increased with combined therapy.
Warfarin	Disulfiram	Disulfiram may increase the anticoagulant effects of warfarin.
Warfarin	Dronedarone	The anticoagulant effect of warfarin is increased.
Warfarin	Gefitinib	The anticoagulant effect of warfarin may be potentiated, increasing the risk of bleeding.
Warfarin	Glucagon	The anticoagulant effect of warfarin may be enhanced in patients receiving sustained doses of glucagon (bleeding may occur).
Warfarin	Glutethimide	Glutethimide appears to increase the clearance of coumarin anticoagulants by stimulation of hepatic microsomal enzymes.
Warfarin	Griseofulvin	The anticoagulant activity of warfarin may be decreased.
Warfarin	Nevirapine	Induction of warfarin metabolism (CYP2C9) by nevirapine is suspected.
Warfarin	Tramadol	The effect of the oral anticoagulant may be increased.
Warfarin	Trazodone	The hypoprothrombinemic effect of warfarin may be decreased. Suboptimal anticoagulation with possible exacerbation of the disease being treated may occur.
Warfarin	Vitamin K	Vitamin K may inhibit the effect of warfarin on vitamin K–dependent clotting factors.

VI. Adverse Drug Events

The most common adverse drug events reported with the oral anticoagulants are listed in Table 6. The boxed warning for apixaban, dabigatran, and rivaroxaban is included in Table 7, edoxaban in Table 8, and warfarin in Table 9.

Table 6. Adverse Drug Events (%) Reported with the Oral Anticoagulants[7]

Adverse Event	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	Warfarin
Abdominal pain	-	✔	-	2	✔
Alopecia	-	-	-	-	✔

Adverse Event	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	Warfarin
Anemia	3	1 to 4	2	-	-
Back pain	-	-	-	4	-
Bloating	-	-	-	-	✔
Bruising	1 to 2	-	-	-	-
Chills	-	-	-	-	✔
Cholestatic hepatitis	-	-	-	-	✔
Cholesterol microemboli	-	-	-	-	✔
Confusion		-	-	-	-
Dermatitis	-	-	-	-	✔
Diarrhea	-	-	-	-	✔
Dyspepsia	-	8	-	1	-
Elevated liver enzymes	≤1	2 to 3	-	-	✔
Epistaxis	≤4	-	5	-	-
Fatigue	-	-	-	1	-
Flatulence	-	-	-	-	✔
Gastrointestinal symptoms	-	25 to 40	-	-	-
GERD	-	✔	-	✔	-
Hematuria	≤2	-	≤2	-	-
Hemoptysis	≤1	-	-	-	-
Hemorrhage	1 to 12	11 to 19	22	✔	✔
Hepatic function abnormal	-	-	5 to 8	-	-
Hepatitis	-	-	-	-	✔
Hypermenorrhea	1	-	-	-	-
Hypersensitivity/allergic reactions	✔	✔	-	✔	✔
Hypotension	✔	-	-	-	-
Increased Gamma-Glutamyl Transferase	≤1	-	-	-	-
Increased serum transaminases	≤1	-	-	2	-
Infection, sinusitis or urinary tract infection	-	-	-	✔	-
Myocardial infarction, fatal and non-fatal	-	✔	-	-	-
Nausea	3	-	-	1 to 3	✔
Necrosis of the skin	-	-	-	-	✔
Oropharyngeal pain	-	-	-	1	-
Osteoarthritis	-	-	-	2	-
Pruritus	-	-	-	2	✔
Rash	✔	-	4	-	✔
Syncope	-	-	-	1	-
Systemic atheroemboli	-	-	-	-	✔
Taste perversion	-	-	-	-	✔
Toothache	-	-	-	1	-
Tracheal or tracheobronchial calcification	-	-	-	-	✔
Ulcer, gastrointestinal	-	✔	-	-	-
Vomiting	-	-	-	-	✔

✔ Percent not specified.
- Event not reported.

Table 7. Boxed Warning for Apixaban, Rivaroxaban, and Dabigatran[1,2,4]

WARNING
(A) Premature discontinuation of any oral anticoagulant, including Pradaxa, Xarelto, and Eliquis increases the

risk of thrombotic events. If anticoagulation is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.

(B) Epidural or spinal hematomas may occur in patients treated with oral anticoagulants who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

-Use of indwelling epidural catheters
-Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
-History of traumatic or repeated epidural or spinal punctures
-History of spinal deformity or spinal surgery
-Optimal timing between the administration of oral anticoagulants and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

Table 8. Boxed Warning for Edoxaban[3]

WARNING

WARNING: REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) >95 ML/MIN; PREMATURE DISCONTINUATION OF EDOXABAN INCREASES THE RISK OF ISCHEMIC EVENTS; SPINAL/EPIDURAL HEMATOMA
 	
Reduced efficacy in nonvalvular atrial fibrillation patients with CrCl >95 ml/min
• Edoxaban should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with edoxaban 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used.
 	
Premature discontinuation of edoxaban increases the risk of ischemic events
• Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance.
 	
Spinal/epidural hematoma
• Epidural or spinal hematomas may occur in patients treated with edoxaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
  ○ use of indwelling epidural catheters
  ○ concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
  ○ a history of traumatic or repeated epidural or spinal punctures
  ○ a history of spinal deformity or spinal surgery
  ○ optimal timing between the administration of edoxaban and neuraxial procedures is not known
• Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
• Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.

Table 9. Boxed Warning for Warfarin[5]

WARNING
Bleeding risk: Warfarin can cause major or fatal bleeding. Perform regular monitoring of international normalized ratio (INR) on all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin therapy. Instruct patients about prevention measures to minimize the risk of bleeding and to report immediately to their health care provider signs and symptoms of bleeding.

VII. Dosing and Administration

The usual dosing regimens for the oral anticoagulants are listed in Table 10.

Table 10. Usual Dosing Regimens for the Oral Anticoagulants[1-5,7,8]

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
Apixaban	Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Tablet: 5 mg BID; 2.5 mg BID in patients with at least two of the following characteristics- age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery: Tablet: 2.5 mg BID for 12 days (knee) or 35 days (hip) Treatment of deep vein thrombosis and pulmonary embolism: Tablet: 10 mg BID for 7 days, followed by 5 mg BID Reduce the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial therapy[‡]: Tablet: 2.5 mg BID	Safety and efficacy in children have not been established.	Tablet: 2.5 mg 5 mg
Dabigatran	Prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have undergone hip replacement surgery: Capsule: 110 mg taken one to four hours post-surgery, then 220 mg QD for 28 to 35 days Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Capsule: 150 mg BID Treatment of deep vein thrombosis and pulmonary embolism[†]: Capsule: 150 mg BID Reduce the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial therapy: Capsule: 150 mg BID	Safety and efficacy in children have not been established.	Capsule: 75 mg 110 mg 150 mg
Edoxaban	Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation:	Safety and efficacy have not been	Tablet: 15 mg

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
	Tablet: 60 mg QD Treatment of deep vein thrombosis and pulmonary embolism†: Tablet: 60 mg QD	established in pediatric patients.	30 mg 60 mg
Rivaroxaban	Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery: Tablet: 10 mg QD for 12 days (knee) or 35 days (hip) Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation*: Tablet: 20 mg QD Treatment of deep vein thrombosis and pulmonary embolism: Tablet: initial, 15 mg BID for the first 21 days; maintenance, 20 mg QD Reduce the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial therapy‡: Tablet: 20 mg QD	Safety and efficacy in children have not been established.	Tablet: 10 mg 15 mg 20 mg Starter Pack: 42 tablets of 15 mg and 9 tablets of 20 mg
Warfarin	Prophylaxis and treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement: Tablet: initial, 2 to 5 mg QD; maintenance, 2 to 10 mg QD; maintain an INR of 2.0 to 3.0 Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism: Tablet: initial, 2 to 5 mg QD; maintenance, 2 to 10 mg QD; treat for six to 12 months or indefinitely Reduce the risk of death, recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction: Tablet: initial, 2 to 5 mg QD; maintenance, 2 to 10 mg QD; maintain an INR of 3.0 to 4.0 (high intensity) or of 2.0 to 3.0 (moderate intensity)	Safety and efficacy in children have not been established.	Tablet: 1 mg 2 mg 2.5 mg 3 mg 4 mg 5 mg 6 mg 7.5 mg 10 mg

BID=twice-daily, INR=International Normalized Ratio, QD=once-daily
*There is limited data on the relative effectiveness of rivaroxaban and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
†Indicated for treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for five to 10 days.
‡Indicated to reduce the risk of recurrent DVT or PE following initial six months of treatment for DVT/PE.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the oral anticoagulants are summarized in Table 11.

Table 11. Comparative Clinical Trials with the Oral Anticoagulants

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Reducing the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation				
Connolly et al.[22] (2011) AVERROES Apixaban 5 mg BID vs aspirin 81 to 324 mg QD An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	AC, DB, MC, PG, RCT Patients ≥50 years of age with AF for at least six months before enrollment or documented by 12-lead ECG on the day of screening and at least one of the following risk factors: prior stroke or TIA, age ≥75, arterial hypertension, diabetes mellitus, heart failure (NYHA Class ≥2), a LVEF ≤35%, or peripheral artery disease Patients could not be receiving VKA therapy because it had already been unsuitable for them or was expected to be unsuitable.	N=5,599 1.1 years	Primary: Incidence of stroke (ischemic or hemorrhagic) or systemic embolism and major bleeding Secondary: Rates of MI, death from vascular causes, death from any cause and composite of major vascular events	Primary: The incidence of stroke or systemic embolism was significantly lower in patients randomized to receive treatment with apixaban compared to treatment with aspirin (1.6 vs 3.7% per year; HR, 0.45; 95% CI, 0.32 to 0.62; P<0.001). The incidence of ischemic stroke was significantly lower in the apixaban treatment group (1.1 vs 3.0% per year; HR, 0.37; 95% CI, 0.25 to 0.55; P<0.001); however, there was no difference between the groups with regard to hemorrhagic stroke (0.2 vs 0.3% per year, respectively; HR, 0.67; 95% CI, 0.24 to 1.88; P=0.45). There was no statistically significant difference in the incidence of major bleeding in the apixaban treatment group compared to the aspirin treatment group (1.4 vs 1.2% per year, respectively; HR, 1.13; 95% CI, 0.74 to 1.75; P=0.57). The incidences of intracranial bleeding (0.4 vs 0.4% per year; P=0.69), extracranial bleeding (1.1 vs 0.9% per year; P=0.42), gastrointestinal bleeding (0.4 vs 0.4% per year; P=0.71), nongastrointestinal bleeding (0.6 vs 0.4% per year; P=0.22) and fatal bleeding (0.1 vs 0.2% per year; P=0.53) were not significantly different between the apixaban and aspirin treatment groups. Secondary: The incidence of MI was similar between the apixaban and aspirin treatment groups (0.8 vs 0.9% per year, respectively; HR, 0.86; 95% CI, 0.50 to 1.48; P=0.59). The incidence of death from vascular causes (2.7 vs 3.1% per year, respectively; HR, 0.87; 95% CI, 0.65 to 1.17; P=0.37) or death from any cause (3.5 vs 4.4% per year; HR, 0.79; 95% CI, 0.62 to 1.02; P=0.07) was not significantly different between patients receiving apixaban or aspirin. The composite rate of stroke, systemic embolism, MI, death from vascular

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				causes or major bleeding was significantly lower in the apixaban group compared to the aspirin group (ITT, 5.3 vs 7.2% per year; HR, 0.74; 95% CI, 0.60 to 0.90; P=0.003; on-treatment analysis, 4.0 vs 6.3% per year; HR, 0.64; 95% CI, 0.51 to 0.80; P<0.001). Treatment with apixaban significantly reduced the incidence of hospitalization for cardiovascular causes compared to treatment with aspirin (12.6 vs 15.9% per year; HR, 0.79; 95% CI, 0.69 to 0.91; P<0.001). The rate of clinically relevant nonmajor bleeding (3.1 vs 2.7% per year; HR, 1.15; 95% CI, 0.86 to 1.54; P=0.35) and minor bleeding (6.3 vs 5.0% per year; HR, 1.24; 95% CI, 1.00 to 1.53; P=0.50) was similar between the apixaban and aspirin treatment groups.
Diener et al.[23] (2012) AVERROES Apixaban 5 mg BID vs aspirin 81 to 324 mg QD An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	Subanalysis of AVERROES[18] Patients enrolled in the AVERROES trial stratified based on previous stroke and TIA	N=5,599 1.1 years	Primary: Incidence of stroke (ischemic or hemorrhagic) or systemic embolism and major bleeding Secondary: Rates of MI, death from vascular causes, death from any cause and composites of major vascular events	Primary: The incidence of stroke or systemic embolism was significantly lower in patients with no previous stroke or TIA compared to patients with a history of stroke or TIA (2.36 vs 5.73% per year; HR, 2.38; 95% CI, 1.66 to 3.34; P<0.0001). There was a significantly lower incidence of stroke or systemic embolism with apixaban treatment compared to aspirin treatment in those without previous stroke or TIA (HR, 0.51; 95% CI, 0.35 to 0.74) and in those with a previous stroke or TIA (HR; 0.29; 95% CI, 0.15 to 0.60); however, the difference between the groups was not statistically significant (P=0.17). The incidence of major bleeding was not significantly different between the apixaban and aspirin treatment groups, regardless of previous stroke or TIA history (P=0.73). Secondary: There was no significant difference between apixaban and aspirin treatment with regard to the incidence of MI. Moreover, the difference in MI between patients with a history of stroke or TIA and those without a history of stroke or TIA was not statistically significant (P=0.33). There was no significant difference between the apixaban and aspirin treatment groups in the incidence of death from vascular causes, regardless of previous

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				stroke history (P=0.79). There was no statistically significant difference between the apixaban and aspirin treatment groups with regard to the incidence of stroke (P=0.26), ischemic or unspecified stroke (P=0.36), hemorrhagic stroke (P=0.25), disabling or fatal stroke (P=0.32) or death from any cause (P=0.89) between patients with and without a prior history of stroke or TIA. Similarly, no significant differences in intracranial bleeding (P=0.92), extracranial or unclassified bleeding (P=0.49) or gastrointestinal bleeding (P=0.89) were observed between the groups with regard to prior stroke or TIA history.
Flaker et al.[24] (2012) AVERROES Apixaban 5 mg BID vs aspirin 81 to 324 mg QD An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	Subanalysis of AVERROES[18] Patients enrolled in the AVERROES trial who experienced bleeding during the treatment period	N=5,599 1.1 years	Primary: Major bleeding and clinically relevant nonmajor bleeding Secondary: Not reported	Primary: There were 44 major hemorrhages in the apixaban group and 39 in the aspirin group. There were 96 clinically relevant nonmajor hemorrhages in the apixaban group and 84 in the aspirin group. Three patients in the apixaban group and seven patients in the aspirin group had both severities of bleeding. There was a similar incidence of major bleeding (HR, 1.13; 95% CI, 0.74 to 1.75; P=0.57), clinically relevant nonmajor bleeding (HR, 1.15; 95% CI, 0.86 to 1.54; P=0.35) and major or clinically relevant nonmajor bleeding (HR, 1.18; 95% CI, 0.92 to 1.51; P=0.19) between the apixaban and aspirin treatment groups. Of patients who experienced bleeding during the treatment with apixaban and aspirin, respectively, the incidence of major intracranial bleeding (0.35 vs 0.41% per year; P=0.69), gastrointestinal bleeding (0.35 vs 0.45% per year; P=0.56), and surgical or trauma bleeding (0.19 vs 0.16% per year; P=0.75) was not significantly different between the groups. With regard to major or clinically relevant nonmajor bleeding, there was no statistically significant difference between apixaban and aspirin at any site of bleeding (P>0.05 for all). The independent predictors of major and clinically relevant nonmajor bleeding that were significantly different between those treated with apixaban and aspirin were the use of nonstudy aspirin >50% of the time (P=0.02 for both treatments)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				and a history of daily/occasional nosebleeds (P=0.02 and P=0.01, respectively). There were no significant differences in major and clinically relevant nonmajor bleeding when patients were stratified by age, sex, body mass index, study dose of aspirin, or estimated glomerular filtration rate (P values not reported). Secondary: Not reported
Granger et al.[25] (2011) ARISTOTLE Apixaban 5 mg BID vs warfarin 2 mg; dose adjusted to maintain an INR of 2.0 to 3.0 An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	AC, DB, DD, MC, NI, RCT Patients with AF or flutter at baseline or two or more episodes of AF or flutter, as documented by ECG at least two weeks apart in the 12 months before enrollment and at least one of the following risk factors for stroke age ≥75, previous stroke, TIA, systemic embolism, symptomatic heart failure within previous three months or LVEF ≤40% and diabetes mellitus or hypertension requiring treatment	N=18,201 1.8 years	Primary: Incidence of stroke (ischemic, hemorrhagic or uncertain type) or systemic embolism and major bleeding Secondary: Death from any cause, rate of MI, composite of stroke, systemic embolism or death from any cause, composite of stroke, systemic embolism, MI or death from any cause, composite of PE or DVT, major bleeding or clinically relevant nonmajor bleeding, any bleeding and	Primary: Stroke or systemic embolism occurred in 212 patients treated with apixaban and 265 patients treated with warfarin (1.27 vs 1.60% per year, respectively; HR, 0.79; 95% CI, 0.66 to 0.95; P<0.001 for non-inferiority and P=0.01 for superiority). Treatment with apixaban significantly lowered the incidence of hemorrhagic stroke compared to treatment with warfarin (0.24 vs 0.47% per year; HR, 0.51; 95% CI, 0.35 to 0.75; P<0.001). There was no statistically significant difference between the apixaban and warfarin treatment groups with regard to a reduction in ischemic or uncertain type of stroke (0.97 vs 1.05% per year, respectively; HR, 0.92; 95% CI, 0.74 to 1.13; P=0.42) or systemic embolism (0.09 vs 0.10% per year, respectively; HR, 0.87; 95% CI, 0.44 to 1.75; P=0.70). There was a significantly lower incidence of major bleeding associated with apixaban treatment compared to warfarin treatment (2.13 vs 3.09% per year; HR, 0.69; 95% CI, 0.60 to 0.80; P<0.001). Apixaban treatment was associated with a significantly lower incidence of major intracranial bleeding (0.33 vs 0.80% per year; HR, 0.42; 95% CI, 0.30 to 0.58; P<0.001), and major bleeding at other locations (1.79 vs 2.27% per year; HR, 0.79; 95% CI, 0.68 to 0.93; P=0.004) compared to warfarin treatment. There was a similar incidence of major gastrointestinal bleeding between the treatment groups (0.76 vs 0.86% per year, respectively; HR, 0.89; 0.70 to 1.15; P=0.37). Secondary: Patients randomized to receive apixaban had a lower incidence of death from any cause (3.52 vs 3.94% per year; HR, 0.89; 95% CI, 0.80 to 0.998; P=0.047)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			adverse events	compared to patients randomized to warfarin treatment. There was a similar rate of MI between the apixaban and warfarin treatment groups with regard to incidence of MI (0.53 vs 0.61% per year, respectively; HR, 0.88; 95% CI, 0.66 to 1.17; P=0.37). The composite of stroke, systemic embolism, or death from any cause was significantly lower in the apixaban treatment group compared to the warfarin treatment group (4.49 vs 5.04% per year; HR, 0.89; 95% CI, 0.81 to 0.98; P=0.02). Similarly, the composite of stroke, systemic embolism, MI or death from any cause was significantly lower in the apixaban treatment group compared to the warfarin treatment group (4.85 vs 5.49% per year; HR, 0.88; 95% CI, 0.80 to 0.97; P=0.01). The incidence of PE or DVT was similar between the apixaban and warfarin treatment groups (0.04 vs 0.05% per year, respectively; HR, 0.78; 95% CI, 0.29 to 2.10; P=0.63). Apixaban treatment was associated with a significantly lower rate of major or clinically relevant nonmajor bleeding compared to warfarin treatment (4.07 vs 6.01% per year; HR, 0.68; 95% CI, 0.61 to 0.75; P<0.001). Moreover, apixaban reduced GUSTO severe bleeding, GUSTO moderate or severe bleeding, TIMI major bleeding and TIMI major or minor bleeding compared to warfarin (P<0.001 for all). There was a statistically significant reduction in any bleeding in the apixaban treatment group compared to the warfarin treatment group (18.1 vs 25.8% per year; HR, 0.71; 95% CI, 0.68 to 0.75; P<0.001). Adverse events occurred in a similar proportion of patients in the apixaban group and in the warfarin group (81.5 and 83.1%, respectively) as did the proportion of patients who experienced serious adverse events (35.0 and 36.5%, respectively). The rates of liver function abnormalities were similar between the treatment groups.
Easton et al.[26]	Subanalysis of	N=18,201	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2012) ARISTOTLE Apixaban 5 mg BID vs warfarin 2 mg; dose adjusted to maintain an INR of 2.0 to 3.0 An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	ARISTOTLE[21] Patients enrolled in the ARISTOTLE trial stratified based on previous stroke and TIA	1.8 years	Incidence of stroke (ischemic, hemorrhagic or uncertain type) or systemic embolism and major bleeding Secondary: Death from any cause, incidence of stroke, hemorrhagic stroke, ischemic or uncertain type of stroke, disabling or fatal stroke, cardiovascular death, intracranial, gastrointestinal and total bleeding	The relative reduction in the risk of stroke or systemic embolism with apixaban compared to warfarin was not significantly different among patients with a history of previous stroke (HR, 0.76; 95% CI, 0.56 to 1.03) and those without (HR, 0.82; 95% CI, 0.65 to 1.03) a previous history of stroke or TIA (P=0.71). Treatment with apixaban significantly reduced the risk of major bleeding compared to warfarin in patients with a history of stroke or TIA (HR, 0.73; 95% CI, 0.55 to 0.98) and patients without a history of stroke or TIA (HR, 0.68; 95% CI, 0.58 to 0.80); however, the difference between the groups was not statistically significant (P=0.69). Secondary: The reduction in death from any cause with apixaban vs warfarin was similar among patients with a history of stroke or TIA (HR, 0.0.89; 95% CI, 0.70 to 1.12) and patients without a stroke or TIA history (HR, 0.90; 95% CI, 0.79 to 1.02; P=0.89). The reduction in the risk of stroke was not significantly different between those with a prior history of stroke or TIA (HR, 0.71; 95% CI, 0.52 to 0.98) and those without a history of stroke or TIA (HR, 0.84; 95% CI, 0.67 to 1.06) who were treated apixaban compared to warfarin (P=0.40). The reduction in the risk of hemorrhagic stroke with apixaban compared to warfarin was similar among patients with a history of stroke or TIA (HR, 0.40; 95% CI, 0.21 to 0.78) and patients without a history of stroke or TIA (HR, 0.59; 95% CI, 0.37 to 0.94; P=0.35). There was no statistically significant difference in the reduction in ischemic or unknown type of stroke with apixaban compared to warfarin among patients with a history of stroke or TIA (HR, 0.86; 95% CI, 0.60 to 1.22) and patients without a stroke or TIA history (HR, 0.97; 95% CI, 0.74 to 1.26; P=0.61). The reduction in disabling or fatal stroke with apixaban compared to warfarin was similar among patients with a history of stroke or TIA (HR, 0.87; 95% CI, 0.57 to 1.34) and patients without a stroke or TIA history (HR, 0.60; 95% CI, 0.41 to 0.86; P=0.18).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The significant reduction in death from any cause with apixaban compared to warfarin was consistent among patients with a history of stroke or TIA (HR, 0.73; 95% CI, 0.55 to 0.98) and patients without a stroke or TIA history (HR, 0.68; 95% CI, 0.58 to 0.80; P=0.69). There was no significant reduction in the risk of total bleeding (P=0.70), intracranial bleeding (P=0.60) or gastrointestinal bleeding (P=0.87) between patients with a previous history of stroke or TIA who received apixaban compared to warfarin and patients without a history of stroke or TIA.
Lopes et al.[27] (2012) ARISTOTLE Apixaban 5 mg BID vs warfarin 2 mg; dose adjusted to maintain an INR of 2.0 to 3.0 An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	Subanalysis of ARISTOTLE[21] Patients enrolled in the ARISTOTLE trial stratified based on $CHADS_2$, CHA_2DS_2-VASc and HAS-BLED scores	N=18,201 1.8 years	Primary: Incidence of stroke (ischemic, hemorrhagic or uncertain type) or systemic embolism and major bleeding Secondary: MI, death from any cause, intracranial bleeding, TIMI major or minor bleeding, GUSTO moderate or severe bleeding, any bleeding and net clinical events (stroke or systemic embolism, major bleeding and all-cause mortality)	Primary: Apixaban significantly reduced stroke or systemic embolism with no evidence of a differential effect by risk of stroke ($CHADS_2$ score; P=0.4457, CHA_2DS_2VASc score P=0.1210) or bleeding (HAS-BLED score P=0.9422). Patients treated with apixaban experienced lower rates of major bleeding compared to patients treated with warfarin, with no difference between score categories ($CHADS_2$; P=0.4018, CHA_2DS_2VASc; P=0.2059 and HAS-BLED; P=0.7127). Secondary: Patients treated with apixaban had significantly lower rates of stroke or systemic embolism (P=0.0114), mortality (P=0.0465), major bleeding (P<0.0001), intracranial bleeding (P<0.0001), and any bleeding (P<0.0001) compared to patients receiving warfarin, regardless of $CHADS_2$ score. The benefits of apixaban compared to warfarin for all endpoints across CHA_2DS_2VASc categories were similar to those seen across $CHADS_2$ score categories. There was no difference in the rate of MI between patients in different risk categories. Regardless of HAS-BLED score, patients receiving treatment with apixaban had lower rates of stroke or systemic embolism (P=0.0114), mortality (P=0.0465), major bleeding (P<0.0001), TIMI major or minor bleeding (P<0.0001), GUSTO severe or moderate bleeding (P<0.0001), and any bleeding (P<0.0001) compared to patients treated with warfarin. The reduction in intracranial bleeding with apixaban compared to warfarin was greater in patients with a HAS-BLED score of three or higher (HR, 0.22; 95% CI, 0.10 to 0.48) compared to patients with a HAS-BLED score of less than one (HR, 0.66;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				95% CI, 0.39 to 1.12); however, the difference was not significant (P=0.0604). Irrespective of $CHADS_2$, CHA_2DS_2VASc, and HAS-BLED score, patients randomized to receive treatment with apixaban experienced lower rates of the composite of stroke, systemic embolism, major bleeding, and all-cause mortality compared to patients randomized to warfarin. These results were driven mainly by reductions in bleeding.
Garcia et al.[28] (2013) ARISTOTLE Apixaban 5 mg BID vs warfarin 2 mg; dose adjusted to maintain an INR of 2.0 to 3.0 An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80 years, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	Subanalysis of ARISTOTLE[21] Patients enrolled in the ARISTOTLE trial stratified based on previous VKA use	N=18,201 1.8 years	Primary: Composite of all stroke (ischemic or hemorrhagic) and systemic embolism. Secondary: Mortality, major bleeding, intracranial bleeding, and permanent early treatment discontinuation	Primary: Compared with patients in the warfarin arm, patients randomized to receive apixaban had numerically lower rates of stroke/systemic embolism irrespective of prior VKA use. For stroke/systemic embolism, the differences favoring apixaban over warfarin were consistent: the HR was 0.86 (95% CI, 0.67 to 1.11) in the VKA-naive patients and 0.73 (95% CI, 0.57 to 0.95) in the VKA-experienced patients (P=0.39). The treatment effects of apixaban (vs warfarin) were not modified by VKA naivety. Secondary: A similar consistency of treatment effect was seen for other key end points; numerically lower rates of major bleeding and all-cause death were seen in the apixaban treated patients, and there is no evidence that this effect was modified by VKA naivety. Apixaban-treated patients had lower rates of intracranial bleeding overall; the effect of apixaban on intracranial bleeding was less pronounced in patients who were VKA naive (HR, 0.60; 95% CI, 0.38 to 0.93) than in those who were VKA-experienced (HR 0.28; 95% CI, 0.17 to 0.46) (P=0.02). Premature permanent study drug discontinuation was numerically less likely in the patients assigned to apixaban whether they were VKA naive (HR, 0.87; 95% CI, 0.79 to 0.95) or VKA experienced (HR, 0.93; 95% CI, 0.85 to 1.02).
Hylek et al.[29] (2014) ARISTOTLE Apixaban 5 mg	Subanalysis of ARISTOTLE[21] Patients enrolled in the ARISTOTLE	N=18,201 1.8 years	Primary: First major hemorrhage Secondary:	Primary: Major hemorrhage occurred in 789 patients (4.3%) overall; 327 in the apixaban group (2.13% per year) compared with 462 in the warfarin group (3.09% per year; HR 0.69, 95% CI: 0.60 to 0.80; P< 0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
BID vs warfarin 2 mg; dose adjusted to maintain an INR of 2.0 to 3.0 An apixaban dose of 2.5 mg BID was used in patients with two or more of the following criteria: age ≥80 years, body weight ≤60 kg or a serum creatinine level ≥1.5 mg/dL.	trial stratified based on bleeding events		Major extracranial hemorrhage, followed by hospitalization, medical or surgical intervention, transfusion, and change in antithrombotic therapy	Apixaban was associated with fewer gastrointestinal hemorrhages than warfarin, but this difference did not achieve statistical significance. There were also fewer soft tissue hematomas associated with apixaban that met the criteria for International Society on Thrombosis and Haemostasis (ISTH) major hemorrhage (HR, 0.46; 95% CI, 0.29 to 0.74). In addition, apixaban was associated with fewer major hemorrhages related to trauma: 37 in the apixaban group (0.24% per year) compared with 60 in the warfarin group (0.40% per year; HR, 0.60; CI, 0.40 to 0.91; P=0.015). Apixaban was associated with fewer intracranial hemorrhages than warfarin (HR, 0.42; CI, 0.30 to 0.58). Secondary: Major extracranial hemorrhage-associated adverse consequences occurred less frequently in the apixaban group than in the warfarin group, including fewer hospitalizations (HR, 0.75; CI, 0.61 to 0.92), fewer medical or surgical interventions to stop the bleeding (HR, 0.72; CI, 0.56 to 0.93), fewer transfusions (HR, 0.71; CI, 0.57 to 0.89), and fewer changes in antithrombotic therapy (HR, 0.78; CI, 0.64 to 0.95). Major ISTH hemorrhage criteria followed by death within 30 days occurred half as often in the apixaban group compared with the warfarin group (P<0.001).
Connolly et al.[30] (2009) RE-LY Dabigatran 110 mg BID vs dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	DB, MC, RCT Patients with AF documented on ECG performed at screening or within six months of enrollment and at least one of the following: previous stroke or TIA, LVEF <40%, heart failure (NYHA Class ≥2) symptoms within six months before screening and ≥75 years of age or 65	N=18,113 2 years	Primary: Composite of stroke or systemic embolism, major hemorrhage Secondary: Death, MI, PE, TIA, hospitalization	Primary: Both doses of dabigatran were non-inferior to warfarin (P<0.001). Stroke or systemic embolism occurred in 182 dabigatran 110 mg- (1.53% per year), 134 dabigatran 150 mg (-1.1% per year) and 199 warfarin-treated patients (1.69% per year). The 150 mg dose of dabigatran was "superior" to warfarin (RR, 0.66; 95% CI, 0.53 to 0.82; P<0.001), but the 110 mg dose was not (RR, 0.91; 95% CI, 0.74 to 1.11; P=0.34). Rates of hemorrhagic stroke were 0.38, 0.12 (RR, 0.31; 95% CI, 0.17 to 0.56; P<0.001) and 0.10% (RR, 0.26; 95% CI, 0.14 to 0.49; P<0.001) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients. The rate of major bleeding (life-threatening, non-life-threatening and gastrointestinal) was 3.36, 2.71 (RR, 0.80; 95% CI, 0.69 to 0.93; P=0.003) and 3.11% (RR, 0.93; 95% CI, 0.81 to 1.07; P=0.31) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients. Rates of life-threatening bleeding, intracranial bleeding and major or minor bleeding were higher in warfarin-treated patients (1.80, 0.74 and 18.15%, respectively)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	to 74 years of age plus diabetes, hypertension or CAD			compared to either dabigatran 110 (1.22, 0.23 and 14.62%, respectively) or 150 mg-treated patients (1.45, 0.30 and 16.42%, respectively) (P<0.05 for all comparisons of dabigatran and warfarin). There was a significantly higher rate of major gastrointestinal bleeding in dabigatran 150 mg-treated patients compared to warfarin-treated patients (P=0.43 for dabigatran 110 mg vs warfarin and P<0.001 for dabigatran 150 mg vs warfarin). The net clinical benefit outcome consisted of major vascular events, major bleeding and death. The rates of this combined outcome were 7.64, 7.09 (RR, 0.92; 95% CI, 0.84 to 1.02; P=0.10) and 6.91% (RR, 0.91; 95% CI, 0.82 to 1.00; P=0.04) per year in warfarin, dabigatran 110 mg- and dabigatran 150 mg-treated patients. Secondary: Rates of death from any cause were 4.13, 3.75 (RR, 0.91; 95% CI, 0.80 to 1.03; P=0.13) and 3.64% (RR, 0.88; 95% CI, 0.77 to 1.00; P=0.051) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients. The rate of MI was 0.53, 0.72 (RR, 1.35; 95% CI, 0.98 to 1.87; P=0.07) and 0.74% (RR, 1.38; 95%, 1.00 to 1.91; P=0.048) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients. The rate of PE was 0.09, 0.12 (RR, 1.26; 95% CI, 0.57 to 2.78; P=0.56) and 0.15% (RR, 1.61; 95% CI, 0.76 to 3.42; P=0.21) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients. Data regarding the incidences of TIA were not reported. The rate of hospitalization was 20.8, 19.4 (RR, 0.92; 95% CI, 0.87 to 0.97; P=0.003) and 20.2% (RR, 0.97; 95% CI, 0.92 to 1.03; P=0.34) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients.
Ezekowitz et al.[31] (2010) RE-LY Dabigatran 110 mg BID	Subanalysis of RE-LY[26] Patients enrolled in the RE-LY trial who were naïve to	N=18,113 2 years	Primary: Composite of stroke or systemic embolism, major hemorrhage	Primary: Approximately half of the patients were VKA-naïve (50.4%). Combined stroke and systemic embolism rates were similar in dabigatran 110 mg-treated patients for both the VKA-naïve and -experienced cohorts compared to warfarin-treated patients (RR, 0.93; 95% CI, 0.70 to 1.25; P=0.65 and RR,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	and experienced with VKAs		Secondary: Death, MI, PE, TIA, hospitalization	0.87; 95% CI, 0.66 to 1.15; P=0.32). In dabigatran 150 mg-treated patients, both VKA-naïve (RR, 0.63; 95% CI, 0.46 to 0.87; P=0.005) and -experienced cohorts (RR, 0.66; 95% CI, 0.49 to 0.89; P=0.007) had significantly lower risk of stroke or systemic embolism compared to warfarin-treated patients. Major bleeding rates were lower in the VKA-experienced cohort in dabigatran 110 mg-treated patients compared to warfarin-treated patients (RR, 0.74; 95% CI, 0.60 to 0.90; P=0.003). The VKA-naïve cohort in dabigatran 110 mg-treated patients (RR, 0.87; 95% CI, 0.72 to 1.07; P=0.19) and the VKA-naïve (RR, 0.94; 95% CI, 0.77 to 1.15; P=0.55) and –experienced cohort (RR, 0.92; 95% CI, 0.76 to 1.12; P=0.41) in dabigatran 150 mg-treated patients were similar compared to warfarin-treated patients. Intracranial bleeding events were lower in dabigatran 110 VKA-naïve and -experienced cohorts (RR, 0.27; 95% CI, 0.14 to 0.52; P<0.001; RR, 0.32; 95% CI, 0.18 to 0.56; P<0.001) and in dabigatran 150 mg VKA-naïve and -experienced cohorts (RR, 0.46; 95% CI, 0.27 to 0.78; P=0.005; RR, 0.40; 95% CI, 0.24 to 0.67; P<0.001) compared to warfarin-treated patients. Secondary: Rates of life threatening bleeding, disabling stroke and death (when combined) were significantly lower in the VKA-experienced patients in both dabigatran 110 mg- (RR, 0.82; 95% CI, 0.70 to 0.96; P=0.01) and 150 mg-treated cohort (RR, 0.80; 95% CI, 0.68 to 0.93; P=0.004) compared to warfarin-treated patients, but similar for the VKA-naïve cohort. When comparing this combined outcome in VKA-naïve and -experienced cohorts within treatments, the rate was lower in VKA-experienced cohort than in the -naïve cohort (RR, 0.83; 95% CI, 0.71 to 0.98; P=0.03), as was the cardiovascular death rate (RR, 0.73; 95% CI, 0.58 to 0.92; P=0.007). In dabigatran 150 mg-treated patients, the rate of this combined outcome trended lower in VKA-experienced cohort. There were no differences in the rates of MI among the treatments. Gastrointestinal bleeding rates were similar for dabigatran 110 mg- and warfarin-treated patients, but significantly higher in both dabigatran 150 mg VKA-naïve (RR, 1.56; 95% CI, 1.15 to 2.10; P=0.004) and -experienced cohorts (RR, 1.42; 95% CI, 1.06 to 1.89; P=0.02) compared to warfarin-treated patients.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Diener et al.[32] (abstract) (2010) RE-LY Dabigatran 110 mg BID vs dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	Subanalysis of RE-LY[26] Patients enrolled in the RE-LY trial who had a previous stroke or TIA	N=18,113 2 years	Primary: Composite of stroke or systemic embolism, major hemorrhage Secondary: Death, MI, PE, TIA, hospitalization	Primary: Within the subgroup of patients with previous stroke or TIA, 1,195, 1,233 and 1,195 patients were from the dabigatran 110 mg, dabigatran 150 mg and warfarin groups. Stroke or systemic embolism occurred in 65 warfarin-treated patients (2.78% per year) compared to 55 (2.32% per year) dabigatran 110 mg-(RR, 0.84; 95% CI, 0.58 to 1.20) and 51 (2.07% per year) dabigatran 150 mg-treated patients (RR, 0.75; 95% CI, 0.52 to 1.08). The rate of major bleeding was significantly lower in dabigatran 110 mg-treated patients (RR, 0.66; 95% CI, 0.48 to 0.90), and similar in dabigatran 150 mg-treated patients (RR, 1.01; 95% CI, 0.77 to 1.34) compared to warfarin-treated patients. Secondary: The effects of both doses of dabigatran compared to warfarin were not different between patients with previous stroke or TIA and those without for any of the outcomes from RE-LY apart from vascular death (dabigatran 110 mg vs warfarin; P=0.038).
Wallentin et al.[33] (2010) RE-LY Dabigatran 110 mg BID vs dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	Subanalysis of RE-LY[26] Patients enrolled in the RE-LY trial across the three treatment groups within four groups defined by quartiles of cTTR (<57.1, 57.1 to 65.5, 65.5 to 72.6 and >72.6%)	N=18,113 2 years	Primary: Composite of stroke or systemic embolism, major hemorrhage Secondary: Death, MI, PE, TIA, hospitalization	Primary: In the total population, the rate of the primary outcome of stroke and systemic embolism was reduced from 1.71% per year in warfarin-treated patients, to 1.54% per year in dabigatran 110 mg-treated patients (non inferiority; P<0.001) and to 11.1% per year in dabigatran 150 mg-treated patients ("superiority"; P<0.001). Event rates seemed to decrease with higher cTTR in warfarin-treated patients; however, there were no significant interactions between cTTR and stroke and systemic embolism in dabigatran- vs warfarin-treated patients. The rate of nonhemorrhagic stroke and systemic embolism seemed to be lower with higher cTTR in warfarin-treated patients (P=0.08). In the total population, the rate of major bleeding was 3.57% per year in warfarin-treated patients compared to 2.87 ("superiority"; P=0.003) and 3.32% ("superiority"; P=0.31) per year in dabigatran 110 mg- and dabigatran 150 mg-treated patients. The rate of major bleeding, as well as major gastrointestinal bleeding, was numerically lower at higher cTTR quartiles in warfarin-treated patients. When comparing major bleedings between dabigatran 150 mg- and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
The cTTR was estimated by averaging the TTR for individual warfarin-treated patients.				warfarin-treated patients, there were benefits at lower cTTR but similar results at higher cTTR (P=0.03). The rates of intracranial bleeding in warfarin-treated patients were associated with the cTTR and were consistently lower in dabigatran-treated patients than warfarin-treated patients irrespective of cTTR. There was a higher rate of major gastrointestinal bleeding in dabigatran 150 mg-treated patients compared to warfarin-treated patients at higher cTTR (P=0.019). There was an increase in total bleeding rate with increasing cTTR with all three treatments, without any significant interactions between them. Secondary: Mortality rates were 4.13, 3.75 (“superiority”; P<0.13) and 3.64% (“superiority”; P<0.051) per year in warfarin-, dabigatran 110 mg- and dabigatran 150 mg-treated patients. Total mortality was lower at higher cTTR in warfarin-treated patients; the interaction P value was 0.052 for the interaction between cTTR and the effects of dabigatran 110 mg and 0.066 for the effects of dabigatran 150 mg, with differences in mortality at lower cTTR but similar rates at higher cTTR. For all cardiovascular events, including total mortality and major bleeding, there were significantly lower event rates at higher cTTR in warfarin-treated patients. There was a significant interaction between cTTR and the composite of all cardiovascular events when comparing dabigatran 150 mg- and warfarin-treated patients (P=0.0006), and dabigatran 110 mg- and warfarin-treated patients (P=0.036). These interactions were mainly attributable to significant differences between treatments in the rates of nonhemorrhagic events (P=0.017 for dabigatran 110 mg vs warfarin and P=0.0046 for dabigatran 150 mg vs warfarin), with advantages at lower cTTR, whereas rates were greater at higher cTTR.
Hohnloser et al.[34] (2012) RE-LY Dabigatran 110 mg BID vs	Subanalysis of RE-LY[26] Patients with AF documented on ECG performed at screening or within six months of enrolment and at	N=18,113 2 years	Primary: Myocardial and ischemic events Secondary: Not reported	Primary: The annual rates of MI with dabigatran 110 and 150 mg were 0.82 (HR, 1.29; 95% CI, 0.96 to 1.75; P=0.09) and 0.81% per year (HR, 1.27; 95% CI, 0.94 to 1.71; P=0.12) compared to 0.64% per year with warfarin. When both doses of dabigatran were compared to warfarin results were similar to those obtained when the two doses were compared separately. With regards to the composite outcome of MI, unstable angina, cardiac arrest, and cardiac death, annual rates were 3.16 (HR, 0.93; 95% CI, 0.80 to 1.06;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	least one of the following: previous stroke or TIA, LVEF<40%, heart failure (NYHA Class ≥2) symptoms within six months before screening and ≥75 years of age or 65 to 74 years of age plus diabetes, hypertension or CAD			P=0.28) and 33.3% per year (HR, 0.98; 95% CI, 0.85 to 1.12; P=0.77) with dabigatran 110 and 150 mg compared to 3.41% per year with warfarin. When revascularization events were included, again no significant differences emerged among the three treatments. With regards to the composite outcome of MI, unstable angina, cardiac arrest, cardiac death, revascularization events, and stroke and systemic embolic events, annual rates were 4.76 (HR, 0.93; 95% CI, 0.83 to 1.05; P=0.24) and 4.47% per year (HR, 0.88; 95% CI, 0.78 to 0.98; P=0.03) with dabigatran 110 and 150 mg compared to 5.10% per year with warfarin. Events prespecified in the net clinical benefit analysis occurred at annual rates of 7.34 (HR, 0.92; 95% CI, 0.84 to 1.01; P=0.09) and 7.11% per year (HR, 0.90; 95% CI, 0.82 to 0.99; P=0.02) with dabigatran 110 and 150 mg compared to 7.91% per year with warfarin. Patients who had at least one myocardial ischemic event were older and had more coronary risk factors compared to the remainder of the population. Across all treatments, these patients received more antiplatelet medications, β-blockers, and statins at baseline, and they also more often had a $CHADS_2$ score >2. Fifty-six of 87 clinical MIs with dabigatran 110 mg, 59/89 with dabigatran 150 mg, and 46/66 with warfarin occurred on the study drug treatment. MIs that occurred greater than six days after study drug discontinuation were observed in 17, 20, and 12 patients in all three treatment groups. Accordingly, 33, 34, and 30% of all clinical MIs were diagnosed when patients were not taking the study drug in the respective treatment arms. There were 1,886 (31%) CAD/MI patients receiving dabigatran 110 mg, 1,915 (31%) receiving dabigatran 150 mg, and 1,849 (31%) receiving warfarin. The effects of dabigatran compared to warfarin were highly consistent between patients with prior CAD/MI compared to those without. Secondary: Not reported
Hart et al.[35] (2012)	Subanalysis of RE-LY[26]	N=18,113	Primary: Intracranial	Primary: There were 154 intracranial hemorrhages, with an overall 30-day mortality of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
RE-LY Dabigatran 110 mg BID vs dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	Patients enrolled in the RE-LY trial who experienced an intracranial hemorrhage while on treatment	2 years	hemorrhages occurring during anticoagulation, including sites, rates, risk factors, associated trauma and outcomes Secondary: Not reported	36%. Intracranial hemorrhages included intracerebral hemorrhages (46%, with 49% mortality), subdural hematomas (45%, with 24% mortality) and subarachnoid hemorrhages (8%, with 31% mortality). Patients with an intracranial hemorrhage were older (P<0.001), had a history of stroke or TIA (P=0.001), more often took aspirin during follow-up (P=0.001), had lower incidence of heart failure (P=0.02) lower estimated creatinine clearances (P<0.001) compared to patients without intracranial hemorrhage. The rate of intracranial hemorrhage was higher with warfarin treatment (0.76% per year) compared to patients receiving dabigatran 150 mg (0.31% per year, RR, 0.40; 95% CI, 0.27 to 0.59) and dabigatran 110 mg (0.23% per year, RR, 0.30; 95% CI, 0.19 to 0.45). Intracranial hemorrhage-related mortality was similar between the treatments. Age was predictive of intracranial hemorrhage among patients treated with dabigatran (RR, 1.06 per year; P=0.002). The independent predictors of developing spontaneous intracerebral bleeding were the assignment to warfarin (RR, 4.1; P<0.001), previous stroke or TIA (RR, 2.7; P<0.001), aspirin use (RR, 1.8; P=0.02) and age (1.04 per year; P=0.02). The rate of spontaneous intracerebral hemorrhage was significantly higher among those assigned to warfarin (0.36% per year) compared to 0.09% per year with dabigatran 150 mg (RR, 0.26; 95% CI, 0.13 to 0.50) and 0.08% with dabigatran 110 mg (RR, 0.23; 95% CI, 0.12 to 0.47). There was no significant difference in mortality associated with spontaneous intracerebral hemorrhage between treatments. Patients with spontaneous intracerebral bleeding in the basal ganglia/thalamus were, on average, younger (P=0.04) and more likely to have diabetes (P=0.02) compared to those with lobar bleeding. The rate of subdural hematoma was 0.31% per year in the warfarin group compared to 0.20% per year in the dabigatran 150 mg group (RR, 0.65; P=0.10) and 0.08% per year in the dabigatran 110 mg group (RR, 0.27; P<0.001). The rate of subdural hematomas was significantly higher with dabigatran 150 mg compared to the 110 mg dosage (RR, 2.4; P=0.02). Fatal subdural bleeding occurred in 10 patients receiving warfarin compared to five and two patients receiving dabigatran 150 mg and 110 mg, respectively

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P<0.05 the 110 mg group). Secondary: Not reported
Healey et al.[36] (2012) RE-LY Dabigatran 110 mg BID vs dabigatran 150 mg BID vs warfarin 1, 3, or 5 mg; dose adjusted to maintain an INR of 2.0 to 3.0 (OL)	Subanalysis of RE-LY[26] Patients enrolled in the RE-LY trial who required surgery, dental procedures, cardiac catheterization, or invasive diagnostic procedures (including percutaneous biopsy, peripheral angiography, and similar procedures)	N=4,591 2 years	Primary: Perioperative major bleeding, fatal bleeding, bleeding requiring surgery and thrombotic events Secondary: Not reported	Primary: The incidence of perioperative major bleeding was not significantly different between patients receiving dabigatran 110 mg (3.8%) or dabigatran 150 mg (5.1%) compared to patients receiving warfarin (4.6%; P>0.05 for both). Perioperative fatal bleeding was similar in the dabigatran 110 mg (RR, 1.57; 95% CI, 0.26 to 9.39; P=0.62) or 150 mg treatment groups (RR, 1.01; 95% CI, 0.14 to 7.15; P=0.99) compared to the warfarin group. Bleeding requiring surgery was not significantly different in the dabigatran 110 mg (RR, 0.59; 95% CI, 0.26 to 1.33; P=0.20) or 150 mg treatment groups (RR, 1.39; 95% CI, 0.73 to 2.63; P=0.32) compared to the warfarin group. The incidences cardiovascular death, stroke (all-cause), ischemic stroke, hemorrhagic stroke, systemic embolism, MI, or PE, were low and not significantly different between patients receiving dabigatran 110 mg, 150 mg or warfarin (P>0.05 for all). Secondary: Not reported
Connolly et al.[37] (2013) RELY-ABLE Dabigatran 110 mg BID vs dabigatran 150 mg BID	Subanalysis of RE-LY[26] Patients enrolled in the RE-LY trial who received dabigatran who were not discontinued medication at the time of the final RE-LY study visit and have AF and at	N=5,891 28 months	Primary: Stroke (ischemic or hemorrhagic), systemic embolism, Secondary: Myocardial infarction, PE, vascular death, and total mortality	Primary: During RELY-ABLE, the annual rates of stroke or systemic embolism were 1.46% and 1.60% per year on dabigatran 150 and 110 mg, respectively (HR, 0.91; 95% CI, 0.69 to 1.20). Annual rates of ischemic stroke (including stroke of uncertain cause) were 1.15% and 1.24% per year on dabigatran 150 and 110 mg, respectively (HR, 0.92; 95% CI, 0.67 to 1.27). Annual rates of hemorrhagic stroke were similar in the two treatment arms and were very low at 0.13% and 0.14% per year on dabigatran 150 and 110 mg, respectively. Secondary: Annual rates of myocardial infarction were also low and similar between the two groups at 0.69% and 0.72% per year. PE occurred in 0.13% and 0.11% per year on dabigatran 150 and 110 mg, respectively (HR, 1.14; 95% CI, 0.41 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	least one risk factor for stroke			3.15). Vascular death and total mortality were not reported.
Ezekowitz et al.[38] (2007) Dabigatran 50, 150, and 300 mg BID vs warfarin, dose adjusted to maintain an INR of 2.0 to 3.0 (OL) The three doses of dabigatran were combined in a 3x3 factorial fashion with no aspirin or 81 to 325 mg of aspirin QD.	AC, DB, MC, RCT Patients with documented AF with CAD and at least one of the following: hypertension requiring medical treatment, diabetes, symptomatic heart failure (LVEF <40%), previous stroke or TIA or age >75	N=502 12 weeks	Primary: Incidence of bleeding Secondary: Suppression of D-dimer	Primary: Major bleeding events were limited to dabigatran 300 mg plus aspirin-treated patients (four patients out of 64); being statistically different compared to dabigatran 300 mg with no aspirin-treated patients (zero patients out of 150; P<0.02). There was a significant difference in major plus clinically relevant bleeding episodes (11 out of 64 vs six out of 105; P=0.03) and total bleeding episodes (25 out of 64 vs 14 out of 105; P=0.0003) between dabigatran 300 mg plus aspirin- and dabigatran 300 mg with no aspirin-treated patients. The frequency of bleeding in both dabigatran 50 mg treatment groups was significantly lower than that within the warfarin treatment group (seven out of 107 vs 12 out of 70; P=0.044). When the doses of dabigatran were compared to each other, irrespective of aspirin use, there were differences in total bleeding episodes in 300 and 150 mg- vs 50 mg-treated patients (37 out of 169 and 30 out of 169 vs seven out of 107; P=0.0002 and P=0.01, respectively). Secondary: Generally, at 12 weeks, a 13% relative increase of D-dimer plasma measurements was observed in dabigatran 50 mg-treated patients (P=0.0008) and a 3% relative increase in dabigatran 150 mg-treated patients (P=0.027) was observed. No significant changes in 300 mg dabigatran- (0%; P=0.413) or warfarin-treated patients (-1%; P=0.267) were seen. Aspirin treatment had no effect on any of these analyses. There were significantly fewer traumatic intracranial hemorrhages in patients receiving either dosage of dabigatran (11 patients for both) compared to patients receiving warfarin (24 patients; (P<0.05 for both dabigatran dosages vs warfarin). Fatal traumatic intracranial hemorrhages occurred in five, three and three patients receiving warfarin, dabigatran 150 mg, and 110 mg, respectively.
Giugliano et al.[39] (2013) ENGAGE AF-	DB, DD, NI, RCT Patients ≥ 21 years	N=21,105 (median	Primary efficacy: Occurrence of	Primary efficacy: The annualized rate of stroke or systemic embolism during treatment was 1.50% (232 of 2,641 patients) with warfarin as compared with 1.18% (182 of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
TIMI 48 Study Edoxaban 60 mg QD† vs edoxaban 30 mg QD† vs warfarin (adjusted dose to maintain an INR between 2.0 and 3.0) †Individuals had their dose halved (60 mg halved to 30 mg or 30 mg halved to 15 mg) if CrCl ≤ 50 mL/min, body weight ≤ 60 kg, or concomitant use of a P-glycoprotein inhibitor such as verapamil or quinidine	of age with non-valvular atrial fibrillation documented by means of electrical tracing within the 12 months preceding randomization, a score of 2 or higher on the $CHADS_2$ risk assessment and anticoagulation therapy planned for the duration of the trial	follow-up 2.8 years)	the first stroke (ischemic or hemorrhagic) or of a systemic embolic event that occurred during treatment or within three days from the last dose taken Primary safety: Major bleeding during treatment Secondary: Composite of stroke, systemic embolism or death from cardiovascular causes	2,669 patients) with high-dose edoxaban (HR, 0.79; 97.5% CI, 0.63 to 0.99; P<0.001) and 1.61% (253 of 2,730 patients) with low-dose edoxaban (HR, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005). Primary safety: The annualized rate of major bleeding was 3.43% with warfarin compared with 2.75% with high-dose edoxaban (HR, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (HR, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The annualized rate of major gastrointestinal bleeding was higher with high-dose edoxaban, 1.51% compared with warfarin, 1.23% (HR, 1.23; 95% CI, 1.02 to 1.50; P=0.03). The rate was lowest with low-dose edoxaban at 0.82% (HR, 0.67; 95% CI, 0.53 to 0.83; P<0.001). Secondary: The key secondary end point of composite of stroke, systemic embolism or death from cardiovascular causes were 4.43% with warfarin compared with 3.85% for high-dose edoxaban tosylate (HR, 0.87; 95% CI, 0.78 to 0.96; P=0.005) and 4.23% for low-dose edoxaban tosylate (HR, 0.95; 95% CI, 0.86 to 1.05; P=0.32)
O'Donoghue et al.[40] (2015) ENGAGE AF-TIMI 48 Study Edoxaban 60 mg	DB, DD, NI, RCT Patients ≥ 21 years of age with non-valvular atrial fibrillation documented by	N=21,105 (median follow-up 2.8 years)	Primary efficacy: Occurrence of the first stroke (ischemic or hemorrhagic) or of a systemic	Primary: Higher-dose edoxaban significantly reduced the risk of stroke or systemic embolic event in patients who were VKA naive (HR, 0.71; 95% CI, 0.56 to 0.90) and was similar to warfarin in the VKA experienced (HR, 1.01; 95% CI, 0.82 to 1.24; P interaction=0.028). Lower-dose edoxaban was similar to warfarin for stroke or systemic embolic event prevention in patients who were VKA naive (HR, 0.92; 95% CI, 0.73 to 1.15), but was inferior to warfarin in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
QD† vs edoxaban 30 mg QD† vs warfarin (adjusted dose to maintain an INR between 2.0 and 3.0) †Individuals had their dose halved (60 mg halved to 30 mg or 30 mg halved to 15 mg) if CrCl ≤ 50 mL/min, body weight ≤ 60 kg, or concomitant use of a P-glycoprotein inhibitor such as verapamil or quinidine	means of electrical tracing within the 12 months preceding randomization, a score of 2 or higher on the $CHADS_2$ risk assessment and anticoagulation therapy planned for the duration of the trial; For the current analysis, subjects were divided into subgroups on the basis of whether they were VKA naïve or VKA experienced		embolic event that occurred during treatment or within three days from the last dose taken Primary safety: Major bleeding during treatment Secondary: Composite of stroke, systemic embolism or death from cardiovascular causes	those who were VKA experienced (HR, 1.31; 95% CI, 1.08 to 1.60; P interaction=0.019). Primary safety: Both higher-dose and lower-dose edoxaban regimens significantly reduced the risk of major bleeding regardless of prior VKA experience (P interaction=0.90 and 0.71, respectively). Secondary: There were similar directional signals towards greater reductions in cardiovascular and all-cause mortality with both doses of edoxaban as compared with warfarin in patients who were VKA naive, as compared with those who were VKA experienced; however, the differences between prior VKA use subgroups were not statistically significant and therefore consistent with the overall study results.
Eisen et al.[41] (2016) ENGAGE AF-TIMI 48 Study Edoxaban 60 mg QD† vs	DB, DD, NI, RCT Patients ≥ 21 years of age with non-valvular atrial fibrillation documented by means of electrical tracing within the 12 months	N=9,387 (FDA-approved cohort) (median follow-up 2.8 years)	Primary efficacy: Occurrence of the first stroke (ischemic or hemorrhagic) or of a systemic embolic event that occurred during treatment	Primary efficacy: Stroke or systemic embolism occurred in 202 patients (1.63%/y) in the edoxaban group as compared with 253 patients (2.02%/y) in the warfarin group (HR, 0.81; 95% CI, 0.67 to 0.97; P=0.023). Patients in the edoxaban group had fewer strokes than did patients in the warfarin group (1.55%/y vs 1.88%/y; HR, 0.82; 95% CI, 0.68 to 1.00; P=0.046). This difference was driven primarily by a significant reduction in hemorrhagic stroke with edoxaban (HR, 0.47; 95% CI, 0.31 to 0.72; P<0.001). Ischemic stroke rates were similar between the treatment groups (1.31%/y vs 1.39%/y; HR, 0.94; 95% CI, 0.76 to 1.16; P=0.97).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
edoxaban 30 mg QD† vs warfarin (adjusted dose to maintain an INR between 2.0 and 3.0) †Individuals had their dose halved (60 mg halved to 30 mg or 30 mg halved to 15 mg) if CrCl ≤ 50 mL/min, body weight ≤ 60 kg, or concomitant use of a P-glycoprotein inhibitor such as verapamil or quinidine	preceding randomization, a score of 2 or higher on the $CHADS_2$ risk assessment and anticoagulation therapy planned for the duration of the trial; For the current analysis, subjects included had been treated with either warfarin or edoxaban 60/30 mg and had a creatinine clearance of ≤95 mL/min		or within three days from the last dose taken Primary safety: Major bleeding during treatment Secondary: Composite of stroke, systemic embolism or death from cardiovascular causes	Primary safety: The rates of major bleeding events were 3.16%/y in the edoxaban group and 3.77%/y in the warfarin group (HR, 0.84; 95% CI, 0.72 to 0.98; P=0.023) Secondary: Key secondary end points also were decreased significantly with edoxaban as compared with warfarin. Edoxaban reduced the rate of cardiovascular death (HR, 0.84; 95% CI, 0.73 to 0.97; P=0.015) and showed a trend for the reduction of the rate of death from any cause (HR, 0.90; 95% CI, 0.81 to 1.01; P=0.084). Edoxaban achieved statistically significant superior net clinical outcomes as compared with warfarin (relative reductions of 9 to 14%).
Geller et al.[42] (2015) ENGAGE AF-TIMI 48 Study Edoxaban 60 mg QD† vs edoxaban 30 mg QD† vs	DB, DD, NI, RCT Patients ≥ 21 years of age with non-valvular atrial fibrillation documented by means of electrical tracing within the 12 months preceding randomization, a score of 2 or higher on the $CHADS_2$	N=21,105 (median follow-up 2.8 years)	Primary: Time to the first systemic embolic events Secondary: Time to the first systemic embolic events in MA of four trials (warfarin vs RE-LY, dabigatran; ROCKET AF,	Primary: Of 1,016 patients who met the primary end point, 67 (6.6%) experienced a systemic embolic event of which 13% were fatal. Of 73 total systemic embolic events (including recurrent events), 85% involved the extremities, and 41% required a surgical or percutaneous intervention. There were 23 (0.12%/year) systemic embolic events with warfarin versus 15 with higher dose edoxaban (0.08%/year; HR vs warfarin, 0.65; 95% CI, 0.34 to 1.24; P=0.19) and 29 with lower dose edoxaban (0.15%/year; HR vs warfarin 1.24; 95% CI, 0.72 to 2.15; P=0.43). Secondary: In a meta-analysis of four warfarin-controlled phase three AF trials, NOACs significantly reduced the risk of systemic embolic event by 37% (relative risk 0.63; 95% CI, 0.43 to 0.91; P=0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
warfarin (adjusted dose to maintain an INR between 2.0 and 3.0) †Individuals had their dose halved (60 mg halved to 30 mg or 30 mg halved to 15 mg) if CrCl ≤ 50 mL/min, body weight ≤ 60 kg, or concomitant use of a P-glycoprotein inhibitor such as verapamil or quinidine	risk assessment and anticoagulation therapy planned for the duration of the trial		rivaroxaban; ARISTOTLE, apixaban; and ENGAGE AF-TIMI 48, edoxaban)	
Patel et al.[43] (2011) ROCKET-AF Rivaroxaban 20 mg QD (15 mg QD in patients with a creatinine clearance 30 to 49 mL/min) vs warfarin (INR of 2.0 to 3.0)	AC, DB, DD, MC, PRO, RCT Patients with nonvalvular AF, as documented on ECG, at moderate- to high-risk for stroke, indicated by a history of stroke, TIA, or systemic embolism or at least two of the following risk factors: heart failure or LVEF ≤35%, hypertension, age	N=14,264 590 days (median duration of treatment; 707 days median follow-up)	Primary: Composite of stroke (ischemic or hemorrhagic) and systemic embolism Secondary: Composite of stroke, systemic embolism, or death from cardiovascular causes; composite of stroke, systemic embolism, death from	Primary: In the PP population, stroke or systemic embolism occurred in 188 rivaroxaban-treated patients (1.7% per year) compared to 241 warfarin-treated patients (2.2% per year). Rivaroxaban was non inferior to warfarin in regard to the primary outcome (HR, 0.79; 95% CI, 0.66 to 0.96; P<0.001 for non inferiority). In the as-treated safety population, the primary outcome occurred in 189 (1.7% per year) and 243 (2.2% per year) rivaroxaban- and warfarin-treated patients (HR, 0.79; 95% CI, 0.65 to 0.95; P=0.01 for superiority). In the ITT population, the primary end point occurred in 269 rivaroxaban-treated patients (2.1% per year) compared to 306 patients in warfarin-treated patients (2.4% per year; HR, 0.88; 95% CI, 0.74 to 1.03; P<0.001 for non inferiority; P=0.12 for superiority). Secondary: In the on-treatment population, the composite of stroke, systemic embolism, or vascular death occurred in significantly fewer rivaroxaban-treated patients

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	≥75 years, or diabetes mellitus The proportion of patients who had not had a previous ischemic stroke, TIA, or systemic embolism and who had less than two risk factors was limited to 10% of the cohort for each region; the remainder of patients were required to have had either previous thromboembolism or at least three risk factors		cardiovascular causes, or MI; individual components of composite outcomes; major and nonmajor clinically relevant bleeding events	compared to warfarin treated patients (3.11 vs 5.79% per year, respectively; HR, 0.86; 95% CI 0.74 to 0.99; P=0.034). In the on-treatment population, the composite of stroke, systemic embolism, vascular death or MI occurred in significantly fewer rivaroxaban-treated patients compared to warfarin treated patients (3.91 vs 4.62% per year, respectively; HR, 0.85; 95% CI 0.74 to 0.96; P=0.010). In the on-treatment population, stroke occurred in 184 (2.61%) and 221 (3.12%) rivaroxaban- and warfarin-treated patients; there was no difference in event rates between the two treatments (1.65 vs 1.96% per year; HR, 0.85; 95% CI, 0.70 to 1.03; P=0.092). In the on-treatment population, non-central nervous system systemic embolism occurred in five (0.07%) and 22 (0.31%) rivaroxaban- and warfarin-treated patients; the event rate was significantly lower with rivaroxaban (0.04 vs 0.19% per year; HR, 0.23; 95% CI, 0.09 to 0.61; P=0.003). In the on-treatment population, vascular death occurred in 170 (2.41%) and 193 (2.73%) rivaroxaban- and warfarin-treated patients; there was no difference in event rates between the two treatments (1.53 vs 1.71% per year; HR, 0.89; 95% CI, 0.73 to 1.10; P=0.289). In the on-treatment population, MI occurred in 101 (1.43%) and 126 (1.78%) rivaroxaban- and warfarin-treated patients; there was no difference in event rates between the two treatments (0.91 vs 1.12% per year; HR, 0.81; 95% CI, 0.63 to 1.06; P=0.121). There was no difference in major and clinically relevant nonmajor bleeding between rivaroxaban and warfarin. Bleeding occurred in 1,475 and 1,449 rivaroxaban- and warfarin-treated patients (14.9 and 14.5% per year, respectively; HR, 1.03; 95% CI, 0.96 to 1.11; P=0.44). The incidence of major bleeding was similar with rivaroxaban and warfarin (3.6 and 3.4%, respectively; P=0.58). Decreases in hemoglobin levels ≥2 g/dL and transfusions were more common among rivaroxaban-treated patients, whereas fatal bleeding and bleeding at critical anatomical sites were less frequent

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				compared to warfarin treated patients. Rates of intracranial hemorrhage were significantly lower with rivaroxaban compared to warfarin (0.5 vs 0.7% per year; HR, 0.67; 95% CI, 0.47 to 0.93; P=0.02). Major bleeding from a gastrointestinal site was more common with rivaroxaban, with 224 bleeding events (3.2%), compared to 154 events (2.2%) with warfarin (P<0.001).
Hankey et al.[44] (2012) ROCKET-AF Rivaroxaban 20 mg QD (15 mg QD in patients with a creatinine clearance 30 to 49 mL/min) vs warfarin (INR of 2.0 to 3.0)	Subanalysis of ROCKET-AF[35] Patients enrolled in the ROCKET-AF trial stratified based on previous stroke and TIA	N=14,264 (previous stroke or TIA; n=7,468) 590 days (median duration of treatment; 707 days median follow-up)	Primary: Composite of stroke (ischemic or hemorrhagic) and systemic embolism Secondary: Safety, major and nonmajor clinically relevant bleeding events	Primary: The number of events per 100 person-years for the primary endpoint in patients receiving rivaroxaban compared to patients receiving warfarin was consistent among patients with previous stroke or TIA (2.79 vs 2.96%; HR, 0.94; 95% CI, 0.77 to 1.16) and those without (1.44 vs 1.88%; HR, 0.77; 95% CI, 0.58 to 1.01; P=0.23). Secondary: The overall number of adverse events per 100 person-years was similar with both treatments and in patients with and without previous stroke or TIA. The number of major and nonmajor clinically relevant bleeding events per 100 person-years in patients receiving rivaroxaban and warfarin was consistent among patients with previous stroke or TIA (13.31 vs 13.87%; HR, 0.96; 95% CI, 0.87 to 1.07) and those without (16.69 vs 15.19%; HR, 1.10; 95% CI, 0.99 to 1.21; P=0.08). The number of major bleeding events per 100 person-years among patients who received at least one dose of study drug was significantly lower among those with previous stroke or TIA (n=318, 3.18%) compared to those without (n=420, 3.89%; HR, 0.81; 95% CI, 0.70 to 0.93; P=0.0037), but the safety of rivaroxaban compared to warfarin with respect to major bleeding showed no interaction among patients with (HR, 0.97; 95% CI, 0.79 to 1.19) and without previous stroke or TIA (HR, 1.11; 95% CI, 0.92 to 1.34; P=0.36). The effect of rivaroxaban compared to warfarin on intracerebral hemorrhage was consistent among patients with (HR, 0.84; 95% CI, 0.50 to 1.41) and without previous stroke or TIA (HR, 0.46; 95% CI, 0.24 to 0.89; P=0.16).
Halperin et al.[45] (2014) ROCKET-AF	Subanalysis of ROCKET-AF[35]	N=14,264 590 days	Primary: Stroke (ischemic or hemorrhagic)	Primary: Stroke and systemic embolism were more common in patients aged ≥75 years than in those aged <75 years (2.57 vs 2.05 per 100 patient-years; P=0.0068). In

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rivaroxaban 20 mg QD (15 mg QD in patients with a creatinine clearance 30 to 49 mL/min) vs warfarin (INR of 2.0 to 3.0)	Patients enrolled in the ROCKET-AF trial stratified by age ≥75 or <75 years	(median duration of treatment; 707 days median follow-up)	and systemic embolism Secondary: Bleeding complications	older patients, the primary event rate was 2.29 (95% CI, 1.92 to 2.73) per 100 patient-years with rivaroxaban compared with 2.85 (95% CI, 2.43 to 3.34) per 100 patient-years with warfarin (HR=0.80; 95% CI, 0.63 to 1.02). In younger patients, the primary event rate was 2.00 (95% CI, 1.69 to 2.35) per 100 patient-years with rivaroxaban compared with 2.10 (95% CI, 1.79 to 2.46) per 100 patient-years with warfarin (HR=0.95; 95% CI, 0.76 to 1.19). There was no significant interaction of treatment efficacy with age for the primary end point (P=0.3131). Secondary: Rates of major bleeding were higher among older patients (4.63 [4.21 to 5.09] per 100 patient-years) than in younger patients (2.74 [2.47 to 3.04]; P<0.0001). There were no significant differences, however, in rates of major bleeding among patients on rivaroxaban compared with those on warfarin in either age group.
Jones et al.[46] (2014) ROCKET-AF Rivaroxaban 20 mg QD (15 mg QD in patients with a creatinine clearance 30 to 49 mL/min) vs warfarin (INR of 2.0 to 3.0)	Subanalysis of ROCKET-AF[35] Patients enrolled in the ROCKET-AF trial stratified by peripheral artery disease (PAD)	N=14,264 (PAD; n=839) 590 days (median duration of treatment; 707 days median follow-up)	Primary: Stroke or systemic embolism, bleeding events Secondary: All-cause death, MI, and the composite (and individual components) of stroke, systemic embolism, or vascular death	Primary: The overall rate of stroke or non-CNS systemic embolism was not statistically significantly different among patients with PAD compared with those without PAD (2.41 vs 2.09 events/100 patient-years; adjusted HR, 1.04; 95% CI, 0.72 to 1.50; P=0.84). The overall rate of major or non-major clinically relevant bleeding was also not statistically significantly different among patients with PAD compared with those without PAD (17.81 vs 14.54; HR, 1.11; CI, 0.96 to 1.28; P=0.17). Secondary: No differences in treatment effect were detected between patients with and without PAD for any of the secondary efficacy endpoints.
Anderson et al.[47] (2008) Warfarin (INR ≥2.0) vs	MA (15 RCTs) Patients ≥18 years of age with AF or atrial flutter	N=16,058 ≥3 months	Primary: Incidence of systemic embolism and major bleeding	Primary: Warfarin vs placebo Four trials compared the efficacy of warfarin vs placebo for prevention of thromboembolic events (n=1,909). Eleven systemic embolic events were observed; two and nine in warfarin- and placebo-treated patients (OR, 0.29; 95% CI, 0.08 to 1.07; P=0.06). The rates of major bleeding were higher in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo, antiplatelet agents (aspirin, aspirin plus clopidogrel, indobufen*), low dose warfarin and low dose warfarin plus aspirin Results for aspirin plus clopidogrel and indobufen were not reported.			Secondary: Not reported	warfarin-treated patients in three trials. The combined OR for major bleeding was higher in warfarin-treated patients (OR, 3.01; 95% CI, 1.31 to 6.92; P=0.01). Warfarin vs antiplatelet agents Nine trials compared the efficacy of warfarin and antiplatelet agents for the prevention of systemic embolism (n=11,756). Thirty four and 71 systemic embolism events occurred in warfarin- and antiplatelet-treated patients (OR, 0.50; 95% CI, 0.33 to 0.75; P<0.001). Pooled analysis for the risk of major bleeding showed no evidence of increased risk with warfarin treatment (OR, 1.07; 95% CI, 0.85 to 1.34; P=0.59). Warfarin vs low dose warfarin or a combination of low dose warfarin and aspirin Five trials compared warfarin vs low dose warfarin or the combination of low dose warfarin and aspirin for the prevention of thromboembolic events. Four trials compared warfarin directly with low dose warfarin (n=1,008), and five and three patients had an embolic event (OR, 1.52; 95% CI, 0.40 to 5.81; P=0.54). Two trials compared warfarin to low dose warfarin and aspirin (n=1,385); two patients in each group had a systemic embolic event (OR, 1.00; 95% CI, 0.17 to 5.81; P=1.00). The risk of major bleeding was higher in warfarin-treated patients compared to low dose warfarin-treated patients (OR, 2.88; 95% CI, 1.09 to 7.60; P=0.03), but there was no difference when comparing warfarin-treated patients to low dose warfarin and aspirin-treated patients (OR, 1.14; 95% CI, 0.55 to 2.36; P=0.72). All trials were stopped early owing to the "superiority" of warfarin treatment in stroke prevention seen in other trials. Secondary: Not reported
Agarwal et al.[48] (2012) Warfarin vs	MA (8 RCTs) Patients with nonvalvular AF	N=32,053 (55,789 patient-years) Duration not specified	Primary: Ischemic or hemorrhagic stroke or non-central nervous system embolism	Primary: The rate of stroke or non-central nervous system embolism varied from 1.2 to 2.3% per year. The pooled event rate for stroke or non-central nervous system embolism was calculated to be 1.66% (95% CI, 1.41 to 1.91) per year. There was a significantly higher incidence of stroke and non-central nervous system embolism in patients ≥75 years (2.27% per year) compared to those <75 years of age (1.62% per year; P<0.001). A significantly higher pooled incidence of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
alternative thromboprophylaxis (ximelagatran*, idraparinux*, aspirin, aspirin plus clopidogrel, dabigatran, rivaroxaban, apixaban)			Secondary: MI, all-cause mortality, composite adverse vascular events (stroke, non-central nervous system embolism, MI, and death), major bleeding, intracranial hemorrhage, clinically relevant nonmajor bleeding, minor bleeding	stroke or non-central nervous system embolism in females compared to males (P<0.01) and in patients with a history of stroke or TIA compared to patients without previous events (P=0.001). Patients with no history of exposure to VKA had a significantly higher incidence of stroke and non-central nervous system embolism compared to patients who reported use of VKA at the time of enrollment (RR, 1.16; 95% CI, 1.01 to 1.33). Pooled analysis stratified by $CHADS_2$ score yielded pooled annual event rates of 0.89% (95% CI, 0.66 to 1.13) per year for scores ≤1, 1.43% (95% CI, 1.19 to 1.66) per year for scores of 2, and 2.50% (95% CI, 2.17 to 2.82) per year for scores ≥3. Compared to with the lowest risk $CHADS_2$ category, the RR of stroke or non-central nervous system embolism was significantly higher with intermediate risk category (RR, 1.46; 95% CI, 1.13 to 1.89; P=0.004) and in the high risk category (RR, 2.89; 95% CI, 2.28 to 3.66; P<0.001). Secondary: Rates of MI, all-cause mortality, and composite vascular events varied from 0.53 to 1.40% per year, 2.21 to 8.00% per year, and 3.93 to 5.90% per year, respectively. Pooled event rates for MI, all-cause mortality, and composite vascular events were calculated to be 0.76% (95% CI, 0.57 to 0.96) per year, 3.83% (95% CI, 3.07 to 4.58) per year, and 4.80% (95% CI, 4.22 to 5.38) per year, respectively. The incidence of major bleeding episodes ranged from 1.40 to 3.40% per year. The annual rate of intracranial hemorrhage in patients with AF taking warfarin ranged from 0.33 to 0.80% per year. MA of intracranial hemorrhage yielded a pooled event rate of 0.61% (95% CI, 0.48 to 0.73) per year. The cumulative adverse event rate, defined as major vascular events reported or death or major bleedings episodes, was observed to range from 3.00% per year in one trial to 7.64% per year in another.
Saxena et al.[49] (2004) Oral anticoagulants (warfarin) vs	SR (2 RCTs) Patients with nonrheumatic AF and a previous TIA or minor ischemic stroke	N=485 1.7 to 2.3 years	Primary: Fatal or non-fatal recurrent stroke, all major vascular events (vascular death, recurrent stroke, MI, and systemic	Primary: In one RCT, the annual rate of all vascular events was eight vs 17% in oral anticoagulation and placebo-treated patients. The risk of stroke was reduced from 12 to four percent per year. In absolute terms, 90 vascular events (mainly strokes) were prevented per 1,000 patients treated with oral anticoagulation per year. There were eleven out of 225 nonvascular deaths in oral anticoagulation-treated patients compared to nine out of 214 nonvascular deaths in placebo-treated patients, and 30 out of 225 and 35 out of 214 vascular deaths. In the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo Target INR ranges in patients receiving oral anticoagulants were 2.5 to 4.0 and 1.4 to 2.8 in the two RCTs included in the review.			embolism), any intracranial bleed, major extracranial bleed Secondary: Not reported	same trial, the incidence of all bleeding events while receiving oral anticoagulation was low (2.8 vs 0.7% per year). The absolute annual excess of major bleeds was 21 per 1,000 patients treated, with no documented intracerebral bleeding. In the second RCT, four and two placebo- and oral anticoagulation-treated patients had a recurrent stroke. The number of all vascular events was eight out of 21 in warfarin-treated patients compared to eleven out of 25 in placebo-treated patients (OR, 0.78; 95% CI, 0.20 to 2.9). In the same trial, no intracranial bleeds occurred. Combined results demonstrate that oral anticoagulation is highly effective; it reduces the odds of recurrent stroke (disabling and non-disabling) by two-thirds (OR, 0.36; 95% CI, 0.22 to 0.58) and it almost halves the odds of all vascular events (OR, 0.55; 95% CI, 0.37 to 0.82). The benefit is not negated by an unacceptable increase of major bleeding complications (OR, 4.32; 95% CI, 1.55 to 12.10). In both trials, no intracranial bleeds were reported in oral anticoagulation-treated patients (OR, 0.13; 95% CI, 0.00 to 6.49). Secondary: Not reported
Aguilar et al.[50] (2005) Oral anticoagulants (warfarin [and congeners*] and orally active DTIs) vs control or placebo	SR (5 RCTs) Patients with AF without prior stroke or TIA	N=2,313 1.5 years (mean follow-up; range, 1.2 to 2.3 years)	Primary: All strokes Secondary: Ischemic strokes, all disabling or fatal stroke, MI, systemic emboli, all intracranial hemorrhage, major extracranial hemorrhage, vascular death, composite of all stroke, MI or	Primary: Consistent reductions were likewise evident in all trials, with an overall OR of 0.39 (95% CI, 0.26 to 0.59). About 25 strokes would be prevented yearly per 1,000 patients given oral anticoagulants. Secondary: Warfarin was associated with a reduction in ischemic stroke in all five trials, which was significant in four (pooled analysis vs control: OR, 0.34; 95% CI, 0.23 to 0.52). With the annualized rate of ischemic stroke in the control group of about four percent per year, the absolute reduction by oral anticoagulants was about 2.6% per year for patients without prior stroke or TIA, or about 25 ischemic strokes saved yearly per 1,000 patients given warfarin. Consistent reductions in all disabling or fatal strokes were seen in all trials, not reaching statistical significance in individual trials but with a significant reduction in pooled analysis (OR, 0.47; 95% CI, 0.28 to 0.80). About 12 of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			vascular death, all-cause mortality	these serious strokes would be prevented yearly for every 1,000 participants given warfarin. Fifteen MIs occurred in three trials; therefore, no meaningful estimate of the effect of oral anticoagulants on this outcome could be made (OR, 0.87; 95% CI, 0.32 to 2.42). Ten systemic emboli occurred in the five trials; therefore, no meaningful estimate of the effect of oral anticoagulants could be made, but with the trend similar to that for ischemic stroke (OR, 0.45; 95% CI, 0.13 to 1.57). Seven intracranial hemorrhages occurred, with a nonsignificant trend toward the expected increase (OR, 2.38; 95% CI, 0.54 to 10.50). Major extracranial hemorrhage was similar in warfarin-treated patients, but with wide CIs due to the relatively small number of events (OR, 1.07; 95% CI, 0.53 to 2.12). A nonsignificant trend favoring treatment with warfarin was seen (OR, 0.84; 95% CI, 0.56 to 1.30) for vascular death. For the composite of stroke, MI or vascular death, the OR with oral anticoagulants was 0.57 (95% CI, 0.42 to 0.76). About 25 of these events would be prevented per year for every 1,000 patients given warfarin. Sixty nine and 99 deaths occurred in warfarin- and control-treated patients (OR, 0.69; 95% CI, 0.50 to 0.94). The mortality rate averaged 5% per year in the control group. About 17 deaths would be prevented per year for every 1,000 AF patients given warfarin.
Ruff et al.[51] (2014) New oral anticoagulant (apixaban, dabigatran, edoxaban,	MA (4 trials; RE-LY[26], ROCKET-AF[35], ARISTOTLE[21], and ENGAGE AF-TIMI) Patients with AF	N=71,683 Median follow-up ranged from 1.8 to 2.8 years	Primary: Stroke and systemic embolic events, ischemic stroke, hemorrhagic stroke, all-cause mortality, MI,	Primary: Allocation to a new oral anticoagulant significantly reduced the composite of stroke or systemic embolic events by 19% compared with warfarin. The benefit was mainly driven by a large reduction in hemorrhagic stroke. New oral anticoagulants were also associated with a significant reduction in all-cause mortality. The drugs were similar to warfarin in the prevention of ischemic stroke and myocardial infarction.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
rivaroxaban) vs warfarin			major bleeding, intracranial hemorrhage, and gastrointestinal bleeding Secondary: Not reported	Randomization to a high-dose new oral anticoagulant was associated with a 14% non-significant reduction in major bleeding. In line with the reduction in hemorrhagic stroke, a substantial reduction in intracranial hemorrhage was observed, which included hemorrhagic stroke, and subdural, epidural, and subarachnoid bleeding. New oral anticoagulants were, however, associated with increased gastrointestinal bleeding. A greater relative reduction in bleeding with new oral anticoagulants was found at centers that achieved a center-based time in therapeutic range of less than 66% than at those achieving a time in therapeutic range of 66% or more. Secondary: Not reported
Ezekowitz et al.[52] (1999) Warfarin vs aspirin vs warfarin plus aspirin A total of 10 trials were included: five primary prevention PC trials, one secondary prevention trial, one trial comparing warfarin to aspirin, and three trials of warfarin plus	MA (10 trials) Patients with AF	N=not reported 1.2 to 2.3 years (average follow-up)	Primary: Not reported Secondary: Not reported	Primary: Not reported Secondary: Not reported Pooled analysis from the five PC, primary prevention trials demonstrate the value of warfarin for reducing the risk of stroke was consistent among trials and decreased the risk by 68% (4.5 to 1.4% per year) with virtually no increase in the frequency of major bleeding (rates: 1.2, 1.0 and 1.0% per year for warfarin, aspirin and placebo, respectively). Two of these trials evaluated aspirin for the primary prevention of stroke. In one trial, aspirin use was associated with a 42% reduction in stroke and in the other; the reduction of stroke with aspirin compared to placebo was 36%. The primary prevention trials demonstrate that warfarin is “superior” to both aspirin and placebo, with aspirin being more effective than placebo for preventing stroke. The annual rate of the main outcome measures of death due to vascular disease, any stroke, MI or systemic embolism in the secondary prevention trial was 8% per year in warfarin-treated patients and 17% per year in placebo-treated patients. Treatment with warfarin reduced the risk of stroke from 12 to 4% per year (66% reduction). Among the aspirin-treated patients, the incidence of outcome events was 15% per year compared to 19% per year among placebo-treated patients. The incidence of major bleeding was low in this trial: 2.8, 0.9

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
aspirin.				and 0.7% per year for warfarin, aspirin and placebo. In the trial comparing warfarin to aspirin for the primary prevention of stroke, the primary event rate was 1.3 and 1.9% per year in warfarin- and aspirin-treated patients (RR, 0.67; P=0.24), and by ITT analysis there was no benefit from treatment with warfarin. Of note, the trial was not adequately powered to show a difference between the two treatments. Patients >75 years of age had a substantial risk of thromboembolism during treatment with aspirin (4.8% per year); treatment with warfarin reduced the risk to 3.6% per year (RR, 0.73; P=0.39). The trial evaluating warfarin in combination with aspirin to warfarin monotherapy in AF patients with at least one prespecified risk factor for thromboembolic disease was terminated after a mean follow-up of 1.1 years because the rate of ischemic stroke and systemic embolization in combination-treated patients was 7.9% per year compared to 1.9% per year in warfarin-treated patients (P<0.001). The rates of major bleeding were similar in both treatments.
Reduce the Risk of Death, Recurrent MI, and Thromboembolic Events Such as Stroke or Systemic Embolization After MI				
Rothberg et al.[53] (2005) Warfarin (high intensity) plus aspirin vs aspirin	MA (10 RCTs) Patients with ACS who were not stented	N=5,938 3 months to 4 years (follow-up)	Primary: MI, stroke, revascularization Secondary: Not reported	Primary: The annualized rate of MI in aspirin-treated patients ranged from 0.03 to 0.93. Nine of the ten trials found a risk reduction attributable to treatment with warfarin, but only two trials were sufficiently powered for the reduction to reach statistical significance. Reductions in RR ranged from 29 to 100%, with an overall RR of 44%. The annualized risk for ischemic stroke in aspirin-treated patients ranged from 0.000 to 0.080, with a weighted average of 0.008. In the five trials in which at least one stroke was reported, a risk reduction for warfarin plus aspirin-treated patients was found, but only one risk reduction was statistically significant. Reductions in the RR ranged from 50 to 100%, with an overall RR of 54% (CI, 23 to 73). Overall, four hemorrhagic strokes occurred in warfarin-treated patients and one in aspirin-treated patients, translating to one additional intracranial hemorrhage per 1,800 patient-years of combined anticoagulation. The annualized risk for revascularization ranged from 0.076 to 1.300. Five of the seven trials showed decreased rates of percutaneous transluminal coronary

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				angioplasty or CABG for warfarin-treated patients, but only one rate reached statistical significance. HRs ranged from 0.51 to 1.70, with an overall RR reduction of 20% (95% CI, 5 to 33). No trial showed a significant difference in mortality. The combined trials showed a four percent decrease in overall mortality in warfarin-treated patients, but this did not reach significance (P value not reported). Nine trials showed an increased risk for major bleeding associated warfarin treatment. The annualized risk for major bleeding in warfarin-treated patients ranged from 0.6 to 18.0%, with an overall risk of 1.5%. The RR for major bleeding with warfarin treatment compared to aspirin was 2.5 (95% CI, 1.7 to 3.7). The RR for minor bleeding was 2.6 (95% CI, 2.0 to 3.3). Secondary: Not reported
Prophylaxis and/or Treatment of Venous Thromboembolism				
Eriksson et al.[54] (2008) RECORD1 Rivaroxaban 10 mg QD for 35 days vs enoxaparin 40 mg SC QD in the evening for 35 days Rivaroxaban was initiated six to eight hours after wound closure. Enoxaparin was	DB, DD, MC, RCT Patients ≥18 years of age undergoing elective total hip replacement	N=4,541 70 days	Primary: The composite of any DVT, nonfatal PE, or death from any cause up to 36 days; incidence of major bleeding beginning after the first dose of the study drug and up to two days after the last dose of the study drug Secondary: Major VTE (composite of	Primary: Rivaroxaban significantly reduced the risk of the primary composite endpoint (1.1 vs 3.7%; ARR, -2.6%; 95% CI, -3.7 to -1.5; P<0.001). There was no difference between rivaroxaban and enoxaparin for major bleeding events (0.3 vs 0.1%; P=0.18). Secondary: Rivaroxaban significantly reduced the risk of major VTE (0.2 vs 2.0%; ARR, -1.7%; 95% CI, -2.5 to 1.0; P<0.001). Rivaroxaban significantly reduced the risk of DVT (0.8 vs 3.4%; ARR, -2.7; 95% CI, -3.7 to -1.7; P<0.001). Rivaroxaban and enoxaparin had similar rates of symptomatic VTE during treatment (0.3 vs 0.5%; ARR, -0.2%; 95% CI, -0.6 to 0.1; P=0.22) and follow-up (<0.1 vs 0.0%; ARR, -0.1%; 95% CI, -0.4 to 0.1; P=0.37). Both treatments had <0.1% cases of death occurring during follow-up (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
administered 12 hours prior to surgery and then reinitiated six to eight hours after wound closure. All patients received either placebo tablets or placebo injection.			proximal DVT, nonfatal PE, or death from VTE), incidence of DVT (any thrombosis, including both proximal and distal), incidence of symptomatic VTE during treatment and follow-up, death during the follow-up period, any on-treatment bleeding, any on-treatment nonmajor bleeding, hemorrhagic wound complications, any bleeding that started after the first dose and up to two days after the last dose of the study drug, adverse events and death	Rivaroxaban and enoxaparin had similar rates for any on-treatment bleeding (6.0 vs 5.9%; P=0.94) and any on-treatment nonmajor bleeding events (5.8 vs 5.8%; P value not reported). The rate of hemorrhagic wound complications was also similar (1.5 vs 1.7%; P value not reported). The rate of any bleeding beginning after the first dose of rivaroxaban or placebo were also similar (5.5 vs 5.0%; P value not reported). Rivaroxaban and enoxaparin had similar rates of any on-treatment adverse event (64.0 vs 64.7%; P value not reported). The incidence of death during the on-treatment period was similar between the two treatments (0.3 vs 0.3%; ARR, 0%; 95% CI, -0.4 to 0.4; P=1.00). Of the four deaths that occurred with rivaroxaban, two were possibly related to VTE. Of the four deaths that occurred with enoxaparin, one was related to VTE.
Kakkar et al.[55] (2008) RECORD2 Rivaroxaban 10	DB, DD, MC, RCT Patients ≥18 years of age undergoing complete hip	N=2,509 75 days	Primary: The composite of any DVT, nonfatal PE, or death from any	Primary: Rivaroxaban significantly reduced the risk of the primary composite endpoint compared to enoxaparin (2.0 vs 9.3%; ARR, 7.3%; 95% CI, 5.2 to 9.4; P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg QD for 31 to 39 days vs enoxaparin 40 mg SC QD for 10 to 14 days Rivaroxaban was initiated six to eight hours after wound closure. Enoxaparin was administered 12 hours prior to surgery and reinitiated six to eight hours after wound closure. All patients received either placebo tablets or placebo injection.	replacement		cause up to day 30 to 42; incidence of major bleeding beginning after the first dose of the study drug and up to two days after the last dose of the study drug Secondary: Major VTE, (composite of proximal DVT, nonfatal PE, or death from VTE), incidence of DVT (any thrombosis, including both proximal and distal), incidence of symptomatic VTE during treatment and follow-up, death during the follow-up period, any on-treatment bleeding, any on-treatment nonmajor bleeding, hemorrhagic	Major bleeding occurred at a rate <0.1% with both rivaroxaban and enoxaparin (P value not reported). The one major bleeding event with enoxaparin was deemed unrelated to the treatment drug by the adjudication committee. Secondary: Rivaroxaban significantly reduced the risk of major VTE (0.6 vs 5.1%; ARR, 4.5%; 95% CI, 3.0 to 6.0; P<0.0001). Rivaroxaban significantly reduced the risk of DVT (1.6 vs 8.2%; ARR, 6.5%; 95% CI, 4.5 to 8.5; P<0.0001). Rivaroxaban significantly reduced the risk of on-treatment symptomatic VTE (0.2 vs 1.2%; ARR, 1.0%; 95% CI, 0.3 to 1.8; P=0.004); however, the rates during follow-up were similar (0.1 vs 0.2%; ARR, 0.1%; 95% CI, -0.2 to 0.4; P=0.62). The incidence of death during the follow-up period was similar between the two treatments (0.0 vs 0.2%; ARR, 0.2%; 95% CI, -0.1 to 0.6; P=0.50). Rates of any on-treatment bleeding (6.6 vs 5.5%; P value not reported) and any on-treatment nonmajor bleeding (6.5 vs 5.5%; P value not reported) were similar between the two treatments. Hemorrhagic wound complications also occurred at similar rates (1.6 vs 1.7%; P value not reported). The rate of any bleeding beginning after initiation of rivaroxaban or placebo was also similar (4.7 vs 4.1%; P value not reported). Adverse events from any cause were similar between the two treatments (62.5 vs 65.7%; P values not reported). The incidence of on-treatment death was similar between the two treatments (0.2 vs 0.7%; ARR, 0.5%; 95% CI, -0.2 to 1.1; P=0.29).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			wound complications, any postoperative bleeding that started after the first dose and up to two days after the last dose of the study drug, adverse events and death	
Lassen et al.[56] (2008) RECORD3 Rivaroxaban 10 mg QD for 10 to 14 days vs enoxaparin 40 mg SC QD for 10 to 14 days Rivaroxaban was initiated six to eight hours after wound closure. Enoxaparin as administered 12 hour preoperatively and reinitiated six to eight hours after	DB, DD, MC, RCT Patients ≥18 years of age undergoing elective total knee replacement	N=2,531 49 days	Primary: The composite of any DVT, nonfatal PE, or death from any cause within 13 to 17 days post surgery; incidence of major bleeding beginning after the first dose of the study drug and up to two days after the last dose of the study drug Secondary: Major VTE (composite of proximal DVT, nonfatal PE, or death from VTE), incidence	Primary: Rivaroxaban significantly reduced the risk of the primary composite endpoint compared to enoxaparin (9.6 vs 18.9%; ARD, -9.2%; 95% CI, -12.4 to -5.9; P<0.001). The rate of major bleeding was similar between the two treatments (0.6 vs 0.5%; P=0.77). Secondary: Rivaroxaban significantly reduced the risk of major VTE (1.0 vs 2.6%; ARD, -1.6%; 95% CI, -2.8 to -0.4; P=0.01). Rivaroxaban significantly reduced the risk of DVT (9.6 vs 18.2%; ARD, -8.4; 95% CI, -11.7 to -5.2; P<0.001). Rivaroxaban significantly reduced the risk of on-treatment symptomatic VTE (0.7 vs 2.0%; ARD, -1.3%; 95% CI, -2.2 to -0.4; P=0.005); however, during follow-up the rates were similar (0.4 vs 0.2%; ARD, 0.2%; 95% CI, -0.3 to 0.6; P=0.44). The incidence of death during follow-up was similar between the two treatments (ARD, -0.2%; 95% CI, -0.6 to 0.2; P=0.21). Rates of any on-treatment bleeding (4.9 vs 4.8%; P=0.93) or any major bleeding between the start of treatment and two days after the last dose (0.6 vs 0.5%;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
wound closure. All patients received either placebo tablets or placebo injection.			of DVT (any thrombosis, including both proximal and distal), incidence of symptomatic VTE during treatment and follow up, death during the follow up period, any on-treatment bleeding or any major bleeding occurring between intake of the first dose of the study medication and two days after the last dose, nonmajor bleeding, adverse events and death	P=0.77) were similar between the two treatments. The rate of nonmajor bleeding was also similar (4.3 vs 4.4%; P value not reported). The rates of drug-related adverse events were similar between the two treatments (12 vs 13%; P value not reported). The incidence of death during treatment was similar between the two treatments (0.0 vs 0.2%; ARD, -0.2%; 95% CI, -0.8 to 0.2; P=0.23)
Turpie et al.[57] (2009) RECORD4 Rivaroxaban 10 mg QD for 10 to 14 days vs enoxaparin 30 mg SC BID for 10 to	DB, DD, MC, RCT Patients ≥18 years of age undergoing total knee replacement	N=3,148 49 days	Primary: The composite of any DVT, nonfatal PE, or death from any cause 17 days after surgery; incidence of major bleeding beginning after the first dose of the study drug	Primary: Rivaroxaban significantly reduced the risk of the primary composite endpoint compared to enoxaparin (6.9 vs 10.1%; ARD, -3.19%; 95% CI, -5.67 to -0.71; P=0.0118). There was no difference in the rate of major bleeding between the two treatments (0.7 vs 0.3%; P=0.1096). Secondary: Rivaroxaban did not reduce the risk of major VTE compared to enoxaparin (1.2 vs 2.0%; ARD, -0.80; 95% CI, -1.34 to 0.60; P=0.1237).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
14 days Rivaroxaban was initiated six to eight hours after wound closure. Enoxaparin was initiated 12 to 24 hours after wound closure. All patients received either placebo tablets or placebo injection.			and up to two days after the last dose of the study drug Secondary: Major VTE (composite of proximal DVT, nonfatal PE, or death from VTE), incidence of asymptomatic DVT (any thrombosis, including both proximal and distal), incidence of symptomatic VTE during treatment and follow up, death during the follow-up period, clinically relevant nonmajor bleeding, any on-treatment bleeding, any nonmajor bleeding, hemorrhagic wound complications, adverse events and death	The rates of asymptomatic DVT were similar between the two treatments (P value not reported). Rivaroxaban did not reduce the risk of symptomatic VTE on-treatment (0.7 vs 1.2%; ARD, -0.47; 95% CI, -1.16 to 0.23; P=0.1868) or during follow-up (0.2 vs 0.2%; ARD, 0.00%; 95% CI, -0.32 to 0.32; P=0.9979). The incidence of death during follow-up was similar between the two treatments (0.3 vs 0.2%; ARD, 0.06%; 95% CI, -0.35 to 0.50; P=0.8044). The rates of clinically relevant nonmajor bleeding (10.2 vs 9.2%; P value not reported) and any on-treatment bleeding (10.5 vs 9.4%; P=0.3287) were similar between the two treatments. The rate of hemorrhagic wound complications was also similar (1.4 vs 1.5%; P value not reported). The rates of drug-related adverse events were similar between the two treatments (20.3 vs 19.6%; P value not reported). The rates of on-treatment death were similar between the two treatments (0.1 vs 0.2%; P=0.7449).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hutten et al.[58] (2006) Oral anticoagulants (dicoumarol*, warfarin) Trials were included if different durations of treatment with a VKA were compared. The eight trials compared seven different periods of treatment with VKAs: four weeks vs three months, six vs 12 weeks, six weeks vs six months, three vs six months, three months vs one year, three vs 27 months, and six months vs four years.	SR (8 trials) Patients with symptomatic VTE	N=2,994 Duration varied	Primary: Recurrent VTE Secondary: Major bleeding, mortality	Primary: All trials reported on the occurrence of symptomatic VTE during the period from cessation in VKA-treated patients in the short duration arm until cessation of treatment in the long duration arm. Four trials demonstrated a significant protection from recurrent VTE complications during prolonged treatment with VKAs, while the others revealed a clear trend. In the combined analysis of all eight trials, a significant reduction in thromboembolic events during prolonged treatment was observed (116 out of 1,495 short duration vs 14 out of 1,499 long duration; OR, 0.18; 95% CI, 0.13 to 0.26). Six trials evaluated the incidence of recurrent VTE in the period after cessation of study medication. No trial demonstrated a significant increase in VTE events among participants in the long arm after cessation of treatment, and combined analysis demonstrated similar results (96 out of 1,304 long duration vs 78 out of 1,301 short duration; OR, 1.24; 95% CI, 0.91 to 1.69). Analyses of pooled data demonstrated a significant reduction in recurrent VTE for the following comparisons: four weeks vs three months (OR, 0.23; 95% CI, 0.06 to 0.70), three vs six months (OR, 0.13; 95% CI, 0.05 to 0.33) and three vs 12 months (OR, 0.22; 95% CI, 0.11 to 0.44). Secondary: Four trials reported the incidence of major bleeding during the period from cessation of treatment with VKAs in the short duration arm until cessation of treatment in the long duration arm. No trial demonstrated a significant increase in bleeding complications during prolonged treatment, but combined results demonstrated a significant increase in major bleeding complications during this period (one out of 405 short duration vs eight out of 403 long duration; OR, 4.87; 95% CI, 1.31 to 18.15). Only one trial reported the incidence of major bleeding in the period after cessation of study medication. All trials reported on the occurrence of major bleeding complications for the entire period after randomization until the end of follow-up. No trial demonstrated a significant increase during prolonged treatment, but combined results demonstrated a significant increase during this period (36 out of 1,499 long duration vs 13 out of 1,495 short duration; OR, 2.61; 95% CI, 1.48 to 4.61).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Three trials reported mortality during the period from cessation of treatment with VKAs in the short duration arm until cessation of treatment in the long duration arm. One trial demonstrated a non-significant decrease in mortality during prolonged treatment, while the others showed no trends. Combined results demonstrated a non-significant reduction in mortality favoring prolonged treatment (12 out of 188 short duration vs 10 out of 188 long duration; OR, 0.80; 95% CI, 0.34 to 1.91). All trials reported on mortality for the entire period after randomization, with none demonstrating a significant reduction in morality. When the results were combined, a nonsignificant reduction in mortality during the entire study period was observed (71 out of 1,498 long duration vs 75 out of 1,496 short duration; OR, 0.93; 95% CI, 0.67 to 1.30).
van der Heijden et al.[59] (2001) VKAs vs LMWH	SR (7 RCTs) Patients with symptomatic DVT receiving long-term treatment	N=1,137 3 to 9 months	Primary: Recurrent symptomatic VTE, major bleeding complications, mortality Secondary: Not reported	Primary: All seven trials reported the occurrence of recurrent symptomatic VTE during the first three to six months after randomization. Six trials showed no differences between treatment with LMWH and VKAs, and one trial found a significant OR of 0.38 (95% CI, 0.17 to 0.86) in favor of treatment with LMWH. When the seven trials are combined, the rate of recurrent symptomatic VTE was 6.7 vs 4.8% in VKA- and LMWH-treated patients, corresponding to a nonsignificant reduction in favor of LMWH (OR, 0.70; 95% CI, 0.42 to 1.16). Six trials evaluated the occurrence of recurrent symptomatic VTE during a period of six to nine months after cessation of the allocated treatment. The rate of recurrent symptomatic VTE was 3.5 vs 5.0% of VKA- and LMWH-treated patients, corresponding to nonsignificant difference in favor of VKA treatment (OR, 1.46; 95% CI, 0.80 to 2.69). All seven trials reported the incidence of major bleeding during allocated treatment, with six trials finding no difference between the two treatments and one finding a significant difference in favor of treatment with LMWH (OR, 0.12; 95% CI, 0.02 to 0.89). When the trials were combined, 2.5 vs 0.9% VKA- and LMWH-treated patients had a major bleed; a significant difference in favor of treatment with LMWH (OR, 0.38; 95% CI, 0.15 to 0.94). No major bleeding occurred in the additional nine months of follow-up.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				All seven trials reported on mortality during the allocated treatment, with the individual trials not finding a significant difference between the two treatments. In the combined analysis, 2.5 vs 3.7% of VKA- and LMWH-treated patients died (OR, 1.51; 95% CI, 0.77 to 2.97). Six trials extended the follow-up period for an additional six to nine months and found that the rate of death was 3.5 vs 3.9% (OR, 1.11; 95% CI, 0.58 to 2.15). Secondary: Not reported
Salazar et al.[60] (2010) DTI (dabigatran†, desirudin, ximelagatran*) vs warfarin or LMWH (dalteparin, enoxaparin)	SR (12 RCTs) Patients who have undergone total hip replacement or total knee replacement	N=21,642 (efficacy) N=27,360 (safety) Duration varied	Primary: Mortality associated with VTE, incidence of proximal VTE, mortality associated with treatment, appearance of serious hepatopathy, appearance of other serious adverse effects associated with treatment Secondary: Incidence of distal VTE, presence of hepatopathy after treatment, morbidity associated with treatment	Primary and Secondary end points are reported together in the groupings below. *Major, total and symptomatic VTE* Combined analysis from two trials comparing DTIs to LMWH demonstrated that when evaluating the combination of both surgery groups, no difference was observed between the two treatments (557 out of 10,736 vs 392 out of 6,692 events/patients; OR, 0.91; 95% CI, 0.69 to 1.19). Evaluation of the individual surgery groups had similar results. No difference was observed between the two treatments for total VTE (data not reported) or symptomatic VTE (234 out of 12,056 vs 143 out of 7,563; OR, 1.04; 95% CI, 0.84 to 1.29). Combined analysis from three trials comparing ximelagatran to warfarin demonstrated no statistical difference between the two treatments (95 out of 2,498 vs 83 out of 1,829 events/patients; OR, 0.85; 95% CI, 0.63 to 1.15). There were fewer total VTE events in DTI-treated patients (555 out of 2,514 vs 543 out of 1,840; OR, 0.68; 95% CI, 0.59 to 0.78). No difference between the two treatments were observed for symptomatic VTE (47 out of 3,022 vs 48 out of 2,237; OR, 0.80; 95% CI, 0.53 to 1.21). *Major/significant and total bleeding events* Combined analysis from eleven trials comparing DTIs to LMWH demonstrated a nonsignificant higher number of major significant bleeding events in DTI-treated patients (334 out of 13,753 vs 138 out of 8,356 events/patients; OR, 1.17; 95% CI, 0.87 to 1.58). In the comparison of each independent dose, only dabigatran 225 mg BID showed more bleeding events in the DTI group (OR, 1.90; 95% CI, 1.05 to 3.44) in the combination of both surgeries and specifically in total hip replacement (26 out of 270 vs 13 out of 270; OR, 2.11; 95% CI, 1.06 to 4.19). Combined analysis from ten trials demonstrated no

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				difference between the two treatments in terms of total bleeding events; however, more events were observed in DTI-treated patients undergoing total hip replacement (2,370 out of 5,949 vs 1,374 out of 4,378; OR, 1.40; 95% CI, 1.06 to 1.85). Combined analysis of three trials comparing ximelagatran to warfarin demonstrated more major/significant bleeding events with ximelagatran, but the difference was not statistically significant (30 out of 3,022 vs 13 out of 2,237 events/patients; OR, 1.76; 95% CI, 0.91 to 3.38). Partial and total bleeding events were very similar to major bleeding events. *All-cause mortality* Combined analysis of eleven trials comparing DTIs to LWMH demonstrated a nonsignificant higher all-cause mortality event rate with DTI treatment (15 out of 13,730 vs four out of 8,335 events/patients; OR, 1.72; 95% CI, 0.68 to 4.35). When including follow-up events the difference met statistical significance (41 out of 13,730 vs 11 out of 8,335; OR, 2.06; 95% CI, 1.10 to 3.87). Combined analysis of three trials comparing ximelagatran to warfarin demonstrated no significant difference between the two treatments (six out of 3,013 vs four out of 2,230 events/patients; OR, 1.19; 95% CI, 0.36 to 4.01), even when follow-up events were included (10 out of 3,013 vs five out of 2,230; OR, 1.62; 95% CI, 0.57 to 4.58). *ALT greater than three times the upper normal limit* The seven trials comparing DTIs to LMWH had high heterogeneity; therefore, results could not be combined. Fewer events were observed in DTI-treated patients, but with high heterogeneity, in the ximelagatran trials. No difference was noted when treatment with dabigatran was compared to treatment with LMWH, but these trials had very high heterogeneity. Combined analysis of two trials comparing ximelagatran to warfarin demonstrated no significant difference between the two treatments (18 out of 2,493 vs 21 out of 1,768 events/patients; OR, 0.52; 95% CI, 0.27 to 0.97), even when follow-up events were included (11 out of 2,484 vs one out of 1,783; OR, 5.61; 95% CI, 1.00 to 31.64).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Volume of blood loss No difference was observed between treatment with DTIs and LMWH in the combined analysis of five trials (n=8,782; WMD, 5.12; 95% CI, -33.81 to 44.04), but these trials had high heterogeneity. No difference was observed between ximelagatran and warfarin in the combined analysis of three trials (n=5,259; WMD, -7.12; 95% CI, -17.08 to 2.84), with no heterogeneity. *Time effect of the beginning of anticoagulation* Trials comparing DTIs to LMWH that began anticoagulation before surgery demonstrated fewer major (OR, 0.54; 95% CI, 0.35 to 0.83) and total (OR, 0.72; 95% CI, 0.63 to 0.82) VTE in DTI-treated patients in both surgery groups. There was also no difference regarding symptomatic VTE. Trials that began anticoagulation after surgery demonstrated more major (OR, 1.68; 95%, 1.12 to 2.52) and total (OR, 1.29; 95% CI, 0.69 to 2.39) VTE events in DTI-treated patients in both surgery groups. Again, there was no difference regarding symptomatic VTE. Trials that began anticoagulation before surgery demonstrated a non- significant greater incidence of major (OR, 1.64; 95% CI, 0.85 to 3.15) and total (OR, 1.45; 95% CI, 0.93 to 2.28) bleeding events in DTI-treated patients in both combined surgeries and in the individual analysis of each surgery. There was no significant difference regarding mortality. *Extended prophylactic anticoagulation vs standard prophylactic anticoagulation* No difference was found in major or total VTE between DTI- and LMWH-treated patients. Symptomatic VTE events in extended anticoagulation occurred more with dabigatran in comparison to LMWH, but the difference was not statistically significant (25 out of 2,293 vs five out of 1,142 events/patients; OR, 2.51; 95% CI, 0.96 to 5.67). In standard anticoagulation, no difference between DTI- and LMWH-treated patients was noted (76 out of 3,351 vs 37 out of 1,542; OR, 0.99; 95% CI, 0.67 to 1.48).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Regarding safety, no difference in major or total bleeding events was noted. All-cause mortality, transaminase levels and blood loss were not evaluated.
Brookenthal et al.[61] (2001) Thromboprophyl-axis (aspirin, dextran, heparin [with or without antithrombin III], LMWH [ardeparin*, enoxaparin, tinzaparin], lower extremity pneumatic compression stockings, or warfarin) vs placebo A prophylactic agent of interest was compared to another method of interest or placebo.	MA (14 trials) Patients receiving prophylaxis for ≥7 days for an elective total knee arthroplasty	N=3,482 Duration varied	Primary: Total DVT, proximal DVT, distal DVT, symptomatic PE, fatal PE, minor bleeding, major bleeding, total bleeding, intracranial hemorrhage, non-PE mortality, all-cause mortality Secondary: Not reported	Primary: For total DVT, all treatments, except dextran and aspirin, protected significantly better than placebo (P<0.0001). For proximal DVT, no comparison against placebo was available, and rates ranged from 1.7 (aspirin) to 12.8% (SC heparin/antithrombin III). The only significant difference was between treatment with LMWH and warfarin (5.9 vs 10.2%; P=0.0002). There was a strong trend that aspirin protected better than warfarin (1.7 vs 10.2%; P=0.0106). For distal DVT, no comparison against placebo was available. LMWH (24.4%) protected significantly better than dextran (71.1%; P=0.0001), warfarin (35.6%; P=0.0001) and aspirin (55.2%; P=0.0001). Warfarin (35.6%) protected significantly better than aspirin (55.2%; P=0.0045) but worse than SC heparin (21.5%; P=0.0029). Aspirin (55.2%) protected significantly less than SC heparin (21.5%; P=0.0001) and pneumatic compression stockings (29.5%; P=0.0051). Rates of symptomatic PE ranged from 0.0 (aspirin, pneumatic compression stockings and placebo) to 0.4% (warfarin, SC heparin); there was no significant detectable difference among the agents. No fatal PE occurred with any treatment. The rate of total bleeding ranged from 8.6 (aspirin) to 18.9% (SC heparin). No comparison with placebo was available. The rate of minor bleeding ranged from 8.6 (aspirin) to 18.3% (SC heparin). Rates of major bleeding ranged from 0.0 (aspirin, pneumatic compression stockings) to 2.4% (LWMH), but no difference between treatments were noted. There were no observed intracranial hemorrhages. Rates for overall and non-PE mortality ranged from 0.0 (aspirin, SC heparin,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				pneumatic compression stockings, placebo, SC heparin/antithrombin III and dextran) to 0.3% (warfarin), but no difference among the treatments were noted. Secondary: Not reported
Cundiff et al.[62] (2006) Anticoagulants (heparin, phenprocoumon*, warfarin) vs NSAIDs (phenylbutazone*) or placebo	SR (2 RCTs) Patients with DVT or PE	N=113 3 months	Primary: Mortality due to PE, PE, DVT and extension of DVT or both Secondary: All-cause mortality, major hemorrhagic events, fatal hemorrhagic events, morbidity and mortality due to HIT with thrombosis	Data were not pooled because of heterogeneity between the trials, and the trials were too small to determine any difference in mortality, occurrence of PE, and progression or return of DVT between patients receiving anticoagulation and those who were not. Primary: In one trial (n=23), no deaths due to PE were reported and in the other trial (n=90), there was no significant difference in deaths due to PE between anticoagulant- and NSAID-treated patients (one vs zero; RR, 2.63; 95% CI, 0.11 to 62.95). In one trial (n=23), there was no difference in the combined outcome PE, DVT progression or return in anticoagulation-treated patients compared to those who did not receive anticoagulation (five vs five; RR, 1.09; 95% CI, 0.43 to 2.77). In one trial (n=90), there was no difference in the combined outcome recurrent DVT or DVT (18 vs 22; RR, 0.72; 95% CI, 0.45 to 1.14). Secondary: There was no difference in the secondary outcomes of all-cause mortality and major hemorrhage in either trial between the two treatments. Neither trial reported morbidity or mortality due to HIT with thrombosis, or VKA necrosis.
Di Nisio et al.[63] (2012) Any oral or parenteral anticoagulant (UFH, LMWH, VKA, direct thrombin or factor	SR (9 RCTs) Ambulatory outpatients of any age with either a solid or hematological cancer, at any stage, and	N=3,538 Duration varied	Primary: Symptomatic VTE, major bleeding Secondary: Symptomatic PE, symptomatic DVT,	Primary: LMWH vs inactive control Pooled analysis of six RCTs demonstrated that when compared to placebo, LMWH was associated with a significant reduction symptomatic VTE (RR, 0.62; 95% CI, 0.41 to 0.93), corresponding to a NNT of 60. Pooled analysis of six RCTs suggested a 60% increased risk of a major bleeding (RR, 1.57; 95% CI, 0.69 to 3.60).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Xa inhibitors), or both vs inactive control (placebo, no treatment, standard care) or active control	receiving chemotherapy, without a positive history of VTE		asymptomatic VTE, overall VTE, minor bleeding, one year overall mortality, arterial thromboembolic events, superficial thrombophlebitis, quality of life, number of patients experiencing any serious adverse event	LMWH vs active control In one trial, LMWH was associated with a 67% reduction in symptomatic VTE relative to warfarin (RR, 0.33; 95% CI, 0.14 to 0.83) while the difference with aspirin was not significant (RR, 0.50; 95% CI, 0.19 to 1.31). In one trial, there were no differences between LMWH, aspirin, and warfarin regarding the incidence of major bleeding. VKA vs inactive control In one trial, a trend for a reduction in symptomatic VTE (RR, 0.15; 95% CI, 0.02 to 1.20) was reported. There was no significant effect on major bleeding (RR, 0.52; 95% CI, 0.05 to 5.71). VKA vs active control One trial reported a nonsignificant difference between VKA and aspirin (RR, 1.50; 95% CI, 0.74 to 3.04). Antithrombin vs inactive control In one trial, the effects of antithrombin on symptomatic VTE (RR, 0.84; 95% CI, 0.41 to 1.73) and major bleeding (RR, 0.78; 95% CI, 0.03 to 18.57) were not significant. Secondary: LMWH vs inactive control Pooled analysis of six RCTs demonstrated that there was no significant effect on symptomatic PE (RR, 0.63; 95% CI, 0.21 to 1.91) or DVT (RR, 0.60; 95% CO. 0.33 to 1.07). In pooled data from six RCTs, the risk of overall VTE was reduced by 45% with LMWH (RR, 0.55; 95% CI, 0.34 to 0.88) whereas there was no significant benefit or harm for asymptomatic VTE, minor bleeding, one-year mortality, symptomatic arterial thromboembolism, superficial thrombophlebitis, or serious adverse events. None of the six trials considered quality of life, heparin-induced thrombocytopenia, or the incidence of osteoporosis as study incomes.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Three trials reported on symptomatic VTE and major bleeding in patient with non-small cell or small cell lung cancer, or both. Pooled analysis showed a nonsignificant 46% reduction in symptomatic VTE (RR, 0.54; 95% CI, 0.27 to 1.09) and a nonsignificant 73% higher risk of major bleeding with LMWH compared to control (RR, 1.73; 95% CI, 0.65 to 4.57). LMWH vs active control In one trial, there were no differences between LMWH, aspirin, and warfarin regarding the incidence of symptomatic PE or DVT, minor bleeding, and symptomatic arterial thromboembolism. VKA vs inactive control In one trial, there was no significant effect on symptomatic PE (RR, 1.05; 95% CI, 0.07 to 16.58), symptomatic DVT (RR, 0.08; 95% CI, 0.00 to 1.42), or minor bleeding (RR, 2.44; 95% CI, 0.64 to 9.27). No symptomatic arterial thromboembolic events were observed in the VKA or placebo groups. VKA vs active control and antithrombin vs inactive control Secondary outcomes were not reported for these comparisons.
Castellucci et al.[64] (2014) Unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), or fondaparinux in combination with vitamin K antagonists; LMWH with dabigatran or edoxaban*; rivaroxaban; apixaban; and LMWH alone	SR and MA (45 trials) Patients who had objectively confirmed symptomatic acute VTE (lower extremity deep vein thrombosis, pulmonary embolism, or both) and who had qualifying recurrent VTE events that were symptomatic and objectively	N=44,989 Duration varied	Primary: Recurrent VTE and major bleeding Secondary: Fatal recurrent VTE and fatal bleeding episodes	Primary: Compared with the LMWH–vitamin K antagonist combination, use of the UFH–vitamin K antagonist combination in patients with index deep vein thrombosis was associated with the lowest efficacy and was associated with an increased risk of recurrent venous thromboembolism (HR, 1.74; 95% credible interval [CrI], 1.27 to 2.44). All remaining treatment regimens were not associated with differences in outcomes from the LMWH–vitamin K antagonist combination in this population. Compared with the LMWH–vitamin K antagonist combination, rivaroxaban (HR, 0.55; 95% CrI, 0.35 to 0.89) and apixaban (HR, 0.31; 95% CrI, 0.15 to 0.62) were associated with the lowest bleeding risk. All other treatment regimens were associated with bleeding risks that did not differ from the LMWH–vitamin K antagonist combination. Secondary: Fatal events were rare. One hundred sixty-five patients (0.37%) experienced fatal recurrent venous thromboembolism and 64 (0.14%), fatal bleeding events.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	confirmed			
Schulman et al.[65] (2009) RE-COVER Dabigatran 150 mg BID vs Warfarin dose adjusted QD All patients received parenteral anticoagulation for a mean of 10 days	DB, DD, MC, RCT Patients ≥ 18 years of age with acute symptomatic, objectively verified proximal DVT thrombosis of the legs or PE and for who six months of anticoagulant therapy was considered to be an appropriate treatment	N= 2,539 6 months	Primary: Time to the first occurrence of symptomatic VTE or death associated with VTE Secondary: Symptomatic DVT, symptomatic nonfatal PE, death related to VTE, all deaths	Primary: After central adjudication, the primary outcome for efficacy was confirmed in 30 patients in the dabigatran group (2.4%) and 27 patients in the warfarin group (2.1%). The difference in risk was 0.4% (95% CI; −0.8 to 1.5; HR, 1.10; 95% CI, 0.65 to 1.84). As compared with warfarin, dabigatran was noninferior with regard to the prevention of recurrent or fatal VTE (P<0.001 for the criteria of both HR and the difference in risk). Secondary: Symptomatic DVT occurred in 16 patients in the dabigatran group (1.3%) and 18 patients in the warfarin group (2.1%), HR 0.87 (95% CI; 0.44 to 1.71). Symptomatic nonfatal PE occurred in 13 patients in the dabigatran group (1.0%) and 7 patients in the warfarin group (0.6%), HR 1.85 (95% CI; 0.74 to 4.64). Death related to VTE occurred in one patient in the dabigatran group (0.1%) and three patients in the warfarin group (0.3%), HR 0.33 (95% CI; 0.03 to 3.15). All deaths occurred in 21 patients in the dabigatran group (1.6%) and 21 patients in the warfarin group (1.7%), HR 0.98 (95% CI; 0.53 to 1.79).
Schulman et al.[66] (2014) RE-COVER II Dabigatran 150 mg BID vs warfarin dose adjusted QD All patients received five to 11 days of therapy with LMWH or unfractionated heparin	DB, DD, MC, RCT Patients ≥ 18 years of age with acute symptomatic, objectively verified proximal DVT thrombosis of the legs or PE and for who six months of anticoagulant therapy was considered to be an appropriate treatment	N=2,589 6 months	Primary: Recurrent symptomatic, objectively confirmed VTE and related deaths during six months of treatment. Secondary: Symptomatic DVT, symptomatic non-fatal PE, death related to PE, and all death	Primary: Recurrent non-fatal or fatal VTE was confirmed after central adjudication in 30 patients in the dabigatran group (2.3%) and in 28 patients in the warfarin group (2.2%) (HR, 1.08; 95% CI, 0.64 to 1.80). The difference in risk was 0.2% (95% CI, −1.0 to 1.3) in favor of warfarin. Dabigatran was non-inferior to warfarin for the prevention of recurrent or fatal VTE (P<0.001 for both HR and difference in absolute risk criteria). Efficacy results were consistent in all the predefined subgroups (data not shown). Secondary: Symptomatic DVT occurred in 25 patients (2.0%) in the dabigatran group and 2.2 patients (1.3%) in the warfarin group (HR, 1.08; 95% CI, 0.80 to 2.74). Symptomatic nonfatal PE occurred in seven patients (0.5%) in the dabigatran group and 13 (1.0%) patients in the warfarin group (HR, 0.54; 95% CI, 0.21 to 1.35). There occurred that were related to PE in the dabigatran group with zero in the warfarin group. There were 25 deaths (2.0%) in the dabigatran group and 25 deaths (1.9%) in the warfarin group (HR, 0.98; 95% CI, 0.56 to 1.71)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Schulman et al.[67] (2013) Study 1: RE-MEDY Dabigatran 150 mg BID vs warfarin (dose adjusted) QD Study 2: RE-SONATE Dabigatran 150 mg BID vs placebo	Study 1: AC, DB, MC, NI, RCT Study 2: PC, DB, MC, RCT Patients ≥18 years of age diagnosed with VTE who completed at least the first three months of therapy (six months for the second study)	N= 4,199 6 to 36 months	Primary: Recurrent symptomatic and objectively verified VTE or death associated with VTE (or unexplained death in the placebo-control study), major bleeding and clinically relevant non-major bleeding Secondary: Not reported	Primary: In the active-control study, recurrent VTE occurred in 26 of 1,430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (HR, 1.44; 95% CI, 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (HR, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (HR, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and three patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (HR, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in two patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (HR, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in one patient each in the dabigatran and placebo groups. Secondary: Not reported
Lassen et al.[68] (2009) ADVANCE-1 Apixaban 2.5 mg BID and matching placebo injection vs enoxaparin 30 mg SC every 12 hours and matching	AC, DB, DD, MC, RCT Patients who were to undergo total knee replacement surgery for one or both knees, including revision of a previously inserted artificial joint	N=3,195 10 to 14 days of treatment (plus 60 days follow-up)	Primary: Composite of asymptomatic and symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, and death from any cause during the intended treatment period	Primary: The statistical criterion for the noninferiority of apixaban as compared with twice-daily administration of enoxaparin was not met. The primary efficacy outcome occurred in 104 of 1157 patients (9.0%) in the apixaban group, as compared with 100 of 1130 patients (8.8%) in the enoxaparin group (RR, 1.02; 95% CI, 0.78 to 1.32; P=0.06 for noninferiority; difference in risk, 0.1%; 95% CI, –2.2% to 2.4%; P<0.001). Secondary: Composite major thromboembolism and death from any cause occurred in 26 of 1269 patients (2.1%) in the apixaban group and in 20 of 1216 patients (1.6%) in the enoxaparin group (RR, 1.25; 95% CI, 0.70 to 2.23; difference in risk, 0.36%; 95% CI, –0.68% to 1.40%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo tablets BID Patients received the first doses of the study medications 12 to 24 hours after surgery in order to be consistent with FDA label for enoxaparin.			Secondary: Composite of major thromboembolism and death from any cause, and symptomatic thromboembolism during the intended treatment period	Symptomatic thromboembolism and death from any cause occurred in 26 of 1269 patients (2.1%) in the apixaban group and in 20 of 1216 patients(1.6%) in the enoxaparin group (RR, 1.25; 95% CI, 0.70 to 2.23; difference in risk, 0.36%; 95% CI, –0.68% to 1.40%). Follow-up for 60 days after the last dose of study medication was completed in 1562 of the 1599 patients (97.7%) assigned to apixaban and in 1554 of the 1596 patients (97.4%) assigned to enoxaparin. During the 60-day follow-up period, symptomatic venous thromboembolism occurred in 4 of 1562 patients (0.3%) in the apixaban group and in 7 of 1554 patients (0.5%) in the enoxaparin group. Major bleeding events occurred in 11 of 1596 patients (0.7%) who received apixaban and in 22 of 1588 patients (1.4%) who received enoxaparin (adjusted difference in event rates according to type of surgery, -0.81%; 95% CI, -1.49% to −0.14%; P=0.053). The composite outcome of major bleeding and clinically relevant non-major bleeding occurred in 46 patients (2.9%) in the apixaban group and 68 patients (4.3%) in the enoxaparin group (adjusted difference in event rates according to type of surgery, −1.46%; 95% CI, −2.75% to −0.17%; P=0.03).
Lassen et al.[69] (2010) ADVANCE-2 Apixaban 2.5 mg BID and matching placebo injection QD vs enoxaparin 40 mg SC QD and matching placebo tablets BID	AC, DB, DD, MC, RCT Patients who were scheduled to have unilateral elective total knee replacement or same-day bilateral knee replacement, including revision	N=3,057 10 to 14 days of treatment (plus 60 days follow-up)	Primary: Composite of adjudicated asymptomatic or symptomatic deep vein thrombosis, non-fatal pulmonary embolism, and all-cause death during the intended treatment period or within two days of last dose of study drug, whichever was	Primary: Apixaban was had statistically significant reduction in risk compared to enoxaparin for prevention of all VTE and all-cause death (RR, 0.62; 95% CI, 0.51 to 0.74, one-sided P<0.0001 when tested for non-inferiority and for superiority). ARR was 9.3% (95% CI, 5.8% to 12.7%) in favor of apixaban (one-sided p<0·0001 for non-inferiority). Secondary: Apixaban was also provided a statistically significant risk reduction compared with enoxaparin for major VTE prevention (RR, 0.50; 95% CI, 0.26 to 0.97, one-sided P=0.0186 for superiority; ARR, 1.04%; 95% CI, 0.05% to 2.03%). Rates of symptomatic VTE and VTE-related death did not differ between study groups (RR, 1.00; 0.35 to 2.85; ARR, 0.00%; (95% CI, −0.48% to 0.48%). One apixaban patient died of pulmonary embolism during. 1458 (95%) of 1528

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
The first subcutaneous injection of study drug was given 12 hours (within three hours) before operation, and injections were resumed after surgery according to investigators' standard of care. The first dose of oral study drug was given 12 to 24 h after wound closure.			longer Secondary: Composite major VTE; composite of symptomatic DVT, non-fatal PE and VTE-related death; composite of all DVTs (including asymptomatic); components of all DVT, including symptomatic DVT, proximal DVT, non-fatal PE, and VTE-related death; composite of PE and VTE-related death; VTE-related death	apixaban patients and 1469 (96%) of 1529 enoxaparin patients completed 60 days of follow-up after last dose of study drug. Symptomatic venous thromboembolism developed during follow-up in five (<1%) of 1458 apixaban patients and two (<1%) of 1469 enoxaparin patients. There were no statistically significant differences between treatments for the remaining secondary outcomes. Frequency of major bleeding events did not differ between treatment groups (P=0.3014).
Lassen et al.[70] (2010) ADVANCE-3 Apixaban 2.5 mg BID plus matching placebo injection vs enoxaparin 40 mg SC QD plus	AC, DB, DD, MC, RCT Patients who were scheduled to undergo elective total hip replacement or revision of a previously inserted hip prosthesis	N=5,407 32 to 38 days of treatment (plus 95 day follow-up)	Primary: Composite of adjudicated asymptomatic or symptomatic DVT, nonfatal PE, or death from any cause during the intended treatment period	Primary: The primary efficacy outcome occurred in 27 of the 1949 patients in the apixaban group who could be evaluated for that outcome (1.4%) and in 74 of the 1917 patients in the enoxaparin group who could be evaluated (3.9%) (RR with apixaban, 0.36; 95% CI, 0.22 to 0.54; one-sided P<0.001 for noninferiority and two-sided P<0.001 for superiority). The ARR with apixaban was 2.5% (95% CI, 1.5% to 3.5%). Secondary: Major VTE occurred in 10 of the 2199 patients (0.5%) in the apixaban group who could be evaluated for that outcome and in 25 of the 2195 (1.1%) in the enoxaparin group (RR, 0.40; 95% CI, 0.15 to 0.80; one-sided P<0.001 for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
matching placebo tablets BID The first subcutaneous injection of study drug was given 12 hours (within three hours) before operation, and injections were resumed after surgery according to investigators' standard of care. The first dose of oral study drug was given 12 to 24 h after wound closure.			Secondary: Major VTE (composite of adjudicated symptomatic or asymptomatic proximal DVT [popliteal, femoral, or iliac-vein thrombosis]), nonfatal PE, or death related to VTE during the intended treatment period	noninferiority and two-sided P=0.01 for superiority). The ARR with apixaban was 0.7% (95% CI, 0.2% to 1.3%). With this reduction in risk, one additional episode of VTE would be prevented for every 147 patients treated with apixaban rather than enoxaparin. Major bleeding during the treatment period occurred in 22 of the 2673 patients who received apixaban (0.8%) and 18 of the 2659 patients who received enoxaparin (0.7%) with an absolute difference in risk of 0.1% (95% CI, −0.3% to 0.6%). Thirteen of the 22 major bleeding events in the apixaban group occurred before the first dose was administered; therefore, major bleeding with an onset after the first dose of apixaban occurred in 9 of 2673 patients (0.3%; 95% CI, 0.2% to 0.7%). No bleeding event in either group was related to spinal or epidural anesthesia. The composite of major and clinically relevant non-major bleeding occurred in 129 patients who received apixaban (4.8%) and in 134 patients who received enoxaparin (5.0%) with an absolute difference in risk of −0.2% (95% CI, −1.4% to 1.0%). Of the 129 events that occurred in the apixaban group, 33 occurred before the first dose was administered. Thus, major or clinically relevant non-major bleeding with onset after the first dose of apixaban occurred in 96 of the 2673 patients (3.6%; 95% CI, 3.0% to 4.4%).
Treatment of DVT and PE, and for the reduction in the risk of recurrence of DVT and of PE				
Fuji et al.[71] (2014) STARS E-3 Edoxaban 30 mg QD vs enoxaparin 2000 IU SC BID	DB, DD, RCT Men and women aged 20 to 84 years who were scheduled to undergo unilateral TKA, excluding revision arthroplasty	N=716 11 to 14 days	Primary: Composite of symptomatic PE and symptomatic and asymptomatic DVT, bleeding, adverse events Secondary: Proportion of patients with one or more thromboembolic events	Primary: The composite primary efficacy occurred in 22 of 299 (7.4%) patients receiving edoxaban and 41 of 295 (13.9%) patients receiving enoxaparin (relative risk reduction, 46.8%), indicating non-inferiority (P<0.001) and superiority (P=0.010) of edoxaban relative to enoxaparin. The incidence of major bleeding events was 1.1% (4/354) compared with 0.3% (1/349) in the edoxaban and enoxaparin treatment groups, respectively (P=0.373). The incidence of all bleeding events (major bleeding, clinically relevant non-major bleeding, and minor bleeding) was 22.3% (79/354) in the edoxaban group and 18.9% (66/349) in the enoxaparin group (P=0.265). The incidence of adverse events was slightly lower in the edoxaban group (66.9% [237/354]) compared with the enoxaparin group (73.4% [256/349]), and no difference was observed in the incidence of serious adverse events between

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				the treatment groups. Secondary: The incidence of symptomatic DVT, proximal DVT, symptomatic PE, or VTE-related mortality, were 1.3% (4/299) in the edoxaban group and 0.7% (2/295) in the enoxaparin group (P=NS).
Buller et al.[72] (2013) HOKUSAI-VTE Study Edoxaban 60 mg QD vs edoxaban 30 mg QD (patients with CrCl 30 to 50 mL/min, a body weight < 60 kg, or receiving a concomitant P-glycoprotein inhibitor such as verapamil or quinidine) vs warfarin (adjusted dose to maintain an INR between 2.0 and 3.0)	DB, NI, RCT Patients ≥ 18 years of age with objectively diagnosed, acute, symptomatic DVT or PE initially started on heparin therapy with either LMWH or unfractionated heparin	N=8,292 12 months	Primary Efficacy: Incidence of adjudicated symptomatic recurrent venous thromboembolism, defined as a composite of DVT or nonfatal or fatal PE Primary Safety: Incidence of adjudicated clinically relevant bleeding, defined as a composite of major or clinically relevant non major bleeding Secondary: Not reported	Primary Efficacy: A recurrence of venous thromboembolism during the overall study period occurred in 130 of 4118 patients (3.2%) in the edoxaban group and in 146 of 4122 patients (3.5%) in the warfarin group (HR, 0.89; 95% CI, 0.70 to 1.13; P<0.001). Primary Safety: Clinically relevant bleeding (major or non-major) occurred in 349 of 4118 patients (8.5%) in the edoxaban group as compared with 423 of 4122 patients (10.3%) in the warfarin group (HR, 0.81; 95% CI, 0.71 to 0.94; P=0.004). Secondary: Not reported
Weitz et al.[73] (2017) EINSTEIN	DB, RCT Patients ≥18 years	N=3,365 1 year (after	Primary: Composite of symptomatic,	Primary: A primary efficacy outcome event occurred in 17 of 1107 patients (1.5%) who were receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) who

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
CHOICE Rivaroxaban 10 mg QD vs rivaroxaban 20 mg QD vs aspirin 100 mg QD	of age with objectively confirmed, symptomatic proximal deep-vein thrombosis or pulmonary embolism; who had been treated for 6 to 12 months with an anticoagulant agent, including a vitamin K antagonist or a direct oral anticoagulant agent such as dabigatran, rivaroxaban, apixaban, or edoxaban; and had not interrupted therapy for more than 7 days before randomization	6 to 12 months of therapy)	recurrent fatal or nonfatal venous thromboembolism and unexplained death for which pulmonary embolism could not be ruled out; major bleeding Secondary: Myocardial infarction, ischemic stroke, systemic embolism, venous thrombosis in locations other than the deep veins of the lower limbs, and death from any cause	were receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) who were receiving aspirin. Fatal venous thromboembolism occurred in two patients (0.2%) who were receiving 20 mg of rivaroxaban, in no patients who were receiving 10 mg of rivaroxaban, and in two patients (0.2%) who were receiving aspirin. Both rivaroxaban doses were superior to aspirin with respect to the primary efficacy outcome (HR for 20 mg of rivaroxaban vs aspirin, 0.34; 95% CI, 0.20 to 0.59; HR for 10 mg of rivaroxaban vs aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). The HR for the comparison between the 20-mg and 10-mg rivaroxaban regimens was 1.34 (95% CI, 0.65 to 2.75; P=0.42). Similar results were found for the other efficacy outcomes. Major bleeding occurred in six patients (0.5%) in the 20-mg rivaroxaban group and in five patients (0.4%) in the 10-mg rivaroxaban group, as compared with three patients (0.3%) in the aspirin group. Secondary: Myocardial infarction, stroke, or systemic embolism occurred in three patients (0.3%) in the 20-mg rivaroxaban group, in five patients (0.4%) in the 10-mg rivaroxaban group, and in seven patients (0.6%) in the aspirin group. The rates of death from any cause were 0.7% and 0.2% in the 20-mg and 10-mg rivaroxaban groups, respectively, as compared with 0.6% in the aspirin group. Rates of adverse events were similar in the three study groups.
EINSTEIN Investigators[74] (2010) EINSTEIN-DVT and EINSTEIN-EXT Rivaroxaban 15 mg BID for three weeks followed by 20 mg QD	AC, MC, OL, NI, RCT (EINSTEIN-DVT) DB, MC, PC, RCT (EINSTEIN-EXT) Patients with acute, symptomatic, objectively confirmed proximal DVT	N=3,449 Up to 12 months (both studies)	Primary: Symptomatic, recurrent VTE (composite of DVT or nonfatal or fatal PE), clinically relevant bleeding (EINSTEIN-DVT) or major bleeding (EINSTEIN-	Primary: EINSTEIN-DVT A symptomatic, recurrent VTE occurred in 2.1% of patients treated with rivaroxaban and 3.0% of patients receiving standard therapy with enoxaparin (HR, 0.68; 95% CI, 0.44 to 1.04; P<0.001 for non inferiority, and P=0.08 for superiority). There was no statistically significant difference in the occurrence of clinically relevant (first major or clinically relevant nonmajor) bleeding between patients receiving rivaroxaban or standard therapy with enoxaparin (8.1% for both, HR, 0.97; 95% CI, 0.76 to 1.22; P=0.77).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs enoxaparin 1 mg/kg SC BID plus warfarin or acenocoumarol started within 48 hours of randomization and adjusted to maintain an INR of 2.0 to 3.0 Enoxaparin was discontinued when the INR was ≥2.0 for two consecutive days and the patient had received at least five days of enoxaparin treatment. In the EINSTEIN-EXT trial, patients were randomized to receive rivaroxaban 20 mg QD or placebo for six to 12 months.	without symptomatic PE; for enrollment into the extension phase, patients had objectively confirmed symptomatic DVT or PE and had been treated for six to 12 months with rivaroxaban or acenocoumarol or warfarin (in the EINSTEIN studies or from routine care)		EXT) Secondary: All-cause mortality, vascular events (ACS, ischemic stroke, TIA, or systemic embolism), and net clinical benefit (composite of the primary efficacy outcome or major bleeding)	EINSTEIN-EXT Symptomatic, recurrent VTE occurred in eight patients in the rivaroxaban group and 42 patients in the placebo group (1.3 vs 7.1%; HR, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Major bleeding occurred in four patients in the rivaroxaban group and zero patients in the placebo group (P=0.11). Secondary: EINSTEIN-DVT All-cause mortality was similar between patients treated with rivaroxaban or standard therapy with enoxaparin (2.2 vs 2.9%, respectively; HR, 0.67; 95% CI, 0.44 to 1.02; P=0.06). There was no statistically significant difference in vascular events between patients receiving rivaroxaban or standard therapy with enoxaparin (0.7 vs 0.8%, respectively; HR, 0.79; 95% CI, 0.36 to 1.71; P=0.55). There was a significantly greater net clinical benefit with rivaroxaban compared to standard therapy with enoxaparin (2.9 vs 4.2%; HR, 0.67; 95% CI, 0.47 to 0.95; P=0.03). EINSTEIN-EXT There was one death in the rivaroxaban treatment group and two deaths in the placebo group during follow up (P value not reported). There was no statistically significant difference in vascular events between patients receiving treatment with rivaroxaban or placebo (0.5 vs 0.7%, respectively; HR, 0.74; 95% CI, 0.17 to 3.3; P=0.69). There was a significantly greater net clinical benefit in patients who received rivaroxaban compared to placebo (2.0 vs 7.1%; HR, 0.28; 95% CI, 0.15 to 0.53; P<0.001).
EINSTEIN PE Investigators[75] (2012) EINSTEIN-PE Rivaroxaban 15	AC, MC, NI, OL, RCT Patients with an acute, symptomatic PE with objective	N=4,832 Up to 12 months	Primary: Symptomatic, recurrent VTE (composite of DVT or nonfatal or fatal PE) and	Primary: Symptomatic, recurrent VTE occurred in 50 patients (2.1%) receiving rivaroxaban and 44 patients (1.8%) receiving standard therapy with enoxaparin (HR, 1.12; 95% CI, 0.75 to 1.68; P=0.003 for non inferiority and P=0.57 for superiority).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg BID for three weeks followed by 20 mg QD vs enoxaparin 1 mg/kg SC BID plus warfarin or acenocoumarol started within 48 hours of randomization and adjusted to maintain an INR of 2.0 to 3.0 Enoxaparin was discontinued when the INR was ≥2.0 for two consecutive days and the patient had received at least five days of enoxaparin treatment.	confirmation, with or without symptomatic DVT Patients were ineligible if they had received a therapeutic dose of LMWH, fondaparinux, or UFH for more than 48 hours or if they had received more than a single dose of a VKA before randomization.		clinically relevant bleeding Secondary: Major bleeding, death from any cause, vascular events (ACS, ischemic stroke, TIA, or systemic embolism) and net clinical benefit (composite of the primary efficacy outcome and major bleeding)	Recurrent, nonfatal VTE was suspected in 491 patients in the rivaroxaban group and in 453 patients in the standard therapy group. Major or clinically relevant nonmajor bleeding occurred in 249 patients (10.3%) receiving rivaroxaban and 274 patients (11.4%) receiving standard therapy with enoxaparin (HR, 0.90; 95% CI, 0.76 to 1.07; P=0.23). Secondary: Major bleeding occurred in 26 patients (1.1%) receiving rivaroxaban treatment compared to 52 patients (2.2%) receiving standard therapy with enoxaparin (HR, 0.49; 95% CI, 0.31 to 0.79, P=0.003). There was no statistically significant difference in death from any cause between patients receiving rivaroxaban or standard therapy (2.4 vs 2.1%, respectively, HR, 1.13; 95% CI, 0.77 to 1.65; P=0.53). Fifteen patients in the rivaroxaban group and 21 patients in the standard therapy group experienced an acute coronary event (P value not reported). A cerebrovascular event was reported in 12 and 13 patients receiving rivaroxaban or standard therapy with enoxaparin, respectively (P value not reported). A systemic embolism occurred in five patients receiving rivaroxaban and three patients receiving standard therapy (P value not reported). A net clinical benefit was reported in 83 patients (3.4%) in the rivaroxaban group and 96 patients (4.0%) in the standard therapy group (HR, 0.85; 95% CI, 0.63 to 1.14; P=0.28).
Safety				
Uchino et al.[76] (2012) Dabigatran vs control (warfarin, enoxaparin, or	MA (7 RCTs; 2 trials of stroke prophylaxis in AF, 1 trial in acute VTE, 1 in ACS, and 3 of short term prophylaxis in DVT)	N=30,514 Duration not specified	Primary: Acute coronary events (MI or ACS) Secondary: Overall mortality	Primary: Dabigatran was significantly associated with a higher risk of MI or ACS compared to control (237/20,000 [1.19%] vs 83/10,514 [0.79%]; OR, 1.33; 95% CI, 1.03 to 1.71; P=0.03). The risk of MI or ACS was similar when using revised RE-LY trial results (OR, 1.27; 95% CI, 1.00 to 1.61; P=0.05) or after exclusion of short term trials (OR, 1.33; 95% CI, 1.03 to 1.72; P=0.03). No relationship between the baseline risk of acute coronary events and the OR for acute coronary events associated with dabigatran use (P=0.61).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo)	Patient population not specified			Secondary: Six trials reported on overall mortality. Dabigatran was significantly associated with lower mortality compared to control (945/19,555 [4.83%] vs 524/10,444 [5.02%]; OR, 0.89; 95% CI, 0.80 to 0.99; P=0.04).

*Agent not available in the United States.
†Not Food and Drug Administration approved for this indication.
Drug regimen abbreviations: BID=twice daily, SC=subcutaneous, QD=once daily
Study abbreviations: AC=active control, ARD=absolute risk difference, ARR=absolute risk reduction, CI=confidence interval, DB=double-blind, DD=double dummy, HR=hazard ratio, ITT=intention-to-treat, MA=meta analysis, MC=multicenter, NI=non inferiority, NNT=number needed to treat, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel group, PP=per-protocol, PRO=prospective, RCT=randomized controlled trial, RR=relative risk, SR=systematic review, WMD=weighted mean difference
Miscellaneous abbreviations: ACS=acute coronary syndrome, AF=atrial fibrillation, ALT=alanine transaminase, CABG=coronary artery bypass graft surgery, CAD=coronary artery disease, cTTR=center's mean time in therapeutic range, DTI=direct thrombin inhibitor, DVT=deep vein thrombosis, ECG=electrocardiogram, FDA=Food and Drug Administration, GUSTO= Global Utilization Of Streptokinase and Tpa For Occluded Arteries, HIT=heparin induced thrombocytopenia, INR=International Normalized Ratio, LMWH=low molecular weight heparin, LVEF=left ventricular ejection fraction, MI=myocardial infarction, NSAID=nonsteroidal anti-inflammatory drug, NYHA=New York Heart Association, PE=pulmonary embolism, TIA=transient ischemic attack, TIMI=Thrombolysis in Myocardial Infarction, TKA=total knee arthroplasty, TTR=time in therapeutic range, UFH=unfractionated heparin, VKA=vitamin k antagonist, VTE=venous thromboembolism

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 11. Relative Cost of the Oral Anticoagulants

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Apixaban	tablet	Eliquis®	$$$$$	N/A
Dabigatran	capsule	Pradaxa®	$$$$$	N/A
Edoxaban	tablet	Savaysa®	$$$$$	N/A
Rivaroxaban	tablet	Xarelto®	$$$$$	N/A
Warfarin	tablet	Coumadin®*	$$$	$

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.
N/A=Not available.

X. Conclusions

The oral anticoagulants include apixaban, dabigatran etexilate mesylate, edoxaban, rivaroxaban, and warfarin. Warfarin has various indications, including prophylaxis and/or treatment of pulmonary embolism (PE); prophylaxis and/or treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement prophylaxis and/or treatment of venous thrombosis and its extension; and to reduce the risk of death, recurrent myocardial infarction (MI) and thromboembolic events such as stroke or systemic embolization after MI.[5] Warfarin has been the principle oral anticoagulant for the past 60 years in high-risk AF patients.[6] Apixaban, edoxaban, and rivaroxaban are selective factor Xa inhibitors while dabigatran etexilate mesylate is a direct thrombin inhibitor (DTI). All are non-vitamin K oral anticoagulants (NOACs) and are approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF and for treatment

and/or reduction in the risk of recurrence of deep vein thrombosis (DVT) and PE in patients who have previously been treated.[1-4] Rivaroxaban and apixaban are also indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.[1,4] Dabigatran was also recently approved for prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have undergone hip replacement surgery.[2] Warfarin is the only product available in a generic formulation.

In 2014, the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society released an updated guideline on the management of AF. The guidelines state that antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke, bleeding, and the patient's values and preferences. Dietary limitations and the need for repeated International Normalized Ratio (INR) testing are eliminated with the new agents. If patients are stable, their condition is easily controlled, and they are satisfied with warfarin therapy, it is not necessary to change to a new agent. Notably, patients with mechanical heart valves or hemodynamically significant mitral stenosis were excluded from all three major trials (RE-LY[30], ROCKET AF[43], and ARISTOTLE[25]); therefore, these patients should be managed with warfarin.[11] The American College of Chest Physicians released Antithrombotic Therapy for VTE Disease in 2016 which state that NOACs are suggested over warfarin for initial and long-term treatment of VTE in patients without cancer.[9] No NOAC is preferred over another.[9] Since publication of the 9th edition, new studies show that NOACs are as effective as VKA therapy with reduced risk of bleeding and increased convenience for patients and health-care providers.[6] A Science Advisory by the American Heart Association and American Stroke Association states that apixaban, dabigatran etexilate mesylate, and rivaroxaban are recommended as alternatives to warfarin in patients with AF who have at least one additional risk factor for stroke.[10] The American Heart Association/American Stroke Association Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack from 2014 offer recommendations consistent with other published guidelines.[20]

In a large head-to-head trial comparing apixaban to warfarin, less major bleeding and intracranial bleeding was found in the apixaban group, and a similar incidence of gastrointestinal bleeding was found between the groups. Notably, apixaban reduced stroke or systemic embolism and death from any cause compared to warfarin.[25] In two studies apixaban was shown to reduce the risk of DVT and PE after hip or knee surgery, with similar bleeding rates compared to once daily enoxaparin.[69,70]

Dabigatran etexilate mesylate 110 mg twice-daily demonstrated similar efficacy for reducing the risk of stroke and systemic embolism when compared to warfarin. In this trial, the incidence of major bleeding was reduced with dabigatran etexilate mesylate treatment. In general, evidence suggests that the two agents are comparable in terms of overall bleeding, with more intracranial bleeding being associated with warfarin and more gastrointestinal bleeding being associated with dabigatran etexilate mesylate.[30] Studies have also shown that dabigatran etexilate mesylate is more effective than placebo and similarly effective to warfarin for the short- and long-term therapy after VTE to prevent recurrent VTE.[65-67]

Rivaroxaban was compared to warfarin in a large, double-blind trial including over 14,000 patients at risk for stroke. Rivaroxaban performed similarly to warfarin in regard to the primary endpoint, a composite of stroke or systemic embolism. The incidence of major and clinically relevant nonmajor bleeding between rivaroxaban and warfarin was similar. The rate of intracranial bleeding was significantly lower with rivaroxaban compared to warfarin, but major bleeding from a gastrointestinal site was more common with rivaroxaban.[43] For the prophylaxis of DVT, rivaroxaban was evaluated in trials compared to enoxaparin, a low molecular weight heparin agent (LMWH), for use as thromboprophylaxis in patients undergoing hip and knee replacement surgeries. In all four trials, rivaroxaban significantly reduced the risk of the primary composite endpoint of any DVT, nonfatal PE, or death from any cause compared to enoxaparin. In addition, there were similar rates of major bleeding and hemorrhagic wound complications between rivaroxaban and enoxaparin. These trials evaluated both short (10 to 14 days) and extended (31 to 30 days) thromboprophylaxis with rivaroxaban.[54-56] In patients with an acute, symptomatic, proximal DVT without symptomatic PE, and acute, symptomatic PE with or without symptomatic DVT, treatment with rivaroxaban was associated with a reduction in symptomatic, recurrent VTE (composite of DVT or nonfatal or fatal PE) compared to standard therapy, without an increase in bleeding events.[74,75]

As with the other NOACs, edoxaban is predominately cleared by the kidneys. Recommendations per the package insert are to decrease the dose if CrCl is < 50 mL/min and to avoid use altogether in AF patients with normal renal function (CrCl is > 95 mL/min).[3] For the treatment of nonvalvular AF, the ENGAGE AF-TIMI 48 study demonstrated that high dose edoxaban (60 mg or 30 mg dose adjusted) was noninferior to adjusted dose warfarin

for the reduction of the primary composite endpoint of stroke (ischemic or hemorrhagic) or systemic embolic event (P<0.001 for noninferiority). The rate of ischemic stroke was similar with high-dose edoxaban and warfarin but was higher with the low-dose edoxaban regimen.[39] Results from the HOKUSAI-VTE study demonstrated noninferiority of edoxaban to adjusted dose warfarin for the reduction of recurrent, symptomatic DVT and PE in patients treated up to 12 months.[72]

The evidence demonstrating the efficacy of warfarin for FDA-approved indications, including reducing the risk of stroke and systemic embolism in patients with AF, is well established, and warfarin has been considered the standard of care in high-risk patients with AF.[11] Warfarin therapy is associated with several challenges including a slow onset and offset of action, significant and unpredictable inter-individual variability in pharmacologic response, a narrow therapeutic window necessitating frequent monitoring and numerous food and drug interactions. Moreover, maintenance of a therapeutic level of anticoagulation may be difficult for some patients and requires a good understanding of the pharmacokinetic and pharmacodynamic properties of warfarin.[6,11] In situations where a major bleed occurs, dabigatran is the only NOAC with an FDA-approved reversal agent. Reversal of warfarin anticoagulation may be obtained by discontinuing warfarin therapy and, if necessary, administering oral or parenteral vitamin K.[5] In comparison to warfarin, treatment with apixaban, edoxaban, dabigatran etexilate mesylate, or rivaroxaban does not require routine monitoring, but clinicians may find it difficult to objectively assess a patient's adherence to therapy and to verify if a fixed-dose regimen can be universally applied to all patients. Additionally, compliance with these new oral anticoagulants is critical. Missing even one dose could result in a period without protection from thromboembolism; As a result, the FDA issued black box warnings that discontinuation of these new agents can increase the risk of thromboembolism and that coverage with another anticoagulant may be needed.[1-4,11] Warfarin does not require a dosage adjustment in patients with renal impairment, while a lower dose of apixaban, dabigatran etexilate mesylate, and rivaroxaban (in AF only) is recommended.[1-5] Moreover, apixaban requires a dosage adjustment when two or more of the following factors are present: age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL.[1] Edoxaban also has a boxed warning for reduced efficacy in nonvalvular atrial fibrillation patients with CrCl >95 ml/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL >95 mL/min had an increased rate of ischemic stroke with edoxaban 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used.[3]

In summary, the NOACs have been shown to be at least as effective as VKA therapy. New guidelines recommend NOACs over warfarin for initial and long-term treatment of VTE in patients without cancer. AF guidelines state that antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke, bleeding, and the patient's values and preferences. However, VKA therapy is recommended for stroke prevention in AF patients with moderate-to-severe mitral stenosis or mechanical heart valves. There is insufficient evidence to conclude that one NOAC is safer or more efficacious than another.

NOACs may offer significant clinical advantages in VTE patients, but are comparable to each other. VKA products may offer significant clinical advantages in AF patients with mitral stenosis or mechanical heart valves, but are comparable to each other. In other patient populations with FDA-approved indications for an oral anticoagulant, all brand products within the class reviewed are comparable to each other and to the generics and over-the-counter products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand oral anticoagulant, with the exception of a non-vitamin K oral anticoagulant (NOAC) agent, is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

Alabama Medicaid should work with manufacturers on cost proposals so that at least one brand NOAC is selected as a preferred agent.

XII. References

1. Eliquis® [package insert]. Princeton (NJ): Bristol-Myers Squibb Co.; 2016 July.
2. Pradaxa® [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2015 Nov.
3. Savaysa® [package insert]. Parsippany (NJ): Daiichi Sankyo, Inc.; 2016 Sep.
4. Xarelto® [package insert]. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2016 Aug.
5. Coumadin® [package insert]. Princeton (NJ): Bristol-Myers Squibb Co.; 2016 Sep.
6. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(Suppl 2):7-47.
7. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited Apr 2017]. Available from: http://online.factsandcomparisons.com.
8. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 Apr]. Available from: http://www.thomsonhc.com/.
9. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy For VTE Disease: Chest Guideline And Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.
10. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 Dec;43(12):3442-53.
11. January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.
12. National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. CG180. 2014. http://www.nice.org.uk/guidance/CG180.
13. Frendl G, Sodickson AC, Chung MK, et al. 2014 AATS Guidelines for the Prevention and Management of Peri-Operative Atrial Fibrillation and Flutter (POAF) for Thoracic Surgical Procedures. The Journal of thoracic and cardiovascular surgery. 2014;148(3):e153-e193. doi:10.1016/j.jtcvs.2014.06.036.
14. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg NA, Goldhaber SZ, et al; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Peripheral Vascular Disease, and Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011 Apr 26;123(16):1788-830.
15. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):485-510.
16. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology (2014), doi: 10.1016/j.jacc.2014.09.017.
17. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2016) 37 (3): 267-315. DOI: https://doi.org/10.1093/eurheartj/ehv320..
18. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007 Dec 4;116(23):2762-72.
19. Anderson JL, Halperin JL, Albert N, et al. Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations). Journal of the American College of Cardiology Apr 2013, 61 (14) 1555-1570; DOI: 10.1016/j.jacc.2013.01.004.

20. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
21. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May. Available from: http://www.nice.org.uk/guidance/cg172.
22. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17.
23. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, et al. Apixaban vs aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012 Mar;11(3):225-31.
24. Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, et al. Bleeding during treatment with aspirin vs apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban vs acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012 Dec;43(12):3291-7.
25. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92.
26. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, et al. Apixaban compared to warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11.
27. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared to warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58.
28. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25.
29. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014 May 27;63(20):2141-2147.
30. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
31. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al. Dabigatran and warfarin in vitamin K antagonist naïve and experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-53.
32. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al. Dabigatran compared to warfarin in patients with atrial fibrillation and previous transient ischemic attack or stroke: a subgroup analysis of the RE-LY trial [abstract]. Lancet Neurol. 2010;12:1157-63.
33. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared to warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.
34. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation. 2012;125:669-76.
35. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012 Jun;43(6):1511-7.
36. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8.
37. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.
38. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with or without concomitant aspirin compared to warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419-26.

39. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov;369(22): 2093-104.
40. O'Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J. 2015 Jun 14;36(23):1470-7.
41. Eisen A, Giugliano RP, Ruff CT, et al. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J. 2016 Feb;172:144-51.
42. Geller BJ, Giugliano RP, Braunwald E, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J. 2015 Oct;170(4):669-74.
43. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91.
44. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, et al. Rivaroxaban compared to warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012 Apr;11(4):315-22.
45. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-146.
46. Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J. 2014 Jan;35(4):242-249.
47. Anderson LV, Vestergaard P, Deichgraeber P, Lindhold JS, Mortenson LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart. 2008 Dec;94(12):1607-13.
48. Agarwal S, Hachmovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation. A meta-analysis. Arch Intern Med. 2012;172(8):623-31.
49. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic stroke. Cochrane Database of Systematic Reviews. 2004, Issue 2. Art. No.:CD000185.
50. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic stroke. Cochrane Database of Systematic Reviews. 2005, Issue 3. Art. No.:CD001927.
51. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-962.
52. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830-5.
53. Rothberg MB, Celestin C, Flore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:41-250.
54. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman M, Kakkar AK, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75.
55. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban vs short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet. 2008 Jul 5;372(9632):31-9.
56. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86.
57. Turpie AG, Lassen MR, Davidson BL,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80.
58. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database of Systematic Reviews. 2006, Issue 1. Art. No.:CD0001367.
59. van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term management of symptomatic venous thromboembolism. Cochrane Database of Systematic Reviews. 2001, Issue 3. Art. No.:CD002001.

60. Salazar CA, Malaga G, Malasquez G. Direct thrombin inhibitors vs vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Cochrane Database of Systematic Reviews. 2010, Issue 4. Art. No.:CD005981.
61. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001;16(3):293-300.
62. Cundiff DK, Manyemba J, Pezzullo JC. Anticoagulants vs non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism. Cochrane Database of Systematic Reviews. 2006, Issue 1. Art. No.:CD003746.
63. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AWS. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008500.
64. Castellucci LA, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA. 2014 Sep 17;312(11):1122-1135. doi: 10.1001/jama.2014.10538.
65. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598.
66. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation. 2014;129:764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16.
67. Schulman S, Kearon C, Kakkar AK, Schellong S, et al. Extended Use of Dabigatran, Warfarin or Placebo in Venous Thromboembolism. N Engl J Med. 2013 Feb; 368(8):709-18.
68. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. doi: 10.1056/NEJMoa0810773.
69. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5.
70. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.
71. Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014 Dec;134(6):1198-204.
72. Buller HR, Decousus H, Grosso MA, Mercuri M, Middleldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct;369(15): 1406-1415.
73. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222.
74. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510.
75. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97.
76. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Meta-analysis of non inferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397-402.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Platelet-Aggregation Inhibitors
AHFS Class 201218
August 9, 2017

I. Overview

The platelet-aggregation inhibitors play a major role in the management of cardiovascular, cerebrovascular, and peripheral vascular diseases. They are approved for the treatment and/or prevention of acute coronary syndromes, angina, intermittent claudication, myocardial infarction, stroke, and transient ischemic attack. In addition, they are indicated to prevent thrombosis in patients undergoing cardiovascular procedures and/or surgery.[1-7]

The platelet-aggregation inhibitors exert their pharmacologic effects through several different mechanisms. Clopidogrel and ticlopidine are both thienopyridines, which work by blocking the adenosine diphosphate (ADP) receptors found on platelets, leading to a subsequent inhibition of both platelet aggregation and activation.[5,7] The platelet inhibition effects of thienopyridines are delayed; therefore, a loading dose is typically required with these agents.[1-2] Prasugrel is a third generation thienopyridine ADP receptor antagonist; therefore, it has a similar mechanism of action to that of clopidogrel and ticlopidine. Prasugrel has been reported to be the most potent of these agents with a 10 mg dose of prasugrel being approximately 2.5 to 2.7 times more potent than a 75 mg dose of clopidogrel in inhibiting platelet aggregation and thrombus formation.[8] This reported greater efficacy in platelet inhibition is due to the difference in cytochrome activation between the agents. Clopidogrel requires a multi-step cytochrome activation process, whereas prasugrel requires only a single step.[9] Prasugrel has been shown to have more desirable characteristics when compared to clopidogrel with regards to drug-drug interactions and interpatient enzyme variability. Looking more specifically at drug-drug interactions, potent cytochrome P450 (CYP) 3A4 inhibitors have been shown to affect clopidogrel; however, no effect has been seen with prasugrel, suggesting that no dosage adjustments are necessary when faced with this type of interaction. Regarding polymorphism, studies have shown that clinical outcomes with prasugrel are not affected by patient genetic variations of the CYP2C9 and 2C19 isoenzymes, which have been reported with clopidogrel.[10] Ticagrelor also works in a similar manner to the other thienopyridine platelet inhibitors. Specifically, ticagrelor is a cyclopentyltriazolopyrimidine, and the agent and its equipotent active metabolite reversibly bind to the $P2Y_{12}$ receptor located on the surface of platelets, preventing platelet signal transduction and activation.[2,3] In contrast to ticagrelor, the other available thienopyridines work via the irreversible binding to the $P2Y_{12}$ receptor. In addition, these agents are all prodrugs, while ticagrelor is not. Therefore, ticagrelor does not require enzymatic conversion to become pharmacologically active, and is not subject to potential drug interactions associated with the other platelet inhibitors.[3,5,7] When compared to clopidogrel, ticagrelor resulted in lower platelet receptor expression and a greater extent of inhibition of platelet aggregation, suggesting increased potency at the $P2Y_{12}$ receptor.[11] Cilostazol inhibits phosphodiesterase activity and suppresses the degradation of cyclic-3',5'-adenosine monophosphate in platelets and blood vessels.[7]

The newest platelet inhibitor to be approved by the Food and Drug Administration, vorapaxar, is a reversible antagonist of protease-activated receptor 1 (PAR-1). Blocking PAR-1 results in potent inhibition of thrombin-induced platelet aggregation.[12] Due to vorapaxar's long half-life, it acts as an irreversible inhibitor. Unlike other platelet inhibitors, vorapaxar does not inhibit platelet aggregation induced by ADP, collagen, or a thromboxane mimetic.[2,7]

The platelet-aggregation inhibitors that are included in this review are listed in Table 1. Currently, cilostazol, clopidogrel, and ticlopidine are the platelet-aggregation inhibitors that are available generically. This review encompasses all dosage forms and strengths. This class was last reviewed in February 2013.

Table 1. Platelet-Aggregation Inhibitors Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Cilostazol	tablet	N/A	cilostazol
Clopidogrel	tablet	Plavix®*	clopidogrel
Prasugrel	tablet	Effient®	none
Ticagrelor	tablet	Brilinta®	none

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Ticlopidine	tablet	N/A	ticlopidine
Vorapaxar	tablet	Zontivity®	none

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List
N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the platelet-aggregation inhibitors are summarized in Table 2.

Table 2. Treatment Guidelines Using the Platelet-Aggregation Inhibitors

Clinical Guideline	Recommendations
American College of Chest Physicians: **Antithrombotic Therapy and Prevention of Thrombosis, 9th edition (2012)**[13]	<u>Management of anticoagulant therapy</u> • For outpatients, vitamin K antagonist (VKA) therapy with warfarin 10 mg/day for the first two days, followed by dosing based on international normalized ratio (INR) measurements rather than starting with the estimated maintenance dose is suggested. • Routine use of pharmacogenetic testing for guiding doses of VKA therapy is not recommended. • For acute venous thromboembolism (VTE), it is suggested that VKA therapy be started on day one or two of low molecular weight heparin (LMWH) or low dose unfractionated heparin (UFH) therapy rather than waiting for several days to start. • For VKA therapy with stable INRs, INR testing frequency of up to 12 weeks is suggested rather than every four weeks. • For patients receiving previously stable VKA therapy who present with a single out-of-range INR ≤0.5 below or above therapeutic, it is suggested to continue the current dose and test the INR within one to two weeks. • For patients receiving stable VKA therapy presenting with a single subtherapeutic INR value, routine administering of bridging heparin is not recommended. • Routine use of vitamin K supplementation is suggested against with VKA therapy. • For patients receiving VKA therapy who are motivated and can demonstrate competency in self-management strategies, it is suggested that patient self-management be utilized rather than usual outpatient INR monitoring. • For maintenance VKA dosing, it is suggested that validated decision support tools be utilized rather than no decision support. • Concomitant use of nonsteroidal anti-inflammatory drugs and certain antibiotics should be avoided in patients receiving VKA therapy. • Concomitant use of platelet inhibitors should be avoided in patients receiving VKA therapy, except in situations where benefit is known or is highly likely to be greater than harm from bleeding. • With VKA therapy, a therapeutic INR range of 2.0 to 3.0 (target, 2.5) is recommended rather than a lower (<2.0) or higher (range, 3.0 to 5.0) range. • In patients with antiphospholipid syndrome with previous arterial or VTE, VKA therapy should be titrated to a moderate intensity INR (range, 2.0 to 3.0) rather than higher intensity (range, 3.0 to 4.5). • For discontinuations of VKA therapy, it is suggested that discontinuation be done abruptly rather than gradual tapering of the dose. • For initiation of intravenous (IV) UFH, the initial bolus and rate of continuous infusion should be weight adjusted or fixed-dose rather than alternative regimens.

Clinical Guideline	Recommendations
	• In outpatients with VTE receiving subcutaneous (SC) UFH, dosing should be weight-based without monitoring rather than fixed or weight-adjusted dosing with monitoring. • A reduction in therapeutic LMWH dose is suggested in patients with severe renal insufficiency rather than using standard doses. • In patients with VTE and body weight >100 kg, the treatment dose of fondaparinux should be increased from 7.5 to 10 mg/day SC. • For INRs between 4.5 and 10.0 with VKA therapy and no evidence of bleeding, routine use of vitamin K is not recommended. • For INRs >10.0 with VKA therapy and no evidence of bleeding, it is suggested that oral vitamin K be administered. • In patients initiating VKA therapy, routine use of clinical prediction rules for bleeding as the sole criterion to withhold VKA therapy is not recommended. • For VKA-associated major bleeding, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate is suggested over plasma. Additional use of vitamin K 5 to 10 mg administered by slow IV injection is recommended rather than reversal with coagulation factors alone. <u>Prevention of VTE in nonsurgical patients</u> • Acutely ill hospitalized medical patients at increased risk of thrombosis: anticoagulant thromboprophylaxis with LMWH, low dose UFH (two or three times daily), or fondaparinux is recommended. Choice should be based on patient preference, compliance, and ease of administration, as well as on local factors affecting acquisition costs. • Acutely ill hospitalized patients at low risk of thrombosis: pharmacologic or mechanical prophylaxis is not recommended. • Acutely ill hospitalized medical patients who are bleeding or at high risk for bleeding: anticoagulant thromboprophylaxis is not recommended. • Acutely ill hospitalized medical patients at increased risk for thrombosis who are bleeding or at high risk of major bleeding: optimal use of mechanical thromboprophylaxis is suggested rather than no mechanical thromboprophylaxis. When bleeding risk decreases, and if VTE risk persists, it is suggested that pharmacologic thromboprophylaxis be substituted for mechanical thromboprophylaxis. • Acutely ill hospitalized medical patients who receive an initial course of thromboprophylaxis: extending the duration of thromboprophylaxis beyond the period of patient immobilization or acute hospital stay is suggested against. • Critically ill patients: routine ultrasound screening for deep vein thrombosis (DVT) is suggested against. • Critically ill patients: use of LMWH or low dose UFH thromboprophylaxis is suggested over no prophylaxis. • Critically ill patients who are bleeding or are at high risk for major bleeding: use of mechanical thromboprophylaxis until the bleeding risk decreases is suggested rather than no mechanical thromboprophylaxis. When bleeding risk decreases, pharmacologic thromboprophylaxis is suggested to be substituted for mechanical thromboprophylaxis. • Outpatients with cancer who have no additional risk factors for VTE: routine prophylaxis with LMWH or low dose UFH is suggested against, and prophylactic use of VKAs is not recommended. • Outpatients with solid tumors who have additional risk factors for VTE with low risk of bleeding: prophylaxis with LMWH or low dose UFH is suggested over no prophylaxis. • Outpatients with cancer and indwelling central venous catheters: routine prophylaxis with LMWH or low dose UFH is suggested against, and prophylactic use of VKAs is suggested against.

Clinical Guideline	Recommendations
	• Chronically immobilized patients residing at home or at a nursing home: routine thromboprophylaxis is suggested against. • Long distance travelers at increased risk of VTE: frequent ambulation, calf muscle exercise, or sitting in an aisle seat if feasible is suggested. • Long distance travelers at increased risk of VTE: use of properly fitted, below-knee graduated compression stockings during travel is suggested. For all other long distance travelers, use of graduated compression stockings is suggested against. • Long distance travelers: use of aspirin or anticoagulants to prevent VTE is suggested against. • Patients with asymptomatic thrombophilia: long term daily use of mechanical or pharmacologic thromboprophylaxis to prevent VTE is not recommended. <u>Prevention of VTE in nonorthopedic surgical patients</u> • General and abdominal-pelvic surgery patients at very low risk for VTE: no specific pharmacologic or mechanical prophylaxis is recommended for use other than early ambulation. • General and abdominal-pelvic surgery patients at low risk for VTE: mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients at moderate risk for VTE who are not at high risk major bleeding complications: LMWH, low dose UFH, or mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients at moderate risk for VTE who are at high risk for major bleeding complication or those in whom the consequences of bleeding are thought to be particularly severe: mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients at high risk for VTE who are not at high risk for major bleeding complications: LMWH or low dose UFH is recommended over no prophylaxis. It is suggested that mechanical prophylaxis be added to pharmacologic prophylaxis. • High-VTE-risk patients undergoing abdominal or pelvic surgery for cancer who are not otherwise at high risk for major bleeding complications: extended duration (four weeks) of LMWH prophylaxis is recommended over limited duration prophylaxis. • High-VTE-risk general and abdominal-pelvic surgery patients who are at high risk for major bleeding complications or those in whom the consequences of bleeding are thought to be particularly severe: mechanical prophylaxis is suggested over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated. • General and abdominal-pelvic surgery patients at high risk for VTE in whom both LMWH and UFH are contraindicated or unavailable and who are not at high risk for major bleeding complications: low dose aspirin, fondaparinux, or mechanical prophylaxis is suggested over no prophylaxis. • General and abdominal-pelvic surgery patients: it is suggested that an inferior vena cava filter not be used for primary VTE prevention. • General and abdominal-pelvic surgery patients: it is suggested that periodic surveillance with venous compression ultrasound not be performed. • Cardiac surgery patients with an uncomplicated postoperative course: mechanical prophylaxis is suggested over either no prophylaxis or pharmacologic prophylaxis. • Cardiac surgery patients whose hospital course is prolonged by one or more nonhemorrhagic surgical complications: adding pharmacologic prophylaxis with low dose UFH or LMWH to mechanical prophylaxis is suggested. • Thoracic surgery patients at moderate risk for VTE who are not at high risk for perioperative bleeding: low dose UFH, LMWH, or mechanical prophylaxis is

Clinical Guideline	Recommendations
	suggested over no prophylaxis. • Thoracic surgery patients at high risk for VTE who are not at high risk for perioperative bleeding: low dose UFH or LWMH is suggested over no prophylaxis. It is suggested that mechanical prophylaxis be added to pharmacologic prophylaxis. • Thoracic surgery patients who are at high risk for major bleeding: mechanical prophylaxis over no prophylaxis is suggested until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated. • Craniotomy patients: mechanical prophylaxis is suggested over no prophylaxis or pharmacologic prophylaxis. • Craniotomy patients at very high risk for VTE: it is suggested that pharmacologic prophylaxis be added to mechanical prophylaxis once adequate hemostasis is established and the risk of bleeding decreases. • Patients undergoing spinal surgery: mechanical prophylaxis is suggested over no prophylaxis, UFH, or LMWH. • Patients undergoing spinal surgery at high risk of VTE: it is suggested that pharmacologic prophylaxis be added to mechanical prophylaxis once adequate hemostasis is established and the risk of bleeding decreases. • Major trauma patients: low dose UFH, LMWH, or mechanical prophylaxis is suggested over no prophylaxis. • Major trauma patients at high risk for VTE: it is suggested that mechanical prophylaxis be added to pharmacologic prophylaxis when not contraindicated by lower extremity injury. • Major trauma patients in whom LMWH and low dose UFH are contraindicated: mechanical prophylaxis is suggested over no prophylaxis when not contraindicated by lower extremity injury. It is suggested that either LMWH or low dose UFH be added when the risk of bleeding diminishes or the contraindication to heparin resolves. • Major trauma patients: it is suggested that an interior vena cava filter not be used for primary VTE prevention. • Major trauma patients: it is suggested that periodic surveillance with venous compression ultrasound not be performed. <u>Prevention of VTE in orthopedic surgery patients</u> • Total hip arthroplasty or total knee arthroplasty: use of one of the following for a minimum of 10 to 14 days rather than no antithrombotic prophylaxis is recommended: LMWH, fondaparinux, apixaban, dabigatran, rivaroxaban, low dose UFH, adjusted-dose VKA, aspirin, or an intermittent pneumatic compression device. • Hip fracture surgery: use of one of the following for a minimum of 10 to 14 days rather than no antithrombotic prophylaxis is recommended: LMWH, fondaparinux, low dose UFH, adjusted-dose VKA, aspirin, or intermittent pneumatic compression device. • Patients undergoing major orthopedic surgery (total hip arthroplasty, total knee arthroplasty, hip fracture surgery) and receiving LMWH as thromboprophylaxis: it is recommended to start either 12 hours or more preoperatively or postoperatively rather than within four hours or less preoperatively or postoperatively. • Total hip or knee arthroplasty, irrespective of the concomitant use of an intermittent pneumatic compression device or length of treatment: LMWH is suggested in preference to other agents recommended as alternatives: fondaparinux, apixaban, dabigatran, rivaroxaban, low dose UFH, adjusted-dose VKA, or aspirin. • Hip replacement surgery, irrespective of the concomitant use of an intermittent pneumatic compression device or length of treatment: LMWH is suggested in

Clinical Guideline	Recommendations
	preference to other agents recommended as alternatives: fondaparinux, low dose UFH, adjusted-dose VKA, or aspirin. • Major orthopedic surgery: it is suggested to extend thromboprophylaxis in the outpatient period for up to 35 days from the day of surgery rather than for only 10 to 14 days. • Major orthopedic surgery: it is suggested to use dual prophylaxis with an antithrombotic agent and an intermittent pneumatic compression device during the hospital stay. • Major orthopedic surgery in patients at an increased risk of bleeding: intermittent pneumatic compression device or no prophylaxis is suggested over pharmacologic prophylaxis. • Major orthopedic surgery in patients who decline or are uncooperative with injections or intermittent pneumatic compression device: apixaban or dabigatran etexilate mesylate (alternatively rivaroxaban or adjusted-dose VKA if apixaban or dabigatran etexilate mesylate are unavailable) is recommended over alternative forms of prophylaxis. • Major orthopedic surgery in patients with an increased bleeding risk or contraindications to both pharmacologic and mechanical prophylaxis: inferior vena cava filter placement for primary prevention of VTE is suggested against over no thromboprophylaxis. • Asymptomatic patients following major orthopedic surgery: Doppler ultrasound screening before hospital discharge is not recommended. • Patients with lower leg injuries requiring leg immobilization: no prophylaxis is suggested rather than pharmacologic thromboprophylaxis. • Knee arthroscopy in patients without a history of prior VTE: no thromboprophylaxis is suggested rather than prophylaxis. <u>Antithrombotic therapy for VTE disease</u> • Acute DVT of the leg or pulmonary embolism (PE) treated with VKA therapy: initial treatment with parenteral anticoagulation (LMWH, fondaparinux, or IV or SC UFH) is recommended over no such initial treatment. • High clinical suspicion of acute VTE or PE: treatment with parenteral anticoagulation is suggested over no treatment while awaiting the results of diagnostic tests. • Intermediate clinical suspicion of acute VTE or PE: treatment with parenteral anticoagulation is suggested over no treatment if the results of diagnostic tests are expected to be delayed for more than four hours. • Low clinical suspicion of acute VTE or PE: it is suggested to not treat with parenteral anticoagulants while awaiting the results of diagnostic tests, provided test results are expected within 24 hours. • Acute isolated distal DVT of the leg without severe symptoms or risk factors for extension: serial imaging of the deep veins for two weeks is suggested over initial anticoagulation. • Acute isolated distal DVT of the leg and severe symptoms or risk factors for extension: initial anticoagulation is suggested over serial imaging of the deep veins. • Acute isolated distal DVT of the leg in patients managed with initial anticoagulation: using the same approach as for patients with acute proximal DVT is recommended. • Acute isolated distal DVT of the leg who are managed with serial imaging: no anticoagulation if the thrombus does not extend is recommended; anticoagulation is suggested if the thrombus extends but remains confined to the distal veins; and anticoagulation is recommended if the thrombus extends into the proximal veins. • Acute DVT of the leg or PE: early initiation of VKA therapy is recommended

Clinical Guideline	Recommendations
	over delayed initiation, and continuation of parenteral anticoagulation for a minimum on five days and until the INR is 2.0 or above for at least 24 hours. • Acute DVT of the leg or PE: LMWH or fondaparinux is suggested over IV or SC UFH. • Patients with acute DVT of the leg or PE receiving LMWH: once daily LMWH administration is suggested over twice daily administration. • Acute DVT of the leg and home circumstances are adequate: initial treatment at home is recommended over treatment in hospital. • Low risk PE and home circumstances are adequate: early discharge is suggested over standard discharge. • Acute proximal DVT of the leg: anticoagulation therapy alone is suggested over catheter-directed thrombolysis. • Acute proximal DVT of the leg: anticoagulation therapy alone is suggested over systemic thrombolysis. • Acute proximal DVT of the leg: anticoagulation therapy alone is suggested over venous thrombectomy. • Acute DVT of the leg in patients who undergo thrombosis removal: the same intensity and duration of anticoagulant therapy as in comparable patients who do not undergo thrombosis removal is recommended. • Acute DVT of the leg: use of an inferior vena cava filter in addition to anticoagulants is not recommended. • Acute proximal DVT of the leg in patients with contraindication to anticoagulation: use of an inferior vena cava filter is recommended. • Acute proximal DVT of the leg in patients with an inferior vena cava filter inserted as an alternative to anticoagulation: a conventional course of anticoagulant therapy is suggested if the risk of bleeding resolves. • Acute DVT of the leg: early ambulation is suggested over initial bed rest. • Acute VTE in patients receiving anticoagulant therapy: long term therapy is recommended over stopping anticoagulant therapy after about one week of initial therapy. • Acute symptomatic DVT of the leg: compression stockings are suggested. • Acute PE associated with hypotension in patients who do not have a high bleeding risk: systemically administered thrombolytic therapy is suggested over no such therapy. • In most patients with acute PE not associated with hypotension: systemically administered thrombolytic therapy is not recommended. • In selected patients with acute PE not associated with hypotension and with a low bleeding risk who initial clinical presentation or clinical course after starting anticoagulant therapy, suggests a high risk of developing hypotension: administration of thrombolytic therapy is suggested. • Proximal DVT of the leg or PE provoked by surgery: treatment with anticoagulation for three months is recommended over treatment for a shorter period, treatment of a longer time limited period, or extended therapy. • Proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor: treatment with anticoagulation for three months is recommended over treatment for a shorter period, treatment for a longer time limited period, extended therapy if there is high bleeding risk. Anticoagulation treatment for three months is suggested over extended therapy if there is a low or moderate bleeding risk. • Isolated distal DVT of the leg provoked by surgery or by a nonsurgical transient risk factor: treatment with anticoagulation for three months is suggested over treatment for a shorter period, and anticoagulation treatment for three months is recommended over treatment of longer time limited period or extended therapy. • Unprovoked DVT of the leg or PE: treatment with anticoagulation for three

Clinical Guideline	Recommendations
	months is recommended over treatment of a shorter duration. After three months, patients should be evaluated for the risk-benefit ratio of extended therapy. • First VTE that is an unprovoked proximal DVT of the leg or PE in patients who have a low or moderate bleeding risk: extended anticoagulant therapy is suggested over three months of therapy. • First VTE that is an unprovoked proximal DVT of the leg or PE in patients who have a high bleeding risk: three months of anticoagulant therapy is recommended over extended therapy. • First VTE that is an unprovoked isolated distal DVT of the leg: three months of anticoagulation therapy is suggested over extended therapy in those with a low or moderate bleeding risk, and three months of anticoagulant treatment is recommended in those with a high bleeding risk. • Second unprovoked VTE or PE: extended anticoagulant therapy is recommended over three months of therapy in those who have a low bleeding risk, and extended anticoagulant therapy is suggested in patients with a moderate bleeding risk. • Second unprovoked VTE or PE in patients with a high bleeding risk: three months of anticoagulant therapy is suggested over extended therapy. • DVT of the leg or PE and active cancer: if the risk of bleeding is not high, extended anticoagulation therapy is recommended over three months of therapy, and if there is a high bleeding risk, extended anticoagulant therapy is suggested. • DVT of the leg or PE in patients treated with VKA: a therapeutic INR range of 2.0 to 3.0 (target, 2.5) is recommended over a lower (<2.0) or higher (range, 3.0 to 5.0) range for all treatment durations. • DVT of the leg or PE in patients with no cancer: VKA therapy is suggested over LMWH for long-term therapy. For patients with DVT or PE and no cancer who are not treated with VKA therapy, LMWH is suggested over dabigatran etexilate mesylate or rivaroxaban for long term therapy. • DVT of the leg or PE and cancer: LMWH is suggested over VKA therapy. In patients with DVT of the leg or PE and cancer who are not treated with LMWH, VKA is suggested over dabigatran etexilate mesylate or rivaroxaban for long-term therapy. • DVT of the leg or PE in patients who receive extended therapy: treatment with the same anticoagulant chosen for the first three months is suggested. • Patients incidentally found to have asymptomatic DVT of the leg or PE: treatment with the same anticoagulant is suggested as for comparable patients with symptomatic DVT or PE. • In patients with chronic thromboembolic pulmonary hypertension, extended anticoagulation is recommended over stopping therapy. • Superficial vein thrombosis of the lower limb of at least 5 cm in length: use of a prophylactic dose of fondaparinux or LMWH for 45 days is suggested over no anticoagulation. • Superficial vein thrombosis in patients treated with anticoagulation: fondaparinux 2.5 mg/day is suggested over a prophylactic dose of LMWH. • Upper-extremity DVT that involves the axillary or more proximal veins: acute treatment with parenteral anticoagulation (LMWH, fondaparinux, or IV or SC UFH) over no such acute treatment. • Acute upper-extremity DVT that involves the axillary or more proximal veins: LMWH or fondaparinux is suggested over IV or SC UFH, and anticoagulation therapy alone is suggested over thrombolysis. • Upper-extremity DVT in patients undergoing thrombolysis: the same intensity and duration of anticoagulant therapy as in similar patients who do not undergo thrombolysis is recommended.

Clinical Guideline	Recommendations
	• In most patients with upper-extremity DVT that is associated with a central venous catheter: it is suggested that the catheter not be removed if it is functional and there is an ongoing need for the catheter. • Upper-extremity DVT that involves the axillary or more proximal veins: a minimum duration of anticoagulation of three months is suggested over a shorter duration. • Upper-extremity DVT that is associated with a central venous catheter that is removed: three months of anticoagulation is recommended over a longer duration of therapy in patients with no cancer, and this is suggested in patients with cancer. • Upper-extremity DVT that is associated with a central venous catheter that is not removed: it is recommended that anticoagulation is continued as long as the central venous catheter remains over stopping after three months of treatment in patients with cancer, and this is suggested in patients with no cancer. • Upper-extremity DVT that is not associated with a central venous catheter or with cancer: three months of anticoagulation is recommended over a longer duration of therapy. • Acute symptomatic upper-extremity DVT: use of compression sleeves or venoactive medications is suggested against. • Symptomatic splanchnic vein thrombosis: anticoagulation is recommended over no anticoagulation. • Symptomatic hepatic vein thrombosis: anticoagulation is suggested over no anticoagulation. • In patients with incidentally detected splanchnic vein thrombosis or hepatic vein thrombosis: no anticoagulation is suggested over anticoagulation. <u>Antithrombotic therapy for atrial fibrillation (AF)</u> • Patients with AF, including those with paroxysmal AF, who are at low risk of stroke: no therapy is suggested over antithrombotic therapy. For patients who choose antithrombotic therapy, aspirin is suggested over oral anticoagulation or combination therapy with aspirin and clopidogrel. • Patients with AF, including those with paroxysmal AF, who are at intermediate risk of stroke: oral anticoagulation is recommended over no therapy. Oral anticoagulation is suggested over aspirin or combination therapy with aspirin and clopidogrel. For patients who are unsuitable for or choose not to take an oral anticoagulant, combination therapy with aspirin and clopidogrel are suggested over aspirin. • Patients with AF, including those with paroxysmal AF, who are at high risk of stroke: oral anticoagulation is recommended over no therapy, aspirin, or combination therapy with aspirin and clopidogrel. For patients who are unsuitable for or choose not to take an oral anticoagulant, combination therapy with aspirin and clopidogrel is recommended over aspirin. • Patients with AF, including those with paroxysmal AF: for recommendations in favor of oral anticoagulation, dabigatran etexilate mesylate 150 mg twice daily is suggested over adjusted-dose VKA therapy (target INR range, 2.0 to 3.0). • Patients with AF and mitral stenosis: adjusted-dose VKA therapy is recommended over no therapy, aspirin, or combination therapy with aspirin and clopidogrel. For patients who are unsuitable for or choose not to take adjusted-dose VKA therapy, combination therapy with aspirin and clopidogrel is recommended over aspirin alone. • Patients with AF and stable coronary artery disease and who choose oral anticoagulation: adjusted-dose VKA therapy alone is suggested over the combination of adjusted-dose VKA therapy and aspirin.

Clinical Guideline	Recommendations

	• Patients with AF at high risk of stroke during the first month after placement of a bare-metal stent or the first three to six months after placement of a drug-eluting stent: triple therapy (e.g., VKA therapy, aspirin, and clopidogrel) is suggested over dual antiplatelet therapy (e.g., aspirin and clopidogrel). After this initial period, a VKA plus a single antiplatelet agent is suggested over a VKA alone. At 12 months after stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease.
	• Patients with AF at intermediate risk of stroke during the first 12 months after placement of a stent: dual antiplatelet therapy is suggested over triple therapy. At 12 months after stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease.
	• Patients with AF at intermediate to high risk of stroke who experience an acute coronary syndrome (ACS) and do not undergo stent placement, for the first 12 months: adjusted-dose VKA therapy plus single antiplatelet therapy is suggested over dual antiplatelet therapy or triple therapy. After the first 12 months, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease.
	• Patients with AF at low risk of stroke: dual antiplatelet therapy is suggested over adjusted-dose VKA therapy plus single antiplatelet therapy or triple therapy. After the first 12 months, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease.
	• Patients with AF being managed with a rhythm control strategy: it is suggested that antithrombotic therapy decisions follow the general risk-based recommendations for patients with nonrheumatic AF, regardless of the apparent persistence of normal sinus rhythm.
	• Patients with atrial flutter: it is suggested that antithrombotic therapy decisions follow the same risk-based recommendations as for AF.
	
	<u>Antithrombotic therapy for ischemic stroke</u>
	• In patients with acute ischemic stroke or transient ischemic attack (TIA), early (within 48 hours) aspirin 160 to 325 mg is recommended over therapeutic parenteral anticoagulation.
	• In patients with a history of noncardioembolic ischemic stroke or TIA, aspirin (75 to 100 mg daily), clopidogrel (75 mg daily), aspirin-dipyridamole extended-release (ER) (25 mg-200 mg twice daily) or cilostazol (100 mg twice daily) is recommended over oral anticoagulants, the combination of clopidogrel plus aspirin or triflusal.
	  ○ Clopidogrel or aspirin-dipyridamole ER is recommended over aspirin or cilostazol.
	• In patients with a history of ischemic stroke or TIA and AF, oral anticoagulation with dabigatran 150 mg twice daily is recommended over VKA therapy.
	  ○ In patients who are unable to or choose not to take an oral anticoagulant, the combination of aspirin plus clopidogrel is recommended over aspirin alone.
	
	<u>Primary and secondary prevention of cardiovascular disease</u>
	• Patients ≥50 years of age without symptomatic cardiovascular disease: low dose aspirin (75 to 100 mg/day) is suggested over no aspirin therapy.
	• Patients with established coronary artery disease: long term single antiplatelet therapy with aspirin (75 to 100 mg/day) or clopidogrel (75 mg/day) is recommended over no antiplatelet therapy, and single antiplatelet therapy is suggested over dual antiplatelet therapy.
	• Patients in the first year after ACS who have not undergone percutaneous coronary intervention (PCI): dual antiplatelet therapy (ticagrelor 90 mg twice

Clinical Guideline	Recommendations
	daily plus low dose aspirin 75 to 100 mg/day or clopidogrel 75 mg/day plus low dose aspirin 75 to 100 mg/day) is recommended over single antiplatelet therapy. Ticagrelor 90 mg twice daily plus low dose aspirin is suggested over clopidogrel 75 mg/day plus low dose aspirin. • Patients in the first year after an ACS who have undergone PCI with stent placement: dual antiplatelet therapy (ticagrelor 90 mg twice daily plus low dose aspirin 75 to 100 mg/day, clopidogrel 75 mg/day plus low dose aspirin, or prasugrel 10 mg/day plus low dose aspirin) is recommended over single antiplatelet therapy. Ticagrelor 90 mg twice daily plus low dose aspirin is suggested over clopidogrel 75 mg/day plus low dose aspirin. • Patients with anterior myocardial infarction (MI) and left ventricular thrombus, or at high risk for left ventricular thrombus, who do not undergo stenting: warfarin plus low dose aspirin (75 to 100 mg/day) is recommended over single antiplatelet therapy or dual antiplatelet therapy for the first three months. Thereafter, it is recommended that warfarin be discontinued and dual antiplatelet therapy should be continued for up to 12 months. After 12 months, single antiplatelet therapy is recommended as per the established coronary artery disease recommendations. • Patients with anterior MI and left ventricular thrombus, or at high risk for left ventricular thrombus, who undergo bare-metal stent placement: triple therapy (warfarin, low dose aspirin, clopidogrel 75 mg/day) for one month is suggested over dual antiplatelet therapy. Warfarin and single antiplatelet therapy for the second and third month post-bare-metal stent is suggested over alternative regimens and alternative time frames for warfarin use. Thereafter, it is recommended that warfarin be discontinued and dual antiplatelet therapy should be continued for up to 12 months. After 12 months, antiplatelet therapy is recommended as per the established coronary artery disease recommendations. • Patients with anterior MI and left ventricular thrombus, or at high risk for left ventricular thrombus who undergo drug-eluting stent placement: triple therapy (warfarin, low dose aspirin, clopidogrel 75 mg/day) for up to three to six months is suggested over alternative regimens and alternative durations of warfarin therapy. Thereafter, it is recommended that warfarin be discontinued and dual antiplatelet therapy should be continued for up to 12 months. After 12 months, antiplatelet therapy is recommended as per the established coronary artery disease recommendations. • Patients who have undergone elective PCI with placement of bare-metal stent: dual antiplatelet therapy with aspirin 75 to 325 mg/day and clopidogrel 75 mg/day for one month is recommended over single antiplatelet therapy. For the subsequent 11 months, dual antiplatelet therapy with combination low dose aspirin 75 to 100 mg/day and clopidogrel 75 mg/day is suggested over single antiplatelet therapy. After 12 months, single antiplatelet therapy is recommended over continuation of dual antiplatelet therapy. • Patients who have undergone elective PCI with placement of drug-eluting stent: dual antiplatelet therapy with aspirin 75 to 325 mg/day and clopidogrel 75 mg/day for three to six months is recommended over single antiplatelet therapy. After three to six months, continuation of dual antiplatelet therapy with low dose aspirin 75 to 100 mg/day and clopidogrel 75 mg/day is suggested to be continued until 12 months over antiplatelet therapy. After 12 months, single antiplatelet therapy is recommended over continuation of dual antiplatelet therapy. Single antiplatelet therapy thereafter is recommended as per the established coronary artery disease recommendations. • Patients who have undergone elective bare-metal stent or drug-eluting stent placement: low dose aspirin 75 to 100 mg/day and clopidogrel 75 mg/day is recommended over cilostazol in addition to these drugs. Aspirin 75 to 100 mg/day or clopidogrel 75 mg/day as part of dual antiplatelet therapy is

Clinical Guideline	Recommendations

	suggested over the use of either drug with cilostazol. Cilostazol 100 mg twice daily as a substitute for either low dose aspirin or clopidogrel as part of a dual antiplatelet regimen in patients with an allergy or intolerance of either drug class is suggested.
	• Patients with coronary artery disease undergoing elective PCI but no stent placement: for the first month dual antiplatelet therapy with aspirin 75 to 325 mg/day and clopidogrel 75 mg/day is suggested over single antiplatelet therapy. Single antiplatelet therapy thereafter is recommended as per the established coronary artery disease recommendations.
	• Patients with systolic left ventricular dysfunction without established coronary artery disease and no left ventricular thrombus: it is suggested that antiplatelet therapy and warfarin not be used.
	• Patients with systolic left ventricular dysfunction without established coronary artery disease with identified acute left thrombus: moderate intensity warfarin for at least three months is suggested.
	• Patients with systolic left ventricular dysfunction and established coronary artery disease: recommendations are as per the established coronary artery disease recommendations.
	
	<u>Antithrombotic therapy in peripheral artery disease (PAD)</u>
	• In patients with asymptomatic PAD, aspirin 75 to 100 mg daily is recommended.
	• In patients with symptomatic PAD, long-term therapy with aspirin (75 to 100 mg daily) or clopidogrel (75 mg daily) is recommended for secondary prevention of cardiovascular events. Dual antiplatelet therapy or the combination of an antiplatelet agent with moderate-intensity warfarin is not recommended.
	• Use of cilostazol in addition to aspirin or clopidogrel is recommended in patients with intermittent claudication refractory to exercise therapy and smoking cessation.
	• Use of prostanoids in addition to aspirin or clopidogrel is recommended in patients with symptomatic PAD and critical leg ischemia who are not candidates for vascular intervention.
	• In patients undergoing peripheral artery percutaneous transluminal angioplasty with or without stenting, long-term therapy with aspirin or clopidogrel is recommended over dual antiplatelet therapy.
	• Following peripheral artery bypass graft surgery, long-term therapy with aspirin or clopidogrel is recommended over the combination of antiplatelet agent plus warfarin. Clopidogrel plus aspirin for one year is recommended in patients undergoing below-knee bypass graft surgery with prosthetic grafts.
	• In patients with asymptomatic carotid stenosis, aspirin 75 to 100 mg daily is recommended.
	• In patients with symptomatic carotid stenosis, long-term therapy with clopidogrel (75 mg daily) or aspirin/dipyridamole ER (25 mg/200 mg twice daily) is recommended over aspirin (75 to 100 mg daily).
	
	<u>Antithrombotic and thrombolytic therapy for valvular disease</u>
	• Antithrombotic therapy in the first three months after surgery:
	  ○ In patients with aortic bioprosthetic valves, who are in sinus rhythm and have no other indication for VKA therapy, aspirin (50 to 100 mg/day) over VKA therapy is suggested in the first three months.
	  ○ In patients with transcatheter aortic bioprosthetic valves, aspirin (50 to 100 mg/day) plus clopidogrel (75 mg/day) is suggested over VKA therapy and over no antiplatelet therapy in the first three months.
	  ○ In patients with a bioprosthetic valve in the mitral position, VKA therapy

Clinical Guideline	Recommendations

	over no VKA therapy for the first three months after valve insertion is suggested.
	• Long-term antithrombotic therapy for patients with bioprosthetic valves:
	  o In patients with bioprosthetic valves in normal sinus rhythm, aspirin therapy over no aspirin therapy after three months postoperative is suggested.
	• Early postoperative bridging to intermediate/long-term therapy (postoperative day 0 to 5):
	  o In patients with mechanical heart valves, bridging with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) over intravenous (IV) therapeutic UFH until stable on VKA therapy.
	• Long-term antithrombotic therapy for patients with mechanical valves:
	  o VKA therapy is recommended over no VKA therapy for long-term management.
	• Intensity of VKA therapy for patients with mechanical aortic valve prostheses:
	  o VKA therapy at a target of 2.5 over lower targets is suggested. A target of 2.5 is recommended over higher targets.
	• Intensity of VKA therapy for patients with mechanical mitral valve prostheses:
	  o VKA therapy with a target of 3.0 over lower INR targets is suggested.
	• Intensity of VKA therapy in patients with double mechanical valve or with additional risk factors:
	  o VKA therapy with a target of 3.0 is suggested over target INR 2.5.
	• Antiplatelet agent in addition to VKA therapy for patients with mechanical aortic or mitral valve prostheses:
	  o Patients who are at low risk of bleeding, adding over not adding an antiplatelet agent such as low-dose (50 to 100 mg/day) to VKA therapy is suggested.
	• For patients with mechanical aortic or mitral valves VKA therapy over antiplatelet agents is recommended.
	• In patients undergoing mitral valve repair with a prosthetic band in normal sinus rhythm, the use of antiplatelet therapy for the first three months is suggested over VKA therapy.
	• In patients undergoing aortic valve repair, aspirin (50 to 100 mg/day) is suggested over VKA therapy.

American College of Chest Physicians: **Antithrombotic Therapy for VTE Disease (2016)**[14]	Choice of long-term (first three months) and extended (no scheduled stop date) anticoagulant • In patients with proximal deep vein thrombosis (DVT) or pulmonary embolism (PE), long-term (three months) anticoagulant therapy is recommended over no such therapy. • In patients with DVT of the leg or PE and no cancer, as long-term (first three months) anticoagulant therapy, dabigatran, rivaroxaban, apixaban, or edoxaban is recommended over vitamin K antagonist (VKA) therapy. • No non-vitamin K oral anticoagulant is preferred over another. • Initial parenteral anticoagulation is given before dabigatran and edoxaban, is not given before rivaroxaban and apixaban, and is overlapped with VKA therapy. • In patients with DVT of the leg or PE and cancer ("cancer-associated thrombosis"), as long-term anticoagulant therapy, LMWH is recommended over VKA therapy, dabigatran, rivaroxaban, apixaban, or edoxaban. • In patients with DVT of the leg or PE who receive extended therapy, there is no need to change the choice of anticoagulant after the first three months. Duration of anticoagulant therapy • In patients with a proximal DVT of the leg or PE provoked by surgery, treatment with anticoagulation for three months is recommended over (i)

Clinical Guideline	Recommendations
	treatment of a shorter period, (ii) treatment of a longer time-limited period (e.g., six, 12, or 24 months), or (iii) extended therapy (no scheduled stop date). • In patients with a proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor, treatment with anticoagulation for three months is recommended over (i) treatment of a shorter period and (ii) treatment of a longer time-limited period (e.g., six, 12, or 24 months). Treatment with anticoagulation for three months is suggested over extended therapy if there is a low or moderate bleeding risk, and treatment for three months is recommended over extended therapy if there is a high risk of bleeding. • In patients with an isolated distal DVT of the leg provoked by surgery or by a nonsurgical transient risk factor, treatment with anticoagulation for three months is suggested over treatment of a shorter period, treatment with anticoagulation for three months is recommended over treatment of a longer time-limited period (e.g., six, 12, or 24 months), and treatment with anticoagulation for three months is recommended over extended therapy (no scheduled stop date). • In patients with an unprovoked DVT of the leg (isolated distal or proximal) or PE, treatment with anticoagulation for at least three months is recommended over treatment of a shorter duration), and treatment with anticoagulation for three months is recommended over treatment of a longer time-limited period (e.g., six, 12, or 24 months). • In patients with a first VTE that is an unprovoked proximal DVT of the leg or PE and who have a (i) low or moderate bleeding risk, extended anticoagulant therapy (no scheduled stop date) is suggested over three months of therapy, and (ii) high bleeding risk, three months of anticoagulant therapy is recommended over extended therapy (no scheduled stop date). • In patients with a second unprovoked VTE and who have a (i) low bleeding risk, extended anticoagulant therapy (no scheduled stop date) is recommended over three months; (ii) moderate bleeding risk, extended anticoagulant therapy is suggested over three months of therapy; or (iii) high bleeding risk, three months of anticoagulant therapy is suggested over extended therapy (no scheduled stop date). • In patients with "cancer-associated thrombosis" and who (i) do not have a high bleeding risk, extended anticoagulant therapy (no scheduled stop date) is recommended over three months of therapy, or (ii) have a high bleeding risk, extended anticoagulant therapy (no scheduled stop date) is suggested over three months of therapy. <u>Aspirin for extended treatment of VTE</u> • In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, aspirin is suggested over no aspirin to prevent recurrent VTE. <u>Whether to anticoagulate subsegmental PE</u> • In patients with subsegmental PE (no involvement of more proximal pulmonary arteries) and no proximal DVT in the legs who have a (i) low risk for recurrent VTE, clinical surveillance is suggested over anticoagulation or (ii) high risk for recurrent VTE, anticoagulation is suggested over clinical surveillance. <u>Treatment of acute PE out of the hospital</u> • In patients with low-risk PE and whose home circumstances are adequate, treatment at home or early discharge is suggested over standard discharge (e.g., after the first five days of treatment). <u>Systemic thrombolytic therapy for PE</u>

Clinical Guideline	Recommendations
	• In patients with acute PE associated with hypotension (e.g., systolic BP <90 mm Hg) who do not have a high bleeding risk, systemically administered thrombolytic therapy is suggested over no such therapy. • In most patients with acute PE not associated with hypotension, systemically administered thrombolytic therapyis NOT recommended. • In selected patients with acute PE who deteriorate after starting anticoagulant therapy but have yet to develop hypotension and who have a low bleeding risk, systemically administered thrombolytic therapy is suggested over no such therapy. Thrombolytic therapy in patients with upper extremity DVT • In patients with acute upper extremity DVT (UEDVT) that involves the axillary or more proximal veins, anticoagulant therapy alone is suggested over thrombolysis. • In patients with UEDVT who undergo thrombolysis, the same intensity and duration of anticoagulant therapy as in patients with UEDVT who do not undergo thrombolysis is recommended. Management of recurrent VTE on anticoagulant therapy • In patients who have recurrent VTE on VKA therapy (in the therapeutic range) or on dabigatran, rivaroxaban, apixaban, or edoxaban (and are believed to be compliant), switching to treatment with LMWH at least temporarily is suggested. • In patients who have recurrent VTE on long-term LMWH (and are believed to be compliant), increasing the dose of LMWH by about one-quarter to one-third is suggested. • Recurrent VTE while on therapeutic-dose anticoagulant therapy is unusual and should prompt the following assessments: (1) reevaluation of whether there truly was a recurrent VTE; (2) evaluation of compliance with anticoagulant therapy; and (3) consideration of an underlying malignancy. A temporary switch to LMWH will usually be for at least one month.

American Heart Association/American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (2014)**[15]	Recommendations for Nonvalvular Atrial Fibrillation:
	• For patients who have experienced an acute ischemic stroke or TIA with no other apparent cause, prolonged rhythm monitoring (~30 days) for AF is reasonable within six months of the index event.
	• VKA therapy, apixaban, dabigatran and rivaroxaban are all indicated for the prevention of recurrent stroke in patients with nonvalvular AF, whether paroxysmal or permanent.
	  ○ Selection of agent should be individualized based on risk factors, cost, tolerability, patient preference, drug interactions and other characteristics including renal function and time in INR therapeutic range if the patient has been taking VKA therapy.
	• Target INR for patients with ischemic stroke or TIA with paroxysmal (intermittent), persistent or permanent AF on VKA therapy is 2.5 (range 2.0 to 3.0).
	• Combination oral anticoagulation (warfarin or a newer agent) with antiplatelet therapy is not recommended for all patients after ischemic stroke or TIA.
	  ○ Combination therapy is reasonable in patients with clinically apparent coronary artery disease particularly an acute coronary syndrome or stent placement.
	• For patients with ischemic stroke or TIA and AF who unable to take oral anticoagulants, aspirin alone is recommended.
	  ○ Adding clopidogrel to aspirin therapy, compared with aspirin therapy alone, might be reasonable.
	• For most patients with a stroke or TIA in the setting of AF, it is reasonable to

Clinical Guideline	Recommendations
	initiate oral anticoagulation within 14 days after the onset of neurological symptoms. • In the presence of high risk for hemorrhagic conversion, it is reasonable to delay initiation of oral anticoagulation beyond 14 days. • For patients with AF and a history of stroke or TIA who require temporary interruption of oral anticoagulation, bridging therapy with an LMWH (or equivalent) is reasonable, depending on perceived risk for thromboembolism and bleeding. • The usefulness of closure of the left atrial appendage with the WATCHMAN device in patients with ischemic stroke or TIA and AF is uncertain. <u>Recommendations for Acute MI and LV Thrombus:</u> • Treatment with VKA therapy (target INR, 2.5; range, 2.0 to 3.0) for three months is recommended in most patients with ischemic stroke or TIA in this setting. ○ Additional antiplatelet therapy for cardiac protection may be guided by recommendations such as those from the American College of Chest Physicians. • Treatment with VKA therapy (target INR, 2.5; range, 2.0 to 3.0) for three months may be considered in patients with ischemic stroke or TIA in the setting of acute anterior STEMI without demonstrable LV mural thrombus formation but with anterior apical akinesis or dyskinesis identified by echocardiography or other imaging. • In patients with ischemic stroke or TIA in the setting of acute MI complicated by LV mural thrombus formation or anterior or apical wall-motion abnormalities with an LV ejection fraction <40% who are intolerant to VKA therapy because of nonhemorrhagic adverse events, treatment with an LMWH, dabigatran, rivaroxaban, or apixaban for three months may be considered as an alternative to VKA therapy for prevention of recurrent stroke or TIA. <u>Recommendations for Cardiomyopathy:</u> • In patients with ischemic stroke or TIA in sinus rhythm who have left atrial or LV thrombus, anticoagulant therapy with a VKA is recommended for ≥3 months. • In patients with ischemic stroke or TIA in the setting of a mechanical LVAD, treatment with VKA therapy (target INR, 2.5; range, 2.0 to 3.0) is reasonable in the absence of major contraindications. • In patients with ischemic stroke or TIA in sinus rhythm with either dilated cardiomyopathy (LV ejection fraction ≤35%) or restrictive cardiomyopathy without evidence of left atrial or LV thrombus, the effectiveness of anticoagulation compared with antiplatelet therapy is uncertain, and the choice should be individualized. • In patients with ischemic stroke or TIA in sinus rhythm with dilated cardiomyopathy (LV ejection fraction ≤35%), restrictive cardiomyopathy, or a mechanical LVAD who are intolerant to VKA therapy because of nonhemorrhagic adverse events, the effectiveness of treatment with dabigatran, rivaroxaban, or apixaban is uncertain compared with VKA therapy for prevention of recurrent stroke. <u>Recommendations for Mitral Stenosis, Mitral Regurgitation, Mitral Prolapse, Mitral Annular Calcification, and Aortic Valve Disease</u>: • For patients with ischemic stroke or TIA who have rheumatic mitral valve disease and AF, long-term VKA therapy with INR target of 2.5 (range, 2.0 to 3.0) is recommended. • For patients with ischemic stroke or TIA who have rheumatic mitral valve

Clinical Guideline	Recommendations
	disease without AF or another likely cause for their symptoms (e.g., carotid stenosis), long-term VKA therapy with an INR target of 2.5 (range, 2.0 to 3.0) may be considered instead of antiplatelet therapy. • For patients with rheumatic mitral valve disease who are prescribed VKA therapy after an ischemic stroke or TIA, antiplatelet therapy should not be routinely added. • For patients with rheumatic mitral valve disease who have an ischemic stroke or TIA while being treated with adequate VKA therapy, the addition of aspirin might be considered. • For patients with ischemic stroke or TIA and native aortic or nonrheumatic mitral valve disease who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended. • For patients with ischemic stroke or TIA and mitral annular calcification who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended as it would be without the mitral annular calcification. • For patients with mitral valve prolapse who have ischemic stroke or TIAs and who do not have AF or another indication for anticoagulation, antiplatelet therapy is recommended as it would be without mitral valve prolapse. <u>Recommendations for Prosthetic Heart Valves:</u> • For patients with a mechanical aortic valve and a history of ischemic stroke or TIA before its insertion, VKA therapy is recommended with an INR target of 2.5 (range, 2.0 to 3.0). • For patients with a mechanical mitral valve and a history of ischemic stroke or TIA before its insertion, VKA therapy is recommended with an INR target of 3.0 (range, 2.5 to 3.5). • For patients with a mechanical aortic or mitral valve and a history of ischemic stroke or TIA before its insertion and who are at low risk for bleeding, the addition of aspirin 75 to 100 mg/day to VKA therapy is recommended. • For patients with a mechanical heart valve who have an ischemic stroke or systemic embolism despite adequate antithrombotic therapy, it is reasonable to intensify therapy by increasing the dose of aspirin to 325 mg/day or increasing the target INR, depending on bleeding risk. • For patients with a bioprosthetic aortic or mitral valve and a history of ischemic stroke or TIA before its insertion and no other indication for anticoagulation therapy beyond three to six months form the valve placement, long-term therapy with aspirin 75 to 100 mg/day is recommended in preference to long-term anticoagulation. • For patients with a bioprosthetic aortic or mitral valve who have a TIA, ischemic stroke, or systemic embolism despite antiplatelet therapy, the addition of VKA therapy with an INR target of 2.5 (range, 2.0 to 3.0) may be considered. <u>Recommendations for Noncardioembolic Stroke or TIA</u>: • For patients with noncardioembolic ischemic stroke or TIA, the use of antiplatelet agents rather than oral anticoagulation is recommended to reduce the risk of recurrent stroke and other cardiovascular events. • Aspirin (50 to 325 mg/day) monotherapy or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg twice daily is indicated as initial therapy after TIA or ischemic stroke for prevention of future stroke. • Clopidogrel (75 mg) monotherapy is a reasonable option for secondary prevention of stroke in place of aspirin or combination aspirin/dipyridamole. This recommendation also applies to patients who are allergic to aspirin. • The selection of an antiplatelet agent should be individualized on the basis of patient risk facto profiles, cost, tolerance, relative known efficacy of the

Clinical Guideline	Recommendations
	agents, and other clinical characteristics. • The combination of aspirin and clopidogrel might be considered for initiation within 24 hours of a minor ischemic stork or TIA and for continuation for 90 days. • The combination of aspirin and clopidogrel, when initiated days to years after a minor stroke or TIA and continued for two to three years, increases the risk of hemorrhage relative to either agent alone and is not recommended for routine long-term secondary prevention after ischemic stroke or TIA). • For patients who have an ischemic stroke or TIA while taking aspirin, there is no evidence that increasing the dose of aspirin provides additional benefit. Although alternative antiplatelet agents are often considered, no single agent or combination has been adequately studied in patients who have had an event while receiving aspirin. • For patients with a history of ischemic stroke or TIA, AF and coronary artery disease, the usefulness of adding antiplatelet therapy to VKA therapy is uncertain for purposes of reducing the risk of ischemic cardiovascular and cerebrovascular events. Unstable angina and coronary artery stenting represent special circumstances in which management may warrant dual antiplatelet or VKA therapy. • For patients with noncardioembolic ischemic stroke or TIA, the use of antiplatelet agents rather than oral anticoagulation is recommended to reduce the risk of recurrent stroke and other cardiovascular events.

American College of Cardiology Foundation/American Heart Association: **2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes (2014)[16]**	<u>Early hospital care- standard medical therapies</u>
	• Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia.
	• Anti-ischemic and analgesic medications
	  ○ Nitrates
	  ▪ Patients with NSTE-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin.
	  ▪ Intravenous nitroglycerin is indicated for patients with NSTE-ACS for the treatment of persistent ischemia, heart failure, or hypertension.
	  ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil.
	  ○ Analgesic therapy
	  ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTE-ACE if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications.
	  ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use
	  ○ Beta-adrenergic blockers
	  ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease)
	  ▪ In patients with concomitant NSTE-ACS, stabilized heart failure,

Clinical Guideline	Recommendations
	and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. o Calcium channel blockers (CCBs) ▪ In patients with NSTE-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTE-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-clockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTE-ACS in the absence of beta-blocker therapy. o Other anti-ischemic interventions ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTE-ACS patients due to a reduction in recurrent ischemia. o Cholesterol management ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTE-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTE-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system o ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. o ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. o Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS treated with an initial invasive or ischemia-guided strategy o Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTE-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. o In patients who are unable to take aspirin because of hypersensitivity or

Clinical Guideline	Recommendations
	major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A $P2Y_{12}$ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for $P2Y_{12}$ treatment in patients with NSTE-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTE-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatide or tirofiban. ▪ Fibrinolytic therapy in patients with definite NSTE-ACS <u>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</u> • Antiplatelet agents ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a $P2Y_{12}$ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, $P2Y_{12}$ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. • Anticoagulant therapy ○ An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTE-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTE-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. • Timing of CABG in relation to use of antiplatelet agents

Clinical Guideline	Recommendations
	○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <u>Late hospital care, hospital discharge, and posthospital discharge care</u> • Medications at discharge ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post–NSTE-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTE-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post–NSTE-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post–NSTE-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. • Late hospital and post-hospital oral antiplatelet therapy ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a $P2Y_{12}$ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given for at least 12 months. • Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTE-ACS ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor in patients with NSTE-ACS should

Clinical Guideline	Recommendations
	be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor.
European Society of Cardiology: **Guideline for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2015)**[17]	Pharmacological treatment of ischemia • Early initiation of beta-blocker treatment is recommended in patients with ongoing ischaemic symptoms and without contraindications. • Sublingual or intravenous nitrates are recommended to relieve angina; intravenous treatment is recommended in patients with recurrent angina, uncontrolled hypertension, or signs of heart failure. • In patients with suspected/confirmed vasospastic angina, calcium channel blockers, and nitrates should be considered and beta-blockers avoided. Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes • Aspirin is recommended for all patients without contraindications at an initial oral loading dose of 150 to 300 mg (in aspirin-naïve patients) and a maintenance dose of 75 to 100 mg/day long-term regardless of treatment strategy. • A $P2Y_{12}$ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risks of bleeds. ○ Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindication, for all patients at moderate-to-high risk of ischemic events (e.g., elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). ○ Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no contraindication. ○ Clopidogrel (300 to 600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation. • $P2Y_{12}$ inhibitor administration for a shorter duration of three to six months after DES implantation may be considered in patients deemed at high bleeding risk. • It is not recommended to administer prasugrel in patients whom coronary anatomy is not known. • GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications. • Cangrelor may be considered in $P2Y_{12}$ inhibitor-naïve patients undergoing PCI. • It is not recommended to administer GPIIb/IIIa inhibitors in patients whom coronary anatomy is not known. • $P2Y_{12}$ inhibitor administration in addition to aspirin beyond one year may be considered after careful assessment of the ischemic and bleeding risks of the patient. Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes • Parenteral anticoagulation is recommended at the time of diagnosis according to both ischemic and bleeding risks. • Fondaparinux is recommended as having the most favorable efficacy-safety profile regardless of the management strategy. • Bivalirudin is recommended as an alternative to UFH plus GPIIb/IIIa inhibitors

Clinical Guideline	Recommendations
	during PCI. • UFH is recommended in patients undergoing PCI who did not receive any anticoagulant. • In patients on fondaparinux undergoing PCI, a single intravenous bolus of UFH is recommended during the procedure. • Enoxaparin or UFH are recommended when fondaparinux is not available. • Enoxaparin should be considered as an anticoagulant for PCI in patients pretreated for PCI with subcutaneous enoxaparin. • Additional activated clotting time-guided intravenous boluses of UFH during PCI may be considered following initial UFH treatment. • Discontinuation of anticoagulation should be considered after PCI, unless otherwise indicated. • Crossover between UFH and LMWH is not recommended. • In NSTEMI patients with no prior stroke/TIA and at high ischemic risk as well as low bleeding risk receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily for approximately one year) may be considered after discontinuation of parenteral anticoagulation. <u>Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation</u> • In patients with a firm indication for oral anticoagulation (e.g., atrial fibrillation with a CHADS2-VASc score ≥2, recent VTE, mechanical valve prosthesis), oral anticoagulation is recommended in addition to antiplatelet therapy. • An early invasive coronary angiography (within 24 hours) should be considered in moderate- to high-risk patients, irrespective of oral anticoagulant exposure, to expedite treatment allocation (medical vs PCI vs CABG) and to determine optimal antithrombotic regimen. • Initial dual antiplatelet therapy with aspirin plus a $P2Y_{12}$ inhibitor in addition to oral anticoagulation before coronary angiography is not recommended. • During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all non-vitamin K antagonist oral anticoagulants (NOACs) and if INR is <2.5 in VKA-treated patients. • Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase. • Following coronary stenting, dual (oral) antiplatelet therapy (DAPT) including new $P2Y_{12}$ inhibitors should be considered as an alternative to triple therapy for patients with non-ST-elevation acute coronary syndromes and atrial fibrillation with a CHADS2-VASc score of 1 (in males) or 2 (in females). • If at low bleeding risk (HAS-BLED ≤2), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for six months, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months. • If at high bleeding risk (HAS-BLED ≥3), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for one month, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months irrespective of the stent type. • Dual therapy with oral anticoagulant and clopidogrel may be considered as an alternative to triple antithrombotic therapy in selected patients (HAS-BLED ≥3 and low risk of stent thrombosis). • The use of ticagrelor or prasugrel as part of triple therapy is not recommended. • In medically managed patients, one antiplatelet agent in addition to oral anticoagulant should be considered for up to one year.
American College of Cardiology Foundation/American	<u>Antiplatelet therapy to support primary PCI for STEMI</u> • Aspirin 162 to 325 mg should be given before primary PCI. • After PCI, aspirin should be continued indefinitely.

Clinical Guideline	Recommendations
Heart Association: **Guideline for the Management of ST-Elevation Myocardial Infarction (2013)**[18]	• A loading dose of a $P2Y_{12}$ receptor inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI. Options include clopidogrel 600 mg, prasugrel 60 mg or ticagrelor 180 mg. • $P2Y_{12}$ inhibitor therapy should be given for one year to patients with STEMI who receive a stent (bare-metal or drug-eluting) during primary PCI using clopidogrel 75 mg/day, prasugrel 10 mg/day or ticagrelor 90 mg twice daily. • It is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses after primary PCI. • It is reasonable to start treatment with an IV GP IIb/IIIa receptor antagonist such as abciximab, high bolus-dose tirofiban or double-bolus eptifibatide at the time of primary PCI (with or without stenting or clopidogrel pre-treatment) in selected patients with STEMI who are receiving UFH. • It may be reasonable to administer IV GP IIb/IIIa receptor antagonist in the precatheterization laboratory setting (e.g., ambulance, emergency department) to patients with STEMI for whom primary PCI is intended. • It may be reasonable to administer intracoronary abciximab to patients with STEMI undergoing primary PCI. • Continuation of a $P2Y_{12}$ inhibitor beyond one year may be considered in patients undergoing drug-eluting stent placement. • Prasugrel should not be administered to patients with a history of prior stroke or TIA. <u>Anticoagulant therapy to support primary PCI</u> • For patients with STEMI undergoing primary PCI, the following supportive anticoagulant regimens are recommended: UFH, with additional boluses administered as needed to maintain therapeutic activated clotting time levels, taking into account whether a GP IIb/IIIa receptor antagonist has been administered or bivalirudin with or without prior treatment with UFH. • In patients with STEMI undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist. • Fondaparinux should not be used as the sole anticoagulant to support primary PCI because of the risk of catheter thrombosis. <u>Adjunctive antiplatelet therapy with fibrinolysis</u> • Aspirin (162- to 325-mg loading dose) and clopidogrel (300 mg loading dose for ≤75 year of age, 75-mg dose for patients >75 years of age) should be administered to patients with STEMI who receive fibrinolytic therapy. • Aspirin should be continued indefinitely and clopidogrel (75 mg daily) should be continued for at least 14 days and up to one year in patients with STEMI who receive fibrinolytic therapy. • It is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses after fibrinolytic therapy. <u>Adjunctive anticoagulant therapy with fibrinolysis</u> • Patients with STEMI undergoing reperfusion with fibrinolytic therapy should receive anticoagulant therapy for a minimum of 48 hours, and preferably for the duration of the hospitalization, up to eight days or until revascularization if performed. • Recommended regimens include UFH administered as a weight-adjusted IV bolus and infusion to obtain an activated partial thromboplastin time of 1.5 to 2.0 times control, for 48 hours or until revascularization; enoxaparin administered according to age, weight, and creatinine clearance, given as an IV bolus, followed in 15 minutes by subcutaneous injection for the duration of the index hospitalization, up to eight days or until revascularization; or

Clinical Guideline	Recommendations
	fondaparinux administered with initial IV dose, followed in 24 hours by daily subcutaneous injections if the estimated creatinine clearance is greater than 30 mL/min, for the duration of the index hospitalization, up to eight days or until revascularization. <u>Antiplatelet therapy to support PCI after fibrinolytic therapy</u> • After PCI, aspirin should be continued indefinitely. • Clopidogrel should be provided as a 300 mg loading dose given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI within 24 hours of receiving fibrinolytic therapy; a 600 mg loading dose given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI more than 24 hours after receiving fibrinolytic therapy; and a dose of 75 mg daily should be given after PCI. • After PCI, it is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses. • Prasugrel, in a 60 mg loading dose, is reasonable once the coronary anatomy is known in patients who did not receive a previous loading dose of clopidogrel at the time of administration of a fibrinolytic agent, but prasugrel should not be given sooner than 24 hours after administration of a fibrin-specific agent or 48 hours after administration of a non–fibrin-specific agent. • Prasugrel, in a 10 mg daily maintenance dose, is reasonable after PCI. • Prasugrel should not be administered to patients with a history of prior stroke or TIA. <u>Anticoagulant therapy to support PCI after fibrinolytic therapy</u> • For patients with STEMI undergoing PCI after receiving fibrinolytic therapy with IV UFH, additional boluses of IV UFH should be administered as needed to support the procedure, taking into account whether GP IIb/IIIa receptor antagonists have been administered. • For patients with STEMI undergoing PCI after receiving fibrinolytic therapy with enoxaparin, if the last subcutaneous dose was administered within the prior eight hours, no additional enoxaparin should be given; if the last subcutaneous dose was administered between eight and 12 hours earlier, enoxaparin 0.3 mg/kg IV should be given.

European Society of Cardiology: **Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-segment Elevation (2012)**[19]	<u>Periprocedural antithrombotic medication in primary PCI</u>
	• Aspirin oral or intravenous is recommended.
	• An adenosine diphosphate-receptor blocker is recommended in addition to aspirin. Options include:
	  ○ Prasugrel (in clopidogrel-naïve patients, if no history of prior stroke/transient ischemic stroke, age <75 years)
	  ○ Ticagrelor
	  ○ Clopidogrel (preferably when prasugrel or ticagrelor are either not available or contraindicated)
	
	<u>Routine therapies in the acute, subacute, and long-term phase of STEMI</u>
	• Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI.
	• Patients who are intolerant to aspirin, clopidogrel is indicated as an alternative to aspirin.
	• Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI.
	• Dual antiplatelet therapy with aspirin and an oral adenosine diphosphate receptor antagonist must be continued for up to 12 months after STEMI, with a

Clinical Guideline	Recommendations
	strict minimum of one month for patients receiving bare metal stent and six months for patients receiving drug eluting stent.

American College of Cardiology Foundation/American Heart Association/ Society for Cardiovascular Angiography and Interventions: **2011 Guideline for Percutaneous Coronary Intervention (2011)[20]**	<u>Interventional pharmacotherapy-oral antiplatelet therapy</u>
	• Patients already taking daily aspirin therapy should take 81 to 325 mg before PCI.
	• Patients not on aspirin therapy should be given non-enteric aspirin 325 mg before PCI.
	• After PCI, use of aspirin should be continued indefinitely.
	• A loading dose of one of the following $P2Y_{12}$ receptor inhibitors should be given to patients undergoing PCI with stenting: clopidogrel 600 mg (ACS and non-ACS patients), prasugrel 60 mg (ACS patients), or ticagrelor 180 mg (ACS) patients.
	• The loading dose of clopidogrel for patients undergoing PCI after fibrinolytic therapy should be 300 mg within 24 hours and 600 mg more than 24 hours after receiving fibrinolytic therapy.
	• Patients should be counseled on the need for and risks of dual antiplatelet therapy before placement of intracoronary stents, especially drug-eluting stents, and alternative therapies should be pursued if patients are unwilling or unable to comply with the recommended duration of dual antiplatelet therapy.
	• The duration of $P2Y_{12}$ inhibitor therapy after stent implantation should generally be as follows:
	  ○ In patients receiving a stent (bare metal or drug eluting stent) during PCI for ACS, $P2Y_{12}$ inhibitor therapy with one of the following options should be given for at least 12 months: clopidogrel 75 mg/day, prasugrel 10 mg/day, or ticagrelor 90 mg twice-daily.
	  ○ In patients receiving drug-eluting stent for a non-ACS indication, clopidogrel 75 mg/day should be given for at least 12 months if patients are not at high risk of bleeding.
	  ○ In patients receiving bare-metal stents for a non-ACS indication, clopidogrel should be given for a minimum of one month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of two weeks).
	• After PCI, it is reasonable to use aspirin 81 mg/day in preference to higher maintenance doses.
	• If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of $P2Y_{12}$ inhibitor therapy after stent implantation, earlier discontinuation (e.g., <12 months) of $P2Y_{12}$ inhibitor therapy is reasonable.
	• Continuation of dual antiplatelet therapy beyond 12 months may be considered in patients undergoing drug-eluting stent implantation.
	• Prasugrel should not be administered to patients with a prior history of stroke or TIA.
	
	<u>Post-procedural recommendations for patients undergoing PCI</u>
	Aspirin:
	• Use of aspirin should be continued indefinitely.
	• It is reasonable to use aspirin 81 mg/day in preference to higher maintenance doses.
	$P2Y_{12}$ inhibitors:
	• In patients receiving a stent (bare-metal or drug-eluting stent) during PCI for ACS, therapy with either clopidogrel 75 mg/day, prasugrel 10 mg/day, or ticagrelor 90 mg twice-daily should be given for at least 12 months.
	• In patients receiving drug-eluting stent for a non-ACS indication, clopidogrel 75 mg/day should be given for at least 12 months if patients are not at high risk of bleeding.

Clinical Guideline	Recommendations
	• In patients receiving bare-metal stent for a non-ACS indication, clopidogrel should be given for a minimum of one month and ideally up to 12 months (unless the patient is at an increased risk of bleeding; then it should be given for a minimum of two weeks). • Patients should be counseled on the importance of compliance with dual antiplatelet therapy and that therapy should not be discontinued before discussion with their cardiologist. • Proton pump inhibitors should be used in patients with a history of prior gastrointestinal bleeding who require dual antiplatelet therapy. • If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of $P2Y_{12}$ inhibitor therapy after stent implantation, either discontinuation (e.g., <12 months) of $P2Y_{12}$ inhibitor therapy is reasonable. • Use of proton pump inhibitors is reasonable in patients with an increased risk of gastrointestinal bleeding (e.g., advanced age, concomitant use of warfarin, steroids, nonsteroidal anti-inflammatory drugs, *Helicobacter pylori* infection) who require dual antiplatelet therapy. • Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 months may be considered in patients undergoing placement of drug-eluting stent. • Routine use of a proton pump inhibitor is not recommended for patients at low risk of gastrointestinal bleeding, who have much less potential to benefit from prophylactic therapy. <u>Clopidogrel genetic testing</u> • Genetic testing might be considered to identify whether a patient at high risk for poor clinical outcomes is predisposed to inadequate platelet inhibition with clopidogrel. • When a patient predisposed to inadequate platelet inhibition with clopidogrel is identified by genetic testing, treatment with an alternative $P2Y_{12}$ inhibitor (e.g., prasugrel, ticagrelor) might be considered. • The routine clinical use of genetic testing to screen patients treated with clopidogrel who are undergoing PCI is not recommended.

National Institute for Health and Clinical Excellence: **Myocardial Infarction: cardiac rehabilitation and prevention of further cardiovascular disease (2013)**[21]	<u>Drug therapy</u>
	• Offer all people who have had an acute MI treatment with the following drugs:
	  ○ ACE inhibitor
	  ○ Dual antiplatelet therapy (aspirin plus a second antiplatelet agent)
	  ○ Beta-blocker
	  ○ Statin
	
	<u>Antiplatelet therapy</u>
	• Offer aspirin to all people after an MI and continue indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation.
	• Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely.
	• For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment.
	• Special considerations should be made for people with dyspepsia.
	• After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for Helicobacter pylori should be considered for treatment in line with dyspepsia.
	• Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI).
	• Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent.

Clinical Guideline	Recommendations
	• Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and stopped dual antiplatelet therapy or had an MI more than 12 months ago). Antiplatelet therapy in people with an indication for anticoagulation • Take bleeding risk, thromboembolic risk, and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes. • Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. • Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban, or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it.
National Institute for Health and Clinical Excellence: **Clopidogrel and Modified-Release Dipyridamole for the Prevention of Occlusive Vascular Events (2010)**[22]	• This guidance applies to people who have had an occlusive vascular event, or who have established peripheral arterial disease. This guidance does not apply to people who have had, or are at risk of, a stroke associated with AF, or who need treatment to prevent occlusive events after coronary revascularization or carotid artery procedures. • For people who have had an ischemic stroke, clopidogrel is recommended as a treatment option. For people who have a contraindication or intolerance to clopidogrel, modified-release dipyridamole plus aspirin is recommended as a treatment option. For people who have a contraindication or intolerance to both clopidogrel and aspirin, modified-release dipyridamole alone is recommended as a treatment option. • For people who have had a TIA, modified-release dipyridamole plus aspirin is recommended as a treatment option. For people who have a contraindication or intolerance to aspirin, modified-release dipyridamole alone is recommended as a treatment option. • For people who have had a MI, clopidogrel is recommended only when treatment with aspirin is contraindicated or not tolerated. • For people with peripheral arterial disease, clopidogrel is recommended as a treatment option. • For people with multi-vascular disease, clopidogrel is recommended as a

Clinical Guideline	Recommendations
	treatment option. • Treatment with clopidogrel to prevent occlusive vascular events should be started with the least costly licensed preparation.
American College of Cardiology/American Heart Association: **2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007)**[23]	• Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients unless contraindicated. • The use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely.

European Society of Cardiology: **Guidelines on the Management of Stable Coronary Artery Disease (2013)**[24]	Pharmacological management of stable coronary artery disease (CAD) patients
	• The two aims of the pharmacological management of stable CAD patients are to obtain relief of symptoms and to prevent CV events.
	• Optimal medical treatment indicates at least one drug for angina/ischaemia relief plus drugs for event prevention.
	• It is recommended to educate patients about the disease, risk factors and treatment strategy.
	• It is indicated to review the patient's response soon after starting therapy.
	• Angina/ischemia relief:
	  ○ Short-acting nitrates are recommended.
	  ○ First-line treatment is indicated with ß-blockers and/or calcium channel blockers to control heart rate and symptoms.
	  ○ For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil or ranolazine, according to heart rate, blood pressure and tolerance.
	  ○ For second-line treatment, trimetazidine may be considered.
	  ○ According to comorbidities/tolerance, it is indicated to use second-line therapies as firs-line treatment in selected patients.
	  ○ In asymptomatic patients with large areas of ischaemia (>10%) ß-blockers should be considered.
	  ○ In patients with vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided.
	• Event prevention:
	  ○ Low-dose aspirin daily is recommended in all stable CAD patients.
	  ○ Clopidogrel is indicated as an alternative in case of aspirin intolerance.
	  ○ Statins are recommended in all stable CAD patients.
	  ○ It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g., heart failure, hypertension or diabetes).
	
	Treatment in patients with microvascular angina
	• It is recommended that all patients receive secondary prevention medications including aspirin and statins.
	• ß-blockers are recommended as a first-line treatment.
	• Calcium antagonists are recommended if ß-blockers do not achieve sufficient symptomatic benefit or are not tolerated.
	• ACE inhibitors or nicorandil may be considered in patients with refractory symptoms.
	• Xanthine derivatives or nonpharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
	
	Stenting and peri-procedural antiplatelet strategies in stable CAD patients

Clinical Guideline	Recommendations
	• Drug-eluting stent (DES) is recommended in stable CAD patients undergoing stenting if there is no contraindication to prolonged dual antiplatelet therapy (DAPT). • Aspirin is recommended for elective stenting. • Clopidogrel is recommended for elective stenting. • Prasugrel or ticagrelor should be considered in patients with stent thrombosis on clopidogrel without treatment interruption. • GP IIb/IIIa antagonists should be considered for bailout situation only. • Platelet function testing or genetic testing may be considered in specific or high risk situations (e.g., prior history of stent thrombosis; compliance issue; suspicion of resistance; high bleeding risk) if results may change the treatment strategy. • Prasugrel or ticagrelor may be considered in specific high risk situations of elective stenting (e.g., left main stenting, high risk of stent thrombosis, diabetes). • Pretreatment with clopidogrel (when coronary anatomy is not known) is not recommended. • Routine platelet function testing (clopidogrel and aspirin) to adjust antiplatelet therapy before or after elective stenting is not recommended. • Prasugrel or ticagrelor is not recommended in low risk elective stenting. <u>Follow-up of revascularized stable coronary artery disease patients</u> • It is recommended that all revascularized patients receive a secondary prevention and be scheduled for follow-up visit. • It is recommended to instruct patients before discharge about return to work and reuptake of full activities. Patients have to be advised to seek immediate medical contact if symptoms (re-) occur. • Single antiplatelet therapy, usually aspirin, is recommended indefinitely. • DAPT is indicated after bare metal stent (BMS) for at least one month. • DAPT is indicated for six to 12 months after 2nd generation DES. • DAPT may be used for more than one year in patients at high ischaemic risk (e.g., stent thrombosis, recurrent acute coronary syndrome on DAPT, post MI/diffuse CAD) and low bleeding risk. • DAPT for one to three months may be used after DES implantation in patients at high bleeding risk or with undeferrable surgery or concomitant anticoagulant treatment.

American Heart Association/American College of Cardiology Foundation: **Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update (2011)**[25]	<u>Antiplatelet agents/anticoagulants</u>
	• Aspirin 75 to 162 mg daily is recommended in all patients with coronary artery disease unless contraindicated.
	  • Clopidogrel 75 mg daily is recommended as an alternative for patients who are intolerant of or allergic to aspirin.
	  • Combination therapy with both aspirin 75 to 162 mg daily and clopidogrel 75 mg daily may be considered in patients with stable coronary artery disease.
	• A $P2Y_{12}$ receptor antagonist in combination with aspirin is indicated in patients after ACS or PCI with stent placement.
	  • For patients receiving a bare-metal stent or drug-eluting stent during PCI or ACS, clopidogrel 75 mg daily, prasugrel 10 mg daily or ticagrelor 90 mg twice daily should be given for at least 12 months.
	  • If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by thienopyridine therapy after stent implantation, earlier discontinuation (e.g., 12 months) is reasonable. The risk for serious cardiovascular events because of early discontinuation of thienopyridines is greater for patients with drug-eluting stents than

Clinical Guideline	Recommendations
	those with bare-metal stents. • After PCI, it is reasonable to use aspirin 81 mg daily in preference to higher maintenance doses. • For patients undergoing CABG, aspirin should be started within six hours after surgery to reduce saphenous vein graft closure. Dosing regimens ranging from 100 to 325 mg daily for one year appear to be efficacious. • For patients undergoing CABG, clopidogrel (75 mg daily) is a reasonable alternative in patients who are intolerant of or allergic to aspirin. • In patients with extracranial carotid or vertebral atherosclerosis who have had ischemic stroke or TIA, treatment with aspirin alone (75 to 325 mg daily), clopidogrel alone (75 mg daily) or the combination of aspirin plus dipyridamole ER (25 mg and 200 mg twice daily, respectively) should be started and continued. • For patients with symptomatic atherosclerotic PAD of the lower extremity, antiplatelet therapy with aspirin (75 to 325 mg daily) or clopidogrel (75 mg daily) should be started and continued. • The benefits of aspirin in patients with asymptomatic PAD of the lower extremities are not well established. • Antiplatelet therapy is recommended in preference to anticoagulant therapy with warfarin or other VKA to treat patients with atherosclerosis. • If there is a compelling indication for anticoagulant therapy, such as AF, prosthetic heart valve, left ventricular thrombus or concomitant venous thromboembolic disease, warfarin should be administered in addition to the low-dose aspirin (75 to 81 mg daily). • For patients requiring warfarin, therapy should be administered to achieve the recommended INR for the specific condition. • Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with increased risk of bleeding and should be monitored closely.
European Association for Cardiovascular Prevention and Rehabilitation: **European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2012)**[26]	Antithrombotic therapy • Antiplatelet therapy, in particular low-dose aspirin, is recommended for hypertensive patients with cardiovascular events. • Antiplatelet therapy with aspirin is not recommended for people with diabetes who do not have clinical evidence of atherosclerotic disease. • In ACS and for the following 12 months, dual antiplatelet therapy with $P2Y_{12}$ inhibitor (ticagrelor or prasugrel) added to aspirin is recommended unless contraindicated due to such as excessive risk of bleeding. • Clopidogrel (600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel. • In the chronic phase (>12 months) after MI, aspirin is recommended for secondary prevention. • In patients with noncardioembolic TIA or ischemic stroke, secondary prevention with dipyridamole plus aspirin or clopidogrel alone is recommended. • In the case of intolerance to dipyridamole or clopidogrel, aspirin alone is recommended. • In patients with noncardioembolic cerebral ischemic events, anticoagulation is not superior to aspirin and is not recommended. • Aspirin or clopidogrel cannot be recommended in individuals without cardiovascular or cerebrovascular disease due to the increased risk of major bleeding.
The American College of Cardiology/ American Heart Association:	Exercise and lower extremity peripheral artery disease (PAD) rehabilitation • A program of supervised exercise training is recommended as an initial treatment modality for patients with intermittent claudication.

Clinical Guideline	Recommendations
Practice Guidelines for the Management of Patients with Peripheral Artery Disease (2011)[27]	• Supervised exercise training should be performed for a minimum of 30 to 45 minutes, in sessions performed at least three times/week for a minimum of 12 weeks. • The usefulness of unsupervised exercise programs is not well established as an effective initial treatment modality for patients with intermittent claudication. <u>Smoking cessation</u> • Patients who are smokers or former smokers should be asked about status of tobacco use at every visit. Patients with lower extremity PAD who use tobacco should be advised to stop smoking. • Patients should be provided with counseling and assistance with developing a plan for smoking cessation. • One or more of the following pharmacological therapies should be offered if not contraindicated: varenicline, bupropion and nicotine replacement therapy. <u>Antiplatelet and antithrombotic drugs</u> • Antiplatelet therapy is indicated to reduce the risk of MI, stroke and vascular death in patients with symptomatic atherosclerotic lower extremity PAD and in asymptomatic patients with ankle brachial index ≤0.90. The usefulness of antiplatelet therapy is not well established in asymptomatic patients with ankle brachial index between 0.91 and 0.99. • Aspirin (75 to 325 mg/day) is recommended to reduce the risk of cardiovascular events. Clopidogrel (75 mg/day) is recommended as an alternative to aspirin. • Combination of aspirin and clopidogrel may be considered to reduce the risk of cardiovascular events in patients with symptomatic atherosclerotic lower extremity PAD who are at high cardiovascular risk and not at increased risk of bleeding. • The addition of warfarin to antiplatelet therapy is of no proven benefit and is potentially harmful due to increased risk of major bleeding. <u>Medical and pharmacological treatment for claudication</u> • Cilostazol (100 mg orally twice daily) is indicated as an effective therapy to improve symptoms and increase walking distance in patients with lower extremity PAD and intermittent claudication (in the absence of heart failure). • A therapeutic trial of cilostazol should be considered in all patients with lifestyle-limiting claudication (in the absence of heart failure). • Pentoxifylline (400 mg three times daily) may be considered as second-line alternative therapy to cilostazol to improve walking distance in patients with intermittent claudication. • The clinical effectiveness of pentoxifylline as therapy for intermittent claudication is marginal and not well established. • The effectiveness of L-arginine for patients with intermittent claudication is not well established. • The effectiveness of propionyl L-carnitine as a therapy to improve walking distance in patients with intermittent claudication is not well established. • The effectiveness of ginkgo biloba as a therapy to improve walking distance in patients with intermittent claudication is not well established. • Oral vasodilator prostaglandins such as beraprost* and iloprost are not effective medications to improve walking distance in patients with intermittent claudication. • Vitamin E is not recommended as a treatment for patients with intermittent claudication. • Chelation (e.g. ethylenediaminetetraacetic acid) is not indicated for treatment of intermittent claudication and may have harmful adverse effects.

Clinical Guideline	Recommendations
European Society of Cardiology, Task Force on the Use of Antiplatelet Agents in Patients With Atherosclerotic Cardiovascular Disease: **Expert Consensus Document on the Use of Antiplatelet Agents (2004)**[28]	<u>Major recommendations for individual antiplatelet agents</u> Aspirin: • Aspirin once-daily is recommended in all clinical conditions in which antiplatelet prophylaxis has a favorable benefit/risk profile. • Because of gastrointestinal toxicity and its potential impact on compliance, physicians are encouraged to use the lowest dose of aspirin that was shown to be effective in each clinical setting. • The available evidence supports daily doses of aspirin in the range of 75 to 100 mg for the long-term prevention of serious vascular events in high-risk patients (e.g., ≥3% per annum). • In clinical situations where an immediate antithrombotic effect is required (such as in ACS or in acute ischemic stroke), a loading dose of 160 to 300 mg should be given at diagnosis in order to ensure rapid and complete inhibition of thromboxane A2-dependent platelet aggregation. • No test of platelet function is recommended to assess the antiplatelet effect of aspirin in the individual patient. • The routine use of proton pump inhibitors or cytoprotective agents is not recommended in patients taking daily doses of aspirin in the range of 75 to 100 mg, because of lack of randomized trials demonstrating the efficacy of such protective strategies in this setting. • Nonsteroidal anti-inflammatory drugs have been investigated inadequately in terms of their potential cardiovascular effects. Thus, physicians prescribing these drugs to arthritic patients with prior vascular complications should not discontinue treatment with low-dose aspirin. • Because of potential pharmacodynamic interactions between traditional nonsteroidal anti-inflammatory drugs (e.g., ibuprofen) and aspirin, patients treated with low-dose aspirin requiring nonsteroidal ant-inflammatory drug therapy may benefit from the use of selective cyclooxegenase-2 inhibitors. Ticlopidine: • The role of ticlopidine in the present therapeutic armamentarium is uncertain. • Although there are no large head-to-head comparisons between the two thienopyridines, indirect comparisons are highly suggestive of a lower burden of serious bone-marrow toxicity with clopidogrel as compared to ticlopidine. • In contrast to clopidogrel, ticlopidine does not have an approved indication for patients with a recent MI. Clopidogrel: • Although clopidogrel may be slightly more effective than aspirin, the size of any additional benefit is statistically uncertain and the drug has not been granted a claim of "superiority" vs aspirin by regulatory authorities. • Clopidogrel 75 mg/day is an appropriate alternative for high-risk patients with coronary, cerebrovascular or peripheral arterial disease who have a contraindication to low-dose aspirin. • The results of the Clopidogrel in Unstable Angina to Prevent Recurrent Events trial have led to Food and Drug Administration approval of a new indication for clopidogrel in patients with NSTE ACS. A loading dose of 300 mg clopidogrel should be used in this setting, followed by 75 mg daily. Revision of the existing guidelines will need a consensus agreement by the experts with respect to timing of PCI, length of clopidogrel treatment and combination with GP IIb/IIIa antagonists. Dipyridamole: • Although the combination of low-dose aspirin and dipyridamole ER (200 mg twice-daily) is considered an acceptable option for initial therapy of patients with noncardioembolic cerebral ischemic events, there is no basis to recommend this combination in patients with ischemic heart disease.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the platelet-aggregation inhibitors are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Platelet-Aggregation Inhibitors[1-7]

Indication	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Acute Coronary Syndromes						
Reduce the rate of myocardial infarction and stroke in patients with non-ST-segment elevation ACS (unstable angina/non-ST-elevation myocardial infarction), including patients who are to be managed medically and those who are to be managed with coronary revascularization		✔				
Reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically		✔				
Reduce the rate of cardiovascular death, MI, and stroke in patients with acute coronary syndrome or a history of MI and reduce the rate of stent thrombosis in patients who have been stented for treatment of ACS				✔		
Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)						✔
Reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: patients with unstable angina or NSTEMI OR patients with STEMI when managed with primary or delayed percutaneous coronary intervention			✔			
Atherothrombotic/Vascular Events						
Reduce the rate of MI and stroke in patients with established peripheral arterial disease or with a history of recent MI or recent stroke		✔				
Reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation as adjunctive therapy with aspirin					✔	
Intermittent Claudication						
For the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance	✔					
Ischemic Stroke or Transient Ischemic Attack						
Reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke					✔ †	

†Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia, agranulocytosis and aplastic anemia, it should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.

IV. Pharmacokinetics

The pharmacokinetic parameters of the platelet-aggregation inhibitors are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Platelet-Aggregation Inhibitors[2]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Cilostazol	87 to 100	95 to 98	Liver (% not reported)	Renal (74) Feces (20)	11 to 13
Clopidogrel	≥50	Not reported	Liver (% not reported)	Renal (50) Feces (46)	6
Prasugrel	79	98	Liver (% not reported)	Renal (68 to 70) Feces (25 to 27)	7 to 8
Ticagrelor	36	>99	Liver (% not reported)	Renal (26) Feces (58)	7
Ticlopidine	80 to 90	98	Liver (% not reported)	Renal (60) Feces (23)	12.6 (4 to 5 days with repeat dosing)
Vorapaxar	100	>99	Liver (% not reported)	Renal (25) Feces (58)	192

V. Drug Interactions

Major drug interactions with the platelet-aggregation inhibitors are listed in Table 5.

Table 5. Major Drug Interactions with the Platelet-Aggregation Inhibitors[2]

Generic Name(s)	Interaction	Mechanism
Cilostazol, clopidogrel, prasugrel, ticagrelor, ticlopidine, vorapaxar	Defibrotide	Concomitant use of defibrotide and a systemic antithrombotic agent is contraindicated as the pharmacodynamic activity of the antithrombotic agent may be enhanced, leading to an increased risk of bleeding.
Cilostazol, clopidogrel, prasugrel, ticagrelor, ticlopidine, vorapaxar	SSRIs	Concurrent use may result in an increased risk of bleeding.
Cilostazol, ticagrelor	CYP3A4 inhibitors	Certain agents inhibit the metabolism (CYP3A4) of cilostazol leading to increased plasma concentrations of cilostazol and resulting in increased therapeutic and adverse effects.
Cilostazol	CYP2C19 inhibitors	These agents inhibit the metabolism (CYP2C19) of cilostazol leading to increased plasma concentrations of cilostazol and resulting in increased therapeutic and adverse effects.
Cilostazol	Amiodarone	Concurrent use of amiodarone and cilostazol may result in increased amiodarone and cilostazol exposure.
Cilostazol	Nefazodone	Concurrent use of cilostazol and nefazodone may result in increased cilostazol exposure and increased risk of bleeding.
Clopidogrel	Calcium channel blockers	Concurrent use of calcium channel blockers and clopidogrel may result in decreased antiplatelet effect and increased risk of thrombotic events.
Clopidogrel	Proton-pump Inhibitors	Proton pump inhibitors interfere with the metabolic conversion of clopidogrel at cytochrome P450 (CYP) 2C19 to its active

Generic Name(s)	Interaction	Mechanism
		metabolite, thus decreasing the antiplatelet activity of clopidogrel.
Clopidogrel	Ketoconazole	Ketoconazole may inhibit the isozymes (CYP3A4 and CYP3A5) that convert the prodrug clopidogrel to its active metabolite. If possible, avoid coadministration of these agents since the antiplatelet effect of clopidogrel may be inhibited.
Clopidogrel	Warfarin	The mechanism by which the risk of nonfatal and fatal bleeding may be increased with combined therapy is unknown. When indicated, coadminister clopidogrel and warfarin with caution. Closely monitor coagulation and the patient for bleeding events.
Ticagrelor	Strong 3A4 inducers	Concurrent use of ticagrelor and strong CYP3A4 inducers may result in decreased ticagrelor plasma concentrations.
Vorapaxar	Azole antifungals	Inhibition of vorapaxar metabolism (CYP3A4) by azole and related antifungal agents may elevate vorapaxar plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions.
Vorapaxar	Protease inhibitors	Inhibition of vorapaxar metabolism (CYP3A4) by certain protease inhibitors may elevate vorapaxar plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions.
Vorapaxar	Boceprevir, telaprevir	Inhibition of vorapaxar metabolism (CYP3A4) by HCV protease inhibitors may elevate vorapaxar plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions.
Vorapaxar	Clarithromycin, telithromycin	Inhibition of vorapaxar metabolism (CYP3A4) by certain macrolide and related antibiotics may elevate vorapaxar plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions.
Vorapaxar	Conivaptan	Inhibition of vorapaxar metabolism (CYP3A4) by conivaptan may elevate vorapaxar plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions.
Vorapaxar	Nefazodone	Inhibition of vorapaxar metabolism (CYP3A4) by nefazodone may elevate vorapaxar plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions.
Vorapaxar	Carbamazepine	Increased vorapaxar metabolism (CYP3A4) by carbamazepine may decrease vorapaxar plasma concentrations and pharmacologic effects.
Vorapaxar	Hydantoins	Increased vorapaxar metabolism (CYP3A4) by hydantoins may decrease vorapaxar plasma concentrations and pharmacologic effects.
Vorapaxar	Rifamycins	Increased vorapaxar metabolism (CYP3A4) by rifamycins may decrease vorapaxar plasma concentrations and pharmacologic effects.
Vorapaxar	St. John’s Wort	Increased vorapaxar metabolism (CYP3A4) by St. John's Wort may decrease vorapaxar plasma concentrations and pharmacologic effects.

VI. Adverse Drug Events

The most common adverse drug events reported with the platelet-aggregation inhibitors are listed in Table 6. The boxed warnings for the platelet-aggregation inhibitors are listed in Tables 7 through 11.

Table 6. Adverse Drug Events (%) Reported with the Platelet-Aggregation Inhibitors[1-7]

Adverse Events	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Cardiovascular						
Angina pectoris	-	-	-	-	-	-
Arrhythmia	-	-	-	-	-	-
Atrial fibrillation/flutter	<2	1 to 3	3	4.2	-	-
Bradycardia	-	-	3	-	-	-
Cardiac arrest	<2	-	-	-	-	-
Cardiac failure	-	1 to 3	-	-	-	-
Chest pain	-	8	3	3.1	-	-
Congestive heart failure	<2	-	-	-	-	-
Edema	-	4	3	-	-	-
Hypertension	-	4	8	3.8	-	-
Hypotension	<2	-	4	3.2	-	-
Myocardial infarction/ischemia	<2	-	-	-	-	-
Nodal arrhythmia	<2	1 to 3	-	-	-	-
Palpitation	5 to 10	-	-	-	-	-
Peripheral edema	7 to 9	-	-	-	-	-
Postural hypotension	<2	-	-	-	-	-
QTc prolongation	<2	-	-	-	-	-
Supraventricular tachycardia	<2	-	-	-	-	-
Syncope	<2	1 to 3	-	-	-	-
Tachycardia	4	-	-	-	-	-
Torsades de pointes	<2	-	-	-	-	-
Ventricular tachycardia	<2	-	-	-	-	-
Central Nervous System						
Amnesia	-	-	-	-	-	-
Anxiety	-	1 to 3	-	-	-	-
Cerebral edema	-	-	-	-	-	-
Cerebral hemorrhage	-	<1	-	-	<1	-
Cerebral infarction/ischemia	<2	-	-	-	-	-
Coma	-	-	-	-	-	-
Confusion	-	<1	-	-	-	-

Adverse Events	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Depression	-	4	-	-	-	2
Dizziness	9 to 10	2 to 6	4	4.5	-	-
Extremity pain	-	-	3	-	-	-
Fatigue	-	3	4	3.2	-	-
Fever	-	1 to 3	5	-	-	-
Flushing	-	-		-	-	-
Hallucination	<1	-		-	-	-
Headache	27 to 34	3 to 8	2	6.5	-	-
Insomnia	-	1 to 3	-	-	-	-
Lethargy/malaise	-	-	-	-	-	-
Pain	-	6	-	-	-	-
Seizure	-	-	-	-	-	-
Somnolence	-	-	-	-	-	-
Subdural hematoma	<2	-	-	-	-	-
Vertigo	<3	1 to 3	-	-	-	-
Dermatologic						
Alopecia	-	-	-	-	-	-
Angioedema	-	-	-	-	-	-
Bullous eruption	-	<1	-	-	-	-
Eczema	-	1 to 3	-	-	-	-
Erythema multiforme	-	<1	-	-	<1	-
Erythema nodosum	-	-	-	-	<1	-
Exfoliative dermatitis	-	-	-	-	<1	-
Extradural hematoma	<2	-	-	-	-	-
Ischemic necrosis	-	<1	-	-	-	-
Lichen planus	-	<1	-	-	-	-
Maculopapular rash	-	<1	-	-	<1	-
Purpura	-	-	-	-	2	-
Pruritus	-	3	-	-	1	-
Rash	-	4	3	-	5	2
Stevens-Johnson syndrome	<2	-	-	-	<1	-
Toxic epidermal necrolysis	-	<1	-	-	-	-
Ulceration	-	-	-	-	-	-
Urticaria	-	<1	-	-	<1	-
Endocrine and Metabolic						
Diabetes mellitus	<2	-	-	-	-	-

Adverse Events	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Gout/hyperuricemia	<2	1 to 3	-	-	-	-
Hypercholesterolemia	4	-	7	-	>10	-
Hyponatremia	-	-	-	-	<1	-
Pancreatitis	-	<1	-	-	-	-
Gastrointestinal						
Abdominal distress	-	-	-	-	-	-
Abdominal pain	4 to 5	2 to 6	-	-	4	-
Abnormal stools	12 to 15	-	-	-	1	-
Anorexia	-	-	-	-	-	-
Bleeding	-	-	-	-	-	-
Chronic diarrhea	-	-	-	-	<1	-
Colitis	<2	-	-	-	-	-
Constipation	-	1 to 3	-	-	-	-
Diarrhea	12 to 19	2 to 5	-	3.7	13	-
Duodenal ulcer	<2	-	2	-	-	-
Duodenitis	<2	-	-	-	-	-
Dyspepsia	6	2 to 5	-	-	7	-
Esophageal hemorrhage	<2	-	-	-	-	-
Esophagitis	<2	-	-	-	-	-
Flatulence	2 to 3	-	-	-	2	-
Gastrointestinal hemorrhage	-	1 to 3	2	-	<1	4
Hematemesis	-	-	-	-	-	-
Hemorrhoids	-	-	-	-	-	-
Nausea	6 to 7	3	5	4.3	7	-
Peptic ulcer	<2	-	-	-	<1	-
Periodontal abscess	<2	-	-	-	-	-
Rectal bleeding	<2	-	-	-	-	-
Retroperitoneal hemorrhage	<2	<1	-	-	-	-
Vomiting	-	1 to 3	-	-	2	-
Genitourinary			-			
Blood urea nitrogen increased	-	-	-	-	-	-
Cystitis	<2	1 to 3	-	-	-	-
Hematuria	-	<1	-	-	<1	-
Interstitial nephritis	-	-	-	-	-	-
Menorrhagia	-	-	-	-	<1	-
Papillary necrosis	-	-	-	-	-	-

Adverse Events	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Renal failure	-	-	-	-	<1	-
Serum creatinine increased	-	-	-	-	<1	-
Urinary tract infection	-	3	-	-	-	-
Uterine hemorrhage	-	-	-	-	-	-
Hematologic						
Agranulocytosis	<2	<1	-	-	<1	-
Anemia	<2	1 to 3	2	-	-	5
Aplastic anemia	-	<1	-	-	<1	-
Bleeding	-	4 to 5	-	8.7*, 85.8†	-	-
Disseminated intravascular coagulation	-	-	-	-	-	-
Eosinophilia	-	-	-	-	<1	-
Epistaxis	-	3	-	-	-	-
Granulocytopenia	<2	<1	-	-	-	-
Hematoma	-	1 to 3	✔	-	-	-
Hemolytic anemia	-	-	-	-	<1	-
Hemorrhage	<2	-	✔	-	-	3
Hypochromic anemia	-	<1	-	-	-	-
Iron deficiency	-	-	-	-	-	<2
Leukopenia	<2	<1	3	-	-	-
Neutropenia	-	<1	-	-	2	-
Pancytopenia	-	<1	-	-	<1	-
Polycythemia	<2	-	-	-	-	-
Prothrombin time prolonged	-	-	-	-	-	-
Purpura	-	5	-	-	-	-
Thrombocytopenia	<2	<1	✔	-	<1	-
Thrombocytosis	-	-	-	-	<1	-
Thrombosis	<2	-	-	-	-	-
Thrombotic thrombocytopenic purpura	-	-	-	-	<1	-
Hepatic						
Acute liver failure	-	<1	-	-	-	-
Bilirubinemia	-	<1	-	-	-	-
Cholelithiasis	<2	-	-	-	-	-
Fatty liver	-	<1	-	-	-	-
Hepatic dysfunction	<2	-	✔	-	-	-
Hepatic failure	-	-	-	-	-	-
Hepatic necrosis	-	-	-	-	<1	-

Adverse Events	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Hepatitis	-	<1	-	-	<1	-
Hepatotoxicity	-	-	-	-	-	-
Jaundice	-	-	-	-	<1	-
Liver dysfunction	-	-	-	-	-	-
Liver function test abnormalities	-	<3	-	-	1	-
Musculoskeletal						
Arthralgia	-	6	-	-	-	-
Arthritis	-	1 to 3	-	-	-	-
Arthropathy	-	-	-	-	<1	-
Arthrosis	-	-	-	-	-	-
Back pain	6 to 7	6	5	3.6	-	-
Bursitis	<2	-	-	-	-	-
Fatigue	-	-	-	-	-	-
Leg cramps	-	1 to 3	-	-	-	-
Myalgia	2 to 3	-	-	-	-	-
Myositis	-	-	-	-	<1	-
Neuralgia	<2	1 to 3	-	-	-	-
Paresthesia	-	1 to 3	-	-	-	-
Peripheral neuropathy	-	-	-	-	<1	-
Rhabdomyolysis	-	-	-	-	-	-
Weakness	-	1 to 3	-	-	-	-
Respiratory						
Asthma	<2	-	-	-	-	-
Bronchiolitis obliterans	-	-	-	-	<1	-
Bronchitis	-	4	-	-	-	-
Bronchospasm	-	-	-	-	-	-
Cough	3 to 4	3	4	4.9	-	-
Dyspnea	-	5	5	13.8	-	-
Epistaxis	-	-	6	-	-	-
Hemoptysis	-	<1	-	-	-	-
Hemothorax	-	<1	-	-	-	-
Intestinal pneumonitis	-	<1	-	-	-	-
Larynx edema	-	-	-	-	-	-
Pharyngitis	7 to 10	-	-	-	-	-
Pneumonia	<2	-	-	-	-	-
Pneumonitis	-	-	-	-	<1	-

Adverse Events	Cilostazol	Clopidogrel	Prasugrel	Ticagrelor	Ticlopidine	Vorapaxar
Pulmonary edema	-	-	-	-	-	-
Pulmonary hemorrhage	-	<1	-	-	-	-
Rhinitis	7 to 12	4	-	-	-	-
Tachypnea	-	-	-	-	-	-
Upper respiratory infection	-	-	-	-	-	-
Other						
Allergic reaction	-	<1	✔	-	-	-
Anaphylactoid reaction/anaphylaxis	-	<1	-	-	<1	-
Angioedema	-	<1	✔	-	<1	-
Ante-/peri-/postpartum bleeding	-	-	-	-	-	-
Blindness	<2	-	-	-	-	-
Cataract	-	1 to 3	-	-	-	-
Conjunctival bleeding	-	-	-	-	<1	-
Conjunctivitis	-	1 to 3	-	-	-	-
Deafness	-	-	-	-	-	-
Fever	-	<1	-	-	-	-
Flu symptoms	-	8	-	-	-	-
Hypersensitivity reaction	-	<1	-	-	-	-
Infection	10 to 14	-	-	-	-	-
Lower weight infants	-	-	-	-	-	-
Noncardiac chest pain	-	-	-	3.7	-	-
Ocular/retinal hemorrhage	<2	<1	-	-	-	-
Positive antinuclear antibody	-	-	-	-	<1	-
Retinopathy	-	-	-	-	-	<2
Reye's syndrome	-	-	-	-	-	-
Sepsis	-	-	-	-	<1	-
Serum sickness	-	<1	-	-	<1	-
Stillbirths	-	-	-	-	-	-
Systemic lupus erythematosus	-	-	-	-	<1	-
Vasculitis	-	<1	-	-	<1	-

✔ Percent not specified.
- Event not reported.
*Non-coronary artery bypass graft-related bleeding.
†Coronary artier bypass graft-related bleeding.

Table 7. Boxed Warning for Cilostazol[1]

WARNING
Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Cilostazol is contraindicated in patients with congestive heart failure of any severity.

Table 8. Boxed Warning for Clopidogrel[1]

WARNING
The effectiveness of clopidogrel is dependent on its activation to an active metabolite by the cytochrome P450 system (CYP), primarily CYP2C19. Clopidogrel at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used an as aid in determining therapeutic strategy. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.

Table 9. Boxed Warning for Prasugrel[1]

WARNING
Prasugrel can cause significant, sometimes fatal, bleeding. Do not use prasugrel in patients with active pathological bleeding or a history of transient ischemic attack or stroke. In patients 75 years of age and older, prasugrel is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction) in which its effect appears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent coronary artery bypass graft surgery. When possible, discontinue prasugrel at least seven days prior to any surgery. Additional risk factors for bleeding include body weight less than 60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs. Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention, coronary artery bypass grafting, or other surgical procedures in the setting of prasugrel. If possible, manage bleeding without discontinuing prasugrel. Discontinuing prasugrel, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.

Table 10. Boxed Warning for Ticagrelor[1]

WARNING
Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal, bleeding. Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage. Do not initiate therapy with ticagrelor in patients planning to undergo urgent coronary artery bypass graft (CABG) surgery. When possible, discontinue ticagrelor at least five days prior to any surgery. Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention, CABG, or other surgical procedures in the setting of ticagrelor. If possible, manage bleeding without discontinuing ticagrelor. Stopping ticagrelor increases the risk of subsequent cardiovascular events. Maintenance doses of aspirin above 100 mg reduce the effectiveness of ticagrelor; avoid such doses. After any initial dose, use with aspirin 75 to 100 mg/day.

Table 11. Boxed Warning for Ticlopidine[1]

WARNING
Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia. Neutropenia/Agranulocytosis: Among 2,048 patients in clinical trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than 1,200 neutrophils/mm^3), and the neutrophil count was below 450/mm^3 in 17 of these patients (0.8% of the total population). TTP: One case of thrombotic thrombocytopenic purpura was reported during clinical trials in stroke patients. Based on postmarketing data, United States physicians reported about 100 cases between 1992 and 1997. Based on an estimated patient exposure of 2 million to 4 million, and assuming an event reporting rate of 10% (the true rate is not known), the incidence of ticlopidine-associated TTP may be as high as one case in every 2,000 to 4,000 patients exposed. Aplastic Anemia: Aplastic anemia was not seen during clinical trials in stroke patients, but US physicians reported about 50 cases between 1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million, and assuming an event reporting rate of 10% (the true rate is not known), the incidence of ticlopidine-associated aplastic anemia may be as high as one case in every 4,000 to 8,000 patients exposed. Monitoring of Clinical and Hematologic Status: Severe hematological adverse reactions may occur within a few days of the start of therapy. The incidence of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately 4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks of therapy. The incidence of the hematologic adverse reactions declines thereafter. Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more than 3 months of therapy. Hematological adverse reactions cannot be reliably predicted by any identified demographic or clinical characteristics. During the first 3 months of treatment, patients receiving ticlopidine must, therefore, be hematologically and clinically monitored for evidence of neutropenia or TTP. If any such evidence is seen, ticlopidine should be immediately discontinued.

Table 12. Boxed Warning for Vorapaxar[10]

WARNING
Do not use vorapaxar in patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage; or active pathological bleeding. Antiplatelet agents, including vorapaxar, increase the risk of bleeding, including intracranial hemorrhage and fatal bleeding.

VII. Dosing and Administration

The usual dosing regimens for the platelet-aggregation inhibitors are listed in Table 12.

Table 12. Usual Dosing Regimens for the Platelet-Aggregation Inhibitors[1-7]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Cilostazol	Intermittent claudication: Tablet: 100 mg orally twice daily	Safety and efficacy in children have not been established.	Tablet: 50 mg 100 mg
Clopidogrel	Acute coronary syndrome, non-ST-segment elevation (unstable angina/non-Q-wave myocardial infarction): Tablet: initial, 300 mg once; maintenance, 75 mg orally once daily, administered in	Safety and efficacy in children have not been established.	Tablet: 75 mg 300 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	combination with aspirin (75 to 325 mg once daily) Acute coronary syndrome, ST-segment elevation acute myocardial infarction: Tablet: initial, 300 mg once; 75 mg once daily, administered in combination with aspirin (75 to 325 mg once daily), with or without thrombolytics; clopidogrel may be initiated with or without a loading dose Recent myocardial infarction, recent stroke, or established peripheral arterial disease: Tablet: 75 mg once daily		
Prasugrel	Acute coronary syndrome: Tablet: initial, 60 mg once; maintenance, 10 mg once daily (consider 5 mg once daily for patients <60 kg), administered with aspirin (75 to 325 mg)	Safety and efficacy in children have not been established.	Tablet : 5mg 10 mg
Ticagrelor	Acute coronary syndrome: Tablet: initial, 180 mg once; maintenance, 90 mg twice daily for 12 months, then 60 mg twice daily, administered with aspirin (75 to 100 mg)*	Safety and efficacy in children have not been established.	Tablet : 90 mg
Ticlopidine	Coronary artery stent implantation, adjunct: Tablet: 250 mg twice daily together with antiplatelet doses of aspirin for up to 30 days of therapy following successful stent implantation Stroke: Tablet: 250 mg twice daily	Safety and efficacy in children have not been established.	Tablet: 250 mg
Vorapaxar	Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease: Tablet: 2.08 mg once daily in combination with aspirin and/or clopidogrel	Safety and efficacy in children have not been established.	Tablet: 2.08 mg

*After the initial loading dose of aspirin (usually 325 mg), use ticagrelor with a daily maintenance dose of aspirin 75 to 100 mg.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the platelet-aggregation inhibitors are summarized in Table 13.

Table 13. Comparative Clinical Trials with the Platelet-Aggregation Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cerebrovascular Conditions				
International Stroke Trial[29] (1997) Aspirin 300 mg/day vs heparin 5,000 or 12,500 IU BID vs aspirin and heparin vs placebo	MC, OL, RCT Patients with acute ischemic stroke (randomized within 48 hours of stroke onset), 61% of patients were >70 years	N=19,435 Up to 14 days	Primary: Death from any cause within 14 days, death or dependency at six months Secondary: Symptomatic intracranial or extracranial hemorrhage, ischemic stroke or other major event within 14 days	Primary: Aspirin-allocated patients experienced slightly fewer deaths within 14 days (9.0 vs 9.4%; P value not significant). There was a trend toward a reduction in death or dependence at six months (62.2 vs 63.5%; P=0.07; a difference of 13 per 1,000 patients) and after adjustment for baseline prognosis the benefit from aspirin was significant (P=0.03; a difference of 14 per 1,000 patients). More aspirin-allocated patients reported complete recovery from their stroke (17.6 vs 16.6%; P=0.07). Secondary: Aspirin-allocated patients had significantly fewer recurrent ischemic strokes within 14 days (2.8 vs 3.9%; P<0.001) with no significant excess of hemorrhagic strokes (0.9 vs 0.8%), so the reduction in death or nonfatal recurrent stroke with aspirin was significant (11.3 vs 12.4%; P=0.02; 11 fewer per 1,000 patients treated). Aspirin was associated with a significant excess of 5 transfused or fatal extracranial bleeds per 1,000 patients (1.1 vs 0.6%; P=0.0004), in the absence of heparin the excess was two and was not significant. There was no interaction between aspirin and heparin in the main outcomes.
CAST[30] (1997) Aspirin 160 mg/day vs	MC, PC, RCT Hospitalized patients with acute ischemic stroke (were randomized within 48 hours of stroke	N=21,106 Up to 4 weeks	Primary: Death from any cause during the four week treatment period, death or dependence at	Primary: Patients in the aspirin group experienced a small but significant reduction in both early mortality (3.3 vs 3.9%; P=0.04) and recurrent ischemic strokes (1.6 vs 2.1%; P=0.01) but slightly more hemorrhagic strokes than placebo (1.1 vs 0.9%; P>0.1). At discharge, the aspirin-treated group experienced a smaller proportion of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	onset), mean age 63 years		discharge Secondary: Fatal or nonfatal recurrent stroke, death or nonfatal stroke during the scheduled treatment period	patients who were dead or dependent (30.5 vs 31.6%; P=0.08), corresponding to 11.4 fewer per 1,000 patients. Secondary: Fatal and nonfatal recurrent strokes occurred in 3.2% of aspirin-allocated patients vs 3.4% for placebo (P value not significant). For the combined in hospital end point of death or nonfatal stroke at 4 weeks, there was a 12% proportional risk reduction with aspirin (5.3 vs 5.9%; P=0.03), an absolute difference of 6.8 fewer cases per 1,000 patients.
Diener et al.[31] (1996) ESPS 2 Aspirin 25 mg BID vs aspirin and dipyridamole ER 25-200 mg BID (Aggrenox®) vs dipyridamole ER* 200 mg BID vs placebo	DB, MC, PC, RCT Male and female patients who had an ischemic stroke (76%) or TIA (24%) within 3 months prior to study entry, mean age 66.7 years	N=6,602 24 months	Primary: Stroke (fatal or nonfatal), death (all-cause mortality), combined stroke or death Secondary: TIA, adverse events	Primary: In comparison to placebo, stroke risk was reduced by 18% with aspirin alone (P=0.013), 37% with the fixed-dose combination product of aspirin and ER dipyridamole (P<0.001) and 16% with dipyridamole alone (P=0.039). There was no significant difference in all-cause mortality among the active treatment groups. In comparison to placebo, the risk of stroke or death was reduced by 13% with aspirin alone (P=0.016), 24% with the fixed-dose combination (P<0.001) and 15% with dipyridamole alone (P=0.015). Secondary: Aspirin alone (P<0.001), the fixed-dose combination product (P<0.001) and dipyridamole alone (P<0.01) were significantly effective in preventing TIA compared to placebo. Headache was the most common adverse event, occurring more frequently in the dipyridamole-treated patients. All-site bleeding and gastrointestinal bleeding were significantly more common in patients who received aspirin in comparison to placebo or dipyridamole.
Leonardi-Bee et al.[32] (2005)	MA (5 trials) Patients with previous ischemic	N=11,036 15 to 72 months	Primary: Incidence of combined fatal and nonfatal stroke	Primary: The incidence of recurrent stroke was reduced by dipyridamole as compared to control (OR, 0.82; 95% CI, 0.68 to 1.00; P<0.05), and by combined aspirin and dipyridamole vs aspirin alone (OR, 0.78; 95% CI,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Aspirin and dipyridamole vs dipyridamole vs aspirin vs control Two formulations of dipyridamole were assessed: conventional (daily dose 150 to 300 mg) and modified release (daily dose 400 mg). The daily dose of aspirin was 50 to 1,300 mg.	stroke and/or TIA		Secondary: Nonfatal stroke; combined fatal and nonfatal MI; vascular death; composite of nonfatal stroke, nonfatal MI and vascular death	0.65 to 0.93; P<0.05), dipyridamole alone (OR, 0.74; 95% CI, 0.60 to 0.90; P<0.05), or control (OR, 0.61; 95% CI, 0.51 to 0.71; P<0.05). Secondary: The combination of dipyridamole and aspirin also significantly reduced the composite outcome of nonfatal stroke, nonfatal MI, and vascular death as compared to aspirin alone (OR, 0.84; 95% CI, 0.72 to 0.97; P<0.05), dipyridamole alone (OR, 0.76; 95% CI, 0.64 to 0.90; P<0.05), or control (OR, 0.66; 95% CI, 0.57 to 0.75; P<0.05). The combination of dipyridamole and aspirin significantly reduced the incidence of fatal and nonfatal MI compared to control (P<0.05) but not compared to monotherapy with aspirin or dipyridamole (P>0.05). Vascular death was not altered in any group.
Sacco et al.[33] (2005) Aspirin and dipyridamole ER 25-200 mg BID (Aggrenox®) vs aspirin 25 mg BID	DB, MC, PC, RCT (Post-hoc analysis of the ESPS 2 trial) Male and female patients who had an ischemic stroke (76%) or TIA (24%) within 3 months prior to study entry, mean age 66.7 years	N=1,650 (Aggrenox®) N=1,649 (aspirin) Duration not specified	Primary: Rates of annual strokes and combined strokes and vascular events Secondary: Not reported	Primary: Compared to aspirin alone, aspirin plus ER dipyridamole was more effective in reducing the risk of stroke (relative risk reduction, 23%; P=0.006) and stroke or vascular events (relative risk reduction, 22%, P=0.003). A more pronounced efficacy was observed for patients <70 years; those with hypertension, prior MI, prior stroke or TIA, and any prior cardiovascular disease; and smokers (P<0.01 for all). The greatest relative hazard reduction (44.6%) was noted for patients with a stroke or TIA before the qualifying event.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Significant hazard reductions were reported for the combined outcome of stroke or vascular events with the greatest reductions found in patients with prior stroke or TIA, previous MI and among current smokers. The difference in efficacy increased in higher-risk patients. Secondary: Not reported
ESPRIT Study Group[34] (2006) ESPRIT Aspirin (30 to 325 mg/day) and dipyridamole ER (200 mg BID), either as a fixed-dose combination or individual components vs aspirin 30 to 325 mg/day	MC, OL, RCT Patients with a TIA or minor stroke	N=2,739 3.5 years (mean follow-up)	Primary: Composite of death from all vascular causes, nonfatal stroke, nonfatal MI or major bleeding complication (whichever happened first) Secondary: Death from all causes, death from all vascular causes, death from all vascular causes and nonfatal stroke, all major ischemic events, all vascular events, major bleeding complications	Primary: Primary outcome events occurred in 173 (13%) of patients on aspirin plus dipyridamole vs 216 (16%) on aspirin monotherapy (HR, 0.80; 95% CI, 0.66 to 0.98; absolute risk reduction, 1.0% per year; 95% CI, 0.1 to 1.8). Patients on aspirin and dipyridamole discontinued trial medication more often than those on aspirin alone (470 vs 184), mainly because of headache. Secondary: The HRs for death from all causes and all vascular causes were 0.88 (95% CI, 0.67 to 1.17) and 0.75 (95% CI, 0.51 to 1.10). Ischemic events were less frequent in the combination group than in the monotherapy group (HR, 0.81; 95% CI, 0.65 to 1.01). Major bleeding complications arose in 35 patients allocated to aspirin and dipyridamole vs 53 patients allocated to aspirin alone, whereas minor bleeding was reported in 171 patients allocated to the combination regimen vs 168 patients allocated to aspirin (RR, 1.03; 95% CI, 0.84 to 1.25).
Uchiyama et al.[35] (2011) JASAP Aspirin and dipyridamole ER 25 to 200 mg BID	AC, DB, MC, PG, RCT Patients ≥50 years of age with an ischemic stroke ≥1 week (but no more than 6	N=1,294 12 months	Primary: Recurrent ischemic stroke (fatal or nonfatal) Secondary: Cerebral	Primary: Recurrent ischemic stroke occurred in 6.9 (n=45) and 5.0% (n=32) of patients receiving combination therapy and aspirin, respectively. Noninferiority of combination therapy compared to aspirin was not shown (HR, 1.47; 95% CI, 0.93 to 2.31). Results were consistent in the per protocol population.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs aspirin 81 mg QD Concomitant use of anticoagulation and antiplatelet therapies was prohibited.	months) prior to enrollment, with ≥2 additional risk factors, stable neurological signs and symptoms, and responsible lesion confirmed by CT or MRI		hemorrhage; subarachnoid hemorrhage; TIA; ACS; other vascular events; composite of ischemic stroke, TIA, MI, unstable angina, or sudden death attributable to thromboembolism; stroke (composite of ischemic stroke, cerebral hemorrhage, or subarachnoid hemorrhage); safety A post hoc analysis was performed evaluating the event rate of intracranial hemorrhage and the composite of stroke or major bleeding for different subgroups	Secondary: The event rate of stroke was significantly higher with combination therapy compared to aspirin. There was no difference between the two treatments for any other secondary endpoint. Combination therapy and aspirin were both well tolerated. There was a significantly higher total number of adverse events with combination therapy (640 vs 611; P=0.04). The difference in drug-related adverse events was mainly due to headache in the early stages of treatment with combination therapy. More patients receiving combination therapy discontinued treatment because of headache. Major bleeding events and clinically relevant minor bleeding events were comparable between the two treatments. No relevant changes in laboratory parameters, vital signs, and electrocardiography were noted with either treatment. There were four (0.6%) and 10 (1.6%) deaths with combination therapy and aspirin. A multivariate analysis taking into account potential confounders for recurrence of ischemic stroke but only keeping covariates with a significant contribution in the model revealed a similar result for the comparison between treatments as the primary analysis. The analysis also revealed that higher modified Rankin Scale values and established end organ damage at baseline had a deleterious effect on the primary outcome, whereas the concomitant therapy with statins had a beneficial effect.
Verro et al.[36] (2008) Aspirin and dipyridamole (IR and ER formulations)	MA (6 trials) Patients with a history of non-cardioembolic stroke or TIA	N=7,648 Duration varied	Primary: Incidence of nonfatal stroke Secondary: Composite of stroke, MI or	Primary: Dipyridamole plus aspirin significantly reduced the risk of nonfatal ischemic and hemorrhagic stroke compared to aspirin alone (RR, 0.77; 95% CI, 0.67 to 0.89). Secondary: Dipyridamole plus aspirin significantly reduced the risk of the composite

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs aspirin			vascular death, subset analysis comparing outcomes with IR and ER dipyridamole	of stroke, MI or vascular death (RR, 0.85; 95% CI, 0.76 to 0.94). Based on four trials, IR dipyridamole plus aspirin did not show a statistically significant reduction in the risk of stroke (RR, 0.83; 95% CI, 0.59 to 1.15) or the composite outcome (RR, 0.95; 95% CI, 0.75 to 1.19) compared to aspirin alone. Based on 2 trials (ESPS 2 and ESPRIT), ER dipyridamole plus aspirin showed a significant reduction in risk for stroke (RR, 0.76; 95% CI, 0.65 to 0.89) and for the composite outcome (RR, 0.82; 95% CI, 0.73 to 0.92) compared to aspirin alone.
Geeganage et al.[37] (2012) Dual therapy with clopidogrel or dipyridamole plus aspirin vs monotherapy with aspirin, clopidogrel or dipyridamole	MA (12 RCTs) Patients with acute ischemic stroke or TIA	N=3,766 Duration varied	Primary: Recurrent stroke Secondary: Composite of stroke, TIA, ACS and death; composite of nonfatal stroke, nonfatal MI and vascular death; MI, severe stroke, intracerebral hemorrhage, major bleeding, all-cause death and vascular death	Primary: Dual antiplatelet therapy was associated with a significant decrease in stroke recurrence in comparison to monotherapy (3.3 vs 5.0%; RR, 0.67; 95% CI, 0.49 to 0.93). Secondary: Compared to monotherapy, dual antiplatelet therapy was associated with a significant reduction in the risk of composite endpoint of stroke, TIA, ACS and death (1.7 vs 9.1%; RR, 0.71; 95% CI, 0.56 to 0.91) as well as the composite endpoint of nonfatal stroke, nonfatal MI and vascular death (4.4 vs 6.0%; RR, 0.75; 95% CI, 0.56 to 0.99). No significant differences were seen between dual therapy and monotherapy with regard to the occurrence of MI (RR, 0.71; 95% CI, 0.25 to 2.03), severe stroke (RR, 1.01; 95% CI, 0.91 to 1.12), intracerebral hemorrhage (RR, 1.39; 95% CI, 0.22 to 8.75), all-cause death (RR, 1.34; 95% CI, 0.76 to 2.34) and vascular death (RR, 1.31; 95% CI, 0.59 to 2.93). Major bleeding occurred more frequently with dual therapy compared to monotherapy, though this increase was not statistically significant (RR, 2.09; 95% CI, 0.86 to 5.06).
Sacco et al.[38] (2008) PROFESS Aspirin 25 mg and	DB, RCT Patients ≥55 years of age with a recent ischemic stroke	N=20,332 2.5 years	Primary: Recurrent stroke of any type Secondary:	Primary: Of those in the aspirin/dipyridamole group, 916 patients (9%) experienced a recurrent stroke compared to 898 patients (8.8%) in the clopidogrel group (HR, 1.01; 95% CI, 0.92 to 1.11).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
dipyridamole ER 200 mg BID vs clopidogrel 75 mg QD	within 90 days of randomization		Composite of stroke, MI, or death from vascular causes	Secondary: Each group had 1,333 patients (13.1%) experience MI or death from a vascular cause (HR, 0.99; 95% CI, 0.92 to 1.07).
Markus et al.[39] (2005) CARESS Clopidogrel 300 mg on day 1, followed by 75 mg QD on days 2 to7 plus aspirin 75 mg QD vs aspirin 75 mg QD	DB, PC, RCT Patients with ≥50% carotid stenosis	N=107 7 days	Primary: Proportion of patients who were MES positive on day seven Secondary: Proportion of patients who were MES positive on day two, rate of embolization on both days two and seven and their percent change from baseline, safety	Primary: ITT analysis revealed a significant reduction in the primary end point: 43.8% of dual-therapy patients were MES positive on day seven, as compared to 72.7% of monotherapy patients (RR reduction, 39.8%; 95% CI, 13.8 to 58.0; P=0.0046). Secondary: MES frequency per hour was reduced compared to baseline by 61.4% (95% CI, 31.6 to 78.2; P=0.0013) in the dual-therapy group at day seven and by 61.6% (95% CI, 34.9 to 77.4; P=0.0005) on day two. There were four recurrent strokes and seven TIAs in the monotherapy group vs no stroke and four TIAs in the dual-therapy group that were considered treatment emergent and ipsilateral to the qualifying carotid stenosis. MES frequency was greater in the 17 patients with recurrent ipsilateral events compared to the 90 without (P=0.0003).
Diener et al.[40] (2004) MATCH Clopidogrel 75 mg/day vs clopidogrel 75 mg/day and aspirin 75 mg/day	DB, PC, RCT High-risk patients with recent ischemic stroke or TIA and had at least one additional vascular risk factor who were already receiving clopidogrel	N=7,599 18 months	Primary: Composite of ischemic stroke, MI, vascular death or rehospitalization for an acute ischemic event Secondary: Death, stroke, individual components and	Primary: There was no significant benefit of combination therapy compared to clopidogrel monotherapy in reducing the primary outcome (15.7 vs 16.7%, respectively; P=0.244). Secondary: There was no significant benefit of combination therapy compared to clopidogrel alone in reducing the secondary outcomes. Life-threatening bleedings were higher in the group receiving aspirin and clopidogrel vs clopidogrel monotherapy (2.6 vs 1.3%; P<0.0001). Major and minor bleeding were also significantly higher with combination

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			various combinations of the primary end points	therapy vs clopidogrel monotherapy (P<0.0001 for both).
Wang et al.[41] (2015) CHANCE Clopidogrel-aspirin therapy (loading dose of 300 mg of clopidogrel on day one, followed by 75 mg of clopidogrel per day for 90 days, plus 75 mg of aspirin per day for the first 21 days) vs aspirin-alone group (75 mg/d for 90 days)	DB, PC, RCT Patients ≥40 years of age within 24 hours after onset of minor stroke or high-risk transient ischemic attack	N=5,170 1 year	Primary: Stroke event (ischemic or hemorrhagic) during 1-year follow-up Secondary: A new clinical vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes	Primary: Throughout the trial, stroke occurred in 275 patients (10.6%) in the clopidogrel-aspirin group, in comparison with 362 patients (14.0%) in the aspirin group (HR, 0.78; 95% CI, 0.65 to 0.93; P=0.006). Beyond month three, 63 (2.7%) of 2346 patients in the clopidogrel-aspirin group and 59 (2.6%) of 2260 patients in the aspirin group had a stroke (HR, 0.96; 95% CI, 0.68 to 1.35; P=0.81). Secondary: The clopidogrel-aspirin group had lower rates of combined secondary vascular events (HR, 0.78; 95% CI, 0.65 to 0.93; P=0.005) and ischemic stroke (HR, 0.77; 95% CI, 0.64 to 0.93; P=0.006) in comparison with the aspirin group. No significant difference was detected between the two groups for other secondary end points. Moderate-to-severe hemorrhage occurred in seven patients (0.3%) in the clopidogrel-aspirin group and in nine patients (0.4%) in the aspirin group (P=0.44).
Kennedy et al.[42] (2007) FASTER <u>Group 1</u> Clopidogrel 300 mg loading dose, followed by 75 mg QD vs placebo	DB, PC, RCT Patients ≥40 years of age with TIA or minor stroke	N=392 90 days	Primary: Incidence of stroke (ischemic and hemorrhagic), safety (hemorrhage, myositis) Secondary: Composite of stroke, MI and vascular death	Primary: The trial was stopped early due to a failure to recruit patients at the prespecified minimum enrollment rate because of increased use of statins. Within 90 days, 7.1% of patients on clopidogrel had a stroke compared to 10.8% of patients on placebo (RR, 0.7; 95% CI, 0.3 to 1.2) for an absolute risk reduction of -3.8% (95% CI, -9.4 to 1.9; P=0.19). In the simvastatin group, 10.6% of patients had a stroke within 90 days compared to 7.3% of patients on placebo (RR, 1.3; 95% CI, 0.7 to 2.4) for an absolute risk increase of 3.3% (95% CI, -2.3 to 8.9; P=0.25). Two patients on clopidogrel had intracranial hemorrhage compared to none on placebo (absolute risk increase 1.0%; 95% CI, -0.4 to 2.4; P=0.5).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Group 2 Simvastatin 40 mg QD vs placebo All patients were also given aspirin 81 mg QD with a 162 mg loading dose if naïve to aspirin.				There was no difference between groups for the simvastatin safety outcomes. Secondary: Clopidogrel was associated with a -3.3% risk difference in the secondary end point compared to placebo (95% CI, -9.3% to 2.7%; P=0.28). Simvastatin was associated with a 2.7% risk difference compared to placebo (95% CI, -3.2% to 8.7%; P=0.37).
Uchiyama et al.[43] (2009) Clopidogrel 75mg QD vs ticlopidine 200 mg QD	DB, RCT Japanese men 20 to 80 years of age with a history of cerebral infarctions	N=1,869 26 weeks and 52 weeks	Primary: Safety Secondary: Combined efficacy end point of cerebral infarction, MI, and vascular death	Primary: Significantly fewer patients experienced a safety event in the clopidogrel group than the ticlopidine group (P<0.001; HR, 0.610; 95% CI 0.529, 0.703). Almost twice as many patients in the ticlopidine group (25.6%) experienced hepatic dysfunction than in the clopidogrel group (13.4%). Secondary: There was no significant difference in the incidence of the combined efficacy endpoint between clopidogrel (2.6% of patients) and ticlopidine (2.5%). Clopidogrel was better tolerated than ticlopidine; there was no difference in the efficacy of the two products with regard to the secondary prevention of vascular events in patients with prior stroke.
Johnston et al.[44] (2016) SOCRATES Ticagrelor (180 mg loading dose on day	DB, DD, MC, RCT Patients with a nonsevere ischemic stroke or high-risk transient ischemic	N=13,199 90 days	Primary: Time to the occurrence of stroke, myocardial infarction, or death within 90 days	Primary: A primary composite end-point event occurred in 442 of the 6589 patients (6.7%) in the ticagrelor group and in 497 of the 6610 patients (7.5%) in the aspirin group (HR, 0.89; 95% CI, 0.78 to 1.01; P=0.07). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
one followed by 90 mg twice daily for days two through 90) vs aspirin (300 mg on day one followed by 100 mg daily for days two through 90).	attack who had not received intravenous or intraarterial thrombolysis and were not considered to have had a cardioembolic stroke who underwent randomization within 24 hours after symptom onset		Secondary: Time to ischemic stroke	On the basis of the hierarchical testing plan, all analyses of secondary end points were therefore considered to be exploratory and were not used to make conclusions regarding significance. The main secondary end point, ischemic stroke, occurred in 385 patients (5.8%) in the ticagrelor group and 441 patients (6.7%) in the aspirin group (HR, 0.87; 95% CI, 0.76 to 1.00; nominal P=0.046).
Fukuuchi et al.[45] (2008) Ticlopidine 200 mg QD vs clopidogrel 75 mg QD	DB, DD, MC, RCT Japanese patients between the ages of 20 and 80 years who experienced a non-cardioembolic cerebral infarction ≥8 days prior to enrollment	N=1,151 52 weeks	Primary: Safety with emphasis on hematologic changes, hepatic dysfunction, nontraumatic hemorrhage and other serious adverse reactions Secondary: Combined incidence of nonfatal or fatal cerebral infarction or MI, or death due to other vascular causes	Primary: During the 52-week study period, 15.1% of ticlopidine patients and 7.0% of clopidogrel patients had at least one primary safety end point (P<0.001). Significant differences were primarily noted between ticlopidine and clopidogrel for hematologic disorders (2.4 vs 1.0%; P=0.043) and hepatic dysfunction (11.9 vs 4.2%; P<0.001). Study medication was discontinued prematurely due to safety end points in 27 and 17% of patients receiving ticlopidine and clopidogrel, respectively (P<0.001). The HR for the risk of discontinuing study medication due to a primary safety end point was 0.559 (95% CI, 0.434 to 0.721) in favor of clopidogrel. Secondary: The incidence of vascular events did not differ significantly between ticlopidine and clopidogrel (2.6 vs 3.0%, respectively; P=0.948; HR, 0.977; 95% CI, 0.448 to 1.957).
Gent et al.[46] (1989) CATS Ticlopidine 250 mg BID	DB, MC, PC, RCT Patients with ischemic strokes occurring from 1 week to 4 months	N=1,072 Up to 3 years	Primary: Event rate per year for stroke, MI, or vascular death Secondary:	Primary: The event rate per year for stroke, MI or vascular death was 10.8% in the ticlopidine group and 15.3% in the placebo group. Compared to placebo, ticlopidine reduced the RR of stroke, MI or vascular death by 30% (P=0.006) in the on-treatment analysis and by 23% (P=0.020) using the intent-to-treat approach.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo			Adverse events	Ticlopidine reduced the RR of ischemic stroke by 33% (P=0.008) in the on-treatment analysis. Ticlopidine was beneficial for both men and women (RR, 28.1%; P=0.037 and RR, 34.2%; P=0.045, respectively). Secondary: Adverse events associated with ticlopidine included neutropenia (severe in about 1% of cases), skin rash (severe 2%) and diarrhea (severe 2%).
Hass et al.[47] (1989) TASS Ticlopidine 250 mg BID vs aspirin 650 mg BID	Blinded, MC, RCT Patients with recent (within 3 months) minor stroke or TIA	N=3,069 2 to 6 years	Primary: Nonfatal stroke or death Secondary: Adverse events	Primary: Compared to aspirin, ticlopidine showed a 12% reduction in nonfatal stroke or death (three-year event rate was 17% for ticlopidine vs 19% for aspirin; P=0.048). Ticlopidine reduced the risk of stroke after three years by 21% (10% for ticlopidine vs 13% for aspirin; P=0.024). Secondary: Ticlopidine significantly increased total cholesterol compared to aspirin (9 vs 2%; P<0.01). Serious gastrointestinal adverse effects were 2.5 times more common in the aspirin group but bleeding from other anatomic sites was infrequent and about equal in the two treatment groups. Severe neutropenia occurred in 0.9% of patients.
Gorelick et al.[48] (2003) AAASPS Ticlopidine 250 mg BID vs aspirin 325 mg BID	DB, MC, RCT African American men and women who recently had a non-cardioembolic ischemic stroke	N=1,809 Up to 2 years	Primary: Composite of recurrent stroke, MI, or vascular death Secondary: Fatal or nonfatal stroke	Primary: There was no statistically significant difference in the percent of patients reaching the primary outcome of recurrent stroke, MI or vascular death between ticlopidine and aspirin (14.7 vs 12.3%, respectively; P=0.12). Secondary: There was a nonsignificant trend for reduction of fatal or nonfatal stroke among those in the aspirin group (P=0.08). The frequency of laboratory-determined serious neutropenia was 3.4% for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				ticlopidine vs 2.2% for aspirin (P=0.12).
Combined Cardiovascular and Cerebrovascular Conditions				
Simpson et al.[49] (2011) Aspirin vs no aspirin therapy	MA (17 RCTs and 4 cohort trials) Trials evaluating the use of aspirin in diabetic patients for primary and/or secondary prevention	N=17,522 Duration varied	Primary All-cause mortality Secondary: Cardiovascular-related mortality, MI, stroke	Primary: Analysis of all-cause mortality was based on 1,172 (15.4%) deaths in 7,592 patients receiving aspirin and 1,520 (18.4%) deaths in 8,269 control patients. The pooled RR (25 trials) was 0.93 (95% CI, 0.81 to 1.07; P=0.31). Stratification according to daily aspirin dose did not reveal a significant dose-response relationship. Secondary: Cardiovascular mortality was reported in 447 (7.7%) of 5,798 of patients receiving aspirin and 599 (9.3%) of 6,456 of control patients. The pooled RR (16 trials) was 0.98 (95% CI, 0.76 to 1.25; P=0.86). An MI occurred in 547 (8.3%) of 6,605 patients receiving aspirin and 720 (10.0%) of control patients. The pooled RR (18 trials) was 0.84 (95% CI, 0.65 to 1.09; P=0.20). A stroke occurred in 344 (5.0%) of 6,902 patients receiving aspirin and 418 (5.6%) of 7,420 control patients. The pooled RR (21 trials) was 0.89 (95% CI, 0.892 to 1.16; P=0.80).
Antithrombotic Trialists' Collaboration.[50] (2002) Antiplatelet agents vs control vs one antiplatelet regimen vs another	MA (287 trials) Patients at high risk of occlusive vascular events	N=135,640 Duration varied	Primary: "Serious vascular event" (nonfatal MI, nonfatal stroke or vascular death) Secondary: Not reported	Primary: Overall, antiplatelet therapy reduced the combined outcome of any serious vascular event by 25%, nonfatal MI by 34%, nonfatal stroke by 25%, and vascular mortality by 15% with no apparent adverse effect on other deaths. Aspirin was the most widely studied antiplatelet drug and low dose (75 to 150 mg daily) was at least as effective as higher daily doses for long-term use. In acute settings an initial loading dose of at least 150 mg aspirin may be required. Clopidogrel reduced serious vascular event by 10% compared to aspirin, which was similar to the 12% reduction observed with ticlopidine. The addition of dipyridamole to aspirin produced no significant further reduction in vascular events compared to aspirin alone.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Sudlow et al.[51] (2009) Aspirin (325 mg/day for most studies) vs clopidogrel (75 mg QD for most studies) or ticlopidine (250 mg BID for most studies)	MA (10 trials) Patients at high risk for serious vascular events, including those with a previous TIA or ischemic stroke	N=26,865 Duration varied	Primary: Composite outcome of stroke, MI, or death from a vascular cause Secondary: Outcomes of adverse drug events	Primary: Treatment with clopidogrel or ticlopidine produced a modest reduction in the odds of a serious vascular event (11.6%) vs aspirin (12.5%; OR, 0.92; 95% CI, 0.85 to 0.99). This corresponds to the avoidance of 10 serious vascular events per 1,000 patients treated with clopidogrel or ticlopidine rather than aspirin for an average of about two years. Secondary: Compared to aspirin, clopidogrel and ticlopidine significantly reduced gastrointestinal adverse effects. However, clopidogrel and ticlopidine increased the odds of skin rash and diarrhea, ticlopidine more than clopidogrel. Allocation to ticlopidine, but not clopidogrel, significantly increased the odds of neutropenia.
CAPRIE Steering Committee[52] (1996) CAPRIE Clopidogrel 75 mg QD vs aspirin 325 QD	DB, MC, PG, RCT Patients with recent ischemic stroke (within 6 months with at least a week of residual neurological signs), recent MI (within 35 days) or symptomatic peripheral arterial disease	N=19,185 1 to 3 years	Primary: Composite outcome of ischemic stroke, MI or vascular death Secondary: Primary outcome and amputation, vascular death, all-cause mortality, safety	Primary: Intention–to-treat analysis showed that patients treated with clopidogrel had an annual 5.32% risk of ischemic stroke, MI, or vascular death compared to 5.83% with aspirin, for a RR reduction of 8.7% (95% CI, 0.3 to 16.5; P=0.043) in favor of clopidogrel. Corresponding on-treatment analysis yielded a RR reduction of 9.4% in favor of clopidogrel. For the 6,431 patients admitted to the study with prior stroke, the RR reduction for ischemic stroke, MI, or vascular death was 7.3% in favor of clopidogrel (P=0.26), and the RR reduction for the end point of stroke was 8.0% (P=0.28). For the 6,302 patients admitted to the study with myocardial infarction, an RR increase of 3.7% was associated with clopidogrel (P=0.66). For the 6,452 patients admitted to the study with peripheral arterial disease, an RR of 23.8% was noted in favor of clopidogrel (P=0.0028).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Clopidogrel reduced the risk of the primary outcome plus amputation by 7.6% compared to aspirin (P=0.076). There was no significant difference between clopidogrel and aspirin with regards to vascular death (1.90 vs 2.06%; P=0.29) and all-cause mortality (3.05 vs 3.11%; P=0.71). There were no major differences in terms of safety. Severe rash (P=0.017) and severe diarrhea (P=0.080) were reported more frequently with clopidogrel and severe upper gastrointestinal discomfort (P=0.096), intracranial hemorrhage (P=0.23) and gastrointestinal hemorrhage (P=0.05) were reported more frequently with aspirin.
Zhou et al.[53] (2012) Aspirin plus clopidogrel vs aspirin vs clopidogrel	MA, SR (7 RCTs) Trials evaluating the use of aspirin and/or clopidogrel patients for primary and/or secondary prevention	N=48,248 Duration varied	Primary: Major cardiovascular events Secondary: Not reported	Primary: Overall, with combination therapy the harm of major cardiovascular events was significantly reduced by 9% (RR, 0.91; 95% CI, 0.83 to 0.98) compared to monotherapy with aspirin and clopidogrel (six trials; n=46,132). Combination therapy resulted in a significant 14% reduction in the harm of MI compared to monotherapy with aspirin and clopidogrel (RR, 0.86; 95% CI, 0.76 to 0.97) (seven trials; n=48,248). Combination therapy resulted in a significant 16% reduction in the harm of stroke compared to monotherapy with aspirin and clopidogrel (RR, 0.84; 95% CI, 0.72 to 0.99) (seven trials; n=48,248). There was no evidence to show that combination therapy could reduce the risk of mortality, regardless of total mortality, vascular death, or non-vascular death compared to monotherapy aspirin and clopidogrel. There was no effect of combination therapy on the harm of revascularization events compared to monotherapy with aspirin and clopidogrel. Combination therapy significantly increased the harm of major bleeding

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				events by 62% compared to monotherapy with aspirin and clopidogrel (RR, 1.62; 95% CI, 1.26 to 2.08) (seven trials; n=46,073). Secondary: Not reported
DeSchryver et al.[54] (2007) Dipyridamole with or without other antiplatelet drugs vs control (no drug or another antiplatelet drug)	MA (29 trials) Patients with arterial vascular disease (angina, CAD, MI, nephropathy, PAD, retinopathy, stroke and TIA)	N=23,019 Duration varied	Primary: Secondary prevention of vascular death and vascular events (defined as vascular death or any death from an unknown cause, nonfatal stroke or nonfatal MI) Secondary: Not reported	Primary: Compared to control, dipyridamole had no clear effect on vascular death (RR, 0.99; 95% CI, 0.87 to 1.12). The dose of dipyridamole or type of presenting vascular disease did not influence this result. Compared to control, dipyridamole appeared to reduce the risk of vascular events (RR, 0.88; 95% CI, 0.81 to 0.95). This effect was only statistically significant in patients presenting with cerebral ischemia. There was no evidence that dipyridamole alone was more efficacious than aspirin. Secondary: Not reported
Cardiovascular Conditions (Acute Coronary Syndrome, Myocardial Infarction, Angina Pectoris)				
CURE Trial Investigators[55] (2001) CURE Clopidogrel (300 mg immediately, followed by 75 mg QD) plus aspirin vs aspirin	DB, PC, RCT Patients with NSTEMI, presenting within 24 hours of symptom onset	N=12,562 3 to 12 months	Primary: Composite of death from cardiovascular causes, nonfatal MI, or stroke (first primary outcome); composite of the first primary outcome or refractory ischemia (second primary outcome) Secondary: Severe ischemia, heart failure, need	Primary: A composite of death from cardiovascular causes, nonfatal MI, or stroke occurred in 9.3% of patients in the clopidogrel and aspirin group compared to 11.4% of patients in the aspirin group (RR, 0.80; 95% CI, 0.72 to 0.90; P<0.001). When refractory ischemia was included with the first primary outcome, the composite rate was 16.5% in the clopidogrel and aspirin group compared to 18.8% for aspirin alone (RR, 0.86; 95% CI, 0.79 to 0.94; P<0.001). Secondary: Significant reductions in nonfatal MI (5.2 vs 6.7%) and trends toward reduction in death (5.1 vs 5.5%) and stroke (1.2 vs 1.4%) with clopidogrel plus aspirin vs aspirin alone were noted. The percentages of patients with in hospital refractory or severe ischemia,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			for revascularization, safety	recurrent angina, heart failure and revascularization procedures were also significantly lower with clopidogrel plus aspirin vs aspirin alone (P<0.05 for all). There were significantly more patients with major bleeding in the clopidogrel plus aspirin group than in the aspirin group (3.7 vs 2.7%; RR, 1.38; 95% CI, 1.13 to 1.67; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 vs 1.8%; RR, 1.21; 95% CI, 0.95 to 1.56; P=0.13).
COMMIT Collaborative Group[56] (2005) COMMIT Clopidogrel 75 mg/day plus aspirin 162 mg/day vs aspirin 162 mg/day	MC, PC, RCT Patients admitted to the hospital within 24 hours of suspected acute MI, mean age 61 years	N=45,852 15 days (mean duration)	Primary: Composite of death, reinfarction or stroke; death from any cause Secondary: Safety	Primary: Allocation to clopidogrel plus aspirin produced a highly significant 9% proportional reduction in death, reinfarction or stroke compared to aspirin alone (actual reductions 9.2 vs 10.1%, respectively; P=0.002), corresponding to nine fewer events per 1,000 patients treated for about two weeks. There was also a significant 7% proportional reduction in any death in the clopidogrel plus aspirin group compared to aspirin alone (7.5 vs 8.1%; P=0.03). Secondary: Considering all fatal, transfused, or cerebral bleeds together, no significant excess risk was noted with clopidogrel plus aspirin vs aspirin alone, either overall (0.58 vs 0.55%, respectively; P=0.59) or in patients older than 70 years or in those given fibrinolytic therapy.
Sabatine et al.[57] (2005) CLARITY-TIMI 28 Clopidogrel 300 mg loading dose, followed by 75 mg QD plus aspirin vs aspirin	DB, MC, PC, RCT Patients 18 to 75 years of age who presented within 12 hours after the onset of an STEMI	N=3,491 30 days	Primary: Composite of an occluded infarct-related artery on angiography or death or recurrent MI before angiography (death or recurrent MI by day 8 or hospital discharge in patients who did	Primary: The primary end point was reached in 15.0% of patients receiving clopidogrel vs 21.7% for placebo, representing an absolute reduction of 6.7% in the rate and 36% in the odds of reaching the end point with clopidogrel therapy (95% CI, 27 to 47; P<0.001). By 30 days, clopidogrel therapy reduced the odds of the composite end point of death from cardiovascular causes, recurrent myocardial infarction, or recurrent ischemia leading to the need for urgent revascularization by 20% (from 14.1 to 11.6%; P=0.03). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients received a fibrinolytic agent, and heparin when appropriate.			not undergo angiography) Secondary: Safety	The rates of major bleeding and intracranial hemorrhage were similar in the two groups.
Ahmed et al.[58] (2011) Clopidogrel 300 mg once, followed by 75 mg/day vs placebo Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin.	Substudy of CLARITY-TIMI 28 trial Patients 18 to 75 years of age who presented within 12 hours after the onset of an STEMI stratified by baseline GFR	N=3,252 30 days (study medication given up to, and including, the day of angiography, or up to day 8 or hospital discharge if no angiography)	Primary: Composite of an occluded infarct-related artery on angiography, all-cause mortality or recurrent MI prior to angiography (death or recurrent MI by day eight or hospital discharge in patients who did not undergo angiography) Secondary: Composite clinical endpoint of cardiovascular death, MI, or recurrent ischemia leading to urgent revascularization at 30 days; cardiovascular death; safety	Primary: There was a significant trend for an increased rate of the primary composite endpoint with lower GFR and was the highest rate (23.4%) in patients with moderately reduced GFR (P=0.003). Secondary: By day 30, both the rates of the composite clinical endpoint (P<0.0001) and the safety endpoints of bleeding (P=0.0008) and intracranial hemorrhage (P=0.03) also trended towards a significant increase with lower GFRs. By day 30, there was a significant trend for an increased rate of cardiovascular death with lower GFR and was the highest rate (11.3%) in patients with moderately reduced GFR (P<0.0001).
Bhatt et al.[59] (2006) CHARISMA Clopidogrel 75 mg QD plus aspirin 75	DB, MC, PC, RCT Patients 45 years of age or older with clinically evident cardiovascular	N=15,603 28 months	Primary: Composite of first occurrence of MI, stroke, or death from cardiovascular	Primary: The composite of MI, stroke or death from cardiovascular causes was 6.8% with clopidogrel plus aspirin and 7.3% with aspirin (RR, 0.93; 95% CI, 0.83 to 1.05; P=0.22). The rate of the primary end point among patients with multiple risk factors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
to 162 mg QD vs aspirin 75 to 162 mg QD	disease (e.g., documented coronary, cerebrovascular or peripheral arterial disease) or multiple atherothrombotic risk factors		causes Secondary: First occurrence of MI, stroke, death from cardiovascular causes, or hospitalization for unstable angina, TIA or revascularization procedure; safety	was 6.6% with clopidogrel plus aspirin and 5.5% with aspirin alone (RR, 1.2; 95% CI, 0.91 to 1.59; P=0.20) and the rate of death from cardiovascular causes also was higher with clopidogrel plus aspirin than aspirin alone (3.9 vs 2.2%; P=0.01). In the subgroup with clinically evident atherothrombosis, the rate was 6.9% with clopidogrel plus aspirin and 7.9% with aspirin alone (RR, 0.88; 95% CI, 0.77 to 1.00; P=0.046). Secondary: The secondary end point was reached in 16.7 and 17.9% (RR, 0.92; 95% CI, 0.86 to 1.00; P=0.04) of patients receiving clopidogrel plus aspirin vs aspirin alone, respectively. The rate of severe bleeding was 1.7 and 1.3% (RR, 1.25; 95% CI, 0.97 to 1.61; P=0.09) for patients receiving clopidogrel plus aspirin vs aspirin.
Dasgupta et al.[60] (2009) Clopidogrel 75 mg/day plus aspirin 75 to 162 mg/day vs aspirin 75 to 162 mg/day	Post hoc analysis of CHARISMA Post hoc analysis of patients with diabetic neuropathy in the CHARISMA trial, who were ≥45 years of age with clinically evident cardiovascular disease or multiple atherothrombotic risk factors	N=2,009 Median 28 months	Primary: Composite of first occurrence of MI, stroke or death from cardiovascular causes Secondary: First occurrence of MI, stroke, death from cardiovascular causes or hospitalization for unstable angina, TIA or revascularization procedure; safety	Primary: Almost all cardiovascular events occurred significantly more frequently in diabetic patients with neuropathy. Patients with diabetic neuropathy had a higher case fatality rate of MI compared to diabetic patients without nephropathy and nondiabetic patients (20 vs 14 vs 11%, respectively), but this higher rate was not significant (P=0.240). Secondary: Patients with nephropathy who were assigned clopidogrel experienced a significant increase in overall mortality (HR, 1.8; 95% CI, 1.2 to 2.7; P=0.006) compared to placebo, as well as significantly increased cardiovascular mortality (HR, 1.7; 95% CI, 1.1 to 2.9; P=0.028). The frequency of bleeding in patients with diabetic nephropathy who received clopidogrel tended to be higher compared to placebo, but this increase was not significant (2.6 vs 1.5%; HR, 1.8; P=0.075).
Hart et al.[61] (2008) CHARISMA	DB, MC, PC, RCT (Post hoc analysis of participants with a history of atrial	N=593 28 months (median	Primary: Composite of first occurrence of MI, stroke or death	Primary: There was no difference in the composite of stroke, MI or vascular death between patients receiving clopidogrel plus aspirin (35 of 298 patients) and aspirin alone (27 of 285 patients; P=0.40).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Clopidogrel 75 mg QD plus aspirin 75 to 162 mg QD vs aspirin 75 to 162 mg QD	fibrillation in the CHARISMA trial) Patients 45 years of age or older with clinically evident cardiovascular disease or multiple atherothrombotic risk factors; patients receiving oral anticoagulation were excluded	duration)	from cardiovascular causes Secondary: First occurrence of MI, stroke, death from cardiovascular causes, or hospitalization for unstable angina, TIA or revascularization procedure; safety	Secondary: There was no difference in the composite of stroke, MI, vascular death or rehospitalization (70 vs 66 patients; P=0.93) or all-cause mortality (29 vs 25 patients; P=0.69) among patients receiving clopidogrel plus aspirin and aspirin alone. Stroke (ischemic and hemorrhagic) occurred in 15 patients receiving clopidogrel plus aspirin (2.2% per year) and in 14 patients receiving aspirin alone (2.1% per year; HR, 1.03; 95% CI, 0.49 to 2.13; P=0.94). Severe or fatal extracranial hemorrhage occurred in 6 patients given clopidogrel plus aspirin vs 3 patients given aspirin alone (P=0.51), while intracranial bleeding occurred in 3 patients vs 1 patients (P=0.62), respectively.
Ho et al.[62] (2008) Clopidogrel (dose not specified)	RETRO Patients with ACS discharged on clopidogrel from Veterans Affairs hospitals	N=3,137 Duration varied	Primary: Rate of all-cause mortality or acute MI after stopping clopidogrel Secondary: Not reported	Primary: Among medically treated patients, mean duration of clopidogrel treatment was 302 days. Death or acute MI occurred in 17.1% of patients, with 60.8% of events occurring during 0 to 90 days, 21.3% during 91 to 180 days, and 9.7% during 181 to 270 days after stopping treatment with clopidogrel. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping treatment with clopidogrel was associated with a significantly higher risk of adverse events (IRR, 1.98; 95% CI, 1.46 to 2.69 vs the interval 91-180 days). Among the PCI-treated patients with ACS, mean duration of clopidogrel treatment was 278 days and death or acute MI occurred in 7.9% of patients, with 58.9% of events occurring during 0 to 90 days, 23.4% during 91 to 180 days, and 6.5% during 181 to 270 days after stopping clopidogrel treatment. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping clopidogrel treatment was associated with a significantly higher risk of adverse events (IRR,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				1.82; 95% CI, 1.17 to 2.83). Secondary: Not reported
Wiviott et al.[63] (2007) TRITON-TIMI 38 Clopidogrel 300 mg loading dose followed by 75mg daily plus aspirin 75 to 162 mg/daily vs prasugrel 60 mg loading dose followed by 10 mg daily plus aspirin 75 to 162 mg/daily	AC, DB, MC, RCT Patients with moderate-to-high risk ACS (unstable angina, NSTEMI, or STEMI) and scheduled PCI	N=13,608 Mean 14.5 months	Primary: Composite of death from CV causes, nonfatal MI, or nonfatal stroke Secondary: Stent thrombosis, composite of CV death, nonfatal MI, nonfatal stroke, or rehospitalization due to cardiac ischemic event, 30 and 90 day event rates for the primary endpoint and composite of CV death, nonfatal MI, or urgent target vessel revascularization	Primary: Compared to clopidogrel, treatment with prasugrel was associated with a reduction in the composite primary efficacy endpoint of death from CV causes, nonfatal MI, or nonfatal stroke (9.9 vs 12.1%, respectively; HR, 0.81; 95% CI, 0.73 to 0.9; P<0.001). This difference was driven primarily by a reduction in nonfatal MI, which was evident early on in therapy. Secondary: In a post-hoc analysis, probable or definite stent thrombosis was also significantly reduced in the prasugrel vs clopidogrel group (1.1 vs 2.4%; HR, 0.48; 95% CI 0.36 to 0.64; P<0.001), a finding that was observed with both bare metal and drug eluding stents. The composite of CV death, nonfatal MI, nonfatal stroke, and re-hospitalization for ischemia was 12.3% for prasugrel compared to 14.6% for clopidogrel (HR, 0.78; 95% CI, 0.69 to 0.89). The improvement in efficacy outcomes with prasugrel was accompanied by an increased risk of bleeding compared to clopidogrel. A higher percentage of patients treated with prasugrel had major bleeding than those treated with clopidogrel (2.4 vs 1.8%; P=0.03). There was a significant increase in life-threatening bleeding with prasugrel and a significant increase in fatal bleeding (0.4 vs 0.1%; P=0.002) compared to clopidogrel.
Wiviott et al.[64] (2008) Prasugrel 60 mg once, followed by 10 mg/day	Subanalysis of TRITON-TIMI 38 TRITON-TIMI 38 patients with a median age of 63 stratified by diabetes	N=13,608 (n=3,146 diabetes population) 6 to 15 months	Primary: Composite of death from cardiovascular causes, nonfatal MI or nonfatal stroke	Primary: The composite endpoint in patients with diabetes was significantly lower in the prasugrel group (12.2%) than in the clopidogrel group (17.0%; HR, 0.70; 95% CI, 0.58 to 0.85; P<0.001). A 14.0% overall reduction in the primary endpoint was seen in the prasugrel and no diabetes group compared to the clopidogrel group (HR,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs clopidogrel 300 mg once, followed by 75 mg/day Patients were also on concurrent aspirin (75 to 162 mg/day).		(median, 14.5 months)	Secondary: Rate of cardiovascular death, MI (fatal or nonfatal) or stent thrombosis; safety; net clinical benefit	0.86; 95% CI, 0.76 to 0.98; P=0.02). Among the diabetes group the reduction was 30% in the prasugrel group compared to the clopidogrel group (HR, 0.70; 95% CI, 0.58 to 0.85; P<0.001). Secondary: The rate of cardiovascular death in patients with diabetes was not significantly lower in the prasugrel group (3.4%) than in the clopidogrel group (4.2%; HR, 0.85; 95% CI, 0.58 to 1.24; P=0.40). The rate of MI in patients with diabetes was significantly lower in the prasugrel group (8.2%) than in the clopidogrel group (13.2%; HR, 0.60; 95% CI, 0.48 to 0.76; P<0.001). The rate of MI in patients without diabetes was also significantly lower in the prasugrel group (8.7%) than in the clopidogrel group (7.2%; HR, 0.82; 95% CI, 0.72 to 0.95; P=0.006). There was an 18.0% reduction in MI among nondiabetic prasugrel patients compared to a 40.0% reduction in MI among diabetic prasugrel patients. The rate of stent thrombosis in patients with diabetes was significantly lower in the prasugrel group (2.0%) than in the clopidogrel group (3.6%; HR, 0.52; 95% CI, 0.33 to 0.84; P=0.007). The rate of TIMI major non-CABG bleeding in patients with diabetes was not significantly greater in the prasugrel group (2.5%) compared to the clopidogrel group (2.6%; HR, 1.06; 95% CI, 0.66 to 1.69; P=0.81). The rate of TIMI major or minor non-CABG bleeding in patients with diabetes was not significantly greater in the prasugrel group (5.3%) compared to the clopidogrel group (4.3%; HR, 1.30; 95% CI, 0.92 to 1.82; P=0.13). The rate of net clinical benefit was significantly greater in the prasugrel group (14.6%) than in the clopidogrel group (19.2%; HR, 0.74; 95% CI, 0.62 to 0.89; P=0.001).
Antman et al.[65] (2008)	Subanalysis of TRITON-TIMI 38	N=13,608	Primary: Rate of MI, stent	Primary: The rate of MI was significantly lower in the prasugrel group (4.27%) than

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Prasugrel 60 mg once, followed by 10 mg/day vs clopidogrel 300 mg once, followed by 75 mg/day Patients were also on concurrent aspirin (75 to 162 mg/day).	Patients with ACS (unstable angina, NSTEMI or STEMI) with a scheduled PCI; for patients with unstable angina or NSTEMI ischemic symptoms lasting ≥10 minutes and occurring within 72 hours of randomization, a TIMI score ≥3 and either ST-segment deviation ≥1 mm or elevated cardiac necrosis biomarker levels; STEMI patients were included within 12 hours after symptom onset if PCI was planned or within 14 days after receiving medical treatment for STEMI	6 to 15 months (median, 14.5 months)	thrombosis and urgent target vessel revascularization from randomization to day three and from day three to the end of the trial Secondary: Safety, percent net clinical benefit	in the clopidogrel group by day three (5.24%; HR, 0.81; 95% CI, 0.70 to 0.95; P=0.008) and from day three until the end of the study (3.40 vs 4.79%; HR, 0.69; 95% CI, 0.58 to 0.83; P<0.0001). The rate of stent thrombosis was significantly lower in the prasugrel group than in the clopidogrel group by day three (0.33 vs 0.67%; HR, 0.49; 95% CI, 0.29 to 0.82; P=0.006) and from day three until the end of the study (0.08 vs 1.74%; HR, 0.45; 95% CI, 0.32 to 0.64; P<0.0001). The rate of urgent target vessel revascularization was significantly lower in the prasugrel group than in the clopidogrel group by day three (0.54 vs 0.83%; HR, 0.66; 95% CI, 0.43 to 0.99; P=0.047) and from day three until the end of the study (1.94 vs 2.97%; HR, 0.65; 95% CI, 0.52 to 0.82; P=0.0003). Secondary: Through the first three days the rate of TIMI major non-CABG bleeding was numerically greater in the prasugrel group (0.74%) compared to the clopidogrel group (0.61%), however the difference between the two groups was not significant, (P=0.35). From day three to the end of the trial prasugrel was associated with a significantly greater risk of TIMI major non-CABG bleeding (1.71%) compared to clopidogrel (1.23%; HR, 1.39; 95% CI, 1.02 to 1.89; P=0.036). The rate of net clinical benefit was significantly greater in the prasugrel group than in the clopidogrel group by day three (6.19 vs 5.29%; HR, 0.85; 95% CI, 0.74 to 0.98; P=0.025) and from day three until the end of the study (8.33 vs 7.35%; HR, 0.87; 95% CI, 0.77 to 0.98; P=0.028).
Murphy et al.[66] (2008) Prasugrel 60 mg once, followed by 10 mg/day	Subanalysis of TRITON-TIMI 38 Patients with ACS (unstable angina, NSTEMI or STEMI) with a scheduled	N=13,608 6 to 15 months (median, 14.5 months)	Primary: Total number of reoccurrences of the composite endpoint (rate of death from cardiovascular	Primary: Prasugrel demonstrated a significant overall reduction in subsequent events with 195 fewer total primary events compared to clopidogrel (HR, 0.79; 95% CI, 0.71 to 0.87; P<0.001). From the time of the first event to the recurrent event or last follow up a second event occurred in 10.8% of the prasugrel group compared to 15.4%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs clopidogrel 300 mg once, followed by 75 mg/day Patients were also on concurrent aspirin (75 to 162 mg/day).	PCI; for patients with unstable angina or NSTEMI ischemic symptoms lasting ≥10 minutes and occurring within 72 hours of randomization, a TIMI score ≥3 and either ST-segment deviation ≥1 mm or elevated cardiac necrosis biomarker levels; STEMI patients were included within 12 hours after symptom onset if PCI was planned or within 14 days after receiving medical treatment for STEMI		causes, nonfatal MI or nonfatal stroke), risk of second event following initial event, cardiovascular deaths following nonfatal event Secondary: Safety	in the clopidogrel group (HR, 0.65; 95% CI, 0.46 to 0.92; P=0.016). Cardiovascular death following the nonfatal event was also reduced in the prasugrel group (3.7%) compared to the clopidogrel group (7.1%; HR, 0.46; 95% CI, 0.25 to 0.82; P=0.008). Secondary: Recurrent bleeding events occurred infrequently, with TIMI major non-CABG bleeds in four patients treated with prasugrel and two with clopidogrel. There were also five repeat TIMI minor non-CABG bleeds in each treatment group. Among patients with at least one TIMI non-CABG major or minor bleeding event, 17 were reported in the prasugrel group and 13 were reported in the clopidogrel group.
Montalescot et al.[67] (2009) Clopidogrel 300 mg loading dose followed by 75mg daily plus aspirin 75 to 162 mg/daily vs prasugrel 60 mg loading dose followed by 10 mg daily plus aspirin 75	Subanalysis of TRITON-TIMI 38 Patients who presented within 12 hours of onset of symptoms of STEMI for whom primary PCI was planned	N=3,534 (Subgroup analysis of STEMI patients) 15 months	Primary: Composite of CV death, non-fatal MI, or non-fatal stroke Secondary: CV death, non-fatal MI, or urgent target vessel revascularization at 30 days	Primary: At 30 days, 115 (9.5%) individuals assigned prasugrel group had met the primary endpoint compared to 166 (9.5%) allocated to the clopidogrel group (HR, 0.68 [95% CI 0.54 to 0.87]; P=0.0017). This effect continued to 15 months (174 [10·0%] vs 216 [12·4%]; 0.79 [0.65 to 0.97]; P=0.0221). Secondary: At 30 days, the secondary endpoints of CV death, MI, or urgent target vessel revascularization were significantly reduced with prasugrel (HR, 0.75; 95% CI, 0.59 to 0.96; P=0.0205) and 15 months (HR, 0.79; 0.65 to 0.97; P=0.0250), as was stent thrombosis.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
to 162 mg/daily				
Pride et al.[68] (2009) Prasugrel 60 mg once, followed by 10 mg/day vs clopidogrel 300 mg once, followed by 75 mg/day Patients were also on concurrent aspirin (75 to 162 mg/day).	Subanalysis of TRITON-TIMI 38 TRITON-TIMI 38 patients who underwent PCI without stent implantation	N=13,608 (n=569 PCI population) 6 to 15 months (median, 14.5 months)	Primary: Composite of death from cardiovascular causes, nonfatal MI or nonfatal stroke Secondary: Composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke or urgent target vessel revascularization; safety	Primary: The primary endpoint occurred in 14.2% of patients randomized to prasugrel and 17.1% of patients randomized to clopidogrel, a nonsignificant 18.0% RR reduction (HR, 0.82; 95% CI, 0.53 to 1.25; P=0.27). Overall, the unadjusted incidence of the primary composite outcome was significantly higher among patients who underwent PCI without stent implantation compared to those who received stents (15.6 vs 10.8%; P=0.001). Secondary: There were significant reductions in the incidence of urgent target vessel revascularization (3.6 vs 8.2%; HR, 0.46; 95% CI, 0.22 to 0.98; P=0.040), any target vessel revascularization (4.0 vs 10.1%; HR, 0.40; 95% CI, 0.20 to 0.82; P=0.009), the composite of any revascularization procedure (6.3 vs 12.9%; HR, 0.48; 95% CI, 0.27 to 0.87; P=0.014), and CABG surgery (12.5 vs 19.4%; HR, 0.62; 95% CI, 0.40 to 0.98; P=0.041) with prasugrel compared to clopidogrel. There were trends towards reductions in nonfatal MI (9.1 vs 13.5%; HR, 0.65; 95% CI, 0.39 to 1.10; P=0.11) and all MI (9.8 vs 13.9%; HR, 0.69; 95% CI, 0.41 to 1.14; P=0.14) favoring prasugrel. The incidence of all cause mortality, cardiovascular death and nonfatal and all stroke did not differ significantly between the groups. Non-CABG-related major bleeding was more frequent among patients randomized to prasugrel (2.1 vs 0.0%; P=0.033), and there was a trend toward an increased incidence of non-CABG-related life-threatening bleeding (1.7 vs 0.0%; P=0.057). The incidence of intracranial hemorrhage and the composite of non-CABG TIMI major and minor bleeding did not differ significantly between the groups (4.3 vs 2.2%; HR, 1.85; 95% CI, 0.63 to 5.42), although there was no significant interactions between bleeding rates and treatment with prasugrel compared to clopidogrel as a function of PCI stent (stent vs no stent).
O'Donoghue et al.[69]	Subanalysis of	N=13,608	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2009) Prasugrel 60 mg once, followed by 10 mg/day vs clopidogrel 300 mg once, followed by 75 mg/day Patients were also on concurrent aspirin (75 to 162 mg/day).	TRITON-TIMI 38 TRITON-TIMI 38 patients stratified by GB IIb/IIIa inhibitor use	(n=7,414 GP IIb/IIIa inhibitor population) 30 days	Composite of death from cardiovascular causes, nonfatal MI or nonfatal stroke Secondary: Periprocedural MI, urgent target vessel revascularization, stent thrombosis, safety	There was a consistent benefit of prasugrel over clopidogrel in reducing cardiovascular death, MI or stroke at 30 days in patients who did (HR, 0.76; 95% CI, 0.64 to 0.90) and did not (HR, 0.78; 95% CI, 0.63 to 0.97; P=0.83) receive a GP IIb/IIIa inhibitor. Secondary: Prasugrel significantly reduced the risk of recurrent MI in subjects by approximately 25% regardless of the use of a GP IIb/IIIa inhibitor, including a comparable benefit toward a reduction in periprocedural MI across both subgroups. Patients treated with prasugrel also exhibited a significant reduction in urgent target vessel revascularization, irrespective of whether or not they were treated with a GP IIb/IIIa inhibitor (P=0.63). At the end of 30 days, prasugrel significantly reduced the risk of stent thrombosis by 54% in patients treated with a GP IIb/IIIa inhibitor (HR, 0.46; 95% CI, 0.29 to 0.71) and by 66% in patients not treated with a GP IIb/IIIa inhibitor (HR, 0.34; 95% CI, 0.17 to 0.65; P=0.46). In the overall cohort, prasugrel significantly increased the risk of TIMI non-CABG-related major or minor bleeding compared to clopidogrel (2.6 vs 2.1; HR, 1.26; 95% CI, 1.01 to 1.57; P=0.04). The excess risk of TIMI non-CABG-related major or minor bleeding observed with prasugrel was comparable regardless of whether a GP IIb/IIIa inhibitor was used (HR, 1.16; 95% CI, 0.89 to 1.50) or was not used (HR, 1.63; 95% CI, 1.05 to 2.52; P=0.19). The absolute excess in the risk of TIMI non-CABG-related major bleeding with prasugrel vs clopidogrel was 0.1% in patients treated with a GP IIb/IIIa inhibitor (1.2 vs 1.1%; HR, 1.06; 95% CI, 0.69 to 1.64) and 0.3% in subjects not treated with a GP IIb/IIIa inhibitor (0.9 vs 0.6%; HR, 1.47; 95% CI, 0.81 to 2.66), a difference that was not significantly different between subgroups (P=0.39). Similarly, the relative hazard of TIMI life-threatening bleeding with prasugrel compared to clopidogrel did not differ significantly in the presence or absence of a GP IIb/IIIa inhibitor (P=0.19). The incidence of procedure-related TIMI major bleeding was similar for subjects treated with prasugrel or clopidogrel and was not significantly influenced by the use of a GP IIb/IIIa inhibitor (P value not

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				reported). Consistent with the overall trial, there was no significant difference in the incidence of intracranial hemorrhage between treatment arms in either stratum (P value not reported).
Zeymer et al.[70] (2015) Clopidogrel vs prasugrel	OBS, PRO Patients with STEMI of less than 24 hour duration undergoing angiography and treated with a loading dose of either clopidogrel or prasugrel	N=3,291 median of 6 days after start of treatment	Primary: Major adverse cardiac and cerebral events (MACCE), defined as death, non-fatal infarction and non-fatal stroke; major bleeding Secondary: Not reported	Primary: Prasugrel was predominantly used in patients <75 years, body weight >60 kg and those without prior stroke. In-hospital mortality was numerically lower in the prasugrel group (1.7 vs 4.4%), as well as non-fatal reinfarction (0.2 vs 0.5%), non-fatal stroke (0.1 vs 0.3%) and MACCE (2.1 vs 5.2%), while there was no difference in major bleeding complications (0.8 vs 0.9%). In the multivariate analysis the MACCE-rate tended to be lower in prasugrel treated patients (odds ratio 0.71, 95% CI, 0.42 to 1.08) but bleeding-rates tended to be higher. Secondary: Not reported
Roe et al.[71] (2012) TRILOGY ACS Prasugrel 10 mg/day or 5 mg/day (patients who were ≥75 years of age or who weighed <60 kg received 5 mg/day) vs clopidogrel 75 mg/day Patients who underwent randomization within 72 hours after the first	AC, DB, DD, event-driven, RCT Patients with ACS if selected for a final treatment strategy of medical management without revascularization within 10 days after the index event; patients with MI without ST-segment elevation had elevated cardiac markers and patients with unstable angina with negative cardiac markers had an ST-segment depression of >1 mm in ≥2	N=7,243 (primary analysis; patients <75 years of age) N=2,083 (secondary analysis; patients ≥75 years of age) Up to 30 months	Primary: Composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke among patients <75 years of age Secondary: Incidence of cardiovascular death, MI, and stroke; all-cause mortality; bleeding events; safety	Primary: At a median follow-up of 17 months, the primary endpoint occurred in 13.9 vs 16.0% of prasugrel- and clopidogrel-treated patients (HR in the prasugrel group, 0.91; 95% CI, 0.79 to 1.05; P=0.21). Similar results were observed in the overall population (18.7 vs 20.3%; HR, 0.96; 95% CI, 0.86 to 1.07; P=0.45). Because superiority was not established in the primary cohort, the prespecified testing strategy did not direct further superiority testing. The frequency of the primary end point in the two treatment groups did not differ significantly among prespecified subgroups of patients who were <75 years of age, but an interaction with prasugrel treatment was apparent in current or recent smokers, those who underwent angiography before randomization, and those taking a PPI at randomization. The prespecified analysis that was performed to account for multiple recurrent ischemic events suggested a lower risk among patients <75 years of age with prasugrel (HR, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Among patients who had an ischemic event, 364 patients treated with prasugrel (10.1%) had at least one ischemic event compared to 397 patients (11.0%) with clopidogrel, whereas 77 (2.1%) vs 109 (3.0%) had a least two recurrent ischemic events, and 18 (0.5%) vs 24 (0.7%) had at least three

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
medical contact without previous clopidogrel treatment received a loading dose of 30 mg of prasugrel or 300 mg of clopidogrel. Patients who did not undergo randomization within 72 hours were required to be treated with OL clopidogrel before randomization and were started on daily maintenance administration of a study drug after randomization.	electrocardiographic leads, and patients had ≥1 of 4 risk criteria: age ≥60 years of age, the presence of diabetes, previous MI, or previous revascularization with either PCI or CABG			recurrent ischemic events, respectively. Secondary: Among patients <75 years of age, there were no differences in the incidences of cardiovascular death (6.6 vs 6.8%; HR, 0.93; 95% CI, 0.75 to 1.15; P=0.48), MI (8.3 vs 10.5%; HR, 0.89; 95% CI, 0.74 to 1.07; P=0.21), and stroke (1.5 vs 2.2%; HR, 0.67; 95% CI, 0.42 to 1.06; P=0.08) between prasugrel- and clopidogrel-treated patients. Similar results were observed in the overall population (P=0.38, P=0.58, and P=0.52) Among patients <75 years of age, all-cause mortality was similar between the two treatments (7.8 vs 8.1%; HR, 0.96; 95% CI, 0.79 to 1.16; P=0.63). Similar results were observed in the overall population (P=0.40). At 30 months, the key bleeding end points of non-CABG-related severe or life-threatening events and major bleeding occurred with similar frequency among patients <75 years of age in the two treatment groups. The only subgroup in which there was a significant treatment interaction for TIMI major bleeding was patients receiving a reduced dose of aspirin. The frequency of new, benign neoplasms in the overall treated population did not differ significantly between prasugrel and clopidogrel (1.9 vs 1.8%; P=0.79); similar findings were observed among treated patients with no history of cancer or a history of previous cancer that had been cured before randomization. The incidence of common (>1.0%) nonhemorrhagic serious adverse events was balanced between the two treatments among patients <75 years of age, and the only significant difference observed was a higher rate of heart failure with clopidogrel.
Gurbel et al.[72] (2012) Prasugrel 10 mg/day or 5 mg/day (patients who were ≥75 years of age or who weighed <60 kg received 5	Substudy of TRILOGY ACS Patients with ACS if selected for a final treatment strategy of medical management without revascularization	N=2,564 Up to 30 months	Primary: Platelet reactivity (measured in $P2Y_{12}$ reaction units); composite of cardiovascular death, MI, or stroke through 30 months	Primary: Among patients <75 years of age and weighing ≥60 kg, median $P2Y_{12}$ reaction unit values at 30 days were 64 (interquartile range, 33-128) with prasugrel compared to 200 (interquartile range, 141-260) with clopidogrel (P<0.001), a difference that persisted through all subsequent time points. Among patients <75 years of age and weighing <60 kg, corresponding values were 139 (interquartile range, 86 to 203) vs 209 (interquartile range, 148 to 283) (P<0.001). Among patients >75 years of age, corresponding values were 164 (interquartile range, 105 to 216) vs 222

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day) vs clopidogrel 75 mg/day Patients who underwent randomization within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 30 mg of prasugrel or 300 mg of clopidogrel. Patients who did not undergo randomization within 72 hours were required to be treated with OL clopidogrel before randomization and were started on daily maintenance administration of a study drug after randomization	within 10 days after the index event; patients with MI without ST-segment elevation had elevated cardiac markers and patients with unstable angina with negative cardiac markers had an ST-segment depression of >1 mm in ≥2 electrocardiographic leads, and patients had ≥1 of 4 risk criteria: age ≥60 years of age, the presence of diabetes, previous MI, or previous revascularization with either PCI or CABG		Secondary: Not reported	(interquartile range, 148 to 268) (P<0.001). At 30 months, the rate of the composite endpoint was 17.2 (160 events) vs 18.9% (180 events) with prasugrel and clopidogrel (P=0.29). There were no significant differences in the continuous distributions of 30 day $P2Y_{12}$ reaction unit values for patients with a primary efficacy endpoint compared to patients without an event (P=0.07) and no significant relationship between the occurrence of the primary efficacy endpoint and continuous $P2Y_{12}$ reaction unit values (adjusted HR for increase of 60 $P2Y_{12}$ reaction units, 1.03; 95% CI, 0.96 to 1.11; P=0.44). Similar findings were observed with 30 day $P2Y_{12}$ reaction unit cut points used to define high on-treatment platelet reactivity; $P2Y_{12}$ reaction unit >280 (adjusted HR, 1.16; 95% CI, 0.89 to 1.52; P=0.28) and $P2Y_{12}$ reaction unit >230 (adjusted HR, 1.20; 95% CI, 0.90 to 1.61; P=0.21). Secondary: Not reported
Wiviott et al.[73] (2013) TRILOGY ACS	Substudy of TRILOGY ACS Patients enrolled in	N=7,243 (primary analysis; patients <75	Primary: CV death, MI, or stroke at 30 months	Primary: Fewer patients who had angiography before enrolment reached the primary endpoint according to Kaplan-Meier analysis (12.8%) than did those who did not have angiography (16.5%; adjusted HR 0.63, 95% CI,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Prasugrel 10 mg/day or 5 mg/day (patients who were ≥75 years of age or who weighed <60 kg received 5 mg/day) vs clopidogrel 75 mg/day Patients who underwent randomization within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 30 mg of prasugrel or 300 mg of clopidogrel. Patients who did not undergo randomization within 72 hours were required to be treated with OL clopidogrel before randomization and were started on daily maintenance administration of a	the TRILOGY ACS trial stratified based on whether or not patients had coronary angiography before treatment	years of age) Up to 30 months	Secondary: All-cause mortality; bleeding events; safety; components of primary endpoint	0.53 to 0.75; P<0.0001). Of the patients who had angiography before enrolment, fewer patients assigned to prasugrel reached the primary endpoint at 30 months compared with those assigned to clopidogrel (10.7% vs 14.9%; HR, 0.77; 95% CI, 0.61 to 0.98; P=0.032). We recorded no such difference at 30 months in patients who had not had pre-enrolment angiography (16.3% vs 16.7%; HR, 1.01; 95% CI, 0.84 to 1.20; P=0.94). For the difference in treatment effect between angiography cohorts, P=0.08. Secondary: A significantly smaller proportion of patients who had angiography before treatment also had cardiovascular death or all-cause death. GUSTO and TIMI bleeding did not differ significantly between groups. Prasugrel treatment in the angiography cohort, but not the no angiography cohort, was associated with fewer MIs and strokes than clopidogrel treatment. By contrast, the risk of CV death did not differ significantly between treatment groups in both angiography and no angiography cohorts.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
study drug after randomization				
Roe et al.[74] (2013) TRILOGY ACS Prasugrel 10 mg/day or 5 mg/day (patients who were ≥75 years of age or who weighed <60 kg received 5 mg/day) vs clopidogrel 75 mg/day Patients who underwent randomization within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of 30 mg of prasugrel or 300 mg of clopidogrel. Patients who did not undergo randomization within 72 hours were required to be	Substudy of TRILOGY ACS Patients enrolled in the TRILOGY ACS trial stratified based on age ≥75 or <75 years	N=7,243 (primary analysis; patients <75 years of age) N=2,083 (secondary analysis; patients ≥75 years of age) Up to 30 months	Primary: Composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke Secondary: Incidence of cardiovascular death, MI, and stroke; all-cause mortality; bleeding events; safety	Primary: The Kaplan–Meier estimate of the primary efficacy end point through 30 months was >2.5-fold higher in participants ≥75 years of age compared with those <75 years of age (35.7 vs 14.9%; HR, 2.65; 95% CI, 2.37 to 2.97). The cumulative risk of the primary efficacy end point and non–CABG-related TIMI major bleeding through 30 months among participants ≥75 years of age was not significantly different with reduced-dose prasugrel compared with clopidogrel treatment. Secondary: The risk of non–CABG-related bleeding assessed with both GUSTO and TIMI bleeding scales was 2- to 3-fold higher with older age. Fatal bleeding events (1.1 vs 0.3%; HR, 4.31; 95% CI, 1.61 to 11.5) and intracranial hemorrhage (1.2 vs 0.6%; HR, 2.67; 95% CI, 1.33 to 5.37) were infrequent, but the risk was 3- to 4-fold higher in older and younger participants, respectively. The age-by-treatment interaction P value for stroke was 0.052 and for TIMI major/minor bleeding was 0.098. All other interaction P values were >0.1. Rates of intracranial hemorrhage (0.9 vs 1.5%; HR, 0.90; 95% CI, 0.30 to 2.67) and fatal bleeding (1.0 vs 1.1%; HR, 0.62; 95% CI, 0.15 to 2.59) were not significantly different between the prasugrel and clopidogrel groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
treated with OL clopidogrel before randomization and were started on daily maintenance administration of a study drug after randomization				
Jackson et al.[75] (2016) TRILOGY ACS Prasugrel 10 mg/day or 5 mg/day (patients who were ≥75 years of age or who weighed <60 kg received 5 mg/day) vs clopidogrel 75 mg/day	Substudy of TRILOGY ACS Patients included in this secondary analysis had a history of AF prior to or during the index hospitalization and were not taking an oral anticoagulant	N=710 (AF+) Compared to N=8,391 (AF-) Up to 30 months	Primary: Composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke Secondary: Incidence of cardiovascular death, MI, and stroke; all-cause mortality; bleeding events; safety	Primary: The unadjusted association of the primary composite endpoint of cardiovascular death, MI, or stroke occurred with increased risk in AF+ patients at 30 months: 31.1 vs 18.4% (HR, 1.61; 95% CI, 1.35 to 1.92; P<0.001). After adjustment, there was no difference in rates of the composite endpoint of cardiovascular death, MI, or stroke (HR, 1.16; 95% CI, 0.97 to 1.39; P=0.11). Secondary: When all secondary outcomes were evaluated, there was a significantly increased risk of events, particularly stroke, in AF+ patients at 30 months, although the overall incidence of stroke was low. The rate of all-cause death was significantly higher in AF+ patients at 30 months: 18.1 vs 11.1% (HR, 1.62; 95% CI, 1.30 to 2.02; P<0.001). Rates of all-cause death were also similar between AF+ and AF− patients (HR, 1.10; 95% CI, 0.87 to 1.39; P=0.42). Rates of major bleeding at 30 months were similar between both AF groups.
Bonaca et al.[76] (2015) PEGASUS-TIMI 54 Ticagrelor 90 mg twice daily vs	DB, MC, RCT Patients had had a spontaneous MI one to three years before enrollment, were ≥50 years of age, and had one of the following additional high-risk features:	N=21,162 Median of 33 months	Primary: Composite of cardiovascular death, myocardial infarction, or stroke; Thrombolysis in Myocardial Infarction (TIMI) major bleeding	Primary: The two ticagrelor doses each significantly reduced, as compared with placebo, the rate of the primary composite end point. Kaplan–Meier rates at three years were 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (HR for 90 mg of ticagrelor vs placebo, 0.85; 95% CI, 0.75 to 0.96; P=0.008; HR for 60 mg of ticagrelor vs placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). The rate of the primary safety end point of TIMI major bleeding was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
ticagrelor 60 mg twice daily vs placebo	age ≥65 years, diabetes mellitus requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or chronic renal dysfunction, defined as an estimated creatinine clearance <60 ml/minute		Secondary: cardiovascular death and death from any cause	higher with the two ticagrelor doses than with placebo. Kaplan–Meier rates at three years were 2.60% in the group that received 90 mg of ticagrelor, 2.30% in the group that received 60 mg of ticagrelor, and 1.06% in the placebo group (HR for 90 mg of ticagrelor vs placebo, 2.69; 95% CI, 1.96 to 3.70; P<0.001; HR for 60 mg of ticagrelor vs placebo, 2.32; 95% CI, 1.68 to 3.21; P<0.001) Secondary: There was a trend with ticagrelor toward a reduction in the rate of cardiovascular death alone, but this effect was not significant. Therefore, on the basis of the prespecified hierarchical testing procedure, the assessment of all the other efficacy end points was considered to be exploratory. The rate of death from any cause did not differ significantly with either ticagrelor dose, as compared with placebo.
Wallentin et al.[77] (2009) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant.	AC, DB, DD, MC, PG, PRO, RCT Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation	N=18,624 12 months	Primary: Composite endpoint of the rate of vascular death, MI, or stroke; major bleeding Secondary: Effect in patients for whom invasive treatment was planned; composite endpoint of all-cause mortality, MI, or stroke; composite endpoint of vascular death, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, TIA, or other	Primary: At 12 months, ticagrelor was associated with significantly fewer composite events compared to clopidogrel (9.8 vs 11.7%; HR, 0.84; 95% CI, 0.77 to 0.92; P<0.001). A treatment effect was seen within 30 days and persisted throughout the trial. The rate of major bleeding was not different between ticagrelor and clopidogrel (11.6 vs 11.2%; HR, 1.04; 95% CI, 0.95 to 1.13; P=0.43). Secondary: In patients undergoing invasive procedures, significantly fewer composite events occurred with ticagrelor (8.9 vs 10.6%; HR, 8.4; 95% CI, 0.75 to 0.94; P=0.003). Ticagrelor was associated with significantly fewer events with regards to the composite of all-cause mortality, MI or stroke (10.2 vs 12.3%; HR, 0.84; 95% CI, 0.77 to 0.92; P<0.001). Ticagrelor was associated with significantly fewer events with regards to the composite of vascular death, MI, stroke, severe recurrent ischemia, recurrent ischemia, TIA, or other thrombotic event (14.6 vs 16.7; HR, 0.88; 95% CI, 0.81 to 0.95; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.			arterial thrombotic event; individual components of the primary endpoint; all-cause mortality; other bleeding events; dyspnea; bradyarrhythmia; any other adverse event; results of laboratory safety tests	The rates of MI (5.8 vs 6.9%; HR, 0.84; 95% CI, 0.75 to 0.95; P=0.005) and vascular death (4.0 vs 5.1%; HR, 0.84; 95% CI, 0.69 to 0.91; P=0.001) were significantly lower with ticagrelor. The rate of stroke was not different between the two treatments (1.5 vs 1.3%; HR, 1.17; 95% CI, 0.91 to 1.52; P=0.22). The rate of all-cause mortality was significantly lower with ticagrelor (4.5 vs 5.9%; HR, 0.78; 95% CI, 0.69 to 0.89; P<0.001). Data on minor bleeding events were not reported. Rates of fatal bleeding were not different between the two treatments (0.3 vs 0.3%; HR, 0.87; 95% CI, 0.48 to 1.59; P=0.66). The rate of fatal non-intracranial bleeding was significantly higher with clopidogrel (0.3 vs 0.1%, respectively; P=0.03). The rate of fatal intracranial bleeds was significantly higher with ticagrelor (0.10 vs 0.01%, respectively; P=0.02). The rate of dyspnea was significantly higher with ticagrelor (13.8 vs 7.8%; HR, 1.84; 95% CI, 1.68 to 2.02; P<0.001). From this group, 0.9 and 0.1% of patients discontinued treatment (HR, 6.12; 95% CI, 3.41 to 11.01; P<0.001). Rates of pacemaker insertion (P=0.87), syncope (P=0.08), bradycardia (P=0.21) and heart block (P=1.00) were not different between the two treatments. Laboratory testing revealed significant increases in baseline serum uric acid with ticagrelor at one (P<0.001) and 12 months (P<0.001). Similar results were observed with serum creatinine (P<0.001 for both). One month after the end of treatment, there were no differences between the two treatments for either serum uric acid (P=0.56) or creatinine (P=0.59).
James et al. [78] (2011) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg	Substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or	N=5,216 12 months	Primary: Composite endpoint of the rate of vascular death, MI, or stroke; major bleeding events	Primary: At 12 months, ticagrelor was associated with significantly fewer composite events compared to clopidogrel (12.0 vs 14.3%; HR, 0.85; 95% CI, 0.73 to 1.00; P=0.045). The rate of major bleeding did not differ between ticagrelor and clopidogrel (11.9 vs 10.3%; HR, 1.17; 95% CI, 0.98 to 1.39; P=0.079).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.	without ST-segment elevation, undergoing noninvasive procedures		Secondary: Individual components of the primary composite endpoint; all-cause mortality; nonvascular mortality; composite of vascular death, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, TIA, or other arterial thrombotic event; subclasses of stroke; other bleeding events	Secondary: The rate of vascular death was significantly lower with ticagrelor (5.5 vs 7.2%; HR, 0.76; 95% CI, 0.61 to 0.96; P=0.019). The rates of MI (7.2 vs 7.8%; HR, 0.94; 95% CI, 0.77 to 1.15; P=0.555) and stroke (2.1 vs 1.7%; HR, 1.35; 95% CI, 0.89 to 2.07; P=0.162) were not different between the two treatments. The rates of all-cause mortality was significantly lower with ticagrelor (6.1 to 8.2%; HR, 0.75; 95% CI, 0.61 to 0.93; P=0.010). The rate of nonvascular death was not different between the two treatments (0.6 vs 1.0%; HR, 0.68; 95% CI, 0.35 to 1.31; P=0.252). The rate of the composite of vascular death, MI, stroke, composite ischemic events, or other arterial thrombotic events was not different between the two treatments (18.6 vs 20.3%; HR, 0.94; 95% CI, 0.82 to 1.06; P=0.309). The rates of ischemic (1.5 vs 1.4%; P=0.530), hemorrhagic (0.5 vs 0.2%; P=0.069) or unknown (0.20 vs 0.06%; P=0.124) strokes were not different between the two treatments. The rates of life threatening or fatal (5.5 vs 5.6%; HR, 0.99; 95% CI, 0.77 to 1.26; P=0.911) and intracranial bleeding (0.5 vs 0.2%; HR, 2.83; 95% CI, 0.90 to 8.90; P=0.075) were not different between the two treatments. The rate of other major bleeding was significantly higher with ticagrelor (6.8 vs 4.9%; HR, 1.38; 95% CI, 1.09 to 1.76; P=0.009). The rates of non-CABG-related (P=1.03), CABG-related (P=0.335), coronary procedure related (P=0.231), noncoronary procedure related (P=0.072) bleeding were not different between the two treatments. The rate of major and minor bleeding was significantly higher with ticagrelor (16.4 vs 14.4%; HR, 1.17; 95% CI, 1.01 to 1.36; P=0.0358).
Cannon et al.[79] (2010) PLATO	Substudy of PLATO Adult patients hospitalized with	N=13,408 12 months	Primary: Composite endpoint of vascular death, MI,	Primary: At 12 months, ticagrelor was associated with significantly fewer composite events compared to clopidogrel (9.0 vs 10.7%; HR, 0.84; 95% CI, 0.75 to 0.94; P=0.0025).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.	documented ACS within the previous 24 hours, with or without ST-segment elevation, undergoing invasive procedures		or stroke; total major bleeding Secondary: Composite endpoint of all-cause mortality, MI, or stroke; composite endpoint of vascular death, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, TIA, or other arterial thrombotic event; components of the primary endpoint; all-cause mortality; stent thrombosis; other bleeding events; safety	The rate of major bleeding did not differ between ticagrelor and clopidogrel (P=0.8803). Secondary: Ticagrelor was associated with significantly fewer events with regards to the composite of all-cause mortality, MI or stroke (9.4 vs 11.2%; HR, 0.84; 95% CI, 0.75 to 0.94; P=0.0016). Ticagrelor was associated with significantly fewer events with regards to the composite of vascular death, MI, stroke, composite ischemic events or other arterial thrombotic events (9.4 vs 11.2%; HR, 0.85; 95% CI, 0.77 to 0.93; P=0.0005). The rates of MI (5.3 vs 6.6%; HR, 0.80; 95% CI, 0.69 to 0.92; P=0.0023) and vascular death (3.4 vs 4.3%; HR, 0.82; 95% CI, 0.68 to 0.98; P=0.0250) were significantly lower with ticagrelor. The rate of stroke was not different between the two treatments (1.2 vs 1.1%; HR, 1.08; 95% CI, 0.78 to 1.50; P=0.6460). The rate of all-cause mortality was significantly lower with ticagrelor (3.9 vs 5.0%; HR, 0.81; 95% CI, 0.68 to 0.95; P=0.0054). The rates of definite (1.3 vs 2.0%; HR, 0.64; 95% CI, 0.46 to 0.88; P=0.0054), definite or probable (2.2 vs 3.0%; HR, 0.73; 95% CI, 0.57 to 0.94; P=0.0142) and total (definite, probable or possible) (2.8 vs 3.8%; HR, 0.73; 95% CI, 0.59 to 0.92; P=0.0068) stent thrombosis were significantly lower with ticagrelor. The rates of life-threatening or fatal (P=0.6095), intracranial (P=0.4364) and other major bleeding (P=0.4030) were not different between the two treatments. The rates of total major or minor (P=0.0700), CABG-related (P=0.0710), coronary procedure-related (P=0.7768) and noncoronary procedure-related (P=0.3998) bleeding were not different between the two treatments. The rate of non-CABG-related bleeding was significantly higher with ticagrelor (8.9 vs 7.1%; HR, 1.26; 95% CI, 1.11 to 1.43; P=0.0004).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The rate of dyspnea was significantly higher with ticagrelor (13.9 vs 8.0%; P<0.0001). Of the patients experiencing dyspnea, 0.8 and 0.2% discontinued treatment (P value not reported).
Steg et al.[80] (2010) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6	Substudy of the PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with ST-segment elevation or left bundle-branch block	N=7,544 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; major bleeding Secondary: Composite endpoint of vascular death or MI (excluding silent); composite endpoint of all-cause mortality, MI (excluding silent), or stroke; composite endpoint of vascular death, total MI, stroke, severe recurrent cardiac ischemia, recurrent ischemia, TIA, or other arterial thrombotic events; components of the primary endpoint; all-cause mortality; severe recurrent cardiac ischemia; recurrent ischemia;	Primary: At 12 months, there was no difference in the rate of the primary composite endpoint between ticagrelor and clopidogrel (9.4 vs 10.8%; HR, 0.87; 95% CI, 0.75 to 1.01; P=0.07). The rate of major bleeding did not differ between ticagrelor and clopidogrel (HR, 0.98; 95% CI, 0.8 to 1.14; P=0.76). Secondary: Ticagrelor was associated with significantly fewer events with regards to the composite of vascular death and MI (8.4 vs 10.2%; HR, 0.82; 95% CI, 0.71 to 0.69; P=0.01). Ticagrelor was associated with significantly fewer events with regards to the composite of all-cause mortality, MI or stroke (9.8 vs 11.3%; HR, 0.87; 95% CI, 0.75 to 1.00; P=0.05). Ticagrelor was associated with significantly fewer events with regards to the composite of vascular death, MI, stroke, composite ischemic events or other arterial thrombotic events (13.3 vs 15.0%; HR, 0.87; 95% CI, 0.77 to 0.99; P=0.03). The rates of MI (4.7 vs 5.8%; HR, 0.80; 95% CI, 0.65 to 0.98; P=0.03) and stroke (1.7 vs 1.0%; HR, 1.63; 95% CI, 1.07 to 2.48; P=0.02) were significantly lower with ticagrelor, but not vascular death (4.5 vs 5.5%; HR, 0.83; 95% CI, 0.67 to 1.02; P=0.07). The rate of all-cause mortality was significantly lower with ticagrelor (5.0 vs 6.1%; HR, 0.82; 95% CI, 0.67 to 1.00; P=0.05). The rates of severe recurrent cardiac ischemia (2.7 vs 3.2%; HR, 0.81; 95% CI, 0.61 to 1.06; P=0.13), TIA (0.2 vs 0.2%; P value not reported) and arterial thrombotic events (0.3 vs 0.4%; HR, 0.65; 95% CI, 0.28 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
months.			TIA; arterial thrombotic events; stent thrombosis; safety	1.51; P=0.32) were not different between the two treatments. The rate of recurrent ischemia was significantly lower with ticagrelor (4.3 vs 5.1%; HR, 0.81; 95% CI, 0.65 to 1.01; P=0.05). The rates of definite or probable stent thrombosis was not different between the two treatments (2.6 vs 3.4%; HR, 0.74; 95% CI, 0.55 to 1.00; P=0.05). The rates of definite, probable or possible (3.3 vs 4.3%; HR, 0.75; 95% CI, 0.57 to 0.99; P=0.04) and definite (1.6 vs 2.4%; HR, 0.66; 95% CI, 0.45 to 0.95; P=0.03) stent thromboses were significantly lower with ticagrelor. The rates of fatal (P value not reported), life-threatening (P=0.86), major (P=0.76), major and minor (P=0.43), CABG-related (major; P=0.30, major and minor; P=0.26), non-CABG-related (major; P=0.61, major and minor; P=0.11), procedure-related (major; P=0.83, major and minor; P=0.72) and major non-procedure-related (P=0.30) bleeding were not different between the two treatments. The rate of non-procedure-related major and minor bleeding was significantly lower with clopidogrel (5.1 vs 3.7%; HR, 1.31; 95% CI, 1.04 to 1.66; P=0.02). The rate of dyspnea was significantly higher with ticagrelor (12.6 vs 8.4%; P<0.0001), and caused significantly more treatment discontinuations (0.5 vs 0.1%; P=0.0004). Rates of bradycardia (P=0.83), syncope (P=0.18), heart block (P=0.64) and pacemaker insertion (P=0.20) were not different between the two treatments.
James et al.[81] (2010) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg	Substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation and chronic kidney disease (creatine clearance <60	N=15,202 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; major bleeding Secondary: All-cause mortality, other bleeding events, safety	Primary: In patients with chronic kidney disease, there was no difference in the rate of the primary composite endpoint between ticagrelor and clopidogrel (17.3 vs 22.0%; HR, 0.77; 95% CI, 0.65 to 0.90; P=0.13). In patients with chronic kidney disease, there was no difference in the rate of major bleeding between ticagrelor and clopidogrel (15.1 vs 14.3%; HR, 1.07; 95% CI, 0.88 to 1.03; P=0.92). Secondary: In patients with chronic kidney disease, the rate of all-cause mortality was not different between the two treatments (10.0 vs 14.0%; HR, 0.72; 95%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.	mL/minute)			CI, 0.58 to 0.89; P=0.16). In patients with chronic kidney disease, the rates of major or minor (P=0.54), non-CABG-related major (P=0.77), fatal major (P=0.06) and intracranial bleeding (P=0.69) were not different between the two treatments. In patients with chronic kidney disease, the rate of dyspnea was significantly less with clopidogrel (16.4 vs 11.5%; HR, 1.54; 95% CI, 1.27 to 1.88; P=0.04). In patients with chronic kidney disease, the rate of ventricular pauses was no different between the two treatments (5.4 vs 4.6%; HR, 1.16; 95% CI, 0.51 to 2.52; P=0.56).
James et al.[82] (2010) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD	Substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation and diabetes	N=4,662 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; major bleeding Secondary: All-cause mortality, MI, definite stent thrombosis, other bleeding events	Primary: In patients with diabetes, there was no difference in the rate of the primary composite endpoint between ticagrelor and clopidogrel (14.1 vs 16.2%; HR, 0.88; 95% CI, 0.76 to 1.03). In patients with diabetes, there was no difference in the rate of major bleeding between ticagrelor and clopidogrel (14.1 vs 14.8%; HR, 0.95; 95% CI, 0.81 to 1.12). Secondary: In patients with diabetes, the rate of all-cause mortality was not different between the two treatments (7.0 vs 8.7%; HR, 0.82; 95% CI, 0.66 to 1.01). In patients with diabetes, the rate of MI was not different between the two treatments (8.4 vs 9.1%; HR, 0.92; 95% CI, 0.75 to 1.13).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.				In patients with diabetes, the rate of definite stent thrombosis was not different between the two treatments (1.6 vs 2.4%; HR, 0.65; 95% CI, 0.36 to 1.17). In patients with diabetes, the rates of non-CABG-related major (5.5 vs 4.9%; HR, 1.13; 95% CI, 0.86 to 1.49) and CABG-related major bleeding (9.3 vs 10.4%; HR, 0.90; 95% CI, 0.74 to 1.09) were not different between the two treatments.
Held et al.[83] (2011) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100	RETRO substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation who underwent CABG	N=1,261 12 months	Primary: Composite endpoint of vascular death, MI, or stroke after CABG; major CABG-related bleeding Secondary: Individual components of the primary endpoint after CABG; all-cause mortality after CABG; other bleeding events after CABG	Primary: There was no difference between ticagrelor and clopidogrel with regards to the primary composite endpoint (10.6 vs 13.1%; HR, 0.84; 95% CI, 0.60 to 1.16; P=0.2862). There was no difference between ticagrelor and clopidogrel in the rate of major CABG-related bleeding (81.3 vs 80.1%; HR, 1.01; 95% CI, 0.90 to 1.15; P=0.84). Secondary: Rates of MI (excluding silent) (6.0 vs 5.7%; HR, 1.06; 95% CI, 0.66 to 1.68; P=0.8193) and stroke (2.1 vs 2.1%; HR, 1.17; 95% CI, 0.53 to 2.62; P=0.6967) were not different between the two treatments. The rate of vascular death was significantly less with ticagrelor (4.1 vs 7.9%; HR, 0.52; 95% CI, 0.32 to 0.85; P=0.0092). The rate of all-cause mortality was significantly less with ticagrelor (4.7 vs 9.7%; HR, 0.49; 95% CI, 0.32 to 0.77; P=0.0018).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.				The rates of life-threatening or fatal CABG-related bleeding were not different between the two treatments (42.6 vs 43.7%; HR, 1.02; 95% CI, 0.87 to 1.21; P=0.77).
Wallentin et al.[84] (2010) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless	Genetic (CYP 2C19 and ABCB1) substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation	N=10,285 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; major bleeding (loss-of-function allele) Secondary: Composite endpoint of vascular death or MI, definite stent thrombosis, major bleeding (gain-of-function allele), other bleeding events, net clinical benefit	Primary: In patients with any loss-of-function allele, ticagrelor was associated with significantly fewer composite events compared to clopidogrel (8.3 vs 10.7%; HR, 0.77; 95% CI, 0.60 to 0.99; P=0.0380). In patients with any loss-of-function allele, there was no difference in the rate of major bleeding between ticagrelor and clopidogrel (10.8 vs 10.4%; HR, 1.04; 95% CI, 0.82 to 1.30; P=0.77). Secondary: In patients with any loss-of-function allele, ticagrelor was association with significantly fewer events with regards to the composite of vascular death or MI (7.4 vs 9.9%; HR, 0.73; 95% CI, 0.51 to 0.95; P=0.0184). In patients with any loss-of-function allele, the rate of definite stent thrombosis was not different between the two treatments (1.6 vs 2.2%; HR, 0.71; 95% CI, 0.36 to 1.37; P=0.30). In patients with any gain-of-function allele, the rate of major bleeding was not different between the two treatments (9.5 vs 10.8%; HR, 0.86; 95% CI, 0.71 to 1.05; P=0.13).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.				In patients with any loss-of-function allele, the rates of non-CABG-related major (4.1 vs 3.0%; HR, 1.39; 95% CI, 0.93 to 2.08; P=0.11) and CABG-relate major bleeding (7.0 vs 7.8%; HR, 0.87; 95% CI, 0.66 to 1.14; P=0.31) were not different between the two treatments. In patients with any loss-of-function allele, the net clinical benefit was not different between the two treatments (14.7 vs 16.6%; HR, 0.88; 95% CI, 0.72 to 1.06; P=0.17). In patients with no loss-of-function, clopidogrel was significantly favored (13.4 vs 15.2%; HR, 0.86, 95% CI, 0.76 to 0.97; P=0.0172).
Mahaffey et al.[85] (2011) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who	Substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation who received treatment in the United States	N=1,413 12 months	Primary: Composite endpoint of the vascular death, MI, or stroke; major bleeding Secondary: Individual components of the primary composite endpoint, all-cause mortality, other bleeding events	Primary: Within the United States, there was no difference in the rate of the primary composite endpoint between ticagrelor and clopidogrel (11.9 vs 9.5%; HR, 1.27; 95% CI, 0.92 to 1.75; P=0.1459). For the rest of world, ticagrelor was significantly favored (9.0 vs 11.0%; HR, 0.81; 95% CI, 0.74 to 0.90; P<0.001). Within the United States, there was no difference in the rates of major bleeding between ticagrelor and clopidogrel (11.3 vs 11.0%; HR, 1.05; 95% CI, 0.76 to 1.45; P=0.7572). Secondary: Within the United States, the rates of vascular death (3.4 vs 2.7%; HR, 1.26; 95% CI, 0.69 to 2.31; P=0.4468), MI (9.1 vs 6.7%; HR, 1.38; 95% CI, 0.95 to 2.01; P=0.0956) and stroke (1.0 vs 0.6%; HR, 1.75; 95% CI, 0.51 to 0.597; P=0.3730) were not different between the two treatments. For the rest of world, ticagrelor was significantly favored for reducing vascular death (3.8 vs 4.9%; HR, 0.77; 95% CI, 0.67 to 0.89; P=0.0005) and MI (5.1 vs 6.4%; HR, 0.80; 95% CI, 0.70 to 0.90; P=0.0004). Within the United States, the rate of all-cause mortality was not different between the two treatments (4.0 vs 3.4%; HR, 1.17; 95% CI, 0.68 to 2.01; P=0.5812). For the rest of world, ticagrelor was significantly favored (4.3 vs 5.6%; HR, 0.77; 95% CI, 0.67 to 0.88; P=0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.				Within the United States, the rates of non-CAGB-related major (4.3 vs 3.7%; HR, 1.20; 95% CI, 0.70 to 2.04; P=0.5115) and major or minor bleeding (14.8 vs 13.6%; HR, 1.11; 95% CI, 0.84 to 1.84; P=0.4599) were not different between the two treatments. For the rest of the world, clopidogrel was significantly favored (3.9 vs 3.3%; HR, 1.19; 95% CI, 1.01 to 1.39; P=0.0330 and 14.5 vs 13.2%; HR, 1.11; 95% CI, 1.02 to 1.20; P=0.0114). For the entire population, results for the overall cohort yields an HR of 1.45 (95% CI, 1.01 to 2.09) favoring clopidogrel for maintenance aspirin doses ≥300 mg/day and HR of 0.77 (95% CI, 0.69 to 0.86) favoring ticagrelor for a maintenance aspirin dose ≤100 mg/day. The interaction between aspirin dose category and treatment is significant (P=0.00006). Within the United States, for patients receiving daily aspirin doses ≥300 mg, the event rate was 40 vs 27 with ticagrelor and clopidogrel (HR, 1.62; 95% CI, 0.99 to 2.94). The event rate was 19 vs 24 in patients receiving ≤100 mg/day of aspirin (HR, 0.73; 95% CI, 0.40 to 1.33).
Storey et al.[86] (2011) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day	Substudy of PLATO Adult patients hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation	N=199 12 months	Primary: FEV_1 after the completion of study treatment (six, nine, or 12 months depending on phase of entry into the PLATO trial) Secondary: FEV_1 after one month of treatment and one month after the discontinuation of treatment, other measures of pulmonary	Primary: FEV_1 values at the different evaluated time points were similar between treatments before and 20 minutes after inhalation of a β agonist (P values not reported). Secondary: There was no apparent change in FEV_1 before and 20 minutes after inhalation of a β agonist over time with either treatment and after the discontinuation of the study medication (P value not reported). Similar numbers of ticagrelor- and clopidogrel-treated patients showed >10% improvement in FEV_1 over time (seven and 12), with similar numbers of these patients showing improvement at the first visit after inhaled β agonist. The results of other pulmonary function parameters were also similar between the two treatments, with no apparent change over time and after discontinuation of study medication. Dyspnea or heart failure was noted in six and seven patients receiving

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.			function, safety	ticagrelor and clopidogrel; pulmonary function parameters for these patients were consistent with findings in the rest of the treatment cohorts.
James et al.[87] (2012) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant.	Substudy of PLATO Adult patients with and without a history of prior stroke or TIA and who were hospitalized with documented ACS within the previous 24 hours, with or without ST-segment elevation	N=18,624 12 months	Primary: Composite endpoint of the vascular death, MI or stroke and major bleeding Secondary: Components of primary composite endpoint and all-cause mortality	Primary: A total of 1,152 patients (6.2%) had a history of stroke or TIA. Overall, patients with prior history of stroke had higher rates of the primary composite endpoint compared to those without prior stroke or TIA; however, safety and efficacy in these patients were similar in the overall study population. The RR reduction of the primary composite endpoint with ticagrelor compared to clopidogrel was similar in patients with (HR, 0.87) and without (HR, 0.84) prior stroke or TIA (P=0.84). The risk of major bleeding with ticagrelor vs clopidogrel in patients with prior history of stroke or TIA was similar in patients without prior history (P=0.77). Secondary: When comparing patients with prior history of stroke or TIA to those without prior history, the RR reduction of cardiovascular death (P=0.42), MI (P=0.19) and overall stroke (P=0.89) was similar. The HR of all-cause mortality with ticagrelor compared to clopidogrel was 0.62 in patients with prior stroke or TIA and 0.81 in those without a prior

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.				history (P=0.19).
Kotsia et al.[88] (2014) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve,	Substudy of PLATO Patients enrolled in the PLATO trial with extensive CAD (defined as 3-vessel disease, left main disease, or prior CABG irrespective of graft patency)	N=15,388 (4,646 with extensive CAD; 10,742 without extensive CAD) 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; total major bleeding Secondary: Composite endpoint of all-cause mortality, MI, or stroke; composite endpoint of vascular death, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, TIA, or other arterial thrombotic event; components of the primary endpoint; all-cause mortality; stent	Primary: Patients with extensive CAD had 2.32-fold higher risk for the primary composite end point compared with those without extensive CAD (16.3 vs 7.4%, P<0.0001). Ticagrelor, compared with clopidogrel, reduced the composite end point to a similar extent by 15% both in patients with extensive CAD (14.9 vs 17.6%; HR, 0.85; 95% CI, 0.73 to 0.98) and in patients without extensive CAD (6.8 vs 8.0%; HR, 0.85; 95% CI, 0.74 to 0.98; P=0.99). The absolute risk reduction with the use of ticagrelor was higher in patients with extensive CAD compared with patients without extensive CAD (2.7 vs 1.2%, respectively). Major bleeding was similar with ticagrelor vs clopidogrel among patients without (7.3 vs 6.4%; HR, 1.14; 95% CI, 0.98 to 1.33) and with (25.7 vs 25.5%; HR, 1.02; 95% CI, 0.90 to 1.15; P =0.24) extensive CAD. Secondary: The absolute risk reduction in all-cause death was higher in patients with extensive CAD compared with patients without extensive CAD (2.3 vs 0.6%, respectively). There was also a similar relative decrease with the use of ticagrelor, regardless of CAD extent, in all-cause mortality (24% in patients with extensive CAD vs 16% in patients without extensive CAD; P=0.53), MI (12 vs 20%; P=0.44), and stent thrombosis (20 vs 29%, P=0.57).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for 6 months.			thrombosis; other bleeding events; safety	
Brilakis et al.[89] (2013) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose.	Substudy of PLATO Patients enrolled in the PLATO trial who had undergone prior CABG	N=1,133 (prior CABG) N=17,480 (no prior CABG) 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; total major bleeding Secondary: Composite endpoint of all-cause mortality, MI, or stroke; composite endpoint of vascular death, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, TIA, or other arterial thrombotic event; components of the primary endpoint; all-cause mortality; stent thrombosis; other bleeding events; safety	Primary: The incidence of the primary end point was reduced by ticagrelor by 16% in patients without prior CABG (9.2% ticagrelor vs 11.0% clopidogrel) and by 10% in patients with prior CABG (19.6 vs 21.4%; P =0.66). The incidence of MI was reduced by 16% in patients without prior CABG and by 9% in patients with prior CABG. The incidence of major bleeding was similar in patients receiving ticagrelor vs clopidogrel in both the prior-CABG and the no-prior-CABG subgroup. The adjusted hazard ratio for the primary end point for ticagrelor vs clopidogrel in the prior-CABG and no-prior-CABG groups was 0.91 (95% CI, 0.67 to 1.24) for prior CABG and 0.86 (95% CI, 0.77 to 0.96) for no prior CABG (P=0.7347). Secondary: The adjusted HR for all-cause death was 1.17 (95% CI, 0.72 to 1.89) for prior CABG and 0.82 (95% CI, 0.70 to 0.96) for no prior CABG (P=0.1757); and that for major bleed was 0.89 (95% CI, 0.55 to 1.47) for prior CABG and 1.08 (95% CI, 0.98 to 1.20) for no prior CABG (P=0.4570).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
In patients receiving a stent, 325 mg was allowed for 6 months.				
Kohli et al.[90] (2013) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent,	Substudy of PLATO Patients enrolled in the PLATO trial who experienced a primary end point event during follow-up for 6 to 12 months	N=1,570 (developed 1 event) N=318 (recurrent events) 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; total major bleeding Secondary: Composite endpoint of all-cause mortality, MI, or stroke; composite endpoint of vascular death, MI, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, TIA, or other arterial thrombotic event; components of the primary endpoint; all-cause mortality; stent thrombosis; other bleeding events; safety	Primary: The first occurrence of the primary end point of the trial (CVD/MI/stroke) was reduced (HR, 0.84; 95% CI, 0.77 to 0.92; P<0.001) in patients on ticagrelor as compared with clopidogrel. The hazard for the time to second occurrence of this composite end point or all-cause death was also significantly reduced by ticagrelor (HR, 0.80; 95% CI, 0.70 to 0.90; P<0.001). With respect to total number of events during the trial, ticagrelor resulted in fewer total CVD/MI/Stroke events as compared to clopidogrel (1057 vs 1225; NNT=54). Beyond the first event, there were numerically fewer additional events with ticagrelor (189 vs 205; P=0.40). Potent platelet inhibition resulted in no difference in first, second, or total occurrences of major bleeding. In an on-treatment cohort, there were 961 first occurrences of PLATO major bleeding events with ticagrelor, compared with 929 with clopidogrel (HR, 1.04; P=0.43). Secondary: Ticagrelor also effectively reduced the hazard for time to first of any atherothrombotic event to 0.88 (95% CI, 0.82 to 0.95; P<0.001). Recurrent events were similarly reduced (740 vs 834; P=0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
325 mg was allowed for 6 months.				
Patel et al.[91] (2015) PLATO Ticagrelor 180 mg loading dose, followed by 90 mg BID vs clopidogrel 300 mg loading dose, followed by 75 mg QD Patients received aspirin 70 to 100 mg/day maintenance therapy, unless intolerant. For patients who were aspirin-naïve, 325 mg was the preferred loading dose. In patients receiving a stent, 325 mg was allowed for six months.	Substudy of PLATO Patients enrolled in the PLATO trial stratified according to reported PAD status at baseline	N=18,624 12 months	Primary: Composite endpoint of vascular death, MI, or stroke; total major bleeding Secondary: Not reported	Primary: At one year, CV death, MI, or stroke occurred in 19.3% of patients with PAD (n=1144) compared to 10.2% in patients without PAD (P<0.001). The Kaplan-Meier one year event rate for the primary composite endpoint in PAD patients treated with ticagrelor as compared with clopidogrel, was 18 vs 20.6% (HR, 0.85; 95% CI, 0.64 to 1.11; for PAD status by treatment interaction, P=0.99) and for death from any cause 8.7 vs 11.9%, (HR, 0.74; 95% CI, 0.50 to 1.08; interaction P=0.73). PLATO-defined major bleeding event rates at one year were 14.8% for ticagrelor compared to 17.9% for clopidogrel, (HR, 0.81; 95% CI, 0.59 to 1.10; interaction P=0.09). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Jackson et al.[92] (2015) TRANSLATE-ACS Aspirin plus anticoagulant plus clopidogrel (triple-C) vs aspirin plus anticoagulant plus prasugrel (triple-P) vs aspirin plus clopidogrel (dual-C) vs aspirin plus prasugrel (dual-P)	OBS, PRO Patients in the United States who had either ST-segment elevation myocardial infarction (STEMI) or non-STEMI treated with PCI and a P2Y12 receptor inhibitor during their index hospitalization	N=11,756 15 months	Primary: Post-discharge bleeding and major adverse cardiovascular events (MACE) during the 6-month follow-up period after the index MI hospitalization Secondary: Not reported	Primary: Of 11,756 MI patients, 526 (4.5%) were discharged on triple-C, 91 (0.8%) on triple-P, 7,715 (66%) on dual-C, and 3,424 (29%) on dual-P. At six months post-discharge, triple-C was associated with a significantly higher risk of any BARC-defined bleeding compared with dual-C after multivariable analysis (28.7 vs 19.7%; adjusted incidence rate ratio [IRR], 1.68; 95% CI, 1.29 to 2.18; P=0.0001). Similarly, triple-P was associated with significantly higher any BARC bleeding compared with dual-P (38.5 vs 26.7%; adjusted IRR, 1.88; 95% CI, 1.10 to 3.20; P=0.02). Among patients treated with triple therapy, triple-P was associated with significantly higher bleeding compared with triple-C (39.0 vs. 24.4%; adjusted IRR, 2.37; 95% CI, 1.36 to 4.15; P=0.003). There were no statistically significant differences in risk-adjusted MACE between groups. Secondary: Not reported
Tricoci et al.[12] (2012) TRACER Vorapaxar loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter vs	DB, MC, RCT Adults with acute symptoms of coronary ischemia within 24 hours before hospital presentation and at least one of the following findings: a cardiac troponin or creatine kinase MB	N=12,944 Median follow-up period of 502 days	Primary: Composite of death from CV causes, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization; composite of moderate or severe bleeding according	Primary: The primary efficacy endpoint corresponded to a 2-year rate of 18.5% in the vorapaxar group and 19.9% in the placebo group (HR in the vorapaxar group, 0.92; 95% CI, 0.85 to 1.01; P=0.07). Vorapaxar increased the rate of GUSTO moderate or severe bleeding, as compared with placebo (7.2 vs 5.2%; HR, 1.35; 95% CI, 1.16 to 1.58; P<0.001). The rate of clinically significant TIMI bleeding was increased among patients treated with vorapaxar (20.2 vs 14.6%; HR, 1.43; 95% CI, 1.31 to 1.57; P<0.001). The excess bleeding events continued to accrue during follow-up. The vorapaxar group also had higher rates of GUSTO severe bleeding (P<0.001), TIMI major bleeding (P<0.001), and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo Either treatment in addition to physician-guided standard therapy	level that was higher than the upper limit of the normal range or new ST-segment depression or transient ST-segment elevation (<30 minutes). Also required were one or more of the following four criteria: age ≥ 55 years; previous MI, PCI, or CABG; diabetes mellitus; or PAD.		to the GUSTO classification and clinically significant bleeding according to the TIMI classification Secondary: Composite of death from CV causes, MI, or stroke	intracranial hemorrhage (P<0.001), with an incremental risk over time. Rates of CABG-related bleeding during the index hospitalization did not differ significantly between the two study groups, and rates of reoperation for bleeding and fatal bleeding were similar. Secondary: The key secondary end point occurred in 822 patients in the vorapaxar group and 910 patients in the placebo group, for 2-year Kaplan–Meier estimates of 14.7% and 16.4%, respectively (HR, 0.89; 95% CI, 0.81 to 0.98; P=0.02). Among the individual components of the efficacy end points, the reduction in the rate of MI was the main effect observed in the vorapaxar group, as compared with the placebo group (11.1 vs 12.5% at 2 years; HR, 0.88; 95% CI, 0.79 to 0.98; P=0.02). A reduction in the rate of type 1 (spontaneous) MI in the vorapaxar group largely accounted for the difference (5.6 vs 6.8%).
Leonardi et al.[93] (2013) TRACER Vorapaxar loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter vs placebo Either treatment in addition to physician-guided standard therapy	Outcome analysis of TRACER (exploratory subanalysis) Patients enrolled in the TRACER trial with an outcome of MI	N=12,944 (1,580 MIs occurred, including recurrent events) Median follow-up period of 502 days	Primary: First occurrence of MI, incidence of MI Secondary: Not reported	Primary: Compared with placebo, vorapaxar reduced the hazard of a first MI of any type by 12% (HR, 0.88; 95% CI, 0.79 to 0.98; P=0.021). The effect of vorapaxar was similar when the endpoint included all MIs, including recurrent MIs after the first event (HR 0.86; 95% CI, 0.77 to 0.97; P=0.014). A type 1 (spontaneous) MI occurred in 5.9% of patients in the vorapaxar group and in 7.0% of patients of the placebo group (HR, 0.83; 95% CI, 0.73 to 0.95; P=0.007). Vorapaxar effect on MI was consistent across key subgroups, and no interaction test was statistically significant. Secondary: Not reported
Whellan et al.[94] (2014) TRACER	Subgroup analysis of TRACER	N=1,312 (of 12,944 total patients;	Primary: Composite of death from CV causes,	Primary: In patients undergoing CABG during index hospitalization (N=1,312), the primary endpoint occurred in 43 patients in the vorapaxar group and in 70

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Vorapaxar loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter vs placebo Either treatment in addition to physician-guided standard therapy	Patients enrolled in the TRACER trial undergoing CABG	10.1%) Median follow-up period of 502 days	MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization; composite of moderate or severe bleeding according to the GUSTO classification and clinically significant bleeding according to the TIMI classification Secondary: Composite of death from CV causes, MI, or stroke	patients in the placebo group (2-year Kaplan-Meier rates: 8.2 and 12.9%, respectively), corresponding to a 45% reduction (adjusted HR: 0.55; 95% CI: 0.36 to 0.83; P=0.005). The CABG-related TIMI major bleeding was not a statistically significant difference between vorapaxar and placebo, although it was numerically higher with vorapaxar (HR: 1.36; 95% CI: 0.92 to 2.02; P=0.12), as it was for GUSTO severe bleeding related to CABG (HR: 1.35; 95% CI: 0.80 to 2.29; P=0.26). Secondary: Vorapaxar was also associated with lower occurrence of the key secondary endpoint (43 events; 2-year Kaplan-Meier rate of 8.2%) compared with placebo (58 events; 2-year Kaplan-Meier rate of 10.2%) in patients undergoing CABG (adjusted HR: 0.66; 95% CI: 0.43 to 1.01; P=0.057).
Mahaffey et al.[95] (2014) TRACER Vorapaxar loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter vs placebo Either treatment in addition to	Subgroup analysis of TRACER Patients enrolled in the TRACER trial stratified by aspirin dose (low, ≤100 mg; medium, >100 and <300 mg; high, ≥300 mg)	N=12,944 (7,523, 1,049, and 3,943 participants were treated with low-, medium-, and high-dose ASA at baseline, respectively) Median follow-up period of 502	Primary: Composite of death from CV causes, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization; composite of moderate or severe bleeding according to the GUSTO classification and clinically significant	Primary: Participants treated with ≥300 mg ASA had higher event rates compared with participants treated with ≤100 mg ASA. There were no statistically significant interactions between vorapaxar effect and ASA dose. Compared with participants treated with ≤100 mg of ASA, participants treated with ≥300 mg ASA had similar GUSTO severe bleeding event rates and slightly higher TIMI major bleeding rates. There were no statistically significant interactions between study treatment effect on bleeding and ASA dose. The unadjusted and adjusted hazard ratios in participants treated with ≤100 versus ≥300 mg of ASA suggested a trend toward more prominent bleeding risk associated with vorapaxar compared with placebo. Secondary: There were no statistically significant interactions between vorapaxar

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
physician-guided standard therapy		days	bleeding according to the TIMI classification Secondary: Composite of death from CV causes, MI, or stroke	effect and ASA dose.
Valgimigli et al.[96] (2014) TRACER Vorapaxar loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter vs placebo Either treatment in addition to physician-guided standard therapy	Subgroup analysis of TRACER Patients enrolled in the TRACER trial who underwent PCI during the index hospitalization	N=12,944 (7,479 patients [57.8%] underwent PCI) Median follow-up period of 502 days	Primary: Composite of death from CV causes, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization; composite of moderate or severe bleeding according to the GUSTO classification and clinically significant bleeding according to the TIMI classification Secondary: Composite of death from CV causes, MI, or stroke	Primary: At 2 years after the index PCI, the primary efficacy end point occurred in 15.6% of patients who received vorapaxar and 16.7% of patients who received placebo (adjusted HR, 0.96; 95% CI, 0.84 to 1.09). The cumulative incidence of hemorrhage was overall increased with vorapaxar. The relative increase of intracranial hemorrhage with vorapaxar was lesser in patients undergoing PCI compared with those not undergoing PCI, with a borderline statistical significant interaction (P=0.073). Secondary: The secondary end point occurred in 10.6% of patients who received vorapaxar and 12.5% of patients who received placebo (adjusted HR, 0.90; 95% CI, 0.78 to 1.05).
Procedures and/or Surgery				
Leon et al.[97] (1998) Aspirin 325 mg QD	MC, RCT Patients undergoing stent implantation	N=1,653 30 days	Primary: Composite of death, revascularization	Primary: The primary end point was observed in 38 patients: 3.6% assigned to aspirin alone, 2.7% assigned to aspirin plus warfarin and 0.5% assigned to aspirin plus ticlopidine (P=0.001 for the comparison of all 3 groups).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs aspirin 325 mg QD and warfarin (dose adjusted to INR 2.0 to 2.5) vs aspirin 325 mg QD and ticlopidine 250 mg BID			of target lesion, angiographically evident thrombosis or MI within 30 days Secondary: Achievement of <50% residual stenosis without death or emergency bypass surgery, procedure-related MI, hematologic dyscrasias, hemorrhagic and vascular surgical complications	Secondary: Compared to aspirin alone, and aspirin plus warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis (P=0.001) following coronary stenting. Hemorrhagic complications occurred in 10 patients: 1.8% with aspirin alone, 6.2% with aspirin plus warfarin and 5.5% with aspirin plus ticlopidine (P<0.001 for the comparison of all 3 groups); the incidence of vascular surgical complications was 0.4, 2.0, and 2.0%, respectively (P=0.02). There were no significant differences in the incidence of neutropenia or thrombocytopenia among the 3 treatment groups and the overall incidence was 0.3%.
Ahn et al.[98] (2008) CIDES Aspirin 100 to 200 mg/day and cilostazol 200 mg/day vs aspirin 100 to 200 mg/day and clopidogrel 75 mg/day	MC, RCT Diabetic patients who underwent successful stenting	N=280 7.1 months (mean duration)	Primary: Change in luminal diameter Secondary: Rate of angiographic restenosis	Primary: The minimal luminal diameter at follow-up period for the aspirin and cilostazol group was 2.55 mm compared to 2.4 mm in the aspirin and clopidogrel group (P value not significant). Secondary: The rate of angiographic restenosis (stent plus 5-mm borders) was 9 (8.0%) in the aspirin and cilostazol group and 20 (16.1%) in the aspirin and clopidogrel group (P=0.041).
Lee et al.[99] (2008) DECLARE-	MC, PRO, RCT Diabetic patients	N=400 9 months	Primary: In-stent late loss at six months	Primary: At six months, the in-stent late loss was significantly lower in the triple therapy vs dual therapy group (0.25 vs 0.38 mm; P=0.025).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
DIABETES Aspirin 200 mg/day and clopidogrel 300 mg loading dose, followed by 75 mg QD vs aspirin 200 mg/day, clopidogrel 300 mg loading dose, followed by 75 mg QD, and cilostazol 200 mg loading dose, followed by 100 mg BID	≥18 years of age undergoing drug-eluting stent implantation		Secondary: In-segment late loss and restenosis rate at six months; stent thrombosis, target vessel revascularization, major adverse cardiac events (death, MI, and target lesion revascularization) at 9 months; safety	Secondary: At six months, the in-segment late loss (0.42 vs 0.53 mm; P=0.031) and restenosis (8.0 vs 15.6%; P=0.033) were significantly lower in the triple therapy vs dual therapy group. At 9 months, there was no difference in the rate of stent thrombosis (0.0 vs 0.5%; P=0.999). Target vessel revascularization was lower in the triple therapy vs dual therapy group (3.5 vs 8.0%; P=0.053). At 9 months, major adverse cardiac events tended to be lower in the triple therapy than in the dual therapy group (3.0 vs 7.0%; P=0.066). Drug discontinuation was more common in the triple therapy vs dual therapy group (14.5 vs 2.5%; P<0.001) with skin rash and gastrointestinal disturbance the most common reasons for termination of cilostazol.
Han et al.[100] (2009) Aspirin 300 mg QD for 1 month, followed by 100 mg QD and clopidogrel 300 ti 600 mg loading dose, followed by 75 mg QD vs aspirin 300 mg QD for 1 month, followed by 100 mg QD, clopidogrel 300 to 600 mg	OL Patients aged 20 to 80 years admitted with ACS (unstable angina, NSTEMI, or STEMI) undergoing successful coronary stenting	N=1,212 12 months	Primary: Major adverse cardiac or cerebral event at one year (defined as the composite of cardiac death, nonfatal MI, stroke, or target vessel revascularization) Secondary: Bleeding events at one year	Primary: Triple-antiplatelet treatment was associated with a significantly lower incidence of the primary end points (10.3 vs 15.1%; P=0.011). The need for target vessel revascularization was similar between patients who received triple- and dual-antiplatelet treatment (7.9 vs 10.7%; P=0.10). Multivariate analysis showed that female patients and clinically or angiographically high-risk patients benefited more from the triple-antiplatelet treatment. Secondary: There were no significant differences between the two regimens in terms of the risks for major and minor bleeding.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
loading dose, followed by 75mg QD and cilostazol 100 mg BID				
Jeong et al.[101] (2009) ACCEL-RESISTANCE Aspirin 200 mg QD, clopidogrel 75 mg QD, and cilostazol 200 mg/day vs aspirin 200 mg QD and clopidogrel 150 mg QD	RCT Patients with high post-treatment platelet reactivity undergoing coronary stenting	N=60 30 days	Primary: Platelet function Secondary: Not reported	Primary: After 30 days, significantly fewer patients in the triple vs high maintenance dose group had high post-treatment platelet reactivity (3.3 vs 26.7%; P=0.012). Percent inhibitions of 5 µmol/l ADP-induced Agg_{max} and late platelet aggregation (Agg_{late}) were significantly greater in the triple vs high maintenance group (51.1±22.5 vs 28.0±18.5%; P<0.001, and 70.9±27.3 vs 45.3±23.4%; P<0.001, respectively). Percent inhibitions of 20 µmol/l ADP-induced Agg_{max} and Agg_{late} were consistently greater in the triple vs high maintenance dose group. Percent change of P2Y12 reaction units demonstrated a higher antiplatelet effect in the triple vs high maintenance dose group (39.6±24.1 vs 23.1±29.9%; P=0.022). Secondary: Not reported
Mehta et al.[102] (2001) PCI-CURE Aspirin and clopidogrel or placebo prior to PCI; after PCI, stented patients received OL clopidogrel or ticlopidine in combination with aspirin for 2 two 4	DB, RCT Patients with non-ST-elevation ACS from the CURE study undergoing PCI	N=2,658 Average duration of follow-up after PCI was 8 months	Primary: Composite of cardiovascular death, MI or urgent target-vessel revascularization within 30 days of PCI (main primary end point); cardiovascular death or MI from time of PCI to scheduled end of trial	Primary: A total of 4.5% of patients in the clopidogrel and aspirin group reached the primary end point compared to 6.4% in the aspirin group (P=0.03). Long-term administration of clopidogrel after PCI was associated with a lower rate of cardiovascular death, MI, or any revascularization (P=0.03) and of cardiovascular death or MI (P=0.047). Overall, clopidogrel was associated with a 31% reduction in cardiovascular death or MI, including events before and after PCI (P=0.002). At follow-up, there was no significant difference in major bleeding between the groups (P=0.64).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
weeks; then clopidogrel or placebo was resumed (for 3 two 12 months after initial randomization)			Secondary: Not reported	Secondary: Not reported
Takeyasu et al.[103] (2005) Cilostazol 200 mg/day and aspirin 81 to 200 mg/day vs ticlopidine 200 mg/day and aspirin 81 to 200 mg/day	OL, RCT Patients with ischemic heart disease receiving stents	N=642 6 months	Primary: Rate of stenosis according to qualitative coronary angiography analysis of minimal lumen diameter of artery, safety Secondary: Not reported	Primary: The rates of restenosis (27.8 vs 29.3%; P value not significant) and target lesion revascularization (22.4 vs 23.5%; P value not significant) were similar between patients receiving cilostazol and ticlopidine. The rate of subacute thrombosis was significantly greater with cilostazol than ticlopidine (2.5 vs 0.3%; P=0.02). There were no differences in the incidence of adverse reactions with the exception of purpura, which was reported more frequently with ticlopidine than cilostazol (1.0 vs 0.0%; P=0.045). Secondary: Not reported
Sabatine et al.[104] (2005) PCI-CLARITY Clopidogrel (300 mg loading dose, followed by 75 mg QD) plus aspirin (150 to 325 mg on the first day, followed by 75 to 162 mg QD) vs placebo plus aspirin	DB, MC, PC, RCT Patients with STEMI who received fibrinolytics and underwent PCI (after mandated angiography in CLARITY-TIMI 28)	N=1,863 30 days	Primary: Composite of cardiovascular death, recurrent MI or stroke from PCI to 30 days after randomization Secondary: MI or stroke before PCI and the primary end point from randomization to 30 days	Primary: Pretreatment with clopidogrel in patients receiving concurrent aspirin significantly reduced the primary end point following PCI compared to aspirin alone (3.6 vs 6.2%; adjusted OR, 0.54; 95% CI, 0.35 to 0.85; P=0.008). Pretreatment with clopidogrel and aspirin also reduced the incidence of MI or stroke prior to PCI (4.0 vs 6.2%; OR, 0.62; 95% CI, 0.40 to 0.95; P=0.03). Secondary: Overall, pretreatment with clopidogrel significantly reduced the secondary outcome (7.5 vs 12.0%; adjusted OR, 0.59; 95% CI, 0.43 to 0.81; P=0.001). There was no significant excess in the rates of major or minor bleeding in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(150 to 325 mg on the first day, followed by 75 to 162 mg QD)				patients receiving dual therapy vs aspirin alone (2.0 vs 1.9%, respectively; P>0.99).
Steinhubl et al.[105] (2002) CREDO Clopidogrel 300 mg loading dose (3 to 24 hours before PCI), then clopidogrel 75 mg QD through 12 months vs placebo (3 to 24 hours before PCI), then clopidogrel 75 mg QD through day 28, then placebo through 12 months All patients received aspirin 325 mg prior to PCI, then 325 mg QD through day 28, then 81m to 325 mg QD thereafter.	DB, MC, PC, RCT Patients undergoing PCI	N=2,116 12 months	Primary: One-year incidence of the composite of death, MI, or stroke; 28-day incidence of the composite of death, MI or urgent target vessel revascularization Secondary: Components of composite end points, administration of clopidogrel <6 hours or ≥6 hours before PCI, need for target vessel revascularization or any revascularization at one year	Primary: Long-term (one year) clopidogrel and aspirin therapy was associated with a 26.9% relative reduction in the combined risk of death, MI or stroke vs aspirin alone (95% CI, 3.9 to 44.4; P=0.02; absolute reduction, 3%). Clopidogrel pretreatment did not significantly reduce the combined risk of death, MI or urgent revascularization at 28 days (-18.5%; 95% CI, -14.2 to 41.8; P=0.23). Secondary: A similar level of benefit was found in the individual components of the primary end point at one year, although individual outcomes were not significant. Treatment randomization did not appear to influence the rate of target vessel revascularization or any other revascularization during the follow-up period. In a prespecified subgroup analysis, patients who had received clopidogrel at least 6 hours before PCI experienced a reduction in the relative combined risk of death, MI, or stroke by 38.6% (95% CI, -1.6 to 62.9; P=0.051) compared to no reduction when treatment was given less than 6 hours before PCI (P=0.051). Risk of major bleeding at one year increased, but not significantly (8.8% with clopidogrel vs 6.7% with aspirin alone; P=0.07).
Lev et al.[106] (2008) Clopidogrel 300 to 600 mg before PCI	PRO Patients with chest pain and STEMI undergoing	N=292 6 months	Primary: Occurrence of TIMI myocardial perfusion grade 3 after PCI	Primary: TIMI myocardial perfusion grade 3 occurred in a higher proportion of patients in the clopidogrel pretreatment group than in the no pretreatment group (85 vs 71%; P=0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs clopidogrel 300 to 600 mg immediately after PCI Patients were treated with aspirin before PCI, then aspirin and clopidogrel 75 mg QD for 3 to 12 months after PCI	emergency PCI		Secondary: Incidence of reinfarction, stent thrombosis, target vessel revascularization, death	Secondary: The incidence of reinfarction at 30 days (0.0 vs 3.2%, respectively; P=0.04) and six months (0.6 and 3.9%, respectively; P=0.09) was lower in the pretreatment group than in the no pretreatment group. The incidence of stent thrombosis at 30 days (0.0 vs 2.4%, respectively; P=0.08) and 6 months (0.0 and 3.9%, respectively; P=0.02) was lower in the pretreatment group than in the no pretreatment group. The incidence of death and target vessel revascularization were not significantly different between the two treatment groups at 30 days (P=0.6 and P=1.0) or six months (P=0.7 and P=0.9).
Banerjee et al.[107] (2008) Clopidogrel for ≥1 year following PCI vs clopidogrel for <1 year following PCI Patients were free of cardiovascular events for 6 months after PCI, and had follow-up available for >12 months.	RETRO Patients who underwent PCI	N=530 2.4±0.8 years (mean follow-up)	Primary: All cause mortality Secondary: Incidence of major adverse cardiovascular events (composite of all cause death, nonfatal MI and repeat coronary revascularization by PCI or CABG)	Primary: Twelve (3.5%) patients who received clopidogrel for ≥1 year died compared to 28 (15%) patients who received clopidogrel for <1 year (P<0.001). On a multivariate analysis, the use of clopidogrel for ≥1 year was associated with lower mortality (HR, 0.28; 95% CI, 0.14 to 0.59; P<0.001), independent of traditional cardiovascular risk factors, clinical presentation and drug eluting stent use. Survival in the <1 and ≥1 year clopidogrel groups was 97 and 99%, respectively, at two years after PCI, and 80 and 93%, respectively, at three years after PCI. Secondary: There were no significant differences in the incidence of nonfatal MI (P=0.50), repeat coronary revascularization (P=0.16) or major adverse cardiovascular events between the two groups (P=0.10). Patients who experienced major adverse cardiovascular events were significantly older and had preexisting CAD, and those who died were more likely to have chronic renal disease and heart failure.
Han et al.[108]	RCT	N=813	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2009) Clopidogrel 600 mg once, followed by 75 mg/day vs clopidogrel 600 mg once, followed by 150 mg/day All patients received aspirin 300 mg/day. All patients received dual antiplatelet therapy on admission followed by maintenance dose administration according to study protocol and PCI was performed within 48 hours of admission.	Patients ≥18 years of age, diagnosed with ACS, planned pretreatment with 600 mg clopidogrel loading dose, presence of ≥1 severe coronary stenosis requiring PCI located in native arteries and suitable for drug eluting stent implantation	30 days	Major adverse cardiac event (composite of cardiac death, nonfatal MI and urgent target vessel revascularization) Secondary: Stent thrombosis, major and minor bleeding events	A total of 13 patients reached the primary end points, including four (1.0%) patients in the 150 mg group and nine (2.2%) patients in the 75 mg group (P>0.05). There was no significant difference in cumulative major adverse cardiac event-free survival between the two groups. The incidences of MI (two vs five; P>0.05), urgent target vessel revascularization (three vs eight; P>0.05) and cardiac death (one vs one; P>0.05) were similar between the two groups. Secondary: The incidence of stent thrombosis (zero vs six; P<0.05) was significantly lower in the 150 mg group compared to the 75 mg group. There was no significant differences between both groups regarding the risk of major (one vs zero; P>0.05) or minor (two vs one; P>0.05) bleedings.
Valgimigli et al.[109] (2012) PRODIGY Clopidogrel 300 or 600 mg once, followed by 75 mg/day plus aspirin 160 to 325 mg orally or 500 mg	MC, OL, RCT Patients ≥18 years of age with chronic stable CAD, NSTEMI or STEMI ACS who were receiving a stent placement	N=2,013 24 months	Primary: Composite of death of any cause, nonfatal MI and cerebrovascular accident Secondary: Components of the composite primary	Primary: The cumulative risk of the primary endpoint at 24 months was 10.1% in the 24- month group and 10.0% in the six-month group (HR, 0.98; 95% CI, 0.74 to 1.29; P=0.91). Secondary: When individual components were analyzed separately, there were no differences between the six-month and 24-month groups with regard to risks of death of any cause (6.6% for both; HR, 1.00; 95% CI, 0.72 to 1.40; P=0.98), nonfatal MI (4.2 vs 4.0%; HR, 1.06; 95% CI, 0.69 to 1.63;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
intravenously once, followed by 80 to 160 mg/day for six months vs clopidogrel 300 or 600 mg once, followed by 75 mg/day plus aspirin 160 to 325 mg orally or 500 mg intravenously once, followed by 80 to 160 mg/day for 24 months Patients in the six-month group who received bare metal stent were allowed to discontinue treatment after 30 days.			endpoint, cardiovascular death, stent thrombosis and bleeding outcomes	P=0.80), cerebrovascular accident (1.4 vs 2.1%; HR, 0.60; 95% CI, 0.29 to 1.23; P=0.17), cardiovascular death (3.8 vs 3.7%; HR, 1.03; 95% CI, 0.66 to 1.61; P=0.89) and stent thrombosis (4.7 vs 3.9%; HR, 1.21; 95% CI, 0.79 to 1.86; P=0.38). Safety end point was a composite end point of fatal bleeding, overt bleeding plus hemoglobin drop of ≥3 g/dL, bleeding that requires nonsurgical/medical intervention, bleeding that leads to hospitalization or increased level of care and bleeding that prompts evaluation. Dual-antiplatelet therapy for six months was associated with a lower risk of bleeding compared to the 24-month therapy (3.5 vs 7.4%; HR, 0.46; 95% CI, 0.31 to 0.69; P=0.00018).
Gwon et al.[110] (2012) EXCELLENT Clopidogrel 75 mg/day plus aspirin 100 to 200 mg/day for six months then aspirin alone for six months vs	MC, OL, PRO, RCT Korean patients with coronary vessel occlusion and who were undergoing PCI with drug-eluting stent placement	N=1,443 12 months	Primary: Target vessel failure defined as a composite of cardiac death, MI and target vessel revascularization Secondary: Components of the composite primary endpoint, death of	Primary: Incidence of target vessel failure was similar between the six- and 12-month dual antiplatelet treatment groups (4.8 vs 4.3%; HR, 1.14; 95% CI, 0.70 to 1.86). In the pre-specified subgroup analysis, the incidence of target vessel failure was higher with the six-month group compared to the 12-month group for patients with diabetes (HR, 3.16; 95% CI, 1.42 to 7.03). Secondary: No differences were seen between the six- and 12-month groups in the rate of cardiac death (0.3 vs 0.4%; HR, 0.67; 95% CI, 0.11 to 3.99), MI (1.8 vs

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
clopidogrel 75 mg/day plus aspirin 100 to 200 mg/day for 12 months All patients received aspirin ≥300 mg plus clopidogrel 300 to 600 mg once before PCI.			any cause, death or MI, stent thrombosis, major bleeding according to TIMI criteria, major adverse cardiocerebral events and composite safety endpoint	1.0%; HR, 1.86; 95% CI, 0.74 to 4.67) and target vessel revascularization (3.1 vs 3.2%; HR, 2.00; 95% CI, 0.75 to 5.34). Risk of death of any cause was 0.6 and 1.0% in the six-month and 12-month groups (HR, 0.57; 95% CI, 0.17 to 1.95). Death or MI occurred in 2.4 and 1.9% of patients in the six- and 12-month groups (HR, 1.21; 95% CI, 0.60 to 2.47). Incidence of stent thrombosis was higher with the six-month group but was not statistically different from the 12-month group (0.9 vs 0.1%; HR, 6.02; 95% CI, 0.72 to 49.96). Risk of TIMI major bleeding was similar between the six- and 12-month groups (0.3 vs 0.6%; HR, 0.5; 95% CI, 0.09 to 2.73). Risk of major cardiocerebral event, which is a composite of death, MI, stroke, stent thrombosis and any revascularization, was similar between the six- and 12-month groups (8.0 vs 8.5%; HR, 0.94; 95% CI, 0.65 to 1.35). Safety endpoint, defined as a composite of death, MI, stroke, stent thrombosis and TIMI major bleeding, was also similar between the six- and 12-month groups (3.3 vs 3.0%; HR, 1.15; 95% CI, 0.64 to 2.06).
CURRENT-OASIS 7.[111] (2010) Clopidogrel 600 mg once, followed by 150 mg/day for 6 days, followed by clopidogrel 75 mg/day through day 30 (double dose) vs	2x2 factorial design, RCT Patients ≥18 years of age who presented with a NSTE ACS or a STEMI	N=25,086 (n=17,263 underwent PCI) 30 days	Primary: Composite of cardiovascular death, MI or stroke Secondary: Composite of death from cardiovascular causes, MI, stroke or recurrent ischemia; the individual components of the	Primary: The primary outcome occurred in 4.2% of patients in the double-dose group compared to 4.4% with the standard dose group (HR, 0.94; 95% CI, 0.83 to 1.06; P=0.30). Overall, 4.2% of the patients in the high-dose aspirin group had a primary outcome event compared to 4.4% of patients in the low-dose aspirin group (HR, 0.97; 95% CI, 0.86 to 1.09; P=0.61). A nominally significant interaction between the clopidogrel dose comparison and the aspirin dose comparison for the primary outcome was noted (P=0.04). Among patients assigned to high-dose aspirin, the primary outcome occurred in 3.8 and 4.6% in the double and standard clopidogrel dose groups (HR, 0.82; 95% CI, 0.69 to 0.98; P=0.03). Among patients assigned to low-dose aspirin, there was no significant difference between

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
clopidogrel 300 mg once, followed by 75 mg/day for 6 days, followed by 75 mg/day through day 30 (standard dose) and aspirin ≥300 mg/day once, followed by 75 to 100 mg/day through day 30 (low-dose) vs aspirin ≥300 mg/day once, followed by 300 to 325 mg/day through day 30 (high-dose) All patients were to undergo early angiography and PCI, if appropriate, no later than 72 hours after randomization.			primary endpoint; death from any cause; bleeding	the double and standard clopidogrel groups (4.5 vs 4.2%; HR, 1.07; 95% CI, 0.90 to 1.26; P=0.46). Secondary: Consistent results were observed for each component of the primary outcome, as well as for the expanded composite endpoint for the clopidogrel and aspirin dose comparison. A nominally significant reduction in recurrent ischemia alone was associated with high-dose aspirin as compared to low-dose aspirin (0.3 vs 0.5%; HR, 0.63; 95% CI, 0.43 to 0.94; P=0.02). The rate of death from any cause did not differ significantly between the double and standard dose groups (2.3 vs 2.4%; HR with the double dose, 0.96; 95% CI, 0.82 to 1.13; P=0.61). Death from any cause occurred in 2.2 and 2.5% of patients in the high- and low-dose groups (HR, 0.87; 95% CI, 0.74 to 1.03; P=0.10). Major bleeding occurred in 2.5 and 2.0% of patients in the double and standard dose groups (HR, 1.24; 95% CI, 1.05 to 1.46; P=0.01). The aspirin groups did not differ significantly with respect to major bleeding (P value not reported). There was a nominally significant increase in the increase of minor bleeding among patients who received high-dose aspirin (HR, 1.13; 95% CI, 1.00 to 1.27; P=0.04). There was a small increase in the incidence of major gastrointestinal bleeding among patients who received high-dose aspirin, as compared to those who received low-dose aspirin (0.4 vs 0.2%; P=0.04).
Bertrand et al.[112] (2000) CLASSICS Clopidogrel 300 mg loading dose,	RCT Patients receiving a stent placement	N=1,020 28 days	Primary: Major peripheral or bleeding complications, neutropenia, thrombocytopenia	Primary: Primary end point occurred in 4.6% of patients in the combined clopidogrel group and in 9.1% of patients in the ticlopidine group (RR, 0.50; 95% CI, 0.31 to 0.81; P=0.005). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
followed by 75 mg QD and aspirin 325 mg QD vs clopidogrel 75 mg QD and aspirin 325 mg QD vs ticlopidine 250 mg BID and aspirin 325 mg QD			or early discontinuation due to noncardiac adverse event Secondary: Incidence of cardiac events	Overall rates of major adverse cardiac events (cardiac death, MI, target lesion revascularization) were low and comparable between treatment groups (1.2% with clopidogrel loading dose, 1.5% with clopidogrel without the loading dose and 0.9% with ticlopidine; P value not significant for all comparisons).
Isshiki et al.[113] (2012) CLEAN Clopidogrel 300 mg once, followed by 75 mg/day plus aspirin 81 to 100 mg/day vs ticlopidine 100 mg BID plus aspirin 81 to 100 mg/day	DB, MC, RCT Japanese patients ≥20 years of with stable angina or history of MI and who were undergoing PCI	N=931 12 weeks	Primary: Composite of clinically significant bleeding, blood disorders, elevated liver function tests and study drug discontinuation due to an adverse reaction Secondary: Composite of all-cause mortality, acute MI, revascularization, stent thrombosis or ischemic stroke	Primary: The composite primary endpoint occurred in 10.1% of patients in the clopidogrel group and 34.2% in the ticlopidine group (HR, 0.259; 95% CI, 0.187 to 0.359; P<0.0001). When individual components were analyzed separately, there were no differences between clopidogrel and ticlopidine with regard to the risks of clinically significant bleeding (0.9 vs 0.6%; HR, 1.328; 95% CI, 0.297 to 5.936) and blood disorder (1.7 vs 3.4%; HR, 0.495; 95% CI, 0.212 to 1.158). Clopidogrel was associated with lower risk of liver function test elevation (6.0 vs 30.3%; HR, 0.172; 95% CI, 0.115 to 0.258) and treatment discontinuation due to an adverse reaction (3.9 vs 13.1%; HR, 0.281; 95% CI, 0.166 to 0.476) compared to ticlopidine. Secondary: There was no difference in the cumulative risk of the composite cardiovascular endpoint between the clopidogrel and ticlopidine groups (9.2 vs 10.3%; HR, 0.886; 95% CI, 0.587 to 1.337). Acute MI was reported in 7.7 and 9.2% of patients in the clopidogrel and ticlopidine groups, revascularization in 1.5 and 0.4% of patients and ischemic stroke in 0.2 and 0.6% of patients in the respective treatment group (P values not reported). No death or stent thrombosis was reported during the study.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Gao et al.[114] (2009) Clopidogrel 75 mg/day and aspirin 100 mg/day vs clopidogrel 75 mg/day	RCT Patients undergoing elective CABG	N=197 12 months	Primary: CABG graft patency rates Secondary: Not reported	Primary: At 1 month and 12 months after CABG graft patency rates of clopidogrel monotherapy group were, respectively, 99.0 and 96.9% for the left internal mammary artery, and 98.1 and 93.5% for the saphenous vein grafts. Those of the dual antiplatelet therapy group were, respectively, 98.9 and 97.8% for left internal mammary artery, and 98.2 and 96.3% for saphenous vein grafts. Thus, there were no significant differences in graft patency between the two groups (P>0.05). Secondary: Not reported
Park et al.[115] (2010) Clopidogrel 75 mg/day and aspirin (100 to 200 mg/day) vs aspirin 100 to 200 mg/day	OL Patients who had undergone drug eluting stent implantation ≥12 months prior to enrollment, who had not had a major cardiovascular event, or major bleeding since implantation	N=2,701 19.2 months (mean duration)	Primary: First occurrence of MI or death from cardiac causes after assignment to a treatment group Secondary: Death from any cause	Primary: The cumulative risk of the primary outcome at two years was 1.8% with dual antiplatelet therapy, as compared to 1.2% with aspirin monotherapy (HR, 1.65; 95% CI, 0.80 to 3.36; P=0.17). Secondary: There was no significant difference between the two treatment groups in the risk of individual secondary end points. In the dual antiplatelet therapy group as compared to the aspirin-monotherapy group, there was a nonsignificant increase in the composite risk of myocardial infarction, stroke, or death from any cause (HR, 1.73; 95% CI, 0.99 to 3.00; P=0.051) and in the composite risk of myocardial infarction, stroke, or death from cardiac causes (HR, 1.84; 95% CI, 0.99 to 3.45; P=0.06).
Sibbing et al.[116] (2009) Clopidogrel 75 mg/day vs pantoprazole vs	CS, OB Patients on maintenance clopidogrel therapy scheduled for a coronary angiography who were also taking a PPI at the time point of platelet function testing	N=1,000 Duration varied	Primary: Platelet aggregation in patients treated with pantoprazole Secondary: Platelet aggregation in patients treated with omeprazole or esomeprazole	Primary: Those treated with pantoprazole (P=0.88) had similar platelet aggregation compared to those not treated with a PPI. Secondary: Those treated with omeprazole experienced significantly higher platelet aggregation compared to patients without PPI treatment (P=0.001). Those treated with esomeprazole (P=0.69) had similar platelet aggregation compared to those not treated with a PPI.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
omeprazole vs esomeprazole				
Trenk et al.[117] (2012) TRIGGER-PCI Prasugrel 60 mg loading dose followed by 10 mg/day vs clopidogrel 75 mg/day All patients received clopidogrel 600 mg loading dose plus aspirin ≥250 mg within 24 hours before PCI and one-time clopidogrel 75 mg the morning after PCI.	RCT Patients 18 to 80 years of age with stable CAD who underwent PCI with at least one drug-eluting stent placement and demonstrated high on-treatment platelet reactivity after clopidogrel loading dose followed by one-time clopidogrel 75 mg	N=423 6 months	Primary: Composite of cardiovascular death and MI and non-CABG-related TIMI major bleeding Secondary: Composite of cardiovascular death, MI and target vessel revascularization, composite of cardiovascular death, MI, stroke and rehospitalization for cardiac ischemic event and composite safety endpoint	Primary: Composite primary endpoint occurred in one patient in the clopidogrel group vs none in the prasugrel group (P>0.05). Non-CABG-related TIMI major bleeding occurred in three patients in the prasugrel group and one in the clopidogrel group (P>0.05). Secondary: Composite endpoint of cardiovascular death, MI and revascularization occurred in two patients in each treatment group (P>0.05). Composite endpoint of cardiovascular death, MI, stroke and rehospitalization for cardiac ischemic event occurred in two patients treated with prasugrel and six patients treatment with clopidogrel (HR, 0.493; 95% CI, 0.090 to 2.692). Secondary safety endpoint, a composite of any non-CABG-related bleeding, occurred in 2.9 and 1.9% in the prasugrel and clopidogrel groups, respectively (HR, 1.517; 95% CI, 0.428 to 5.376). The authors concluded that due to low event rate, the utility of prasugrel in patients with high on-treatment platelet reactivity could not be determined.
Wiviott et al.[9] (2007) Prasugrel 60 mg loading dose, followed by 10 mg/day	AC, DB, DD, RCT, XO Patients ≥18 years of age, who were scheduled to undergo cardiac catheterization with	N=201 28 days (treatment periods were 14 days each)	Primary: Inhibition of platelet aggregation with 20 μmol/L adenosine diphosphate at six hours during the	Primary: For the loading dose phase, mean inhibition of platelet aggregation with 20 μmol/L adenosine diphosphate at six hours was significantly greater (higher inhibition of platelet aggregation indication of greater antiplatelet effect) in the prasugrel group (74.8%) compared to the clopidogrel group (31.8%). The mean difference between the two groups was 43.2% (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs clopidogrel 600 mg loading dose, followed by 150 mg/day Maintenance dose administered upon PCI completion.	planned PCI for angina and ≥1 of the following: angiograph within 14 days with ≥1 PCI amendable legion, objective findings of ischemia within 8 weeks of study, or prior PCI or CABG		loading dose phase and at 14±2 days of the maintenance dose Secondary: Mean maximal platelet aggregation with 20 μmol/L adenosine diphosphate, mean $P2Y_{12}$ assay percent inhibition, safety	For the maintenance dose phase mean inhibition of platelet aggregation with 20 μmol/L adenosine diphosphate at 14±2 days was significantly greater in the prasugrel group (61.3%) compared to the clopidogrel group (46.1%). The mean difference between the two groups was 14.9% (P<0.0001). Secondary: For the loading dose phase mean maximal platelet aggregation with 20 μmol/L adenosine diphosphate was significantly lower (lower maximal platelet aggregation indication of greater antiplatelet effect) in the prasugrel group (18.9%) compared to the clopidogrel group (52.1%). The mean difference between the two groups was 33.1% (P<0.0001). For the maintenance dose phase mean maximal platelet aggregation with 20 μmol/L adenosine diphosphate at 14±2 days was significantly lower in the prasugrel group (29.2%) compared to the clopidogrel group (40.9%). The mean difference between the two groups was 11.3% (P<0.0001). For the loading dose phase prasugrel also showed significantly greater platelet inhibition with the $P2Y_{12}$ assay (89.5%) compared to clopidogrel (38.4%). The mean difference between the two groups was 51.4% (P<0.0001). For the maintenance dose phase prasugrel also showed significantly greater platelet inhibition with the $P2Y_{12}$ assay (83.3%) compared to clopidogrel (65.1%). The mean difference between the two groups was 18.9% (P<0.0001). There were no TIMI major bleeding episodes in either treatment group. For TIMI minor bleeding episodes 2% of patients in the prasugrel group experienced a minor bleed compared to 0% in the clopidogrel group. In the prasugrel group 18.6% of the patients reported a hemorrhagic event whether minor or major, compared to 14.1% in the clopidogrel group, however the difference was not significant (P value not reported).
Peripheral Artery Disease				

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Berger et al.[118] (2009) Aspirin vs aspirin/ dipyridamole vs placebo	MA (18 trials) Patients with PAD	N=5,269 Duration varied	Primary: Relative risk reduction of aspirin therapy on the composite end point of nonfatal MI, nonfatal stroke, and cardiovascular death Secondary: All-cause mortality and each component of the primary end point	Primary: There was no overall statistically significant difference in the composite outcome of nonfatal MI, nonfatal stroke and cardiovascular death between the aspirin and placebo or control groups (18 RCTs: RR, 0.88; 95% CI, 0.76 to 1.04) There was a significantly lower incidence of nonfatal stroke in the aspirin groups (18 RCTs: RR, 0.66; 95% CI, 0.47 to 0.94). Secondary: There were no statistically significant differences between the groups for any other secondary efficacy outcome. There was no statistically significant difference between the groups in incidence of major bleeding, but this was not formally assessed in many included RCTs.
Hiatt et al.[119] (2008) CASTLE Cilostazol 50 to 100 mg BID vs placebo	DB, MC, PA, PC, RCT Patients ≥17 years with a clinical diagnosis of PAD and symptoms of claudication	N=1,435 Up to 3.5 years	Primary: All-cause mortality on treatment (defined as period while taking the study drug and for 30 days after discontinuing therapy) Secondary: Safety	Primary: Long-term adherence to cilostazol was poor with >60% of participants discontinuing therapy by 36 months. There were 18 deaths in patients receiving cilostazol (N=717) and 19 deaths in patients receiving placebo (N=718) (HR, 0.99; 95% CI, 0.52 to 1.88). The study was underpowered to meet its primary end point. In the full ITT population at 36 months, there were 49 deaths for cilostazol patients and 52 deaths for placebo patients (HR, 0.94; 95% CI, 0.64 to 1.39). Thus most deaths occurred >30 days after study drug discontinuation. The incidence of cardiovascular deaths was similar between the two treatment groups (14 patients in each group). Secondary: Serious bleeding events affected 18 patients taking cilostazol and 22 patients taking placebo. The rates of bleeding events were similar in patients who used aspirin, aspirin plus clopidogrel or anticoagulants at any time during the course of the study.
Hiatt et al.[120]	DB, MC, RCT	N=13,885	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2017) Ticagrelor 90 mg twice daily vs clopidogrel 75 mg once daily	Patients ≥50 years of age with symptomatic PAD and one of two inclusion criteria: previous revascularization of the lower limbs for symptomatic disease more than 30 days before randomization or hemodynamic evidence of peripheral artery disease, as evidenced by an ankle–brachial index (ABI) of 0.80 or less at screening	Median follow-up of 30 months	First occurrence of any event in the composite of cardiovascular death, myocardial infarction, or ischemic stroke Secondary: Acute limb ischemia leading to hospitalization	The primary efficacy composite end point occurred in 751 of 6930 patients (10.8%) in the ticagrelor group and in 740 of 6955 (10.6%) in the clopidogrel group (HR, 1.02; 95% CI, 0.92 to 1.13; P=0.65). Secondary: The only significant between-group difference was in the rate of ischemic stroke, which occurred in 1.9% of the patients in the ticagrelor group, versus 2.4% in the clopidogrel group (HR, 0.78; 95% CI, 0.62 to 0.98; P=0.03). Other key secondary and composite end points including acute limb ischemia and revascularization were similar in the two groups.
Morrow et al.[121] (2012) TRA2P-TIMI 50 Vorapaxar 2.5 mg daily vs placebo Concomitant medical therapy, including the use of other antiplatelet agents, was	DB, MC, RCT Patients with a history of atherosclerosis or PAD associated with a history of intermittent claudication in conjunction with either an ankle–brachial index of less than 0.85 or previous revascularization for limb ischemia	N=26,449 Median follow-up of 30 months (patients with a history of stroke in the vorapaxar group discontinued therapy due to intracranial hemorrhage	Primary: Composite of CV death, MI, or stroke Secondary: Composite of CV death, MI, stroke, or recurrent ischemia leading to urgent coronary revascularization; GUSTO moderate or severe bleeding	Primary: At three years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group, as compared with 1176 patients (10.5%) in the placebo group (HR, 0.87; 95% CI, 0.80 to 0.94; P<0.001). Among patients with no history of stroke, the primary end point occurred in 8.3% of patients in the vorapaxar group, as compared with 9.6% of those in the placebo group (HR, 0.84; 95% CI, 0.76 to 0.93; P<0.001). Secondary: The major secondary end point of cardiovascular death, myocardial infarction, stroke, or urgent coronary revascularization occurred in 1259 patients (11.2%) in the vorapaxar group, as compared with 1417 patients (12.4%) in the placebo group (HR, 0.88; 95% CI, 0.82 to 0.95; P=0.001). The rate of death from any cause did not differ significantly between the vorapaxar group and the placebo group (5.0 and 5.3%, respectively; HR,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
managed by the clinicians according to local standards of care		rates after a median of 24 months)		0.95; 95% CI, 0.85 to 1.07; P=0.41). The major safety end point of moderate or severe bleeding occurred in 438 patients (4.2%) in the vorapaxar group, as compared with 267 patients (2.5%) in the placebo group (HR, 1.66; 95% CI, 1.43 to 1.93; P<0.001). Among patients with a history of stroke, the rate of intracranial hemorrhage in the vorapaxar group was 2.4%, as compared with 0.9% in the placebo group (P<0.001). Among patients without a history of stroke, the rates of intracranial hemorrhage were lower in the two study groups (0.6% in the vorapaxar group and 0.4% in the placebo group; P=0.049).
Scirica et al.[122] (2012) TRA2P-TIMI 50 Vorapaxar 2.5 mg daily vs placebo Concomitant medical therapy, including the use of other antiplatelet agents, was managed by the clinicians according to local standards of care	Subgroup analysis of TRA2P-TIMI 50 Patients enrolled in the TRA2P-TIMI 50 trial with a qualifying MI within the previous 2 weeks to 12 months	N=17,779 of 26,449 Median follow-up of 30 months (patients with a history of stroke in the vorapaxar group discontinued therapy due to intracranial hemorrhage rates after a median of 24 months)	Primary: First, a composite of CV death, MI, or stroke, followed by CV death, MI, stroke, or urgent coronary revascularization, and then CV death or MI Secondary: GUSTO moderate or severe bleeding	Primary: The vorapaxar group had 610 patients (8.1%, 3-year Kaplan-Meier estimate) versus 750 patients in the placebo group (9.7%, 3-year Kaplan-Meier estimate) with CV death, MI, or stroke (HR, 0.80, 95% CI 0.72 to 0.89; P<0.0001). The incidence of the composite of CV death, MI, stroke, or urgent coronary revascularization was 10.5% in the vorapaxar group compared with 12.1% in the placebo group (HR, 0.83; 0.76 to 0.92; P=0.0001). Chance of CV death or MI was lower in patients allocated to vorapaxar than in those allocated to placebo (7.2 vs 8.6%, 3-year Kaplan-Meier estimate; P=0.0003). Secondary: The principal safety endpoint of GUSTO moderate or severe bleeding occurred in 241 of 8880 patients (3.4%, 3-year Kaplan-Meier estimate) in the vorapaxar group compared with 151 of 8849 patients (2.1%, 3-year Kaplan-Meier estimate) in the placebo group (HR, 1.61; 1.31 to 1.97; P<0.0001). For all patients who qualified for the trial with myocardial infarction, risk of CV death, MI, stroke, urgent coronary revascularization, or GUSTO moderate or severe bleeding was lower in the vorapaxar group than in the placebo group (12.5 vs 13.4%; P=0.038).
Morrow et al.[123] (2013) TRA2P-TIMI 50 Vorapaxar 2.5 mg	Subgroup analysis of TRA2P-TIMI 50 Patients enrolled in the TRA2P-TIMI 50	N=4,883 (out of 26,449 total) Median	Primary: First, a composite of CV death, MI, or stroke, followed by CV death, MI,	Primary: For patients who qualified with an ischemic stroke, the 3-year incidence of CV death, MI, or stroke was 13.0% in the vorapaxar group compared with 11.7% in the placebo group; hazard ratio (HR) 1.03 (95% CI, 0.85 to 1.25; P=0.75). No significant difference between vorapaxar and placebo was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
daily vs placebo Concomitant medical therapy, including the use of other antiplatelet agents, was managed by the clinicians according to local standards of care	trial with a prior ischemic stroke	follow-up of 24 months	stroke, or urgent coronary revascularization, and then CV death or MI Secondary: GUSTO moderate or severe bleeding	found in any of the efficacy end points examined. In particular, recurrent stroke alone was not reduced with vorapaxar (10.1 vs 7.5%; HR, 1.13; 95% CI, 0.90 to 1.40; P=0.30) in this cohort. Secondary: GUSTO moderate or severe bleeding was higher in patients treated with vorapaxar compared with placebo (4.2 vs 2.4%; HR, 1.93; 95% CI, 1.33 to 2.79; P<0.001). Intracranial hemorrhage, inclusive of intracerebral and subdural bleeding, was significantly increased with vorapaxar (2.5 vs 1.0%; HR, 2.52; 95% CI, 1.46 to 4.36; P<0.001).
Bonaca et al.[124] (2013) TRA2P-TIMI 50 Vorapaxar 2.5 mg daily vs placebo Concomitant medical therapy, including the use of other antiplatelet agents, was managed by the clinicians according to local standards of care	Subgroup analysis of TRA2P-TIMI 50 Patients enrolled in the TRA2P-TIMI 50 trial with PAD	N=3,787 (out of 26,449 total) Median follow-up of 36 months	Primary: First, a composite of CV death, MI, or stroke, followed by CV death, MI, stroke, or urgent coronary revascularization, and then CV death or MI; GUSTO moderate or severe bleeding Secondary: Acute limb ischemia, peripheral revascularization (urgent and elective), and urgent hospitalization for	Primary: Vorapaxar did not significantly reduce the composite of CV death, MI, or stroke compared with placebo (11.3% vs 11.9%; HR, 0.94; 95% CI, 0.78 to 1.14; P=0.53) or CV death, MI, stroke, or urgent coronary revascularization (P=0.57). Compared with placebo, in the PAD cohort, vorapaxar increased the risk of bleeding, including GUSTO moderate or severe bleeding (7.4 vs 4.5%; HR, 1.62; 95% CI, 1.21 to 2.18; P=0.001) The rates of intracranial hemorrhages with vorapaxar compared with placebo were 0.9 vs 0.4% (HR, 2.03; 95% CI, 0.82 to 5.02; P=0.13) Secondary: Vorapaxar significantly reduced the risk of limb ischemic events, including hospitalization for acute limb ischemia (2.3 vs 3.9%; HR, 0.58; 95% CI, 0.39 to 0.86; P=0.006) and peripheral revascularization (18.4 vs 22.2%; HR, 0.84; 95% CI, 0.73 to 0.97; P=0.017). This reduction was consistent for both urgent (3.1 vs 4.7%; HR, 0.65; 95% CI, 0.46 to 0.91; P=0.012) and elective (16.5 vs 19.5%; HR, 0.86; 95% CI, 0.74 to 0.9995; P=0.049) peripheral revascularization.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			vascular cause of an ischemic nature	

*Agent not available in the United States.
Drug regimen abbreviations: BID=twice-daily, ER=extended-release, IR=immediate-release, QD=once-daily
Study abbreviations: AC=active-controlled, CS=cross sectional, DB=double-blind, DD=double-dummy, MA=meta-analysis, MC=multicenter, OB=observational, OL=open-label, PA=parallel arm, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, XO=cross over trial
Miscellaneous abbreviations: ACS=acute coronary syndrome, BARC= Bleeding Academic Research Consortium, CABG=coronary artery bypass graft, CAD=coronary artery disease, CHD=coronary heart disease, CI=confidence interval, CT=computerized tomography, CV=cardiovascular, FEV_1=forced expiratory volume in one second, GFR=glomerular filtration rate, GP IIb/IIIa inhibitor=glycoprotein IIb/IIIa inhibitor, GUSTO= Global Use of Strategies to Open Occluded Coronary Arteries, HR=hazard ratio, INR=International Normalized Ratio, IRR=incidence rate ratio, ITT=intention to treat, IU=international units, MES=microembolic signal, MI=myocardial infarction, MRI=magnetic resonance imaging, NSTE ACS=non-ST-segment elevation acute coronary syndromes, NSTEMI=non-ST-segment elevation myocardial infarction, OR=odds ratio, PAD=peripheral arterial disease, PCI=percutaneous coronary intervention, PPI=proton pump inhibitor, RR=relative risk, STEMI=ST-segment elevation myocardial infarction, TIA=transient ischemic attack, TIMI=thrombolysis in myocardial infarction, TRACER=Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome, TRA2P-TIMI 50=Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 14. Relative Cost of the Platelet-Aggregation Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Cilostazol	tablet	Pletal®*	$$$$	$
Clopidogrel	tablet	Plavix®*	$$$$	$
Prasugrel	tablet	Effient®	$$$$$	N/A
Ticagrelor	tablet	Brilinta®	$$$$$	N/A
Ticlopidine	tablet	N/A	N/A	$$$
Vorapaxar	tablet	Zontivity®	$$$$$	N/A

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The platelet-aggregation inhibitors play a major role in the management of cardiovascular, cerebrovascular, and peripheral vascular diseases. They are approved for the treatment and/or prevention of acute coronary syndromes (ACS), angina, intermittent claudication, myocardial infarction (MI), stroke, and transient ischemic attack (TIA). They are also approved for the prevention of thrombosis in patients undergoing cardiovascular procedures and/or surgery.[1-7] Cilostazol, clopidogrel, and ticlopidine are available in a generic formulation.
Aspirin has been the most frequently studied platelet-aggregation inhibitor and is usually the reference drug to which other treatments are compared.[50] Aspirin is the platelet-aggregation inhibitor recommended as first-line in most treatment guidelines for general use. Aspirin is recommended as a first-line option for the initial management of noncardioembolic stroke or TIA, ACS, and MI, as well as for primary and secondary prevention in patients with cerebrovascular, cardiovascular, and peripheral vascular diseases. Low-dose aspirin (75 to 150 mg/day) is an effective platelet-aggregation inhibitor regimen for long-term use, but in acute settings, an initial loading dose of ≥150 mg may be required. Other platelet inhibitors are usually reserved for patients with contraindications or severe intolerance to aspirin or who have failed aspirin monotherapy or in high-risk patients when dual antiplatelet therapy is recommended. Dual antiplatelet therapy with aspirin plus clopidogrel, prasugrel, or ticagrelor is recommended for patients with ACS (non ST-segment elevation myocardial infarction [NSTEMI] and unstable angina). Antiplatelet therapy is also recommended in patients with ST-segment elevation myocardial infarction (STEMI). For patients with noncardioembolic ischemic strokes or TIAs, fixed-dose aspirin and dipyridamole is suggested instead of aspirin alone, and clopidogrel may be considered instead of aspirin alone to reduce the risk of recurrent stroke and other cardiovascular events.[13-21] For patients who have an ischemic stroke while taking aspirin, there is no evidence that increasing the dose of aspirin provides additional benefit. Although alternative antiplatelet agents are often considered, no single agent or combination product has been studied in patients who have had an event while receiving aspirin.[15]

Clopidogrel and ticlopidine are adenosine diphosphate receptor antagonists and have been shown to significantly reduce the odds of a serious vascular event in high-risk patients. The CAPRIE trial reported that clopidogrel significantly reduced the combined risk of ischemic stroke, MI, and vascular death by 8.7% compared to aspirin in patients with a recent ischemic stroke, MI, or established peripheral vascular disease. In a subanalysis of over 6,000 patients who were enrolled in the trial based on a recent ischemic stroke, clopidogrel reduced the risk of the composite endpoint by 7.3% and stroke by 8.0% compared to aspirin; however, these differences were not statistically significant.[52] On the basis of the CURE, COMMIT, and CLARITY trials, clopidogrel received a Food and Drug Administration (FDA) indication for the reduction of atherothrombotic events in patients with ACS and MI, and clopidogrel has been incorporated into the current treatment guidelines for the management of these conditions.[16,18,55,56,104] Prasugrel is a relatively new adenosine diphosphate receptor antagonist which has been reported to be the most potent of these agents and to have more desirable characteristics when compared to clopidogrel with regards to drug-drug interactions and interpatient enzyme variability.[8-10] Approval of this agent was based on the results from the TRITON-TIMI 38 trial, in which prasugrel was significantly more effective in reducing ischemic events in patients with ACS who underwent percutaneous coronary intervention (PCI) intervention. Of note, no reduction in the mortality rate was seen with prasugrel, and a significantly greater incidence of major, minor, life-threatening, and fatal bleeding events was associated with prasugrel.[97] The overall recommendation for patients with a STEMI in which PCI is planned is for a thienopyridine to be used, with both clopidogrel and prasugrel listed as potential options. Of note, use of prasugrel in STEMI patients with a prior history of stroke or TIA undergoing primary PCI is not recommended.[18]

Ticagrelor is indicated to reduce the rate of cardiovascular death, MI, and stroke in patients with ACS or a history of MI. The package insert has been updated to state that "for at least the first 12 months following ACS, it is superior to clopidogrel." It is also approved to reduce the rate of stent thrombosis in patients who have been stented for treatment of ACS.[3] As a cyclopentyltriazolopyrimidine, ticagrelor works in a similar manner to the other thienopyridine platelet inhibitors (clopidogrel, prasugrel, ticlopidine); however, ticagrelor is a reversible inhibitor of the $P2Y_{12}$ receptors. In addition, ticagrelor is not a prodrug and therefore does not require enzymatic conversion to become pharmacologically active, and is not subject to potential drug interactions associated with the other agents.[2,3] The pivotal clinical trial establishing the safety and efficacy of ticagrelor in reducing the rate of thrombotic cardiovascular events in patients with ACS is the PLATO trial. PLATO was a large, international, prospective, double-blind, randomized-controlled trial comparing ticagrelor and clopidogrel in hospitalized patients with documented ACS, with or without ST-segment elevation (N=18,624). After 12 months of treatment, ticagrelor significantly reduced the primary composite endpoint of cardiovascular death, MI, or stroke, without

increasing the risk of major bleeding.[55] Within the United States, clopidogrel, prasugrel, and ticagrelor are all recommended as potential options in patients receiving PCI, while clopidogrel and ticagrelor are both recommended as potential options in patients with unstable angina/NSTEMI who are not undergoing PCI.[16,20] The 2015 European Society of Cardiology guidelines recommend that patients presenting without persistent ST-elevation receive dual antiplatelet therapy with aspirin and a platelet inhibitor. Specifically, ticagrelor is recommended for all patients at moderate to high risk of ischemic events, regardless of initial treatment strategy (i.e., invasive vs noninvasive), including those pretreated with clopidogrel. Prasugrel is recommended for $P2Y_{12}$ inhibitor-naïve patients who are proceeding to PCI, while clopidogrel is recommended for patients who cannot receive ticagrelor or prasugrel.[17]

Clinical trials have shown that ticlopidine reduces the risk of stroke and other vascular outcomes in patients with cerebrovascular disease. Randomized trials that compared ticlopidine with aspirin in stroke or TIA patients produced conflicting results regarding whether ticlopidine is more effective than aspirin.[47,48] When compared to aspirin alone, and aspirin plus warfarin, treatment with aspirin plus ticlopidine resulted in a lower rate of stent thrombosis following coronary stenting.[97] Because ticlopidine is associated with a risk of life-threatening blood dyscrasias, ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.[1,2]

Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of MI or with peripheral arterial disease (PAD).[6] The TRACER study was a randomized, double-blind, placebo-controlled trial evaluating the efficacy of vorapaxar in addition to standard therapy in 12,944 patients who had acute coronary syndromes without ST-segment elevation. This trial was stopped early due to a significant increase in the risk of major bleeding, including intracranial hemorrhage, in vorapaxar-treated patients. The preliminary clinical outcomes data showed no significant advantage of vorapaxar over placebo in preventing the primary composite endpoint of death from cardiovascular causes, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization ($P=0.07$).[12] Vorapaxar increased the rate of moderate or severe bleeding, as compared with placebo ($P<0.001$).[12] FDA approval of vorapaxar was based on the TRA2P-TIMI 50 trial. A population of 26,449 patients with peripheral arterial disease or a history of MI or ischemic stroke was randomized to receive either vorapaxar or placebo, in addition to standard care. After two years, the data and safety monitoring board recommended that patients with a history of stroke stop taking vorapaxar because of an increased risk of intracranial hemorrhage; the trial was continued in all other patients. At three years, the composite efficacy endpoint of cardiovascular death, MI, or stroke had occurred in 9.3% of patients treated with vorapaxar, compared to 10.5% of those given placebo, a statistically significant difference.[122] In a prespecified subgroup analysis, among the 17,779 patients with a previous MI, the primary endpoint occurred in 8.1% of those taking vorapaxar compared to 9.7% of those taking placebo, a statistically significant difference.[123] In another subgroup analysis, among the 3,787 patients who had peripheral arterial disease, vorapaxar did not significantly reduce the composite endpoint of cardiovascular death, MI, or stroke compared with placebo, but it did significantly reduce the rate of hospitalization for acute limb ischemia (2.3 vs 3.9%).[124] Due to the increased risk of bleeding events with vorapaxar, it is contraindicated in patients with a history of stroke, transient ischemic attack, intracranial hemorrhage, or active pathologic bleeding.[6]

The effectiveness of clopidogrel is dependent on its activation to an active metabolite by cytochrome P450 (CYP) 2C19. Clopidogrel forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Consider alternative treatments in patients identified as CYP2C19 poor metabolizers.[5] Prasugrel can cause significant bleeding and should not be used in patients with active bleeding or a history of TIA or stroke. It is also not recommended in patients ≥75 years of age due to the increased risk of fatal and intracranial bleeding and because of uncertain benefit, except in high-risk situations.[4] Because ticlopidine is associated with a risk of life-threatening blood dyscrasias, it should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.[1,2]

Therefore, all brand platelet-aggregation inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use. Prasugrel (Effient®) and ticagrelor (Brilinta®) should be available as first-line therapy (in combination with aspirin) through the medical justification portion of the prior authorization process for patients who have experienced an ACS who are going to be managed medically or with PCI.

XI. Recommendations

No brand platelet-aggregation inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited Apr 2017]. Available from: http://online.factsandcomparisons.com.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 Apr]. Available from: http://www.thomsonhc.com/.
3. Brilinta® [prescribing information]. Wilmington (DE): AstraZeneca LP; 2013 Dec.
4. Effient® [package insert]. Indianapolis, IN: Eli Lilly and Company; 2013 Nov.
5. Plavix® [package insert]. Bridgewater, NJ: Sanofi Aventis; 2013 Dec.
6. Zontivity™ [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2014 May.
7. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2017 [cited 2017 Apr]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
8. Serebruany V, Shalito I, Kopyleva O. Prasugrel development-Claims and achievements. Thromb Haemost. 2009;101:14-22.
9. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared to high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923-32.
10. Spinler SA, Rees C. Review of prasugrel for the secondary prevention of atherothrombosis. J Manage Care Pharm. 2009;15(5):383-95.
11. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor vs clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22; 120(25):2577-85.
12. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20-33.
13. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(Suppl 2):7-47.
14. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy For VTE Disease: Chest Guideline And Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.
15. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
16. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology (2014), doi: 10.1016/j.jacc.2014.09.017.
17. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2016) 37 (3): 267-315. DOI: https://doi.org/10.1093/eurheartj/ehv320.
18. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):485-510.
19. Steg PH, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619.
20. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122.
21. National Institute for Health and Clinical Excellence. Myocardial Infarction: cardiac rehabilitation and prevention of further cardiovascular disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May [cited 2017 Apr]. Available from: http://www.nice.org.uk/guidance/cg172.

22. National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. London (UK): National Institute for Health and Clinical Excellence; 2010 Dec [cited 2012 Dec]. Available from: http://guidance.nice.org.uk/TA210.
23. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007 Dec 4;116(23):2762-72.
24. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.
25. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 Nov 29;124(22):2458-73.
26. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WMM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol. 2012 Aug;19(4):585-667.
27. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2011;58:2020-45.
28. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J. 2004;25:166-81.
29. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997 May 31;349(9065):1569-81.
30. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997 Jun 7;349:1641-49.
31. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci.* 1996 Nov;143(1-2):1-13.
32. Leonardi-Bee J, Bath PMW, Bousser MG, Davalos A, Diener HC, Guiraud-Chaumeil B, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005 Jan;36(1):162-8.
33. Sacco R, Sivenius J, Diener HC. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol. 2005 Mar;62(3):403-8.
34. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole vs aspirin alone after cerebral ischemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet. 2006 May 20;367(9523):1665-73.
35. Uchiyama S, Ikeda Y, Urano Y, Horie Y, Yamaguchi T. The Japanese Aggrenox (extended-release dipyridamole plus aspirin) Stroke Prevention vs Aspirin Program (JASAP) study: a randomized, double-blind, controlled trial. Cerebrovasc Dis. 2011;31:601-13.
36. Verro P, Gorelick P, Nguyen D. Aspirin plus dipyridamole vs aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008 Apr;39(4):1358-63.
37. Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012 Apr;43(4):1058-66.
38. Sacco RL, Diener HC, Yusef S, et al. Aspirin and extended-release dipyridamole vs clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
39. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005 May 3;111:2233-40.

40. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al, on behalf of the MATCH investigators. Aspirin and clopidogrel compared to clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004 Jul 24;364:331-7.
41. Wang Y, Pan Y, Zhao X, et al. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. Circulation. 2015 Jul 7;132(1):40-6.
42. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, for the FASTER Investigators. Fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007 Nov;6:961-9.
43. Uchiyama S, Fukuuchi Y, Yamaguchi T. The safety and efficacy of clopidogrel vs ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. J Neurol 2009;256:888-897.
44. Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Jul 7;375(1):35-43.
45. Fukuuchi Y, Tohgi H, Okudera T, Ikeda Y, Miyanaga Y, Uchiyama S, et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel vs ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis. 2008;25:40-9.
46. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet. 1989 Jun 3;1(8649):1215-20.
47. Hass W, Easton J, Adams H, Pryse-Phillips W, Molony B, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study (TASS) Group. N Engl J Med. 1989 Aug;8(321):501-7.
48. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003 Jun 11;289(22):2947-57.
49. Simpson SH, Gamble JM, Mere L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011;16(11):1336-44.
50. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324:71-86.
51. Sudlow C. Thienopyridine derivatives vs aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009;(4):CD001246.
52. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996 Nov 16;348(9038):1329-39.
53. Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS one. 2012;7(2):e31642. doi: 10.1371/journal.pone.0031642.
54. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular diseases. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001820.
55. The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502.
56. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005 Nov 5;366:1607-21.
57. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al; for the CLARITY-TIMI 28 Investigators. N Engl J Med. 2005 Mar 24;352(12):1179-89.
58. Ahmed S, Gibson CM, Cannon CP, Murphy SA, Sabatine MS. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thromboylsis. 2011;31:493-500.
59. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al; for the CHARISMA Investigators. Clopidogrel and aspirin vs aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17.
60. Dapgusta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin vs aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial. Am J Cardiol. 2009;103:1359-63.
61. Hart RG, Bhatt DL, Hacke W, Fox KAA, Hankey GJ, Berger PB, et al for the CHARISMA Investigators. Clopidogrel and aspirin vs aspirin alone for the prevention of stroke in patients with a history of atrial

fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008 Feb 27;25(4):344-7.
62. Ho MP, Peterson ED, Wang L, Magid DJ, Fihn SD, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008 Feb 6; 299(5):532-9.
63. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel vs clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.
64. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38. Circulation. 2008;118:1626-36.
65. Antman EM, Wiviott SD, Murphy SA, Voitk J, Widimsky P, Chandna H, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 analysis. J Am Coll Cardiol. 2008;51(21):2028-33.
66. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, et al. Reduction in recurrent cardiovascular events with prasugrel compared to clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29:2473-9.
67. Montalescot G, Wiviott S, Braunwald E, et al. Prasugrel compared to clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-731.
68. Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, et al. Effect of prasugrel vs clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a trial to assess improvement in therapeutic outcomes by optimizing platelet inhibitor with prasugrel (TRITON)-thrombolysis in myocardial infarction (TIMI) 38 substudy. Am Heart J. 2009;158:e21-6.
69. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention. J Am Coll Cardiol. 2009;54:678-85.
70. Zeymer U, Hochadel M, Lauer B, et al. Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry. Int J Cardiol. 2015 Apr 1;184:122-7.
71. Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel vs clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309.
72. Grubel PA, Erlinge D, Ohman EM, Neely B, Neely M, Foodman SG, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization. The TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785-94.
73. Wiviott SD, White HD, Ohman EM, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013;382(9892):605-613.
74. Roe MT, Goodman SG, Ohman EM, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013;128(8):823-833.
75. Jackson LR 2nd, Piccini JP, Cyr DD, et al. Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. Clin Cardiol. 2016 Sep;39(9):497-506.
76. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7;372(19):1791-800.
77. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57.
78. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17;342:d3527.
79. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet. 2010 Jan 23;375(9711):283-93.
80. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. Ticagrelor vs clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous

coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23;122(21):2131-41.
81. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor vs clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122:1056-67.
82. James S, Angiolillo DJ, Corenal JH, Erlinge D, Husted S, Kontny F, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndrome and diabetes: a substudy from the platelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2010;31:3006-16.
83. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 8;57(6):672-84.
84. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor vs clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010 Oct 16;376(9749):1320-8.
85. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angioloillo DJ, et al. Ticagrelor compared to clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2011;124:544-54.
86. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patients Outcomes [PLATO] Pulmonary Function Substudy). Am J Cardiol. 2011;108:1542-6.
87. James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012 Jun 12;125(23):2914-21.
88. Kotsia A, Brilakis ES, Held C, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014;168(1):68-75.e2.
89. Brilakis ES, Held C, Meier B, et al. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2013;166(3):474-480.
90. Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013;127(6):673-680.
91. Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol. 2015 Jun;22(6):734-42.
92. Jackson LR 2nd, Ju C, Zettler M, et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9.
93. Leonardi S, Tricoci P, White HD, et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. Eur Heart J. 2013 Jun;34(23):1723-1731.
94. Whellan DJ, Tricoci P, Chen E, et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(11):1048-1057.
95. Mahaffey KW, Huang Z, Wallentin L, et al. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014;113(6):936-944.
96. Valgimigli M, Tricoci P, Huang Z, et al. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014;114(5):665-673.
97. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998 Dec 3;339(23):1665-71.
98. Ahn Y, Jeong MH, Jeong JW et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients –cilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008;72:35-39.
99. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus; the DECLARE-DIABETES Trial (a

randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients. J Am Coll Cardiol 2008;51:1181-7.

100. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-739.
101. Jeong Y, Lee S, Choi B, et al. Randomized comparison of adjunctive cilostazol vs high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Vs High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-1109.
102. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 Aug 18;358:9281):527-33.
103. Takeyasu N, Watanabe S, Noguchi Y, Ishikawa K, Fumikura Y, Yamaguchi I. Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Circ J. 2005 Jul;69(7):780-5.
104. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY Study. N Engl J Med. 2005 Sep 14;294 (10):1224-32.
105. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, et al; for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411-20.
106. Lev EI, Kornowski R, Vaknin-Assa H, Brosh D, Fuchs S, Battler A, Assali A. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol. 2008;101:435-9.
107. Banerjee S, Varghese C, Samuel J, Weideman RA, Little BB, Kelly KC, et al. Comparison of the impact of short (<1 year) and long-term (≥1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol. 2008;102:1159-62.
108. Han Y, Wang B, Li Y, Xu K, Wang S, Jing Q, et al. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation. Chinese Medical Journal. 2009;122(7):793-7.
109. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- vs long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012 Apr 24;125(16):2015-26.
110. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month vs 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Vs Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012 Jan;125(3):505-13.
111. CURRENT-OASIS 7 Investigators. Dose comparison of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med. 2010;363:930-42.
112. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared to ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 Aug 8;102;624-9.
113. Isshiki T, Kimura T, Ueno T, Nakamura M, Igarashi K, Yokoi H, et al. Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN). Int Heart J. 2012;53(2):91-101.
114. Gao C, Ren C, Li D, Li L. Clopidogrel and aspirin vs clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg 2009;88:59-62.
115. Park S, Park D, Kim Y, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-1382.
116. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-19.
117. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, et al. A randomized trial of prasugrel vs clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet

Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012 Jun 12;59(24):2159-64.
118. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009;301:1909-19.
119. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008;47(2):330-6.
120. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017 Jan 5;376(1):32-40.
121. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366(15):1404-1413.
122. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012;380(9850):1317-1324.
123. Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar;44(3):691-698.
124. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013;127(14):1522-1529, 1529e1-6.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Antiarrhythmic Agents
AHFS Class 240404
August 9, 2017

I. Overview

Cardiac contractions are regulated by electrical activity in the heart originating in the sinoatrial node and propagated through ion channels, chiefly sodium (Na^+), potassium (K^+), calcium (Ca^{2+}), and chloride (Cl^-) channels. Arrhythmias are caused by abnormalities in formation and transmission of impulses and are classified based on their origin: supraventricular (atrial or atrioventricular junction) or ventricular.[1]

Research in recent years has provided extensive data regarding the cellular mechanisms by which some of the antiarrhythmic drugs exert their action; however, the general approach to antiarrhythmic therapy remains largely empirical.[2] The antiarrhythmic agents are generally grouped into specific categories or classes based on their predominant mechanisms: (1) sodium channel blockade, (2) blockade of sympathetic autonomic effects in the heart, (3) prolongation of the effective refractory period, and (4) calcium channel blockade.[1] E. M. Vaughan Williams proposed the first antiarrhythmic classification system in 1970 and it is now the most widely used scheme. The Vaughan Williams classification system divides the antiarrhythmic agents into the following classes: Class I: fast sodium channel blockers, Class II: β-blockers, Class III: repolarization potassium current blockers, and Class IV: calcium channel antagonists.[2] The agents included in this review differ with regards to their Food and Drug Administration-approved indications, mechanism of action, pharmacokinetic properties, drug interactions, and adverse events.

The antiarrhythmic agents that are included in this review, as well as their Vaughan Williams Classifications, are listed in Table 1. This review encompasses all dosage forms and strengths. All of the antiarrhythmic agents are available in a generic formulation, with the exception of dofetilide. This class was last reviewed in May 2015.

Table 1. Antiarrhythmic Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Vaughan Williams Classification	Current PDL Agent(s)
Amiodarone	injection, tablet	Cordarone®*, Nexterone®, Pacerone®*	III	amiodarone
Disopyramide	capsule, extended-release capsule	Norpace®*, Norpace CR®	IA	disopyramide
Dofetilide	capsule	Tikosyn®*	III	dofetilide
Dronedarone	tablet	Multaq®	I, II, III, IV	none
Flecainide	tablet	N/A	IC	flecainide
Mexiletine	capsule	N/A	IB	mexiletine
Propafenone	extended-release capsule, tablet	Rythmol SR®*	IC	propafenone
Quinidine	extended-release tablet, injection, tablet	N/A	IA	quinidine

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.
N/A=Not available.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the antiarrhythmic agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Antiarrhythmic Agents

Clinical Guideline	Recommendation (s)
North American Society of Pacing and Electrophysiology/ Heart Rhythm Society Practice Guidelines Subcommittee: **A Practical Guide for Clinicians Who Treat Patients With Amiodarone (2007)**[3]	<u>Ventricular arrhythmias</u> • Oral amiodarone is the recommended agent of choice for use in combination with additional appropriate therapies, including β-blockers, in patients with sustained ventricular tachyarrhythmias associated with structural heart disease, especially those with left ventricular dysfunction, and who are not candidates for an implantable cardioverter-defibrillator. • It is recommended that amiodarone therapy be reserved for symptomatic patients with non-sustained ventricular tachyarrhythmias that are refractory to β-blocker therapy and concerning enough to require treatment. <u>Atrial fibrillation (AF)</u> • This guideline refers to the recommendations provided by the American College of Cardiology/ American Heart Association/ European Society of Cardiology 2006 guidelines that recommend oral amiodarone be used for treatment of AF in particular subsets of patients including: 1) patients post-myocardial infarction (MI) who are not candidates for sotalol or dofetilide; 2) those with congestive heart failure (CHF) and left ventricular dysfunction who are not candidates for dofetilide; 3) patients with significant left ventricular hypertrophy, and 4) those symptomatic patients who are refractory to antiarrhythmic treatments and an alternative to catheter ablation is preferred. • Amiodarone therapy should only be considered in those patients with AF who need ventricular rate control and have failed or are unable to use other appropriate agents including digoxin, β-blockers, or calcium channel blockers. • If prophylactic amiodarone therapy is to be used prior to aortocoronary bypass surgery, it is recommended to only consider this therapy in those patients that are high-risk (prior history of AF, valve replacement surgery) and therapy with β-blocker monotherapy will most likely still be associated with a high post-operative AF occurrence rate. <u>Pregnant patients</u> • Due to some unfavorable characteristics possessed by amiodarone, including end-organ toxicity, therapy with it in pregnant patients is not recommended unless there are no other treatment options available. <u>Pediatric patients</u> • There is a lack of data studying intravenous amiodarone in pediatric patients; however, in some lethal tachyarrhythmias, amiodarone is often used in these situations. • It is recommended that children receiving amiodarone therapy be supervised by a pediatric electrophysiologist. <u>Patient follow-up</u> • Patient follow-up is recommended for patients receiving amiodarone therapy for either atrial or ventricular arrhythmias. • Follow-up recommendations include continued assessment of drug therapy, efficacy and toxicities. • It is recommended that follow-up evaluations with patients on amiodarone take place with personnel who are experienced with the agent. • It is recommended that initial assessments occur every three to six months to ensure efficacy and safety of the medication and arrhythmia stability. Following

Clinical Guideline	Recommendation (s)
	the initial period, follow-up assessments may occur every six months. Pulmonary toxicity • Pulmonary toxicity is a well-known adverse event associated with amiodarone therapy. It is recommended that a pulmonologist be consulted when: 1) there is an abnormal chest radiography at baseline or follow-up; 2) there is an abnormal pulmonary function test value (particularly forced vital capacity and [D_LCO]) at baseline or follow-up evaluation; and/or 3) a new cough and/or dyspnea, especially if otherwise unexplained or unexpected. • It is recommended that all patients who are referred to a pulmonologist undergo full pulmonary function testing and high-resolution computed tomography scanning of the chest. Effects on thyroid function • Amiodarone is known to have adverse effects on thyroid function, either by causing hypo- or hyperthyroidism. It is recommended that an endocrinologist be consulted: 1) any time hyperthyroidism is suspected, even if suppression of thyroid-stimulating hormone is mild and subclinical disease is possible; 2) an acutely ill patient where interpretation of thyroid function tests will be complicated by euthyroid sick syndrome; and/or 3) when considering treating subclinical hypothyroidism. • It is recommended to discontinue amiodarone therapy, if possible, in those patients who have underlying thyroid disease and treat them with high-doses of antithyroid drugs. The decision to discontinue amiodarone therapy should be based on the patient's cardiac needs. Follow-up visits • A history of complaints from the patient should be noted. In patients with implantable cardioverter-defibrillators, amiodarone therapy should not be altered without the involvement of an electrophysiologist or a cardiologist in charge of device follow-up. • A physical examination with documentation should be performed. If visual changes are reported, an examination by an ophthalmologist is required. • The following are recommended baseline tests that should be performed: liver function tests, thyroid function tests, chest x-ray, ophthalmologic evaluation, pulmonary function tests, high-resolution computed tomography scan, and an electrocardiogram. The follow-up evaluation should include, at minimum, a yearly electrocardiogram and chest x-ray and semiannual thyroid tests and liver enzymes. Amiodarone levels may be obtained after dose adjustments or to help determine if the dose may be decreased. When to refer to an electrophysiologist • Refer when worsening arrhythmia symptoms. • Refer when evidence of amiodarone toxicity requiring changes in drug dosing or drug discontinuation. Until the arrhythmia problem stabilizes, the patient may require intensive monitoring, electrophysiologic testing, ablative therapy, or pacemaker or implantable cardioverter-defibrillator implantation. • Repeat defibrillation threshold testing is recommended for patients with an implantable cardioverter-defibrillator due to the drugs effect of increasing this threshold. • Assess amiodarone-induced slowing of ventricular tachyarrhythmias rate in patients with an implantable cardioverter-defibrillator such that ventricular tachyarrhythmias would not be detected by the device and therapy not delivered. • Refer for pregnant patients who require amiodarone.

Clinical Guideline	Recommendation (s)
	• Refer for pediatric patients who require amiodarone.
American Heart Association/American College of Cardiology/ Heart Rhythm Society: **Guideline for the Management of Patients with Atrial Fibrillation (2014)**[4]	Recommendations for risk-based antithrombotic therapy: Class I • In patients with atrial fibrillation (AF), antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke, bleeding and the patient's values and preferences (Level of Evidence: C). • Selection of antithrombotic therapy should be based on the risk of thromboembolism irrespective of whether the AF patter is paroxysmal, persistent, or permanent (Level of Evidence: B). • In patients with nonvalvular AF, the CHA_2DS_2-VASc score is recommended for assessment of stroke risk (Level of Evidence: B). • For patients with AF who have mechanical heart valves, warfarin is recommended and the target international normalized ratio (INR) should be based on type and location of the prosthesis (Level of Evidence: B). • For patients with nonvalvular AF with prior stroke, TIA, or a CHA_2DS_2-VASc score ≥2, oral anticoagulants are recommended. Options include warfarin (INR 2.0 to 3.0) (Level of Evidence: A), dabigatran, rivaroxaban, or apixaban (Level of Evidence: B). • For patients treated with warfarin, the INR should be determined at least weekly during initiation of antithrombotic therapy and at least monthly when anticoagulation (INR in range) is stable (Level of Evidence: A) • For patients with nonvalvular AF unable to maintain a therapeutic INR level with warfarin, use of a direct thrombin or factor Xa inhibitor is recommended (Level of Evidence: C). • Re-evaluation of the need for and choice of antithrombotic therapy at periodic intervals is recommended to reassess stroke and bleeding risks (Level of Evidence: C). • Bridging therapy with UFH or LMWH is recommended for patients with AF and a mechanical heart valve undergoing procedures that require interruption of warfarin. Decisions regarding bridging therapy should balance the risks of stroke and bleeding (Level of Evidence: C). • For patients with AF without mechanical heart valves who require interruption of warfarin or newer anticoagulants for procedures, decisions about bridging therapy (LMWH or UFH) should balance the risks of stroke and bleeding and the duration of time a patient will not be anticoagulated (Level of Evidence: C). • Renal function should be evaluated prior to initiation of direct thrombin or factor Xa inhibitors and should be re-evaluated when clinically indicated and at least annually (Level of Evidence: B). • For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF (Level of Evidence: C). Class IIa • For patients with nonvalvular AF and a CHA_2DS_2-VASc score of 0, it is reasonable to omit antithrombotic therapy (Level of Evidence: B). • For patients with nonvalvular AF with a CHA_2DS_2-VASc score of ≥2 and who have end-stage chronic kidney disease (creatine clearance <15 mL/min) or who are on hemodialysis, it is reasonable to prescribe warfarin (INR 2.0 to 3.0) for oral anticoagulation (Level of Evidence: B). Class IIb • For patients with nonvalvular AF and a CHA_2DS_2-VASc score of 1, no antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered (Level of Evidence: C). • For patients with nonvalvular AF and moderate-to-severe chronic kidney disease with a CHA_2DS_2-VASc score of ≥2, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (e.g., dabigatran,

Clinical Guideline	Recommendation (s)
	rivaroxaban, or apixaban), but safety and efficacy have not been established (Level of Evidence: C). • In patients with AF undergoing PCI, bare-metal stents may be considered to minimize the required duration of dual antiplatelet therapy. Anticoagulation may be interrupted at the time of the procedure to reduce the risk of bleeding ant the site of peripheral arterial puncture (Level of Evidence: C). • Following coronary revascularization (percutaneous or surgical) in patients with AF and a CHA_2DS_2-VASc score of ≥2, it may be reasonable to use clopidogrel (75 mg once daily) concurrently with oral anticoagulants but without aspirin (Level of Evidence: B). Class III: No Benefit • The direct thrombin inhibitor, dabigatran, and the factor Xa inhibitor, rivaroxaban, are not recommended in patients with AF and end-stage chronic kidney disease or on hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits (Level of Evidence: C). Class III: Harm • The direct thrombin inhibitor, dabigatran, should not be used in patients with AF and a mechanical heart valve (Level of Evidence: B). <u>Recommendations for rate control:</u> Class I • Control of the ventricular rate using a beta blocker or nondihydropyridine (non-DHP) calcium channel blocker (CCB) is recommended for patients with paroxysmal, persistent, or permanent AF (Level of Evidence: B). • Intravenous administration of a beta blocker or non-DHP CCB is recommended to slow the ventricular heart rate in the acute setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated (Level of Evidence: B). • In patients who experience AF-related symptoms during activity, the adequacy of heart rate control should be assessed during exertion, adjusting pharmacological treatment as necessary to keep the ventricular rate within the physiological range (Level of Evidence: C). Class IIa • A heart rate control (resting heart rate <80 beats per minute [bpm]) strategy is reasonable for symptomatic management of AF (Level of Evidence: B). • Intravenous amiodarone can be useful for rate control in critically ill patients without pre-excitation (Level of Evidence: B). • Atrioventricular (AV) nodal ablation with permanent ventricular pacing is reasonable to control heart rate when pharmacological therapy is inadequate and rhythm control is not achievable (Level of Evidence: B). Class IIb • A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable as long as patients remain asymptomatic and left ventricular systolic function is preserved (Level of Evidence: B). • Oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated (Level of Evidence: C). Class III: Harm • AV nodal ablation with permanent ventricular pacing should not be performed to improve rate control without prior attempts to achieve rate control with medications (Level of Evidence: C). • Non-DHP CCBs should not be used in patients with decompensated HF as these may lead to further hemodynamic compromise (Level of Evidence: C). • In patients with pre-excitation and AF, digoxin, non-DHP CCBs, or intravenous amiodarone should not be administered as they may increase the ventricular response and may result in ventricular fibrillation. (Level of Evidence: B).

Clinical Guideline	Recommendation (s)
	• Dronedarone should not be used to control the ventricular rate in patients with permanent AF as it increases the risk of the combined endpoint of stroke, myocardial infarction, systemic embolism, or cardiovascular death (Level of Evidence: B). <u>Recommendations for thromboembolism prevention</u>: Class I • For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with warfarin (INR 2.0 to 3.0) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the CHA_2DS_2-VASc score and the method used to restore sinus rhythm (Level of Evidence: B). • For patients with AF or atrial flutter of more than 48 hours duration that requires immediate cardioversion for hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least four weeks after cardioversion unless contraindicated (Level of Evidence: C). • For patients with AF or atrial flutter of less than 48-hour duration and with high risk stroke, intravenous heparin or LMWH, or administration of a factor Xa or direct thrombin inhibitor, is recommended as soon as possible before or immediately after cardioversion, followed by long-term anticoagulation therapy (Level of Evidence: C). • Following cardioversion for AF of any duration, the decision regarding long-term anticoagulation therapy should be based on the thromboembolic risk profile (Level of Evidence: C). Class IIa • For patients with AF or atrial flutter of 48-hour duration or longer or of unknown duration who have not been anticoagulated for the preceding three weeks, it is reasonable to perform a TEE prior to cardioversion and proceed with cardioversion if no LA thrombus is identified, including in the LAA, provided that anticoagulation is achieved before TEE and maintained after cardioversion for at least four weeks (Level of Evidence: B). • For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for at least three weeks prior to and four weeks after cardioversion (Level of Evidence: C). Class IIb • For patients with AF or atrial flutter of less than 48-hour duration who are at low thromboembolic risk, anticoagulation (heparin, LMWH, or a new oral anticoagulant) or no antithrombotic therapy may be considered for cardioversion, without the need for post cardioversion oral anticoagulation (Level of Evidence: C). <u>Recommendations for pharmacological cardioversion</u> Class I • Flecainide, dofetilide, propafenone, and intravenous ibutilide are useful for pharmacological cardioversion of AF or atrial flutter, provided contraindications to the selected drug are absent (Level of Evidence: A). Class IIa • Administration of oral amiodarone is a reasonable option for pharmacological cardioversion of AF (Level of Evidence: A). • Propafenone or flecainide ("pill-in-the-pocket") in addition to a beta blocker or non-DHP CCB is reasonable to terminate AF outside the hospital once this treatment has been observed to be safe in a monitored setting for selected patients (Level of Evidence: B). Class III: Harm

Clinical Guideline	Recommendation (s)

	• Dofetilide therapy should not be initiated out of hospital because of the risk of excessive QT prolongation that can cause torsades de pointes (Level of Evidence: B).
	
	<u>Recommendations for antiarrhythmic drugs to maintain sinus rhythm</u>
	Class I
	• Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level of Evidence: C).
	• The following antiarrhythmic drugs are recommended in patients with AF to maintain sinus rhythm, depending on underlying heart disease and comorbidities (Level of Evidence: A):
	  ○ Amiodarone
	  ○ Dofetilide
	  ○ Dronedarone
	  ○ Flecainide
	  ○ Propafenone
	  ○ Sotalol
	• The risks of the antiarrhythmic drug, including proarrhythmia, should be considered before initiating therapy with each drug (Level of Evidence: C).
	• Because of its potential toxicities, amiodarone should only be used after consideration of risks and when other agents have failed or are contraindicated (Level of Evidence: C).
	Class IIa
	• A rhythm-control strategy with pharmacological therapy can be useful in patients with AF for the treatment of tachycardia-induced cardiomyopathy (Level of Evidence: C).
	Class IIb
	• It may be reasonable to continue current antiarrhythmic drug therapy in the setting of infrequent, well-tolerated recurrences of AF when the drug has reduced the frequency or symptoms of AF (Level of Evidence: C).
	Class III: Harm
	• Antiarrhythmic drugs for rhythm control should not be continued when AF becomes permanent (Level of Evidence: C), including dronedarone (Level of Evidence: B).
	• Dronedarone should not be used for treatment of AF in patients with New York Heart Association class III and IV HF or patients who have had an episode of decompensated HF in the past 4 weeks. (Level of Evidence: B).
	
	<u>Upstream therapy</u>
	Class IIa
	• An angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced left ventricular ejection fraction (Level of Evidence: B).
	Class IIb
	• Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension (Level of Evidence: B).
	• Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery (Level of Evidence: A).
	Class III: No Benefit
	• Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease (Level of Evidence: B).

National Institute for Health and Clinical	• Dronedarone is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial

Clinical Guideline	Recommendation (s)
Excellence: **Dronedarone for the Treatment of Non-permanent Atrial Fibrillation (2010)[5]** (last modified Dec 2012)	fibrillation (AF): ○ Whose AF is not controlled by first-line therapy (usually including β-blockers), that is, as a second-line treatment option and after alternative options have been considered AND ○ Who have at least one of the following cardiovascular risk factors: ▪ Hypertension requiring drugs of at least two different classes. ▪ Diabetes mellitus. ▪ Previous transient ischemic attack, stroke, or systemic embolism. ▪ Left atrial diameter of 50 mm or greater, OR ▪ Age ≥70 years. ○ And in patients who do not have left ventricular systolic dysfunction AND who do not have a history of, or current, heart failure. • Patients who do not meet the above criteria who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
National Institute for Health and Clinical Excellence: **Atrial Fibrillation: The Management of Atrial Fibrillation (2014)[6]**	<u>Interventions to prevent stroke</u> • Do not offer stroke prevention to people aged <65 years with atrial fibrillation (AF) and no risk factors other than their sex (that is, very low risk of stroke equating to CHA_2DS_2-VASc score of 0 for men or 1 for women). • Consider anticoagulation for men with a CHA_2DS_2-VASc score of 1. Take the bleeding risk into account. • Offer anticoagulation to people with a CHA_2DS_2-VASc score of 2 or above, taking bleeding risk into account. • Discuss the options for anticoagulation with the person and base the choice on their clinical features and preferences. • Apixaban ○ Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorization, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as: ▪ Prior stroke of transient ischemic attack (TIA). ▪ Age 75 years or older. ▪ Hypertension. ▪ Diabetes mellitus. ▪ Symptomatic heart failure. • Dabigatran etexilate ○ Dabigatran etexilate is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more of the following risk factors: ▪ Previous stroke, TIA, or systemic embolism. ▪ Left ventricular ejection fraction (LVEF) <40%. ▪ Symptomatic heart failure (HF) of New York Heart Association (NYHA) class 2 or above. ▪ Age 75 years or older. ▪ Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease, or hypertension. • Rivaroxaban ○ Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular AF with one or more risk factors such as: ▪ Congestive heart failure. ▪ Hypertension. ▪ Age 75 years or older. ▪ Diabetes mellitus. ▪ Prior stroke or TIA.

Clinical Guideline	Recommendation (s)

	• The decision about whether to start treatment with a new oral anticoagulant should be made after an informed discussion between the clinician and the person about the risks and benefits of the agent compared with the alternatives, including warfarin. For people who are taking warfarin, the potential risks and benefits of switching to a different oral agent should be considered in light of their level of international normalized ratio (INR) control.
	
	<u>Assessing anticoagulation control with vitamin K antagonists</u>
	• Calculate the person's time in therapeutic range (TTR) at each visit. When calculating TTR:
	  o Use a validated method of measurement such as the Rosendaal method for computer-assisted dosing or proportion of tests in range for manual dosing.
	  o Exclude measurements taken during the first six weeks of treatment.
	  o Calculate TTR over a maintenance period of at least six months.
	• Reassess anticoagulation for a person with poor anticoagulation control shown by any of the following:
	  o Two INR values higher than 5 or one INR value higher than 8 within the past six months.
	  o Two INR values less than 1.5 within the past six months.
	  o TTR <65%.
	• When assessing anticoagulation, take into account and if possible address the following factors that may contribute to poor anticoagulation control: Cognitive function, adherence, illness, drug interactions, and lifestyle factors including diet and alcohol consumption.
	• If poor anticoagulation control cannot be improved, evaluate the risks and benefits of alternative stroke prevention strategies and discuss these with the person.
	
	<u>When to offer rate and rhythm control</u>
	• Offer rate control as the first-line strategy to people with AF, except in people whose AF has a reversible cause, who have HF thought to be primarily caused by AF, with new-onset AF, with atrial flutter whose condition is considered suitable for an ablation strategy to restore sinus rhythm, and for whom a rhythm control strategy would be more suitable based on clinical judgement.
	
	<u>Rate control</u>
	• Offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium channel blocker (CCB) as initial monotherapy to people with AF who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities, and preferences when considering drug treatment.
	• Consider digoxin monotherapy for people with non-paroxysmal AF only if they are sedentary.
	• If monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any two of the following: a beta-blocker, diltiazem, and digoxin.
	• Do not offer amiodarone for long-term rate control.
	
	<u>Rhythm control</u>
	• Consider pharmacological and/or electrical rhythm control for people with AF whose symptoms continue after heart rate has been controlled or for whom a rate-control strategy has not been successful.
	
	<u>Drug treatment for long-term rhythm control</u>

Clinical Guideline	Recommendation (s)

	• Assess the need for drug treatment for long-term rhythm control, taking into account the person's preferences, associated comorbidities, risks of treatment, and likelihood of recurrence of AF.
	• If drug treatment for long-term rhythm control is needed, consider a standard beta-blocker as first-line treatment unless there are contraindications.
	• If beta-blockers are contraindicated or unsuccessful, assess the suitability of alternative drugs for rhythm control, taking comorbidities into account.
	• Dronedarone is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial fibrillation:
	  o Whose AF is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option and after alternative options have been considered AND
	  o Who have at least one of the following cardiovascular risk factors:
	  ▪ Hypertension requiring drugs of at least two different classes.
	  ▪ Diabetes mellitus.
	  ▪ Previous TIA, stroke, or systemic embolism.
	  ▪ Left atrial diameter of 50 mm or greater, OR
	  ▪ Age ≥70 years, AND
	  o Who do not have left ventricular systolic dysfunction, AND
	  o Who do not have a history of, or current, HF.
	• People who do not meet the criteria above who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
	• Consider amiodarone for people with left ventricular impairment or HF.
	• Do not offer class 1c antiarrhythmic drugs such as flecainide or propafenone to people with known ischemic or structural heart disease.
	• Where people have infrequent paroxysms and few symptoms, or where symptoms are induced by known precipitants (such as alcohol, caffeine), a 'no drug treatment' strategy or a 'pill-in-the-pocket' strategy should be considered and discussed with the person.

American College of Cardiology/American Heart Association/ European Society of Cardiology Committee for Practice Guidelines: **Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2006)**[7]	<u>Drug therapy for ventricular arrhythmias</u> • β-blockers are currently the mainstay of pharmacologic therapy for the treatment of arrhythmias, due to their safety profile and effectiveness. • Other than β-blockers, alternative antiarrhythmic agents currently available have not been proven effective in the primary management of patients with life-threatening ventricular arrhythmias or in the prevention of sudden cardiac death. • For patients that are arrhythmia-prone, antiarrhythmic agents may be effective as adjunctive therapy in particular situations. • Caution should be used when any antiarrhythmic agent is used for therapy, as there are many side effects associated with these agents. • β-blockers, or alternatively, amiodarone or sotalol, may be used in patients with ventricular tachycardia who do not meet criteria for an implantable cardioverter-defibrillator. • Sotalol or, alternatively the combination of β-blockers and amiodarone, may be used in patients with implantable cardioverter-defibrillators who have recurrent ventricular tachycardia/ventricular fibrillation with frequent appropriate implantable cardioverter-defibrillator firing. <u>Ventricular arrhythmia and sudden cardiac death related to specific pathology</u> Left ventricular dysfunction due to prior MI: • Amiodarone, often in combination with β-blockers, can be useful for patients with left ventricular dysfunction due to prior MI and symptoms due to ventricular tachycardia unresponsive to β-blocking agents.

Clinical Guideline	Recommendation (s)
	• Sotalol is reasonable therapy to reduce symptoms resulting from ventricular tachycardia for patients with left ventricular dysfunction due to prior MI unresponsive to β-blocking agents. • Alternative therapies to the implantable cardioverter-defibrillator to improve symptoms due to frequent episodes of sustained ventricular tachycardia or ventricular fibrillation in patients with left ventricular dysfunction due to prior MI include agents such as amiodarone or sotalol. • To reduce symptoms in patients due to recurrent hemodynamically stable ventricular tachycardia with left ventricular dysfunction due to prior MI and who cannot or refuse to have an implantable cardioverter-defibrillator implanted, amiodarone may be used as an alternative therapy. • To improve symptoms in patients with left ventricular dysfunction due to prior MI and recurrent hemodynamically stable ventricular tachycardia whose LVEF is >40% and an implantable cardioverter-defibrillator is not appropriate, amiodarone may be considered an alternative treatment option. • In patients with left ventricular dysfunction due to prior MI where an implantable cardioverter-defibrillator is indicated but is not appropriate or desired by the patient, amiodarone may be considered an alternative treatment option. • Prophylactic antiarrhythmic drug therapy is not indicated to reduce mortality in patients with asymptomatic nonsustained ventricular arrhythmias. • Class Ic antiarrhythmic agents are not recommended in patients with a past history of MI. <u>Congenital heart disease</u>: • Prophylactic antiarrhythmic therapy is not indicated for asymptomatic patients with congenital heart disease and isolated premature ventricular contractions. <u>Metabolic and inflammatory conditions</u>: • Antiarrhythmic therapy can be useful in patients with symptomatic non-sustained ventricular tachycardia or sustained ventricular tachycardia during the acute phase of myocarditis. <u>Pericardial disease</u>: • Prophylactic antiarrhythmic therapy generally is not indicated for primary prevention of sudden cardiac death in patients with pulmonary arterial hypertension or other pulmonary conditions. <u>Ventricular arrhythmias associated with cardiomyopathies</u> Dilated cardiomyopathy (nonischemic): • Amiodarone may be considered for sustained ventricular tachycardia or ventricular fibrillation in patients with nonischemic dilated cardiomyopathy. <u>Hypertrophic cardiomyopathy</u> • Amiodarone therapy can be effective for treatment in patients with hypertrophic cardiomyopathy with a history of sustained ventricular tachycardia and/or ventricular fibrillation when implantable cardioverter-defibrillator is not feasible. • Amiodarone may be considered for primary prophylaxis against sudden cardiac death in patients with hypertrophic cardiomyopathy who have one or more major risk factor for sudden cardiac death, if implantable cardioverter-defibrillator implantation is not feasible. <u>Arrhythmogenic right ventricular cardiomyopathy</u> • Amiodarone or sotalol can be effective for treatment of sustained ventricular

Clinical Guideline	Recommendation (s)
	tachycardia or ventricular fibrillation in patients with arrhythmogenic right ventricular cardiomyopathy when implantable cardioverter-defibrillator implantation is not feasible. Heart failure • Amiodarone, sotalol and/or other β-blockers are recommended pharmacological adjuncts to implantable cardioverter-defibrillator therapy to suppress symptomatic ventricular tachyarrhythmias (both sustained and nonsustained) in otherwise optimally treated patients with heart failure. • Amiodarone is indicated for the suppression of acute hemodynamically compromising ventricular or supraventricular tachyarrhythmias when cardioversion and/or correction of reversible causes have failed to terminate the arrhythmia or prevent its early recurrence. • Amiodarone, sotalol, and/or β-blockers may be considered as pharmacological alternatives to implantable cardioverter-defibrillator therapy to suppress symptomatic ventricular tachyarrhythmias (both sustained and nonsustained) in optimally treated patients with heart failure for whom implantable cardioverter-defibrillator therapy is not feasible. Genetic arrhythmia syndromes Long QT syndrome: • β-blockers are recommended for patients with a long QT syndrome clinical diagnosis (i.e., in the presence of prolonged QT interval). • Implantation of an implantable cardioverter-defibrillator along with use of β-blockers is recommended for long QT syndrome patients with previous cardiac arrest and who have reasonable expectation of survival with a good functional status for more than one year. • β-blockers can be effective to reduce sudden cardiac death in patients with a molecular long QT syndrome analysis and normal QT interval. • Implantation of an implantable cardioverter-defibrillator with continued use of β-blockers can be effective to reduce sudden cardiac death in long QT syndrome patients experiencing syncope and/or ventricular tachycardia while receiving β-blockers and who have reasonable expectation of survival with a good functional status for more than one year. Short QT syndrome and Brugada syndrome: • Quinidine might be reasonable for the treatment of electrical storm in patients with Brugada syndrome. Catecholaminergic polymorphic ventricular tachycardia: • β-blockers are indicated for patients who are clinically diagnosed with catecholaminergic polymorphic ventricular tachycardia on the basis of the presence of spontaneous or documented stress-induced ventricular arrhythmias. • β-blockers can be effective in patients without clinical manifestations when the diagnosis of catecholaminergic polymorphic ventricular tachycardia is established during childhood based on genetic analysis. • β-blockers may be considered for patients with catecholaminergic polymorphic ventricular tachycardia who were genetically diagnosed in adulthood and never manifested clinical symptoms of tachyarrhythmias. Arrhythmias in structurally normal hearts Idiopathic ventricular tachycardia: • Drug therapy with β-blockers and/or calcium channel blockers can be useful in patients with structurally normal hearts with symptomatic ventricular tachycardia arising from the right ventricle.

Clinical Guideline	Recommendation (s)
	Ventricular arrhythmias and sudden cardiac death related to specific populations Pregnancy: • In pregnant women with the long QT syndrome who have had symptoms, it is beneficial to continue β-blocker medications throughout pregnancy and afterward, unless there are definite contraindications. Elderly: • The dosing and titration schedule of antiarrhythmic drugs prescribed to elderly patients should be adjusted to the altered pharmacokinetics of such patients.
American Association for Thoracic Surgery: **2014 AATS Guidelines for the Prevention and Management of Peri-Operative Atrial Fibrillation and Flutter (POAF) for Thoracic Surgical Procedures (2014)**[8]	Recommended prevention strategies for all postoperative atrial fibrillation (POAF) patients • Patients taking β-blockers prior to thoracic surgery should continue them in the postoperative period to avoid β-blockade withdrawal. • Intravenous magnesium supplementation may be considered to prevent postoperative AF when serum magnesium level is low or it is suspected that total body magnesium is depleted. • Digoxin should not be used for prophylaxis against AF. Recommended prevention strategies for intermediate to high-risk POAF patients • It is reasonable to administer diltiazem to those patients with preserved cardiac function who are not taking β-blockers preoperatively in order to prevent POAF. • It is reasonable to consider the postoperative administration of amiodarone to reduce the incidence of POAF for intermediate and high risk patients undergoing pulmonary resection. • Postoperative administration of intravenous amiodarone may be considered to prevent POAF in patients undergoing esophagectomy. • Atorvastatin may be considered to prevent POAF for statin naïve patients scheduled for intermediate and high risk thoracic surgical procedures. Rate control recommendations for patients with new onset POAF • Intravenous administration of beta-blockers (e.g., esmolol or metoprolol) or nondihydropyridine calcium channel blockers (diltiazem or verapamil) is recommended to achieve rate control (heart rate ≤110 bpm) for patients who develop POAF with rapid ventricular response. • Caution should be used with patients with hypotension, left ventricular (LV) dysfunction, or heart failure. • Combination use of atrioventricular (AV) nodal blocking agents, such as beta-blockers (e.g., esmolol or metoprolol), nondihydropyridine calcium channel antagonists (e.g., diltiazem or verapamil), or digoxin, can be useful to control heart rates when a single agent fails to control rates of POAF. The choice should be individualized and doses modified to avoid bradycardia. • For patients with hypotension, heart failure or LV dysfunction, or when other measures are unsuccessful or contraindicated, intravenous amiodarone can be useful for control of heart rate. Amiodarone could result in conversion to sinus rhythm, and if it is initiated after 48 hours of AF, both a transesophageal echocardiography (TEE) when possible, to rule out left atrial/LA appendage (LA/LAA) thrombus, and full anticoagulation should be considered. • For patients with heart failure, LV dysfunction or hypotension, intravenous digoxin may be considered for rate control of POAF. • For patients with ventricular preexcitation (i.e., Wolff-Parkinson-White syndrome) and POAF, use of AV nodal blocking agents, such as beta-blockers (e.g., esmolol or metoprolol), intravenous amiodarone, nondihydropyridine calcium channel antagonists (e.g., diltiazem or verapamil), or digoxin, should be avoided.

Clinical Guideline	Recommendation (s)
	Recommendations for the use of antiarrhythmic drugs for pharmacologic cardioversion of POAF • Restoration of sinus rhythm with pharmacologic cardioversion is reasonable in patients with symptomatic, hemodynamically stable POAF. Intravenous amiodarone can be useful for pharmacologic cardioversion of POAF. • It is reasonable to administer antiarrhythmic medications in an attempt to maintain sinus rhythm for patients with recurrent or refractory POAF. • Amiodarone, sotalol, flecainide, propafenone, or dofetilide can be useful to maintain sinus rhythm in patients with POAF, depending on underlying heart disease, renal status and other comorbidities. • Flecainide or propafenone may be considered for pharmacologic cardioversion of POAF and maintenance of sinus rhythm if the patient has had no prior history of myocardial infarction, coronary artery disease, impaired LV function, significant LV hypertrophy, or valvular heart disease that is considered moderate or greater. These agents may need to be combined with an AV nodal blocking agent. • Intravenous ibutilide or procainamide may be considered for pharmacologic conversion of POAF for patients with structural heart disease and new onset POAF, but no hypotension or manifestations of congestive heart failure. Serum electrolytes and QTc interval must be within a normal range and patients must be closely monitored during and for at least six hours after the infusion if either ibutilide or procainamide. • Intravenous ibutilide or procainamide may be considered for patients with POAF and an accessory pathway. • Flecainide and propafenone should not be used to treat POAF in patients with a history of a prior myocardial infarction, coronary artery disease, and/or severe structural heart disease, including severe left ventricular hypertrophy, or significantly reduced left ventricular ejection fraction. • Dronedarone should not be used for treatment of POAF in patients with heart failure. Recommendations for prevention of thromboembolism for patients with stable atrial fibrillation/flutter undergoing direct current cardioversion • For stable patients with POAF of 48-hours duration or longer, anticoagulation (with warfarin for INR 2.0 to 3.0, a novel oral anti-coagulant [NOAC] or LMWH) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the method (electrical or pharmacological) used to restore sinus rhythm. • During the first 48 hours after the onset of POAF, the need for anticoagulation before and after direct current (DC) cardioversion may be based on the patient's risk of thromboembolism (CHA2DS2-VASc score) balanced by the risk of postoperative bleeding. • For POAF lasting longer than 48 hours, as an alternative to three weeks of therapeutic anticoagulation prior to cardioversion of POAF, it is reasonable to perform TEE in search of thrombus in the LA or LA appendage, preferably with full anticoagulation at the time of TEE in anticipation of DC cardioversion after the TEE. • For POAF lasting longer than 48 hours in patients who are not candidates for TEE (e.g., post-esophageal surgery), an initial rate control strategy combined with therapeutic anticoagulation using warfarin (aiming for INR 2.0 to 3.0), a direct thrombin inhibitor (e.g. dabigatran), factor Xa inhibitor (e.g. rivaroxaban, apixaban), or LMWH is recommended for at least three weeks prior to and four weeks after cardioversion. • Anticoagulation recommendations for cardioversion of atrial flutter are similar

Clinical Guideline	Recommendation (s)
	to those for atrial fibrillation. • For patients with an identified thrombus, cardioversion should not be performed until a longer period of anticoagulation is achieved (usually at least three weeks) and in accordance with established AF guidelines. <u>Management of anticoagulation for new onset POAF</u> • For the prevention of strokes for patients who develop POAF lasting longer than 48 hours, it is recommended to administer antithrombotic medications similarly to non-surgical patients. Anticoagulation within the first 48-hours of POAF should be considered based on the CHA2DS2-VASc risk score of the patient for stroke weighed against the risk of postoperative bleeding. • New oral anticoagulants (dabigatran, rivaroxaban, apixaban) are reasonable as an alternative to warfarin for patients who do not have a prosthetic heart valve, hemodynamically significant valve disease, and/or severe renal impairment or risk of GI bleeding. • It is reasonable to continue anticoagulation therapy for four weeks after the return of sinus rhythm because of the possibility of slowly resolving impairment of atrial contraction with an associated ongoing risk for thrombus formation and for delayed embolic events. • New oral anticoagulants should be avoided for patients at risk for serious bleeding (including GI bleeding) as they cannot be readily reversed. However, their use may be recommended in situations where achievement of a therapeutic INR with warfarin has proved to be difficult.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the antiarrhythmic agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Antiarrhythmic Agents[9-17]

Indication	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Atrial Arrhythmias								
Chronic therapy in patients at high risk of symptomatic atrial fibrillation (AF)/flutter								✔ *
Conversion of AF and atrial flutter to normal sinus rhythm			✔					
Maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter) in patients with AF/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm			✔ †					
Prevention of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms and paroxysmal supraventricular tachycardias (PSVT) associated with disabling symptoms in patients without structural heart disease					✔			
Prolong the time to recurrence of symptomatic AF in patients without structural heart disease							✔ ‡	
Prolong the time to recurrence of PAF and PSVT associated with disabling symptoms in patients without structural heart disease							✔ §	
Reduce the risk of hospitalization for AF in patients in sinus rhythm with a history of paroxysmal or persistent AF				✔				

Indication	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Restore normal sinus rhythm in patients with symptomatic AF/atrial flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response								✔
Ventricular Arrhythmias								
Initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy	✔ (Nexterone®)‖							
Prevention of life-threatening ventricular arrhythmias (e.g., sustained VT)					✔			
Suppression of recurrent life-threatening ventricular arrhythmias (e.g., sustained VT)								✔
Treatment of life-threatening ventricular arrhythmias (e.g., sustained VT)		✔				✔	✔ §	
Treatment of recurrent VF	✔ ¶ (Cordarone®, Pacerone®)							
Treatment of recurrent hemodynamically unstable VT	✔ ¶ (Cordarone®, Pacerone®)							
Miscellaneous								
Treatment of life-threatening *Plasmodium falciparum* malaria								✔

*This includes patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. The increased risk of death should specifically be considered. Quinidine sulfate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate.
†Because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic.
‡Sustained-release formulation.
§Immediate-release formulation.
‖Nexterone® can also be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medications. During or after treatment with Nexterone®, patients may be transferred to oral amiodarone therapy. Use Nexterone® for acute treatment until patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but Nexterone® may be safely administered for longer periods if necessary.
¶ Because of its life-threatening side effects and the substantial management difficulties associated with its use, amiodarone is indicated only for the treatment of the life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated.

IV. Pharmacokinetics

The pharmacokinetic parameters of the antiarrhythmic agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Antiarrhythmic Agents[18]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life
Amiodarone	35 to 65	96	Liver (% not reported; extensive)	Renal (<1) Bile (% not reported; primary)	26 to 107 days
Disopyramide	80	50 to 65	Liver (45)	Renal (40 to 80) Feces (15)	4 to 10 hours
Dofetilide	>90	60 to 70	Liver (50)	Renal (80) Feces (<10)	7.5 to 10 hours
Dronedarone	15	>98	Liver (% not reported; extensive)	Renal (6) Feces 84)	13 to 19 hours
Flecainide	70 to 95	40	Liver (% not reported; extensive)	Renal (81 to 90) Feces (4 to 6)	7 to 22 hours
Mexiletine	80 to 90	50 to 70	Liver (% not reported; extensive)	Renal (8 to 15)	6 to 17 hours
Propafenone	12	85 to 97	Liver (% not reported; extensive)	Renal (<1) Feces (53)	5 to 8 hours
Quinidine	70 to 80 (oral)	80 to 90	Liver 50 to 90)	Renal (5 to 20) Feces (1 to 3)	6 to 8 hours

V. Drug Interactions

Major drug interactions with the antiarrhythmic agents are listed in Table 5.

Table 5. Major Drug Interactions with the Antiarrhythmic Agents[18]

Generic Name(s)	Interaction	Mechanism
Amiodarone, Disopyramide, Flecainide, Propafenone, Quinidine	Cisapride	Possible additive prolongation of the QT interval, increasing the risk of life-threatening cardiac arrhythmias.
Amiodarone, Disopyramide, Dofetilide, Flecainide, Propafenone, Quinidine	Dronedarone	Possible additive or synergistic prolongation of the QT interval, increasing the risk of life-threatening cardiac arrhythmias.
Amiodarone, Disopyramide, Dofetilide, Dronedarone, Quinidine	Macrolide and related antibiotics	An additive or synergistic increase in the QT interval may result, increasing the risk of life-threatening cardiac arrhythmias.
Amiodarone, Disopyramide, Dofetilide, Dronedarone,	Phenothiazines	Concurrent use may lead to the prolongation of the QT interval which may increase the risk of life-threatening cardiac arrhythmias, including torsades de pointes.

Generic Name(s)	Interaction	Mechanism
Quinidine		
Amiodarone, Disopyramide, Dofetilide, Quinidine	Quinolones	Concurrent use of these agents may lead to additive prolongation of the QT interval which may increase the risk of life-threatening cardiac arrhythmias, including torsades de pointes.
Amiodarone, Disopyramide, Dofetilide, Quinidine	Ziprasidone	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility with concurrent administration.
Amiodarone, Mexiletine, Quinidine	Hydantoins	Phenytoin may increase the hepatic metabolism of certain antiarrhythmics via stimulation of microsomal enzymes.
Amiodarone, Dronedarone	Protease inhibitors	Protease inhibitors may inhibit the metabolism (CYP3A4) of certain antiarrhythmics, thereby increasing antiarrhythmic concentrations and increasing the risk of toxicity.
Amiodarone, Disopyramide	Vardenafil	Mechanism of interaction is unknown. The risk of life-threatening cardiac arrhythmias may be increased with concurrent use.
Dofetilide, Quinidine	Azole antifungals	Certain azole antifungal agents may inhibit the metabolism (CYP3A4) and active renal secretion of dofetilide or quinidine. Plasma dofetilide or quinidine concentrations may be elevated, increasing the risk of serious cardiovascular events.
Disopyramide, Quinidine	Hydantoins	Phenytoin appears to increased hepatic metabolism of disopyramide via stimulation of microsomal enzymes.
Propafenone, Quinidine	Rifamycins	Rifamycins may induce the hepatic microsomal enzymes responsible for metabolizing certain antiarrhythmics, whose increased clearance may lead to a decrease in plasma levels and a possible loss of therapeutic effects.
Amiodarone	Digoxin	Amiodarone may increase the oral bioavailability and decrease the systemic clearance of digoxin; additional mechanisms may exist. Mechanism of interaction is unknown but it is thought that multiple mechanisms are involved.
Amiodarone	Fentanyl	Mechanism of interaction is unknown. Profound bradycardia, sinus arrest, and hypotension have occurred with concurrent administration.
Amiodarone	HMG-CoA reductase inhibitors	Amiodarone may inhibit the metabolism of HMG-CoA reductase inhibitors (cytochrome P450 [CYP] 3A4) thereby increasing plasma concentrations and increasing the risk of toxicity.
Amiodarone	Quinidine	Mechanism of interaction is unknown. Concurrent therapy may lead to an increase in quinidine concentrations and produce potentially fatal cardiac dysrhythmias.
Amiodarone	Warfarin	Amiodarone inhibits the metabolism (CYP1A2 and CYP2C9) of the R- and S-enantiomers of warfarin; therefore the hypoprothrombinemic effects may be augmented.
Amiodarone	Cyclosporine	Mechanism of the interaction is unknown. Amiodarone may inhibit the metabolism of cyclosporine which may lead to an increase in cyclosporine blood concentrations, possibly increasing the risk of nephrotoxicity.
Amiodarone	Flecainide	Amiodarone may decrease the metabolism of flecainide and plasma levels may be increased.
Amiodarone	Procainamide	Mechanism of the interaction is unknown. Amiodarone may increase serum concentrations of procainamide.
Disopyramide	Rifampin	Hepatic metabolism of disopyramide is increased with concurrent use.
Dofetilide	Cimetidine	Cimetidine may increase dofetilide concentrations by inhibiting the renal cation transport system, which is responsible for dofetilide

Generic Name(s)	Interaction	Mechanism
		elimination. Elevated dofetilide concentrations may increase the risk of ventricular arrhythmias, including torsades de pointes.
Dofetilide	Megestrol	Concurrent use results in inhibition of the renal cation transport system responsible for dofetilide elimination, increasing the risk of ventricular arrhythmias.
Dofetilide	Thiazide diuretics	Thiazide diuretics may increase potassium excretion causing hypokalemia which may increase the risk of torsades de pointes.
Dofetilide	Trimethoprim	Trimethoprim may increase dofetilide concentrations by inhibiting the renal cation transport system, which is responsible for dofetilide elimination. Elevated dofetilide concentrations may increase the risk of ventricular arrhythmias, including torsades de pointes.
Dofetilide	Verapamil	Verapamil may increase the rate of dofetilide absorption by increasing portal blood flow thereby increasing dofetilide plasma concentrations which may increase the risk of ventricular arrhythmias, including torsades de pointes.
Dronedarone	Azole antifungal agents	Dronedarone plasma concentrations may be elevated, increasing the risk of toxicity, including life-threatening cardiotoxicity.
Dronedarone	Cyclosporine	Dronedarone plasma concentrations may be elevated, increasing the risk of toxicity, including life-threatening cardiotoxicity.
Dronedarone	Nefazodone	Plasma concentrations and pharmacologic effects of dronedarone may be increased by nefazodone. Inhibition of CYP3A by nefazodone may decrease the metabolic elimination of dronedarone.
Dronedarone	Tricyclic antidepressants	The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.
Dronedarone	Digoxin	Plasma concentrations and pharmacologic effects of digoxin may be increased, due to inhibition of P-glycoprotein efflux transport.
Flecainide	Amiodarone	Flecainide plasma levels may be increased.
Flecainide	Ritonavir	Large increases in serum flecainide concentrations may occur, increasing the risk of flecainide toxicity.
Mexiletine	Propafenone	Mexiletine plasma concentrations may be elevated in extensive metabolizers, increasing the risk of side effects.
Mexiletine	Theophylline	Mexiletine may impair hepatic elimination and increase plasma concentrations of theophylline. Additive arrhythmogenic effects may also occur.
Mexiletine	Tizanidine	Tizanidine plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions.
Propafenone	Digoxin	Mechanism of interaction is unknown. Serum digoxin levels may be increased, resulting in toxicity.
Propafenone	Ritonavir	Large increases in serum propafenone concentrations may occur, increasing the risk of propafenone toxicity.
Propafenone	β-blockers	The pharmacologic effects of beta-blockers metabolized by the liver may be increased.
Propafenone	Quinidine	Serum propafenone levels may be increased in rapid, extensive metabolizers of the drug (≈ 90% of the patients), increasing the pharmacologic effects of propafenone.
Propafenone	Serotonin reuptake inhibitors	Propafenone plasma concentrations may be increased by serotonin-norepinephrine reuptake inhibitors, due to inhibition of cytochrome CYP2D6 isoenzymes.
Quinidine	Digoxin	Quinidine may reduce the renal clearance, biliary clearance and volume of distribution of digoxin thereby increasing serum digoxin levels and increasing the risk of toxicity.
Quinidine	Mifepristone	Quinidine plasma concentrations may be elevated due to inhibition of metabolism by mifepristone, increasing the pharmacologic effects and risk of adverse reactions
Quinidine	Protease	Protease inhibitors may inhibit the metabolism (CYP3A4) of

Generic Name(s)	Interaction	Mechanism
	inhibitors	quinidine. Large increases in serum quinidine concentrations may occur, increasing the risk of quinidine toxicity.
Quinidine	Verapamil	Verapamil may decrease the clearance of quinidine and prolong its half-life which may lead to hypotension, bradycardia, ventricular tachycardia and atrioventricular block.
Quinidine	Warfarin	Quinine derivatives also may inhibit the hepatically synthesized clotting factors. Anticoagulation may be potentiated by quinine derivatives and hemorrhage may occur.
Quinidine	Antacids	Certain antacids may increase serum quinidine concentrations, which may result in toxicity.
Quinidine	Anti-cholinesterases	Quinidine derivatives may reverse the effects of anticholinesterases and vice versa.
Quinidine	Aripiprazole	Quinidine may inhibit the hepatic metabolism (CYP2D6) of aripiprazole thereby increasing plasma concentrations and potentiating the pharmacologic effects and adverse reactions.
Quinidine	Barbiturates	Barbiturates may increase the metabolic clearance of quinidine thereby decreasing quinidine serum concentrations and elimination half-life.
Quinidine	β-blockers	Quinidine may inhibit the oxidative metabolism of certain beta-blockers. The effects of certain β-blockers may be increased in "extensive metabolizers."
Quinidine	Cimetidine	Inhibition of hepatic microsomal enzymes by cimetidine may decrease the metabolic elimination of quinidine. Additional mechanisms may exist including a decrease in renal clearance of quinidine possibly due to competition with cimetidine for renal tubular secretion.
Quinidine	Codeine	Quinidine may decrease pharmacologic effects of codeine, due to inhibition of CYP2D6 isoenzymes and thereby decreased metabolic conversion of codeine to morphine. Loss of analgesic effect may occur.
Quinidine	Diltiazem	The therapeutic and adverse effects of quinidine may be increased due to inhibition of the hepatic metabolism of quinidine by competition for the same isozyme.
Quinidine	Nifedipine	Plasma concentrations and pharmacologic effects of quinidine may be decreased by nifedipine. Plasma concentrations and pharmacologic effects of nifedipine may be increased by quinidine, which may decrease the first-pass metabolism of nifedipine by inhibiting aromatization.
Quinidine	Non-depolarizing muscle relaxants	Concurrent use of these agents may cause synergistic pharmacologic effects. Non-depolarizing muscle relaxants effects may be enhanced by quinine and quinine derivatives.
Quinidine	Succinylcholine	Quinidine may produce a decrease in plasma cholinesterase activity resulting in a slowed metabolic rate for succinylcholine. The neuromuscular blockade produced by succinylcholine may be prolonged.

VI. Adverse Drug Events

The most common adverse drug events reported with the antiarrhythmic agents are listed in Table 6. The boxed warnings for the antiarrhythmic agents are listed in Tables 7 through 14.

Table 6. Adverse Drug Events (%) Reported with the Antiarrhythmic Agents[9-17]

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Cardiovascular								
Alters pacing threshold	-	-	-	-	<1	-	-	-
Angina	-	-	-	-	<1	2	2 to 5	6
Arrhythmia	1 to 10	-	-	-	-	-	-	1 to 10
Asystole	1 to 10	-	-	-	-	-	-	-
Atrial fibrillation	-	-	-	-	-	-	1	-
AV block	5	<1	0.4 to 1.5	-	<1	<1	1 to 3	-
AV dissociation	-	-	-	-	-	-	<1	-
Bradycardia	3 to 5	-	-	3	<1	-	1 to 2	<1
Bundle branch block	-	-	<2	-	-	-	0 to 1	-
Cardiac arrest	1 to 10	-	<2	-	-	-	<1	-
Cardiogenic shock	1 to 10	-	-	-	-	<1	-	-
Chest pain	-	1 to 10	10	-	5	3 to 8	1 to 2	-
Conduction abnormalities	1 to 10	1 to 10	-	-	-	-	0 to 1	-
Congestive heart failure	-	1 to 10	-	-	-	-	-	-
Edema	1 to 10	1 to 10	-	✔	3.5	-	0 to 1	-
Electromechanical dissociation	1 to 10	-	-	-	-	-	-	-
Heart block	-	-	<2	-	<1	-	-	<1
Hypertension	-	-	-	-	-	-	0 to 1	-
Hypotension	<1	1 to 10	-	-	-	<1	-	✔
Myocardial infarction	-	-	<2	-	-	-	-	-
Palpitations	-	-	-	-	6	4 to 8	1 to 3	7
Premature ventricular contractions	-	-	-	-	-	1 to 2	1 to 2	-
Proarrhythmia	<1	<1	-	-	4 to 12	10 to 15	2 to 10	-
P-R increased	-	-	-	-	<1	-	-	-
QRS duration	-	-	-	-	<1	-	1 to 2	-
QT interval increased	<1	-	-	-	-	-	-	>10
QTc prolonged	-	-	-	28	-	-	-	-
SA node dysfunction	1 to 3	-	-	-	-	-	-	-
Sinus arrest	<1	-	-	-	-	<1	-	-
Sinus node dysfunction	-	-	-	-	1.2	-	<1	-
Stroke	-	-	<2	-	-	-	-	-

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Tachycardia	-	-	-	-	1 to 3	-	-	<1
Torsades de pointes	<1	-	0.9 to 10.5	-	-	<1	-	<1
Ventricular arrhythmia	-	-	-	-	<1	-	-	-
Ventricular fibrillation	<1	-	0 to 0.4	-	-	-	-	<1
Ventricular rate increase	-	-	-	-	<1	-	-	<1
Ventricular tachycardia	1 to 10	-	2.6 to 3.7	-	-	-	1 to 3	<1
Central Nervous System								
Abnormal gait/ataxia	3 to 40	-	-	-	-	-	-	-
Amnesia	-	-	-	-	<1	-	<1	-
Anxiety	-	-	-	-	1 to 3	-	1 to 2	-
Ataxia	-	-	-	-	1 to 3	10 to 20	0 to 2	-
Cerebral hypoperfusion	-	-	-	-	-	-	-	<1
Coma	-	-	-	-	-	-	<1	-
Confusion	<1	-	-	-	-	1 to 10	<1	<1
Delirium	-	-	-	-	-	-	-	<1
Depersonalization	-	-	-	-	<1	-	-	-
Depression	-	<1	-	-	1 to 3	2	<1	<1
Disorientation	<1	-	-	-	-	-	-	-
Dizziness	3 to 40	1 to 10	8	-	19 to 30	20 to 25	4 to 15	-
Drowsiness	-	-	-	-	-	-	1	-
Encephalopathy	<1	-	-	-	-	-	-	-
Euphoria	-	-	-	-	<1	-	-	-
Fatigue	3 to 40	1 to 10	-	-	8	-	2 to 6	7
Fever	-	-	-	-	1 to 3	-	-	<1
Flushing	-	-	-	-	-	-	-	<1
Hallucinations	<1	-	-	-	-	<1	-	<1
Headache	3 to 40	1 to 10	11	-	4 to 10	1 to 10	2 to 5	7
Impaired memory	3 to 40	-	-	-	-	-	-	-
Insomnia	3 to 40	<1	4	-	1 to 3	5 to 7	0 to 2	-
Involuntary movement	3 to 40	-	-	-	-	-	-	-
Lightheadedness	-	-	-	-	-	11 to 25	-	15
Malaise	3 to 40	1 to 10	-	-	1 to 3	-	-	-
Memory loss	-	-	-	-	-	-	<1	-
Nervousness	-	1 to 10	-	-	5	5 to 10	-	2
Paresis	-	-	-	-	1 to 3	-	-	-
Peripheral neuropathy	3 to 40	-	-	-	-	-	-	-
Poor coordination	3 to 40	-	-	-	-	10	-	1

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Psychotic reaction/psychosis	-	<1	-	-	-	<1	<1	<1
Seizure	-	-	-	-	-	<1	0.3	-
Sleep disturbances	3 to 40	-	-	-	-	-	-	3
Somnolence	-	-	-	-	1 to 3	-	-	-
Syncope	-	1 to 10	<2	-	1 to 10	<1	1 to 2	1 to 8
Tardive dyskinesia	-	-	-	-	<1	-	-	-
Vertigo	-	-	-	-	1 to 3	-	<1	<1
Visual disturbances	<10	-	-	-	16	-	-	<1
Dermatological								
Abnormal pigmentation	-	-	-	-	-	-	-	<1
Allergic dermatitis	-	-	-	≤5	-	-	-	-
Alopecia	<1	-	-	-	<1	<1	<1	-
Eczematous dermatitis	-	-	-	≤5	-	-	-	<1
Epididymitis	<1	-	-	-	-	-	-	-
Erythema multiforme	<1	-	-	-	-	-	-	-
Exfoliative dermatitis	<1	-	-	-	<1	<1	-	<1
Flushing	1 to 10	-	-	-	-	-	-	-
Generalized dermatoses	-	1 to 10	-	-	-	-	-	-
Leukocytoclastic vasculitis	<1	-	-	-	-	-	-	-
Lichen planus	-	-	-	-	-	-	-	<1
Livedo reticularis	-	-	-	-	-	-	-	<1
Melanin pigmentation of hard palate	-	-	-	-	-	-	-	<1
Phlebitis	1 to 10	-	-	-	-	-	-	-
Photophobia	<1	-	-	-	<1	-	-	-
Photosensitivity	10 to 75	-	-	<1	-	-	-	<1
Pruritus	<1	1 to 10	-	≤5	<1	-	<1	<1
Purpura	-	-	-	-	-	-	<1	-
Rash	<1	1 to 10	3	≤5	1 to 3	4	1 to 3	5
Slate blue skin discoloration	<10	-	-	-	-	-	-	-
Spontaneous ecchymosis	<1	-	-	-	-	-	-	-
Stevens-Johnson syndrome	<1	-	-	-	-	<1	-	-
Toxic cutaneous blisters	-	<1	-	-	-	-	-	-
Toxic epidermal necrolysis	<1	-	-	-	-	-	-	-
Urticaria	-	-	-	-	<1	<1	-	<1
Vasculitis	<1	-	-	-	-	-	-	-
Endocrine and Metabolic								
Decreased libido	1 to 10	-	-	-	-	-	-	-

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Erectile dysfunction	<1	-	-	-	-	-	-	-
Gynecomastia	-	<1	-	-	-	-	-	-
Hyperthyroidism	3 to 10	-	-	-	-	-	-	-
Hypothyroidism	1 to 22	-	-	-	-	-	-	-
Impotence	<1	1 to 3	-	-	-	<1	<1	-
Gastrointestinal								
Abdominal bloating	-	1 to 10	-	-	-	-	-	-
Abdominal distention	-	1 to 10	-	-	-	-	-	-
Abdominal pain	1 to 10	-	3	4	3	1	1 to 2	-
Abnormal salivation	1 to 10	-	-	-	-	-	-	-
Abnormal taste	1 to 10	-	-	-	<1	-	3 to 23	>10
Angioedema	<1	-	<2	-	-	-	-	<1
Anorexia	10 to 33	1 to 10	-	-	1 to 3	-	1 to 2	>10
Cholestasis	-	-	-	-	-	-	0.1	-
Constipation	10 to 33	11	-	-	1	4 to 5	2 to 7	-
Diarrhea	-	1 to 10	3	9	0.7 to 3.0	4 to 5	1 to 3	35
Dry throat	-	1 to 10	-	-	-	-	-	-
Dysgeusia	-	-	-	<1	-	-	-	-
Dyspepsia	-	-	-	2	-	-	1 to 3	-
Dysphagia	-	-	-	-	-	<1	-	-
Esophagitis	-	-	-	-	-	-	-	<1
Flatulence	-	1 to 10	-	-	-	-	0 to 1	-
Gastrointestinal distress	-	-	-	-	-	41	-	>10
Nausea	10 to 33	1 to 10	5	5	9	40	2 to 11	>10
Stomach cramping	-	-	-	-	-	-	-	22
Swollen lips/tongue/mouth	-	-	-	-	<1	-	-	-
Upper gastrointestinal bleeding	-	-	-	-	-	<1	-	-
Vomiting	10 to 33	1 to 10	-	2	-	40	2 to 11	>10
Weight gain	-	1 to 10	-	-	-	-	-	-
Xerostomia	-	32	-	-	-	3	1 to 2	-
Genitourinary								
Urinary frequency	-	1 to 10	-	-	-	-	-	-
Urinary hesitancy	-	14 to 23	-	-	-	-	-	-
Urinary retention	-	1 to 10	-	-	<1	<1	-	-
Urinary urgency	-	1 to 10	-	-	-	-	-	-
Hematological								
Agranulocytosis	<1	<1	-	-	-	<1	<1	-

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Aplastic anemia	<1	-	-	-	-	-	-	-
Coagulation abnormalities	1 to 10	-	-	-	-	-	-	-
Granulocytopenia	-	-	-	-	<1	-	<1	-
Hemolytic anemia	<1	-	-	-	-	-	-	<1
Hemoptysis	<1	-	-	-	-	-	-	-
Leukopenia	-	-	-	-	<1	<1	<1	-
Neutropenia	<1	-	-	-	-	-	-	-
Pancytopenia	<1	-	-	-	-	-	-	<1
Thrombocytopenia	<1	<1	-	-	<1	<1	<1	<1
Hepatic								
AST or ALT level >2x normal	15 to 50	<1	-	-	-	-	-	-
Cirrhosis	<3	-	-	-	-	-	-	-
Hepatic necrosis	-	-	-	-	-	<1	-	-
Hepatitis	<3	-	-	-	-	<1	0.03	<1
Hepatotoxicity	-	<1	<2	-	-	-	-	<1
Laboratory Test Abnormalities								
Hypercholesterolemia	-	1 to 10	-	-	-	-	-	-
Hyperglycemia	<1	-	-	-	-	-	<1	-
Hypertriglyceridemia	<1	1 to 10	-	-	-	-	-	-
Hypoglycemia	-	<1	-	-	-	-	-	-
Hypokalemia	-	1 to 10	-	✔	-	-	-	-
Hypomagnesemia	-	-	-	✔	-	-	-	-
Serum creatinine increased	-	<1	-	51	-	-	-	-
Musculoskeletal								
Arthralgia	-	-	-	-	-	1	0 to 1	<1
Back pain	-	-	3	-	-	-	-	-
Facial paralysis	-	-	<2	-	-	-	-	-
Flaccid paralysis	-	-	<1	-	-	-	-	-
Lupus	-	<1	-	-	-	<1	<1	-
Lupus-like syndrome	-	-	-	-	-	-	-	<1
Muscle pain (myalgia)	-	1 to 10	-	-	-	-	-	<1
Myopathy	<1	-	-	-	-	-	-	-
Neuropathy	-	<1	-	-	<1	2 to 4	<1	-
Paralysis	-	-	<2	-	-	-	-	-
Paresthesia	-	<1	<2	-	1	2	<1	-
Parkinsonian symptoms	<1	-	-	-	-	-	-	-
Rhabdomyolysis	<1	-	-	-	-	-	-	-

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Trembling	-	-	-	-	-	>10	-	-
Tremor	3 to 40	-	-	-	5	13	0 to 1	2
Unsteady gait	-	-	-	-	-	>10	-	-
Weakness	<1	1 to 10	-	7	5	5	1 to 2	5
Ocular								
Blurred vision	-	1 to 10	-	-	1 to 10	5 to 7	1 to 6	1 to 10
Corneal micro-deposits	>90	-	-	-	<1	-	-	-
Diplopia	-	-	-	-	1 to 3	-	-	-
Dry eyes	-	1 to 10	-	-	-	-	-	-
Halo vision	<5	-	-	-	-	-	-	-
Mydriasis	-	-	-	-	-	-	-	<1
Nystagmus	-	-	-	-	-	6	-	-
Optic neuritis	1	-	-	-	-	-	-	<1
Optic neuropathy	<1	-	-	-	-	-	-	-
Uveitis	-	-	-	-	-	-	-	<1
Visual disturbances	2 to 9	-	-	-	-	-	-	-
Renal								
Acute renal failure	<1	-	-	-	-	-	<1	-
Nephropathy	-	-	-	-	-	-	-	<1
Nephrotic syndrome	-	-	-	-	-	-	<1	-
Respiratory								
Acute respiratory distress syndrome	2	-	-	-	-	-	-	-
Alveolar pneumonitis	✔	-	-	-	-	-	-	-
Apnea	-	-	-	-	-	-	<1	-
Bronchiolitis obliterans organizing pneumonia	<1	-	-	-	-	-	-	-
Bronchospasm	<1	-	-	-	<1	-	-	<1
Dyspnea	<1	1 to 10	6	-	~10	3	2 to 5	-
Hypersensitivity pneumonitis	✔	-	-	-	-	-	-	-
Pleuritis	<1	-	-	-	-	-	-	-
Pneumonitis	✔	-	-	-	<1	-	-	<1
Pulmonary alveolar hemorrhage	<1	-	-	-	-	-	-	-
Pulmonary edema	<1	-	-	-	-	-	-	-
Pulmonary fibrosis	✔	-	-	-	-	<1	-	-
Pulmonary inflammation	✔	-	-	-	-	-	-	-
Pulmonary mass	<1	-	-	-	-	-	-	-
Pulmonary toxicity	2 to 17	-	-	-	-	-	-	-
Respiratory failure	<1	<1	-	-	-	-	-	<1

Adverse Events	Amiodarone	Disopyramide	Dofetilide	Dronedarone	Flecainide	Mexiletine	Propafenone	Quinidine
Respiratory tract infection	-	-	7	-	-	-	-	-
Wheezing	<1	-	-	-	-	-	-	1 to 10
Other								
Abnormal smell	1 to 10	-	-	-	-	-	-	-
Anaphylactic shock	<1	-	-	-	-	-	-	-
Blood urea nitrogen increased	-	<1	-	-	-	-	-	-
Bone marrow granuloma	<1	-	-	-	-	-	-	-
Cholestatic jaundice	-	<1	-	-	-	-	-	-
Cinchonism	-	-	-	-	-	-	-	<1
Diaphoresis	-	-	-	-	-	-	1	-
Flu syndrome	-	-	4	-	-	-	-	-
Hearing impairment	-	-	-	-	-	-	-	<1
Hypoxia	<1	-	-	-	-	-	-	-
Increased bleeding time	-	-	-	-	-	-	<1	-
Increased creatine phosphokinase	-	-	-	-	-	-	-	<1
Lymphadenopathy	-	-	-	-	-	-	-	<1
Myelofibrosis	-	-	-	-	-	<1	-	-
Pancreatitis	<1	-	-	-	-	<1	-	-
Pseudotumor cerebri	<1	-	-	-	-	-	-	-
Sicca syndrome	-	-	-	-	-	-	-	<1
Syndrome of inappropriate antidiuretic hormone secretion	<1	-	-	-	-	-	<1	-
Thyroid cancer/nodules	<1	-	-	-	-	-	-	-
Thyrotoxicosis	<1	-	-	-	-	-	-	-
Tinnitus	-	-	-	-	1 to 3	2 to 3	<1	1 to 10
Vascular collapse	-	-	-	-	-	-	-	<1
Vasculitis	-	-	-	-	-	-	-	<1

✓ Percent not specified.
- Event not reported.

Table 7. Boxed Warning for Amiodarone[17]

WARNING
Life-threatening arrhythmias: Amiodarone is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity. **Potentially fatal toxicities:** Amiodarone has several potentially fatal toxicities, the most important of which is pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 10% to 17% in some series of patients with ventricular arrhythmias given doses of approximately 400 mg/day, and as abnormal diffusion capacity without symptoms in a much higher percentage of patients. Pulmonary toxicity has been fatal approximately 10% of the time. Liver injury is common with amiodarone, but is usually mild and evidenced only by abnormal liver enzymes. Overt liver disease can occur, however, and has been fatal in a few cases. Like other antiarrhythmics, amiodarone can exacerbate the arrhythmia (e.g., by making the arrhythmia less well tolerated or more difficult to reverse). This has occurred in 2% to 5% of patients in various series, and significant heart block or sinus bradycardia has been seen in 2% to 5%. In most cases, all of these events should be manageable in the proper clinical setting. Although the frequency of such proarrhythmic events does not appear greater with amiodarone than with many other agents used in this population, the effects are prolonged when they occur. **High-risk patients:** Even in patients at high risk of arrhythmic death in whom the toxicity of amiodarone is an acceptable risk, amiodarone poses major management problems that could be life-threatening in a population at risk of sudden death; therefore, make every effort to utilize alternative agents first. The difficulty of using amiodarone effectively and safely poses a significant risk to patients. Patients with the indicated arrhythmias must be hospitalized while the loading dose of amiodarone is given, and a response generally requires at least one week, usually two weeks or more. Because absorption and elimination are variable, maintenance dose selection is difficult, and it is not unusual to require dosage decrease or discontinuation of treatment. In a retrospective survey of 192 patients with ventricular tachyarrhythmias, 84 patients required dose reduction and 18 required at least temporary discontinuation because of adverse reactions, and several series have reported 15% to 20% overall frequencies of discontinuation because of adverse reactions. The time at which a previously controlled life-threatening arrhythmia will recur after discontinuation or dose adjustment is unpredictable, ranging from weeks to months. The patient is obviously at great risk during this time and may need prolonged hospitalization. Attempts to substitute other antiarrhythmic agents when amiodarone must be stopped will be made difficult by the gradually, but unpredictably, changing amiodarone body burden. A similar problem exists when amiodarone is not effective; it still poses the risk of an interaction with whatever subsequent treatment is tried.

Table 8. Boxed Warning for Disopyramide[17]

WARNING
In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had an myocardial infarction more than six days but less than two years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared to that seen in patients assigned to carefully matched placebo-treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of disopyramide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Table 9. Boxed Warning for Dofetilide[17]

WARNING
To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed for a minimum of three days in a facility that can provide calculations of creatinine clearance, continuous

WARNING
electrocardiographic monitoring, and cardiac resuscitation. For detailed instructions regarding dose selection, see Administration and Dosage. Dofetilide is available only to hospitals and prescribers who have received appropriate dofetilide dosing and treatment initiation education.

Table 10. Boxed Warning for Dronedarone[17]

WARNING
Increased risk of death, stroke, and heart failure: Dronedarone is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or New York Heart Association class IV heart failure. Dronedarone doubles the risk of death in these patients. Dronedarone is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AF, dronedarone doubles the risk of death, stroke, and hospitalization for heart failure.

Table 11. Boxed Warning for Flecainide[17]

WARNING
Mortality: Flecainide was included in the National Heart Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously. An excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with flecainide compared to that seen in patients assigned to a carefully matched placebo-treated group. This rate was 5.1% for flecainide and 2.3% for the matched placebo. The average duration of treatment with flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain, but at present, it is prudent to consider the risks of Class Ic agents (including flecainide), coupled with the lack of any evidence of improved survival, generally unacceptable in patients without life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs. **Ventricular proarrhythmic effects in patients with atrial fibrillation/flutter:** A review of the world literature revealed reports of 568 patients treated with oral flecainide for paroxysmal atrial fibrillation/flutter. Ventricular tachycardia was experienced in 0.4% of these patients. Of 19 patients in the literature with chronic atrial fibrillation, 10.5% experienced ventricular tachycardia (VT) or ventricular fibrillation (VF). Flecainide is not recommended for use in patients with CAF. Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased premature ventricular contractions, VT, VF, and death. As with other Class I agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate. A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive flecainide. Concomitant negative chronotropic therapy such as digoxin or β-blockers may lower the risk of this complication.

Table 12. Boxed Warning for Mexiletine[17]

WARNING
In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non–life-threatening ventricular arrhythmias who had an myocardial infarction (MI) more than six days but less than two years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent MI) is uncertain.

Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Table 13. Boxed Warning for Propafenone[17]

WARNING
In the National Heart, Lung, and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had an myocardial infarction more than 6 days but less than 2 years previously, an increased rate of death or reversed cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide (Class 1C antiarrhythmics) compared to that seen in patients assigned to placebo (3%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any 1C antiarrhythmic to have a significant risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with nonlife-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening symptoms or signs.

Table 14. Boxed Warning for Quinidine[17]

WARNING
In many trials of antiarrhythmic therapy for non–life-threatening arrhythmias, active antiarrhythmic therapy has resulted in increased mortality; the risk of active therapy is probably greatest in patients with structural heart disease. In the case of quinidine used to prevent or defer recurrence of atrial flutter/fibrillation, the best available data come from a meta-analysis. In the patients studied in the analyzed trials, the mortality associated with the use of quinidine was more than 3 times as great as the mortality associated with the use of placebo. Another meta-analysis showed that in patients with various non–life-threatening ventricular arrhythmias, the mortality associated with the use of quinidine was consistently greater than that associated with the use of any of a variety of alternative antiarrhythmics.

VII. Dosing and Administration

The usual dosing regimens for the antiarrhythmic agents are listed in Table 15.

Table 15. Usual Dosing Regimens for the Antiarrhythmic Agents[9-18]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Amiodarone	Ventricular arrhythmias: Injection (Nexterone®): initial, 1,000 mg IV over 24 hours; maintenance, 720 mg IV per 24 hours; in the event of breakthrough episodes of ventricular fibrillation or hemodynamically unstable ventricular tachycardia, use 150 mg IV supplemental infusions Injection, tablet: initial, loading dose of 800 to 1,600 mg/day for one to three weeks, followed by 600 to 800 mg/day for one month; maintenance, 400 to 600 mg/day	Safety and efficacy in pediatrics have not been established.	Tablet: 100 mg 200 mg 400 mg Injection: 50 mg/mL 1.5 mg/mL 1.8 mg/mL
Disopyramide	Ventricular arrhythmias:	Safety and efficacy in	Capsule:

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Capsule, extended-release capsule: 400 to 800 mg/day administered in divided doses Capsule (when rapid control of ventricular arrhythmia is essential): initial, loading dose of 200 or 300 mg; maintenance, 400 to 800 mg/day administered in divided doses	pediatrics have not been established.	100 mg 150 mg Extended-release capsule: 100 mg 150 mg
Dofetilide	Atrial arrhythmias: Capsule: 500 µg twice daily; dosage must be individualized according to calculated creatinine clearance and QTc	Safety and efficacy in pediatrics have not been established.	Capsule: 125 µg 250 µg 500 µg
Dronedarone	Atrial arrhythmias: 400 mg twice daily	Safety and efficacy in pediatrics have not been established.	Tablet: 400 mg
Flecainide	Atrial arrhythmias: Tablet (prevention of paroxysmal atrial fibrillation/flutter): initial, 50 mg every 12 hours; maintenance, doses may be increased in increments of 50 mg twice daily every four days until efficacy is achieved Ventricular arrhythmias: Tablet (prevention of paroxysmal supraventricular tachycardias): initial, 50 mg every 12 hours; maintenance, doses may be increased in increments of 50 mg twice daily every four days until efficacy is achieved; maximum, 300 mg/day Tablet (prevention of ventricular arrhythmias): initial, 100 mg every 12 hours; maintenance, up to 150 mg every 12 hours; maximum, 400 mg/day	Safety and efficacy in pediatrics have not been established.	Tablet: 50 mg 100 mg 150 mg
Mexiletine	Ventricular arrhythmias: Capsule: initial, loading dose of 400 mg, followed by 200 mg every eight hours OR 200 mg every eight hours; maintenance, 200 to 300 mg given every eight hours; maximum, 1,200 mg/day	Safety and efficacy in pediatrics have not been established.	Capsule: 150 mg 200 mg 250 mg
Propafenone	Atrial arrhythmias: Extended-release capsule: initial, 225 mg every 12 hours; maintenance, 325 to 425 mg every 12 hours Tablet: initial, 150 mg every eight hours; maintenance, 225 to 300 mg every eight hours; maximum, usefulness and safety of doses >900 mg/day have not been established Ventricular arrhythmias: Tablet: initial, 150 mg every eight hour; maintenance, 225 to 300 mg every eight	Safety and efficacy in pediatrics have not been established.	Extended-release capsule: 225 mg 325 mg 425 mg Tablet: 150 mg 225 mg 300 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	hours; maximum, usefulness and safety of doses >900 mg/day have not been established		
Quinidine	Atrial arrhythmias: Extended-release tablet: initial, 324 mg every eight to 12 hours; dosage must be individualized according to tolerance and QTc Injection: <5 to 10 mg/kg IV as a total dose; if conversion to sinus rhythm has not been achieved after infusion of 10 mg/kg, then the infusion should be discontinued, and other means of conversion should be considered Tablet: initial, 200 mg every six hours; dosage must be individualized according to tolerance and QTc Ventricular arrhythmias: Injection: <5 to 10 mg/kg IV as a total dose; if conversion to sinus rhythm has not been achieved after infusion of 10 mg/kg, then the infusion should be discontinued, and other means of conversion should be considered *Plasmodium falciparum* malaria: Injection: initial, loading dose of 15 mg/kg; maintenance, 7.5 mg/kg infused over four hours every eight hours for seven days OR initial, loading dose of 6.25 mg/kg; maintenance, 12.5 µg/kg/min Tablet: maintenance, 300 mg every eight hours for seven days OR maintenance, provide approximately as much daily quinine base as the patient had been receiving quinidine base	Safety and efficacy for the treatment of atrial and ventricular arrhythmias in pediatrics have not been established. *Plasmodium falciparum* malaria: Injection: initial, loading dose of 6.25 mg/kg; maintenance, 12.5 µg/kg/min Tablet: maintenance, 300 mg every eight hours for seven days OR maintenance, provide approximately as much daily quinine base as the patient had been receiving quinidine base	Extended-release tablet: 324 mg (quinidine gluconate) Injection (quinidine gluconate): 80 mg/mL Tablet (quinidine sulfate): 200 mg 300 mg

IV=intravenous.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the antiarrhythmic agents are summarized in Table 16.

Table 16. Comparative Clinical Trials with the Antiarrhythmic Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cairns et al.[19] (1997) CAMIAT Amiodarone loading dose of 10 mg/kg in 2 divided doses daily for 2 weeks, followed by 300 to 400 mg/day for 3 to 5 months, then 200 to 300 mg/day for 4 months, and finally 200 mg/day for 5 to 7 days per week for 16 months vs placebo	DB, MC, PC, RCT Patients >19 years who had an acute MI within the previous 6 to 45 days, and the development of new 40 ms Q-waves in ≥2 adjacent ECG leads or the development of a dominant R-wave in V1, 24 hour ambulatory ECG monitoring that recorded a mean of ≥10 VDPs per hour (≥18 hours of monitoring required), or at ≥1 run of VT	N=1,202 2 years	Primary: RVF or AD Secondary: AD, cardiac death, all-cause mortality	Primary: Twenty five patients receiving amiodarone compared to 39 patients receiving placebo experienced an RVF or AD (RR reduction, 38.2; 95% CI, -2.1 to 62.6; P=0.029). Secondary: Twenty four patients receiving amiodarone compared to 33 patients receiving placebo experienced an AD (RR reduction, 29.3; 95% CI, -19.6 to 58.2; P=0.097). Cardiac mortality was not significant between amiodarone and the placebo groups (44 vs 55 patients respectively; RR reduction 22.0; 95% CI, -15.9 to 47.6; P=0.108). All-cause mortality was not significant between the amiodarone and placebo groups (57 vs 68 patients respectively; RR reduction, 18.3; 95% CI, -16.1 to 42.6; P=0.129).
Julian et al.[20] (1997) EMIAT Amiodarone 800 mg daily for 2 weeks, followed by 400 mg/day for 14 weeks, followed by 200	DB, MC, PC, RCT Patients 18 to 75 years who survived ≥5 days post documentation of an MI, LVEF of ≤40% on MUGA done 5 to 21 days after admission to the	N=1,486 2 years	Primary: All-cause mortality Secondary: Cardiac mortality, AD and AD plus resuscitated cardiac arrest	Primary: There was not a significant difference in all-cause mortality between the amiodarone and placebo groups (102 vs 103 patients in group; risk ratio, 0.99; 95% CI, 0.76 to 1.31; P=0.96). Secondary: There was not a significant difference in total cardiac mortality between the amiodarone and placebo groups (89 vs 85 patients; risk ratio, 0.94; 95% CI, 0.70 to 1.26; P=0.67).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day until the end of the trial vs placebo	coronary-care unit			The amiodarone group had a lower number of patients who experienced an AD compared to the patients in the placebo group (50 vs 33 patients; risk ratio, 0.65; 95% CI, 0.42 to 1.00; P=0.05). The amiodarone group had a lower number of patients who experienced an AD and resuscitated cardiac arrest compared to the patients in the placebo group (61 vs 42 patients; risk ratio, 0.68; 95% CI, 0.46 to 1.00; P=0.05).
Deedwania et al.[21] (1998) CHF-STAT Amiodarone 800 mg QD for 2 weeks, followed by 400 mg QD for 50 weeks, followed by 300 mg QD vs placebo	DB, MC, PC Patients with history of heart failure (≥3 months), NYHA class II, III, or IV, LVEF ≤40%, evidence of dilated cardiomyopathy, dyspnea on exertion or history of paroxysmal nocturnal dyspnea, and frequent ventricular premature beats on 24-hour Holter monitoring	N=667 4.5 years	Primary: Rate control vs conversion to sinus rhythm in atrial fibrillation patients Secondary: Occurrence of new atrial fibrillation	Primary: From time points at two weeks and beyond, the ventricular rates of those patients in the amiodarone treatment group were significantly lower than those in the placebo group (P=0.001 at week 2, and P=0.006 at months 6 and 12). Of the patients that had AF at baseline, 16 patients in the amiodarone group compared to four patients in the placebo group, spontaneously converted to sinus rhythm (P=0.002). Secondary: Eleven patients in the amiodarone group compared 22 patients in the placebo group experienced new-onset AF (P=0.005). Patients in the amiodarone group who spontaneously converted to sinus rhythm and maintained it during the follow-up period had significantly lower mortality compared to those who remained in AF (P=0.04).
Kochiadakis et al.[22] (2004) Amiodarone 15 mg/kg QD for 7 days, followed by 10 mg/kg QD for 7 days, then tapered dose over 7 to 12 days to maintenance levels	RCT, SB Patients >18 years of age, ECG documentation of AF, symptoms such as light-headedness, palpitation, chest pain, and dyspnea in association with AF; successful chemical or	N=146 3 years	Primary: Time to adverse events (relapse to AF or intolerable side effects), whichever occurred first Secondary: Maintenance of AF free time	Primary: There was not a significant difference between the amiodarone and propafenone groups for the suppression of recurrent symptomatic AF or in side effects (P=0.44). Secondary: Amiodarone and propafenone were equally effective in maintaining sinus rhythm without side effects included (P=0.058).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
over 7 to 12 days to a maintenance dose of 200 mg QD vs propafenone 150 to 300 mg followed by a maintenance dose of 150 mg TID	electrical cardioversion to sinus rhythm in the patients with persistent AF			
Gulizia et al.[23] (2008) PITAGORA Amiodarone 600 mg/day for 10 days, followed by 400 mg/day for 10 days, followed by 200 mg/day thereafter vs class Ic antiarrhythmic drugs (flecainide 200 mg/day, propafenone 450 to 600 mg/day)	MC, RCT, SB Patients with SND, ≥3 episodes of symptomatic AT in the 12 months before enrollment, and ≥1 AT episode documented by ECG or Holter recording	N=176 21 months	Primary: Composite of death, permanent AT, cardiovascular hospitalization, atrial cardioversion, or interruption of the randomly assigned antiarrhythmic drug regimen Secondary: AT-related composite end point (permanent AT, hospitalizations due to AT recurrences, atrial cardioversions, and assigned antiarrhythmic drug discontinuation	Primary: The primary end point occurred in 30.7% of patients in the class Ic group and 40.0% of patients in the amiodarone group (P=0.24). Secondary: Death occurred in 2.7% of patients receiving class Ic agents and 8.6% of patients receiving amiodarone (P=0.16). Twelve patients receiving amiodarone were hospitalized for cardiovascular causes compared to nine patients receiving class Ic drugs. Ischemic stroke occurred in two amiodarone patients. After one year, the AT-related composite end point was 22% for amiodarone and 22% for class Ic agents (23% for propafenone and 21% for flecainide; P=0.1). After one year, freedom from AT episodes at >10 minutes, one day, and seven days was 40, 73, and 91%, respectively, for amiodarone and 28, 78, and 86%, respectively for class Ic agents. The mean number of AT-related symptoms at the baseline was 2.0 in the amiodarone group and 2.2 in class Ic group. At the first follow-up visit, the mean number of AT-related symptoms decreased to 0.7 and 1.1, respectively (P<0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			because of lack of efficacy), AT-related symptoms, QOL	QOL scores improved from baseline values of 52 in the amiodarone group and 54 in the class Ic group to 67 and 67, respectively, at the first follow-up visit (P<0.01). There was no significant difference between the treatment groups with regards to AT-related symptoms and QOL scores.
Kojuri et al.[24] (2009) Amiodarone 200 mg BID from 7 days before surgery to 5 days post surgery vs propranolol 20 mg BID from 7 days before surgery to 5 days post surgery vs amiodarone 200 mg BID plus propranolol 20 mg BID from 7 days before surgery to 5 days post surgery	DB, PRO, RCT Patients who underwent elective CABG	N=240 12 days	Primary: Percentage of patients who developed post-CABG AF Secondary: Not reported	Primary: Post-CABG AF developed in 22 patients (9.2%), of whom 13 (16.3%) received propranolol, five (6.3%) received amiodarone and four (5.0%) received combination therapy. The difference in AF between propranolol and amiodarone monotherapy was significant (P=0.02), but not between either monotherapy with combination therapy (P=0.6 and P=0.76). The duration of AF episodes was <24 hours in four patients (80%) receiving amiodarone, nine patients (69.2%) receiving propranolol and four patients (100%) receiving combination therapy (P values not reported). Secondary: Not reported
Piccini et al.[25] (2014) Amiodarone vs sotalol	RETRO Patients with CAD and AF	N=2,838 Median follow-up 4.2 years	Primary: All-cause mortality Secondary: Not reported	Primary: In unadjusted and adjusted settings, mortality rates were lower in patients treated with sotalol compared with amiodarone or no AAD. After adjustment for baseline characteristics only, the 1-year mortality rate was 10% in those treated with sotalol, 20% in those treated with amiodarone, and 14% in those treated with no AAD (no P-value reported). Landmark analysis at 60 days and one year was also performed. After

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs no antiarrhythmic drug (AAD)				adjustment and weighting, sotalol was associated with improved survival from 0 to 60 days compared with amiodarone (HR, 0.14; 95% CI, 0.06 to 0.32) but not at later time points (≥60 days or ≥1 year). Similarly, compared with no AAD therapy, sotalol was not associated with improved survival beyond 60 days. Cumulative survival after one year in patients treated with sotalol vs no AAD was also not improved (P=0.64). Secondary: Not reported
Lee et al.[26] (2008) Amiodarone vs sotalol vs beta-blockers (agents not specified) Doses of the agents were not specified.	RETRO Patients with AF and/or CHF (NYHA class ≥III) and an implantable cardioverter defibrillator	N=55 2.6±2.0 years	Primary: Cumulative rates of inappropriate shocks Secondary: Not reported	Primary: Amiodarone demonstrated a significantly lower rate of inappropriate shock compared to the beta-blockers (27.3 vs 70.6% at four years; P=0.003). This demonstrated an 83% reduction compared to the beta-blockers (HR, 0.17; 95% CI, 0.05 to 0.64; P=0.008). There was not a significant difference in rates of inappropriate shocks observed between the amiodarone and sotalol groups (27.3 vs 54.3% at four years; P=0.29). There was not a significant difference in rates of inappropriate shocks observed between the sotalol and beta-blocker groups (54.3 vs 70.6% at four years; P=0.16). Secondary: Not reported
Connolly et al.[27] (2006) OPTIC Beta-blocker (bisoprolol, carvedilol or metoprolol) vs	DB, MC, RCT Patients who received an implantable cardioverter defibrillator within 21 days of randomization, had sustained	N=412 12 months	Primary: Implantable cardioverter defibrillator shock for any reason Secondary: Not reported	Primary: Shocks occurred in 41 patients (38.5%) in the beta-blocker group, 26 (24.3%) patients in the sotalol group, and 12 (10.3%) patients in the amiodarone plus beta-blocker group. A reduction in the risk of shock was observed with use of amiodarone plus beta-blocker or sotalol vs beta-blocker alone (HR, 0.44; 95% CI, 0.28 to 0.68; P<0.001). The amiodarone plus beta-blocker group significantly reduced the risk of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
sotalol 240 mg/day in 2 to 3 divided doses vs amiodarone 200 mg/day plus β-blocker (bisoprolol, carvedilol or metoprolol) Amiodarone was loaded at 400 mg BID for 2 weeks, followed by 400 mg/day for 4 weeks, and then 200 mg/day until then end of the study	ventricular tachycardia, ventricular fibrillation or cardiac arrest (not ≤72 hours of acute MI), LVEF ≤40%, inducible ventricular tachycardia or ventricular fibrillation by programmed ventricular stimulation with LVEF ≤40% or unexplained syncope with ventricular tachycardia or ventricular fibrillation, inducible by programmed stimulation			shock compared to the beta-blocker alone group (HR, 0.27; 95% CI, 0.14 to 0.52; P<0.001) and the sotalol group (HR, 0.43; 95% CI, 0.22 to 0.85; P=0.02). The sotalol group did not significantly reduce the risk of shock compared to the beta-blocker alone group (HR, 0.61; 95% CI, 0.37 to 1.01; P=0.055). Secondary: Not reported
Torp-Pederson et al.[28] (1999) Dofetilide 250 µg QD to 500 µg BID vs placebo	DB, MC, PC, RCT Patients ≥18 years hospitalized with new or worsening CHF and who had ≥1 episode of shortness of breath on minimal exertion or at rest or paroxysmal nocturnal dyspnea	N=1,518 1 year	Primary: Death from any cause Secondary: Death from cardiac causes, death from arrhythmia, death from cardiac causes or successful resuscitation after	Primary: Death did not differ significantly between dofetilide treatment group and placebo (311 [41%] vs 317 [42%] respectively; HR, 0.95; 95% CI, 0.81 to 1.11; P=0.54). Secondary: There was not a significant difference in death from cardiac causes between dofetilide treatment group and placebo (33 vs 33%, respectively). There was not a significant difference in death from arrhythmias between dofetilide treatment group and placebo (20 vs 20%, respectively).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			cardiac arrest, arrhythmias requiring treatment, worsening CHF and MI, and in patients with baseline AF, incidence of conversion to and maintenance of sinus rhythm	Fewer hospitalizations due to worsening heart failure were experienced in the dofetilide group compared to placebo (30 vs 38%, respectively). There was a significant greater number of patients with AF at baseline who converted to sinus rhythm in the dofetilide compared to those patients with AF at baseline in the placebo group. At one month: 12 vs 2%, respectively (P<0.001) and at 12 months: 44 vs 13%, respectively (P<0.001). After cardioversion, more patients with baseline AF in the dofetilide group maintained sinus rhythm compared to those patients in the placebo group (HR, 0.35; 95% CI, 0.22 to 0.57; P<0.001).
Singh et al.[29] (2007) EURIDIS and ADONIS Dronedarone 400 mg BID vs placebo	DB, MC, RCT Patients ≥21 years of age with ≥1 episode of AF in the preceding 3 months who were in sinus rhythm for ≥1 hour before randomization	N=1,237 1 year	Primary: Time from randomization to the first documented recurrence of AF Secondary: Symptoms related to AF during recordings of 12-lead electro-cardiography or transtelephonic monitoring and the mean ventricular rate during the first recurrence	Primary: In EURIDIS, the median times from randomization to a documented recurrence of AF were 96 days in the dronedarone group and 41 days in the placebo group. At 12 months, 67.1% of patients in the dronedarone group and 77.5% of patients in the placebo group had had a recurrence of atrial fibrillation (HR, 0.78; 95% CI, 0.64 to 0.96; P=0.01). In ADONIS, the median times from randomization to a documented recurrence of AF were 158 days in the dronedarone group and 59 days in the placebo group. At 12 months, 61.1% of patients in the dronedarone group and 72.8% of patients in the placebo group had had a recurrence of AF (HR, 0.73; 95% CI, 0.59 to 0.89; P=0.002). In the combined analysis, the median times to a documented recurrence of AF were 116 days in the dronedarone group and 53 days in the placebo group. At 12 months, the rates of recurrence were 64.1% in the dronedarone group and 75.2% in the placebo group (HR, 0.75; 95% CI, 0.65 to 0.87; P<0.001). Secondary: In EURIDIS, 37.1% of patients in the dronedarone group and 47.5% of those in the placebo group had symptomatic recurrences of AF (P=0.006). In ADONIS, symptomatic recurrences occurred in 38.3% of patients in the dronedarone group and 44.5% of those in the placebo group (P=0.02). In the combined analysis, the corresponding numbers were 37.7 and 46.0%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P<0.001). In EURIDIS, the mean ventricular rate during the first adjudicated recurrence was 102.3beats per minute in the dronedarone group and 117.5 beats per minute in the placebo group (P<0.001). In ADONIS, the mean ventricular rate during the first adjudicated recurrence was 104.6 beats per minute in the dronedarone group and 116.6 beats per minute in the placebo group (P<0.001). In EURIDIS, 21.2% of patients in the dronedarone group were hospitalized or died at 12 months compared to 32.0% of those in the placebo group (HR, 0.66; 95% CI, 0.47 to 0.93; P=0.02). In ADONIS, 24.5% of patients in the dronedarone group were hospitalized or died compared to 29.8% of those in the placebo group (HR, 0.80; 95% CI, 0.56 to 1.14; P=0.22). In the combined analysis, the corresponding numbers were 22.8 and 30.9% (HR, 0.73; 95% CI, 0.57 to 0.93; P=0.01). There was a higher incidence of elevated serum creatinine levels in the dronedarone group than in the placebo group (2.4 vs 0.2%, P=0.004). Ventricular arrhythmias occurred infrequently in both groups and no episodes of torsades de pointes were reported.
Hohnloser et al.[30] (2009) ATHENA Dronedarone 400 mg BID vs placebo	DB, MC, PC, RCT Patients with paroxysmal or persistent AF or atrial flutter with ≥1 of the following risk factors: ≥70 years of age, arterial hypertension (treated with ≥2 antihypertensive drugs), diabetes mellitus, previous stroke, TIA, or systemic embolism,	N=4,628 21 months	Primary: First hospitalization due to cardiovascular events or death Secondary: Death from any cause, death from cardiovascular causes, hospitalization due to cardiovascular events	Primary: In the dronedarone group, 31.9% of patients experienced the primary outcome compared to 39.4% of patients in the placebo group (HR, 0.76; 95% CI, 0.69 to 0.84; P<0.001). Secondary: Death from any cause occurred in 5.0% of patients in the dronedarone group and 6.0% of patients in the placebo group (HR, 0.84; 95% CI, 0.66 to 1.08; P=0.18). Cardiovascular death occurred in 2.7% of patients in the dronedarone group and 3.9% of patients in the placebo group (HR, 0.71; 95% CI, 0.51 to 0.98; P=0.03). In the dronedarone group, 29.3% of patients had a first hospitalization due to cardiovascular events compared to 36.9% of patients in the placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	left atrial diameter ≥50 mm, and LVEF ≤40%			group (HR, 0.74; 95% CI, 0.67 to 0.82; P<0.001). Bradycardia, QT-interval prolongation, diarrhea, nausea, rash, and an increase in the serum creatinine level were significantly more common in the dronedarone group than in the placebo group. Pulmonary symptoms, interstitial lung disease, and abnormalities of thyroid function were not significantly more common with dronedarone than with placebo.
Page et al.[31] (2011) ATHENA Dronedarone 400 mg BID vs placebo Randomization was stratified according to sinus rhythm status at baseline	Post-hoc analysis of ATHENA Patients with paroxysmal or persistent AF or atrial flutter and additional cardiovascular risk factors, and a 12-lead ECG <6 months before randomization available showing AF or atrial flutter, and a second 12-lead ECG within the same time period had to show sinus rhythm	N=3,473 (patients in sinus rhythm at baseline) 21 months	Primary: Time to first AF or atrial flutter recurrence, incidence of electrical cardioversion, likelihood of permanent AF and atrial flutter Secondary: Not reported	Primary: The median time to first AF or atrial flutter recurrence of patients in sinus rhythm at baseline was 498 and 737 days with placebo and dronedarone (HR, 0.749; 95% CI, 0.681 to 0.824; P<0.001). At the time of first AF and atrial flutter recurrence, the mean heart rates were 85.3 and 95.5 bpm with dronedarone and placebo, respectively (P<0.001). Three hundred and thirty nine patients (15%) receiving dronedarone had at least one electrical cardioversion compared to 481 (21%) patients receiving placebo (HR, 0.684; 95% CI, 0.596 to 0.786; P<0.001). The likelihood of permanent AF and atrial flutter was lower with dronedarone (7.6 vs 12.8% of patients; HR, 0.749; 95% CI, 0.681 to 0.824; P<0.001). Secondary: Not reported
Torp-Pedersen et al.[32] (2011) ATHENA Dronedarone 400 mg BID vs	Post-hoc analysis of ATHENA Patients with paroxysmal or persistent AF or atrial flutter with ≥1 of the following risk factors: ≥70 years of age, arterial	N=4,628 21 months	Primary: Number of first hospitalizations per treatment group, number of hospitalizations after first AF/atrial flutter recurrence, number of all hospitalizations,	Primary: Overall, the number of first cardiovascular hospitalizations was significantly decreased with dronedarone compared to placebo (675 vs 859 patients; HR, 0.74; 95% CI, 0.67 to 0.82; P<0.001). There was no difference between the number of first non-cardiovascular hospitalizations between the two treatments (516 vs 533; P=0.77). Among the patients experiencing at least one AF-related hospitalization during the trial, 50% remained in the hospital for at least four nights and 25% for at least eight nights. The total number of hospitalizations for AF

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	hypertension (treated with ≥2 antihypertensive drugs), diabetes mellitus, previous stroke, TIA, or systemic embolism, left atrial diameter ≥50 mm, and LVEF ≤40%		duration of hospital stay, hospitalization burden over time Secondary: Not reported	was reduced from 829 with placebo to 514 with dronedarone (HR, 0.626; 95% CI, 0.546 to 0.719; P<0.001) and the number of days in hospital from 4,637 to 3,132, respectively (P<0.001). Dronedarone significantly reduced total hospitalizations for acute coronary syndrome (73 vs 113; P=0.0105) and the number of hospitalization days (816 vs 1,188 days; P=0.04). Dronedarone significantly reduced the time between the first AF/atrial flutter recurrence and cardiovascular hospitalization/death (HR, 0.771; 95% CI, 0.643 to 0.925; P=0.0048). Hospitalization burden was significantly reduced across all levels of care (P<0.05). Secondary: Not reported
Duray et al.[33] (2011) ATHENA/ EURIDIS/ ADONIS Dronedarone 400 mg BID vs placebo	Pooled post-hoc analysis of ATHENA/ EURIDIS/ADONIS trials Individual patients with lone AF who were enrolled in the ATHENA, EURIDIS, and ADONIS trials were entered in a center database	N=432 13.8±7.2 months	Primary: Composite of cardiovascular hospitalizations or death, and the individual components Secondary: Not reported	Primary: The risk of first cardiovascular hospitalizations or all-cause mortality in patients receiving placebo after one year was 25% in the lone AF group compared to 29% in the rest of the population. In patients with lone AF, dronedarone led to a 44% reduction in cardiovascular hospitalizations or all-cause mortality (HR, 0.56; 95% CI, 0.36 to 0.88; P=0.004) and to a 46% reduction in cardiovascular hospitalization (HR, 0.54; 95% CI, 0.34 to 0.87; P=0.004) compared to placebo. There was no significant difference between dronedarone and placebo with regards to all-cause mortality (HR, 1.02; 95% CI, 0.31 to 3.34; P=0.885). Secondary: Not reported
Kober et al.[34] (2008) ANDROMEDA Dronedarone 400 mg BID	DB, MC, PC, PG, RCT Patients ≥18 years of age who were hospitalized with	N=627 An average of 62.1 days and a median follow-up of 2	Primary: Composite of death from any cause or hospitalization for worsening heart failure	The study terminated prematurely due to increased death in the active treatment group. During a median follow-up of two months, 25 (8.1%) patients in the dronedarone group and 12 (3.8%) patients in the placebo group died (HR, 2.13; 95% CI, 1.07 to 4.25; P=0.03). After an additional six months without study treatment, 42 (13.5%)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	new or worsening heart failure and who had ≥1 episode of shortness of breath on minimal exertion (NYHA functional class III or IV) or paroxysmal nocturnal dyspnea within the month before screening	months	Secondary: Death from all causes, hospitalization for cardiovascular causes, hospitalization for worsening heart failure, occurrence of AF/atrial flutter, death from arrhythmia, or sudden death	patients in the dronedarone group and 39 (12.3%) patients in the placebo group died (HR, 1.13; 95% CI, 0.73 to 1.71; P=0.60). Subgroup analysis of the study population, after adjustment for risk factors, showed that the most powerful predictor of death was treatment with dronedarone (HR, 2.19; 95% CI, 1.06 to 4.52; P=0.03). Primary: The primary composite endpoint was not significantly different between groups (17.1% [53 events] for dronedarone vs 12.6% [40 events] for placebo; HR, 1.38; 95% CI, 0.92 to 2.09; P=0.12). After an additional six months of follow-up after treatment discontinuation, 74 patients (23.9%) and 72 patients (22.7%) in the dronedarone and placebo groups, respectively, had reached the primary composite endpoint (HR, 1.09; 95% CI, 0.79 to 1.51; P=0.60). Secondary: First hospitalization for cardiovascular cause was higher in the dronedarone group than the placebo group (71 vs 50; P=0.02) with the main reason being worsening heart failure (49.3% for the dronedarone group and 60.0% for the placebo group). Other reasons for hospitalization for cardiovascular causes included MI (18.3 and 16.0%; in the dronedarone and placebo groups, respectively), ventricular arrhythmia (4.2 and 4.0%), supraventricular arrhythmia (5.6 and 2.0%), stroke (5.6 and 6.0%), other cardiovascular events (12.7 and 8.0%), and presumed cardiovascular events (4.2 and 4.0%). At one month, there was no significant difference between the two groups in the percentage of patients who had AF (21.4% for the dronedarone group vs 24.8% for the placebo group; P value not reported). Ten (3.2%) patients and six (1.9%) patients in the dronedarone and placebo groups died from arrhythmia or sudden death during the double-blind, randomized study period. This difference was not significantly different (P value not reported).
Touboul et al.[35]	DB, PC, RCT	N=270	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2003) DAFNE Dronedarone 400 mg BID vs dronedarone 600 mg BID vs dronedarone 800 mg BID vs placebo	Patients 21 to 85 years of age with persistent AF for whom cardioversion and antiarrhythmic treatment was warranted	6 months	Time to first documented AF recurrence Secondary: Spontaneous conversion of AF following randomization, heart rate in case of AF recurrence, and incidence of side effects	Only in the 400 mg twice daily arm was the time to AF relapse significantly different from placebo (60.0 vs 5.3 days; RR reduction, 55%; 95% CI, 72 to 28; P=0.001). Secondary: There was a dose-effect relationship to the incidence of spontaneous conversion to sinus rhythm (P=0.0261) with patients in all dronedarone groups (400, 600, and 800 mg) exhibiting spontaneous conversion to sinus rhythm (5.8, 8.2 and 14.8%, respectively, vs 3.1% for the placebo group). Dronedarone appeared to slow ventricular rate during AF recurrence in a dose-dependent manner. The rate was reduced by 13.2, 19.2 and 17.8 bpm vs placebo (P=0.0001). Discontinuation rates due to adverse events were 10.8% with dronedarone treated patients (3.9, 7.6 and 22.6%, respectively) vs 0% with placebo treated patients (P value not reported). Most commonly reported effects were gastrointestinal related.
Davy et al.[36] (2008) ERATO Dronedarone 400 mg BID vs placebo	DB, MC, PC, RCT Adult patients ≥21 years with documented, symptomatic permanent AF, for which cardioversion was not considered an option	N=174 6 months	Primary: Change in mean ventricular rate measured by 24-hour Holter recording on day 14 Secondary: Change in mean ventricular rate during submaximal and maximal exercise at day 14, change in maximal exercise duration at day 14, change in mean	Primary: There was a mean reduction in mean 24-hour ventricular rate of 11.0 beat/min in the dronedarone group at day 14 compared to an increase of 0.7 beat/min in the placebo group (P<.0001). Secondary: There was a reduction in mean heart rate of 25.6 beat/min in the dronedarone group compared to 2.2 beat/min in the placebo group during submaximal exercise (P<0.0001). There was a reduction in mean heart rate of 27.4 beat/min in the dronedarone group compared to 2.9 beat/min in the placebo group at maximal exercise (P<0.0001). There was a mean increase in maximal exercise duration of 0.14 and 0.26 minutes in the dronedarone and placebo groups, respectively (P=0.514). The mean change in 24-hour Holter-monitored ventricular heart rate was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			ventricular rate measured by 24-hour Holter after 4 months, safety and tolerability	greater with dronedarone compared to placebo at four months (-10.1 vs -1.3 beat/min, respectively; P<0.001). Dronedarone was well tolerated throughout the study. There were no cases of torsades de pointes or sustained ventricular tachycardia reported in either treatment group. The incidence of treatment-emergent adverse events was higher with dronedarone than placebo. Gastrointestinal disturbances occurred in 20% of patients receiving dronedarone compared to 13.5% of those receiving placebo.
Køber et al.[37] (2008) ANDROMEDA Dronedarone 400 mg BID vs placebo	DB, MC, PC, RCT Patients ≥18 years of age who were hospitalized with new or worsening heart failure and who had had ≥1 episode of shortness of breath on minimal exertion or at rest (NYHA III or IV), paroxysmal nocturnal dyspnea, or a wall-motion index ≤1.2	N=627 7 months	Primary: Death from any cause or hospitalization for worsening heart failure Secondary: Death from all causes, hospitalization for cardiovascular causes, hospitalization for worsening heart failure, occurrence of AF or atrial flutter, death from arrhythmia, or sudden death	Primary: The data and safety monitoring board recommended that the trial be terminated early due to an excess of deaths in the dronedarone group. Death from any cause occurred in 8.1% of patients receiving dronedarone and 3.8% of patients receiving placebo (HR, 2.13; 95% CI, 1.07 to 4.25; P=0.03). The number of deaths that were attributed to arrhythmia or sudden death did not differ significantly between the two groups. The primary combined end point of all-cause mortality or hospitalization for worsening heart failure was not different between dronedarone and placebo (17.1 vs 12.6%, respectively; HR, 1.38; 95% CI, 0.92 to 2.09; P=0.12). Secondary: The total number of patients who had a first hospitalization for an acute cardiovascular cause was higher in the dronedarone group than in the placebo group (P=0.02). The main reason for hospitalization for a cardiovascular cause was worsening heart failure (49.3% in the dronedarone group and 60.0% in the placebo group). Other cardiovascular events requiring a first hospitalization in the dronedarone group compared to placebo were myocardial ischemia (18.3 vs 16.0%, respectively), ventricular arrhythmia (4.2 vs 4.0%, respectively), supraventricular arrhythmia (5.6 vs 2.0%, respectively), stroke (5.6 vs 6.0%, respectively), other cardiovascular events (12.7 vs 8.0%, respectively), and presumed cardiovascular events (4.2 vs 4.0%, respectively).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were no significant differences detected between the two groups with regards to serious adverse events, except for increases in the serum creatinine concentration, which were observed more frequently in the dronedarone group than in the placebo group. At the one month visit, 21.4% of the patients in the dronedarone group had AF compared to 24.8% of patients receiving placebo (P value not significant). No cases of torsades de pointes were observed in either group.
Connolly et al.[38] (2011) PALLAS Dronedarone 400 mg BID vs placebo	DB, MC, PC, RCT Patients ≥65 years of age with ≥6 month history of permanent AF or atrial flutter and risk factors for major vascular events (coronary artery disease; pervious stroke or TIA; symptomatic heart failure; LVEF ≤40%; peripheral arterial disease; or the combination of age ≥75 years, hypertension, and diabetes)	N=3,236 1 year	Primary: Composite of stroke, MI, systemic embolism, or death from cardiovascular causes; composite of unplanned hospitalization for a cardiovascular cause or death Secondary: Safety	After enrollment of 3,236 patients the trial was stopped for safety reasons. Primary: The first coprimary endpoint (composite of stroke, MI, systemic embolism, or death from cardiovascular causes) occurred in 43 and 19 patients receiving dronedarone and placebo (HR, 2.29; 95% CI, 1.34 to 3.94; P=0.002). There were 21 and 10 cardiovascular deaths with dronedarone and placebo (HR, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 and four patients, respectively (HR, 3.26; 95% CI, 1.06 to 10.0; P=0.03). Stroke occurred in 23 and 10 patients receiving dronedarone and placebo (HR, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 and 24 patients receiving dronedarone and placebo (HR, 1.81; 95% CI, 1.10 to 2.99; P=0.02). Secondary: The most common adverse events were diarrhea, asthenic condition, nausea and vomiting, dizziness, dyspnea, and bradycardia. An increase of alanine aminotransferase of more than three times the upper limit of normal range occurred in 1.5 and 0.6% of patients receiving dronedarone and placebo (P=0.013).
Ezekowitz et al.[39] (2015) HESTIA	DB, MC, PC, RCT Patients ≥21 years of age with	N=112 12 weeks	Primary: Change in AF burden from baseline over the	Primary: Over the 12-week treatment period, mean AF burden increased from 8.8% to 9.9% (increase of 12.8%; P=0.450) in the placebo group and decreased from 10.1% to 4.6% (decrease of 54.4%; P=0.0009) in the dronedarone

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Dronedarone 400 mg BID vs placebo	documented AF with a permanent pacemaker and sinus rhythm within the previous six months		12-week treatment period Secondary: Patient-perceived AF burden; and symptom severity as reported by patients using the Atrial Fibrillation Severity Scale (AFSS)	group. The absolute changes in AF burden from baseline increased by 1.1% in the placebo group and decreased by 5.5% in the dronedarone group. Compared to placebo, AF burden in the dronedarone group was decreased by 59.1% (P=0.0015). Secondary: AF burden changes with dronedarone compared to placebo in secondary efficacy analyses were consistent with the overall result (weeks 1 to 4, 63.2% reduction, P=0.0009; weeks 5 to 12, 60.3% reduction, P=0.003). AFSS changes from baseline were not significantly different between groups.
Le Huezey et al.[40] (2010) DIONYSOS Dronedarone 400 mg BID vs amiodarone 600 mg/day for 28 days then 200 mg/day thereafter	DB, MC, PG, RCT Patients ≥21 years of age with documented AF for >72 hours, for whom antiarrhythmic drugs and cardioversion were indicated, and who received oral anticoagulation	N=504 6 months	Primary: Composite of time to first AF recurrence or premature study drug discontinuation for intolerance or lack of efficacy, and safety evaluation of occurrence of thyroid, hepatic, pulmonary, neurological, skin, ocular, or gastrointestinal events or premature drug discontinuation following an adverse event Secondary: Not reported	Primary: At 12 months the incidence of the primary composite endpoint was 75.1% in the dronedarone group and 58.8% in the amiodarone group (HR, 1.59; 95% CI, 1.28 to 1.98; P<0.0001). The crude rates of the components of the primary composite endpoints of AF recurrence compared to premature study drug discontinuation was 63.5 vs 10.4% in the dronedarone group and 42.0 vs 13.3% in the amiodarone group. This demonstrates that the primary endpoint was mainly driven by AF recurrence. In the AF recurrence component of the endpoint, AF after electrical cardioversion occurred in 36.5 and 24.3% of patients in the dronedarone and amiodarone groups, respectively (P value not reported). At 12 months the incidence of the primary safety endpoint was 39.3% in the dronedarone group and 44.5% in the amiodarone group (HR, 0.8; 95% CI, 0.60 to 1.07; P=0.129). The difference between the two groups was mainly driven by increased thyroid, neurologic, skin, and ocular events in the amiodarone group. There was a higher incidence of gastrointestinal events, mainly diarrhea in the dronedarone group (9.2%) compared to the amiodarone group (3.1%). A pre-specified endpoint of the main safety event excluding gastrointestinal effects showed a 39% RR reduction in favor of dronedarone (HR, 0.61; 95% CI, 0.44 to 0.84; P=0.002). When the components of the main safety events were analyzed separately, there was a RR reduction of 84.2% (P=0.0006) in the incidence of thyroid events and 87.6% (P=0.0001) in the incidence of neurologic events favoring dronedarone.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Piccini et al.[41] (2009) Dronedarone 400 mg BID vs amiodarone 200 mg QD	MA Patients with AF	N=7,140 13 to 16 months (mean duration)	Primary: Recurrence of AF, all-cause mortality, adverse events Secondary: Not reported	Primary: *Dronedarone vs placebo* For prevention of AF, the effect of dronedarone had an OR of 0.79 (95% CI, 0.33 to 1.87), with a risk difference of -0.040 (95% CI, -0.19 to 0.11) equivalent to 40 fewer events per 1,000 patients treated. For mortality, the OR was 0.85 (95% CI, 0.66 to 1.11), with a risk difference of -0.003 (95% CI, -0.011 to 0.006). For adverse events requiring discontinuation, there was a significant increase over placebo with OR of 1.166 (95% CI, 1.36 to 2.02) and risk difference 0.045 (95% CI, 0.028 to 0.062). *Amiodarone vs placebo* Amiodarone significantly prevented AF, with an OR of 0.12 (95% CI, 0.08 to 0.19) and a risk difference of -0.401 (95% CI, -0.46 to -0.34) equivalent to 401 fewer events per 1,000 patients treated. For mortality, the OR was 1.88 (95% CI, 0.54 to 6.56), with a risk difference of 0.005 (95% CI, -0.016 to 0.026). For adverse events requiring discontinuation, there was a significant increase over placebo with an OR of 11.04 (95% CI, 1.89 to 64.5) and risk difference of 0.128 (95% CI, 0.023 to 0.230). *Dronedarone vs amiodarone* In the indirect MA, amiodarone significantly reduced the risk of recurrent AF compared to dronedarone (OR, 0.16; 95% CI, 0.06 to 0.42), with a risk difference of -0.36 (95% CI, -0.52 to -0.19), which is equivalent to 360 fewer events per 1,000 patients treated. This was consistent with the direct results from DIONYSOS (OR, 0.44; 95% CI, 0.30 to 0.64), with a risk difference of -0.186 (95% CI, -0.266 to -0.1028).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was a mortality trend favoring dronedarone in the indirect MA (amiodarone vs dronedarone OR, 2.20; 95% CI, 0.61 to 7.88; risk difference: 0.008; 95% CI: -0.015 to 0.030). This finding was consistent with the DIONYSOS trial (OR, 2.44; 95% CI, 0.48 to 12.6), risk difference 0.011 (95% CI, -0.010 to 0.033). For adverse effects requiring interruption of therapy, the indirect MA estimate favored dronedarone; amiodarone was associated with an increased odds of study drug termination (OR, 6.65; 95% CI, 1.13 to 39.3) with a risk difference of 0.083 (95% CI, -0.022 to 0.1866). The effect was similar in DIONYSOS (OR, 2.24; 95% CI, 1.13 to 4.43) with a risk difference of 0.057 (95% CI, 0.010 to 0.105). The incidence of thyroid toxicity (4 vs 3%), symptomatic bradyarrhythmias (2.8 vs 1.1%), and hepatotoxicity (3.5 vs 2.5%) leading to treatment discontinuation were comparable between dronedarone and placebo. There were no cases of torsades de pointes in any of the patients administered amiodarone or in the DIONYSOS trial. There was a single case of torsades de pointes in a patient receiving dronedarone in ATHENA. Secondary: Not reported
Kirchhof et al.[42] (2012) Flec-SL Flecainide 200 to 300 mg/day for 4 weeks vs flecainide 200 to 300 mg/day for 6 months	Blinded endpoint, MC, OL, PRO, RCT Adults with persistent AF undergoing planned cardioversion	N=635 6 months	Primary: Time to persistent AF or death, QOL Secondary: Safety	Primary: The first analysis performed with the four week follow-up data for 242 patients, and demonstrated that flecainide (short- and long-term treatment combined) was superior to no treatment (control; 28-day Kaplan-Meier survival of 70.2% [95% CI, 63.0 to 77.3] of patients receiving flecainide vs 52.5% [95% CI, 41.4 to 63.6] of patients receiving control; P=0.0160). On the basis of these findings, an additional analysis was conducted to compare short-term and long-term maintenance treatment; enrollment into the control group ended, and sample size was adjusted from 725 to 635. In the per protocol population, 120 (46%) of 261 patients receiving short-term treatment developed persistent AF (48.4%; 95% CI, 41.9 to 55.0) vs 103 (39%) of 263 receiving long-term treatment (56.4%; 95% CI, 49.1 to 63.6). No deaths occurred. The difference between the two groups

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
no treatment (control) Patients were randomized to trial medication after successful cardioversion.				receiving flecainide in the mean percentage of patients who did not have persistent AF was 7.9% (95% CI, -1.9 to 17.7); therefore, noninferiority of short-term to long-term treatment could not be shown (P=0.2081). In the intention-to-treat population, the difference between short-term and long-term treatment was 6.3% (95% CI, -2.6 to 15.3; P=0.1073). In a post-hoc analysis of patients who had not reached the primary endpoint in the first month confirmed that long-term treatment was superior to short-term treatment in the prevention of persistent AF or death (difference between Kaplan-Meier estimates 14.3%; 95% CI, 5.1 to 23.6; P=0.0001; HR, 0.31; 95% CI, 0.118 to 0.56; P<0.0001). QOL improved with short-term and long-term flecainide treatment. In the control group, only physical sores of the SF-12 improved, not mental. Number of admissions because of AF, number of medical visits without admission, left ventricular function at six months, and QOL did not differ between short-term and long-term treatment. Secondary: The number of serious adverse events was low with all treatments, and did not vary between treatments. The number did not differ between patients with coronary artery disease and those without the disorder.
Cast Investigators[43,44] (1993 and 1989) CAST I Encainide* 35 to 50 mg TID, flecainide 100 to 150 mg BID or moricizine* 200 to 250 mg TID vs placebo	MC, OL, PC, RCT Patients 6 days to 2 years post documented MI who had ≥6 VDPs per hour during an ambulatory ECG recording, and a LVEF of ≤55% if recorded 6 to 90 days after MI, or ≤40% if recorded 90 days to 2 years post-MI	N=2,371 1 year	Primary: Overall survival and free of cardiac arrest or AD Secondary: Not reported	Primary: After one year of therapy 90% of patients in the active treatment group survived compared to 95% of patients in the placebo group (P=0.0006). A higher total mortality rate was seen in the encainide and flecainide groups: 56 patients (7.7%) taking encainide or flecainide compared to 22 patients (3.0%) taking placebo (RR, 2.5; 95% CI, 1.6 to 4.5). After one year of therapy, 93% of patients in the active treatment group were free of cardiac arrest or AD compared to 96% of patients in the placebo group (P=0.003). Encainide and flecainide accounted for the excess of deaths from arrhythmia and nonfatal cardiac arrests: 33 patients (4.5%) taking encainide or flecainide compared to nine patients (1.2%) taking placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(RR, 3.6; 95% CI, 1.7 to 8.5). After a mean follow up of 10 months, due to a significantly higher death rate in the active treatment group (63 patients) compared to the placebo group (26 patients; P=0.000), the flecainide and encainide arms of this trial were stopped early. Also, death or cardiac arrest due to arrhythmia was significantly higher in the active treatment group (43 patients) compared to the placebo group (16 patients; P=0.0004).
Balla et al.[45] (2011) Flecainide 3 mg/kg, single dose vs amiodarone 30 mg/kg, single dose vs propafenone 8.5 mg/kg, single dose vs placebo	PC, PRO, RCT, SB Patients with recent AF	N=160 48 hours	Primary: Conversion rate at 24 hours after the drug intake Secondary: Safety	Primary: The primary endpoint occurred in 87.5, 85, 85, and 17.5% of patients receiving flecainide, amiodarone, propafenone, and placebo (P<0.001 vs placebo for all three comparisons). Conversion rates within three hours after drug intake was greater with propafenone (57.5%) or flecainide (45%) compared to amiodarone (0%) or placebo (10%). Between six and 24 hours, significantly more patients were converted to sinus rhythm with amiodarone compared to flecainide or propafenone. The use of antiarrhythmic drugs was a significant predictor of conversion to sinus rhythm compared to placebo (adjusted OR, 19.53; 95% CI, 3.14 to 121.55; P<0.001). Secondary: There were no significant adverse effects during the follow-up period in the drug arm. Two patients receiving amiodarone had mild diarrhea.
Kosior et al.[46] (2009) Propafenone 600 mg orally, followed by 300 mg after 8 hours if sinus rhythm had not been restored by	RCT Patients 18 to 85 years of age admitted to the Emergency Department with symptomatic recent onset AF <48 hours duration,	N=81 24 hours	Primary: Restoration of sinus rhythm, safety Secondary: Not reported	Primary: Within the first 24 hours, sinus rhythm was restored in 90.7% of patients receiving propafenone and in 91.4% of patients receiving digoxin/quinidine. There was no significant difference in the efficacy after 24 hours of follow-up (90.1 vs 91.4%, respectively; P=0.78). Propafenone was more effective at restoring sinus rhythm than digoxin/quinidine during the first eight hours (83.3 vs 54.3%, respectively; P<0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
then vs digoxin 1 mg IV, followed by an oral loading of quinidine (400 mg, followed by 200 mg every 2 hours)	mean ventricular rate >70 beats per minute, and NYHA functional class <II			No life-threatening adverse events were reported during the follow-up. There was no difference in mild adverse events with propafenone compared to digoxin/quinidine (37.2 vs 45.7%, respectively; P=0.56). No case of significant heart failure exacerbation was observed. Secondary: Not reported
Wyse et al.[47] (2002) AFFIRM Rhythm control therapy: amiodarone, disopyramide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, dofetilide and combinations of these drugs (doses not specified and adjusted to maintain normal sinus rhythm) vs rate control therapy: β-blockers, calcium-channel	MC, RCT Patients 65 years and older who had AF that was likely recurrent, AF was likely to cause illness or death, long-term treatment for AF was warranted, no contraindicated to anticoagulation therapy, eligible to undergo trials of at least two drugs in both treatment strategies; and treatment with either strategy could be initiated immediately after randomization	N=4,060 3.5 years	Primary: Overall mortality Secondary: Composite death, disabling stroke, disabling anoxic encephalopathy, major bleeding, or cardiac arrest	Primary: The difference in mortality between the two groups was not significant (HR, 1.15; 95% CI, 0.99 to 1.34; P=0.08). Secondary: The rates of the composite end point of death, disabling stroke, disabling anoxic encephalopathy, major bleeding, or cardiac arrest were also similar in the two groups (P=0.33).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
blockers, digoxin, and combinations of these drugs (doses not specified and adjusted to maintain normal sinus rhythm)				
Van Gelder et al.[48] (2002) RACE Rhythm control therapy: electrical cardioversion, then sotalol 160 to 320 mg (based on weight and renal function); if recurrence within 6 months, repeat electrical cardioversion, then flecainide 200 to 300 mg QD or propafenone 450 to 900 mg QD; if recurrence again, electrical cardioversion repeated along with amiodarone 600 mg QD for 4 weeks then 200 mg QD vs	MC, RCT Patients with recurrent persistent AF or atrial flutter, who have undergone one electrical cardioversion during the previous 2 years, with a maximum of 2	N=522 2 years	Primary: Composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, the need for implantation of a pacemaker, or severe adverse effects of antiarrhythmic drugs Secondary: Not reported	Primary: The composite end point occurred in 44 (17.2%) patients in rate-control group and in 60 (22.6%) patients in the rhythm-control group (absolute difference of -5.4; 90% CI, -11.0 to 0.4). Death from cardiovascular causes occurred in 18 (7.0%) patients in rate-control group and in 18 (6.8%) patients in the rhythm-control group (absolute difference of 0.2; 90% CI, -3.4 to 3.9). Heart failure occurred in nine (3.5%) patients in rate-control group and in 12 (4.5%) patients in the rhythm-control group (absolute difference of -1.0; 90% CI, -3.8 to 1.8). Thromboembolic complications occurred in 14 (5.5%) patients in rate-control group and in 21 (7.9%) patients in the rhythm-control group (absolute difference of -2.4; 90% CI, -6.0 to 1.2). Bleeding occurred in 12 (4.7%) patients in rate-control group and in nine (3.4%) patients in the rhythm-control group (absolute difference of 1.3; 90% CI, -1.5 to 4.1). Severe adverse effects of antiarrhythmic drugs occurred in two (0.8%) patients in rate-control group and in 12 (4.5%) patients in the rhythm-control group (absolute difference of -3.7; 90% CI, -6.0 to -1.4). A pacemaker was implanted in three (1.2%) patients in rate-control group and in eight (3.0%) patients in the rhythm-control group (-1.8; 90% CI, -3.9 to 0.2).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
rate control therapy: digitalis, non-dihydropyridine calcium channel blocker, and β-blocker, alone or in combination				Secondary: Not reported
Opolski et al.[49] (2004) HOT CAFÉ Rhythm control therapy: propafenone 450 to 600 mg QD, disopyramide 300 to 600 mg QD, or sotalol 160 to 320 mg QD vs rate control therapy: β-blockers, non-dihydropyridine calcium channel blockers, digoxin, or a combination of these drugs. All patients underwent electric cardioversion prior to the initiation of	MC, OL, RCT Patients between 50 to 75 years of age with AF known to be present continuously for between seven days and two years with acceptable etiology of the arrhythmia related to ischemic heart disease, arterial hypertension, hemodynamically insignificant valvular heart disease, or lack of assessable etiology	N=205 1 year	Primary: Composite of death from any cause (thromboembolic complications and intracranial or other major hemorrhage) Secondary: Rate control, sinus rhythm maintenance, discontinuation of therapy (proarrhythmic effects), hemorrhage, hospitalization, new or worsening CHF, or changes in exercise tolerance	Primary: There was not a significant difference in composite of death from any cause between the rate control group and the rhythm control group (OR, 1.98; 95% CI, 0.28 to 22.3; P>0.71). Secondary: The patients in the rhythm control group had a significantly lower mean heart rate (79.1±8.6 beats/min) in 24-hour Holter monitoring compared to the patients in the rate control group (85.8±7.5 beats/min; P<0.003). Four patients in the rhythm control group experienced proarrhythmic effects. Whether this lead to discontinuation of therapy was not mentioned. At the end of the study, 66 patients (63.5%) in the rhythm control arm were in sinus rhythm, with 27 of these patients successfully maintained with the first antiarrhythmic compound administered after the first cardioversion. There was not a statistical difference seen in bleeding complications between the rhythm control group (eight patients) and rate control group (five patients). A significantly lower number of hospitalizations were seen in the rate control arm compared to the rhythm control arm (12 vs 74%, respectively; P<0.001). Both the rhythm control group and rate control group had significant

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
study medication.				improvements in CHF class at some point during follow-up compared to baseline (P<0.001 and P<0.05, respectively). No difference in NYHA functional class between patients initially randomized to the two strategies was found at the end of the follow-up period. At the end of the study, both maximal workload and exercise duration were higher in the rhythm control arm compared to the rate control arm (P<0.001 and P<0.001, respectively).
Shelton et al.[50] (2009) CAFE´-II Rhythm control therapy: amiodarone therapy (200 mg TID for 1 month, followed by 200 mg BID for 1 month, followed by 200 mg/day thereafter) vs rate control therapy: digoxin and β-blockers Cardioversion was allowed if patients in the rhythm control group remained in AF despite amiodarone	MC, RCT Patients >18 years of age with persistent AF and chronic symptomatic heart failure (NYHA >Class II symptoms) with evidence of systolic dysfunction on echocardiography	N=61 1 year	Primary: QOL using the Medical Outcomes Study Short Form-36 version II questionnaire Secondary: Proportion of patients in sinus rhythm, scores on the MLWHF questionnaire, NTproBNP, 6MWT, severity of left ventricular systolic dysfunction	Primary: Patients assigned to rhythm control had a greater improvement in QOL over one year compared to rate control (P=0.020 for Medical Outcomes Study Short Form-36 version II as a whole; P=0.050 for mental functioning and P=0.029 for physical functioning subgroups). Secondary: At one year, target ventricular rate control was achieved in 90% of patients assigned to the rate control group. Digoxin and β-blocker use at one year was 84 and 90%, respectively. All patients in the rate control group were in AF at each and every follow-up visit. Sinus rhythm was restored in 20% of patients using amiodarone alone. Cardioversion restored sinus rhythm in 78% patients in whom it was attempted. Overall, 87% of patients were converted from AF to sinus rhythm at some time during the study. The prevalence of AF in the rhythm control group was 53% at four months, 30% at eight months, and 34% at one year. The difference in QOL using the MLWHF questionnaire was not significant in patients assigned to rhythm control vs rate control (P=0.140). The median NTproBNP concentrations at one year were 1,480 and 685 pg/mL for rate and rhythm groups, respectively. A greater reduction was seen for those in the rhythm control group compared to rate control (P=0.047). The mean change in distance walked at one year was 27 and five meters

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
therapy.				for rate and rhythm control, respectively (P=0.342). Patients assigned to rhythm control had a greater improvement in left ventricular function over one year compared to patients assigned to rate control (P=0.014).
Lafuente-Lafuente et al.[51] (2009) Antiarrhythmic drugs (amiodarone, aprindine, azimilide, bidisomide, flecainide, disopyramide, dofetilide, dronedarone, quinidine, propafenone, sotalol) vs placebo, drugs for rate control (digoxin, calcium channel blockers, β-blockers) or no treatment	MA (45 trials) Adults >16 years of age who had AF of any type and duration and in whom sinus rhythm had been restored, spontaneously or by any therapeutic intervention	N=12,559 Variable duration	Primary: Mortality, embolic complications, adverse events Secondary: Use of anticoagulation, recurrence of AF	Primary: No deaths were reported with flecainide in the three trials. Quinidine showed a trend to increase mortality compared to controls (OR, 2.26; 95% CI, 0.93 to 5.45; P=0.07). This trend was significant if missing patients were counted as deaths (OR, 2.29; 95% CI, 1.05 to 5.01; P=0.04), and when class IA drugs (quinidine and disopyramide) were combined (OR, 2.39; 95% CI 1.03 to 5.59; P=0.04). The number NNH for class IA drugs was 109 patients treated for one year to have one excess death. Sotalol showed a trend to increased mortality (OR, 2.09; 95% CI, 0.97 to 4.49; P=0.06) compared to controls. This trend was significant if missing patients were counted as deaths (OR, 2.27; 95% CI, 1.36 to 3.77; P=0.002). Amiodarone was associated with a reduction in mortality compared to combined class I drugs (OR, 0.39; 95% CI, 0.19 to 0.79; NNT, 17). When compared to controls, amiodarone showed no significant difference in mortality. No other significant difference in mortality was detected, either vs control or between different antiarrhythmics. The analysis of cardiovascular mortality gave the same results as that of all-cause mortality. Only five of the 30 studies comparing antiarrhythmics with a control reported stroke outcomes. They reported six strokes in 650 patients in the control groups and 20 strokes in 1,755 patients treated with antiarrhythmics. Withdrawals due to adverse effects were more frequent with all drugs, except aprindine and dofetilide, compared to controls. Pooled events rates varied from 9 to 23% for withdrawals due to adverse effects. The mean

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				number of patients needed to treat for one year to have one excess withdrawal from treatment ranged from nine (quinidine) to 27 (amiodarone, propafenone, or sotalol). Quinidine caused more withdrawals than the other class I drugs (OR, 2.25; 95% CI 1.45 to 3.51; P=0.0003). Amiodarone produced significantly fewer withdrawals than other class I drugs combined (OR, 0.52; 95% CI, 0.34 to 0.81; P=0.004). All antiarrhythmics increased proarrhythmic effects, with the exception of amiodarone and propafenone. Pooled events rates varied from 1 to 7% for proarrhythmia. The NNH for proarrhythmia ranged between 17 (flecainide) and 119 (dofetilide). Amiodarone produced significantly less proarrhythmic events than other class I drugs combined (OR, 0.28; 95% CI, 0.13 to 0.59; P=0.0007). Secondary: All class IA, class IC and class III drugs significantly reduced the recurrence of AF. Pooled recurrence rates of AF at one year were 71 to 84% in controls and were reduced to 42% to 67% in patients treated with antiarrhythmics. The NNT for one year to avoid one recurrence of AF were three with amiodarone, four with flecainide, five with dofetilide and propafenone, eight with quinidine and sotalol and 10 with dronedarone. Amiodarone reduced recurrences of AF significantly more than combined class I drugs (OR, 0.31; 95% CI, 0.21 to 0.45; P<0.0001) and more than sotalol (OR, 0.43; 95% CI 0.29 to 0.64; P<0.0001). No other differences between antiarrhythmics were detected. Chronic anticoagulation with warfarin was mandatory in only three studies. The decision on anticoagulation was left to the judgment of the attending physician in the remaining studies.
Gillinov et al.[52] (2016) Rhythm control therapy: amiodarone with or without a rate-slowing agent	MC, RCT Patients with new-onset postoperative AF in hemodynamically stable condition who were	N=523 60 days	Primary: Total number of days of hospitalization (including emergency department visits) within 60 days	Primary: The total numbers of hospital days in the rate-control group and the rhythm-control group were similar (median, 5.1 days and 5.0 days, respectively; P=0.76). Secondary: The mean length of stay for the index hospitalization after randomization was 5.5 days in the rate-control group and 5.8 days in the rhythm-control

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs rate control therapy: "medications to slow the heart rate"	undergoing elective cardiac surgery to treat coronary artery disease or heart-valve disease; none of the patients had a history of AF		after randomization Secondary: Duration of the hospital stay from randomization to the time of eligibility for discharge on the basis of criteria regarding AF, the length of the index hospitalization, the need for readmission, heart rhythm and time to conversion to a sustained stable rhythm without AF, the need for permanent placement of a pacemaker, and the rates of death and adverse events	group (median, 4.3 in each group; P=0.88). A sensitivity analysis to determine the influence of treatment nonadherence confirmed the results of the intention-to-treat analysis (P=0.51 for the total hospital stay, P=0.72 for the index hospital stay). During the study period, there were 159 hospital readmissions, including emergency department visits, with no significant between-group difference in the rate per 100 patient-months. The proportion of patients who were readmitted within 30 days after hospital discharge was 22.8% in the rate-control group and 21.4% in the rhythm-control group (P=0.71). A total of 89.9% of the patients in the rate-control group and 93.5% of those in the rhythm-control group had a stable, sustained heart rhythm without atrial fibrillation at hospital discharge (P=0.14). At 60 days, five patients had died: three in the rate-control group and two in the rhythm-control group (P=0.64). There were no significant differences in the overall rates of serious adverse events between the rate-control group and the rhythm-control group (24.8 per 100 patient-months and 26.4 per 100 patient-months, respectively; P=0.61)

*Agent not available in the United States.
Drug regimen abbreviations: BID=twice daily, IV=intravenous, QD=once daily, TID=three times daily
Study abbreviations: DB=double-blind, MA=meta-analysis, MC=multicenter, OL=open-label, PC=placebo-controlled, PRO=prospective, RCT=randomized control trial, RETRO=retrospective, SB=single-blinded
Miscellaneous abbreviations: 6MWT=6-minute corridor walk test, AD=arrhythmic death, AF=atrial fibrillation, AT=atrial tachyarrhythmias, CABG=coronary artery bypass graft, CHF=congestive heart failure, CI=confidence interval, ECG=electrocardiographic, HR=hazard ratio, LVEF=left ventricular ejection fraction, MI=myocardial infarction, MLWHF=Minnesota Living with Heart Failure, MUGA=multiple-gated nuclear angiography, NNH=number needed to harm, NNT=number needed to treat, NTproBNP=N-terminal prohormone of brain natriuretic peptide, NYHA=New York Heart Association, OR=odd ratio, QOL=quality of life, RR=relative risk, RVF=resuscitated ventricular fibrillation, SF-12=12-Item Short Form Health Survey, SND=sinus node disease, TIA=transient ischemic attack, VDPs=ventricular premature depolarizations, VT=ventricular tachycardia

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 15. Relative Cost of the Antiarrhythmic Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Amiodarone	injection, tablet	Cordarone®*, Nexterone®, Pacerone®*	$	$$
Disopyramide	capsule, extended-release capsule	Norpace®*, Norpace CR®	$$$-$$$$$	$-$$$
Dofetilide	capsule	Tikosyn®*	$$$$$	$$$$$
Dronedarone	tablet	Multaq®	$$$$$	N/A
Flecainide	tablet	N/A	N/A	$
Mexiletine	capsule	N/A	N/A	$$$
Propafenone	extended-release capsule, tablet	Rythmol SR®*	$$$$$	$$$$
Quinidine	extended-release tablet, injection, tablet	N/A	N/A	$$$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The antiarrhythmic agents are effective for the treatment of atrial fibrillation/flutter and ventricular arrhythmias. These agents differ with regards to their Food and Drug Administration (FDA)-approved indications, mechanism of action, pharmacokinetic properties, drug interactions, and adverse events. All of the antiarrhythmic agents are available in a generic formulation, with the exception of dronedarone.

There are several guidelines that provide recommendations on the use of antiarrhythmic agents for the treatment of both atrial and ventricular arrhythmias. The antiarrhythmics are generally not recommended as first-line agents for the treatment of ventricular arrhythmias. Amiodarone and sotalol may be used to treat ventricular tachycardias in patients with left ventricular dysfunction due to a prior myocardial infarction (MI) and who are not responding to β-blockade from other agents. In those patients with atrial fibrillation (AF), rate control is the recommended treatment strategy but rhythm control may be appropriate in certain circumstances, particularly in patients whose quality of life is affected by AF. Some antiarrhythmic agents may be appropriate to use for rhythm control in patients with particular disease states, for instance sotalol and Class IA antiarrhythmics may be used for postoperative AF or atrial flutter in patients with coronary artery disease without congestive heart failure.[3-8] Overall, the AFFIRM, RACE, and HOT CAFE trials demonstrated similar outcomes with rate control compared to rhythm control strategies.[4,47-49] There are many factors that should be addressed prior to the selection of an antiarrhythmic agent for a patient, including the type of arrhythmia, concurrent disease states, and potential risk to benefit ratio of therapy. These agents have not been shown to improve mortality in patients with atrial or ventricular arrhythmias.[3-8]

Amiodarone is an effective treatment option for AF; however, its use is limited by toxicity (pulmonary, thyroid, and gastrointestinal), photosensitivity reactions, and bluish discoloration of the skin. Amiodarone is associated with a low risk of proarrhythmia in patients with left ventricular hypertrophy, heart failure, coronary artery disease, and previous MI.[9,15,17] Trials also support the efficacy of dofetilide for the prevention of atrial fibrillation/flutter. To reduce the risk of early proarrhythmia, dofetilide must be initiated in the hospital. Dofetilide is available only to hospitals and prescribers who have received appropriate dofetilide dosing and treatment initiation education.[16-17]

Dronedarone is a non-iodinated analog of amiodarone, and as a result, it is less lipophilic and has a shorter half-life than amiodarone. These structural changes were made to reduce the risk of thyroid and pulmonary toxicity. Clinical trials have shown that dronedarone reduces the risk of recurrent atrial fibrillation/flutter and is effective for the long-term maintenance of sinus rhythm.[29,30,36] However, the ANDROMEDA trial was terminated early due to an excess number of deaths in patients with heart failure who received dronedarone. Death from any cause occurred in 8.1% of patients receiving dronedarone and 3.8% of patients receiving placebo (hazard ratio, 2.13; 95% confidence interval, 1.07 to 4.25; P=0.03).[34] As a result, dronedarone is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II to III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic.[10] In a comparative study, dronedarone was found to be less effective than amiodarone for the composite end point of AF recurrence or premature drug discontinuation for intolerance or lack of efficacy. There were fewer thyroid and neurological adverse events with dronedarone, as well as fewer patients discontinuing therapy due to adverse events compared to amiodarone.[40,53] There were no studies found in the medical literature which evaluated the use of dronedarone for the prevention or treatment of ventricular arrhythmias. In December 2011, the FDA released a safety warning regarding an increased risk of death or serious cardiovascular events with dronedarone. A completed safety review, which included data from the PALLAS and ATHENA trials, demonstrated that dronedarone increased the risk of serious cardiovascular events, including death, when used by patients in permanent AF. Based on the findings of the FDA safety review, the approved package labeling changed to include additional recommendations for the use of dronedarone in patients with non-permanent AF.[54]

There is insufficient evidence to support that one brand antiarrhythmic agent is more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand antiarrhythmic agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand antiarrhythmic agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Hume JR, Grant AO. Agents used in cardiac arrhythmias. In: Katzung BG, editor. Basic and clinical pharmacology [monograph on the Internet]. 13th ed. New York (NY): McGraw-Hill: 2015 [cited 2017 May]. Available from: http://accesspharmacy.mhmedical.com/.
2. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129–47.
3. Goldschlager N, Epstein AE, Naccarelli GV, et al. Practice Guidelines Sub-committee, North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-9.
4. January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.
5. National Institute for Health and Clinical Excellence (NICE). Dronedarone for the treatment of non-permanent atrial fibrillation [guideline on the Internet]. London (UK): National Institute for Health and Clinical Excellence, 2010 Aug [cited 2012 Dec]. Available from: http://www.nice.org.uk/nicemedia/live/13115/50469/50469.pdf.
6. National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. CG180. 2014. http://www.nice.org.uk/guidance/CG180.
7. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385-e484.
8. Frendl G, Sodickson AC, Chung MK, et al. 2014 AATS Guidelines for the Prevention and Management of Peri-Operative Atrial Fibrillation and Flutter (POAF) for Thoracic Surgical Procedures. The Journal of thoracic and cardiovascular surgery. 2014;148(3):e153-e193. doi:10.1016/j.jtcvs.2014.06.036..
9. Cordarone® [package insert]. Philadelphia, PA; Wyeth Pharmaceuticals, Inc.; 2014 Dec.
10. Multaq® [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S., LLC; 2014 Mar.
11. Nexterone® [package insert]. Deerfield (IL): Baxter Healthcare Corporation; 2016 Nov.
12. Norpace® and Norpace® CR [package insert]. New York, NY: Pfizer; 2010 Feb.
13. Rythmol® [package insert]. Research Triangle Park, NC; GlaxoSmithKline; 2013 Mar.
14. Rythmol SR® [package insert]. Research Triangle Park, NC; GlaxoSmithKline; 2013 Feb.
15. Pacerone® [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2013 Aug.
16. Tikosyn® [package insert]. New York, NY: Pfizer; 2016 Mar.
17. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited Apr 2017]. Available from: http://online.factsandcomparisons.com.
18. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 Apr]. Available from: http://www.thomsonhc.com/.
19. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet. 1997; 349: 675-82.
20. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74.
21. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients with Heart Failure and Atrial Fibrillation: Observation from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998; 98: 2574-79.
22. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation. Chest. 2004; 125: 377-83.
23. Gulizia M, Mangiameli S, Orazi S, et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J 2008;155:100-107.

24. Kojuri J, Mahmoodi Y, Jannati M, Shafa M, Ghazinoor M, Sharifkazemi MB. Ability of amiodarone and propranolol alone or in combination to prevent post-coronary bypass atrial fibrillation. Cardiovasc Ther. 2009 Winter;27(4):253-8.
25. Piccini JP, Al-Khatib SM, Wojdyla DM, et al. Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. Am J Cardiol. 2014;114(5):716-722.
26. Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, et al. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. Circ J. 2008 Jan;72(1):102-5.
27. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial. JAMA. 2006 Jan 11;295:165-71.
28. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999; 341: 857-65.
29. Singh B, Connolly S, Crijns H, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-999.
30. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009:360:668-78.
31. Page RL, Connolly SJ, Crijns HJGM, van Eickels M, Guadin C, Torp-Pedersen C, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011;107:1019-22.
32. Torp-Pedersen C, Crijns HJGM, Gaudin C, Page RL, Connolly SJ, Hohnloser SH, et al. Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace. 2011;13:1118-26.
33. Duray GZ, Torp-Pedersen C, Connolly SJ, Hohnloser SH. Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. J Cardiovasc Electrophysiol. 2011 Jul;22:770-6.
34. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008 Jun 19;358(25):2678-87.
35. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003 Aug;24(16):1481-7.
36. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527.e1-9.
37. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
38. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76.
39. Ezekowitz MD, Ellenbogen KA, DiMarco JP, et al. A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers. J Interv Card Electrophysiol. 2015 Mar;42(2):69-76.
40. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone vs amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. Epub 2010 Apr 6.
41. Piccini, J, Hasselblad V, Peterson E, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089-1095.
42. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al. Short-term vs long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012;380:238-46.
43. Epstein AE, Hallstrom AP, Rogers WJ, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993; 270(20): 2451-5.
44. Cardiac Arrhythmia Suppression Trial (Cast) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. In: N Engl J Med. 1989; 321: 406–12.
45. Balla I, Petrela E, Kondili A. Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs. Anadolu Kardiyol Derg. 2011;11:600-6.

46. Kosior D, Kochanowski J, Scisło P, et al. Efficacy and tolerability of oral propafenone vs quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. Cardiol J 2009;16:521-527.
47. Wyse DG, Waldo AL, DiMarco JP, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347 (23): 1825-33.
48. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation (RACE). N Engl J Med. 2002; 347 (23): 1834-40.
49. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the polish how to treat chronic atrial fibrillation (HOT CAFE) Study. Chest. 2004; 126:476–86.
50. Shelton R, Clark A, Goode K, et al. A randomised, controlled study of rate vs rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-930.
51. Lafuente-Lafuente C, Mouly S, Longas-Tejero M, Bergmann J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;(4):CD005049.
52. Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med. 2016 May 19;374(20):1911-21.
53. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [press release on the Internet]. Paris (France); Sanofi-aventis: 2008 [cited 2012 Dec]. Available from: http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf.
54. Multaq (dronedarone): drug safety communication – increased risk of death or serious cardiovascular events [press release on the Internet]. Rockville (MD): Food and Drug Administration; 2011 Dec 19 [cited 2012 Dec]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264204.htm.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Cardiotonic Agents
AHFS Class 240408
August 9, 2017

I. Overview

Digoxin is the only cardiotonic agent that is currently available. It inhibits sodium-potassium ATPase, which increases the intracellular concentration of sodium and calcium. This leads to an increase in the force/velocity of myocardial contractions, decreased activation of the sympathetic nervous system and renin-angiotensin system, and a decrease in heart rate and conduction velocity through the atrioventricular node. Digoxin is an effective treatment for heart failure due to its positive inotropic and neurohormonal deactivating effects. It is also beneficial for atrial arrhythmias due to its vagomimetic actions. In high doses, digoxin increases sympathetic outflow from the central nervous system, which may lead to toxicity.[1-3]

The cardiotonic agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Digoxin injection, solution, and tablets are all available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Cardiotonic Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Digoxin	injection, solution, tablet	Lanoxin®*, Lanoxin Pediatric®	digoxin

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the cardiotonic agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Cardiotonic Agents

Clinical Guideline	Recommendation(s)
American Heart Association/ American College of Cardiology/ Heart Rhythm Society: **Guideline for the Management of Patients with Atrial Fibrillation (2014)**[4]	Recommendations for risk-based antithrombotic therapy: Class I • In patients with atrial fibrillation (AF), antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke, bleeding and the patient's values and preferences (Level of Evidence: C). • Selection of antithrombotic therapy should be based on the risk of thromboembolism irrespective of whether the AF patter is paroxysmal, persistent, or permanent (Level of Evidence: B). • In patients with nonvalvular AF, the CHA_2DS_2-VASc score is recommended for assessment of stroke risk (Level of Evidence: B). • For patients with AF who have mechanical heart valves, warfarin is recommended and the target international normalized ratio (INR) should be based on type and location of the prosthesis (Level of Evidence: B). • For patients with nonvalvular AF with prior stroke, TIA, or a CHA_2DS_2-VASc score $\geq$2, oral anticoagulants are recommended. Options include warfarin (INR 2.0 to 3.0) (Level of Evidence: A), dabigatran, rivaroxaban, or apixaban (Level of Evidence: B). • For patients treated with warfarin, the INR should be determined at least weekly during initiation of antithrombotic therapy and at least monthly when anticoagulation (INR in range) is stable (Level of Evidence: A) • For patients with nonvalvular AF unable to maintain a therapeutic INR level

Clinical Guideline	Recommendation(s)
	with warfarin, use of a direct thrombin or factor Xa inhibitor is recommended (Level of Evidence: C). • Re-evaluation of the need for and choice of antithrombotic therapy at periodic intervals is recommended to reassess stroke and bleeding risks (Level of Evidence: C). • Bridging therapy with UFH or LMWH is recommended for patients with AF and a mechanical heart valve undergoing procedures that require interruption of warfarin. Decisions regarding bridging therapy should balance the risks of stroke and bleeding (Level of Evidence: C). • For patients with AF without mechanical heart valves who require interruption of warfarin or newer anticoagulants for procedures, decisions about bridging therapy (LMWH or UFH) should balance the risks of stroke and bleeding and the duration of time a patient will not be anticoagulated (Level of Evidence: C). • Renal function should be evaluated prior to initiation of direct thrombin or factor Xa inhibitors and should be re-evaluated when clinically indicated and at least annually (Level of Evidence: B). • For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF (Level of Evidence: C). Class IIa • For patients with nonvalvular AF and a CHA_2DS_2-VASc score of 0, it is reasonable to omit antithrombotic therapy (Level of Evidence: B). • For patients with nonvalvular AF with a CHA_2DS_2-VASc score of ≥2 and who have end-stage chronic kidney disease (creatine clearance <15 mL/min) or who are on hemodialysis, it is reasonable to prescribe warfarin (INR 2.0 to 3.0) for oral anticoagulation (Level of Evidence: B). Class IIb • For patients with nonvalvular AF and a CHA_2DS_2-VASc score of 1, no antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered (Level of Evidence: C). • For patients with nonvalvular AF and moderate-to-severe chronic kidney disease with a CHA_2DS_2-VASc score of ≥2, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (e.g., dabigatran, rivaroxaban, or apixaban), but safety and efficacy have not been established (Level of Evidence: C). • In patients with AF undergoing PCI, bare-metal stents may be considered to minimize the required duration of dual antiplatelet therapy. Anticoagulation may be interrupted at the time of the procedure to reduce the risk of bleeding ant the site of peripheral arterial puncture (Level of Evidence: C). • Following coronary revascularization (percutaneous or surgical) in patients with AF and a CHA_2DS_2-VASc score of ≥2, it may be reasonable to use clopidogrel (75 mg once daily) concurrently with oral anticoagulants but without aspirin (Level of Evidence: B). Class III: No Benefit • The direct thrombin inhibitor, dabigatran, and the factor Xa inhibitor, rivaroxaban, are not recommended in patients with AF and end-stage chronic kidney disease or on hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits (Level of Evidence: C). Class III: Harm • The direct thrombin inhibitor, dabigatran, should not be used in patients with AF and a mechanical heart valve (Level of Evidence: B). <u>Recommendations for rate control:</u> Class I • Control of the ventricular rate using a beta blocker or nondihydropyridine (non-DHP) calcium channel blocker (CCB) is recommended for patients with

Clinical Guideline	Recommendation(s)
	paroxysmal, persistent, or permanent AF (Level of Evidence: B). • Intravenous administration of a beta blocker or non-DHP CCB is recommended to slow the ventricular heart rate in the acute setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated (Level of Evidence: B). • In patients who experience AF-related symptoms during activity, the adequacy of heart rate control should be assessed during exertion, adjusting pharmacological treatment as necessary to keep the ventricular rate within the physiological range (Level of Evidence: C). Class IIa • A heart rate control (resting heart rate <80 beats per minute [bpm]) strategy is reasonable for symptomatic management of AF (Level of Evidence: B). • Intravenous amiodarone can be useful for rate control in critically ill patients without pre-excitation (Level of Evidence: B). • Atrioventricular (AV) nodal ablation with permanent ventricular pacing is reasonable to control heart rate when pharmacological therapy is inadequate and rhythm control is not achievable (Level of Evidence: B). Class IIb • A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable as long as patients remain asymptomatic and left ventricular systolic function is preserved (Level of Evidence: B). • Oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated (Level of Evidence: C). Class III: Harm • AV nodal ablation with permanent ventricular pacing should not be performed to improve rate control without prior attempts to achieve rate control with medications (Level of Evidence: C). • Non-DHP CCBs should not be used in patients with decompensated HF as these may lead to further hemodynamic compromise (Level of Evidence: C). • In patients with pre-excitation and AF, digoxin, non-DHP CCBs, or intravenous amiodarone should not be administered as they may increase the ventricular response and may result in ventricular fibrillation. (Level of Evidence: B). • Dronedarone should not be used to control the ventricular rate in patients with permanent AF as it increases the risk of the combined endpoint of stroke, myocardial infarction, systemic embolism, or cardiovascular death (Level of Evidence: B). <u>Recommendations for Thromboembolism Prevention</u>: Class I • For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with warfarin (INR 2.0 to 3.0) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the CHA_2DS_2-VASc score and the method used to restore sinus rhythm (Level of Evidence: B). • For patients with AF or atrial flutter of more than 48 hours duration that requires immediate cardioversion for hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least four weeks after cardioversion unless contraindicated (Level of Evidence: C). • For patients with AF or atrial flutter of less than 48-hour duration and with high risk stroke, intravenous heparin or LMWH, or administration of a factor Xa or direct thrombin inhibitor, is recommended as soon as possible before or immediately after cardioversion, followed by long-term anticoagulation therapy (Level of Evidence: C). • Following cardioversion for AF of any duration, the decision regarding long-term anticoagulation therapy should be based on the thromboembolic risk

Clinical Guideline	Recommendation(s)

	profile (Level of Evidence: C).
	Class IIa
	• For patients with AF or atrial flutter of 48-hour duration or longer or of unknown duration who have not been anticoagulated for the preceding three weeks, it is reasonable to perform a TEE prior to cardioversion and proceed with cardioversion if no LA thrombus is identified, including in the LAA, provided that anticoagulation is achieved before TEE and maintained after cardioversion for at least four weeks (Level of Evidence: B).
	• For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for at least three weeks prior to and four weeks after cardioversion (Level of Evidence: C).
	Class IIb
	• For patients with AF or atrial flutter of less than 48-hour duration who are at low thromboembolic risk, anticoagulation (heparin, LMWH, or a new oral anticoagulant) or no antithrombotic therapy may be considered for cardioversion, without the need for post cardioversion oral anticoagulation (Level of Evidence: C).
	
	<u>Recommendations for pharmacological cardioversion</u>
	Class I
	• Flecainide, dofetilide, propafenone, and intravenous ibutilide are useful for pharmacological cardioversion of AF or atrial flutter, provided contraindications to the selected drug are absent (Level of Evidence: A).
	Class IIa
	• Administration of oral amiodarone is a reasonable option for pharmacological cardioversion of AF (Level of Evidence: A).
	• Propafenone or flecainide ("pill-in-the-pocket") in addition to a beta blocker or non-DHP CCB is reasonable to terminate AF outside the hospital once this treatment has been observed to be safe in a monitored setting for selected patients (Level of Evidence: B).
	Class III: Harm
	• Dofetilide therapy should not be initiated out of hospital because of the risk of excessive QT prolongation that can cause torsades de pointes (Level of Evidence: B).
	
	<u>Recommendations for antiarrhythmic drugs to maintain sinus rhythm</u>
	Class I
	• Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level of Evidence: C).
	• The following antiarrhythmic drugs are recommended in patients with AF to maintain sinus rhythm, depending on underlying heart disease and comorbidities (Level of Evidence: A):
	  ○ Amiodarone
	  ○ Dofetilide
	  ○ Dronedarone
	  ○ Flecainide
	  ○ Propafenone
	  ○ Sotalol
	• The risks of the antiarrhythmic drug, including proarrhythmia, should be considered before initiating therapy with each drug (Level of Evidence: C).
	• Because of its potential toxicities, amiodarone should only be used after consideration of risks and when other agents have failed or are contraindicated (Level of Evidence: C).
	Class IIa

Clinical Guideline	Recommendation(s)
	• A rhythm-control strategy with pharmacological therapy can be useful in patients with AF for the treatment of tachycardia-induced cardiomyopathy (Level of Evidence: C). Class IIb • It may be reasonable to continue current antiarrhythmic drug therapy in the setting of infrequent, well-tolerated recurrences of AF when the drug has reduced the frequency or symptoms of AF (Level of Evidence: C). Class III: Harm • Antiarrhythmic drugs for rhythm control should not be continued when AF becomes permanent (Level of Evidence: C), including dronedarone (Level of Evidence: B). • Dronedarone should not be used for treatment of AF in patients with New York Heart Association class III and IV HF or patients who have had an episode of decompensated HF in the past 4 weeks. (Level of Evidence: B). <u>Upstream therapy</u> Class IIa • An angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced left ventricular ejection fraction (Level of Evidence: B). Class IIb • Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension (Level of Evidence: B). • Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery (Level of Evidence: A). Class III: No Benefit • Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease (Level of Evidence: B).

National Institute for Health and Clinical Excellence:
Atrial Fibrillation: The Management of Atrial Fibrillation (2014)[5]
	<u>Interventions to prevent stroke</u>
	• Do not offer stroke prevention to people aged <65 years with atrial fibrillation (AF) and no risk factors other than their sex (that is, very low risk of stroke equating to CHA_2DS_2-VASc score of 0 for men or 1 for women).
	• Consider anticoagulation for men with a CHA_2DS_2-VASc score of 1. Take the bleeding risk into account.
	• Offer anticoagulation to people with a CHA_2DS_2-VASc score of 2 or above, taking bleeding risk into account.
	• Discuss the options for anticoagulation with the person and base the choice on their clinical features and preferences.
	• Apixaban
	  ○ Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorization, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as:
	  ▪ Prior stroke of transient ischemic attack (TIA).
	  ▪ Age 75 years or older.
	  ▪ Hypertension.
	  ▪ Diabetes mellitus.
	  ▪ Symptomatic heart failure.
	• Dabigatran etexilate
	  ○ Dabigatran etexilate is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more of the following risk factors:
	  ▪ Previous stroke, TIA, or systemic embolism.

Clinical Guideline	Recommendation(s)
	▪ Left ventricular ejection fraction (LVEF) <40%. ▪ Symptomatic heart failure (HF) of New York Heart Association (NYHA) class 2 or above. ▪ Age 75 years or older. ▪ Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease, or hypertension. • Rivaroxaban o Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular AF with one or more risk factors such as: ▪ Congestive heart failure. ▪ Hypertension. ▪ Age 75 years or older. ▪ Diabetes mellitus. ▪ Prior stroke or TIA. • The decision about whether to start treatment with a new oral anticoagulant should be made after an informed discussion between the clinician and the person about the risks and benefits of the agent compared with the alternatives, including warfarin. For people who are taking warfarin, the potential risks and benefits of switching to a different oral agent should be considered in light of their level of international normalized ratio (INR) control. <u>Assessing anticoagulation control with vitamin K antagonists</u> • Calculate the person's time in therapeutic range (TTR) at each visit. When calculating TTR: o Use a validated method of measurement such as the Rosendaal method for computer-assisted dosing or proportion of tests in range for manual dosing. o Exclude measurements taken during the first six weeks of treatment. o Calculate TTR over a maintenance period of at least six months. • Reassess anticoagulation for a person with poor anticoagulation control shown by any of the following: o Two INR values higher than 5 or one INR value higher than 8 within the past six months. o Two INR values less than 1.5 within the past six months. o TTR <65%. • When assessing anticoagulation, take into account and if possible address the following factors that may contribute to poor anticoagulation control: Cognitive function, adherence, illness, drug interactions, and lifestyle factors including diet and alcohol consumption. • If poor anticoagulation control cannot be improved, evaluate the risks and benefits of alternative stroke prevention strategies and discuss these with the person. <u>When to offer rate and rhythm control</u> • Offer rate control as the first-line strategy to people with AF, except in people whose AF has a reversible cause, who have HF thought to be primarily caused by AF, with new-onset AF, with atrial flutter whose condition is considered suitable for an ablation strategy to restore sinus rhythm, and for whom a rhythm control strategy would be more suitable based on clinical judgement. <u>Rate control</u> • Offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium channel blocker (CCB) as initial monotherapy to people with AF who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities, and

Clinical Guideline	Recommendation(s)

	preferences when considering drug treatment.
	• Consider digoxin monotherapy for people with non-paroxysmal AF only if they are sedentary.
	• If monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any two of the following: a beta-blocker, diltiazem, and digoxin.
	• Do not offer amiodarone for long-term rate control.
	
	<u>Rhythm control</u>
	• Consider pharmacological and/or electrical rhythm control for people with AF whose symptoms continue after heart rate has been controlled or for whom a rate-control strategy has not been successful.
	
	<u>Drug treatment for long-term rhythm control</u>
	• Assess the need for drug treatment for long-term rhythm control, taking into account the person's preferences, associated comorbidities, risks of treatment, and likelihood of recurrence of AF.
	• If drug treatment for long-term rhythm control is needed, consider a standard beta-blocker as first-line treatment unless there are contraindications.
	• If beta-blockers are contraindicated or unsuccessful, assess the suitability of alternative drugs for rhythm control, taking comorbidities into account.
	• Dronedarone is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial fibrillation:
	  ○ Whose AF is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option and after alternative options have been considered AND
	  ○ Who have at least one of the following cardiovascular risk factors:
	  ▪ Hypertension requiring drugs of at least two different classes.
	  ▪ Diabetes mellitus.
	  ▪ Previous TIA, stroke, or systemic embolism.
	  ▪ Left atrial diameter of 50 mm or greater, OR
	  ▪ Age ≥70 years, AND
	  ○ Who do not have left ventricular systolic dysfunction, AND
	  ○ Who do not have a history of, or current, HF.
	• People who do not meet the criteria above who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
	• Consider amiodarone for people with left ventricular impairment or HF.
	• Do not offer class 1c antiarrhythmic drugs such as flecainide or propafenone to people with known ischemic or structural heart disease.
	• Where people have infrequent paroxysms and few symptoms, or where symptoms are induced by known precipitants (such as alcohol, caffeine), a 'no drug treatment' strategy or a 'pill-in-the-pocket' strategy should be considered and discussed with the person.

American Association for Thoracic Surgery: **2014 AATS Guidelines for the Prevention and Management of Peri-Operative Atrial Fibrillation and Flutter (POAF) for**	<u>Recommended prevention strategies for all postoperative atrial fibrillation (POAF) patients</u> • Patients taking β-blockers prior to thoracic surgery should continue them in the postoperative period to avoid β-blockade withdrawal. • Intravenous magnesium supplementation may be considered to prevent postoperative AF when serum magnesium level is low or it is suspected that total body magnesium is depleted. • Digoxin should not be used for prophylaxis against AF.

Clinical Guideline	Recommendation(s)
Thoracic Surgical Procedures (2014)[6]	Recommended prevention strategies for intermediate to high-risk POAF patients • It is reasonable to administer diltiazem to those patients with preserved cardiac function who are not taking β-blockers preoperatively in order to prevent POAF. • It is reasonable to consider the postoperative administration of amiodarone to reduce the incidence of POAF for intermediate and high risk patients undergoing pulmonary resection. • Postoperative administration of intravenous amiodarone may be considered to prevent POAF in patients undergoing esophagectomy. • Atorvastatin may be considered to prevent POAF for statin naïve patients scheduled for intermediate and high risk thoracic surgical procedures. Rate control recommendations for patients with new onset POAF • Intravenous administration of beta-blockers (e.g., esmolol or metoprolol) or nondihydropyridine calcium channel blockers (diltiazem or verapamil) is recommended to achieve rate control (heart rate ≤110 bpm) for patients who develop POAF with rapid ventricular response. • Caution should be used with patients with hypotension, left ventricular (LV) dysfunction, or heart failure. • Combination use of atrioventricular (AV) nodal blocking agents, such as beta-blockers (e.g., esmolol or metoprolol), nondihydropyridine calcium channel antagonists (e.g., diltiazem or verapamil), or digoxin, can be useful to control heart rates when a single agent fails to control rates of POAF. The choice should be individualized and doses modified to avoid bradycardia. • For patients with hypotension, heart failure or LV dysfunction, or when other measures are unsuccessful or contraindicated, intravenous amiodarone can be useful for control of heart rate. Amiodarone could result in conversion to sinus rhythm, and if it is initiated after 48 hours of AF, both a transesophageal echocardiography (TEE) when possible, to rule out left atrial/LA appendage (LA/LAA) thrombus, and full anticoagulation should be considered. • For patients with heart failure, LV dysfunction or hypotension, intravenous digoxin may be considered for rate control of POAF. • For patients with ventricular preexcitation (i.e., Wolff-Parkinson-White syndrome) and POAF, use of AV nodal blocking agents, such as beta-blockers (e.g., esmolol or metoprolol), intravenous amiodarone, nondihydropyridine calcium channel antagonists (e.g., diltiazem or verapamil), or digoxin, should be avoided. Recommendations for the use of antiarrhythmic drugs for pharmacologic cardioversion of POAF • Restoration of sinus rhythm with pharmacologic cardioversion is reasonable in patients with symptomatic, hemodynamically stable POAF. Intravenous amiodarone can be useful for pharmacologic cardioversion of POAF. • It is reasonable to administer antiarrhythmic medications in an attempt to maintain sinus rhythm for patients with recurrent or refractory POAF. • Amiodarone, sotalol, flecainide, propafenone, or dofetilide can be useful to maintain sinus rhythm in patients with POAF, depending on underlying heart disease, renal status and other comorbidities. • Flecainide or propafenone may be considered for pharmacologic cardioversion of POAF and maintenance of sinus rhythm if the patient has had no prior history of myocardial infarction, coronary artery disease, impaired LV function, significant LV hypertrophy, or valvular heart disease that is considered moderate or greater. These agents may need to be combined with an AV nodal blocking agent. • Intravenous ibutilide or procainamide may be considered for pharmacologic

Clinical Guideline	Recommendation(s)
	conversion of POAF for patients with structural heart disease and new onset POAF, but no hypotension or manifestations of congestive heart failure. Serum electrolytes and QTc interval must be within a normal range and patients must be closely monitored during and for at least six hours after the infusion if either ibutilide or procainamide. • Intravenous ibutilide or procainamide may be considered for patients with POAF and an accessory pathway. • Flecainide and propafenone should not be used to treat POAF in patients with a history of a prior myocardial infarction, coronary artery disease, and/or severe structural heart disease, including severe left ventricular hypertrophy, or significantly reduced left ventricular ejection fraction. • Dronedarone should not be used for treatment of POAF in patients with heart failure. <u>Recommendations for prevention of thromboembolism for patients with stable atrial fibrillation/flutter undergoing direct current cardioversion</u> • For stable patients with POAF of 48-hours duration or longer, anticoagulation (with warfarin for INR 2.0 to 3.0, a novel oral anti-coagulant [NOAC] or LMWH) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the method (electrical or pharmacological) used to restore sinus rhythm. • During the first 48 hours after the onset of POAF, the need for anticoagulation before and after direct current (DC) cardioversion may be based on the patient's risk of thromboembolism (CHA2DS2-VASc score) balanced by the risk of postoperative bleeding. • For POAF lasting longer than 48 hours, as an alternative to three weeks of therapeutic anticoagulation prior to cardioversion of POAF, it is reasonable to perform TEE in search of thrombus in the LA or LA appendage, preferably with full anticoagulation at the time of TEE in anticipation of DC cardioversion after the TEE. • For POAF lasting longer than 48 hours in patients who are not candidates for TEE (e.g., post-esophageal surgery), an initial rate control strategy combined with therapeutic anticoagulation using warfarin (aiming for INR 2.0 to 3.0), a direct thrombin inhibitor (e.g. dabigatran), factor Xa inhibitor (e.g. rivaroxaban, apixaban), or LMWH is recommended for at least three weeks prior to and four weeks after cardioversion. • Anticoagulation recommendations for cardioversion of atrial flutter are similar to those for atrial fibrillation. • For patients with an identified thrombus, cardioversion should not be performed until a longer period of anticoagulation is achieved (usually at least three weeks) and in accordance with established AF guidelines. <u>Management of anticoagulation for new onset POAF</u> • For the prevention of strokes for patients who develop POAF lasting longer than 48 hours, it is recommended to administer antithrombotic medications similarly to non-surgical patients. Anticoagulation within the first 48-hours of POAF should be considered based on the CHA2DS2-VASc risk score of the patient for stroke weighed against the risk of postoperative bleeding. • New oral anticoagulants (dabigatran, rivaroxaban, apixaban) are reasonable as an alternative to warfarin for patients who do not have a prosthetic heart valve, hemodynamically significant valve disease, and/or severe renal impairment or risk of GI bleeding. • It is reasonable to continue anticoagulation therapy for four weeks after the return of sinus rhythm because of the possibility of slowly resolving impairment of atrial contraction with an associated ongoing risk for thrombus formation and

Clinical Guideline	Recommendation(s)
	for delayed embolic events. • New oral anticoagulants should be avoided for patients at risk for serious bleeding (including GI bleeding) as they cannot be readily reversed. However, their use may be recommended in situations where achievement of a therapeutic INR with warfarin has proved to be difficult.
American College of Cardiology Foundation/ American Heart Association: **ACCF/AHA Guideline for the Management of Heart Failure (2013)**[7]	ACCF/AHA Stages of Heart Failure (HF) • Stage A: At high risk for HF but without structural heart disease or symptoms of HF. • Stage B: Structural heart disease but without signs or symptoms of HF. • Stage C: Structural heart disease with prior or current symptoms of HF. • Stage D: Refractory HF requiring specialized interventions. Treatment of Stage A: Recommendations • Hypertension and lipid disorders should be controlled in accordance with contemporary guidelines to lower the risk of HF. • Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. Treatment of Stage B: Recommendations • In all patients with a recent or remote history of myocardial infarction (MI) or acute coronary syndrome (ACS) and reduced ejection fraction (EF), ACE inhibitors should be used to prevent symptomatic HF and reduce mortality. In patients intolerant of ACE inhibitors, ARBs are appropriate unless contraindicated. • In all patients with a recent or remote history of MI or ACS and reduced EF, evidence-based beta blockers should be used to reduce mortality. • In all patients with a recent or remote history of MI or ACS, statins should be used to prevent symptomatic HF and cardiovascular events. • In patients with structural cardiac abnormalities, including left ventricular (LV) hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic HF. • ACE inhibitors should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. • Beta blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. • Nondihydropyridine calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of HF after MI. Treatment of Stage C HF with reduced EF (HFrEF): Recommendations • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. • ARBs are recommended in patients with HFrEF with current or prior symptoms who are ACE inhibitor intolerant, unless contraindicated, to reduce morbidity and mortality. • Use of one of the three beta blockers proven to reduce mortality (bisoprolol, carvedilol, and sustained-release metoprolol succinate) is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. • Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are

Clinical Guideline	Recommendation(s)
	recommended in patients with NYHA class II to IV HF and who have LVEF of ≤35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤2.5 mg/dL in men or ≤2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2), and potassium should be less than 5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III to IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. <u>Treatment of Stage C HF with preserved EF (HFpEF): Recommendations</u> • Systolic and diastolic blood pressure should be controlled in patients with HFpEF in accordance with published clinical practice guidelines to prevent morbidity. • Diuretics should be used for relief of symptoms due to volume overload in patients with HFpEF. • Management of AF according to published clinical practice guidelines in patients with HFpEF is reasonable to improve symptomatic HF. • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF.
American College of Cardiology/ American Heart Association/ Heart Failure Society of America: **ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (2016)**[8]	<u>Renin-angiotensin system inhibition with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker or ARNI: Recommendations</u> • The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors OR ARBs OR ARNI in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic HFrEF to reduce morbidity and mortality. • The use of ACE inhibitors is beneficial for patients with prior or current symptoms of chronic HFrEF to reduce morbidity and mortality. • The use of ARBs to reduce morbidity and mortality is recommended in patients with prior or current symptoms of chronic HFrEF who are intolerant to ACE inhibitors because of cough or angioedema. • In patients with chronic symptomatic HFrEF class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality. • ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor. • ARNI should not be administered to patients with a history of angioedema. <u>Ivabradine recommendations</u> • Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II to III) stable chronic HFrEF who are receiving guideline-directed evaluation and management, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest.
Institute for Clinical Systems Improvement: **Heart Failure in Adults**	<u>Pharmacologic management:</u> • Carvedilol, metoprolol succinate (extended-release), and bisoprolol have demonstrated reductions in mortality for patients with all classes of heart failure. These agents should be used before using other generic β-blockers.

Clinical Guideline	Recommendation(s)

(2013)[9]	• ACE inhibitors should be prescribed for all patients with left ventricular systolic dysfunction unless contraindications are present. An elevated baseline creatinine is not a specific contraindication.
	• If non-African American, ACE inhibitors are recommended for decreasing heart failure mortality than isosorbide dinitrate/hydralazine. In contrast, combination hydralazine and nitrates is recommended for patients self-described as African Americans, with moderate to severe symptoms on optimal therapy with ACE inhibitors, β-blockers, and diuretics.
	• ARBs should be considered primarily for patients who are intolerant to ACE inhibitors or in patients receiving standard drug therapy (including ACE inhibitors) who continue to show clinical deterioration.
	• Routine use of ARBs and ACE inhibitors and aldosterone antagonists cannot be recommended.
	• Diuretics should not be the sole therapy for patients with signs of volume overload; vasoactive drugs should be considered.
	• In severe heart failure, loop diuretics should be used over thiazide diuretics and combination therapy with thiazide. Loop diuretics are also effective in refractory cases of volume overload.
	• Patients with New York Heart Association (NYHA) class III-IV heart failure on stable doses of digoxin and ACE inhibitors can reduce mortality by administering aldosterone-blocking agents.
	• Nesiritide is recommended to be reserved for patients with decompensated heart failure who remain volume overloaded despite aggressive treatment with diuretics/vasodilators display tolerance and/or resistance to vasodilators or diuretics, or demonstrate significant side effects to other vasodilators.
	• When considering the use of calcium channel blockers, only dihydropyridine calcium channel blockers have been shown safe. Non-dihydropyridine calcium channel blockers can be used in patients with preserved systolic heart failure.
	
	<u>Pharmacologic management-digoxin</u>
	• In patients in normal sinus rhythm with preserved systolic function and mild to moderate heart failure symptoms on optimal therapy, digoxin had no effect on the endpoints of all-cause or cardiovascular mortality or hospitalization.
	• Serum levels less than 1.0 ng/mL are considered therapeutic. Levels greater than 1.2 have been associated with greater side effects. Serum levels do not always correlate to symptoms of digoxin toxicity.
	• Digoxin has been found useful:
	  o In heart failure patients with atrial fibrillation with a rapid ventricular response.
	  o In combination with ACE inhibitors in reducing hospitalizations in heart failure patients.
	• Digoxin should not:
	  o Be initiated in asymptomatic heart failure patients as it remains unsupported by clinical trials.
	  o Be “loaded” either orally or intravenously. Loading doses are generally not needed and steady state generally takes one week to reach.
	• Monitor for symptoms of toxicity, reduction of renal function or conduction abnormality.
	• To avoid digitalis toxicity, use lower doses in the elderly and those with renal impairment, check level in one to two weeks after start of therapy in elderly or renal-impaired patients, and be aware of drug interactions with new medications.
	• If continuing digoxin therapy in women, it may be reasonable to recommend that lower dosing (0.125 mg/day) should be used and lower serum levels (1.0 or less) should be maintained.

Clinical Guideline	Recommendation(s)
Heart Failure Society of America: **Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (2010)**[10]	• Digoxin should be considered for patients with left ventricular systolic dysfunction (left ventricular ejection fraction ≤40%) who have signs or symptoms of heart failure while receiving standard therapy, including ACE inhibitors and β-blockers. • It is recommended that the dose of digoxin, which should be based on lean body mass, renal function and concomitant medications, should be 0.125 mg daily in the majority of patients and the serum digoxin level should be <1.0 ng/mL, generally 0.7 to 0.9 ng/mL. • Doses >0.25 mg daily, for the purpose of rate control, are not recommended. • Digoxin should be considered for adequate control of the ventricular response to AF in patients with heart failure. • For patients taking amiodarone and digoxin concurrently, it is recommended that the maintenance dose of digoxin be reduced when amiodarone is initiated and then carefully monitored for the possibility of adverse drug interactions. Adjustment in doses of these drugs and laboratory assessment of drug activity or serum concentration after initiation of amiodarone is recommended.
European Society of Cardiology: **Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2016)**[11]	Pharmacological treatments indicated in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction • An ACE inhibitor is recommended, in addition to a beat-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death. • A mineralocorticoid receptor antagonist is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker, to reduce the risk of HF hospitalization and death. • Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. • Sacubitril-valsartan is recommended as a replacement for an ACE inhibitor to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker, and a mineralocorticoid receptor antagonist. • Ivabradine should be considered to reduce the risk of HF hospitalization or cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm despite treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose below that), ACE inhibitor (or ARB), and a mineralocorticoid receptor antagonist (or ARB). • Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contraindications for a beta-blocker. Patients should also receive an ACE inhibitor (or ARB) and a mineralocorticoid receptor antagonist (or ARB). • An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to tolerate an ACE inhibitor (patients should also receive a beta-blocker and mineralocorticoid receptor antagonist). • An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate a mineralocorticoid receptor antagonist. • Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with LVEF ≤35% or with an LVEF <45% combined with a dilated LV in NYHA Class III–IV despite treatment with an ACE-I a beta-blocker and a mineralocorticoid receptor antagonist to reduce the risk of HF hospitalization and death. • Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE inhibitor nor an ARB (or they are contraindicated) to reduce the risk of death.

Clinical Guideline	Recommendation(s)
	• Digoxin is a treatment with less-certain benefits and may be considered in symptomatic patients in sinus rhythm despite treatment with an ACE inhibitor (or ARB), a beta-blocker and a mineralocorticoid receptor antagonist, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations). Recommendations for treatment of patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction • It is recommended to screen patients with HFpEF or HFmrEF (mid-range) for both cardiovascular and noncardiovascular comorbidities, which, if present, should be treated provided safe and effective interventions exist to improve symptoms, well-being and/or prognosis. • Diuretics are recommended in congested patients with HFpEF or HFmrEF in order to alleviate symptoms and signs. Recommendations for initial management of a rapid ventricular rate in patients with heart failure and atrial fibrillation in the acute or chronic setting • Urgent electrical cardioversion is recommended if AF is thought to be contributing to the patient's haemodynamic compromise in order to improve the patient clinical condition. • For patients in NYHA Class IV, in addition to treatment for acute HF, an intravenous bolus of amiodarone or, in digoxin-naïve patients, an intravenous bolus of digoxin should be considered to reduce the ventricular rate. • For patients in NYHA Class I–III, a beta-blocker, usually given orally, is safe and therefore is recommended as first-line treatment to control ventricular rate, provided the patient is euvolaemic. • For patients in NYHA Class I–III, digoxin should be considered when ventricular rate remains high despite beta-blockers or when beta-blockers are not tolerated or contraindicated. • Treatment with dronedarone to improve ventricular rate control is not recommended due to safety concerns. Recommendations for cardiac imaging in patients with suspected or established heart failure • Transthoracic Echocardiogram (TTE) is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of HFrEF, HFmrEF, or HFpEF. • TTE is recommended for the assessment of LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device treatment recommended for HFrEF. Recommendations aiming to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms • Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life. • ACE inhibitor is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to prevent or delay the onset of HF and prolong life. • Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order to prevent or delay the onset of HF and prolong life. Pharmacological treatments indicated in patients with symptomatic heart failure with reduced ejection fraction • An ACE inhibitor is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and

Clinical Guideline	Recommendation(s)
	death. • A beta-blocker is recommended, in addition to an ACE inhibitor, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. • A mineralocorticoid receptor antagonist is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker, to reduce the risk of HF hospitalization and death. Other pharmacological treatments recommended in selected patients with symptomatic heart failure with reduced ejection fraction • Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. • Sacubitril-valsartan is recommended as a replacement for an ACE inhibitor to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and a mineralocorticoid receptor antagonist. Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (New York Heart Association Class II–IV) heart failure with reduced ejection fraction • Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization. • The addition of an ARB (or a renin inhibitor) to the combination of an ACE inhibitor and a mineralocorticoid receptor antagonist is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalemia. Not-recommended treatments of co-morbidities in patients with heart failure • Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. • NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. Recommendations for the management of patients with acute heart failure – pharmacotherapy • Intravenous loop diuretics are recommended for all patients with acute HF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of intravenous diuretics. • In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20 to 40 mg intravenous furosemide (or equivalent); for those on chronic diuretic therapy, initial intravenous dose should be at least equivalent to oral dose. • It is recommended to give diuretics either as intermittent boluses or a continuous infusion, and the dose and duration should be adjusted according to the patients' symptoms and clinical status. • Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.
National Institute for Health and Clinical Excellence: **Chronic heart failure in adults: management**	Heart failure due to left ventricular systolic dysfunction • As first-line treatment, offer both ACE inhibitors and β-blockers licensed for heart failure to all patients. • As second-line treatment, seek advice from a specialist and consider adding one of the following if a patient remains symptomatic despite optimal therapy with ACE inhibitor or a β-blocker:

Clinical Guideline	Recommendation(s)
(2010)[12] **(Reviewed Nov 2014)**	○ An aldosterone antagonist licensed for heart failure (especially moderate or severe heart failure or previous MI within the past month). ○ An ARB licensed for heart failure (especially mild to moderate heart failure). ○ Hydralazine in combination with nitrate (especially if patient is of African or Caribbean origin and has moderate to severe heart failure). • Hydralazine in combination with nitrate may be used first-line in patients intolerant to ACE inhibitors and ARBs. • ARBs may be used first-line in patients intolerant to ACE inhibitors. • Digoxin is recommended for worsening or severe heart failure due to left ventricular systolic dysfunction despite first- and second-line treatment for heart failure. <u>Monitoring</u> • Routine monitoring of serum digoxin concentrations is not recommended. A digoxin concentration measured within eight to 12 hours of the last dose may be useful to confirm a clinical impression of toxicity or non-adherence. • The serum digoxin concentration should be interpreted in the clinical context as toxicity may occur even when the concentration is within the 'therapeutic' range.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the cardiotonic agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Cardiotonic Agents[1-2]

Indication	Digoxin
Control of ventricular response rate in adult patients with chronic atrial fibrillation	✔
Increase myocardial contractility in pediatric patients with heart failure	✔
Treatment of mild to moderate heart failure in adults	✔

IV. Pharmacokinetics

The pharmacokinetic parameters of the cardiotonic agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Cardiotonic Agents[13]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (days)
Digoxin	60 to 85 (tablet) 70 to 85 (oral solution)	25	Liver (13)	Renal (50 to 70) Bile (6 to 8) Feces (3 to 5)	1.5 to 2.0

V. Drug Interactions

Major drug interactions with the cardiotonic agents are listed in Table 5.

Table 5. Major Drug Interactions with the Cardiotonic Agents[13]

Generic Name(s)	Interaction	Mechanism
Digoxin	Acarbose	Pharmacologic effects and plasma concentrations of digoxin may be decreased by acarbose. The mechanism of this interaction is unknown.
Digoxin	Activated charcoal	Charcoal can reduce gastrointestinal absorption of many drugs and actually remove drugs from the systemic circulation which will reduce the effectiveness or toxicity of a given agent.
Digoxin	Antineoplastic agents	Drug-induced alterations of the intestinal mucosa may be involved in reduced gastrointestinal absorption of digoxin; therefore, serum levels of digoxin may be reduced and actions may be decreased.
Digoxin	Amifampridine	Concurrent use of amifampridine and drugs with narrow therapeutic window may result in increased or decreased exposure of drugs with a narrow therapeutic index.
Digoxin	Aminoglycosides	The mechanism of this interaction is unknown. The rate and extent of digoxin absorption may be reduced, which could reduce the pharmacologic effect of the drug.
Digoxin	Amiodarone	Serum digoxin levels may be increased, resulting in an increase in the pharmacologic and toxic effects of digoxin. Mechanism of interaction is unknown.
Digoxin	β-blockers	Carvedilol may increase digoxin bioavailability. Possible additive depression of myocardial conduction and decreased renal tubular digoxin secretion may occur. Serum digoxin concentrations may be increased by coadministration of carvedilol. Synergistic bradycardia may occur in some patients.
Digoxin	Cholestyramine	Bioavailability and pharmacologic effects of digoxin may be decreased by bile acid sequestrants. The gastrointestinal absorption of digoxin may be decreased due to formation of a physical or chemical complex with bile acid sequestrants.
Digoxin	Colestipol	Colestipol may physically bind with digoxin and cause a decrease in its gastrointestinal absorption and normal enterohepatic recycling. Colestipol may decrease the half-life of digoxin, possibly reducing its therapeutic effect.
Digoxin	Cyclosporine	Mechanism of interaction unknown. The pharmacologic effects of digoxin may be increased, possibly leading to toxicity.
Digoxin	Diltiazem	Pharmacologic effects of digoxin may be increased by diltiazem. Elevated digoxin serum concentrations and toxicity, characterized by gastrointestinal and neuropsychiatric symptoms and cardiac arrhythmias, may occur. Pharmacodynamic effects of diltiazem and digoxin may be additive. The clearance of digoxin may be decreased by diltiazem.
Digoxin	Dronedarone	Plasma concentrations and pharmacologic effects of digoxin may be increased due to inhibition of P-glycoprotein (P-gp) efflux transport by dronedarone. Digoxin may also enhance the electrophysiologic effects of dronedarone.
Digoxin	Indomethacin	Serum concentrations and pharmacologic effects of digoxin may be increased by indomethacin. By decreasing renal blood flow, indomethacin may decrease renal elimination of digoxin.
Digoxin	Itraconazole	Itraconazole may increase pharmacologic effects and plasma concentrations of digoxin by decreasing renal the renal excretion of digoxin; toxicity may occur.
Digoxin	Loop diuretics	Increased urinary excretion of potassium and magnesium affecting cardiac muscle action, and other factors may also be involved. Diuretic-induced electrolyte disturbances may predispose patients to digoxin-induced arrhythmias.
Digoxin	Macrolides and	Macrolides and ketolides may increase serum concentrations and

Generic Name(s)	Interaction	Mechanism
	ketolides	toxic effects of digoxin. Inhibition of the P-glycoprotein transport system by macrolides and ketolides may increase the oral absorption and reduce the renal secretion of digoxin. Macrolides and ketolides-related alterations in gut flora may also play a role.
Digoxin	Metoclopramide	By increasing gastrointestinal motility, metoclopramide may decrease the plasma levels of digoxin, decreasing therapeutic effects. This interaction may not occur with high-bioavailability digoxin formulations.
Digoxin	Paroxetine	Inhibition of renal tubular P-glycoprotein excretion of digoxin by paroxetine is suspected, increasing digoxin serum concentrations, increasing the pharmacologic and toxic effects.
Digoxin	Penicillamine	Pharmacologic effects of digoxin may be decreased. Reduced digoxin serum levels, possibly with a suboptimal therapeutic response may result. The mechanism of this interaction is unknown.
Digoxin	Protease inhibitors	Protease inhibitors may increase plasma concentrations and pharmacologic effects of digoxin. Although the exact mechanism is unknown, P-glycoprotein inhibition by protease inhibitors may enhance the absorption and decrease the renal excretion of digoxin.
Digoxin	Propafenone	Actual mechanism of the interaction is unknown. The volume of distribution of digoxin may be decreased along with a decrease in the renal and non-renal clearance which may increase serum digoxin levels, resulting in toxicity.
Digoxin	Quinidine	Quinidine may reduce the renal clearance, biliary clearance and volume of distribution of digoxin thereby increasing serum digoxin levels and increasing the risk of toxicity.
Digoxin	Quinine	Quinine may increase digoxin serum concentrations. Toxicity characterized by gastrointestinal and neuromuscular symptoms and cardiac arrhythmias may occur.
Digoxin	Spironolactone	Spironolactone may attenuate the positive inotropic effect of digoxin. Serum levels of digoxin also may be increased. Additionally, spironolactone may interfere with the digoxin radioimmunoassay, resulting in falsely elevated digoxin levels.
Digoxin	Tetracyclines	Tetracycline may reverse the process by which digoxin is metabolized by gastrointestinal flora by altering gastrointestinal flora, allowing for more digoxin to be absorbed and increasing digoxin serum levels.
Digoxin	Thiazide diuretics	Increased urinary excretion of potassium and magnesium affecting cardiac muscle, and other factors may be involved. Thiazide-induced electrolyte disturbances may predispose to digoxin-induced arrhythmias.
Digoxin	Thioamines	Thioamines may alter pharmacologic effects and plasma concentrations of digoxin. The mechanism of this interaction is unknown.
Digoxin	Thyroid hormones	The therapeutic effectiveness of digoxin may be decreased, with possible exacerbation of cardiac arrhythmias or congestive heart failure. The mechanism of this interaction is unknown.
Digoxin	Verapamil	Verapamil may alter the pharmacokinetics and increase serum concentrations of digoxin. Toxicity characterized by gastrointestinal symptoms, neuropsychiatric symptoms, and cardiac arrhythmias may result.

VI. Adverse Drug Events

The most common adverse drug events reported with the cardiotonic agents are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Cardiotonic Agents[3]

Adverse Events	Digoxin
Cardiovascular	
Cardiac dysrhythmia	✔
Heart arrest	✔
Palpitation	✔
Tachycardia	✔
Ventricular extrasystole	✔
Central Nervous System	
Apathy	✔
Confusion	✔
Dizziness	✔
Headache	✔
Mental disturbances	✔
Weakness	✔
Gastrointestinal	
Abdominal pain	✔
Anorexia	✔
Diarrhea	✔
Hemorrhagic necrosis of the intestines	✔
Intestinal ischemia	✔
Nausea	✔
Vomiting	✔
Other	
Death	✔
Gynecomastia	✔
Macropapular rash	✔
Other skin reactions	✔
Thrombocytopenia	✔

✔ Percent not specified.

VII. Dosing and Administration

The usual dosing regimens for the cardiotonic agents are listed in Table 7. Several factors must be taken into account when dosing digoxin, including the patient's lean body weight, renal function, age, concomitant disease states, concurrent medications, and other factors that may alter the pharmacokinetic properties of digoxin.[4-5]

Table 7. Usual Dosing Regimens for the Cardiotonic Agents[1-3,13]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Digoxin	Control of ventricular response rate in patients with chronic atrial fibrillation: Injection: doses should be titrated to the minimum dose that achieves the desired ventricular rate control without causing undesirable side effects Solution, tablet: dose is based on patient-specific factors (e.g., age, lean body weight, renal function,	Increase myocardial contractility in pediatric patients with heart failure in children >10 years of age: Injection: dose is based on patient-specific factors (e.g., age, lean body weight, renal function, etc); dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired OR initiated with	Injection*: 100 µg/mL 250 µg/mL Solution: 50 µg/mL Tablet: 62.5 µg 125 µg 187.5 µg 250 µg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	etc); dosing can be either initiated with a loading dose (10 to 15 µg/kg) followed by maintenance dosing (3.4 to 5.1 µg/kg/day) if rapid titration is desired OR initiated with maintenance dosing (3.4 to 5.1 µg/kg/day) without a loading dose Treatment of mild to moderate heart failure: Injection: dose is based on patient-specific factors (e.g., age, lean body weight, renal function, etc); dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired OR initiated with maintenance dosing without a loading dose Solution, tablet: dose is based on patient-specific factors (e.g., age, lean body weight, renal function, etc); dosing can be either initiated with a loading dose (10 to 15 µg/kg) followed by maintenance dosing (3.4 to 5.1 µg/kg/day) if rapid titration is desired OR initiated with maintenance dosing (3.4 to 5.1 µg/kg/day) without a loading dose	maintenance dosing without a loading dose Solution, tablet: dose is based on patient-specific factors (e.g., age, lean body weight, renal function, etc); dosing can be either initiated with a loading dose (10 to 15 µg/kg) followed by maintenance dosing (3.4 to 5.1 µg/kg/day) if rapid titration is desired OR initiated with maintenance dosing (3.4 to 5.1 µg/kg/day) without a loading dose Increase myocardial contractility in pediatric patients with heart failure in children 5 to 10 years of age: Injection: dose is based on patient-specific factors (e.g., age, lean body weight, renal function, etc); dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired OR initiated with maintenance dosing without a loading dose Solution, tablet: dose is based on patient-specific factors (e.g., age, lean body weight, renal function, etc); dosing can be either initiated with a loading dose (20 to 45 µg/kg) followed by maintenance dosing (6.4 to 12.9 µg/kg/day OR 3.2 to 6.4 µg/kg/day twice daily) if rapid titration is desired OR initiated with maintenance dosing (3.4 to 5.1 µg/kg/day) without a loading dose	

*Parenteral administration of digoxin should be used only when the need for rapid digitalization is urgent or when the drug cannot be taken orally. Intramuscular injection can lead to severe pain at the injection site; therefore, intravenous administration is preferred. If the drug must be administered by the intramuscular route, it should be injected deep into the muscle followed by massage.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the cardiotonic agents are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Cardiotonic Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Atrial Fibrillation				
Hallberg et al.[14] (2007) AF group: Patients with atrial fibrillation on digoxin vs patients with atrial fibrillation not on digoxin CHF group: patients with CHF on digoxin vs patients with CHF not on digoxin AF and CHF group: Patients with atrial fibrillation and CHF on digoxin vs patients with AF and CHF not on	Cohort AF group: ECG finding of atrial fibrillation at admission, at discharge or had a discharge diagnosis of atrial fibrillation CHF group: History of CHF, a diagnosis of CHF at discharge or pulmonary edema on admission AF and CHF group: ECG finding of atrial fibrillation on admission, ECG finding of atrial fibrillation at discharge or a discharge diagnosis of atrial fibrillation, and a medical history of CHF, a diagnosis of CHF at discharge or pulmonary edema on admission	N=60,764 1 year	Primary: One year mortality Secondary: Effects on LVEF, s-creatinine and AMI	Primary: Patients with AF who received digoxin did significantly worse than those AF patients who did not receive digoxin therapy (RR of death was 1.42; 95% CI, 1.29 to 1.56). Patients with CHF who received digoxin therapy did significantly worse than those CHF patients who did not receive digoxin therapy (RR of death was 1.11; 95% CI, 1.04 to 1.19). In the group of patients with AF and CHF, there was no mortality difference between those that received digoxin therapy and those that did not receive digoxin therapy (RR of death was 1.00; 95% CI, 0.94 to 1.06). Secondary: In patients with an LVEF of ≤30%, there was not a significant difference in rate of death between patients who received digoxin therapy and those that did not (RR of death was 1.06; 95% CI, 0.86 to 1.31). In patients with an LVEF of >30%, there was not a significant difference in rate of death between patients who received digoxin therapy and those that did not (RR of death was 1.14; 95% CI, 0.98 to 1.32). Regardless of level of s-creatinine (low, normal, high), there was not a significant difference in mortality between those who received digoxin therapy and those who did not: low s-creatinine (RR of death was 1.23; 95% CI, 0.91 to 1.66), normal s-creatinine (RR of death was 1.22; 95% CI, 0.94 to 1.58), high s-creatinine (RR of death was 0.98; 95% CI, 0.83 to 1.16) respectively. In patients with an AMI, the RR for death was 1.17; 95% CI, 1.10 to 1.24 between those that received digoxin therapy and those that did not receive digoxin therapy.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
digoxin				In patients without an AMI, the RR for death was 1.10; 95% CI, 1.04 to 1.16 between those that received digoxin therapy and those that did not receive digoxin therapy.
Turakhia et al.[15] (2014) TREAT-AF Patients on digoxin vs patients not on digoxin	Cohort, RETRO Patients with newly diagnosed, nonvalvular atrial fibrillation/flutter seen within 90 days of diagnosis in an outpatient VA care setting	N=122,465 353,168 person-years of follow-up	Primary: Cumulative mortality rates Secondary: Not reported	Primary: Digoxin treatment was significantly associated with death in the multivariate Cox regression model (HR, 1.26; 95% CI, 1.23 to 1.29; P<0.001) and after propensity matching (HR, 1.21; 95% CI, 1.17 to 1.25; P<0.001). Subgroup findings were similar to the point estimates for the full and propensity-matched cohorts. There was evidence of possible effect modification in the full cohort and increased risk in patients with prior MI (P=0.002 in the full cohort; P=0.077 in the propensity-matched cohort). In all other subgroups, tests for interaction were not significant in full and propensity-matched analyses. Secondary: Not reported
Shah et al.[16] (2014) <u>Patients with HF:</u> patients on digoxin vs patients not on digoxin <u>Patients without HF:</u> patients on digoxin vs patients not on digoxin	Cohort, RETRO Patients aged ≥65 years admitted to a hospital with a primary or secondary diagnosis of AF	N=27,972 (propensity matched cohort of patients with AF and HF) N=46,262 (propensity matched cohort of patients with AF and without HF) 3.0 to 4.2 years mean follow-up time	Primary: All-cause mortality Secondary: Not reported	Primary: In the propensity score–matched cohort of patients with concomitant AF and HF, digoxin use was associated with a 14% greater risk of all-cause mortality (adjusted HR, 1.14; 95% CI, 1.10 to 1.17) and a similar result was observed with unadjusted analysis in this cohort (unadjusted HR, 1.14; 95% CI, 1.11 to 1.17). In the propensity score–matched cohort of patients with AF and without HF, digoxin use was associated with a 17% greater risk of all-cause mortality (adjusted HR, 1.17; 95% CI, 1.14 to 1.19) and a similar result was observed with unadjusted analysis in this cohort (unadjusted HR, 1.16; 95% CI, 1.13 to 1.19). There was a significant interaction between digoxin and gender (P=0.008), in which risk of all-cause mortality was greater in men compared with women (21 vs 13%).
Khand et al.[17] (2003)	DB, PC, PG, RCT	N=47	Primary: Assessment of	Primary: *Phase 1:*

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Phase 1: Digoxin with placebo vs digoxin with carvedilol Phase 2: digoxin vs carvedilol	Patients with persistent AF for >1 month and heart failure who were receiving digoxin and diuretics	Phase 1: 4 months Phase 2: 6 months	LVEF, ventricular rate control, symptom improvement, exercise test Secondary: Not reported	The patients in the digoxin with carvedilol group experienced a reduction in mean ventricular rate compared to the patients in the digoxin with placebo group (65.2±15 vs 74.9±11.2, respectively; P<0.0001). The patients in the digoxin with carvedilol group experienced improved LVEF compared to the patients in the digoxin with placebo group (30±9.6 vs 26±12.4, respectively; P=0.048). The patients in the digoxin with carvedilol group experienced an improvement in symptom scores compared to the patients in the digoxin with placebo group (7 [3 to 12.5] vs 8 [3 to 15], respectively; P=0.039). The patients in the digoxin with carvedilol group experienced a reduced ventricular rate at rest and throughout steady-state exercise (peak ventricular rate 106 beats/min) compared to those patients in the digoxin with placebo group (peak ventricular rate 123 beats/min; P<0.05). *Phase 2:* There was no significant difference in ventricular rate control between the digoxin and the carvedilol treatment groups (88.8±18.7 vs 75.7±10.6, respectively; P=0.13). There was no significant difference in LVEF between the digoxin and the carvedilol treatment groups (21.6±11 vs 27.2±11.7, respectively; P=0.15). There was no significant difference in symptom scores between the digoxin and the carvedilol treatment groups (6 [2 to 17] vs 8 [5 to 15.5], respectively; P=0.08). There was no significant difference in ventricular rate at steady-state exercise between the digoxin and the carvedilol treatment groups. Secondary: Not reported
Koh et al.[18] (1995) Digoxin 0.125 to 0.5 mg QD plus	PRO, RCT, XO Patients with persistent AF for >1 month	N=37 7 months	Primary: Effects on ventricular rate, BP, rate-pressure, maximal exercise	Primary: Patients in the digoxin plus betaxolol group experienced a significant reduction in ventricular rates both at rest and during exercise (67±3 and 135±5 beats/min, respectively) compared to the patients in the digoxin plus diltiazem group (80±7 and 154±5 beats/min, respectively; P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
diltiazem 90 mg BID vs digoxin 0.125 to 0.5 mg QD plus betaxolol QD			tolerance Secondary: Safety	Patients in the digoxin plus betaxolol group experienced a significant reduction in SBP during maximal exercise (164±4 mm Hg) but not at rest (127±3 mm Hg) compared to the patients in the digoxin plus diltiazem group (173±4 and 130±4 mm Hg, respectively; P<0.05, P>0.05, respectively). Patients in the digoxin plus betaxolol group experienced significantly less rate-pressure products at rest (85±4 x 10^2 mm Hg/min) and during exercise (213±12 x 10^2 mm Hg/min) compared to the patients in the in digoxin plus diltiazem group (105±6 and 269±12, respectively; P<0.05 for both). Both the digoxin plus betaxolol group and the digoxin plus diltiazem group experienced a significant improvement in exercise capacity compared to baseline (P<0.05), but the groups were not statistically significant from one another (9.3±0.5 vs 9.7±0.5 MET; P>0.05). There were no statistical differences between the treatment groups in any of the efficacy points measured between time points at weeks four and seven months. Secondary: No patients withdrew from the study in either treatment groups due to side effects. The digoxin plus betaxolol group experienced more side effects, which were considered minimal, compared to the digoxin plus diltiazem group. The minimal side effects observed in the digoxin plus betaxolol group included dyspnea, gastric pain, fatigue and constipation.
Hemels et al.[19] (2006) Group 1: Digoxin 0.125 to 0.25 mg QD plus acute (within 24 hours) ECV vs digoxin 0.125 to 0.25 mg QD plus	MC, PRO, RCT Patients with persistent AF, defined as non–self-terminating arrhythmia and requiring ECV to obtain sinus rhythm), and no contraindications to anticoagulation therapy	N=144 18 months	Primary: Freedom from permanent AF Secondary: QOL	Primary: At the end of the 18 month follow-up period, there was not a statistically significant difference in patients with permanent AF between the acute and routine ECV groups (32%; 95% CI, 22 to 44 vs 31%; 95% CI, 21 to 44, respectively; P=0.85), despite more ECVs in the acute vs the routine group ([median 3 vs 2 ECVs; P<0.05] and [≥3 ECVs in 54 vs 33% of patients, respectively; P<0.01]). At the end of the 18 month follow-up period, there was not a statistically significant difference in patients with permanent AF between the verapamil and digoxin groups (28%; 95% CI, 19 to 40 vs 36%; 95% CI, 25 to 48, respectively; P=0.33), despite more ECVs in the digoxin group compared to the verapamil group ([median 3 vs 2 ECVs, respectively; P<0.001] and [≥3

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
routine ECV Group 2: verapamil 120 to 360 mg QD with acute (within 24 hours) ECV vs verapamil 120 to 360 mg QD plus routine ECV Study medications were dosed to reach a target heart rate <100 beats/min and were administered for 4 weeks before ECV and continued during total follow-up. ECV was done one month after randomization and was only performed if anticoagulation therapy had been adequate (goal INR 2.5 to 3.5).				ECVs in 60 vs 28% of patients, respectively; P<0.001]). Secondary: At the end of the 18 month follow-up period, there were no significant differences in QOL between the acute and the routine cardioversion groups. Also, at the end of the 18 months, there were no significant differences in QOL between the digoxin and verapamil groups.
Wyse et al.[20] (2002) AFFIRM Rhythm control therapy:	MC, RCT Patients 65 years and older who had AF that was likely recurrent, AF was	N=4,060 3.5 years	Primary: Overall mortality Secondary: Composite death, disabling stroke,	Primary: The difference in mortality between the two groups was not significant (HR, 1.15; 95% CI, 0.99 to 1.34; P=0.08). Secondary: The rates of the composite end point of death, disabling stroke, disabling

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
amiodarone, disopyramide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, dofetilide and combinations of these drugs (doses not specified and adjusted to maintain normal sinus rhythm) vs rate control therapy: β-blockers, calcium-channel blockers, digoxin, and combinations of these drugs (doses not specified and adjusted to maintain normal sinus rhythm)	likely to cause illness or death, long-term treatment for AF was warranted, no contraindicated to anticoagulation therapy, eligible to undergo trials of at least two drugs in both treatment strategies; and treatment with either strategy could be initiated immediately after randomization		disabling anoxic encephalopathy, major bleeding, or cardiac arrest	anoxic encephalopathy, major bleeding, or cardiac arrest were also similar in the two groups (P=0.33).
Gheorghiade et al.[21] (2013) AFFIRM Patients taking digoxin vs	Post hoc analysis of AFFIRM Patients enrolled in the AFFIRM trial taking digoxin as initial therapy	N=1,756 3.5 years	Primary: All-cause mortality Secondary: all-cause mortality at 1, 2, 3, and 12 months of follow-up	Primary: All-cause mortality occurred in 14 and 13% of matched patients receiving and not receiving digoxin as an initial therapy, respectively (P=0.540). Secondary: Digoxin had no association with mortality at one month (P=0.421), two months (P=0.997), three months (P=0.620), or 12 months (P=0.612) of follow-up.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
propensity-matched patients not taking digoxin				
Whitbeck et al.[22] (2013) AFFIRM Patients taking digoxin vs propensity-matched patients not taking digoxin	Post hoc analysis of AFFIRM Patients enrolled in the AFFIRM trial (analyses were conducted in all patients and in subsets according to the presence or absence of HF)	N=4,060 3.5 years	Primary: All-cause mortality, CV mortality Secondary: Not reported	Primary: Digoxin was associated with an increase in all-cause mortality [estimated hazard ratio (EHR), 1.41; 95% CI 1.19 to 1.67; P<0.001], CV mortality (EHR, 1.35; 95% CI, 1.06 to 1.71; P=0.016), and arrhythmic mortality (EHR, 1.61; 95% CI, 1.12 to 2.30; P=0.009). The all-cause mortality was increased with digoxin in patients without or with HF (EHR, 1.37; 95% CI, 1.05 to 1.79; P=0.019 and EHR, 1.41; 95% CI, 1.09 to 1.84; P=0.010, respectively). The greatest change in the EHR followed addition of NYHA functional class, with a decrease from 1.66 (95% CI, 1.42 to 1.94; P<0.001) to 1.49 (95% CI, 1.27 to 1.74; P<0.001). There was no significant digoxin–gender interaction for all-cause (P=0.70) or cardiovascular (P=0.95) mortality. Secondary: Not reported
Okin et al.[23] (2015) Losartan-based treatment vs atenolol-based treatment	Post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial Hypertensive patients with ECG left ventricular hypertrophy in AF at baseline or who developed AF during follow-up stratified by digoxin use	N=937 4.7±1.1 years of mean follow-up	Primary: All-cause mortality, and cardiovascular and sudden cardiac death Secondary: Not reported	Primary: Among 937 hypertensive patients who were in atrial fibrillation at baseline or developed atrial fibrillation during follow-up, 372 patients (39.7%) were treated with digoxin during follow-up and 565 patients (60.3%) were never on digoxin. During follow-up, 167 patients died (17.8%) from any cause, including 109 cardiovascular deaths (11.6%) and 40 sudden cardiac deaths (4.3%). In univariate Cox analyses, in-treatment digoxin use, entered as a time-varying covariate, was associated with a 61% higher risk of dying (HR, 1.61; 95% CI, 1.18 to 2.19; P=0.003). After adjusting for other univariate predictors of death in this population, including age, diabetes, history of ischemic heart disease, stroke, or heart failure, baseline Cornell product, QRS duration, heart rate, serum glucose, creatinine and high-density lipoprotein cholesterol, and a propensity score for digoxin use entered as standard covariates, and for in-treatment heart rate, pulse pressure, and Sokolow-Lyon voltage treated as time-varying covariates, digoxin use was no longer a significant predictor of mortality (HR, 1.04; 95% CI, 0.73 to 1.48; P=0.839).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				In parallel analyses excluding the 175 patients on digoxin at baseline, in-treatment digoxin use was no longer a univariate (HR, 1.10; 95% CI, 0.71 to 1.68) or multivariate (HR, 0.84, 95% CI, 0.53 to 1.32) predictor of death. Similarly, if the 45 patients with a history of heart failure were excluded, in-treatment digoxin use was of borderline significance in univariate analyses (HR, 1.38; 95% CI, 0.99 to 1.93) but was not a significant predictor of death in multivariate Cox analyses (HR, 0.96; 95% CI, 0.65 to 1.39). Of note, in-treatment digoxin use had statistically similar performance in relevant subsets of the population, with no significant interactions between in-treatment digoxin use and sex (P=0.114), randomized treatment (P=0.536), history of heart failure (P=0.258) or ischemic heart disease (P=0.258), or in-treatment potassium levels (P=0.591) in Cox analyses. Secondary: Not reported
Van Gelder et al.[24] (2002) RACE Rhythm control therapy: electrical cardioversion, then sotalol 160 to 320 mg (based on weight and renal function); if recurrence within 6 months, repeat electrical cardioversion, then flecainide 200 to 300 mg QD or propafenone 450 to 900 mg QD; if recurrence again, electrical cardioversion repeated along	MC, RCT Patients with recurrent persistent AF or atrial flutter, who have undergone one electrical cardioversion during the previous 2 years, with a maximum of 2	N=522 2 years	Primary: Composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, the need for implantation of a pacemaker, or severe adverse effects of antiarrhythmic drugs Secondary: Not reported	Primary: The composite end point occurred in 44 (17.2%) patients in rate-control group and in 60 (22.6%) patients in the rhythm-control group (absolute difference of -5.4; 90% CI, -11.0 to 0.4). Death from cardiovascular causes occurred in 18 (7.0%) patients in rate-control group and in 18 (6.8%) patients in the rhythm-control group (absolute difference of 0.2; 90% CI, -3.4 to 3.9). Heart failure occurred in nine (3.5%) patients in rate-control group and in 12 (4.5%) patients in the rhythm-control group (absolute difference of -1.0; 90% CI, -3.8 to 1.8). Thromboembolic complications occurred in 14 (5.5%) patients in rate-control group and in 21 (7.9%) patients in the rhythm-control group (absolute difference of -2.4; 90% CI, -6.0 to 1.2). Bleeding occurred in 12 (4.7%) patients in rate-control group and in nine (3.4%) patients in the rhythm-control group (absolute difference of 1.3; 90% CI, -1.5 to 4.1). Severe adverse effects of antiarrhythmic drugs occurred in two (0.8%) patients in rate-control group and in 12 (4.5%) patients in the rhythm-control

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
with amiodarone 600 mg QD for 4 weeks then 200 mg QD vs rate control therapy: digitalis, non-dihydropyridine calcium channel blocker, and β-blocker, alone or in combination				group (absolute difference of -3.7; 90% CI, -6.0 to -1.4). A pacemaker was implanted in three (1.2%) patients in rate-control group and in eight (3.0%) patients in the rhythm-control group (-1.8; 90% CI, -3.9 to 0.2). Secondary: Not reported
Van Gelder et al.[25] (2010) RACE II Lenient rate control (resting heart rate <110 bpm) vs strict rate control (resting heart rate <80 bpm and heart rate during moderate exercise <100 bpm) During the dose-adjustment phase, patients were administered one or more negative dromotropic drugs	MC, NI, OL, PRO, RCT Patients ≤80 years with permanent AF for up to 12 months, mean resting heart rate>80 bpm, and current use of oral anticoagulation therapy (or aspirin)	N=614 Up to 2 years of follow-up (3 years maximum)	Primary: Composite of death from cardiovascular causes, hospitalization for heart failure, stroke, systemic embolism, major bleeding, and arrhythmic events Secondary: Components of the primary, all-cause mortality, symptoms, functional status	Primary: Eighty one patients (38 patients receiving lenient rate control vs 43 patients receiving strict rate control) reached the primary outcome. The three year estimated cumulative incidence was 12.9 vs 14.9% receiving lenient rate control and strict rate control, with an absolute difference between lenient control and strict control of -2.0 percentage points (90% CI, -7.6 to 3.5) and a HR of 0.84 (90% CI, 0.58 to 1.21). As compared to strict rate control, lenient rate control was noninferior with regard to the prevention of the primary outcome, for both the criteria of the difference in risk (P<0.001) and the HR (P=0.001). The HR was 0.80 (90% CI, 0.55 to 1.17) after statistical adjustment for the unbalanced distribution of the presence of coronary artery disease, the use of statins, and the diastolic blood pressure. Secondary: A total of 2.9 and 3.9% of patients receiving lenient rate control and strict rate control died from cardiovascular causes (HR, 0.79; 90% CI, 0.38 to 1.65). A total of 3.8 vs 4.1% of patients were admitted for heart failure (HR, 0.97; 90% CI, 0.48 to 1.96). A total of 1.6 vs 3.9% of patients experienced a stroke (HR, 0.35; 90% CI, 0.13 to 0.92). A total of 5.3 vs 4.5% of patients experienced major bleeding (HR, 1.12; 90% CI, 0.60 to 2.08). All-cause mortality occurred in 17 patients receiving lenient rate control (5.6% at three years) compared to 18 patients receiving strict rate control (6.6% at three years; HR, 0.91; 90% CI, 0.52 to 1.59). Death from

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(i.e., beta-blockers, non-dihydropyridine calcium channel blockers, and digoxin), used alone or in combination and at various doses, until the heart-rate target or targets were achieved.				noncardiovascular causes occurred in eight and seven patients receiving lenient and strict rate control. At the end of the follow-up period, 129/283 (45.6%) and 126/274 (46.0%) of patients receiving lenient and strict rate control had symptoms associated with AF (P=0.92); dyspnea (30.0 vs 29.6%; P=0.90), fatigue (24.4 vs 22.6%; P=0.63), and palpitations (10.6 vs 9.5%; P=0.66). At the end of follow-up period, in the lenient rate control group and in the strict control group, 70.0 and 70.4% of patients, respectively, were in NYHA functional class I, 23.3 vs 23.4% were in class II, and 6.7 vs 6.2% were in class II (P=0.74 for all comparisons).
Groenveld et al.[26] (2011) RACE II Lenient rate control (resting heart rate <110 bpm) vs strict rate control (resting heart rate <80 bpm and heart rate during moderate exercise <100 bpm) During the dose-adjustment phase, patients were administered one or more negative dromotropic drugs (i.e., beta-blockers, non-dihydropyridine	Post-hoc analysis of RACE II Patients ≤80 years with permanent AF for up to 12 months, mean resting heart rate>80 bpm, and current use of oral anticoagulation therapy (or aspirin)	N=614 Up to 2 years of follow-up (3 years maximum)	Primary: QOL (SF-36), AF severity scores (MFI-20) Secondary: Not reported	Primary: At the end of follow-up all SF-36 subscales were comparable between patients receiving lenient and strict rate control. At baseline and at the end of the trial there were no differences in the MFI-20 subscales between patients receiving lenient and strict rate control. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
calcium channel blockers, and digoxin), used alone or in combination and at various doses, until the heart-rate target or targets were achieved.				
Opolski et al.[27] (2004) HOT CAFÉ Rhythm control therapy: propafenone 450 to 600 mg QD, disopyramide 300 to 600 mg QD, or sotalol 160 to 320 mg QD vs rate control therapy: β-blockers, non-dihydropyridine calcium channel blockers, digoxin, or a combination of these drugs. All patients underwent electric cardioversion prior to the initiation of study medication.	MC, OL, RCT Patients between 50 to 75 years of age with AF known to be present continuously for between seven days and two years with acceptable etiology of the arrhythmia related to ischemic heart disease, arterial hypertension, hemodynamically insignificant valvular heart disease, or lack of assessable etiology	N=205 1 year	Primary: Composite of death from any cause (thromboembolic complications and intracranial or other major hemorrhage) Secondary: Rate control, sinus rhythm maintenance, discontinuation of therapy (proarrhythmic effects), hemorrhage, hospitalization, new or worsening CHF, or changes in exercise tolerance	Primary: There was not a significant difference in composite of death from any cause between the rate control group and the rhythm control group (OR, 1.98; 95% CI, 0.28 to 22.3; P>0.71). Secondary: The patients in the rhythm control group had a significantly lower mean heart rate (79.1±8.6 beats/min) in 24-hour Holter monitoring compared to the patients in the rate control group (85.8±7.5 beats/min; P<0.003). Four patients in the rhythm control group experienced proarrhythmic effects. Whether this lead to discontinuation of therapy was not mentioned. At the end of the study, 66 patients (63.5%) in the rhythm control arm were in sinus rhythm, with 27 of these patients successfully maintained with the first antiarrhythmic compound administered after the first cardioversion. There was not a statistical difference seen in bleeding complications between the rhythm control group (eight patients) and rate control group (five patients). A significantly lower number of hospitalizations were seen in the rate control arm compared to the rhythm control arm (12 vs 74%, respectively; P<0.001). Both the rhythm control group and rate control group had significant improvements in CHF class at some point during follow-up compared to baseline (P<0.001 and P<0.05, respectively). No difference in NYHA functional class between patients initially randomized to the two strategies was found at the end of the follow-up period.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				At the end of the study, both maximal workload and exercise duration were higher in the rhythm control arm compared to the rate control arm (P<0.001 and P<0.001, respectively).
Lafuente-Lafuente et al.[28] (2009) Antiarrhythmic drugs (amiodarone, aprindine, azimilide, bidisomide, flecainide, disopyramide, dofetilide, dronedarone, quinidine, propafenone, sotalol) vs placebo, drugs for rate control (digoxin, calcium channel blockers, β-blockers) or no treatment	MA (45 trials) Adults >16 years of age who had AF of any type and duration and in whom sinus rhythm had been restored, spontaneously or by any therapeutic intervention	N=12,559 Variable duration	Primary: Mortality, embolic complications, adverse events Secondary: Use of anticoagulation, recurrence of AF	Primary: No deaths were reported with flecainide in the three trials. Quinidine showed a trend to increase mortality compared to controls (OR, 2.26; 95% CI, 0.93 to 5.45; P=0.07). This trend was significant if missing patients were counted as deaths (OR, 2.29; 95% CI, 1.05 to 5.01; P=0.04), and when class IA drugs (quinidine and disopyramide) were combined (OR, 2.39; 95% CI 1.03 to 5.59; P=0.04). The number NNH for class IA drugs was 109 patients treated for one year to have one excess death. Sotalol showed a trend to increased mortality (OR, 2.09; 95% CI, 0.97 to 4.49; P=0.06) compared to controls. This trend was significant if missing patients were counted as deaths (OR, 2.27; 95% CI, 1.36 to 3.77; P=0.002). Amiodarone was associated with a reduction in mortality compared to combined class I drugs (OR, 0.39; 95% CI, 0.19 to 0.79; NNT 17). When compared to controls, amiodarone showed no significant difference in mortality. No other significant difference in mortality was detected, either vs control or between different antiarrhythmics. The analysis of cardiovascular mortality gave the same results as that of all-cause mortality. Only five of the 30 studies comparing antiarrhythmics with a control reported stroke outcomes. They reported six strokes in 650 patients in the control groups and 20 strokes in 1,755 patients treated with antiarrhythmics. Withdrawals due to adverse effects were more frequent with all drugs, except aprindine and dofetilide, compared to controls. Pooled events rates varied from 9 to 23% for withdrawals due to adverse effects. The mean number of patients needed to treat for one year to have one excess withdrawal from treatment ranged from nine (quinidine) to 27 (amiodarone, propafenone, or sotalol). Quinidine caused more withdrawals than the other class I drugs (OR, 2.25; 95% CI 1.45 to 3.51; P=0.0003). Amiodarone produced significantly fewer withdrawals than other class I drugs combined

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(OR, 0.52; 95% CI, 0.34 to 0.81; P=0.004). All antiarrhythmics increased proarrhythmic effects, with the exception of amiodarone and propafenone. Pooled events rates varied from 1 to 7% for proarrhythmia. The NNH for proarrhythmia ranged between 17 (flecainide) and 119 (dofetilide). Amiodarone produced significantly less proarrhythmic events than other class I drugs combined (OR, 0.28; 95% CI, 0.13 to 0.59; P=0.0007). Secondary: All class IA, class IC and class III drugs significantly reduced the recurrence of atrial fibrillation. Pooled recurrence rates of atrial fibrillation at 1 year were 71 to 84% in controls and were reduced to 42% to 67% in patients treated with antiarrhythmics. The NNT for one year to avoid one recurrence of atrial fibrillation were three with amiodarone, four with flecainide, five with dofetilide and propafenone, eight with quinidine and sotalol and 10 with dronedarone. Amiodarone reduced recurrences of AF significantly more than combined class I drugs (OR, 0.31; 95% CI, 0.21 to 0.45; P<0.0001) and more than sotalol (OR, 0.43; 95% CI 0.29 to 0.64; P<0.0001). No other differences between antiarrhythmics were detected. Chronic anticoagulation with warfarin was mandatory in only three studies. The decision on anticoagulation was left to the judgment of the attending physician in the remaining studies.
Heart Failure				
Koh, Kwan et al.[29] (1995) Without digoxin, diltiazem, or betaxolol (Group I) vs digoxin 0.125 to 0.5 mg QD (Group II)	PRO, RCT Patients with chronic heart failure for >1 month	N=45 4 weeks	Primary: Heart rate, BP, rate-pressure Secondary: Not reported	Primary: Resting ventricular rates were lower in all patients receiving active treatment (groups II, III, IV) compared those patients in group I who did not receive digoxin (P<0.01). Ventricular rates during exercise were lower in groups III and IV compared to groups I and II (P<0.01). No significant differences in ventricular rate were noted between groups III and IV, either at rest or during exercise (P<0.01). SBP was not significantly different between the four groups (P=0.09). Rate-pressure product at rest and during exercise was significantly lower in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs digoxin 0.125 to 0.5 mg QD and diltiazem 90 mg BID (Group III) vs digoxin 0.125 to 0.5 mg QD and betaxolol 20 mg QD (Group IV)				groups III and IV compared to groups I and II (P<0.01). Secondary: Not reported
DIG[30] (1997) Digoxin 0.125 to 0.5 mg QD vs placebo Patients continued on their other CHF therapies (including diuretics and ACE inhibitor). Initial dosing of digoxin was based on patient's age, sex, weight and renal function.	DB, MC, PC, RCT Patients ≥21 years old with heart failure and LVEF ≤45% who were in normal sinus rhythm	N=6,800 37 months	Primary: Mortality Secondary: Mortality from cardiovascular causes, death from worsening heart failure, hospitalization for worsening heart failure, and hospitalization for other causes (specifically due to digoxin toxicity)	Primary: In the digoxin group, there were 1,181 (34.8%) deaths compared to 1,194 (35.1%) deaths in patients receiving placebo (95% CI, 0.91 to 1.07; P=0.80). Secondary: In the digoxin group, 1,016 (29.9%) patients died from cardiovascular compared to 1,004 (29.5%) patient deaths in the placebo group (95% CI, 0.93 to 1.10; P=0.78). There were 394 deaths in the digoxin group that were attributed to worsening heart failure compared to 449 deaths in the placebo (95% CI, 0.77 to 1.01; P=0.06). In the digoxin group, 910 patients were hospitalized for worsening heart failure compared to 1,180 patients in the placebo group (95% CI, 0.66 to 0.79; P<0.001). Overall, the placebo group had a significantly higher number of patients hospitalized compared to the digoxin group, 2,184 vs 2,282 respectively (95% CI, 0.87 to 0.98; P<0.006). Other reasons for hospitalizations included cardiac events and respiratory infection. There was a statistically significantly higher number of patients in the digoxin group hospitalized for suspected digoxin toxicity compared to placebo, 67 vs 31, respectively (95% CI, 1.42 to 3.32; P<0.001).
Ather et al.[31]	Post-hoc analysis of	N=6,800	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2011) DIG Digoxin 0.125 to 0.5 mg QD vs placebo	DIG Patients ≥21 years old with heart failure and LVEF ≤45% who were in normal sinus rhythm; the DIG database was partitioned into 20 clusters	37 months	Multivariate Cox regression analyses were used to identify clusters in which digoxin is associated with either an increase ($Mortality_{dig}HR>1$), decrease ($Mortality_{dig}HR<1$), or no association with all-cause mortality ($Mortality_{dig}HR$-NS); and separately, with an increase ($HFA_{dig}HR>1$), decrease ($HFA_{dig}HR<1$), or no association with heart failure admissions ($HFA_{dig}HR$-NS) Secondary: Not reported	Nine hundred and thirty eight patients were identified in the $Mortality_{dig}HR>1$ group, 6,818 patients in the $Mortality_{dig}HR$-NS group, and non in the $Mortality_{dig}HR<1$. The $Mortality_{dig}HR>1$ group had a higher prevalence of females, diabetes, hypertension, higher age, SBP, heart rate, and ejection fraction compared to the $Mortality_{dig}HR$-NS group. Six thousand three hundred and twenty five patients were identified in the $HFA_{dig}HR<1$ group, 1,431 patients in the $HFA_{dig}HR$-NS group, and none in the $HFA_{dig}HR>1$ group. The $HFA_{dig}HR$-NS group had a higher prevalence of females and hypertension, higher SBP, body mass index, and ejection fraction; and lower prevalence of peripheral edema and third heart sound compared to the $HFA_{dig}HR<1$ group. Secondary: Not reported
Meyer et al.[32] (2008) DIG Digoxin 0.125 to 0.5mg QD vs placebo The majority of	Subgroup analysis of DIG trial (comparing equal numbers of patients with systolic [n=916] and diastolic heart failure [916]) Patients ≥21 years old with chronic heart failure and	N=1,832 2 to 3.2 years	Primary: Heart failure hospitalization or heart failure mortality (combined and separately) at the end of 3.2 years and 2 years of follow-up Secondary:	Primary: After 3.2 years of median follow-up, the combined end point of heart failure hospitalization or heart failure mortality occurred in 28 and 32% of patients with systolic heart failure (HR, 0.85; 95% CI, 0.67 to 1.08, P=0.188) and in 20 and 25% of patients with diastolic heart failure (HR, 0.79; 95% CI, 0.60 to 1.03; P=0.085) who were receiving digoxin and placebo, respectively. After 3.2 years of median follow-up, the effect of digoxin on heart failure hospitalization was similar in patients with systolic heart failure (HR, 0.80; 95% CI, 0.62 to 1.03, P=0.079) and diastolic heart failure (HR, 0.77; 95% CI, 0.57 to 1.03, P=0.074).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
patients enrolled were also receiving diuretics and ACE inhibitors	LVEF ≤45% who were in normal sinus rhythm		Not reported	At the end of two years of follow-up, the effect of digoxin on the combined end point was similar in patients with systolic heart failure (HR, 0.72; 95% CI, 0.55 to 0.95; P=0.022) and those with diastolic heart failure (HR, 0.69; 95% CI, 0.50 to 0.95; P=0.025). At the end of two years of follow-up, digoxin decreased heart failure hospitalization for systolic heart failure (HR, 0.73; 95% CI, 0.54 to 0.97; P=0.033) and diastolic heart failure (HR, 0.64; 95% CI, 0.45 to 0.90; P=0.010). Secondary: Not reported
Ahmed, Rich, Love et al.[33] (2006) DIG Digoxin 0.125 to 0.5 mg QD vs placebo QD Patients continued on their other CHF therapies (including diuretics and ACE inhibitors) Initial dosing of digoxin was based on patient's age, sex, weight and renal function.	Post hoc analysis of DIG Patients with heart failure, regardless of ejection fraction, and who were in normal SR	N=5,548 40 months	Primary: All-cause mortality Secondary: Mortality due to cardiovascular causes and heart failure, hospitalizations due to all causes, cardiovascular causes, and worsening heart failure	Primary: At 40 months, all cause death rate was 33% in the placebo group, 29% in the group of patients with a SDC of 0.5 to 0.9 ng/mL, and 42% in the group of patients with the SDC of ≥1.0 ng/mL (placebo vs SDC 0.5 to 0.9 ng/mL; adjusted HR, 0.77; 95% CI, 0.67 to 0.89; P<0.0001 and placebo vs SDC ≥1 ng/mL; adjusted HR, 1.06; 95% CI, 0.93 to 1.20; P=0.406). Secondary: At 40 months, cardiovascular mortality rate was 26% in the placebo group, 24% in the SDC of 0.5 to 0.9 ng/mL group, and 33% in the SDC of ≥1.0 ng/mL group (placebo vs SDC 0.5 to 0.9 ng/mL; adjusted HR, 0.83; 95% CI, 0.71 to 0.97; P=0.019 and placebo vs SDC ≥1 ng/mL; adjusted HR, 1.07; 95% CI, 0.93 to 1.24; P=0.339). At 40 months, mortality rate due to heart failure was 12% in the placebo group, 9% in the SDC of 0.5 to 0.9 ng/mL group, and 14% in the SDC of ≥1.0 ng/mL group (placebo vs SDC 0.5 to 0.9 ng/mL; adjusted HR, 0.63; 95% CI, 0.49 to 0.82; P<0.0001 and placebo vs SDC ≥1 ng/mL; adjusted HR, 0.87; 95% CI, 0.70 to 1.09; P=0.236). At 40 months, all cause hospitalization rates were 67% in the placebo group, 64% in the SDC of 0.5 to 0.9 ng/mL group, and 71% in the SDC of ≥1.0 ng/mL group (placebo vs SDC 0.5 to 0.9 ng/mL; adjusted HR, 0.85; 95% CI, 0.78 to 0.92; P<0.0001 and placebo vs SDC ≥1 ng/mL; adjusted HR, 0.95; 95% CI, 0.87 to 1.05; P=0.331). At 40 months, cardiovascular hospitalization rates were 53% in the placebo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				group, 48% in the SDC of 0.5 to 0.9 ng/mL group, and 55% in the SDC of ≥1.0 ng/mL group (placebo vs SDC 0.5 to 0.9 ng/mL; adjusted HR, 0.79; 95% CI, 0.72 to 0.88; P<0.0001 and placebo vs SDC ≥1 ng/mL; adjusted HR, 0.91; 95% CI, 0.82 to 1.01; P=0.086). At 40 months, hospitalization rates due to heart failure were 33% in the placebo group, 23% in the SDC of 0.5 to 0.9 ng/mL group, and 29% in the SDC of ≥1.0 ng/mL group (placebo vs SDC 0.5 to 0.9 ng/mL; adjusted HR, 0.62; 95% CI, 0.54 to 0.72; P<0.0001 and placebo vs SDC ≥1 ng/mL; adjusted HR, 0.68; 95% CI, 0.59 to 0.79; P=0.086).
Gheorghiade et al.[34] (2013) Digoxin 0.125 to 0.5 mg QD vs placebo QD Patients continued on their other CHF therapies (including diuretics and ACE inhibitors) Initial dosing of digoxin was based on patient's age, sex, weight and renal function.	Subanalysis of DIG Patients enrolled in the DIG trial in a high-risk subgroup (NYHA class III–IV symptoms, LVEF <25%, or cardiothoracic ratio (CTR) >55%)	NYHA class III–IV symptoms (N=2223), LVEF <25% (N=2256), and CTR>55% (N=2345). 2 years	Primary: Combined endpoints of HF mortality or HF hospitalization and all-cause mortality or all-cause hospitalization during the first 2 years after randomization Secondary: Not reported	Primary: Compared with patients receiving placebo, digoxin-associated HRs for the combined endpoint of 2-year HF death or HF hospitalization in subgroups with NYHA class III–IV symptoms, LVEF <25%, and CTR >55% were 0.65 [95% CI, 0.57 to 0.75; P<0.001], 0.61 (95% CI, 0.53 to 0.71; P<0.001), and 0.65 (95% CI, 0.57 to 0.75; P<0.001), respectively. Compared with the patients receiving placebo, digoxin-associated HRs for the combined endpoint of 2-year total death or all-cause hospitalization in subgroups with NYHA class III–IV symptoms, LVEF <25%, and CTR >55% were 0.88 (95% CI, 0.80 to 0.97; P=0.012), 0.84 (95% CI, 0.76 to 0.93; P=0.001), and 0.85 (95% CI, 0.77 to 0.94; P=0.002), respectively. Secondary: Not reported
Bourge et al.[35] (2013) Digoxin 0.125 to 0.5 mg QD	Subanalysis of DIG Patients enrolled in the DIG trial ≥65 years	N=3,405 30 days	Primary: 30-day all-cause hospital admission Secondary: 30-day	Primary: All-cause hospital admission occurred in 8.1 and 5.4% of older patients with HF and reduced ejection fraction assigned to placebo and digoxin, respectively (HR when digoxin was compared with placebo, 0.66; 95% CI, 0.51 to 0.86; P=0.002). This effect of digoxin remained unchanged when adjusted for baseline characteristics (HR, 0.65; 95% CI, 0.50 to 0.85;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo QD Patients continued on their other CHF therapies (including diuretics and ACE inhibitors) Initial dosing of digoxin was based on patient's age, sex, weight and renal function.			cardiovascular and heart failure hospitalizations, 30-day all-cause mortality and cause-specific mortalities, and the composite outcome of 30-day all-cause hospitalization or mortality	P=0.002). Secondary: Patients in the digoxin group had a lower risk of 30-day cardiovascular (HR, 0.53; 95% CI, 0.38 to 0.72; P<0.001) and 30-day heart failure (HR, 0.40; 95% CI, 0.26 to 0.62; P<0.001) hospitalizations, with similar trends for 30-day total mortality that did not reach statistical significance because of a low number of events.
Abdul-Rahim et al.[36] (2016) DIG Digoxin 0.125 to 0.5 mg QD vs placebo QD Patients continued on their other CHF therapies (including diuretics and ACE inhibitors) Initial dosing of digoxin was based on patient's age, sex, weight and	Subanalysis of DIG Patients enrolled in the DIG trial stratified by diabetes status	N=6,800 4 years	Primary: Composite of CV death or heart failure hospitalization; composite of heart failure death or heart failure hospitalization; all-cause death Secondary: Not reported	Primary: Of the 6,800 patients randomised in DIG, 1,933 patients (28.4%) were reported by investigators to have diabetes. Overall, 1,653 placebo treated patients (rate 20.6 per 100 patient years) and 1,501 (rate 17.3) digoxin treated patients experienced the composite outcome of CV death or heart failure hospitalisation (HR, 0.85; 95% CI, 0.79 to 0.91; P<0.001). Although the relative risk reduction with digoxin in patients with diabetes (10%) was numerically smaller than in those without diabetes (17%), the test for interaction was not significant (P=0.27). Overall, 1,004 placebo treated patients (rate 10.1 per 100 patient years) and 1,016 (rate 10.3) digoxin treated patients died from a CV death (HR, 1.01; 95% CI, 0.93 to 1.11; P=0.782). The lack of effect of digoxin on this outcome was similar, irrespective of diabetes status. Overall, 1,180 placebo treated patients (rate 14.7 per 100 patient years) and 910 (rate 10.5) digoxin treated patients were hospitalised at least once for heart failure (HR, 0.72; 95% CI, 0.66 to 0.79; P<0.001). The relative risk reduction with digoxin in patients with diabetes (21%) was numerically smaller than in patients without diabetes (31%) although the test for interaction was not significant (P=0.14).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
renal function.				Overall, 1,291 placebo treated patients (rate 16.1 per 100 patient years) and 1,041 (rate 12.0) digoxin treated patients experienced the composite outcome of heart failure death or heart failure hospitalisation (HR, 0.75; 95% CI, 0.69 to 0.82; P<0.001). Although the relative risk reduction with digoxin in patients with diabetes (20%) was numerically smaller than in those without diabetes (27%), the test for interaction was not significant (P=0.30). Overall, 1,194 placebo treated patients (rate 12.1 per 100 patient years) and 1181 (rate 11.9) digoxin treated patients died from all-cause death (HR, 0.99; 95% CI, 0.91 to 1.07; P=0.801). The lack of effect of digoxin on this outcome was similar, irrespective of diabetes status. Secondary: Not reported
Ahmed et al.[37] (2006) Digoxin 0.125 to 0.5 mg QD vs placebo Patients continued on their other CHF therapies (including diuretics and ACE inhibitor). Initial dosing of digoxin was based on patient's age, sex, weight and renal function.	MC, PC, RCT Patients with diastolic heart failure (LVEF >45%) and normal SR at baseline This was an ancillary trial conducted in parallel with the main DIG trial.[22]	N=988 37 months	Primary: Combined end point of heart failure hospitalization or heart failure mortality Secondary: Not prespecified, however the following outcomes were studied: all-cause and cardiovascular mortality, all-cause and cardiovascular hospitalizations, and the combined outcome of heart failure hospitalization and cardiovascular mortality	Primary: At the end of the study, there was not a statistically significant difference in the number of patients who experienced heart failure hospitalization or heart failure mortality between the digoxin group and the placebo group (102 [21%] vs 119 [24%], respectively; HR, 0.82; 95% CI, 0.63 to 1.07; P=0.136). Secondary: At the end of the study, there was not a statistically significant difference in the number of all-cause deaths between the digoxin group and the placebo group (115 [23%] vs 116 [23%], respectively; HR, 0.99; 95% CI, 0.76 to 1.28; P=0.925). Also, the difference in the number of cardiovascular deaths was not significantly different between the digoxin and the placebo group (81 patients in each group; HR, 1.00; 95% CI, 0.73 to 1.36; P=0.978). At the end of the study, there was not a statistically significant difference in the number of all-cause hospitalizations between the digoxin group and the placebo group (68% vs 67%, respectively; HR, 1.03; 95% CI, 0.89 to 1.20; P=0.683). Also, the difference in the number of cardiovascular hospitalizations was not significantly different between the digoxin and the placebo group (241 [49%] vs 225 [45%], respectively; HR, 1.10; 95% CI, 0.92 to 1.32; P=0.301). At the end of the study, there was not a statistically significant difference in the number of patients who experienced heart failure hospitalization or

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				cardiovascular mortality between the digoxin group and the placebo group (142 [29%] vs 154 [31%], respectively; HR, 0.88; 95% CI, 0.70 to 1.11; P=0.269).
Hashim et al.[38] (2014) Digoxin 0.125 to 0.5 mg QD vs placebo Patients continued on their other CHF therapies (including diuretics and ACE inhibitor). Initial dosing of digoxin was based on patient's age, sex, weight and renal function.	MC, PC, RCT Patients with diastolic heart failure (LVEF >45%) and normal SR at baseline This was a substudy of patients ≥65 years in the ancillary trial conducted in parallel with the main DIG trial.	N=631 37 months	Primary: Hospitalization due to all causes occurring during the first 30 days after randomization Secondary: Cause-specific hospitalizations and mortality, and the combined end point of all-cause hospitalization or all-cause mortality during the first 30 days after randomization	Primary: Among patients aged ≥65 years, the main endpoint occurred in 3.8, 8.9, and 9.0% of patients in the placebo group, and those in the digoxin group receiving 0.125 mg, and ≥0.25 mg of digoxin a day, respectively (P=0.026). When compared with placebo, HR for 30-day all-cause admission for patients in the digoxin group as a whole was 2.46 (95% CI, 1.25 to 4.83). Secondary: There were six hospitalizations due to worsening heart failure, two of which occurred in the digoxin group (HR, 0.51; 95% CI, 0.09 to 2.79) and there were seven hospitalizations due to unstable angina, all but one occurred in the digoxin group (HR, 6.21; 95% CI, 0.75 to 51.62). Among the 357 patients <65 years, 30-day all-cause hospitalization occurred in 7.4 and 6.1% of patients in the placebo and digoxin groups, respectively (HR for digoxin, 0.80; 95% CI, 0.36 to 1.79). Digoxin had no significant effect on any other outcomes.
Uretsky et al.[39] (1993) PROVED Digoxin 0.125, 0.25, 0.375, or 0.5 mg QD vs placebo QD Digoxin was dosed to obtain a serum	DB, MC, PC, PG, RCT Patients ≥18 years old with NYHA Class II or III heart failure, normal sinus rhythm, receiving digoxin and diuretics, LVEF ≤35%, a LVED dimension of ≥60 mm or 34 mm/m^2	N=88 12 weeks	Primary: Treadmill time on maximal exercise testing, distance covered in a 6-minute walking test, incidence of treatment failure, time to treatment failure Secondary: Change in signs and symptoms of	Primary: At 12 weeks, patients in the placebo group experienced a median decline of 96 seconds in maximal exercise testing compared to a 4.5 second increase in the digoxin group (P=0.003). Digoxin did not display a significantly different effect on distance covered in a 6-minute walking test. Patients in the placebo group experienced a 39% rate of treatment failures compared to 19% in the digoxin group (P=0.039). The patients in the placebo group also experienced a decreased time to treatment failure compared to the digoxin group (P=0.037). Treatment failures included hospital admissions, increase in drug therapy and death.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
digoxin concentration of 0.9 to 2.0 ng/mL Patients continued on background therapy of diuretics.			heart failure, MLHF questionnaire, heart failure score, 7-point GEP, LVEF, vital signs, body weight	Secondary: At the end of the 12-week study, there was not a statistically significant difference between the placebo and digoxin groups in changes in signs and symptoms of heart failure, MLHF questionnaire or heart failure score. At the end of 12 weeks, patients in the digoxin group experienced a mean increase in LVEF by 2±2% compared to a mean decrease in LVEF of 3±2% for the patients in the placebo group (P=0.016). Heart rate and body weight were significantly lower in the digoxin group compared to the patients in the placebo group (P=0.03 and P=0.044, respectively).
Packer et al.[40] (1993) Digoxin QD vs placebo QD All patients started in an 8 week, single-blind run-in period during which the doses of background therapy for heart failure were adjusted to achieve optimal clinical benefits. After the run-in period, patients were randomized to either continue receiving digoxin therapy or receive placebo. Digoxin	DB, MC, PC, RCT Patients ≥18 years old with NYHA Class II or III heart failure, LVEF ≤35%, a LVED dimension of ≥60 mm or 34 mm/m^2, evidence of reduced exercise capacity, and normal sinus rhythm, who were clinically stable while receiving digoxin, diuretics, and an ACE inhibitor	N=178 12 weeks	Primary: Rates of withdrawal from the study due to worsening heart failure, time to withdrawal, changes in exercise tolerance Secondary: Effects of discontinuing digoxin therapy on symptoms, QOL, functional class, overall progress during the study and cardiac dimensions and function	Primary: Four patients who received digoxin, compared to 23 patients in the placebo group, withdrew from the study due to worsening of heart failure (P<0.001). The patients in the placebo group had a higher risk of worsening heart failure compared to the patients in the digoxin group over the 12 week study (RR, 5.9; 95% CI, 2.1 to 17.2; P<0.001). Exercise tolerance remained stable in patients receiving digoxin compared to deterioration in exercise tolerance in patients receiving placebo. The median difference in exercise duration between the two groups after 12 weeks was 42 seconds (P=0.006). Exercise endurance remained constant in patients receiving digoxin compared to a decrease in patients receiving placebo. The median difference in submaximal exercise endurance between the two groups after 10 weeks was 41 meters (P=0.01). Secondary: Of the patients in the placebo group, 38% experienced worsening dyspnea and fatigue compared to 16 and 18% of patients in the digoxin group (P=0.14 and P=0.04, respectively). Thirty-three percent of patients in the placebo group experienced a less of an improved quality of life compared to 47% in the digoxin group (P=0.04). Also, 48% of patients in the placebo group experienced a more frequent decline in quality of life compared to 41% in the digoxin group (P=0.04).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
was dosed to obtain a serum digoxin concentration of 0.9 to 2.0 ng/mL Patients continued on background therapy of diuretics and an ACE inhibitor.				In the placebo group, 27% of patients were reported as having a deterioration in NYHA class compared to 10% of patients in the digoxin group (P=0.019). Thirty-one percent of patients in the placebo group reported that they felt moderately worse or much worse, compared to 9% of patients in the digoxin group (P=0.007).
Dhaliwal et al.[41] (2008) Digoxin, renin-angiotensin inhibition and beta-blockade vs renin-angiotensin inhibition and beta-blockade	RETRO Patients with a diagnosis of congestive heart failure with depressed LVEF (≤45%) and who were on a regimen of rennin-angiotensin inhibitor(s) and beta-blocker(s) with or without digoxin	N=347 26 months	Primary: Combined and individual rates of heart failure-related hospitalizations and total mortality Secondary: Not reported	Primary: In the adjusted analysis, heart failure hospitalizations (HR, 1.08; 95% CI, 0.77 to 1.50; P=0.66), total mortality (HR, 1.03; 95% CI, 0.78 to 1.35, P=0.85), and the combined end point of heart failure hospitalization and total mortality (HR, 1.11; 95% CI 0.81 to 1.53, P=0.52) were similar between individuals who had digoxin as part of their drug regimen and those who did not. In unadjusted analyses, digoxin use was associated with a nonsignificant increase in heart failure hospitalization rates. The combined endpoint of heart failure hospitalization and total mortality and individual end points were not different between patients on digoxin therapy and those not on digoxin therapy in any of the prespecified analyses according to subgroups of ejection fraction (≤25 vs >25%), NYHA class (III or IV vs I or II), use vs nonuse of β-blockers, presence or absence of atrial fibrillation, and admission or discharge heart rates of ≤60 or ≥60 beats/minute. Secondary: Not reported
Fauchier et al.[42] (2009) Digoxin vs beta-blockers	RETRO Patients with primary or secondary diagnosis of both AF and heart failure between January 2000 and January	N=1,269 881 days	Primary: All cause mortality Secondary: Not reported	Primary: Compared to the control group (no β-blocker or digoxin), treatment with a β-blocker (RR, 0.58; P=0.005) or digoxin plus beta-blockers (RR, 0.59; P=0.008) was associated with a lower risk of death. Treatment with digoxin alone was not associated with a better survival. There was a similar reduction in mortality when considered separately: heart failure patients with atrial fibrillation, association or not with coronary artery disease, and heart failure with decreased or preserved systolic function.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs digoxin plus beta-blockers vs No digoxin or beta-blockers (control group)	2004 were retroactively identified and followed until September 2007			The initial multivariate model was constructed using the predictors of all cause mortality as potential confounders. After adjustment, treatment with β-blocker alone or in combination with digoxin remained significantly associated with a better survival (RR, 0.618; P=0.04 and RR, 0.543; P=0.01, respectively). A stepwise selection technique was used to determine the final model, which included four factors associated with mortality: older age (P<0.001), decreased left ventricular ejection fraction (P=0.001), chronic renal insufficiency (P=0.007), and lack of treatment with beta-blockers alone or in combination with digoxin was associated with better survival (RR, 0.618; P=0.04 and RR, 0.543; P=0.01). Secondary: Not reported
Friberg et al.[43] (2009) Digoxin vs no digoxin	COHORT, OB Individuals treated as inpatients or outpatients for AF or atrial flutter	N=2,824 4.6 years (mean duration)	Primary: Mortality Secondary: Rates of hospitalization for heart failure, number of days at hospital for any cause, frequency of MI, frequency of ischemic stroke, and rate of pacemaker implantations	Primary: In the unadjusted analysis, 1,038 patients died; 412 were prescribed digoxin at index and 626 did not receive digoxin. The mortality rate was higher among individuals who were treated with digoxin (51 vs 31%; P<0.001; HR, 1.94; 95% CI, 1.71 to 2.20). When adjusted for age, gender, comorbidities and medications, the difference in mortality was not significant (HR, 1.10; 95% CI, 0.94 to 1.28). The relationship between mortality and digoxin treatment at the latest, rather than the first, contact during the observation period was also studied. Unadjusted mortality was higher among patients treated with digoxin (48 vs 31%, P<0.001); However, after multivariable adjustment, there was no difference (HR, 1.05; 95% CI, 0.92 to 1.20). When patients were matched according to their individual propensity scores, there was no difference in mortality related to digoxin use (HR, 1.05; 95% CI, 0.90 to 1.23). Secondary: Individuals treated with digoxin, who had high propensity scores for this treatment, were less often hospitalized for heart failure. The number of days in the hospital for any cause did not differ between groups. There was no difference in the frequency of myocardial infarctions or

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				ischemic strokes related to digoxin use. There was an increased rate of pacemaker implantations among patients with digoxin as compared to those without digoxin (HR, 1.99; 95% CI, 1.16 to 3.43).
Georgiopoulou et al.[44] (2009) Digoxin (median daily dose of 0.13mg/day) vs no digoxin	COHORT, RETRO Patients 18 to 70 years of age with advanced heart failure, LVEF ≤30% on maximum tolerated medical therapy, and NYHA Class II to IV	N=455 27 months (median duration)	Primary: Time to death, urgent transplantation, or left ventricular assist device implantation Secondary: Composite of the primary outcome plus hospitalization for heart failure, all-cause hospitalizations, and heart failure-related hospitalizations	Primary: Death, urgent transplantation, or left ventricular assist device implantation occurred in 36.6% of patients on digoxin compared to 15.8% of patients not receiving digoxin (HR, 2.28; 95% CI, 1.51 to 3.43; P<0.001). Secondary: The composite of primary outcome plus heart failure hospitalization occurred in 63.0% of patients on digoxin compared to 40.4% of patients not receiving digoxin (HR, 1.71; 95% CI, 1.32 to 2.23; P<0.001). All-cause hospitalization rates (HR, 1.58; 95% CI, 1.18 to 2.13; P<0.01) and heart failure-related hospitalization rates (HR, 1.81; 95% CI, 1.17 to 2.80; P<0.05) were higher in patients taking digoxin compared to those who were not taking digoxin.
Butler et al.[45] (2010) Val-HeFT Digoxin vs no digoxin The analyses of this trial were carried out in patient groups based on digoxin use at baseline.	Post-hoc analysis of Val-HeFT (DB, PC, MC, RCT) Patients with symptomatic heart failure	N=5,010 (n=3,374 digoxin-treated patients, n=1,636 patients not receiving digoxin) 23 months (mean duration)	Primary: All-cause mortality, first morbid event, heart failure hospitalizations Secondary: Not reported	Primary: Risk of death (n=3,249; HR, 1.28; 95% CI, 1.05 to 1.57; P=0.02), first morbid event (n=3,249; HR, 1.35; 95% CI, 1.15 to 1.59; P<0.001), first hospitalization for heart failure (n=3,249; HR, 1.41; 95% CI, 1.12 to 1.78; P=0.004), and sudden deaths (n=3,067; HR, 1.36; 95% CI, 1.04 to 1.78; P=0.03), but not pump failure deaths (n=2,875; HR, 1.48; 95% CI, 0.95 to 2.30; P=0.08), remained were significantly higher among patients receiving baseline digoxin compared to those were not. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Siu et al.[46] (2009) Digoxin IV 0.5 mg bolus dose, followed by 0.25 mg every 8 hours vs diltiazem IV 0.25 mg/kg bolus injection over 2 minutes, followed by a second bolus of 0.35 mg/kg if ventricular rate remained >90 bpm 15 minutes later, and then a maintenance infusion at 10 mg/hr for 24 hours vs amiodarone IV loading infusion of 300 mg over the first hour, followed by 10 mg/kg over 24 hours	OL, RCT Patients who presented to the Emergency Department with symptomatic acute AF for <48 hours and rapid ventricular rate >120 bpm requiring hospitalization	N=150 3 years	Primary: Sustained ventricular rate control (<90 bpm) within 24 hours Secondary: Time to ventricular rate control, sinus rhythm conversion, symptom severity, hospital stay, and adverse drug events	Primary: After the initial 24 hours, ventricular rate control was achieved in 119 of 150 patients (79%). Secondary: The median time to ventricular rate control in patients assigned to the diltiazem regimen was three hours (range: 1 to 21 hours) and was noticeably shorter than that of digoxin (six hours, 3 to 15 hours) and amiodarone (seven hours, 1 to 18 hours) based on the log-rank test (P<0.0001). Among the patients, 45 assigned to diltiazem achieved ventricular rate control (90%), which was significantly more than among those assigned to digoxin (74%; P=0.047) and amiodarone (74%; P=0.047). Patients assigned to diltiazem had persistently the lowest mean ventricular rate after the first hour of drug administration compared to the other two groups (P<0.05). Sinus rhythm conversion rate was 31% within the first 24 hours and 38% upon discharge. There was no significant difference in sinus rhythm conversion rate among the diltiazem regimen, digoxin regimen, and amiodarone regimen within the first 24 hours (34 vs 24 vs 36%; P>0.05) and on discharge (42 vs 28 vs 44%; P>0.05). There were no differences among the three groups in the median time to sinus conversion: five hours (1 to 16 hours), six hours (1 to 19 hours), and seven hours (1 to 17 hours), respectively (P>0.05). Patients receiving diltiazem had lower AF symptom severity scores at 24 hours compared to digoxin (P=0.047) and amiodarone (P=0.01). There was no significant difference in AF symptom frequency scores at 24 hours among the three groups. At 24 hours, patients receiving diltiazem had the greatest reduction in both AF symptom frequency score (12.7; P=0.001) and severity score (9.8; P<0.0001) compared to those who received digoxin (8.6 and 6.1) or amiodarone (9.0 and 6.1). Patients who achieved spontaneous sinus conversion had the greatest reduction in AF symptom frequency score and severity score (17.2 and 11.0, respectively) compared to those who achieved ventricular rate control (9.4 and 7.7) or failed ventricular rate control (1.2 and 0.1; all, P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Among patients who remained in AF, those receiving diltiazem had the greatest reduction in both AF symptom frequency score (9.0) and severity score (7.8) in comparison with patients receiving digoxin (6.3 and 5.3; P=0.049), and patients receiving amiodarone (5.6 and 3.3; P<0.01). The mean hospital stay was 4.4 days. There was a significantly shorter hospital stay (P=0.023) in the diltiazem group (3.9 days) compared to the digoxin (4.7 days) and amiodarone groups (4.7 days). Only one patient who received amiodarone demonstrated a major adverse event with phlebitis at the intravenous access site requiring prolonged hospitalization. No bradycardia, hypotension, new-onset CHF, or MI was observed in any of the patients.

Drug regimen abbreviations: BID=twice daily, IV=intravenous, QD=once daily
Study abbreviations: DB=double-blind, MA=meta-analysis, MC=multicenter, NI=noninferiority, OB=observational, OL=open-label, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized control trial, RETRO=retrospective, XO=cross-over
Miscellaneous abbreviations: ACE inhibitor=angiotensin-converting enzyme inhibitor, AF=atrial fibrillation, AMI=acute myocardial infarction, BP=blood pressure, CHF=congestive heart failure, CI=confidence interval, CV=cardiovascular, ECG=electrocardiogram, ECV=electrical cardioversions, HR=heart rate, INR=international normalized ratio, LVED=left ventricular end-diastolic, LVEF=left ventricular ejection fraction, MET=mean exercise tolerance, MFI-20=Multidimensional Fatigue Inventory-20, MI=myocardial infarction, MLHF=Minnesota Living with Heart Failure, NNH=number needed to harm, NNT=number needed to treat, NYHA=New York Heart Association, OR=odds ratio, QOL=quality of life, RR=relative risk, SBP=systolic blood pressure, SDC=serum digoxin concentration, SF-36=Short Form Health Survey

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Cardiotonic Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Digoxin	injection, solution, tablet	Lanoxin®*, Lanoxin Pediatric®	$	$$

*Generic is available in at least one dosage form or strength.

X. Conclusions

Digoxin is the only cardiotonic agent that is currently available. It is an effective treatment option for heart failure due to its positive inotropic and neurohormonal deactivating effects. It is also beneficial for atrial arrhythmias due to its vagomimetic actions. Digoxin injection, solution, and tablets are all available in a generic formulation. Although there are minor differences with respect to pharmacokinetic parameters, all digoxin products are equally effective. Due to its potential for drug interactions and other toxicities, digoxin therapy should be monitored closely.[1-3,13]

There are several guidelines that discuss the role of digoxin for the treatment of atrial fibrillation and heart failure. Digoxin slows atrioventricular conduction more effectively at rest than during exercise, but does not block exercise-induced tachycardia, which limits its use. For the treatment of atrial fibrillation, β-blockers and nondihydropyridine calcium channel antagonists are recommended as initial therapy to control heart rate.[4,10] Digoxin can effectively control heart rate at rest, but it is ineffective at controlling the ventricular response during exercise.[4] A combination of digoxin and either a β-blocker or nondihydropyridine calcium channel antagonist is reasonable to control the heart rate both at rest and during exercise.[4,10] Studies finding an association between

digoxin therapy and mortality raise concerns about its use, particularly long term.[4] In the AFFIRM trial, digoxin was associated with an increase in mortality, which in a post hoc analysis was found to be irrespective of sex or heart failure.[22] Arrhythmias, which are dose related, are a potential source of mortality; in the DIG trial, serum levels >0.9 ng/mL were associated with increased mortality.[4,33] However, in another AFFIRM subgroup propensity-matched analysis with paroxysmal and persistent AF, there was no increase in mortality or hospitalization in those taking digoxin as baseline initial therapy.[21] Digoxin should not be used for the pharmacologic cardioversion of atrial fibrillation. It has not been proven to be effective in preventing postoperative atrial fibrillation and is not recommended in this setting.[5,6] For the treatment of heart failure, angiotensin converting enzyme inhibitors, β-blockers, and diuretics are the cornerstone of therapy. Digoxin may be considered for patients with systolic dysfunction who have signs/symptoms of heart failure while receiving standard therapy. It has been shown to improve symptoms, exercise tolerance, and quality of life and decrease hospitalizations for heart failure; however, it has no effect on survival. Digoxin is not useful for the acute management of decompensated heart failure.[8-12] The available guidelines do not give preference to one particular digoxin formulation over another.[4-12]

Therefore, all brand cardiotonic agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand cardiotonic agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Lanoxin® tablets [package insert]. St. Michael, Barbados: Concordia Pharmaceuticals Inc.; 2016 Dec.
2. Lanoxin® injection [package insert]. Cary, NC: Covis Pharmaceuticals, Inc.; 2016 Dec.
3. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited May 2017]. Available from: http://online.factsandcomparisons.com.
4. January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.
5. National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. CG180. 2014. http://www.nice.org.uk/guidance/CG180.
6. Frendl G, Sodickson AC, Chung MK, et al. 2014 AATS Guidelines for the Prevention and Management of Peri-Operative Atrial Fibrillation and Flutter (POAF) for Thoracic Surgical Procedures. The Journal of thoracic and cardiovascular surgery. 2014;148(3):e153-e193. doi:10.1016/j.jtcvs.2014.06.036.
7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019.
8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435.
9. Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Institute for Clinical Systems Improvement. Heart Failure in Adults. Updated July 2013.
10. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194.
11. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.
12. National Institute for Health and Clinical Excellence (NICE). Chronic heart failure in adults: management. [guideline on the Internet]. London (UK): NICE; 2010 Aug [cited 2017 Mar]. Available from: http://www.nice.org.uk/guidance/cg108.
13. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 May]. Available from: http://www.thomsonhc.com/.
14. Hallberg P, Lindbäck J, Lindahl B, et al. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007;63:959–71.
15. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660-668.
16. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure. Am J Cardiol. 2014;114(3):401-406.
17. Khand AU, Rankin, AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42:1944–51.
18. Koh KK, Song JH, Kwon KS et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. International Journal of Cardiology. 1995;52(2):167–74.
19. Hemels MEW, T Van Noord, Crijns HJGM, et al. Verapamil vs digoxin and acute vs routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol. 2006;48:1001–9.
20. Wyse DG, Waldo AL, DiMarco JP, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347 (23): 1825-33.

21. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489-1497.
22. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481-1488.
23. Okin PM, Hille DA, Wachtell K, et al. Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. J Hypertens. 2015 Jul;33(7):1480-6.
24. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation (RACE). N Engl J Med. 2002; 347 (23): 1834-40.
25. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings M, et al. Lenient vs strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73.
26. Groenveld HF, Crijns HJGM, Van den Berg MP, Sonderen EV, Alings AM , Tijssen JGP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation. Data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58(17):1795-803.
27. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the polish how to treat chronic atrial fibrillation (HOT CAFE) Study. Chest. 2004; 126:476–86.
28. Lafuente-Lafuente C, Mouly S, Longas-Tejero M, Bergmann J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;(4):CD005049.
29. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol. 1995;75:88-90.
30. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.
31. Ather S, Peterson LE, Divakaran VG, Deswal A, Ramasubbu K, Giorgberidze I, et al. Digoxin treatment in heart failure – unveiling risk by cluster analysis of DIG data. Int J Cardiol. 2011;150:264-9.
32. Meyer P, White M, Mujib M, et al. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol 2008;102:1681-1686.
33. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure; a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178-86.
34. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551-559.
35. Bourge RC, Fleg JL, Fonarow GC, et al. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med. 2013;126(8):701-708.
36. Abdul-Rahim AH, MacIsaac RL, Jhund PS, et al. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. Int J Cardiol. 2016 Apr 15;209:310-6.
37. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary Digitalis Investigation Group trial. Circulation. 2006;114;397-403.
38. Hashim T, Elbaz S, Patel K, et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014;127(2):132-139.
39. Uretsky B, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic heart failure: Results of the PROVED trial. J Am Coll Cardiol. 1993;22:955-62.
40. Packer M, Gheorghiade M, Young J, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med. 1993;329:1-7.
41. Dhaliwal A, Bredikis A, Habib G, Carabello B, Ramasubbu K, Bozkurt B. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am J Cardiol 2008;102:1356-1360.
42. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009;103:248-254.
43. Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart 2010;96:275-280.
44. Georgiopoulou V, Kalogeropoulos A, Giamouzis G, et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2009;2:90-97.
45. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, et al. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16:191-5.

46. Siu C, Lau C, Lee W, Lam K, Tse H. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009;37:2174-2179.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Cardiac Drugs, Miscellaneous
AHFS Class 240492
August 9, 2017

I. Overview

Angina occurs when myocardial oxygen demand exceeds supply, which results in chest discomfort or pain. Common treatments for chronic angina include nitrates, β-blockers, and calcium channel blockers.[1] Ranolazine is approved for the treatment of chronic angina. It may be used in combination with β-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid lowering therapy, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers. The exact mechanism of ranolazine is unknown. The anti-ischemic and antianginal effects do not depend upon reductions in heart rate or blood pressure.[2]

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of β-blockers or have a contraindication to β-blocker use. Ivabradine reduces sinus rate by blocking the hyperpolarization-activated cyclic nucleotide-gated channel responsible for the cardiac pacemaker I_f current, which regulates heart rate.[3,4]

The miscellaneous cardiac drugs that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. No agents are available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Cardiac Drugs, Miscellaneous Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Ivabradine	tablet	Corlanor®	none
Ranolazine	extended-release tablet	Ranexa®	none

PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the miscellaneous cardiac drugs are summarized in Table 2.

Table 2. Treatment Guidelines Using the Cardiac Drugs, Miscellaneous

Clinical Guideline	Recommendations
Institute for Clinical Systems Improvement: **Stable Coronary Artery Disease (2013)**[5]	• The use of one aspirin tablet daily (81 to 162 mg) is strongly recommended unless there are medical contraindications. • In patients with mild, stable coronary artery disease (CAD), drug therapy may be limited to short-acting sublingual nitrates on an as-needed basis. • β-blockers should be used in all status post-myocardial infarction (MI) patients, based on studies showing mortality reduction. • β-blockers are the preferred first-line therapy for reducing symptoms of angina in patients with stable CAD. • Drugs with intrinsic sympathomimetic activity should be avoided. • Abrupt withdrawal of all β-blockers should be avoided. • If β-blockers cannot be prescribed as first-line therapy, nitrates are the preferred alternative first-line therapy because of efficacy, low cost, and relatively few adverse events. • For patients who are unable to take β-blockers or long-acting nitrates, the use of calcium channel blockers has been shown to be clinically effective in decreasing

Clinical Guideline	Recommendations
	symptoms of angina. Dihydropyridines as monotherapy may exacerbate angina. • Combination therapy may be necessary in selected patients, but it increases adverse events and medical costs. A combination of β-blockers and long-acting nitrates is preferred because of cost, efficacy, and reduced potential for adverse events. • If after several attempts at adjusting the medications, a therapeutic combination is not achieved for the patient, a cardiology consultation or referral may be appropriate. • Among patients with stable angina, angiotensin converting enzyme (ACE) inhibitors are most beneficial to patients with left ventricular dysfunction post-MI, persistent hypertension, and diabetes. If the patient cannot tolerate ACE inhibitors, a potential substitute would be an angiotensin II receptor blocker (ARB). • The decision to initiate daily drug therapy for CAD is based upon the symptom complex of the patient in combination with findings from the history, physical examination, laboratory studies and prognostic testing. • Ranolazine is not a first-line drug and should be used in conjunction with a cardiologist. Consider the use of ranolazine when β-blockers, calcium channel blockers, and nitrates are not adequately effective or are not tolerated.
American College of Cardiology /American Heart Association: **2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007)[6]**	• Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. • Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. • Patients with hypertension and established CAD should be treated with blood pressure medication(s) as tolerated, including ACE inhibitors and/or β-blockers with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes. • Long-acting calcium channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. • Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. • ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) of ≤40% and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. • ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. • ARBs are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a MI and have a LVEF of ≤40%. • ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. • Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF ≤40% and have either diabetes or heart failure. • It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. • Annual influenza vaccination is recommended in patients with cardiovascular disease. • No recommendation was made regarding the use of ranolazine.

Clinical Guideline	Recommendations
American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons: **Management of Stable Ischemic Heart Disease (2012)**[7]	<u>Medical therapy to prevent MI and death in patients with stable IHD</u> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin in contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction ≤40%) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction ≤40%), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <u>Medical therapy for relief of symptoms in patients with stable IHD</u> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.

American College of Cardiology Foundation/ American Heart Association: **2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes (2014)**[8]	<u>Early hospital care- standard medical therapies</u>
	• Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia.
	• Anti-ischemic and analgesic medications
	  ○ Nitrates
	  ▪ Patients with NSTE-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin.
	  ▪ Intravenous nitroglycerin is indicated for patients with NSTE-ACS for the treatment of persistent ischemia, heart failure, or hypertension.
	  ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil.
	  ○ Analgesic therapy
	  ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTE-ACE if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications.
	  ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin)

Clinical Guideline	Recommendations
	should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use o Beta-adrenergic blockers ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTE-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. o Calcium channel blockers (CCBs) ▪ In patients with NSTE-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTE-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-clockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTE-ACS in the absence of beta-blocker therapy. o Other anti-ischemic interventions ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTE-ACS patients due to a reduction in recurrent ischemia. o Cholesterol management ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTE-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTE-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system o ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. o ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. o Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes

Clinical Guideline	Recommendations

	mellitus, or heart failure.
	• Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS treated with an initial invasive or ischemia-guided strategy
	  ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTE-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely.
	  ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered.
	  ○ A $P2Y_{12}$ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include:
	  ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily.
	  ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily.
	  ▪ It is reasonable to use ticagrelor in preference to clopidogrel for $P2Y_{12}$ treatment in patients with NSTE-ACS who undergo an early invasive or ischemia-guided strategy.
	  ▪ In patients with NSTE-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatide or tirofiban.
	
	<u>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</u>
	• Antiplatelet agents
	  ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI
	  ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI.
	  ○ After PCI, aspirin should be continued indefinitely.
	  ○ A loading dose of a $P2Y_{12}$ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg.
	  ○ In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI.
	  ○ In patients receiving a stent (bare metal or drug eluting) during PCI, $P2Y_{12}$ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily.
	• Anticoagulant therapy
	  ○ An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation.
	  ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTE-ACS undergoing PCI.
	  ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH.
	  ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTE-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI.
	  ○ If PCI is performed while the patient is on fondaparinux, an additional 85

Clinical Guideline	Recommendations
	IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). o Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. • Timing of CABG in relation to use of antiplatelet agents o Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. o In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. o In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. o In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <u>Late hospital care, hospital discharge, and posthospital discharge care</u> • Medications at discharge o Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. o All patients who are post–NSTE-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. o Before hospital discharge, patients with NSTE-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. o Before hospital discharge, patients who are post–NSTE-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. o For patients who are post–NSTE-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. o If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. o Before discharge, patients should be educated about modification of cardiovascular risk factors. • Late hospital and post-hospital oral antiplatelet therapy o Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. o In addition to aspirin, a $P2Y_{12}$ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. o In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given for at least 12 months. • Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTE-ACS o The duration of triple antithrombotic therapy with a vitamin K antagonist,

Clinical Guideline	Recommendations
	aspirin, and a $P2Y_{12}$ receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor.
European Society of Cardiology: **Guideline for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2015)**[9]	Pharmacological treatment of ischemia • Early initiation of beta-blocker treatment is recommended in patients with ongoing ischaemic symptoms and without contraindications. • Sublingual or intravenous nitrates are recommended to relieve angina; intravenous treatment is recommended in patients with recurrent angina, uncontrolled hypertension, or signs of heart failure. • In patients with suspected/confirmed vasospastic angina, calcium channel blockers, and nitrates should be considered and beta-blockers avoided. Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes • Aspirin is recommended for all patients without contraindications at an initial oral loading dose of 150 to 300 mg (in aspirin-naïve patients) and a maintenance dose of 75 to 100 mg/day long-term regardless of treatment strategy. • A $P2Y_{12}$ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risks of bleeds. ○ Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindication, for all patients at moderate-to-high risk of ischemic events (e.g., elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). ○ Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no contraindication. ○ Clopidogrel (300 to 600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation. • $P2Y_{12}$ inhibitor administration for a shorter duration of three to six months after DES implantation may be considered in patients deemed at high bleeding risk. • It is not recommended to administer prasugrel in patients whom coronary anatomy is not known. • GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications. • Cangrelor may be considered in $P2Y_{12}$ inhibitor-naïve patients undergoing PCI. • It is not recommended to administer GPIIb/IIIa inhibitors in patients whom coronary anatomy is not known. • $P2Y_{12}$ inhibitor administration in addition to aspirin beyond one year may be considered after careful assessment of the ischemic and bleeding risks of the patient. Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes • Parenteral anticoagulation is recommended at the time of diagnosis according to both ischemic and bleeding risks. • Fondaparinux is recommended as having the most favorable efficacy-safety profile regardless of the management strategy. • Bivalirudin is recommended as an alternative to UFH plus GPIIb/IIIa inhibitors during PCI. • UFH is recommended in patients undergoing PCI who did not receive any anticoagulant. • In patients on fondaparinux undergoing PCI, a single intravenous bolus of UFH is recommended during the procedure.

Clinical Guideline	Recommendations
	• Enoxaparin or UFH are recommended when fondaparinux is not available. • Enoxaparin should be considered as an anticoagulant for PCI in patients pretreated for PCI with subcutaneous enoxaparin. • Additional activated clotting time-guided intravenous boluses of UFH during PCI may be considered following initial UFH treatment. • Discontinuation of anticoagulation should be considered after PCI, unless otherwise indicated. • Crossover between UFH and LMWH is not recommended. • In NSTEMI patients with no prior stroke/TIA and at high ischemic risk as well as low bleeding risk receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily for approximately one year) may be considered after discontinuation of parenteral anticoagulation. <u>Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation</u> • In patients with a firm indication for oral anticoagulation (e.g., atrial fibrillation with a CHADS2-VASc score ≥2, recent VTE, mechanical valve prosthesis), oral anticoagulation is recommended in addition to antiplatelet therapy. • An early invasive coronary angiography (within 24 hours) should be considered in moderate- to high-risk patients, irrespective of oral anticoagulant exposure, to expedite treatment allocation (medical vs PCI vs CABG) and to determine optimal antithrombotic regimen. • Initial dual antiplatelet therapy with aspirin plus a $P2Y_{12}$ inhibitor in addition to oral anticoagulation before coronary angiography is not recommended. • During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all non-vitamin K antagonist oral anticoagulants (NOACs) and if INR is <2.5 in VKA-treated patients. • Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase. • Following coronary stenting, dual (oral) antiplatelet therapy (DAPT) including new $P2Y_{12}$ inhibitors should be considered as an alternative to triple therapy for patients with non-ST-elevation acute coronary syndromes and atrial fibrillation with a CHADS2-VASc score of 1 (in males) or 2 (in females). • If at low bleeding risk (HAS-BLED ≤2), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for six months, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months. • If at high bleeding risk (HAS-BLED ≥3), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for one month, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months irrespective of the stent type. • Dual therapy with oral anticoagulant and clopidogrel may be considered as an alternative to triple antithrombotic therapy in selected patients (HAS-BLED ≥3 and low risk of stent thrombosis). • The use of ticagrelor or prasugrel as part of triple therapy is not recommended. • In medically managed patients, one antiplatelet agent in addition to oral anticoagulant should be considered for up to one year.
American College of Cardiology/ American Heart Association/ Heart Failure Society of America: **ACC/AHA/HFSA Focused Update on New Pharmacological**	<u>Renin-angiotensin system inhibition with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker or ARNI: Recommendations</u> • The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors OR ARBs OR ARNI in conjunction with evidence-based beta blockers, and aldosterone antagonists in selected patients, is recommended for patients with chronic HFrEF to reduce morbidity and mortality. • The use of ACE inhibitors is beneficial for patients with prior or current symptoms of chronic HFrEF to reduce morbidity and mortality. • The use of ARBs to reduce morbidity and mortality is recommended in patients

Clinical Guideline	Recommendations
Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (2016)[10]	with prior or current symptoms of chronic HFrEF who are intolerant to ACE inhibitors because of cough or angioedema. • In patients with chronic symptomatic HFrEF class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality. • ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor. • ARNI should not be administered to patients with a history of angioedema. <u>Ivabradine recommendations</u> • Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II- III) stable chronic HFrEF who are receiving guideline-directed evaluation and management, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest.
European Society of Cardiology: **Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2016)[11]**	<u>Pharmacological treatments indicated in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction</u> • An ACE inhibitor is recommended, in addition to a beat-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death. • A mineralocorticoid receptor antagonist is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker, to reduce the risk of HF hospitalization and death. • Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. • Sacubitril-valsartan is recommended as a replacement for an ACE inhibitor to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker, and a mineralocorticoid receptor antagonist. • Ivabradine should be considered to reduce the risk of HF hospitalization or cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm despite treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose below that), ACE inhibitor (or ARB), and a mineralocorticoid receptor antagonist (or ARB). • Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contraindications for a beta-blocker. Patients should also receive an ACE inhibitor (or ARB) and a mineralocorticoid receptor antagonist (or ARB). • An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to tolerate an ACE inhibitor (patients should also receive a beta-blocker and mineralocorticoid receptor antagonist). • An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate a mineralocorticoid receptor antagonist. • Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with LVEF ≤35% or with an LVEF <45% combined with a dilated LV in NYHA Class III–IV despite treatment with an ACE-I a beta-blocker and a mineralocorticoid receptor antagonist to reduce the risk of HF hospitalization and death. • Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE inhibitor nor an ARB (or they are contraindicated) to reduce the risk of death. • Digoxin is a treatment with less-certain benefits and may be considered in

Clinical Guideline	Recommendations
	symptomatic patients in sinus rhythm despite treatment with an ACE inhibitor (or ARB), a beta-blocker and a mineralocorticoid receptor antagonist, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations). Recommendations for treatment of patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction • It is recommended to screen patients with HFpEF or HFmrEF (mid-range) for both cardiovascular and noncardiovascular comorbidities, which, if present, should be treated provided safe and effective interventions exist to improve symptoms, well-being and/or prognosis. • Diuretics are recommended in congested patients with HFpEF or HFmrEF in order to alleviate symptoms and signs. Recommendations for initial management of a rapid ventricular rate in patients with heart failure and atrial fibrillation in the acute or chronic setting • Urgent electrical cardioversion is recommended if AF is thought to be contributing to the patient's haemodynamic compromise in order to improve the patient clinical condition. • For patients in NYHA Class IV, in addition to treatment for acute HF, an intravenous bolus of amiodarone or, in digoxin-naïve patients, an intravenous bolus of digoxin should be considered to reduce the ventricular rate. • For patients in NYHA Class I–III, a beta-blocker, usually given orally, is safe and therefore is recommended as first-line treatment to control ventricular rate, provided the patient is euvolaemic. • For patients in NYHA Class I–III, digoxin should be considered when ventricular rate remains high despite beta-blockers or when beta-blockers are not tolerated or contraindicated. • Treatment with dronedarone to improve ventricular rate control is not recommended due to safety concerns. Recommendations for cardiac imaging in patients with suspected or established heart failure • Transthoracic Echocardiogram (TTE) is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of HFrEF, HFmrEF, or HFpEF. • TTE is recommended for the assessment of LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device treatment recommended for HFrEF. Recommendations aiming to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms • Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life. • ACE inhibitor is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to prevent or delay the onset of HF and prolong life. • Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order to prevent or delay the onset of HF and prolong life. Pharmacological treatments indicated in patients with symptomatic heart failure with reduced ejection fraction • An ACE inhibitor is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.

Clinical Guideline	Recommendations
	• A beta-blocker is recommended, in addition to an ACE inhibitor, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. • A mineralocorticoid receptor antagonist is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker, to reduce the risk of HF hospitalization and death. Other pharmacological treatments recommended in selected patients with symptomatic heart failure with reduced ejection fraction • Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. • Sacubitril-valsartan is recommended as a replacement for an ACE inhibitor to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and a mineralocorticoid receptor antagonist. Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (New York Heart Association Class II–IV) heart failure with reduced ejection fraction • Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization. • The addition of an ARB (or a renin inhibitor) to the combination of an ACE inhibitor and a mineralocorticoid receptor antagonist is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalemia. Not-recommended treatments of co-morbidities in patients with heart failure • Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. • NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. Recommendations for the management of patients with acute heart failure – pharmacotherapy • Intravenous loop diuretics are recommended for all patients with acute HF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of intravenous diuretics. • In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20 to 40 mg intravenous furosemide (or equivalent); for those on chronic diuretic therapy, initial intravenous dose should be at least equivalent to oral dose. • It is recommended to give diuretics either as intermittent boluses or a continuous infusion, and the dose and duration should be adjusted according to the patients' symptoms and clinical status. • Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the miscellaneous cardiac drugs are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed

in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Cardiac Drugs, Miscellaneous[2,3]

Indication	Ivabradine	Ranolazine
Treatment of chronic angina		✔
Reduction in the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use	✔	

IV. Pharmacokinetics

The pharmacokinetic parameters of the miscellaneous cardiac drugs are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Cardiac Drugs, Miscellaneous[12]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Ivabradine	40	70	Intestines (extensive, % not reported) Liver (extensive, % not reported)	Renal and Feces (% not reported)	6
Ranolazine	55	62	Intestines (rapid and extensive, % not reported) Liver (rapid and extensive, % not reported)	Renal (75) Feces (25)	7.0 to 8.9

V. Drug Interactions

Major drug interactions with the miscellaneous cardiac drugs are listed in Table 5.

Table 5. Major Drug Interactions with the Cardiac Drugs, Miscellaneous[12]

Generic Name(s)	Interaction	Mechanism
Ivabradine	CYP3A4 Inhibitors	Concurrent use of ivabradine and CYP3A4 inhibitors may result in increased exposure of ivabradine.
Ivabradine	CYP3A4 Inducers	Concurrent use of ivabradine and CYP3A4 inducers may result in decreased exposure of ivabradine.
Ivabradine	QT Interval Prolonging Drugs	Concurrent use of ivabradine and QT interval prolonging drugs may result in increased risk of QT prolongation.
Ivabradine	Diltiazem, Verapamil	Concurrent use may result in increased exposure of ivabradine, increased risk for exacerbation of bradycardia, and increased risk of conduction disturbances.
Ivabradine	Conivaptan	Concurrent use of conivaptan and ivabradine may result in increased ivabradine exposure.
Ivabradine	Fluconazole	Concurrent use of fluconazole and ivabradine may result in increased ivabradine exposure and risk for QT interval prolongation.
Ivabradine	Fosphenytoin	Concurrent use of fosphenytoin and ivabradine may result in decreased exposure of ivabradine and increased risk of QT prolongation.
Ranolazine	Azole antifungals	Certain azole antifungals inhibit the metabolism of ranolazine, increasing plasma concentrations of ranolazine and the risk of

Generic Name(s)	Interaction	Mechanism
		toxicity.
Ranolazine	HMG-CoA reductase inhibitors	Ranolazine inhibits the metabolism of certain HMG-CoA reductase inhibitors, increasing plasma concentrations of HMG-CoA reductase inhibitors and the risk of adverse reactions.
Ranolazine	Macrolides and related antibiotics	Macrolide antibiotics inhibit the metabolism of ranolazine by the cytochrome P450 (CYP) 3A system. Concomitant use may increase the plasma levels of ranolazine and cause QT prolongation.
Ranolazine	Nefazodone	Plasma concentrations and pharmacologic effects of ranolazine may be increased by coadministration of nefazodone. Inhibition of cytochrome P4503A4 by nefazodone may decrease the metabolic elimination of ranolazine.
Ranolazine	Protease inhibitors	Protease inhibitors inhibit the metabolism of ranolazine by the CYP3A system. Concurrent administration may increase the plasma levels of ranolazine and cause QT prolongation.
Ranolazine	Aprepitant	Plasma concentrations and pharmacologic effects of ranolazine may be increased by coadministration of aprepitant. Inhibition of CYP3A4 by aprepitant may decrease the metabolic elimination of ranolazine.
Ranolazine	Barbiturates	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by barbiturates. Induction of CYP3A isoenzymes by barbiturates may increase the metabolic elimination of the ranolazine.
Ranolazine	Carbamazepine	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by carbamazepine. Induction of CYP3A isoenzymes by carbamazepine may increase the metabolic elimination of the ranolazine.
Ranolazine	Diltiazem	Diltiazem inhibits the metabolism of ranolazine by the CYP3A system. Concurrent administration may increase the plasma levels of ranolazine and cause QT prolongation.
Ranolazine	Erythromycin	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by erythromycin. Induction of cytochrome P450 3A isoenzymes by erythromycin may increase the metabolic elimination of the ranolazine.
Ranolazine	Fluconazole	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by fluconazole. Induction of CYP3A isoenzymes by fluconazole may increase the metabolic elimination of the ranolazine.
Ranolazine	Hydantoins	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by hydantoins. Induction of CYP3A isoenzymes by hydantoins may increase the metabolic elimination of the ranolazine.
Ranolazine	Rifamycins	Pharmacologic effects and plasma concentrations of ranolazine may be decreased by rifamycins. Induction of CYP3A isoenzymes by rifamycins may increase the metabolic elimination of the ranolazine.
Ranolazine	Verapamil	Verapamil inhibits the metabolism of ranolazine by the CYP3A system. Concurrent administration may increase the plasma levels of ranolazine and cause QT prolongation.

VI. Adverse Drug Events

The most common adverse drug events reported with the miscellaneous cardiac drugs are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Cardiac Drugs, Miscellaneous[13]

Adverse Events	Ivabradine	Ranolazine
Cardiovascular		
Atrial fibrillation	5 to 8	-
Bradycardia	6 to 10	0.5 to 4.0
Heart block	✔	-
Hypertension	9	-
Hypotension	<1	0.5 to 4.0
Orthostatic hypotension	-	0.5 to 4.0
Palpitation	-	0.5 to 4.0
Prolonged QT interval	-	≤ 1
Sinoatrial arrest	✔	-
Syncope	<1	0.5 to 4.0
Central Nervous System		
Confusional state	-	0.5 to 4.0
Dizziness	-	1 to 6
Headache	-	5.5
Phosphene	3	-
Vertigo	<1	0.5 to 4.0
Gastrointestinal		
Abdominal pain	-	0.5 to 4.0
Anorexia	-	0.5 to 4.0
Constipation	-	4.5
Dry mouth	-	0.5 to 4.0
Dyspepsia	-	0.5 to 4.0
Nausea	-	4.4
Vomiting	-	0.5 to 4.0
Respiratory		
Dyspnea	-	0.5 to 4.0
Other		
Angioedema	<1	-
Asthenia	-	0.5 to 4.0
Blurred vision	-	0.5 to 4.0
Erythema	<1	-
Hematuria	-	0.5 to 4.0
Hyperhidrosis	-	0.5 to 4.0
Peripheral edema	-	0.5 to 4.0
Pruritus	<1	-
Tinnitus	-	0.5 to 4.0
Urticaria	<1	-
Visual impairment	<1	-

✔ Percent not specified.
- Event not reported.

VII. Dosing and Administration

The usual dosing regimens for the miscellaneous cardiac drugs are listed in Table 7.

Table 7. Usual Dosing Regimens for the Cardiac Drugs, Miscellaneous[2,3]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Ivabradine	To reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥	Safety and efficacy in children have not been established.	Tablet: 5 mg 7.5 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use: Tablet: 5 mg twice daily; after two weeks adjust dose based on resting heart rate to a maximum of 7.5 mg twice daily		
Ranolazine	Treatment of chronic angina: Extended-release tablet: initial, 500 mg twice daily; maximum: 1,000 mg twice daily	Safety and efficacy in children have not been established.	Extended-release tablet: 500 mg 1,000 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the miscellaneous cardiac drugs are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Cardiac Drugs, Miscellaneous

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Swedberg et al.[14] (2010) SHIFT Ivabradine 5 mg BID vs placebo Following the 14–day titration period, doses were either increased to 7.5 mg BID (or corresponding placebo) if resting HR was > 60 bpm; continued on 5 mg BID if resting HR was 50 to 60 bpm; or decreased to 2.5 mg BID if resting HR < 50 bpm or patient had signs or symptoms related to bradycardia.	DB, MC, PC, PG, RCT Patients ≥ 18 years of age with symptomatic systolic HF in sinus rhythm with resting heart rate ≥ 70 bpm, a LVEF ≤ 35%, receiving maximally tolerated doses of β-blockers and other guidelines-based HF therapies and hospitalized for HF within 12 months prior to study entry	N=6,558 22.9 months	Primary: Composite of CV death or hospital admission for worsening HF Secondary: Composite of CV death or hospital admission for worsening HF in patients receiving ≥ 50% of the target daily dose of a β -blocker (as defined by ESC guidelines) at randomization; all-cause death, any CV death; death from HF; all-cause admission to hospital; any CV admission and the composite of CV, hospital admission for worsening HF or hospital admission for non-fatal MI	Primary: Compared to placebo, ivabradine reduced the risk of the combined endpoint of hospitalization for worsening HF or CV death based on a time-to-event analysis (HR, 0.82; 95% CI, 0.75 to 0.90; P<0.0001). Secondary: The composite of CV death, or hospital admission for worsening HF or hospital admission for non-fatal MI was reduced for the ivabradine group compared to placebo (HR, 0.82; 95% CI, 0.74 to 0.89; P<0.0001). Hospital admissions for worsening HF occurred in 672 (21%) of patients on placebo versus 514 (16%) of those on ivabradine (HR, 0.74; 95% CI, 0.66 to 0.83; P<0.0001). All cause hospital admission was reduced in the ivabradine group compared to placebo (HR, 0.89; 95% CI, 0.82 to 0.96; P=0.003). Any CV hospital admission was also reduced in the ivabradine group compared to placebo (HR, 0.85; 95% CI, 0.78 to 0.92; P=0.0002). CV mortality was not significantly reduced in ivabradine group (P=0.128), but deaths due to HF did fall significantly (HR, 0.74; 95% CI, 0.58 to 0.94; P=0.014). Serious adverse events occurred at a lower rate in ivabradine group than in placebo (P=0.025). The incidence of symptomatic and asymptomatic bradycardia was more frequent in ivabradine group than in patients taking placebo (both P<0.0001). Reported visual symptoms occurred in 89 (3%) of patients taking ivabradine compared to < 1% in those taking placebo (P<0.0001).
Fox et al.[15] (2008) BEAUTIFUL	DB, MC, PC, RCT Patients ≥ 55 years	N=10,917 Median	Primary: Composite of CV death or	Primary: There was no significant difference between the ivabradine- and placebo-treated patients in CV death or admission to hospital for MI or new-onset

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ivabradine 5 mg BID vs placebo Following the 14–day titration period, doses were increased to 7.5 mg BID if resting HR was ≥ 60 bpm; dose reduced from 7.5 mg to 5 mg BID if resting heart rate was < 50 bpm, or if they had signs or symptoms related to bradycardia; study drug was discontinued in patients given 5 mg BID if resting HR was < 50 bpm, or if they had signs or symptoms related to bradycardia.	of age (18 years of age if diabetic) with documented CAD, LVEF < 40%, end-diastolic short-axis internal dimension > 56 mm by echocardiography, in normal sinus rhythm with resting heart rate ≥ 60 bpm, stable angina and/or HF symptoms for ≥3 months, and receiving optimal conventional CV medication on appropriate and stable doses for ≥1 month	duration of follow-up was 19 months with a maximum of 35 months	hospitalization for acute MI or new onset or worsening HF Secondary: Composite of hospitalization for acute coronary syndrome, for new onset or worsening HF, or coronary revascularization; mortality due to coronary artery disease; all-cause mortality; the individual components of the composite primary and secondary endpoints	or worsening HF (HR, 1.00; 95% CI, 0.91 to 1.10; P=0.94). A total of 1,119 patients died during the study, 572 (10%) in the ivabradine group and 547 (10%) in the placebo group (HR, 1.04; 95% CI, 0.92 to 1.16; P=0.55). Secondary: Ivabradine reduced secondary endpoints of admission to hospital for fatal or non-fatal MI in a prespecified subgroup of individuals with HR of ≥ 70 bpm (HR, 0.64; 95% CI, 0.49 to 0.84; P=0.001) and coronary revascularization (HR, 0.70; 95% CI, 0.52 to 0.93; P=0.016). This was not seen in the total study population. There was no statistical significance seen with the ivabradine group compared to placebo for any of the mortality endpoints (all-cause death: HR, 1.04; 95% CI, 0.92 to 1.16; P=0.55; cardiovascular death: HR, 1.07; 95% CI, 0.94 to 1.22; P=0.32; cardiac death: HR, 0.89; 95% CI, 0.71 to 1.12; P=0.33).
Fox et al.[16] (2014) SIGNIFY Ivabradine 7.5 mg BID	DB, MC, PC, RCT Patients ≥ 55 years of age with documented and treated stable CAD	N=19,102 Median follow-up 27.8 months	Primary: Composite of death from CV causes or nonfatal MI Secondary:	Primary: There was no significant difference between the ivabradine group and the placebo group in the incidence of death from CV causes or nonfatal MI (6.8% and 6.4%, respectively; HR, 1.08; 95% CI, 0.96 to 1.20; P=0.20). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo ivabradine dose was titrated up to 10 mg BID or down to 5 mg BID to achieve a target HR of 55 to 60 bpm	with no evidence of clinical HF, in sinus rhythm with a resting HR of ≥ 70 bpm on two consecutive electrocardiographic readings and at least one major adverse prognostic factor, or two minor adverse prognostic factors or a LDL cholesterol level > 160 mg per deciliter		Death from CV causes, nonfatal MI and death from any cause	There was no significant difference between the ivabradine group and the placebo group in the incidence of death from CV causes (3.4% and 3.2%, respectively; HR, 1.10; 95% CI, 0.94 to 1.28; P=0.25), nonfatal MI (2.8% and 2.6%, respectively; HR, 1.06; 95% CI, 0.89 to 1.26; P=0.52) or death from any cause (5.1% and 4.8%, respectively; HR, 1.06; 95% CI, 0.94 to 1.21; P=0.35). The incidence of bradycardia was higher with ivabradine compared to placebo (18.0% vs 2.3%; P<0.001).
Chaitman et al.[17] (2004) CARISA Ranolazine ER 750 to 1,000 mg BID in combination with diltiazem, atenolol, or amlodipine vs placebo in combination with diltiazem, atenolol, or amlodipine	DB, MC, PC, PG, RCT Patients with symptomatic chronic angina despite treatment with diltiazem, atenolol, or amlodipine	N=823 12 weeks with long-term follow-up of up to 39 months	Primary: Exercise duration on treadmill Secondary: Time to inset of angina, time to ≥1 mm ST-segment depression, angina frequency, nitroglycerin use, survival	Primary: In the ranolazine group, exercise duration was significantly increased compared to placebo (P=0.01). Secondary: Time to angina and time to 1 mm ST-segment depression were significantly increased compared to placebo. Treatment with ranolazine significantly reduced the frequency of angina attacks (3.3 vs 2.5 attacks per week for the 750 mg group; P=0.006; and 3.3 vs 2.1 attacks per week for the 1,000 mg group; P<0.001), and nitroglycerin use compared to placebo. The most common adverse effects were constipation, dizziness, nausea, and asthenia (≤7.3% in the ranolazine group vs ≥0.7% in the placebo group). The survival rates for patients taking ranolazine were 98.4% (95% CI, 97.4 to 99.5) at year one and 95.9% (95% CI, 94.0 to 97.7) at year two.
Timmis et al.[18] (2006) CARISA	Post-hoc analysis of CARISA	N=823 12 weeks with	Primary: Exercise duration on treadmill	Primary: In the CARISA trial, 23% of the patients were diabetic and 77% were not diabetic.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ranolazine ER 750 to 1,000 mg BID in combination with diltiazem, atenolol, or amlodipine vs placebo in combination with diltiazem, atenolol, or amlodipine	Patients with type 2 diabetes who had symptomatic chronic angina despite treatment with diltiazem, atenolol, or amlodipine	long-term follow-up of up to 39 months	Secondary: Time to onset of angina, time to ≥1 mm ST-segment depression, angina frequency, nitroglycerin usage, and HbA_{1c} levels in diabetic patients only and lipid panel as post hoc analysis	The effects of ranolazine in the diabetic patients were comparable to those in the nondiabetic patients. There was no significant difference between the diabetic and nondiabetic patients in exercise duration (P=0.89), time to onset of angina (P=0.54), or time to ≥1 mm ST-segment depression (P=0.44). There was also no difference in the diabetic patients compared to the nondiabetic patients in angina frequency (P=0.81) or nitroglycerin consumption (P=0.063). Secondary: Compared to placebo, there were significant reductions in the HbA_{1c} levels in the ranolazine 750 mg (P=0.008) and ranolazine 1,000 mg (P=0.0002) treatment groups. A subgroup analysis showed that there were significant reductions in the HbA_{1c} levels in insulin-dependent diabetics treated with ranolazine (P=0.016 in the 750 mg group and P=0.008 in the 1,000 mg group). The non-insulin-dependent patients in the ranolazine-treated group showed a significant reduction in HbA_{1c} with the 1,000 mg dose (P=0.007), but not with the 750 mg dose (P=0.087). Treatment with ranolazine 750 mg was associated with an increase in low-density lipoprotein and total cholesterol, while treatment with ranolazine 1,000 mg did not have any effects on the lipids profile.
Stone et al.[19] (2006) ERICA Ranolazine ER 1,000 mg BID in combination with amlodipine vs placebo in combination with amlodipine	DB, PC, PG, RCT Stable patients with coronary disease and ≥3 anginal attacks per week despite maximum recommended dosage of amlodipine	N=565 6 weeks	Primary: Frequency of angina episodes per week Secondary: Average weekly nitroglycerin consumption rate, SAQ, safety as assessed by adverse events and electrocardiogram	Primary: Angina frequency at baseline averaged 5.63 episodes per week. Treatment with ranolazine significantly reduced the frequency of angina episodes per week compared to placebo (2.88 vs 3.31; P=0.028). Secondary: Nitroglycerin consumption use at baseline averaged 4.72 tablets per week. Ranolazine treatment significantly reduced the use of nitroglycerin compared to placebo (2.03 vs 2.68; P=0.014). The SAQ scores on angina frequency were significantly improved in the ranolazine arm compared to placebo arm (P=0.008). There were no significant differences between treatment groups in the other SAQ measures, such as physical limitation, anginal stability, disease perception, and treatment satisfaction.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Chaitman et al.[20] (2004) MARISA Ranolazine ER 500 to 1,500 mg BID vs placebo Patients discontinued anti-anginal medications prior to randomization.	DB, PC, RCT, XO Patients with coronary artery disease and ≥3 month history of effort angina that had previously responded to antianginal agents	N=191 4 weeks with long-term follow-up of up to 36 months	Primary: Exercise duration Secondary: Time to angina onset, time to 1 mm ST-segment depression at trough and peak, exercise duration at peak, long-term survival	Primary: Treatment with ranolazine at all doses resulted in significant increases in exercise duration (P<0.001). Secondary: Treatment with ranolazine at all doses resulted in significant increases in time to angina (P<0.001) and time to 1 mm ST-segment depression (P<0.001). No clinically significant changes in heart rate or BP at rest or exercise were observed. The rates of adverse events were similar for the 500 mg and placebo group, but higher with the 1,000 and 1,500 mg groups (15.6% for placebo, 16.0% for 500 mg, 21.7% for 1,000 mg, and 34.2% for 1,500 mg). The survival rates were 96.3% (95% CI, 93.0 to 99.5) at one year and 93.6% (95% CI, 89.3 to 98.0) at two years.
Koren et al.[21] (2007) Ranolazine ER 500 to 1,000 mg BID	MC, OL Patients with chronic angina who had completed the MARISA or CARISA trial	N=746 2.82 years (mean duration)	Primary: Discontinuation, adverse events, electrocardiogram findings, and mortality	Primary: 571 patients (76.7%) remained on therapy while 72 patients (9.7%) discontinued due to adverse events two years after initial dosing. There was a significant correlation between patient age >64 years and increased rates of discontinuation related to adverse events (RR, 2.32; P<0.001). A significantly lower correlation of adverse event-related discontinuation was seen in patients with a history of congestive heart failure (RR, 0.55; P=0.030). Compared to baseline, a mean prolongation of approximately 2.4 microseconds in the QT interval was observed (P<0.001). However there were no significant differences in PR or QRS intervals during this time. A total of 64 deaths (all causes) occurred during the 2,102 patient-years (3.0% annual incidence) of the study. This translates to a 97.2% and 94.4%, one- and two-year survival from this incidence.
Rich et al.[22] (2007)	MA	N=1,387 (2 trials)	Primary: Improvement in	Primary: Overall ranolazine significantly improved exercise duration and time to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ranolazine ER 750 to 1,000 mg BID vs placebo	Patients ≥70 years of age with symptomatic chronic angina despite treatment diltiazem, atenolol, or amlodipine	6 weeks	younger patients (<70 years of age) and older patients (≥70 years of age) in exercise times, angina frequency, and adverse events Secondary: Not reported	onset of angina during exercise testing (P≤0.03). There was no difference on exercise time in younger patients compared to older patients (P>0.8). Older patients tended to have fewer angina episodes (a mean of 3.21 in the placebo group and 2.08 in the ranolazine 1,000 mg group) than younger patients (a mean of 4.16 in the placebo group and 3.11 in the ranolazine 1,000 mg group). Adverse events were more commonly reported in the older patient population (32.6% in the placebo group and 44.2% in the ranolazine group) compared to the younger patients (31.2% in the placebo group and 32.1% in the ranolazine group). Secondary: Not reported
Kosiborod et al.[23] (2013) TERISA Ranolazine (target dose 1000 mg BID) vs placebo (all patients underwent 4 week placebo run-in period)	DB, MC, PC, RCT Patients with diabetes, CAD, and stable angina treated with 1 to 2 antianginals	N=927 8 weeks	Primary: Average weekly number of anginal episodes over the last 6 weeks of the study Secondary: Average weekly frequency of SL NTG use, number of angina-free days, proportion of subjects with ≥50% reduction in average weekly angina frequency, and health-related quality of life, as assessed by SF-36	Primary: Though patients treated with placebo had a substantial decrease in angina frequency, weekly angina frequency was significantly lower in the ranolazine group than in the placebo group during weeks two to eight after randomization (3.8 vs 4.3 episodes; P=0.008). Secondary: At baseline, there was no statistical difference in average weekly SL NTG use between the ranolazine and placebo groups (4.1 vs 4.5 doses; P=0.27). During weeks two to eight after randomization, the average weekly number of SL NTG doses was significantly lower in the ranolazine group, and was significantly lower in the ranolazine group than in the placebo group (1.7 vs 2.1 doses; P=0.003). The proportion of angina-free days did not differ between the ranolazine and placebo groups (67 vs 64%; P=0.068). The proportion of patients achieving at least 50% reduction in weekly angina frequency was higher in the ranolazine than placebo group (47 vs 42%; P=0.034), and the increase from baseline to end of treatment in SF-36 Physical Component Summary Score was also greater in the ranolazine than placebo group (2.9 [95% CI,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				2.3 to 3.5] points vs 1.9 [95% CI, 1.3 to 2.5] points; P=0.005). However, these latter two differences were not considered statistically significant (despite P-values <0.05) based on the pre-specified multiple testing procedure.
Weisz et al.[24] (2016) RIVER-PCI Ranolazine 1000 mg BID vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with a history of chronic angina with incomplete revascularisation after PCI (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter)	N=2,604 median follow-up of 643 days	Primary: Time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation Secondary: Time from randomisation to the first occurrence of sudden cardiac death, cardiovascular death, or MI	Primary: The composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (HR, 0.95; 95% CI, 0.82 to 1.10; P=0.48). Secondary: The key secondary efficacy endpoints of sudden cardiac death, cardiovascular death, and MI occurred with similar frequency in both groups. The incidence of major adverse cardiovascular events, all-cause mortality, stroke, or hospitalisation for heart failure likewise did not differ significantly between groups; however, the incidence of adjudicated transient ischaemic attack events was higher in patients given ranolazine. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (P=0.04).
Cocco et al.[25] (1992) Ranolazine IR* 10, 60, 120, or 240 mg single dose in addition to beta-blocker or diltiazem vs placebo in addition to beta-blocker or	DB, MC, PC, RCT, XO Patients with chronic stable angina who remained symptomatic despite treatment with beta-blockers or diltiazem	N=104 4 to 9 days	Primary: Exercise duration, time to angina, time to ≥1 mm ST-segment depression Secondary: Heart rate, BP	Primary: Exercise duration, time to angina, and time to 1 mm ST-segment depression were significantly improved with ranolazine 240 mg dose only in the beta-blocker group and the groups combined (P<0.05 for both). There was no significant difference in exercise duration, time to angina, or time to 1 mm ST-segment depression with ranolazine treatment in patients that were on the diltiazem regimen (P>0.05 for all). Secondary: Treatment with ranolazine did not result in significant changes in heart rate or BP compared to placebo (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
diltiazem				
Pepine et al.[26] (1999) Ranolazine IR* 400 mg BID, 267 mg TID, or 400 mg TID vs placebo	DB, MC, PC, RCT, XO Patients with chronic stable angina that responded to conventional antianginal therapy	N=312 5 weeks	Primary: Time to angina onset, exercise duration, and time to 1 mm ST-segment depression at peak and trough concentrations Secondary: Safety	Primary: At peak ranolazine concentrations, time to angina onset (P≤0.02), exercise duration (P=0.013), and time to 1 mm ST-segment depression were significantly improved with all dosing regimens. At trough ranolazine concentrations, only time to 1 mm ST-segment depression was significantly improved (P=0.047). Secondary: The rates of adverse effects were similar in the ranolazine groups and placebo group. Only minor gastrointestinal adverse effects were reported more frequently with ranolazine than placebo (6.6 to 10.7 vs 3.2%).
Rousseau et al.[27] (2005) Ranolazine IR* 400 mg TID for 7 to 10 days vs atenolol 100 mg QD for 7 to 10 days vs placebo for 7 to 10 days	DB, MC, PC, XO Patients with coronary artery disease and chronic angina who were on standard doses of atenolol	N=158 7 to 10 days	Primary: Time to onset of angina Secondary: Time to 1 mm ST-segment depression, total exercise duration, angina frequency, nitroglycerin use	Primary: Treatment with ranolazine and atenolol both resulted in significant increases in time to angina, exercise duration, and time to 1 mm ST-segment depression when compared to placebo (P<0.05 for all). Secondary: There was no significant difference between ranolazine and atenolol in the time to angina (P=0.18), time to 1 mm ST-segment depression (P=0.86), angina frequency, or nitroglycerin use. However, the increase in exercise duration was significantly greater in the ranolazine group than atenolol (mean difference of 21.1 seconds, 95% CI, 6.2 to 36.0; P=0.006).
Morrow et al.[28] (2007) MERLIN-TIMI 36 Ranolazine IV* administered for 12 to 96 hours,	DB, MC, PC, RCT Patients ≥18 years of age with myocardial ischemia at rest (≥10 minutes) who	N=6,560 1 year	Primary: Composite of cardiovascular death, MI, or recurrent ischemia Secondary:	Primary: The composite of cardiovascular death, MI or recurrent ischemia occurred in 21.8% of the patients in the ranolazine group and 23.5% of patients in the placebo group (HR, 0.92; 95% CI, 0.83 to 1.02; P=0.11). Secondary: The composite of cardiovascular death, MI, or severe recurrent ischemia

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
followed by ranolazine ER 1,000 mg orally BID vs placebo Study medication was administered in addition to standard therapy.	had ≥1 indicator of moderate to high risk of death or recurrent ischemic events (elevated biomarkers of necrosis, ST depression of at least 0.1 mV, diabetes, or a TIMI risk score for unstable angina/non-STEMI ≥3)		Composite of cardiovascular death, MI, or severe recurrent ischemia, rate of failure of therapy (cardiovascular death, MI, recurrent ischemia, positive Holter for ischemia, hospitalization for new or worsening heart failure, or an early positive ETT), safety	occurred in 18.7% of patients in the ranolazine group compared to 19.2% of patients in the placebo group (HR, 0.96; 95% CI, 0.86 to 1.08; P=0.50). Failure of therapy occurred in 36.8% of patients in the ranolazine group and 38.3% of patients in the placebo group (HR, 0.94; 95% CI, 0.87 to 1.02; P=0.16). Cardiovascular death occurred in 4.4% of patients in the ranolazine group and 4.5% of patients in the placebo group (HR, 1.00; 95% CI, 0.79 to 1.25; P=0.98). MI occurred in 7.4% of patients in the ranolazine group and 7.6% of patients in the placebo group (HR, 0.97; 95% CI, 0.81 to 1.16; P=0.76). Recurrent ischemia occurred in 13.9% of patients in the ranolazine group and 16.1% of patients in the placebo group (HR, 0.97; 95% CI, 0.76 to 0.99; P=0.03). There was no difference in the documented symptomatic arrhythmias in the ranolazine group (3.0%) and the placebo group (3.1%; P=0.84).
Scirica et al.[29] (2007) MERLIN-TIMI 36 Ranolazine IV* administered for 12 to 96 hours, followed by ranolazine ER 1,000 mg orally BID vs placebo Study medication	DB, MC, PC, RCT Patients ≥18 years of age with myocardial ischemia at rest (≥10 minutes) who had ≥1 indicator of moderate to high risk of death or recurrent ischemic events (elevated biomarkers of necrosis, ST depression of at least 0.1 mV, diabetes, or a TIMI	N=6,560 7 days	Primary: Incidence of clinically significant arrhythmias Secondary: Not reported	Primary: Ventricular tachycardia ≥3 beats ≥100 bpm was significantly less in the ranolazine group (52.1%) compared to placebo (60.6%) (RR, 0.86; 95% CI, 0.82 to 0.90; P<0.001). Ventricular tachycardia ≥4 beats ≥100 bpm was significantly less in the ranolazine group (20.9%) compared to placebo (29.5%) (RR, 0.71; 95% CI, 0.6 to 0.78; P<0.001). Ventricular tachycardia ≥8 beats (lasting <30 seconds) was significantly less in the ranolazine group (5.3%) compared to placebo (8.3%) (RR, 0.63; 95% CI, 0.52 to 0.76; P<0.001). There was no significant difference in polymorphic ventricular tachycardia ≥8 beats in the ranolazine group (1.2%) compared to placebo (1.4%) (RR, 0.83; 95% CI, 0.54 to 1.28; P=0.40).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
was administered in addition to standard therapy.	risk score for unstable angina/non-STEMI ≥3)			There was no significant difference in sustained ventricular tachycardia (≥30 seconds) in the ranolazine group (0.44%) compared to placebo (0.44%) (RR, 1.01; 95% CI, 0.48 to 2.13; P=0.98). This includes monomorphic (0.13 vs 0.22%; RR, 0.59; 95% CI, 0.17 to 2.06; P=0.37) and polymorphic (0.32 vs 0.22%; RR, 1.41; 95% CI, 0.52 to 3.78; P=0.46). There was no significant difference in new-onset AF in the ranolazine group (1.7%) compared to placebo (2.4%) (RR, 0.74; 95% CI, 0.52 to 1.05; P=0.08). Other supraventricular arrhythmias ≥120 bpm lasting at least 4 beats were significantly less in the ranolazine group (44.7%) compared to placebo (55.0%) (RR, 0.81; 95% CI, 0.77 to 0.85; P<0.001). Secondary: Not reported
Wilson et al.[30] (2009) MERLIN-TIMI 36 Ranolazine IV* administered for 12 to 96 hours, followed by ranolazine ER 1,000 mg orally BID vs placebo Study medication was administered in addition to standard therapy.	Subgroup analysis of MERLIN-TIMI 36 of patients with a history of prior chronic angina Patients ≥18 years of age with myocardial ischemia at rest (≥10 minutes) who had ≥1 indicator of moderate to high risk of death or recurrent ischemic events (elevated biomarkers of necrosis, ST depression of at least 0.1 mV,	N=3,565 1 year	Primary: Time to first occurrence of any element of the composite of cardiovascular death, MI, or recurrent ischemia Secondary: Anginal episodes, need for an increase or addition of any antianginal therapy, and exercise duration on treadmill or bicycle ETT performed at 8	Primary: The time to the first occurrence of the composite of cardiovascular death, MI, or recurrent ischemia was lower in patients treated with ranolazine compared to placebo among patients with prior angina (25.2 vs 29.4%, respectively, HR, 0.86; 95% CI, 0.75 to 0.97; P=0.017). This effect was due to the effects of ranolazine on recurrent ischemia. Ranolazine had no effect on the risk of cardiovascular death or MI among patients with prior angina (HR, 0.97; 95% CI, 0.80 to 1.16; P=0.71). Secondary: Ranolazine reduced the incidence of recurrent ischemia (HR, 0.78; 95% CI, 0.67 to 0.91; P=0.002), worsening angina (HR, 0.77; 95% CI, 0.59 to 1.00; P=0.048), and intensification of antianginal therapy (HR, 0.77; 95% CI, 0.64 to 0.92, P=0.005) compared to placebo among patients with prior angina. Ranolazine improved severe recurrent ischemia compared to placebo among patients with prior angina (11.9 vs 14.4%, respectively; HR, 0.81; 95% CI, 0.67 to 0.98; P=0.026).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	diabetes, or a TIMI risk score for unstable angina/non-STEMI ≥3)		months, safety, incidence of clinically significant arrhythmias	The mean number of traditional antianginal agents was decreased with ranolazine compared to placebo among patients with prior angina (2.8 vs 2.9, respectively; P=0.045). Ranolazine significantly improved all metrics of exercise performance on ETT or bicycle exercise testing compared to placebo among patients with prior angina. Ranolazine was generally well tolerated in patients with prior angina. The most common adverse effects with ranolazine compared to placebo were dizziness (12.4 vs 7.4%, respectively), nausea (9.7 vs 6.1%, respectively), and constipation (8.5 vs 3.3%, respectively). No significant increase in frequency of symptomatic documented arrhythmias was observed with ranolazine compared to placebo among patients with prior angina (risk ratio, 0.98; 95% CI, 0.67 to 1.43; P=0.92). Clinically significant arrhythmias were significantly lower in the ranolazine group (73.9 vs 83.1%, respectively; P=0.0001).
Mega et al.[31] (2010) MERLIN-TIMI 36 Ranolazine IV* administered for 12 to 96 hours, followed by ranolazine ER 1,000 mg orally BID vs placebo Study medication was administered in addition to	Subgroup analysis of MERLIN-TIMI 36 of women Women ≥18 years of age with myocardial ischemia at rest (≥10 minutes) who had ≥1 indicator of moderate to high risk of death or recurrent ischemic events (elevated biomarkers of necrosis, ST depression of at least 0.1 mV, diabetes, or a TIMI	N=2,291 1 year	Primary: Time to first occurrence of any element of the composite of cardiovascular death, MI, or recurrent ischemia in women Secondary: Anginal episodes, incidence of clinically significant arrhythmias	Primary: Treatment with ranolazine was associated with a 29% reduction in recurrent ischemia in women compared to placebo (13.0 vs 18.2%; HR, 0.71; 95% CI, 0.57 to 0.88; P=0.002). There was no significant reduction in cardiovascular death or MI with ranolazine compared to placebo in women (P=0.80). Secondary: Treatment with ranolazine was associated with less angina compared to placebo in women (P<0.001). Fewer women treated with ranolazine needed to undergo intensification of their antianginal medical regimen compared to placebo (10.4 vs 14.4%, respectively; P=0.003). There was no difference in symptomatic documented arrhythmias in women treated with ranolazine vs placebo (2.6 vs 2.6%, respectively; P=0.95). Treatment with ranolazine was associated with fewer episodes of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
standard therapy.	risk score for unstable angina/non-STEMI ≥3)			ventricular arrhythmias compared to placebo (P=0.008).
Metha et al.[32] (2011) Ranolazine for 4 weeks vs placebo for 4 weeks	DB, PC, XO (pilot trial) Women with angina, evidence of myocardial ischemia (signs and symptoms), but no obstructive coronary artery disease	N=20 10 weeks	Primary: Seattle Angina Questionnaire, cardiac magnetic resonance Secondary: Not reported	Primary: Patients receiving ranolazine had significantly higher (better) Seattle Angina Questionnaire scores, including physical functioning (P=0.046), angina stability (P=0.008), and QOL (P=0.021). There was a trend toward a higher (better) cardiac magnetic resonance mid-ventricular myocardial perfusion reserve index (2.4 vs 2.1; P=0.074) with ranolazine. Secondary: Not reported

*Agent not available in the United States.
Drug regimen abbreviations: BID=twice daily, ER=extended release, IR=immediate-release, IV=intravenous, TID=three times daily
Study abbreviations: DB=double-blind, MA=meta-analysis, MC=multicenter, OL=open-label, PC=placebo-controlled, PG=parallel-group, RCT=randomized controlled trial, SR=sustained-release, XO=cross-over
Miscellaneous abbreviations: AF=atrial fibrillation, BP=blood pressure, CI=confidence interval, ETT=exercise tolerance test, HbA_{1c}=glycosylated hemoglobin, HR=hazard ratio, MI=myocardial infarction, PCI= percutaneous coronary intervention, QOL=quality of life, RR=relative risk, SAQ=Seattle Angina Questionnaire, STEMI=ST-elevation myocardial infarction, TIMI=thrombolysis in myocardial infarction

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
Ling et al retrospectively reviewed the medical records of 150 consecutive patients with refractory angina treated with ranolazine. During the 12 months prior to and during the 12 months of treatment with ranolazine there were fewer clinic visits and emergency department visits during ranolazine treatment than in the pre-ranolazine period, but the difference in frequency of these visits was not statistically significant. The number of hospitalizations was significantly reduced during treatment with ranolazine compared with the pre-ranolazine treatment period (P=0.002).[33]

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Cardiac Drugs, Miscellaneous

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Ivabradine	tablet	Corlanor®	$$$$$	N?A
Ranolazine	extended-release tablet	Ranexa®	$$$$$	N/A

N/A=Not available.

X. Conclusions

Ranolazine is approved for the treatment of chronic angina. It may be used in combination with β-blockers, nitrates, calcium channel blockers, antiplatelet therapy, lipid lowering therapy, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers. The exact mechanism of ranolazine is unknown. The anti-ischemic and antianginal effects do not depend upon reductions in heart rate or blood pressure.[2] Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of β-blockers or have a contraindication to β-blocker use. Ivabradine reduces sinus rate by

blocking the hyperpolarization-activated cyclic nucleotide-gated channel responsible for the cardiac pacemaker I_f current, which regulates heart rate.[3,4] No agents are available in a generic formulation.

There are several organizations that provide recommendations on the treatment of chronic angina. β-blockers are considered first-line therapy for reducing symptoms of angina in patients with coronary artery disease. Long-acting calcium channel blockers or long-acting nitrates may be used in combination with β-blockers if initial therapy is not successful, or if β-blockers are contraindicated. Available guidelines recommend ranolazine as an alternative agent when β-blockers, calcium channel blockers, and nitrates are not adequately effective or are not tolerated.[5,7] The American College of Cardiology/American Heart Association Guideline for the Management of Patients with Non–ST-Elevation Acute Coronary Syndromes states that ranolazine may also improve outcomes in NSTE-ACS patients due to a reduction in recurrent ischemia.[8]

Four trials have evaluated the efficacy and safety of ranolazine SR in patients with chronic angina. Ranolazine (administered either as monotherapy or in combination with other anti-anginal drugs) was more effective compared to placebo with regards to exercise duration, time to onset of angina, frequency of angina, and nitroglycerin use.[17,19,20,23] In the MERLIN-TIMI 36 trial, there was no beneficial effect on cardiovascular outcomes with ranolazine compared to placebo in patients with acute coronary syndrome.[2,28] Ventricular arrhythmias were less common with ranolazine; however, this did not lead to a reduction in mortality, arrhythmia hospitalization or arrhythmia symptoms.[2,28,29] Tolerance to ranolazine did not develop after 12 weeks of therapy. Rebound increases in angina, as measured by exercise duration, have not been observed following abrupt discontinuation of ranolazine.[2]

Corlanor® (ivabradine) is a novel agent indicated to reduce the risk of hospitalization for worsening HF in a small subset of HF patients.[3,4] Many current treatment guidelines have not yet been updated to include recommendations for ivabradine. However, a 2016 American College of Cardiology/ American Heart Association/ Heart Failure Society of America Focused Update on New Pharmacological Therapy for Heart Failure and the 2016 European Society of Cardiology Heart Failure Guidelines both recommend considering the use of ivabradine in line with the FDA-approved indication.[10,11]

The approval of ivabradine was based mainly on global clinical data from a phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial named SHIFT (Systolic Heart Failure treatment with the I_f inhibitor ivabradine Trial). This trial compared the use of ivabradine to placebo in addition to standard of care (SOC) therapies in 6,558 clinically stable patients in sinus rhythm with reduced LVEF ≤ 35%, heart rate (HR) ≥70 bpm, and with a hospitalization for HF within the past 12 months. The SOC generally included a β-blocker (89%), ACEI and/or ARB (91%), diuretics (83%) and an aldosterone antagonist (60%).[14] Results showed that ivabradine significantly reduced the risk of hospitalization or cardiovascular death for worsening HF, with 672 (21%) of patients on placebo compared to 514 (16%) of those on ivabradine experiencing a hospital admission (hazard ratio, 0.74; 95% confidence interval, 0.66 to 0.83; P<0.0001).

There is insufficient evidence to support that one brand miscellaneous cardiac drug is safer or more efficacious than other agents commonly used for the approved indication. Since ranolazine is not recommended as first-line therapy for the treatment of chronic angina, it should be managed through the medical justification portion of the prior authorization process. Due to the limited FDA-approved indication, ivabradine should be available through the medical justification portion of the prior authorization process for adults with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of β-blockers or have a contraindication to β-blocker use.

Therefore, all brand miscellaneous cardiac drugs within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand miscellaneous cardiac drug is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Kannam JP, Aroesty JM, Gersh BJ. Stable ischemic heart disease: Overview of care. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 May 22]. Available from: http://www.utdol.com/utd/index.do.
2. Ranexa® [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2016 Jan.
3. Corlanor® [package insert]. Thousand Oaks (CA): Amgen Inc.; 2017 Jan.
4. Colucci WS. Use of ivabradine in heart failure with reduced ejection fraction. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 May 22]. Available from: http://www.utdol.com/utd/index.do.
5. Goblirsch G, Bershow S, Cummings K, Hayes R, Kokoszka M, Lu Y, Sanders D, Zarling K. Institute for Clinical Systems Improvement. Stable Coronary Artery Disease. Updated May 2013.
6. Fraker TD Jr, Fihn SD; 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007 Dec 4;50(23):2264-74.
7. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
8. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology (2014), doi: 10.1016/j.jacc.2014.09.017.
9. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2016) 37 (3): 267-315. DOI: https://doi.org/10.1093/eurheartj/ehv320.
10. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435.
11. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.
12. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 May]. Available from: http://www.thomsonhc.com/.
13. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited May 2017]. Available from: http://online.factsandcomparisons.com.
14. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. The Lancet. 2010 Sep 11;376:875-885.
15. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. The Lancet. 2008 Sep 6;372:807-816.
16. Fox K, Ford I, Steg PG, Tardif JC, Yendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371 (12):1091-1099.
17. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):309-16.
18. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA_{1C} in patients with chronic angina and diabetes. Eur Heart J. 2006 Jan;27(1):42-8.

19. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75.
20. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004 Apr 21;43(8):1375-82.
21. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina. The ranolazine open label experience (ROLE). J Am Coll Cardiol. 2007 Jul 1;49(10):1027-34.
22. Rich MW, Crager M, McKay CR. Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris. AJGC. 2007;16:216-21.
23. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038-2045.
24. Weisz G, Généreux P, Iñiguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Jan 9;387(10014):136-45.
25. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. J Cardiovasc Pharmacol. 1992 Jul;20(1):131-8.
26. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 1999 Jul 1;84(1):46-50.
27. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine vs atenolol for chronic angina pectoris. Am J Cardiol. 2005 Feb 1;95(3):311-6.
28. Morrow DA, Scirica BM, Karwatowska-Prokopczul E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297(16):1775-83.
29. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth C, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary Syndrome. Results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN_TIMI 36) randomized controlled trial. Circulation. 2007 Oct 9;116:1647-52.
30. Wilson S, Scirica B, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53:1510-1516.
31. Mega J, Hochman J, Scirica B, et al. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). Circulation 2010;121:1809-1817.
32. Mehta PK, Goykhman P, Thomson LEJ, Shufelt C, Wei J, Yang Y, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. J Am Coll Cardiol Img. 2011;4:514-22.
33. Ling H, Packard KA, Burns TL, and Hilleman DE. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris. Am J Cardiovasc Drugs. 2013 Dec;13(6):407-412.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Bile Acid Sequestrants
AHFS Class 240604
August 9, 2017

I. Overview

Dyslipidemia is a complex of related conditions that affects many individuals. Low-density lipoprotein cholesterol (LDL-C) is considered the primary target of cholesterol lowering therapy. Many studies have demonstrated that elevated concentrations of LDL-C are a major risk factor for coronary heart disease, and lowering LDL-C will reduce the risk for major coronary events. Non-high-density lipoprotein cholesterol is a secondary target of therapy in patients with elevated triglycerides (≥200 mg/dL). This parameter takes into account the atherogenic potential associated with remnant lipoproteins in patients with hypertriglyceridemia. High-density lipoprotein cholesterol (HDL-C) has been shown to be an independent predictor of cardiovascular mortality and is considered an LDL modifying risk factor; however, there is insufficient data to warrant setting a specific goal for raising HDL-C. The independent effect of raising HDL-C or lowering triglycerides on the risk of cardiovascular morbidity and mortality has not been determined.[1]

The antilipemic agents are categorized into six different American Hospital Formulary Service (AHFS) classes, including bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, HMG-CoA reductase inhibitors (statins), proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, and miscellaneous antilipemic agents. The agents which make up these classes differ with regards to their Food and Drug Administration-approved indications, mechanism of action, efficacy, safety profiles, tolerability, and ease of use.

Bile acids are secreted into the intestines during digestion to emulsify fat and lipids to facilitate their absorption. Most of the bile acids are reabsorbed and returned to the liver via enterohepatic circulation. The bile acid sequestrants bind to bile acids and form a complex, which is then excreted in the feces. The reduction in bile acids increases the oxidation of cholesterol to bile acids.[2-4] There is a subsequent increase in the number of LDL receptors in the liver, which increases hepatic uptake of LDL-C and reduces serum cholesterol levels. Bile acid sequestrants can decrease LDL-C by 15 to 30% and increase HDL-C by 3 to 5%. Triglycerides may increase or remain unchanged.[1]

The bile acid sequestrants that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Cholestyramine (regular and light) and colestipol are available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Bile Acid Sequestrants Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Cholestyramine	packet for oral suspension, powder for oral suspension	Questran®*†, Questran Light®*‡	cholestyramine, cholestyramine light
Colesevelam	packet for oral suspension, tablet	Welchol®	none
Colestipol	granules for oral suspension, packet for oral suspension, tablet	Colestid®*	colestipol

*Generic is available in at least one dosage form or strength.
†Contains sucrose.
‡Contains aspartame.
PDL=Preferred Drug List.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the bile acid sequestrants are summarized in Table 2.

Table 2. Treatment Guidelines Using the Bile Acid Sequestrants

Clinical Guideline	Recommendation
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004)**[5]	• Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. • When low density lipoprotein cholesterol (LDL-C) lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard HMG-CoA reductase inhibitors (statins) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrants, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), especially in combination with statins. • In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of coronary heart disease (CHD) risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u> • Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously). • Bile acid sequestrants (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrants and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u> • TLC indicated for all persons. • All LDL-C lowering drugs are effective.

Clinical Guideline	Recommendation
	• If necessary to reach LDL-C goals, consider combined drug therapy.
National Cholesterol Education Program: **Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002)[1]**	General recommendations • With regards to TLC, higher dietary intakes of omega-3 fatty acids in the form of fatty fish or vegetable oils are an option for reducing risk for CHD. This recommendation is optional because the strength of evidence is only moderate at present. National Cholesterol Education Program supports the American Heart Association's recommendation that fish be included as part of a CHD risk reduction diet. Fish in general is low in saturated fat and may contain some cardioprotective omega-3 fatty acids. However, a dietary recommendation for a specific amount of omega-3 fatty acids is not made. • Initiate LDL lowering drug therapy with a statin, bile acid sequestrant, or nicotinic acid. • Statins should be considered as first line drugs when LDL lowering drugs are indicated to achieve LDL-C treatment goals. • After six weeks if LDL-C goal is not achieved, intensify LDL lowering therapy. Consider a higher dose of a statin or add a bile acid sequestrant or nicotinic acid. Statins • Statins should be considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. Bile acid sequestrants • Bile acid sequestrants should be considered as LDL lowering therapy for patients with moderate elevations in LDL-C, for younger patients with elevated LDL-C, for women with elevated LDL-C who are considering pregnancy, and for patients needing only modest reductions in LDL-C to achieve target goals. • Bile acid sequestrants should be considered in combination therapy with statins in patients with very high LDL-C levels. Nicotinic acid • Nicotinic acid should be considered as a therapeutic option for higher risk patients with atherogenic dyslipidemia. • Nicotinic acid should be considered as a single agent in higher risk patients with atherogenic dyslipidemia who do not have a substantial increase in LDL-C levels, and in combination therapy with other cholesterol lowering drugs in higher risk patients with atherogenic dyslipidemia combined with elevated LDL-C levels. • Nicotinic acid should be used with caution in patients with active liver disease, recent peptic ulcer, hyperuricemia, gout, and type 2 diabetes. • High doses of nicotinic acid (>3 g/day) generally should be avoided in patients with type 2 diabetes, although lower doses may effectively treat diabetic dyslipidemia without significantly worsening hyperglycemia. Fibric acid derivatives (fibrates) • Fibrates can be recommended for patients with very high TG to reduce risk for acute pancreatitis. • They also can be recommended for patients with dysbetalipoproteinemia (elevated beta-very LDL). • Fibrate therapy should be considered an option for treatment of patients with established CHD who have low levels of LDL-C and atherogenic dyslipidemia. • They also should be considered in combination with statin therapy in patients who have elevated LDL-C and atherogenic dyslipidemia. Omega-3 fatty acids

Clinical Guideline	Recommendation
	• Omega-3 fatty acids (e.g., linolenic acid, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA]) have two potential uses. • In higher doses, DHA and EPA lower serum TGs by reducing hepatic secretion of TG-rich lipoproteins. They represent alternatives to fibrates or nicotinic acid for treatment of hypertriglyceridemia, particularly chylomicronemia. Doses of 3 to 12 g/day have been used depending on tolerance and severity of hypertriglyceridemia. • Recent trials also suggest that relatively high intakes of omega-3 fatty acids (1 to 2 g/day) in the form of fish, fish oils, or high-linolenic acid oils will reduce the risk for major coronary events in persons with established CHD. Omega-3 fatty acids can be a therapeutic option in secondary prevention (based on moderate evidence). The omega-3 fatty acids can be derived from either foods (omega-3 rich vegetable oils or fatty fish) or from fish-oil supplements. More definitive trials are required before strongly recommending relatively high intakes of omega-3 fatty acids (1 to 2 g/day) for either primary or secondary prevention.
American Association of Clinical Endocrinologists: **Guidelines for the management of dyslipidemia and prevention of atherosclerosis (2017)**[6]	Cholesterol Goals • For individuals at low risk (i.e., with no risk factors), an LDL-C goal of <130 mg/dL is recommended. • For individuals at moderate risk (i.e., with two or fewer risk factors and a calculated 10-year risk of <10%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or CKD stage 3 or 4 with no other risk factors, or individuals with two or more risk factors and a 10-year risk of 10 to 20%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at very high risk (i.e., with established or recent hospitalization for ACS, coronary, carotid or peripheral vascular disease; diabetes or CKD stage 3 or 4 with one or more risk factors; a calculated 10-year risk >20%; or heterozygous familial hypercholesterolemia [HeFH]), an LDL-C goal of <70 mg/dL is recommended. • For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dL, or established clinical ASCVD in individuals with diabetes, CKD stage 3 or 4, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal of <55 mg/dL is recommended. • An LDL-C goal of <100 mg/dL is considered "acceptable" for children and adolescents, with 100 to 129 mg/dL considered "borderline" and 130 mg/dL or greater considered "high" (based on recommendations from the American Academy of Pediatrics). • HDL-C should be >40 mg/dL, but also as high as possible, primarily through the use of lifestyle interventions (e.g., weight loss, physical activity, and tobacco cessation), and if risk factors are present (e.g., borderline elevated LDL-C levels, a family history of premature ASCVD, or a personal history of ASCVD), also through the use of pharmacotherapy primarily focused on reducing LDL-C. • For most individuals, a non–HDL-C goal (total cholesterol minus HDL-C) 30 mg/dL higher than the individual's specific LDL-C goal is recommended. • For individuals at extreme risk, a non-HDL-C goal 25 mg/dL higher than the individual specific LDL-C goal is recommended. • For individuals at increased risk of ASCVD, including those with diabetes, an optimal apo B goal is <90 mg/dL, while for individuals with established ASCVD or diabetes plus one or more additional risk factor(s), an optimal apo B goal is <80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is <70 mg/dL.

Clinical Guideline	Recommendation
	• TG goals of <150 mg/dL are recommended. General Recommendations • A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended primarily using lifestyle changes and patient education with pharmacotherapy as needed to achieve evidence based targets. • A reasonable and feasible approach to fitness therapy (i.e., exercise programs that include ≥30 minutes of moderate-intensity physical activity [consuming 4 to 7 kcal/min] four to six times weekly, with an expenditure of ≥200 kcal/day) is recommended; suggested activities include brisk walking, riding a stationary bike, water aerobics, cleaning/scrubbing, mowing the lawn, and sporting activities. • Daily physical activity goals can be met in a single session or in multiple sessions throughout the course of a day (10 minutes minimum per session); for some individuals, breaking activity up throughout the day may help improve adherence with physical activity programs. • In addition to aerobic activity, muscle-strengthening activity is recommended at least two days a week. • For adults, a reduced-calorie diet consisting of fruits and vegetables (combined ≥5 servings/day), grains (primarily whole grains), fish, and lean meats is recommended. • For adults, the intake of saturated fats, trans-fats, and cholesterol should be limited, while LDL-C-lowering macronutrient intake should include plant stanols/sterols (~2 g/ day) and soluble fiber (10 to 25 g/day). • Primary preventive nutrition consisting of healthy lifestyle habits is recommended in all healthy children. • Tobacco cessation should be strongly encouraged and facilitated. • In individuals at risk for ASCVD, aggressive lipid-modifying therapy is recommended to achieve appropriate LDL-C goals. Statins • Statin therapy is recommended as the primary pharmacologic agent to achieve target LDLC goals on the basis of morbidity and mortality outcome trials. • For clinical decision making, mild elevations in blood glucose levels and/or an increased risk of new-onset T2DM associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction. • In individuals within high-risk and very high-risk categories, further lowering of LDL-C beyond established targets with statins results in additional ASCVD event reduction and may be considered. • Very high-risk individuals with established coronary, carotid, and peripheral vascular disease, or diabetes, who also have at least one additional risk factor, should be treated with statins to target a reduced LDL-C treatment goal of <70 mg/dL. • Extreme risk individuals should be treated with statins to target an even lower LDL-C treatment goal of <55 mg/dL. Fibrates • Fibrates should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). • Fibrates may improve ASCVD outcomes in primary and secondary prevention when TG concentrations are ≥200 mg/dL and HDL-C concentrations <40 mg/dL. Omega-3 Fish Oil • Prescription omega-3 oil, 2 to 4 g daily, should be used to treat severe

Clinical Guideline	Recommendation

	hypertriglyceridemia (TG >500 mg/dL). Dietary supplements are not FDA-approved for treatment of hypertriglyceridemia and generally are not recommended for this purpose.
	
	Niacin
	• Niacin therapy is recommended principally as an adjunct for reducing TG.
	• Niacin therapy should not be used in individuals aggressively treated with statin due to absence of additional benefits with well-controlled LDL-C.
	
	Bile Acid Sequestrants
	• Bile acid sequestrants may be considered for reducing LDL-C and apo B and modestly increasing HDL-C, but they may increase TG.
	
	Cholesterol Absorption Inhibitors
	• Ezetimibe may be considered as monotherapy in reducing LDL-C and apo B, especially in statin-intolerant individuals.
	• Ezetimibe can be used in combination with statins to further reduce both LDL-C and ASCVD risk.
	
	PCSK9 Inhibitors
	• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors should be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH.
	• PCSK9 inhibitors should be considered in patients with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals.
	
	Combination Therapy
	• Combination therapy of lipid-lowering agents should be considered when the LDL-C/non-HDL-C level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal.
	
	Special Considerations: Women
	• Women should be evaluated for their ASCVD risk and be treated with pharmacotherapy if lifestyle intervention is insufficient.
	• Hormone replacement therapy for the treatment of dyslipidemia in postmenopausal women is not recommended.
	
	Special Considerations: Children and Adolescents
	• Pharmacotherapy is recommended for children and adolescents older than 10 years who do not respond sufficiently to lifestyle modification, and particularly for those satisfying the following criteria:
	  ○ LDL-C ≥190 mg/dL
	  ○ LDL-C ≥160 mg/dL and the presence of two or more cardiovascular risk factors, even after vigorous intervention
	  ○ Family history of premature ASCVD (before 55 years of age), or
	  ○ Having overweight, obesity, or other elements of the insulin resistance syndrome
	
	Follow-up and Monitoring
	• Reassess individuals' lipid status six weeks after therapy initiation and again at six-week intervals until the treatment goal is achieved.
	• While on stable lipid therapy, individuals should be tested at 6- to 12-month intervals.

Clinical Guideline	Recommendation
	• While on stable lipid therapy, the specific interval of testing should depend on individual adherence to therapy and lipid profile consistency; if adherence is a concern or the lipid profile is unstable, the individual will probably benefit from more frequent assessment. • More frequent lipid status evaluation is recommended in situations such as deterioration of diabetes control, use of a new drug known to affect lipid levels, progression of atherothrombotic disease, considerable weight gain, unexpected adverse change in any lipid parameter, development of a new ASCVD risk factor, or convincing new clinical trial evidence or guidelines that suggest stricter lipid goals. • Liver transaminase levels should be measured before and three months after niacin or fibric acid treatment initiation because most liver abnormalities occur within three months of treatment initiation. Liver transaminase levels should be measured periodically thereafter (e.g., semiannually or annually). • Creatine kinase levels should be assessed and the statin discontinued, at least temporarily, when an individual reports clinically significant myalgias or muscle weakness on statin therapy.
American Heart Association/American College of Cardiology/National Heart, Lung, and Blood Institute: **American Heart Association/American College of Cardiology Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update (2011)**[7]	Lipid management • Goal: treatment with statin therapy; use statin therapy to achieve LDL-C of <100 mg/dL; for very high risk patients an LDL-C <70 mg/dL is reasonable; if TG are ≥200 mg/dL, non-HDL-C should be <130 mg/dL, whereas non-HDL-C <100 mg/dL for very high risk patients is reasonable. • Lifestyle modifications (daily physical activity and weight management) are strongly recommended for all patients. • In addition to lifestyle modifications, statin therapy should be prescribed in the absence of contraindications or documented adverse events. • An adequate dose of statin should be used that reduces LDL-C to <100 mg/dL and achieves ≥30% lowering of LDL-C. • Patients who have TG ≥200 mg/dL should be treated with statins to lower non-HDL-C to <130 mg/dL. • Patients who have TG >500 mg/dL should be started on fibrate therapy in addition to statin therapy to prevent acute pancreatitis. • If treatment with a statin does not achieve the goal selected for an individual patient, intensification of LDL-C-lowering drug therapy with a bile acid sequestrant or niacin is reasonable. • For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid sequestrants and/or niacin is reasonable. • It is reasonable to treat very high risk patients with statin therapy to lower LDL-C to <70 mg/dL. • In patients who are at very high risk and who have TG ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable. • The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with statins, bile acid sequestrants, and/or niacin. • For patients who continue to have an elevated non-HDL-C while on adequate statin therapy, niacin or fibrate therapy or fish oil may be reasonable. • For all patients, it may be reasonable to recommend omega-3 fatty acids from fist or fish oil capsules (1 g/day) for cardiovascular disease risk reduction.
Institute for Clinical Systems Improvement: **Lipid Management in Adults (2013)**[8]	Clinical highlights • Initiate a statin with patients who have established atherosclerotic cardiovascular disease (ASCVD). • Establish lipid goals based on risk level. • Instruct patients on healthy lifestyle and adjunctive measures. • Patient adherence with recommended therapy should be reinforced during scheduled follow-up.

Clinical Guideline	Recommendation
	<u>Lifestyle modifications</u> • Patients who are overweight should be advised to reduce their caloric intake to achieve weight loss. • Patients should follow a dietary pattern that emphasizes fruits, vegetables, planetoids, fish, nuts, and legumes. • A diet low saturated and trans fats, and added sugars; and high in soluble fiber, with consideration given to adding 2 grams of plant sterol/stanol is recommended. <u>Statin treatment</u> • Initiate a statin regardless of LDL in patients with established ASCVD. • Initiate statin therapy in patients whose LDL is >100 and have a 10-year CHD risk ≥10% or diabetes. • Combination therapy can be considered on an individual basis, as no studies have shown a benefit to use at this time, and some studies have shown an increased risk of harm over statin monotherapy. <u>Monotherapy</u> • Reducing LDL-cholesterol (LDL-C) levels is the primary approach to lowering risk of CHD in both primary and secondary prevention. • Patients with risk factors for coronary heart disease but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of coronary heart disease. • Patients with a history of coronary disease (including unstable angina and acute myocardial infarction) often benefit from treatment with a statin. Studies have consistently shown a decrease in risk of death from coronary heart disease. • Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Statins also have a modest effect on reducing TG and increasing HDL-C. • Several trials with clinical endpoints support the use of statins in primary and secondary prevention. • If a patient is intolerant to a statin, patients should try another statin before ruling all of them out. • Provide patient education regarding recognition and reporting of symptoms of myopathy during statin therapy. • If patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available. • Many crystalline (immediate-release) and sustained-release preparations of niacin are available over-the-counter. The extended-release preparation of niacin is a prescription drug. Niacin exerts favorable effects on all lipids and lipoproteins, and is good for mixed hyperlipidemia. • Long-term use of niacin is usually limited for many patients due to side effects (e.g., flushing and pruritus, liver toxicity, gastrointestinal complaints, etc). • Niacin should not be used in combination therapy with a statin, as two major trials have shown increased side effects without any reduction in cardiovascular outcomes. • Prior to initiating a fibric acid (gemfibrozil, fenofibrate, and fenofibrate micronized), lifestyle therapies should be intensified for moderately elevated TG. These include reduction of liquid sugar, all refined starches and saturated fat; increased moderate-intensity exercise; and weight reduction. • With fibric acids, TG are reduced 30 to 50%, HDL-C is increased 10 to 20%, TC is reduced 5 to 20% in patients without elevated TG, and the effect on LDL-C is variable. Fibric acids are good for severe hypertriglyceridemia (>500 mg/dL) in patients at risk for pancreatitis and for prevention of CHD (not

Clinical Guideline	Recommendation

	proven for fenofibrate).
	• Myositis, cholelithiasis, and cholecystitis can occur with fibric acid, and caution should be exercised with a history of liver disease.
	• The long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown. Ezetimibe is associated with a LDL-C lowering of about 18%, and additive LDL-C lowering occurs when used in combination with a statin.
	• The short-term tolerability of ezetimibe is similar to placebo, and the long-term safety is unknown.
	• Bile acid sequestrants reduce LDL-C by 15 to 30% and TG may increase 15%; therefore, are these agents are useful for patients with moderately elevated LDL-C. The effects of the bile acid sequestrants are apparent within one week and maximum at two to three weeks. Bile acid sequestrants are good for combination therapy and are most potent with a statin.
	• Bile acid sequestrants are not systemically absorbed; therefore, side effects are limited to the gastrointestinal tract. In addition, drug interactions are minimized by taking other medications one hour before the sequestrant or four hours after.
	
	<u>Combination therapy</u>
	• It has become common practice to adjust medication therapy, including using combinations of medications, to achieve LDL-C goals. Common combinations include statin/fibrate, statin/niacin, and statin/ezetimibe.
	  ○ A fibrate is commonly added to a statin, which results in enhanced lowering of LDL-C, as well as a higher incidence of myopathy.
	  ○ Recent clinical trials have not demonstrated improved outcomes by increasing HDL-cholesterol with niacin among individuals with CVD and optimally controlled LDL-cholesterol on statins.
	  ○ The addition of ezetimibe to a statin significantly improves LDL-C over either agent alone. To date no large clinical trials have been completed evaluating this combination therapy compared to statin monotherapy on clinical vascular endpoints.
	• Studies of combination therapy have failed to show any benefit beyond statin monotherapy.
	• Combination therapy can be considered on an individual basis, but the additional cost, complexity, and risk for side effects argue against routine use until further trials indicate what groups of patients might benefit.
	• There are negative trials of cholesterylester transfer protein inhibitors when used in combination with statins.
	• No randomized-controlled trials looking at clinical vascular endpoints are available for other agents such as fish oils or bile-acid sequestrants used in combination therapy.
	• A systematic review of combination therapy for dyslipidemia concluded that the limited evidence available suggests that combinations of lipid-lowering agents do not improve clinical outcomes more than statin monotherapy.

American College of Cardiology/American Heart Association Task Force on Practice Guidelines: **Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)[9]**	<u>Statin treatment</u> • The panel makes no recommendations for or against specific low density lipoprotein cholesterol (LDL-C) or non-high density lipoprotein cholesterol (HDL-C) targets for the primary or secondary prevention of arteriosclerotic cardiovascular disease (ASCVD). • High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. • In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if

Clinical Guideline	Recommendation
	tolerated. • In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it. • Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity. • For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction. • For individuals ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences. • Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus. • High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a ≥7.5% estimated 10-year ASCVD risk unless contraindicated. • In adults with diabetes mellitus, who are <40 or >75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions, and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy. • Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk ≥7.5% should be treated with moderate- to high-intensity statin therapy. • It is reasonable to offer treatment with a moderate intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinica ASCVD or diabetes and an estimated 10-year ASCVD risk of 5.0 to <7.5%. • Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 to 189 mg/dL without clinical ASCVD or diabetes it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment. • In adults with LDL-C <190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of patient preference. <u>Statin safety</u> • To maximize the safety of statins, selection of the appropriate statin and dose in men and nonpregnant/non-nursing women should be based on patient characteristics, level of ASCVD risk, and potential for adverse effects. • Moderate-intensity statin therapy should be used in individuals in whom high-intensity statin therapy would otherwise be recommended when characteristics predisposing them to statin associated adverse effects are present. • Characteristics predisposing individuals to statin adverse effects include, but are not limited to:

Clinical Guideline	Recommendation
	○ Multiple or serious comorbidities, including impaired renal or hepatic function. ○ History of previous statin intolerance or muscle disorders. ○ Unexplained alanine transaminase elevations >3 times upper limit of normal. ○ Patient characteristics or concomitant use of drugs affecting statin metabolism. ○ >75 years of age. • Additional characteristics that may modify the decision to use higher statin intensities may include, but are not limited to: ○ History of hemorrhagic stroke. ○ Asian ancestry. • Creatine kinase should not be routinely measured in individuals receiving statin therapy. • Baseline measurement of creatinine kinase is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy. • During statin therapy, it is reasonable to measure creatinine kinase in individuals with muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or generalized fatigue. • Baseline measurement of hepatic transaminase levels should be performed before initiating statin therapy. • During statin therapy, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine or yellowing of the skin or sclera). • Decreasing the statin dose may be considered when two consecutive values of LDL-C levels are <40 mg/dL. • It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily. • Individuals receiving statin therapy should be evaluated for new-onset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during statin therapy should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce their risk of ASCVD events. • For individuals taking any dose of statins, it is reasonable to use caution in individuals >75 years of age, as well as in individuals that are taking concomitant medications that alter drug metabolism, taking multiple drugs, or taking drugs for conditions that require complex medication regimens (e.g., those who have undergone solid organ transplantation or are receiving treatment for human immunodeficiency virus (HIV). A review of the manufacturer's prescribing information may be useful before initiating any cholesterol-lowering drug). • It is reasonable to evaluate and treat muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated patients according to the following management algorithm: ○ To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline before initiating statin therapy. ○ If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly discontinue the statin and address the possibility of rhabdomyolysis by evaluating creatinine kinase, creatinine, and a urinalysis for myoglobinuria. • If mild to moderate muscle symptoms develop during statin therapy:

Clinical Guideline	Recommendation
	○ Discontinue the statin until the symptoms can be evaluated. ○ Evaluate the patient for other conditions that might increase the risk for muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). ○ If muscle symptoms resolve, and if no contraindication exists, give the patient the original or a lower dose of the same statin to establish a causal relationship between the muscle symptoms and statin therapy. ○ If a causal relationship exists, discontinue the original statin. Once muscle symptoms resolve, use a low dose of a different statin. ○ Once a low dose of a statin is tolerated, gradually increase the dose as tolerated. ○ If, after two months without statin treatment, muscle symptoms or elevated creatinine kinase levels do not resolve completely, consider other causes of muscle symptoms listed above. ○ If persistent muscle symptoms are determined to arise from a condition unrelated to statin therapy, or if the predisposing condition has been treated, resume statin therapy at the original dose. • For individuals presenting with a confusional state or memory impairment while on statin therapy, it may be reasonable to evaluate the patient for non-statin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy. <u>Monitoring and optimizing statin therapy</u> • Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. This should also include a fasting lipid panel performed within four to 12 weeks after initiation or dose adjustment, and every three to 12 months thereafter. Other safety measurements should be measured as clinically indicated. • The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated. • Individuals who have a less-than anticipated therapeutic response or are intolerant of the recommended intensity of statin therapy, the following should be performed: ○ Reinforce medication adherence. ○ Reinforce adherence to intensive lifestyle changes. ○ Exclude secondary causes of hyperlipidemia. • It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of statin therapy. Focus is on the intensity of the statin therapy. As an aid to monitoring: ○ High-intensity statin therapy generally results in an average LDL-C reduction of ≥50% from the untreated baseline; ○ Moderate-intensity statin therapy generally results in an average LDL-C reduction of 30 to <50% from the untreated baseline; ○ LDL-C levels and percent reduction are to be used only to assess response to therapy and adherence. They are not to be used as performance standards. • Individuals at higher ASCVD risk receiving the maximum tolerated intensity of statin therapy who continue to have a less than-anticipated therapeutic response, addition of a non-statin cholesterol-lowering drug(s) may be considered if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. • Higher-risk individuals include: ○ Individuals with clinical ASCVD <75 years of age. ○ Individuals with baseline LDL-C ≥190 mg/dL. ○ Individuals 40 to 75 years of age with diabetes mellitus.

Clinical Guideline	Recommendation
	○ Preference should be given to non-statin cholesterol-lowering drugs shown to reduce ASCVD events in controlled trials. • In individuals who are candidates for statin treatment but are completely statin intolerant, it is reasonable to use non-statin cholesterol lowering drugs that have been shown to reduce ASCVD events in controlled trials if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. <u>Non statin safety</u> • Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric acid should be obtained before initiating niacin, and again during up-titration to a maintenance dose and every six months thereafter. • Niacin should not be used if: ○ Hepatic transaminase elevations are higher than two to three times upper limit of normal. ○ Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout or unexplained abdominal pain or gastrointestinal symptoms occur. ○ New-onset atrial fibrillation or weight loss occurs. • In individuals with adverse effects from niacin, the potential for ASCVD benefits and the potential for adverse effects should be reconsidered before reinitiating niacin therapy. • To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to: ○ Start niacin at a low dose and titrate to a higher dose over a period of weeks as tolerated. ○ Take niacin with food or premedicating with aspirin 325 mg 30 minutes before niacin dosing to alleviate flushing symptoms. ○ If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over four to eight weeks, with the dose of extended release niacin increasing not more than weekly. ○ If immediate-release niacin is chosen, start at a dose of 100 mg three times daily and up-titrate to 3 g/day, divided into two or three doses. • Bile acid sequestrants should not be used in individuals with baseline fasting triglyceride levels ≥300 mg/dL or type III hyperlipoproteinemia, because severe triglyceride elevations might occur. • A fasting lipid panel should be obtained before bile acid sequestrants are initiated, three months after initiation, and every six to 12 months thereafter. • It is reasonable to use bile acid sequestrants with caution if baseline triglyceride levels are 250 to 299 mg/dL, and evaluate a fasting lipid panel in four to six weeks after initiation. Discontinue the bile acid sequestrants if triglycerides exceed 400 mg/dL. • It is reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase levels as clinically indicated, and discontinue ezetimibe if persistent alanine transaminase elevations >3 times upper limit of normal occur. • Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis. • Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, are judged to outweigh the potential risk for adverse effect. • Renal status should be evaluated before fenofibrate initiation, within three months after initiation, and every six months thereafter. Assess renal safety with both a serum creatinine level and an estimated glomerular filtration rate based

Clinical Guideline	Recommendation
	on creatinine. • Fenofibrate should not be used if moderate or severe renal impairment, defined as estimated glomerular filtration rate <30 mL/min per 1.73 m^2, is present. • If estimated glomerular filtration rate is between 30 and 59 mL/min per 1.73 m^2, the dose of fenofibrate should not exceed 54 mg/day. • If, during follow-up, the estimated glomerular filtration rate decreases persistently to ≤30 mL/min per 1.73 m^2, fenofibrate should be discontinued. • If eicosapentaenoic acid and/or docosahexanoic acid are used for the management of severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal disturbances, skin changes, and bleeding.

American College of Cardiology:
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016)[10]
	Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention
	• These patients should be treated first with maximally tolerated statin intensity. If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <100 mg/dL), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response (<50% reduction in LDL-C and may consider LDL-C ≥100 mg/dL):
	  o Assess statin adherence.
	  o If an adherent patient has not been tried on a high-intensity statin, the dose should be increased to a high-intensity dose at this time.
	  o Intensify lifestyle modifications.
	  o Consider adding ezetimibe 10 mg daily as the first non-statin agent.
	  o A bile acid sequestrant (BAS) may be considered as a second-line agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL, but there is no evidence for benefit of BAS in addition to statins in this population.
	• If ASCVD patients without comorbidities, who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response with <50% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL):
	  o It is reasonable to consider the net benefit of alirocumab or evolocumab (in addition to or in place of ezetimibe) as a second step to achieve further LDL-C reduction.
	  o If a PCSK9 inhibitor is prescribed, clinicians should continue maximally tolerated statin and monitoring for adherence to medications and lifestyle, side effects, and ongoing LDL-C response to therapy.
	
	Clinical ASCVD with comorbidities, on statin for secondary prevention
	• These patients should be treated first with maximally tolerated statin intensity.
	• If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <70 mg/dL or non–HDL-C <100 mg/dL for patients with diabetes), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response:
	  o Address statin intolerance.
	  o Intensify lifestyle modifications (may consider phytosterols).
	  o Increase to high-intensity statin if not already taking.
	  o Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  o Control other risk factors.
	  o Consider ezetimibe first.
	  o Consider adding or replacing with PCSK9 inhibitor second.

Clinical Guideline	Recommendation

	Clinical ASCVD and baseline LDL-C ≥190 mg/dL not due to secondary causes, on statin for secondary prevention
	• Patients with LDL-C ≥190 mg/dL are more likely to have heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia.
	• In patients who have a less-than-anticipated response on maximally tolerated statin therapy with <50% reduction in LDL-C (and may consider LDL-C ≥70 mg/dL):
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe (or BAS second line) first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	Adults Aged 40 to 75 Years Without ASCVD, but With Diabetes
	• In patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C despite adherence to lifestyle recommendations and moderate-intensity statin therapy, the recommended threshold for consideration of the net benefit of increasing to high-intensity statin therapy is failure to achieve 30 to <50% reduction in LDL-C (and may consider on -treatment LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL).
	• If a patient with diabetes and 10-year ASCVD risk <7.5% without high-risk features has a less-than-anticipated response, with <30% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL), additional clinical approaches may be warranted.
	• Ezetimibe is the preferred initial non-statin therapy due to tolerability, convenience, and single-tablet daily dose.
	• BAS may have a modest hypoglycemic effect that may be of benefit in some diabetic patients if fasting triglycerides are <300 mg/dL. BAS may also be considered if patients have an inadequate response to ezetimibe or if patients are ezetimibe intolerant.
	• In the absence of ASCVD or baseline LDL-C ≥190 mg/dL not due to secondary causes, the PCSK9 inhibitors do not have an established role for primary prevention of ASCVD in patients with diabetes.

National Institute for Health and Clinical Excellence: **Cardiovascular disease: risk assessment and reduction, including lipid modification (2014)**[11] Updated Sep 2016	• Be aware that when deciding on lipid modification therapy for the prevention of cardiovascular disease (CVD), drugs are preferred for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality • When a decision is made to prescribe a statin use a statin of high intensity and low acquisition cost. Lipid Measurement and Referral: • Measure both total and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk. • Before starting lipid modification therapy for the primary prevention of CVD, take at least one lipid sample to measure a full lipid profile. This should include measurement of total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglyceride concentrations. A fasting sample is not needed. • Use the clinical findings, lipid profile and family history to judge the likelihood of a familial lipid disorder rather than the use of strict lipid cut-off values alone. • Exclude possible common secondary causes of dyslipidemia (such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome) before referring for specialist review. • Consider the possibility of familial hypercholesterolemia if they have a total

Clinical Guideline	Recommendation

	cholesterol concentration >7.5 mmol/L and a family history of premature coronary heart disease.
	• Arrange for specialist assessment of people with a total cholesterol concentration of more than 9.0 mmol/L or a non-HDL cholesterol concentration of more than 7.5 mmol/L even in the absence of a first-degree family history of premature coronary heart disease.
	• Refer for urgent specialist review if a person has a triglyceride concentration of more than 20 mmol/L that is not a result of excess alcohol or poor glycemic control.
	• In people with a triglyceride concentration between 10 and 20 mmol/L:
	  o Repeat the triglyceride measurement with a fasting test (after an interval of five days, but within two weeks) and
	  o Review for potential secondary causes of hyperlipidemia and
	  o See specialist advice if the triglyceride concentration remains above 10 mmol/L
	• In people with a triglyceride concentration between 4.5 and 9.9 mmol/L:
	  o Be aware that the CVD risk may be underestimated by risk assessment tools and
	  o Optimize the management of other CVD risk factors present and
	  o Seek specialist advice if non-HDL cholesterol concentration is more than 7.5 mmol/litre.
	
	<u>Statins for the prevention of CVD</u>:
	• The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.
	• Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidemia. Include smoking status, alcohol consumption, blood pressure, body mass index or other obesity measure, total cholesterol, non-HDL cholesterol, HDL cholesterol, triglyceride level, glycosylated hemoglobin (HbA_{1c}), renal function and estimated glomerular filtration rate (eGFR), transaminase levels, and thyroid stimulating hormone in the assessment.
	
	<u>Statins for the Primary Prevention of CVD</u>:
	• Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimize the management of all other modifiable CVD risk factors if possible.
	• Recognize that people may need support to change their lifestyle. To help them do this, refer them to programs such as exercise referral schemes.
	• Offer people the opportunity to have their risk of CVD assessed again after they have tried to change their lifestyle.
	• If lifestyle modification is ineffective or inappropriate, offer statin treatment after risk assessment.
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	• For people 85 years or older consider atorvastatin 20 mg as statins may be of benefit in reducing the risk of non-fatal myocardial infarction. Be aware of factors that may make treatment inappropriate.
	
	<u>Statins for the Secondary Prevention of CVD</u>:
	• Start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower

Clinical Guideline	Recommendation

	dose of atorvastatin if there are potential drug interactions, high risk of adverse effects, or patient preference.
	• Do not delay statin treatment in secondary prevention to manage modifiable risk factors.
	• If a person has acute coronary syndrome, do not delay statin treatment. Take a lipid sample on admission and about three months after the start of treatment.
	
	Statins for the Primary Prevention of CVD for People with Type 1 Diabetes:
	• Consider statin treatment for the primary prevention of CVD in all adults with type 1 diabetes.
	• Offer statin treatment for the primary prevention of CVD to adults with type 1 diabetes who are older than 40 years, have had diabetes for more than 10 years, have established nephropathy, or have other CVD risk factors.
	• Start treatment for adults with type 1 diabetes with atorvastatin 20 mg.
	
	Statins for the Primary Prevention of CVD in People with Type 2 Diabetes:
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people with type 2 diabetes who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	
	Statins for People with CKD:
	• Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
	  o Increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 mL/min/1.73 m^2 or more.
	  o Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73 m^2.
	
	Follow-up of People Started on Statin Therapy:
	• Measure total cholesterol, HDL cholesterol and non-HDL cholesterol in all people who have been started on high-intensity statin treatment at three months of treatment and aim for a greater than 40% reduction in non-HDL cholesterol.
	• If a greater than 40% reduction in non-HDL cholesterol is not achieved, discuss adherence to lifestyle modifications and drug therapy, timing of dose.
	  o Consider increasing the dose if started on less than atorvastatin 80 mg and the person is judged to be at higher risk because of comorbidities, risk score or using clinical judgement.
	• Provide annual medication reviews for people taking statins.
	• Discuss with people who are stable on a low- or middle-intensity statin the likely benefits and potential risks of changing to a high-intensity statin when they have a medication review and agree with the person whether a change is needed.
	
	Monitoring Statin Therapy for Adverse Effects:
	• Advise people who are being treated with a statin that other drugs, some foods (e.g., grapefruit juice) and some supplements may interfere with statins and to always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements.
	• Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses.
	• Before offering a statin, ask the person if they have had persistent generalized unexplained muscle pain, whether associated or not with previous lipid-lowering therapy. If they have, measure creatine kinase levels.
	  o If creatine kinase levels are more than five times the upper limit of normal, re-measure creatine kinase after seven days. If creatine kinase

Clinical Guideline	Recommendation

	levels are still five times the upper limit of normal, do not start statin treatment.
	  ○ If creatine kinase levels are raised but less than five times the upper limit of normal, start statin treatment at a lower dose.
	• Advise people who are being treated with a statin to seek medical advice if they develop muscle symptoms (pain, tenderness or weakness). If this occurs, measure creatine kinase.
	• If people report muscle pain or weakness while taking a statin, explore other possible causes of muscle pain or weakness and raised creatine kinase if they have previously tolerated statin therapy for more than three months.
	• Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin.
	• Measure baseline liver transaminase before starting a statin. Measure liver transaminase within three months of starting treatment and at 12 months, but not again unless clinically indicated.
	• Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than three times the upper limit of normal.
	• Do not stop statins because of an increase in blood glucose level or HbA_{1c}.
	• Statins are contraindicated in pregnancy and women of childbearing potential should be advised of the potential teratogenic risk of statins and to stop taking them if pregnancy is a possibility.
	  ○ Advise women planning pregnancy to stop taking statins three months before they attempt to conceive and to not restart them until breastfeeding is finished.
	
	<u>Intolerance to Statin Therapy</u>:
	• If a person is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose.
	• Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statins discuss the following possible strategies with them:
	  ○ stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin and
	  ○ reducing the dose within the same intensity group and
	  ○ changing the statin to a lower intensity group.
	• Seek specialist advice about options for treating people at high risk of CVD such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidemias, and those with CVD, who are intolerant to three different statins.
	
	<u>Fibrates for Preventing CVD</u>:
	• Do not routinely offer fibrates for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2.
	
	<u>Nicotinic Acid for Preventing CVD</u>:
	• Do not offer nicotinic acid (niacin) for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2.
	
	<u>Bile Acid Sequestrants (Anion Exchange Resins) for Preventing CVD</u>:
	• Do not offer bile acid sequestrants for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2.

Clinical Guideline	Recommendation
	Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer omega-3 fatty acid compounds for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. • Tell people that there is no evidence that omega-3 fatty acid compounds help to prevent CVD. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. Ezetimibe for Preventing CVD: • People with primary hypercholesterolemia should be considered for ezetimibe treatment.
American Heart Association: **Drug Therapy of High Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association (2007)**[12]	• For children meeting criteria for lipid-lowering drug therapy, a statin is recommended as first line treatment. The choice of statin is dependent upon preference but should be initiated at the lowest dose once daily, usually at bedtime. • For patients with high risk lipid abnormalities, the presence of additional risk factors or high risk conditions may reduce the recommended LDL level for initiation of drug therapy and the desired target LDL levels. Therapy may also be considered for initiation in patients <10 years of age. • Additional research regarding drug therapy of high risk lipid abnormalities in children is needed to evaluate the long term efficacy and safety and impact on the atherosclerotic disease process. • Niacin is rarely used to treat the pediatric population. • Given the reported poor tolerance, the potential for very serious adverse effects, and the limited available data, niacin cannot be routinely recommended but may be considered for selected patients. • This guideline does not contain recommendations regarding the use of omega-3 acid ethyl esters.
European Society of Cardiology and Other Societies: **Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2016)**[13]	Drugs • Currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g. ezetimibe) and, more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Response to all therapy varies widely among individuals and therefore monitoring the effect on LDL-C levels is recommended. • Statins, by reducing LDL-C, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions. • Statins should be used as the drugs of first choice in patients with hypercholesterolemia or combined hyperlipidemia. • Selective cholesterol absorption inhibitors are not usually used as monotherapy to decrease LDL-C concentrations, unless patients are intolerant to statins. They are recommended as combination therapy with statins in selected patients when a specific goal is not reached with the maximal tolerated dose of a statin. • Bile acid sequestrants also decrease TC and LDL-C, but are poorly tolerated and tend to increase plasma triglyceride concentrations. They are therefore not recommended for routine use in CVD prevention. • Fibrates and niacin are used primarily for triglyceride lowering and increasing HDL-C, while fish oils (n-3 fatty acids) are used for triglyceride lowering. Evidence supporting the use of these drugs for CVD event reduction is limited and, given the strong evidence favouring statins, routine use of these drugs in

Clinical Guideline	Recommendation
	CVD prevention is not recommended. In order to prevent pancreatitis, when triglycerides are >10 mmol/L (>900 mg/dL) they must be reduced not only by drugs but also by restriction of alcohol, treatment of DM, withdrawal of estrogen therapy, etc. In those rare patients with severe primary hypertriglyceridaemia, specialist referral must be considered. • Regarding new therapies, recent data from phase I to III trials show that PCSK9 inhibitors sharply decrease LDL-C by up to 60%, either as monotherapy or in addition to the maximal statin dose. Whether this approach results in the predicted reduction in CV events is being addressed in large outcome trials; preliminary evidence suggests that this is the case. Drug combinations • Patients with dyslipidemia, particularly those with established cardiovascular disease, diabetes, or asymptomatic high risk patients, may not always reach treatment targets; therefore, combination treatment may be needed. • The only combination that has evidence of clinical benefit (one large RCT) is that of a statin combined with ezetimibe. Based on the relatively limited body of evidence, clinicians may restrict the use of this combination to patients at high or very-high risk of CVD. • Combinations of niacin and a statin increase HDL-C and decrease TG better than either drug used as monotherapy, but flushing is the main adverse event with niacin, which may affect compliance. • Fibrates, particularly fenofibrate, may be useful, not only for decreasing TG and increasing HDL-C, but can further lower LDL-C when administered in combination with a statin. • If target levels cannot be reached with maximal doses of lipid-lowering therapy or combination therapy, patients will still benefit from treatment to the extent to which dyslipidemia has been improved. In these patients, increased attention to other risk factors may help to reduce total risk.
American Heart Association/ American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (2014)**[14]	• Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or transient ischemic attack (TIA) presumed to be of atherosclerotic origin and an LDL-C level ≥100mg/dL with or without evidence for other clinical ASCVD. • Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin, and LDL-C level <100 mg/dL, and no evidence for other clinical ASCVD. • Patients with ischemic stroke or TIA and other comorbid ASCVD should be otherwise managed according to the 2013 ACC/AHA cholesterol guidelines, which include lifestyle modifications, dietary recommendations, and medication recommendations.
American Association of the Study of Liver Disease: **Primary Biliary Cirrhosis (2009)**[15] **Reaffirmed October 2014**	• Ursodeoxycholic acid therapy is the only Food and Drug Administration-approved agent for the treatment of primary biliary cirrhosis. It is currently supported by the most data and is recommended for use in appropriately selected patients who have abnormal liver chemistry. • Issues of patient compliance, development of superimposed liver disease, or coadministration with bile sequestrants (e.g., cholestyramine or colestipol) should be considered for patients with suboptimal response. • Pruritus is a complication of primary biliary cirrhosis and cholestyramine is the drug of choice for the treatment of this complication. Alternative treatments of pruritus include rifampin, opioid antagonists, and liver transplantation.
American Association of Clinical Endocrinologists: **Consensus Statement**	Principles underlying the algorithm • Lifestyle optimization is essential for all patients with diabetes; however, it should not delay needed pharmacotherapy, which can be initiated simultaneously and adjusted based on patient response to lifestyle efforts. The

Clinical Guideline	Recommendation

on the Comprehensive Type 2 Diabetes Management Algorithm 2016 (2016)[16]	need for medical therapy should not be interpreted as a failure of lifestyle management, but as an adjunct to it.
	• Achieving an HbA_{1c} ≤6.5% is recommended as the primary goal if it can be achieved in a safe and affordable manner; however, higher targets may be appropriate for certain individuals and may change for a given individual over time.
	• Minimizing risk of hypoglycemia and weight gain is a priority. It is a matter of safety, adherence, and cost.
	• For optimal glycemic control, therapies with complementary mechanisms of action must typically be used in combination.
	• Therapeutic effectiveness must be evaluated frequently until stable (e.g., every three months).
	• Safety and efficacy should be given higher priority than the initial acquisition cost of medications, as medication cost is only a small part of the total cost of diabetes care. In assessing the cost of a medication, consideration should be given to monitoring requirements and risks of hypoglycemia and weight gain.
	• The therapeutic regimen should be as simple as possible to optimize adherence.
	
	<u>Monotherapy</u>
	• Patients with recent-onset diabetes and those with mild hyperglycemia (HbA_{1c} <7.5%), initial monotherapy with metformin (at doses of 1,500 to 2,000 mg/day) and life-style modifications will achieve their glycemic goals in a majority of patients.
	• In patients with intolerance or contraindications to metformin, acceptable therapeutic alternatives that reduce glucose without weight gain or hypoglycemia (in order based on suggested hierarchy of usage) include:
	  ○ GLP-1 receptor agonists.
	  ○ Sodium glucose cotransporter 2 (SGLT-2) inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZDs (use with caution).
	  ○ Alpha-glucosidase inhibitors.
	• sulfonylureas, and glinides (in order based on suggested hierarchy of usage) may be used but with caution due to possible weight gain and hypoglycemia.
	
	<u>Combination therapy</u>
	• Patients who present with an initial HbA_{1c} >7.5% or who do not reach their target HbA_{1c} with metformin in three months should be started on a second agent to be used in combination with metformin.
	• Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy.
	• In metformin-intolerant patients, two drugs from other classes with complimentary mechanisms of action should be used.
	• Combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent) plus:
	  ○ GLP-1 receptor agonists.
	  ○ SGLT-2 inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZD.
	  ○ Basal insulin.
	  ○ Colesevelam.
	  ○ Bromocriptine quick release.
	  ○ Alpha-glucosidase inhibitors.
	  ○ Sulfonylureas and glinides.
	
	<u>Three-drug combination therapy</u>

Clinical Guideline	Recommendation

	• Generally, the efficacy of a third antidiabetic agent added to dual therapy is reduced compared to the efficacy of the same drug used as monotherapy or combination therapy with one other agent.
	• Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy.
	• Patients who present with an HbA_{1c} <8.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs after three months have a high likelihood of reaching target with a third agent.
	• Patients who present with an HbA_{1c} >9.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs has are less likely of reaching target with a third agent or fourth agent and insulin should be considered.
	• Continuation with noninsulin therapies while starting basal insulin is common and does not increase cardiovascular risk, but may increase risk of hypoglycemia when sulfourea are used in conjunction with insulin.
	• Three-drug combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent), a second-line agent plus:
	  ○ GLP-1 receptor agonists.
	  ○ SGLT-2 inhibitors.
	  ○ TZD.
	  ○ Basal insulin.
	  ○ DPP-4 inhibitors.
	  ○ Colesevelam.
	  ○ Bromocriptine quick release.
	  ○ Alpha-glucosidase inhibitors.
	  ○ Sulfonylureas and glinides.
	
	<u>Insulin therapy algorithm</u>
	• Patients who present with an initial HbA_{1c} >9.0% and are symptomatic, should initiate therapy with insulin with or without other antidiabetic agents.
	• Start insulin if a patient has marked hyperglycemia despite treatment with several oral antidiabetic agents and is symptomatic with polyuria and weight loss.
	• Patients who are not at target HbA_{1c} despite the use of oral antidiabetic agents or GLP-1 therapy should be considered for insulin therapy.
	• Patients with an HbA_{1c} level >8.0% while receiving ≥2 antidiabetic agents, particularly individuals with long duration of diabetes, have significant impairment of beta cell insulin secretory capacity and are unlikely to reach the recommended target by the addition of further oral antidiabetic drugs.
	
	<u>Basal insulin</u>
	• Patients with an HbA_{1c} level >8.0% while receiving ≥2 oral antidiabetic agents or GLP-1 therapy can be started on single daily dose of basal insulin as an add-on to the patient's existing regimen.
	• Titrate insulin dose every two to three days to reach glycemic goals.
	• Basal insulin analogues (glargine and detemir) are preferred over protamine Hagedorn insulin because they have been shown to provide a relatively flat serum insulin concentration for up to 24 hours from a single daily injection.
	• Patients who fail to achieve glucose control with basal insulin or premixed insulin formulations can also be considered for basal intensification with a DPP-4 inhibitor or GLP-1 receptor agonist if the glucose level is not markedly elevated, because this approach tends to not cause weight gain or additional hypoglycemia.
	
	<u>Basal-bolus insulin regimens</u>
	• Patients who fail to achieve glucose control with basal insulin or premixed

Clinical Guideline	Recommendation
	insulin formulations and those with symptomatic hyperglycemia and HbA_{1c} >10% often respond better to combined basal and mealtime bolus insulin. • A full basal-bolus program with an insulin basal analogue once or twice daily and a rapid-acting analogue at each meal is most effective and provides flexibility for patients with variable mealtimes and meal carbohydrate content. • Doses of insulin may be titrated every two to three days to reach glycemic goals. <u>Basal insulin and incretin therapy regimens</u> • Use of the amylin analog pramlintide in conjunction with bolus insulin improves both glycemia and weight in patients with type 2 diabetes. • The incretin therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have similar properties, and also increase endogenous insulin secretion. Therefore, the combination of basal insulin and incretin therapy decreases basal and postprandial glucose and may minimize the weight gain and hypoglycemia risk observed with basal-bolus insulin replacement.

National Institute for Health and Clinical Excellence: **Identification and management of familial hypercholesterolaemia (2008)**[17]
 	
Last updated July 2016
	<u>Drug treatment in adults</u>
	• When offering lipid-modifying drug therapy to adults with familial hypercholesterolemia (FH), inform the patient that this treatment should be life-long.
	• Statins should be the initial treatment for all adults with FH.
	• Consider prescribing a high-intensity statin to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• Offer treatment with a statin with a low acquisition cost for adults with FH in whom the diagnosis is made after the age of 60 and who do not have coronary heart disease.
	• Ezetimibe monotherapy is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who would otherwise be initiated on statin therapy but who are unable to do so because of contraindications or intolerance to initial statin therapy.
	• Ezetimibe, coadministered with initial statin therapy, is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who have been initiated on statin therapy when:
	  ○ Serum total or LDL-C concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy AND
	  ○ Consideration is being given to changing from initial statin therapy to an alternative statin.
	• Prescribing of drug therapy for adults with homozygous FH should be undertaken within a specialist center.
	• Adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
	• Exercise caution when adding a fibrate or nicotinic acid to a statin because of the risk of muscle-related side effects (including rhabdomyolysis). Gemfibrozil and statins should not be used together.
	
	<u>Drug treatment in children and young people</u>
	• All children and young people diagnosed with, or being investigated for, a diagnosis of FH should have a referral to a specialist with expertise in FH in children and young people.

Clinical Guideline	Recommendation
	• Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-modifying drug therapy for a child or young person should take into account: o Their age. o The age of onset of coronary heart disease within the family. o And the presence of other cardiovascular risk factors, including LCL-C concentration. • When offering lipid-modifying drug therapy for children or young people, inform the child/young person and their parent/carer that this treatment should be life-long. • When the decision to initiate lipid-modifying drug therapy has been made in children and young people, statins should be the initial treatment. Healthcare professionals with expertise in FH in children and young people should choose a statin that is licensed for use in the appropriate age group. • In exceptional instances, for example, when there is a family history of coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering: o A higher dose of statin than is licensed for use in the age group and/or o More than one lipid-modifying drug therapy, and/or o Lipid-modifying drug therapy before the age of 10 years. • In children and young people with homozygous FH, LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis. • In children and young people with FH who are intolerant of statins, consider offering other lipid-modifying drug therapies capable of reducing LDL-C concentration (such as bile acid sequestrants [resins], fibrates or ezetimibe). • Routine monitoring of growth and pubertal development in children and young people with FH is recommended.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the bile acid sequestrants are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Bile Acid Sequestrants[2-4,18]

Indication	Cholestyramine	Colesevelam	Colestipol
Hypercholesterolemia			
Adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an HMG CoA reductase inhibitor (statin)		✔	
Adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet	✔ *		
Adjunctive therapy to diet for the reduction of elevated serum total cholesterol and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet			✔
Monotherapy or in combination with a statin to reduce		✔	

Indication	Cholestyramine	Colesevelam	Colestipol
LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL with a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present in the pediatric patient			
Miscellaneous			
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus		✔ †	
Relief of pruritus associated with partial biliary obstruction	✔		

*May be useful to lower LDL-C in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
†Colesevelam has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase-4 inhibitor and has not been extensively studied in combination with thiazolidinediones.

IV. Pharmacokinetics

The pharmacokinetic parameters of the bile acid sequestrants are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Bile Acid Sequestrants[2-4,19]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Cholestyramine	0	Not reported	None	Feces (100)	Not reported
Colesevelam	0	Not reported	None	Renal (0.05) Feces (majority; % not reported)	Not reported
Colestipol	0	Not reported	None	Renal (<0.05) Feces (100)	Not reported

V. Drug Interactions

Major drug interactions with the bile acid sequestrants are listed in Table 5.

Table 5. Major Drug Interactions with the Bile Acid Sequestrants[19]

Generic Name(s)	Interaction	Mechanism
Cholestyramine, Colesevelam, Colestipol	Bezafibrate	Concurrent use of bezafibrate and ion exchange resins may result in decreased bezafibrate efficacy.
Cholestyramine, Colesevelam, Colestipol	Deferasirox	Gastrointestinal absorption and enterohepatic recycling of deferasirox may be decreased due to the formation of physical chemical complexes with cholestyramine. Plasma concentrations and pharmacologic effects of deferasirox may be decreased.
Cholestyramine, Colesevelam, Colestipol	Mycophenolate	Concurrent use of cholestyramine and mycophenolate mofetil may result in reduced mycophenolic acid exposure.

VI. Adverse Drug Events

The most common adverse drug events reported with the bile acid sequestrants are listed in Table 6. Cholestyramine and colestipol can decrease plasma folate levels with long-term administration; therefore, folic

acid supplementation may be necessary.[2,4] Bile acid sequestrants may also decrease the absorption of fat-soluble vitamins A, D, E, and K.[2-4]

Table 6. Adverse Drug Events (%) Reported with the Bile Acid Sequestrants[2-4]

Adverse Events	Cholestyramine	Colesevelam	Colestipol
Cardiovascular			
Angina	-	-	✔
Aortic stenosis	-	✔	-
Bradycardia	-	✔	-
Chest pain	-	-	✔
Hypertension	-	2.8	-
Myocardial infarction	-	✔	-
Tachycardia	-	-	✔
Central Nervous System			
Anxiety	✔	-	-
Dizziness	✔	-	✔
Drowsiness	✔	-	-
Fatigue	✔	3.9	✔
Femoral nerve pain	✔	-	-
Headache	✔	3.9 to 7.6	✔
Insomnia	-	-	✔
Light-headedness	-	-	✔
Migraine	-	-	✔
Paresthesia	✔	-	-
Syncope	✔	-	-
Tinnitus	✔	-	-
Vertigo	✔	-	-
Weakness	-	-	✔
Gastrointestinal			
Abdominal pain/discomfort	✔	-	✔
Abdominal distention	-	-	-
Anorexia	✔	-	✔
Black stools	✔		✔
Bleeding from a known duodenal ulcer	✔	-	-
Bloating	✔	-	✔
Cholecystitis	-	-	✔
Cholelithiasis	✔	-	✔
Constipation	✔	9 to 11	✔
Diarrhea	✔	5	✔
Diverticulitis	✔	-	-
Dyspepsia	-	3.9 to 8.3	-
Dysphagia	✔	-	-
Eructation	✔	-	-
Flatulence	✔		-
Heartburn	-	-	✔
Hemorrhoidal bleeding	✔		✔
Hiccups	✔	-	-
Indigestion	-	-	✔
Intestinal gas	-	-	✔
Intestinal obstruction	✔	-	-
Malabsorption syndrome	✔	-	-
Nausea	✔	3.0 to 4.2	✔
Pancreatitis	✔	-	-
Peptic ulcer	-	-	✔
Rectal bleeding	✔		

Adverse Events	Cholestyramine	Colesevelam	Colestipol
Rectal pain	✔	-	-
Sour taste	✔	-	-
Steatorrhea	✔	-	-
Ulcer attack	✔		
Vomiting	✔	2.3	✔
Genitourinary			
Burnt odor to urine	✔	-	-
Diuresis	✔	-	-
Dysuria	✔	-	-
Hematuria	✔	-	-
Hematological			
Anemia	✔	-	-
Ecchymosis	✔		
Hypoprothrombinemia	✔	-	-
Ecchymosis	✔	-	-
Prolonged prothrombin time	✔	-	-
Laboratory Test Abnormalities			
Creatinine phosphokinase increased	-	2.3	-
Hypoglycemia	-	3	-
Liver function test abnormalities	✔	-	✔
Triglycerides increased	-	✔	-
Musculoskeletal			
Aches	-	-	✔
Arthritis	✔	-	✔
Backache	✔	-	✔
Joint pain	-	-	✔
Muscle and joint pain	✔	-	-
Myalgia	-	2.1	-
Osteoporosis	✔	-	-
Pain	-	-	✔
Respiratory			
Nasopharyngitis	-	4.1 to 6.2	-
Pharyngitis	-	3.2	-
Rhinitis	-	2.3 to 3.2	-
Sinusitis	-	-	-
Upper respiratory tract infection	-	4.9	-
Other			
Accidental injury	-	3.7	-
Asthenia	-	3.6	-
Asthma	✔	-	-
Dental bleeding	✔	-	-
Dental caries	✔	-	-
Edema	✔	-	-
Erosion of tooth enamel	✔	-	-
Flu syndrome	-	3.2	-
Increased libido	✔	-	-
Influenza	-	3.8	-
Irritation of skin, tongue, perianal area	✔	-	-
Metabolic acidosis	✔	-	-
Rash	✔	-	✔
Shortness of breath	✔		✔
Swelling of hands or feet	-	-	✔
Swollen glands	✔	-	-
Tooth discoloration	✔	-	-

Adverse Events	Cholestyramine	Colesevelam	Colestipol
Urticaria	✔	-	✔
Uveitis	✔	-	-
Vitamin A deficiency	✔	-	-
Vitamin D deficiency	✔	-	-
Weight gain	✔	-	-
Weight loss	✔	-	-
Wheezing	✔		

✔ Percent not specified
- Event not reported

VII. Dosing and Administration

The usual dosing regimens for the bile acid sequestrants are listed in Table 7.

Table 7. Usual Dosing Regimens for the Bile Acid Sequestrants[2-4,18]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Cholestyramine	Primary hyperlipidemia: Powder: initial, one packet or one level spoonful once or twice daily; maintenance, two to four packets or scoopfuls daily (8 to 16 g) divided into two doses; maximum, six packets or scoopfuls (24 g) daily Relief of pruritus associated with partial biliary obstruction: Powder: initial, one packet or one level spoonful once or twice daily; maintenance, two to four packets or scoopfuls daily (8 to 16 g) divided into two doses; maximum, six packets or scoopfuls (24 g) daily	Primary hyperlipidemia: Powder: although an optimal dosage schedule has not been established, standard texts list a usual pediatric dose of 240 mg/kg/day in two to three divided doses, normally not to exceed 8 g/day* Relief of pruritus associated with partial biliary obstruction: Powder: although an optimal dosage schedule has not been established, standard texts list a usual pediatric dose of 240 mg/kg/day in two to three divided doses, normally not to exceed 8 g/day*	Powder (for oral suspension): 4 g
Colesevelam	Primary hyperlipidemia (as monotherapy or in combination with an HMG CoA reductase inhibitor): Powder: one 3.75 g packet once daily Tablet: six tablets once daily or three tablets twice daily Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: Powder: 3.75 g once daily Tablet: six tablets once daily or three tablets twice daily	Heterozygous familial hypercholesterolemia in children 10 to 17 years of age: Powder: one 3.75 g packet once daily Tablet: six tablets once daily or three tablets twice daily Safety and efficacy has not been established in children <10 years of age or in premenarchal girls. Due to tablet size, the oral suspension is recommended for use in the pediatric population.	Powder (for oral suspension): 3.75 g Tablet: 625 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Colestipol	Primary hyperlipidemia: Granules: one to six packets or level scoopfuls given once or in divided doses; initiate treatment with one dose once or twice daily with an increment of one dose/day at one- or two-month intervals Tablet: initial, 2 g once or twice daily; maintenance, 2 to 16 g/day administered once or in divided doses	Safety and efficacy in children have not been established.	Granules (for oral suspension): 5 g (Colestid®) 7.5 g (Colestid Flavored®)† Tablet: 1 g

*The effects of long-term administration, as well as its effect in maintaining lowered cholesterol levels in pediatric patients are unknown.
†One dose contains 5 g of colestipol hydrochloride.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the bile acid sequestrants are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Bile Acid Sequestrants

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hypercholesterolemia				
Ballantyne et al.[20] (2004) Cholestyramine 16 g/day and rosuvastatin 80 mg/day vs rosuvastatin 80 mg/day	MC, OL, PG, RCT Adults ≥18 years of age with severe hypercholesterolemia (LDL-C 190 to 400 mg/dL) and fasting TG <400 mg/dL	N=147 12 weeks	Primary: Percent change in LDL-C from baseline to end of treatment Secondary Percent change from baseline in LDL-C after 6 weeks of 40 mg rosuvastatin; percent change from baseline at 6 and 12 weeks of rosuvastatin treatment for: TC, HDL-C, TG, apo AI, apo B, lipid ratios (LDL:HDL) and inflammatory markers (CRP, IL6); compliance	Primary: At 12 weeks, no significant difference between the groups was seen: the rosuvastatin group had an LDL-C reduction of 56.4% and rosuvastatin with cholestyramine group had an LDL-C reduction of 60.5% (P<0.08). Secondary: LDL-C reductions were 52.2% after treatment with 40 mg rosuvastatin. Other measurements, TC, HDL-C, TG, apo B, apo AI and lipid ratios were not significantly different between the groups (P=0.20, 0.71, 0.47, 0.75, 0.53, 0.17, respectively). Decreases in CRP were 29% after six weeks, 42% after rosuvastatin 80 mg and 48% after rosuvastatin 80 mg with cholestyramine. 49% of patients in the cholestyramine group were not compliant with the cholestyramine treatment.
Eriksson et al.[21] (1998) Cholestyramine 16 g/day vs	MC, RCT Men and women, aged 30 to 65 years old	N=2,036 12 months	Primary: Reduction in LDL-C Secondary: Compliance	Primary: Percent change in LDL-C from baseline to end point was as follows: cholestyramine -26% (95% CI, -23 to -29), cholestyramine and pravastatin -36% (95% CI, -33 to -39), pravastatin (20 mg) -27% (95% CI, -25 to -29), pravastatin (40 mg) -32% (95% CI, -30 to -34). Secondary: Compliance rates with each regimen were as follows: cholestyramine

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
cholestyramine 8 g/day and pravastatin 20 mg/day vs pravastatin 20 mg/day vs pravastatin 40 mg/day				44%, cholestyramine and pravastatin 53%, pravastatin (20 mg) 76%, and pravastatin (40 mg) 78%. Pravastatin adverse events were the most common reasons for withdrawal. Adverse events were most common in the cholestyramine group and the cholestyramine with pravastatin group.
Davidson et al.[22] (2010) Colesevelam 0.75 g BID, titrated up to a maximum of 1.875 g BID If a 15 to 30% LDL-C reduction was not achieved with the maximum colesevelam dose by week 12, low dose statin or niacin therapy could be added.	ES, OL Patients ≥18 years of age with primary hypercholesterolemia (LDL-C ≥160 mg/dL and TG ≤300 mg/dL)	N=260 50 weeks	Primary: Mean change from baseline in LDL-C Secondary: Mean percent change from baseline in LDL-C; mean change and mean percent change from baseline in TC, TG and HDL-C; safety	Primary: Colesevelam monotherapy or combination therapy resulted in significant mean LDL-C level reduction of 29.6 mg/dL (from 185.8 to 156.2 mg/dL), corresponding to a mean 15.0% reduction from baseline (P<0.00 for both). Secondary: Colesevelam reduced the mean TC level from baseline to week 50 (270.2 to 258.3 mg/dL) by 11.9 mg/dL (4.0%; P<0.001). The median TG level increased from baseline to week 50 (145.5 to 165.0 mg/dL) by 13.0 mg/dL (10.3%). The median HDL-C level increased from baseline to week 50 (49.5 to 54.0 mg/dL) by 5.0 mg/dL (10.8%; P<0.001). Twenty three patients discontinued colesevelam due to treatment-emergent adverse events. Treatment-emergent adverse events were reported by 225 patients (86.5%), with the majority of adverse events (74.7%) classified as mild to moderate in severity. The most common adverse events included infection (28.5%), constipation (16.5%), flatulence (13.5%) and general pain (13.1%).
Rosenson et al.[23] (2006) Colesevelam 1.5 to 3.75 g/day	DB, MC, PC, RCT Hypercholesterolemia patients, LDL-C >160 mg/dL, average age of	N=137 6 weeks	Primary: LDL particle size and LDL particle number	Primary: Mean LDL particle size increased significantly in the group receiving colesevelam 3.75 g/day (P=0.01). Mean LDL particle number decreased significantly in the group receiving

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	56 years old		Secondary: Not reported	colesevelam 3.75 g/day by 13.7% (P=0.0002). Mean LDL particle number decreased significantly in the group receiving colesevelam 3.0 g/day by 6.8% (P=0.03). Secondary: Not reported
Bays et al.[24] (2006) Colesevelam 3.75 g/day vs placebo	MA (3 trials) Patients ≥18 years of age with LDL-C 100 mg/dL to 250 mg/dL, TG ≤300 mg/dL and on stable doses of statin therapy, either atorvastatin, pravastatin or simvastatin for ≥4 weeks	N=204 6 weeks	Primary: Mean percent change in LDL-C level from baseline to end point Secondary: HsCRP, absolute and percent change in HDL-C, TC, apo AI, apo B, TG, and absolute change in HsCRP; safety (measured by incidence of treatment-emergent adverse events)	Primary: Patients receiving colesevelam with a statin had significantly greater reductions in LDL-C than those receiving placebo plus a statin at the end of the study (P<0.01 for absolute difference; P≤0.001 for % treatment difference). Secondary: HsCRP levels decreased significantly as compared to placebo when colesevelam was combined with simvastatin or pravastatin (P=0.0154 and P=0.0279, respectively). Patients receiving colesevelam with a statin did not have a significant increase in HDL-C as compared to those receiving placebo plus a statin at the end of the study (P>0.05). Patients receiving colesevelam with a statin had significantly greater reductions in TC than those receiving placebo plus a statin at the end of the study (P<0.05). Apo B levels were not significantly different. No serious drug-related adverse events were reported. The incidence of drug-related adverse events was higher in the groups receiving colesevelam with a statin (13 to 26%) than placebo with a statin (0 to 13%).
Huijgen et al.[25] (2010) Colesevelam 3,750 mg/day	DB, PC, RCT Patients 18 to 75 years of age with familial hyper-cholesterolemia	N=86 12 weeks	Primary: Percent change from baseline to week six in LDL-C	Primary: The between-group difference in change from baseline LDL-C was significant at week six, with an least squares means change of -18.5% (95% CI, -25.3 to -11.8)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo All patients were receiving ezetimibe/ simvastatin.	refractory to treatment		Secondary: Percentage change from weeks six to 12 in HDL-C, TC, TG, apo A1, apo B, apo B/A1; percentage change from baseline to week 12 in LDL-C; proportion of patients achieving an LDL-C target of ≤2.5 mmol/L at weeks six and 12; proportion of patients with a decrease from baseline in LDL-C ≥15% at weeks six and 12; absolute changes in fasting glucose, HbA_{1c}, and hsCRP at weeks six and 12	Secondary: Between group differences (95% CI) in LDL-C, TC, HDL-C, TG and apo B/A1 after 12 weeks were -12.0 (-17.8 to -6.3), -7.3 (-12.0 to -2.6), 3.3 (-2.4 to 9.0), 2.8 (-10.4 to 15.9) and -12.2% (-20.2 to -4.2). Mean TC concentrations were significantly reduced with colesevelam compared to placebo at weeks six and 12 (least squares means between-group differences, -11.1 and -7.3%; *P*<0.001 and *P*<0.003). On average, TG levels increased with colesevelam from baseline to weeks six and 12. There was no significant group differences in HDL-C at week six and 12 (*P* values not reported). The difference in the proportions of patients who achieved the target LDL-C (≤2.5 mmol/L) with colesevelam and placebo was not significant (9 vs 3%; *P* value not reported). The proportion of patients who achieved ≥15% reduction in LDL-C at week six was significantly higher with colesevelam (32 vs 0%; *P*<0.001). This difference remained significant at week 12 (30 vs 8%; *P*=0.012). Although not significant at week six (-0.06%), the least squares means between-group difference in change from baseline to week 12 in mean HbA_{1c} concentration was significant (-0.12%; *P*=0.027). There were no significant between-group differences in fasting glucose or hsCRP at week six and 12.
Stein et al.[26] (2010) Colesevelam 1.875 g/day vs colesevelam 3.75 g/day vs	DB, PC, PG, RCT Patients 10 to 17 years of age with heFH, TC >160 mg/dL who were naïve to cholesterol lowering therapy or LDL-C >130 mg/dL who were on a statin	N=194 32 weeks	Primary: Percent change in LDL-C from baseline Secondary: Percent change in non-HDL-C, adverse events	Primary: Treatment with colesevelam 3.75 and 1.875 g/d led to a significant reduction in LDL-C (-12.5%; P<0.001) and (-6.3%; P=0.031), respectively, compared to placebo at week 8. Reductions in LDL-C were observed for statin-naïve (-10.6%; P<0.001) or statin non-naïve patients (-20.2%; P=0.031) receiving colesevelam 3.75 g/day compared to placebo. The mean change in LDL-cholesterol was -9.3% (P<0.001) from week 8 to week 26. Those who received placebo had the greatest change in mean LDL-C (-14.5%; P<0.001), followed by patients receiving 1.875 g/day (-11.6%; P<0.001) and 3.75 g/day colesevelam (-1.9%; P=0.482). Reductions in LDL-cholesterol were also observed for statin-naïve and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				statin-stable patients, and patients who either changed or added a statin. Those treated with colesevelam 3.75 g/day resulted in a mean reduction from baseline in LDL-cholesterol of -14.0% (P<0.001) across all patients. Secondary: Treatment with colesevelam 3.75 g/day resulted in a reduction in TC (-7.4%; P=0.001), non-HDL-C (-10.9%; P=0.0001), apo B (-8.3%; P=0.0009), HDL-C (6.1%; P=0.008), and apo AI (6.9%; P=0.006) at week 8. There was no significant difference in TG among the treatment groups (P=0.466). Individuals receiving colesevelam 3.75 g/day also experienced clinically significant mean reductions in TC (-8.0%; P<0.001), non-HDL-C (-11.3%; P<0.001), and apo B (-11.3%; P<0.001), clinically significant increases in mean HDL-Cl (8.1%; P<0.001) and apo AI (5.6%; P<0.001), and a median increase in triglycerides (11.5%; P<0.001) at week 32.
Insull et al.[27] (2001) Colesevelam 2.3 g vs colesevelam 3.0 g vs colesevelam 3.8 g vs colesevelam 4.5 g vs placebo	DB, MC, PC, RCT Patients with primary hypercholesterolemia, LDL-C levels between 130-220 mg/dL	N=467 32 weeks	Primary: Mean absolute change in LDL-C from baseline to the end of 24-week treatment Secondary: Mean percent change in LDL-C, mean absolute and percent change in TC, apo B, apo AI, and median absolute change and percent change in HDL-C and TG	Primary: All doses of colesevelam resulted in significant absolute and percent change decreases in LDL-C at the end point as compared to placebo (P<0.001 for all). Absolute change decreases and percent decreases in LDL-C for the 2.3, 3.0, 3.8, and 4.5 g doses were 14 (9%), 19 (12%), 24 (15%), and 28 mg/dL (18%). Secondary: All doses of colesevelam resulted in significant reductions of TC (P<0.001). Absolute change decreases and percent decreases in TC for the 2.3, 3.0, 3.8, and 4.5 g doses were 10 (4%), 15 (6%), 18 (7%) and 24 mg/dL (10%). All doses of colesevelam resulted in significant increases in HDL-C (P<0.001). Absolute changes (increases) and percent increases in TC for the 2.3, 3.0, 3.8, and 4.5 g doses were 2 (3%), 2 (4%), 2 (3%) and 2 mg/dL (3%). All doses of colesevelam resulted in significant reductions in apo B relative to baseline (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Changes in apo AI and lipoprotein did not result in significant changes relative to baseline, except the 2.3 and 3.0 g doses resulted in significant changes in apo AI (P=0.02 and 0.03, respectively) TG levels did not change significantly as compared to placebo, however increases, 5 to 10%, were seen within groups from baseline to end point (P<0.05).
Hunninghake et al.[28] (2001) Colesevelam 3.8 g vs atorvastatin 10 mg vs colesevelam 3.8 g/day and atorvastatin 10 mg/day vs atorvastatin 80 mg/day vs placebo	DB, MC, PC, RCT Patients with elevated LDL-C levels ≥160 mg/dL and TG ≤300 mg/dL	N=91 4 weeks	Primary: Change in LDL-C Secondary: Change in TC, HDL-C, TG, apo B, apo AI and lipoprotein(a) from baseline	Primary: All treatment groups resulted in significant LDL-C reductions as compared to baseline. LDL-C reductions were -12% in the colesevelam 3.8 g group, -38% in the atorvastatin 10 mg group, -48% in the colesevelam 3.8 g and atorvastatin 10 mg group and -53% for the atorvastatin 80 mg group (P<0.05, P<0.0001, P<0.0001, and P<0.0001, respectively, for change from baseline to end point). Secondary: Colesevelam 3.8 g/day reduced TC -6% (P<0.05), increased HDL-C 3% (P<0.05), and increased TG 10%. Atorvastatin 10 mg reduced TC -27% (P<0.0001), increased HDL-C 8% (P<0.05), and reduced TG -24% (P<0.05). Colesevelam 3.8 g and atorvastatin 10 mg reduced TC -31% (P<0.0001), increased HDL-C 11% (P<0.05), and reduced TG -1%. Atorvastatin 80 mg reduced TC -39% (P<0.0001), increased HDL-C 5% (P<0.05), and reduced TG -33% (P<0.0001). Reductions in TC were significant between all treatment groups except atorvastatin 10 mg relative to colesevelam 3.8 g with atorvastatin 10 mg. No significant differences in HDL-C were found between the groups. Apo B levels decreased significantly for all groups relative to baseline (P<0.01). No significant changes in Apo AI and lipoprotein were reported.
Davidson et al.[29]	DB, MC, PC, RCT	N=135	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2001) Colesevelam 2.3 g vs lovastatin 10 mg vs colesevelam 2.3 g and lovastatin 10 mg taken together vs colesevelam 2.3 g and lovastatin 10 mg taken apart vs placebo	Patients with elevated LDL-C levels	4 week	Percent change in LDL-C Secondary: Changes in TC, HDL-C, TG, apo B	Colesevelam 2.3 g and lovastatin 10 mg together significantly reduced LDL-C 34% (-60 mg/dL; P<0.0001). Colesevelam 2.3 g and lovastatin 10 mg apart significantly reduced LDL-C 32% (-53 mg/dL; P<0.0001). Lovastatin 10 mg reduced LDL-C 22% (-39 mg/dL). Colesevelam 2.3 g reduced LDL-C 7% (-13 mg/dL). Both combination treatments were more effective than either treatment alone (P<0.05). Secondary: Both combination treatments resulted in reductions in TC by 21% and apo B by 24% (P<0.0001 for each). No significant effect on HDL-C or TG was found for the combination treatments.
Knapp et al.[30] (2001) Colesevelam 2.3 g vs colesevelam 3.8 g vs simvastatin 10 mg vs	DB, MC, PC, RCT Men and women, age 18 years and older, with elevated LDL-C levels, ≥160 mg/dL and TG ≤300 mg/dL and not taking cholesterol-lowering medication	N=258 6 weeks	Primary: Change in serum LDL-C from baseline to end point Secondary: Percent change in LDL-C, mean and percent change in TC, HDL-C, TG, apo B and apo AI from baseline	Primary: LDL-C serum changes were -7 mg/dL in the placebo group, -31 mg/dL in the colesevelam 3.8 g group, -48 mg/dL in the simvastatin 10 mg group -80 mg/dL in the colesevelam 3.8 g and simvastatin 10 mg group, -17 mg/dL in the colesevelam 2.3 g group, -61 mg/dL in the simvastatin 20 mg group and -80 mg/dL for the colesevelam 2.3 g and simvastatin 20 mg group (P<0.05, P<0.0001, P<0.0001, P<0.0001, P<0.0001, P<0.0001, and P<0.0001, respectively, for change from baseline to end point). Secondary: LDL-C percent changes were -4% in the placebo group, -16% in the colesevelam 3.8 g group,-26% in the simvastatin 10 mg group, -42% in the colesevelam 3.8 g and simvastatin 10 mg group, -8% in the colesevelam 2.3 g group, -34% in the simvastatin 20 mg group and -42% for the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
simvastatin 20 mg vs colesevelam 3.8 g and simvastatin 10 mg vs colesevelam 2.3 g and simvastatin 20 mg vs placebo				colesevelam 2.3 g and simvastatin 20 mg group (P<0.05, P<0.0001, P<0.0001, P<0.0001, P<0.0001, P<0.0001, and P<0.0001, respectively, for change from baseline to end point). Significant changes from baseline were found for all treatment groups in mean and percent change in TC (P<0.0001 for all except colesevelam 2.3 g for which P<0.05). Significant changes from baseline were found for mean and percent change in HDL-C for simvastatin 10 mg (P<0.05), colesevelam 3.8 g with simvastatin 10 mg (P<0.0001), colesevelam 2.3 g (P<0.05), simvastatin 20 mg (P<0.05), and colesevelam 2.3 g with simvastatin 20 mg (P<0.05). Significant changes from baseline were found for mean and percent change in TG for colesevelam 3.8 g (P<0.05), simvastatin 10 mg (P<0.05), simvastatin 20 mg (P<0.05), and colesevelam 2.3 g with simvastatin 20 mg (P<0.05). Significant reductions from baseline for apo B were found for all groups. Reductions were significant (P<0.05) compared to placebo for all treatment groups except colesevelam 2.3 g. Significant increases in apo AI were seen in all treatment groups except simvastatin 10 mg (P<0.05).
Romanelli et al.[31] (2013) Colesevelam treatment (previous drug therapies remained in place)	RETRO New colesevelam users ≥ 18 years of age as of index date, diagnosis of hypercholesterolemia, ≥12 months of colesevelam treatment	Hyperchole-sterolemia: N=468 with 12 months of follow-up; N=181 with 24 months of follow-up Additional diagnosis of	Primary: Changes in LDL-C and percentage of patients at LDL-C goal; Among patients with diabetes mellitus (DM), changes in glycated hemoglobin (HBA_{1C}) and percentage of	Primary: LDL-C decreased significantly from baseline by a mean of 11.4 mg/dL and 15.7 mg/dL (P<0.0001, for each) at 12 and 24 months, respectively, and the percentages of patients at LDL-C goal increased by 13.9% and 21.0%. Among patients with DM and a baseline HBA_{1C} ≥8%, HBA_{1C} decreased significantly by a mean of 0.72% (P=0.0001) and 0.75% (P=0.010), and 11.5 and 12.8% were at HBA_{1C} goal at 12 and 24 months, respectively. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
		diabetes: N=113 with 12 months of follow-up; N=39 with 24 months of follow-up	patients at HBA_{1C} goal Secondary: Not reported	
Davidson et al.[32] (2013) Colesevelam 3,750 mg vs placebo All patients took niacin at highest tolerated dose (up to 2000 mg)	PC, RCT Patients ≥18 years of age, with dyslipidemia (non–HDL-C ≥100 and ≤220 mg/dL), HDL-C <60 mg/dL, and FPG ≥90 mg/dL and ≤145 mg/dL	N=140 12 weeks	Primary: LDL-C Secondary: FPG, HDL-C, non–HDL-C, and TGs	Primary: The LDL-C reduction from baseline with colesevelam (-20.67%) was significantly greater than placebo (-12.86%; P=0.0088). Secondary: Both groups experienced increased HDL-C levels (between group difference P=0.879). Non–HDL-C levels decreased to a greater extent in the colesevelam group than in the placebo group (−17.92 vs −13.08%, respectively; P=0.0983). TG levels were also decreased in both groups (−15.2 and −10.3%, respectively; P=0.096). Total cholesterol levels were decreased in both groups (−3.94 and −7.44%, respectively; P=0.1203).
Blankernhorn et al.[33] (1987) Colestipol 30 g/day plus niacin 3 to 12 g/day vs placebo	DB, PC, RCT Nonsmoking men 49 to 59 years of age with progressive atherosclerosis who had coronary bypass surgery not involving valve replacement performed ≥3 months prior and a fasting blood cholesterol level 185 to 350 mg/dL	N=188 2 years	Primary: Coronary global change score Secondary: Change from baseline in lipid parameters	Primary: Deterioration in overall coronary status was significantly less with combination therapy compared to placebo (P<0.001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2 and 2.4% of patients receiving combination therapy and placebo (P=0.002). Combination therapy resulted in a significant reduction in the average number of lesions per patient that progressed (P<0.03) and the percentage of patients with new atheroma formation in native coronary arteries (P<0.03). The percentage of patients receiving combination therapy with new lesions (P<0.04) or any adverse change in bypass grafts (P<0.03) was significant

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				reduced. Secondary: Large, significant decreases in TC (26 vs 4%), TG (22 vs 5%), LDL-C (43 vs 5%) and LDL-C/HDL-C (57 vs 6%), and a large, significant increase in HDL-C (37 vs 2%) were achieved with combination therapy compared to placebo (P<0.001 for all). Modifications in lipid parameters achieved with combination therapy were significant compared to baseline values (P values not reported).
Brown et al.[34] (2009) Colestipol 5 to 10 g TID plus niacin 125 mg BID titrated to 1 to 1.5 g TID vs Colestipol 5 to 10 g TID plus lovastatin 20 mg BID titrated to 40 mg BID vs placebo (or colestipol if LDL-C was elevated)	DB, RCT Men ≤62 years of age with elevated apo B and a family history of CAD	N=120 32 months	Primary: Average change in the percent stenosis for the worst lesion in each of the nine proximal segments Secondary: Average changes in all lesions measured in each patient and in proximal lesions causing ≥50% (severe) stenosis or <50% (mild) stenosis at baseline	Primary: On average, placebo (conventional therapy) increased the index of stenosis by 2.1 percentage points a baseline of 34%. By contrast, it decreased by 0.7 percentage points with colestipol plus lovastatin and by 0.9 percentage points with colestipol and niacin (P<0.003 for trend). At trial end, on average, these nine lesions were almost 3 percentage points less severe among patients treated intensively compared to conventionally. This difference represents almost 1/10 of the amount of disease present at baseline (34% stenosis). Secondary: Placebo (conventional therapy) resulted in consistent worsening of disease when looking at the effect of treatment on certain subsets of lesions (all lesions measured in each patient, lesions causing severe or mild stenosis and those that did not cause total occlusion at baseline). The results with both treatment groups were significantly difference from those receiving conventional therapy for each subset, demonstrating either a mean regression or no change in severity of disease.
Primary Prevention of Cardiovascular Events				
The Lipid Research Clinics Coronary Primary Prevention Trial[35,36]	DB, MC, RCT Asymptomatic males with primary hypercholesterolemia,	N=3,806 7.4 years average	Primary: CHD death and/or nonfatal MI Secondary:	Primary: The cholestyramine group had a 19% reduction in risk of CHD death or nonfatal MI compared to placebo (P<0.05). Secondary

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1984) Cholestyramine vs placebo	following a moderate cholesterol-lowering diet		TC and LDL-C changes, incidence rates of: positive stress tests, angina, coronary bypass surgery	The cholestyramine group had a reduction in TC of 13.4% and a reduction in LDL-C of 20.3%. The placebo group had a TC reduction of 4.9% and a LDL reduction of 7.7%. Incidence rates of positive stress tests, angina and coronary bypass surgery were decreased in the cholestyramine group by 25, 20, and 21%, respectively.
Type 2 Diabetes Mellitus				
Rosenstock et al.[37] (abstract) (2010) Colesevelam 3.75 g/day vs placebo All patients received OL metformin 850 mg/day, titrated at week 2 to 1,700 mg/day.	DB, PC, RCT Adult patients with type 2 diabetes (HbA_{1c} 6.5 to 10.0%) and hypercholesterolemia (LDL-C ≥100 mg/dL)	N=286 16 weeks	Primary: Change from baseline in HbA_{1c} Secondary: Change from baseline in LDL-C, TC, non-HDL-C, apo B, hsCRP, apo A-1 and TG; proportion of patients who achieved recommended treatment goals; safety and tolerability	Primary: Mean HbA_{1c} was reduced by 1.1 and 0.8% with colesevelam (from 7.8% at baseline to 6.6% at trial end) and placebo (from 7.5 to 6.7% at trial end), resulting in a treatment difference of -0.3% at trial end (P=0.0035). Secondary: Colesevelam significantly reduced LDL-C (-16.3%), TC (-6.1%), non-HDL-C (-8.3%), apo B (-8.0%) and hsCRP (-17%) (P<0.01 for all). Colesevelam significantly increased apo A-1 (4.4%) and TG (18.6%) compared to placebo (P<0.01 for all). The proportion of patients who achieved recommended goals with colesevelam compared to placebo, respectively, were as follows: HbA_{1c} <7; 67 vs 56% (P=0.0092), LDL-C <100 mg/dL; 48 vs 18% (P<0.001) and composite HbA_{1c} <7% plus LDL-C <100 mg/dL; 40 vs 12 (P<0.001). Safety and tolerability were similar between the two treatment groups.
Rosenson et al.[38] (2009) Colesevelam 3.75 g/day vs placebo	DB, PC, RCT Patients with type 2 diabetes who were receiving antihyperglycemic therapy (metformin, sulfonylurea, or both)	N=65 12 weeks	Primary: Effects on atherogenic lipoprotein subclasses (LDL-P, VLDL-P, IDL-P Secondary: Not reported	Primary: Colesevelam therapy was associated with a change in HbA_{1c} of -0.3% compared to a change of 0.2% in the placebo group (P=0.007). The mean percentage change in LDL-C was -9.6% in the colesevelam group compared to 2.1% in the placebo group (P=0.007). The mean percentage change in apo B was -6.3% (in the colesevelam group compared to 5.5% in the placebo group (P=0.003). There was no significant difference in TG (P=0.570) or HDL-C (P=0.585) among the treatment groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				The mean percent reduction in LDL-P was -15.5% (P=0.006) with colesevelam. The mean percent change of total atherogenic lipoproteins (LDL-P, IDL-P and VLDL-P) was reduced by -14.2% in colesevelam-treated patients (P=0.011 vs placebo). Secondary: Not reported
Zieve et al.[39] (2007) GLOWS Colesevelam 3.75 g/day vs placebo	DB, PC, PG, PRO, RCT Patients diagnosed with type 2 diabetes, an A1C 7.0%-10.0%, and on a stable dose of a sulfonylurea and/or metformin as their only antidiabetic agent for ≥90 days	N=65 12 weeks	Primary: Change in HbA_{1c} from baseline Secondary: Changes in fructosamine levels, FPG levels, postprandial glucose level, meal glucose response (difference between pre and postprandial glucose levels) % change in lipids: LDL, TC, TG, apo AI and B	Primary: The change in HbA_{1c} from baseline to 12 weeks for the colesevelam group was -0.3% and for placebo 0.2%, for a treatment difference of 0.5% (P=0.007). For patients with a baseline HbA_{1c} ≥8.0, there was a greater difference in HbA_{1c}, -1.0%, after 12 weeks of treatment (P=0.002). The reduction in HbA_{1c} in the treatment groups did not differ based on oral antidiabetic treatment. Secondary: Significantly lower FPG was seen in the colesevelam group at weeks 4 and 8, (P=0.016, P=0.011), but not at week 12. Significantly lower fructosamine levels were seen in the colesevelam group at week 12 (P=0.011). Significantly lower postprandial glucose levels were seen in the colesevelam group at week 12 (P=0.026). No significant difference was seen in meal glucose response (P=0.195). Significantly lower lipid parameters, including LDL, TC, apo B and LDL particle concentration, were seen in the colesevelam group as compared to placebo (P=0.007, P=0.019, P=0.003, and P=0.037, respectively).
Bays et al.[40] (2008)	DB, PC, PG Patients aged 18-75	N=316 26 weeks	Primary: Mean change from baseline in HbA_{1c}	Primary: Colesevelam reduced mean HbA_{1c} by 0.39% compared to a 0.15% increase with placebo (P<001). The treatment difference was observed as

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Colesevelam 3.75 g/day vs placebo	years with inadequately controlled type 2 diabetes mellitus taking a stable dose of metformin monotherapy or metformin in combination with other oral anti-diabetic medications (sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, and/or meglitinides)		level Secondary: Mean change in HbA_{1c}, FPG, fructosamine levels, reduction in FPG >30 mg/dL or HbA_{1c} >0.7%, C-peptide, adiponectin, insulin levels, TC, LDL-C, HDL-C, non–HDL-C, TG, apo AI, apo B, TC:HDL-C, LDL-C:HDL-C, non–HDL-C:HDL-C, apo B:apo AI, hsCRP	early as week 6 (P<001). Secondary: Colesevelam added to metformin monotherapy reduced HbA_{1c} by -0.44% compared to an increase of 0.02% with placebo (P=0.002). Colesevelam added to metformin in combination with other oral anti-diabetic drugs reduced HbA_{1c} by -0.35% compared to an increase of 0.27% with placebo (P<001). Colesevelam reduced FPG compared to placebo (-13.9 mg/dL; P=0.01), with a significant treatment difference observed at week 6 (-20.8 mg/dL; P<001). Colesevelam reduced fructosamine level compared to placebo (-23.2 µmol/L; P<0.001), with a significant treatment difference reported by 6 weeks (-25.5 µmol/L; P<0.001). Altogether, 47.7% of patients in the colesevelam group and 35.5% of patients in the placebo group experienced either a reduction in FPG >30 mg/dL or HbA_{1c} >0.7% (P=0.03). A greater percentage of patients in the colesevelam group compared to placebo achieved a reduction in HbA_{1c} >0.7% (38.3 vs 20.4%, respectively; P<0.001). Colesevelam did not produce a significant treatment difference for C-peptide compared to placebo (-0.1 ng/mL; P=0.54). Colesevelam was not associated with a significant treatment difference in adiponectin (-0.3 µg/mL; P=0.52), insulin (-0.9 µIU/mL; P=0.51), or the HOMA index (-0.3; P=0.68). Compared to placebo, colesevelam reduced LDL-C, TC, non–HDL-C, and apo B levels (P<0.001 for all). There was no significant difference in HDL-C, TG or apo AI between the treatment groups. Treatment with colesevelam led to a greater reduction in hsCRP compared to placebo (-14.4%; P=0.02).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fonseca et al.[41] (2008) Colesevelam 3.75 g/day vs placebo	DB, PC, PG Adults with type 2 diabetes mellitus that were inadequately controlled on a stable dose of sulfonylurea alone or in combination with additional oral antidiabetes agents for at least 90 days	N=461 26 weeks	Primary: Mean change in HbA_{1c} Secondary: FPG, fructosamine, C-peptide, mean change in A1C for the sulfonylurea monotherapy and sulfonylurea combination therapy cohorts; percentage of patients achieving a reduction in FPG ≥30 mg/dl or A1C ≥0.7%; lipids, lipoproteins, and lipid and lipoprotein ratios; high-sensitivity C-reactive protein (hsCRP)	Primary: Colesevelam reduced HbA_{1c} by -0.32%, whereas placebo increased A1C by 0.23% (P<0.001). Secondary: Colesevelam significantly lowered FPG compared to placebo (-13.5 mg/dl; P<0.009), with a difference observed as early as 6 weeks (-13.7 mg/dl; P<0.001). A significant difference in fructosamine was reported with colesevelam compared to placebo (-21.4 µmol/l; P<0.001). There was no significant difference in C-peptide among the treatment groups (P=0.102). A similar effect on HbA_{1c} was observed in the sulfonylurea monotherapy group (-0.79%; P<0.001) and the sulfonylurea combination therapy (-0.42%; P<0.001) groups. A significantly greater percentage of patients in the colesevelam group achieved an HbA_{1c} reduction ≥0.7% compared to placebo (35.2 vs 16.5%, respectively; P<0.001). There was a significantly greater number of individuals in the colesevelam group who achieved either a reduction in HbA_{1c} ≥0.7% or a reduction in FPG ≥30 mg/dl compared to placebo (47.5 vs 32.1%, respectively; P=0.001). Significant treatment differences in LDL-C, non–HDL-C, TC, TG, apo AI, and apo B were observed after 26 weeks of treatment with colesevelam compared to placebo (P<0.001 for all). The least squares mean percent change in LDL-C from baseline to week 26 (LOCF) was -16.1% in the colesevelam group and 0.6% in the placebo group (-16.7%; P<0.001). There was no significant difference in HDL-C among the treatment groups (P=0.916). Significant treatment differences between colesevelam and placebo were reported in TC:HDL-C, LDL-C:HDL-C, non–HDL-C:HDL-C, and apo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				B:apo AI (P≤0.003 for all). There was no significant difference in hsCRP among the treatment groups (P=0.063).
Goldberg et al.[42] (2008) Colesevelam 3.75 g/day vs placebo	DB, MC, PC, PG, PRO Patients 18 to 75 years of age with type 2 diabetes not adequately controlled with insulin alone or in combination with oral antidiabetes agents (a biguanide, a biguanide sulfonylurea combination, a sulfonylurea, a thiazolidinedione, or a meglitinide)	N=287 16 Weeks	Primary: Mean change in HbA_{1c} Secondary: FPG, fructosamine, HbA_{1c}, percentage of patients achieving a reduction in FPG ≥30 mg/dl or HbA_{1c} ≥0.7%, C-peptide, TC, LDL-C, HDL-C, non–HDL-C, TG, apo AI, apo B, TC:HDL-C, LDL-C:HDL-C, non–HDL-C:HDL-C, apo B:apo AI, hsCRP	Primary: The mean change in the HbA_{1c} was -0.41% in the colesevelam group and 0.09% in the placebo group (P<.001). Secondary: There was no significant difference in FPG among the treatment groups (P=0.08). Colesevelam significantly decreased mean fructosamine levels compared to placebo (P<0.001). Approximately 48.6% of patients in the colesevelam group and 31.6% of patients in the placebo group had a reduction in the FPG level >30 mg/dL or a reduction in the HbA_{1c} of >0.7% (P=0.004). More than twice as many patients in the colesevelam-treated group had a reduction in the HbA_{1c} level of 0.7% or greater compared to those in the placebo group (34.7% vs 14.0%; P<001). However, no significant difference was noted in the percentage of individuals achieving a reduction in FPG level of 30 mg/dL or higher between the colesevelam treated and placebo groups at week 16. Mean change from baseline in C-peptide levels was similar in both groups. No significant least squares mean treatment difference was evident at week 16 LOCF (P=0.65). Colesevelam resulted in a significantly greater percentage reduction in LDL-C compared to placebo (P<0.001). The median percent change and median change in triglycerides for the colesevelam and placebo groups were 22.7 vs 0.3% and 32.0 vs -1.3 mg/dL, respectively (P<0.001 for both). Treatment with colesevelam significantly reduced apo B levels by 5.3% compared to placebo (P=0.04), but did not result in a significant increase in apo AI. Colesevelam led to a significant decrease in LDL-C:HDL-C and apo B:apo AI, but not in the TC:HDL-C or non– HDL-C:HDL-C.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was no significant difference in hsCRP among the treatment groups (P=0.13).
Goldfine et al.[43] (2010) Colesevelam 3.75 g/day vs placebo	ES, OL Patients 18 to 75 years of age with type 2 diabetes who were inadequately controlled on insulin-based therapy, metformin-based therapy or sulfonylurea-based therapy	N=509 52 weeks	Primary: Safety and tolerability Secondary: Change in HbA_{1c} and FPG, percent change in lipid and lipoprotein levels, change in lipid ratios, percentage of patients who achieved either a reduction in HbA_{1c} ≥0.7% or FPG ≥30 mg/dL, percentage of patients who achieved HbA_{1c} <7.0%	Primary: During the extension, 70.9% of patients experienced an adverse event. The majority (88.1%) were mild or moderate in severity. Fifty-six patients (11%) experienced a drug-related adverse event. Most drug-related adverse events were gastrointestinal (constipation and flatulence) in nature. Thirty five (6.9%) discontinued use due to an adverse event; 16 patients (3.1%) discontinued due to a drug-related adverse event. Fifty-four patients (10.6%) had a serious adverse drug reaction; only one was considered to be drug related; 12 patients (2.4%) discontinued the drug due to a serious event. Seventeen patients (3.3%) reported an episode of hypoglycemia; most were considered mild and two were considered moderate severity. Secondary: Treatment with colesevelam reduced the HbA_{1c} by -0.6% compared to -0.1% with placebo. At week 52, 14.1% of patients achieved HbA_{1c} <7.0% and 26.9% of patients had a reduction in HbA_{1c} of ≥0.7%. One-hundred-twenty-six patients (24.8%) achieved a reduction in FPG ≥30 mg/dl from baseline A at 52 weeks. Improvements in mean LDL-C with colesevelam were maintained. Both groups that received colesevelam had sustained effects over time. Baseline A had lipid and lipoprotein levels were nearly the same between colesevelam and placebo. By the conclusion of the double-masked study (baseline B), the individuals that received colesevelam had reduced mean levels of LDL-C, non-HDL-C, TC, and apo B, and increased mean levels of HDL-C, median levels of TG, and mean levels of apo AI relative to baseline (baseline A). For those who received colesevelam in the double-masked study, the lipid effects were maintained through the extension. For those who received colesevelam in the 52-week extension, mean LDL-C, non-HDL-C, TC and apo B levels decreased while mean HDL-C, median TG, and mean apo A-I levels increased.
Jialal et al.[44]	DB, PC, RCT (Pooled	N=1,018	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2009) Colesevelam 3.75 g/day vs placebo	analysis of 3 trials) Patients 18 to 75 years of age with type 2 diabetes who were inadequately controlled on insulin-based therapy, metformin-based therapy or sulfonylurea-based therapy	16 to 26 weeks	Glycemic and lipid effects Secondary: Lipid effects on those patients on concomitant statin treatment	Mean HbA_{1c} was significantly reduced with colesevelam compared to placebo (-0.54%; P<0.0001). Mean FPG was significantly reduced with colesevelam vs placebo (-15.1 mg/dL; P<0.0001). Colesevelam therapy resulted in a significant reduction in TC and LDL-C compared to placebo (-5.15 and -15.3%, respectively; P<0.0001). TG was significantly increased in the colesevelam group relative to placebo (15.0%; P<0.0001). Non-HDL-C and apo B were reduced with colesevelam vs placebo (-6.80 and -6.6%, respectively; P<0.0001). There was no significant effect on HDL-C between the two groups. Apo AI levels increased significantly in the colesevelam group relative to placebo (2.8%; P<0.0001). Median levels of hsCRP were significantly reduced with colesevelam relative to placebo treatment (-0.4 mg/L; P=0.0009). Secondary: Colesevelam treatment resulted in a significant decrease in HbA_{1c} (-0.45%; P<0.0001) and LDL-C (-15.6%; P<0.0001) in patients on statin therapy at baseline.
Bays (abstract).[45] (2011) Colesevelam 3.75 g/day vs placebo	Post hoc analysis of 3 DB, PC, RCT Patients with type 2 diabetes receiving metformin, sulfonylurea, or insulin monotherapy or combination therapy as part of their background therapy	N=696 26 weeks	Primary: Change in baseline HbA_{1c}, change in baseline lipid parameters Secondary: Safety	Primary: Compared to placebo, colesevelam significantly reduced HbA_{1c} and FPG (mean treatment difference, -0.5% and -15.7 mg/dL, respectively; *P*<0.001 for both). Compared to placebo, colesevelam significantly reduced LDL-C (mean treatment difference, -16.5%), TC (-5.8%), non-HDL-C (-8.2%), and apo B (-7.6%) (P<0.0001 for all). Median TG levels (median treatment difference, 12.8%; P<0.0001) and mean apo AI levels (mean treatment difference, 3.3%; P<0.0001) were increased with colesevelam. There was an increase in HDL-C with colesevelam, compared to placebo, that was not significant (P value not reported). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Colesevelam was generally well tolerated.
Aggarwal et al.[46] (2012) Colesevelam vs placebo	MA (8 clinical trials) Patients with type 2 diabetes	N=1,038 Duration not specified	Primary: Change in baseline FPG, HbA_{1c}, LDL-C, HDL-C, TG, and TC Secondary: Not reported	Primary: Compared to placebo, there was a significant reduction in FPG with colesevelam (OR, -0.302; 95% CI, -0.448 to -0.156). Compared to placebo, there was a significant reduction in HbA_{1c} with colesevelam (OR, -0.594; 95% CI, -0.747 to -0.442). Compared to placebo, there was a significant reduction in LDL-C with colesevelam (OR, -1.346; 95% CI, -2.411 to -0.279). Compared to placebo, there was an insignificant reduction in TC with colesevelam (OR, -0.487; 95% CI, -1.641 to 0.667). Compared to placebo, there was a significant increase in TG with colesevelam (OR, -0.300; 95% CI, 0.0130 to 0.587). Secondary: Not reported
Rigby et al.[47] (2010) Rosiglitazone 4 mg/day (QD or BID) and metformin (existing therapy) vs sitagliptin 100 mg QD and metformin (existing therapy) vs colesevelam 3.75	OL Patients 18 to 80 years of age with type 2 diabetes mellitus who had inadequate glycemic control (HbA_{1c} 6.5% to 10.0% on a stable regimen of metformin (1,500-2,550 mg daily), with LDL-C ≥60 mg/dL and TGs <500 mg/dL	N=169 16 weeks	Primary: Change in HbA_{1c} from baseline to week 16 Secondary: Change in HbA_{1c} from baseline to week eight, change in FPG and fasting insulin from baseline to weeks 8 and 16, change in 2-hour PPG and postprandial insulin after a meal tolerance test, change in lipid	Primary: At week 16, HbA_{1c} was reduced from baseline in all treatment groups (LS mean change from baseline): colesevelam -0.3% (95% CI, -0.52 to -0.02; P=0.031); rosiglitazone -0.6% (95% CI, -0.83 to -0.32; P<0.001); sitagliptin -0.4% (95% CI, -0.64 to -0.13; P=0.009). Secondary: At week eight, HbA_{1c} was reduced from baseline with colesevelam and sitagliptin (-0.3%; P=0.006 and -0.5%; P<0.001, respectively), but not with rosiglitazone (-0.2%; P=0.109). FPG was significantly reduced from baseline at week eight and week 16 in all treatment groups. The two-hour PPG levels were significantly reduced from baseline at week 16 in all treatment groups. There was no significant change in fasting insulin or 2-hour postprandial

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
g/day (QD or BID) and metformin (existing therapy)			parameters, percentage of participants who achieved an HbA_{1c} reduction >0.7% from baseline, percentage of participants who achieved HbA_{1c} <7.0%	insulin from baseline to week 16 in any treatment group. Insulin resistance did not change with colesevelam or sitagliptin; however, there was a significant reduction with rosiglitazone from baseline to week 16 (P=0.008). LDL-C was significantly reduced from baseline with colesevelam (-11.6%; P=0.001), but was significantly increased with both rosiglitazone (7.8%; P=0.040) and sitagliptin (7.7%; P=0.011). TC levels were unchanged from baseline with colesevelam and sitagliptin; however, they were significantly increased with rosiglitazone from baseline to week 16 (P=0.006). Non-HDL-C levels were unchanged with colesevelam; however, they were significantly increased with rosiglitazone (P=0.001) and sitagliptin (P=0.029). Median TG levels increased significantly from baseline with colesevelam (P<0.00l) and rosiglitazone (P<0.00l); however, sitagliptin did not significantly affect TG levels. HDL-C levels did not change significantly from baseline with any treatment. At week 16, 23.2% of patients in the colesevelam group, 48.l % of patients in the rosiglitazone group, and 34.5% of patients in the sitagliptin group achieved a reduction in HbA_{1c} of 0.7% or greater from baseline. In addition, 10 patients in the colesevelam group, 19 in the rosiglitazone group, and 15 in the sitagliptin group achieved HbA_{1c} <7.0%. The percentages of patients who had an adverse event were 61.4% in the colesevelam group, 46.4% in the rosiglitazone group, and 48.2% in the sitagliptin group. Most of the adverse events were mild to moderate in severity.

Drug regimen abbreviations: BID=twice daily, QD=once daily, TID=three times daily
Study abbreviations: DB=double-blind, ES=extension study, MA=meta-analysis, MC=multicenter, OL=open-label, PC=placebo-controlled, PG=parallel group, RCT=randomized controlled trial
Miscellaneous abbreviations: apo=apolipoprotein, CAD=coronary artery disease, CHD=coronary heart disease, CI=confidence interval, CRP=C-reactive protein, FPG=fasting plasma glucose, HbA_{1c}=glycosylated hemoglobin, HDL-C=high-density lipoprotein cholesterol, heFH=heterozygous familial hypercholesterolemia, HOMA=homeostasis model assessment, hsCRP=high-sensitivity C-reactive protein, IDL-P=intermediate-density lipoprotein particle, IL6=interleukin 6, LDL-C=low density lipoprotein cholesterol, LDL-P=low density lipoprotein particle, LOCF=last observation carried forward, MI=myocardial infarction, TC=total cholesterol, TG=triglycerides, VLDL-C=very low density lipoprotein cholesterol

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Bile Acid Sequestrants

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Cholestyramine	packet for oral suspension, powder for oral suspension	Questran®*†, Questran Light®*‡	$$$$$	$$$$
Colesevelam	packet for oral suspension, tablet	Welchol®	$$$$$	N/A
Colestipol	granules for oral suspension, packet for oral suspension, tablet	Colestid®*	$-$$$$$	$$$$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The bile acid sequestrants are approved as an adjunct to diet and exercise to reduce total cholesterol and low-density lipoprotein cholesterol (LDL-C). In addition, cholestyramine is indicated to relieve pruritus associated with partial biliary obstruction.[2-4,18] Colesevelam is also indicated for the treatment of type 2 diabetes mellitus. Bile acid sequestrants can lower LDL-C by 15 to 30% and raise high-density lipoprotein cholesterol (HDL-C) by 3 to 5%. Serum triglyceride levels may increase or remain unchanged.[1] Cholestyramine (regular and light) and colestipol are available in a generic formulation.

In general, therapeutic lifestyle changes, including diet, exercise, and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia. When LDL lowering is required, initial treatment with a statin, a bile acid sequestrant, or niacin is recommended. However, in general, the statins are considered first line therapy for decreasing LDL-C levels and are recommended in patients with established coronary heart disease or coronary heart disease equivalents. If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or ezetimibe should be considered. Statins are also considered first line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy.[1,5-7,13] American College of Cardiology/American Heart Association and Institute for Clinical Systems Improvement both released updated guidelines in 2013 which support initiating a statin in patients with established atherosclerotic cardiovascular disease (ASCVD). According to these recommendations, percent reduction in LDL-C is an indicator of response and adherence to therapy, but treating to a targeted level is not a primary goal.[8-9] Combination therapy can be considered on an individual basis, but studies of combination therapy have generally not shown benefit beyond statin monotherapy. Additionally, if patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available.[8-9]

Pruritus is a complication of primary biliary cirrhosis and bile acid sequestrants are the drug of choice for the treatment of this complication.[15] With regards to the use of bile acid sequestrants in the management of patients with type 2 diabetes, the American Association of Clinical Endocrinologists/American College of Endocrinology algorithm, notes that colesevelam reduces blood glucose levels in patient with type 2 diabetes, especially in patients not adequately controlled with metformin, a sulfonylurea, or insulin.[16] Guidelines do not give preference to one bile acid sequestrant over another.[1,5-17]

Clinical trials have demonstrated that the bile acid sequestrants can effectively lower LDL-C, non-HDL-C, and total cholesterol and positively impact other lipid/lipoprotein parameters.[20-47] There are few trials that directly compare the efficacy and safety of these agents. Treatment with cholestyramine led to a 19% reduction in the risk of fatal and non-fatal myocardial infarction in the Lipid Research Clinics Coronary Primary Prevention Trial.[35,36] Positive cardiovascular outcomes have also been detected in clinical trials which combined bile acid sequestrants with other lipid-modifying drugs.[1] The efficacy of colesevelam as monotherapy for the treatment of type 2 diabetes has not been assessed. Furthermore, the efficacy of combination therapy with colesevelam and a DPP-4 inhibitor and a thiazolidinediones has not been and has not been extensively evaluated for the treatment of type 2 diabetes.[3] When added to existing diabetic regimens, colesevelam lowered the glycosylated hemoglobin by 0.3 to 0.6% compared to the addition of placebo.[39-47]

There is insufficient evidence to support that one brand bile acid sequestrant is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand bile acid sequestrants within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand bile acid sequestrant is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. National Cholesterol Education Program (NCEP). Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, 2002 [guideline on the internet]. NCEP. 2002 [cited 2014 Dec]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
2. Questran® and Questran Light® [package insert]. Spring Valley, NY: Par Pharmaceutical Companies, Inc; 2005 May.
3. Welchol® [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2014 Jan.
4. Colestid® and Flavored Colestid® [package insert]. New York, NY: Pfizer Inc.; 2014 May.
5. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
6. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2017 Feb 3. doi: 10.4158/EP171764.GL..
7. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.
8. Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Institute for Clinical Systems Improvement. Lipid Management in Adults. Updated November 2013.
9. The American Heart Association requests that this document be cited as follows: Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000–000. DOI: 10.1161/01.cir.0000437738.63853.7a.
10. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519.
11. National Institute for Health and Clinical Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. National Institute for Health and Clinical Excellence; London (UK): 2014 [cited 2017 Jan]. Available from: https://www.nice.org.uk/Guidance/cg181.
12. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr;115(14):1948-67.
13. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106.
14. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
15. Lindor KD, Gershwin ME, Poupon R, et al. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
16. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 Executive Summary. Endocr Pract. 2016;22(1):84-113.

17. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. National Institute for Health and Clinical Excellence; London (UK): 2008 [cited 2017 Jan 6]. Available from: http://www.nice.org.uk/guidance/cg71.
18. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited May 2017]. Available from: http://online.factsandcomparisons.com.
19. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 May]. Available from: http://www.thomsonhc.com/.
20. Ballantyne C, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004 Nov;26(11):1855-64.
21. Eriksson M, Hådell K, Holme I, Walldius G, Kjellström T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med. 1998 May;243(5):373-80.
22. Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study of the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010;10(5):306-14.
23. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006;185:327-30.
24. Bays HE, Davidson M, Jones MR and Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity c-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15;97(8):1198-205.
25. Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AFH, Imholz BPM, Durrington PN, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010;32(4):615-25.
26. Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric patients with heterozygous familial hypercholesterolemia. J Pediatr 2010;156:231-6.e1-3.
27. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, Davidson MH. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001 Oct;76(10):971-82.
28. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 Oct;158(2):407-16.
29. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 Jun;24(6):467-74.
30. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr 1;110(5):352-60.
31. Romanelli RJ, Leahy A, Jukes T, Ye X, Qian C, and Ishisaka DY. Colesevelam in the treatment of hypercholesterolemia and hyperglycemia: a retrospective analysis from an ambulatory care medical network. Curr Med Res Opin. 2013;29(12):1747-1756.
32. Davidson MH, Rooney M, Pollock E, Drucker J, and Choy Y. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013;7(5):423-432.
33. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-40.
34. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
35. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.I. JAMA. 1984 Jan 20;251(3):351-64.
36. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984 Jan 20;251(3):365-74.
37. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes (abstract). Endocr Pract. 2010 Jul-Aug;16(4):629-40.
38. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in patients with type 2 diabetes. Atherosclerosis 2009;204:342-4.

39. Zieve FJ, Kalin MF, Schwartz S et al. Results of the Glucose-Lowering Effect of Welchol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in patients with type 2 diabetes. Clin Ther. 2007 Jan;29(1):74-83.
40. Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83.
41. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84.
42. Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40.
43. Goldfine AB, Fonseca VA, Jones MR, et al. Long-term Safety and Tolerability of Colesevelam HCl in Patients with Type 2 Diabetes. Horm Metab Res 2010;42:23-30.
44. Jialal I, Abby SL, Misir S, et al. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord 2009;7:255-8.
45. Bays HE. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical trials (abstract). Endocr Pract. 2011 Nov-Dec;17(6):933-8.
46. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol. 2012;59:198-205.
47. Rigby SP, Handelsman Y, Lai YL, et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Cholesterol Absorption Inhibitors
AHFS Class 240605
August 9, 2017

I. Overview

The antilipemic agents are categorized into six different American Hospital Formulary Service (AHFS) classes, including bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, HMG-CoA reductase inhibitors (statins), and miscellaneous antilipemic agents. The agents which make up these classes differ with regards to their Food and Drug Administration-approved indications, mechanism of action, efficacy, safety profiles, tolerability, and ease of use.

Ezetimibe is the only cholesterol absorption inhibitor that is currently available. It inhibits the intestinal absorption of cholesterol, which decreases the delivery of cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood. Ezetimibe can lower low-density lipoprotein cholesterol by about 18%.[1]

The cholesterol absorption inhibitors that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Ezetimibe is available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Cholesterol Absorption Inhibitors Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Ezetimibe	tablet	Zetia®*	Ezetimibe

PDL=Preferred Drug List.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the cholesterol absorption inhibitors are summarized in Table 2.

Table 2. Treatment Guidelines Using the Cholesterol Absorption Inhibitors

Clinical Guideline	Recommendation
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004)**[2]	• Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. • When low density lipoprotein cholesterol (LDL-C) lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard HMG-CoA reductase inhibitors (statins) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrants, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), especially in combination with statins.

Clinical Guideline	Recommendation
	• In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of coronary heart disease (CHD) risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u> • Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously). • Bile acid sequestrants (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrants and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u> • TLC indicated for all persons. • All LDL-C lowering drugs are effective. • If necessary to reach LDL-C goals, consider combined drug therapy.
National Cholesterol Education Program: **Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002)**[3]	<u>General recommendations</u> • With regards to TLC, higher dietary intakes of omega-3 fatty acids in the form of fatty fish or vegetable oils are an option for reducing risk for CHD. This recommendation is optional because the strength of evidence is only moderate at present. National Cholesterol Education Program supports the American Heart Association's recommendation that fish be included as part of a CHD risk reduction diet. Fish in general is low in saturated fat and may contain some cardioprotective omega-3 fatty acids. However, a dietary recommendation for a specific amount of omega-3 fatty acids is not made. • Initiate LDL lowering drug therapy with a statin, bile acid sequestrant, or nicotinic acid. • Statins should be considered as first line drugs when LDL lowering drugs are indicated to achieve LDL-C treatment goals. • After six weeks if LDL-C goal is not achieved, intensify LDL lowering therapy. Consider a higher dose of a statin or add a bile acid sequestrant or nicotinic acid. <u>Statins</u> • Statins should be considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. <u>Bile acid sequestrants</u> • Bile acid sequestrants should be considered as LDL lowering therapy for patients with moderate elevations in LDL-C, for younger patients with elevated LDL-C, for women with elevated LDL-C who are considering pregnancy and for patients

Clinical Guideline	Recommendation
	needing only modest reductions in LDL-C to achieve target goals. • Bile acid sequestrants should be considered in combination therapy with statins in patients with very high LDL-C levels. Nicotinic acid • Nicotinic acid should be considered as a therapeutic option for higher risk patients with atherogenic dyslipidemia. • Nicotinic acid should be considered as a single agent in higher risk patients with atherogenic dyslipidemia who do not have a substantial increase in LDL-C levels, and in combination therapy with other cholesterol lowering drugs in higher risk patients with atherogenic dyslipidemia combined with elevated LDL-C levels. • Nicotinic acid should be used with caution in patients with active liver disease, recent peptic ulcer, hyperuricemia, gout, and type 2 diabetes. • High doses of nicotinic acid (>3 g/day) generally should be avoided in patients with type 2 diabetes, although lower doses may effectively treat diabetic dyslipidemia without significantly worsening hyperglycemia. Fibric acid derivatives (fibrates) • Fibrates can be recommended for patients with very high TG to reduce risk for acute pancreatitis. • They also can be recommended for patients with dysbetalipoproteinemia (elevated beta-very LDL). • Fibrate therapy should be considered an option for treatment of patients with established CHD who have low levels of LDL-C and atherogenic dyslipidemia. • They also should be considered in combination with statin therapy in patients who have elevated LDL-C and atherogenic dyslipidemia. Omega-3 fatty acids • Omega-3 fatty acids (e.g., linolenic acid, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA]) have two potential uses. • In higher doses, DHA and EPA lower serum TGs by reducing hepatic secretion of TG-rich lipoproteins. They represent alternatives to fibrates or nicotinic acid for treatment of hypertriglyceridemia, particularly chylomicronemia. Doses of 3 to 12 g/day have been used depending on tolerance and severity of hypertriglyceridemia. • Recent trials also suggest that relatively high intakes of omega-3 fatty acids (1 to 2 g/day) in the form of fish, fish oils, or high-linolenic acid oils will reduce the risk for major coronary events in persons with established CHD. Omega-3 fatty acids can be a therapeutic option in secondary prevention (based on moderate evidence). The omega-3 fatty acids can be derived from either foods (omega-3 rich vegetable oils or fatty fish) or from fish-oil supplements. More definitive trials are required before strongly recommending relatively high intakes of omega-3 fatty acids (1 to 2 g/day) for either primary or secondary prevention.
American Association of Clinical Endocrinologists: **Guidelines for the management of dyslipidemia and prevention of atherosclerosis (2017)**[4]	Cholesterol Goals • For individuals at low risk (i.e., with no risk factors), an LDL-C goal of <130 mg/dL is recommended. • For individuals at moderate risk (i.e., with two or fewer risk factors and a calculated 10-year risk of <10%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or CKD stage 3 or 4 with no other risk factors, or individuals with two or more risk factors and a 10-year risk of 10 to 20%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at very high risk (i.e., with established or recent hospitalization for ACS, coronary, carotid or peripheral vascular disease; diabetes or CKD stage 3 or 4 with one or more risk factors; a calculated 10-year risk >20%; or heterozygous

Clinical Guideline	Recommendation
	familial hypercholesterolemia [HeFH]), an LDL-C goal of <70 mg/dL is recommended. • For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dL, or established clinical ASCVD in individuals with diabetes, CKD stage 3 or 4, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal of <55 mg/dL is recommended. • An LDL-C goal of <100 mg/dL is considered "acceptable" for children and adolescents, with 100 to 129 mg/dL considered "borderline" and 130 mg/dL or greater considered "high" (based on recommendations from the American Academy of Pediatrics). • HDL-C should be >40 mg/dL, but also as high as possible, primarily through the use of lifestyle interventions (e.g., weight loss, physical activity, and tobacco cessation), and if risk factors are present (e.g., borderline elevated LDL-C levels, a family history of premature ASCVD, or a personal history of ASCVD), also through the use of pharmacotherapy primarily focused on reducing LDL-C. • For most individuals, a non–HDL-C goal (total cholesterol minus HDL-C) 30 mg/dL higher than the individual's specific LDL-C goal is recommended. • For individuals at extreme risk, a non-HDL-C goal 25 mg/dL higher than the individual specific LDL-C goal is recommended. • For individuals at increased risk of ASCVD, including those with diabetes, an optimal apo B goal is <90 mg/dL, while for individuals with established ASCVD or diabetes plus one or more additional risk factor(s), an optimal apo B goal is <80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is <70 mg/dL. • TG goals of <150 mg/dL are recommended. <u>General Recommendations</u> • A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended primarily using lifestyle changes and patient education with pharmacotherapy as needed to achieve evidence based targets. • A reasonable and feasible approach to fitness therapy (i.e., exercise programs that include ≥30 minutes of moderate-intensity physical activity [consuming 4 to 7 kcal/min] four to six times weekly, with an expenditure of ≥200 kcal/day) is recommended; suggested activities include brisk walking, riding a stationary bike, water aerobics, cleaning/scrubbing, mowing the lawn, and sporting activities. • Daily physical activity goals can be met in a single session or in multiple sessions throughout the course of a day (10 minutes minimum per session); for some individuals, breaking activity up throughout the day may help improve adherence with physical activity programs. • In addition to aerobic activity, muscle-strengthening activity is recommended at least two days a week. • For adults, a reduced-calorie diet consisting of fruits and vegetables (combined ≥5 servings/day), grains (primarily whole grains), fish, and lean meats is recommended. • For adults, the intake of saturated fats, trans-fats, and cholesterol should be limited, while LDL-C-lowering macronutrient intake should include plant stanols/sterols (~2 g/ day) and soluble fiber (10 to 25 g/day). • Primary preventive nutrition consisting of healthy lifestyle habits is recommended in all healthy children. • Tobacco cessation should be strongly encouraged and facilitated. • In individuals at risk for ASCVD, aggressive lipid-modifying therapy is recommended to achieve appropriate LDL-C goals. <u>Statins</u>

Clinical Guideline	Recommendation
	• Statin therapy is recommended as the primary pharmacologic agent to achieve target LDLC goals on the basis of morbidity and mortality outcome trials. • For clinical decision making, mild elevations in blood glucose levels and/or an increased risk of new-onset T2DM associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction. • In individuals within high-risk and very high-risk categories, further lowering of LDL-C beyond established targets with statins results in additional ASCVD event reduction and may be considered. • Very high-risk individuals with established coronary, carotid, and peripheral vascular disease, or diabetes, who also have at least one additional risk factor, should be treated with statins to target a reduced LDL-C treatment goal of <70 mg/dL. • Extreme risk individuals should be treated with statins to target an even lower LDL-C treatment goal of <55 mg/dL. <u>Fibrates</u> • Fibrates should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). • Fibrates may improve ASCVD outcomes in primary and secondary prevention when TG concentrations are ≥200 mg/dL and HDL-C concentrations <40 mg/dL. <u>Omega-3 Fish Oil</u> • Prescription omega-3 oil, 2 to 4 g daily, should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). Dietary supplements are not FDA-approved for treatment of hypertriglyceridemia and generally are not recommended for this purpose. <u>Niacin</u> • Niacin therapy is recommended principally as an adjunct for reducing TG. • Niacin therapy should not be used in individuals aggressively treated with statin due to absence of additional benefits with well-controlled LDL-C. <u>Bile Acid Sequestrants</u> • Bile acid sequestrants may be considered for reducing LDL-C and apo B and modestly increasing HDL-C, but they may increase TG. <u>Cholesterol Absorption Inhibitors</u> • Ezetimibe may be considered as monotherapy in reducing LDL-C and apo B, especially in statin-intolerant individuals. • Ezetimibe can be used in combination with statins to further reduce both LDL-C and ASCVD risk. <u>PCSK9 Inhibitors</u> • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors should be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH. • PCSK9 inhibitors should be considered in patients with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals. <u>Combination Therapy</u> • Combination therapy of lipid-lowering agents should be considered when the LDL-C/non-HDL-C level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal.

Clinical Guideline	Recommendation

	Special Considerations: Women
	• Women should be evaluated for their ASCVD risk and be treated with pharmacotherapy if lifestyle intervention is insufficient.
	• Hormone replacement therapy for the treatment of dyslipidemia in postmenopausal women is not recommended.
	
	Special Considerations: Children and Adolescents
	• Pharmacotherapy is recommended for children and adolescents older than 10 years who do not respond sufficiently to lifestyle modification, and particularly for those satisfying the following criteria:
	  ○ LDL-C ≥190 mg/dL
	  ○ LDL-C ≥160 mg/dL and the presence of two or more cardiovascular risk factors, even after vigorous intervention
	  ○ Family history of premature ASCVD (before 55 years of age), or
	  ○ Having overweight, obesity, or other elements of the insulin resistance syndrome
	
	Follow-up and Monitoring
	• Reassess individuals' lipid status six weeks after therapy initiation and again at six-week intervals until the treatment goal is achieved.
	• While on stable lipid therapy, individuals should be tested at 6- to 12-month intervals.
	• While on stable lipid therapy, the specific interval of testing should depend on individual adherence to therapy and lipid profile consistency; if adherence is a concern or the lipid profile is unstable, the individual will probably benefit from more frequent assessment.
	• More frequent lipid status evaluation is recommended in situations such as deterioration of diabetes control, use of a new drug known to affect lipid levels, progression of atherothrombotic disease, considerable weight gain, unexpected adverse change in any lipid parameter, development of a new ASCVD risk factor, or convincing new clinical trial evidence or guidelines that suggest stricter lipid goals.
	• Liver transaminase levels should be measured before and three months after niacin or fibric acid treatment initiation because most liver abnormalities occur within 3 months of treatment initiation. Liver transaminase levels should be measured periodically thereafter (e.g., semiannually or annually).
	• Creatine kinase levels should be assessed and the statin discontinued, at least temporarily, when an individual reports clinically significant myalgias or muscle weakness on statin therapy.

American Heart Association/American College of Cardiology/National Heart, Lung, and Blood Institute: **American Heart Association/American College of Cardiology Guidelines for Secondary Prevention for Patients With Coronary and Other**	Lipid management • Goal: treatment with statin therapy; use statin therapy to achieve LDL-C of <100 mg/dL; for very high risk patients an LDL-C <70 mg/dL is reasonable; if TG are ≥200 mg/dL, non-HDL-C should be <130 mg/dL, whereas non-HDL-C <100 mg/dL for very high risk patients is reasonable. • Lifestyle modifications (daily physical activity and weight management) are strongly recommended for all patients. • In addition to lifestyle modifications, statin therapy should be prescribed in the absence of contraindications or documented adverse events. • An adequate dose of statin should be used that reduces LDL-C to <100 mg/dL and achieves ≥30% lowering of LDL-C. • Patients who have TG ≥200 mg/dL should be treated with statins to lower non-HDL-C to <130 mg/dL. • Patients who have TG >500 mg/dL should be started on fibrate therapy in addition to statin therapy to prevent acute pancreatitis.

Clinical Guideline	Recommendation
Atherosclerotic Vascular Disease: 2011 Update (2011)[5]	• If treatment with a statin does not achieve the goal selected for an individual patient, intensification of LDL-C-lowering drug therapy with a bile acid sequestrant or niacin is reasonable. • For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid sequestrants and/or niacin is reasonable. • It is reasonable to treat very high risk patients with statin therapy to lower LDL-C to <70 mg/dL. • In patients who are at very high risk and who have TG ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable. • The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with statins, bile acid sequestrants, and/or niacin. • For patients who continue to have an elevated non-HDL-C while on adequate statin therapy, niacin or fibrate therapy or fish oil may be reasonable. • For all patients, it may be reasonable to recommend omega-3 fatty acids from fist or fish oil capsules (1 g/day) for cardiovascular disease risk reduction.
Institute for Clinical Systems Improvement: **Lipid Management in Adults (2013)[6]**	<u>Clinical highlights</u> • Initiate a statin with patients who have established atherosclerotic cardiovascular disease (ASCVD). • Establish lipid goals based on risk level. • Instruct patients on healthy lifestyle and adjunctive measures. • Patient adherence with recommended therapy should be reinforced during scheduled follow-up. <u>Lifestyle modifications</u> • Patients who are overweight should be advised to reduce their caloric intake to achieve weight loss. • Patients should follow a dietary pattern that emphasizes fruits, vegetables, planetoids, fish, nuts, and legumes. • A diet low saturated and trans fats, and added sugars; and high in soluble fiber, with consideration given to adding 2 grams of plant sterol/stanol is recommended. <u>Statin treatment</u> • Initiate a statin regardless of LDL in patients with established ASCVD. • Initiate statin therapy in patients whose LDL is >100 and have a 10-year CHD risk ≥10% or diabetes. • Combination therapy can be considered on an individual basis, as no studies have shown a benefit to use at this time, and some studies have shown an increased risk of harm over statin monotherapy. <u>Monotherapy</u> • Reducing LDL-cholesterol (LDL-C) levels is the primary approach to lowering risk of CHD in both primary and secondary prevention. • Patients with risk factors for coronary heart disease but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of coronary heart disease. • Patients with a history of coronary disease (including unstable angina and acute myocardial infarction) often benefit from treatment with a statin. Studies have consistently shown a decrease in risk of death from coronary heart disease. • Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Statins also have a modest effect on reducing TG and increasing HDL-C. • Several trials with clinical endpoints support the use of statins in primary and secondary prevention. • If a patient is intolerant to a statin, patients should try another statin before ruling all of them out.

Clinical Guideline	Recommendation

	• Provide patient education regarding recognition and reporting of symptoms of myopathy during statin therapy.
	• If patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available.
	• Many crystalline (immediate-release) and sustained-release preparations of niacin are available over-the-counter. The extended-release preparation of niacin is a prescription drug. Niacin exerts favorable effects on all lipids and lipoproteins, and is good for mixed hyperlipidemia.
	• Long-term use of niacin is usually limited for many patients due to side effects (e.g., flushing and pruritus, liver toxicity, gastrointestinal complaints, etc).
	• Niacin should not be used in combination therapy with a statin, as two major trials have shown increased side effects without any reduction in cardiovascular outcomes.
	• Prior to initiating a fibric acid (gemfibrozil, fenofibrate, and fenofibrate micronized), lifestyle therapies should be intensified for moderately elevated TG. These include reduction of liquid sugar, all refined starches and saturated fat; increased moderate-intensity exercise; and weight reduction.
	• With fibric acids, TG are reduced 30 to 50%, HDL-C is increased 10 to 20%, TC is reduced 5 to 20% in patients without elevated TG, and the effect on LDL-C is variable. Fibric acids are good for severe hypertriglyceridemia (>500 mg/dL) in patients at risk for pancreatitis and for prevention of CHD (not proven for fenofibrate).
	• Myositis, cholelithiasis, and cholecystitis can occur with fibric acid, and caution should be exercised with a history of liver disease.
	• The long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown. Ezetimibe is associated with a LDL-C lowering of about 18%, and additive LDL-C lowering occurs when used in combination with a statin.
	• The short-term tolerability of ezetimibe is similar to placebo, and the long-term safety is unknown.
	• Bile acid sequestrants reduce LDL-C by 15 to 30% and TG may increase 15%; therefore, are these agents are useful for patients with moderately elevated LDL-C. The effects of the bile acid sequestrants are apparent within one week and maximum at two to three weeks. Bile acid sequestrants are good for combination therapy and are most potent with a statin.
	• Bile acid sequestrants are not systemically absorbed; therefore, side effects are limited to the gastrointestinal tract. In addition, drug interactions are minimized by taking other medications one hour before the sequestrant or four hours after.
	
	<u>Combination therapy</u>
	• It has become common practice to adjust medication therapy, including using combinations of medications, to achieve LDL-C goals. Common combinations include statin/fibrate, statin/niacin, and statin/ezetimibe.
	  o A fibrate is commonly added to a statin, which results in enhanced lowering of LDL-C, as well as a higher incidence of myopathy.
	  o Recent clinical trials have not demonstrated improved outcomes by increasing HDL-cholesterol with niacin among individuals with CVD and optimally controlled LDL-cholesterol on statins.
	  o The addition of ezetimibe to a statin significantly improves LDL-C over either agent alone. To date no large clinical trials have been completed evaluating this combination therapy compared to statin monotherapy on clinical vascular endpoints.
	• Studies of combination therapy have failed to show any benefit beyond statin monotherapy.
	• Combination therapy can be considered on an individual basis, but the additional cost, complexity, and risk for side effects argue against routine use until further

Clinical Guideline	Recommendation
	trials indicate what groups of patients might benefit. • There are negative trials of cholesterylester transfer protein inhibitors when used in combination with statins. • No randomized-controlled trials looking at clinical vascular endpoints are available for other agents such as fish oils or bile-acid sequestrants used in combination therapy. • A systematic review of combination therapy for dyslipidemia concluded that the limited evidence available suggests that combinations of lipid-lowering agents do not improve clinical outcomes more than statin monotherapy.
American College of Cardiology/American Heart Association Task Force on Practice Guidelines: **Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)**[7]	<u>Statin treatment</u> • The panel makes no recommendations for or against specific low density lipoprotein cholesterol (LDL-C) or non-high density lipoprotein cholesterol (HDL-C) targets for the primary or secondary prevention of arteriosclerotic cardiovascular disease (ASCVD). • High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. • In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated. • In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it. • Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity. • For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction. • For individuals ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences. • Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus. • High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a ≥7.5% estimated 10-year ASCVD risk unless contraindicated. • In adults with diabetes mellitus, who are <40 or >75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions, and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy. • Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk ≥7.5% should be treated with moderate- to high-intensity statin therapy. • It is reasonable to offer treatment with a moderate intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinica ASCVD or diabetes and an estimated 10-year ASCVD risk of 5.0 to <7.5%. • Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 to 189 mg/dL without clinical ASCVD or diabetes it is reasonable

Clinical Guideline	Recommendation

	for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment.
	• In adults with LDL-C <190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of patient preference.
	
	<u>Statin safety</u>
	• To maximize the safety of statins, selection of the appropriate statin and dose in men and nonpregnant/non-nursing women should be based on patient characteristics, level of ASCVD risk, and potential for adverse effects.
	• Moderate-intensity statin therapy should be used in individuals in whom high-intensity statin therapy would otherwise be recommended when characteristics predisposing them to statin associated adverse effects are present.
	• Characteristics predisposing individuals to statin adverse effects include, but are not limited to:
	  o Multiple or serious comorbidities, including impaired renal or hepatic function.
	  o History of previous statin intolerance or muscle disorders.
	  o Unexplained alanine transaminase elevations >3 times upper limit of normal.
	  o Patient characteristics or concomitant use of drugs affecting statin metabolism.
	  o >75 years of age.
	• Additional characteristics that may modify the decision to use higher statin intensities may include, but are not limited to:
	  o History of hemorrhagic stroke.
	  o Asian ancestry.
	• Creatine kinase should not be routinely measured in individuals receiving statin therapy.
	• Baseline measurement of creatinine kinase is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy.
	• During statin therapy, it is reasonable to measure creatinine kinase in individuals with muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or generalized fatigue.
	• Baseline measurement of hepatic transaminase levels should be performed before initiating statin therapy.
	• During statin therapy, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine or yellowing of the skin or sclera).
	• Decreasing the statin dose may be considered when two consecutive values of LDL-C levels are <40 mg/dL.
	• It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.
	• Individuals receiving statin therapy should be evaluated for new-onset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during statin therapy should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce their

Clinical Guideline	Recommendation

	risk of ASCVD events.
	• For individuals taking any dose of statins, it is reasonable to use caution in individuals >75 years of age, as well as in individuals that are taking concomitant medications that alter drug metabolism, taking multiple drugs, or taking drugs for conditions that require complex medication regimens (e.g., those who have undergone solid organ transplantation or are receiving treatment for human immunodeficiency virus (HIV). A review of the manufacturer's prescribing information may be useful before initiating any cholesterol-lowering drug).
	• It is reasonable to evaluate and treat muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated patients according to the following management algorithm:
	  o To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline before initiating statin therapy.
	  o If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly discontinue the statin and address the possibility of rhabdomyolysis by evaluating creatinine kinase, creatinine, and a urinalysis for myoglobinuria.
	• If mild to moderate muscle symptoms develop during statin therapy:
	  o Discontinue the statin until the symptoms can be evaluated.
	  o Evaluate the patient for other conditions that might increase the risk for muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases).
	  o If muscle symptoms resolve, and if no contraindication exists, give the patient the original or a lower dose of the same statin to establish a causal relationship between the muscle symptoms and statin therapy.
	  o If a causal relationship exists, discontinue the original statin. Once muscle symptoms resolve, use a low dose of a different statin.
	  o Once a low dose of a statin is tolerated, gradually increase the dose as tolerated.
	  o If, after two months without statin treatment, muscle symptoms or elevated creatinine kinase levels do not resolve completely, consider other causes of muscle symptoms listed above.
	  o If persistent muscle symptoms are determined to arise from a condition unrelated to statin therapy, or if the predisposing condition has been treated, resume statin therapy at the original dose.
	• For individuals presenting with a confusional state or memory impairment while on statin therapy, it may be reasonable to evaluate the patient for non-statin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy.
	
	<u>Monitoring and optimizing statin therapy</u>
	• Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. This should also include a fasting lipid panel performed within four to 12 weeks after initiation or dose adjustment, and every three to 12 months thereafter. Other safety measurements should be measured as clinically indicated.
	• The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated.
	• Individuals who have a less-than anticipated therapeutic response or are intolerant of the recommended intensity of statin therapy, the following should be performed:
	  o Reinforce medication adherence.
	  o Reinforce adherence to intensive lifestyle changes.

Clinical Guideline	Recommendation
	○ Exclude secondary causes of hyperlipidemia. • It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of statin therapy. Focus is on the intensity of the statin therapy. As an aid to monitoring: ○ High-intensity statin therapy generally results in an average LDL-C reduction of ≥50% from the untreated baseline; ○ Moderate-intensity statin therapy generally results in an average LDL-C reduction of 30 to <50% from the untreated baseline; ○ LDL-C levels and percent reduction are to be used only to assess response to therapy and adherence. They are not to be used as performance standards. • Individuals at higher ASCVD risk receiving the maximum tolerated intensity of statin therapy who continue to have a less than-anticipated therapeutic response, addition of a non-statin cholesterol-lowering drug(s) may be considered if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. • Higher-risk individuals include: ○ Individuals with clinical ASCVD <75 years of age. ○ Individuals with baseline LDL-C ≥190 mg/dL. ○ Individuals 40 to 75 years of age with diabetes mellitus. ○ Preference should be given to non-statin cholesterol-lowering drugs shown to reduce ASCVD events in controlled trials. • In individuals who are candidates for statin treatment but are completely statin intolerant, it is reasonable to use non-statin cholesterol lowering drugs that have been shown to reduce ASCVD events in controlled trials if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. <u>Non statin safety</u> • Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric acid should be obtained before initiating niacin, and again during up-titration to a maintenance dose and every six months thereafter. • Niacin should not be used if: ○ Hepatic transaminase elevations are higher than two to three times upper limit of normal. ○ Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout or unexplained abdominal pain or gastrointestinal symptoms occur. ○ New-onset atrial fibrillation or weight loss occurs. • In individuals with adverse effects from niacin, the potential for ASCVD benefits and the potential for adverse effects should be reconsidered before reinitiating niacin therapy. • To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to: ○ Start niacin at a low dose and titrate to a higher dose over a period of weeks as tolerated. ○ Take niacin with food or premedicating with aspirin 325 mg 30 minutes before niacin dosing to alleviate flushing symptoms. ○ If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over four to eight weeks, with the dose of extended release niacin increasing not more than weekly. ○ If immediate-release niacin is chosen, start at a dose of 100 mg three times daily and up-titrate to 3 g/day, divided into two or three doses. • Bile acid sequestrants should not be used in individuals with baseline fasting triglyceride levels ≥300 mg/dL or type III hyperlipoproteinemia, because severe triglyceride elevations might occur. • A fasting lipid panel should be obtained before bile acid sequestrants are initiated, three months after initiation, and every six to 12 months thereafter.

Clinical Guideline	Recommendation
	• It is reasonable to use bile acid sequestrants with caution if baseline triglyceride levels are 250 to 299 mg/dL, and evaluate a fasting lipid panel in four to six weeks after initiation. Discontinue the bile acid sequestrants if triglycerides exceed 400 mg/dL. • It is reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase levels as clinically indicated, and discontinue ezetimibe if persistent alanine transaminase elevations >3 times upper limit of normal occur. • Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis. • Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, are judged to outweigh the potential risk for adverse effect. • Renal status should be evaluated before fenofibrate initiation, within three months after initiation, and every six months thereafter. Assess renal safety with both a serum creatinine level and an estimated glomerular filtration rate based on creatinine. • Fenofibrate should not be used if moderate or severe renal impairment, defined as estimated glomerular filtration rate <30 mL/min per 1.73 m^2, is present. • If estimated glomerular filtration rate is between 30 and 59 mL/min per 1.73 m^2, the dose of fenofibrate should not exceed 54 mg/day. • If, during follow-up, the estimated glomerular filtration rate decreases persistently to ≤30 mL/min per 1.73 m^2, fenofibrate should be discontinued. • If eicosapentaenoic acid and/or docosahexanoic acid are used for the management of severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal disturbances, skin changes, and bleeding.

American College of Cardiology: **2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016)**[8]	Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention
	• These patients should be treated first with maximally tolerated statin intensity. If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <100 mg/dL), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response (<50% reduction in LDL-C and may consider LDL-C ≥100 mg/dL):
	  ○ Assess statin adherence.
	  ○ If an adherent patient has not been tried on a high-intensity statin, the dose should be increased to a high-intensity dose at this time.
	  ○ Intensify lifestyle modifications.
	  ○ Consider adding ezetimibe 10 mg daily as the first non-statin agent.
	  ○ A bile acid sequestrant (BAS) may be considered as a second-line agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL, but there is no evidence for benefit of BAS in addition to statins in this population.
	• If ASCVD patients without comorbidities, who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response with <50% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL):
	  ○ It is reasonable to consider the net benefit of alirocumab or evolocumab (in addition to or in place of ezetimibe) as a second step to achieve further LDL-C reduction.
	  ○ If a PCSK9 inhibitor is prescribed, clinicians should continue maximally tolerated statin and monitoring for adherence to medications and lifestyle,

Clinical Guideline	Recommendation

	side effects, and ongoing LDL-C response to therapy.
	
	Clinical ASCVD with comorbidities, on statin for secondary prevention
	• These patients should be treated first with maximally tolerated statin intensity.
	• If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <70 mg/dL or non–HDL-C <100 mg/dL for patients with diabetes), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response:
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	Clinical ASCVD and baseline LDL-C ≥190 mg/dL not due to secondary causes, on statin for secondary prevention
	• Patients with LDL-C ≥190 mg/dL are more likely to have heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia.
	• In patients who have a less-than-anticipated response on maximally tolerated statin therapy with <50% reduction in LDL-C (and may consider LDL-C ≥70 mg/dL):
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe (or BAS second line) first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	Adults Aged 40 to 75 Years Without ASCVD, but With Diabetes
	• In patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C despite adherence to lifestyle recommendations and moderate-intensity statin therapy, the recommended threshold for consideration of the net benefit of increasing to high-intensity statin therapy is failure to achieve 30 to <50% reduction in LDL-C (and may consider on -treatment LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL).
	• If a patient with diabetes and 10-year ASCVD risk <7.5% without high-risk features has a less-than-anticipated response, with <30% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL), additional clinical approaches may be warranted.
	• Ezetimibe is the preferred initial non-statin therapy due to tolerability, convenience, and single-tablet daily dose.
	• BAS may have a modest hypoglycemic effect that may be of benefit in some diabetic patients if fasting triglycerides are <300 mg/dL. BAS may also be considered if patients have an inadequate response to ezetimibe or if patients are ezetimibe intolerant.
	• In the absence of ASCVD or baseline LDL-C ≥190 mg/dL not due to secondary causes, the PCSK9 inhibitors do not have an established role for primary prevention of ASCVD in patients with diabetes.

National Institute for Health and Clinical	• Be aware that when deciding on lipid modification therapy for the prevention of

Clinical Guideline	Recommendation

Excellence: **Cardiovascular disease: risk assessment and reduction, including lipid modification (2014)**[9]
 	
Updated Sep 2016
	cardiovascular disease (CVD), drugs are preferred for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality
	• When a decision is made to prescribe a statin use a statin of high intensity and low acquisition cost.
	
	Lipid Measurement and Referral:
	• Measure both total and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk.
	• Before starting lipid modification therapy for the primary prevention of CVD, take at least one lipid sample to measure a full lipid profile. This should include measurement of total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglyceride concentrations. A fasting sample is not needed.
	• Use the clinical findings, lipid profile and family history to judge the likelihood of a familial lipid disorder rather than the use of strict lipid cut-off values alone.
	• Exclude possible common secondary causes of dyslipidemia (such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome) before referring for specialist review.
	• Consider the possibility of familial hypercholesterolemia if they have a total cholesterol concentration >7.5 mmol/L and a family history of premature coronary heart disease.
	• Arrange for specialist assessment of people with a total cholesterol concentration of more than 9.0 mmol/L or a non-HDL cholesterol concentration of more than 7.5 mmol/L even in the absence of a first-degree family history of premature coronary heart disease.
	• Refer for urgent specialist review if a person has a triglyceride concentration of more than 20 mmol/L that is not a result of excess alcohol or poor glycemic control.
	• In people with a triglyceride concentration between 10 and 20 mmol/L:
	  ○ Repeat the triglyceride measurement with a fasting test (after an interval of five days, but within two weeks) and
	  ○ Review for potential secondary causes of hyperlipidemia and
	  ○ See specialist advice if the triglyceride concentration remains above 10 mmol/L
	• In people with a triglyceride concentration between 4.5 and 9.9 mmol/L:
	  ○ Be aware that the CVD risk may be underestimated by risk assessment tools and
	  ○ Optimize the management of other CVD risk factors present and
	  ○ Seek specialist advice if non-HDL cholesterol concentration is more than 7.5 mmol/litre.
	
	Statins for the prevention of CVD:
	• The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.
	• Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidemia. Include smoking status, alcohol consumption, blood pressure, body mass index or other obesity measure, total cholesterol, non-HDL cholesterol, HDL cholesterol, triglyceride level, glycosylated hemoglobin (HbA_{1c}), renal function and estimated glomerular filtration rate (eGFR), transaminase levels, and thyroid stimulating hormone in the assessment.
	
	Statins for the Primary Prevention of CVD:

Clinical Guideline	Recommendation

	• Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimize the management of all other modifiable CVD risk factors if possible.
	• Recognize that people may need support to change their lifestyle. To help them do this, refer them to programs such as exercise referral schemes.
	• Offer people the opportunity to have their risk of CVD assessed again after they have tried to change their lifestyle.
	• If lifestyle modification is ineffective or inappropriate, offer statin treatment after risk assessment.
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	• For people 85 years or older consider atorvastatin 20 mg as statins may be of benefit in reducing the risk of non-fatal myocardial infarction. Be aware of factors that may make treatment inappropriate.
	
	<u>Statins for the Secondary Prevention of CVD</u>:
	• Start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower dose of atorvastatin if there are potential drug interactions, high risk of adverse effects, or patient preference.
	• Do not delay statin treatment in secondary prevention to manage modifiable risk factors.
	• If a person has acute coronary syndrome, do not delay statin treatment. Take a lipid sample on admission and about three months after the start of treatment.
	
	<u>Statins for the Primary Prevention of CVD for People with Type 1 Diabetes</u>:
	• Consider statin treatment for the primary prevention of CVD in all adults with type 1 diabetes.
	• Offer statin treatment for the primary prevention of CVD to adults with type 1 diabetes who are older than 40 years, have had diabetes for more than 10 years, have established nephropathy, or have other CVD risk factors.
	• Start treatment for adults with type 1 diabetes with atorvastatin 20 mg.
	
	<u>Statins for the Primary Prevention of CVD in People with Type 2 Diabetes</u>:
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people with type 2 diabetes who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	
	<u>Statins for People with CKD</u>:
	• Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
	  o Increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 mL/min/1.73 m^2 or more.
	  o Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73 m^2.
	
	<u>Follow-up of People Started on Statin Therapy</u>:
	• Measure total cholesterol, HDL cholesterol and non-HDL cholesterol in all people who have been started on high-intensity statin treatment at three months of treatment and aim for a greater than 40% reduction in non-HDL cholesterol.
	• If a greater than 40% reduction in non-HDL cholesterol is not achieved, discuss adherence to lifestyle modifications and drug therapy, timing of dose.
	  o Consider increasing the dose if started on less than atorvastatin 80 mg and the person is judged to be at higher risk because of comorbidities, risk score or using clinical judgement.

Clinical Guideline	Recommendation

	• Provide annual medication reviews for people taking statins.
	• Discuss with people who are stable on a low- or middle-intensity statin the likely benefits and potential risks of changing to a high-intensity statin when they have a medication review and agree with the person whether a change is needed.
	
	<u>Monitoring Statin Therapy for Adverse Effects</u>:
	• Advise people who are being treated with a statin that other drugs, some foods (e.g., grapefruit juice) and some supplements may interfere with statins and to always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements.
	• Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses.
	• Before offering a statin, ask the person if they have had persistent generalized unexplained muscle pain, whether associated or not with previous lipid-lowering therapy. If they have, measure creatine kinase levels.
	  o If creatine kinase levels are more than five times the upper limit of normal, re-measure creatine kinase after seven days. If creatine kinase levels are still five times the upper limit of normal, do not start statin treatment.
	  o If creatine kinase levels are raised but less than five times the upper limit of normal, start statin treatment at a lower dose.
	• Advise people who are being treated with a statin to seek medical advice if they develop muscle symptoms (pain, tenderness or weakness). If this occurs, measure creatine kinase.
	• If people report muscle pain or weakness while taking a statin, explore other possible causes of muscle pain or weakness and raised creatine kinase if they have previously tolerated statin therapy for more than three months.
	• Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin.
	• Measure baseline liver transaminase before starting a statin. Measure liver transaminase within three months of starting treatment and at 12 months, but not again unless clinically indicated.
	• Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than three times the upper limit of normal.
	• Do not stop statins because of an increase in blood glucose level or HbA_{1c}.
	• Statins are contraindicated in pregnancy and women of childbearing potential should be advised of the potential teratogenic risk of statins and to stop taking them if pregnancy is a possibility.
	  o Advise women planning pregnancy to stop taking statins three months before they attempt to conceive and to not restart them until breastfeeding is finished.
	
	<u>Intolerance to Statin Therapy</u>:
	• If a person is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose.
	• Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statins discuss the following possible strategies with them:
	  o stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin and
	  o reducing the dose within the same intensity group and
	  o changing the statin to a lower intensity group.
	• Seek specialist advice about options for treating people at high risk of CVD such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidemias, and those with CVD, who are intolerant to three different statins.

Clinical Guideline	Recommendation
	Fibrates for Preventing CVD: • Do not routinely offer fibrates for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Nicotinic Acid for Preventing CVD: • Do not offer nicotinic acid (niacin) for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Bile Acid Sequestrants (Anion Exchange Resins) for Preventing CVD: • Do not offer bile acid sequestrants for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer omega-3 fatty acid compounds for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. • Tell people that there is no evidence that omega-3 fatty acid compounds help to prevent CVD. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. Ezetimibe for Preventing CVD: • People with primary hypercholesterolemia should be considered for ezetimibe treatment.
American Heart Association: **Drug Therapy of High Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association (2007)**[10]	• For children meeting criteria for lipid-lowering drug therapy, a statin is recommended as first line treatment. The choice of statin is dependent upon preference but should be initiated at the lowest dose once daily, usually at bedtime. • For patients with high risk lipid abnormalities, the presence of additional risk factors or high risk conditions may reduce the recommended LDL level for initiation of drug therapy and the desired target LDL levels. Therapy may also be considered for initiation in patients <10 years of age. • Additional research regarding drug therapy of high risk lipid abnormalities in children is needed to evaluate the long term efficacy and safety and impact on the atherosclerotic disease process. • Niacin is rarely used to treat the pediatric population. • Given the reported poor tolerance, the potential for very serious adverse effects, and the limited available data, niacin cannot be routinely recommended but may be considered for selected patients. • This guideline does not contain recommendations regarding the use of omega-3 acid ethyl esters.
European Society of Cardiology and Other Societies: **Guidelines on Cardiovascular Disease Prevention in Clinical Practice**	Drugs • Currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g. ezetimibe) and, more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Response to all therapy varies widely among individuals and therefore monitoring the effect on LDL-C levels is

Clinical Guideline	Recommendation
(2016)[11]	recommended. • Statins, by reducing LDL-C, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions. • Statins should be used as the drugs of first choice in patients with hypercholesterolemia or combined hyperlipidemia. • Selective cholesterol absorption inhibitors are not usually used as monotherapy to decrease LDL-C concentrations, unless patients are intolerant to statins. They are recommended as combination therapy with statins in selected patients when a specific goal is not reached with the maximal tolerated dose of a statin. • Bile acid sequestrants also decrease TC and LDL-C, but are poorly tolerated and tend to increase plasma triglyceride concentrations. They are therefore not recommended for routine use in CVD prevention. • Fibrates and niacin are used primarily for triglyceride lowering and increasing HDL-C, while fish oils (n-3 fatty acids) are used for triglyceride lowering. Evidence supporting the use of these drugs for CVD event reduction is limited and, given the strong evidence favouring statins, routine use of these drugs in CVD prevention is not recommended. In order to prevent pancreatitis, when triglycerides are >10 mmol/L (>900 mg/dL) they must be reduced not only by drugs but also by restriction of alcohol, treatment of DM, withdrawal of estrogen therapy, etc. In those rare patients with severe primary hypertriglyceridaemia, specialist referral must be considered. • Regarding new therapies, recent data from phase I to III trials show that PCSK9 inhibitors sharply decrease LDL-C by up to 60%, either as monotherapy or in addition to the maximal statin dose. Whether this approach results in the predicted reduction in CV events is being addressed in large outcome trials; preliminary evidence suggests that this is the case. <u>Drug combinations</u> • Patients with dyslipidemia, particularly those with established cardiovascular disease, diabetes, or asymptomatic high risk patients, may not always reach treatment targets; therefore, combination treatment may be needed. • The only combination that has evidence of clinical benefit (one large RCT) is that of a statin combined with ezetimibe. Based on the relatively limited body of evidence, clinicians may restrict the use of this combination to patients at high or very-high risk of CVD. • Combinations of niacin and a statin increase HDL-C and decrease TG better than either drug used as monotherapy, but flushing is the main adverse event with niacin, which may affect compliance. • Fibrates, particularly fenofibrate, may be useful, not only for decreasing TG and increasing HDL-C, but can further lower LDL-C when administered in combination with a statin. • If target levels cannot be reached with maximal doses of lipid-lowering therapy or combination therapy, patients will still benefit from treatment to the extent to which dyslipidemia has been improved. In these patients, increased attention to other risk factors may help to reduce total risk.
American Heart Association/American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (2014)[12]**	• Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or transient ischemic attack (TIA) presumed to be of atherosclerotic origin and an LDL-C level ≥100mg/dL with or without evidence for other clinical ASCVD. • Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin, and LDL-C level <100 mg/dL, and no evidence for other clinical ASCVD. • Patients with ischemic stroke or TIA and other comorbid ASCVD should be otherwise managed according to the 2013 ACC/AHA cholesterol guidelines,

Clinical Guideline	Recommendation
	which include lifestyle modifications, dietary recommendations, and medication recommendations.
American Association of the Study of Liver Disease: **Primary Biliary Cirrhosis (2009)[13]** **Reaffirmed October 2014**	• Ursodeoxycholic acid therapy is the only Food and Drug Administration-approved agent for the treatment of primary biliary cirrhosis. It is currently supported by the most data and is recommended for use in appropriately selected patients who have abnormal liver chemistry. • Issues of patient compliance, development of superimposed liver disease, or coadministration with bile sequestrants (e.g., cholestyramine or colestipol) should be considered for patients with suboptimal response. • Pruritus is a complication of primary biliary cirrhosis and cholestyramine is the drug of choice for the treatment of this complication. Alternative treatments of pruritus include rifampin, opioid antagonists, and liver transplantation.

National Institute for Health and Clinical Excellence: **Identification and management of familial hypercholesterolaemia (2008)[14]**
 	
Last updated July 2016
	<u>Drug treatment in adults</u>
	• When offering lipid-modifying drug therapy to adults with familial hypercholesterolemia (FH), inform the patient that this treatment should be life-long.
	• Statins should be the initial treatment for all adults with FH.
	• Consider prescribing a high-intensity statin to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• Offer treatment with a statin with a low acquisition cost for adults with FH in whom the diagnosis is made after the age of 60 and who do not have coronary heart disease.
	• Ezetimibe monotherapy is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who would otherwise be initiated on statin therapy but who are unable to do so because of contraindications or intolerance to initial statin therapy.
	• Ezetimibe, coadministered with initial statin therapy, is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who have been initiated on statin therapy when:
	  ○ Serum total or LDL-C concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy AND
	  ○ Consideration is being given to changing from initial statin therapy to an alternative statin.
	• Prescribing of drug therapy for adults with homozygous FH should be undertaken within a specialist center.
	• Adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
	• Exercise caution when adding a fibrate or nicotinic acid to a statin because of the risk of muscle-related side effects (including rhabdomyolysis). Gemfibrozil and statins should not be used together.
	
	<u>Drug treatment in children and young people</u>
	• All children and young people diagnosed with, or being investigated for, a diagnosis of FH should have a referral to a specialist with expertise in FH in children and young people.
	• Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-

Clinical Guideline	Recommendation
	modifying drug therapy for a child or young person should take into account: ○ Their age. ○ The age of onset of coronary heart disease within the family. ○ And the presence of other cardiovascular risk factors, including LCL-C concentration. • When offering lipid-modifying drug therapy for children or young people, inform the child/young person and their parent/carer that this treatment should be life-long. • When the decision to initiate lipid-modifying drug therapy has been made in children and young people, statins should be the initial treatment. Healthcare professionals with expertise in FH in children and young people should choose a statin that is licensed for use in the appropriate age group. • In exceptional instances, for example, when there is a family history of coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering: ○ A higher dose of statin than is licensed for use in the age group and/or ○ More than one lipid-modifying drug therapy, and/or ○ Lipid-modifying drug therapy before the age of 10 years. • In children and young people with homozygous FH, LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis. • In children and young people with FH who are intolerant of statins, consider offering other lipid-modifying drug therapies capable of reducing LDL-C concentration (such as bile acid sequestrants [resins], fibrates or ezetimibe). Routine monitoring of growth and pubertal development in children and young people with FH is recommended.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the cholesterol absorption inhibitors are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Cholesterol Absorption Inhibitors[1]

Indication	Ezetimibe
Adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia	✔
Adjunctive therapy to diet for the reduction of elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary hyperlipidemia	✔
Administered in combination with a HMG-CoA reductase inhibitor (statin), as adjunctive therapy to diet for the reduction of elevated TC, LDL-C, apo B, and non-HDL-C in patients with primary hyperlipidemia	✔
Administered in combination with fenofibrate, as adjunctive therapy to diet for the reduction of elevated TC, LDL-C, apo B, and non-HDL-C in adult patients with mixed hyperlipidemia	✔
Administered in combination with simvastatin or atorvastatin for the reduction of elevated TC and LDL-C levels in patient with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments or if such treatments are unavailable	✔

IV. Pharmacokinetics

The pharmacokinetic parameters of the cholesterol absorption inhibitors are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Cholesterol Absorption Inhibitors[15]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Ezetimibe	Not reported	>90	Intestine (extensive; % not reported); Liver (% not reported)	Renal (11) Feces (78)	19 to 30

V. Drug Interactions

Major drug interactions with the cholesterol absorption inhibitors are listed in Table 5.

Table 5. Major Drug Interactions with the Cholesterol Absorption Inhibitors[15]

Generic Name(s)	Interaction	Mechanism
Ezetimibe	Clofibrate	Concurrent use of clofibrate and ezetimibe may result in increased risk of cholelithiasis.
Ezetimibe	Gemfibrozil	Concurrent use of ezetimibe and gemfibrozil may result in increased ezetimibe concentrations and an increased risk of cholelithiasis.

VI. Adverse Drug Events

The most common adverse drug events reported with the cholesterol absorption inhibitors are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Cholesterol Absorption Inhibitors[1]

Adverse Events	Ezetimibe
Central Nervous System	
Depression	✔
Dizziness	✔
Fatigue	1.6 to 2.4
Headache	✔
Paresthesia	✔
Dermatologic	
Erythema multiforme	✔
Rash	✔
Urticaria	✔
Gastrointestinal	
Abdominal pain	✔
Diarrhea	2.2 to 4.1
Nausea	✔
Hematologic	
Thrombocytopenia	✔
Laboratory Test Abnormalities	
Creatine phosphokinase increased	✔
Liver transaminases increased	1
Musculoskeletal	
Arthralgia	2.4 to 3.0
Back pain	2.3
Myalgia	3.2 to 3.7
Myopathy	✔

Adverse Events	Ezetimibe
Pain in extremities	1.9 to 2.7
Rhabdomyolysis	✔
Respiratory	
Coughing	2.3
Nasopharyngitis	3.3 to 3.7
Sinusitis	2.8
Upper respiratory tract infection	2.8 to 4.3
Other	
Anaphylaxis	✔
Angioedema	✔
Cholecystitis	✔
Cholelithiasis	✔
Hepatitis	✔
Hypersensitivity reactions	✔
Influenza	2.0 to 2.1
Pancreatitis	✔

✔ Percent not specified.
- Event not reported.

VII. Dosing and Administration

The usual dosing regimens for the cholesterol absorption inhibitors are listed in Table 7.

Table 7. Usual Dosing Regimens for the Cholesterol Absorption Inhibitors[1,16]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Ezetimibe	Homozygous familial hypercholesterolemia: Tablet: 10 mg once daily Homozygous sitosterolemia: Tablet: 10 mg once daily Primary hypercholesterolemia: Tablet: 10 mg	Heterozygous familial hypercholesterolemia in children ≥10 years of age: 10 mg once daily Safety and efficacy in children <10 years of age and in premenarchal girls have not been established.	Tablet: 10 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the cholesterol absorption inhibitors are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Cholesterol Absorption Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hypercholesterolemia				
Pearson et al.[17] (2006) Ezetimibe 10 mg QD Patients either received ezetimibe as monotherapy, in combination with a low-dose statin (20 mg/day or less of atorvastatin or its equivalent), or in combination with a high-dose statin (20 mg/day or more of atorvastatin or its equivalent).	Cohort, RETRO Men and women ≥18 years old who took ezetimibe for a minimum of two weeks	N=84 2 to 6 weeks	Primary: Change in fasting lipid profile at baseline to 2 to 6 weeks of ezetimibe therapy, clinical effectiveness results stratified by primary vs secondary prevention Secondary: Percentage of patients able to achieve their LDL-C target levels in accordance with their calculated Framingham risk category and defined Canadian guidelines and safety and tolerability	Primary: The mean reductions from baseline to two to six weeks of ezetimibe therapy were: TC 1.11mmol/L (16.5%), LDL-C level 1.01 mmol/L (22.3%), and ratio of TC:HDL 0.68 mmol/L (12.8%) (P<0.001 for all). The HDL-C level increased by 0.06 mmol/L (4.6%) from baseline to two to six weeks of ezetimibe therapy (P<0.001). Results were similar when stratified by primary (n=28) vs secondary (n=56) prevention. Among the primary prevention group, only the TC levels, LDL-C levels and TC:HDL ratio reductions were statistically significant (P<0.001). In the secondary prevention group, the reductions in TC levels, LDL-C levels, HDL-C levels and TC:HDL ratio all achieved statistical significance (P<0.001). LDL-C level reductions from baseline, stratified by drug regimen, were -1.03 mmol/L (-20.5%) for ezetimibe monotherapy, -1.19 mmol/L (-30.1%) for ezetimibe and a low-dose statin, and -0.95 mmol/L (-22.5%) for ezetimibe plus a high-dose statin (P<0.001 for ezetimibe monotherapy and ezetimibe plus a high-dose statin; P=0.0017 for ezetimibe plus a low-dose statin). Secondary: There were seven patients out of 34 (20.6%) in the ezetimibe monotherapy group, five out of 12 (41.6%) in the ezetimibe plus low-dose statin group and 18 out of 38 (47.4%) in the ezetimibe plus high-dose statin group who achieved previously unattainable target LDL-C levels. There were four patients who discontinued therapy due to treatment-related adverse event.
Jelesoff et al.[18] (2006) Ezetimibe 10	RETRO Patients who received ezetimibe as add-on	N=53 Not reported	Primary: TC, LDL-C, TG, HDL-C	Primary: The addition of ezetimibe resulted in reductions of 18, 25, and 17% (P<0.001) for TC, LDL-C, and TG, respectively. There were no significant differences in HDL-C (P value not significant).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day All patients were receiving niacin.	therapy to stable doses of niacin and other lipid medications		Secondary: Percent change in patients meeting NCEP ATP III treatment guidelines	Secondary: Thirteen percent of patients met goals prior to addition of ezetimibe while 45% of patients met goals following addition of ezetimibe (P<0.001).
Simons et al.[19] (2007) EASY Ezetimibe 10 mg QD All patients were receiving statin therapy.	OL Men and women from Australia, mean age 65.6 years, with CHD or diabetes mellitus who had already used ≥40 mg/day of a statin for ≥3 months with current TC of >4 mmol/L for existing CHD or >6.5 mmol/L for diabetes or >5.5 mmol/L for diabetes if HDL-C is <1.0 mmol/L	N=130 6 weeks	Primary: LDL reduction and percentage of patients who reached LDL goal of <2.5 mmol/L or <2.0 mmol/L and other lipid parameters Secondary: Not reported	Primary: The LDL-C levels after six weeks were reduced by 29% (95% CI, 25 to 34) in patients receiving ezetimibe. Goal LDL-C of <2.5 and <2.0 mmol/L were reached by 70 and 50% of patients receiving ezetimibe (95% CI, 59 to 79 and 39 to 60, respectively). TC and TG levels were reduced by 19 and 11%, respectively, in patients receiving ezetimibe (95% CI, -21 to -16 and -16 to -5). There were no significant changes in HDL-C observed (95% CI, 0 to 6). Secondary: Not reported
Bissonnette et al.[20] (2006) Ezetimibe 10 mg QD All patients were receiving statin therapy.	MC, OL, PRO Men and women ≥18 years of age with a confirmed diagnoses of hypercholesterolemia and elevated plasma LDL-C levels of ≥2.5 mmol/L for patients at high 10-year CAD risk, ≥3.5 mmol/L for patients at moderate 10-year CAD risk and ≥4.5 mmol/L for patients at low 10-year	N=953 6 weeks	Primary: Percentage of change in LDL-C during the 6 week treatment period Secondary: Percentage of patients who had achieved the recommended target LDL-C levels at the end of the 6 week treatment period	Primary: After six weeks of treatment with ezetimibe, a statistically significant mean reduction was observed in LDL-C (30.5%; P<0.001). Secondary: At six weeks, 674 patients (80.5%) achieved the recommended target LDL-C levels. After six weeks of treatment with ezetimibe, statistically significant mean reductions were observed in TC (20.8%), TG (10.1%), apo B (19.8%), and TC:HDL ratio (19.9%) (P<0.001). There were 50 mild, nonserious adverse events related to ezetimibe reported by 32 patients (3.4%). Frequently reported adverse events included constipation (0.7%), diarrhea (0.4%) and dizziness (0.4%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	CAD risk category, on a stable diet and statin regimen for ≥4 weeks before study entry		and the percentage of change in TC, TG, HDL-C, apo B and the TC:HDL-C ratio, safety and tolerability	
Pitsavos et al.[21] (2009) Ezetimibe 10 mg QD All patients were receiving high-dose statin therapy.	OL Patients with HeFH who were receiving treatment with high-dose statins (atorvastatin 80 mg, pravastatin 40 mg, rosuvastatin 40 mg, simvastatin 80 mg, fluvastatin 80 mg)	N=70 12 months	Primary: Lipid and lipoprotein parameters Secondary: Not reported	Primary: After three months, treatment with ezetimibe led to a significant reduction in TC (P<0.05), LDL-C (P<0.05), TG (P<0.05) and apo B (P<0.05), which persisted until 12 months. There were no significant changes in HDL-C, apoA, Lp(a), fibrinogen, or hsCRP with ezetimibe. Secondary: Not reported
Strony et al.[22] (2008) Ezetimibe 10 mg QD coadministered with either pravastatin 10 to 40 mg QD or simvastatin 10 to 80 mg QD	Pooled analysis of 2 ES, MC, OL Patients with primary hypercholesterolemia	N=795 12 to 15 months	Primary: Tolerability Secondary: LDL-C, HDL-C, TG, TC, and proportion of patients achieving LDL-C goal	Primary: Treatment-emergent adverse events were reported in 81% of patients receiving ezetimibe plus pravastatin (15 months) and in 84% of patients receiving ezetimibe plus simvastatin (12 months). The most commonly reported treatment-emergent adverse events were upper respiratory tract infection (18%), headache (11%), musculoskeletal pain (10%), arthralgia (10%), sinusitis (10%), abdominal pain (8%), bronchitis (6%), coughing (6%), nausea (6%), back pain (5%), myalgia (5%), chest pain (5%), and fatigue (5%) with ezetimibe plus pravastatin. The most commonly reported treatment-emergent adverse events were upper respiratory tract infection (19%), arthralgia (11 %), musculoskeletal pain (10%), headache (9%), back pain (8%), myalgia (8%), abdominal pain (7%), nausea (7%), pharyngitis (6%), coughing (5%), fatigue (5%), and urinary tract infection (19%) with ezetimibe plus simvastatin. During the ezetimibe plus pravastatin extension study, 7% experienced serious adverse events. During the ezetimibe plus simvastatin extension

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				study, serious adverse events were reported in 10% of patients. Life-threatening adverse events were reported in four patients in the ezetimibe plus simvastatin study. The incidence of newly reported adverse events did not increase over time in either study. In the ezetimibe plus pravastatin study, 1% of patients experienced increases in ALT/AST >3 X upper limit of normal, whereas this was not reported in the patients receiving ezetimibe plus simvastatin. Secondary: The mean LDL-C was reduced by 36.5 and 40.4% in the ezetimibe plus pravastatin and ezetimibe plus simvastatin studies, respectively. Similar reductions in TC and TG, and an increase in HDL-C, were achieved and maintained throughout the study period in both studies. In the ezetimibe plus pravastatin study, 85% of patients achieved their NCEP ATP III LDL-C goal and 80% of patients in the ezetimibe plus simvastatin study achieved their recommended goal.
Salen et al.[23] (2004) Ezetimibe 10 mg/day vs placebo	DB, MC, PC, RCT Patients ≥10 years of age with a diagnosis of sitosterolemia who had plasma sitosterol levels >0.12 mmol/L despite current treatment	N=37 8 weeks	Primary: Percent change from baseline in sitosterol concentration Secondary: Not reported	Primary: Ezetimibe resulted in a mean percent reduction in sitosterol of 21% (P<0.001) compared to a nonsignificant increase of 4% with placebo (P value not reported). The between-group difference in mean percent change in sitosterol was -25% (95% CI, -36.7 to -13.2; P<0.001). The reduction in plasma sitosterol during the DB period was progressive beginning at week two, with greater reduction from baseline observed at each subsequent visit. Secondary: Not reported
Lutjohann et al.[24] (2008) Ezetimibe 10 mg/day	ES Patients ≥10 years of age with a diagnosis of sitosterolemia who had plasma sitosterol levels	N=21 2 years	Primary: Percent change from baseline in sitosterol concentration	Primary: Ezetimibe resulted in significant mean percent reductions in sitosterol (-43.9%; 95% CI, -52.2 to -35.6; P<0.001). Progressively larger reductions in sitosterol were observed during the first 40 weeks of the OL extension phase, with maximal reductions achieved by 52 weeks of treatment (-47.6%; 95% CI, -50.9 to -44.4; P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	>0.12 mmol/L despite current treatment		Secondary: Percent change from baseline in campesterol concentration and LDL-C	Secondary: Ezetimibe resulted in significant mean reductions in campesterol (-50.8%; 95% CI, -58.8 to -42.7; P<0.001). Plasma concentrations progressively declined over the first 40 weeks of the trial reaching a maximum reduction of -53.6% (95% CI, -56.9 to -50.3) at week 52. After week 52, plasma concentrations remained generally stable for the remainder of the 104 week treatment period. Ezetimibe resulted in significant mean reductions from baseline in LDL-C (-13.1%; 95% CI, -25.0 to -1.2; P=0.032) at week 104.
Musliner et al.[25] (2008) Ezetimibe 30 mg/day vs placebo All patients continued on OL ezetimibe 10 mg/day for the duration of the trial.	DB, MC, PC, PG, RCT Patients ≥18 years of age with homozygous sitosterolemia who were taking ezetimibe 10 mg/day for ≥6 months prior to enrollment	N=27 26 weeks	Primary: Percent between-group change from baseline in sitosterol Secondary: Between-group changes in campesterol, lathosterol and achilles tendon thickness size; safety	Primary: Ezetimibe 40 mg/day resulted in a median percent change in sitosterol of 3.3 vs -10.0% with ezetimibe 10 mg/day, resulting in a between-group difference of 9.6% (P=0.180). Secondary: Median percent changes in campesterol were -9.7 vs -0.5% with ezetimibe 10 and 40 mg/day, resulting in a between-group difference of 7.6% (P=0.359). Median percent changes in lathosterol were 0.8 vs 1.1% with ezetimibe 40 and 10 mg/day, resulting in a between-group difference of 5.2% (P=0.701). Achilles tendon thickness increased slightly with ezetimibe 10 mg/day (2.2%) and remained unchanged with 40 mg/day, resulting in a nonsignificant between-group difference of -2.2% (P=0.404). Ezetimibe 40 mg/day was generally well tolerated. Laboratory safety parameters remained stable during the treatment period. No patients receiving ezetimibe in the trial experienced elevations in AST or AST greater than threefold or in creatinine kinase greater than tenfold the upper limit of normal.
Dujovne et al.[26] (2002)	DB, MC, PC, RCT Adult men and women	N=892 12 weeks	Primary: Percent change from baseline to	Primary: The ezetimibe group achieved a mean percent reduction from baseline to end point in the plasma concentration of LDL-C of 16.9% compared to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ezetimibe 10 mg QD vs placebo	aged ≥18 years with a diagnosis of primary hypercholesterolemia (LDL-C 130 to 250 mg/dL and plasma TG ≤350 mg/dL after adequate lipid-lowering drug washout)		end point in plasma concentration of direct LDL-C Secondary: Changes and percent changes from baseline in LDL-C (calculated via the Friedewald equation), TC, TG, and HDL-C at end point, changes from baseline HDL_2-C and HDL_3-C, apo AI, apo B, Lp(a) at end point, adverse events	0.4% in the placebo group (P<0.01). Secondary: There was a -17.68% compared to a 1.11% change in the calculated LDL-C from baseline in the ezetimibe and placebo groups, respectively (P<0.01). Ezetimibe also significantly decreased the apo B, TC, and TG as well as significantly increased HDL-C and HDL_3-C from baseline (P<0.01). However, there was no significant change in HDL_2-C and apo AI with ezetimibe compared to placebo (P=0.76 and P=0.50, respectively). Treatment-emergent adverse events occurred in 66% of patients taking ezetimibe and 63% of patients taking placebo. The most commonly reported adverse event in both treatment groups were upper respiratory tract infections and headache. The adverse events were considered to be mild to moderate and were similar between treatment groups.
Knopp et al.[27] (2003) Ezetimibe 10 mg QD vs placebo	DB, MC, PC, RCT Adult men and women aged ≥18 years with a diagnosis of primary hypercholesterolemia (calculated LDL-C 130 to 250 mg/dL and TG ≤350 mg/dL)	N=827 12 weeks	Primary: Percentage change from baseline to end point in the plasma concentration of direct LDL-C Secondary: Changes and percentage changes from baseline in LDL-C (calculated via the Friedewald equation), TC, TG, HDL-C at end point, HDL_2-C,	Primary: The mean plasma concentration of direct LDL-C from baseline to end point was 17.7% in the ezetimibe group compared to 0.8% in the placebo group (P<0.01). Secondary: Ezetimibe significantly decreased calculated LDL-C, apo B, TC and Lp(a) and significantly increased HDL-C and HDL_2-C (P≤0.01 for all). However, the change in HDL_3-C, apo AI, and TG from baseline did not result in significant differences between treatment groups (P=0.49, P=0.27, P=0.09). The percentage of patients reporting treatment-emergent adverse events was 61% in the ezetimibe group and 65% in the placebo group. No individual adverse event was prevalent in either group and all were considered mild to moderate in severity. Overall, the adverse event profiles were similar between both treatment groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			HDL_3-C, apo AI, apo B, Lp(a), adverse events	
Knopp et al.[28] (2003) Ezetimibe 10 mg QD vs placebo	Pooled analysis of 2 DB, MC, PC, RCT Men and women aged ≥18 years with a diagnosis of primary hypercholesterolemia (calculated LDL-C 130 to 250 mg/dL and plasma TG ≤350 mg/dL after adequate lipid-lowering drug washout)	N=1,719 12 weeks	Primary: Percentage change from baseline to end point in the plasma concentration of LDL-C Secondary: Percentage change from baseline in TC, TG, HDL-C, HDL_2-C, HDL_3-C, apo AI, apo B, Lp(a), adverse events	Primary: In the pooled analysis, LDL-C was reduced by a mean 18.2% from baseline in the ezetimibe group compared to an increase of 0.9% in the placebo group (P<0.01). Secondary: Ezetimibe significantly decreased TC, apo B, Lp(a), and TG and increased HDL-C compared to placebo (P<0.01). However, there were no statistically significant differences in the change of HDL_2-C, HDL_3-C and apo AI between ezetimibe and placebo (P=0.08, P=0.06, and P=0.26). The overall adverse event profiles were similar between the ezetimibe and placebo groups. Approximately 62% of patients in the ezetimibe group and 62% of patients in the placebo group reported adverse events. Also, there were no significant between-group differences in the laboratory or clinical safety parameters or gastrointestinal, liver, or muscle side effects.
Wierzbicki et al.[29] (2005) Ezetimibe 10 mg QD vs placebo	PRO Patients with refractory familial hyperlipidemia or intolerance to statin therapy	N=200 Not reported	Primary: LDL-C, TG, HDL-C, CRP, ALT Secondary: Not reported	Primary: Ezetimibe was associated with 7% reductions in LDL-C and 11% reductions in apo B. The proportion of patients achieving LDL-C <3 mmol/L increased from 6 to 18%. There were no significant differences in TG, HDL-C, CRP, or ALT. Secondary: Not reported
Kalogirou et al.[30] (2007) Ezetimibe 10 mg QD vs placebo	PRO Patients with primary dyslipidemia and no evidence of CHD, average 54 years of age, average BMI of 26.9 kg/m^2	N=50 16 weeks	Primary: Lipoprotein subfractions Secondary: Not reported	Primary: A significant median reduction in serum HDL-C concentration from 1.5 mmol/L (1.1 to 2.6) at baseline to 1.4 mmol/L (0.9 to 2.6) posttreatment was observed with ezetimibe treatment. The median change in HDL-C was -6.6% (P<0.001). A significant median reduction in TC from 7.1 mmol/L (4.9 to 11.1) at baseline to 5.8 mmol/L (4.3 to 8.9) posttreatment was observed with ezetimibe treatment. The median change in TC was -15.5% (-34.5 to 4.2%) with ezetimibe

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				treatment (P<0.001 vs placebo). Mean serum TG decreased from 1.5 mmol/L (0.6 to 4.28) at baseline to 1.4 mmol/L (0.6 to 3.2) posttreatment; a median percent change of 9.3% (-32.4 to 15.7%; P<0.05). Mean serum LDL-C levels significantly decreased from 3.8 mmol/L (2.5 to 7.3) at baseline to 3.2 mmol/L (1.8 to 5.4) posttreatment; a median percent change of –20.1% (-51.1 to 23.1%; P<0.001). Secondary: Not reported
Gonzalez-Ortiz et al.[31] (2006) Ezetimibe 10 mg QD vs placebo	DB, PC, RCT Obese, dyslipidemic patients 18 to 45 years old	N=12 90 days	Primary: TC, LDL-C Secondary: HDL-C, TG, VLDL-C	Primary: Ezetimibe-treated patients compared to placebo-treated patients had decreased TC (6.0 vs 4.2 mmol/L; P=0.011) and LDL-C (4.0 vs 2.2 mmol/L; P=0.003) without affecting insulin sensitivity. Secondary: There were no differences in HDL-C, TG, and VLDL-C (P values not significant).
Pearson et al.[32] (2005) Ezetimibe 10 mg QD vs placebo Patients in both groups continued to receive their current dose of statin therapy.	DB, MC, PC, PG Hypercholesterolemic patients ≥18 years of age with LDL-C levels exceeding NCEP ATP III goals while taking a stable, approved dose of any statin, following a cholesterol-lowering diet for ≥6 weeks	N=3,030 6 weeks	Primary: Percent reduction in LDL-C level from baseline after 6 weeks of DB treatment Secondary: Percentage of patients who achieved NCEP ATP III target LDL-C levels in the total population and by NCEP ATP III risk categories	Primary: Ezetimibe added to a statin significantly reduced mean LDL-C levels by an additional 25.8% compared to a reduction of 2.7% with the addition of placebo to statin (95% CI, -24.4 to -21.7%; P<0.001). Secondary: The addition of ezetimibe to statin resulted in an additional 23.8 to 25.7% reduction in LDL-C in all NCEP ATP III risk categories. Treatment differences were -24.0, -19.7, and -19.9% in the CHD or CHD risk equivalent, multiple risk factors, or <2 risk factors groups, respectively (P<0.001 ezetimibe vs placebo for each risk category). No significant differences were found according to age, sex, or race category (P>0.05).
Bays et al.[33] (2006)	DB, MC, PC, PG, RCT	N=86	Primary: Mean percent	Primary: After six weeks of treatment, ezetimibe produced a mean percent decrease

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ezetimibe 10 mg QD vs placebo All patients were receiving colesevelam 3.8 QD.	Men and women with primary hypercholesterolemia	4 to 8 weeks washout period and 6 weeks of treatment	change in LDL-C, mean absolute and mean percent change in HDL-C, non-HDL-C, TC, apo AI and apo B, and median absolute and percent changes in TG and hsCRP from baseline to end of treatment Secondary: Safety and tolerability	in LDL-C of 32.3 vs 21.4% with placebo (P<0.0001). Ezetimibe was significantly more effective placebo at producing mean percent reductions in TC, non-HDL-C, apo B and increases in apo AI (P<0.005 for all). Neither treatment resulted in significant changes in median TG levels compared to baseline (P value not significant). Secondary: Both treatment groups were safe and generally well tolerated.
Blagden et al.[34] (2007) Ezetimibe 10 mg QD vs placebo All patients received atorvastatin 10 mg QD.	DB, MC, PC, RCT Men and women with primary hypercholesterolemia and CHD	N=148 6 weeks	Primary: Mean percentage change in LDL-C from baseline to study end point Secondary: Percentage of patients achieving the new JBS 2 recommended LDL-C goal of <2 mmol/L and the JBS 2 minimum treatment standard of <3 mmol/L, percentage of patients reaching LDL-C targets, safety and tolerability	Primary: From baseline to week six, ezetimibe and atorvastatin provided significantly greater reductions in adjusted mean LDL-C level compared to atorvastatin monotherapy, (-50.5 vs -36.5%; P<0.0001), equating to an additional 14.1% reduction (95% CI, -17.90 to -10.19). Secondary: A significantly higher proportion of patients on ezetimibe and atorvastatin achieved the new JBS 2 recommended LDL-C goal of <2 mmol/L and the JBS 2 minimum treatment standard of <3 mmol/L compared to atorvastatin monotherapy (62 vs 12%; P<0.0001 and 93 vs 79%, respectively). Patients receiving ezetimibe and atorvastatin were 12 times more likely to reach LDL-C targets (OR, 12.1; 95% CI, 5.8 to 25.1; P<0.0001) compared to patients receiving atorvastatin monotherapy. Clinical chemistry profiles and the incidence of adverse events were similar in both groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Rodney et al.[35] (2006) Ezetimibe 10 mg QD vs placebo All patients received simvastatin 20 mg/day.	DB, MC, PC, PG, RCT African-American patients with LDL-C ≥145 mg/dL but ≤250 mg/dL, TG ≤350 mg/dL	N=247 12 weeks	Primary: Mean change from baseline in LDL-C level, total cholesterol, TG, HDL-C, non-HDL-C, apo B Secondary: Not reported	Primary: Patients receiving ezetimibe experienced a statistically significant LDL-C reduction from baseline compared to patients receiving placebo (45.6 vs 28.3%; P≤0.01). Patients receiving ezetimibe experienced a statistically significant reduction in TC from baseline compared to patients receiving placebo (33 vs 21%; P≤0.01). Patients receiving ezetimibe experienced a statistically significant TG reduction from baseline compared patients receiving placebo (22 vs 15%; P≤0.01). Patients receiving ezetimibe experienced a statistically significant non-HDL-C reduction from baseline compared to patients receiving placebo (42 vs 26%; P≤0.01). Patients receiving ezetimibe experienced a statistically significant apo B reduction from baseline compared to patients receiving placebo (38 vs 25%; P≤0.01). There was no difference in the change of HDL-C level from baseline between the two groups (~1-2% increase in each group). There was no statistically significant difference in side effects between the two groups. Secondary: Not reported
Patel et al.[36] (2006) Ezetimibe 10 mg vs placebo	DB, MC, PC, PG, RCT Men and women aged 18 to 75 years with primary hypercholesterolemia (LDL ≥3.3 mmol/L and ≤4.9 mmol/L, TG	N=153 6 weeks	Primary: Mean change in LDL-C level from baseline to 6 weeks, proportion of patients who reached an LDL-C goal of <3 mmol/L	Primary: At six weeks, patients receiving ezetimibe had a mean LDL-C reduction of 14.6% (95% CI, 10.1 to 19.1). At six weeks, a greater number of patients receiving ezetimibe reached an LDL-C goal <3 mmol/L compared to patients receiving placebo (93 vs 75%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
All patients received simvastatin.	<3.99 mmol/L) and documented CHD ≥3 months prior to baseline who were not receiving pharmacologic lipid management therapy		at end point Secondary: Changes in serum TC, TG and HDL-C levels, safety and tolerability	Secondary: At six weeks, there was a significant additional reduction in TC of 0.69 mmol/L in patients receiving ezetimibe compared to patients receiving placebo (95% CI, 0.48 to 0.90; P<0.0001). There was a 20.4% reduction in TG levels in the ezetimibe group compared to a 12.4% reduction in the placebo group (P=0.06). Baseline HDL-C levels increased by 6% in both treatment groups. In the ezetimibe group, 40% of patients had at least one treatment-emergent adverse event compared to 25% in the placebo group. The overall incidence of adverse events were not significant among the two groups (P=0.07). Two patients in the ezetimibe group and one patient in the placebo group experienced a serious adverse event unrelated to the study medications.
Landry et al.[37] (2006) Ezetimibe 10 mg QD vs placebo All patients received simvastatin.	MC, PC, RCT Men and women ≥18 years of age, patients on predialysis with creatinine level ≥1.7 mg/dL, hemodialysis, or peritoneal dialysis	N=203 6 months	Primary: LDL-C, TC, non-HDL-C, HDL-C, TG, apo B, apo AI Secondary: Tolerability and safety	Primary: Both groups had statistically reduced LDL-C at one, three, and six months compared to baseline (P<0.0001). The addition of ezetimibe to simvastatin was associated with 27, 26, and 21% reductions in LDL-C at one, three, and six months, respectively. The addition of ezetimibe to simvastatin was associated with 16, 16, and 14% reductions in TC at one, three, and six months, respectively. The addition of ezetimibe to simvastatin was associated with 24, 25, and 19% reductions in non-HDL-C at one, three, and six months, respectively. The addition of ezetimibe to simvastatin was associated with 15, 14, and 12% reductions in apo B at one, three, and six months, respectively. There were no significant effects in HDL-C, TG, or apo AI (P value not significant) except for 7% increase of HDL-C at three months (P=0.02). Secondary: There were no significant differences in muscle pain, muscle weakness, abdominal discomfort, nausea, constipation, or appetite loss between groups (P value not significant). More patients on ezetimibe reported diarrhea (27 vs 12%; P=0.009).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were no significant differences in CK levels or abnormal hepatic transaminase levels.
Bays et al.[38] (2008) Ezetimibe 10 mg QD vs placebo All patients received simvastatin 80 mg QD.	ES Patients ≥18 years of age with primary hypercholesterolemia	N=768 48 weeks	Primary: Safety and tolerability Secondary: Not reported	Primary: In general, combination therapy did not substantively differ from simvastatin with respect to total adverse events (73 vs 69%), treatment related adverse events (13.5 vs 11.4%), treatment related serious adverse events (1 vs 0%), discontinuations due to treatment related adverse events (2.8 vs 2.6%) or discontinuations due to treatment-related serious adverse events (1 vs 0%). Combination therapy had a slightly higher rate of serious adverse events (5.2 vs 2.6%) and discontinuations due to adverse events (4.5 vs 2.6%) compared to simvastatin (P>0.20). Based on investigator assessment of causality, rates were similar between the treatments. There are no remarkable observations of between-treatment group differences whether or not they are related to a specific tissue or body system. In general, combination therapy did not differ from simvastatin with respect to total laboratory adverse events (12 vs 12%), treatment related laboratory adverse events (6.2 vs 5.3%), total laboratory serious adverse events (0 vs 0%), treatment related laboratory serious adverse events (0 vs 0%) or discontinuations due to laboratory serious adverse events (0 vs 0%). Secondary: Not reported
van der Graaf et al.[39] (2008) Ezetimibe 10 mg QD vs	DB, MC, PC, RCT Patients 10 to 17 years of age with heFH	N=248 53 weeks	Primary: Percent change from baseline in LDL-C after six weeks Secondary: TC, HDL-C, TG,	Primary: After six weeks of therapy, ezetimibe lowered LDL-C by -49.5% compared to -34.4% with placebo (P<0.01). Secondary: After six weeks of therapy, ezetimibe was more effective compared to placebo in lowering TC (-38.2 vs 26.3%; P<0.01), non-HDL-C (-46.8 vs -32.7%; P<0.01), and apo B (-38.9 vs -26.7%; P<0.01). There was no

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo All patients received simvastatin 10 to 40 mg QD			non-HDL-C, apo B after six weeks, 33 weeks and 53 weeks, percentage of patients achieving LDL-C goals	significant difference in HDL-C (P<0.95) or TG (P<0.48) among the treatment groups. After 33 weeks of therapy, ezetimibe was more effective compared to placebo in lowering LDL-C (-54 vs 38.1%; P<0.01), TC (-42.5 vs 29.3%; P<0.01), non-HDL-C (-51.3 vs -35.7%; P<0.01), TG (-20 vs -13.4%; P<0.01) and apo B (-42.6 vs -27.9%; P<0.01). There was no significant difference in HDL-C (P=0.58) among the treatment groups. The percentage of patients achieving the American Academy of Pediatrics acceptable LDL-C goal of <130 mg/dL and ideal LDL-C goal of <110 mg/dL was significantly higher with ezetimibe (77 and 63%, respectively) compared to placebo (53 and 27%, respectively; P<0.01) in patients receiving simvastatin 40 mg/day. After 53 weeks of therapy, the mean percent change in LDL-C in the overall population was -49.1% from baseline. Mean percent changes were -38.5% in TC, -46.4% in non-HDL-C, and median percent changes of -16.6% were observed in TG. The HDL-C levels were 3.3% above baseline levels at trial end.
Masana et al.[40] (2005) Ezetimibe 10 mg QD vs placebo All patients received simvastatin 10 mg/day, titrated up to 80 mg/day.	DB, ES, MC, RCT Patients with primary hypercholesterolemia ≥18 years of age, currently taking a stable daily dose of a statin ≥6 weeks, with LDL-C above the NCEP ATP II guideline target level, TG <350 mg/dL	N=355 48 weeks	Primary: Percent change from baseline in LDL-C between the study groups at week 12 Secondary: Percent change from baseline in total cholesterol, TG, HDL-C, non-HDL-C, the ratios of LDL-C:HDL-C and TC:HDL-C at 12 weeks	Primary: At week 12, patients receiving ezetimibe experienced a statistically significant 27% reduction in LDL-C compared to patients receiving placebo (P<0.001). The benefit was maintained up to week 48 of the study. Secondary: At week 12, patients receiving ezetimibe experienced a statistically significant reduction in total cholesterol, TG, non-HDL-C, ratios of LDL-C:HDL-C, and TC:HDL-C, compared to patients receiving placebo (P<0.001). At week 12, patients receiving ezetimibe experienced a non-significant 2.6% increase in HDL-C compared to patients receiving placebo (P=0.07). Treatment-related adverse effects were similar between the two treatments (17 and 19%, respectively).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There were no cases of rhabdomyolysis or myopathy during the study.
Gagné et al.[41] (2002) Ezetimibe 10 mg QD vs placebo All patients were receiving statin therapy.	DB, MC, PC, RCT Adults aged ≥18 years, currently on a stable daily dose of a statin for ≥6 weeks, must have been previously instructed on a cholesterol-lowering diet, LDL-C at or above recommended target level for patient's risk category (<160 mg/dL for patients without CHD and ≤1 risk factor, <130 mg/dL for patients without CHD and ≥2 risk factors, ≤100 mg/dL for patients with established but stable CHD or CHD-equivalent disease)	N=769 8 weeks	Primary: Mean percentage change in LDL-C from baseline to end point Secondary: Percentage of patients who achieved NCEP ATP II target levels for LDL-C, HDL-C, TC, TG, adverse events	Primary: There was an additional LDL-C reduction of 25.1% in patients receiving ezetimibe therapy compared to a reduction of 3.7% in patients receiving placebo (P<0.001 for between-group differences). Secondary: Including patients who were technically at LDL-C goal at baseline, 75.5% of patients taking ezetimibe plus statin achieved the prespecified NCEP ATP II target LDL-C levels at end point compared to 27.3% of patients taking placebo plus statin (OR, 19.6; P<0.001). For those patients who were not at target LDL-C levels at baseline, 71.5 vs 18.9% of patients taking ezetimibe and placebo, respectively, achieved target LDL-C goals. HDL-C was increased by 2.7% compared to an increase of 1.0% in patients taking ezetimibe and placebo, respectively (P<0.05). TG decreased by 14.0 and 2.9%, respectively (P<0.001). TC was also improved significantly with coadministration of ezetimibe compared to placebo (P<0.001). The overall incidence of treatment-related adverse events was similar between both groups (21 vs 17%).
Denke et al.[42] (2006) Ezetimibe 10 mg QD vs placebo All patients were	DB, MC, PC, PG, RCT Men and women ≥18 years of age with diabetes, metabolic syndrome without diabetes, or neither disorder who had LDL-C levels exceeding the NCEP ATP III goals who	N=3,030 6 weeks	Primary: LDL-C reduction and additional lipid parameters, safety and tolerability Secondary: Not reported	Primary: After six weeks of treatment, the addition of ezetimibe to ongoing statin therapy reduced LDL-C levels in patients with diabetes by 28%, metabolic syndrome by 24%, or elevated LDL-C levels without diabetes or the metabolic syndrome by 26%, compared to a 3% reduction in the placebo group (P<0.001 for all). TG and HDL-C levels were significantly reduced in patients with diabetes and metabolic syndrome when ezetimibe was added to statin therapy compared to placebo (P<0.002). Non-HDL levels, TC, apo B:apo AI ratio, and CRP levels improved significantly in patients with diabetes and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
receiving statin therapy.	were taking a stable, approved dose of any statin, had been following a cholesterol -lowering diet for ≥6 weeks prior to study entry with TG levels ≤350 mg/dL			patients with elevated LDL-C levels without diabetes or metabolic syndrome when ezetimibe was added to statin therapy compared to placebo. Drug-related adverse events occurred in 5.2% in the placebo group and 5.1% in the ezetimibe group. Drug-related adverse events that led to drug discontinuation occurred in 1.6% in the placebo group and 0.9% in the ezetimibe group. There were no significant differences between the two groups in elevation of ALT, AST or in muscle CK beyond predefined limits. Secondary: Not reported
Pearson et al.[43] (2006) Ezetimibe 10 mg QD vs placebo All patients were receiving statin therapy.	DB, MC, PG, PC, RCT Men and women ≥18 years of age including white, African American, Hispanic or other who followed a cholesterol-lowering diet, were taking a stable approved dose of any US marketed statin for ≥6 weeks before study entry, with LDL-C levels greater than the NCEP ATP III goal	N=3,030 6 weeks	Primary: LDL-C and additional parameters and percentage of patients reaching LDL goal for the NCEP ATP III in racial and ethnic subgroups Secondary: Safety and tolerability	Primary: The addition of ezetimibe to ongoing statin therapy significantly reduced LDL-C, TC, non-HDL and HDL-C levels compared to placebo (P<0.001). This effect was consistent across race and ethnicity (P>0.50 for treatment-by-race interactions). CRP level reduction was statistically significant in patients receiving ezetimibe compared to placebo (P<0.001). The treatment-by-race interaction was not statistically significant (P=0.83), indicating a consistent treatment effect of lowering CRP levels across race and ethnicity groups. Ezetimibe added to statin therapy significantly increased the percentage of patients attaining their LDL-C goal for the NCEP ATP III in African Americans by 63%, Hispanics by 64.8% and whites by 72.3%, compared to placebo (P<0.001). Secondary: The addition of ezetimibe to ongoing statin therapy was well tolerated with an overall safety profile similar in all patient groups by race or ethnicity.
Pearson et al.[44] (2005) EASE	DB, MC, PG, RCT Subanalysis of the	N=3,030 6 weeks	Primary: Mean change from baseline in LDL-C	Primary: Compared to placebo, patients receiving ezetimibe experienced an LDL-C reduction of 23% (white patients), 23% (African American patients), and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ezetimibe 10 mg QD vs placebo All patients were receiving statin therapy.	EASE study; patients >65 years old with hypercholesterolemia, with LDL-C levels exceeding the NCEP ATP goals, on an approved dose of a statin for 6 weeks prior to study entry, following a cholesterol-lowering diet		level, proportion of patients who reached LDL-C target across different races and ethnicities, change in serum cholesterol, TG, HDL at 6 weeks Secondary: Not reported	21% (Hispanic patients) from baseline (P<0.001). The difference in LDL-C lowering among the three races studied was not statistically significant (P>0.5). A significantly greater proportion of patients randomized to ezetimibe achieved their NCEP ATP LDL-C goal compared to placebo (P<0.001). Patients receiving ezetimibe experienced a TC reduction of 15.3 mg/dL from baseline compared to patients receiving placebo (P<0.001). Patients receiving ezetimibe experienced a TG reduction of 11.5 mg/dL from baseline compared patients receiving placebo (P<0.001). Patients receiving ezetimibe experienced an increase in HDL-C of 2.1 mg/dL from baseline compared to patients receiving placebo (P<0.001). Side effects were similar across treatment groups and races. Secondary: Not reported
Mikhailidis et al.[45] (2007) Ezetimibe 10 mg QD vs placebo All patients were receiving statin therapy.	MA (21 trials) Adults ≥18 years with diagnoses of nonfamilial or familial hypercholesterolemia, hyperlipidemia, and homozygous familial sitosterolemia; with LDL-C levels above NCEP ATP II/III guideline criteria	N=5,039 6 to 48 weeks	Primary: Total number of patients attaining LDL-C goal; changes in TC, LDL-C, and HDL-C from baseline to end point Secondary: Not reported	Primary: The analysis of five RCTs indicated that when compared to placebo in combination with a statin, the RR of obtaining the LDL-C treatment goal was higher for patients in the ezetimibe and statin groups (P<0.0001). A WMD between treatments significantly favored the ezetimibe and statin combination therapy over placebo and statin: for TC, a WMD of -16.1% (CI, -17.3 to -14.8); for LDL-C, a WMD of -23.6% (CI, -25.6 to -21.7); and for HDL-C, a WMD of 1.7% (CI, 0.9 to 2.5) (P<0.0001 for all). In an analysis of patients with or without CHD (in addition to hypercholesterolemia), the ezetimibe and statin combination was favored over placebo and statin for the following WMD: LDL-C -23.6% (P<0.0001); TC -16.1% (P<0.0001); HDL-C 1.7% (P<0.0001); TG -10.7%; apo B -17.3%; RR, LDL-C treatment goal 3.4% (P<0.0001). The difference between treatments in all studies favored the ezetimibe and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				statin combination therapy for all outcomes except TG and HDL-C. An analysis of data from a 48-week ES correlated with the pooled estimates of the short-term studies in the MA. This data showed that the ezetimibe and simvastatin combination resulted in significantly lower levels of LDL-C, TC, and TG when compared to the placebo and simvastatin combination (reductions of 20.4, 13.4 and 13.6%, respectively; P<0.001 for the difference between treatments). Secondary: Not reported
Pearson et al.[46] (2009) Group 1 Ezetimibe 10 mg QD vs placebo and Group 2 Ezetimibe 10 mg QD vs placebo All patients in Group 2 were receiving statin therapy.	MA (11 trials) Patients with hypercholesterolemia and hsCRP ≤10 mg/L	N=5,271 (11 trials) 6 to 12 weeks	Primary: Mean change in hsCRP and LDL-C Secondary: Not reported	Primary: Treatment with ezetimibe monotherapy led to a mean 1% reduction in CRP compared to a mean 5% increase with placebo after 12 weeks (P=0.09). Treatment with ezetimibe and statin combination therapy led to a mean 12% decrease in CRP compared to a mean 1% decrease with statin monotherapy after six to eight weeks (P<0.001). Treatment with ezetimibe monotherapy led to a mean 18% reduction in LDL-C compared to a mean 0.5% increase with placebo after 12 weeks of therapy (P<0.001). Treatment with ezetimibe and statin combination therapy led to a mean 27% decrease in LDL-C compared to a mean 3% decrease with statin monotherapy after six to eight weeks (P<0.001). Secondary: Not reported
Farnier et al.[47] (2005)	DB, MC, PC, RCT	N=619	Primary: Percent change in	Primary: The mean percent change in LDL-C reduction was significantly greater in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ezetimibe 10 mg and fenofibrate 160 mg QD vs ezetimibe 10 mg QD vs fenofibrate 160 mg QD vs placebo	Men and women 18 to 75 years of age with mixed hyperlipidemia and no CHD, CHD-equivalent disease (except for type 2 diabetes), or 10-year CHD risk >20%	12 weeks	LDL-C from baseline to study end point Secondary: Percent change in other lipid, non-lipid, and lipoprotein parameters from baseline to study end point	the micronized fenofibrate and ezetimibe group when compared to the other treatment groups (P<0.001 compared to micronized fenofibrate and ezetimibe). These reductions were 13.4% in the ezetimibe group, 5.5% in the micronized fenofibrate group, and 20.4% in the micronized fenofibrate and ezetimibe group. Secondary: When compared to micronized fenofibrate or ezetimibe monotherapy, significant reductions in apo B, non-HDL-C and LDL-C were observed in the micronized fenofibrate and ezetimibe group; P<0.001. When compared to placebo, significant decreases in TG levels and significant increases in HDL-C level were observed in both the micronized fenofibrate plus ezetimibe and micronized fenofibrate treatment groups; P<0.001. The percent changes from baseline to study end point were as follows: -11.8% in TC, 3.9% in HDL-C, -11.1% in TG, and -6.1% in high sensitivity CRP in the ezetimibe group; -10.8% in TC, 18.8% in HDL-C, -43.2% in TG, and -28.0% in hsCRP in the micronized fenofibrate group; -22.4% in TC, 19.0% in HDL-C, -44.0% in TG, and -27.3% in hsCRP in the micronized fenofibrate and ezetimibe group (P<0.05 for all).
Tribble et al.[48] (2008) Ezetimibe 10 mg and fenofibrate 160 mg QD (FENO + EZE) vs ezetimibe 10 mg QD (EZE) vs fenofibrate 160 mg QD (FENO)	DB, MC, PC, RCT Patients 18 to 75 years of age with mixed hyperlipidemia (LDL-C 130 to 220 mg/dL and TG 200 to 500 mg/dL) and no CHD or CHD-risk equivalent disease, or 10-year CHD risk >20% according to NCEP ATP III criteria	N=625 12 weeks	Primary: Changes in cholesterol mass within the major lipoprotein fractions and subfractions and LDL particle distribution profiles and particle size Secondary: Not reported	Primary: The effects of EZE, FENO, and FENO + EZE on VLDL subfractions were similar to those for VLDL overall. All active treatments reduced IDL-C. Treatment with FENO significantly reduced LDL-C1, LDL-C3, and LDL-C4 and significantly increased LDL-C2 compared to placebo. FENO + EZE produced a pattern of changes similar to those of FENO alone. The reductions in LDL-C1 and LDL-C3 were greater with the combination due to the added effects of EZE. There were no significant changes in cholesterol associated with Lp(a). Fenofibrate and FENO + EZE increased median HDL-C2 and HDL-C3 compared to EZE and placebo. In patients treated with EZE, there were reductions in VLDL-C, IDL-C, and LDL-C density ranges without a shift in LDL density distributions or

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				changes in the HDL-C range. In patients treated with FENO, there were reductions in VLDL-C and IDL-C. HDL-C was increased and there was a shift in the distribution of LDL toward larger, more buoyant LDL particles with a small effect on LDL-C values overall. In patients treated with FENO + EZE, there were reductions in VLDL-C, IDL-C, and LDL-C. HDL-C was increased and there was a shift from smaller, more dense to larger, more buoyant LDL subfractions. EZE did not significantly affect LDL peak particle size. FENO and FENO + EZE increased LDL peak particle size. Secondary: Not reported
McKenney et al.[49] (2006) Fenofibrate 160 mg QD and ezetimibe 10 mg QD vs fenofibrate 160 mg QD vs ezetimibe 10 mg QD for 12 weeks, then fenofibrate 160 mg and ezetimibe 10 mg QD for 48 weeks	DB Patient who completed base study with mixed hyperlipidemia	N=576 48 weeks	Primary: Percent change in LDL-C from baseline of the base study to study end point in the extension Secondary: Percent change from baseline to study end point in TC, HDL-C, TG, non-HDL-C, apo B, apo AI, and hsCRP	Primary: Fenofibrate plus ezetimibe showed significantly greater percent reductions in LDL-C compared to fenofibrate alone (-22.0 vs -8.6; P<0.001). Secondary: Fenofibrate plus ezetimibe showed significantly greater percent reductions from baseline to extension study end point in TC (-23.2 vs -13.6; P<0.001), TG (-46.0 vs -41.0; P=0.002), non-HDL-C (-31.6 vs -19.4; P<0.001), and apo B (-25.2 vs -16.2; P<0.001) compared to fenofibrate. There was a significantly greater percent increase in HDL-C (20.9 vs 17.8; P=0.02) with fenofibrate plus ezetimibe vs fenofibrate alone. There was not a significantly greater percent increase in apo AI (10.1 vs 7.8; P=0.12) with fenofibrate plus ezetimibe vs fenofibrate alone. Reductions in median hsCRP levels were not different between treatments (-25.3 vs -21.1; P=0.46) for fenofibrate plus ezetimibe vs fenofibrate alone, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo for 12 weeks, then fenofibrate 160 mg for 48 weeks				
Ballantyne et al.[50] (2003) Ezetimibe 10 mg QD and atorvastatin 10 to 80 mg QD vs ezetimibe 10 mg QD vs atorvastatin 10 to 80 mg QD vs placebo	DB, PC, RCT Men and women aged ≥18 years with primary hypercholesterolemia (LDL-C 145 to 250 mg/dL and TG ≤350 mg/dL)	N=628 12 weeks	Primary: Percentage reduction in direct LDL-C from baseline to final assessment Secondary: Change from baseline to final assessment for calculated LDL-C, TC, TG, HDL-C, TC:HDL-C ratio, apo B, non–HDL-C, HDL_2-C, HDL_3-C, apo AI, Lp(a), direct LDL-C:HDL-C ratio, adverse events	Primary: There was a significantly greater mean reduction of direct LDL-C from baseline to final assessment in the ezetimibe plus atorvastatin group compared to either atorvastatin alone (P<0.01) or ezetimibe alone (P<0.01). Mean changes in direct LDL-C ranged from -50 to -60% in the combination group compared to -35 to -51% in the atorvastatin alone group (P<0.01). Secondary: Calculated LDL-C was also significantly reduced more commonly in the combination group than all doses of atorvastatin monotherapy (P<0.01). Greater reductions in LDL-C, TC, and TG were observed with increasing doses of atorvastatin monotherapy. However, there was not a favorable dose response with HDL-C. There were similar reductions in LDL-C (50 vs 51%), TC:HDL-C ratio (43 vs 41%), and TG (both 31%) with coadministration of ezetimibe plus atorvastatin 10 mg and the maximal dose of atorvastatin monotherapy, respectively. However, there was a significantly greater increase in HDL-C (9 vs 3%) with the combination group. Reductions in apo B, non–HDL-C, and direct LDL-C:HDL-C ratio from baseline were significantly greater in the combination group compared to both atorvastatin monotherapy (P<0.01 for all) and ezetimibe monotherapy (P<0.01 for all). However, increases in HDL_2-C (P=0.53), HDL_3-C (P=0.06), apo AI (P=0.31), and Lp(a) (P=0.50) did not significantly differ between the combination therapy and atorvastatin monotherapy groups. There also was no significant difference between the combination therapy and ezetimibe

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				monotherapy groups for increases in these same parameters: HDL_2-C (P=0.08), HDL_3-C (P=0.67), apo AI (P=0.80), and Lp(a) (P=0.92). The combination of ezetimibe plus atorvastatin was well-tolerated. Treatment-emergent adverse events were reported in 17% of patients receiving atorvastatin monotherapy and 23% of patients receiving combination therapy. The majority of adverse events were mild to moderate in severity.
Kerzner et al.[51] (2003) Ezetimibe 10 mg QD and lovastatin 10 to 40 mg QD vs ezetimibe 10 mg QD vs lovastatin 10 to 40 mg QD vs placebo	DB, MC, PC, RCT Men and women aged ≥18 years with mean plasma LDL-C 145 to 250 mg/dL as calculated by Friedewald equation, mean TG ≤350 mg/dL	N=548 12 weeks	Primary: Percentage decrease in directly measured LDL-C from baseline to study end point Secondary: Change from baseline to end point for calculated LDL-C, TC, TG, HDL-C, apo B, non-HDL-C, HDL_2-C, HDL_3-C, apo AI, direct LDL-C:HDL-C ratio, adverse events	Primary: The reduction in plasma levels of direct LDL-C from baseline to end point was significantly greater in the combination group of ezetimibe plus lovastatin compared to either lovastatin or ezetimibe monotherapy (P<0.01 for both). The mean percentage decrease in direct LDL-C in the combination group was significantly greater than the decrease obtained from the corresponding lovastatin dose or next higher dose of lovastatin monotherapy (P<0.01). The mean percentage change in LDL-C achieved with combination ezetimibe plus lovastatin 10 mg was similar to the highest lovastatin dose of 40 mg monotherapy (P=0.10). Secondary: In comparison to lovastatin monotherapy, the combination group significantly improved calculated LDL-C, TC, TG, HDL-C, apo B, non–HDL-C, HDL_2-C, HDL_3-C, direct LDL-C:HDL-C ratio (P<0.01 for all), and apo AI (P=0.04). The combination of ezetimibe plus lovastatin significantly increased HDL-C at lovastatin doses of 20 and 40 mg compared to the same lovastatin monotherapy dose (P<0.01 and P<0.02, respectively) and significantly decreased TG levels (P<0.01 for both). Treatment-related adverse events were reported for 16% of patients receiving lovastatin monotherapy and 17% of patients receiving combination therapy. The safety profile for the combination group was similar to that for the lovastatin monotherapy and placebo group.
Melani et al.[52]	DB, MC, PC, RCT	N=538	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2003) Ezetimibe 10 mg QD and pravastatin 10 to 40 mg QD vs ezetimibe 10 mg QD vs pravastatin 10 to 40 mg QD vs placebo	Men and women 20 to 86 years old with primary hypercholesterolemia (LDL-C 150 to 250 mg/dL and TG ≤350 mg/dL)	12 weeks	Percent change in direct LDL-C from baseline to study end point Secondary: Mean change and percent change from baseline in LDL-C as calculated by the Friedewald equation, TC, TG, HDL-C, direct LDL-C:HDL-C and TC:HDL-C ratio, non–HDL-C, apo AI, apo B, HDL_2-C, HDL_3-C, Lp(a)	A mean percent change of –38% for the combination therapy and -24% for pravastatin monotherapy was observed. The combination therapy was significantly more effective at reducing plasma levels of direct LDL-C from baseline to end point (P<0.01). The combination group had a mean percentage change in direct LDL-C ranging from -34 to -41% compared to -20 to –29% for individual doses of pravastatin monotherapy. When the combination therapy was compared to its corresponding pravastatin dose, the incremental mean percentage reductions in direct LDL-C were statistically significant in favor of the combination therapy (P≤0.01). In addition, the coadministration of ezetimibe plus pravastatin 10 mg produced a larger mean percentage reduction in direct LDL-C compared to the highest dose of pravastatin monotherapy (P≤0.05). Secondary: In comparison to pravastatin monotherapy, the combination therapy improved calculated LDL-C, TG, TC, apo B, non–HDL-C, direct LDL-C:HDL-C, and TC:HDL-C (P<0.01 for all). Both direct and calculated LDL-C levels at all pravastatin doses were significantly reduced in the combination group (P<0.01). TG was also significantly reduced in the combination group at pravastatin doses of 10 and 20 mg compared to pravastatin monotherapy (P<0.05). Although the combination therapy produced greater increases in HDL-C at the 10 and 40 mg doses, it was not significant. The differences in change in HDL_2-C, HDL_3-C, apo AI, and Lp(a) between the combination group and pravastatin monotherapy were determined to be not significant. Coadministration of ezetimibe and pravastatin was well tolerated and the overall safety profile was similar to pravastatin monotherapy and placebo. There was no evidence to suggest that combination therapy would increase the risk of developing any non-laboratory adverse event.
Ose et al.[53] (2007) Simvastatin 10, 20,	DB, ES, MC, RCT Patients 22 to 83 years, with primary hyper-	N=1,037 14 weeks	Primary: Change from baseline in LDL-C level, TG, TC,	Primary: Across all doses, patients receiving ezetimibe-simvastatin experienced a statistically significant LDL-C reduction from baseline compared to the simvastatin monotherapy group (53.7 vs 38.8%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
40, or 80 mg/day vs ezetimibe-simvastatin 10-10, 10-20, 10-40, and 10-80 mg/day vs ezetimibe 10 mg QD vs placebo	cholesterolemia (LDL-C between 145 and 250 mg/dL and TG <350 mg/dL) who were randomized to ezetimibe-simvastatin 10-10, 10-20, 10-40, or 10-80 mg combination tablet, simvastatin 10, 20, 40, or 80 mg monotherapy, ezetimibe 10 mg, or placebo		non-HDL, CRP, LDL-C:HDL-C ratio, TC:HDL-C ratio, proportion of patients reaching LDL-C target (<100 or <70 mg/dL) Secondary: Not reported	Across all doses, patients receiving ezetimibe-simvastatin combination therapy experienced a statistically significant reduction from baseline in TG, TC, non-HDL, CRP, LDL-C:HDL-C ratio, and TC:HDL-C ratio compared to the simvastatin monotherapy group (P<0.001). Significantly greater proportion of patients randomized to the ezetimibe-simvastatin combination therapy achieved LDL-C <100 mg/dL, compared to the simvastatin group (79.2 vs 47.9%; P<0.001). A greater proportion of patients randomized to the ezetimibe-simvastatin combination therapy achieved LDL-C <70 mg/dL, compared to the simvastatin group (30.4 vs 7%; P<0.001). The incidence of drug-related adverse effects was similar in the ezetimibe-simvastatin and simvastatin monotherapy groups (7.4 vs 5.5%, respectively). Secondary: Not reported
Goldberg et al.[54] (2004) Ezetimibe 10 mg/day and simvastatin 10, 20, 40 or 80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day	DB, MC, RCT Patients ≥18 years of age with primary hypercholesterolemia, ALT and AST ≤2 times the upper limit of normal, no active liver disease, CK ≤1.5 times the upper limit of normal	N=887 20 weeks	Primary: Mean percent change from baseline in LDL-C Secondary: Mean and percent changes from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B, apo AI and hsCRP; proportion of patients reaching their NCEP ATP	Primary: Averaged across all doses, combination therapy was associated with a significant 14.8% reduction in LDL-C at 12 weeks compared to simvastatin (53.2 vs 38.5%; P<0.001). Secondary: At each corresponding dose of simvastatin, combination therapy was associated with a significant reduction in LDL-C at 12 weeks (P<0.001). Combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to the next highest dose of simvastatin (P<0.001). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B and hsCRP at 12 weeks compared to simvastatin (P<0.001 for all).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo			III LDL-C goal <130 or <100 mg/dL at 12 weeks	Averaged across all doses, combination therapy resulted in a greater proportion of patients reaching their NCEP ATP III LDL-C goal <130 or <100 mg/dL at 12 weeks compared to simvastatin (92 and 82% vs 82 and 43%, respectively; P<0.001). Averaged across all doses, combination therapy was not associated with a significant change in HDL-C compared to simvastatin (P=0.53). Treatment-related adverse effects were similar in the pooled simvastatin and combination therapy groups, but were more frequent than with ezetimibe and placebo (13, 14, 9 and 9%, respectively; P values not reported).
Davidson et al.[55] (2002) Ezetimibe 10 mg/day plus simvastatin 10, 20, 40, or 80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day vs placebo	DB, MC, RCT Patients >18 years of age with primary hypercholesterolemia	N=668 20 week	Primary: Mean percent change from baseline in LDL-C Secondary: Mean and percent change from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B, apo AI and hsCRP	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to simvastatin (49.9 vs 36.1%; P<0.001). Similar results were observed with combination therapy compared to ezetimibe (49.9 vs 18.1%; P<0.001). Combination therapy (simvastatin 10 mg) and simvastatin 80 mg produced a 44% reduction in LDL-C at 12 weeks (P value not reported). Secondary: At each corresponding dose of simvastatin, combination therapy was associated with a significant reduction in LDL-C at 12 weeks (P<0.001). Combination therapy was associated with a significant reduction in LDL-C at 12 weeks, compared to the next highest dose of simvastatin (P<0.01). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non-HDL-C and apo B at 12 weeks compared to simvastatin (P<0.01 for all). Averaged across all doses, combination therapy was associated with a significant increase in HDL-C compared to simvastatin (P=0.03). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non–HDL-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				C and apo B at 12 weeks compared to ezetimibe (P<0.01 for all). Averaged across all doses, combination therapy was associated with a significant increase in HDL-C compared to ezetimibe (P=0.02). A significantly greater proportion of patients receiving combination therapy experienced a reduction in LDL-C >50% from baseline compared to simvastatin (P value not reported). Treatment-related adverse effects were similar in the pooled simvastatin and combination therapy groups (72 vs 69%, respectively; P value not reported).
Bays et al.[56] (2004) Ezetimibe-simvastatin 10-10, 10-20, 10-40 or 10-80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day vs placebo	DB, MC, RCT Patients 18 to 80 years of age with primary hypercholesterolemia with LDL-C >145 but ≤150 mg/dL and TG ≤350 mg/dL	N=1,528 24 weeks	Primary: Percent change from baseline in LDL-C Secondary: Mean and percent changes from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B, apo AI and hsCRP; proportion of patients reaching their NCEP ATP III LDL-C goal of <130, <100 or <70 mg/dL at 12 weeks	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to simvastatin (53 vs 39%; P<0.001) and ezetimibe (53 vs 18.9%; P<0.001). Secondary: At each corresponding dose of simvastatin, combination therapy was associated with a significant reduction in LDL-C at 12 weeks (P<0.001). Combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to the next highest dose of simvastatin (P<0.001). Averaged across all doses, combination therapy resulted in a greater proportion of patients reaching their NCEP ATP III LDL-C goal <130, <100 or <70 mg/dL at 12 weeks compared to simvastatin (92.2, 78.6 and 38.7 vs 79.2, 45.9 and 7.0%, respectively; P<0.001 for al). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B and hsCRP at 12 weeks compared to simvastatin (P<0.001 for all). Averaged across all doses, combination therapy was not associated with a significant change in HDL-C compared to simvastatin (P=0.607).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Treatment-related adverse effects were similar in the pooled simvastatin, combination and ezetimibe groups, but were more frequent than placebo (14.8, 15.1, 12.8 and 8.1%, respectively; P values not reported).
Rosen et al.[57] (2013) Ezetimibe/ simvastatin (EZ/S) 10/20 mg vs doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) vs switching to rosuvastatin 10 mg	AC, DB, MC, RCT Patients ≥18 and <80 years old with type 1 or 2 diabetes mellitus ($HbA_{1c} \leq 8.5\%$) and symptomatic CVD, who were naïve to statin and/or ezetimibe or were taking a stable dose of approved lipid-lowering therapy	N=808 12 weeks (6 weeks of DB treatment after run-in period)	Primary: Percent change from baseline in LDL-C at week 6 Secondary: Percent change from baseline in TC, TG, HDL-C, non-HDL-C, Apo B, Apo A-I, and high-sensitivity C-reactive protein (hsCRP) at week 6 and the percent of patients with LDL-C <70 mg/dL at week 6, safety	Primary: Treatment with EZ/S 10/20 mg resulted in a significantly greater reduction in LDL-C compared with doubling the baseline statin dose (−23.13 vs −8.37%; P< 0.001). In the population of patients receiving simvastatin 20 mg or atorvastatin 10 mg at baseline, the percent reduction in LDL-C was numerically greater when switched to EZ/S than when switched to rosuvastatin 10 mg following six weeks of treatment (−23.13 vs −19.32%; P=0.060). Secondary: There were significantly greater reductions in TC, Apo B, and non-HDL-C in subjects taking EZ/S 10/20 mg compared with subjects who doubled their statin dose and with those taking rosuvastatin 10 mg. For all other lipids and lipoproteins, the percent changes were not statistically significantly different between treatments. The percent of patients reaching LDL-C goal of <70 mg/dL was significantly greater with ezetimibe/simvastatin (54.5%) vs doubling the baseline statin dose (27.0%) or switching to rosuvastatin 10 mg (42.5%). The safety profile appeared generally comparable between all groups.
Foody et al.[58] (2013) Add-on group (patients who were initially on simvastatin, atorvastatin, or rosuvastatin monotherapy and added ezetimibe onto this therapy)	OS, RETRO Patients ≥18 years of age with a diagnosis of CHD or CHD risk-equivalent who had a prescription for statin monotherapy with baseline and follow-up LDL-C values, as well as no overlap with other lipid-lowering therapy and who had	N=15,365 Minimum of 6 weeks	Primary: Mean percent change from baseline in LDL-C and percentage of patients attaining LDL-C goals <70 mg/dL and <100 mg/dL Secondary: Not reported	Primary: The mean LDL-C levels at baseline were significantly higher in the add-on groups for each statin compared with those of the titrators. At follow-up, LDL-C levels were reduced more in the add-on groups (80 to 85 mg/dL) than in the titrator groups (87 to 95 mg/dL). Both the absolute changes in LDL-C levels and the percent changes from baseline were significantly greater in the add-on groups than in the titrator groups. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs titrator group (patients who either titrated their initial statin dose or switched to higher-potency statin monotherapy)	no discontinuations of lipid-lowering therapy at baseline or follow-up during the study period			
Feldman et al.[59] (2006) Ezetimibe-simvastatin 10-10, 10-20, 10-40, or 10-80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day vs placebo	MA (3 DB, PC, RCTs) Patients with primary hypercholesterolemia	N=3,083 28 weeks	Primary: Percent change from baseline in LDL-C, TG, non-HDL-C, apo B and hsCRP; achievement of LDL-C <100 mg/dL at week-12 among patients <65 and ≥65 years of age Secondary: Not reported	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C, TG, non-HDL-C, apo B and hsCRP at 12 weeks compared to simvastatin (*P*<0.001 for all). These affects did not differ between the older and younger patients (*P* value not reported). Combination therapy and simvastatin produced comparable increases in HDL-C (8 vs 7%, respectively; *P* value not reported). Significantly more patients, in all age groups, receiving combination therapy, regardless of the dose, achieved an LDL-C level <100 mg/dL at week 12 compared to patients receiving simvastatin (79 vs 42%; *P*<0.001). Similar results were observed with a LDL-C goal <70 mg/dL (37 vs 6%; *P*<0.001). Treatment-related adverse effects were similar with simvastatin and combination therapy, regardless of dose used and age group (*P* values not reported). Secondary: Not reported
Pearson et al.[60] (2007) Atorvastatin 10, 20, 40, or 80 mg/day for 6	MA (4 trials) Three identical, prospective 12-week studies randomizing patients to placebo,	N=4,373 up to 12 weeks	Primary: Change from baseline in LDL-C level, CRP, proportion of patients reaching	Primary: Across all doses, patients receiving ezetimibe plus simvastatin combination therapy experienced a statistically significant LDL-C reduction from baseline compared to the simvastatin monotherapy group (52.5 vs 38%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
weeks vs simvastatin 10, 20, 40, or 80 mg/day for 12 weeks vs ezetimibe 10 mg/day for 12 weeks vs ezetimibe 10 mg/day added to simvastatin 10, 20, 40, or 80 mg/day for up to 12 weeks vs placebo for 12 weeks	ezetimibe, ezetimibe with simvastatin or simvastatin alone, and one phase III double-blind, active-controlled study allocating patients to ezetimibe/simvastatin or atorvastatin for 6 weeks		LDL-C target (<100 mg/dL or <70 mg/dL) Secondary: Not reported	Across all doses, patients receiving ezetimibe plus simvastatin combination therapy experienced a statistically significant LDL-C reduction from baseline compared to the atorvastatin monotherapy group (53.4 vs 45.3%; P<0.001). Across all doses, patients on the ezetimibe plus simvastatin combination therapy experienced a statistically significant CRP reduction from baseline compared to the simvastatin monotherapy group (31 vs 14.3%; P<0.001). Patients on the ezetimibe plus simvastatin combination therapy experienced a similar CRP reduction from baseline compared to the atorvastatin monotherapy group (25.1 vs 24.8%). The reduction in CRP from baseline was not significantly different between simvastatin 10 mg and placebo groups (P>0.10). Significantly greater proportion of patients randomized to the ezetimibe plus simvastatin combination therapy achieved LDL-C <100 mg/dL, compared to the simvastatin group (78.9 vs 43.1%; P<0.001). Significantly greater proportion of patients randomized to the ezetimibe plus simvastatin combination therapy achieved LDL-C <70 mg/dL, compared to the simvastatin group (37 vs 5.7%; P<0.001). Significantly greater proportion of patients randomized to the ezetimibe plus simvastatin combination therapy achieved LDL-C <100 mg/dL, compared to the atorvastatin group (79.8 vs 61.9%; P<0.001). Significantly greater proportion of patients randomized to the ezetimibe plus simvastatin combination therapy achieved LDL-C <70 mg/dL, compared to the atorvastatin group (36.2 vs 16.8%; P<0.001). Secondary: Not reported
Ansquer et al.[61] (2009)	DB, MC, RCT Patients 18 to 70 years	N=60 12 weeks	Primary: Percentage change from baseline in	Primary: Fenofibrate plus ezetimibe and fenofibrate reduced TG by -38.3% (P value not significant) and increased HDL-C to a similar extent (11.5 and 7.9%,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ezetimibe 10 mg QD and fenofibrate (Tricor®) 145 mg QD vs ezetimibe 10 mg QD vs fenofibrate (Tricor®) 145 mg QD	of age with type IIb dyslipidemia (LDL-C ≥160 mg/dL, TG 150-405 mg/dL) and ≥2 features of the metabolic syndrome according to the NCEP ATP III definition		TG and HDL-C Secondary: Percentage change in LDL-C, non-HDL-C, remnant-like particle cholesterol (RLP-C) and related parameters, change in glucose metabolism parameters, hsCRP, safety	respectively; P=0.282). Secondary: Fenofibrate plus ezetimibe reduced LDL-C by -36.2% compared to -22.4% with fenofibrate and -22.8% with ezetimibe (P<0.001 for both). Fenofibrate plus ezetimibe lowered non-HDL-C by -36.2% compared to fenofibrate (-24.8%) and ezetimibe (-20.9%) (P value not reported). There was no significant difference between fenofibrate plus ezetimibe and fenofibrate with regards to RLP-C (-36.2 vs -30.7%; P value not significant). Ezetimibe was less effective than fenofibrate plus ezetimibe (-17.3%; P<0.001). The effect of fenofibrate plus ezetimibe on LDL particle size (+2.1%) was similar to that of fenofibrate (+1.9%). Fenofibrate plus ezetimibe was more effective than monotherapy with fenofibrate or ezetimibe in reducing apo B (-33.3%). Fenofibrate plus ezetimibe had the same effect as fenofibrate on apo AI (+7.9 vs +5.1%, respectively) and apo AII (+24.2 vs +21.2%, respectively; P value not reported). Fenofibrate plus ezetimibe and fenofibrate reduced hsCRP to a similar degree. There was a higher incidence of treatment-related adverse events with fenofibrate/ezetimibe, which was primarily due to abnormal laboratory changes, including moderate increases in CK, liver enzymes, and blood creatinine.
Coll et al.[62] (2006) Ezetimibe 10 mg QD	RCT HIV patients, ≥6 months on stable HAART, ≥18 years of age, fasting LDL-C	N=20 6 weeks	Primary: LDL-C, TC, endothelial function Secondary:	Primary: Ezetimibe-treated patients experienced a 20% (P=0.002) LDL-C reduction and a 10% TC reduction (P=0.003). Fluvastatin-treated patients experienced a 24% LDL-C reduction (P=0.02) and a 17% TC reduction (P=0.06).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs fluvastatin XR 80 mg QD	≥3.30 mmol/L		Not reported	There were no significant differences in lipid-lowering ability between groups. Ezetimibe-treated patients did not experience significant changes in endothelial function. Fluvastatin-treated patients experienced an increase in the rate of endothelial function by 11% (P=0.5). Secondary: Not reported
Stein et al.[63] (2004) Ezetimibe 10 mg QD and atorvastatin 10 mg QD (titrated up to 40 mg/day) vs atorvastatin 20 mg QD (titrated up to 80 mg/day)	DB, DD, MC Patients ≥18 years of age with primary hypercholesterolemia and documented CHD, ≥2 cardiovascular risk factors, or heFH with an LDL-C level ≥130 mg/dL despite treatment with atorvastatin 10 mg	N=621 14 weeks	Primary: Percentage of patients achieving an LDL-C level ≤100 mg/dL after 14 weeks randomization Secondary: Effects on other lipid parameters four weeks after randomization	Primary: When compared to atorvastatin monotherapy, a significantly higher percentage of patients in the ezetimibe and atorvastatin reached an LDL-C level ≤100 mg/dL after 14 weeks randomization, respectively (7 vs 22%; P<0.01). Secondary: When compared to atorvastatin monotherapy, significant reductions in LDL-C, TC and TG levels were observed in patients in the ezetimibe and atorvastatin (P<0.01). Respectively, percent changes between combination vs atorvastatin monotherapy were -22.8 vs -8.6% (mean change) in LDL-C levels, -17.3 vs -6.1% in TC levels (mean change), and -9.3 vs -3.9% (median change) in TG levels (P<0.01 for all). Nonsignificant changes were observed in HDL-C levels.
Piorkowski et al.[64] (2007) Ezetimibe 10 mg QD and atorvastatin 10 mg QD vs atorvastatin 40 mg QD	RCT Patients 18 to 80 years of age with clinically stable angiographically documented CHD and LDL-C >2.5 mmol/L despite ongoing atorvastatin 10 to 20 mg/day, receiving aspirin and clopidogrel	N=56 4 weeks	Primary: Change in liver transaminases, CK, HDL-C, LDL-C, and TG from baseline, percentage of patients achieving the NCEP ATP III LDL-C goal (≤2.5 mmol/L) Secondary: Not reported	Primary: There were no statistically significant differences from baseline in liver transaminases, CK, or HDL-C in either group. Both groups exhibited a statistically significant reduction in LDL-C from baseline (P<0.005). There was no statistically significant difference between the two groups in degree of LDL-C reduction from baseline. Both the atorvastatin 40 mg and the combination therapy groups exhibited a statistically significant reduction in TG level from baseline (P<0.005 and P<0.05, respectively). There was no statistically significant difference between the two groups in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				the percentage of patients achieving the NCEP ATP III LDL-C goal (≤2.5 mmol/L). Secondary: Not reported
Zieve et al.[65] (2010) ZETELD Ezetimibe 10 mg QD for 12 weeks and atorvastatin 10 mg QD for 6 weeks, followed by atorvastatin 20 mg QD for 6 weeks vs atorvastatin 20 mg QD for 6 weeks, followed by atorvastatin 40 mg for 6 weeks	DB, MC, PG, RCT Patients ≥65 years of age at high risk for CHD with or without AVD who had not reached a LDL-C <70 mg/dL or <100 mg/dL, respectively, after receiving atorvastatin 10 mg/day	N=1.053 12 weeks	Primary: Percent change in LDL-C after six weeks Secondary: Percentage of patients achieving LDL-C <70 mg/dL and <100 mg/dL for high-risk patients without AVD and <70 mg/dL for high-risk patients with AVD, HDL-C, non-HDL-C, TG, TG, apo B, apo AI, TC:HDL-C, apo B:apo AI, LDL-C:HDL-C, non-HDL-C:HDL-C	Primary: After six weeks of therapy, treatment with ezetimibe plus atorvastatin led to a significantly greater reduction in LDL-C compared to atorvastatin monotherapy (-29 vs -15%; P<0.001). Secondary: The percentage of patients achieving LDL-C <70 mg/dL and LDL-C <100 mg/dL (without AVD) or <70 mg/dL (with AVD) was significantly greater with ezetimibe plus atorvastatin compared to atorvastatin monotherapy at week six and week 12 (P<0.001). After six weeks of therapy, treatment with ezetimibe plus atorvastatin led to significantly greater changes in HDL-C (+3 vs +1%; P=0.02), TC (-16 vs -8%; P<0.001), non-HDL-C (-24 vs -11%; P<0.001), TG (-13 vs -6%; P<0.001), apo B (-17 vs -8%; P<0.001), TC:HDL-C (-17 vs -8%; P<0.001), LDL-C:HDL-C (-27 vs -13%; P<0.001), apo B:apo AI (-15 vs -5%; P<0.001), and non- HDL-C:HDL-C (-24 vs -11%; P<0.001). At week 12, significantly greater changes in favor of ezetimibe plus atorvastatin occurred in HDL-C, TC, non-HDL-C, apo B, apo AI, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C. There was no significant difference among the treatment groups in apo AI at week six, high-sensitivity C-reactive protein at weeks six and 12, and TG at week 12.
Conard et al.[66] (2008) Ezetimibe 10 mg QD and atorvastatin 20 mg QD	DB, MC, PG, RCT Patients 18 to 79 years of age at moderately high risk for CHD who were receiving atorvastatin 20 mg QD	N=196 6 weeks	Primary: Percent change in LDL-C Secondary: Percentage of patients achieving	Primary: Treatment with ezetimibe plus atorvastatin led to a significantly greater reduction in LDL-C compared to doubling the dose of atorvastatin (-31 vs -11%, respectively; P<0.001). Secondary: Significantly more patients treated with ezetimibe plus atorvastatin

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs atorvastatin 40 mg QD	with LDL-C levels of 100 mg/dL to 160 mg/dL and TG ≤350 mg/dL		LDL-C <100 mg/dL, percent change TG, TC, HDL-C, non-HDL-C, apo AI, apo B, TC: HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C, hsCRP	achieved the NCEP ATP III LDL-C goal <100 mg/dL compared to atorvastatin 40 mg (84 vs 49%, P<0.001). Treatment with ezetimibe plus atorvastatin led to greater improvements in non-HDL-C, TC, apo B, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C than treatment with atorvastatin 40 mg (P<0.001). There was no significant difference in HDL-C, TG, apo AI, and hsCRP among the treatment groups.
Leiter et al.[67] (2008) Ezetimibe 10 mg QD and atorvastatin 40 mg QD vs atorvastatin 80 mg QD	DB, MC, PG, RCT Patients 18 to 79 years of age at high risk for CHD (CHD or those with a CHD risk equivalent medical condition) who were receiving atorvastatin 40 mg QD with LDL-C levels of 70 mg/dL to 160 mg/dL and TG ≤350 mg/dL	N=579 6 weeks	Primary: Percent change in LDL-C Secondary: Percentage of patients achieving LDL-C <70 mg/dL, percent change TG, TC, HDL-C, non-HDL-C, apo AI, apo B, TC: HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C, hsCRP	Primary: Treatment with ezetimibe plus atorvastatin led to a significantly greater reduction in LDL-C compared to doubling the dose of atorvastatin (-27 vs -11%, respectively; P<0.001). Secondary: Significantly more patients treated with ezetimibe plus atorvastatin achieved the NCEP ATP III LDL-C goal <70 mg/dL compared to atorvastatin 80 mg (74 vs 32%, respectively; P<0.001). Treatment with ezetimibe plus atorvastatin led to greater improvements in non-HDL-C, TC, apo B, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C compared to atorvastatin 80 mg (P<0.001). There was no significant difference in HDL-C, TG, apo AI, and hsCRP among the treatment groups.
Conrad et al.[68] (2010) Atorvastatin 40 mg/day plus ezetimibe 10 mg/day vs	DB, MC, PG, RCT Patients 18 to 80 years of age at NCEP ATP III high risk with CHD or CHD risk equivalent, LDL-C ≥70 and ≤160 mg/dL and taking a stable dose of a statin of equal or	N=568 6 weeks	Primary: Proportion of patients reaching LDL-C <70 mg/dL; percent changes from baseline in LDL-C, HDL-C, non-HDL-C, TC, TG, apo B, apo AI, TC:HDL-	Primary: The proportion of patients reaching LDL-C <70 mg/dL was greater with combination therapy, with a larger between-treatment difference in proportions in patients with metabolic syndrome (without type 2 diabetes) compared to patients with type 2 diabetes or neither condition, which had similar between-treatment differences in proportions. In patients with type 2 diabetes, metabolic syndrome and those with neither condition, the reduction in LDL-C was greater in patients treated with combination therapy compared to doubling the dose of atorvastatin.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
atorvastatin 80 mg/day	lesser potency than atorvastatin 40 mg/day or were taking atorvastatin 40 mg/day with good adherence or were stain, ezetimibe or ezetimibe/simvastatin naïve		C, LDL-C/HDL-C, apo B/AI, non-HDL-C/HDL-C and hsCRP Secondary: Adverse events	The mean between-treatment difference (95% CI) was -17.4 (-21.7 to -13.1), -16.0 (-22.3 to -9.6) and -14.3% (-20.9 to -7.8). Reductions in TC, non-HDL-C and apo B were greater with combination therapy in all three patient populations. The magnitude of the differences between treatments in TG was numerically greater in patients with type 2 diabetes compared to the other two patient populations, but overall the differences were relatively small. There were no appreciable changes or between-treatment differences in HDL-C and apo AI in any patient population. The percent reduction in lipid ratios was greater with combination therapy in all three patient populations and between-treatment differences were consistent. Combination therapy resulted in numerically greater reductions from baseline in hsCRP in all three patient populations. The between-treatment differences in patients with metabolic syndrome (-11.8) and type 2 diabetes (-10.3) were larger than in patients with neither condition (-3.2). Secondary: There were comparable proportions of patients with one or more adverse event in the type 2 diabetes and metabolic syndrome populations regardless of treatment. The most commonly reported adverse events were gastrointestinal related.
Uemura et al.[69] (2012) Ezetimibe 10 mg/day plus atorvastatin 10 mg/day vs atorvastatin 20 mg	AC, DB, OL, PRO, XO Patients with impaired glucose tolerance or type 2 diabetes who were receiving atorvastatin (10 mg/day) for dyslipidemia, and had CAD with angiographic stenosis (≥50% diameter stenosis on quantitative coronary angiography)	N=39 24 weeks	Primary: Change from baseline in MDA-LDL, HDL, triglycerides, apo AI, apo B, and RLP Secondary: Not reported	Primary: Ezetimibe plus atorvastatin significantly reduced the serum concentration of MDA-LDL from 109.0±31.9 IU/L at baseline to 87.7±29.4 IU/L after 12 weeks (P=0.0009). The MDA-LDL was not significantly decreased in patients receiving atorvastatin monotherapy (from 109.0±31.9 IU/L to 106.0±34.9 IU/L (P value not significant)). The MDA-LDL level was significantly lower after treatment with ezetimibe plus atorvastatin compared to monotherapy with a higher dose of atorvastatin (P=0.0006). Both treatments significantly improved HDL from baseline (P<0.05 for both); however, there was no difference between the treatment groups (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	or a history of coronary revascularization for stable angina			There were no statistically significant differences between combination therapy and atorvastatin monotherapy with regard to a reduction in serum triglycerides (P>0.05). Both treatment regimens significantly reduced total cholesterol from baseline (P<0.05 for both comparisons); however, combination therapy reduced total cholesterol significantly further than atorvastatin monotherapy (147.8±21.3 vs 164.3±25.8 mg/dL; P<0.05). Combination treatment with ezetimibe and atorvastatin increased apo AI compared to baseline (P<0.05). Both treatment groups reduced apo B compared to their respective baseline values (P<0.05 for both). Combination therapy was associated with a statistically significant reduction in apo B compared to atorvastatin monotherapy (73.9±18.0 mg/dL vs 83.7±17.2 mg/dL, respectively; P<0.05). A significantly lower apo B/apo AI ratio was achieved with combination therapy compared to atorvastatin monotherapy (P<0.05). No statistically significant difference occurred between combination therapy and atorvastatin monotherapy with regard to RLP-cholesterol (P>0.05).
Constance et al.[70] (2007) Atorvastatin 20 mg QD for 6 weeks, following a 4 week atorvastatin 10 mg QD run-in period vs ezetimibe 10 mg QD added to simvastatin 20 mg QD for 6 weeks,	DB, MC, PG, RCT Patients ≥18 years of age, with type 2 diabetes, HbA_{1c} ≤10%, ALT/AST levels <1.5 times the upper limit of normal, CK <1.5 times the upper limit of normal	N=661 6 weeks	Primary: Change from baseline in LDL-C at six weeks Secondary: Change from baseline in TC, HDL-C, TG, non-HDL-C, apo B, LDL-C:HDL-C ratio, and TC:HDL-C ratio	Primary: Across all doses, patients on the ezetimibe plus simvastatin combination therapy experienced a statistically significant LDL-C reduction from baseline compared to the atorvastatin 20 mg monotherapy group (P≤0.001). Secondary: Across all doses, patients on the ezetimibe plus simvastatin combination therapy experienced a statistically significant reduction from baseline in TC, non-HDL, apo B, LDL-C:HDL-C ratio, and TC:HDL-C ratio compared to the atorvastatin 20 mg monotherapy group (P≤0.001). Patients on the ezetimibe 10 mg plus simvastatin 40 mg combination therapy experienced a statistically significant reduction in CRP from baseline compared to the atorvastatin 20 mg monotherapy group

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
following a 4 week atorvastatin 10 mg QD run-in period vs ezetimibe 10 mg QD added to simvastatin 40 mg QD for 6 weeks, following a 4 week atorvastatin 10 mg QD run-in period				(P=0.006). Significantly greater proportion of patients randomized to the ezetimibe 10 mg plus simvastatin 20 mg and ezetimibe 10 mg and simvastatin 40 mg combination therapy achieved LDL-C <2.5 mmol/L, compared to the atorvastatin 20 mg group (90.5, 87, and 70.4%, respectively; P≤0.001). The incidence of drug-related adverse effects was similar in the ezetimibe/simvastatin 10/20 mg and 10/40 mg combination therapy and atorvastatin monotherapy groups (0.5, 0.5, and 2.3%, respectively).
Hing Ling et al.[71] (2012) Atorvastatin 40 mg/day vs ezetimibe 10 mg/day plus simvastatin 40 mg/day All patients received atorvastatin 20 mg/day for six weeks at baseline.	AC, DB, MC, RCT Patients 18 to 79 years of age at high risk for CHD with primary hypercholesterolemia, LDL >100 mg/dL and <160 mg/dL, triglycerides <350 mg/dL, liver function tests within normal limits without active liver disease	N=250 6 weeks	Primary: Change from baseline in LDL-C, Secondary: TC, HDL, CRP, Apo AI, Apo B, TG, non-HDL, LDL-C/HDL ratio, TC/HDL ratio, non-HDL/HDL ratio, Apo AI/Apo B ratio	Primary: After six weeks, treatment with ezetimibe/simvastatin resulted in significantly greater reductions from baseline in LDL-C levels compared to treatment with atorvastatin 40 mg (-26.8 vs -11.8%; P<0.001). Secondary: Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in TC (P<0.001), non-HDL-C (P<0.001), Apo B (P=0.002), Apo AI (P<0.001), and all lipid ratios (P<0.001 for all). There were no significant differences between treatments with regard to the change from baseline in TG (P=0.593), HDL-C (P=0.211), or CRP (P=0.785).
Bays et al.[72] (2013) PACE Period I:	AC, DB, RCT Patients aged ≥18 and <80 years with primary hypercholesterolemia	N=1,547 12 weeks	Primary: Percent change from treated baseline in LDL-C levels at the end of	Primary: The addition of ezetimibe to atorvastatin 10 mg produced a greater reduction in LDL-C than doubling the atorvastatin dose to 20 mg or switching to rosuvastatin 10 mg (-22.2, -9.5, and -13.0, respectively; P<0.001, both groups).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
adding ezetimibe 10 mg to stable atorvastatin 10 mg vs doubling atorvastatin to 20 mg vs switching to rosuvastatin 10 mg Subjects in the latter 2 groups who persisted with elevated LDL-C levels (≥100 and ≤160 mg/dL) after period I, entered period II: subjects on atorvastatin 20 mg had ezetimibe added to their atorvastatin, or uptitrated atorvastatin to 40 mg; subjects on rosuvastatin 10 mg switched to atorvastatin 20 mg	at high CV risk, lipid-lowering therapy naïve with an LDL-C between 166 and 190 mg/dL, or on a stable dose of statin, ezetimibe, or statin plus ezetimibe having LDL-C-lowering efficacy equivalent to or less than atorvastatin 10 mg After enrollment all patients were administered atorvastatin 10 mg daily as only lipid-lowering therapy for 5 weeks		period I Secondary: Percent change from treated baseline in LDL-C at the end of period II; percentage of subjects achieving LDL-C <100 or <70 mg/dl at the end of periods I and II; percent change from treated baseline in other lipids, lipoproteins, and high-sensitivity C-reactive protein (hsCRP) at the end of periods I and II; assessment of safety and tolerability	Secondary: The addition of ezetimibe to atorvastatin 10 mg produced significantly greater attainment of LDL-C <100 or <70 mg/dl and significantly greater reductions in total cholesterol, non–HDL cholesterol, apo B, and LDL-C/HDL-C, total/HDL-C, and non-HDL-C/HDL-C ratios than atorvastatin 20 mg or rosuvastatin 10 mg. The change from baseline in HDL-C, triglycerides, apo AI, and hsCRP were similar among treatments. At the end of period II, ezetimibe plus atorvastatin 20 mg reduced LDL-C significantly more than atorvastatin 40 mg (17.4 vs 6.9%, P<0.001); switching from rosuvastatin 10 mg to ezetimibe plus atorvastatin 20 mg reduced LDL-C significantly more than uptitrating to rosuvastatin 20 mg (17.1 vs 7.5%, P<0.001). All treatments were generally well-tolerated.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
plus ezetimibe or uptitrated rosuvastatin to 20 mg				
Goldberg et al.[73] (2006) VYTAL Atorvastatin 10, 20, or 40 mg/day vs simvastatin 20 or 40 mg/day and ezetimibe 10 mg/day	DB, MC, PG, RCT Adult patients with type 2 diabetes between 18 and 80 years of age with HbA_{1c} ≤8.5%, LDL-C >100 mg/dL and a TG level <400 mg/dL	N=1,229 6 weeks	Primary: Percent reduction in LDL-C level at week six Secondary: Proportion of patients who achieved the NCEP ATP III LDL-C goal (<70 mg/dL), proportion of patients who achieved LDL-C level of <100 mg/dL, percent change from baseline in HDL-C, non-HDL-C, TC, TG, and CRP	Primary: Patients randomized to simvastatin 20 mg plus ezetimibe 10 mg combination therapy experienced a greater reduction in LDL-C from baseline at week six of the study compared to patients receiving atorvastatin 10 or 20 mg (53.6, 38.3, and 44.6%, respectively; P<0.001). Patients randomized to simvastatin 40 mg plus ezetimibe 10 mg combination therapy experienced a greater reduction in LDL-C from baseline at week six of the study compared to patients receiving atorvastatin 40 mg (57.6 and 50.9%, respectively; P<0.001). Secondary: A greater proportion of patients randomized to simvastatin 20 mg plus ezetimibe 10 mg combination therapy achieved LDL-C <70 mg/dL compared to patients receiving atorvastatin 10 or 20 mg (59.7, 21.5, and 35%, respectively; P<0.001). A greater proportion of patients randomized to simvastatin 40 mg plus ezetimibe 10 mg therapy achieved LDL-C <70 mg/dL compared to patients receiving atorvastatin 40 mg (74.4 and 55.2%, respectively; P<0.001). A greater proportion of patients randomized to simvastatin 20 mg plus ezetimibe 10 mg therapy achieved LDL-C <100 mg/dL compared to patients receiving atorvastatin 10 or 20 mg (90.3, 70, and 82.1%, respectively; P=0.007). A greater proportion of patients randomized to simvastatin 40 mg plus ezetimibe 10 mg therapy achieved LDL-C <100 mg/dL compared to patients receiving atorvastatin 40 mg (93.4 and 88.8%, respectively; P=0.07). Patients randomized to simvastatin plus ezetimibe combination therapy, at

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				all doses, experienced a significant increase in HDL-C level (P≤0.001), a greater reduction in TC, and non-HDL-C (P<0.001) compared to patients receiving atorvastatin, at all doses. Patients randomized to simvastatin 20 mg plus ezetimibe 10 mg combination therapy experienced a significant reduction in CRP and TG level compared to patients receiving atorvastatin (P=0.02). Side effects were similar in the simvastatin plus ezetimibe and atorvastatin groups (19.85 vs 22.7%).
Kumar et al.[74] (2009) Ezetimibe 10 mg/day plus fenofibrate 160 mg/day vs atorvastatin 10 mg/day	RCT, XO Patients with hypercholesterolemia requiring pharmacotherapy	N=43 12 weeks	Primary: Percentage reduction of LDL-C Secondary: Percent changes from baseline in TC, HDL-C and TG	Primary: LDL-C decreased by 34.6 vs 36.7% with combination therapy and atorvastatin (P=0.46). Secondary: Both treatments provided similar improvements in TC (-25.1 vs -24.6%; P=0.806) and HDL-C (10.1 vs 8.9%; P=0.778). Combination therapy showed a trend towards a greater reduction in TGs (25.4 vs 14.5%; P=0.079), although there were no significant difference between the two treatments in terms of the improvement in TC:HDL-C (-29.0 vs -28.7%; P=0.904).
Stojakovic et al.[75] (2010) Ezetimibe 10 mg/day plus fluvastatin 80 mg/day vs fluvastatin 80 mg/day	PRO, RCT, SB Patients with CHD or CHD risk equivalent with LDL-C 100 to 160 mg/dL	N=90 12 weeks	Primary: Changes from baseline in lipids, apolipoproteins and lipoprotein subfractions Secondary: Not reported	Primary: After 12 weeks, TC, LDL-C and apo B were significantly lowered with both treatments, but the reductions were significantly greater with combination therapy (P<0.001 for all). Combination therapy significantly reduced TG, apo CII, apo CIII and apo E compared to baseline (P<0.001 for all) and fluvastatin (P=0.008, P=0.002 and P=0.007). Apo AI and AII increased with fluvastatin and decreased with combination therapy. Accordingly, HDL-C increased with fluvastatin and decreased with combination therapy, but the difference was not significant (P=0.080). Similar results were observed when only patients with type 2 diabetes were analyzed. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Stein et al.[76] (2008) Fluvastatin XL 80 mg QD vs ezetimibe 10 mg QD vs fluvastatin XL 80 mg QD and ezetimibe 10 mg QD	DB, MC, PG, RCT Patients ≥18 years of age with dyslipidemia who had previously documented muscle related side effects that had led to cessation of statin treatment or patients currently receiving statin treatment whose quality of life was affected by muscle related side effects and required switching to an alternative treatment	N=218 12 weeks	Primary: Percent decrease in LDL-C Secondary: LDL:HDL-C, TC, TG, apo B, proportion of patients achieving LDL-C goal	Primary: LDL-C was reduced by 15.6, 32.8, and 46.1% with ezetimibe monotherapy, fluvastatin XL monotherapy, and fluvastatin XL plus ezetimibe combination therapy, respectively (fluvastatin XL vs ezetimibe: -17.1%, P<0.0001; fluvastatin XL plus ezetimibe vs ezetimibe: -30.4%, P<0.0001). Secondary: Treatment with fluvastatin XL monotherapy and fluvastatin XL plus ezetimibe combination therapy led to a greater reduction in LDL:HDL-C, TC, TG, and apo B levels compared to ezetimibe monotherapy (all, P<0.0001). More patients achieved their target LDL-C goal with fluvastatin XL monotherapy and fluvastatin XL plus ezetimibe combination therapy compared to ezetimibe monotherapy (P<0.001 for fluvastatin XL monotherapy or combination therapy vs ezetimibe monotherapy). There were no serious adverse events, rhabdomyolysis, or creatine kinase increases ≥10 times upper limit of normal. Muscle related side effects were reported in 24% of patients receiving ezetimibe monotherapy compared to 17% of patients in the fluvastatin XL group and 14% of patients in the fluvastatin XL plus ezetimibe combination group. Differences in recurrence of muscle related side effects were not statistically different between treatment groups.
Alvarez-Sala et al.[77] (2008) Fluvastatin XL 80 mg QD (nighttime) and ezetimibe 10 mg QD vs	MC, OL, PG, RCT Patients 18 to 75 years of age with primary hypercholesterolemia (LDL-C ≥130 mg/dL and TG ≤400 mg/dL)	N=89 12 weeks	Primary: Percentage change in LDL-C Secondary: Percentage change in HDL-C and TG, proportions of patients achieving NCEP ATP III LDL-C goals, change in hsCRP	Primary: Fluvastatin XL plus ezetimibe lowered mean LDL-C from 197 mg/dL to 97 mg/dL (-49.9%) and fluvastatin XL alone lowered mean LDL-C from 216 to 135 mg/dL (-35.2%) after 12 weeks of therapy (P<0.001). Secondary: Fluvastatin XL plus ezetimibe combination was associated with a significantly greater reduction from baseline in TC, TG, and apo B than fluvastatin XL alone (P<0.05 for all). There was no significant change in HDL-C level with either treatment regimen. A greater proportion of patients receiving the fluvastatin XL plus

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
fluvastatin XL 80 mg QD (nighttime)			and other markers of inflammation, and safety	ezetimibe achieved NCEP ATP III LDL-C goals at week 12 compared to those receiving fluvastatin XL alone (86.5 vs 66.7%; P=0.042). There were no significant changes in levels of hsCRP with either treatment regimen. In patients with higher baseline hsCRP levels, the coadministration of fluvastatin XL with ezetimibe was associated with a reduced level of this inflammatory marker. Treatment with fluvastatin XL plus ezetimibe or fluvastatin XL alone was associated with significant reductions in IL-1β (21%; P<0.001 and 13%; P<0.002, respectively). No significant changes were seen in levels of interleukin-6, tumor necrosis factor-α, soluble P-selectin, or soluble vascular cell adhesion molecule-1. There was no significant difference in the incidence of adverse events between the treatment groups. Most adverse events were mild or moderate in intensity, with headache being the most common (8.5%).
Winkler et al.[78] (2009) Fluvastatin 80 mg/day plus fenofibrate 200 mg/day vs ezetimibe 10 mg/day plus simvastatin 20 mg/day	MC, OL, RCT, XO Patients 18 to 75 years of age with metabolic syndrome, low HDL-C, waist circumference ≥94 (men) or ≥80 cm (females) plus 1 of the following: TG ≥150 mg/dL, BP (≥85/≥130 mm Hg), fasting glucose ≥100 mg/dL or prevalent type 2 diabetes	N=75 6 weeks	Primary: Changes from baseline in lipids, lipoproteins and apolipoproteins; LDL subfractions Secondary: Not reported	Primary: Reductions in TC, LDL-C and apo B were greater with ezetimibe plus simvastatin compared to fluvastatin plus fenofibrate, but differences only reached significance in patients without small, dense LDL (P=0.043, P=0.006 and P=0.20). Reductions in TG were only significant with fluvastatin plus fenofibrate compared to ezetimibe plus simvastatin in patients with small, dense LDL (P=0.029). Increases in HDL-C and apo AI were only significant with ezetimibe plus simvastatin compared to fluvastatin plus fenofibrate in patients without small, dense LDL (P=0.020 and P=0.015). In patients with small, dense LDL, apo AII was markedly increased by fluvastatin plus fenofibrate, whereas ezetimibe plus simvastatin had no or little effect. Although only significant in small, dense LDL patients, apo CIII was more effectively reduce by fluvastatin plus fenofibrate, while the reduction of apo CII was more pronounced with ezetimibe plus simvastatin in all patients. Secondary: Not reported
Ballantyne et al.[79] (2007)	MC, OL, PG, RCT	N=469	Primary: Percentage of	Primary: Significantly more patients in the combination therapy group achieved the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
EXPLORER Ezetimibe 10 mg QD and rosuvastatin 40 mg QD vs rosuvastatin 40 mg QD	Men and women aged ≥18 years with hypercholesterolemia, history of CHD or clinical evidence of atherosclerosis or CHD risk equivalent (10-year CHD risk score >20%), 2 most recent fasting LDL-C levels of ≥160 mg/dL and <250 mg/dL	6 weeks	patients achieving the NCEP ATP III LDL-C goal (<100 mg/dL) after 6 weeks of treatment Secondary: Percentage of patients achieving the ATP III non-HDL-C goal of <130 mg/dL and LDL level <100 mg/dL when baseline TG ≥200 mg/dL, percentage of patients achieving the 2003 European LDL goal of <100 or 115 mg/dL and combined LDL and TC goals of <100 or 115 mg/dL and <175 or 190 mg/dL, respectively, depending on risk category, percentage change from baseline in LDL, HDL, TC, TG, non-HDL, lipid ratios (LDL:HDL, TC:HDL and non-HDL:HDL), apo	LDL-C goal of <100 mg/dL at week six compared to rosuvastatin alone (94 vs 79.1%; P<0.001). Secondary: The non-HDL-C goal of <130 mg/dL and LDL level <100 mg/dL when baseline TG ≥200 mg/dL were achieved by a significantly higher percentage of patients in the combination therapy group than the monotherapy group (88 patients or 37.4% and 80 patients or 34.8%, respectively; P<0.001). There was a significantly higher percent of patients in the combination therapy group achieving the European LDL goal of <100 or 115 mg/dL and combined LDL and TC goals (LDL <100 or 115 mg/dL and TC <175 or 190 mg/dL), depending on risk category compared to the rosuvastatin group alone at week six (LDL 93.6 vs 74.3%, LDL and TC 90.6 vs 68.3%, respectively; P<0.001). At week six, the combination therapy group had a significantly greater percent reduction of 69.8% in the LDL level compared to a 57.1% reduction in the monotherapy group (P<0.001). Significantly greater reductions in TC, non-HDL-C and TG levels were seen in the combination group compared to the monotherapy group (P<0.001). Both treatment groups increased HDL level to a similar extent (P=0.151). LDL:HDL, TC:HDL and non-HDL:HDL cholesterol ratios decreased significantly more in patients receiving combination therapy compared to patients receiving monotherapy (all P<0.001). Significant decreases in apo B and the apo B:apo AI ratios were seen in the combination therapy group compared to the monotherapy group (P<0.001 for both). Apo AI increased by 3.2% and 1.6% in the combination therapy and monotherapy groups, respectively (P=0.202). The median percent decrease in CRP was significantly higher with combination therapy than monotherapy (-46.4 vs -28.6%; P<0.001). The overall frequency and type of adverse events were similar in both groups, with 31.5% of patients on combination therapy and 33.5% of patients on monotherapy reporting any adverse event. No adverse events were considered related to ezetimibe; the most frequently reported adverse

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			AI, apo B, and apo B:apo AI ratio, and changes in hsCRP in at week 6, safety and tolerability	event was myalgia (3.0% of patients in the rosuvastatin-alone group and 2.9% in the rosuvastatin plus ezetimibe group). There were two patients (0.8%) in the combination therapy group and three patients (1.3%) in the monotherapy group who discontinued the study due to treatment-related adverse events. One death occurred in the combination therapy group due to acute myocardial infarction and this was not considered to be related to study treatment. ALT increases >3 times the upper limit of normal were recorded in three patients, all in the combination therapy group.
Chenot et al.[80] (2007) Simvastatin 40 mg/day vs ezetimibe 10 mg/day and simvastatin 40 mg/day vs no lipid-lowering therapy	RCT Patients, average age 61 years, admitted for an acute MI (with or without ST-segment elevation) to the coronary unit, with pain that started within 24 hours of admission	N=60 7 days	Primary: Change from baseline in LDL-C at days 2, 4 and 7, and the achievement of LDL-C <70 mg/dL Secondary: Not reported	Primary: Patients receiving ezetimibe plus simvastatin combination therapy experienced a statistically significant LDL-C reduction from baseline on days two, four, and seven (27, 41, and 51%, respectively; P<0.001). Patients on the simvastatin monotherapy experienced a statistically significant LDL-C reduction from baseline on days two, four, and seven (15, 27, and 25%, respectively; P<0.001). There was no statistically significant change from baseline in LDL-C in the no lipid-lowering therapy group (P≥0.09). Patients on the ezetimibe plus simvastatin combination therapy achieved lower LDL-C levels compared to the simvastatin monotherapy group at day four (P=0.03) and day seven (P=0.002) of the study. A greater proportion of patients randomized to the ezetimibe plus simvastatin combination therapy achieved LDL-C <70 mg/dL, compared to the simvastatin monotherapy group at day four and day seven (45 vs 5, and 55 vs 10%, respectively). Secondary: Not reported
Gaudiani et al.[81] (2005) Simvastatin 20 mg/day and ezetimibe 10	DB, MC, PG, RCT Patients 30 to 75 years of age with type 2 diabetes (HbA_{1c} ≤9.0%), treated with a	N=214 30 weeks	Primary: Percent change from baseline in LDL-C Secondary:	Primary: LDL-C was reduced more by the addition of ezetimibe to simvastatin than by doubling the dose of simvastatin (20.8 vs 0.3%; P<0.001). Secondary: TC (14.5 vs 1.5%; P<0.001), non-HDL-C (20.0 vs 1.7%; P<0.001), apo B

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs simvastatin 40 mg/day All patients received simvastatin 20 mg/day for a 6 week run in period.	stable dose of pioglitazone (15 to 45 mg/day) or rosiglitazone (2 to 8 mg/day) for ≥3 months, LDL-C >100 mg/dL and TG <600 mg/dL (if already on a statin therapy)		Percent change from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B and apo AI	(14.1 vs 1.8%; P<0.001), LDL-C:HDL-C (P<0.001), TC:HDL-C (P<0.001) and apo AI (P<0.001) were reduced more by the addition of ezetimibe to simvastatin than by doubling the dose of simvastatin. The increase in HDL-C was similar between the two treatments (P value not reported). The incidence of treatment-related adverse effects was lower with simvastatin compared to combination therapy (10.0 vs 18.3%, respectively; P value not reported).
Feldman et al.[82] (2004) Ezetimibe 10 mg/day plus simvastatin 10, 20, or 40 mg/day vs simvastatin 20 mg/day	DB, MC, RCT Patients 18 to 80 years of age with CHD or CHD risk equivalent disease and LDL-C ≥130 mg/dL and TG ≤350 mg/dL	N=710 23 weeks	Primary: Proportion of patients with LDL-C <100 mg/dL at week five Secondary: Proportion of patients with LDL-C <100 mg/dL at 23 weeks	Primary: A significantly greater proportion of patients receiving combination therapy achieved LDL-C <100 mg/dL at week five compared to patients receiving simvastatin (P<0.001). Secondary: A significantly greater proportion of patients receiving combination therapy achieved LDL-C <100 mg/dL at week 23 compared to patients receiving simvastatin (P<0.001). At five weeks, there was a significant reduction in TC, non-HDL-C, apo B, TC:HDL-C and LDL-C:HDL-C with combination therapy compared to simvastatin (P<0.001 for all). HDL-C was significantly increased with combination therapy (10/20 mg) compared to simvastatin (P<0.05). At five weeks, combination therapy was associated with a significant reduction in TG compared to simvastatin (P<0.05). Treatment-related adverse effects were similar with simvastatin and combination therapy (10/10, 10/20 and 10/40 mg) (7.5, 9.6, 14.0 and 10.0%, respectively; P values not reported).
Okada et al.[83]	MC, OL, PG, PRO,	N=171	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2011) Ezetimibe 10 mg/day plus atorvastatin 10 mg/day vs ezetimibe 10 mg/day plus rosuvastatin 2.5 mg/day vs atorvastatin 20 mg/day vs rosuvastatin 5 mg/day	RCT Patients ≥20 years of age with CAD whose LDL-C levels were ≥100 mg/dL after ≥4 weeks of treatment with atorvastatin 10 mg/day or rosuvastatin 2.5 mg/day	12 weeks	Change from baseline in LDL-C, HDL, TG, TC, proportion of patients achieving an LDL-C <100 mg/dL Secondary: Not reported	In both the ezetimibe plus statin group and the double-dose statin group, LDL-C levels decreased from baseline to 12 weeks; however, the decrease was significantly greater in the ezetimibe plus statin group (24.7±12.1 vs -16.4±11.7%; P<0.01). The proportion of patients achieving the LDL-C goal of <100 mg/dL was significantly higher in the ezetimibe plus statin group compared to doubling the statin dose (76.1 vs 58.9%; P<0.05). The HDL-C level increased in the ezetimibe plus statin group and decreased in the double-dose statin group (2.7±16.6 vs -1.0±17.2%; P<0.05). The triglyceride level decreased for patients receiving ezetimibe plus a statin compared to an increase in triglycerides for patients who received an increased dose of statin (-9.4±30.2 vs 3.1± 40.7%, P<0.05).
Gagné et al.[84] (2002) Statin 40 mg for up to 14 weeks, followed by the addition of ezetimibe 10 mg QD for another 12 weeks, administered as separate entities vs	DB, MC, RCT Patients ≥12 years old (or with body weight ≥40 kg) with hoFH, LDL-C ≥100 mg/dL and TG ≤350 mg/dL (if on atorvastatin or simvastatin 40 mg/day)	N=50 26 weeks	Primary: Percent change in LDL-C from baseline to the end of treatment period Secondary: Percent change from baseline in total cholesterol, TG, HDL-C, the ratios of LDL-C:HDL-C and TC:HDL-C, non–	Primary: LDL-C was reduced more by the addition of ezetimibe 10 mg to the statin than by doubling the dose of statin (20.7 vs 6.7%; P=0.007). Secondary: TC was reduced more by the addition of ezetimibe 10 mg to the statin than by doubling the dose of statin (18.7 vs 5.3%; P<0.01). There was no statistically significant difference in any of the other secondary outcome measures between the two groups (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
statin 40 mg for up to 14 weeks, followed by titration to 80 mg daily and addition of ezetimibe 10 mg QD daily for another 12 weeks, administered as separate vs statin 40 mg for up to 14 weeks, followed by titration to 80 mg daily Statins used in the study included simvastatin and atorvastatin.			HDL-C, apo B, apo AI, and CRP	
McKenney et al.[85] (2007) COMPELL Rosuvastatin 10 mg/day for 4 weeks, followed by 20 mg/day for 4 weeks, followed by 40 mg/day vs	MC, OL, PG, RCT Patients ≥21 years of age with hyper-cholesterolemia, eligible for treatment based on the NCEP ATP III guidelines, with 2 consecutive LDL-C levels within 15% of each other and mean TG ≤300 mg/dL	N=292 12 weeks	Primary: Change from baseline in LDL-C Secondary: Change from baseline in HDL-C non-HDL-C, TG, Lp(a) and apo B; side effects	Primary: Atorvastatin plus niacin SR, rosuvastatin plus niacin SR, simvastatin plus ezetimibe and rosuvastatin were associated with similar reductions in LDL-C (56, 51, 57 and 53%, respectively; P=0.093). Secondary: Atorvastatin plus niacin SR was associated with a significant increase in HDL-C compared to simvastatin plus ezetimibe and rosuvastatin-containing therapy (22, 10 and 7%, respectively; P≤0.05). There was no significant differences in the reduction of non-HDL-C from baseline with any treatment (P=0.053).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
atorvastatin 20 mg/day plus niacin SR 500 mg/day for 4 weeks, followed by atorvastatin 20 mg/day plus niacin SR 1,000 mg/day for 4 weeks, followed by atorvastatin 40 mg/day plus niacin SR 2,000 mg/day vs simvastatin 20 mg/day plus ezetimibe 10 mg/day for 8 weeks, followed by simvastatin 40 mg/day plus ezetimibe 10 mg/day vs rosuvastatin 10 mg/day plus niacin SR 500 mg/day for 4 weeks, followed by rosuvastatin 10 mg/day plus niacin SR 1,000 mg/day for 4 weeks, followed by rosuvastatin 20				Atorvastatin plus niacin SR was associated with a significant reduction in TG compared to simvastatin plus ezetimibe and rosuvastatin-containing therapy (47, 33 and 25%, respectively; P≤0.05). Atorvastatin plus niacin SR was associated with a significant reduction in Lp(a) compared to simvastatin plus ezetimibe and rosuvastatin (20 mg)-containing therapy (-14, 7 and 18%, respectively; P≤0.05). Atorvastatin plus niacin SR was associated with a significant reduction in apo B compared to rosuvastatin (43 vs 39%, respectively; P≤0.05). Side effects were similar across treatments (P values not reported). There were no cases of myopathy or hepatotoxicity reported.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day plus niacin SR 1,000 mg/day				
Cannon et al.[86,87] (2015) ODYSSEY COMBO II Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 12 if LDL ≥1.8 mmol/L) vs ezetimibe 10 mg QD Patients continued to take statin therapy. Other lipid lowering therapy was not permitted. All patients were instructed to follow a stable Therapeutic Lifestyle Changes diet, as outlined by the ATP III or an equivalent diet for the duration of the study.	AC, DB, DD, MC, PG, RCT Patients ≥18 years of age with established heart disease or CHD equivalent, LDL-C ≥70 mg/dL and established heart disease or LDL-C ≥ 100 mg/dL and no established heart disease but at a high risk for CVE and elevated LDL-C despite maximal doses of statins at maximum tolerated dosage for at least four weeks before screening	N=720 104 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Absolute cholesterol change, percent of patients achieving goal of LDL-C <70 mg/dL, other lipoprotein evaluations and safety evaluations	Primary: Alirocumab was associated with a significantly greater reduction in mean LDL-C from baseline at week 24 compared to ezetimibe (50.6 ± 1.4% vs 20.7 ± 1.9%; 29.8% ± 2.3% difference; P<0.0001). Secondary: Seventy seven percent of alirocumab and 45.6% of ezetimibe patients achieved LDL-C <1.8 mmol/L (P<0.0001). As compared with the ezetimibe group, the alirocumab group had greater reductions from baseline to week 24 in levels of non–HDL-C, apoB, TC, lipoprotein(a) and had a modest increase in levels of HDL-C (P<0.0001 for all comparisons). TG were reduced from baseline to week 24 by 13.0 ± 1.5% in the alirocumab group and by 12.8 ± 2.0% in the ezetimibe group, but the difference between treatment arms was not statistically significant. Alirocumab was generally well tolerated, with no evidence of an excess of treatment-emergent adverse events. Adjudicated cardiovascular events were infrequent, occurring in 4.8% (n=23) of the alirocumab group vs 3.7% (n=9) in the ezetimibe group. Treatment-emergent local injection site reactions occurred in 2.5% of patients in the alirocumab arm vs 0.8% for ezetimibe arm.
Roth et al.[88]	DB, MC, PC, RCT	N=103	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2015) ODYSSEY MONO Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 8 if LDL ≥70 mg/dL) vs ezetimibe 10 mg QD	Patients with primary hyper-cholesterolemia and moderate risk for CVE and LDL-C ≥100mg/ dL and ≤190mg/dL	34 weeks	Percent change in calculated LDL-C from baseline to week 24 Secondary: Safety evaluations	There was a significantly greater decrease in LDL-C with alirocumab from baseline at week 24 compared to ezetimibe (47.2% vs 15.6%; P<0.0001). Secondary: Safety parameters and adverse events were similar between the two groups. The most common class of adverse events was infections (39.2% with ezetimibe vs 42.3% with alirocumab), which included nasopharyngitis, influenza, and upper respiratory tract infection. Injection-site reactions occurred in less than 2% of patients in both groups. Muscle-related adverse events occurred in 3.9% of patients treated with ezetimibe and 3.8% of patients treated with alirocumab.
Bays et al.[89,90] (2015) ODYSSEY OPTIONS I Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 12 if LDL ≥70 mg/dL) vs ezetimibe 10 mg QD vs atorvastatin (at double baseline dose)	AC, DB, MC, PG, RCT Patients ≥18 years of age with LDL-C ≥70 mg/dL and established heart disease or LDL-C ≥ 100 mg/dL and risk factors for CVE	N=355 24 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Safety evaluations	Primary: Among atorvastatin 20 and 40 mg regimens respectively, there was a significantly greater decrease in LDL-C with alirocumab add-on from baseline at week 24 compared to add-on ezetimibe, double dose atorvastatin and switching to rosuvastatin (44.1% and 54.0% vs 20.5% and 22.6%, 5.0% and 4.8%, and 21.4%; P<0.001 vs all comparators). Most alirocumab-treated patients (86%) maintained their 75 mg every two weeks regimen. Secondary: Treatment-emergent adverse events occurred in 65.4% of alirocumab patients, compare to 64.4% ezetimibe and 63.8% double atorvastatin/switch to rosuvastatin (data pooled).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs rosuvastatin 40 mg QD (atorvastatin 40 mg baseline dose cohort only) Prior to randomization, patients were stabilized on atorvastatin 20 mg to 40 mg QD.				
Moriarty et al.[97] (2015) ODYSSEY ALTERNATIVE Alirocumab 75 mg SC every 2 weeks vs ezetimibe 10 mg/ day vs atorvastatin 20 mg/ day	AC, DB, MC, PG, RCT Patients with primary hypercholesterolemia at moderate to high cardiovascular risk with statin intolerance (unable to tolerate ≥2 statins, including one at the lowest approved starting dose) due to muscle symptoms	N=314 24 weeks	Primary: Percent change in calculated LDL–C from baseline to 24 weeks Secondary: Change from baseline to 24 weeks using on-treatment (modified ITT) LDL-C values, and percent change from baseline to 12 and 24 weeks in LDL-C, apolipoprotein B, non–HDL-C, total cholesterol, lipoprotein(a), HDL-C, apolipoprotein A1,	Primary: For the primary ITT efficacy analysis, LS mean change in LDL-C concentrations from baseline to week 24 were −45.0% for alirocumab and −14.6% for ezetimibe, with a difference between groups of −30.4% (P<0.0001). Secondary: For the on-treatment analysis, the change from baseline was −52.2% for alirocumab and −17.1% for ezetimibe (LS mean difference of −35.1%; P<0.0001). A substantial reduction in LDL-C concentration occurred over the first four weeks, which was greater in the alirocumab arm and persisted throughout the 24-week treatment period. At week 24, 52 (41.9%) patients on alirocumab and 5 (4.4%) of those on ezetimibe (P<0.0001; ITT analysis) reached an LDL-C goal of <70 mg/dL in very high cardiovascular risk patients or <100 mg/dL in moderate-to-high-risk patients. Corresponding results in the on-treatment population were 51.2% and 5.6% (P<0.0001). The greater effect of alirocumab relative to ezetimibe on LDL-C-lowering from baseline to week 24 was consistent across most of the prespecified subgroups in the ITT population. In addition, reductions in apolipoprotein B, non–HDL-C, total cholesterol and lipoprotein(a) concentrations were greater for alirocumab vs ezetimibe (all P<0.0001). There were no statistically significant differences between the two groups in changes in triglyceride, HDL-C, and apolipoprotein A1

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			and fasting triglyceride concentrations; adverse events	concentrations. Overall rates of treatment-emergent and serious AEs were generally similar between treatment arms, and there were no deaths in the study.
Farnier et al.[92] (2016) ODYSSEY OPTIONS II Add-on alirocumab 75 mg every 2 weeks (1-mL subcutaneous injection via pre-filled pen) vs add-on ezetimibe 10 mg/day vs double-dose rosuvastatin All patients received baseline rosuvastatin regimens (10 or 20 mg)	DB, DD, MC, RCT Patients with cardiovascular disease and LDL–C ≥70 mg/dL or cardiovascular disease risk factors and LDL–C ≥100 mg/dL	N=305 24 weeks	Primary: Percent change in calculated LDL–C from baseline to 24 weeks Secondary: Percent change from baseline in calculated LDL–C on-treatment at Week 24 in the modified ITT (mITT) population (on-treatment analysis), percent change in LDL–C from baseline to Week 12 (ITT and on-treatment), the percent change in other lipid parameters, and the proportion of very-high and high CV risk patients reaching LDL–C <70 mg/ or <100 mg/ at Week 24, respectively, in both ITT and on-treatment analyses; Safety	Primary: In the baseline rosuvastatin 10 mg regimen ITT analysis, alirocumab add-on treatment significantly reduced LDL–C levels at Week 24 versus the other comparators (P<0.0001). From baseline, add-on alirocumab reduced LDL–C by 50.6%, add-on ezetimibe reduced LDL–C by 14.4%, and double-dose (20 mg) rosuvastatin reduced LDL–C by 16.3%. In the baseline rosuvastatin 20 mg regimen ITT analysis, mean reductions from baseline in LDL–C at Week 24 were greater in the alirocumab add-on group versus the other comparators. LDL–C reductions were 36.3% in the add-on alirocumab group, compared with 11.0% in the add-on ezetimibe group (P=0.0136) and with 15.9% in the double-dose (40 mg) rosuvastatin group (P=0.0453). However, the pre-specified threshold P-value for these 4-way comparisons was 0.0125; therefore, both primary comparisons failed to reach statistical significance in the baseline rosuvastatin 20 mg regimen. Secondary: As a result of both primary comparisons failing to reach statistical significance, all key secondary efficacy endpoints were not tested for statistical significance with respect to the two comparisons in the baseline rosuvastatin 20 mg regimen. In the baseline rosuvastatin 10 mg regimen groups, the proportion of patients at very-high and high CV risk who reached a LDL–C level of <70 mg/dL or <100 mg/dL at Week 24, depending on risk status, was significantly greater in the alirocumab add-on group (84.9%) compared with the ezetimibe add-on group (57.2%; P=0.0007) and the rosuvastatin 20 mg group (45.0%; P<0.0001). The proportion of patients who reached the more stringent LDL–C level of <70 mg/dL at Week 24 was also significantly greater in the alirocumab add-on group (77.8%) compared with the ezetimibe add-on and rosuvastatin 20 mg groups (43.1%; P<0.0001 and 31.3%; P<0.0001), respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Treatment-emergent adverse events occurred in 56.3% of alirocumab patients versus 53.5% ezetimibe and 67.3% double-dose rosuvastatin (pooled data).
Stroes et al.[93] (2014) GAUSS-2 Evolocumab 140 mg injected SC every two weeks vs evolocumab 420 mg injected SQ monthly vs ezetimibe 10 mg QD	AC, DB, MC, RCT Patients 18 to 80 years of age with an LDL-C above ATP III goal and a previous intolerance to ≥2 statins	N=307	Primary: LDL-C at week 12 and mean of weeks 10 and 12 Secondary: Percentage of patients with LDL-C <70 mg/dL, non HDL-C, apoB, apoB/apolipoprotein A1, lipoprotein (a), TG, TC/HDL-C, VLDL and safety evaluations.	Primary: Evolocumab reduced LDL-C from baseline by 53% (every two weeks) to 56% (monthly), corresponding to treatment differences versus ezetimibe of 37 to 39% (P<0.001). Mean percent reductions from baseline and treatment differences at week 12 were similar (P<0.001). Secondary: Evolocumab-treated patients were more likely to achieve LDL-C target levels than ezetimibe-treated patients. Compared with ezetimibe, evolocumab led to significant reductions in apoB, lipoprotein(a), non–HDL-C and the apoB/apolipoprotein A-I and TC/HDL-C ratios (P<0.001) Muscle adverse events occurred in 12% of evolocumab-treated patients and 23% of ezetimibe-treated patients. Treatment-emergent adverse events and laboratory abnormalities were comparable across treatment groups.
Nissen et al.[94] (2016) GAUSS-3 Evolocumab (420 mg monthly subcutaneously) vs ezetimibe (10 mg daily by mouth)	DB, DD, RCT Patients 18 to 80 years of age with elevated LDL-C levels who were unable to tolerate an effective dose of a statin because of muscle-related adverse effects	N=491 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not	Primary: Mean percent change in LDL-C level from baseline to the mean of weeks 22 and 24 levels and from baseline to week 24 levels Secondary: Absolute change from baseline in LDL-C level; percent change	Primary: Mean percent change in LDL-C level from baseline to the mean of weeks 22 and 24 levels showed a least-squares mean change of −16.7% (95% CI, −20.5 to −12.9%) for ezetimibe and −54.5% (95% CI, −57.2 to −51.8%) for evolocumab: a mean difference of −37.8% (95% CI, −42.3 to −33.3%; P<0.001). Mean percent change in LDL-C level from baseline to the week 24 showed a least-squares mean change of −16.7% (95% CI, −20.8 to −12.5%) for ezetimibe and −52.8% (95% CI, −55.8 to −49.8%) for evolocumab: a mean difference of −36.1% (95% CI, −41.1 to −31.1%; P<0.001). Secondary: Secondary end points including percent changes in levels of total

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
		placebo; followed by 2-week washout; followed by 24-week comparison	from baseline in levels of total cholesterol, non–high-density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (ApoB); percent change from baseline in total cholesterol to HDL-C ratio and ApoB to apoliprotein A1 ratio; and the percentage of patients achieving an LDL-C level less than 70 mg/dL; safety	cholesterol, non–HDL-C, and ApoB; total cholesterol to HDL-C ratio; and ApoB to apolipoprotein A1 ratio showed similar results, with P<0.001 demonstrating greater cholesterol reductions in the evolocumab group. Muscle symptoms were reported in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treated patients (P=0.17). Active study drug was stopped for muscle symptoms in 5 of 73 ezetimibe-treated patients (6.8%) and 1 of 145 evolocumab-treated patients (0.7%).
Trials Assessing Atherosclerosis Progression and Cardiovascular Outcomes				
Kastelein et al.[95] (2008) ENHANCE Ezetimibe 10 mg QD vs placebo All patients received simvastatin 80 mg QD.	DB, MC, PC, PRO, RCT Men and women between the ages of 30 and 75 years with familial hypercholesterolemia regardless of their previous treatment with lipid-lowering drugs, baseline LDL-C ≥210 mg/dL without treatment	N=720 24 months	Primary Change in mean CIMT (defined as average of means of far wall IMT of right and left common carotid arteries and bulbs and internal carotid arteries) Secondary: Proportion of patients with regression in the	Primary The mean change in the carotid artery IMT was 0.0058±0.0037 mm with placebo and 0.0111±0.0038 mm with ezetimibe (P=0.29). Secondary: There was no significant difference in the proportion of patients with regression in the mean carotid artery IMT (44.4 vs 45.3%; P=0.92) or new plaque formation (2.8 vs 4.7%; P=0.20) receiving placebo vs ezetimibe, respectively. No significant change from baseline was reported in the mean maximum carotid artery IMT (0.0103±0.0049 and 0.0175±0.0049 mm, respectively; P=0.27). No significant changes were observed between study groups regarding

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			mean CIMT or new carotid artery plaques of more than 1.3 mm, change from baseline in mean maximal carotid artery IMT and average mean IMT of carotid and common femoral arteries, lipid parameters, CRP, adverse events	mean measures of IMT of the common carotid artery (P=0.93), carotid bulb (P=0.37), internal carotid artery (P=0.21) and femoral artery (P=0.16) or average of the mean values for carotid and femoral artery IMT (P=0.15). After 24 months, mean LDL-C decreased by 39.1 mg/dL in the placebo group and by 55.6 mg/dL in the ezetimibe group (between-group difference of 16.5%; P<0.01). Reductions in TG (between-group difference of 6.6%; P<0.01) and CRP (between-group difference of 25.7%; P<0.01) were significantly higher with ezetimibe compared to placebo. Adverse events (29.5 vs 34.2%; P=0.18) and discontinuation rates (9.4 vs 8.1%; P=0.56) were similar between placebo and ezetimibe.
Rossebø et al.[96] (2008) SEAS Ezetimibe 10 mg QD and simvastatin 40 mg QD vs placebo OL lipid-lowering therapy, which included up to 40 mg of simvastatin or an equipotent dose of another lipid-lowering drug, could be	DB, MC, RCT Patients 45 to 85 years of age who had asymptomatic, mild-to-moderate aortic valve stenosis with a peak aortic-jet velocity of 2.5 to 4 m per second	N=1,873 52.2 months (median duration)	Primary: Composite of major cardiovascular events (death from cardiovascular causes, aortic-valve replacement, CHF as a result of progression of aortic-valve stenosis, nonfatal MI, hospitalization for unstable angina, CABG, PCI, non-hemorrhagic stroke) Secondary: Aortic-valve	Primary: The composite of major cardiovascular events occurred in 35.3% of patients in the simvastatin plus ezetimibe group and in 38.2% of patients in the placebo group (HR, 0.96; 95% CI, 0.83 to 1.12; P=0.59). Secondary: There was no significant difference between the treatments in aortic-valve-related events (HR, 0.97; 95% CI, 0.83 to 1.14; P=0.73). Aortic-valve replacement occurred in 28.3% of patients in the simvastatin plus ezetimibe group and in 29.9% of patients in the placebo group (HR, 1.00; 95% CI, 0.84 to 1.18; P=0.97). Ischemic cardiovascular events occurred in 15.7% of patients in the simvastatin plus ezetimibe group compared to 20.1% of patients in the placebo group (HR, 0.78; 95% CI, 0.63 to 0.97; P=0.02). A total of 7.3% of patients in the simvastatin plus ezetimibe group required CABG compared to 10.8% of patients in the placebo group (HR, 0.68; 95% CI, 0.50 to 0.93; P=0.02). There was no significant difference in the progression of aortic stenosis

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
administered in addition to the study drug at the discretion of each treating physician.			events, progression of aortic stenosis, safety	between the treatment groups. The mean peak aortic jet velocity was 3.71 m per second in the placebo group compared to 3.69 m per second in the simvastatin plus ezetimibe group at the end of the study (95% CI, -0.06 to 0.05; P=0.83). The mean pressure gradient increased to 34.4 mm Hg in the placebo group compared to 34.0±15.1 mm Hg in the simvastatin plus ezetimibe group at the end of the study. There was no significant difference in the aortic-valve area between the treatment groups. There was no significant difference in overall mortality among the treatment groups (P=0.80). The composite outcome of death from cardiovascular causes and the individual components of this composite outcome did not differ significantly between the two groups (P=0.34). There was a significant increase in the number of patients with elevated liver enzyme levels in the simvastatin plus ezetimibe group. There was also a higher incidence of cancer in the simvastatin plus ezetimibe group (11.1%) compared to placebo (7.5%; P=0.01).
Sampalis et al.[97] (2007) Ezetimibe 10 mg/day vs placebo All patients received statin therapy.	Post-hoc analysis Adult patients with hypercholesterolemia, with LDL-C levels exceeding the NCEP ATP goals on statin therapy	N=825 6 weeks	Primary: Reduction in the 10-year risk of CAD after six weeks Secondary: Not reported	Primary: The addition of ezetimibe to ongoing statin therapy was associated with a 25.3% reduction in the 10-year risk of CAD (P<0.001). Secondary: Not reported
Cannon et al.[98] (2015) Ezetimibe 10 mg (simvastatin–	DB, RCT Patients ≥50 years of age who had been hospitalized within the	N=18,144 ≥2.5 years (median of 6 years)	Primary: Composite of death from cardiovascular disease, a major	Primary: Kaplan–Meier event rates for the primary end point at seven years were 32.7% in the simvastatin–ezetimibe group and 34.7% in the simvastatin-monotherapy group (absolute risk reduction, 2.0 percentage points; HR, 0.936; 95% CI, 0.89 to 0.99; P=0.016).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
ezetimibe group) vs placebo (simvastatin-monotherapy group) All patients received simvastatin 40 mg	preceding 10 days for an acute coronary syndrome (an acute myocardial infarction, with or without ST-segment elevation on electrocardiography, or high-risk unstable angina) who had LDL-C >50 mg/dL		coronary event (nonfatal MI, documented unstable angina requiring hospital admission, or coronary revascularization occurring at least 30 days after randomization), or nonfatal stroke Secondary: A composite of death from any cause, major coronary event, or nonfatal stroke; a composite of death from coronary heart disease, nonfatal MI, or urgent coronary revascularization ≥30 days after randomization; and a composite of death from cardiovascular causes, nonfatal MI, hospitalization for unstable angina, all revascularization ≥30 days after randomization, or	Secondary: A composite of death from any cause, major coronary event, or nonfatal stroke: HR, 0.95; 95% CI, 0.90 to 1.0; P=0.03 A composite of death from coronary heart disease, nonfatal MI, or urgent coronary revascularization ≥30 days after randomization: HR, 0.91; 95% CI, 0.85 to 0.98; P=0.02 A composite of death from cardiovascular causes, nonfatal MI, hospitalization for unstable angina, all revascularization ≥30 days after randomization, or nonfatal stroke: HR, 0.95; 95% CI, 0.90 to 1.0; P=0.04

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			nonfatal stroke	
Fleg et al.[99] (2008) SANDS Ezetimibe 10 mg QD vs placebo All patients received aggressive statin therapy. Patients in the standard treatment arm served as the control group for this post-hoc analysis.	Subgroup analysis OL, RCT American Indian men and women ≥40 years of age with type 2 diabetes, LDL-C >100 mg/dL, SBP >130 mm Hg, and no prior cardiovascular events; this trial examined the effects of aggressive goals for LDL-C (<70 mg/dl), non-HDL-C (<100 mg/dL), and BP (<115/75 mm Hg) reduction vs standard goals of <100 mg/dL, <130 mg/dL, and <130/80 mm Hg, respectively.	N=427 3 years	Primary: CIMT after 36 months of treatment Secondary: Not reported	Primary: After 36 months, CIMT progressed in the standard group and regressed in the aggressive subgroups (ezetimibe plus statin and placebo; P<0.001 vs the standard group). There was a similar percent of patients in the aggressive treatment arms who demonstrated no change or a decrease in CIMT with ezetimibe plus statin compared to placebo (62 vs 61%, respectively). Only 39% of patients in the standard arm demonstrated no change or a decrease in CIMT (P<0.0001 vs the aggressive arm). Cardiovascular events occurred in 3.5, 5.8, and 3.3% of patients in the standard, aggressive with ezetimibe plus statin, and aggressive statin monotherapy subgroups (placebo), respectively (P=0.62). Secondary: Not reported
Taylor et al.[100] (2009) Ezetimibe 10 mg QD vs niacin SR (Niaspan®) 2 g (titrated) QD	OL, PG, RCT Patients ≥30 years of age with atherosclerotic coronary or vascular disease or a CHD risk equivalent (diabetes mellitus, 10-year Framingham risk score ≥20%, coronary calcium score >200 for women or >400 for	N=208 14 months	Primary: Change in CIMT after 14 months Secondary: Change in lipid values, composite of major adverse cardiovascular events (MI, myocardial revascularization, admission to the	Primary: Treatment with niacin led to a significant reduction in mean and maximal CIMT at eight months (P=0.001 and P=0.004, respectively) and 14 months (P=0.001 and P<0.001, respectively). There was no significant change in mean or maximal CIMT with ezetimibe at eight or 14 months compared to baseline. There was a significant difference between the niacin group and the ezetimibe group (P=0.003). Secondary: The change in LDL-C in the ezetimibe group was -17.6 mg/dL compared to -10.0 mg/dL in the niacin group (P=0.01). The change in HDL-C in the ezetimibe group was -2.8 mg/dL compared to 7.5 mg/dL in the niacin group (P<0.001). There were significant reductions in TG in both groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	men who were receiving treatment with a statin (LDL-C <100 mg/dL and HDL-C <50 mg/dL for men or <55 mg/dL for women)		hospital for an acute coronary syndrome, and death from CHD), discontinuation of study drug due to adverse effects, health-related quality of life	Major adverse cardiovascular events occurred in 5% of patients receiving ezetimibe compared to 1% of patients receiving niacin (P=0.04). Adverse drug effects led to withdrawal from the study in three of nine patients receiving ezetimibe and 17 of 27 patients receiving niacin (P=0.12). There was no significant difference between the two groups in the quality of life at baseline or at 14 months.
Pauriah et al.[101] (2014) Simvastatin monotherapy vs high-potency statin group (patients who started on simvastatin and switched to atorvastatin or rosuvastatin vs ezetimibe/statin combination group	OS, RETRO Patients who had survived 30 days after their first acute MI, had not received prior statin or ezetimibe therapy, and were started on a statin within 30 days of acute MI	N=9,597 Mean follow-up of 3.2 years	Primary: Mortality, lipid levels Secondary: Not reported	Primary: The adjusted HR for the high-potency statin group was 0.72 (95% CI, 0.59 to 0.88; P<0.001), and for the ezetimibe/statin combination group, the adjusted HR was 0.96 (95% CI, 0.64 to 1.43; P<0.85). In the subgroup analysis of 2787 patients with complete data for GFR, cholesterol, and blood pressure, the HR for ezetimibe use and high-potency statin use were 1.03 (95% CI, 0.47 to 2.23; P=0.943) and 0.79 (95% CI, 0.55 to 1.131; P=0.19), respectively. There was a decrease in total cholesterol and LDL-C in all three groups with significantly greater percentage decrease in these measures in the high-potency statin group and the ezetimibe/statin combination group compared with the simvastatin monotherapy group. Because of higher baseline total cholesterol levels, the best achieved total cholesterol levels were not lower in the high-potency statin and ezetimibe/statin combination groups. Secondary: Not reported
Meaney et al.[102] (2009) VYCTOR Pravastatin 40 mg QD (ezetimibe 10 mg/day could be	RCT, OL Patients 40 to 72 years of age with a 10-year absolute risk for coronary death or myocardial infarction	N=90 1 year	Primary: Change in CIMT Secondary: Changes in LDL-C and hsCRP	Primary: After one year, CIMT values were 0.93mm (-30%; P<0.01 vs baseline), 0.90 mm (-30%; P<0.01 vs baseline), and 0.92 mm (-25%; P<0.01 vs baseline) for pravastatin, simvastatin, and simvastatin-ezetimibe groups, respectively. There was no significant difference among the treatment groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
added if LDL <100 mg/dL if they had CHD or diabetes or <70 mg/dL if they had both conditions) vs simvastatin 40 mg QD (dose could be increased to 80 mg/day if LDL <100 mg/dL if they had CHD or diabetes or <70 mg/dL if they had both conditions) vs simvastatin-ezetimibe 20-10 mg QD (dose of simvastatin could be increased to 40 mg/day if LDL <100 mg/dL if they had CHD or diabetes or <70 mg/dL if they had both conditions)	≥20 according to the ATP III recommendations			Secondary: At the end of the study, LDL-C levels were 48, 45, and 48 mg/dL for pravastatin, simvastatin, and simvastatin-ezetimibe groups, respectively (P<0.01 vs baseline for all). There was no significant difference among the treatment groups. The proportion of diabetic patients who attained LDL-C <70 mg/dL at the end of the trial were 62, 80, and 78% for pravastatin, simvastatin, and simvastatin-ezetimibe groups, respectively (P values not significant). There was no significant difference among the treatment groups. There were no significant differences in hsCRP, HDL-C, TG among the treatment groups.

Drug regimen abbreviations: QD=once-daily, SR=sustained-release, XR=extended-release
Study abbreviations: AC=active comparator, DB=double=blind, DD=double dummy, ES=extension study, MA=meta-analysis, MC=multicenter, OL=open label, OR=odds ratio, OS= observational study, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized control trial, RETRO=retrospective, SB=single-blind, XO=cross-over
Miscellaneous abbreviations: apo=apolipoprotein, ALT=alanine aminotransferase, AST=aspartate aminotransferase, AVD=atherosclerotic vascular disease, BP=blood pressure, BMI=body mass index, CABG=coronary artery bypass graft, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, CIMT=carotid intima-media thickness, CK=creatine kinase, CRP=C-reactive protein, FPG=fasting plasma glucose, HAART=highly active antiretroviral therapy, HbA_{1c}=glycosylated hemoglobin, HDL-C=high-density lipoprotein cholesterol,

heFH=heterozygous familial hypercholesterolemia, HIV=human immunodeficiency virus, HR=hazard ratio, hoFH=homozygous familial hypercholesterolemia, hsCRP=high-sensitivity C-reactive protein, IDL-C=intermediate-density lipoprotein cholesterol, IMT=intima-media thickness, JBS2=Joint British Society 2, LDL-C=low-density lipoprotein cholesterol, Lp(a)=lipoprotein(a), MDA-LDL= malondialdehydemodified LDL, MI=myocardial infarction, NCEP ATP=National Cholesterol Education Program Adult Treatment Panel, OR=odds ratio, PCI=percutaneous intervention, RLP-C=remnant-like particle cholesterol, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol, TG=triglyceride, US=United States, VLDL-C=very low-density lipoprotein cholesterol, WMD=weighted mean difference

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Cholesterol Absorption Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Ezetimibe	tablet	Zetia®*	$$$$$	$$$$$

N/A=Not available.

X. Conclusions

Ezetimibe is the only cholesterol absorption inhibitor in this class and it is available in a generic formulation. It is approved for the treatment of primary hypercholesterolemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, and homozygous familial sitosterolemia.[1]

In general, therapeutic lifestyle changes, including diet, exercise, and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia. When low-density lipoprotein lowering is required, initial treatment with a statin, a bile acid sequestrant, or niacin is recommended. However, in general, the statins are considered first line therapy for decreasing low-density lipoprotein cholesterol (LDL-C) levels and are recommended in patients with established coronary heart disease or coronary heart disease equivalents. If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or ezetimibe should be considered. Statins are also considered first line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy. With regards to the specific use of ezetimibe in lipid management, treatment guidelines recognize ezetimibe as a potential option to be added to statin therapy if lipid goals have not been met, or as a potential treatment option in

patients who are unable to take statins, bile acid sequestrants, and/or niacin. Of note, the long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown.[2-10]

American College of Cardiology/American Heart Association and Institute for Clinical Systems Improvement both released updated guidelines in 2013 which support initiating a statin in patients with established atherosclerotic cardiovascular disease (ASCVD). According to these recommendations, percent reduction in LDL-C is an indicator of response and adherence to therapy, but treating to a targeted level is not a primary goal.[6,7] Combination therapy can be considered on an individual basis, but studies of combination therapy have generally not shown benefit beyond statin monotherapy. Additionally, if patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available.[6,7]

Clinical trials have demonstrated that monotherapy with ezetimibe significantly lowers total cholesterol, LDL-C, apolipoprotein B, and triglycerides, as well as increases high-density lipoprotein cholesterol compared to placebo.[1,27-31] The majority of available clinical trials evaluate ezetimibe as combination therapy with colesevelam, fenofibrates, niacin, and statins, and results demonstrate that complementary effects on various lipid/lipoprotein parameters are achieved.[17-25,32-85,95-102] Recent clinical trials comparing ezetimibe with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors demonstrate greater reductions in LDL-C with the PCSK9 inhibitors; however, data on the extent of benefit on cardiovascular morbidity and mortality is limited, or has not been determined.[86-94] The effects of ezetimibe given either alone or in addition to a statin or fenofibrate on cardiovascular morbidity and mortality have not been established.[1] Ezetimibe should be available as adjunctive therapy through the medical justification portion of the prior authorization process.

Therefore, all brand cholesterol absorption inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand cholesterol absorption inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Zetia® [package insert]. Whitehouse Station (NJ): Merck & Co., INC.; 2012 Jan.
2. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
3. National Cholesterol Education Program (NCEP). Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, 2002 [guideline on the internet]. NCEP. 2002 [cited 2012 Dec]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
4. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2017 Feb 3. doi: 10.4158/EP171764.GL.
5. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.
6. Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Institute for Clinical Systems Improvement. Lipid Management in Adults. Updated November 2013.
7. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000–000. DOI: 10.1161/01.cir.0000437738.63853.7a.
8. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519.
9. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment: the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Institute for Health and Clinical Excellence; London (UK): 2014 [cited 2017 Jan 15]. Available from: https://www.nice.org.uk/Guidance/cg181.
10. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr;115(14):1948-67.
11. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106.
12. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
13. Lindor KD, Gershwin ME, Poupon R, et al. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
14. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. National Institute for Health and Clinical Excellence; London (UK): 2008 [cited 2017 Jan 6]. Available from: http://www.nice.org.uk/guidance/cg71.
15. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 May]. Available from: http://www.thomsonhc.com/.
16. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited May 2017]. Available from: http://online.factsandcomparisons.com.

17. Pearson GJ, Francis GA, Romney JS, Gilchrist DM, Opgenorth A, and Gyenes GT. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Can J Cardiol. 2006;22(11):939-45.
18. Jelesoff NE, Ballantyne CM, Xydakis AM, et al. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocrine Practice. 2006;12(2):159-64.
19. Simons L, Symons J. Ezetimibe added to statin therapy (EASY study). An evaluation by Australian general practitioners. Aust Fam Physician. 2007 Jan-Feb;36(1-2):90-2, 96.
20. Bissonnette S, Habib R, Sampalis F, Boukas S and Sampalis JS. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study–the Ezetrol add-on study. Can J Cardiol. 2006;22(12):1035-44.
21. Pitsavos C, Skoumas I, Tousoulis D, et al. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. Int J Cardiol 2009;134:280-1.
22. Strony J, Hoffman R, Hanson M, et al. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin Ther 2008;30:2280-97.
23. Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004;109:966-71.
24. Lutjohann D, von Bergmann K, Sirah W, Macdonell G, Johnson-Levonas AO, Shah A, et al. Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J Clin Pract. 62(10):1499-510.
25. Musliner T, Cselovszky D, Sirah W, Sisk M, Sapre A, Salen G. Efficacy and safety of ezetimibe 40 mg vs ezetimibe 10 mg in the treatment of patients with homozygous sitosterolemia. Int J Clin Pract. 2008 Jul;62(7):995-1000.
26. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002 Nov 15;90(10):1092-7.
27. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003 Apr;24(8):729-41.
28. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Sresh R, Veltri EP, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003 Jun;57(5):363-8.
29. Wierzbicki AS, Doherty E, Lumb PJ, et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipaemias. Curr Med Res Opin. 2005;21(3):333-8.
30. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007 May; 23(5):1169-76.
31. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM et al. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther. 2006:20(2):143-6.
32. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, and Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005; May 80(5):587-95.
33. Bays H, Rhyne J, Abby S, Lai, YL, and Jones, M. Lipid-lowering effects of colesevelam HCL in combination with ezetimibe. Curr Med Res Opin. 2006 Nov;22(11)2191-200.
34. Blagden M, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007 Apr;23(4):767-75.
35. Rodney RA, Sugimoto D, Wagman B, Zieve F, Kerzner B, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc. 2006 May;98(5):772-8.
36. Patel JV. Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract. 2006 Aug;60(8):914-21.

37. Landry M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47(3):385-95.
38. Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 2008;24:2953-66.
39. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52:1421-9.
40. Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther. 2005 Feb;27(2):174-84.
41. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002 Nov 15;90(10):1084-91.
42. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006 Sep;3(2):93-102.
43. Pearson T, Denke M, McBride PE, Batisti WP, Gazzara RA, Brady WE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin Prac. 2006 Sept;81(9):1177-85.
44. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28.
45. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, and Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy[abstract]. Curr Med Res Opin. 2007 Aug;23(8):2009-26.
46. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009;103:369-74.
47. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005; 26:897-905.
48. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism. 2008;57:796-801.
49. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol. 2006 Apr 18;47(8):1584-7.
50. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20;107(19):2409-15. Epub 2003 Apr 28.
51. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003 Feb 15;91(4):418-24.
52. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003 Apr;24(8):717-28.
53. Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, et al. A multi-centre, randomized, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract. 2007 Sep;61(9):1469-80.
54. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004 May;79(5):620-9.

55. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18;40(12):2125-34.
56. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared to ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004 Nov;26(11):1758-73.
57. Rosen JB, Jimenez JG, Pirags V, et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab Vasc Dis Res. 2013 May;10(3):277-286.
58. Foody JM, Toth PP, Tomassini JE, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag. 2013;9:719-727.
59. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older vs younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun;28(6):849-59.
60. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin vs simvastatin vs atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15;99(12):1706-13.
61. Ansquer JC, Bekaert I, Guy M, et al. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared to each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 2009;9 :91-101.
62. Coll B, Aragones G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infection patients. AIDS. 2006;20(12):1675-7.
63. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004 Sep;447-55.
64. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, et al. Treatment with ezetimibe plus low-dose atorvastatin compared to higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007 Mar 13;49(10):1035-42.
65. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin vs up titration of atorvastatin to 40 mg in patients >or = 65 years of age (ZETELD). Am J Cardiol 2010;105:656-63.
66. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) vs uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008;102:1489-94.
67. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared to uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008;102:1495-501.
68. Conrad S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, et al. Ezetimibe added to atorvastatin compared to doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010;12:210-8.
69. Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. Atorvastatin 10 mg plus ezetimibe 10mg compared to atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012 Jan;59(1):50-6.
70. Constance C, Westphal S, Chung N, Lund M, McCrary Sisk C, Johnson-Levonas AO, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared to atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2007 Jul;9(4):575-84.
71. Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, et al. Ezetimibe/simvastatin 10/40 mg vs atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis. 2012 Jan 31;11:18.
72. Bays HE, Averna M, Majul C, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013 Dec;112(12):1885-1895.

73. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006 Dec;81(12):1579-88.
74. Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate vs atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 2009;8(56):1-8.
75. Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmolzer I, Wascher TC, et al. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest. 2010;40(3):187-94.
76. Stein E, Ballantyne C, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101:490-496.
77. Alvarez-Sala L, Cachofeiro V, Masana L, et al. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther 2008;30:84-97.
78. Winkler K, Schewe T, Putz G, Odunc N, Schafer G, Siegel E, et al. Fluvastatin/fenofibrate vs simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009;39(6):463-70.
79. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar;99(5):673-80.
80. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest. 2007 May;37(5):357-63.
81. Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005 Jan;7(1):88-97.
82. Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration vs simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004 Jun 15;93(12):1481-6.
83. Okada K, Kimura K, Iwahashi N, Endo T, Himeno H, Fukui K, et al. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism. Circ J. 2011 Sep 22;75(10):2496-504.
84. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002 May 28;105(21):2469-75.
85. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe vs a statin alone (the COMPELL study). Atherosclerosis. 2007 Jun;192(2):432-7.
86. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun;169(6):906-915.e13. doi: 10.1016/j.ahj.2015.03.004.
87. Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014 Sep 20;14:121. doi: 10.1186/1471-2261-14-121.
88. Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37. doi: 10.2217/fca.14.82.
89. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF , Gouni-Berthold I et al. Alirocumab as Add-on To Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015 Jun 1:jc20151520.
90. Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with

atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct;37(10):597-604. doi: 10.1002/clc.22327.

91. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758-69.
92. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016 Jan;244:138-46.
93. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2541-8. doi: 10.1016/j.jacc.2014.03.019.
94. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90.
95. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431-43. Epub 2008 Mar 30.
96. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
97. Sampalis JS, Bissonnette S, Habib R, Boukas S. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Ann Pharmacother. 2007 Sep;41(9):1345-51.
98. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97.
99. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone vs statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52:2198-205.
100. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22.
101. Pauriah M, Elder DH, Ogston S, et al. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart. 2014 Jun;100(11):867-872.
102. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media Thickness and Overall arterial Rigidity study (VYCTOR). J Clin Pharmacol 2009;49:838-847.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Fibric Acid Derivatives
AHFS Class 240606
August 9, 2017

I. Overview

The antilipemic agents are categorized into six different American Hospital Formulary Service (AHFS) classes, including bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, HMG-CoA reductase inhibitors (statins), and miscellaneous antilipemic agents. The agents which make up these classes differ with regards to their Food and Drug Administration-approved indications, mechanism of action, efficacy, safety profiles, tolerability, and ease of use.

The fibric acid derivatives are agonists of the peroxisome proliferator activated receptor α (PPARα). Activation of PPARα increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of Apo CIII. The resulting decrease in triglycerides (TG) produces an alteration in the size and composition of low-density lipoprotein cholesterol (LDL-C) from small, dense particles to large buoyant particles. There is also an increase in the synthesis of high-density lipoprotein cholesterol (HDL-C), as well as apo AI and AII.[1-9] The fibric acid derivatives can decrease TG by 20 to 50% and increase HDL-C by 10 to 35%. They also lower LDL-C by 5 to 20%; however, in patients with hypertriglyceridemia, LDL-C may increase with the use of fibric acid derivatives.[10]

There are several fenofibrate products that are currently available, including micronized and non-micronized formulations. The different fenofibrate formulations are not equivalent on a milligram-to-milligram basis. Micronized fenofibrate is more readily absorbed than non-micronized formulations, which allows for a lower daily dose. Fenofibric acid is the active metabolite of fenofibrate.[11,12] All products are available in a generic formulation.

The fibric acid derivatives that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. This class was last reviewed in May 2015.

Table 1. Fibric Acid Derivatives Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Fenofibrate	capsule, tablet	Fenoglide®*, Lipofen®*	fenofibrate
Fenofibrate, micronized	capsule	Antara®*	fenofibrate, micronized
Fenofibrate, nanocrystallized	tablet	Tricor®*, Triglide®	fenofibrate, nanocrystallized
Fenofibric acid	delayed-release capsule, tablet	Fibricor®*, Trilipix®*	fenofibric acid
Gemfibrozil	tablet	Lopid®*	gemfibrozil

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the fibric acid derivatives are summarized in Table 2.

Table 2. Treatment Guidelines Using the Fibric Acid Derivatives

Clinical Guideline	Recommendation
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol**	• Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. • When low density lipoprotein cholesterol (LDL-C) lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C

Clinical Guideline	Recommendation
Education Program Adult Treatment Panel III Guidelines (2004)[13]	levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard HMG-CoA reductase inhibitors (statins) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrants, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), especially in combination with statins. • In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of coronary heart disease (CHD) risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u> • Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously). • Bile acid sequestrants (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrants and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u> • TLC indicated for all persons. • All LDL-C lowering drugs are effective. • If necessary to reach LDL-C goals, consider combined drug therapy.
National Cholesterol Education Program: **Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in**	<u>General recommendations</u> • With regards to TLC, higher dietary intakes of omega-3 fatty acids in the form of fatty fish or vegetable oils are an option for reducing risk for CHD. This recommendation is optional because the strength of evidence is only moderate at present. National Cholesterol Education Program supports the American Heart Association's recommendation that fish be included as part of a CHD risk reduction diet. Fish in general is low in saturated fat and may contain some cardioprotective omega-3 fatty acids. However, a dietary recommendation for a specific amount of omega-3 fatty acids is not made.

Clinical Guideline	Recommendation
Adults (Adult Treatment Panel III) Final Report (2002)[10]	• Initiate LDL lowering drug therapy with a statin, bile acid sequestrant, or nicotinic acid. • Statins should be considered as first line drugs when LDL lowering drugs are indicated to achieve LDL-C treatment goals. • After six weeks if LDL-C goal is not achieved, intensify LDL lowering therapy. Consider a higher dose of a statin or add a bile acid sequestrant or nicotinic acid. <u>Statins</u> • Statins should be considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. <u>Bile acid sequestrants</u> • Bile acid sequestrants should be considered as LDL lowering therapy for patients with moderate elevations in LDL-C, for younger patients with elevated LDL-C, for women with elevated LDL-C who are considering pregnancy and for patients needing only modest reductions in LDL-C to achieve target goals. • Bile acid sequestrants should be considered in combination therapy with statins in patients with very high LDL-C levels. <u>Nicotinic acid</u> • Nicotinic acid should be considered as a therapeutic option for higher risk patients with atherogenic dyslipidemia. • Nicotinic acid should be considered as a single agent in higher risk patients with atherogenic dyslipidemia who do not have a substantial increase in LDL-C levels, and in combination therapy with other cholesterol lowering drugs in higher risk patients with atherogenic dyslipidemia combined with elevated LDL-C levels. • Nicotinic acid should be used with caution in patients with active liver disease, recent peptic ulcer, hyperuricemia, gout, and type 2 diabetes. • High doses of nicotinic acid (>3 g/day) generally should be avoided in patients with type 2 diabetes, although lower doses may effectively treat diabetic dyslipidemia without significantly worsening hyperglycemia. <u>Fibric acid derivatives (fibrates)</u> • Fibrates can be recommended for patients with very high TG to reduce risk for acute pancreatitis. • They also can be recommended for patients with dysbetalipoproteinemia (elevated beta-very LDL). • Fibrate therapy should be considered an option for treatment of patients with established CHD who have low levels of LDL-C and atherogenic dyslipidemia. • They also should be considered in combination with statin therapy in patients who have elevated LDL-C and atherogenic dyslipidemia. <u>Omega-3 fatty acids</u> • Omega-3 fatty acids (e.g., linolenic acid, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA]) have two potential uses. • In higher doses, DHA and EPA lower serum TGs by reducing hepatic secretion of TG-rich lipoproteins. They represent alternatives to fibrates or nicotinic acid for treatment of hypertriglyceridemia, particularly chylomicronemia. Doses of 3 to 12 g/day have been used depending on tolerance and severity of hypertriglyceridemia. • Recent trials also suggest that relatively high intakes of omega-3 fatty acids (1

Clinical Guideline	Recommendation
	to 2 g/day) in the form of fish, fish oils, or high-linolenic acid oils will reduce the risk for major coronary events in persons with established CHD. Omega-3 fatty acids can be a therapeutic option in secondary prevention (based on moderate evidence). The omega-3 fatty acids can be derived from either foods (omega-3 rich vegetable oils or fatty fish) or from fish-oil supplements. More definitive trials are required before strongly recommending relatively high intakes of omega-3 fatty acids (1 to 2 g/day) for either primary or secondary prevention.
American Association of Clinical Endocrinologists: **Guidelines for the management of dyslipidemia and prevention of atherosclerosis (2017)**[14]	Cholesterol Goals • For individuals at low risk (i.e., with no risk factors), an LDL-C goal of <130 mg/dL is recommended. • For individuals at moderate risk (i.e., with two or fewer risk factors and a calculated 10-year risk of <10%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or CKD stage 3 or 4 with no other risk factors, or individuals with two or more risk factors and a 10-year risk of 10 to 20%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at very high risk (i.e., with established or recent hospitalization for ACS, coronary, carotid or peripheral vascular disease; diabetes or CKD stage 3 or 4 with one or more risk factors; a calculated 10-year risk >20%; or heterozygous familial hypercholesterolemia [HeFH]), an LDL-C goal of <70 mg/dL is recommended. • For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dL, or established clinical ASCVD in individuals with diabetes, CKD stage 3 or 4, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal of <55 mg/dL is recommended. • An LDL-C goal of <100 mg/dL is considered "acceptable" for children and adolescents, with 100 to 129 mg/dL considered "borderline" and 130 mg/dL or greater considered "high" (based on recommendations from the American Academy of Pediatrics). • HDL-C should be >40 mg/dL, but also as high as possible, primarily through the use of lifestyle interventions (e.g., weight loss, physical activity, and tobacco cessation), and if risk factors are present (e.g., borderline elevated LDL-C levels, a family history of premature ASCVD, or a personal history of ASCVD), also through the use of pharmacotherapy primarily focused on reducing LDL-C. • For most individuals, a non–HDL-C goal (total cholesterol minus HDL-C) 30 mg/dL higher than the individual's specific LDL-C goal is recommended. • For individuals at extreme risk, a non-HDL-C goal 25 mg/dL higher than the individual specific LDL-C goal is recommended. • For individuals at increased risk of ASCVD, including those with diabetes, an optimal apo B goal is <90 mg/dL, while for individuals with established ASCVD or diabetes plus one or more additional risk factor(s), an optimal apo B goal is <80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is <70 mg/dL. • TG goals of <150 mg/dL are recommended. General Recommendations • A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended primarily using lifestyle changes and patient education with pharmacotherapy as needed to achieve evidence based targets.

Clinical Guideline	Recommendation
	• A reasonable and feasible approach to fitness therapy (i.e., exercise programs that include ≥30 minutes of moderate-intensity physical activity [consuming 4 to 7 kcal/min] four to six times weekly, with an expenditure of ≥200 kcal/day) is recommended; suggested activities include brisk walking, riding a stationary bike, water aerobics, cleaning/scrubbing, mowing the lawn, and sporting activities. • Daily physical activity goals can be met in a single session or in multiple sessions throughout the course of a day (10 minutes minimum per session); for some individuals, breaking activity up throughout the day may help improve adherence with physical activity programs. • In addition to aerobic activity, muscle-strengthening activity is recommended at least two days a week. • For adults, a reduced-calorie diet consisting of fruits and vegetables (combined ≥5 servings/day), grains (primarily whole grains), fish, and lean meats is recommended. • For adults, the intake of saturated fats, trans-fats, and cholesterol should be limited, while LDL-C-lowering macronutrient intake should include plant stanols/sterols (~2 g/ day) and soluble fiber (10 to 25 g/day). • Primary preventive nutrition consisting of healthy lifestyle habits is recommended in all healthy children. • Tobacco cessation should be strongly encouraged and facilitated. • In individuals at risk for ASCVD, aggressive lipid-modifying therapy is recommended to achieve appropriate LDL-C goals. <u>Statins</u> • Statin therapy is recommended as the primary pharmacologic agent to achieve target LDLC goals on the basis of morbidity and mortality outcome trials. • For clinical decision making, mild elevations in blood glucose levels and/or an increased risk of new-onset T2DM associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction. • In individuals within high-risk and very high-risk categories, further lowering of LDL-C beyond established targets with statins results in additional ASCVD event reduction and may be considered. • Very high-risk individuals with established coronary, carotid, and peripheral vascular disease, or diabetes, who also have at least one additional risk factor, should be treated with statins to target a reduced LDL-C treatment goal of <70 mg/dL. • Extreme risk individuals should be treated with statins to target an even lower LDL-C treatment goal of <55 mg/dL. <u>Fibrates</u> • Fibrates should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). • Fibrates may improve ASCVD outcomes in primary and secondary prevention when TG concentrations are ≥200 mg/dL and HDL-C concentrations <40 mg/dL. <u>Omega-3 Fish Oil</u> • Prescription omega-3 oil, 2 to 4 g daily, should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). Dietary supplements are not FDA-approved for treatment of hypertriglyceridemia and generally are not recommended for this purpose. <u>Niacin</u> • Niacin therapy is recommended principally as an adjunct for reducing TG. • Niacin therapy should not be used in individuals aggressively treated with statin due to absence of additional benefits with well-controlled LDL-C.

Clinical Guideline	Recommendation

	Bile Acid Sequestrants
	• Bile acid sequestrants may be considered for reducing LDL-C and apo B and modestly increasing HDL-C, but they may increase TG.
	
	Cholesterol Absorption Inhibitors
	• Ezetimibe may be considered as monotherapy in reducing LDL-C and apo B, especially in statin-intolerant individuals.
	• Ezetimibe can be used in combination with statins to further reduce both LDL-C and ASCVD risk.
	
	PCSK9 Inhibitors
	• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors should be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH.
	• PCSK9 inhibitors should be considered in patients with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals.
	
	Combination Therapy
	• Combination therapy of lipid-lowering agents should be considered when the LDL-C/non-HDL-C level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal.
	
	Special Considerations: Women
	• Women should be evaluated for their ASCVD risk and be treated with pharmacotherapy if lifestyle intervention is insufficient.
	• Hormone replacement therapy for the treatment of dyslipidemia in postmenopausal women is not recommended.
	
	Special Considerations: Children and Adolescents
	• Pharmacotherapy is recommended for children and adolescents older than 10 years who do not respond sufficiently to lifestyle modification, and particularly for those satisfying the following criteria:
	  ○ LDL-C ≥190 mg/dL
	  ○ LDL-C ≥160 mg/dL and the presence of two or more cardiovascular risk factors, even after vigorous intervention
	  ○ Family history of premature ASCVD (before 55 years of age), or
	  ○ Having overweight, obesity, or other elements of the insulin resistance syndrome
	
	Follow-up and Monitoring
	• Reassess individuals' lipid status six weeks after therapy initiation and again at six-week intervals until the treatment goal is achieved.
	• While on stable lipid therapy, individuals should be tested at 6- to 12-month intervals.
	• While on stable lipid therapy, the specific interval of testing should depend on individual adherence to therapy and lipid profile consistency; if adherence is a concern or the lipid profile is unstable, the individual will probably benefit from more frequent assessment.
	• More frequent lipid status evaluation is recommended in situations such as deterioration of diabetes control, use of a new drug known to affect lipid levels, progression of atherothrombotic disease, considerable weight gain, unexpected adverse change in any lipid parameter, development of a new ASCVD risk

Clinical Guideline	Recommendation
	factor, or convincing new clinical trial evidence or guidelines that suggest stricter lipid goals. • Liver transaminase levels should be measured before and three months after niacin or fibric acid treatment initiation because most liver abnormalities occur within 3 months of treatment initiation. Liver transaminase levels should be measured periodically thereafter (e.g., semiannually or annually). • Creatine kinase levels should be assessed and the statin discontinued, at least temporarily, when an individual reports clinically significant myalgias or muscle weakness on statin therapy.
American Heart Association/American College of Cardiology/National Heart, Lung, and Blood Institute: **American Heart Association/American College of Cardiology Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update (2011)**[15]	Lipid management • Goal: treatment with statin therapy; use statin therapy to achieve LDL-C of <100 mg/dL; for very high risk patients an LDL-C <70 mg/dL is reasonable; if TG are ≥200 mg/dL, non-HDL-C should be <130 mg/dL, whereas non-HDL-C <100 mg/dL for very high risk patients is reasonable. • Lifestyle modifications (daily physical activity and weight management) are strongly recommended for all patients. • In addition to lifestyle modifications, statin therapy should be prescribed in the absence of contraindications or documented adverse events. • An adequate dose of statin should be used that reduces LDL-C to <100 mg/dL and achieves ≥30% lowering of LDL-C. • Patients who have TG ≥200 mg/dL should be treated with statins to lower non-HDL-C to <130 mg/dL. • Patients who have TG >500 mg/dL should be started on fibrate therapy in addition to statin therapy to prevent acute pancreatitis. • If treatment with a statin does not achieve the goal selected for an individual patient, intensification of LDL-C-lowering drug therapy with a bile acid sequestrant or niacin is reasonable. • For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid sequestrants and/or niacin is reasonable. • It is reasonable to treat very high risk patients with statin therapy to lower LDL-C to <70 mg/dL. • In patients who are at very high risk and who have TG ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable. • The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with statins, bile acid sequestrants, and/or niacin. • For patients who continue to have an elevated non-HDL-C while on adequate statin therapy, niacin or fibrate therapy or fish oil may be reasonable. • For all patients, it may be reasonable to recommend omega-3 fatty acids from fist or fish oil capsules (1 g/day) for cardiovascular disease risk reduction.
Institute for Clinical Systems Improvement: **Lipid Management in Adults (2013)**[16]	Clinical highlights • Initiate a statin with patients who have established atherosclerotic cardiovascular disease (ASCVD). • Establish lipid goals based on risk level. • Instruct patients on healthy lifestyle and adjunctive measures. • Patient adherence with recommended therapy should be reinforced during scheduled follow-up. Lifestyle modifications • Patients who are overweight should be advised to reduce their caloric intake to achieve weight loss. • Patients should follow a dietary pattern that emphasizes fruits, vegetables, planetoids, fish, nuts, and legumes. • A diet low saturated and trans fats, and added sugars; and high in soluble fiber, with consideration given to adding 2 grams of plant sterol/stanol is

Clinical Guideline	Recommendation
	recommended. <u>Statin treatment</u> • Initiate a statin regardless of LDL in patients with established ASCVD. • Initiate statin therapy in patients whose LDL is >100 and have a 10-year CHD risk ≥10% or diabetes. • Combination therapy can be considered on an individual basis, as no studies have shown a benefit to use at this time, and some studies have shown an increased risk of harm over statin monotherapy. <u>Monotherapy</u> • Reducing LDL-cholesterol (LDL-C) levels is the primary approach to lowering risk of CHD in both primary and secondary prevention. • Patients with risk factors for coronary heart disease but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of coronary heart disease. • Patients with a history of coronary disease (including unstable angina and acute myocardial infarction) often benefit from treatment with a statin. Studies have consistently shown a decrease in risk of death from coronary heart disease. • Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Statins also have a modest effect on reducing TG and increasing HDL-C. • Several trials with clinical endpoints support the use of statins in primary and secondary prevention. • If a patient is intolerant to a statin, patients should try another statin before ruling all of them out. • Provide patient education regarding recognition and reporting of symptoms of myopathy during statin therapy. • If patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available. • Many crystalline (immediate-release) and sustained-release preparations of niacin are available over-the-counter. The extended-release preparation of niacin is a prescription drug. Niacin exerts favorable effects on all lipids and lipoproteins, and is good for mixed hyperlipidemia. • Long-term use of niacin is usually limited for many patients due to side effects (e.g., flushing and pruritus, liver toxicity, gastrointestinal complaints, etc). • Niacin should not be used in combination therapy with a statin, as two major trials have shown increased side effects without any reduction in cardiovascular outcomes. • Prior to initiating a fibric acid (gemfibrozil, fenofibrate, and fenofibrate micronized), lifestyle therapies should be intensified for moderately elevated TG. These include reduction of liquid sugar, all refined starches and saturated fat; increased moderate-intensity exercise; and weight reduction. • With fibric acids, TG are reduced 30 to 50%, HDL-C is increased 10 to 20%, TC is reduced 5 to 20% in patients without elevated TG, and the effect on LDL-C is variable. Fibric acids are good for severe hypertriglyceridemia (>500 mg/dL) in patients at risk for pancreatitis and for prevention of CHD (not proven for fenofibrate). • Myositis, cholelithiasis, and cholecystitis can occur with fibric acid, and caution should be exercised with a history of liver disease. • The long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown. Ezetimibe is associated with a LDL-C lowering of about 18%, and additive LDL-C lowering occurs when used in combination with a statin. • The short-term tolerability of ezetimibe is similar to placebo, and the long-term

Clinical Guideline	Recommendation

	safety is unknown.
	• Bile acid sequestrants reduce LDL-C by 15 to 30% and TG may increase 15%; therefore, are these agents are useful for patients with moderately elevated LDL-C. The effects of the bile acid sequestrants are apparent within one week and maximum at two to three weeks. Bile acid sequestrants are good for combination therapy and are most potent with a statin.
	• Bile acid sequestrants are not systemically absorbed; therefore, side effects are limited to the gastrointestinal tract. In addition, drug interactions are minimized by taking other medications one hour before the sequestrant or four hours after.
	
	<u>Combination therapy</u>
	• It has become common practice to adjust medication therapy, including using combinations of medications, to achieve LDL-C goals. Common combinations include statin/fibrate, statin/niacin, and statin/ezetimibe.
	  ○ A fibrate is commonly added to a statin, which results in enhanced lowering of LDL-C, as well as a higher incidence of myopathy.
	  ○ Recent clinical trials have not demonstrated improved outcomes by increasing HDL-cholesterol with niacin among individuals with CVD and optimally controlled LDL-cholesterol on statins.
	  ○ The addition of ezetimibe to a statin significantly improves LDL-C over either agent alone. To date no large clinical trials have been completed evaluating this combination therapy compared to statin monotherapy on clinical vascular endpoints.
	• Studies of combination therapy have failed to show any benefit beyond statin monotherapy.
	• Combination therapy can be considered on an individual basis, but the additional cost, complexity, and risk for side effects argue against routine use until further trials indicate what groups of patients might benefit.
	• There are negative trials of cholesterylester transfer protein inhibitors when used in combination with statins.
	• No randomized-controlled trials looking at clinical vascular endpoints are available for other agents such as fish oils or bile-acid sequestrants used in combination therapy.
	• A systematic review of combination therapy for dyslipidemia concluded that the limited evidence available suggests that combinations of lipid-lowering agents do not improve clinical outcomes more than statin monotherapy.

American College of Cardiology/American Heart Association Task Force on Practice Guidelines: **Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)**[17]	<u>Statin treatment</u> • The panel makes no recommendations for or against specific low density lipoprotein cholesterol (LDL-C) or non-high density lipoprotein cholesterol (HDL-C) targets for the primary or secondary prevention of arteriosclerotic cardiovascular disease (ASCVD). • High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. • In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated. • In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin

Clinical Guideline	Recommendation

	therapy in those who are tolerating it.
	• Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.
	• For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction.
	• For individuals ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences.
	• Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus.
	• High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a ≥7.5% estimated 10-year ASCVD risk unless contraindicated.
	• In adults with diabetes mellitus, who are <40 or >75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions, and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy.
	• Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk ≥7.5% should be treated with moderate- to high-intensity statin therapy.
	• It is reasonable to offer treatment with a moderate intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinica ASCVD or diabetes and an estimated 10-year ASCVD risk of 5.0 to <7.5%.
	• Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 to 189 mg/dL without clinical ASCVD or diabetes it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment.
	• In adults with LDL-C <190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of patient preference.
	
	<u>Statin safety</u>
	• To maximize the safety of statins, selection of the appropriate statin and dose in men and nonpregnant/non-nursing women should be based on patient characteristics, level of ASCVD risk, and potential for adverse effects.
	• Moderate-intensity statin therapy should be used in individuals in whom high-intensity statin therapy would otherwise be recommended when characteristics predisposing them to statin associated adverse effects are present.
	• Characteristics predisposing individuals to statin adverse effects include, but are not limited to:
	  o Multiple or serious comorbidities, including impaired renal or hepatic function.
	  o History of previous statin intolerance or muscle disorders.
	  o Unexplained alanine transaminase elevations >3 times upper limit of

Clinical Guideline	Recommendation

	normal.
	  ○ Patient characteristics or concomitant use of drugs affecting statin metabolism.
	  ○ >75 years of age.
	• Additional characteristics that may modify the decision to use higher statin intensities may include, but are not limited to:
	  ○ History of hemorrhagic stroke.
	  ○ Asian ancestry.
	• Creatine kinase should not be routinely measured in individuals receiving statin therapy.
	• Baseline measurement of creatinine kinase is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy.
	• During statin therapy, it is reasonable to measure creatinine kinase in individuals with muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or generalized fatigue.
	• Baseline measurement of hepatic transaminase levels should be performed before initiating statin therapy.
	• During statin therapy, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine or yellowing of the skin or sclera).
	• Decreasing the statin dose may be considered when two consecutive values of LDL-C levels are <40 mg/dL.
	• It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.
	• Individuals receiving statin therapy should be evaluated for new-onset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during statin therapy should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce their risk of ASCVD events.
	• For individuals taking any dose of statins, it is reasonable to use caution in individuals >75 years of age, as well as in individuals that are taking concomitant medications that alter drug metabolism, taking multiple drugs, or taking drugs for conditions that require complex medication regimens (e.g., those who have undergone solid organ transplantation or are receiving treatment for human immunodeficiency virus (HIV). A review of the manufacturer's prescribing information may be useful before initiating any cholesterol-lowering drug).
	• It is reasonable to evaluate and treat muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated patients according to the following management algorithm:
	  ○ To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline before initiating statin therapy.
	  ○ If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly discontinue the statin and address the possibility of rhabdomyolysis by evaluating creatinine kinase, creatinine, and a urinalysis for myoglobinuria.
	• If mild to moderate muscle symptoms develop during statin therapy:
	  ○ Discontinue the statin until the symptoms can be evaluated.
	  ○ Evaluate the patient for other conditions that might increase the risk for muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica,

Clinical Guideline	Recommendation

	steroid myopathy, vitamin D deficiency, or primary muscle diseases).
	  ○ If muscle symptoms resolve, and if no contraindication exists, give the patient the original or a lower dose of the same statin to establish a causal relationship between the muscle symptoms and statin therapy.
	  ○ If a causal relationship exists, discontinue the original statin. Once muscle symptoms resolve, use a low dose of a different statin.
	  ○ Once a low dose of a statin is tolerated, gradually increase the dose as tolerated.
	  ○ If, after two months without statin treatment, muscle symptoms or elevated creatinine kinase levels do not resolve completely, consider other causes of muscle symptoms listed above.
	  ○ If persistent muscle symptoms are determined to arise from a condition unrelated to statin therapy, or if the predisposing condition has been treated, resume statin therapy at the original dose.
	• For individuals presenting with a confusional state or memory impairment while on statin therapy, it may be reasonable to evaluate the patient for non-statin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy.
	
	<u>Monitoring and optimizing statin therapy</u>
	• Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. This should also include a fasting lipid panel performed within four to 12 weeks after initiation or dose adjustment, and every three to 12 months thereafter. Other safety measurements should be measured as clinically indicated.
	• The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated.
	• Individuals who have a less-than anticipated therapeutic response or are intolerant of the recommended intensity of statin therapy, the following should be performed:
	  ○ Reinforce medication adherence.
	  ○ Reinforce adherence to intensive lifestyle changes.
	  ○ Exclude secondary causes of hyperlipidemia.
	• It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of statin therapy. Focus is on the intensity of the statin therapy. As an aid to monitoring:
	  ○ High-intensity statin therapy generally results in an average LDL-C reduction of ≥50% from the untreated baseline;
	  ○ Moderate-intensity statin therapy generally results in an average LDL-C reduction of 30 to <50% from the untreated baseline;
	  ○ LDL-C levels and percent reduction are to be used only to assess response to therapy and adherence. They are not to be used as performance standards.
	• Individuals at higher ASCVD risk receiving the maximum tolerated intensity of statin therapy who continue to have a less than-anticipated therapeutic response, addition of a non-statin cholesterol-lowering drug(s) may be considered if the ASCVD risk-reduction benefits outweigh the potential for adverse effects.
	• Higher-risk individuals include:
	  ○ Individuals with clinical ASCVD <75 years of age.
	  ○ Individuals with baseline LDL-C ≥190 mg/dL.
	  ○ Individuals 40 to 75 years of age with diabetes mellitus.
	  ○ Preference should be given to non-statin cholesterol-lowering drugs shown to reduce ASCVD events in controlled trials.
	• In individuals who are candidates for statin treatment but are completely statin

Clinical Guideline	Recommendation

	intolerant, it is reasonable to use non-statin cholesterol lowering drugs that have been shown to reduce ASCVD events in controlled trials if the ASCVD risk-reduction benefits outweigh the potential for adverse effects.
	
	<u>Non statin safety</u>
	• Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric acid should be obtained before initiating niacin, and again during up-titration to a maintenance dose and every six months thereafter.
	• Niacin should not be used if:
	  o Hepatic transaminase elevations are higher than two to three times upper limit of normal.
	  o Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout or unexplained abdominal pain or gastrointestinal symptoms occur.
	  o New-onset atrial fibrillation or weight loss occurs.
	• In individuals with adverse effects from niacin, the potential for ASCVD benefits and the potential for adverse effects should be reconsidered before reinitiating niacin therapy.
	• To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to:
	  o Start niacin at a low dose and titrate to a higher dose over a period of weeks as tolerated.
	  o Take niacin with food or premedicating with aspirin 325 mg 30 minutes before niacin dosing to alleviate flushing symptoms.
	  o If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over four to eight weeks, with the dose of extended release niacin increasing not more than weekly.
	  o If immediate-release niacin is chosen, start at a dose of 100 mg three times daily and up-titrate to 3 g/day, divided into two or three doses.
	• Bile acid sequestrants should not be used in individuals with baseline fasting triglyceride levels ≥300 mg/dL or type III hyperlipoproteinemia, because severe triglyceride elevations might occur.
	• A fasting lipid panel should be obtained before bile acid sequestrants are initiated, three months after initiation, and every six to 12 months thereafter.
	• It is reasonable to use bile acid sequestrants with caution if baseline triglyceride levels are 250 to 299 mg/dL, and evaluate a fasting lipid panel in four to six weeks after initiation. Discontinue the bile acid sequestrants if triglycerides exceed 400 mg/dL.
	• It is reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase levels as clinically indicated, and discontinue ezetimibe if persistent alanine transaminase elevations >3 times upper limit of normal occur.
	• Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis.
	• Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, are judged to outweigh the potential risk for adverse effect.
	• Renal status should be evaluated before fenofibrate initiation, within three months after initiation, and every six months thereafter. Assess renal safety with both a serum creatinine level and an estimated glomerular filtration rate based on creatinine.
	• Fenofibrate should not be used if moderate or severe renal impairment, defined

Clinical Guideline	Recommendation
	as estimated glomerular filtration rate <30 mL/min per 1.73 m^2, is present. • If estimated glomerular filtration rate is between 30 and 59 mL/min per 1.73 m^2, the dose of fenofibrate should not exceed 54 mg/day. • If, during follow-up, the estimated glomerular filtration rate decreases persistently to ≤30 mL/min per 1.73 m^2, fenofibrate should be discontinued. • If eicosapentaenoic acid and/or docosahexanoic acid are used for the management of severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal disturbances, skin changes, and bleeding.

American College of Cardiology:
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016)[18]
	<u>Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention</u>
	• These patients should be treated first with maximally tolerated statin intensity. If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <100 mg/dL), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response (<50% reduction in LDL-C and may consider LDL-C ≥100 mg/dL):
	  ○ Assess statin adherence.
	  ○ If an adherent patient has not been tried on a high-intensity statin, the dose should be increased to a high-intensity dose at this time.
	  ○ Intensify lifestyle modifications.
	  ○ Consider adding ezetimibe 10 mg daily as the first non-statin agent.
	  ○ A bile acid sequestrant (BAS) may be considered as a second-line agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL, but there is no evidence for benefit of BAS in addition to statins in this population.
	• If ASCVD patients without comorbidities, who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response with <50% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL):
	  ○ It is reasonable to consider the net benefit of alirocumab or evolocumab (in addition to or in place of ezetimibe) as a second step to achieve further LDL-C reduction.
	  ○ If a PCSK9 inhibitor is prescribed, clinicians should continue maximally tolerated statin and monitoring for adherence to medications and lifestyle, side effects, and ongoing LDL-C response to therapy.
	
	<u>Clinical ASCVD with comorbidities, on statin for secondary prevention</u>
	• These patients should be treated first with maximally tolerated statin intensity.
	• If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <70 mg/dL or non–HDL-C <100 mg/dL for patients with diabetes), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response:
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	<u>Clinical ASCVD and baseline LDL-C ≥190 mg/dL not due to secondary causes, on</u>

Clinical Guideline	Recommendation

	statin for secondary prevention
	• Patients with LDL-C ≥190 mg/dL are more likely to have heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia.
	• In patients who have a less-than-anticipated response on maximally tolerated statin therapy with <50% reduction in LDL-C (and may consider LDL-C ≥70 mg/dL):
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe (or BAS second line) first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	Adults Aged 40 to 75 Years Without ASCVD, but With Diabetes
	• In patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C despite adherence to lifestyle recommendations and moderate-intensity statin therapy, the recommended threshold for consideration of the net benefit of increasing to high-intensity statin therapy is failure to achieve 30 to <50% reduction in LDL-C (and may consider on -treatment LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL).
	• If a patient with diabetes and 10-year ASCVD risk <7.5% without high-risk features has a less-than-anticipated response, with <30% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL), additional clinical approaches may be warranted.
	• Ezetimibe is the preferred initial non-statin therapy due to tolerability, convenience, and single-tablet daily dose.
	• BAS may have a modest hypoglycemic effect that may be of benefit in some diabetic patients if fasting triglycerides are <300 mg/dL. BAS may also be considered if patients have an inadequate response to ezetimibe or if patients are ezetimibe intolerant.
	• In the absence of ASCVD or baseline LDL-C ≥190 mg/dL not due to secondary causes, the PCSK9 inhibitors do not have an established role for primary prevention of ASCVD in patients with diabetes.

National Institute for Health and Clinical Excellence: **Cardiovascular disease: risk assessment and reduction, including lipid modification (2014)**[19] Updated Sep 2016	• Be aware that when deciding on lipid modification therapy for the prevention of cardiovascular disease (CVD), drugs are preferred for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality • When a decision is made to prescribe a statin use a statin of high intensity and low acquisition cost. Lipid Measurement and Referral: • Measure both total and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk. • Before starting lipid modification therapy for the primary prevention of CVD, take at least one lipid sample to measure a full lipid profile. This should include measurement of total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglyceride concentrations. A fasting sample is not needed. • Use the clinical findings, lipid profile and family history to judge the likelihood of a familial lipid disorder rather than the use of strict lipid cut-off values alone. • Exclude possible common secondary causes of dyslipidemia (such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome) before referring for specialist review.

Clinical Guideline	Recommendation

	• Consider the possibility of familial hypercholesterolemia if they have a total cholesterol concentration >7.5 mmol/L and a family history of premature coronary heart disease.
	• Arrange for specialist assessment of people with a total cholesterol concentration of more than 9.0 mmol/L or a non-HDL cholesterol concentration of more than 7.5 mmol/L even in the absence of a first-degree family history of premature coronary heart disease.
	• Refer for urgent specialist review if a person has a triglyceride concentration of more than 20 mmol/L that is not a result of excess alcohol or poor glycemic control.
	• In people with a triglyceride concentration between 10 and 20 mmol/L:
	  o Repeat the triglyceride measurement with a fasting test (after an interval of five days, but within two weeks) and
	  o Review for potential secondary causes of hyperlipidemia and
	  o See specialist advice if the triglyceride concentration remains above 10 mmol/L
	• In people with a triglyceride concentration between 4.5 and 9.9 mmol/L:
	  o Be aware that the CVD risk may be underestimated by risk assessment tools and
	  o Optimize the management of other CVD risk factors present and
	  o Seek specialist advice if non-HDL cholesterol concentration is more than 7.5 mmol/litre.
	
	<u>Statins for the prevention of CVD</u>:
	• The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.
	• Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidemia. Include smoking status, alcohol consumption, blood pressure, body mass index or other obesity measure, total cholesterol, non-HDL cholesterol, HDL cholesterol, triglyceride level, glycosylated hemoglobin (HbA_{1c}), renal function and estimated glomerular filtration rate (eGFR), transaminase levels, and thyroid stimulating hormone in the assessment.
	
	<u>Statins for the Primary Prevention of CVD</u>:
	• Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimize the management of all other modifiable CVD risk factors if possible.
	• Recognize that people may need support to change their lifestyle. To help them do this, refer them to programs such as exercise referral schemes.
	• Offer people the opportunity to have their risk of CVD assessed again after they have tried to change their lifestyle.
	• If lifestyle modification is ineffective or inappropriate, offer statin treatment after risk assessment.
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	• For people 85 years or older consider atorvastatin 20 mg as statins may be of benefit in reducing the risk of non-fatal myocardial infarction. Be aware of factors that may make treatment inappropriate.
	
	<u>Statins for the Secondary Prevention of CVD</u>:

Clinical Guideline	Recommendation

	• Start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower dose of atorvastatin if there are potential drug interactions, high risk of adverse effects, or patient preference.
	• Do not delay statin treatment in secondary prevention to manage modifiable risk factors.
	• If a person has acute coronary syndrome, do not delay statin treatment. Take a lipid sample on admission and about three months after the start of treatment.
	
	<u>Statins for the Primary Prevention of CVD for People with Type 1 Diabetes</u>:
	• Consider statin treatment for the primary prevention of CVD in all adults with type 1 diabetes.
	• Offer statin treatment for the primary prevention of CVD to adults with type 1 diabetes who are older than 40 years, have had diabetes for more than 10 years, have established nephropathy, or have other CVD risk factors.
	• Start treatment for adults with type 1 diabetes with atorvastatin 20 mg.
	
	<u>Statins for the Primary Prevention of CVD in People with Type 2 Diabetes</u>:
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people with type 2 diabetes who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	
	<u>Statins for People with CKD</u>:
	• Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
	  ○ Increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 mL/min/1.73 m^2 or more.
	  ○ Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73 m^2.
	
	<u>Follow-up of People Started on Statin Therapy</u>:
	• Measure total cholesterol, HDL cholesterol and non-HDL cholesterol in all people who have been started on high-intensity statin treatment at three months of treatment and aim for a greater than 40% reduction in non-HDL cholesterol.
	• If a greater than 40% reduction in non-HDL cholesterol is not achieved, discuss adherence to lifestyle modifications and drug therapy, timing of dose.
	  ○ Consider increasing the dose if started on less than atorvastatin 80 mg and the person is judged to be at higher risk because of comorbidities, risk score or using clinical judgement.
	• Provide annual medication reviews for people taking statins.
	• Discuss with people who are stable on a low- or middle-intensity statin the likely benefits and potential risks of changing to a high-intensity statin when they have a medication review and agree with the person whether a change is needed.
	
	<u>Monitoring Statin Therapy for Adverse Effects</u>:
	• Advise people who are being treated with a statin that other drugs, some foods (e.g., grapefruit juice) and some supplements may interfere with statins and to always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements.
	• Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses.
	• Before offering a statin, ask the person if they have had persistent generalized unexplained muscle pain, whether associated or not with previous lipid-lowering therapy. If they have, measure creatine kinase levels.
	  ○ If creatine kinase levels are more than five times the upper limit of

Clinical Guideline	Recommendation

	normal, re-measure creatine kinase after seven days. If creatine kinase levels are still five times the upper limit of normal, do not start statin treatment.
	  o If creatine kinase levels are raised but less than five times the upper limit of normal, start statin treatment at a lower dose.
	• Advise people who are being treated with a statin to seek medical advice if they develop muscle symptoms (pain, tenderness or weakness). If this occurs, measure creatine kinase.
	• If people report muscle pain or weakness while taking a statin, explore other possible causes of muscle pain or weakness and raised creatine kinase if they have previously tolerated statin therapy for more than three months.
	• Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin.
	• Measure baseline liver transaminase before starting a statin. Measure liver transaminase within three months of starting treatment and at 12 months, but not again unless clinically indicated.
	• Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than three times the upper limit of normal.
	• Do not stop statins because of an increase in blood glucose level or HbA_{1c}.
	• Statins are contraindicated in pregnancy and women of childbearing potential should be advised of the potential teratogenic risk of statins and to stop taking them if pregnancy is a possibility.
	  o Advise women planning pregnancy to stop taking statins three months before they attempt to conceive and to not restart them until breastfeeding is finished.
	
	<u>Intolerance to Statin Therapy</u>:
	• If a person is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose.
	• Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statins discuss the following possible strategies with them:
	  o stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin and
	  o reducing the dose within the same intensity group and
	  o changing the statin to a lower intensity group.
	• Seek specialist advice about options for treating people at high risk of CVD such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidemias, and those with CVD, who are intolerant to three different statins.
	
	<u>Fibrates for Preventing CVD</u>:
	• Do not routinely offer fibrates for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2.
	
	<u>Nicotinic Acid for Preventing CVD</u>:
	• Do not offer nicotinic acid (niacin) for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2.
	
	<u>Bile Acid Sequestrants (Anion Exchange Resins) for Preventing CVD</u>:
	• Do not offer bile acid sequestrants for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or

Clinical Guideline	Recommendation
	diabetes type 1 or 2. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer omega-3 fatty acid compounds for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. • Tell people that there is no evidence that omega-3 fatty acid compounds help to prevent CVD. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. Ezetimibe for Preventing CVD: • People with primary hypercholesterolemia should be considered for ezetimibe treatment.
American Heart Association: **Drug Therapy of High Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association (2007)[20]**	• For children meeting criteria for lipid-lowering drug therapy, a statin is recommended as first line treatment. The choice of statin is dependent upon preference but should be initiated at the lowest dose once daily, usually at bedtime. • For patients with high risk lipid abnormalities, the presence of additional risk factors or high risk conditions may reduce the recommended LDL level for initiation of drug therapy and the desired target LDL levels. Therapy may also be considered for initiation in patients <10 years of age. • Additional research regarding drug therapy of high risk lipid abnormalities in children is needed to evaluate the long term efficacy and safety and impact on the atherosclerotic disease process. • Niacin is rarely used to treat the pediatric population. • Given the reported poor tolerance, the potential for very serious adverse effects, and the limited available data, niacin cannot be routinely recommended but may be considered for selected patients. • This guideline does not contain recommendations regarding the use of omega-3 acid ethyl esters.
European Society of Cardiology and Other Societies: **Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2016)[21]**	Drugs • Currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g., ezetimibe) and, more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Response to all therapy varies widely among individuals and therefore monitoring the effect on LDL-C levels is recommended. • Statins, by reducing LDL-C, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions. • Statins should be used as the drugs of first choice in patients with hypercholesterolemia or combined hyperlipidemia. • Selective cholesterol absorption inhibitors are not usually used as monotherapy to decrease LDL-C concentrations, unless patients are intolerant to statins. They are recommended as combination therapy with statins in selected patients when a specific goal is not reached with the maximal tolerated dose of a statin. • Bile acid sequestrants also decrease TC and LDL-C, but are poorly tolerated and tend to increase plasma triglyceride concentrations. They are therefore not recommended for routine use in CVD prevention. • Fibrates and niacin are used primarily for triglyceride lowering and increasing HDL-C, while fish oils (n-3 fatty acids) are used for triglyceride lowering.

Clinical Guideline	Recommendation
	Evidence supporting the use of these drugs for CVD event reduction is limited and, given the strong evidence favouring statins, routine use of these drugs in CVD prevention is not recommended. In order to prevent pancreatitis, when triglycerides are >10 mmol/L (>900 mg/dL) they must be reduced not only by drugs but also by restriction of alcohol, treatment of DM, withdrawal of estrogen therapy, etc. In those rare patients with severe primary hypertriglyceridaemia, specialist referral must be considered. • Regarding new therapies, recent data from phase I–III trials show that PCSK9 inhibitors sharply decrease LDL-C by up to 60%, either as monotherapy or in addition to the maximal statin dose. Whether this approach results in the predicted reduction in CV events is being addressed in large outcome trials; preliminary evidence suggests that this is the case. Drug combinations • Patients with dyslipidemia, particularly those with established cardiovascular disease, diabetes, or asymptomatic high risk patients, may not always reach treatment targets; therefore, combination treatment may be needed. • The only combination that has evidence of clinical benefit (one large RCT) is that of a statin combined with ezetimibe. Based on the relatively limited body of evidence, clinicians may restrict the use of this combination to patients at high or very-high risk of CVD. • Combinations of niacin and a statin increase HDL-C and decrease TG better than either drug used as monotherapy, but flushing is the main adverse event with niacin, which may affect compliance. • Fibrates, particularly fenofibrate, may be useful, not only for decreasing TG and increasing HDL-C, but can further lower LDL-C when administered in combination with a statin. • If target levels cannot be reached with maximal doses of lipid-lowering therapy or combination therapy, patients will still benefit from treatment to the extent to which dyslipidemia has been improved. In these patients, increased attention to other risk factors may help to reduce total risk.
American Heart Association/ American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (2014)**[22]	• Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or transient ischemic attack (TIA) presumed to be of atherosclerotic origin and an LDL-C level ≥100mg/dL with or without evidence for other clinical ASCVD. • Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin, and LDL-C level <100 mg/dL, and no evidence for other clinical ASCVD. • Patients with ischemic stroke or TIA and other comorbid ASCVD should be otherwise managed according to the 2013 ACC/AHA cholesterol guidelines, which include lifestyle modifications, dietary recommendations, and medication recommendations.
American Association of the Study of Liver Disease: **Primary Biliary Cirrhosis (2009)**[23] **Reaffirmed October 2014**	• Ursodeoxycholic acid therapy is the only Food and Drug Administration-approved agent for the treatment of primary biliary cirrhosis. It is currently supported by the most data and is recommended for use in appropriately selected patients who have abnormal liver chemistry. • Issues of patient compliance, development of superimposed liver disease, or coadministration with bile sequestrants (e.g., cholestyramine or colestipol) should be considered for patients with suboptimal response. • Pruritus is a complication of primary biliary cirrhosis and cholestyramine is the drug of choice for the treatment of this complication. Alternative treatments of pruritus include rifampin, opioid antagonists, and liver transplantation.
American Association of	Principles underlying the algorithm

Clinical Guideline	Recommendation

Clinical Endocrinologists: **Consensus Statement on the Comprehensive Type 2 Diabetes Management Algorithm 2016 (2016)**[24]	• Lifestyle optimization is essential for all patients with diabetes; however, it should not delay needed pharmacotherapy, which can be initiated simultaneously and adjusted based on patient response to lifestyle efforts. The need for medical therapy should not be interpreted as a failure of lifestyle management, but as an adjunct to it.
	• Achieving an HbA_{1c} ≤6.5% is recommended as the primary goal if it can be achieved in a safe and affordable manner; however, higher targets may be appropriate for certain individuals and may change for a given individual over time.
	• Minimizing risk of hypoglycemia and weight gain is a priority. It is a matter of safety, adherence, and cost.
	• For optimal glycemic control, therapies with complementary mechanisms of action must typically be used in combination.
	• Therapeutic effectiveness must be evaluated frequently until stable (e.g., every three months).
	• Safety and efficacy should be given higher priority than the initial acquisition cost of medications, as medication cost is only a small part of the total cost of diabetes care. In assessing the cost of a medication, consideration should be given to monitoring requirements and risks of hypoglycemia and weight gain.
	• The therapeutic regimen should be as simple as possible to optimize adherence.
	
	<u>Monotherapy</u>
	• Patients with recent-onset diabetes and those with mild hyperglycemia (HbA_{1c} <7.5%), initial monotherapy with metformin (at doses of 1,500 to 2,000 mg/day) and life-style modifications will achieve their glycemic goals in a majority of patients.
	• In patients with intolerance or contraindications to metformin, acceptable therapeutic alternatives that reduce glucose without weight gain or hypoglycemia (in order based on suggested hierarchy of usage) include:
	  ○ GLP-1 receptor agonists.
	  ○ Sodium glucose cotransporter 2 (SGLT-2) inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZDs (use with caution).
	  ○ Alpha-glucosidase inhibitors.
	• sulfonylureas, and glinides (in order based on suggested hierarchy of usage) may be used but with caution due to possible weight gain and hypoglycemia.
	
	<u>Combination therapy</u>
	• Patients who present with an initial HbA_{1c} >7.5% or who do not reach their target HbA_{1c} with metformin in three months should be started on a second agent to be used in combination with metformin.
	• Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy.
	• In metformin-intolerant patients, two drugs from other classes with complimentary mechanisms of action should be used.
	• Combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent) plus:
	  ○ GLP-1 receptor agonists.
	  ○ SGLT-2 inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZD.
	  ○ Basal insulin.
	  ○ Colesevelam.
	  ○ Bromocriptine quick release.

Clinical Guideline	Recommendation
	○ Alpha-glucosidase inhibitors. ○ Sulfonylureas and glinides. Three-drug combination therapy • Generally, the efficacy of a third antidiabetic agent added to dual therapy is reduced compared to the efficacy of the same drug used as monotherapy or combination therapy with one other agent. • Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy. • Patients who present with an HbA_{1c} <8.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs after three months have a high likelihood of reaching target with a third agent. • Patients who present with an HbA_{1c} >9.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs has are less likely of reaching target with a third agent or fourth agent and insulin should be considered. • Continuation with noninsulin therapies while starting basal insulin is common and does not increase cardiovascular risk, but may increase risk of hypoglycemia when sulfourea are used in conjunction with insulin. • Three-drug combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent), a second-line agent plus: ○ GLP-1 receptor agonists. ○ SGLT-2 inhibitors. ○ TZD. ○ Basal insulin. ○ DPP-4 inhibitors. ○ Colesevelam. ○ Bromocriptine quick release. ○ Alpha-glucosidase inhibitors. ○ Sulfonylureas and glinides. Insulin therapy algorithm • Patients who present with an initial HbA_{1c} >9.0% and are symptomatic, should initiate therapy with insulin with or without other antidiabetic agents. • Start insulin if a patient has marked hyperglycemia despite treatment with several oral antidiabetic agents and is symptomatic with polyuria and weight loss. • Patients who are not at target HbA_{1c} despite the use of oral antidiabetic agents or GLP-1 therapy should be considered for insulin therapy. • Patients with an HbA_{1c} level >8.0% while receiving ≥2 antidiabetic agents, particularly individuals with long duration of diabetes, have significant impairment of beta cell insulin secretory capacity and are unlikely to reach the recommended target by the addition of further oral antidiabetic drugs. Basal insulin • Patients with an HbA_{1c} level >8.0% while receiving ≥2 oral antidiabetic agents or GLP-1 therapy can be started on single daily dose of basal insulin as an add-on to the patient's existing regimen. • Titrate insulin dose every two to three days to reach glycemic goals. • Basal insulin analogues (glargine and detemir) are preferred over protamine Hagedorn insulin because they have been shown to provide a relatively flat serum insulin concentration for up to 24 hours from a single daily injection. • Patients who fail to achieve glucose control with basal insulin or premixed insulin formulations can also be considered for basal intensification with a DPP-4 inhibitor or GLP-1 receptor agonist if the glucose level is not markedly elevated, because this approach tends to not cause weight gain or additional

Clinical Guideline	Recommendation
	hypoglycemia. Basal-bolus insulin regimens • Patients who fail to achieve glucose control with basal insulin or premixed insulin formulations and those with symptomatic hyperglycemia and HbA_{1c} >10% often respond better to combined basal and mealtime bolus insulin. • A full basal-bolus program with an insulin basal analogue once or twice daily and a rapid-acting analogue at each meal is most effective and provides flexibility for patients with variable mealtimes and meal carbohydrate content. • Doses of insulin may be titrated every two to three days to reach glycemic goals. Basal insulin and incretin therapy regimens • Use of the amylin analog pramlintide in conjunction with bolus insulin improves both glycemia and weight in patients with type 2 diabetes. • The incretin therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have similar properties, and also increase endogenous insulin secretion. Therefore, the combination of basal insulin and incretin therapy decreases basal and postprandial glucose and may minimize the weight gain and hypoglycemia risk observed with basal-bolus insulin replacement.

National Institute for Health and Clinical Excellence: **Identification and management of familial hypercholesterolaemia (2008)**[25]
 	
Last updated July 2016
	Drug treatment in adults
	• When offering lipid-modifying drug therapy to adults with familial hypercholesterolemia (FH), inform the patient that this treatment should be life-long.
	• Statins should be the initial treatment for all adults with FH.
	• Consider prescribing a high-intensity statin to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• Offer treatment with a statin with a low acquisition cost for adults with FH in whom the diagnosis is made after the age of 60 and who do not have coronary heart disease.
	• Ezetimibe monotherapy is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who would otherwise be initiated on statin therapy but who are unable to do so because of contraindications or intolerance to initial statin therapy.
	• Ezetimibe, coadministered with initial statin therapy, is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who have been initiated on statin therapy when:
	  ○ Serum total or LDL-C concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy AND
	  ○ Consideration is being given to changing from initial statin therapy to an alternative statin.
	• Prescribing of drug therapy for adults with homozygous FH should be undertaken within a specialist center.
	• Adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
	• Exercise caution when adding a fibrate or nicotinic acid to a statin because of the risk of muscle-related side effects (including rhabdomyolysis). Gemfibrozil and statins should not be used together.

Clinical Guideline	Recommendation

	Drug treatment in children and young people
	• All children and young people diagnosed with, or being investigated for, a diagnosis of FH should have a referral to a specialist with expertise in FH in children and young people.
	• Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-modifying drug therapy for a child or young person should take into account:
	  o Their age.
	  o The age of onset of coronary heart disease within the family.
	  o And the presence of other cardiovascular risk factors, including LCL-C concentration.
	• When offering lipid-modifying drug therapy for children or young people, inform the child/young person and their parent/carer that this treatment should be life-long.
	• When the decision to initiate lipid-modifying drug therapy has been made in children and young people, statins should be the initial treatment. Healthcare professionals with expertise in FH in children and young people should choose a statin that is licensed for use in the appropriate age group.
	• In exceptional instances, for example, when there is a family history of coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering:
	  o A higher dose of statin than is licensed for use in the age group and/or
	  o More than one lipid-modifying drug therapy, and/or
	  o Lipid-modifying drug therapy before the age of 10 years.
	• In children and young people with homozygous FH, LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis.
	• In children and young people with FH who are intolerant of statins, consider offering other lipid-modifying drug therapies capable of reducing LDL-C concentration (such as bile acid sequestrants [resins], fibrates or ezetimibe).
	• Routine monitoring of growth and pubertal development in children and young people with FH is recommended.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the fibric acid derivatives are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Fibric Acid Derivatives[1-9]

Indication	Fenofibrate	Fenofibric Acid	Gemfibrozil
Hypertriglyceridemia			
Adjunct to diet for treatment of adult patients with hypertriglyceridemia	✔ (Lofibra®)		
Adjunct to diet for treatment of severe hypertriglyceridemia	✔ (Antara®, Fenoglide®, Lipofen®, Tricor®, Triglide®)	✔ *	

Indication	Fenofibrate	Fenofibric Acid	Gemfibrozil
Adjunct to diet for treatment of adult patients with very high elevations of serum triglyceride (TG) levels who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them			✔ †
Primary Hypercholesterolemia and Mixed Dyslipidemia			
Adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), TG, and apolipoprotein B (apo B), and to increase high density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia	✔ ‡	✔	
Adjunct to diet to reduce the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL-C and raise HDL-C) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated TG			✔

*Fibricor®: TG ≥500 mg/dL.
†Patients who present such risk typically have serum triglycerides over 2,000 mg/dl and have elevations of very low-density lipoprotein cholesterol (VLDL)-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Patients who consistently have total serum or plasma TG below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil may be considered for those patients with triglyceride elevations between 1000 and 2000 mg/dl who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis.
‡Antara® and Triglide®: when response to diet and nonpharmacological interventions alone has been inadequate.

IV. Pharmacokinetics

The pharmacokinetic parameters of the fibric acid derivatives are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Fibric Acid Derivatives[12]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Fenofibrate	60 to 90	99	Liver (% not reported) Kidneys (% not reported)	Renal (60 to 93) Feces (5 to 25)	20 to 22
Fenofibric acid	81	99	Conjugation with glucuronic acid (% not reported)	Renal (primary; % not reported)	20
Gemfibrozil	Well absorbed (% not reported)	99	Liver (extensive; % not reported)	Renal (70) Feces (6)	1.5

V. Drug Interactions

Major drug interactions with the fibric acid derivatives are listed in Table 5.

Table 5. Major Drug Interactions with the Fibric Acid Derivatives[12]

Generic Name(s)	Interaction	Mechanism
Fenofibrate, Fenofibric acid, Gemfibrozil	Statins	The mechanism of interaction is not known. Severe myopathy may occur if fenofibrate and statins are coadministered.

Generic Name(s)	Interaction	Mechanism
Fenofibrate, Fenofibric acid, Gemfibrozil	Colchicine	Concurrent use of colchicine and fibric acid derivatives may result in an increased risk of myopathy, including rhabdomyolysis.
Fenofibrate, Fenofibric acid	Anticoagulants	Fibric acid derivatives may potentiate the inhibition of vitamin K dependent clotting factor synthesis by anticoagulants. The hypoprothrombinemic effect of anticoagulants may be increased by fibric acid derivatives and bleeding may occur.
Gemfibrozil	Bexarotene	Concurrent use of bexarotene and gemfibrozil may result in increased plasma concentrations of bexarotene.
Gemfibrozil	Dabrafenib	Inhibition of dabrafenib metabolism (CYP2C8) by gemfibrozil may elevate dabrafenib plasma concentrations, increasing the pharmacologic effects and risk for adverse reactions.
Gemfibrozil	Dasabuvir	Concurrent use of dasabuvir and gemfibrozil may result in increased dasabuvir exposure.
Gemfibrozil	Eltrombopag	Concurrent use of eltrombopag and gemfibrozil may result in increased eltrombopag plasma concentrations.
Gemfibrozil	Enzalutamide	Concurrent use of enzalutamide and gemfibrozil may result in increased enzalutamide exposure.
Gemfibrozil	Ezetimibe	Concurrent use of ezetimibe and gemfibrozil may result in increased ezetimibe concentrations and an increased risk of cholelithiasis.
Gemfibrozil	Imatinib	Concurrent use of gemfibrozil and imatinib may result in increased imatinib trough level or reduced imatinib exposure.
Gemfibrozil	Repaglinide	Gemfibrozil may inhibit the metabolism of repaglinide, resulting in an increase in the plasma concentrations and the risk of severe and protracted hypoglycemia.

VI. Adverse Drug Events

The most common adverse drug events reported with the fibric acid derivatives are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Fibric Acid Derivatives[1-9,11]

Adverse Events	Fenofibrate	Fenofibric Acid	Gemfibrozil
Cardiovascular			
Angina pectoris	✔	-	-
Arrhythmia	✔	-	-
Atrial fibrillation	✔	-	1
Cardiovascular disorder	✔	-	-
Coronary artery disorder	✔	-	-
Edema	✔	-	-
Electrocardiogram abnormal	✔	-	-
Hypertension	✔	✔	-
Hypesthesia	-	-	✔
Hypotension	✔	-	-
Migraine	✔	-	-
Myocardial infarction	✔	-	-
Palpitation	✔	-	-
Peripheral edema	✔	-	-
Peripheral vascular disorder	✔	-	✔
Phlebitis	✔	-	-
Syncope	-	-	✔
Tachycardia	✔	-	-
Varicose vein	✔	-	-

Adverse Events	Fenofibrate	Fenofibric Acid	Gemfibrozil
Vascular disorder	✔	-	-
Vasodilatation	✔	-	-
Ventricular extrasystoles	✔	-	-
Central Nervous System			
Anxiety	✔	-	-
Confusion	-	-	✔
Convulsion	-	-	✔
Depression	✔	-	✔
Dizziness	✔	3 to 4	✔
Fatigue	-	2 to 3	4
Fever	✔	-	-
Headache	3	12 to 13	1
Hypertonia	✔	-	-
Insomnia	✔	✔	-
Libido decreased	✔	-	✔
Nervousness	✔	-	-
Neuralgia	✔	-	-
Paresthesia	✔	-	✔
Pain	✔	-	-
Peripheral neuritis	-	-	✔
Somnolence	✔	-	✔
Vertigo	✔	-	2
Dermatological			
Acne	✔	-	-
Alopecia	✔	-	-
Angioedema	-	-	✔
Contact dermatitis	✔	-	-
Eczema	✔	-	2
Exfoliative dermatitis	-	-	✔
Fungal dermatitis	✔	-	-
Herpes simplex	✔	-	-
Herpes zoster	✔	-	-
Nail disorder	✔	-	-
Maculopapular rash	✔	-	-
Photosensitivity reaction	✔	-	✔
Pruritus	✔	-	-
Rash	-	-	2
Skin disorder	✔	-	-
Skin ulcer	✔	-	-
Stevens-Johnson syndrome	✔	✔	-
Sweating	✔	-	-
Toxic epidermal necrolysis	✔	✔	-
Urticaria	✔	-	✔
Vasculitis	-	-	✔
Endocrine and Metabolic			
Diabetes mellitus	✔	-	-
Gout	✔	-	-
Gynecomastia	✔	-	-
Hypoglycemia	✔	-	-
Hyperuricemia	✔	-	-
Gastrointestinal			
Abdominal pain	5	✔	10
Anorexia	✔	-	-
Cholestatic jaundice	-	-	✔

Adverse Events	Fenofibrate	Fenofibric Acid	Gemfibrozil
Colitis	✔	-	-
Constipation	2	3	1
Diarrhea	2	3 to 4	7
Duodenal ulcer	✔	3 to 5	-
Dyspepsia	✔	-	20
Eructation	✔	-	-
Esophagitis	✔	-	-
Flatulence	✔	-	-
Nausea	2	4 to 6	2
Peptic ulcer	✔	-	-
Vomiting	✔	-	2
Weight gain/loss	✔	-	-
Genitourinary			
Creatinine increased	✔	-	-
Cystitis	✔	-	-
Decreased male fertility	-	-	✔
Dysuria	✔	-	-
Impotence	-	-	✔
Kidney function abnormal	✔	-	✔
Nephrotoxicity	✔	✔	✔
Prostatic disorder	✔	-	-
Unintended pregnancy	✔	-	-
Urinary frequency	✔	-	-
Urinary tract infection	-	✔	-
Vaginal moniliasis	✔	-	-
Hematologic			
Agranulocytosis	✔	✔	-
Anemia	✔	✔	✔
Ecchymosis	✔	-	-
Eosinophilia	✔	-	-
Hematocrit decreased	-	✔	-
Hemoglobin decreased	-	✔	-
Leukopenia	✔	✔	✔
Lymphadenopathy	✔	-	-
Thrombocytopenia	✔	✔	✔
Hepatic			
Alkaline phosphokinase increased	-	-	✔
ALT increased	3	1 to 3	✔
AST increased	3	✔	✔
Bilirubin increased	-	-	✔
Cirrhosis	✔	✔	-
CPK increased	3	✔	✔
Hepatic enzymes increased	✔	✔	-
Hepatitis	✔	✔	-
Jaundice	-	-	✔
Liver fatty deposit	✔	-	-
Laboratory Test Abnormalities			
Serum creatinine increased	✔	✔	-
Musculoskeletal			
Arthralgia	✔	4	✔
Arthritis	✔	-	-
Arthrosis	✔	-	-
Bursitis	✔	-	-
Back pain	3	4 to 6	-

Adverse Events	Fenofibrate	Fenofibric Acid	Gemfibrozil
Joint disorder	✔	-	-
Leg cramps	✔	-	-
Muscle pain/spasm	✔	3 to 4	-
Myalgia	✔	3 to 4	-
Myasthenia	✔	-	✔
Myopathy	✔	-	✔
Myositis	✔	✔	-
Painful extremities	-	3 to 5	✔
Paresthesia	✔	-	✔
Rhabdomyolysis	✔	✔	✔
Synovitis	-	-	✔
Tenosynovitis	✔	-	-
Weakness	✔	✔	-
Respiratory			
Asthma	✔	-	-
Bronchitis	✔	✔	-
Cough	✔	✔	-
Dyspnea	✔	-	-
Laryngeal edema	-	-	✔
Laryngitis	✔	-	-
Nasopharyngitis	-	4 to 5	-
Pharyngitis	✔	-	-
Pneumonia	✔	-	-
Pulmonary embolism	✔	✔	-
Respiratory disorder	6	-	-
Rhinitis	2	-	-
Sinusitis	✔	3 to 4	-
Upper respiratory infection	-	4 to 5	-
Other			
Allergic reaction	✔	-	-
Amblyopia	✔	-	-
Anaphylaxis	-	-	✔
Appendicitis, acute	-	-	1
Asthenia	2	-	-
Blurred vision	-	-	✔
Cataracts	✔	-	✔
Chest pain	✔	-	-
Cholecystitis	✔	-	✔
Cholelithiasis	✔	✔	✔
Conjunctivitis	✔	-	-
Cyst	✔	-	-
Deep vein thrombosis	✔	✔	-
Drug-induced lupus syndrome	-	-	✔
Dry mouth	✔	-	-
Ear pain	✔	-	-
Eye disorder	✔	-	-
Flu syndrome	2	-	-
Hernia	✔	-	-
Hypersensitivity reaction	✔	✔	-
Infection	✔	-	-
Influenza	-	✔	-
Intracerebral hemorrhage	-	-	✔
Malaise	✔	-	-
Otitis media	✔	-	-

Adverse Events	Fenofibrate	Fenofibric Acid	Gemfibrozil
Pancreatitis	✔	✔	✔
Pharyngolaryngeal pain	-	✔	-
Raynaud's phenomenon	-	-	✔
Refraction disorder	✔	-	-
Retinal edema	-	-	✔
Seizure	-	-	✔
Syncope	-	-	✔
Taste perversion	-	-	✔
Vision abnormalities	✔	-	-

✔ Percent not specified.
- Event not reported.

VII. Dosing and Administration

The usual dosing regimens for the fibric acid derivatives are listed in Table 7.

Table 7. Usual Dosing Regimens for the Fibric Acid Derivatives[1-9,11]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Fenofibrate	Hypertriglyceridemia: Capsule (Lofibra®): initial, 67 to 200 mg/day; maximum 200 mg/day Tablet (Lofibra®): initial, 54 to 160 mg/day; maximum, 160 mg/day Primary hypercholesterolemia or mixed hyperlipidemia: Capsule (Antara®): 90 mg/day Capsule (Lofibra®): initial, 200 mg/day; maximum 200 mg/day Capsule (Lipofen®): 150 mg/day Tablet (Fenoglide®): 120 mg/day Tablet (Lofibra®): initial, 160 mg/day Tablet (Tricor®): initial, 145 mg once daily Tablet (Triglide®): 160 mg/day Severe hypertriglyceridemia: Capsule (Antara®): 30 to 90 mg/day Capsule (Lipofen®): 50 to 150 mg/day Tablet (Fenoglide®): 40 to 120 mg/day Tablet (Tricor®): initial, 48 to 145 mg once daily; maximum, 145 mg/day Tablet (Triglide®): 50 to 160 mg/day	Safety and efficacy in pediatric patients have not been established.	Capsule: 30 mg (Antara®) 50 mg (Lipofen®) 67 mg (Lofibra®) 90 mg (Antara®) 134 mg (Lofibra®) 150 mg (Lipofen®) 200 mg (Lofibra®) Tablet: 40 mg (Fenoglide®) 48 mg (Tricor®) 50 mg (Lipofen®) 54 mg (Lofibra®) 120 mg (Fenoglide®) 145 mg (Tricor®) 160 mg (Lofibra®, Triglide®)
Fenofibric acid	Primary hypercholesterolemia or mixed		Delayed-release

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	hyperlipidemia: Tablet: 105 mg/day Severe hypertriglyceridemia: Delayed-release capsule: 45 to 135 mg once daily Tablet: 35 to 105 mg/day		capsule: 45 mg (Trilipix®) 135 mg (Trilipix®) Tablet: 35 mg (Fibricor®) 105 mg (Fibricor®)
Gemfibrozil	Hypertriglyceridemia (very high elevations of serum triglyceride): Tablet: 600 mg twice daily 30 minutes before breakfast and dinner Primary hypercholesterolemia or mixed hyperlipidemia: Tablet: 600 mg twice daily 30 minutes before breakfast and dinner		Tablet: 600 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the fibric acid derivatives are summarized in Table 8. Clinical trials have not been conducted with Lipofen®.[5] The pharmacological effects of fenofibric acid have been extensively studied through oral administration of fenofibrate, which is converted in vivo to fenofibric acid.[2]

Table 8. Comparative Clinical Trials with the Fibric Acid Derivatives

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hypercholesterolemia				
Rosenson et al.[26] (2007) Fenofibrate 160 mg QD vs placebo	DB, PC, RCT Patients with fasting hypertriglyceridemia (≥1.7 and <6.9 mmol/L) and 2 or more of the NCEP ATP III criteria for the metabolic syndrome	N=59 19 weeks	Primary: Fasting TG, postprandial TG, oxidative stress, inflammatory response Secondary: Not reported	Primary: Fenofibrate treatment lowered fasting TG (-46.1%; P<0.0001) and postprandial (area under the curve) TG (-45.4%; P<0.0001) due to significant reductions in postprandial levels of large (-40.8%; P<0.0001), medium (-49.5%; P<0.0001) and VLDL particles. The number of fasting total LDL particles was reduced in fenofibrate-treated patients (-19.0%; P=0.0033) primarily due to reductions in small LDL particles (-40.3%; P<0.0001); these treatment differences persisted postprandially. Fasting and postprandial oxidized fatty acids were reduced in fenofibrate-treated patients compared to placebo-administered patients (-15.3%; P=0.0013, and 31.0%; P<0.0001, respectively). Fenofibrate therapy lowered inflammatory markers as follows: fasting and postprandial soluble VCAM-1 decreased by -10.9% for fasting VCAM-1 (P=0.0005), and by -12.0% for postprandial VCAM-1 (P=0.0001); and fasting and postprandial soluble ICAM-1 decreased by -14.8% for fasting ICAM-1 (P<0.0001) and by -15.3% for postprandial ICAM-1 (P<0.0001). Reductions in VCAM-1 and ICAM-1 were correlated with reductions in fasting and postprandial large VLDL particles (P<0.0001) as well as postprandial oxidized fatty acids (P<0.0005). Secondary: Not reported
Davidson et al.[27] (2006) TRIMS	DB, MC, PC, RCT Patients between the ages of 21 and 79	N=146 8 weeks	Primary: Changes or percent changes from baseline to the end-	Primary: There was a significant change from baseline in the mean percent decrease of TG in the fenofibrate group (36.6%) compared to essentially no change in the placebo group (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fenofibrate 130 mg QD vs placebo	years, with fasting TG levels ≥300 and <1,000 mg/dL, and ≥2 of 4 additional components of the metabolic syndrome as defined by the NCEP ATP III		of-treatment in fasting TG Secondary: Changes or percent changes from baseline in TC, LDL-C, HDL-C, the TC:HDL-C ratio, VLDL-C, non-HDL-C; apo AI, B, and C-III; and remnant lipoprotein cholesterol	Secondary: There was no significant difference in TC change between the fenofibrate treatment and the placebo groups (P=0.085). LDL-C increased by a mean of 15.0% in the fenofibrate group compared to 3.2% in the placebo group (P=0.006). HDL-C increased by a mean of 14.0% in the fenofibrate group compared to 0.8% for placebo (P<0.001). The ratio of TC to HDL-C decreased with fenofibrate compared to placebo (-14.2 vs 0.8%; P<0.001). VLDL-C declined by 33% with fenofibrate compared to a 1.6% decline with placebo treatment (P<0.001). Non-HDL-C decreased significantly more in the fenofibrate group (-7.5 vs -1.1%; P=0.009). There was no significant difference in the rise in apo AI among the fenofibrate group vs the placebo response (5.3 vs 2.0%; P=0.212). Apo B declined significantly with fenofibrate compared to placebo (P<0.001, respectively). Apo CIII was markedly reduced in the fenofibrate group (P<0.001 compared to placebo). A significant reduction in remnant lipoprotein cholesterol was observed with fenofibrate treatment (-35.1 vs 12.3%; P<0.001).
Jones et al.[28] (2010) Fenofibric acid 135 mg/day vs	DB, MC, RCT Patients ≥18 years of age with mixed dyslipidemia (fasting TG ≥150 and <400 mg/dL, HDL-C <40	N=543 12 weeks	Primary: Percentage changes from baseline in HDL-C and TG Secondary:	Primary: The addition of fenofibric acid resulted in a significantly greater mean percentage improvement in HDL-C (13.0 vs 4.2%; P<0.001) and TG (-57.3 vs -39.7%; P<0.001) compared to placebo. Secondary: The addition of fenofibric acid resulted in significantly greater effect on all

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo All patients received atorvastatin 40 mg/day and ezetimibe 10 mg/day	mg/dL in men and <50 mg/dL in women and LDL-C ≥130 mg/dL)		Changes from baseline in apo AI, VLDL-C, apo CIII, non-HDL-C, apo B, hsCRP, LDL-C; proportion of patients achieving lipoprotein and apoprotein goals after 12 weeks of treatment; safety	secondary variables on non-HDL-C (P<0.001), apo B (P<0.001), apo AI (P=0.004), VLDL-C (P<0.001), apo CIII (P<0.001) and hsCRP (P<0.001) compared to placebo. The addition of fenofibric acid and placebo resulted in a >50% reduction in LDL-C (52.9 vs 52.0%; P value not reported), for final mean levels of 70.3 and 72.2 mg/dL. A numerically higher proportion of patients who added fenofibric acid achieved the LDL-C goal <100 mg/dL (92.7 vs 86.3%), the combined target of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL (91.2 vs 84.0%) and the combined target of LDL-C <100 mg/dL, non-HDL-C <130 mg/dL and apo B <90 mg/dL (88.4 vs 80.8%) (P values not reported). Similar proportions of patients receiving both treatments achieved the LDL-C goal <70 mg/dL (55.0 vs 56.5%) and the combined target of LDL-C <70 mg/dL, non-HDL-C <100 mg/dL and apo B <80 mg/dL specified for high risk patients (53.4 vs 51.3%) (P values not reported). Both treatments were generally well tolerated. The percentages of patients discontinuing treatment were similar (9.6 vs 11.0%; P value not reported). The most common adverse events leading to discontinuations were myalgia and increases in ALT and/or AST. The treatments were similar in the incidence of adverse events experienced, treatment-related adverse events, serious adverse events and adverse events leading to withdrawal. The most commonly reported adverse events (≥3%) were muscle spasms, myalgia, arthralgia, fatigue, diarrhea, nausea, and headache.
Hogue et al.[29] (2008) Fenofibrate 200 mg QD vs atorvastatin 20 mg QD	RCT Patients with type 2 diabetes and hypertriglyceridemia	N=40 6 weeks	Primary: Lipids and TRL, inflammation and adhesion molecules Secondary: Not reported	Primary: Treatment with atorvastatin led to a significant decrease in plasma TC (-37.7%; P<0.0001), plasma TG (-37.6%, P<0.0001), plasma apo B (-43.2%, P<.0001), TRL-C (-44.1%, P<0.0001), TRL-TG (-36.9%, P<0.0001), TRL apo B (-13.8%, P=0.04), LDL-C (-43.0%, P<0.0001), LDL apo B (-42.7%, P<0.0001), and a significant increase in HDL-C (17.9%, P=0.001), and HDL apo A-I levels (10.3%, P=0.004). Treatment with fenofibrate led to a significant decrease in plasma C (-10.9%, P=0.0001), plasma TG (-41.4%, P=0.0002), plasma apo B (-9.9%, P=0.01), TRL-C (-52.8%, P<0.0001), TRL-TG (-46.3%,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				P=0.0002), and TRL apo B (-14.8%, P=0.02) and a significant increase in LDL-C (15.9%, P=0.04) and HDL-C (8.9%, P=0.05). There were significant differences in the percentage changes of plasma cholesterol, plasma apo B, LDL-C, and LDL apo B between the two treatment groups. There was no significant difference in the percentage in changes of plasma TG between the treatment groups. Treatment with atorvastatin significantly decreased plasma levels of CRP (-26.9%, P=0.004), soluble ICAM-1 (-5.4%, P=0.03), soluble VCAM-1 (-4.4%, P=0.008), soluble E-selectin (-5.7%, P=0.02), MMP-9 (-39.6%, P=0.04), soluble phospholipase A2 (-14.8%, P=0.04), and oxidized LDL (-38.4%, P<0.0001). Fenofibrate significantly decreased soluble E-selectin levels only (-6.0, P=0.04) and increased soluble phospholipase A2 levels (22.5%, P=0.004). Secondary: Not reported
Arca et al.[30] (2007) Fenofibrate 200 mg/day vs atorvastatin 10 mg/day, titrated up to 80 mg/day	OL, RCT Patients 30 to 75 years of age with diagnosis of familial combined hyperlipidemia with TC and/or TG levels ≥90th Italian population percentiles, and/or hyper-apobeta-lipoproteinemia	N=56 24 weeks	Primary: Change in TC, LDL-C, HDL-C, TG, apo A and endothelin-1 Secondary: Not reported	Primary: Atorvastatin was associated with a significant 9% reduction in TC compared to fenofibrate (95% CI, 3.0 to 15.1; P=0.004). Atorvastatin was associated with a significant 17% reduction in LDL-C compared to fenofibrate (95% CI, 8.0 to 26.1; P<0.001). Fenofibrate was associated with a significant 15.5% reduction in TG compared to atorvastatin (95% CI, 3.35 to 27.70; P=0.013). Fenofibrate was associated with a significant 14.2% increase in HDL-C compared to atorvastatin (95% CI, 3.8 to 24.6%; P=0.008). Fenofibrate was associated with a significant 5.2 and 22.0% increase in apo AI and apo AII compared to atorvastatin (P=0.044 and P<0.001, respectively). Fenofibrate was associated with a significant 16.7% reduction in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				endothelin-1 from baseline (P<0.05). Atorvastatin was not associated with a significant change in endothelin-1 (P value not reported). Secondary: Not reported
Goldberg et al.[31] (2009) Fenofibric acid 135 mg QD plus atorvastatin 20 to 40 mg QD vs fenofibric acid 135 mg QD vs atorvastatin 20 to 40 mg QD	AC, DB, MC, RCT Patients ≥18 years of age with mixed dyslipidemia (fasting TG ≥150 mg/dL, HDL-C <40 mg/dL for men and <50 mg/dL for women and LDL-C ≥130 mg/dL after lipid therapy washout)	N=613 12 weeks	Primary: Percent changes from baseline in TG, HDL-C and LDL-C Secondary: Percent changes from baseline in VLDL-C, TC, apo B and hsCRP; safety	Primary: Combination therapy (atorvastatin 20 mg) resulted in significantly greater improvements in TG (-45.6 vs -16.5%; P<0.001) and HDL-C (14.0 vs 6.3%; P=0.005) compared to atorvastatin 20 mg and LDL-C (-33.7 vs -3.4%; P<0.001) compared to fenofibric acid. Similarly, significantly greater improvements were observed with combination therapy (40 mg) in TG (-42.1 vs -23.2%; P<0.001) and HDL-C (12.6 vs 5.3%; P=0.010) compared to atorvastatin 40 mg and LDL-C (-35.4 vs -3.4%; P<0.001) compared to fenofibric acid. Secondary: Combination therapy (20 mg) resulted in significantly higher mean percentages of decrease in non-HDL-C compared to fenofibric acid (P=0.026) and in VLDL-C compared to atorvastatin 20 mg (P=0.046). Combination therapy (40 mg) also resulted in significantly higher mean percentage of decrease in non-HDL-C compared to fenofibric acid (P<0.001) and in VLDL-C compared to atorvastatin 40 mg (P<0.001). Improvements in other secondary variables were similar between combination therapy and atorvastatin (TC; P=0.688, apo B; P=0.688 and hsCRP; P=0.074).
Roth et al.[32] (2010) Rosuvastatin 5 mg/day vs fenofibric acid 135 mg/day	DB, MC, RCT Patients with fasting LDL-C ≥130 mg/dL, TG ≥150 mg/dL and HDL-C <40 mg/dL	N=760 12 weeks (plus a 30 day safety follow up period)	Primary: Composite of mean percent changes from baseline in HDL-C, TG and LDL-C Secondary: Changes from baseline in non-HDL-C, VLDL-C,	Primary: Combination therapy resulted in a significantly greater mean percent change in HDL-C (23.0 vs 12.4%; *P*<0.001) and TG (-43.0 vs -17.5%; *P*<0.001) compared to rosuvastatin, and resulted in significantly higher mean percent decrease in LDL-C compared to fenofibric acid (28.7 vs 4.1%; *P*<0.001). Secondary: Combination therapy resulted in significantly greater improvements in non-HDL-C compared to either monotherapy, and significantly greater improvements in apo B, hsCRP, VLDL-C and TC compared to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs rosuvastatin 5 mg/day plus fenofibric acid 135 mg/day			apo B, hsCRP and TC; safety; proportion of patients achieving LDL-C (<100 mg/dL) and non-HDL-C (<130 mg/dL) goals	rosuvastatin. All treatments were generally well tolerated, with discontinuations due to adverse events being higher with combination therapy (8.3%) and fenofibric acid (7.5%) compared to rosuvastatin (4.4%). The most common adverse events leading to discontinuation were myalgia and muscle spasms and nausea, fatigue and ALT and AST increases. The overall incidence of treatment-emergent adverse events was similar across treatments (58.5 to 63.0%). No significant differences were observed between the combination therapy and either monotherapy in the incidence of any category of adverse events (muscle, hepatic and renal related). In patients with a 10 year CHD risk >20%, the LDL-C goal <100 mg/dL was achieved by 50.5% of patients receiving combination therapy and rosuvastatin; the non-HDL-C goal <130 mg/dL was achieved by 49.5% of patients receiving combination therapy compared to 33.3% of patients receiving rosuvastatin (*P*=0.03). Both LDL-C and non-HDL-C goals were achieved by 44.3 vs 32.3% (*P*=0.10).
Jones et al.[33] (2009) Fenofibric acid 135 mg QD and rosuvastatin (10 or 20 mg) QD vs fenofibric acid 135 mg QD vs rosuvastatin 10, 20, or 40 mg QD	AC, DB, MC, RCT Patients ≥18 years of age with mixed dyslipidemia (TG ≥150 mg/dL, HDL-C <40 mg/dL for men or <50 mg/dL for women and LDL-C ≥130 mg/dL)	N=1,445 16 weeks (includes 30 day safety evaluation)	Primary: Composite of mean percent changes from baseline in HDL-C, TG and LDL-C Secondary: Composite of mean percent changes from baseline in non-HDL-C, VLDL-C, TC, apo B and hsCRP	Primary: Combination therapy (rosuvastatin 10 and 20 mg) was associated with a significantly greater increase in HDL-C (10 mg: 20.3 vs 8.5%; P<0.001 and 20 mg: 19.0 vs 10.3%; P<0.001) and a significantly greater decrease in TG (10 mg: 47.1 vs 24.4%; P<0.001 and 20 mg: 42.9 vs 25.6%; P<0.001) compared to rosuvastatin (10 and 20 mg). Combination therapy was associated with a significantly greater decrease in LDL-C (10 mg: 37.2 vs 6.5%; P<0.001 and 20 mg: 38.8 vs 6.5%; P<0.001) compared to fenofibric acid. Secondary: Combination therapy (rosuvastatin 10 mg) was associated with a significantly greater reduction in non-HDL-C compared to fenofibric acid or rosuvastatin (10 mg) (P<0.001). Combination therapy was also associated with significantly greater improvements in VLDL-C (P<0.001), apo B (P<0.001) and hsCRP (P=0.013) compared to rosuvastatin. Combination therapy (rosuvastatin 20 mg) significantly improved non-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				HDL-C compared to fenofibric acid (P<0.001) and was associated with a significantly greater improvement in VLDL-C (P=0.038) and hsCRP (P=0.010) compared to rosuvastatin (20 mg), with similar reductions in non-HDL-C, apo B and TC (P values not reported).
Ferdinand et al.[34] (2012) Fenofibric acid 135 mg QD and rosuvastatin 10 mg QD for 12 weeks, followed by fenofibric acid 135 mg QD and rosuvastatin 20 mg QD for up to 52 weeks Outcomes were evaluated from the end of the initial 12 week period (baseline) up to 52 weeks of treatment.	Post-hoc analysis Patients ≥18 years of age with mixed dyslipidemia (TG ≥150 mg/dL, HDL-C <40 mg/dL for men or <50 mg/dL for women and LDL-C ≥130 mg/dL)	N=187 1 year	Primary: Change in baseline LDL-C, HDL-C, non-HDL-C, apo B, TG, hsCRP; proportion of patients achieving individual and combined goals for LDL-C and non-HDL-C; safety Secondary: Not reported	Primary: Increasing rosuvastatin from 10 to 20 mg, in combination with fenofibric acid for up to 52 weeks, resulted in significant changes from baseline in LDL-C (-9.5%), non-HDL-C (-0.6%), apoB (-8.5%), and HDL-C (3.6%) (P≤0.005 for all). TG levels remained unchanged (0.8%; P=0.055) at week 52. A greater proportion of patients achieved risk-stratified lipid goals at week 52 compared to baseline for LDL-C (89 vs 84%; P=0.26), non-HDL-C (50 vs 25%; P value not reported), and both LDL-C and non-HDL-C (50 vs 19%; P value not reported). The incidences of muscle-, hepatic-, and renal-related adverse events and laboratory values were within the expected range for combination therapy. The most commonly reported treatment-emergent adverse events (>10%) were upper respiratory tract infection (14.4%), headache (13.9%), and back pain (10.7%)/ Treatment-emergent serious adverse events occurred in seven percent of patients, and one death (MI) occurred, none of which were deemed to be treatment-related. Secondary: Not reported
Mohiuddin et al.[35] (2009) Fenofibric acid 135 mg QD plus simvastatin 20 to 40 mg QD vs fenofibric acid 135	AC, DB, MC Patients >18 years of age with mixed dyslipidemia (TG ≥150 mg/dL, HDL-C <40 mg/dL for men or <50 mg/dL for women, and LDL-C ≥130 mg/dL)	N=657 16 weeks (includes 30 day safety evaluation)	Primary: Composite of mean percent changes from baseline in HDL-C, TG and LDL-C Secondary: Composite of mean percent changes from baseline in	Primary: Combination therapy was associated with a significantly greater increase in HDL-C (20 mg: 17.8 vs 7.2%; P<0.001 and 40 mg: 18.9 vs 8.5%; P<0.001) and a significantly greater decrease in TG (20 mg: 37.4 vs 14.2%; P<0.001 and 40 mg: 42.7 vs 22.4%; P<0.001) compared to simvastatin (20 and 40 mg). Combination therapy was associated with a significantly greater decrease in LDL-C (20 mg: 24.0 vs 4.0%; P<0.001 and 40 mg: 25.3 vs 4.0%; P<0.001) compared to fenofibric acid.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg QD vs simvastatin 20 to 80 mg QD			non-HDL-C, VLDL-C, TC, apo B and hsCRP	Secondary: Combination therapy (simvastatin 20 mg) was associated with a significantly greater decrease in non-HDL-C (P<0.001) compared to fenofibric acid and simvastatin (20 mg). Combination therapy (simvastatin 20 mg) was associated with significant improvements in VLDL-C (P<0.001), apo B (P<0.001) and hsCRP (P=0.013) compared to simvastatin (20 mg). Combination therapy (simvastatin 40 mg) significantly (P<0.001) improved non-HDL-C compared to fenofibric acid, and resulted in a significantly greater improvement in VLDL-C (P=0.005) compared to simvastatin (40 mg), with similar reductions in non-HDL-C, apo B and TC (P values not reported).
Derosa et al.[36] (2009) Fenofibrate 145 mg/day and simvastatin 40 mg/day vs fenofibrate 145 mg/day vs simvastatin 40 mg/day	DB, MC, RCT Caucasian patients ≥18 years of age with type 2 diabetes mellitus and combined dyslipidemia who had never been treated with lipid-lowering medications	N=241 12 months	Primary: Lipid and lipoprotein profiles at six and 12 months Secondary: Not reported	Primary: After six months of therapy, there was a significant reduction in TC and LDL-C with simvastatin and fenofibrate plus simvastatin (P<0.05 and P<0.01, respectively). There was no significant change in the fenofibrate group. After 12 months of therapy, there was a significant decrease in TC and LDL-C in all treatment groups (P<0.05 for fenofibrate, P<0.01 for the simvastatin and P<0.001 for fenofibrate plus simvastatin). TC was significantly lower with fenofibrate plus simvastatin compared to simvastatin monotherapy and fenofibrate monotherapy (P<0.05). LDL-C was significantly lower with fenofibrate plus simvastatin compared to simvastatin monotherapy and fenofibrate monotherapy (P<0.01). After six months of therapy, there was a significant reduction in TG with fenofibrate and fenofibrate plus simvastatin (P<0.05, respectively). There was no significant change in the simvastatin group. After 12 months of therapy, there was a significant decrease in TG in all treatment groups (P<0.01 for fenofibrate, P<0.05 for simvastatin and P<0.001 for fenofibrate plus simvastatin). TG was significantly lower with fenofibrate + simvastatin compared to fenofibrate (P<0.05) or simvastatin (P<0.01). After six months of therapy, there was a significant increase in HDL-C with fenofibrate and fenofibrate plus simvastatin (P<0.05 and P<0.01, respectively). There was no change in the simvastatin group. After 12

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				months of therapy, there was a significant increase in HDL-C in all treatment groups (P<0.01 for fenofibrate, P<0.05 for simvastatin and P<0.001 for fenofibrate plus simvastatin). HDL-C was significantly higher with fenofibrate plus simvastatin compared to simvastatin monotherapy and fenofibrate monotherapy (P<0.05). After six months of therapy, there was no significant change in apo A1 or apo B in any treatment group. After 12 months of therapy, there was a significant increase of apo A1 with fenofibrate plus simvastatin. There was no significant difference between the treatment groups. After 12 months of therapy, there was a significant decrease of apo B in all groups (P<0.05 for fenofibrate, P<0.05 for simvastatin and P<0.01 for fenofibrate plus simvastatin). There was no significant difference between the treatment groups. There were no significant differences in Lp(a) after six or 12 months of therapy in any of the treatment groups. After six months of therapy, there was a significant decrease in hsCRP with fenofibrate plus simvastatin (P<0.05), but not in the other groups. After 12 months of therapy, there was a significant decrease in hsCRP with simvastatin and with fenofibrate plus simvastatin (P<0.05 and P<0.01, respectively), but not with fenofibrate. The hsCRP value was significantly lower with fenofibrate plus simvastatin compared to fenofibrate or simvastatin (P<0.05). Secondary: Not reported
May et al.[37] (2008) DIACOR Fenofibrate 160 mg and simvastatin 20 mg QD vs	DB, PC, RCT Patients with type 2 diabetes, no CHD, and biochemical evidence of mixed dyslipidemia (having 2 of the following 3 lipid parameters: LDL-C >100 mg/dL, TG >200 mg/dL, and	N=300 12 weeks	Primary: Lipid and lipoprotein profiles Secondary: Not reported	Primary: Fenofibrate plus simvastatin significantly reduced dense VLDL-C compared to fenofibrate (P<0.001) and simvastatin (P<0.0001). Simvastatin significantly reduced IDL-C compared to fenofibrate (P<0.003). The percentage of LDL-C pattern B constituting total LDL-C was significantly reduced by fenofibrate (-13.7%; P<0.0001) and fenofibrate plus simvastatin (-11.1%, P<0.0001). There was no significant change with simvastatin (-2.4%; P=0.27).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
fenofibrate 160 mg QD vs simvastatin 20 mg QD	HDL-C <40 mg/dL)			Fenofibrate and fenofibrate plus simvastatin significantly increased the percentage of buoyant LDL-C constituting total LDL-C (-19.6%; P<0.0001 and -16.9%; P<0.0001, respectively). There was no significant change with simvastatin (-3.1%; P=0.06). Secondary: Not reported
Jones et al.[38] (2009) Fenofibric acid 135 mg QD vs low-dose statin (rosuvastatin 10 mg, simvastatin 20 mg, or atorvastatin 20 mg) QD vs fenofibric acid 135 mg plus low-dose statin (rosuvastatin 10 mg, simvastatin 20 mg, or atorvastatin 20 mg) QD vs moderate-dose statin (rosuvastatin 20 mg, simvastatin	Pooled analysis of 3 AC, DB, MC, RCT Patients >18 years of age, with HDL-C <40 mg/dL (men) or <50 mg/dL (women), TGs ≥150 mg/dL, and LDL-C ≥130 mg/dL ≥130 mg/dL	N=2,715 12 weeks	Primary: Mean percent change in HDL-C, TGs (fenofibric acid plus atorvastatin vs atorvastatin), and LDL-C (fenofibric acid plus atorvastatin vs fenofibric acid) Secondary: Mean percent change in non-HDL-C, VLDL-C, TC, apo B, and hsCRP; safety	Primary: Fenofibric acid plus low-dose statin combination therapy resulted in a greater mean percent increase in HDL-C (18.1 vs 7.4%; P<0.001) and a greater mean percent decrease in TG (-43.9 vs -16.8%; P<0.001) compared to low-dose statin monotherapy, and a greater mean percent decrease in LDL-C (-33.1 vs -5.1%; P<0.001) compared to fenofibric acid monotherapy. Fenofibric acid plus moderate-dose statin combination therapy resulted in a greater mean percent increase in HDL-C (17.5 vs 8.7%; P<0.001) and a greater mean percent decrease in TG (-42.0 vs -23.7%; P<0.001) compared to moderate-dose statin monotherapy, and a greater mean percent decrease in LDL-C (-34.6 vs -5.1%; P<0.001) compared to fenofibric acid monotherapy. No formal comparisons were made between the high-dose statin monotherapy group and the other treatment groups. Secondary: Greater improvements in non-HDL-C, VLDL-C, TC, and apo B were observed for fenofibric acid plus low-dose statin combination therapy compared to corresponding monotherapies (P≤0.001). Combination therapy was generally well tolerated, and safety profiles were similar to monotherapies. No rhabdomyolysis was reported.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
40 mg, or atorvastatin 40 mg) QD vs fenofibric acid 135 mg QD plus moderate-dose statin QD vs high-dose statin (rosuvastatin 40 mg, simvastatin 80 mg, or atorvastatin 80 mg) QD				
Bays et al.[39] (2008) Fenofibric acid 135 mg plus moderate dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) Extension study patients received the same type of statin that was used in the statin-containing arms of the controlled	MC, OL Patients with mixed dyslipidemia completing 1 of 3 MC, PRO, DB, RCT 12-week studies were eligible	N=2,201 1 year	Primary: Safety, percent changes from baseline in TG, HDL-C, and LDL-C Secondary: Percent changes in non-HDL-C, VLDL-C, TC, apoB, and hs-CRP	Primary: Of the 2,201 patients who received at least one dose of fenofibric acid plus statin combination therapy, six patients (0.3%) died during the conduct of the ES; no death was considered by the investigator to be treatment related. Overall, 148 (6.7%) patients had treatment-emergent serious adverse events (fenofibric acid plus rosuvastatin, 7.2%; fenofibric acid plus simvastatin, 7.8%; fenofibric acid + atorvastatin 4.6%). The most common treatment-emergent serious adverse events were osteoarthritis, deep vein thrombosis, CAD, MI, and chest pain, diverticulitis, syncope, and intervertebral disc protrusion. A total of 1,856 patients (84.3%) had one or more treatment-emergent adverse events (fenofibric acid plus rosuvastatin, 83.1%; fenofibric acid plus simvastatin, 86.2%; fenofibric acid plus atorvastatin, 85.2%). The most frequently reported adverse events were headache, upper respiratory tract infection, nasopharyngitis, and back pain.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
study in which they participated				Among patients who received fenofibric acid monotherapy in a controlled study, treatment with fenofibric acid plus moderate-dose statin combination therapy for 52 weeks resulted in an additional median percent decrease in TG (-22.0%), mean percent decrease in LDL-C (-38.1%), and mean percent increase in HDL-C (6.2%). Among patients who received moderate-dose statin monotherapy in a controlled study, treatment with fenofibric acid plus moderate-dose statin combination therapy for 52 weeks resulted in an additional median percent decrease in TG (-30.5%) and mean percent increases in HDL-C (13.1%) and LDL-C (3.1%). Among patients who received fenofibric acid plus low-dose statin combination therapy in a controlled study, there was an additional median percent decrease in TG (-4.2%), mean percent increase in HDL-C (4.8%), and mean percent decrease in LDL-C (-9.7%) after the statin dose was increased for 52 weeks. The group of patients who were treated with fenofibric acid plus moderate-dose statin in a controlled study and continued the same therapy in the extension study exhibited sustained improvements in lipid parameters throughout the course of therapy. For this group of patients, treatment with fenofibric acid plus moderate-dose statin combination therapy for a total of 64 weeks decreased TG from a mean baseline of 297.8 mg/dL to a mean final level of 138.0 mg/dL, decreased LDL-C from a mean baseline of 153.1 mg/dL to a mean final level of 94.2 mg/dL, and increased HDL-C from a mean baseline of 38.2 mg/dL to a mean final level of 47.7 mg/dL. Secondary: Among patients who received fenofibric acid monotherapy or moderate-dose statin monotherapy in the controlled studies, treatment with fenofibric acid plus moderate-dose statin combination therapy in the extension study resulted in additional mean percent decreases in non-HDL-C, VLDL-C, TC, and apo B, and median percent decrease in hsCRP that were sustained throughout 52 weeks of combination therapy.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				For patients initially treated with fenofibric acid plus low-dose statin combination therapy, increasing the statin dose resulted in additional mean percent decreases in non-HDL-C, TC, and apo B and median percent decrease in hsCRP, which were sustained throughout the study.
Kipnes et al.[40] (2010) Fenofibric acid 135 mg plus moderate dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) ES patients received the same type of statin that was used in the statin-containing arms of the controlled study in which they participated.	ES, OL Patients with mixed dyslipidemia at the start of a 1 year, ES, OL	N=310 1 year (2 years of total therapy)	Primary: Safety and efficacy Secondary: Not reported	Primary: No deaths occurred during the two year trial. The incidence of serious adverse events was numerically highest with fenofibric acid plus rosuvastatin (14.9%) compared to fenofibric acid plus simvastatin (8.0%) or atorvastatin (5.8%). The incidences of adverse events were similar among all treatments as well (94.8, 90.0 and 97.7%). Adverse events tended to occur early in treatment, without the development of new types of adverse events over time. The most common treatment-related adverse events were muscle spasms (3.9%), increased blood creatine phosphokinase (3.5%), headache (2.9%), myalgia (2.9%), dyspepsia (2.3%) and nausea (2.3%). Rhabdomyolysis was not reported with any treatment. Nine patients discontinued therapy due to adverse events, with similar incidences among all treatments. Myalgia was the most common reason for discontinuation. No significant difference in the incidence of laboratory elevations was observed among the treatment groups. Incremental improvements in mean percentage changes in all efficacy variables were observed after the first visit in the year one ES (week 16). This effect was sustained for greater than two years and sizable mean percentage changes in all efficacy variables were observed at week 116. In the overall population, the mean percentage changes from baseline to week 116 in efficacy variables were: 17.4 (HDL-C), -46.4 (TG), -40.4 (LDL-C), -47.3 (non-HDL-C), -37.8 (TC) and -52.8% (VLDL-C). Significant differences among treatments were observed for non-HDL-C (-48.60±13.58 vs -41.70±13.10 vs -47.30±12.50%; *P*=0.011), TC (-38.70±12.16 vs -32.50±10.86 vs -38.60±10.85%; *P*=0.007) and VLDL-C (-56.80±25.17 vs -40.30±51.25 vs -51.20±35.42%; *P*=0.019). Secondary: Not reported
Farnier et al.[41] (2005)	DB, MC, PC, RCT Men and women 18	N=619 12 weeks	Primary: Percent change in LDL-C from	Primary: The mean percent change in LDL-C reduction was significantly greater in the micronized fenofibrate and ezetimibe group when compared to the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fenofibrate 160 mg QD and ezetimibe 10 mg QD vs fenofibrate 160 mg QD vs ezetimibe 10 mg QD vs placebo	to 75 years of age with mixed hyperlipidemia and no CHD, CHD-equivalent disease (except for type 2 diabetes), or 10-year CHD risk >20%		baseline to study end point Secondary: Percent change in other lipid, non-lipid, and lipoprotein parameters from baseline to study end point	other treatment groups (P<0.001 compared to micronized fenofibrate and ezetimibe). These reductions were 13.4% in the ezetimibe group, 5.5% in the micronized fenofibrate group, and 20.4% in the micronized fenofibrate and ezetimibe group. Secondary: When compared to micronized fenofibrate or ezetimibe monotherapy, significant reductions in apo B, non-HDL-C and LDL-C were observed in the micronized fenofibrate and ezetimibe group; P<0.001. When compared to placebo, significant decreases in TG levels and significant increases in HDL-C level were observed in both the micronized fenofibrate plus ezetimibe and micronized fenofibrate treatment groups; P<0.001. The percent changes from baseline to study end point were as follows: -11.8% in TC, 3.9% in HDL-C, -11.1% in TG, and -6.1% in hsCRP in the ezetimibe group; -10.8% in TC, 18.8% in HDL-C, -43.2% in TG, and -28.0% in hsCRP in the micronized fenofibrate group; -22.4% in TC, 19.0% in HDL-C, -44.0% in TG, and -27.3% in hsCRP in the micronized fenofibrate and ezetimibe group (P<0.05 for all).
Tribble et al.[42] (2008) Ezetimibe 10 mg and fenofibrate 160 mg QD (FENO + EZE) vs ezetimibe 10 mg QD (EZE) vs fenofibrate 160 mg QD (FENO)	DB, MC, PC, RCT Patients 18 to 75 years of age with mixed hyperlipidemia (LDL-C 130 to 220 mg/dL and TG 200 to 500 mg/dL) and no CHD or CHD-risk equivalent disease, or 10-year CHD risk >20% according to NCEP ATP III criteria	N=625 12 weeks	Primary: Changes in cholesterol mass within the major lipoprotein fractions and subfractions and LDL particle distribution profiles and particle size Secondary: Not reported	Primary: The effects of EZE, FENO, and FENO + EZE on VLDL subfractions were similar to those for VLDL overall. All active treatments reduced IDL-C. Treatment with FENO significantly reduced LDL-C1, LDL-C3, and LDL-C4 and significantly increased LDL-C2 compared to placebo. FENO + EZE produced a pattern of changes similar to those of FENO alone. The reductions in LDL-C1 and LDL-C3 were greater with the combination due to the added effects of EZE. There were no significant changes in cholesterol associated with Lp(a). Fenofibrate and FENO + EZE increased median HDL-C2 and HDL-C3 compared to EZE and placebo. In patients treated with EZE, there were reductions in VLDL-C, IDL-C, and LDL-C density ranges without a shift in LDL density distributions or

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				changes in the HDL-C range. In patients treated with FENO, there were reductions in VLDL-C and IDL-C. HDL-C was increased and there was a shift in the distribution of LDL toward larger, more buoyant LDL particles with a small effect on LDL-C values overall. In patients treated with FENO + EZE, there were reductions in VLDL-C, IDL-C, and LDL-C. HDL-C was increased and there was a shift from smaller, more dense to larger, more buoyant LDL subfractions. EZE did not significantly affect LDL peak particle size. FENO and FENO + EZE increased LDL peak particle size. Secondary: Not reported
McKenney et al.[43] (2006) Fenofibrate 160 mg QD and ezetimibe 10 mg QD vs fenofibrate 160 mg QD vs ezetimibe 10 mg QD for 12 weeks, then fenofibrate 160 mg and ezetimibe 10 mg QD for 48 weeks	DB Patient who completed base study with mixed hyperlipidemia	N=576 48 weeks	Primary: Percent change in LDL-C from baseline of the base study to study end point in the extension Secondary: Percent change from baseline to study end point in TC, HDL-C, TG, non-HDL-C, apo B, apo AI, and hsCRP	Primary: Fenofibrate plus ezetimibe showed significantly greater percent reductions in LDL-C compared to fenofibrate alone (-22.0 vs -8.6; P<0.001). Secondary: Fenofibrate plus ezetimibe showed significantly greater percent reductions from baseline to extension study end point in TC (-23.2 vs -13.6; P<0.001), TG (-46.0 vs -41.0; P=0.002), non-HDL-C (-31.6 vs -19.4; P<0.001), and apo B (-25.2 vs -16.2; P<0.001) compared to fenofibrate. There was a significantly greater percent increase in HDL-C (20.9 vs 17.8; P=0.02) with fenofibrate plus ezetimibe vs fenofibrate alone. There was not a significantly greater percent increase in apo AI (10.1 vs 7.8; P=0.12) with fenofibrate plus ezetimibe vs fenofibrate alone. Reductions in median hsCRP levels were not different between treatments (-25.3 vs -21.1; P=0.46) for fenofibrate plus ezetimibe vs fenofibrate alone, respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo for 12 weeks, then fenofibrate 160 mg for 48 weeks				
Ansquer et al.[44] (2009) Fenofibrate (Tricor®) 145 mg and ezetimibe 10 mg QD vs fenofibrate (Tricor®) 145 mg QD vs ezetimibe 10 mg QD	DB, MC, RCT Patients 18 to 70 years of age with type IIb dyslipidemia (LDL-C ≥160 mg/dL, TG 150 to 405 mg/dL) and ≥2 features of the metabolic syndrome according to the NCEP ATP III definition	N=60 12 weeks	Primary: Percentage change from baseline in TG and HDL-C Secondary: Percentage change in LDL-C, non-HDL-C, remnant-like particle cholesterol (RLP-C) and related parameters, change in glucose metabolism parameters, hsCRP, safety	Primary: Fenofibrate plus ezetimibe and fenofibrate reduced TG by -38.3% (P value not significant) and increased HDL-C to a similar extent (11.5 and 7.9%, respectively; P=0.282). Secondary: Fenofibrate plus ezetimibe reduced LDL-C by -36.2% compared to -22.4% with fenofibrate and -22.8% with ezetimibe (P<0.001 for both). Fenofibrate plus ezetimibe lowered non-HDL-C by -36.2% compared to fenofibrate (-24.8%) and ezetimibe (-20.9%) (P value not reported). There was no significant difference between fenofibrate plus ezetimibe and fenofibrate with regards to RLP-C (-36.2 vs -30.7%; P value not significant). Ezetimibe was less effective than fenofibrate plus ezetimibe (-17.3%; P<0.001). The effect of fenofibrate plus ezetimibe on LDL particle size (+2.1%) was similar to that of fenofibrate (+1.9%). Fenofibrate plus ezetimibe was more effective than monotherapy with fenofibrate or ezetimibe in reducing apo B (-33.3%). Fenofibrate plus ezetimibe had the same effect as fenofibrate on apo AI (+7.9 vs +5.1%, respectively) and apo AII (+24.2 vs +21.2%, respectively; P value not reported). Fenofibrate plus ezetimibe and fenofibrate reduced hsCRP to a similar degree.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was a higher incidence of treatment-related adverse events with fenofibrate/ezetimibe, which was primarily due to abnormal laboratory changes, including moderate increases in CK, liver enzymes, and blood creatinine.
Farnier et al.[45] (2007) Fenofibrate 160 mg QD and simvastatin-ezetimibe 20-10 mg QD vs fenofibrate 160 mg QD vs simvastatin-ezetimibe 20-10 mg QD vs placebo	DB, MC, PA, PC, RCT Patients 18 to 79 years old with mixed hyperlipidemia and no CHD or CHD-risk equivalent disease, or 10-year CHD risk >20% according to NCEP ATP III criteria	N=611 12 weeks	Primary: Percent change from baseline in LDL-C Secondary: Percent change from baseline in TC, TG, HDL-C, non-HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C/HDL-C, apo B	Primary: Simvastatin-ezetimibe plus fenofibrate group exhibited significant reduction in LDL-C from baseline compared to the fenofibrate monotherapy group (45.8 vs 15.7%; P<0.05). There was no significant difference between LDL-C reduction seen with the simvastatin-ezetimibe plus fenofibrate therapy and simvastatin-ezetimibe therapy (45.8 vs 47.1%; P>0.2). Secondary: Simvastatin-ezetimibe plus fenofibrate group exhibited significant reduction from baseline in non-HDL-C, TG, and apo B compared to the other treatment groups (P<0.01). There was no significant difference between TC reduction seen with the simvastatin-ezetimibe plus fenofibrate therapy and simvastatin-ezetimibe therapy (38.7 vs 35.4%; P>0.05). Simvastatin-ezetimibe plus fenofibrate group exhibited significant increase from baseline in HDL-C compared to the simvastatin-ezetimibe group (18.7 vs 9.3%; P<0.01). Simvastatin-ezetimibe plus fenofibrate group exhibited significant reduction from baseline in LDL-C:HDL-C, TC:HDL-C compared to the simvastatin-ezetimibe group (P=0.03). There was no significant difference between the percentage of patients able to reach their LDL-C goal with the simvastatin-ezetimibe plus fenofibrate therapy and simvastatin-ezetimibe therapy (88.5 vs 92.9%).
Farnier et al.[46] (2008) Fenofibrate 160	RCT, DB, MC, PC Patients 18 to 79 years of age with	N=611 12 weeks	Primary: Percent change in cholesterol associated with	Primary: The effects of ezetimibe-simvastatin, fenofibrate, and ezetimibe/simvastatin plus fenofibrate on VLDL subclasses were similar to those for VLDL-C overall.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg and ezetimibe-simvastatin 10-20 mg QD vs fenofibrate 160 mg QD vs ezetimibe-simvastatin 10-20 mg QD vs placebo	mixed hyperlipidemia and no CHD, CHD-equivalent disease (except for type 2 diabetes), or CHD risk score >20% (as defined by NCEP ATP III), LDL-C 130 to 220 mg/dL and TG 150 to 500 mg/dL		lipoprotein subfractions (VLDL-C 1+2 and VLDL-C 3, IDL-C, LDL-C 1 to 4, Lp[a], HDL-C_2 and HDL-C_3, and changes in LDL particle size) Secondary: Not reported	The maximal changes in IDL-C are achieved by ezetimibe-simvastatin with little additional effect of fenofibrate. Significant reductions were observed for all LDL-C subfractions with ezetimibe-simvastatin treatment. When coadministered with fenofibrate, the effects of both treatments were evident. Ezetimibe-simvastatin plus fenofibrate resulted in a pattern of changes that were similar to fenofibrate monotherapy indicating that the change in LDL-C pattern was primarily a function of fenofibrate. There was no significant difference in cholesterol associated with Lp(a) among the treatment groups. Fenofibrate and ezetimibe-simvastatin plus fenofibrate led to similar increases in median HDL-C_2 and HDL-C_3 compared to ezetimibe-simvastatin and placebo. Ezetimibe-simvastatin did not significantly affect LDL particle size. Fenofibrate and ezetimibe-simvastatin plus fenofibrate increased LDL particle size. At the end of the study, the percentages of patients exhibiting LDL size pattern B was 64, 49, 14, and 17% in the placebo, ezetimibe-simvastatin, fenofibrate, and ezetimibe-simvastatin plus fenofibrate groups, respectively. Secondary: Not reported
Kumar et al.[47] (2009) Ezetimibe 10 mg/day plus fenofibrate 160 mg/day vs	RCT, XO Patients with hypercholesterolemia requiring pharmacotherapy	N=43 12 weeks	Primary: Percentage reduction of LDL-C Secondary: Percent changes from baseline in TC, HDL-C and TG	Primary: LDL-C decreased by 34.6 vs 36.7% with combination therapy and atorvastatin (P=0.46). Secondary: Both treatments provided similar improvements in TC (-25.1 vs -24.6%; P=0.806) and HDL-C (10.1 vs 8.9%; P=0.778). Combination therapy showed a trend towards a greater reduction in TGs (25.4 vs 14.5%; P=0.079), although there were no significant difference between the two treatments in terms of the improvement in TC:HDL-C (-29.0 vs -28.7%;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
atorvastatin 10 mg/day				P=0.904).
Winkler et al.[48] (2009) Fluvastatin 80 mg/day plus fenofibrate 200 mg/day vs ezetimibe 10 mg/day plus simvastatin 20 mg/day	MC, OL, RCT, XO Patients 18 to 75 years of age with metabolic syndrome, low HDL-C, waist circumference ≥94 (men) or ≥80 cm (females) plus 1 of the following: TG ≥150 mg/dL, BP (≥85/≥130 mm Hg), FPG ≥100 mg/dL or prevalent type 2 diabetes	N=75 6 weeks	Primary: Changes from baseline in lipids, lipoproteins and apolipoproteins; LDL subfractions Secondary: Not reported	Primary: Reductions in TC, LDL-C and apo B were greater with ezetimibe plus simvastatin compared to fluvastatin plus fenofibrate, but differences only reached significance in patients without small, dense LDL (P=0.043, P=0.006 and P=0.20). Reductions in TG were only significant with fluvastatin plus fenofibrate compared to ezetimibe plus simvastatin in patients with small, dense LDL (P=0.029). Increases in HDL-C and apo AI were only significant with ezetimibe plus simvastatin compared to fluvastatin plus fenofibrate in patients without small, dense LDL (P=0.020 and P=0.015). In patients with small, dense LDL, apo AII was markedly increased by fluvastatin plus fenofibrate, whereas ezetimibe plus simvastatin had no or little effect. Although only significant in small, dense LDL patients, apo CIII was more effectively reduce by fluvastatin plus fenofibrate, while the reduction of apo CII was more pronounced with ezetimibe plus simvastatin in all patients. Secondary: Not reported
Wi et al.[49] (2010) Niacin ER 500 mg/day for 5 weeks, followed by 1,000 mg/day for 4 weeks, followed by 1,500 mg/day vs fenofibrate 160 mg/day After	OL, RCT Patients 20 to 79 years of age with TG 150 to 499 mg/dL and HDL-C <45 mg/dL	N=201 24 weeks (includes 8 week dietary run in period)	Primary: Percent change from randomization to week 16 in apo B/apo AI Secondary: Percent changes in other lipid parameters, levels of glucose metabolism-related parameters, hsCRP	Primary: Apo B/apo AI was reduced with both treatments with no difference between the two (P=0.47). The percent reduction in apo B was greater with niacin, whereas the percent elevation in apo AI was higher with fenofibrate. Secondary: TC significantly decreased with both treatments, and TG decreased and HDL-C increased. LDL-C increased with fenofibrate but decreased with niacin. The percent reduction in TC was greater with niacin (P=0.01). TG decreased significantly more with fenofibrate (P=0.045), whereas the percent elevation in HDL-C was not different between the two treatments (P=0.22). The percent change in LDL-C was significantly different with the two treatments (P<0.001). Lp(a) levels were reduced with niacin only, and the change was significantly different compared to fenofibrate (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
discontinuation of any lipid modifying drug, patients entered an 8 week dietary run in period.				FPG levels decreased with fenofibrate and increased significantly with niacin. HbA_{1c} levels increased with both treatments; the increase was borderline with fenofibrate and significant with niacin. The percent changes in FPG (P<0.001) and HbA_{1c} (P<0.001) levels were significantly different between the two treatments. Fasting insulin levels showed a borderline reduction with fenofibrate and a significant increase with niacin. HOMA-IR was decreased with fenofibrate and was increased with niacin. Percent changes of insulin (P<0.001) and HOMA-IR (P<0.001) were significantly different between the two treatments. hsCRP levels were significantly lowered with both treatments, but the percent change was greater with niacin (P=0.03).
Alrasadi et al.[50] (2008) <u>Protocol 1</u> Fenofibrate 200 mg/day for 8 weeks vs atorvastatin 20 mg/day for 8 weeks vs niacin SR 1 g BID for 8 weeks <u>Protocol 2</u> Fenofibrate 200 mg/day and atorvastatin 20 mg/day for 8 weeks	XO Men with HDL-C <5th percentile for age- and gender-matched patients and an identified genetic cause of HDL deficiency or ≥1 first degree relative affected with HDL deficiency	N=19 32 weeks	Primary: Percent changes in HDL-C and TC/HDL-C ratio Secondary: Not reported	Primary: <u>Protocol 1</u> The mean percent change in HDL-C was +6, -6, and +22% in patients receiving fenofibrate, atorvastatin, and niacin, respectively. Only niacin significantly raised HDL-C (P<0.05). The mean percent change in TC/HDL-C ratio was +19, -26, and -22% in patients receiving fenofibrate, atorvastatin, and niacin, respectively. Both niacin and atorvastatin significantly lowered TC/HDL-C (P<0.05 and P<0.01, respectively). <u>Protocol 2</u> The mean percent change in HDL-C was -2 and +18% in patients receiving fenofibrate plus atorvastatin and niacin plus atorvastatin, respectively. Only the group receiving niacin experienced a significant increase in HDL-C (P<0.05). The mean percent change in TC/HDL-C ratio was +32 and -32% in patients receiving fenofibrate plus atorvastatin and niacin plus atorvastatin, respectively. Only the group receiving niacin experienced a significant decrease in TC/HDL-C (P<0.01). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs niacin SR 1 g BID and atorvastatin 20 mg/day for 8 weeks Patients in whom a statin was required were switched or maintained on atorvastatin 20 mg throughout the study in Protocol 2.				
Balasubramanyam et al.[51] (2011) Usual care vs low saturated fat diet and exercise (D/E) vs D/E and fenofibrate 145 mg/day (Tricor®) vs D/E and niacin SR	DB, PC, RCT Patients 21 to 65 years of age with hypertriglyceridemia (fasting TG >150 mg/dL) and receiving stable ART therapy for 6 months	N=191 24 weeks	Primary: Baseline changes in lipid parameters Secondary: Baseline changes in insulin sensitivity, glycemia, adiponectin, CRP, energy expenditure, and body composition	Primary: Patients receiving fenofibrate achieved significant improvements in TG (P=0.002), TC (P=0.02), and non-HDL-C (P=0.003), compared to patients receiving niacin who achieved significant improvements in HDL-C (P=0.03), and both groups of patients achieved significant improvements in TC:HDL-C (P=0.005 and P=0.01). The combination of D/E plus fenofibrate plus niacin provided maximal benefit, reducing TG (-52% vs usual care; P=0.003), increasing HDL-C (12% vs usual care; P<0.001), and decreasing non-HDL-C (-18.5% vs usual care; P=0.003) and TC:HDL-C (-24.5% vs usual care; P<0.001). Secondary: Of the secondary endpoints evaluated, there was an effect of niacin on FPG (P=0.0002), oral glucose tolerance test area under the curve for glucose (P=0.02), fasting insulin (P=0.03), HOMA-IR (P=0.008), insulin sensitivity index (P=0.007), and adiponectin (P<0.0001), and an effect of fenofibrate on creatinine (P=0.002).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
2,000 mg/day (Niaspan®) vs D/E and fenofibrate 145 mg/day and niacin SR 2,000 mg/day				
Roth et al.[52] (2009) <u>Phase I</u> Fenofibrate 130 mg (FENO) QD and omega-3 acid ethyl esters 4 g (P-OM3) QD for 8 weeks vs fenofibrate 130 mg (FENO) QD and placebo for 8 weeks <u>Phase II</u> Fenofibrate 130 mg (FENO) QD and omega-3 acid ethyl esters 4 g (P-OM3) QD for 8 weeks	DB, MC, PC, RCT Patients 18 to 79 years of age with Fredrickson type IV dyslipidemia, BMI 25 to 43 kg/m^2, and TG 500 to 1,300 mg/dL	N=167 16 weeks	Primary: Median percent change in TG Secondary: Additional lipid and cardiovascular risk factors	Primary: After eight weeks of therapy, median TG values were reduced from 649.5 to 267.5 mg/dL (-60.8%) with P-OM3 + FENO and from 669.3 to 310 mg/dL (-53.8%) with FENO monotherapy (P=0.059). There was no significant difference between the treatment groups (P=0.059). Secondary: LDL-C was significantly increased with P-OM3 + FENO compared to FENO monotherapy (48.2 vs 39.0%, respectively; P=0.030). There was no significant difference in non-HDL-C among the treatment groups (-8.2% for P-OM3 + FENO vs -7.1% for FENO; P=0.767). There was a greater reduction in VLDL-C with P-OM3 + FENO than with FENO monotherapy (-57.6 vs -47.6%, respectively; P=0.016). There was a greater reduction in RLP-C with P-OM3 + FENO than with FENO monotherapy (-72.0 vs -62.1%; P=0.029). In the first eight week ES, the addition of P-OM3 to FENO monotherapy significantly reduced TGs compared to the end of the DB treatment period (-17.5%, P=0.003). In the first eight week ES, the addition of P-OM3 to FENO monotherapy significantly increased LDL-C (+8.1%; P=0.001) compared to the group previously receiving P-OM3 + FENO (+0.4%). There was no significant change in non-HDL-C following the addition of P-OM3 to FENO. VLDL-C and RLP-C were significantly reduced by the addition of P-OM3 (-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				15.4%, P=0.030 and -25.8%, P=0.035, respectively). There was no significant difference in final lipid results for those who received P-OM3 + FENO for 16 weeks and those in which P-OM3 was added to FENO monotherapy during the OL phase of the study. In the pooled analysis of all patients enrolled in the eight week OL extension phase, the overall reductions of TGs and VLDL-C were -60.0 and -56.5%, respectively (P<0.001 for both). Non-HDLC and TC were also significantly reduced (P<0.001) over the 16 week treatment period in the pooled analysis. LDL-C increased 52.2% (P<0.001). There was no significant change in apo B at the end of the 16 week treatment study (P=0.544). The treatments were generally well tolerated and there was no significant difference in the safety profiles. The most adverse events were upper respiratory infection, nausea, diarrhea, constipation, gastroenteritis, dyspepsia, and headache.
Koh et al.[53] (2012) Fenofibrate 160 mg/day vs omega-3 fatty acids 2 g/day vs placebo	PC, PG, RCT, SB Patients with primary hypertriglyceridemia (>150 mg/dL)	N=50 2 months	Primary: Change in baseline lipid profile; change in baseline vasomotor function, hsCRP, and fibrinogen; change in baseline adiponectin, HbA_{1c}, and insulin resistance Secondary: Not reported	Primary: Placebo treatment significant reduced TG and TG:HDL-C, but increased LDL-C from baseline. Omega-3 fatty acids significantly reduced TG and TG:HDL-C from baseline. Fenofibrate significantly reduced T C, TG, apo B, TG:HDL-C, and non-HDL-C, and increased HDL-C and apo AI from baseline. Effects of fenofibrate on TC and T G were both significant compared to placebo (P<0.05). The magnitude of change in HDL-C, apo AI, TG:HDL-C, and non-HDL-C were significantly different when omega-3 fatty acids and fenofibrate therapy were compared, but both treatments resulted in comparable improvements in TG (P<0.05). Placebo did not significantly improve flow-mediated dilator response to hyperemia, but omega-3 fatty acids and fenofibrate significantly improved flow-mediated dilator response to hyperemia after two months when compared to baseline (P<0.001), and when compared to placebo (P<0.001). Brachial artery dilator responses to nitroglycerin were not significantly different between any of the therapies. Placebo and omega-3 fatty acids did not significantly change hsCRP and fibrinogen levels relative to baseline measurements. Fenofibrate significantly reduced

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				hsCRP and fibrinogen levels after two months compared to baseline (P<0.001) or when compared to placebo (P<0.05). Omega-3 fatty acids did not significantly change insulin, plasma adiponectin levels, or insulin sensitivity compared to placebo. Compared omega-3 fatty acids, fenofibrate significantly decreased fasting insulin (P=0.023) and increased plasma adiponectin (P=0.002) and insulin sensitivity (P=0.015). Secondary: Not reported
Koh et al.[54] (2006) Fenofibrate 200 mg QD and candesartan 16 mg QD vs fenofibrate 200 mg QD vs candesartan 16 mg QD	DB, PC, RCT, XO Patients with hypertriglyceridemia (≥150 mg/dL) and hypertension (≥140/90 mm Hg)	N=46 6 months	Primary: BP, lipid profile, inflammatory markers, vasomotor function, plasma malondialdehyde, adiponectin, and insulin resistance Secondary: Not reported	Primary: Fenofibrate, combined therapy, or candesartan therapy significantly reduced BP. However, combined therapy significantly reduced BP more than fenofibrate or candesartan alone (P<0.001). When compared to candesartan, fenofibrate or combined therapy significantly improved the lipoprotein profile. Fenofibrate alone or combined therapy significantly lowered TC, TG, apo B, and non-HDL-C levels (P<0.001 for all) and increased HDL-C levels (P<0.001) when compared to baseline. These reductions were significantly greater than those observed with candesartan alone (P<0.001). However, there were no significant differences between fenofibrate alone and fenofibrate plus candesartan for these parameters (P value not significant). All three treatment arms significantly improved flow-mediated dilator response to hyperemia. Combined therapy significantly decreased plasma malondialdehyde (a biomarker for oxidative stress), hsCRP, and soluble CD40L levels relative to baseline measurements. Importantly, these parameters were changed to a greater extent with combined therapy when compared to monotherapy (P<0.001, P=0.002, P=0.050, and P=0.032, respectively). Fenofibrate, combined therapy, and candesartan significantly increased plasma adiponectin levels and insulin sensitivity relative to baseline measurements. However, the magnitudes of these increases were not significantly different among the three therapies (P=0.246 for adiponectin

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				levels and P=0.153 for insulin sensitivity). Secondary: Not reported
Insua et al.[55] (2002) Gemfibrozil 900 mg daily vs fenofibrate 200 mg QD	DB, DD, RCT, XO Patients between the ages of 45 and 70 years with primary hyperlipo-proteinemia, Fredrickson phenotypes IIa and IIb	N=21 6 weeks	Primary: Cholesterol-lowering effectiveness Secondary: Not reported	Primary: Both drugs significantly reduced TC, calculated LDL-C, TG, apo B, and fibrinogen (P<0.01 for all calculations, except P<0.05 for fibrinogen with gemfibrozil therapy) and increased HDL-C (P<0.01). Neither drug affected Lp(a), whereas uric acid was reduced only by fenofibrate (P<0.01). The percentage decrease in TC and LDL-C was greater with fenofibrate compared to gemfibrozil (-22 vs -15%; P<0.02; and -27 vs -16%; P<0.02, respectively). In contrast, reductions in levels of TG (-54 vs -46.5%), apo B, and fibrinogen, as well as the increase in HDL-C (9% for both drugs), showed no significant difference between treatments. Separate analysis of patients with type IIb hyperlipoproteinemia showed essentially the same plasma lipid changes as for the overall group, but with greater modifications in TG and HDL-C concentrations. Secondary: Not reported
Corbelli et al.[56] (2002) Gemfibrozil (mean daily dose 1,200 mg) vs fenofibrate (mean daily dose of 201 mg)	RETRO Patients who were switched from gemfibrozil to fenofibrate, due to inadequate lipid response or adverse effects	N=92 23 months	Primary: Mean TC, TG, HDL-C, and non-HDL-C Secondary: Not reported	Primary: Compared to gemfibrozil, patients showed statistically significant improvements in mean TC, TG, HDL-C, and non-HDL (P<0.005). Specifically, more patients achieved a TG goal <200 mg/dL with fenofibrate (64%) compared to gemfibrozil (39%; P<0.0005). The study demonstrated that patients switched from gemfibrozil to fenofibrate due to an inadequate lipid response experienced significant improvements in lipid parameters for up to 18 months. Secondary: Not reported
Guyton et al.[57]	DB, MC, PC, RCT	N=173	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2000) Niacin ER (Niaspan®) titrated up to 1,000 mg at bedtime for 4 weeks, followed by 1,500 mg at bedtime for 4 weeks, followed by 2,000 mg at bedtime for 8 weeks vs gemfibrozil 600 mg BID	Patients 21 to 75 years of age with HDL-C ≤40 mg/dL, LDL-C ≤160 mg/dL or <130 mg/dL with atherosclerotic disease and TG ≤400 mg/dL	8 weeks	Effect on HDL-C Secondary: Change in other lipoproteins, adverse effects	Niacin 1,500 and 2,000 mg/day significantly increased HDL-C by 21 and 26%, respectively, compared to 13% with gemfibrozil (P<0.02). Secondary: Compared to gemfibrozil, niacin 1,500 and 2,000 mg/day significantly increased apo AI (9 and 11 vs 4%), reduced TC:HDL-C ratio (-17 and -22 vs -12%), reduced Lp(a) (-7 and -20 vs no change) and had no adverse effect on LDL-C (2 and 0 vs 9%; P<0.001 to P<0.02.). TG decreased by 40% with gemfibrozil compared to 16 and 29% with niacin 1,000 (P<0.001) and 2,000 mg/day (P<0.06). Effects on plasma fibrinogen levels were significantly favorable for niacin compared to gemfibrozil (-1 to -6% vs 5 to 9%, respectively; P<0.02). Flushing was significantly more frequent with niacin compared to gemfibrozil at every point (78 vs 10%; P values not reported). Flu syndrome occurred more frequently with niacin (P=0.006). Dyspepsia was more frequent with gemfibrozil (P=0.009).
Stalenhoef et al.[58] (2000) Omega-3-acid ethyl esters (Omacor*) 4 g/day vs gemfibrozil 1,200 mg/day	DB, DD, RCT Patients with primary hyper-triglyceridemia	N=28 12 weeks	Primary: Change in lipid profile, LDL-C subfraction profile Secondary: Not reported	Primary: Both omega-3-acid ethyl esters and gemfibrozil resulted in similar and significant decreases in serum TG, VLDL-TG and VLDL-C concentrations and increases in HDL-C and LDL-C (P=0.05 to P<0.001 from baseline and P=0.29 to P=1.00 between groups). Both therapies resulted in a more buoyant LDL-C subfraction profile (P=0.05 for omega-3-acid ethyl esters, P<0.01 for gemfibrozil and P=0.09 between groups in favor of gemfibrozil). Secondary: Not reported
van Dam et al.[59] (2001) Omega-3 acid ethyl esters (Omacor*) 4 g/day	RCT, DB Patients with hypertriglyceridemia (TG >400 mg/dL)	N=89 12 weeks	Primary: Percent change in TG Secondary: Percent change in	Primary: The mean percent change in TG was -28.9% with omega-3 acid ethyl esters and -51.2% with gemfibrozil (P=0.007). Secondary: The mean percent change in HDL-C and TC were +1.2 and -10.2%,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs gemfibrozil 1,200 mg/day			TC, HDL-C, VLDL-C	respectively, with omega-3 acid ethyl esters and +27.9 and -13.0%, respectively, with gemfibrozil (P=0.012 and P=0.513, respectively). The mean percent change in VLDL-C was -11.8% with omega-3 acid ethyl esters and -19.4% with gemfibrozil (P=0.494).
Prevention of Coronary Heart Disease Events				
Keech et al.[60] (2005) FIELD Fenofibrate 200 mg QD vs placebo	DB, PC, RCT Patients aged 50 to 75 years with type 2 diabetes mellitus	N=9,975 5 years	Primary: Coronary events (CHD, death or nonfatal MI) Secondary: Total cardiovascular events which included the composite of cardiovascular death, MI, stroke, and coronary and carotid revascularization; total mortality	Primary: Coronary events occurred in 5.9% of patients on placebo and 5.2% of patients on fenofibrate (HR, 0.89; 95% CI, 0.75 to 1.05; P=0.16). There was a 24% reduction in nonfatal MI with fenofibrate (HR, 0.76; 95% CI, 0.62 to 0.94; P=0.010). There was a nonsignificant increase in coronary heart disease mortality (HR, 1.19; 95% CI, 0.90 to 1.57; P=0.22). Secondary: Total cardiovascular disease events were significantly reduced from 13.9 to 12.5% with fenofibrate (HR, 0.89; 95% CI, 0.80 to 0.99; P=0.035). There was a 21% reduction in coronary revascularization with fenofibrate (HR, 0.79; 95% CI, 0.68 to 0.93; P=0.003). Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (P=0.18).
Tonkin et al.[61] (2012) FIELD Fenofibrate 200 mg QD vs placebo	Subgroup analysis of FIELD comparing the effect of fenofibrate on cardiovascular disease between patients with prior cardiovascular disease and those without Patients aged 50 to	N=9,975 (n=2,131 with prior cardio-vascular disease and n=7,664 without prior cardio-vascular disease)	Primary: Lipids and the effect of fenofibrate treatment, compliance with trial medication and use of other drugs, unadjusted effect of treatment on outcomes, components of	Primary: There were small but significant differences between patients with and without prior cardiovascular disease in their pattern of lipid response to treatment. At 12 months after randomization, the effect of fenofibrate on increasing HDL-C and decreasing LDL-C and TG was greater in patients with no prior cardiovascular disease compared to those with prior cardiovascular disease (P<0.05 for all). At 24 months after randomization, difference in treatment effect between prior cardiovascular subgroups were observed for HDL-C (P=0.046) and TG (P=0.002). At trial end, differences were observed for LDL-C (P=0.01) and TG (P=0.006). Over the course of the trial, patients receiving placebo had a higher uptake

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	75 years with type 2 diabetes mellitus	5 years	total cardiovascular disease, adjusted analyses of treatment effect Secondary: Not reported	of lipid-lowering therapy (mainly statins) compared to those receiving fenofibrate (17 vs 8%). There was a higher uptake of statins among patients with prior cardiovascular disease compared those without and a slightly higher uptake of other cardiovascular medications. Patients with prior cardiovascular disease discontinued fenofibrate more often than those without prior cardiovascular disease (14 vs 9%). The unadjusted effect of fenofibrate on future total cardiovascular disease events differed by prior cardiovascular disease status (interaction P=0.05). There was an independently significant reduction in the risk of a cardiovascular disease event (HR, 0.81; 95% CI, 0.70 to 0.94; P=0.004) in the group without prior cardiovascular disease, whereas in the prior cardiovascular disease group, there was no significant effect of treatment (HR, 1.02; 95% CI, 0.86 to 1.20; P=0.9). There was a significant difference in treatment effect between those with and those without prior cardiovascular disease for coronary events (interaction P=0.03) but not stroke (P=0.56) or revascularization (P=0.053). For coronary events, there was an independently significant reduction in the risk of an event (HR, 0.75; 95% CI, 0.59 to 0.94; P=0.01) in the group without prior cardiovascular disease, whereas in the prior cardiovascular disease group, there was no significant effect of treatment (HR, 1.08; 95% CI, 0.84 to 1.38; P=0.55). After the adjustment for uneven uptake of statins and other cardiovascular disease medications across treatment arms, the treatment-by-prior-cardiovascular disease interaction term remained significant (statins only; P=0.05 and statins plus other cardiovascular disease medications; P=0.04). However, after adjustment for baseline covariates, differences in treatment effects were no longer significant (P=0.06). Secondary: Not reported
Ting et al.[62] (abstract) (2012) FIELD	Subgroup analysis of FIELD evaluating the effects of fenofibrate on cardiovascular and	N=9,975 5 years	Primary: Coronary events (CHD, death or nonfatal MI),	Primary: The benefit of fenofibrate observed within the FIELD trial (HR, 0.89; 95% CI, 0.80 to 0.99; P=0.035), was not statistically different across eGFR groupings analyzed within this subgroup analysis (interaction P=0.2)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fenofibrate 200 mg QD vs placebo	ESRD events, according to eGFR Patients aged 50 to 75 years with type 2 diabetes mellitus		safety Secondary: Not reported	(eGFR 30 to 50 mL/min/1.73m^2: HR, 0.68; 95% CI, 0.47 to 0.97; P=0.035; eGFR ≥90 mL/min/1.73m^2: HR, 0.85; 95% CI, 0.70 to 1.02; P=0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment. Secondary: Not reported
DAIS[63] (2001) Fenofibrate, micronized 200 mg QD vs placebo	PC, RCT Men and women with type 2 diabetes with good glycemic control, who had mild lipoprotein abnormalities typical of type 2 diabetes and at least one visible coronary lesion	N=418 3 years	Primary: Mean percentage stenosis, minimum coronary artery lumen diameter, mean segment diameter Secondary: Not reported	Primary: Plasma TC, HDL-C, LDL-C, and TG concentrations all changed significantly more from baseline in the fenofibrate group (N=207) compared to the placebo group (N=211). The fenofibrate group showed a significantly smaller increase in percentage diameter stenosis than the placebo group (mean 2.11 vs 3.65; P=0.02), a significantly smaller decrease in minimum lumen diameter (-0.06 vs -0.10 mm; P=0.029), and an insignificant smaller decrease in mean segment diameter (-0.06 vs -0.08 mm; P=0.171). The trial was not powered to examine clinical end points. Secondary: Not reported
No authors listed.[64] ACCORD (2010) Fenofibrate 160 mg/day vs placebo All patients were receiving	DB, MC, PC, RCT Patients 40 to 79 years of age with type 2 diabetes and HbA_{1c} ≥7.5%, LDL-C 60 to 180 mg/dL, HDL-C <55 mg/dL for women or <50 mg/dL for men and TG <750 mg/dL if they were not receiving lipid	N=5,518 5 years	Primary: First occurrence of a major cardiovascular event (nonfatal MI, nonfatal stroke or death from cardiovascular causes) Secondary: Combination of the primary outcome	Primary: The annual rate of the primary outcome was 2.2% with fenofibrate and 2.4% with placebo (HR, 0.92; 95% CI, 0.79 to 1.08; P=0.32). Secondary: The annual rate of the primary outcome plus revascularization or hospitalization for CHF was 5.35% with fenofibrate and 5.64% with placebo (HR, 0.94; 95% CI, 0.85 to 1.05; P=0.30). The annual rate of major coronary disease events was 2.58% with fenofibrate and 2.79% with placebo (HR, 0.92; 95% CI, 0.79 to 1.07; P=0.26).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
simvastatin.	therapy or <400 mg/dL if they were		plus revascularization or hospitalization for CHF; a combination of a fatal coronary event, nonfatal MI or unstable angina; nonfatal MI; fatal or nonfatal stroke; nonfatal stroke; death from any cause; death from cardiovascular causes; hospitalization or death due to heart failure	The annual rate of nonfatal MI was 1.32% with fenofibrate and 1.44% with placebo (HR, 0.91; 95% CI, 0.74 to 1.12; P=0.39). The annual rate of stroke was 0.38% with fenofibrate and 0.36% with placebo (HR, 1.05; 95% CI, 0.71 to 1.56; P=0.80). The annual rate of death from any cause was 1.47% with fenofibrate and 1.61% with placebo (HR, 0.91; 95% CI, 0.75 to 1.10; P=0.33). Rates for death from a cardiovascular cause were 0.72 and 0.83% (HR, 0.86; 95% CI, 0.66 to 1.12; P=0.26). The annual rate of fatal or nonfatal CHF was 0.90% with fenofibrate and 1.09% with placebo (HR, 0.82; 95% CI, 0.62 to 1.05; P=0.10).
Bonds et al.[65] (2012) ACCORD Fenofibrate 160 mg/day vs placebo All patients were receiving simvastatin.	Subgroup analysis of ACCORD, evaluating outcomes in patients with a fenofibrate-associated creatinine increase (increase in serum creatinine of ≥20% from baseline to month 4 in patients receiving fenofibrate) Patients 40 to 79 years of age with type 2 diabetes and HbA_{1c} ≥7.5%, LDL-C 60 to 180 mg/dL, HDL-C <55 mg/dL for women or <50	N=1,212 (patients who experienced a fenofibrate-associated creatinine increase) 5 years	Primary: Characteristics predicting creatinine elevation Secondary: Long-term renal and cardiovascular outcomes	Primary: Patients who were older, male, used an angiotensin converting enzyme-inhibitor at baseline, used a thiazolidinedione at four months post-randomization, had baseline cardiovascular disease, and had lower baseline serum creatinine and LDL-C were all more likely to meet the criteria for fenofibrate-associated creatinine increase). Secondary: No differences in study outcomes were seen by fenofibrate-associated creatinine increase; there was no increase in renal disease or cardiovascular outcome observed in patients demonstrating fenofibrate-associated creatinine increases.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	mg/dL for men and TG <750 mg/dL if they were not receiving lipid therapy or <400 mg/dL if they were			
Davidson et al.[66] (2014) FIRST Fenofibric acid 135 mg vs placebo All patients on background atorvastatin	DB, MC, PC, RCT Patients with mixed dyslipidemia (fasting TG ≥150 mg/dL; HDL-C ≤45 [men] or 55 mg/dL [women]; LDL-C ≤100 mg/dL once and averaging ≤105 mg/dL) and a history of CHD or risk equivalent	N=682 104 weeks	Primary: Between-group difference in the rate of change from baseline through week 104 of the mean posterior-wall cIMT Secondary: Ranked multiple testing plan including measures of: maximal posterior- and anterior-wall cIMT of common carotid artery, internal carotid artery, and carotid bifurcation	Primary: The primary end point was −0.006 mm/y (FA plus atorvastatin group, −0.006 mm/y; atorvastatin monotherapy group, 0.000 mm/y), but did not reach statistical significance (P=0.22). Secondary: Secondary cIMT end points were not statistically different between treatment groups in the overall study population. The significance of between-treatment group differences varied among the lipid parameters. Starting at the first postbaseline assessment and continuing through week 104, fenofibric acid plus atorvastatin therapy resulted in significant improvements, compared with atorvastatin monotherapy, in HDL-C (week 104 mean change, +8.3 vs +3.6%), TG (−31.3 vs –2.3%, respectively), and non–HDL-C (−3.3 vs +4.9%). Fenofibric acid plus atorvastatin therapy resulted in LDL-C values that were significantly higher versus atorvastatin monotherapy through week 52, but no significant difference was observed subsequently through week 104.
Frick et al.[67] (1987) Helsinki Heart Study Gemfibrozil 600 mg BID vs	DB, RCT Asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL-C ≥200 mg/dL in 2 consecutive pretreatment	N=4,081 5 years	Primary: Risk of CHD measured by incidence of cardiac events Secondary: Total mortality	Primary: There were minimal changes in serum lipid levels in the placebo group. The cumulative rate of cardiac end points at five years was 27.3 per 1,000 in the gemfibrozil group and 41.4 per 1,000 in the placebo group, a reduction of 34% in the incidence of CAD (95% CI, 8.2 to 52.6; P<0.02; two-tailed test). The decline in incidence in the gemfibrozil group became evident in the second year and continued throughout the study. Secondary: There was no difference between the groups in the total death rate, nor did

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo	measurements)			the treatment influence the cancer rates.
Frick et al.[68] (1993) Helsinki Heart Study Gemfibrozil 600 mg BID vs placebo	DB, RCT Individuals who exhibited symptoms and signs of possible CHD during screening in the Helsinki Heart Study	N=311 5 years	Primary: Risk of CAD measured by incidence of cardiac events Secondary: Total mortality	Primary: The end point rate, consisting of fatal and nonfatal MI and cardiac death, did not differ significantly between the placebo and gemfibrozil groups. Since there were key prognostic factors missing (e.g., true prevalence of CHD, extent of coronary artery obstructions, degree of left ventricular dysfunction, and their distribution in the groups render the results less reliable), the data cannot be used to refute the thesis that treatment of dyslipidemia in manifest CHD is successful. Secondary: Total mortality did not differ significantly between the placebo and gemfibrozil groups.
Heinonen et al.[69] (1994) Helsinki Heart Study Gemfibrozil 600 mg BID vs placebo	DB, MC Asymptomatic middle-aged men (40 to 55 years of age) with non-HDL-C greater than or equal to 200 mg/dL in 2 consecutive pretreatment measurements)	N=2,046 3.5 years	Primary: Definite fatal and nonfatal CHD events Secondary: Not reported	Primary: During the post-trial period the numbers of definite CHD events in both groups (54 vs 47; P value not significant) were smaller than expected without treatment, namely a reduction of around 40% for the original treatment groups. The mean incidence rates were in fact similar to that in the placebo group five years earlier. Cardiovascular mortality over the entire study period was similar but all-cause mortality was slightly higher among men of the original gemfibrozil group compared to the placebo group men (P=0.19). Secondary: Not reported
Huttunen et al.[70] (1994) Gemfibrozil 600 mg BID vs placebo	ES Asymptomatic adult patients with primary dyslipidemia (non-HDL-C ≥200 mg/dL in 2 consecutive pretreatment measurements)	N=4,081 8.5 years (follow-up)	Primary: Gastrointestinal symptoms, surgery, strokes, cancer incidence, morality by cause Secondary: Not reported	Primary: A first occurrence of a moderate to severe gastrointestinal side effect, mainly dyspepsia and abdominal pain, was reported by 20.1 and 15.1% of patients receiving gemfibrozil and placebo during the original five year trial (P<0.001). Side effects were reported at a consistently lower rate during the post-trial follow up than during the DB trial period. After switching from placebo to gemfibrozil, 4.6% of patients interrupted treatment as a result of adverse events (3.7% due to gastrointestinal symptoms). There was a nonsignificant excess of some illnesses and surgical

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				procedures with gemfibrozil during the five year trial period. During the 3.5 year post trial follow-up, cholecystectomies and appendectomies continued to be more common with gemfibrozil. Strokes due to any cause were slightly less common with gemfibrozil. Ischemic strokes continued to occur less frequently in the original gemfibrozil groups, whereas hemorrhagic strokes were about equal post-trial. The cumulative incidences of malignancies and cancer cases by type during the 8.5 years of follow-up were similar, except basal cell skin carcinoma (16 vs 9; *P*=0.18). Over the 8.5 year follow up there were 101 deaths with gemfibrozil and 83 deaths with placebo. The distributions by causes of death did not differ significantly (*P*=0.12). The difference in cancer-specific deaths (30 vs 18) was mainly because of cancer deaths during the post-trial follow up (20 vs 7), while post-trial cardio- and cerebrovascular mortality was equal (25 vs 23, respectively). Deaths caused by cerebrovascular accidents were similar during the entire 8.5 year follow up (8 vs 6). There were fewer fatal cerebral infarctions (1 vs 5) and more fatal intracranial hemorrhages (7 vs 1) with gemfibrozil. The excess mortality due to accidents or violence was reversed during the post-trial follow up, resulting in approximately equal numbers by the end of the trial. Total mortality with the two treatments remained almost equal during the trial period and the first year of the post-trial follow up; the excess mortality emerged towards the end (*P*=0.19). Secondary: Not reported
Robins et al.[71] (2001) VA-HIT Gemfibrozil 1,200 mg daily vs	DB, MC, PC, RCT Men with a history of CHD who had low HDL-C levels and low LDL-C levels	N=2,531 7 years	Primary: Nonfatal MI or death from coronary causes Secondary: Not reported	Primary: Compared to placebo, gemfibrozil showed a 22% decreased risk of nonfatal MI or death due to CHD (17.3 vs 21.7%; P=0.006). Compared to placebo, gemfibrozil showed a 24% decreased risk for nonfatal MI, death due to CHD or confirmed stroke (20 vs 26%; P<0.001). A nonsignificant difference was seen in all-cause mortality with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				gemfibrozil compared to placebo (15.7 vs 17.4%; P=0.23). Concentrations of HDL-C were inversely related to CHD events. Multivariable Cox proportional hazards analysis showed that CHD events were reduced by 11% with gemfibrozil for every 5 mg/dL (0.13 mmol/L) increase in HDL-C (P=0.02). Events were reduced even further with gemfibrozil beyond that explained by increases in HDL-C values, particularly in the second through fourth quintiles of HDL-C values during treatment. During gemfibrozil treatment, only the increase in HDL-C significantly predicted a lower risk of CHD events; according to multivariable analyses, neither TG nor LDL-C levels at baseline or during the trial predicted CHD events. Secondary: Not reported
Rubins et al.[72] (1999) Gemfibrozil 1,200 mg/day vs placebo	DB, MC, PC, RCT Men <74 years of age with CHD, HDL-C ≤40 mg/dL, LDL-C ≤140 mg/dL, TG ≤300 mg/dL and no serious coexisting conditions	N=2,531 5.1 years (mean follow up)	Primary: Combined incidence of nonfatal MI or death from CHD Secondary: Incidence of stroke, death from any cause, TIA, revascularization procedures, carotid endarterectomy and hospitalization for unstable angina or CHF	Primary: The combined primary endpoint occurred in 21.7 vs 17.3% of patients receiving placebo and gemfibrozil, which led to gemfibrozil being associated with a reduction of 22% (95% CI, 7 to 35; P=0.006). The effect was consistent for both components of the endpoint, but was only significant for a reduction in nonfatal MI (death from CHD, 22%; 95% CI, -2 to 41; P=0.07 and nonfatal MI, 23%; 95% CI, 4 to 38; P=0.02). The beneficial effect of gemfibrozil did not become apparent until about two years after randomization. Secondary: Gemfibrozil was not associated with a reduction in the incidence of stroke (6.0 vs 4.6%; RR reduction, 25%; 95% CI, -6 to 47; P=0.10). Gemfibrozil resulted in a RR reduction of 24% for the combined outcome of death from CHD, nonfatal MI or confirmed stroke (95% CI, 11 to 36; P<0.001). Gemfibrozil was associated with a significant reduction in the risk of TIA (RRR, 59%; 95% CI, 33 to 75; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Gemfibrozil was associated with a significant reduction in the risk of carotid endarterectomy (RR reduction, 65%; 95% CI, 37 to 80; P<0.001). The rates of death from any case, coronary revascularization, hospitalization for unstable angina and cancer did not differ significantly between treatments.
Saha et al.[73] (2007) Fibrate therapy (bezafibrate*, clofibrate*, fenofibrate, gemfibrozil)	MA, SR (10 RCTs) Patients receiving fibrate therapy for the prevention of cardiovascular events (primary and secondary prevention)	N=36,489 Mean duration of follow up ≥1 year (32 months to 18 years)	Primary: All-cause mortality, cardiovascular and non-cardiovascular mortality, fatal and nonfatal MI and stroke Secondary: Incidence of cancer and cancer related mortality	Primary: On pooled MA, the use of fibrate therapy tended to increase all-cause mortality (pooled OR, 1.07; P=0.08) and significantly increased the odds of noncardiovascular mortality by about 16% (pooled OR, 1.16; P=0.004). Fibrate therapy had no significant effect on cardiovascular mortality, with a pooled OR of 0.98 (P=0.68). The use of fibrate therapy did not affect the occurrence of fatal MI (pooled OR, 0.96; P=0.76), but significantly reduced the odds of nonfatal MI by about 22% (pooled OR, 0.78; P<0.00001). Fibrate therapy also had no significant effect on stroke, with a pooled OR of 0.96 (P=0.56). Secondary: The use of fibrates was not associated with an increase in the odds of developing cancer (pooled OR, 1.00; P=0.98) or cancer related mortality (pooled odds ratio, 1.11; P=0.17). Subgroup analyses revealed that the risk of all-cause mortality did not significantly differ among the various fibrates used. Noncardiovascular mortality was significantly higher with the use of clofibrate on pooled analysis of data from two primary prevention trials (pooled OR, 1.35; 95% CI, 1.13 to 1.62; P=0.001). The odds of cardiovascular mortality tended to be lower with gemfibrozil with a pooled OR of 0.77 (P=0.05), whereas neither bezafibrate nor fenofibrate had any significant effect on mortality. The odds of nonfatal MI were lower with gemfibrozil (pooled OR, 0.72; P=0.001) than with bezafibrate (pooled OR, 0.78; P=0.02) or fenofibrate (pooled OR, 0.77; P=0.01). No significant differences were observed among the different fibrates with regard to their effects on fatal MI, stroke, cancer or cancer related mortality.
Jun et al.[74] (2010)	MA, SR (18 PRO, RCTs)	N=45,058 Duration	Primary: Major cardiovascular	Primary: Data for coronary events were available from 16 trials, including 44,667 patients in whom 4,552 coronary events were recorded.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Fibrate therapy (bezafibrate*, clofibrate*, etofibrate*, fenofibrate and gemfibrozil) vs placebo	Demographics not reported	varied	events, coronary events, stroke, heart failure, coronary revascularization, all-cause mortality, cardiovascular death, nonvascular death, sudden death, new onset albuminuria, drug related adverse events Secondary: Not reported	Overall, fibrate therapy reduced the risk of coronary events by 13% (RR, 0.87; 95% CI, 0.81 to 0.93; P<0.0001). Ten trials, including 42,131 patients, reported 2,485 nonfatal coronary outcomes with fibrate therapy, reducing the risk by 19% (RR, 0.81; 95% CI, 0.75 to 0.89); P<0.0001). For the 1,740 coronary deaths recorded in 13 trials no effect was noted (RR, 0.93; 95% CI, 0.85 to 1.02; P=0.116). Effects on coronary revascularization were reported in four trials, including 15,834 patients whom 1,737 events were reported, with fibrate therapy significantly reducing the risk by 12% (RR, 0.88; 95% CI, 0.78 to 0.98; P=0.025). A cumulative MA of all trials reporting coronary outcomes demonstrated consistent benefit from fibrate therapy on the risk of coronary events. Eight trials, including 27,021 patients, reported 1,391 stroke events, with no evidence that fibrate therapy protected against stroke risk (RR, 1.03; 95% CI, 0.91 to 1.16; P=0.687). Three trials, including 8,581 patients, reported 584 heart failure events, with no evidence that fibrate therapy protected against heart failure risk (RR, 0.94; 95% CI, 0.65 to 1.37; P=0.759). Sixteen trials, including 44,813 patients, reported 3,880 deaths, with six trials reporting separate data for vascular death (22,066 patients with 1,545 reported vascular deaths) and five trials providing separate data for sudden death (12,277 patients reported 596 sudden deaths). No effect of fibrate therapy on the risk of all-cause mortality (RR, 1.00; 95% CI, 0.93 to 1.08; P=0.918), vascular mortality (RR, 0.97; 95% CI, 0.88 to 1.07; P=0.587) or sudden death (RR, 0.89; 95% CI, 0.74 to 1.06; P=0.190) was noted. An increased risk of nonvascular mortality was noted; however, this finding did not reach significance (RR, 1.10; 95% CI, 0.995 to 1.21; P=0.063).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Three trials reported on the progression of albuminuria, including 15,731 patients and 3,859 events, with fibrate therapy reducing the risk by 14% (RR, 0.86; 95% CI, 0.75 to 0.98; P=0.028). Four trials reported data for total adverse events (17,413 patients reporting 225 events), demonstrating no significant increase in the risk of serious drug-related adverse events (RR, 22%; 95% CI, -9 to 61; P=0.19). Fibrate therapy did not significantly increase the risk of rhabdomyolysis (RR, 35%; 95% CI, -59 to 439; P=0.42), muscle abnormalities (RR, 0%; 95% CI, -1 to 2; P=0.69), gastrointestinal disorders (RR, 8%; 95% CI, -1 to 18; P=0.08) and gallbladder disease (RR, 19%; 95% CI, -11 to 60; P=0.24). Fibrate therapy was associated with an increase in creatinine (RR increase, 99%; 95% CI, 46 to 270; P<0.0001). Secondary: Not reported

*Agent not available within the United States.
Drug regimen abbreviations: BID=twice daily, ER=extended-release, QD=once daily, SR=sustained-release
Study abbreviations: AC=active comparator, DB=double-blind, DD=double dummy, ES=extension study, MA=meta-analysis, MC=multicenter, OL=open-label, PA=parallel arm, PC=placebo controlled, PG=parallel-group, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective study, SB=single-blind, SR=systematic review, XO=crossover
Miscellaneous abbreviations: apo=apolipoprotein, ALT=alanine aminotransferase, AST=aspartate aminotransferase, BP=blood pressure, BMI=body mass index, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, cIMT=carotid intima-media thickness, CRP=C-reactive protein, eGFR=estimated glomerular filtration rate, ESRD=end stage renal disease, HbA_{1c}=glycosylated hemoglobin, HDL-C=high-density lipoprotein cholesterol, HOMA-IR=Homeostasis Model of Assessment-Insulin Resistance, HR=hazard ratio, hsCRP=high sensitivity C-reactive protein, ICAM-1=intercellular adhesion molecule-1, IDL-C=intermediate-density lipoprotein-cholesterol , LDL-C=low-density lipoprotein cholesterol, Lp(a)=Lipoprotein(a), MI=myocardial infarction, MMP9=matrix metallopeptidase 9, NCEP ATP=National Cholesterol Education Program Adult Treatment Panel, OR=odds ratio, RLP=remnant like particle cholesterol, RR=relative risk, TC=total cholesterol, TG=triglycerides, TIA=transient ischemic attack, TRL=triglyceride rich lipoproteins, VCAM-1=vascular cell adhesion molecule-1, VLDL-C=very low-density lipoprotein cholesterol

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Fibric Acid Derivatives

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Fenofibrate	capsule, tablet	Fenoglide®*, Lipofen®*	$$$$	$$
Fenofibrate, micronized	capsule	Antara®*	$$$$	$
Fenofibrate, nanocrystallized	tablet	Tricor®*, Triglide®	$$$$	$$$
Fenofibric acid	delayed-release capsule, tablet	Fibricor®*, Trilipix®*	$$$$	$$$
Gemfibrozil	tablet	Lopid®*	$$$$	$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The fibric acid derivatives are approved for the treatment of hypertriglyceridemia, primary hypercholesterolemia, and mixed dyslipidemia.[1-9] They decrease triglycerides by 20 to 50% and increase high-density lipoprotein cholesterol (HDL-C) by 10 to 35%. They can also lower low-density lipoprotein cholesterol (LDL-C) by 5 to 20%; however, LDL-C may increase in patients with hypertriglyceridemia.[10] All fibric acid derivatives are available in a generic formulation.

In general, therapeutic lifestyle changes, including diet, exercise, and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia. When LDL lowering is required, initial treatment with a statin, a bile acid sequestrant, or niacin is recommended. However, in general, the statins are considered first line therapy for decreasing LDL-C levels, and are recommended in patients with established coronary heart disease (CHD) or CHD equivalents. If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or ezetimibe should be considered. Statins are also considered first line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy. The fibric acid derivatives are considered an option in patients who are unable to take a statin, but are typically reserved for the treatment of hypertriglyceridemia, to reduce the risk of pancreatitis, or for an isolated low HDL-C. They can also be considered an option for the treatment of patients with CHD who have low levels of LDL-C and atherogenic dyslipidemia. Guidelines do not give preference to one fibric acid derivative over another.[10,13-22] In 2016, the FDA removed its approved indication for coadministration of statins and fibrate products due to a lack of cardiovascular benefit.[75]

American College of Cardiology/American Heart Association and Institute for Clinical Systems Improvement both released updated guidelines in 2013 which support initiating a statin in patients with established atherosclerotic cardiovascular disease (ASCVD). According to these recommendations, percent reduction in LDL-C is an indicator of response and adherence to therapy, but treating to a targeted level is not a primary goal.[16,17] Combination therapy can be considered on an individual basis, but studies of combination therapy have generally not shown benefit beyond statin monotherapy. Additionally, if patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available.[16,17]

Clinical trials have demonstrated that the fibric acid derivatives can effectively lower triglycerides and increase HDL-C, as well as positively impact other lipid/lipoprotein parameters. Complementary lipid effects were also observed in clinical trials when fibric acid derivatives were coadministered with ezetimibe and statins.[26-59] In the FIELD trial, fenofibrate was associated with a nonsignificant reduction in CHD events in patients with type 2 diabetes, as well as a non-significant increase in total and CHD. However, fenofibric was associated with a significant reduction in total cardiovascular disease events and revascularization compared to placebo.[60] Furthermore, in the ACCORD trial, there was no difference between combination therapy with fenofibrate and simvastatin and monotherapy with simvastatin in the annual rate of first occurrence of major cardiovascular events in high-risk type 2 diabetics.[64] In the Helsinki Heart Study, gemfibrozil was associated with a significant reduction in CHD in asymptomatic men with dyslipidemia compared to placebo.[67] In a secondary prevention component of the Helsinki Heart Study, there was no difference observed between gemfibrozil and placebo in the incidence of fatal and nonfatal myocardial infarction and cardiac death.[68] Overall, because of chemical, pharmacological, and clinical similarities between the fibric acid derivatives, the findings from these studies may apply to all of the agents in this class.[1-10,12,13]

There is insufficient evidence to support that one brand fibric acid derivative is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand fibric acid derivatives within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand fibric acid derivative is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Antara® [package insert]. Baltimore (MD): Lupin Pharma; 2015 Aug.
2. Fenoglide® [package insert]. San Diego (CA): Santarus Inc,; 2012 Oct.
3. Fibricor® [package insert]. Philadelphia (PA): AR Scientific, Inc.; 2014 Jan.
4. Lopid® [package insert]. New York (NY); Pfizer Inc; 2017 Apr.
5. Lipofen® [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; 2013 Jan.
6. Tricor® [package insert]. North Chicago (IL): Abbott Laboratories; 2013 Feb.
7. Triglide® [package insert]. Florham Park (NJ): Shionogi Inc.; 2015 Apr.
8. Trilipix® [package insert]. North Chicago (IL): Abbott Laboratories; 2015 Apr.
9. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2017 [cited 2017 May]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
10. National Institutes of Health: National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
11. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited May 2017]. Available from: http://online.factsandcomparisons.com.
12. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 May]. Available from: http://www.thomsonhc.com/.
13. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
14. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2017 Feb 3. doi: 10.4158/EP171764.GL.
15. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.
16. Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Institute for Clinical Systems Improvement. Lipid Management in Adults. Updated November 2013.
17. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000–000. DOI: 10.1161/01.cir.0000437738.63853.7a.
18. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519.
19. National Institute for Health and Clinical Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. National Institute for Health and Clinical Excellence; London (UK): 2014 [cited 2017 Jan 15]. Available from: https://www.nice.org.uk/Guidance/cg181.
20. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr;115(14):1948-67.
21. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106.

22. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
23. Lindor KD, Gershwin ME, Poupon R, et al. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
24. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 Executive Summary. Endocr Pract. 2016;22(1):84-113.
25. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. National Institute for Health and Clinical Excellence; London (UK): 2008 [cited 2017 Jan 6]. Available from: http://www.nice.org.uk/guidance/cg71.
26. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in patients with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007 Aug;30(8):1945-51.
27. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R; TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic patients. Clin Cardiol. 2006 Jun;29(6):268-73.
28. Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach J, et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J. 2010;160:759-66.
29. Hogue JC, Lamarche B, Tremblay AJ, et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008;57:380-6.
30. Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, et al. Comparison of atorvastatin vs fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism. 2007 Nov;56(11):1534-41.
31. Goldberg A, Bays H, Ballantyne C, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-22.
32. Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-a phase 3 study. Cardiovasc Drugs Ther. 2010;24:421-8.
33. Jones P, Davidson M, Kashyap M, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 2009;204:208-215.
34. Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia. Evaluation of dose response. Am J Cardiovasc Drugs. 2012;12(2):117-25.
35. Mohiuddin S, Pepine C, Kelly M, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009;157:195-203.
36. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83.
37. May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone vs fenofibrate alone vs simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008;101:486-9.
38. Jones P, Davidson M, Goldberg A, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidology 2009;3:125-37.
39. Bays H, Jones P, Mohiuddin S, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidology 2008;2:426-35.
40. Kipnes MS, Roth EM, Rhyne JM, et al. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clin Drug Investig 2010;30:51-61.
41. Farnier M, Freeman M, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005 May;26(9):897-905.

42. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008;57:796-801.
43. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, et al. Safety and efficacy of long-term c-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol. 2006 Apr 18;47(8):1584-7.
44. Ansquer JC, Bekaert I, Guy M, et al. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared to each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 2009;9:91-101.
45. Farnier M, Roth E, Gil-Extremera B, Mendez G, Macdonell G, Hamlin C, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007 Feb;153(2):335.e1-8.
46. Farnier M, Perevozskaya I, Taggart WV, et al. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008;49:2641-7.
47. Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate vs atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 2009;8(56):1-8.
48. Winkler K, Schewe T, Putz G, Odunc N, Schafer G, Siegel E, et al. Fluvastatin/fenofibrate vs simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009;39(6):463-70.
49. Wi J, Kim JY, Park S, Kang SM, Jang Y, Chung N. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1,500 mg. Atherosclerosis. 2010;213:235-40.
50. Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) vs fenofibrate (200 mg) vs extended-release niacin (2 g). Am J Cardiol 2008;102:1341-7.
51. Balasubramanyam A, Coraza I, O'Brian Smith E, Scott LW, Patel P, Iyer D, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96:2236-47.
52. Roth EM, Bays HE, Forker AD, et al. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic patients. J Cardiovasc Pharmacol 2009;54:196-203.
53. Koh KK, Quon MJ, Shin KC, Lim S, Lee Y, Sakuma I, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis. 2012;220:537-44.
54. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Kim JA, et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006 Feb;29(2):195-201.
55. Insua A, Massari F, Rodrigues Moncalvo JJ, Rubén Zanchetta J, Insua AM. Fenofibrate or gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract. 2002 Mar-Apr;8(2):96-101.
56. Corbelli JC, Bullano MF, Willey VJ, Cziraky MJ, Corbelli ME, Waugh W. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy. Am J Cardiol. 2002 Dec 15;90(12):1388-91.
57. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177-84.
58. Stalenhoef AFH, de Graaf J, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids vs gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 2000;153:129-38.
59. Van Dam M, Stalenhoef AFH, Wittekoek J, et al. Efficacy of concentrated omega-3 fatty acids in hypertriglyceridemia: A comparison with gemfibrozil. Clin Drug Invest 2001;21:175–181.
60. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomized controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.
61. Tonkin A, Hunt D, Voysey M, Kesaniemi A, Hamer A, Waites J, et al. Effects of fenofibrate on cardiovascular events in patients with diabetes: the Fenofibrate Intervention and Event Lowering In Diabetes (FIELD) study. A Heart J. 2012;163:508-14.

62. Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study (abstract). Diabetes Care. 2012 Feb;35(2):218-25.
63. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001 Mar 24;357(9260):905-10.
64. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
65. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012;55:1641-50.
66. Davidson MH, Rosenson RS, Maki KC, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1298-1306.
67. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237-45.
68. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Mänttäri M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic patients with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993 Feb;25(1):41-5.
69. Heinonen OP, Huttunen JK, Manninen V, Mänttäri M, Koskinen P, Tenkanen L, et al. The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. J Intern Med. 1994 Jan;235(1):41-9.
70. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med. 1994;235:31-9.
71. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001 Mar 28;285(12):1585-91.
72. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-8.
73. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154:943-53.
74. Jun M, Foote C, Lv Jicheng , Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875-84.
75. FDA Pulls Approval of Niacin, Fibrate in Combo with Statins - Medscape - Apr 15, 2016. Available from: http://www.medscape.com/viewarticle/862022.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of HMG-CoA Reductase Inhibitors
AHFS Class 240608
August 9, 2017

I. Overview

The antilipemic agents are categorized into six different American Hospital Formulary Service (AHFS) classes, including bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, HMG-CoA reductase inhibitors (statins), and miscellaneous antilipemic agents. The agents which make up these classes differ with regards to their Food and Drug Administration-approved indications, mechanism of action, efficacy, safety profiles, tolerability, and ease of use.

The statins include single entity agents (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin), as well as fixed-dose combination products (amlodipine-atorvastatin and ezetimibe-simvastatin). The statins work by inhibiting HMG-CoA reductase, which is the rate-limiting enzyme involved in hepatic cholesterol synthesis. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is a cholesterol precursor. Inhibition of HMG-CoA reductase decreases hepatic cholesterol synthesis, causing up-regulation of low-density lipoprotein cholesterol (LDL-C) receptors. Statins also decrease the release of lipoproteins from the liver.[1-10] Depending on the agent selected, the statins can decrease LDL-C by 18 to 60% when used as monotherapy.[11-13] The effects on LDL-C are dose-dependent and log-linear. There is an additional 6% reduction in LDL-C with each doubling of the dose. The statins also decrease triglycerides by 7 to 30% and increase high-density lipoprotein cholesterol (HDL-C) by 5 to 15%.[13]

Ezetimibe inhibits the intestinal absorption of cholesterol, which decreases the delivery of cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood.[8] Amlodipine is a calcium channel blocker that is approved for the treatment of hypertension, chronic stable angina, and vasospastic angina, as well as to reduce the risk of hospitalization or revascularization in patients with angiographically confirmed coronary artery disease.[2] Previously, extended-release niacin was available in combination with statins as Advicor® (niacin extended-release-lovastatin) and Simcor® (niacin extended-release-simvastatin). Both drugs were voluntarily taken off of the market at the end of 2015. The FDA withdrew approvals it had previously given for use of niacin and fenofibric acid with statins to treat high cholesterol, citing a lack of cardiovascular benefit.[14]

The HMG-CoA reductase inhibitors that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. The lipid-lowering effects of the statins are noted in Table 2. Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, amlodipine-atorvastatin, and ezetimibe-simvastatin are available in a generic formulation. This class was last reviewed in May 2015.

Table 1. HMG-CoA Reductase Inhibitors Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Atorvastatin	tablet	Lipitor®*	atorvastatin
Fluvastatin	capsule, extended-release tablet	Lescol XL®*	fluvastatin
Lovastatin	extended-release tablet, tablet	Altoprev®	lovastatin
Pitavastatin	tablet	Livalo®	none
Pravastatin	tablet	Pravachol®*	pravastatin
Rosuvastatin	tablet	Crestor®*	rosuvastatin
Simvastatin	tablet	Zocor®*	simvastatin
Combination Products			
Amlodipine and atorvastatin	tablet	Caduet®*	amlodipine-atorvastatin
Ezetimibe and simvastatin	tablet	Vytorin®*	ezetimibe-simvastatin

*Generic is available in at least one dosage form or strength.

PDL=Preferred Drug List.

Table 2. Lipid-lowering Effects of the HMG-CoA Reductase Inhibitors*[1-12]

Generic Name(s)	Total Cholesterol ↓ (%)	LDL-C ↓ (%)	Triglycerides ↓ (%)	HDL-C ↑ (%)
Single Entity Agents				
Atorvastatin	25 to 58	27 to 60	17 to 53	5 to 14
Fluvastatin	16 to 25	22 to 38	12 to 25	2 to 11
Lovastatin	16 to 34	21 to 42	10 to 27	5 to 12
Pitavastatin	22 to 35	31 to 45	13 to 22	1 to 8
Pravastatin	16 to 33	22 to 41	10 to 24	1 to 14
Rosuvastatin	24 to 46	28 to 63	10 to 43	3 to 22
Simvastatin	19 to 52	26 to 51	8 to 41	7 to 16
Combination Products				
Amlodipine and atorvastatin	25 to 58	27 to 60	17 to 53	5 to 14
Ezetimibe and simvastatin	31 to 43	45 to 60	23 to 31	6 to 10

*Includes studies in the prescribing information. Data are mean changes from baseline; data are pooled from different studies and may not be directly comparable.
HDL-C=high-density lipoprotein cholesterol, LDL-C=low-density lipoprotein cholesterol.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the HMG-CoA reductase inhibitors are summarized in Table 3.

Table 3. Treatment Guidelines Using the HMG-CoA Reductase Inhibitors

Clinical Guideline	Recommendation
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004)**[15]	• Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. • When low density lipoprotein cholesterol (LDL-C) lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard HMG-CoA reductase inhibitors (statins) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrants, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), especially in combination with statins. • In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of coronary heart disease (CHD) risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u>

Clinical Guideline	Recommendation
	• Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously). • Bile acid sequestrants (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrants and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u> • TLC indicated for all persons. • All LDL-C lowering drugs are effective. • If necessary to reach LDL-C goals, consider combined drug therapy.
National Cholesterol Education Program: **Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002)**[13]	<u>General recommendations</u> • With regards to TLC, higher dietary intakes of omega-3 fatty acids in the form of fatty fish or vegetable oils are an option for reducing risk for CHD. This recommendation is optional because the strength of evidence is only moderate at present. National Cholesterol Education Program supports the American Heart Association's recommendation that fish be included as part of a CHD risk reduction diet. Fish in general is low in saturated fat and may contain some cardioprotective omega-3 fatty acids. However, a dietary recommendation for a specific amount of omega-3 fatty acids is not made. • Initiate LDL lowering drug therapy with a statin, bile acid sequestrant, or nicotinic acid. • Statins should be considered as first line drugs when LDL lowering drugs are indicated to achieve LDL-C treatment goals. • After six weeks if LDL-C goal is not achieved, intensify LDL lowering therapy. Consider a higher dose of a statin or add a bile acid sequestrant or nicotinic acid. <u>Statins</u> • Statins should be considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. <u>Bile acid sequestrants</u> • Bile acid sequestrants should be considered as LDL lowering therapy for patients with moderate elevations in LDL-C, for younger patients with elevated LDL-C, for women with elevated LDL-C who are considering pregnancy and for patients needing only modest reductions in LDL-C to achieve target goals. • Bile acid sequestrants should be considered in combination therapy with statins in patients with very high LDL-C levels. <u>Nicotinic acid</u> • Nicotinic acid should be considered as a therapeutic option for higher risk patients with atherogenic dyslipidemia. • Nicotinic acid should be considered as a single agent in higher risk patients with atherogenic dyslipidemia who do not have a substantial increase in LDL-C levels,

Clinical Guideline	Recommendation
	and in combination therapy with other cholesterol lowering drugs in higher risk patients with atherogenic dyslipidemia combined with elevated LDL-C levels. • Nicotinic acid should be used with caution in patients with active liver disease, recent peptic ulcer, hyperuricemia, gout, and type 2 diabetes. • High doses of nicotinic acid (>3 g/day) generally should be avoided in patients with type 2 diabetes, although lower doses may effectively treat diabetic dyslipidemia without significantly worsening hyperglycemia. Fibric acid derivatives (fibrates) • Fibrates can be recommended for patients with very high TG to reduce risk for acute pancreatitis. • They also can be recommended for patients with dysbetalipoproteinemia (elevated beta-very LDL). • Fibrate therapy should be considered an option for treatment of patients with established CHD who have low levels of LDL-C and atherogenic dyslipidemia. • They also should be considered in combination with statin therapy in patients who have elevated LDL-C and atherogenic dyslipidemia. Omega-3 fatty acids • Omega-3 fatty acids (e.g., linolenic acid, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA]) have two potential uses. • In higher doses, DHA and EPA lower serum TGs by reducing hepatic secretion of TG-rich lipoproteins. They represent alternatives to fibrates or nicotinic acid for treatment of hypertriglyceridemia, particularly chylomicronemia. Doses of 3 to 12 g/day have been used depending on tolerance and severity of hypertriglyceridemia. • Recent trials also suggest that relatively high intakes of omega-3 fatty acids (1 to 2 g/day) in the form of fish, fish oils, or high-linolenic acid oils will reduce the risk for major coronary events in persons with established CHD. Omega-3 fatty acids can be a therapeutic option in secondary prevention (based on moderate evidence). The omega-3 fatty acids can be derived from either foods (omega-3 rich vegetable oils or fatty fish) or from fish-oil supplements. More definitive trials are required before strongly recommending relatively high intakes of omega-3 fatty acids (1 to 2 g/day) for either primary or secondary prevention.
American Association of Clinical Endocrinologists: **Guidelines for the management of dyslipidemia and prevention of atherosclerosis (2017)**[16]	Cholesterol Goals • For individuals at low risk (i.e., with no risk factors), an LDL-C goal of <130 mg/dL is recommended. • For individuals at moderate risk (i.e., with two or fewer risk factors and a calculated 10-year risk of <10%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or CKD stage 3 or 4 with no other risk factors, or individuals with two or more risk factors and a 10-year risk of 10 to 20%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at very high risk (i.e., with established or recent hospitalization for ACS, coronary, carotid or peripheral vascular disease; diabetes or CKD stage 3 or 4 with one or more risk factors; a calculated 10-year risk >20%; or heterozygous familial hypercholesterolemia [HeFH]), an LDL-C goal of <70 mg/dL is recommended. • For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dL, or established clinical ASCVD in individuals with diabetes, CKD stage 3 or 4, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal of <55 mg/dL is recommended. • An LDL-C goal of <100 mg/dL is considered "acceptable" for children and adolescents, with 100 to 129 mg/dL considered "borderline" and 130 mg/dL or

Clinical Guideline	Recommendation
	greater considered "high" (based on recommendations from the American Academy of Pediatrics). • HDL-C should be >40 mg/dL, but also as high as possible, primarily through the use of lifestyle interventions (e.g., weight loss, physical activity, and tobacco cessation), and if risk factors are present (e.g., borderline elevated LDL-C levels, a family history of premature ASCVD, or a personal history of ASCVD), also through the use of pharmacotherapy primarily focused on reducing LDL-C. • For most individuals, a non–HDL-C goal (total cholesterol minus HDL-C) 30 mg/dL higher than the individual's specific LDL-C goal is recommended. • For individuals at extreme risk, a non-HDL-C goal 25 mg/dL higher than the individual specific LDL-C goal is recommended. • For individuals at increased risk of ASCVD, including those with diabetes, an optimal apo B goal is <90 mg/dL, while for individuals with established ASCVD or diabetes plus one or more additional risk factor(s), an optimal apo B goal is <80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is <70 mg/dL. • TG goals of <150 mg/dL are recommended. <u>General Recommendations</u> • A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended primarily using lifestyle changes and patient education with pharmacotherapy as needed to achieve evidence based targets. • A reasonable and feasible approach to fitness therapy (i.e., exercise programs that include ≥30 minutes of moderate-intensity physical activity [consuming 4 to 7 kcal/min] four to six times weekly, with an expenditure of ≥200 kcal/day) is recommended; suggested activities include brisk walking, riding a stationary bike, water aerobics, cleaning/scrubbing, mowing the lawn, and sporting activities. • Daily physical activity goals can be met in a single session or in multiple sessions throughout the course of a day (10 minutes minimum per session); for some individuals, breaking activity up throughout the day may help improve adherence with physical activity programs. • In addition to aerobic activity, muscle-strengthening activity is recommended at least two days a week. • For adults, a reduced-calorie diet consisting of fruits and vegetables (combined ≥5 servings/day), grains (primarily whole grains), fish, and lean meats is recommended. • For adults, the intake of saturated fats, trans-fats, and cholesterol should be limited, while LDL-C-lowering macronutrient intake should include plant stanols/sterols (~2 g/ day) and soluble fiber (10 to 25 g/day). • Primary preventive nutrition consisting of healthy lifestyle habits is recommended in all healthy children. • Tobacco cessation should be strongly encouraged and facilitated. • In individuals at risk for ASCVD, aggressive lipid-modifying therapy is recommended to achieve appropriate LDL-C goals. <u>Statins</u> • Statin therapy is recommended as the primary pharmacologic agent to achieve target LDLC goals on the basis of morbidity and mortality outcome trials. • For clinical decision making, mild elevations in blood glucose levels and/or an increased risk of new-onset T2DM associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction. • In individuals within high-risk and very high-risk categories, further lowering of LDL-C beyond established targets with statins results in additional ASCVD event reduction and may be considered. • Very high-risk individuals with established coronary, carotid, and peripheral

Clinical Guideline	Recommendation
	vascular disease, or diabetes, who also have at least one additional risk factor, should be treated with statins to target a reduced LDL-C treatment goal of <70 mg/dL. • Extreme risk individuals should be treated with statins to target an even lower LDL-C treatment goal of <55 mg/dL. Fibrates • Fibrates should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). • Fibrates may improve ASCVD outcomes in primary and secondary prevention when TG concentrations are ≥200 mg/dL and HDL-C concentrations <40 mg/dL. Omega-3 Fish Oil • Prescription omega-3 oil, 2 to 4 g daily, should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). Dietary supplements are not FDA-approved for treatment of hypertriglyceridemia and generally are not recommended for this purpose. Niacin • Niacin therapy is recommended principally as an adjunct for reducing TG. • Niacin therapy should not be used in individuals aggressively treated with statin due to absence of additional benefits with well-controlled LDL-C. Bile Acid Sequestrants • Bile acid sequestrants may be considered for reducing LDL-C and apo B and modestly increasing HDL-C, but they may increase TG. Cholesterol Absorption Inhibitors • Ezetimibe may be considered as monotherapy in reducing LDL-C and apo B, especially in statin-intolerant individuals. • Ezetimibe can be used in combination with statins to further reduce both LDL-C and ASCVD risk. PCSK9 Inhibitors • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors should be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH. • PCSK9 inhibitors should be considered in patients with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals. Combination Therapy • Combination therapy of lipid-lowering agents should be considered when the LDL-C/non-HDL-C level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal. Special Considerations: Women • Women should be evaluated for their ASCVD risk and be treated with pharmacotherapy if lifestyle intervention is insufficient. • Hormone replacement therapy for the treatment of dyslipidemia in postmenopausal women is not recommended. Special Considerations: Children and Adolescents • Pharmacotherapy is recommended for children and adolescents older than 10 years who do not respond sufficiently to lifestyle modification, and particularly for those

Clinical Guideline	Recommendation
	satisfying the following criteria: ○ LDL-C ≥190 mg/dL ○ LDL-C ≥160 mg/dL and the presence of two or more cardiovascular risk factors, even after vigorous intervention ○ Family history of premature ASCVD (before 55 years of age), or ○ Having overweight, obesity, or other elements of the insulin resistance syndrome Follow-up and Monitoring • Reassess individuals' lipid status six weeks after therapy initiation and again at six-week intervals until the treatment goal is achieved. • While on stable lipid therapy, individuals should be tested at 6- to 12-month intervals. • While on stable lipid therapy, the specific interval of testing should depend on individual adherence to therapy and lipid profile consistency; if adherence is a concern or the lipid profile is unstable, the individual will probably benefit from more frequent assessment. • More frequent lipid status evaluation is recommended in situations such as deterioration of diabetes control, use of a new drug known to affect lipid levels, progression of atherothrombotic disease, considerable weight gain, unexpected adverse change in any lipid parameter, development of a new ASCVD risk factor, or convincing new clinical trial evidence or guidelines that suggest stricter lipid goals. • Liver transaminase levels should be measured before and three months after niacin or fibric acid treatment initiation because most liver abnormalities occur within 3 months of treatment initiation. Liver transaminase levels should be measured periodically thereafter (e.g., semiannually or annually). • Creatine kinase levels should be assessed and the statin discontinued, at least temporarily, when an individual reports clinically significant myalgias or muscle weakness on statin therapy.
American Heart Association/ American College of Cardiology/ National Heart, Lung, and Blood Institute: **American Heart Association/ American College of Cardiology Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update (2011)**[17]	Lipid management • Goal: treatment with statin therapy; use statin therapy to achieve LDL-C of <100 mg/dL; for very high risk patients an LDL-C <70 mg/dL is reasonable; if TG are ≥200 mg/dL, non-HDL-C should be <130 mg/dL, whereas non-HDL-C <100 mg/dL for very high risk patients is reasonable. • Lifestyle modifications (daily physical activity and weight management) are strongly recommended for all patients. • In addition to lifestyle modifications, statin therapy should be prescribed in the absence of contraindications or documented adverse events. • An adequate dose of statin should be used that reduces LDL-C to <100 mg/dL and achieves ≥30% lowering of LDL-C. • Patients who have TG ≥200 mg/dL should be treated with statins to lower non-HDL-C to <130 mg/dL. • Patients who have TG >500 mg/dL should be started on fibrate therapy in addition to statin therapy to prevent acute pancreatitis. • If treatment with a statin does not achieve the goal selected for an individual patient, intensification of LDL-C-lowering drug therapy with a bile acid sequestrant or niacin is reasonable. • For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid sequestrants and/or niacin is reasonable. • It is reasonable to treat very high risk patients with statin therapy to lower LDL-C to <70 mg/dL. • In patients who are at very high risk and who have TG ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable.

Clinical Guideline	Recommendation
	• The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with statins, bile acid sequestrants, and/or niacin. • For patients who continue to have an elevated non-HDL-C while on adequate statin therapy, niacin or fibrate therapy or fish oil may be reasonable. • For all patients, it may be reasonable to recommend omega-3 fatty acids from fist or fish oil capsules (1 g/day) for cardiovascular disease risk reduction.
Institute for Clinical Systems Improvement: **Lipid Management in Adults (2013)**[18]	<u>Clinical highlights</u> • Initiate a statin with patients who have established atherosclerotic cardiovascular disease (ASCVD). • Establish lipid goals based on risk level. • Instruct patients on healthy lifestyle and adjunctive measures. • Patient adherence with recommended therapy should be reinforced during scheduled follow-up. <u>Lifestyle modifications</u> • Patients who are overweight should be advised to reduce their caloric intake to achieve weight loss. • Patients should follow a dietary pattern that emphasizes fruits, vegetables, planetoids, fish, nuts, and legumes. • A diet low saturated and trans fats, and added sugars; and high in soluble fiber, with consideration given to adding 2 grams of plant sterol/stanol is recommended. <u>Statin treatment</u> • Initiate a statin regardless of LDL in patients with established ASCVD. • Initiate statin therapy in patients whose LDL is >100 and have a 10-year CHD risk ≥10% or diabetes. • Combination therapy can be considered on an individual basis, as no studies have shown a benefit to use at this time, and some studies have shown an increased risk of harm over statin monotherapy. <u>Monotherapy</u> • Reducing LDL-cholesterol (LDL-C) levels is the primary approach to lowering risk of CHD in both primary and secondary prevention. • Patients with risk factors for coronary heart disease but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of coronary heart disease. • Patients with a history of coronary disease (including unstable angina and acute myocardial infarction) often benefit from treatment with a statin. Studies have consistently shown a decrease in risk of death from coronary heart disease. • Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Statins also have a modest effect on reducing TG and increasing HDL-C. • Several trials with clinical endpoints support the use of statins in primary and secondary prevention. • If a patient is intolerant to a statin, patients should try another statin before ruling all of them out. • Provide patient education regarding recognition and reporting of symptoms of myopathy during statin therapy. • If patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available. • Many crystalline (immediate-release) and sustained-release preparations of niacin are available over-the-counter. The extended-release preparation of niacin is a prescription drug. Niacin exerts favorable effects on all lipids and lipoproteins, and is good for mixed hyperlipidemia. • Long-term use of niacin is usually limited for many patients due to side effects

Clinical Guideline	Recommendation

	(e.g., flushing and pruritus, liver toxicity, gastrointestinal complaints, etc).
	• Niacin should not be used in combination therapy with a statin, as two major trials have shown increased side effects without any reduction in cardiovascular outcomes.
	• Prior to initiating a fibric acid (gemfibrozil, fenofibrate, and fenofibrate micronized), lifestyle therapies should be intensified for moderately elevated TG. These include reduction of liquid sugar, all refined starches and saturated fat; increased moderate-intensity exercise; and weight reduction.
	• With fibric acids, TG are reduced 30 to 50%, HDL-C is increased 10 to 20%, TC is reduced 5 to 20% in patients without elevated TG, and the effect on LDL-C is variable. Fibric acids are good for severe hypertriglyceridemia (>500 mg/dL) in patients at risk for pancreatitis and for prevention of CHD (not proven for fenofibrate).
	• Myositis, cholelithiasis, and cholecystitis can occur with fibric acid, and caution should be exercised with a history of liver disease.
	• The long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown. Ezetimibe is associated with a LDL-C lowering of about 18%, and additive LDL-C lowering occurs when used in combination with a statin.
	• The short-term tolerability of ezetimibe is similar to placebo, and the long-term safety is unknown.
	• Bile acid sequestrants reduce LDL-C by 15 to 30% and TG may increase 15%; therefore, are these agents are useful for patients with moderately elevated LDL-C. The effects of the bile acid sequestrants are apparent within one week and maximum at two to three weeks. Bile acid sequestrants are good for combination therapy and are most potent with a statin.
	• Bile acid sequestrants are not systemically absorbed; therefore, side effects are limited to the gastrointestinal tract. In addition, drug interactions are minimized by taking other medications one hour before the sequestrant or four hours after.
	
	<u>Combination therapy</u>
	• It has become common practice to adjust medication therapy, including using combinations of medications, to achieve LDL-C goals. Common combinations include statin/fibrate, statin/niacin, and statin/ezetimibe.
	  o A fibrate is commonly added to a statin, which results in enhanced lowering of LDL-C, as well as a higher incidence of myopathy.
	  o Recent clinical trials have not demonstrated improved outcomes by increasing HDL-cholesterol with niacin among individuals with CVD and optimally controlled LDL-cholesterol on statins.
	  o The addition of ezetimibe to a statin significantly improves LDL-C over either agent alone. To date no large clinical trials have been completed evaluating this combination therapy compared to statin monotherapy on clinical vascular endpoints.
	• Studies of combination therapy have failed to show any benefit beyond statin monotherapy.
	• Combination therapy can be considered on an individual basis, but the additional cost, complexity, and risk for side effects argue against routine use until further trials indicate what groups of patients might benefit.
	• There are negative trials of cholesterylester transfer protein inhibitors when used in combination with statins.
	• No randomized-controlled trials looking at clinical vascular endpoints are available for other agents such as fish oils or bile-acid sequestrants used in combination therapy.
	• A systematic review of combination therapy for dyslipidemia concluded that the limited evidence available suggests that combinations of lipid-lowering agents do not improve clinical outcomes more than statin monotherapy.

Clinical Guideline	Recommendation
American College of Cardiology/American Heart Association Task Force on Practice Guidelines: **Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)**[19]	Statin treatment • The panel makes no recommendations for or against specific low density lipoprotein cholesterol (LDL-C) or non-high density lipoprotein cholesterol (HDL-C) targets for the primary or secondary prevention of arteriosclerotic cardiovascular disease (ASCVD). • High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. • In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated. • In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it. • Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity. • For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction. • For individuals ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences. • Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus. • High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a ≥7.5% estimated 10-year ASCVD risk unless contraindicated. • In adults with diabetes mellitus, who are <40 or >75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions, and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy. • Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk ≥7.5% should be treated with moderate- to high-intensity statin therapy. • It is reasonable to offer treatment with a moderate intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinica ASCVD or diabetes and an estimated 10-year ASCVD risk of 5.0 to <7.5%. • Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 to 189 mg/dL without clinical ASCVD or diabetes it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment. • In adults with LDL-C <190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of

Clinical Guideline	Recommendation

	patient preference.
	
	<u>Statin safety</u>
	• To maximize the safety of statins, selection of the appropriate statin and dose in men and nonpregnant/non-nursing women should be based on patient characteristics, level of ASCVD risk, and potential for adverse effects.
	• Moderate-intensity statin therapy should be used in individuals in whom high-intensity statin therapy would otherwise be recommended when characteristics predisposing them to statin associated adverse effects are present.
	• Characteristics predisposing individuals to statin adverse effects include, but are not limited to:
	  o Multiple or serious comorbidities, including impaired renal or hepatic function.
	  o History of previous statin intolerance or muscle disorders.
	  o Unexplained alanine transaminase elevations >3 times upper limit of normal.
	  o Patient characteristics or concomitant use of drugs affecting statin metabolism.
	  o >75 years of age.
	• Additional characteristics that may modify the decision to use higher statin intensities may include, but are not limited to:
	  o History of hemorrhagic stroke.
	  o Asian ancestry.
	• Creatine kinase should not be routinely measured in individuals receiving statin therapy.
	• Baseline measurement of creatinine kinase is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy.
	• During statin therapy, it is reasonable to measure creatinine kinase in individuals with muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or generalized fatigue.
	• Baseline measurement of hepatic transaminase levels should be performed before initiating statin therapy.
	• During statin therapy, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine or yellowing of the skin or sclera).
	• Decreasing the statin dose may be considered when two consecutive values of LDL-C levels are <40 mg/dL.
	• It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.
	• Individuals receiving statin therapy should be evaluated for new-onset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during statin therapy should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce their risk of ASCVD events.
	• For individuals taking any dose of statins, it is reasonable to use caution in individuals >75 years of age, as well as in individuals that are taking concomitant medications that alter drug metabolism, taking multiple drugs, or taking drugs for conditions that require complex medication regimens (e.g., those who have undergone solid organ transplantation or are receiving treatment for human immunodeficiency virus (HIV). A review of the manufacturer's prescribing information may be useful before initiating any cholesterol-lowering drug).
	• It is reasonable to evaluate and treat muscle symptoms, including pain, tenderness,

Clinical Guideline	Recommendation
	stiffness, cramping, weakness, or fatigue, in statin-treated patients according to the following management algorithm: o To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline before initiating statin therapy. o If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly discontinue the statin and address the possibility of rhabdomyolysis by evaluating creatinine kinase, creatinine, and a urinalysis for myoglobinuria. • If mild to moderate muscle symptoms develop during statin therapy: o Discontinue the statin until the symptoms can be evaluated. o Evaluate the patient for other conditions that might increase the risk for muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). o If muscle symptoms resolve, and if no contraindication exists, give the patient the original or a lower dose of the same statin to establish a causal relationship between the muscle symptoms and statin therapy. o If a causal relationship exists, discontinue the original statin. Once muscle symptoms resolve, use a low dose of a different statin. o Once a low dose of a statin is tolerated, gradually increase the dose as tolerated. o If, after two months without statin treatment, muscle symptoms or elevated creatinine kinase levels do not resolve completely, consider other causes of muscle symptoms listed above. o If persistent muscle symptoms are determined to arise from a condition unrelated to statin therapy, or if the predisposing condition has been treated, resume statin therapy at the original dose. • For individuals presenting with a confusional state or memory impairment while on statin therapy, it may be reasonable to evaluate the patient for non-statin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy. <u>Monitoring and optimizing statin therapy</u> • Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. This should also include a fasting lipid panel performed within four to 12 weeks after initiation or dose adjustment, and every three to 12 months thereafter. Other safety measurements should be measured as clinically indicated. • The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated. • Individuals who have a less-than anticipated therapeutic response or are intolerant of the recommended intensity of statin therapy, the following should be performed: o Reinforce medication adherence. o Reinforce adherence to intensive lifestyle changes. o Exclude secondary causes of hyperlipidemia. • It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of statin therapy. Focus is on the intensity of the statin therapy. As an aid to monitoring: o High-intensity statin therapy generally results in an average LDL-C reduction of ≥50% from the untreated baseline; o Moderate-intensity statin therapy generally results in an average LDL-C reduction of 30 to <50% from the untreated baseline; o LDL-C levels and percent reduction are to be used only to assess

Clinical Guideline	Recommendation

	response to therapy and adherence. They are not to be used as performance standards.
	• Individuals at higher ASCVD risk receiving the maximum tolerated intensity of statin therapy who continue to have a less than-anticipated therapeutic response, addition of a non-statin cholesterol-lowering drug(s) may be considered if the ASCVD risk-reduction benefits outweigh the potential for adverse effects.
	• Higher-risk individuals include:
	  o Individuals with clinical ASCVD <75 years of age.
	  o Individuals with baseline LDL-C ≥190 mg/dL.
	  o Individuals 40 to 75 years of age with diabetes mellitus.
	  o Preference should be given to non-statin cholesterol-lowering drugs shown to reduce ASCVD events in controlled trials.
	• In individuals who are candidates for statin treatment but are completely statin intolerant, it is reasonable to use non-statin cholesterol lowering drugs that have been shown to reduce ASCVD events in controlled trials if the ASCVD risk-reduction benefits outweigh the potential for adverse effects.
	
	<u>Non statin safety</u>
	• Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric acid should be obtained before initiating niacin, and again during up-titration to a maintenance dose and every six months thereafter.
	• Niacin should not be used if:
	  o Hepatic transaminase elevations are higher than two to three times upper limit of normal.
	  o Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout or unexplained abdominal pain or gastrointestinal symptoms occur.
	  o New-onset atrial fibrillation or weight loss occurs.
	• In individuals with adverse effects from niacin, the potential for ASCVD benefits and the potential for adverse effects should be reconsidered before reinitiating niacin therapy.
	• To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to:
	  o Start niacin at a low dose and titrate to a higher dose over a period of weeks as tolerated.
	  o Take niacin with food or premedicating with aspirin 325 mg 30 minutes before niacin dosing to alleviate flushing symptoms.
	  o If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over four to eight weeks, with the dose of extended release niacin increasing not more than weekly.
	  o If immediate-release niacin is chosen, start at a dose of 100 mg three times daily and up-titrate to 3 g/day, divided into two or three doses.
	• Bile acid sequestrants should not be used in individuals with baseline fasting triglyceride levels ≥300 mg/dL or type III hyperlipoproteinemia, because severe triglyceride elevations might occur.
	• A fasting lipid panel should be obtained before bile acid sequestrants are initiated, three months after initiation, and every six to 12 months thereafter.
	• It is reasonable to use bile acid sequestrants with caution if baseline triglyceride levels are 250 to 299 mg/dL, and evaluate a fasting lipid panel in four to six weeks after initiation. Discontinue the bile acid sequestrants if triglycerides exceed 400 mg/dL.
	• It is reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase levels as clinically indicated, and discontinue ezetimibe if persistent alanine transaminase elevations >3 times upper limit of normal occur.

Clinical Guideline	Recommendation
	• Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis. • Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, are judged to outweigh the potential risk for adverse effect. • Renal status should be evaluated before fenofibrate initiation, within three months after initiation, and every six months thereafter. Assess renal safety with both a serum creatinine level and an estimated glomerular filtration rate based on creatinine. • Fenofibrate should not be used if moderate or severe renal impairment, defined as estimated glomerular filtration rate <30 mL/min per 1.73 m^2, is present. • If estimated glomerular filtration rate is between 30 and 59 mL/min per 1.73 m^2, the dose of fenofibrate should not exceed 54 mg/day. • If, during follow-up, the estimated glomerular filtration rate decreases persistently to ≤30 mL/min per 1.73 m^2, fenofibrate should be discontinued. • If eicosapentaenoic acid and/or docosahexanoic acid are used for the management of severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal disturbances, skin changes, and bleeding.

American College of Cardiology:
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016)[20]
	Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention
	• These patients should be treated first with maximally tolerated statin intensity. If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <100 mg/dL), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response (<50% reduction in LDL-C and may consider LDL-C ≥100 mg/dL):
	  ○ Assess statin adherence.
	  ○ If an adherent patient has not been tried on a high-intensity statin, the dose should be increased to a high-intensity dose at this time.
	  ○ Intensify lifestyle modifications.
	  ○ Consider adding ezetimibe 10 mg daily as the first non-statin agent.
	  ○ A bile acid sequestrant (BAS) may be considered as a second-line agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL, but there is no evidence for benefit of BAS in addition to statins in this population.
	• If ASCVD patients without comorbidities, who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response with <50% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL):
	  ○ It is reasonable to consider the net benefit of alirocumab or evolocumab (in addition to or in place of ezetimibe) as a second step to achieve further LDL-C reduction.
	  ○ If a PCSK9 inhibitor is prescribed, clinicians should continue maximally tolerated statin and monitoring for adherence to medications and lifestyle, side effects, and ongoing LDL-C response to therapy.
	
	Clinical ASCVD with comorbidities, on statin for secondary prevention
	• These patients should be treated first with maximally tolerated statin intensity.
	• If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <70 mg/dL or non–HDL-C <100 mg/dL for patients with diabetes), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.

Clinical Guideline	Recommendation

	• If a patient has a less-than-anticipated response:
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	<u>Clinical ASCVD and baseline LDL-C ≥190 mg/dL not due to secondary causes, on statin for secondary prevention</u>
	• Patients with LDL-C ≥190 mg/dL are more likely to have heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia.
	• In patients who have a less-than-anticipated response on maximally tolerated statin therapy with <50% reduction in LDL-C (and may consider LDL-C ≥70 mg/dL):
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe (or BAS second line) first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	<u>Adults Aged 40 to 75 Years Without ASCVD, but With Diabetes</u>
	• In patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C despite adherence to lifestyle recommendations and moderate-intensity statin therapy, the recommended threshold for consideration of the net benefit of increasing to high-intensity statin therapy is failure to achieve 30 to <50% reduction in LDL-C (and may consider on -treatment LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL).
	• If a patient with diabetes and 10-year ASCVD risk <7.5% without high-risk features has a less-than-anticipated response, with <30% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL), additional clinical approaches may be warranted.
	• Ezetimibe is the preferred initial non-statin therapy due to tolerability, convenience, and single-tablet daily dose.
	• BAS may have a modest hypoglycemic effect that may be of benefit in some diabetic patients if fasting triglycerides are <300 mg/dL. BAS may also be considered if patients have an inadequate response to ezetimibe or if patients are ezetimibe intolerant.
	• In the absence of ASCVD or baseline LDL-C ≥190 mg/dL not due to secondary causes, the PCSK9 inhibitors do not have an established role for primary prevention of ASCVD in patients with diabetes.

National Institute for Health and Clinical Excellence: **Cardiovascular disease: risk assessment and reduction, including lipid modification (2014)**[21]	• Be aware that when deciding on lipid modification therapy for the prevention of cardiovascular disease (CVD), drugs are preferred for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality • When a decision is made to prescribe a statin use a statin of high intensity and low acquisition cost. <u>Lipid Measurement and Referral</u>: • Measure both total and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk.

Clinical Guideline	Recommendation

Updated Sep 2016	• Before starting lipid modification therapy for the primary prevention of CVD, take at least one lipid sample to measure a full lipid profile. This should include measurement of total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglyceride concentrations. A fasting sample is not needed.
	• Use the clinical findings, lipid profile and family history to judge the likelihood of a familial lipid disorder rather than the use of strict lipid cut-off values alone.
	• Exclude possible common secondary causes of dyslipidemia (such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome) before referring for specialist review.
	• Consider the possibility of familial hypercholesterolemia if they have a total cholesterol concentration >7.5 mmol/L and a family history of premature coronary heart disease.
	• Arrange for specialist assessment of people with a total cholesterol concentration of more than 9.0 mmol/L or a non-HDL cholesterol concentration of more than 7.5 mmol/L even in the absence of a first-degree family history of premature coronary heart disease.
	• Refer for urgent specialist review if a person has a triglyceride concentration of more than 20 mmol/L that is not a result of excess alcohol or poor glycemic control.
	• In people with a triglyceride concentration between 10 and 20 mmol/L:
	  ○ Repeat the triglyceride measurement with a fasting test (after an interval of five days, but within two weeks) and
	  ○ Review for potential secondary causes of hyperlipidemia and
	  ○ See specialist advice if the triglyceride concentration remains above 10 mmol/L
	• In people with a triglyceride concentration between 4.5 and 9.9 mmol/L:
	  ○ Be aware that the CVD risk may be underestimated by risk assessment tools and
	  ○ Optimize the management of other CVD risk factors present and
	  ○ Seek specialist advice if non-HDL cholesterol concentration is more than 7.5 mmol/litre.
	
	<u>Statins for the prevention of CVD</u>:
	• The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.
	• Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidemia. Include smoking status, alcohol consumption, blood pressure, body mass index or other obesity measure, total cholesterol, non-HDL cholesterol, HDL cholesterol, triglyceride level, glycosylated hemoglobin (HbA_{1c}), renal function and estimated glomerular filtration rate (eGFR), transaminase levels, and thyroid stimulating hormone in the assessment.
	
	<u>Statins for the Primary Prevention of CVD</u>:
	• Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimize the management of all other modifiable CVD risk factors if possible.
	• Recognize that people may need support to change their lifestyle. To help them do this, refer them to programs such as exercise referral schemes.
	• Offer people the opportunity to have their risk of CVD assessed again after they have tried to change their lifestyle.
	• If lifestyle modification is ineffective or inappropriate, offer statin treatment after

Clinical Guideline	Recommendation

	risk assessment.
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	• For people 85 years or older consider atorvastatin 20 mg as statins may be of benefit in reducing the risk of non-fatal myocardial infarction. Be aware of factors that may make treatment inappropriate.
	
	<u>Statins for the Secondary Prevention of CVD</u>:
	• Start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower dose of atorvastatin if there are potential drug interactions, high risk of adverse effects, or patient preference.
	• Do not delay statin treatment in secondary prevention to manage modifiable risk factors.
	• If a person has acute coronary syndrome, do not delay statin treatment. Take a lipid sample on admission and about three months after the start of treatment.
	
	<u>Statins for the Primary Prevention of CVD for People with Type 1 Diabetes</u>:
	• Consider statin treatment for the primary prevention of CVD in all adults with type 1 diabetes.
	• Offer statin treatment for the primary prevention of CVD to adults with type 1 diabetes who are older than 40 years, have had diabetes for more than 10 years, have established nephropathy, or have other CVD risk factors.
	• Start treatment for adults with type 1 diabetes with atorvastatin 20 mg.
	
	<u>Statins for the Primary Prevention of CVD in People with Type 2 Diabetes</u>:
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people with type 2 diabetes who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	
	<u>Statins for People with CKD</u>:
	• Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
	  ○ Increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 mL/min/1.73 m^2 or more.
	  ○ Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73 m^2.
	
	<u>Follow-up of People Started on Statin Therapy</u>:
	• Measure total cholesterol, HDL cholesterol and non-HDL cholesterol in all people who have been started on high-intensity statin treatment at three months of treatment and aim for a greater than 40% reduction in non-HDL cholesterol.
	• If a greater than 40% reduction in non-HDL cholesterol is not achieved, discuss adherence to lifestyle modifications and drug therapy, timing of dose.
	  ○ Consider increasing the dose if started on less than atorvastatin 80 mg and the person is judged to be at higher risk because of comorbidities, risk score or using clinical judgement.
	• Provide annual medication reviews for people taking statins.
	• Discuss with people who are stable on a low- or middle-intensity statin the likely benefits and potential risks of changing to a high-intensity statin when they have a medication review and agree with the person whether a change is needed.
	
	<u>Monitoring Statin Therapy for Adverse Effects</u>:
	• Advise people who are being treated with a statin that other drugs, some foods (e.g., grapefruit juice) and some supplements may interfere with statins and to

Clinical Guideline	Recommendation

	always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements.
	• Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses.
	• Before offering a statin, ask the person if they have had persistent generalized unexplained muscle pain, whether associated or not with previous lipid-lowering therapy. If they have, measure creatine kinase levels.
	  o If creatine kinase levels are more than five times the upper limit of normal, re-measure creatine kinase after seven days. If creatine kinase levels are still five times the upper limit of normal, do not start statin treatment.
	  o If creatine kinase levels are raised but less than five times the upper limit of normal, start statin treatment at a lower dose.
	• Advise people who are being treated with a statin to seek medical advice if they develop muscle symptoms (pain, tenderness or weakness). If this occurs, measure creatine kinase.
	• If people report muscle pain or weakness while taking a statin, explore other possible causes of muscle pain or weakness and raised creatine kinase if they have previously tolerated statin therapy for more than three months.
	• Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin.
	• Measure baseline liver transaminase before starting a statin. Measure liver transaminase within three months of starting treatment and at 12 months, but not again unless clinically indicated.
	• Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than three times the upper limit of normal.
	• Do not stop statins because of an increase in blood glucose level or HbA_{1c}.
	• Statins are contraindicated in pregnancy and women of childbearing potential should be advised of the potential teratogenic risk of statins and to stop taking them if pregnancy is a possibility.
	  o Advise women planning pregnancy to stop taking statins three months before they attempt to conceive and to not restart them until breastfeeding is finished.
	
	<u>Intolerance to Statin Therapy</u>:
	• If a person is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose.
	• Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statins discuss the following possible strategies with them:
	  o stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin and
	  o reducing the dose within the same intensity group and
	  o changing the statin to a lower intensity group.
	• Seek specialist advice about options for treating people at high risk of CVD such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidemias, and those with CVD, who are intolerant to three different statins.
	
	<u>Fibrates for Preventing CVD</u>:
	• Do not routinely offer fibrates for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2.
	
	<u>Nicotinic Acid for Preventing CVD</u>:
	• Do not offer nicotinic acid (niacin) for the prevention of CVD to people who are

Clinical Guideline	Recommendation
	being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Bile Acid Sequestrants (Anion Exchange Resins) for Preventing CVD: • Do not offer bile acid sequestrants for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer omega-3 fatty acid compounds for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. • Tell people that there is no evidence that omega-3 fatty acid compounds help to prevent CVD. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. Ezetimibe for Preventing CVD: • People with primary hypercholesterolemia should be considered for ezetimibe treatment.
American Heart Association: **Drug Therapy of High Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association (2007)**[22]	• For children meeting criteria for lipid-lowering drug therapy, a statin is recommended as first line treatment. The choice of statin is dependent upon preference but should be initiated at the lowest dose once daily, usually at bedtime. • For patients with high risk lipid abnormalities, the presence of additional risk factors or high risk conditions may reduce the recommended LDL level for initiation of drug therapy and the desired target LDL levels. Therapy may also be considered for initiation in patients <10 years of age. • Additional research regarding drug therapy of high risk lipid abnormalities in children is needed to evaluate the long term efficacy and safety and impact on the atherosclerotic disease process. • Niacin is rarely used to treat the pediatric population. • Given the reported poor tolerance, the potential for very serious adverse effects, and the limited available data, niacin cannot be routinely recommended but may be considered for selected patients. • This guideline does not contain recommendations regarding the use of omega-3 acid ethyl esters.
European Society of Cardiology and Other Societies: **Guidelines on Cardiovascular Disease Prevention in Clinical Practice (2016)**[23]	Drugs • Currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g., ezetimibe) and, more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Response to all therapy varies widely among individuals and therefore monitoring the effect on LDL-C levels is recommended. • Statins, by reducing LDL-C, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions. • Statins should be used as the drugs of first choice in patients with hypercholesterolemia or combined hyperlipidemia. • Selective cholesterol absorption inhibitors are not usually used as monotherapy to decrease LDL-C concentrations, unless patients are intolerant to statins. They are recommended as combination therapy with statins in selected patients when a

Clinical Guideline	Recommendation
	specific goal is not reached with the maximal tolerated dose of a statin. • Bile acid sequestrants also decrease TC and LDL-C, but are poorly tolerated and tend to increase plasma triglyceride concentrations. They are therefore not recommended for routine use in CVD prevention. • Fibrates and niacin are used primarily for triglyceride lowering and increasing HDL-C, while fish oils (n-3 fatty acids) are used for triglyceride lowering. Evidence supporting the use of these drugs for CVD event reduction is limited and, given the strong evidence favouring statins, routine use of these drugs in CVD prevention is not recommended. In order to prevent pancreatitis, when triglycerides are >10 mmol/L (>900 mg/dL) they must be reduced not only by drugs but also by restriction of alcohol, treatment of DM, withdrawal of estrogen therapy, etc. In those rare patients with severe primary hypertriglyceridaemia, specialist referral must be considered. • Regarding new therapies, recent data from phase I to III trials show that PCSK9 inhibitors sharply decrease LDL-C by up to 60%, either as monotherapy or in addition to the maximal statin dose. Whether this approach results in the predicted reduction in CV events is being addressed in large outcome trials; preliminary evidence suggests that this is the case. <u>Drug combinations</u> • Patients with dyslipidemia, particularly those with established cardiovascular disease, diabetes, or asymptomatic high risk patients, may not always reach treatment targets; therefore, combination treatment may be needed. • The only combination that has evidence of clinical benefit (one large RCT) is that of a statin combined with ezetimibe. Based on the relatively limited body of evidence, clinicians may restrict the use of this combination to patients at high or very-high risk of CVD. • Combinations of niacin and a statin increase HDL-C and decrease TG better than either drug used as monotherapy, but flushing is the main adverse event with niacin, which may affect compliance. • Fibrates, particularly fenofibrate, may be useful, not only for decreasing TG and increasing HDL-C, but can further lower LDL-C when administered in combination with a statin. • If target levels cannot be reached with maximal doses of lipid-lowering therapy or combination therapy, patients will still benefit from treatment to the extent to which dyslipidemia has been improved. In these patients, increased attention to other risk factors may help to reduce total risk.
American Heart Association/American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (2014)**[24]	• Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or transient ischemic attack (TIA) presumed to be of atherosclerotic origin and an LDL-C level ≥100mg/dL with or without evidence for other clinical ASCVD. • Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin, and LDL-C level <100 mg/dL, and no evidence for other clinical ASCVD. • Patients with ischemic stroke or TIA and other comorbid ASCVD should be otherwise managed according to the 2013 ACC/AHA cholesterol guidelines, which include lifestyle modifications, dietary recommendations, and medication recommendations.
American Association of the Study of Liver Disease: **Primary Biliary Cirrhosis**	• Ursodeoxycholic acid therapy is the only Food and Drug Administration-approved agent for the treatment of primary biliary cirrhosis. It is currently supported by the most data and is recommended for use in appropriately selected patients who have abnormal liver chemistry. • Issues of patient compliance, development of superimposed liver disease, or coadministration with bile sequestrants (e.g., cholestyramine or colestipol) should

Clinical Guideline	Recommendation
(2009)[25] **Reaffirmed October 2014**	be considered for patients with suboptimal response. • Pruritus is a complication of primary biliary cirrhosis and cholestyramine is the drug of choice for the treatment of this complication. Alternative treatments of pruritus include rifampin, opioid antagonists, and liver transplantation.

American Association of Clinical Endocrinologists: **Consensus Statement on the Comprehensive Type 2 Diabetes Management Algorithm 2016 (2016)[26]**	Principles underlying the algorithm
	• Lifestyle optimization is essential for all patients with diabetes; however, it should not delay needed pharmacotherapy, which can be initiated simultaneously and adjusted based on patient response to lifestyle efforts. The need for medical therapy should not be interpreted as a failure of lifestyle management, but as an adjunct to it.
	• Achieving an HbA_{1c} ≤6.5% is recommended as the primary goal if it can be achieved in a safe and affordable manner; however, higher targets may be appropriate for certain individuals and may change for a given individual over time.
	• Minimizing risk of hypoglycemia and weight gain is a priority. It is a matter of safety, adherence, and cost.
	• For optimal glycemic control, therapies with complementary mechanisms of action must typically be used in combination.
	• Therapeutic effectiveness must be evaluated frequently until stable (e.g., every three months).
	• Safety and efficacy should be given higher priority than the initial acquisition cost of medications, as medication cost is only a small part of the total cost of diabetes care. In assessing the cost of a medication, consideration should be given to monitoring requirements and risks of hypoglycemia and weight gain.
	• The therapeutic regimen should be as simple as possible to optimize adherence.
	
	Monotherapy
	• Patients with recent-onset diabetes and those with mild hyperglycemia (HbA_{1c} <7.5%), initial monotherapy with metformin (at doses of 1,500 to 2,000 mg/day) and life-style modifications will achieve their glycemic goals in a majority of patients.
	• In patients with intolerance or contraindications to metformin, acceptable therapeutic alternatives that reduce glucose without weight gain or hypoglycemia (in order based on suggested hierarchy of usage) include:
	  ○ GLP-1 receptor agonists.
	  ○ Sodium glucose cotransporter 2 (SGLT-2) inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZDs (use with caution).
	  ○ Alpha-glucosidase inhibitors.
	• sulfonylureas, and glinides (in order based on suggested hierarchy of usage) may be used but with caution due to possible weight gain and hypoglycemia.
	
	Combination therapy
	• Patients who present with an initial HbA_{1c} >7.5% or who do not reach their target HbA_{1c} with metformin in three months should be started on a second agent to be used in combination with metformin.
	• Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy.
	• In metformin-intolerant patients, two drugs from other classes with complimentary mechanisms of action should be used.
	• Combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent) plus:
	  ○ GLP-1 receptor agonists.
	  ○ SGLT-2 inhibitors.
	  ○ DPP-4 inhibitors.

Clinical Guideline	Recommendation
	○ TZD. ○ Basal insulin. ○ Colesevelam. ○ Bromocriptine quick release. ○ Alpha-glucosidase inhibitors. ○ Sulfonylureas and glinides. <u>Three-drug combination therapy</u> • Generally, the efficacy of a third antidiabetic agent added to dual therapy is reduced compared to the efficacy of the same drug used as monotherapy or combination therapy with one other agent. • Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy. • Patients who present with an HbA_{1c} <8.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs after three months have a high likelihood of reaching target with a third agent. • Patients who present with an HbA_{1c} >9.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs has are less likely of reaching target with a third agent or fourth agent and insulin should be considered. • Continuation with noninsulin therapies while starting basal insulin is common and does not increase cardiovascular risk, but may increase risk of hypoglycemia when sulfourea are used in conjunction with insulin. • Three-drug combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent), a second-line agent plus: ○ GLP-1 receptor agonists. ○ SGLT-2 inhibitors. ○ TZD. ○ Basal insulin. ○ DPP-4 inhibitors. ○ Colesevelam. ○ Bromocriptine quick release. ○ Alpha-glucosidase inhibitors. ○ Sulfonylureas and glinides. <u>Insulin therapy algorithm</u> • Patients who present with an initial HbA_{1c} >9.0% and are symptomatic, should initiate therapy with insulin with or without other antidiabetic agents. • Start insulin if a patient has marked hyperglycemia despite treatment with several oral antidiabetic agents and is symptomatic with polyuria and weight loss. • Patients who are not at target HbA_{1c} despite the use of oral antidiabetic agents or GLP-1 therapy should be considered for insulin therapy. • Patients with an HbA_{1c} level >8.0% while receiving ≥2 antidiabetic agents, particularly individuals with long duration of diabetes, have significant impairment of beta cell insulin secretory capacity and are unlikely to reach the recommended target by the addition of further oral antidiabetic drugs. <u>Basal insulin</u> • Patients with an HbA_{1c} level >8.0% while receiving ≥2 oral antidiabetic agents or GLP-1 therapy can be started on single daily dose of basal insulin as an add-on to the patient's existing regimen. • Titrate insulin dose every two to three days to reach glycemic goals. • Basal insulin analogues (glargine and detemir) are preferred over protamine Hagedorn insulin because they have been shown to provide a relatively flat serum insulin concentration for up to 24 hours from a single daily injection. • Patients who fail to achieve glucose control with basal insulin or premixed insulin

Clinical Guideline	Recommendation
	formulations can also be considered for basal intensification with a DPP-4 inhibitor or GLP-1 receptor agonist if the glucose level is not markedly elevated, because this approach tends to not cause weight gain or additional hypoglycemia. Basal-bolus insulin regimens • Patients who fail to achieve glucose control with basal insulin or premixed insulin formulations and those with symptomatic hyperglycemia and HbA_{1c} >10% often respond better to combined basal and mealtime bolus insulin. • A full basal-bolus program with an insulin basal analogue once or twice daily and a rapid-acting analogue at each meal is most effective and provides flexibility for patients with variable mealtimes and meal carbohydrate content. • Doses of insulin may be titrated every two to three days to reach glycemic goals. Basal insulin and incretin therapy regimens • Use of the amylin analog pramlintide in conjunction with bolus insulin improves both glycemia and weight in patients with type 2 diabetes. • The incretin therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have similar properties, and also increase endogenous insulin secretion. Therefore, the combination of basal insulin and incretin therapy decreases basal and postprandial glucose and may minimize the weight gain and hypoglycemia risk observed with basal-bolus insulin replacement.

National Institute for Health and Clinical Excellence: **Identification and management of familial hypercholesterolaemia (2008)**[27]
 	
Last updated July 2016
	Drug treatment in adults
	• When offering lipid-modifying drug therapy to adults with familial hypercholesterolemia (FH), inform the patient that this treatment should be life-long.
	• Statins should be the initial treatment for all adults with FH.
	• Consider prescribing a high-intensity statin to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline.
	• Offer treatment with a statin with a low acquisition cost for adults with FH in whom the diagnosis is made after the age of 60 and who do not have coronary heart disease.
	• Ezetimibe monotherapy is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who would otherwise be initiated on statin therapy but who are unable to do so because of contraindications or intolerance to initial statin therapy.
	• Ezetimibe, coadministered with initial statin therapy, is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who have been initiated on statin therapy when:
	  ○ Serum total or LDL-C concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy AND
	  ○ Consideration is being given to changing from initial statin therapy to an alternative statin.
	• Prescribing of drug therapy for adults with homozygous FH should be undertaken within a specialist center.
	• Adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration.
	• Exercise caution when adding a fibrate or nicotinic acid to a statin because of the risk of muscle-related side effects (including rhabdomyolysis). Gemfibrozil and statins should not be used together.

Clinical Guideline	Recommendation

	<u>Drug treatment in children and young people</u>
	• All children and young people diagnosed with, or being investigated for, a diagnosis of FH should have a referral to a specialist with expertise in FH in children and young people.
	• Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-modifying drug therapy for a child or young person should take into account:
	  ○ Their age.
	  ○ The age of onset of coronary heart disease within the family.
	  ○ And the presence of other cardiovascular risk factors, including LCL-C concentration.
	• When offering lipid-modifying drug therapy for children or young people, inform the child/young person and their parent/carer that this treatment should be life-long.
	• When the decision to initiate lipid-modifying drug therapy has been made in children and young people, statins should be the initial treatment. Healthcare professionals with expertise in FH in children and young people should choose a statin that is licensed for use in the appropriate age group.
	• In exceptional instances, for example, when there is a family history of coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering:
	  ○ A higher dose of statin than is licensed for use in the age group and/or
	  ○ More than one lipid-modifying drug therapy, and/or
	  ○ Lipid-modifying drug therapy before the age of 10 years.
	• In children and young people with homozygous FH, LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis.
	• In children and young people with FH who are intolerant of statins, consider offering other lipid-modifying drug therapies capable of reducing LDL-C concentration (such as bile acid sequestrants [resins], fibrates or ezetimibe).
	• Routine monitoring of growth and pubertal development in children and young people with FH is recommended.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the HMG-CoA reductase inhibitors are noted in Table 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 4. FDA-Approved Indications for the HMG-CoA Reductase Inhibitors[1-11]

Indications	Single Entity Agents							Combination Products	
	Atorva-statin	Fluva-statin	Lova-statin	Pitava-statin	Prava-statin	Rosuva-statin	Simva-statin	Amlodi-pine and atorvastatin*	Ezetimibe and simva-statin
Hypertriglyceridemia									
Reduce elevated triglycerides (TG) in patients with hypertriglyceridemia							✔		
Treatment of adult patients with hypertriglyceridemia						✔			
Treatment of patients with elevated TG levels	✔				✔			✔ (atorva-statin)	
Primary Hypercholesterolemia and Mixed Dyslipidemia									
Reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and TG and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia	✔	✔	✔ § (ER)	✔	✔	✔	✔	✔ (atorva-statin)	✔
Reduce TC, LDL-C, and apo B levels in children with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥189 (lovastatin only) or 190 mg/dL OR LDL-C remains ≥160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other cardiovascular risk factors are present in the pediatric patient	✔ ¶	✔ #	✔ ** (IR)		✔ ††	✔ ‡‡	✔ **	✔ ¶ (atorva-statin)	
Reduce elevated TG and very LDL-C in patients with primary dysbetalipoproteinemia							✔		
Reduce TC and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments or if such treatments are	✔						✔	✔ (atorva-statin)	✔

Indications	Single Entity Agents							Combination Products	
	Atorva-statin	Fluva-statin	Lova-statin	Pitava-statin	Prava-statin	Rosuva-statin	Simva-statin	Amlodi-pine and atorvastatin*	Ezetimibe and simva-statin
unavailable									
Reduce TC, LDL-C, and apo B in adult patients with homozygous familial hypercholesterolemia as adjunctive therapy to other lipid-lowering treatments or alone if such treatments are not available						✔			
Reduce TC and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments or if such treatments are unavailable									
Reduce LDL-C, TC, non-HDL-C, and ApoB in pediatric patients with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments						✔ §§			
Reduction of elevated TC and LDL-C levels in patients with primary hypercholesterolemia			✔ §						
Treatment of patients with primary dysbetalipoproteinemia who do not respond adequately to diet	✔				✔	✔		✔ (atorva-statin)	
Prevention of Cardiovascular Disease									
Adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower TC and LDL-C to target levels						✔			
Reduce the risk of myocardial infarction and stroke in patients with type 2 diabetes, and without clinically evidence coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension	✔							✔ (atorva-statin)	
Reduce the risk of myocardial infarction, stroke, and for revascularization procedures and angina in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease	✔							✔ (atorva-statin)	
Reduce the risk of myocardial infarction, undergoing myocardial revascularization procedures, and					✔				

Indications	Single Entity Agents							Combination Products	
	Atorva-statin	**Fluva-statin**	**Lova-statin**	**Pitava-statin**	**Prava-statin**	**Rosuva-statin**	**Simva-statin**	**Amlodi-pine and atorvastatin***	**Ezetimibe and simva-statin**
cardiovascular mortality with no increase in death from noncardiovascular causes in patients with hypercholesterolemia without clinically evident coronary heart disease									
Reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures in patients without symptomatic cardiovascular disease, average to moderately elevated TC and LDL-C, and below average HDL-C			✔						
Reduce the risk of non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in patients with clinically evidence coronary heart disease	✔							✔ (atorvastatin)	
Reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in patients without clinically evidence coronary heart disease but with an increased risk of cardiovascular disease based on age ≥50 years old in men and ≥60 years old in women, high sensitivity C-reactive protein ≥2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease						✔			
Reduce the risk of total mortality by reducing coronary death, myocardial infarction, undergoing myocardial revascularization procedures, stroke and stroke/transient ischemic attack, and to slow the progression of coronary atherosclerosis in patients with clinically evidence coronary heart disease					✔				
Reduce the risk of total mortality by reducing coronary heart disease deaths, non-fatal myocardial infarction and stroke, and need for coronary and non-coronary revascularization procedures in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel							✔		

Indications	Single Entity Agents							Combination Products	
	Atorva-statin	Fluva-statin	Lova-statin	Pitava-statin	Prava-statin	Rosuva-statin	Simva-statin	Amlodi-pine and atorvastatin*	Ezetimibe and simva-statin
disease, history of stroke or other cerebrovascular disease									
Reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in patients with clinically evidence coronary heart disease		✔							
Slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower TC and LDL-C to target levels			✔						
Other									
Reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction <40%								✔ (amlodi-pine)	
Symptomatic treatment of chronic stable angina								✔ (amlodi-pine)	
Treatment of confirmed or suspected vasospastic angina								✔ (amlodi-pine)	
Treatment of hypertension								✔ (amlodi-pine)	

*Indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.
†Indicated for use when treatment with both niacin and lovastatin is appropriate.
‡Indicated for use when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.
§When the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.
‖When the response to an appropriate diet has been inadequate.
¶In boys and postmenarchal girls 10 to 17 years of age.
#In adolescent boys and adolescents girls who are at least one year post-menarche, 10 to 16 years of age.
**In adolescent boys and girls, who are at least one year post-menarche, 10 to 17 years of age.
††In children and adolescent patients ages eight years of age and older.
‡‡ In children and adolescents 8 to 17 years of age.
§§ In children and adolescents 7 to 17 years of age.
ER=extended-release, IR=immediate-release.

IV. Pharmacokinetics

The pharmacokinetic parameters of the HMG-CoA reductase inhibitors are listed in Table 5. All statins undergo extensive first-pass metabolism, resulting in relatively low bioavailability following oral administration. However, the hepatic HMG-CoA inhibition occurs as a result of the high liver concentrations during first-pass metabolism. Thus, their therapeutic effect is not lessened by this high first-pass extraction.[11,12]

Table 5. Pharmacokinetic Parameters of the HMG-CoA Reductase Inhibitors[12]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Atorvastatin	14	98	Liver (significant; % not reported)	Renal (1 to 2) Bile (primary; % not reported)	7 to 14
Fluvastatin	20 to 30	98	Liver (% not reported)	Renal (5) Bile (95) Feces (95)	<3
Lovastatin	5	>95	Liver (extensive; % not reported)	Renal (10) Feces (83)	Not reported
Pitavastatin	51*	99	Liver (extensive; % not reported)	Renal (15) Bile (extensive; % not reported) Feces (79)	11 to 12
Pravastatin	17	43 to 55	Liver (extensive; % not reported)	Renal (20) Feces (71)	2.6 to 3.2
Rosuvastatin	20	88	Liver (minimal; % not reported)	Renal (10) Feces (90)	19
Simvastatin	5	95	Liver (extensive; % not reported)	Renal (13) Feces (60)	Not reported
Combination Products					
Amlodipine and atorvastatin	AM: 64 to 90 AT: 14	AM: 93 AT: 98	AM: Liver (extensive; % not reported) AT: (significant; % not reported)	AM: Renal (70) AT: Renal (1 to 2) Bile (primary; % not reported)	AM: 30 to 60 AT: 7 to 14
Ezetimibe and simvastatin	E: not reported S: 5	E: >90 S: 95	E: Liver (% not reported) Small intestine (extensive; % not reported) S: Liver (extensive; % not reported)	E: Renal (11) Feces (78) S: Renal (13) Feces (60)	E: 19 to 30 S: not reported

*Oral solution.
AM=amlodipine, AT=atorvastatin, E=ezetimibe, S=simvastatin

V. Drug Interactions

Major drug interactions with the HMG-CoA reductase inhibitors are listed in Table 6.

Table 6. Major Drug Interactions with the HMG-CoA Reductase Inhibitors[12,13]

Generic Name(s)	Interaction	Mechanism
Amlodipine	Simvastatin	The mechanism of interaction is unknown. Simvastatin plasma concentrations may be elevated, increasing the risk of toxicity.
HMG-CoA reductase	Amiodarone	Inhibition of cytochrome P450 isoenzymes by amiodarone may

Generic Name(s)	Interaction	Mechanism
inhibitors (atorvastatin, lovastatin, simvastatin)		decrease the metabolic elimination of HMG-CoA reductase inhibitors. The pharmacologic effects of HMG-CoA reductase inhibitors may be increased by amiodarone. Elevated plasma concentrations with toxicity characterized by muscle injury may occur.
HMG-CoA reductase inhibitors (fluvastatin, lovastatin, rosuvastatin, simvastatin)	Anticoagulants	The hypoprothrombinemic effects of anticoagulants may be increased HMG-CoA reductase inhibitors. Hematuria, epistaxis and rectal bleeding may occur. The mechanism of this interaction is unknown.
HMG-CoA reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)	Azole antifungals	Azole antifungals may inhibit first-pass hepatic metabolism of HMG-CoA reductase inhibitors, increasing plasma levels and adverse reactions of HMG-CoA reductase inhibitors.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Carbamazepine	Induction of CYP3A4 metabolism by carbamazepine may cause increased metabolic elimination of HMG-CoA reductase inhibitors. Plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors may be decreased by carbamazepine.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin)	Cyclosporine	Cyclosporine may decrease the elimination of HMG-CoA reductase inhibitors by inhibiting their metabolism. Toxic effects of HMG-CoA reductase inhibitors including liver enzyme elevation, myopathy, and rhabdomyolysis may be increased by cyclosporine.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Delavirdine	Delavirdine inhibits HMG-CoA reductase metabolism, increasing HMG-CoA reductase inhibitor plasma concentrations and increasing the risk of severe myopathy or rhabdomyolysis.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Diltiazem	The inhibition of cytochrome P450 (CYP) 3A4 isoenzymes by diltiazem may decrease the metabolic elimination of HMG-CoA reductase inhibitors. Plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors may be increased by co-administration of diltiazem. The risk of myopathy and rhabdomyolysis may be increased.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, pravastatin, simvastatin)	Efavirenz	Induction of CYP3A4 isoenzymes by efavirenz may increase the metabolic elimination of HMG-CoA reductase inhibitors. Efavirenz may decrease plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors.
HMG-CoA reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin)	Fibric acid derivatives	Coadministration of fibric acid derivatives with HMG-CoA reductase inhibitors may result in myopathy or rhabdomyolysis.
HMG-CoA reductase	Hepatitis C virus	HCV protease inhibitors may inhibit the metabolism of HMG-

Generic Name(s)	Interaction	Mechanism
inhibitors (all)	(HCV) protease inhibitors	CoA reductase inhibitors, increasing plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Imatinib	Inhibition of CYP3A4 isoenzymes by imatinib may decrease the metabolic elimination of HMG-CoA reductase inhibitors. Plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors may be increased by imatinib.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Macrolides and related antibiotics	Inhibition of CYP3A4 isoenzymes by macrolides and ketolides may decrease the metabolic elimination of HMG-CoA reductase inhibitors. Macrolides and ketolides may increase pharmacologic effects of HMG-CoA reductase inhibitors. Elevated plasma concentrations with toxicity characterized by liver enzyme elevation and myopathy may occur.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Mifepristone	Mifepristone may inhibit the metabolism of HMG-CoA reductase inhibitors, increasing HMG-CoA reductase inhibitor plasma concentrations and pharmacologic effects.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Nefazodone	Inhibition of CYP3A4 isoenzymes by nefazodone may decrease the metabolic elimination of HMG-CoA reductase inhibitors. The risk of myopathy and rhabdomyolysis may be increased when HMG-CoA reductase inhibitors and nefazodone are coadministered.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, pravastatin, simvastatin)	Non-nucleoside reverse transcriptase inhibitors (NNRT inhibitors)	Inhibition of CYP3A4 isoenzymes by NNRT inhibitors may decrease the metabolic elimination of HMG-CoA reductase inhibitors. NNRT inhibitors may increase plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors.
HMG-CoA reductase inhibitors (rosuvastatin)	Protease inhibitors	Inhibition of CYP3A4 isoenzymes by protease inhibitors may decrease the metabolic elimination of HMG-CoA reductase inhibitors. Pharmacologic and toxic effects of HMG-CoA reductase inhibitors may be increased by protease inhibitors.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Ranolazine	Ranolazine inhibits the metabolism of HMG-CoA reductase inhibitors, increasing HMG-CoA reductase inhibitor plasma concentrations and increasing the risk of adverse events.
HMG-CoA reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)	Rifamycins	Induction of pre-hepatic and hepatic CYP3A4-mediated metabolism by rifamycins may increase the metabolic elimination of HMG-CoA reductase inhibitors. Pharmacologic effects of HMG-CoA reductase inhibitors may be decreased by rifamycins and impaired cholesterol-lowering efficacy may result.
HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)	Verapamil	Inhibition of CYP3A4 isoenzymes by verapamil may decrease the metabolic elimination of HMG-CoA reductase inhibitors. Plasma concentrations and pharmacologic effects of HMG-CoA reductase inhibitors may be increased by verapamil. Toxicity, characterized by muscle injury, may occur.
Ezetimibe	Cyclosporine	When cyclosporine and ezetimibe are co-administered, exposure to both drugs may be increased potentially increasing the pharmacologic effects and adverse reactions. The mechanism of this interaction is unknown.

VI. Adverse Drug Events

The most common adverse drug events reported with the HMG-CoA reductase inhibitors are listed in Table 7. These agents are generally well tolerated with only mild side effects, such as abdominal pain, constipation, flatulence, and headache. Myopathy has also been reported with the HMG-CoA reductase inhibitors, which can progress to rhabdomyolysis and acute renal failure. Risk factors for developing rhabdomyolysis include age >65 years, hypothyroidism, and poor renal function. Increases in hepatic transaminases greater than three times the upper limit of normal have also been reported with the HMG-CoA reductase inhibitors.[1-12]

Table 7. Adverse Drug Events (%) Reported with the HMG-CoA Reductase Inhibitors[1-12]

Adverse Event	Single Entity Agents							Combination Products	
	Atorvastatin	Fluvastatin (IR/ER)	Lovastatin (IR/ER)	Pitavastatin	Pravastatin	Rosuvastatin	Simva-statin	Amlodipine and atorvastatin	Ezetimibe and simvastatin
Cardiovascular									
Angina pectoris	<2	-	-	-	3.1	-	-	-	-
Arrhythmia	<2	-	-	-	0.1 to 2.6	-	-	<2/✔	-
Bradycardia	-	-	-	-	-	-	-	-/✔	-
Chest pain	≥2	-	0.5 to 1.0	-	-	-	-	≥2.0/✔	-
Hypertension	<2	-	-	-	-	-	-	-	-
Hypotension	-	-	-		-	-	-	-/✔	-
Migraine	<2	-	-	-	-	-	-	-	-
Palpitation	<2	-	-	-	-	-	-	<2/0.7 to 4.5	-
Peripheral ischemia	-	-	-		-	-	-	✔/-	-
Postural hypotension	<2	-	-	-	-	-	-	<2/✔	-
Syncope	<2	-	-	-	-	-	-	<2/✔	-
Tachycardia	-	-	-	-	-	-	-	-/✔	-
Vasodilatation	<2	-	-	-	-	-	-	-/✔	-
Central Nervous System/Neurological									
Abnormal dreams	<2	-	-	-	-	-	-	<2/✔	-
Amnesia	<2	-	-	-	-	-	-	-	-
Anxiety	-	✔	✔	-	1	-	✔	-/✔	-
Chills	-	✔	✔	-	✔	-	✔	-	-
Cranial nerve dysfunction	-	✔	✔	-	✔	-	✔	-	-
Depersonalization	-	-	-	-	-	-	-	-/✔	-
Depression	<2	✔	✔	-	1	-	✔	<2/✔	-
Dizziness	≥2	✔	0.5 to 1.2/2.0	-	1.0 to 2.2	≤4	✔	≥2.0/1.1 to 3.4	-
Emotional lability	<2	-	-	-	-	-	-	-	-
Facial paralysis/paresis	<2	✔	-	-	✔	-	✔	-	-
Fever	<2	✔	-	-	<1	-	✔	-	-
Flushing	-	✔	✔	-	<1	-	✔	-/0.7 to 4.5	-
Headache	2.5 to 16.7	8.9/4.7	✔	✔	1.7 to 1.9	3.1 to 8.5	3.5	2.5 to 16.7/7.3	5.8
Hyperkinesia	<2	-	-	-	-	-	-	-	-
Hypertonia	<2	-	-	-	-	-	-	-	-
Hypesthesia	<2	-	-	-	-	-	-	-/✔	-
Impairment of extraocular movement	-	✔	-	-	✔	-	-	-	-
Incoordination	<2	-	-	-	-	-	-	-	-
Insomnia	≥2	2.7/0.8	0.5 to 1.0	-	1	-	✔	≥2/✔	-

Adverse Event	Single Entity Agents							Combination Products	
	Atorvastatin	Fluvastatin (IR/ER)	Lovastatin (IR/ER)	Pitavastatin	Pravastatin	Rosuvastatin	Simva-statin	Amlodipine and atorvastatin	Ezetimibe and simvastatin
Libido decreased	<2	✔	✔	-	<1	-	✔	-	-
Memory loss	-	✔	✔	-	<1	✔	✔	-	-
Neck rigidity	<2	-	-	-	-	-	-	-	-
Nervousness	-	-	-	-	-	-	-	-/✔	-
Paresthesia	<2	✔	0.5 to 1.0/-	-	<1	-	✔	<2/✔	-
Peripheral nerve palsy	-	✔	✔	-	<1	-	✔	-	-
Peripheral neuropathy	<2	✔	✔	-	<1	-	✔	-	-
Psychiatric disturbances	-	✔	✔	-	<1	-	✔	<2/✔	-
Somnolence	<2	-	-	-	-	-	-	<2.0/1.3 to 1.6	-
Tremor	-	✔	✔	-	<1	-	✔	-/✔	-
Vertigo	-	✔	✔	-	<1	-	✔	-/✔	-
Dermatological									
Acne	<2	-		-	-	-	-	-	-
Alopecia	<2	✔	0.5 to 1.0/-	-	<1	-	✔	-	-
Contact dermatitis	<2	-	-	-	-	-	-	-	-
Dry skin	<2	✔	✔	-	<1	-	✔	-	-
Eczema	<2	-	-	-	-	-	0.8	-	-
Erythema multiforme	<2	✔	✔	-	✔	-	✔	<2/✔	-
Pruritis	<2	✔	0.5 to 1.0/-	-	<1	<2	0.5	<2/✔	-
Rash	1.1 to 3.9	✔	0.8 to 1.3/-	-	1.3 to 2.1	<2	0.6	<2/✔	-
Rash erythematous	-	-	-	-	-	-	-	-/✔	-
Rash maculopapular	-	-	-	-	-	-	-	-/✔	-
Seborrhea	<2	-	-	-	-	-	-	-	-
Skin ulcer	<2	-	✔	-	-	-	-	-	-
Stevens-Johnson syndrome	✔	✔	-	-	✔	-	✔	-	-
Sweating	<2	-	-	-	-	-	-	<2/✔	-
Toxic epidermal necrolysis	✔	✔	✔	-	✔	-	✔	-	-
Urticaria	<2	✔	✔	-	-	<2	-	-	-
Endocrine and Metabolic									
Gout	<2	-	-	-	-	-	-	-	-
Hyperglycemia	<2	✔	-	-	-	-	-	<2/✔	-
Hypoglycemia	<2	-	-	-	-	-	-	-	-
Peripheral edema	≥2	-	-	-	-	-	-	<2/✔	-
Thirst	-	-	-	-	-	-	-	-/✔	-
Weight decrease	-	-	-	-	-	-	-	-/✔	-
Weight gain	<2	-	-	-	-	-	-	<2/✔	-
Gastrointestinal									
Abdominal pain	0.0 to 3.8	4.9/3.7	2.0 to 2.5/-	-	2.0 to 2.4	≤2.4	0.9 to 3.2	0 to 3.8/1.6	-
Acid regurgitation	-	-	0.5 to 1.0/-	-	-	-	-	-	-
Anorexia	<2	✔	✔	-	-	-	✔	0 to 3.8/1.6	-
Biliary pain	<2	-	-	-	-	-	-	-	-
Cheilitis	<2	-	-	-	-	-	-	-	-

Adverse Event	Single Entity Agents							Combination Products	
	Atorvastatin	Fluvastatin (IR/ER)	Lovastatin (IR/ER)	Pitavastatin	Pravastatin	Rosuvastatin	Simva-statin	Amlodipine and atorvastatin	Ezetimibe and simvastatin
Cholecystitis	-	-	-	-	-	-	-	-	-
Cholestatic jaundice	<2	✔	✔	-	✔	✔	✔	-	-
Cirrhosis	-	✔	✔	-	✔	-	✔	-	-
Colitis	<2	-	-	-	-	-	-	-	-
Constipation	0 to 2.5	-	2.0 to 3.5/-	1.5 to 3.6	1.2 to 2.4	2.1 to 4.7	2.3	0 to 2.5/ ✔	-
Decreased appetite	-	-	-	-	<1	-	-	-	-
Diarrhea	0 to 5.3	4.9/3.3	2.2 to 2.6 to 3.0	1.5 to 2.6	2	-	0.5 to 1.9	0 to 5.3/ ✔	2.8
Dry mouth	<2	-	0.5 to 1.0/-	-	-	-	-	<2/ ✔	-
Duodenal ulcer	<2	-	-	-	-	-	-	-	-
Dyspepsia/heartburn	1.3 to 2.8	7.9/3.5	1.0 to 1.6/-	-	2.0 to 3.5	-	0.6 to 1.1	1.3 to 2.8/ ✔	-
Dysphagia	<2	-	-	-	-	-	-	<2/ ✔	-
Enteritis	<2	-	-	-	-	-	-	-	-
Eructation	<2	-	-	-	-	-	-	-	-
Esophagitis	<2	-	-	-	-	-	-	-	-
Flatulence	1.1 to 2.8	2.6/1.4	3.7 to 4.5	-	1.2 to 2.7	-	0.9 to 1.9	1.1 to 2.8/ ✔	-
Fulminant hepatic necrosis	-	✔	✔	-	✔	-	✔	-	-
Gastritis	<2	-	-	-	-	-	-	-	-
Gastroenteritis	<2	-	-	-	-	-	-	-	-
Gingival hyperplasia	-	-	-	-	-		-	-/ ✔	-
Glossitis	<2	-	-	-	-	-	-	-	-
Gum hemorrhage	<2	-	-	-	-	-	-	-	-
Hepatitis	<2	✔	✔	-	✔	✔	✔	-	-
Hepatoma	-	✔	✔	-	✔	-	✔	-	-
Increased appetite	<2	-	-	-	-	-	-	-	-
Melena	<2	-	-	-	-	-	-	-	-
Mouth ulceration	<2	-	-	-	-	-	-	-	-
Nausea	≥2	3.2/2.5	-	-	1.6 to 2.9	0 to 6.3	0.4 to 1.3	≥2.0/2.9	-
Pancreatitis	<2	✔	✔	-	✔	<2	✔	<2/ ✔	-
Rectal hemorrhage	<2	-	-	-	-	-	-	-	-
Stomach ulcer	<2	-	-	-	-	-	-	-	-
Stomatitis	<2	-	-	-	-	-	-	-	-
Tenesmus	<2	-	-	-	-	-	-	-	-
Ulcerative stomatitis	<2	-	-	-	-	-	-	-	-
Vomiting	<2	✔	0.5 to 1.0/-	-	1.6 to 2.9	-	✔	<2/ ✔	-
Genitourinary									
Abnormal ejaculation	<2	-	-	-	-	-	-	-	-
Albuminuria	≥2	-	-	-	-	-	-	-	-
Breast enlargement	<2	-	-	-	-	-	-	-	-
Cystitis	<2	-	-	-	-	-	-	-	-
Dysuria	<2	-	-	-	<1	-	-	-	-
Epididymitis	<2	-	-	-	-	-	-	-	-

Adverse Event	Single Entity Agents							Combination Products	
	Atorvastatin	Fluvastatin (IR/ER)	Lovastatin (IR/ER)	Pitavastatin	Pravastatin	Rosuvastatin	Simva-statin	Amlodipine and atorvastatin	Ezetimibe and simvastatin
Erectile dysfunction	-	✔	✔	-	<1	-	✔	-	-
Fibrocystic breast	<2	-	-	-	-	-	-	-	-
Gynecomastia	-	✔	✔	-	✔	-	✔	-	-
Hematuria	≥2	-	-	-	-	-	-	-	-
Impotence	<2	-	-	-	-	-	-	-	-
Kidney calculus	<2	-	-	-	-	-	-	-	-
Metrorrhagia	<2	-	-	-	-	-	-	-	-
Nephritis	<2	-	-	-	-	-	-	-	-
Nocturia	<2	-	-	-	<1	-	-	<2/✔	-
Urinary abnormality	-	-	-	-	0.7 to 1.0	-	-	-/✔	-
Urinary frequency	<2	-	-	-	<1	-	-	<2/✔	-
Urinary incontinence	<2	-	-	-	-	-	-	-	-
Urinary retention	<2	-	-	-	-	-	-	-	-
Urinary tract infection	≥2	1.6/2.7	-/2	-	-	-	-	-	-
Urinary urgency	<2	-	-	-	1	-	-	-	-
Uterine hemorrhage	<2	-	-	-	-	-	-	-	-
Vaginal hemorrhage	<2	-	-	-	-	-	-	-	-
Hematologic									
Anemia	<2	-	-	-	-	-	-	-	-
Ecchymosis	<2	-	-	-	-	-	-	-	-
Eosinophilia	-	✔	✔	-	✔	-	✔	-	-
Hemolytic anemia	-	✔	✔	-	✔	-	✔	-	-
Leukopenia	-	✔	✔	-	✔	-	-	-/✔	-
Lymphadenopathy	<2	-	-	-	-	-	-	-	-
Petechia	<2	-	-	-	-	-	-	-	-
Prolongation of prothrombin time	-	-	-	-	-	-	-	-	-
Purpura	-	✔	✔	-	✔	-	✔	-/✔	-
Thrombocytopenia	<2	✔	✔	-		-	✔	2/✔	-
Vasculitis	-	✔	✔	-	✔	-	✔	-/✔	-
Laboratory Test Abnormalities									
γ-glutamyl transpeptidase increase	-	-	-	-	-	-	-	-	-
Abnormal thyroid function tests	-	-	-	-	-	-	-	-	-
Bilirubin elevation	-	✔	✔	✔	-	✔	✔	-	-
Creatine phosphokinase increased	<2	-	-	✔	-	2.6	✔	-	-
Eosinophil sedimentation rate increase	-	✔	✔	-	✔	-	✔	-	-
Fasting glucose increase	-	-	-	-	-	-	-	-	-
Hematuria	-	-	-	-	-	✔	-	-	-
Hyperkalemia									
Lactate dehydrogenase decrease	-	-	-	-	-	-	-	-	-
Liver enzyme abnormalities	-	✔	✔	✔	✔	2.2	✔	-	0.4 to 3.7
Phosphorus decrease	-	-	-	-	-	-	-	-	-
Positive antinuclear antibody	-	✔	✔	-	✔	-	✔	-	-
Proteinuria	-	-	-	-	-	✔	-	-	-
Thyroid level abnormality	-	✔	✔	-	✔	✔	✔	-	-

Adverse Event	Single Entity Agents							Combination Products	
	Atorvastatin	Fluvastatin (IR/ER)	Lovastatin (IR/ER)	Pitavastatin	Pravastatin	Rosuvastatin	Simva-statin	Amlodipine and atorvastatin	Ezetimibe and simvastatin
Uric acid increase	-	-	-	-	-	-	-	-	-
Musculoskeletal									
Arthralgia	0 to 5.1	-/3.2	0.5 to 1.5/5.0	✔	6	10.1	✔	0 to 5.1/ ✔	-
Arthritis	≥2	2.1/1.3	0.5 to 6.0/5.0	-	✔	-	✔	-/ ✔	-
Back pain	0 to 3.8	-	-/5	1.4 to 3.9	-	-	-	0 to 3.8/ ✔	0.4
Bursitis	<2	-	-	-	-	-	-	-	-
Dermatomyositis	-	-	-	-	✔	-	-	-	-
Immune-mediated necrotizing myopathy	-	-	-	-	-	-	-	-	-
Leg cramps	<2	-	0.5 to 1.0/-	-	-	-	-	-	-
Leg pain	-	-	-	-	-	-	-	-	-
Localized pain	-	-	-	-	1.4	-	-	-	-
Muscle cramps	-	✔	0.6 to 1.1/-	-	2	-	✔	-/ ✔	-
Myalgia	0 to 5.6	5.0/3.8	1.8 to 3.0/3.0	1.9 to 3.1	0.6 to 1.4	1.9 to 12.7	1.2	0 to 5.6/ ✔	0.6 to 3.6
Myopathy	-	✔	-	-	✔	-	✔	-	-
Myositis	<2	-	-	-	-	-	-	-	-
Myasthenia	<2	-	-	-	<1	-	-	-	-
Pain in extremity	-	-	-	0.6 to 2.3	-	-	-	-	2.3
Polymyalgia rheumatica	-	✔	✔	-	✔	-	✔	-	-
Rhabdomyolysis	✔	✔	✔	-	✔	-	✔	-	-
Shoulder pain	-	-	0.5 to 1.0/-	-	-	-	-	-	-
Tendinous contracture	<2	-	-	-	-	-	-	-	-
Tendon rupture									
Tenosynovitis	<2	-	-	-	-	-	-	-	-
Respiratory									
Asthma	<2	-	-	-	-	-	-	-	-
Bronchitis	≥2	1.2/2.6	-	-	-	-	-	-	-
Cough	-	-	-	-	0.1 to 1.0	-	-	-	-
Dyspnea	<2	✔	✔	-	1.6	-	✔	<2/ ✔	-
Epistaxis	<2	-	-	-	-	-	-	<2/ ✔	-
Pharyngitis	0 to 2.5	-	-	-	-	-	-	-	-
Pneumonia	<2	-	-	-	-	-	-	-	-
Rhinitis	≥2	-	-	-	0.1	-	-	-	-
Sinusitis	0 to 6.4	2.6/3.5	-/4	-	-	-	-	-	-
Upper respiratory infection	-	-	-	-	1.3	-	2.1	-	3.6
Other									
Abnormal vision	-	-	-	-	-	-	-	-/ ✔	-
Accidental injury	0 to 4.2	5.1/4.2	-/6	-	-	-	-	0 to 2.8/ ✔	-
Allergic reaction	0 to 2.8	2.3/1.0	-	-	<1	-	-	-	-
Amblyopia	<2	-	-	-	-	-	-	-	-
Anaphylaxis	✔	✔	✔	-	✔	-	✔	-	-
Angioedema	-	✔	✔	-	✔	<2	✔	-/ ✔	-
Angioneurotic edema	✔	-	-	-	-	-	-	-	-
Asthenia	0 to 3.8	✔	1.2 to 2.0/3.0	-	✔	0.9 to 4.7	1.6	0 to 3.8/ ✔	-
Blurred vision	-	-	0.9 to 1.2/-	-	-	-	-	-	-

Adverse Event	Single Entity Agents							Combination Products	
	Atorvastatin	Fluvastatin (IR/ER)	Lovastatin (IR/ER)	Pitavastatin	Pravastatin	Rosuvastatin	Simva-statin	Amlodipine and atorvastatin	Ezetimibe and simvastatin
Cataracts	-	✔	✔	-	-	-	0.5	-	-
Conjunctivitis	-	-	-	-	-	-	-	-/✔	-
Deafness	<2	-	-	-	-	-	-	-	-
Diplopia	-	-	-	-	-	-	-	-/✔	-
Dry eyes	<2	-	-	-	-	-	-	-	-
Eye hemorrhage	<2	-	-	-	-	-	-	-	-
Eye irritation	-	-	0.5 to 1.0/-	-	-	-	-	-	-
Eye pain	-	-	-	-	-	-	-	-/✔	-
Facial/general edema	<2	-	-	-	<1	-	-	-	-
Fatigue	✔	2.7/1.6	-	-	1.9 to 3.4	-	-	✔/4.5	-
Flu syndrome	0 to 3.2	5.1/7.1	-/5	-	-	-	-	-	-
Glaucoma	<2	-	-/11	-	-	-	-	-	-
Hot flashes	-	-	-	-	-	-	-	-/✔	-
Infection	2.8 to 10.3	-	-	-	-	-	-	-	-
Influenza	-	-	-	✔	-	-	-	-	2.3
Lupus erythematosus-like syndrome	-	✔	✔	-	✔	-	✔	-	-
Malaise	<2	✔	✔	-	✔	-	✔	-	-
Nasopharyngitis	-	-	-	✔	-	-	-	-	-
Ophthalmoplegia	-	✔	✔	-	-	-	✔	-	-
Pain	-	-	-/3	-	-	-	-	-	-
Parosmia	<2	-	-	-	-	-	-	-	-
Photosensitivity reaction	<2	✔	-	-	✔	-	-	-	-
Refraction disorder	<2	-	-	-	-	-	-	-	-
Rigors	-	-	-	-	-	-	-	-/✔	-
Sexual dysfunction	-	-	-	-	-	-	-	-	-
Taste disturbance	<2	✔	-	-	✔	-	-	-/✔	-
Tinnitus	<2	-	-	-	-	-	-	<2/✔	-
Visual disturbances	-	-	✔	-	✔	-	-	-	-

✔ Percent not specified.
- Event not reported.
ER=extended-release, IR=immediate-release

VII. Dosing and Administration

The usual dosing regimens for the HMG-CoA reductase inhibitors are listed in Table 8. All statins are dosed once daily with the exception of maximum doses of lovastatin and fluvastatin immediate-release products, which should be divided into twice daily dosing. Atorvastatin, rosuvastatin, and fluvastatin extended-release formulation are the only statins that may be administered at any time in the day. The other statins should be administered in the evening or at bedtime to target the time of maximum cholesterol synthesis.[1-11]

Table 8. Usual Dosing Regimens for the HMG-CoA Reductase Inhibitors[1-11]

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Atorvastatin	Hypertriglyceridemia/Prevention of cardiovascular disease/Primary hypercholesterolemia and mixed dyslipidemia: Tablet: initial, 10 to 20 mg once daily; maintenance, 10 to 80 mg once daily	Heterozygous familial hypercholesterolemia in children 10 to 17 years of age: Tablet: initial, 10 mg/day; maximum, 20 mg/day Safety and efficacy in children <10 years of age have not been established.	Tablet: 10 mg 20 mg 40 mg 80 mg
Fluvastatin	Prevention of cardiovascular disease: Capsule, extended-release tablet: 20 to 80 mg/day Primary hypercholesterolemia and mixed dyslipidemia: Capsule: initial, 40 mg once daily or 40 mg twice daily Extended-release tablet: initial, 80 mg once daily	Heterozygous familial hypercholesterolemia in children 10 to 16 years of age: Capsule: initial, 20 mg once daily; maximum, 40 mg twice daily Extended-release tablet: maximum, 80 mg once daily Safety and efficacy in children <9 years of age have not been established.	Capsule: 20 mg 40 mg Extended-release tablet: 80 mg
Lovastatin	Prevention of cardiovascular disease/Primary hypercholesterolemia and mixed dyslipidemia: Extended-release tablet: 20 to 60 mg/day Tablet: initial, 20 mg once daily; maintenance, 10 to 80 mg/day administered in a single or two divided doses; maximum, 80 mg/day	Heterozygous familial hypercholesterolemia in children 10 to 17 years of age: Tablet: 10 to 40 mg/day; maximum, 40 mg/day Safety and efficacy in children have not been established (extended-release tablet). Safety and efficacy in pre-pubertal patients or children <10 years of age have not been established (tablet).	Extended-release tablet: 20 mg 40 mg 60 mg Tablet: 10 mg 20 mg 40 mg
Pitavastatin	Primary hypercholesterolemia and mixed dyslipidemia: Tablet: initial, 2 mg once daily; maintenance, 1 to 4 mg once daily; maximum, 4 mg/day	Safety and efficacy in children have not been established.	Tablet: 1 mg 2 mg 4 mg
Pravastatin	Hypertriglyceridemia/Prevention of cardiovascular disease/Primary hypercholesterolemia and mixed dyslipidemia: Tablet: initial, 40 mg once daily; maintenance, 40 to 80 mg once daily	Heterozygous familial hypercholesterolemia in children >8 to 13 years of age: Tablet: initial, 20 mg once daily	Tablet: 10 mg 20 mg 40 mg 80 mg

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
		Heterozygous familial hypercholesterolemia in children 14 to 18 years of age: Tablet: initial, 40 mg once daily Safety and efficacy in children <8 years of age have not been established.	
Rosuvastatin	Hypertriglyceridemia /Prevention of cardiovascular disease /Primary hypercholesterolemia and mixed dyslipidemia: Tablet: initial, 10 to 20 mg once daily; maintenance, 5 to 40 mg once daily	Heterozygous familial hypercholesterolemia in children 8 to <10 years of age: Tablet: maintenance, 5 to 10 mg/day Heterozygous familial hypercholesterolemia in children 10 to 17 years of age: Tablet: maintenance, 5 to 20 mg/day Homozygous familial hypercholesterolemia in children 7 to 17 years of age: Tablet: maintenance, 20 mg/day	Tablet: 5 mg 10 mg 20 mg 40 mg
Simvastatin	Hypertriglyceridemia/Prevention of cardiovascular disease/Primary hypercholesterolemia and mixed dyslipidemia: Tablet: initial, 10 to 40 mg once daily; 5 to 40 mg/day	Heterozygous familial hypercholesterolemia in children 10 to 17 years of age: Tablet: initial, 10 mg once daily; maintenance, 10 to 40 mg/day; maximum, 40 mg/day Safety and efficacy in pre-pubertal patients or children <10 years of age have not been established.	Tablet: 5 mg 10 mg 20 mg 40 mg 80 mg
Combination Products			
Amlodipine and atorvastatin	Hypertension/Coronary artery disease (amlodipine): Tablet: initial, 5 mg once daily; maximum, 10 mg once daily Hypertriglyceridemia/Prevention of cardiovascular disease/Primary hypercholesterolemia and mixed dyslipidemia (atorvastatin): Tablet: initial, 10 to 20 mg once daily; maintenance, 10 to 80 mg once daily	Safety and efficacy in children have not been established.	Tablet: 2.5-10 mg 2.5-20 mg 2.5-40 mg 5-10 mg 5-20 mg 5-40 mg 5-80 mg 10-10 mg 10-20 mg 10-40 mg 10-80 mg
Ezetimibe and simvastatin	Primary hypercholesterolemia and mixed dyslipidemia: Tablet: initial, 10-10 or 10-20 mg once daily; maintenance, 10-10 to 10-40 mg/day	Safety and efficacy in children have not been established.	Tablet: 10-10 mg 10-20 mg 10-40 mg 10-80 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the HMG-CoA reductase inhibitors are summarized in Table 9.

Table 9. Comparative Clinical Trials with the HMG-CoA Reductase Inhibitors

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Single-entity Agents				
Familial Hypercholesterolemia (Single-Entity Agents)				
Rodenburg et al.[28] (2007) Pravastatin 20 mg (children <14 years of age) or pravastatin 40 mg (children ≥14 years of age)	FU Children diagnosed with FH, between 8 and 18 years of age, on a fat-restricted diet ≥3 months, with LDL-C ≥4.0 mmol/L and triglyceride levels <4.0 mmol/L on 2 different occasions, using adequate contraception, not on any treatment for hypercholesterolemia, including plant sterol or stanol products	N=214 2 years (mean duration of total treatment with a statin was 4.5 years)	Primary: Percentage change in TC, LDL-C, TG, HDL-C, predictors of smaller carotid IMT, and safety Secondary: Not reported	Primary: Statin therapy was associated with a 22.5% reduction in TC from baseline. Statin therapy was associated with a 29.2% reduction in LDL-C from baseline. Statin therapy was associated with a 3.1% increase in HDL-C from baseline. Statin therapy was associated with a 1.9% reduction in TG from baseline. The study found several independent predictors of smaller carotid IMT:IMT at statin initiation (P<0.001), age at statin initiation (P=0.016), male sex (P<0.001), and the duration of statin therapy (P<0.001). Secondary: Not reported
Kusters et al.[29] (2014) Pravastatin 20 to 40 mg/day During follow-up	FU Children diagnosed with HeFH, between 8 and 18 years of age enrolled in	N=214 10 years	Primary: CIMT; safety Secondary: Not reported	Primary: Ten-year follow-up was achieved in 194 (91%) patients with FH and 83 (87%) siblings. After 10 years, mean CIMT was still significantly greater in patients with FH compared with siblings (0.480 mm vs 0.469 mm, respectively; P=0.02). Progression of CIMT from baseline was similar in both groups (patients with FH, 0.039 mm vs siblings, 0.037 mm; P=0.52).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
several patients switched to other statins	Rodenburg et al. (above)			Safety parameters did not differ between patients with FH and siblings. Secondary: Not reported
Avis et al.[30] (2010) PLUTO Rosuvastatin 5, 10 or 20 mg/day for 12 weeks vs placebo All patients were randomized after a 6-week diet lead in period. After 12 weeks, patients entered a 40 week, OL, dose-titration phase. Patients originally randomized to placebo and those with LDL-C <100 mg/dL on their assigned rosuvastatin dose began the OL phase on rosuvastatin 5	DB, MC, PC, RCT Children 10 to 17 years of age with a heFH by documentation of a genetic defect or by predefined clinical criteria, Tanner stage ≥11, with female patients being ≥1 year post menarche and fasting LDL-C ≥190 or >160 mg/dL if there was a family history of premature cardiovascular disease or if the patient had ≥2 other risk factors for cardiovascular disease	N=177 12 weeks	Primary: Percent change from baseline in LDL-C Secondary: Changes from baseline in lipoproteins, proportion of patients achieving LDL-C goal (<110 mg/dL), safety	Primary: Rosuvastatin was associated with a significant reduction in LDL-C compared to placebo (38, 45 and 50 vs 1%; P<0.001 for all). Secondary: Compared to placebo, significant reductions with rosuvastatin were achieved for TC (P<0.001 for all) and apo B (P<0.001), but not for TG (P=0.8, P=0.1 and P=0.1). HDL-C (P=0.4, P=0.2 and P=0.5) and apo AI (P=0.7, P=0.3 and P=0.6) were not significantly different from placebo. No patient receiving placebo achieved the LDL-C goal compared to 12, 41 and 41% of patients receiving rosuvastatin 5, 10 and 20 mg during the DB phase. In the OL phase, the goal was achieved by 40% of patients. A LDL-C goal of <130 mg/dL was achieved by 68% of patients in the OL phase. At the end of the OL phase, 26 patients were receiving rosuvastatin 5 mg, 25 patients were receiving 10 mg and 122 patients were receiving 20 mg. During the DB phase, the overall frequencies of adverse events were 50, 64, 55 and 54% (P value not reported). The most commonly reported adverse events included nasopharyngitis, influenza, myalgia and nausea. One serious adverse event of blurred vision occurred with placebo and one patient receiving rosuvastatin 20 mg had a vesicular rash during the OL phase. There was no hepatic, skeletal muscle or renal adverse events reported.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day. All others continued their rosuvastatin dose from the DB phase.				
Braamskamp et al.[31] (2015) CHARON Rosuvastatin (5-mg starting dose was titrated at 3-monthly intervals to a maximum tolerated dose of 10 mg for 6 to 9 year olds or 20 mg for 10 to 17 year olds)	MC, OL Patients 6 to 17 years of age with HeFH and fasting LDL-C >190 mg/dL or >158 mg/dL with other cardiovascular risk factors	N=197 2 years	Primary: Percentage change from baseline in fasting LDL-C after 3, 12, and 24 months of treatment Secondary: Percentage change from baseline in HDL-C, TC, TG, non-HDL-C, ApoA-1 and ApoB; safety	Primary: At three months, the least-square mean percentage reductions in LDL-C were 41, 41, and 35%, in patients aged six to nine, 10 to 13, and 14 to 17 years, respectively (P<0.001 for all three age groups vs baseline). This effect was sustained over the two years of treatment; the mean percentage reductions in LDL-C at 24 months were 43, 45, and 35%, respectively. Secondary: At 24 months, there was a significant reduction in TC (P<0.001), non-HDL-C (P<.001), and ApoB (P<0.001) and a significant increase in HDL-C level (P≤0.001) compared with baseline across all age groups and overall. The most commonly reported adverse events were nasopharyngitis, headache, influenza, and vomiting (all ≥10% of total patients). Rosuvastatin treatment did not appear to impact height, weight, or sexual maturation.
Avis et al.[32] (2007) Standard statin therapy (pravastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin, atorvastatin) vs	MA (6 RCTs) Patients <18 years of age with heFH	N=798 Up to 2 years	Primary: Percentage change in TC, LDL-C, TG, HDL-C, apo B and apo AI; difference in absolute changes in IMT; safety Secondary: Not reported	Primary: Statin therapy was associated with a 23% reduction in TC compared to placebo (95% CI, 19 to 27; P value not reported). Statin therapy was associated with a 30% reduction in LDL-C compared to placebo (95% CI, 24 to 36; P value not reported). Statin therapy was associated with a 3.6% increase in HDL-C compared to placebo (95% CI, 1.33 to 5.94; P value not reported). Statin therapy was associated with a 25% reduction in apo B compared to placebo (95% CI, 19 to 31; P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
placebo				Statin therapy was associated with a 2.4% reduction in apo AI compared to placebo (95% CI, 0.41 to 4.45; P value not reported). Statin therapy was associated with a significant carotid IMT regression compared to placebo (P=0.02). Statin therapy was not associated with a significant risk of adverse events compared to placebo (RR, 0.99; 95% CI, 0.79 to 1.25). Statin therapy was not associated with a significant risk of AST (RR, 0.98; 95% CI, 0.23 to 4.26), ALT (RR, 2.03; 95% CI, 0.24 to 16.95) or CK elevation (RR, 1.38; 95% CI, 0.18 to 10.82) compared to placebo. Secondary: Not reported
Shafiq et al.[33] (2007) Statins (lovastatin, pravastatin, simvastatin, atorvastatin vs placebo	MA (6 trials) DB, RCTs comparing statins with placebo in pediatric and adolescent patients with FH	N=798 12 to 104 weeks	Primary Percent change in LDL-C, TC, TG, HDL-C Secondary: Not reported	Primary Statin therapy was associated with a significant reduction in LDL-C compared to placebo. Statin therapy was associated with a significant reduction in TC compared to placebo. Statin therapy was associated with a significant reduction in TG compared to placebo. Statin therapy was associated with a significant increase in HDL-C compared to placebo. Secondary: Not reported
Marais et al.[34] (2008) Rosuvastatin 80 mg QD for 6 weeks	DB, RCT, XO Patients >10 years of age, weighing ≥32 kg with hoFH, fasting LDL-C >500	N=44 30 weeks (includes the 18 week OL titration phase)	Primary Percent change in LDL-C from baseline to week 18 Secondary	Primary Rosuvastatin 20 to 80 mg achieved a significant reduction in LDL-C from baseline after 18 weeks of therapy (21.4%; P<0.0001). Patients without a portacaval shunt and those not receiving plasmapheresis who received rosuvastatin 20 to 80 mg experienced a 15% reduction in LDL-C from baseline after 18 weeks of therapy (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs atorvastatin 80 mg QD for 6 weeks All patients were randomized following a 18 week OL titration phase during which patients received rosuvastatin 20 mg QD for 6 weeks, titrated up to 40 mg/day for 6 weeks, titrated up to 80 mg/day for another 6 weeks, all after a 4 week dietary lead in period.	mg/dL, TG <600 mg/dL and either xanthomata before 10 years of age or both parents with FH		Response rate; percent change in TC, apo B, TG and HDL-C	Secondary: Rosuvastatin was associated with an overall 72% response rate (≥15% reduction in baseline LDL-C) (P value not reported). Rosuvastatin 20 to 80 mg was associated with a significant reduction in TC and apo B from baseline after 18 weeks of therapy (20%; P<0.0001). Rosuvastatin 20 to 80 mg was associated with a nonsignificant increase in TG and HDL-C from baseline after 18 weeks of therapy (3.3 and 3.1%, respectively; P>0.05). At week 24, rosuvastatin and atorvastatin did not differ in the magnitude of LDL-C reduction from baseline (19.1 vs 18.0%; P=0.67). At week 24, there was no significant difference between treatments in reductions from baseline TC (17.6 vs 17.9%; P=0.91), TG (6.3 vs 13.9%; P=0.21) or apo B (11.4 vs 11.7%; P=0.90). The only significant difference between the two treatments was in the change from baseline in apo AI. While patients receiving rosuvastatin experienced an increase, atorvastatin-treated patients exhibited a reduction in apo AI (P=0.001).
Arca et al.[35] (2007) Atorvastatin 10 mg/day, titrated up to 80 mg/day vs fenofibrate 200 mg/day	OL, RCT Patients 30 to 75 years of age with diagnosis of familial combined hyperlipidemia with TC and/or TG levels ≥90th Italian population percentiles, and/or hyper-apobeta-lipoproteinemia	N=56 24 weeks	Primary: Change in TC, LDL-C, HDL-C, TG, apo A and endothelin-1 Secondary: Not reported	Primary: Atorvastatin was associated with a significant 9% reduction in TC compared to fenofibrate (95% CI, 3.0 to 15.1; P=0.004). Atorvastatin was associated with a significant 17% reduction in LDL-C compared to fenofibrate (95% CI, 8.0 to 26.1; P<0.001). Fenofibrate was associated with a significant 15.5% reduction in TG compared to atorvastatin (95% CI, 3.35 to 27.70; P=0.013). Fenofibrate was associated with a significant 14.2% increase in HDL-C compared to atorvastatin (95% CI, 3.8 to 24.6%; P=0.008). Fenofibrate was associated with a significant 5.2 and 22.0% increase in apo AI

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				and apo AII compared to atorvastatin (P=0.044 and P<0.001, respectively). Fenofibrate was associated with a significant 16.7% reduction in endothelin-1 from baseline (P<0.05). Atorvastatin was not associated with a significant change in endothelin-1 (P value not reported). Secondary: Not reported
Gagné et al.[33] (2002) Statin 40 mg for up to 14 weeks, followed by the addition of ezetimibe 10 mg QD for another 12 weeks, administered as separate entities vs statin 40 mg for up to 14 weeks, followed by titration to 80 mg daily and addition of ezetimibe 10 mg QD daily for another 12 weeks, administered as separate vs statin 40 mg for	DB, MC, RCT Patients ≥12 years old (or with body weight ≥40 kg) with hoFH, LDL-C ≥100 mg/dL and TG ≤350 mg/dL (if on atorvastatin or simvastatin 40 mg/day)	N=50 26 weeks	Primary: Percent change in LDL-C from baseline to the end of treatment period Secondary: Percent change from baseline in total cholesterol, TG, HDL-C, the ratios of LDL-C:HDL-C and TC:HDL-C, non–HDL-C, apo B, apo AI, and CRP	Primary: LDL-C was reduced more by the addition of ezetimibe 10 mg to the statin than by doubling the dose of statin (20.7 vs 6.7%; P=0.007). Secondary: TC was reduced more by the addition of ezetimibe 10 mg to the statin than by doubling the dose of statin (18.7 vs 5.3%; P<0.01). There was no statistically significant difference in any of the other secondary outcome measures between the two groups (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
up to 14 weeks, followed by titration to 80 mg daily Statins used in the study included simvastatin and atorvastatin.				
Hypercholesterolemia (Single Entity Agents)				
Koshiyama et al.[37] (2008) KISHIMEN Pitavastatin 1 to 2 mg/day	MC, OL, PRO Patients with TC ≥220 mg/dL and TG <400 mg/dL	N=178 12 months	Primary: Changes from baseline in LDL-C, HDL-C, remnant-like particle cholesterol, TG and hsCRP Secondary: Not reported	Primary: LDL-C was significantly reduced by 32.6, 31.0 and 30.3% after three, six and 12 months, respectively (P value not reported). HDL-C was significantly increased by 3.1, 5.9 and 2.6% after three, six and 12 months, respectively. In patients with baseline HDL-C <40 mg/dL, HDL-C increased by 16.2, 22.4 and 19.0% after three, six and 12 months (P values not reported). Remnant-like particle cholesterol were significantly reduced by 14.0, 20.2 and 22.8% after three, six and 12 months, respectively (P value not reported). TG was significantly reduced by 17.7 and 15.9% after three and 12 months, respectively, in patients whose baseline TG >150 mg/dL, although TG was not significantly reduced in the overall population (P value not reported). hsCRP were significantly reduced in 31 patients after 12 months (P<0.01). hsCRP was significantly reduced in patients with diabetes (P<0.05). Secondary: Not reported
Motomura et al.[38] (2009) Pitavastatin 2 mg/day	MC, OL, PRO Patients >20 years of age with type 2 diabetes, LDL-C ≥120 mg/dL, TG	N=65 6 months	Primary: Changes from baseline in lipid panel and hsCRP	Primary: Significant reductions in TC, LDL-C and TG and significant increases in HDL-C were observed at one, three and six months after treatment with pitavastatin was initiated (P<0.05 for all). After six months, average reductions in TC, LDL-C and TG were: 27.1, 41.1

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	<400 mg/dL, HbA_{1c} <9.0% and not on hypolipidemic medication for the preceding 4 weeks		Secondary: Not reported	and 6.2%. Average increase in HDL-C at six months was 4.5%. Changes in hsCRP were not significant after three months of treatment (0.49 to 0.43 mg/L; P=0.057), but was significantly reduced at six months (0.49 to 0.37 mg/L; P<0.05). Secondary: Not reported
Ose et al.[39] (2010) Pitavastatin 4 mg QD	ES, OL Patients with primary hypercholesterolemia or combined dyslipidemia who had previously received pitavastatin, atorvastatin or simvastatin for 12 weeks during a DB, Phase III trial	N=1,353 52 weeks	Primary: Safety and tolerability Secondary: Proportion of patients achieving NCEP and European Atherosclerosis Society LDL-C goals (not specified), changes from baseline in lipid profiles	Primary: Overall, 54.8% of patients reported experiencing at least one treatment emergent adverse event, 12.0% of which were determined by the investigators to be related to pitavastatin. Furthermore, 4.1% (n=55) of patients discontinued due to treatment emergent adverse events and 3.6% (n=49) of patients experienced a serious treatment emergent adverse event, none of which were related to pitavastatin. Two patients died during the trial, neither of which were determined to be related to pitavastatin. The most commonly reported adverse events were increased CK levels (5.8%), nasopharyngitis (5.4%) and myalgia/myalgia intercostals (4.1%). Secondary: At the end of the original DB phases, 71.5 and 69.4% of patients had achieved the LDL-C goals. After 52 weeks, 74.0 and 73.5% of patients achieved the goals. The reductions in mean LDL-C observed at the end of the DB phases were sustained throughout the ES. HDL-C showed a gradual increase; mean HDL-C at week 52 was 57.0 mg/dL (equivalent to a mean change of 14.3% above baseline and 8.7% above end of the DB phases; P value not reported). Non-HDL-C was associated with a sustained decrease from baseline during the ES (38.9% at end of DB phases and 39.6% at week 52). Concentrations of TG, TC, apo AI, apo B, TC:HDL-C, non-HDL-C:HDL-C and apo B:AI were similar at the end of the ES to those observed at the end of the DB phases.
Stein et al.[40] (2007) Rosuvastatin 40 mg/day for ≤96	MC, OL Patients ≥18 years of age with LDL-C ≥190 to ≤260	N=1,380 ≤96 weeks	Primary: Percentage of patients who achieved NCEP ATP III LDL-C	Primary: At 12 weeks, 83% of patients achieved an LDL-C goal (95% CI, 81 to 85; P value not reported). Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
weeks All patients entered a 6 week dietary lead in period.	mg/dL and TG <400 mg/dL		goals (<160, <130 or <100 mg/dL) at 12 weeks Secondary: Reduction in LDL-C, HDL-C, apo ratio, LDL-C:HDL-C, TC, TC:HDL-C, non-HDL-C, TG and apo B	At 48 weeks, rosuvastatin was associated with a significant reduction from baseline in LDL-C, apo ratio, LDL-C:HDL-C, TC, TC:HDL-C, non-HDL-C, TG and apo B (P<0.0001). At 48 weeks, rosuvastatin was associated with a significant increase from baseline in HDL-C (11%; P<0.0001). During the 96-week trial period, 13.0% of patients experienced a serious adverse event, 0.4% of these patients died and 2.0% experienced myalgia (P value not reported).
Preston et al.[41] (2007) RESPOND Amlodipine 5 or 10 mg QD plus atorvastatin 10, 20, 40 or 80 mg QD (all possible dosing combinations) vs amlodipine 5 or 10 mg QD vs atorvastatin 10, 20, 40 or 80 mg QD	DB, RCT Patients 18 to 75 years of age with HTN and dyslipidemia	N=1,660 8 weeks	Primary: Mean change from baseline in SBP and LDL-C Secondary: Augmentation of BP lowering with the addition of atorvastatin and augmentation of LDL-C lowering with the addition of amlodipine, reduction in 10 year Framingham risk scores, adverse effects	Primary: Regardless of dose, combination therapy was associated with significantly greater reductions in SBP compared to atorvastatin (P<0.001 for all comparisons). Overall, combination therapy and atorvastatin achieved comparable decreases in LDL-C. Only the combination of amlodipine 5 mg plus atorvastatin 10 mg achieved significant reductions in LDL-C compared to atorvastatin 10 mg (P=0.007). Secondary: Regardless of dose, there was no difference in terms of SBP lowering between combination therapy and amlodipine (P>0.05 for all comparisons). Regardless of dose, combination therapy significantly reduced LDL-C compared to amlodipine (P<0.001 for all comparisons). A maximal reduction in 10 year Framingham risk scores was observed with combination therapy (5/80 and 10/80 mg; P values not reported). The proportion of patients who discontinued therapy due to adverse effects was similar with all treatments (5.6 vs 5.4 vs 4.1, respectively; P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs placebo				
Ballantyne et al.[42] (2003) Ezetimibe 10 mg QD and atorvastatin 10 to 80 mg QD vs ezetimibe 10 mg QD vs atorvastatin 10 to 80 mg QD vs placebo	DB, PC, RCT Men and women aged ≥18 years with primary hypercholesterolemia (LDL-C 145 to 250 mg/dL and TG ≤350 mg/dL)	N=628 12 weeks	Primary: Percentage reduction in direct LDL-C from baseline to final assessment Secondary: Change from baseline to final assessment for calculated LDL-C, TC, TG, HDL-C, TC:HDL-C ratio, apo B, non–HDL-C, HDL_2-C, HDL_3-C, apo AI, Lp(a), direct LDL-C:HDL-C ratio, adverse events	Primary: There was a significantly greater mean reduction of direct LDL-C from baseline to final assessment in the ezetimibe plus atorvastatin group compared to either atorvastatin alone (P<0.01) or ezetimibe alone (P<0.01). Mean changes in direct LDL-C ranged from -50 to -60% in the combination group compared to -35 to -51% in the atorvastatin alone group (P<0.01). Secondary: Calculated LDL-C was also significantly reduced more commonly in the combination group than all doses of atorvastatin monotherapy (P<0.01). Greater reductions in LDL-C, TC, and TG were observed with increasing doses of atorvastatin monotherapy. However, there was not a favorable dose response with HDL-C. There were similar reductions in LDL-C (50 vs 51%), TC:HDL-C ratio (43 vs 41%), and TG (both 31%) with coadministration of ezetimibe plus atorvastatin 10 mg and the maximal dose of atorvastatin monotherapy, respectively. However, there was a significantly greater increase in HDL-C (9 vs 3%) with the combination group. Reductions in apo B, non–HDL-C, and direct LDL-C:HDL-C ratio from baseline were significantly greater in the combination group compared to both atorvastatin monotherapy (P<0.01 for all) and ezetimibe monotherapy (P<0.01 for all). However, increases in HDL_2-C (P=0.53), HDL_3-C (P=0.06), apo AI (P=0.31), and Lp(a) (P=0.50) did not significantly differ between the combination therapy and atorvastatin monotherapy groups. There also was no significant difference between the combination therapy and ezetimibe monotherapy groups for increases in these same parameters: HDL_2-C (P=0.08), HDL_3-C (P=0.67), apo AI (P=0.80), and Lp(a) (P=0.92). The combination of ezetimibe plus atorvastatin was well-tolerated. Treatment-emergent adverse events were reported in 17% of patients receiving

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				atorvastatin monotherapy and 23% of patients receiving combination therapy. The majority of adverse events were mild to moderate in severity.
Stein et al.[43] (2004) Ezetimibe 10 mg QD and atorvastatin 10 mg QD (titrated up to 40 mg/day) vs atorvastatin 20 mg QD (titrated up to 80 mg/day)	DB, DD, MC Patients ≥18 years of age with primary hypercholesterolemia and documented CHD, ≥2 cardiovascular risk factors, or heFH with an LDL-C level ≥130 mg/dL despite treatment with atorvastatin 10 mg	N=621 14 weeks	Primary: Percentage of patients achieving an LDL-C level ≤100 mg/dL after 14 weeks randomization Secondary: Effects on other lipid parameters four weeks after randomization	Primary: When compared to atorvastatin monotherapy, a significantly higher percentage of patients in the ezetimibe and atorvastatin reached an LDL-C level ≤100 mg/dL after 14 weeks randomization, respectively (7 vs 22%; P<0.01). Secondary: When compared to atorvastatin monotherapy, significant reductions in LDL-C, TC and TG levels were observed in patients in the ezetimibe and atorvastatin (P<0.01). Respectively, percent changes between combination vs atorvastatin monotherapy were -22.8 vs -8.6% (mean change) in LDL-C levels, -17.3 vs -6.1% in TC levels (mean change), and -9.3 vs -3.9% (median change) in TG levels (P<0.01 for all). Nonsignificant changes were observed in HDL-C levels.
Conard et al.[44] (2008) Ezetimibe 10 mg QD and atorvastatin 20 mg QD vs atorvastatin 40 mg QD	DB, MC, PG, RCT Patients 18 to 79 years of age at moderately high risk for CHD who were receiving atorvastatin 20 mg QD with LDL-C levels of 100 mg/dL to 160 mg/dL and TG ≤350 mg/dL	N=196 6 weeks	Primary: Percent change in LDL-C Secondary: Percentage of patients achieving LDL-C <100 mg/dL, percent change TG, TC, HDL-C, non-HDL-C, apo AI, apo B, TC: HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C,	Primary: Treatment with ezetimibe plus atorvastatin led to a significantly greater reduction in LDL-C compared to doubling the dose of atorvastatin (-31 vs -11%, respectively; P<0.001). Secondary: Significantly more patients treated with ezetimibe plus atorvastatin achieved the NCEP ATP III LDL-C goal <100 mg/dL compared to atorvastatin 40 mg (84 vs 49%, P<0.001). Treatment with ezetimibe plus atorvastatin led to greater improvements in non-HDL-C, TC, apo B, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C than treatment with atorvastatin 40 mg (P<0.001). There was no significant difference in HDL-C, TG, apo AI, and hsCRP among the treatment groups.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			hsCRP	
Leiter et al.[45] (2008) Ezetimibe 10 mg QD and atorvastatin 40 mg QD vs atorvastatin 80 mg QD	DB, MC, PG, RCT Patients 18 to 79 years of age at high risk for CHD (CHD or those with a CHD risk equivalent medical condition) who were receiving atorvastatin 40 mg QD with LDL-C levels of 70 mg/dL to 160 mg/dL and TG ≤350 mg/dL	N=579 6 weeks	Primary: Percent change in LDL-C Secondary: Percentage of patients achieving LDL-C <70 mg/dL, percent change TG, TC, HDL-C, non-HDL-C, apo AI, apo B, TC: HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C, hsCRP	Primary: Treatment with ezetimibe plus atorvastatin led to a significantly greater reduction in LDL-C compared to doubling the dose of atorvastatin (-27 vs -11%, respectively; P<0.001). Secondary: Significantly more patients treated with ezetimibe plus atorvastatin achieved the NCEP ATP III LDL-C goal <70 mg/dL compared to atorvastatin 80 mg (74 vs 32%, respectively; P<0.001). Treatment with ezetimibe plus atorvastatin led to greater improvements in non-HDL-C, TC, apo B, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C compared to atorvastatin 80 mg (P<0.001). There was no significant difference in HDL-C, TG, apo AI, and hsCRP among the treatment groups.
Zieve et al.[46] (2010) ZETELD Ezetimibe 10 mg QD for 12 weeks and atorvastatin 10 mg QD for 6 weeks, followed by atorvastatin 20 mg QD for 6 weeks vs atorvastatin 20 mg QD for 6	DB, MC, PG, RCT Patients ≥65 years of age at high risk for CHD with or without atherosclerotic vascular disease who had not reached a LDL-C <70 mg/dL or <100 mg/dL, respectively, after receiving atorvastatin 10 mg/day	N=1,053 12 weeks	Primary: Percent change in LDL-C after six weeks Secondary: Percentage of patients achieving LDL-C <70 mg/dL and <100 mg/dL for high-risk patients without AVD and <70 mg/dL for high-risk patients with	Primary: After six weeks of therapy, treatment with ezetimibe plus atorvastatin led to a significantly greater reduction in LDL-C compared to atorvastatin monotherapy (-29 vs -15%; P<0.001). Secondary: The percentage of patients achieving LDL-C <70 mg/dL and LDL-C <100 mg/dL (without AVD) or <70 mg/dL (with AVD) was significantly greater with ezetimibe plus atorvastatin compared to atorvastatin monotherapy at week six and week 12 (P<0.001). After six weeks of therapy, treatment with ezetimibe plus atorvastatin led to significantly greater changes in HDL-C (+3 vs +1%; P=0.02), TC (-16 vs -8%; P<0.001), non-HDL-C (-24 vs -11%; P<0.001), TG (-13 vs -6%; P<0.001), apo B (-17 vs -8%; P<0.001), TC:HDL-C (-17 vs -8%; P<0.001), LDL-C:HDL-C (-27 vs -13%; P<0.001), apo B:apo AI (-15 vs -5%; P<0.001), and non- HDL-C:HDL-C (-24 vs -11%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
weeks, followed by atorvastatin 40 mg for 6 weeks			AVD, HDL-C, non-HDL-C, TG, TG, apo B, apo AI, TC:HDL-C, apo B:apo AI, LDL-C:HDL-C, non-HDL-C:HDL-C	At week 12, significantly greater changes in favor of ezetimibe plus atorvastatin occurred in HDL-C, TC, non-HDL-C, apo B, apo AI, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C. There was no significant difference among the treatment groups in apo AI at week six, high-sensitivity C-reactive protein at weeks six and 12, and TG at week 12.
Piorkowski et al.[47] (2007) Atorvastatin 40 mg QD vs atorvastatin 10 mg QD and ezetimibe 10 mg QD	RCT Patients 18 to 80 years of age with clinically stable angiographically documented CHD and LDL-C >2.5 mmol/L despite ongoing atorvastatin 10 to 20 mg/day, receiving aspirin and clopidogrel	N=56 4 weeks	Primary: Change in liver transaminases, CK, HDL-C, LDL-C, and TG from baseline, percentage of patients achieving the NCEP ATP III LDL-C goal (≤2.5 mmol/L) Secondary: Not reported	Primary: There were no statistically significant differences from baseline in liver transaminases, CK, or HDL-C in either group. Both groups exhibited a statistically significant reduction in LDL-C from baseline (P<0.005). There was no statistically significant difference between the two groups in degree of LDL-C reduction from baseline. Both the atorvastatin 40 mg and the combination therapy groups exhibited a statistically significant reduction in TG level from baseline (P<0.005 and P<0.05, respectively). There was no statistically significant difference between the two groups in the percentage of patients achieving the NCEP ATP III LDL-C goal (≤2.5 mmol/L). Secondary: Not reported
Goldberg et al.[48] (2006) VYTAL Atorvastatin 10, 20, or 40 mg/day vs	DB, MC, PG, RCT Adult patients with type 2 diabetes between 18 and 80 years of age with HbA_{1c}	N=1,229 6 weeks	Primary: Percent reduction in LDL-C level at week six Secondary: Proportion of	Primary: Patients randomized to simvastatin 20 mg plus ezetimibe 10 mg combination therapy experienced a greater reduction in LDL-C from baseline at week six of the study compared to patients receiving atorvastatin 10 or 20 mg (53.6, 38.3, and 44.6%, respectively; P<0.001). Patients randomized to simvastatin 40 mg plus ezetimibe 10 mg combination therapy experienced a greater reduction in LDL-C from baseline at week six of

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
simvastatin 20 or 40 mg/day and ezetimibe 10 mg/day daily	≤8.5%, LDL-C >100 mg/dL and a TG level <400 mg/dL		patients who achieved the NCEP ATP III LDL-C goal (<70 mg/dL), proportion of patients who achieved LDL-C level of <100 mg/dL, percent change from baseline in HDL-C, non-HDL-C, TC, TG, and CRP	the study compared to patients receiving atorvastatin 40 mg (57.6 and 50.9%, respectively; P<0.001). Secondary: A greater proportion of patients randomized to simvastatin 20 mg plus ezetimibe 10 mg combination therapy achieved LDL-C <70 mg/dL compared to patients receiving atorvastatin 10 or 20 mg (59.7, 21.5, and 35%, respectively; P<0.001). A greater proportion of patients randomized to simvastatin 40 mg plus ezetimibe 10 mg therapy achieved LDL-C <70 mg/dL compared to patients receiving atorvastatin 40 mg (74.4 and 55.2%, respectively; P<0.001). A greater proportion of patients randomized to simvastatin 20 mg plus ezetimibe 10 mg therapy achieved LDL-C <100 mg/dL compared to patients receiving atorvastatin 10 or 20 mg (90.3, 70, and 82.1%, respectively; P=0.007). A greater proportion of patients randomized to simvastatin 40 mg plus ezetimibe 10 mg therapy achieved LDL-C <100 mg/dL compared to patients receiving atorvastatin 40 mg (93.4 and 88.8%, respectively; P=0.07). Patients randomized to simvastatin plus ezetimibe combination therapy, at all doses, experienced a significant increase in HDL-C level (P≤0.001), a greater reduction in TC, and non-HDL-C (P<0.001) compared to patients receiving atorvastatin, at all doses. Patients randomized to simvastatin 20 mg plus ezetimibe 10 mg combination therapy experienced a significant reduction in CRP and TG level compared to patients receiving atorvastatin (P=0.02). Side effects were similar in the simvastatin plus ezetimibe and atorvastatin groups (19.85 vs 22.7%).
Winkler et al.[49] (2007) Fluvastatin 20	MA (30 trials) DB, PC, RCTs assessing ≥6	N=7,043 ≥6 weeks	Primary: Major adverse cardiovascular events defined	Primary: Among patients with metabolic syndrome, pooled fluvastatin was associated with a statistically significant reduction in the risk of any major adverse cardiovascular events compared to placebo (16 vs 22%; HR, 0.728; 95% CI,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg, 40 mg, and 80 mg (pooled group) vs placebo	weeks of fluvastatin therapy in dyslipidemic patients with and without metabolic syndrome		as cardiovascular disease-related death, nonfatal MI, and cardiac re-vascularization, LDL-C, HDL-C, TC, TG, non-HDL-C, apo B Secondary: Not reported	0.6 to 0.9; P=0.001). The difference in the incidence of major adverse cardiovascular events between fluvastatin- and placebo-treated patients without metabolic syndrome was not statistically significant (P=0.083). Among patients with metabolic syndrome, pooled fluvastatin was associated with a statistically significant reduction in the risk of a cardiovascular death compared to placebo (3 vs 4.9%; HR, 0.62; 95% CI, 0.4 to 0.95; P=0.03). The difference in the incidence of cardiovascular death between fluvastatin- and placebo-treated patients without metabolic syndrome was not statistically significant (P=0.478). Among patients with metabolic syndrome, pooled fluvastatin was associated with a statistically significant reduction in the risk of a cardiovascular intervention compared to placebo (12 vs 16%; HR, 0.75; 95% CI, 0.59 to 0.93; P=0.011). The difference in the incidence of cardiovascular intervention between fluvastatin- and placebo-treated patients without metabolic syndrome was not statistically significant (P=0.125). Among patients with metabolic syndrome, pooled fluvastatin was associated with a statistically significant reduction in the risk of a cardiovascular death or nonfatal MI compared to placebo (6.6 vs 9.9%; HR, 0.65; 95% CI, 0.48 to 0.87; P=0.005). The difference in the incidence of cardiovascular death or nonfatal MI between fluvastatin- and placebo-treated patients without metabolic syndrome was not statistically significant (P=0.288). There was no statistically significant difference in the incidence of nonfatal MI, all-cause mortality, or non-cardiovascular-related death between pooled fluvastatin- and placebo-treated patients whether or not they had the metabolic syndrome (P>0.05). In all patients, pooled fluvastatin was associated with a significant reduction from baseline in LDL-C, TC, TG, non-HDL-C, and apo B compared to placebo (P<0.001). Patients with and without the metabolic syndrome taking fluvastatin experienced similar benefits in terms of LDL-C, TC, non-HDL-C, and apo B reduction from baseline.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Patients with the metabolic syndrome experienced a greater increase in HDL-C and a greater reduction in TG from baseline compared to patients without the metabolic syndrome (P<0.01). Secondary: Not reported
Stein et al.[50] (2008) Fluvastatin XL 80 mg QD vs ezetimibe 10 mg QD vs fluvastatin XL 80 mg QD and ezetimibe 10 mg QD	DB, MC, PG, RCT Patients ≥18 years of age with dyslipidemia who had previously documented muscle related side effects that had led to cessation of statin treatment or patients currently receiving statin treatment whose quality of life was affected by muscle related side effects and required switching to an alternative treatment	N=218 12 weeks	Primary: Percent decrease in LDL-C Secondary: LDL:HDL-C, TC, TG, apo B, proportion of patients achieving LDL-C goal	Primary: LDL-C was reduced by 15.6, 32.8, and 46.1% with ezetimibe monotherapy, fluvastatin XL monotherapy, and fluvastatin XL plus ezetimibe combination therapy, respectively (fluvastatin XL vs ezetimibe: -17.1%; P<0.0001; fluvastatin XL plus ezetimibe vs ezetimibe: -30.4%; P<0.0001). Secondary: Treatment with fluvastatin XL monotherapy and fluvastatin XL plus ezetimibe combination therapy led to a greater reduction in LDL:HDL-C, TC, TG, and apo B levels compared to ezetimibe monotherapy (all, P<0.0001). More patients achieved their target LDL-C goal with fluvastatin XL monotherapy and fluvastatin XL plus ezetimibe combination therapy compared to ezetimibe monotherapy (P<0.001 for fluvastatin XL monotherapy or combination therapy vs ezetimibe monotherapy). There were no serious adverse events, rhabdomyolysis, or creatine kinase increases ≥10 times upper limit of normal. Muscle related side effects were reported in 24% of patients receiving ezetimibe monotherapy compared to 17% of patients in the fluvastatin XL group and 14% of patients in the fluvastatin XL plus ezetimibe combination group. Differences in recurrence of muscle related side effects were not statistically different between treatment groups.
Alvarez-Sala et al.[51] (2008) Fluvastatin XL	MC, OL, PG, RCT Patients 18 to 75 years of age with	N=89 12 weeks	Primary: Percentage change in LDL-C	Primary: Fluvastatin XL plus ezetimibe lowered mean LDL-C from 197 mg/dL to 97 mg/dL (-49.9%) and fluvastatin XL alone lowered mean LDL-C from 216 to 135 mg/dL (-35.2%) after 12 weeks of therapy (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
80 mg QD (nighttime) and ezetimibe 10 mg QD vs fluvastatin XL 80 mg QD (nighttime)	primary hypercholesterolemia (LDL-C ≥130 mg/dL and TG ≤400 mg/dL)		Secondary: Percentage change in HDL-C and TG, proportions of patients achieving NCEP ATP III LDL-C goals, change in hsCRP and other markers of inflammation, and safety	Secondary: Fluvastatin XL plus ezetimibe combination was associated with a significantly greater reduction from baseline in TC, TG, and apo B than fluvastatin XL alone (P<0.05 for all). There was no significant change in HDL-C level with either treatment regimen. A greater proportion of patients receiving the fluvastatin XL plus ezetimibe achieved NCEP ATP III LDL-C goals at week 12 compared to those receiving fluvastatin XL alone (86.5 vs 66.7%; P=0.042). There were no significant changes in levels of hsCRP with either treatment regimen. In patients with higher baseline hsCRP levels, the coadministration of fluvastatin XL with ezetimibe was associated with a reduced level of this inflammatory marker. Treatment with fluvastatin XL plus ezetimibe or fluvastatin XL alone was associated with significant reductions in IL-1β (21%; P<0.001 and 13%; P<0.002, respectively). No significant changes were seen in levels of interleukin-6, tumor necrosis factor-α, soluble P-selectin, or soluble vascular cell adhesion molecule-1. There was no significant difference in the incidence of adverse events between the treatment groups. Most adverse events were mild or moderate in intensity, with headache being the most common (8.5%).
Messerli et al.[52] (2006) AVALON Amlodipine 5 mg/day for 8 weeks, followed by the addition of atorvastatin 10 mg/day for another 8 weeks vs	DD, MC, OL, RCT Patients with HTN and dyslipidemia	N=847 28 weeks	Primary: Proportion of patients who reached the JNC 7 and NCEP ATP III goals, side effects Secondary: Not reported	Primary: A significantly greater proportion of patients receiving combination therapy achieved JNC 7 and NCEP ATP goals at eight weeks compared to patients receiving amlodipine or patients receiving atorvastatin monotherapy (45.0 vs 8.3 and 28.6%, respectively; P<0.001). The incidence of side effects was similar across all treatments (P value not reported). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
atorvastatin 10 mg/day for 8 weeks, followed by the addition of amlodipine 5 mg/day for an additional 8 weeks vs amlodipine-atorvastatin 5-10 mg/day for 16 weeks vs placebo for 16 weeks All patients received an additional 12 weeks of OL treatment following the first 16 weeks of therapy.				
Hunninghake et al.[53] (2001) Colesevelam 3.8 g/day	DB, MC, PC, RCT Patients with LDL-C ≥160 mg/dL and TG ≤300 mg/dL	N=91 4 weeks	Primary: Change from baseline in LDL-C Secondary: Change from	Primary: All treatments resulted in significant LDL-C reductions as compared to baseline. LDL-C reductions from baseline were -12% with colesevelam (P<0.05), -38% with atorvastatin 10 mg (P<0.0001), -48% with colesevelam plus atorvastatin (P<0.0001) and -53% with atorvastatin 80 mg (P<0.0001), respectively.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs atorvastatin 10 mg/day vs colesevelam 3.8 g/day plus atorvastatin 10 mg/day vs atorvastatin 80 mg/day vs placebo			baseline in TC, HDL-C, TG, apo B, apo AI and Lp(a)	Secondary: Colesevelam reduced TC by six percent (P<0.05), increased HDL-C by three percent (P<0.05) and increased TG by 10% (P value not reported). Atorvastatin 10 mg reduced TC by 27% (P<0.0001), increased HDL-C by eight percent (P<0.05) and reduced TG by 24% (P<0.05). Colesevelam plus atorvastatin reduced TC by 31% (P<0.0001), increased HDL-C by 11% (P<0.05) and reduced TG by one percent (P value not reported). Atorvastatin 80 mg reduced TC by 39% (P<0.0001), increased HDL-C by five percent (P<0.05) and reduced TG by 33% (P<0.0001). Reductions in TC were significant between all treatment groups except atorvastatin 10 mg relative to colesevelam plus atorvastatin. No significant differences in HDL-C were found between the treatment groups (P values not reported). Apo B levels decreased significantly for with all treatments relative to baseline (P<0.01). No significant changes in apo AI and Lp(a) were reported (P values not reported).
Brown et al.[54] (1990) Colestipol 5 to 10 g TID plus niacin 125 mg BID titrated to 1 to 1.5 g TID vs Colestipol 5 to 10 g TID plus lovastatin 20 mg BID titrated to 40 mg BID	DB, RCT Men ≤62 years of age with elevated apo B and a family history of CAD	N=120 32 months	Primary: Average change in the percent stenosis for the worst lesion in each of the nine proximal segments Secondary: Average changes in all lesions measured in each patient and in proximal lesions causing	Primary: On average, placebo (conventional therapy) increased the index of stenosis by 2.1 percentage points a baseline of 34%. By contrast, it decreased by 0.7 percentage points with colestipol plus lovastatin and by 0.9 percentage points with colestipol and niacin (P<0.003 for trend). At trial end, on average, these nine lesions were almost 3 percentage points less severe among patients treated intensively compared to conventionally. This difference represents almost 1/10 of the amount of disease present at baseline (34% stenosis). Secondary: Placebo (conventional therapy) resulted in consistent worsening of disease when looking at the effect of treatment on certain subsets of lesions (all lesions measured in each patient, lesions causing severe or mild stenosis and those that did not cause total occlusion at baseline). The results with both treatment groups were significantly difference from those receiving conventional therapy for each subset, demonstrating either a mean regression or no change in severity of disease.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs placebo (or colestipol if LDL-C was elevated)			≥50% (severe) stenosis or <50% (mild) stenosis at baseline	
Kerzner et al.[55] (2003) Ezetimibe 10 mg/day vs lovastatin 10, 20 or 40 mg/day vs ezetimibe 10 mg/day plus lovastatin 10, 20 or 40 mg/day vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with mean plasma LDL-C 145 to 250 mg/dL as calculated by Friedewald equation and mean TG ≤350 mg/dL	N=548 12 weeks	Primary: Percentage decrease from baseline in LDL-C Secondary: Changes from baseline in calculated LDL-C, TC, TG, HDL-C, apo B, non-HDL-C, HDL_2-C, HDL_3-C, apo AI and LDL-C:HDL-C; adverse events	Primary: The reduction in LDL-C was significantly greater with combination therapy compared to either lovastatin or ezetimibe (P<0.01 for both). The mean percentage decrease in LDL-C with combination therapy was significantly greater than the decrease obtained from the corresponding lovastatin dose or next higher dose of lovastatin (P<0.01). The mean percentage change in LDL-C achieved with combination therapy (lovastatin 10 mg) was similar to lovastatin 40 mg (P=0.10). Secondary: In comparison to lovastatin, combination therapy significantly improved calculated LDL-C, TC, TG, HDL-C, apo B, non-HDL-C, HDL_2-C, HDL_3-C, LDL-C:HDL-C (P<0.01 for all) and apo AI (P=0.04). Combination therapy significantly increased HDL-C with lovastatin doses of 20 and 40 mg compared to the same lovastatin dose administered as monotherapy (P<0.01 and P<0.02, respectively), and significantly decreased TG levels (P<0.01 for both). Treatment-related adverse events were reported by 16% of patients receiving lovastatin and 17% of patients receiving combination therapy. The safety profile for combination therapy was similar to that for lovastatin and placebo (P values not reported).
Lewis et al.[56] (2007) Pravastatin 80 mg QD vs	DB, MC, PC, RCT Patients ≥18 years of age with hypercholesterolemia, LDL-C ≥100 and TG <400	N=326 36 weeks	Primary: Percent change from baseline at week 12 in LDL-C, TC and TG; ALT event rate (ALT at least two times	Primary: Pravastatin was associated with a significant reduction in LDL-C, TC and TG at week 12 compared to placebo (P<0.0001). There was no significant difference between the two treatments in the ALT event rate at any time during the trial (P>0.05). By week 36, 7.5 and 12.5% of patients receiving pravastatin and placebo had at least one ALT event (P=0.1379).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
placebo	mg/dL, with ≥6 month history of compensated liver disease		the upper limit of normal for those with normal ALT at baseline or a doubling of the baseline ALT for those with elevated ALT at baseline) Secondary: Not reported	Secondary: Not reported
Melani et al.[57] (2003) Ezetimibe 10 mg/day vs pravastatin 10, 20 or 40 mg/day vs ezetimibe 10 mg/day plus pravastatin 10, 20 or 40 mg/day vs placebo	DB, MC, PC, RCT Patients 20 to 86 years of age with primary hypercholesterolemia (LDL-C 3.8 to 6.5 mmol/L as calculated by the Friedewald equation and TG ≤4.0 mmol/L)	N=538 12 weeks	Primary: Percent change from baseline LDL-C Secondary: Mean and percent changes from baseline in calculated LDL-C, TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo AI, apo B, HDL_2-C, HDL_3-C and Lp(a)	Primary: A mean percent change of -38 and -24% in LDL-C with combination therapy and pravastatin were observed (P<0.01). Combination therapy achieved a mean percentage change in LDL-C ranging from -34 to -41% compared to -20 to -29% with pravastatin (all doses). When combination therapy was compared to its corresponding pravastatin dose, the incremental mean percentage reductions in LDL-C were significant in favor of combination therapy (P≤0.01). In addition, combination therapy (pravastatin 10 mg) produced a larger mean percentage reduction in LDL-C compared to pravastatin 40 mg (P≤0.05). Secondary: In comparison to pravastatin, combination therapy improved calculated LDL-C, TG, TC, apo B, non-HDL-C, LDL-C:HDL-C and TC:HDL-C (P<0.01 for all). Both direct and calculated LDL-C levels at all pravastatin doses were significantly reduced with combination therapy (P<0.01). TG was also significantly reduced with combination therapy (pravastatin 10 and 20 mg) compared to pravastatin (P<0.05). Although combination therapy (pravastatin 10 and 40 mg) produced greater increases in HDL-C, it was not significant (P values not reported). The differences in change in HDL_2-C, HDL_3-C, apo AI and Lp(a) between combination therapy and pravastatin were not significant (P values not

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				significant). Combination therapy was well tolerated and the overall safety profile was similar to pravastatin and placebo. There was no evidence to suggest that combination therapy would increase the risk of developing any nonlaboratory adverse event (P value not reported).
Coll et al.[58] (2006) Ezetimibe 10 mg/day vs fluvastatin XR 80 mg/day	RCT Patients ≥18 years of age with HIV receiving stable HAART for ≥6 months and fasting LDL-C ≥3.30 mmol/L	N=20 6 weeks	Primary: LDL-C, TC, endothelial function Secondary: Not reported	Primary: Ezetimibe produced a 20% (P=0.002) LDL-C reduction and a 10% TC reduction (P=0.003). Fluvastatin XR produced a 24% (P=0.02) LDL-C reduction and a 17% TC reduction (P=0.06). There were no significant differences in lipid lowering ability between the two treatments (P values not reported). Ezetimibe did not produce significant changes in endothelial function, while fluvastatin XR produced an increase in the rate of endothelial function by 11% (P=0.5). Secondary: Not reported
Illingworth et al.[59] (1994) Lovastatin 10 to 80 mg/day vs niacin IR 0.25 mg to 1.5 g TID	MC, OL, RCT Patients 21 to 75 years of age with primary hypercholesterolemia and either an LDL-C >160 mg/dL and CHD or ≥2 CHD risk factors without CHD or LDL-C >190 mg/dL without CHD or ≥2 risk factors after rigorous diet	N=136 26 weeks	Primary: Change from baseline in lipid parameters Secondary: Safety	Primary: Lovastatin reduced TC, LDL-C and apo B significantly more than niacin (P<0.01 for all). At weeks 10, 18 and 26, LDL-C was reduced by 26, 28 and 32% with lovastatin compared to five, 16 and 21% with niacin, respectively. The target treatment goal of LDL-C <130 mg/day for patients with CHD or less than two risk factors was achieved in 14, 19 and 35% of patients receiving lovastatin compared to zero, 18 and 26% of patients receiving placebo at weeks 10, 18 and 26, respectively (P values not significant). For the majority of those patients with CHD or two or more risk factors in whom the LDL-C goal was <110 mg/dL, neither drug was effective in achieving this goal. In these patients only 13 and 11% achieved this goal at week 26, respectively (P value not reported). Niacin was more effective in decreasing TG at week 26 (P<0.01 vs lovastatin).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Both treatments were effective in reducing VLDL-C, with no significant difference observed between the two treatments (P value not reported). Niacin produced reductions in Lp(a) of 14, 30 and 35% at weeks 10, 18 and 26, whereas lovastatin had no effect (P<0.05 or P<0.01 between drugs at each time point). Niacin was significantly more effective at increasing HDL-C and apo AI (P<0.01 vs lovastatin), except for the change in apo A1 at week 10 (P value not reported). Niacin increased HDL-C by 20, 29 and 33% and apo AI by 11, 19 and 22% at weeks 10, 18 and 26. Lovastatin resulted in a modest increase in HDL-C and apo AI of 7 and 6%, respectively, at week 26. Secondary: Four deaths occurred in the trial, one with niacin and three with lovastatin. All were related to atherosclerosis, and none were deemed to be drug-related. Five and nine patients receiving lovastatin and niacin discontinued treatment because of adverse experiences (excluding deaths). For those who discontinued treatment, the reason was considered drug-related in four and eight patients receiving lovastatin and niacin (P value not significant). The major reasons for discontinuation of niacin were cutaneous complaints, including flushing, pruritis and rash. One patient discontinued lovastatin because of myalgias. Overall, patient tolerance to the treatments was better with lovastatin. Adverse events (in decreasing frequency) that occurred more frequently with niacin include flushing, paresthesia, pruritis, dry skin, nausea/vomiting, asthenia and diarrhea.
Eriksson et al.[60] (1998) Cholestyramine 16 g/day vs	MC, RCT Patients 30 to 65 years of age	N=2,036 12 months	Primary: Percent change from baseline in LDL-C Secondary: Compliance	Primary: Percent changes in LDL-C from baseline to endpoint with cholestyramine, cholestyramine plus pravastatin, pravastatin 20 mg and pravastatin 40 mg were -26 (95% CI, -23 to -29), -36 (95% CI, -33 to -39), -27 (95% CI, -25 to -29) and -32% (95% CI, -30 to -34). Secondary: Compliance rates with cholestyramine, cholestyramine plus pravastatin,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
cholestyramine 8 g/day plus pravastatin 20 mg/day vs pravastatin 20 or 40 mg/day				pravastatin 20 mg and pravastatin 40 mg were 44, 53, 76 and 78% (P values not reported). Pravastatin adverse events were the most common reasons for withdrawal. Adverse events were most common with cholestyramine and cholestyramine plus pravastatin.
Hing Ling et al.[61] (2012) Atorvastatin 40 mg/day vs ezetimibe 10 mg/day plus simvastatin 40 mg/day All patients received atorvastatin 20 mg/day for six weeks at baseline.	AC, DB, MC, RCT Patients 18 to 79 years of age at high risk for CHD with primary hypercholesterolemia, LDL >100 mg/dL and <160 mg/dL, triglycerides <350 mg/dL, liver function tests within normal limits without active liver disease	N=250 6 weeks	Primary: Change from baseline in LDL-C, Secondary: TC, HDL, CRP, Apo AI, Apo B, TG, non-HDL, LDL-C/HDL ratio, TC/HDL ratio, non-HDL/HDL ratio, Apo AI/Apo B ratio	Primary: After six weeks, treatment with ezetimibe/simvastatin resulted in significantly greater reductions from baseline in LDL-C levels compared to treatment with atorvastatin 40 mg (-26.8 vs -11.8%; P<0.001). Secondary: Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in TC (P<0.001), non-HDL-C (P<0.001), Apo B (P=0.002), Apo AI (P<0.001), and all lipid ratios (P<0.001 for all). There were no significant differences between treatments with regard to the change from baseline in TG (P=0.593), HDL-C (P=0.211), or CRP (P=0.785).
Pearson et al.[62] (2007) Atorvastatin 10, 20, 40 or 80 mg/day vs simvastatin 10,	MA (1 AC, DB; 3 PRO) Patients with primary hypercholesterolemia	N=4,373 12 weeks	Primary: Change from baseline in LDL-C level and hsCRP, proportion of patients reaching LDL-C target (<100 or <70 mg/dL)	Primary: Across all doses, combination therapy was associated with significant reductions in LDL-C compared to simvastatin (52.5 vs 38.0%; P<0.001) and atorvastatin (53.4 vs 45.3%; P<0.001). Across all doses, combination therapy was associated with significant reductions in hsCRP compared to simvastatin (31.0 vs 14.3%; P<0.001). No significant difference was observed between combination therapy and atorvastatin (25.1 vs 24.8%; P value not reported). The reduction in hsCRP was not significantly different between simvastatin 10 mg and placebo

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
20, 40 or 80 mg/day vs ezetimibe 10 mg/day vs ezetimibe 10 mg/day plus simvastatin 10, 20, 40 or 80 mg/day vs placebo			Secondary: Not reported	(P>0.10). A significantly greater proportion of patients receiving combination therapy achieved LDL-C <100 mg/dL compared to simvastatin (78.9 vs 43.1%; P<0.001) and atorvastatin (79.8 vs 61.9%; P<0.001). Similar results were observed with an LDL-C goal <70 mg/dL (37.0 vs 5.7%; P<0.001 and 36.2 vs 16.8%; P<0.001). Secondary: Not reported
Winkler et al.[63] (2009) Fluvastatin 80 mg/day plus fenofibrate 200 mg/day vs ezetimibe 10 mg/day plus simvastatin 20 mg/day	MC, OL, RCT, XO Patients 18 to 75 years of age with metabolic syndrome, low HDL-C, waist circumference ≥94 (men) or ≥80 cm (females) plus 1 of the following: TG ≥150 mg/dL, BP (≥85/≥130 mm Hg), fasting glucose ≥100 mg/dL or	N=75 6 weeks	Primary: Changes from baseline in lipids, lipoproteins and apolipoproteins; LDL subfractions Secondary: Not reported	Primary: Reductions in TC, LDL-C and apo B were greater with ezetimibe plus simvastatin compared to fluvastatin plus fenofibrate, but differences only reached significance in patients without small, dense LDL (P=0.043, P=0.006 and P=0.20). Reductions in TG were only significant with fluvastatin plus fenofibrate compared to ezetimibe plus simvastatin in patients with small, dense LDL (P=0.029). Increases in HDL-C and apo AI were only significant with ezetimibe plus simvastatin compared to fluvastatin plus fenofibrate in patients without small, dense LDL (P=0.020 and P=0.015). In patients with small, dense LDL, apo AII was markedly increased by fluvastatin plus fenofibrate, whereas ezetimibe plus simvastatin had no or little effect. Although only significant in small, dense LDL patients, apo CIII was more effectively reduce by fluvastatin plus fenofibrate, while the reduction of apo CII was more pronounced with ezetimibe plus simvastatin in all patients. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	prevalent type 2 diabetes			
Becker et al.[64] (2008) Simvastatin 40 mg/day plus traditional counseling vs alternative treatment (therapeutic lifestyle changes and ingestion of red yeast rice and fish oil supplements)	RCT Patients 18 to 80 years of age with hypercholesterolemia who met NCEP ATP III criteria for primary prevention using statin therapy	N=74 3 months	Primary: Percent change from baseline in LDL-C Secondary: Percent change from baseline in HDL-C and TG, weight loss	Primary: There was a significant reduction in LDL-C with both simvastatin (39.6±20.0%) and alternative treatment (42.4±15.0%) (P<0.001), with no significant difference noted between the two treatments (P value not reported). Secondary: Alternative treatment was associated with a significant reduction in TG compared to simvastatin (29 vs 9%; 95% CI, 61.0 to 11.7; P=0.003). No differences between the two treatments were noted in improvements with HDL-C (P=0.21). Alternative treatment was associated with a significant reduction in weight loss compared to simvastatin (5.5 vs 0.4%; 95% CI, 5.5 to 3.4; P<0.001).
Meredith et al.[65] (2007) Simvastatin 20 mg QD vs simvastatin 80 mg QD vs placebo	DB, PG, RCT Patients who had undergone elective coronary angiography, had stable CAD and hsCRP >3 mg/L	N=107 16 weeks	Primary: Change from baseline in hsCRP Secondary: Change from baseline in LDL-C, TC and TG	Primary: There was no difference between simvastatin 20 and 80 mg in terms of change from baseline in hsCRP (P=0.82). Secondary: Simvastatin, regardless of dose, was more effective than placebo in baseline reductions of LDL-C (P<0.001). Simvastatin, regardless of dose, was more effective than placebo in baseline reductions in hsCRP (P=0.007). Simvastatin, regardless of dose, was more effective than placebo in baseline reductions in TC (P<0.001). Simvastatin, regardless of dose, was more effective than placebo in baseline reductions in TG (P=0.01).
Knapp et al.[66]	DB, MC, PC,	N=258	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
(2001) Colesevelam 3.8 g/day vs simvastatin 10 mg/day vs colesevelam 3.8 g/day plus simvastatin 10 mg/day vs colesevelam 2.3 g/day vs simvastatin 20 mg/day vs colesevelam 2.3 g/day plus simvastatin 20 mg/day vs placebo	RCT Patients ≥18 years of age with LDL-C ≥160 mg/dL and TG ≤300 mg/dL who are not taking cholesterol lowering medication	6 weeks	Change from baseline in LDL-C Secondary: Percent change in LDL-C; mean and percent change from baseline in TC, HDL-C, TG, apo B and apo AI	LDL-C changes from baseline were -7 mg/dL with placebo (P<0.05), -31 mg/dL with colesevelam 3.8 g (P<0.0001), -48 mg/dL with simvastatin 10 mg (P<0.0001), -80 mg/dL with colesevelam 3.8 g plus simvastatin 10 mg (P<0.0001), -17 mg/dL with colesevelam 2.3 g (P<0.0001), -61 mg/dL with simvastatin 20 mg (P<0.0001) and -80 mg/dL with colesevelam 2.3 g plus simvastatin 20 mg (P<0.0001), respectively. Secondary: LDL-C percent changes from baseline were -4% with placebo (P<0.05), -16% with colesevelam 3.8 g (P<0.0001), -26% with simvastatin 10 mg (P<0.0001), -42% with colesevelam 3.8 g plus simvastatin 10 mg (P<0.0001), -8% with colesevelam 2.3 g (P<0.0001), -34% with simvastatin 20 mg (P<0.0001) and -42% with colesevelam 2.3 g plus simvastatin 20 mg (P<0.0001), respectively. Significant changes from baseline were observed for all treatments in mean and percent change in TC (P<0.0001 for all, except colesevelam 2.3 g; P<0.05). Significant changes from baseline were observed for mean and percent change in HDL-C with simvastatin 10 mg (P<0.05), colesevelam 3.8 g plus simvastatin 10 mg (P<0.0001), colesevelam 2.3 g (P<0.05), simvastatin 20 mg (P<0.05) and colesevelam 2.3 g plus simvastatin 20 mg (P<0.05). Significant changes from baseline were observed for mean and percent change in TG with colesevelam 3.8 g (P<0.05), simvastatin 10 mg (P<0.05), simvastatin 20 mg (P<0.05) and colesevelam 2.3 g plus simvastatin 20 mg (P<0.05). Significant reductions from baseline for apo B were observed with all treatments. Reductions were significant (P<0.05) compared to placebo for all treatments except colesevelam 2.3 g (P value not reported). Significant increases in apo AI were achieved with all treatments except simvastatin 10 mg (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Chenot et al.[67] (2007) Simvastatin 40 mg/day vs simvastatin 40 mg/day plus ezetimibe 10 mg/day vs no lipid lowering therapy	RCT Patients admitted for an acute MI (with or without ST-segment elevation) to the coronary unit, with pain that started within 24 hours of admission	N=60 7 days	Primary: Change from baseline to days two, four and seven in LDL-C; proportion of patients achieving an LDL-C <70 mg/dL Secondary: Not reported	Primary: Combination therapy produced a significant LDL-C reduction from baseline on days two, four and seven (27, 41 and 51%, respectively; P<0.001). Simvastatin produced a significant LDL-C reduction from baseline on days two, four and seven (15, 27 and 25%, respectively; P<0.001). There was no significant reduction in LDL-C with no lipid lowering therapy (P≥0.09). Combination therapy achieved significant LDL-C reductions compared to simvastatin at days four (P=0.03) and seven (P=0.002). A greater proportion of patients receiving combination therapy achieved an LDL-C <70 mg/dL, compared to those receiving simvastatin at days four (45 vs 5%) and seven (55 vs 10%, respectively) (P values not reported). Secondary: Not reported
Davidson et al.[68] (2002) Ezetimibe 10 mg/day plus simvastatin 10, 20, 40 or 80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10	DB, MC, RCT Patients >18 years of age with primary hypercholesterolemia	N=668 20 week	Primary: Mean percent change from baseline in LDL-C Secondary: Mean and percent change from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B, apo AI and hsCRP	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to simvastatin (49.9 vs 36.1%; P<0.001). Similar results were observed with combination therapy compared to ezetimibe (49.9 vs 18.1%; P<0.001). Combination therapy (simvastatin 10 mg) and simvastatin 80 mg produced a 44% reduction in LDL-C at 12 weeks (P value not reported). Secondary: At each corresponding dose of simvastatin, combination therapy was associated with a significant reduction in LDL-C at 12 weeks (P<0.001). Combination therapy was associated with a significant reduction in LDL-C at 12 weeks, compared to the next highest dose of simvastatin (P<0.01). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non-HDL-C and

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day vs placebo				apo B at 12 weeks compared to simvastatin (P<0.01 for all). Averaged across all doses, combination therapy was associated with a significant increase in HDL-C compared to simvastatin (P=0.03). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non–HDL-C and apo B at 12 weeks compared to ezetimibe (P<0.01 for all). Averaged across all doses, combination therapy was associated with a significant increase in HDL-C compared to ezetimibe (P=0.02). A significantly greater proportion of patients receiving combination therapy experienced a reduction in LDL-C >50% from baseline compared to simvastatin (P value not reported). Treatment-related adverse effects were similar in the pooled simvastatin and combination therapy groups (72 vs 69%, respectively; P value not reported).
Goldberg et al.[69] (2004) Ezetimibe 10 mg/day plus simvastatin 10, 20, 40 or 80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day	DB, MC, RCT Patients ≥18 years of age with primary hypercholesterolemia, ALT and AST ≤2 times the upper limit of normal, no active liver disease, CK ≤1.5 times the upper limit of normal	N=887 20 weeks	Primary: Mean percent change from baseline in LDL-C Secondary: Mean and percent changes from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B, apo AI and hsCRP; proportion of patients	Primary: Averaged across all doses, combination therapy was associated with a significant 14.8% reduction in LDL-C at 12 weeks compared to simvastatin (53.2 vs 38.5%; P<0.001). Secondary: At each corresponding dose of simvastatin, combination therapy was associated with a significant reduction in LDL-C at 12 weeks (P<0.001). Combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to the next highest dose of simvastatin (P<0.001). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B and hsCRP at 12 weeks compared to simvastatin (P<0.001 for all). Averaged across all doses, combination therapy resulted in a greater proportion of patients reaching their NCEP ATP III LDL-C goal <130 or <100 mg/dL at 12 weeks compared to simvastatin (92 and 82% vs 82 and 43%,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs placebo			reaching their NCEP ATP III LDL-C goal <130 or <100 mg/dL at 12 weeks	respectively; P<0.001). Averaged across all doses, combination therapy was not associated with a significant change in HDL-C compared to simvastatin (P=0.53). Treatment-related adverse effects were similar in the pooled simvastatin and combination therapy groups, but were more frequent than with ezetimibe and placebo (13, 14, 9 and 9%, respectively; P values not reported).
Brown et al.[70] (2001) HATS Niacin SR (Slo-Niacin®) titrated to 1 g BID and simvastatin vs antioxidants vs niacin SR (Slo-Niacin®) titrated to 1 g BID, simvastatin, and antioxidants vs placebo Patients whose HDL-C had not increased by prespecified	DB, PC Patients with clinical coronary disease (defined as previous MI, coronary interventions or confirmed angina) and with ≥3 stenoses of ≥30% of the luminal diameter or 1 stenosis of ≥50%, low HDL-C, normal LDL-C	N=160 3 years	Primary: Changes in lipid profile, arteriographic evidence of change in coronary stenosis (% stenosis caused by most severe lesion in each of nine proximal coronary segments), occurrence of first cardiovascular event (death from coronary causes, MI, stroke or re-vascularization) Secondary: Mean change in % stenosis in lesions of varying degrees	Primary: The mean levels of LDL-C, HDL-C, and TG were significantly changed by -42% (P<0.001), 26% (P<0.001) and -36% (P<0.001), respectively, in the niacin plus simvastatin group but were unaltered in the antioxidant only and placebo groups. Similar changes were observed when antioxidants were added to niacin plus simvastatin. The protective increase in HDL_2 (considered to be the most protective component of HDL-C) with niacin plus simvastatin (65%) was attenuated by concurrent therapy with antioxidants (28%; P=0.02). The average stenosis progressed by 3.9% with placebo, 1.8% with antioxidants (P=0.16 compared to placebo) and 0.7% with niacin plus simvastatin plus antioxidants (P=0.004), and regressed by 0.4% with niacin plus simvastatin (P<0.001). The frequency of the composite primary end point (death from coronary causes, MI, stroke or revascularization) was 24% with placebos, 3% with niacin plus simvastatin, 21% with antioxidants and 14% with niacin plus simvastatin plus antioxidants. The risk of the composite primary end point was 90% lower in the niacin plus simvastatin group than placebo (P=0.03). The risk in the other treatment groups did not differ significantly from that in the placebo group. Secondary: In general, the treatment effects observed with respect to the primary angiographic end point were confirmed for the various subcategories of stenoses and were supported by the results for the mean minimal luminal diameter.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
amounts were switched to niacin IR (Niacor®) titrated to 4 g per day.			of severity, mean change in luminal diameter in proximal lesions and all lesions	
Zhao et al.[71] (2004) Niacin 2.4±2.0 g/day (mean dose) plus simvastatin 13±6 mg/day (mean dose) vs antioxidants (vitamin E 800 IU/day, vitamin C 1,000 mg/day, beta carotene 25 mg/day and selenium 100 µg/day) vs niacin plus simvastatin plus antioxidants vs placebo	ES Patients with clinical CAD (previous MI, coronary interventions or confirmed angina) including 25 with diabetes with mean LDL-C 128 mg/dL, HDL-C 31mg/dL and TG 217 mg/dL	N=160 38 months	Primary: Side effects, response to the question "Overall, how difficult is it to take the study medication?" Secondary: Not reported	Primary: Patients receiving niacin plus simvastatin experienced similar frequencies of clinical or laboratory side effects compared to placebo; any degree of flushing (30 vs 23%; P value not significant), symptoms of fatigue, nausea and/or muscle aches (9 vs 5%; P value not significant), AST at least three times the upper limit of normal (3 vs 1%; P value not significant), CPK at least two times the upper limit of normal (3 vs 4%; P value not significant), new onset of uric acid ≥7.5 mg/dL (18 vs 15%; P value not significant) and homocysteine ≥15 µmol/L (9 vs 4%; P value not significant). There were no side effects attributable to the antioxidant regimen. Glycemic control among diabetics declined mildly with niacin plus simvastatin, but returned to pre-treatment levels at month eight and remained stable for the rest of the trial. Niacin plus simvastatin was repeatedly described by 91% of treated patients vs 86% of placebo subjects as "very easy" or "fairly easy" to take. Secondary: Not reported
Stalenhoef et al.[72]	DB, DD, PG,	N=401	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
(2005) COMET Rosuvastatin 10 mg/day for 6 weeks, titrated up to rosuvastatin 20 mg/day for 6 weeks vs atorvastatin 10 mg/day for 6 weeks, titrated up to atorvastatin 20 mg/day for 6 weeks vs placebo daily for 6 weeks, followed with rosuvastatin 20 mg/day for 6 weeks	RCT Patients ≥18 years of age with metabolic syndrome, LDL-C ≥3.36 mmol/L and 10 year CHD risk score of >10%	12 weeks	Percentage change from baseline in LDL-C at six weeks Secondary: Percentage changes from baseline in TC, LDL-C, HDL-C, non-HDL-C at 12 weeks	After six weeks, rosuvastatin 10 mg was associated with a significant reduction in LDL-C compared to atorvastatin 10 mg (41.7 vs 35.7%, respectively; P<0.001) and placebo (42.7 vs 0.3%, respectively; P<0.001). Secondary: After 12 weeks, rosuvastatin 20 mg was associated with a significant reduction in LDL-C compared to atorvastatin 20 mg (48.9 vs 42.5%, respectively; P<0.001). After six and 12 weeks, rosuvastatin was associated with significantly greater improvements in TC (P<0.001), HDL-C (P<0.01) and non-HDL-C (P<0.001) compared to atorvastatin.
Constance et al.[73] (2007) Atorvastatin 20 mg/day vs ezetimibe 10 mg/day plus simvastatin 20 or	DB, MC, PG, RCT Patients ≥18 years of age, with type 2 diabetes, HbA_{1c} ≤10.0%, ALT/AST levels <1.5 times the upper limit of normal and CK	N=661 6 weeks	Primary: Change from baseline in LDL-C Secondary: Changes from baseline in TC, HDL-C, TG, non-HDL-C, apo B, LDL-	Primary: Across all doses, combination therapy was associated with a significant reduction in LDL-C compared to atorvastatin (P≤0.001). Secondary: Across all doses, combination therapy was associated with significant reductions in TC, non-HDL, apo B, LDL-C:HDL-C and TC:HDL-C compared to atorvastatin (P≤0.001 for all). Combination therapy (simvastatin 40 mg) was associated with a significant reduction in hsCRP compared to atorvastatin (P=0.006).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
40 mg/day All patients received atorvastatin 10 mg/day during a 4 week run in period.	<1.5 times the upper limit of normal		C:HDL-C and TC:HDL-C	A significantly greater proportion of patients receiving combination therapy achieved LDL-C <2.5 mmol/L compared to atorvastatin (90.5 [10-20 mg], 87.0 [10-40 mg] and 70.4%, respectively; P≤0.001). The incidence of drug-related adverse effects was similar with combination therapy and atorvastatin (0.5 [10-20 mg], 0.5 [10-40 mg] and 2.3%, respectively; P value not reported).
Kumar et al.[74] (2009) Ezetimibe 10 mg/day plus fenofibrate 160 mg/day vs atorvastatin 10 mg/day	RCT, XO Patients with hypercholesterolemia requiring pharmacotherapy	N=43 12 weeks	Primary: Percentage reduction of LDL-C Secondary: Percent changes from baseline in TC, HDL-C and TG	Primary: LDL-C decreased by 34.6 vs 36.7% with combination therapy and atorvastatin (P=0.46). Secondary: Both treatments provided similar improvements in TC (-25.1 vs -24.6%; P=0.806) and HDL-C (10.1 vs 8.9%; P=0.778). Combination therapy showed a trend towards a greater reduction in TGs (25.4 vs 14.5%; P=0.079), although there were no significant difference between the two treatments in terms of the improvement in TC:HDL-C (-29.0 vs -28.7%; P=0.904).
Goldberg et al.[75] (2009) Fenofibric acid 135 mg/day vs atorvastatin 20, 40 or 80 mg/day vs fenofibric acid 135 mg/day plus atorvastatin 20 or 40 mg/day	AC, DB, MC, RCT Patients ≥18 years of age with mixed dyslipidemia (fasting TG ≥150 mg/dL, HDL-C <40 mg/dL for men and <50 mg/dL for women and LDL-C ≥130 mg/dL after lipid therapy washout)	N=613 12 weeks	Primary: Percent changes from baseline in TG, HDL-C and LDL-C Secondary: Percent changes from baseline in VLDL-C, TC, apo B and hsCRP; safety	Primary: Combination therapy (atorvastatin 20 mg) resulted in significantly greater improvements in TG (-45.6 vs -16.5%; P<0.001) and HDL-C (14.0 vs 6.3%; P=0.005) compared to atorvastatin 20 mg and LDL-C (-33.7 vs -3.4%; P<0.001) compared to fenofibric acid. Similarly, significantly greater improvements were observed with combination therapy (40 mg) in TG (-42.1 vs -23.2%; P<0.001) and HDL-C (12.6 vs 5.3%; P=0.010) compared to atorvastatin 40 mg and LDL-C (-35.4 vs -3.4%; P<0.001) compared to fenofibric acid. Secondary: Combination therapy (20 mg) resulted in significantly higher mean percentages of decrease in non-HDL-C compared to fenofibric acid (P=0.026) and in VLDL-C compared to atorvastatin 20 mg (P=0.046). Combination therapy (40 mg) also resulted in significantly higher mean percentage of decrease in non-HDL-C compared to fenofibric acid (P<0.001) and in VLDL-

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				C compared to atorvastatin 40 mg (P<0.001). Improvements in other secondary variables were similar between combination therapy and atorvastatin (TC; P=0.688, apo B; P=0.688 and hsCRP; P=0.074).
Bays et al.[76] (2003) ADVOCATE Niacin ER-lovastatin 1,000-40 mg/day vs niacin ER-lovastatin 2,000-40 mg/day vs simvastatin 40 mg/day vs atorvastatin 40 mg/day	MC, OL, RCT Patients 18 to 70 years of age with 2 consecutive LDL-C ≥160 (if no CAD) or ≥130 mg/dL (with CAD), TG <300 mg/dL and HDL-C <45 (men) or <50 mg/dL (women)	N=315 16 weeks	Primary: Percent change from baseline in LDL-C and HDL-C Secondary: Percent change from baseline in TC, apo B, apo AI, and HDL_2-C and HDL_3-C; median percent change in TG and Lp(a)	Primary: Atorvastatin was associated with a significant 49% reduction in LDL-C compared to a 39, 42 and 39% reduction observed with niacin ER-lovastatin 1,000-40 mg, niacin ER-lovastatin 2,000-40 mg and simvastatin, respectively (P≤0.05 for all). Combination therapy was associated with a significant increase in HDL-C compared to atorvastatin and simvastatin (17, 32, 6 and 7%, respectively; P≤0.05 for all). Secondary: Combination therapy and atorvastatin were associated with significant reductions in TG compared to simvastatin (29, 49, 31 and 19%, respectively; P≤0.05 for all). Combination therapy was associated with a significant reduction in Lp(a) compared to atorvastatin and simvastatin (19, 21, 0 and 2%, respectively; P≤0.05 for all). Combination therapy and simvastatin were associated with significant increases in apo AI compared to atorvastatin (7, 14, 6 and 2%, respectively; P<0.05 for all). Combination therapy (2,000/40 mg) and atorvastatin were associated with significant reductions in apo B compared to combination therapy (2,000/40 mg) and simvastatin (38, 40, 33 and 31%, respectively; P<0.05). Combination therapy was associated with a significant increase in HDL_2-C and HDL_3-C compared to atorvastatin and simvastatin (P<0.05).
Sansanayudh et al.[77] (2010) Pitavastatin 1 mg	OL, PG, RCT Patients ≥18 years of age with hypercholesterole	N=100 8 weeks	Primary: Change from baseline in serum lipid levels	Primary: Both treatments achieved significant reductions in TC and LDL-C (P<0.05). The percentages of reduction in TC and LDL-C with pitavastatin was significantly less compared to atorvastatin (27.55 vs 32.31%; P=0.005 and 37.37 vs 45.75%; P<0.001). Pitavastatin was associated with significant

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
QD vs atorvastatin 10 mg QD	mia who had an indication for statin therapy according to the NCEP ATP III guidelines		Secondary: Proportion of patients who achieved NCEP ATP III LDL-C goal, safety, monthly cost per percent of LDL-C reduction	reductions in TG (P=0.001), while atorvastatin was not (P=0.062); however, the changes between the two treatments were not different (P=0.661). Changes in HDL-C were also not significantly different between the two treatments (P=0.294). Secondary: Overall, 79% of all patients achieved their LDL-C goal and there was no significant difference between the two treatments (74 vs 84%; P=0.220). In the high risk category (LDL-C goal <100 mg/dL), there was no difference in the proportion of patients who achieved their LDL-C goal (42.86 vs 71.43%; P=0.127). The possible adverse events of pitavastatin vs atorvastatin included muscle pain (five vs two patients), vertigo (two vs two patients), nausea (three vs one patients), vomiting (one vs one patient), headache (one vs one patient), muscle weakness (one vs zero patients) and stomach ache (zero vs one patients) (P>0.05). During the trial, two patients receiving pitavastatin withdrew from treatment due to an adverse event.
Gumprecht et al.[78] (2011) Atorvastatin 20 mg/day vs pitavastatin 4 mg/day	AC, DB, DD, MC, NI Patients 18 to 75 with type 2 diabetes mellitus (hemoglobin HbA_{1c} ≤7.5% and combined dyslipidemia and TG despite diet modification and oral antidiabetic treatment or insulin	N=418 56 weeks (12 weeks DB, 44 weeks OL extension)	Primary: Change in LDL-C at 12 weeks, proportion of patients achieving LDL-C targets at weeks 16 and 44 and safety and tolerability at 56 weeks Secondary: TC, HDL-C, TG, TC/HDL-C ratio, non-HDL-C, non-HDL-C/HDL-C	Primary: The mean percent change in LDL-C at week 12 was -40.8% for pitavastatin and -43.3% for atorvastatin. The NI analysis of changes in LDL-C at the week 12 did not fulfill the predefined NI criterion since the mean treatment difference for pitavastatin 4 mg compared to atorvastatin 20 mg was -2.33%, outside the lower bound of the 95% CI (-6.18%). A high proportion of patients in the pitavastatin and atorvastatin groups achieved lipid targets during long-term treatment (percentages not reported). Most adverse events were mild or moderate in severity with few discontinuations due to treatment-related adverse events (2.5 and 3.6% for pitavastatin and atorvastatin in the core study, and 2.1 and 1.4%, respectively, in the extension study). One patient in the pitavastatin group died of a MI during the study, which was not considered to be related to the study drug. The most common adverse events considered to be treatment related were nasopharyngitis and myalgia. The incidence of myalgia during the extension study was slightly lower in the pitavastatin group than in the atorvastatin group (4.2 vs 7.0%, respectively).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			ratio, apo B, apo AI, apo B: apo AI ratio, hs-CRP, adiponectin LDL, remnant-like particle cholesterol, oxidized LDL and safety	The incidence of clinically significant elevation of liver enzymes was low in both groups in both the core and extension studies. During the core study, mean blood glucose levels in the pitavastatin group showed a non-significant increase of 2.1% from baseline to week 12. By contrast, mean blood glucose in the atorvastatin group increased significantly from baseline to week 12 by 7.2% (P<0.05). Secondary: Mean TC, TG and non-HDL-C levels decreased from baseline in both the core study and the end of the extension study to a similar degree in both groups. There were no notable between-treatment differences in the observed effects on other lipid parameters such as TC/HDL-C ratio, non-HDL-C/HDL-C ratio and apo B. Pitavastatin and atorvastatin were similar in their effect on increasing HDL-C. By the end of the extension study, more patients receiving pitavastatin had increased their HDL-C levels. Pitavastatin and atorvastatin treatment also reduced CRP, oxidized LDL and increased levels of adiponectin to similar extents.
Yoshitomi et al.[79] (2006) Pitavastatin 1 mg QD vs atorvastatin 10 mg QD	MC, OL Patients ≥18 years of age with hypercholesterolemia (LDL >140 mg/dL and TG <400 mg/dL) treated with or without lipid lowering agents	N=137 12 weeks	Primary: Mean percent reductions from baseline in TC, LDL-C, HDL-C and TG Secondary: Safety	Primary: There were no significant differences between the two treatments in reducing baseline TC (28±8 vs 29±10%) and LDL-C (38±13 vs 41±12%) (P values not reported). There were no differences between the two treatments in increasing baseline HDL-C (3±12 vs 7±12%; P value not reported). Atorvastatin achieved a significantly greater mean percent reduction from baseline in TG compared to pitavastatin (21±25 vs 11±30%; P<0.05). Secondary: Treatment with both pitavastatin and atorvastatin was well tolerated. No serious adverse event was associated with the treatment. No adverse events of musculoskeletal, renal or hepatocellular toxicity occurred and no patient had an elevation of the CK level that was >3 times the upper limit of normal.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Lee et al.[80] (2007) Pitavastatin 2 mg QD vs atorvastatin 10 mg QD Patients who did not achieve the LDL-C goal by week 4 received a double dose of the assigned medications for an additional 4 weeks.	MC, OL, RCT Patients 20 to 79 years of age with untreated hypercholesterolemia, fasting TG <400 mg/dL and a LDL-C >130 mg/dL after a 4 week dietary lead in period	N=268 8 weeks	Primary: Changes from baseline in lipid parameters and hsCRP Secondary: Tolerability	Nine (8.2%) patients receiving pitavastatin and 12 (10.7%) patients receiving atorvastatin did not achieve the LDL-C goal by week four and received a double dose of their assigned medication for the remaining four weeks. Primary: There was no significant difference between the two treatments in the proportion of patients achieving the LDL-C goal at eight weeks (92.7 vs 92.0%; P value not reported). There was no difference between the two treatments in terms of the mean percent changes in LDL-C (-42.9 vs -44.1%), TC (-28.0 vs -29.6%), TG (-9.9 vs -11.0%), HDL-C (7.1 vs 6.7%) and hsCRP (-23.9 vs -15.4%) (P values not reported). Secondary: Both treatments were well tolerated and 21 adverse reactions considered related to study medication occurred in 14 patients receiving pitavastatin and 23 occurred in 19 patients receiving atorvastatin. There were no clinically relevant changes in laboratory values.
Sasaki et al.[81] (2008) Pitavastatin 2 mg QD vs atorvastatin 10 mg QD	MC, OL, PG, RCT Patients ≥20 years of age with LDL-C ≥140 mg/dL, HDL-C <80 mg/dL, TG <500 mg/dL and glucose intolerance	N=189 52 weeks	Primary: Percent change from baseline in serum HDL-C Secondary: Percent change from baseline in LDL-C, non-HDL-C, LDL-C:HDL-C, TG, apo AI, apo B, apo B:AI and apo E; tolerability	Primary: Pitavastatin was associated with an increase in HDL-C of 8.2%, which was significantly greater than atorvastatin (2.9%; P=0.031). Secondary: Atorvastatin was associated with significant reductions LDL-C (-40.1 vs -33.0%; P=0.002), non-HDL-C (-37.4 vs -31.1%; P=0.004), apo B (-35.1 vs -28.2%; P<0.001) and apo E (-28.1 vs -17.8%; P<0.001) compared to pitavastatin. There were no differences between the two treatments in terms of changes in LDL-C:HDL-C, apo B:AI and TG. Apo AI increased significantly more with pitavastatin compared to atorvastatin (5.1 vs 0.6%; P=0.019).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Effects on glucose metabolism were similar between the two treatments, measured by fasting plasma insulin, FPG and HbA_{1c}. Initiation of medication use for the treatment of diabetes occurred at a similar rate with both treatments (11%). Adverse events occurred at a similar rate between the two treatments.
Saito et al.[82] (2002) Pitavastatin 2 mg/day vs pravastatin 10 mg/day	DB, MC, PG, RCT Patients 20 to 75 years of age with primary hyperlipidemia (TC ≥200 mg/dL and TG <400 mg/dL)	N=240 12 weeks	Primary: Mean percent changes from baseline in TC, LDL-C and TG Secondary: Mean percent changes from baseline in apo B, apo CII, apo CIII and apo E; safety	Primary: Pitavastatin achieved significantly greater mean percent reductions from baseline in TC and LDL-C (28.2 and 37.6%) compared to pravastatin (14.0 and 18.4%; both P<0.001). In cases of a baseline TG level ≥150 mg/dL, the mean percent reduction of TG with pitavastatin (23.3%) showed non-inferiority to that observed with pravastatin (20.2%; P=0.024). Secondary: Mean percent reductions in apo B, apo CII, apo CIII and apo E with pitavastatin (33.8, 15.7, 9.5 and 22.9%) were significantly greater compared to pravastatin (16.9, 6.1, 2.6 and 12.6%; P values not reported). The adverse event profile was similar for both treatments and neither treatment caused clinically relevant laboratory abnormalities. Three patients receiving pitavastatin and two patients receiving pravastatin withdrew from the study due to adverse events considered to be drug-related.
Stender et al.[83] (2013) Pitavastatin (1, 2, or 4 mg) vs pravastatin (10, 20, or 40 mg)	DB, PG, RCT Elderly (≥65 years of age) patients with primary hypercholesterolemia or mixed dyslipidemia with LDL-C between 130 mg/dL and 220 mg/dL despite dietary therapy	N=942 12 week treatment period (6 to 8 week wash-out/dietary period before randomization)	Primary: Percentage change in LDL-C from baseline Secondary: Other lipid parameters; safety	Primary: Mean LDL-C concentrations fell from baseline to endpoint in a dose-dependent manner in all treatment groups. Pitavastatin met the primary endpoint of non-inferiority in LDL-C reduction compared with pravastatin at all dose comparisons (low-dose group, pitavastatin 1 mg vs pravastatin 10 mg; intermediate-dose group, 2 mg vs 20 mg; and higher-dose group, 4 mg vs 40 mg). Secondary: Plasma concentrations of TC, non-HDL-C, oxidized LDL-C, the non-HDL-C:HDL-C ratio, the TC:HDL-C ratio, Apo-B and the Apo-B:Apo-A1 ratio decreased significantly more with pitavastatin than with pravastatin. The percentage of patients who reported at least one treatment-emergent

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				adverse event (TEAE) was comparable between groups and ranged from 49.0 to 55.3%. There was no indication of a relationship between TEAE incidence and dose.
Park et al.[84] (2005) Pitavastatin 2 mg QD vs simvastatin 20 mg QD	MC, OL, Phase III, PRO, RCT Patients 20 to 75 years of age with hypercholesterolemia, fasting TG <600 mg/dL and LDL-C >130 mg/dL after a 4 week dietary lead in period	N=104 8 weeks	Primary: Mean percent change from baseline in LDL-C Secondary: Mean percent change from baseline in TC, TG and HDL-C; safety	Primary: There was no significant difference between the two treatments in the reduction in LDL-C (11.6 vs 12.9%; P=0.648). Secondary: There were no significant differences between the two treatments in the changes in TC (-8.9 vs -8.7%; P=0.405), TG (-20.6 vs 36.9%; P=0.147), or HDL-C (13.4 vs 16.2%; P=0.127). No serious adverse events were observed in either treatment. One patient receiving pitavastatin and four patients receiving simvastatin had to discontinue the study medication due to adverse events. Elevations in CK greater than two times upper limit of normal were observed in 3.8 and 9.8% of pitavastatin- and atorvastatin-treated patients (P=0.269). Mild elevations in AST less than two fold times upper limit of normal was observed in one patient receiving simvastatin.
Ose et al.[85] (2009) Pitavastatin 2 or 4 mg/day vs simvastatin 20 or 40 mg/day	AC, DB, DD, PRO, RCT Patients diagnosed with either primary hypercholesterolemia or combined dyslipidemia	N=857 12 weeks	Primary: Changes in lipid panel Secondary: Safety profiles	Primary: Pitavastatin 2 mg was associated with a significant improvement in LDL-C, non-HDL-C and TC compared to simvastatin 20 mg (P=0.014, 0.021 and 0.041 respectively). LDL-C was reduced by 39% with pitavastatin 2 mg compared to 35% with simvastatin 20 mg. Pitavastatin 4 mg and simvastatin 40 mg had similar effects on the lipid panel. Reductions in LDL-C were 44% with pitavastatin 4 mg and 43% for simvastatin 40 mg. Secondary: Safety profiles were similar at all dose levels.
Eriksson et al.[86] (2011) Pitavastatin 4 mg/day	AC, DB, DD, MC, NI, PG, RCT Patients 18 to 75 years of age with primary	N=355 12 weeks	Primary: Percentage change in LDL-C from baseline Secondary:	Primary: The mean LDL-C concentrations decreased from baseline by -44.0% with pitavastatin compared to -43.8% with simvastatin. The adjusted mean treatment difference was 0.31%, which was within the predefined limits of NI (95% CI, -2.47 to 3.09; P=0.829).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs simvastatin 40 mg/day	hypercholesterolemia or combined dyslipidemia that was uncontrolled (LDL-C ≥130 mg/dL and ≤5,220 mg/dL; TG ≤400 mg/dL) despite dietary measures, and at least two cardiovascular risk factors		Proportion of patients reaching LDL-C targets, percentage changes from baseline in concentrations of TG, TC, HDL-C, non-HDL-C, apo B and apo AI, and absolute changes from baseline in concentrations of oxidized LDL, CRP and ratios of TC:HDL-C, non-HDL:HDL-C, and apo B/apo A1 and safety	Secondary: There was no statistically significant difference in the proportion of patients achieving NCEP LDL-C targets (87.1 vs 85.6%; P=0.695) or EAS LDL-C targets (87.1 vs 81.4%; P=0.170) between patients treated with pitavastatin or simvastatin. Pitavastatin provided a significantly greater reduction in triglycerides compared to simvastatin (-19.8 vs -14.8%; P=0.044), as well as a greater increase in HDL-C with pitavastatin (6.8 vs 4.5%), which was not statistically significant (P=0.083). There were no other significant differences in secondary lipid measures between the two groups. Treatment-emergent adverse events occurred in 51.1% of patients receiving pitavastatin and 50.4% of patients receiving simvastatin. The most commonly reported treatment-emergent adverse events were headache, nasopharyngitis, constipation, myalgia and back pain.
Rosenson et al.[87] (2009) Rosuvastatin 10 mg QD for 6 weeks, followed by 20 mg thereafter vs atorvastatin 10 mg QD for 6	DB, MC, PC, RCT Patients ≥18 years of age with the metabolic syndrome, LDL-C 130 to 250 mg/dL and a 10-year CHD risk score >10%	N=318 12 weeks	Primary: Lipoprotein particle concentrations Secondary: Not reported	Primary: After six weeks of therapy, rosuvastatin 10 mg and atorvastatin 10 mg significantly reduced LDL-C, LDL particle concentration, apo B, and non-HDL-C compared to placebo (P<0.001). Rosuvastatin significantly reduced LDL-C (P<0.001), LDL particle concentration (P<0.05), and non-HDL-C (P<0.01) compared to atorvastatin after six and 12 weeks. After six weeks of therapy, rosuvastatin 10 mg and atorvastatin 10 mg significantly reduced VLDL particle concentration and serum triglycerides compared to placebo (P<0.001). There was no difference between the two statins on either end point at week 6 or 12.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
weeks, followed by 20 mg thereafter vs placebo				After six weeks of therapy, rosuvastatin 10 mg increased HDL particle concentration (15%) and HDL-C (10%) compared to placebo (P<0.001). Atorvastatin significantly increased HDL particle concentration compared to placebo (6%, P=0.013); however, there was no difference in HDL-C (4%, P=0.45). Rosuvastatin significantly increased HDL particle concentration and HDL-C compared to atorvastatin after six and 12 weeks (P≤0.002). Neither statin showed a significant effect on apo AI compared to placebo; however, increases in apo AI were significantly greater with rosuvastatin than atorvastatin at six and 12 weeks (P=0.001 and P=0.02, respectively). A higher proportion of patients receiving rosuvastatin achieved LDL-C <100 mg/dL compared to atorvastatin at six and 12 weeks (P<0.01 and P<0.0001, respectively). Patients receiving rosuvastatin achieved LDL particle concentration <1,300 nmol/L at 12 weeks (P=0.02) and <1,000 nmol/L at six weeks (P=0.02) compared to atorvastatin. The percentage of patients who attained LDL particle concentration <1,300 nmol/L was similar to that achieving LDL-C <100 mg/dL. Secondary: Not reported
Park et al.[88] (2010) Rosuvastatin 10 mg/day vs atorvastatin 10 mg/day	MC, OL, PG Patients ≥18 years of age with nondiabetic metabolic syndrome and hypercholesterolemia	N=351 6 weeks	Primary: Percent change from baseline in TC, LDL-C, HDL-C, TG, non-HDL-C, apo AI and apo B; proportion of patients achieving NCEP ATP III LDL-C goals (<100, <130	Primary: After six weeks, significantly greater reductions in TC (35.94±11.38 vs 30.07±10.46%; P<0.001), LDL-C (48.04±14.45 vs 39.52±14.42%; P<0.001), non-HDL-C (42.93±13.15 vs 35.52±11.76%; P<0.001) and apo B (38.7±18.85 vs 32.57±17.56%; P=0.002) were achieved with rosuvastatin compared to atorvastatin. No differences between treatments were observed in changes in HDL-C (P=0.448), TG (P=0.397) and apo AI (P=0.756). Overall, the proportion of patients achieving the LDL-C goals was significantly greater with rosuvastatin compared to atorvastatin (87.64 vs 69.88%; P<0.001). Corresponding proportions for the LDL-C goals <100,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			and <160 mg/dL); change from baseline in metabolic parameters; safety Secondary: Not reported	<130 and <160 mg/dL were: 82.7 vs 59.2 (P<0.001), 94.3 vs 84.2 (P=0.032) and 96.8 vs 97.3% (P=0.990). Changes in glucose (P=0.231), insulin (P=0.992), HbA_{1c} (P=0.456) and HOMA index (P=0.910) were not significantly different between the two treatments. The safety and tolerability of the two treatments were similar. Secondary: Not reported
Mazza et al.[89] (2008) Rosuvastatin 10 mg QD vs atorvastatin 20 mg QD	OL, RCT Patients 18 to 65 years of age with primary hypercholesterolemia (LDL-C >200 mg/dL) and at high risk for CHD	N=106 48 weeks	Primary: Plasma levels of TC, TG, LDL-C HDL-C, non-HDL-C Secondary: Not reported	Primary: After 48 weeks of treatment, atorvastatin significantly lowered TC, LDL-C, and non HDL-C levels (-21.6; -30; -26.98%, respectively; P<0.001 combined). HDL-C levels increased 4.52% (P value not significant) TG levels decreased 4.62% (P value not significant). After 48 weeks of treatment, rosuvastatin significantly lowered TC, LDL-C, non HDL-C, and TG levels (-35.77, -44.32, -43.12, -36.41%, respectively; P<0.001 combined). HDL-C level also decreased -2.04% (P value not significant). Rosuvastatin was more effective than atorvastatin in reducing plasma levels of TC, LDL-C, non-HDL-C and TG (-35.77, -44.32, -43.12, -36.41%, respectively, with rosuvastatin vs -21.62, -30, -26.98, -4.62%, respectively, with atorvastatin; P<0.005). Both drugs had no significant effect on plasma HDL-C levels relative to baseline. There were no significant differences in either treatment group in parameters related to safety. Secondary: Not reported
Betteridge et al.[90] (2007) ANDROMEDA	DB, MC, PG, RCT Patients ≥18 years	N=509 16 weeks	Primary: Percentage change from baseline in	Primary: Rosuvastatin was associated with a significant reduction in LDL-C compared to atorvastatin (57.4 vs 46.0%; P=0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Rosuvastatin 10 mg/day for 8 weeks, titrated up to 20 mg/day for 8 weeks vs atorvastatin 10 mg/day for 8 weeks, titrated up to 20 mg/day for 8 weeks All patients were randomized after a 4 week dietary lead in period.	of age with type 2 diabetes, ≥2 FPG levels of ≥7 mmol/L and TG ≤6 mmol/L		LDL-C Secondary: Percentage changes from baseline in LDL-C, TC, HDL-C, TG, non-HDL-C, cholesterol ratios, apo B, apo ratio and HbA_{1c}; proportion of patients achieving 2003 Joint European Societies LDL-C (<2.5 mmol/L) and TC (<4.5 mmol/L) goals	Secondary: Rosuvastatin was associated with a significant reduction in apo ratio, LDL-C:HDL-C, TC, TC:HDL-C, non-HDL-C and apo B compared to atorvastatin (P<0.001). Rosuvastatin was associated with a significant reduction in HbA_{1c} compared to atorvastatin (P=0.049). A significantly greater proportion of patients receiving rosuvastatin achieved LDL-C goals compared to patients receiving atorvastatin (95.6 vs 87.3%; P=0.002). A significantly greater proportion of patients receiving rosuvastatin achieved TC goals compared to patients receiving atorvastatin (93.4 vs 86.0%; P=0.01).
Betteridge et al.[91] (2007) ANDROMEDA Rosuvastatin 10 mg/day for 8 weeks, titrated up to 20 mg/day for 8 weeks vs atorvastatin 10 mg/day for 8 weeks, titrated up	Subanalysis of ANDROMEDA Patients ≥18 years of age with type 2 diabetes, ≥2 FPG levels of ≥7 mmol/L and TG of ≤6 mmol/L	N=509 16 weeks	Primary: Composite of changes from baseline in hsCRP <2 mg/L and LDL-C <70 mg/dL Secondary: Not reported	Primary: Rosuvastatin was associated with a significant reduction in the primary endpoint compared to atorvastatin (58 vs 37%; P<0.001). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
to 20 mg/day for 8 weeks All patients were randomized after a 4 week dietary lead in period.				
Clearfield et al.[92] (2006) PULSAR Rosuvastatin 10 mg QD vs atorvastatin 20 mg QD	MC, OL, PG, RCT Patients ≥18 years of age with hypercholesterolemia and either a history of CHD or a CHD risk equivalent, with the mean of the 2 most recent LDL-C (within 15% of each other) ≥130 to <220 mg/dL, as well as TG <400 mg/dL	N=996 6 weeks	Primary: Percentage change from baseline in LDL-C Secondary: Proportion of patients achieving the NCEP ATP III and the 2003 European LDL-C goals (<100 mg/dL), the 2003 European LDL-C goal for patients at greatest risk, the NCEP ATP III non-HDL-C goal (<130 mg/dL), combined LDL-C:TC goal <175 to 190 mg/dL; percentage	Primary: Rosuvastatin was associated with a significant reduction in LDL-C compared to atorvastatin (42.7 vs 44.6%; P<0.05). Secondary: A significantly greater proportion of patients receiving rosuvastatin achieved NCEP ATP III and the 2003 European LDL-C goals compared to patients receiving atorvastatin (68 vs 63%; P<0.05). In addition, a significantly greater proportion of high risk CHD patients receiving rosuvastatin achieved the 2003 European LDL-C goals compared to high risk CHD patients receiving atorvastatin (65.6 vs 60.3%; P>0.05). A nonsignificant greater proportion of patients receiving rosuvastatin achieved the NCEP ATP III non-HDL-C goal compared to patients receiving atorvastatin (69.7 vs 65.0%; P>0.05). A nonsignificant greater proportion of patients receiving rosuvastatin achieved the NCEP ATP III combined LDL-C:TC goal compared to atorvastatin (55.2 vs 53.3%; P>0.05). Rosuvastatin was associated with a significant increase in HDL-C compared to atorvastatin (6.4 vs 3.1%; P<0.001). There was no difference in the changes of TC, TG, non-HDL-C and apo B observed with rosuvastatin and atorvastatin (P>0.05). Rosuvastatin was associated with a significant reduction in LDL-C:HDL-C compared to atorvastatin (47.6 vs 44.0%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			changes from baseline in HDL-C, TC, TG, non-HDL-C, apo B, LDL-C:HDL-C, TC:HDL-C, non-HDL-C:HDL-C and Lp(a); safety	Rosuvastatin was associated with a significant reduction in TC:HDL-C compared to atorvastatin (34.6 vs 32.3%; P<0.01). Rosuvastatin was associated with a significant reduction in non-HDL-C:HDL-C compared to atorvastatin (43.3 vs 40.2%; P<0.001). Atorvastatin was associated with a significant increase in Lp(a) compared to rosuvastatin (13.3 vs 2.1%; P<0.001). The frequency and type of adverse events were similar with both treatments (27.5 vs 26.1%; P value not reported). The most commonly reported adverse effects were myalgia and urinary tract infections.
Deedwania et al.[93] (2007) IRIS Rosuvastatin 10 or 20 mg/day vs atorvastatin 10 or 20 mg/day All patients were randomized after a 6 week dietary lead in period.	MC, OL, RCT South-Asian patients ≥18 years of age with CHD or CHD risk equivalent and LDL-C ≥100 mg/dL or ≥2 risk factors, 10 year CHD risk 10 to 20% and LDL-C ≥130 mg/dL or 0 to 1 risk factor and LDL-C ≥160 mg/dL, with TG <500 mg/dL	N=740 6 weeks	Primary: Percentage change from baseline in LDL-C Secondary: Proportion of patients achieving NCEP ATP III LDL-C goals; percentage change from baseline in non-HDL-C, HDL-C, TC and TG; safety	Primary: At six weeks, rosuvastatin 10 mg was associated with a significant reduction in LDL-C compared to atorvastatin 10 mg (P=0.0023). The difference in LDL-C reduction from baseline at six weeks between rosuvastatin 20 mg and atorvastatin 20 mg was not significant (P value not reported). Secondary: The proportion of patients achieving NCEP ATP III LDL-C goals was similar with rosuvastatin 10 and 20 mg and atorvastatin 10 and 20 mg (79, 89, 76 and 85%, respectively; P value not reported). At six weeks, rosuvastatin 10 mg was associated with a significant reduction in LDL-C:HDL-C compared to atorvastatin 10 mg (P<0.017). There were no clinically relevant differences between treatments in adverse events or incidence of CK >10 times the upper limit of normal, ALT >3 times the upper limit of normal, proteinuria or hematuria.
Ferdinand et al.[94] (2006) ARIES Rosuvastatin 10 or 20 mg QD	OL, RCT African American patients ≥18 years of age with LDL ≥160 to ≤300	N=774 6 weeks	Primary: The change from baseline in LDL-C Secondary:	Primary: Rosuvastatin was associated with a significant reduction in LDL-C compared to atorvastatin (P<0.017). Secondary: Rosuvastatin was associated with a significant reduction in TC, non-HDL-C,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs atorvastatin 10 or 20 mg QD All patients were randomized after a 6 week dietary lead in period.	mg/dL, TG <400 mg/dL		Changes from baseline in other lipid parameters	apo B and lipoprotein and apo ratios compared to atorvastatin (P<0.017). Rosuvastatin was associated with a significant increase in HDL-C compared to atorvastatin (P<0.017). Adverse events were similar with rosuvastatin and atorvastatin (34.4 and 33.6%, respectively; P value not reported).
Lloret et al.[95] (2006) STARSHIP Rosuvastatin 10 or 20 mg QD vs atorvastatin 10 or 20 mg QD All patients were randomized after a 6 week dietary lead in period.	MC, OL, RCT Hispanic American patients ≥18 years of age with a 10 year risk >10% for CHD, current CHD or its equivalent, LDL ≥130 to ≤300 mg/dL on 2 measurements within 15% of each other, TG <400 mg/dL	N=696 6 weeks	Primary: Percent change from baseline in LDL-C Secondary: Proportion of patients achieving NCEP ATP III lipid goals; percent change from baseline in TC, apo B, non-HDL-C, TG, HDL, apo AI, LDL-C:HDL-C, TC:HDL-C and apo B:apo AI; safety	Primary: Rosuvastatin 10 and 20 mg was associated with a significant reduction in LDL-C compared to atorvastatin 10 and 20 mg (45, 50, 36 and 42%, respectively; P<0.0001). Secondary: A greater proportion of patients receiving rosuvastatin 10 and 20 mg achieved LDL-C goals compared to atorvastatin 10 and 20 mg (78, 88, 60 and 73%, respectively; P value not reported). Rosuvastatin 10 and 20 mg was associated with a significant reduction in TC compared to atorvastatin 10 and 20 mg (10 mg; P<0.0001, 20 mg; P<0.01, respectively). Rosuvastatin 10 and 20 mg was associated with a significant reduction in apo B compared to atorvastatin 10 and 20 mg (10 mg; P<0.0001, and 20 mg; P<0.017, respectively). Rosuvastatin 10 and 20 mg was associated with a significant reduction in LDL-C:HDL-C compared to atorvastatin 10 and 20 mg, respectively, at six months (P<0.0001 for both, respectively). Rosuvastatin 10 and 20 mg was associated with a significant reduction in TC:HDL-C compared to atorvastatin 10 and 20 mg (10 mg; P<0.0001, 20 mg; P<0.01, respectively). Rosuvastatin 10 and 20 mg was associated with a significant reduction in non-

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				HDL-C:HDL-C compared to atorvastatin 10 and 20 mg (10 mg; P<0.0001, 20 mg; P<0.01, respectively). Rosuvastatin 10 and 20 mg was associated with a significant reduction in apo B:apo AI compared to atorvastatin 10 and 20 mg (P<0.01 for both, respectively). Adverse events were similar between treatments (P value not reported). There were no cases of myopathy, rhabdomyolysis or clinically significant increases in serum CK.
Milionis et al.[96] (2006) ATOROS Rosuvastatin 10 mg QD for 6 weeks, titrated to 20 mg/day vs atorvastatin 20 mg QD for 6 weeks, titrated to 40 mg/day All patients were randomized after a 6 week dietary lead in period.	OL, PG, RCT Adult patients free of symptomatic ischemic heart disease or any other clinically evident heart disease, at moderate risk for CHD according to NCEP ATP classification, with baseline TC >240 mg/dL and TG <350 mg/dL	N=180 24 weeks	Primary: Proportion of patients achieving the NCEP ATP III LDL-C goal (<130 mg/dL) Secondary: Changes from baseline in LDL-C, HDL-C, TC, TG, non-HDL-C and apo B	Primary: After six weeks, 75.0 and 71.7% of patients achieved the NCEP ATP III LDL-C goal with rosuvastatin and atorvastatin, respectively (P value not reported). Secondary: Both rosuvastatin and atorvastatin were associated with significant reductions in LDL-C (48.7 vs 44.6%; P<0.001). Rosuvastatin was associated with a significant five percent increase in HDL-C (P<0.001). Atorvastatin was associated with a significant 2.1% reduction in HDL-C (P<0.001). Compared to atorvastatin, rosuvastatin was associated with a significantly greater increase in HDL-C (P=0.002). Both rosuvastatin and atorvastatin were associated with significant reductions in TC (36.1 vs 36.9%; P<0.001). Both rosuvastatin and atorvastatin were associated with significant reductions in TG (29.0 vs 27.8%; P<0.001). Both rosuvastatin and atorvastatin were associated with significant reductions in non-HDL-C (45 vs 46%; P<0.001). Both rosuvastatin and atorvastatin were associated with significant reductions in apo B (29 vs 26%; P<0.001). The incidence of myalgia was similar with both treatments (3%; P value not reported). There were no reports of significant ALT or CK elevations.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Ai et al.[97] (2008) STELLAR Rosuvastatin 40 mg/day vs atorvastatin 80 mg/day	OL Patients ≥18 years of age with hypercholesterolemia, LDL-C ≥160 to <250 mg/dL and TG <400 mg/dL	N=271 6 weeks	Primary: Changes from baseline in direct LDL-C and small dense LDL-C Secondary: Percentage changes from baseline in HDL-C, TC, TG, non-HDL-C and TC:HDL-C	Primary: Rosuvastatin was associated with a significant reduction from baseline in direct LDL-C compared to atorvastatin (52 vs 50%; P=0.01). Rosuvastatin was associated with a significant reduction from baseline in small dense LDL-C compared to atorvastatin (53 vs 46%; P<0.001). Secondary: Rosuvastatin was associated with a significant increase from baseline in HDL-C compared to atorvastatin (10 vs 2%; P<0.001). There was no difference between treatments in TC (P=0.10) and TG (P=0.50) reductions. Rosuvastatin was associated with a significant reduction in non-HDL-C compared to atorvastatin (51 vs 48%; P<0.0078). Rosuvastatin was associated with a significant reduction in TC:HDL-C compared to atorvastatin (46 vs 39%; P<0.001).
Leiter et al.[98] (2007) POLARIS Rosuvastatin 40 mg QD vs atorvastatin 80 mg QD	DB, PG, RCT Patients 45 to 80 years of age with hypercholesterolemia and a history of CHD, clinical evidence of atherosclerosis or a 10 year Framingham CHD risk score >20%, with LDL-C ≥160 to <250 mg/dL and TG <400 mg/dL	N=871 26 weeks	Primary: The percentage change from baseline in LDL-C levels at week eight Secondary: Percentage change from baseline in LDL-C levels at week 26, percentage change from baseline in other lipids and lipoproteins at	Primary: After eight weeks, rosuvastatin was associated with a significantly greater reduction in LDL-C compared to atorvastatin (56 vs 52%; P<0.001). Secondary: After 26 weeks, rosuvastatin was associated with a significantly greater reduction in LDL-C compared to atorvastatin (57 vs 53%; P value not reported). After eight weeks, rosuvastatin was associated with a significantly greater reduction in TG (27.0 vs 22.2%; P<0.05), non-HDL-C (50.8 vs 48.3%; P<0.01), LDL-C:HDL-C (58.5 vs 53.6%; P<0.001), TC:HDL-C (44.4 vs 41.1%; P<0.001), non-HDL-C:HDL-C (53.6 vs 49.6%; P<0.001), apo B (44.6 vs 42.3%; P<0.05) and apo AI (4.2 vs -0.5%; P<0.001) compared to atorvastatin. After eight weeks, rosuvastatin was associated with a significantly greater increase in HDL-C compared to atorvastatin (9.6 vs 4.4%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			weeks eight and 26, proportion of patients achieving NCEP ATP III and 2003 European lipid goals at eight and 26 weeks, safety	After six weeks, a significantly greater proportion of patients receiving rosuvastatin achieved the NCEP ATP III LDL-C goals of <100 (80 vs 72%; P<0.01) and <70 mg/dL (36 vs 18%; P<0.001) compared to patients receiving atorvastatin. After six weeks, a significantly greater proportion of patients receiving rosuvastatin achieved the 2003 European lipid goals compared to patients receiving atorvastatin (79 vs 69%; P<0.001). The incidence of drug-related adverse events was low with both treatments (0.5 vs 0.2%; P value not reported).
Wolffenbuttel et al.[99] (2005) CORALL Rosuvastatin 10 mg QD for 6 weeks, titrated to 20 mg QD for 6 weeks, titrated to 40 mg QD for 6 weeks vs atorvastatin 20 mg QD for 6 weeks, titrated to 40 mg QD for 6 weeks, titrated to 80 mg QD for 6 weeks All patients were randomized after	MC, OL, PG, RCT Patients ≥18 years of age with type 2 diabetes for ≥3 months, LDL ≥3.36 mmol/L in statin naïve patients or LDL 2.99 to 5 mmol/L in patients exposed to statin therapy within the previous 4 weeks, TG <4.52 mmol/L and HbA_{1c} <10.0%	N=265 24 weeks	Primary: Reduction in LDL-C, HDL-C, apo ratio, LDL-C:HDL-C, TC, TC:HDL-C, non-HDL-C, TG and apo B; percentage of patients who achieved LDL-C goals (<2.6 or <2.5 mmol/L) at 18 weeks Secondary: Not reported	Primary: Rosuvastatin and atorvastatin were associated with significant reductions from baseline in LDL-C, apo ratio, LDL-C:HDL-C, TC, TC:HDL-C, non-HDL-C, TG and apo B (P<0.001). Rosuvastatin was associated with significant reduction in LDL-C (P<0.01), apo ratio (P<0.05), LDL-C:HDL-C (P<0.01), TC (P<0.05), TC:HDL-C (P<0.05), non-HDL-C (P<0.05) and apo B (P<0.05) compared to atorvastatin. A significantly greater percentage of patients receiving rosuvastatin achieved LDL-C goals at 18 weeks compared to patients receiving atorvastatin (P<0.05). The incidence of treatment-related adverse events was similar between the two treatments (47 vs 50%, respectively; P value not reported). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
a 6 week dietary lead in period.				
Bullano et al.[100] (2007) Rosuvastatin (mean daily dose, 11 mg) vs atorvastatin (mean daily dose, 15 mg)	RETRO Patients ≥18 years of age, initiated on rosuvastatin or atorvastatin between August 1, 2003 and September 30, 2004 with ≥1 lipid level (LDL-C, TG, HDL-C, TC) obtained prior to and after therapy initiation	N=453 Up to 79 days of therapy	Primary: Percentage change from baseline in LDL-C Secondary: Proportion of patients achieving the NCEP ATP III LDL-C goals (<100 mg/dL), percentage change from baseline in HDL-C, TC, TG and non-HDL-C	Primary: Rosuvastatin was associated with a significant reduction in LDL-C compared to atorvastatin (35 vs 26%; P<0.001). Secondary: A significantly greater proportion of patients receiving rosuvastatin achieved NCEP ATP III LDL-C goals compared to atorvastatin, when adjusted for age, sex, LDL-lowering required to reach goal, risk category and duration of therapy (74 vs 65%; P<0.05). Unadjusted attainment rates were similar with both treatments (P=0.088). Patients receiving rosuvastatin required greater LDL-C reduction to reach their LDL-C goal compared to patients receiving atorvastatin (26.3 vs 23.5%; P<0.05). In addition, significantly more patients receiving rosuvastatin reached the updated, optional NCEP ATP III LDL-C goals compared to patients receiving atorvastatin (61 vs 48%; P<0.05). There was no difference between the two treatments in the change in HDL-C (P=0.234). Rosuvastatin was associated with a greater reduction in TC compared to atorvastatin (26 vs 20%; P<0.001). There was no difference between the two treatments in the change in TG (P=0.192). Rosuvastatin was associated with a significant reduction in non-HDL-C compared to atorvastatin (33 vs 25%; P<0.001).
Wlodarczyk et al.[101] (2008) Rosuvastatin 5, 10, 20 or 40 mg/day vs	MA (25 head-to-head RCTs) Patients with hypercholesterolemia	N=19,621 Mean 8.6 weeks (range, 4 to 12 weeks)	Primary: Change from baseline in LDL-C Secondary: Safety	Primary: At equivalent doses, rosuvastatin produced significantly larger reductions in LDL-C compared to atorvastatin (mean treatment difference, -8.52%; 95% CI, -9.23 to -7.81) or a two times higher atorvastatin dose (-3.24%; 95% CI, -4.10 to -2.38). No difference between the two treatments were observed when rosuvastatin was compared to a four times higher atorvastatin dose (1.12%; 95% CI, -0.24 to 2.48). Results were similar for DB and OL trials. The percentage of LDL-C decrease associated with rosuvastatin ranged from

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
atorvastatin 10, 20, 40 or 80 mg/day				41.0 to 56.0% for the 5 and 40 mg dosing regimens, respectively. Atorvastatin ranged from 37.2 to 51.3% for the 10 and 80 mg dosing regimens. Secondary: Event rates for myalgia ranged from 3.5 to 4.2% for atorvastatin 80 mg and rosuvastatin 5 mg. No clear dose-response relation was evident for either treatment and no difference between the two treatments was noted. Rates of withdrawal were low, ranging from 4.1 to 6.4% for rosuvastatin 5 mg and atorvastatin 40 mg. Rates due to adverse events were similar between the two treatments. At the 1:1 dose ratio, the trend toward a higher rate with rosuvastatin did not reach significance (OR, 1.258; 99% CI, 0.972 to 1.627). This trend was no longer evident when only DB trials were included (OR, 0.89; 95% CI, 0.48 to 1.63). Serious adverse events tended to be lower with rosuvastatin at each dose ratio, but there was no strong evidence of a treatment effect. There were nine patients with CK >10 times the upper limit of normal and 23 deaths were reported. Rates of ALT greater than three times the upper limit of normal were highest with atorvastatin 80 mg (2.2/100 patients) and rosuvastatin 40 mg (0.8/100 patients). Within treatment MA showed that GFR tended to increase with atorvastatin and rosuvastatin by 3.8% (99% CI, 2.77 to 4.77) and 2.7% (99% CI, 1.79 to 3.58). No difference was noted between the two treatments.
Fox et al.[102] (2007) Rosuvastatin vs simvastatin	RETRO Adult patients ≥18 years of age switching to either rosuvastatin or simvastatin from another statin between August 2003 and March 2006, not	N=277 Patients received statin therapy between August 2003 and March 2006	Primary: Percent reduction from baseline in LDL-C Secondary: Not reported	Primary: A switch to rosuvastatin was associated with a significant reduction in LDL-C compared to a switch to simvastatin (18.5 vs 5.8%; P<0.05). A significantly greater proportion of patients who switched to rosuvastatin achieved a LDL-C reduction >25% compared to those who switched to simvastatin (44 vs 29%; P<0.05). Patients who switched from atorvastatin to rosuvastatin experienced a significantly greater reduction in LDL-C compared to those who switched to simvastatin therapy (14.6 vs 4.6%; P<0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	receiving other antidyslipidemic medications in the 12 months before or after initiating statin therapy			Secondary: Not reported
Bullano et al.[103] (2006) Rosuvastatin 5 to 40 mg/day vs other statins (atorvastatin 10 to 80 mg/day, simvastatin 5 to 80 mg/day, pravastatin 10 to 80 mg/day, lovastatin 10 to 80 mg/day and fluvastatin 20 to160 mg/day)	RETRO Patients ≥18 years of age initiated on a statin between August 1, 2003 and September 30, 2004 with ≥1 LDL-C level obtained prior to and after therapy initiation	N=8,251 Up to 122 days of therapy	Primary: Percentage change from baseline in LDL-C Secondary: Proportion of patients achieving the NCEP ATP III LDL-C goals (<100 mg/dL), percentage change from baseline in HDL-C, TC and TG	Primary: Rosuvastatin was associated with a significant reduction in LDL-C compared to other statins (33 vs 24 [atorvastatin], 20 [simvastatin], 18 [pravastatin], 13 [fluvastatin] and 16% [lovastatin]; P<0.05). Rosuvastatin 10 mg/day was associated with a significantly greater reduction in LDL-C compared to atorvastatin 10 to 20 mg/day (P<0.05) or simvastatin 10 to 20 mg/day (P<0.05). Secondary: A significantly greater proportion of patients receiving rosuvastatin achieved the NCEP ATP III LDL-C goals compared to patients receiving other statins (P<0.05). Patients receiving rosuvastatin required greater LDL-C reduction to reach their LDL-C goal compared to patients treated with other statins (29 vs 23 to 27%; P<0.05). A significantly greater proportion of patients receiving rosuvastatin achieved the updated, optional NCEP ATP III LDL-C goals compared to patients receiving other statins (58 vs 29 to 48%; P<0.05). There was no difference between rosuvastatin and other statins in HDL-C reductions (P>0.05). Rosuvastatin was associated with a significant reduction in TC compared to other statins (24% vs 18 [atorvastatin], 14 [simvastatin], 13 [pravastatin], 10 [fluvastatin] and 13% [lovastatin]; P<0.05). Rosuvastatin was associated with a significant reduction in TG compared to other statins (11% vs 6 [simvastatin], 4 [pravastatin], 4 [fluvastatin] and 5% [lovastatin]; P<0.05). There was no difference in TG reduction between rosuvastatin and atorvastatin (11 vs 10%; P>0.05).
Nicholls et al.[104] (2010) VOYAGER	MA (37 trials) Patients with	N=32,258 Variable	Primary: Impact of increasing dose	Primary: Increasing doses of all agents resulted in an incremental benefit on LDL-C reduction. The incremental impact of dose doubling was comparable, with a

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Rosuvastatin (variable doses) vs atorvastatin (variable doses) vs simvastatin (variable doses)	hypercholesterolemia	duration	on lowering LDL-C, TG, non-HDL-C, and apo B Secondary: Not reported	5% to 7% increase in LDL-C lowering. A greater percentage of patients achieved LDL-C treatment goals using increasing doses of all agents, as well as in patients with lower cholesterol levels at baseline. Increasing doses of all agents resulted in an incremental benefit on TG reduction. The incremental impact of dose doubling was comparable, with a 2 to 4% increase in TG lowering. Increasing doses of all agents resulted in an incremental benefit on non-HDL-C reduction. The incremental impact of dose doubling was comparable, with a 4 to 6% increase in non-HDL-C lowering. Increasing doses of all agents resulted in an incremental benefit on apo B reduction. The incremental impact of dose doubling was comparable, with a 4 to 6% increase in apo B lowering. Increasing statin dose was not associated with an increase in withdrawal rates due to adverse events. Secondary: Not reported
Harley et al.[105] (2007) Rosuvastatin, after simvastatin therapy vs atorvastatin, after simvastatin therapy vs	RETRO Adult patients ≥18 years of age, receiving simvastatin monotherapy between July 2005 and June 2006, switched to other statin therapy	N=134,160 1 year	Primary: Percentage of patients achieving NCEP ATP III LDL goal after switching from simvastatin to another statin Secondary: Not reported	Primary: Of those patients not at NCEP ATP III LDL goal with simvastatin monotherapy, 73% reached their LDL goal following the switch to another statin. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
lovastatin, after simvastatin monotherapy vs pravastatin, after simvastatin monotherapy vs fluvastatin, after simvastatin monotherapy vs simvastatin-ezetimibe, after simvastatin monotherapy				
Fox et al.[106] (2007) Rosuvastatin (average dose, 11.7 mg/day) vs other statins (atorvastatin, pravastatin, lovastatin, simvastatin,	RETRO Adult patients with diabetes who were newly prescribed a statin between August 2003 and March 2006	N=4,754 Patients received statin therapy between August 2003 and March 2006	Primary: Percent reduction from baseline in LDL-C, proportion of patients achieving LDL-C goal <100 mg/dL Secondary: Not reported	Primary: Rosuvastatin was associated with a significant reduction in small dense LDL-C compared to atorvastatin (22.5%), simvastatin (20.1%), pravastatin (13.7%), lovastatin (17.3%) and fluvastatin (15.8%) (P<0.0001 for all). Compared to other statins, a significantly greater proportion of patients receiving rosuvastatin achieved the LDL-C goal (P<0.05). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
fluvastatin; dosed 17 to 64 mg/day)				
Ballantyne et al.[107] (2007) EXPLORER Ezetimibe 10 mg QD and rosuvastatin 40 mg QD vs rosuvastatin 40 mg QD	MC, OL, PG, RCT Men and women aged ≥18 years with hypercholesterolemia, history of CHD or clinical evidence of atherosclerosis or CHD risk equivalent (10-year CHD risk score >20%), 2 most recent fasting LDL-C levels of ≥160 mg/dL and <250 mg/dL	N=469 6 weeks	Primary: Percentage of patients achieving the NCEP ATP III LDL-C goal (<100 mg/dL) after 6 weeks of treatment Secondary: Percentage of patients achieving the ATP III non-HDL-C goal of <130 mg/dL and LDL level <100 mg/dL when baseline TG ≥200 mg/dL, percentage of patients achieving the 2003 European LDL goal of <100 or 115 mg/dL and combined LDL and TC goals of <100 or 115 mg/dL and <175 or 190 mg/dL,	Primary: Significantly more patients in the combination therapy group achieved the LDL-C goal of <100 mg/dL at week six compared to rosuvastatin alone (94 vs 79.1%; P<0.001). Secondary: The non-HDL-C goal of <130 mg/dL and LDL level <100 mg/dL when baseline TG ≥200 mg/dL were achieved by a significantly higher percentage of patients in the combination therapy group than the monotherapy group (88 patients or 37.4% and 80 patients or 34.8%, respectively; P<0.001). There was a significantly higher percent of patients in the combination therapy group achieving the European LDL goal of <100 or 115 mg/dL and combined LDL and TC goals (LDL <100 or 115 mg/dL and TC <175 or 190 mg/dL), depending on risk category compared to the rosuvastatin group alone at week six (LDL 93.6 vs 74.3%, LDL and TC 90.6 vs 68.3%, respectively; P<0.001). At week six, the combination therapy group had a significantly greater percent reduction of 69.8% in the LDL level compared to a 57.1% reduction in the monotherapy group (P<0.001). Significantly greater reductions in TC, non-HDL-C and TG levels were seen in the combination group compared to the monotherapy group (P<0.001). Both treatment groups increased HDL level to a similar extent (P=0.151). LDL:HDL, TC:HDL and non-HDL:HDL cholesterol ratios decreased significantly more in patients receiving combination therapy compared to patients receiving monotherapy (all P<0.001). Significant decreases in apo B and the apo B:apo AI ratio were seen in the combination therapy group compared to the monotherapy group (P<0.001 for both). Apo AI increased by 3.2% and 1.6% in the combination therapy and monotherapy groups, respectively (P=0.202). The median percent decrease in CRP was significantly higher with combination therapy than monotherapy (-46.4 vs -28.6%; P<0.001). The overall frequency and type of adverse events were similar in both groups, with 31.5% of patients on combination therapy and 33.5% of patients on monotherapy reporting any adverse event. No adverse events were considered

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			respectively, depending on risk category, percentage change from baseline in LDL, HDL, TC, TG, non-HDL, lipid ratios (LDL:HDL, TC:HDL and non-HDL:HDL), apo AI, apo B, and apo B:apo AI ratio, and changes in hsCRP in at week six, safety and tolerability	related to ezetimibe; the most frequently reported adverse event was myalgia (3.0% of patients in the rosuvastatin-alone group and 2.9% in the rosuvastatin plus ezetimibe group). There were two patients (0.8%) in the combination therapy group and three patients (1.3%) in the monotherapy group who discontinued the study due to treatment-related adverse events. One death occurred in the combination therapy group due to acute myocardial infarction and this was not considered to be related to study treatment. ALT increases >3 times the upper limit of normal were recorded in three patients, all in the combination therapy group.
Jones et al.[108] (2009) Fenofibric acid 135 mg QD and rosuvastatin (10 or 20 mg) QD vs fenofibric acid 135 mg QD vs rosuvastatin 10,	AC, DB, MC, RCT Patients ≥18 years of age with mixed dyslipidemia (TG ≥150 mg/dL, HDL-C <40 mg/dL for men or <50 mg/dL for women and LDL-C ≥130 mg/dL)	N=1,445 16 weeks (includes 30 day safety evaluation)	Primary: Composite of mean percent changes from baseline in HDL-C, TG and LDL-C Secondary: Composite of mean percent changes from baseline in non-HDL-C, VLDL-C, TC, apo B and	Primary: Combination therapy (rosuvastatin 10 and 20 mg) was associated with a significantly greater increase in HDL-C (10 mg: 20.3 vs 8.5%; P<0.001 and 20 mg: 19.0 vs 10.3%; P<0.001) and a significantly greater decrease in TG (10 mg: 47.1 vs 24.4%; P<0.001 and 20 mg: 42.9 vs 25.6%; P<0.001) compared to rosuvastatin (10 and 20 mg). Combination therapy was associated with a significantly greater decrease in LDL-C (10 mg: 37.2 vs 6.5%; P<0.001 and 20 mg: 38.8 vs 6.5%; P<0.001) compared to fenofibric acid. Secondary: Combination therapy (rosuvastatin 10 mg) was associated with a significantly greater reduction in non-HDL-C compared to fenofibric acid or rosuvastatin (10 mg) (P<0.001). Combination therapy was also associated with significantly greater improvements in VLDL-C (P<0.001), apo B (P<0.001)

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
20, or 40 mg QD			hsCRP	and hsCRP (P=0.013) compared to rosuvastatin. Combination therapy (rosuvastatin 20 mg) significantly improved non-HDL-C compared to fenofibric acid (P<0.001) and was associated with a significantly greater improvement in VLDL-C (P=0.038) and hsCRP (P=0.010) compared to rosuvastatin (20 mg), with similar reductions in non-HDL-C, apo B and TC (P values not reported).
Roth et al.[109] (2010) Rosuvastatin 5 mg/day vs fenofibric acid 135 mg/day vs rosuvastatin 5 mg/day plus fenofibric acid 135 mg/day	DB, MC, RCT Patients with fasting LDL-C ≥130 mg/dL, TG ≥150 mg/dL and HDL-C 40 mg/dL	N=760 12 weeks (plus a 30 day safety follow up period)	Primary: Composite of mean percent changes from baseline in HDL-C, TG and LDL-C Secondary: Changes from baseline in non-HDL-C, VLDL-C, apo B, hsCRP and TC; safety; proportion of patients achieving LDL-C (<100 mg/dL) and non-HDL-C (<130 mg/dL) goals	Primary: Combination therapy resulted in a significantly greater mean percent change in HDL-C (23.0 vs 12.4%; *P*<0.001) and TG (-43.0 vs -17.5%; *P*<0.001) compared to rosuvastatin, and resulted in significantly higher mean percent decrease in LDL-C compared to fenofibric acid (28.7 vs 4.1%; *P*<0.001). Secondary: Combination therapy resulted in significantly greater improvements in non-HDL-C compared to either monotherapy, and significantly greater improvements in apo B, hsCRP, VLDL-C and TC compared to rosuvastatin. All treatments were generally well tolerated, with discontinuations due to adverse events being higher with combination therapy (8.3%) and fenofibric acid (7.5%) compared to rosuvastatin (4.4%). The most common adverse events leading to discontinuation were myalgia and muscle spasms and nausea, fatigue and ALT and AST increases. The overall incidence of treatment-emergent adverse events was similar across treatments (58.5 to 63.0%). No significant differences were observed between the combination therapy and either monotherapy in the incidence of any category of adverse events (muscle, hepatic and renal related). In patients with a 10 year CHD risk >20%, the LDL-C goal <100 mg/dL was achieved by 50.5% of patients receiving combination therapy and rosuvastatin; the non-HDL-C goal <130 mg/dL was achieved by 49.5% of patients receiving combination therapy compared to 33.3% of patients receiving rosuvastatin (*P*=0.03). Both LDL-C and non-HDL-C goals were achieved by 44.3 vs 32.3% (*P*=0.10).
Ferdinand et al.[110] (2012)	Post-hoc analysis Patients ≥18 years	N=187 1 year	Primary: Change in baseline LDL-	Primary: Increasing rosuvastatin from 10 to 20 mg, in combination with fenofibric acid for up to 52 weeks, resulted in significant changes from baseline in LDL-C (-

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Fenofibric acid 135 mg QD and rosuvastatin 10 mg QD for 12 weeks, followed by fenofibric acid 135 mg QD and rosuvastatin 20 mg QD for up to 52 weeks Outcomes were evaluated from the end of the initial 12 week period (baseline) up to 52 weeks of treatment.	of age with mixed dyslipidemia (TG ≥150 mg/dL, HDL-C <40 mg/dL for men or <50 mg/dL for women and LDL-C ≥130 mg/dL)		C, HDL-C, non-HDL-C, apo B, TG, hsCRP; proportion of patients achieving individual and combined goals for LDL-C and non-HDL-C; safety Secondary: Not reported	9.5%), non-HDL-C (-0.6%), apoB (-8.5%), and HDL-C (3.6%) (P≤0.005 for all). TG levels remained unchanged (0.8%; P=0.055) at week 52. A greater proportion of patients achieved risk-stratified lipid goals at week 52 compared to baseline for LDL-C (89 vs 84%; P=0.26), non-HDL-C (50 vs 25%; P value not reported), and both LDL-C and non-HDL-C (50 vs 19%; P value not reported). The incidences of muscle-, hepatic-, and renal-related adverse events and laboratory values were within the expected range for combination therapy. The most commonly reported treatment-emergent adverse events (>10%) were upper respiratory tract infection (14.4%), headache (13.9%), and back pain (10.7%)/ Treatment-emergent serious adverse events occurred in seven percent of patients, and one death (MI) occurred, none of which were deemed to be treatment-related. Secondary: Not reported
Mohiuddin et al.[111] (2009) Fenofibric acid 135 mg QD plus simvastatin 20 to 40 mg QD vs fenofibric acid 135 mg QD vs simvastatin 20 to 80 mg QD	AC, DB, MC Patients >18 years of age with mixed dyslipidemia (TG ≥150 mg/dL, HDL-C <40 mg/dL for men or <50 mg/dL for women, and LDL-C ≥130 mg/dL)	N=657 16 weeks (includes 30 day safety evaluation)	Primary: Composite of mean percent changes from baseline in HDL-C, TG and LDL-C Secondary: Composite of mean percent changes from baseline in non-HDL-C, VLDL-C, TC, apo B and hsCRP	Primary: Combination therapy was associated with a significantly greater increase in HDL-C (20 mg: 17.8 vs 7.2%; P<0.001 and 40 mg: 18.9 vs 8.5%; P<0.001) and a significantly greater decrease in TG (20 mg: 37.4 vs 14.2%; P<0.001 and 40 mg: 42.7 vs 22.4%; P<0.001) compared to simvastatin (20 and 40 mg). Combination therapy was associated with a significantly greater decrease in LDL-C (20 mg: 24.0 vs 4.0%; P<0.001 and 40 mg: 25.3 vs 4.0%; P<0.001) compared to fenofibric acid. Secondary: Combination therapy (simvastatin 20 mg) was associated with a significantly greater decrease in non-HDL-C (P<0.001) compared to fenofibric acid and simvastatin (20 mg). Combination therapy (simvastatin 20 mg) was associated with significant improvements in VLDL-C (P<0.001), apo B (P<0.001) and hsCRP (P=0.013) compared to simvastatin (20 mg).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Combination therapy (simvastatin 40 mg) significantly (P<0.001) improved non-HDL-C compared to fenofibric acid, and resulted in a significantly greater improvement in VLDL-C (P=0.005) compared to simvastatin (40 mg), with similar reductions in non-HDL-C, apo B and TC (P values not reported).
May et al.[112] (2008) DIACOR Fenofibrate 160 mg and simvastatin 20 mg QD vs fenofibrate 160 mg QD vs simvastatin 20 mg QD	DB, PC, RCT Patients with type 2 diabetes, no CHD, and biochemical evidence of mixed dyslipidemia (having 2 of the following 3 lipid parameters: LDL-C >100 mg/dL, TG >200 mg/dL, and HDL-C <40 mg/dL)	N=300 12 weeks	Primary: Lipid and lipoprotein profiles Secondary: Not reported	Primary: Fenofibrate plus simvastatin significantly reduced dense VLDL-C compared to fenofibrate (P<0.001) and simvastatin (P<0.0001). Simvastatin significantly reduced IDL-C compared to fenofibrate (P<0.003). The percentage of LDL-C pattern B constituting total LDL-C was significantly reduced by fenofibrate (-13.7%, P<0.0001) and fenofibrate plus simvastatin (-11.1%, P<0.0001). There was no significant change with simvastatin (-2.4%, P=0.27). Fenofibrate and fenofibrate plus simvastatin significantly increased the percentage of buoyant LDL-C constituting total LDL-C (-19.6%, P<0.0001 and -16.9%, P<0.0001, respectively). There was no significant change with simvastatin (-3.1%, P=0.06). Secondary: Not reported
Derosa et al.[113] (2009) Fenofibrate 145 mg/day and simvastatin 40 mg/day vs fenofibrate 145 mg/day vs	RCT, DB, MC Caucasian patients ≥18 years of age with type 2 diabetes mellitus and combined dyslipidemia who had never been treated with lipid-lowering medications	N=241 12 months	Primary: Lipid and lipoprotein profiles at six and 12 months Secondary: Not reported	Primary: After six months of therapy, there was a significant reduction in TC and LDL-C with simvastatin and fenofibrate plus simvastatin (P<0.05 and P<0.01, respectively). There was no significant change in the fenofibrate group. After 12 months of therapy, there was a significant decrease in TC and LDL-C in all treatment groups (P<0.05 for fenofibrate, P<0.01 for the simvastatin and P<0.001 for fenofibrate plus simvastatin). TC was significantly lower with fenofibrate plus simvastatin compared to simvastatin monotherapy and fenofibrate monotherapy (P<0.05). LDL-C was significantly lower with fenofibrate plus simvastatin compared to simvastatin monotherapy and fenofibrate monotherapy (P<0.01). After six months of therapy, there was a significant reduction in TG with fenofibrate and fenofibrate plus simvastatin (P<0.05, respectively). There was no significant change in the simvastatin group. After 12 months of therapy,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
simvastatin 40 mg/day				there was a significant decrease in TG in all treatment groups (P<0.01 for fenofibrate, P<0.05 for simvastatin and P<0.001 for fenofibrate plus simvastatin). TG was significantly lower with fenofibrate + simvastatin compared to fenofibrate (P<0.05) or simvastatin (P<0.01). After six months of therapy, there was a significant increase in HDL-C with fenofibrate and fenofibrate plus simvastatin (P<0.05 and P<0.01, respectively). There was no change in the simvastatin group. After 12 months of therapy, there was a significant increase in HDL-C in all treatment groups (P<0.01 for fenofibrate, P<0.05 for simvastatin and P<0.001 for fenofibrate plus simvastatin). HDL-C was significantly higher with fenofibrate plus simvastatin compared to simvastatin monotherapy and fenofibrate monotherapy (P<0.05). After six months of therapy, there was no significant change in apo A1 or apo B in any treatment group. After 12 months of therapy, there was a significant increase of apo A1 with fenofibrate plus simvastatin. There was no significant difference between the treatment groups. After 12 months of therapy, there was a significant decrease of apo B in all groups (P<0.05 for fenofibrate, P<0.05 for simvastatin and P<0.01 for fenofibrate plus simvastatin). There was no significant difference between the treatment groups. There were no significant differences in Lp(a) after six or 12 months of therapy in any of the treatment groups. After six months of therapy, there was a significant decrease in hsCRP with fenofibrate plus simvastatin (P<0.05), but not in the other groups. After 12 months of therapy, there was a significant decrease in hsCRP with simvastatin and with fenofibrate plus simvastatin (P<0.05 and P<0.01, respectively), but not with fenofibrate. The hsCRP value was significantly lower with fenofibrate plus simvastatin compared to fenofibrate or simvastatin (P<0.05). Secondary: Not reported
Rogers et al.[114] (2007) Simvastatin 10, 20, 40 or 80	MA (18 trials) Patients >18 years of age with elevated TC and	N=8,320 Up to 12 weeks	Primary: Reductions in TC, LDL-C and TG; increases in HDL-C	Primary: Simvastatin appeared to be comparable to atorvastatin in terms of TC reduction from baseline at four times the dose of atorvastatin (P>0.05). Simvastatin 20 and 40 mg were less effective at reducing LDL-C from

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day vs atorvastatin 10, 20, 40 or 80 mg/day	LDL-C		Secondary: Not reported	baseline compared to atorvastatin 40 and 80 mg, respectively (P<0.001). Simvastatin 40 to 80 mg was comparable to atorvastatin 20 mg in terms of TG reduction from baseline (P=0.22 and P=0.53, respectively). Atorvastatin 40 to 80 mg was more effective in reducing TG from baseline compared to all simvastatin doses evaluated (P<0.001). Simvastatin 10, 20 and 80 mg were more effective than atorvastatin 80 mg in increasing HDL-C from baseline (P<0.05). Secondary: Not reported
Hall et al.[115] (abstract) (2009) SPACE ROCKET Simvastatin 40 mg/day vs rosuvastatin 10 mg/day	MC, OL, RCT Patients with a history of acute MI	N=1,263 3 months	Primary: Proportion of patients achieving the European Society of Cardiology 2003 TC (<174 mg/dL) or LDL-C (<97 mg/dL) goals Secondary: Not reported	Primary: There was no difference between the two treatments in the proportions of patients who achieved lipid goals (77.6 vs 79.9%; OR, 1.16; 95% CI, 0.88 to 1.53; P=0.29). A post hoc analysis demonstrated a significantly higher achievement of the new European Society of Cardiology, American Heart Association and American College of Cardiology LDL-C goal (<70 mg/dL) with rosuvastatin (37.8 vs 45.0%; OR, 1.37; 95% CI, 1.09 to 1.72; P=0.007). The proportion of patients achieving the Fourth Joint Task Force European Guidelines TC (<155 mg/dL) and LDL-C (<77 mg/dL) goals were also significantly higher with rosuvastatin (38.7 vs 47.7%; OR, 1.48; 95% CI, 1.18 to 1.86; P=0.001). Secondary: Not reported
Feldman et al.[116] (2004) Ezetimibe 10 mg/day plus simvastatin 10, 20 or 40 mg/day vs	DB, MC, RCT Patients 18 to 80 years of age with CHD or CHD risk equivalent disease and LDL-C ≥130 mg/dL and TG ≤350 mg/dL	N=710 23 weeks	Primary: Proportion of patients with LDL-C <100 mg/dL at week five Secondary: Proportion of	Primary: A significantly greater proportion of patients receiving combination therapy achieved LDL-C <100 mg/dL at week five compared to patients receiving simvastatin (P<0.001). Secondary: A significantly greater proportion of patients receiving combination therapy achieved LDL-C <100 mg/dL at week 23 compared to patients receiving simvastatin (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
simvastatin 20 mg/day			patients with LDL-C <100 mg/dL at 23 weeks	At five weeks, there was a significant reduction in TC, non-HDL-C, apo B, TC:HDL-C and LDL-C:HDL-C with combination therapy compared to simvastatin (P<0.001 for all). HDL-C was significantly increased with combination therapy (10/20 mg) compared to simvastatin (P<0.05). At five weeks, combination therapy was associated with a significant reduction in TG compared to simvastatin (P<0.05). Treatment-related adverse effects were similar with simvastatin and combination therapy (10/10, 10/20 and 10/40 mg) (7.5, 9.6, 14.0 and 10.0%, respectively; P values not reported).
Gaudiani et al.[117] (2005) Ezetimibe 10 mg/day plus simvastatin 20 mg/day vs simvastatin 40 mg/day All patients received simvastatin 20 mg/day for a 6 week run in period.	DB, MC, PG, RCT Patients 30 to 75 years of age with type 2 diabetes (HbA_{1c} ≤9.0%), treated with a stable dose of pioglitazone (15 to 45 mg/day) or rosiglitazone (2 to 8 mg/day) for ≥3 months, LDL-C >100 mg/dL and TG <600 mg/dL (if already on a statin therapy)	N=214 30 weeks	Primary: Percent change from baseline in LDL-C Secondary: Percent change from baseline in TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B and apo AI	Primary: LDL-C was reduced more by the addition of ezetimibe to simvastatin than by doubling the dose of simvastatin (20.8 vs 0.3%; P<0.001). Secondary: TC (14.5 vs 1.5%; P<0.001), non-HDL-C (20.0 vs 1.7%; P<0.001), apo B (14.1 vs 1.8%; P<0.001), LDL-C:HDL-C (P<0.001), TC:HDL-C (P<0.001) and apo AI (P<0.001) were reduced more by the addition of ezetimibe to simvastatin than by doubling the dose of simvastatin. The increase in HDL-C was similar between the two treatments (P value not reported). The incidence of treatment-related adverse effects was lower with simvastatin compared to combination therapy (10.0 vs 18.3%, respectively; P value not reported).
Bays et al.[118] (2008)	ES Patients ≥18 years	N=768 48 weeks	Primary: Safety and tolerability	Primary: In general, combination therapy did not substantively differ from simvastatin with respect to total adverse events (73 vs 69%), treatment related adverse

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Ezetimibe 10 mg/day plus simvastatin 10, 20, 40 or 80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day	of age with primary hypercholesterolemia		Secondary: Not reported	events (13.5 vs 11.4%), treatment related serious adverse events (1 vs 0%), discontinuations due to treatment related adverse events (2.8 vs 2.6%) or discontinuations due to treatment-related serious adverse events (1 vs 0%). Combination therapy had a slightly higher rate of serious adverse events (5.2 vs 2.6%) and discontinuations due to adverse events (4.5 vs 2.6%) compared to simvastatin (P>0.20). Based on investigator assessment of causality, rates were similar between the treatments. There are no remarkable observations of between-treatment group differences whether or not they are related to a specific tissue or body system. In general, combination therapy did not differ from simvastatin with respect to total laboratory adverse events (12 vs 12%), treatment related laboratory adverse events (6.2 vs 5.3%), total laboratory serious adverse events (0 vs 0%), treatment related laboratory serious adverse events (0 vs 0%) or discontinuations due to laboratory serious adverse events (0 vs 0%). Secondary: Not reported
Calza et al.[119] (abstract) (2008) Rosuvastatin 10 mg QD vs pravastatin 20 mg QD vs atorvastatin 10 mg QD	OL, PRO, RCT Patients with HIV receiving protease inhibitor therapy ≥12 months with protease inhibitor-associated hypercholesterolemia ≥3 months and unresponsive to a hypolipidemic diet and physical exercise	N=94 12 months	Primary: Changes from baseline in TC and LDL-C Secondary: Not reported	Primary: Statins led to a mean reduction of 21.2 and 23.6% in TC and LDL-C (P=0.002). The mean decrease in TC was significantly greater with rosuvastatin (25.2%) compared to pravastatin (17.6%; P=0.01) and atorvastatin (19.8%; P=0.03). During the 12 months, all statins demonstrated a favorable tolerability profile, and patient's HIV viral load did not present any variation. Secondary: Not reported
Faergeman et	RCT, OL, MC,	N=1,036	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
al.[120] (2008) ECLIPSE Rosuvastatin 10 mg for 6 weeks; dose was force-titrated every 6 weeks to maximal dose (40 mg) vs atorvastatin 10 mg for 6 weeks; dose was force-titrated every 6 weeks to maximal dose (80 mg) Doses could be decreased for safety reasons.	PG Patients ≥18 years of age with hypercholesterolemia and a history of CHD, clinical evidence of atherosclerosis or a 10-year CHD risk score >20% (CHD risk equivalent)	24 weeks	Percentage of patients achieving NCEP ATP III LDL-C goal <100 mg/dL after 24 weeks Secondary: Percentage of patients achieving NCEP ATP III LDL-C goal <100 mg/dL at weeks 6, 12 and 18; achievement of the following NCEP ATP III goals at all time points: non-HDL-C <130 mg/dL, 2003 European LDL-C goals (100-115 mg/dL and combined LDL-C and TC goals (LDL-C 100-115 mg/dL and TC 175 or 190 mg/dL), percentage changes from	A greater percentage of patients achieved the NCEP ATP III LDL-C goal with rosuvastatin than with atorvastatin at week 24 (83.6 vs 74.6%; P<0.001). Secondary: A greater percentage of patients achieved the NCEP ATP III non-HDL-C goal with rosuvastatin than with atorvastatin (week 6, 41.9 vs 19.6%; week 12, 64.5 vs 32.0%; week 18, 76.0 vs 55.0%; week 24, 79.6 vs 68.0%; P<0.02 at each time point). A greater percentage of patients achieved the 2003 European LDL-C goals and the combined LDL-C and TC goals with rosuvastatin than with atorvastatin at all time points (P<0.001). Significantly greater reductions in LDL-C, TC and non-HDL-C levels, and increases in HDL-C were achieved with rosuvastatin than with atorvastatin at all time points. The reductions in TG levels were similar in both treatment groups at all time points except at week 24, when a significantly greater decrease was observed in patients receiving atorvastatin compared to those receiving rosuvastatin (P<0.05). Significantly greater mean reductions in LDL-C:HDL-C, TC:HDL-C, non-HDL-C:HDL-C and apoB:apo AI ratios were achieved with rosuvastatin than with atorvastatin at all time points (P<0.001). Adverse events were experienced by 53.7 and 52.5% of patients receiving rosuvastatin and atorvastatin, respectively. Myalgia was the most frequently reported adverse events.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			baseline in LDL-C, HDL-C, TC, TG, non-HDL-C, and lipid ratios	
Insull et al.[121] (2007) SOLAR Rosuvastatin 10 mg/day daily for 6 weeks, followed by doubling of the dose and treatment for another 6 weeks if LDL-C target (<100 mg/dL) was not achieved vs atorvastatin 10 mg/day for 6 weeks, followed by doubling of the dose and treatment for another 6 weeks if LDL-C target (<100 mg/dL) was not achieved vs simvastatin 20 mg/day for 6	MC, RCT Patients ≥18 years of age who were enrolled in a managed care health plan and classified as high risk by NCEP ATP III risk assessment	N=1,632 12 weeks	Primary: Proportion of patients achieving NCEP ATP III high risk LDL-C goal (<100 mg/dL) at week six Secondary: Proportion of patients achieving the high risk LDL-C goal at 12 weeks, proportion of hyper-triglyceridemic patients who achieved both the LDL-C goal (<100 mg/dL) and the non-HDL-C goal (<130 mg/dL) for high risk patients, changes from baseline in LDL-C and	Primary: After six weeks, a significantly greater proportion of patients receiving rosuvastatin 10 mg achieved the high risk LDL-C goal compared to patients receiving atorvastatin 10 mg and patients receiving simvastatin 20 mg (65 vs 41 vs 39%, respectively; P<0.001). Secondary: After 12 weeks, 76% of patients receiving rosuvastatin 20 mg achieved the high risk LDL-C goal compared to 58 and 53% of patients receiving atorvastatin 20 mg and simvastatin 40 mg, respectively (P<0.001). After six weeks, 44% of hypertriglyceridemic patients receiving rosuvastatin 10 mg achieved the combined LDL-C and non-HDL-C goals compared to 19% of patients receiving simvastatin 20 mg, respectively (P<0.001). There was no difference between rosuvastatin 10 mg and atorvastatin 10 mg (44 vs 22%; P value not reported). After 12 weeks, 57% of hypertriglyceridemic patients taking rosuvastatin 20 mg reached the combined LDL-C and non-HDL-C goal compared to 31% of patients taking simvastatin 40 mg, respectively (P<0.001). There was no difference between rosuvastatin 20 mg and atorvastatin 20 mg (57 vs 36%; P value not reported). Rosuvastatin was associated with a significant reduction in LDL-C compared to atorvastatin and simvastatin at six and 12 weeks (P<0.001 for both). Rosuvastatin was associated with a significant reduction in TC compared to atorvastatin and simvastatin at six and 12 weeks (P<0.001). Rosuvastatin was associated with a significant reduction in non-HDL-C compared to atorvastatin and simvastatin at six and 12 weeks (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
weeks, followed by doubling of the dose and treatment for another 6 weeks if LDL-C target (<100 mg/dL) was not achieved All patients were randomized after a 6 week dietary lead in period.			other lipid parameters at six and 12 weeks	Rosuvastatin was associated with a significant reduction in non-HDL-C:HDL-C compared to atorvastatin and simvastatin at six and 12 weeks (P<0.001). Rosuvastatin was associated with a significant increase in HDL-C compared to atorvastatin and simvastatin at 12 weeks (P<0.001). Patients randomized to rosuvastatin experienced a statistically significant reduction in TG from baseline compared to simvastatin at six and 12 months (P<0.001). The frequency and types of adverse events were similar with all treatments (P value not reported).
Ballantyne et al.[122] (2006) MERCURY II Rosuvastatin 20 mg/day for 8 weeks vs atorvastatin 10 or 20 mg/day for 8 weeks vs simvastatin 20 or 40 mg/day for 8 weeks All patients were randomized after a 6 week dietary	MC, OL, RCT Patients ≥18 years of age, at high risk for CHD events, fasting LDL-C ≥130 to <250 mg/dL on 2 separate measurements within 15% of each other and a fasting TG <400 mg/dL	N=1,993 16 weeks	Primary: The proportion of patients achieving LDL-C <100 mg/dL at week 16 Secondary: The proportion of patients meeting the LDL-C target at week eight, change in lipid and lipoprotein measures at weeks eight and 16, adverse events	Primary: After 16 weeks, a larger proportion of patients receiving rosuvastatin achieved the LDL-C goal compared to patients receiving all other treatments (83, 42, 64, 32 and 56%, respectively; P value not reported). After 16 weeks, significantly more patients who switched to rosuvastatin therapy achieved LDL-C target level <100 mg/dL compared to patients who remained on their initial statin therapy (P<0.001). Secondary: After 16 weeks, patients who switched to rosuvastatin experienced a significant LDL-C reduction from baseline compared to patients remaining on their initial medication regimen (P<0.001). After eight weeks, a significantly greater proportion of patients receiving rosuvastatin achieved the LDL-C goal <100 mg/dL compared to patients receiving all other treatments (82, 43, 62, 33 and 55%, respectively; P<0.0001). After 16 weeks, a significantly greater proportion of patients randomized to rosuvastatin achieved the LDL-C goal <70 mg/dL compared to patients receiving all other treatments (37, 7, 13, 1 and 10%, respectively; P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
lead in period. After 8 weeks of treatment, patients received an additional 8 weeks of either initial statin or rosuvastatin therapy.				After 16 weeks, patients who switched to rosuvastatin experienced a significant atherogenic lipid measure and ratio reduction from baseline compared to patients remaining on their initial medication regimen (P<0.001). After 16 weeks, a significantly greater proportion of hypertriglyceridemic patients receiving rosuvastatin achieved the LDL-C goal <100 mg/dL and non-HDL-C goals compared to patients receiving all other treatments (80, 20, 42, 19 and 29%, respectively; P value not reported). The frequency and type of adverse events were similar with all treatments (P value not reported). In addition, there were no symptomatic adverse events associated with hepatic dysfunction.
Jones et al.[123] (2003) STELLAR Rosuvastatin 10 to 40 mg/day vs pravastatin 10 to 40 mg/day vs atorvastatin 10 to 80 mg/day vs simvastatin 10 to 80 mg/day	OL, PG Patients ≥18 years of age with hypercholesterolemia and LDL-C ≥160 to <250 mg/dL at the 2 most recent consecutive visits	N=2,431 6 weeks	Primary: Percent change from baseline in LDL-C Secondary: Percent changes from baseline in HDL-C, TG and TC	Primary: Compared to all doses of atorvastatin and pravastatin, rosuvastatin was associated with a greater reduction in LDL-C (P<0.001 for both). When compared to baseline, the following reductions in LDL-C were observed: rosuvastatin; 45.8 to 55.0%, atorvastatin; 36.8 to 51.1%, simvastatin; 28.3 to 45.8% and pravastatin; 20.1 to 29.7%. The greatest reductions in LDL-C observed were a 55% reduction with rosuvastatin 40 mg and a 51% reduction with atorvastatin 80 mg (P=0.006). Secondary: Rosuvastatin 10 to 40 mg/day was associated with a 7.7 to 9.6% increase in HDL-C, a 19.8 to 26.1% reduction in TG and a 32.9 to 40.2% reduction in TC (P values not reported). Pravastatin 10 to 40 mg/day was associated with a 3.2 to 5.6% increase in HDL-C, a 7.7 to 13.2% reduction in TG and a 14.7 to 21.5% reduction in TC (P value not reported). Atorvastatin 10 to 80 mg/day was associated with a 2.1 to 5.7% increase in HDL-C, a 20.0 to 28.2% reduction in TG and a 27.1 to 38.9% reduction in TC (P value not reported). Simvastatin 10 to 80 mg/day was associated with a 5.2 to 6.8% increase in HDL-C, an 11.9 to 18.2% reduction in TG and a 20.3 to 32.9% reduction in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				TC (P value not reported).
Welty et al.[124] (2016) STELLAR Rosuvastatin 10 to 40 mg/day vs pravastatin 10 to 40 mg/day vs atorvastatin 10 to 80 mg/day vs simvastatin 10 to 80 mg/day	Subgroup analysis Women in the STELLAR trial with LDL-C ≥160 and <250 mg/dL and triglycerides <400 mg/dL	N=1,146 6 weeks	Primary: Percent change from baseline in LDL-C Secondary: Percent changes from baseline in HDL-C, TG and TC	Primary: Statin treatment produced dose-related decreases in LDL-C levels ranging from 21 to 57% at six weeks, depending on the statin and dose used. At the lowest statin dose, 10 mg, LDL-C was reduced by 49% with rosuvastatin, 39% with atorvastatin, 30% with simvastatin, and 21% with pravastatin (P<0.002 rosuvastatin vs all comparators). A similar pattern was observed for the high-intensity doses of statins defined by the ACC/AHA guideline and recommended for those at risk of atherosclerotic cardiovascular disease: LDL-C reductions were 53% with rosuvastatin 20 mg, 57% with rosuvastatin 40 mg, 47% with atorvastatin 40 mg, and 51% with atorvastatin 80 mg. Rosuvastatin 20 mg produced statistically greater reductions in LDL-C compared with atorvastatin 20 mg and 40 mg (P<0.002 for both comparisons). In addition, rosuvastatin 40 mg produced statistically greater reductions in LDL-C compared with atorvastatin 40 mg (P<0.002). Secondary: Reductions in non-HDL-C levels ranged from 45% to 53% with rosuvastatin, 37% to 48% with atorvastatin, 27% to 44% with simvastatin, and 19% to 28% with pravastatin. Reductions in non-HDL-C with rosuvastatin 10 mg were significantly greater when compared with atorvastatin 10 mg; simvastatin 10, 20, or 40 mg; and pravastatin 10, 20, or 40 mg (P<0.002 for all comparisons). Rosuvastatin 20 mg reduced non-HDL-C significantly more than milligram-equivalent doses of atorvastatin, simvastatin, and pravastatin (P<0.002 for all comparisons). The increases in HDL-C were numerically greater with rosuvastatin than with the other statins, but the differences were not statistically significant, except that rosuvastatin 20 and 40 mg increased HDL-C significantly more than milligram-equivalent or higher doses of atorvastatin. All statins reduced triglyceride levels, with similar effects across the dose range for rosuvastatin and atorvastatin, and a trend for dose-related reductions for simvastatin and pravastatin.
McKenney et al.[125] (2007)	MC, OL, PG, RCT	N=292 12 weeks	Primary: Change from baseline in	Primary: Atorvastatin plus niacin SR, rosuvastatin plus niacin SR, simvastatin plus ezetimibe and rosuvastatin were associated with similar reductions in LDL-C

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
COMPELL Rosuvastatin 10 mg/day for 4 weeks, followed by 20 mg/day for 4 weeks, followed by 40 mg/day vs atorvastatin 20 mg/day plus niacin SR 500 mg/day for 4 weeks, followed by atorvastatin 20 mg/day plus niacin SR 1,000 mg/day for 4 weeks, followed by atorvastatin 40 mg/day plus niacin SR 2,000 mg/day vs simvastatin 20 mg/day plus ezetimibe 10 mg/day for 8 weeks, followed by simvastatin 40 mg/day plus ezetimibe 10 mg/day	Patients ≥21 years of age with hyper-cholesterolemia, eligible for treatment based on the NCEP ATP III guidelines, with 2 consecutive LDL-C levels within 15% of each other and mean TG ≤300 mg/dL		LDL-C Secondary: Change from baseline in HDL-C non-HDL-C, TG, Lp(a) and apo B; side effects	(56, 51, 57 and 53%, respectively; P=0.093). Secondary: Atorvastatin plus niacin SR was associated with a significant increase in HDL-C compared to simvastatin plus ezetimibe and rosuvastatin-containing therapy (22, 10 and 7%, respectively; P≤0.05). There was no significant differences in the reduction of non-HDL-C from baseline with any treatment (P=0.053). Atorvastatin plus niacin SR was associated with a significant reduction in TG compared to simvastatin plus ezetimibe and rosuvastatin-containing therapy (47, 33 and 25%, respectively; P≤0.05). Atorvastatin plus niacin SR was associated with a significant reduction in Lp(a) compared to simvastatin plus ezetimibe and rosuvastatin (20 mg)-containing therapy (-14, 7 and 18%, respectively; P≤0.05). Atorvastatin plus niacin SR was associated with a significant reduction in apo B compared to rosuvastatin (43 vs 39%, respectively; P≤0.05). Side effects were similar across treatments (P values not reported). There were no cases of myopathy or hepatotoxicity reported.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs rosuvastatin 10 mg/day plus niacin SR 500 mg/day for 4 weeks, followed by rosuvastatin 10 mg/day plus niacin SR 1,000 mg/day for 4 weeks, followed by rosuvastatin 20 mg/day plus niacin SR 1,000 mg/day				
Bays et al.[126] (2008) Fenofibric acid 135 mg plus moderate dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) Extension study patients received the same type of statin that was used in the statin-containing arms of the controlled	MC, OL Patients with mixed dyslipidemia completing 1 of 3 MC, PRO, DB, RCT 12-week studies were eligible	N=2,201 1 year	Primary: Safety, percent changes from baseline in TG, HDL-C, and LDL-C Secondary: Percent changes in non-HDL-C, VLDL-C, TC, apoB, and hsCRP	Primary: Of the 2,201 patients who received at least one dose of fenofibric acid plus statin combination therapy, six patients (0.3%) died during the conduct of the ES; no death was considered by the investigator to be treatment related. Overall, 148 (6.7%) patients had treatment-emergent serious adverse events (fenofibric acid plus rosuvastatin, 7.2%; fenofibric acid plus simvastatin, 7.8%; fenofibric acid plus atorvastatin 4.6%). The most common treatment-emergent serious adverse events were osteoarthritis, deep vein thrombosis, coronary artery disease, MI, and chest pain, diverticulitis, syncope, and intervertebral disc protrusion. A total of 1,856 patients (84.3%) had one or more treatment-emergent adverse events (fenofibric acid plus rosuvastatin, 83.1%; fenofibric acid plus simvastatin, 86.2%; fenofibric acid plus atorvastatin, 85.2%). The most frequently reported adverse events were headache, upper respiratory tract infection, nasopharyngitis, and back pain. Among patients who received fenofibric acid monotherapy in a controlled study, treatment with fenofibric acid plus moderate-dose statin combination

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
study in which they participated.				therapy for 52 weeks resulted in an additional median percent decrease in TG (-22.0%), mean percent decrease in LDL-C (-38.1%), and mean percent increase in HDL-C (6.2%). Among patients who received moderate-dose statin monotherapy in a controlled study, treatment with fenofibric acid plus moderate-dose statin combination therapy for 52 weeks resulted in an additional median percent decrease in TG (-30.5%) and mean percent increases in HDL-C (13.1%) and LDL-C (3.1%). Among patients who received fenofibric acid plus low-dose statin combination therapy in a controlled study, there was an additional median percent decrease in TG (-4.2%), mean percent increase in HDL-C (4.8%), and mean percent decrease in LDL-C (-9.7%) after the statin dose was increased for 52 weeks. The group of patients who were treated with fenofibric acid plus moderate-dose statin in a controlled study and continued the same therapy in the extension study exhibited sustained improvements in lipid parameters throughout the course of therapy. For this group of patients, treatment with fenofibric acid plus moderate-dose statin combination therapy for a total of 64 weeks decreased TG from a mean baseline of 297.8 mg/dL to a mean final level of 138.0 mg/dL, decreased LDL-C from a mean baseline of 153.1 mg/dL to a mean final level of 94.2 mg/dL, and increased HDL-C from a mean baseline of 38.2 mg/dL to a mean final level of 47.7 mg/dL. Secondary: Among patients who received fenofibric acid monotherapy or moderate-dose statin monotherapy in the controlled studies, treatment with fenofibric acid plus moderate-dose statin combination therapy in the extension study resulted in additional mean percent decreases in non-HDL-C, VLDL-C, TC, and apo B, and median percent decrease in hsCRP that were sustained throughout 52 weeks of combination therapy. For patients initially treated with fenofibric acid plus low-dose statin combination therapy, increasing the statin dose resulted in additional mean percent decreases in non-HDL-C, TC, and apo B and median percent decrease in hsCRP, which were sustained throughout the study.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Kipnes et al.[127] (2010) Fenofibric acid 135 mg/day plus a moderate dose statin (rosuvastatin 20 mg/day, simvastatin 40 mg/day or atorvastatin 40 mg/day)	ES, OL Patients with mixed dyslipidemia at the start of a 1 year, ES, OL	N=310 1 year (2 years of total therapy)	Primary: Safety and efficacy Secondary: Not reported	Primary: No deaths occurred during the two year trial. The incidence of serious adverse events was numerically highest with fenofibric acid plus rosuvastatin (14.9%) compared to fenofibric acid plus simvastatin (8.0%) or atorvastatin (5.8%). The incidences of adverse events were similar among all treatments as well (94.8, 90.0 and 97.7%). Adverse events tended to occur early in treatment, without the development of new types of adverse events over time. The most common treatment-related adverse events were muscle spasms (3.9%), increased blood creatine phosphokinase (3.5%), headache (2.9%), myalgia (2.9%), dyspepsia (2.3%) and nausea (2.3%). Rhabdomyolysis was not reported with any treatment. Nine patients discontinued therapy due to adverse events, with similar incidences among all treatments. Myalgia was the most common reason for discontinuation. No significant difference in the incidence of laboratory elevations was observed among the treatment groups. Incremental improvements in mean percentage changes in all efficacy variables were observed after the first visit in the year one ES (week 16). This effect was sustained for greater than two years and sizable mean percentage changes in all efficacy variables were observed at week 116. In the overall population, the mean percentage changes from baseline to week 116 in efficacy variables were: 17.4 (HDL-C), -46.4 (TG), -40.4 (LDL-C), -47.3 (non-HDL-C), -37.8 (TC) and -52.8% (VLDL-C). Significant differences among treatments were observed for non-HDL-C (-48.60±13.58 vs -41.70±13.10 vs -47.30±12.50%; P=0.011), TC (-38.70±12.16 vs -32.50±10.86 vs -38.60±10.85%; P=0.007) and VLDL-C (-56.80±25.17 vs -40.30±51.25 vs -51.20±35.42%; P=0.019). Secondary: Not reported
Alrasadi et al.[128] (2008) <u>Protocol 1</u> Fenofibrate 200 mg/day for 8 weeks	XO Men with HDL-C <5th percentile for age- and gender-matched patients and an identified	N=19 32 weeks	Primary: Percent changes in HDL-C and TC/HDL-C ratio Secondary: Not reported	Primary: <u>Protocol 1</u> The mean percent change in HDL-C was +6, -6, and +22% in patients receiving fenofibrate, atorvastatin, and niacin, respectively. Only niacin significantly raised HDL-C (P<0.05). The mean percent change in TC/HDL-C ratio was +19, -26, and -22% in patients receiving fenofibrate, atorvastatin, and niacin, respectively. Both

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs atorvastatin 20 mg/day for 8 weeks vs niacin SR 1 g BID for 8 weeks <u>Protocol 2</u> Fenofibrate 200 mg/day and atorvastatin 20 mg/day for 8 weeks vs niacin SR 1 g BID and atorvastatin 20 mg/day for 8 weeks Patients in whom a statin was required were switched or maintained on atorvastatin 20 mg throughout the study in Protocol 2.	genetic cause of HDL deficiency or ≥1 first degree relative affected with HDL deficiency			niacin and atorvastatin significantly lowered TC/HDL-C (P<0.05 and P<0.01, respectively). <u>Protocol 2</u> The mean percent change in HDL-C was -2 and +18% in patients receiving fenofibrate plus atorvastatin and niacin plus atorvastatin, respectively. Only the group receiving niacin experienced a significant increase in HDL-C (P<0.05). The mean percent change in TC/HDL-C ratio was +32 and -32% in patients receiving fenofibrate plus atorvastatin and niacin plus atorvastatin, respectively. Only the group receiving niacin experienced a significant decrease in TC/HDL-C (P<0.01). Secondary: Not reported
Jones et al.[129] (2009)	Pooled analysis of 3 AC, DB, MC, RCT	N=2,715 12 weeks	Primary: Mean percent change in HDL-	Primary: Fenofibric acid plus low-dose statin combination therapy resulted in a greater mean percent increase in HDL-C (18.1 vs 7.4%; P<0.001) and a greater mean

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Fenofibric acid 135 mg QD vs low-dose statin (rosuvastatin 10 mg, simvastatin 20 mg, or atorvastatin 20 mg) QD vs fenofibric acid 135 mg plus low-dose statin (rosuvastatin 10 mg, simvastatin 20 mg, or atorvastatin 20 mg) QD vs moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) QD vs fenofibric acid	Patients >18 years of age, with HDL-C <40 mg/dL (men) or <50 mg/dL (women), TGs ≥150 mg/dL, and LDL-C ≥130 mg/dL ≥130 mg/dL		C, TGs (fenofibric acid plus atorvastatin vs atorvastatin), and LDL-C (fenofibric acid plus atorvastatin vs fenofibric acid) Secondary: Mean percent change in non-HDL-C, VLDL-C, TC, apo B, and hsCRP; safety	percent decrease in TG (-43.9 vs -16.8%; P<0.001) compared to low-dose statin monotherapy, and a greater mean percent decrease in LDL-C (-33.1 vs -5.1%; P<0.001) compared to fenofibric acid monotherapy. Fenofibric acid plus moderate-dose statin combination therapy resulted in a greater mean percent increase in HDL-C (17.5 vs 8.7%; P<0.001) and a greater mean percent decrease in TG (-42.0 vs -23.7%; P<0.001) compared to moderate-dose statin monotherapy, and a greater mean percent decrease in LDL-C (-34.6 vs -5.1%; P<0.001) compared to fenofibric acid monotherapy. No formal comparisons were made between the high-dose statin monotherapy group and the other treatment groups. Secondary: Greater improvements in non-HDL-C, VLDL-C, TC, and apo B were observed for fenofibric acid plus low-dose statin combination therapy compared to corresponding monotherapies (P≤0.001). Combination therapy was generally well tolerated, and safety profiles were similar to monotherapies. No rhabdomyolysis was reported.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
135 mg QD plus moderate-dose statin QD vs high-dose statin (rosuvastatin 40 mg, simvastatin 80 mg, or atorvastatin 80 mg) QD				
Bays et al.[130] (2010) COMBOS Omega-3-acid ethyl esters (Lovaza®) 4 g/day plus simvastatin 40 mg/day Patients who received placebo in the COMBOS trial were switched to OL treatment with omega-3-acid ethyl esters plus simvastatin (Switchers). Those who received omega-3-acid ethyl esters plus simvastatin	ES, OL of COMBOS Patients 18 to 79 years of age who had been receiving stable dose statin therapy for ≥8 weeks prior to trial enrollment	N=188 Up to 24 months	Primary: The difference between Nonswitchers and Switchers in median percent change in non-HDL-C from COMBOS end of treatment to month four Secondary: Difference in the median percent change in non-HDL-C from COMBOS end of treatment to month 12 and 24; the change in non-HDL-C from COMBOS	Primary: The percent change in non-HDL-C from COMBOS end of treatment to month four revealed a greater response among Switchers when compared to Nonswitchers. At month four, the median percent change in non-HDL-C from the end of DB treatment was -9.4% in Switchers and 0.9% in Nonswitchers (P<0.001). Secondary: After 12 and 24 months of treatment, the median percent change in non-HDL-C from COMBOS end of treatment in Nonswitchers vs Switchers was -0.2 vs -0.64% (P=0.027) and 1.6 vs -6.3% (P=0.004). Reductions in non-HDL-C were maintained throughout the trial. After four, 12 and 24 months of treatment, the median percent change in non-HDL-C from COMBOS baseline in the total population was -8.3, -7.3 and -8.9%, respectively (P<0.001 for all). After four, 12 and 24 months of treatment, the median percent change in non-HDL-C from COMBOS baseline in Nonswitchers vs Switchers was -5.4 vs -10.3% (P=0.062), -6.6 vs -8.1% (P=0.604) and -7.8 vs -9.0% (P=0.496). Consistent with the non-HDL-C response, comparisons of the changes from the COMBOS end of treatment to months four, 12 and 24 in TG and other lipoprotein lipid parameters generally revealed greater reductions in Switchers vs Nonswitchers. The comparisons of the change from COMBOS baseline to these same endpoints reveled generally nonsignificant differences between the

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
in the COMBOS trial were maintained on current therapy (Nonswitchers) All patients continued therapeutic lifestyle changes diet.			baseline to months four, 12 and 24 and from COMBOS end of treatment to months four, 12 and 24; percent changes in TC, HDL-C, LDL-C, VLDL-C, TG and TC:HDL-C for the same time points; HbA_{1c} levels	two groups. Median percent reductions from COMBOS baseline in TG, TC and VLDL-C in the total population were maintained at months four, 12 and 24 of treatment (P<0.001 for all). Omega-3-acid ethyl esters produced small median percent increases from baseline LDL-C levels at months four, 12 and 24. Among the subset of patients who had HbA_{1c} measured at baseline (n=38), the median absolute change in HbA_{1c} after 24 months of treatment was 0.1% (P value not reported).
Rosen et al.[131] (2013) Ezetimibe/ simvastatin (EZ/S) 10/20 mg vs doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) vs switching to rosuvastatin 10 mg	AC, DB, MC, RCT Patients ≥18 and <80 years old with type 1 or 2 diabetes mellitus ($HbA_{1c} \leq 8.5\%$) and symptomatic CVD, who were naïve to statin and/or ezetimibe or were taking a stable dose of approved lipid-lowering therapy	N=808 12 weeks (6 weeks of DB treatment after run-in period)	Primary: Percent change from baseline in LDL-C at week 6 Secondary: Percent change from baseline in TC, TG, HDL-C, non-HDL-C, Apo B, Apo A-I, and high-sensitivity C-reactive protein (hs-CRP) at week 6 and the percent of patients with LDL-C <70 mg/dL at week	Primary: Treatment with EZ/S 10/20 mg resulted in a significantly greater reduction in LDL-C compared with doubling the baseline statin dose (−23.13 vs −8.37%; P< 0.001). In the population of patients receiving simvastatin 20 mg or atorvastatin 10 mg at baseline, the percent reduction in LDL-C was numerically greater when switched to EZ/S than when switched to rosuvastatin 10 mg following six weeks of treatment (−23.13 vs −19.32%; P=0.060). Secondary: There were significantly greater reductions in TC, Apo B, and non-HDL-C in subjects taking EZ/S 10/20 mg compared with subjects who doubled their statin dose and with those taking rosuvastatin 10 mg. For all other lipids and lipoproteins, the percent changes were not statistically significantly different between treatments. The percent of patients reaching LDL-C goal of <70 mg/dL was significantly greater with ezetimibe/simvastatin (54.5%) vs doubling the baseline statin dose (27.0%) or switching to rosuvastatin 10 mg (42.5%). The safety profile appeared generally comparable between all groups.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			6, safety	
Bays et al.[132] (2013) PACE Period I: adding ezetimibe 10 mg to stable atorvastatin 10 mg vs doubling atorvastatin to 20 mg vs switching to rosuvastatin 10 mg Subjects in the latter 2 groups who persisted with elevated LDL-C levels (≥100 and ≤160 mg/dL) after period I, entered period II: subjects on atorvastatin 20 mg had ezetimibe added to their	AC, DB, RCT Patients aged ≥18 and <80 years with primary hypercholesterolemia at high CV risk, lipid-lowering therapy naïve with an LDL-C between 166 and 190 mg/dL, or on a stable dose of statin, ezetimibe, or statin plus ezetimibe having LDL-C-lowering efficacy equivalent to or less than atorvastatin 10 mg After enrollment all patients were administered atorvastatin 10 mg daily as only lipid-lowering therapy for 5 weeks	N=1,547 12 weeks	Primary: Percent change from treated baseline in LDL-C levels at the end of period I Secondary: Percent change from treated baseline in LDL-C at the end of period II; percentage of subjects achieving LDL-C <100 or <70 mg/dl at the end of periods I and II; percent change from treated baseline in other lipids, lipoproteins, and high-sensitivity C-reactive protein (hsCRP) at the end of periods I and II; assessment of safety and tolerability	Primary: The addition of ezetimibe to atorvastatin 10 mg produced a greater reduction in LDL-C than doubling the atorvastatin dose to 20 mg or switching to rosuvastatin 10 mg (-22.2, -9.5, and -13.0, respectively; P<0.001, both groups). Secondary: The addition of ezetimibe to atorvastatin 10 mg produced significantly greater attainment of LDL-C <100 or <70 mg/dl and significantly greater reductions in total cholesterol, non–HDL cholesterol, apo B, and LDL-C/HDL-C, total/HDL-C, and non-HDL-C/HDL-C ratios than atorvastatin 20 mg or rosuvastatin 10 mg. The change from baseline in HDL-C, triglycerides, apo AI, and hsCRP were similar among treatments. At the end of period II, ezetimibe plus atorvastatin 20 mg reduced LDL-C significantly more than atorvastatin 40 mg (17.4 vs 6.9%, P<0.001); switching from rosuvastatin 10 mg to ezetimibe plus atorvastatin 20 mg reduced LDL-C significantly more than uptitrating to rosuvastatin 20 mg (17.1 vs 7.5%, P<0.001). All treatments were generally well-tolerated.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
atorvastatin, or uptitrated atorvastatin to 40 mg; subjects on rosuvastatin 10 mg switched to atorvastatin 20 mg plus ezetimibe or uptitrated rosuvastatin to 20 mg				
Foody et al.[133] (2013) Add-on group (patients who were initially on simvastatin, atorvastatin, or rosuvastatin monotherapy and added ezetimibe onto this therapy) vs titrator group (patients who either titrated their initial statin dose or switched to higher-potency statin monotherapy)	OS, RETRO Patients ≥18 years of age with a diagnosis of CHD or CHD risk-equivalent who had a prescription for statin monotherapy with baseline and follow-up LDL-C values, as well as no overlap with other lipid-lowering therapy and who had no discontinuations of lipid-lowering therapy at baseline or follow-up during the study period	N=15,365 Minimum of 6 weeks	Primary: Mean percent change from baseline in LDL-C and percentage of patients attaining LDL-C goals <70 mg/dL and <100 mg/dL Secondary: Not reported	Primary: The mean LDL-C levels at baseline were significantly higher in the add-on groups for each statin compared with those of the titrators. At follow-up, LDL-C levels were reduced more in the add-on groups (80 to 85 mg/dL) than in the titrator groups (87 to 95 mg/dL). Both the absolute changes in LDL-C levels and the percent changes from baseline were significantly greater in the add-on groups than in the titrator groups. Secondary: Not reported
Hypertriglyceridemia (Single Entity Agents)				

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Hogue et al.[134] (2008) Fenofibrate 200 mg QD vs atorvastatin 20 mg QD	RCT Patients with type 2 diabetes and hypertriglyceridemia	N=40 6 weeks	Primary: Lipids and TRL, inflammation and adhesion molecules Secondary: Not reported	Primary: Treatment with atorvastatin led to a significant decrease in plasma TC (-37.7%; P<0.0001), plasma TG (-37.6%; P<0.0001), plasma apo B (-43.2%; P<.0001), TRL-C (-44.1%; P<0.0001), TRL-TG (-36.9%; P<0.0001), TRL apo B (-13.8%; P=0.04), LDL-C (-43.0%; P<0.0001), LDL apo B (-42.7%; P<0.0001), and a significant increase in HDL-C (17.9%; P=0.001), and HDL apo A-I levels (10.3%; P=0.004). Treatment with fenofibrate led to a significant decrease in plasma C (-10.9%; P=0.0001), plasma TG (-41.4%; P=0.0002), plasma apo B (-9.9%; P=0.01), TRL-C (-52.8%; P<0.0001), TRL-TG (-46.3%; P=0.0002), and TRL apo B (-14.8%; P=0.02) and a significant increase in LDL-C (15.9%; P=0.04) and HDL-C (8.9%; P=0.05). There were significant differences in the percentage changes of plasma cholesterol, plasma apo B, LDL-C, and LDL apo B between the two treatment groups. There was no significant difference in the percentage in changes of plasma TG between the treatment groups. Treatment with atorvastatin significantly decreased plasma levels of CRP (-26.9%; P=0.004), soluble ICAM-1 (-5.4%; P=0.03), soluble VCAM-1 (-4.4%; P=0.008), soluble E-selectin (-5.7%; P=0.02), MMP-9 (-39.6%; P=0.04), soluble phospholipase A2 (-14.8%; P=0.04), and oxidized LDL (-38.4%; P<0.0001). Fenofibrate significantly decreased soluble E-selectin levels only (-6.0, P=0.04) and increased soluble phospholipase A2 levels (22.5%; P=0.004). Secondary: Not reported
Hypercholesterolemia Clinical Outcomes Trials (Single Entity Agents)				
Delaying the Progression of Atherosclerosis (Single Entity Agents)				
Nissen et al.[135] (2006) ASTEROID Rosuvastatin 40	MC, OL, PRO Patients ≥18 years of age requiring coronary	N=507 24 months	Primary: PAV, absolute change in TAV in the 10 mm subsegment of	Primary: Rosuvastatin achieved a significant reduction in PAV from baseline (-0.79%; 95% CI, -1.21 to -0.53; P<0.001). Rosuvastatin achieved significant reduction from baseline in atheroma volume

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg QD	angiography for a stable or unstable ischemic chest pain syndrome or abnormal exercise test, with ≥1 obstruction ≥20% angiographic luminal diameter narrowing in a coronary vessel, not on statin therapy for >3 months within the last 12 months		the coronary artery with the largest plaque volume at baseline Secondary: Change in normalized TAV, lipid parameters	in the most diseased 10 mm subsegment (-5.6 mm^3; 95% CI, -6.82 to -3.96; P<0.001). Secondary: Rosuvastatin achieved a significant reduction from baseline in normalized TAV (-12.5 mm^3; 95% CI, -15.08 to -10.48; P<0.001). Rosuvastatin achieved a significant reduction from baseline in the total normalized TAV (-6.8%; 95% CI, -7.82 to -5.60; P<0.001). Rosuvastatin achieved a significant reduction from baseline in TC (33.0%), LDL-C (53.2%), TG (14.5%), LDL-C:HDL-C ratio (58.5%) and non-HDL-C (47.2%; P<0.001). Rosuvastatin achieved a significant increase from baseline in HDL-C (14.7%; P<0.001).
Furberg et al.[135] (1994) ACAPS Lovastatin 20 to 40 mg QD plus warfarin 1 mg QD vs lovastatin 20 to 40 mg QD plus warfarin placebo vs lovastatin placebo plus warfarin 1 mg QD vs	DB, MC, PC, RCT Asymptomatic patients 40 to 79 years of age, with early carotid atherosclerosis as defined by B-mode ultrasonography and moderately elevated LDL-C (between the 60th and 90th percentiles)	N=919 3 years	Primary Three year change in the mean maximum IMT in 12 walls of the carotid arteries (near and far walls of the common carotid, the bifurcation and the internal carotid arteries on both sides of the neck) Secondary Change in single maximum IMT, incidence of	Primary The progression rate of mean maximum IMT was less with lovastatin plus warfarin than with lovastatin (P=0.04). The overall annualized progression rates of mean maximum IMT with lovastatin and placebo were -0.009 and 0.006 mm/year, respectively (P=0.001). Secondary: The changes in single maximum IMT with lovastatin and placebo were -0.036±0.022 and 0.000±0.011 mm/year, respectively (P=0.12). Fourteen of the 459 patients receiving lovastatin-placebo had a major cardiovascular event (four CHD deaths, five strokes and five nonfatal MI) compared to five of the 460 patients receiving placebo (P=0.04). There was one death in patients receiving lovastatin and eight in patients receiving lovastatin plus placebo (P=0.02). All six cardiovascular deaths were with lovastatin plus placebo, the remaining three deaths were cancer deaths. Lovastatin and lovastatin-placebo demonstrated no difference in ALT elevations of ≥200% the upper limit of normal.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
lovastatin placebo plus warfarin placebo			major cardiovascular events and adverse events	
Byington et al.[137] (1995) PLAC-II Pravastatin 20 mg QD in the evening, titrated up to 40 mg/day vs placebo	DB, PC, RCT Patients with a history of CHD and ≥1 extracranial carotid lesion with the maximum IMT ≥1.3 mm	N=151 3 years	Primary: Change in the mean of maximum IMT measurements in the common, internal and bifurcation carotid artery segments Secondary: Effects on individual carotid artery segments and clinical events	Primary: Pravastatin did not result in a significant reduction in the progression of mean maximum IMT (P=0.44). Pravastatin was associated with a significant 35% reduction in IMT progression in the common carotid artery (P=0.03). There was no significant effect on bifurcation (P=0.49) or on the internal carotid artery (P=0.93) with pravastatin. Secondary: Pravastatin was associated with a 60% reduction in clinical coronary events (P=0.09). When compared to placebo, a significant 61% reduction in the incidence of any coronary events and all-cause mortality was seen with pravastatin (P=0.04).
Yu et al.[138] (2007) Atorvastatin 80 mg QD vs atorvastatin 10 mg QD	DB, RCT Patients with CHD (confirmed by angiographic evidence of coronary stenosis, previous MI, PCI or angina pectoris), hypercholesterolemia and LDL-C >100 mg/dL	N=112 26 weeks	Primary: Improvement in IMT Secondary: Reduction in hsCRP level, proinflammatory cytokines at week 26	Primary: Atorvastatin 10 mg was not associated with a significant improvement in either left or right carotid IMT (P value not reported). Atorvastatin 80 mg led to a significant improvement in left carotid IMT (P=0.02) as well as the right carotid IMT from baseline (P=0.01). Secondary: Atorvastatin 10 mg was not associated with a significant change in hsCRP (P value not reported). Atorvastatin 80 mg led to a significant reduction in hsCRP level from baseline (P=0.01). Atorvastatin 10 mg was associated with a significant reduction in interleukin-8 (P=0.01), interleukin-18 (P<0.001) and tumor necrosis factor (P<0.001). Atorvastatin 80 mg led to a significant reduction in all the proinflammatory cytokines from baseline (P<0.05).
Schmermund et	DB, MC, RCT	N=471	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
al.[139] (2006) Atorvastatin 10 mg QD vs atorvastatin 80 mg QD	Patients 32 to 80 years of age without a history of MI, coronary revascularization or hemodynamically relevant stenoses, with moderate calcified coronary atherosclerosis (coronary artery calcification score ≥30), LDL-C 130 to 250 mg/dL in the absence of statin therapy or between 100 to 130 mg/dL under statin therapy, TG <400 mg/dL, ≥2 cardiovascular risk factors	12 months	The percent change in total coronary artery calcification volume score Secondary: Change in LDL-C	There was no significant difference in the primary endpoint between the two treatments (P=0.6477). Secondary: Atorvastatin 80 mg was associated with a 20% reduction in LDL-C compared to atorvastatin 10 mg (P value not reported).
Crouse et al.[140] (2007) METEOR Rosuvastatin 40 mg QD vs placebo	DB, RCT Patients 45 to 70 years of age with LDL-C 120 to 190 mg/dL among patients whose only CHD risk factor was age, and an LDL-C 120 to 160 mg/dL for patients with ≥2 CHD risk	N=984 2 years	Primary: Annualized rate of change in maximum CIMT of the 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb and internal carotid	Primary: Rosuvastatin was associated with a significant reduction in the annualized rate of change in maximum CIMT from baseline compared to placebo (P<0.001). Secondary: Rosuvastatin was associated with a significant 49% reduction in LDL-C from baseline compared to placebo (P<0.001). Rosuvastatin was associated with a significant reduction in the annualized rate of change in the maximum CIMT for the common carotid artery sites (P<0.001), carotid bulb (P<0.001) and internal carotid artery sites (P=0.02) from baseline compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	factors and a 10 year risk of CHD events of <10%, HDL-C ≤60 mg/dL, TG <500 mg/dL and maximum CIMT 1.2 to 3.5 mm from 2 separate ultrasounds		artery) Secondary: Annualized rate of change in maximum CIMT of the common carotid artery, carotid bulb and internal carotid artery sites; annualized rate of change in mean CIMT	Rosuvastatin was associated with a significant reduction in the annualized rate of change in the mean CIMT for the common carotid artery sites (P<0.001) from baseline compared to placebo.
Chan et al.[141] (2010) ASTRONOMER Rosuvastatin 40 mg/day vs placebo	DB, PC, RCT Patients 18 to 82 years of age with asymptomatic mild to moderate aortic stenosis	N=269 3 to 5 years	Primary: Hemodynamic parameters of aortic stenosis severity Secondary: Composite of aortic valve replacement and cardiac death	Primary: Progression of aortic stenosis measured by the peak gradient and aortic valve area did not differ between the two treatments (P values not reported). The mean changes in the peak aortic stenosis gradient, mean gradient and aortic valve area were no significantly different between the two treatments (P=0.32, P=0.49 and P=0.79, respectively). The annual increase in peak aortic stenosis was 6.1±8.2 and 6.3±6.9 mm Hg with placebo and rosuvastatin (P=0.83). The annual increase in the mean gradient was 3.9±4.9 and 3.8±4.4 mm Hg with placebo and rosuvastatin (P=0.79). The annual decrease in aortic valve area was 0.08±0.21 and 0.07±0.15 cm^2 (P=0.87). The linear mixed models did not show any significant differences in the primary outcomes between the two treatments at any time point during the follow up. Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				There were a total of seven cardiac deaths, one of which was associated with aortic valve replacement, and a total of 55 patients with aortic valve replacement. The survival curves of the outcome events (cardiac death or aortic valve replacement) were not significantly different between the two treatments (P=0.45).
Nissen et al.[142] (2004) REVERSAL Atorvastatin 40 mg BID vs pravastatin 40 mg QD	DB, MC, RCT Patients 30 to 75 years of age with >1 angiographic luminal narrowing ≥20% in diameter in a major epicardial coronary artery and an LDL-C 125 to 210 mg/dL; the vessel for analysis was required to have no stenosis >50% in a target segment >30 mm long	N=654 18 months	Primary: Percentage change in atheroma volume from baseline Secondary: Nominal change in atheroma volume, nominal change in atheroma volume in the 10 contiguous cross-sections with the greatest and the least atheroma volume	Primary: Atorvastatin was associated with a significant delay in atheroma volume progression compared to pravastatin (P=0.02). Secondary: Atorvastatin was associated with a significant nominal change in total atheroma volume compared to pravastatin (P=0.02). Atorvastatin was associated with a significant change in the percentage of atheroma volume compared to pravastatin (P<0.001). Atorvastatin was associated with a significant change in atheroma volume in the most severely diseased 10 mm vessel subsegment compared to pravastatin (P=0.01). Progression of coronary atherosclerosis from baseline occurred in 2.7% of pravastatin-treated patients (P=0.001) and none of the atorvastatin-treated patients (P=0.98). Atorvastatin 80 mg was associated with a significant reduction in TC, LDL-C, TG, apo B and hsCRP (P<0.001) compared to the pravastatin.
Schoenhagen et al.[143] (2006) REVERSAL Atorvastatin 40 mg BID vs	Serial intravascular ultrasound observations from the REVERSAL trial Patients 30 to 75 years of age with	N=654 18 months	Primary: Percentage change from baseline in external elastic membrane area lesion, lumen area lesion, plaque area	Primary: Atorvastatin was associated with a significant 6.6% increase in the external elastic membrane area lesion from baseline (P<0.0001). Atorvastatin was associated with a significant 7.3% increase in the lumen area lesion from baseline (P=0.0002). Atorvastatin was associated with a significant 7.9% increase in the plaque area lesion from baseline (P=0.0002).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
pravastatin 40 mg QD	>1 angiographic luminal narrowing ≥20% in diameter in a major epicardial coronary artery and an LDL-C 125 to 210 mg/dL; the vessel for analysis was required to have no stenosis >50% in a target segment >30 mm long		lesion and remodeling ratio Secondary: Not reported	Atorvastatin was associated with a significant 3.3% reduction in remodeling ratio from baseline (P=0.024). Pravastatin was associated with a significant 9% increase in the external elastic membrane area lesion from baseline (P=0.0002). Pravastatin was associated with a significant 9.5% increase in the lumen area lesion from baseline (P=0.0003). Pravastatin was associated with a significant 9.9% increase in the plaque area lesion from baseline (P=0.0022). Pravastatin was associated with a significant 2.7% reduction in remodeling ratio from baseline (P=0.0013). There was no significant difference between atorvastatin and pravastatin in terms of increase in plaque area from baseline (7.9 vs 9.9%, respectively; P=0.57). There was no significant difference between atorvastatin and pravastatin in terms of reduction in remodeling ratio from baseline (3.3 vs 2.7%, respectively; P=0.68). Secondary: Not reported
Nicholls et al.[144] (2006) REVERSAL Atorvastatin 40 mg BID vs pravastatin 40 mg QD	Subanalysis of REVERSAL trial Obese patients 30 to 75 years of age with >1 angiographic luminal narrowing ≥20% in diameter in a major epicardial	N=654 18 months	Primary: Percentage change from baseline in lipid parameters, atheroma volume Secondary: Not reported	Primary: Compared to the BMI <29.6 kg/m^2 group, obese patients receiving atorvastatin exhibited a significantly lower reduction in TC (40 vs 36%; P=0.007), LDL-C (55 vs 49%; P=0.008) and TG (35 vs 23%; P=0.04). Compared to the BMI <29.6 kg/m^2 group, obese patients receiving atorvastatin exhibited a significantly higher reduction in hsCRP (33 vs 40%; P=0.04). There was no significant difference in lipid parameters between the BMI groups among patients randomized to pravastatin (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	coronary artery and an LDL-C 125 to 210 mg/dL; the vessel for analysis was required to have no stenosis >50% in a target segment >30 mm long, stratified based on BMI >29.6 kg/m^2 or BMI <29.6 kg/m^2			Compared to the BMI <29.6 kg/m^2 group, obese patients receiving atorvastatin exhibited a significantly greater benefit on the total atheroma volume (P=0.01) and percent atheroma volume (P=0.0005). In contrast, pravastatin was associated with a significant 6.5% increase in atheroma volume in the obese group (P=0.006). Secondary: Not reported
Nissen et al.[145] (2005) REVERSAL Atorvastatin 40 mg BID vs pravastatin 40 mg QD	Subanalysis of REVERSAL trial evaluating the effect of statin therapy on LDL-C, hsCRP and CAD Patients 30 to 75 years of age with >1 angiographic luminal narrowing ≥20% in diameter in a major epicardial coronary artery and an LDL-C 125 to 210 mg/dL; the vessel for analysis was required to have no stenosis >50% in a target segment >30 mm	N=654 18 months	Primary: Percent change in TC, TG, CRP, non-HDL-C, HDL-C and atheroma volume Secondary: Not reported	Primary: Both treatments achieved a significant reduction from baseline in TC (63%; P<0.001), LDL-C (56%; P<0.001), TG (40%; P=0.002), CRP (22.4%; P<0.001) and non-HDL-C (33%; P<0.001). HDL-C was not significantly increased from baseline with either treatment (4.2%; P=0.11). Atorvastatin exhibited a slower rate of disease progression (atheroma volume) compared to pravastatin (0.2 vs 1.6%; P value not reported). Patients whose LDL-C and hsCRP reductions were greater than the median experienced a significantly slower rate of disease progression compared to patients with lower LDL-C and hsCRP reductions (P=0.001). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	long, stratified based on BMI >29.6 kg/m^2 or BMI <29.6 kg/m^2			
Ikeda et al.[146] (2013) PEACE Moderate (target LDL-C level is 100 mg/dL) vs intensive (target LDL-C level is 80 mg/dL) cholesterol-lowering therapy with pitavastatin	OL, PRO, RCT Patients with CIMT thickening (>1.1 mm) whose LDL-C level was more than 100 mg/dL	N=303 12 months	Primary: Change in mean CIMT Secondary: Change in maximum CIMT	Primary: The intensive pitavastatin therapy resulted in a significant reduction in mean far wall common CIMT (−0.024 mm). In contrast, there was no significant progression or reduction of mean far wall common CIMT in the moderate group (−0.0078 mm). Nevertheless, the difference of mean far wall common CIMT was not statistically significant between the groups (P=0.29). Secondary: Results similar to the primary end point were observed in the secondary end point. The difference of maximum CIMT between the groups did not reach the statistical significance (P=0.07).
Meaney et al.[147] (2009) VYCTOR Pravastatin 40 mg QD (ezetimibe 10 mg/day could be added if LDL <100 mg/dL if they had CHD or diabetes or <70 mg/dL if they had both conditions) vs	RCT, OL Patients 40 to 72 years of age with a 10-year absolute risk for coronary death or myocardial infarction ≥20 according to the ATP III recommendations	N=90 1 year	Primary: Change in CIMT Secondary: Changes in LDL-C and hsCRP	Primary: After one year, CIMT values were 0.93mm (-30%; P<0.01 vs baseline), 0.90 mm (-30%; P<0.01 vs baseline), and 0.92 mm (-25%; P<0.01 vs baseline) for pravastatin, simvastatin, and simvastatin-ezetimibe groups, respectively. There was no significant difference among the treatment groups. Secondary: At the end of the study, LDL-C levels were 48, 45, and 48 mg/dL for pravastatin, simvastatin, and simvastatin-ezetimibe groups, respectively (P<0.01 vs baseline for all). There was no significant difference among the treatment groups. The proportion of diabetic patients who attained LDL-C <70 mg/dL at the end of the trial were 62, 80, and 78% for pravastatin, simvastatin, and simvastatin-ezetimibe groups, respectively (P values not significant). There was no significant difference among the treatment groups.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
simvastatin 40 mg QD (dose could be increased to 80 mg/day if LDL <100 mg/dL if they had CHD or diabetes or <70 mg/dL if they had both conditions) vs simvastatin-ezetimibe 20-10 mg QD (dose of simvastatin could be increased to 40 mg/day if LDL <100 mg/dL if they had CHD or diabetes or <70 mg/dL if they had both conditions)				There were no significant differences in hsCRP, HDL-C, TG among the treatment groups.
Phan et al.[148] (2014) FATS-OS Combination therapy (lovastatin 40 mg/day, niacin 2 to 3 g/day, and colestipol 20 gm/day for 11 years, then continued with simvastatin 10 to	Case-control study Patients enrolled in the Familial Atherosclerosis Treatment Study (FATS), which randomized 176 men with elevated apo B levels and CAD	N=69 20 years	Primary: Mean common CIMT Secondary: Association between lipids levels and mean common CIMT	Primary: The mean CIMT measured in the combination group was significantly smaller as compared with the usual care group (0.902 ± 0.164 vs 1.056 ± 0.169 mm, P<0.001). Secondary: After 20 years, there were significant changes in lipoprotein levels observed in both groups. The combination therapy group had a greater percent decrease in TC (−42 ± 14 vs −31 ± 17%; P=0.008) and LDL-C (−57 ± 13 vs −38 ± 25%; P<0.001), greater percent increase in HDL-C (38 ± 43 vs 15 ± 23%, P=0.02), and greater decrease in TG (−28 ± 44 vs −1.0 ± 49%, P=0.03) as compared with usual care. CIMT was correlated with combination therapy (−0.154; −0.24 to −0.07;

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
80 mg/day or lovastatin 40 to 80 mg/day plus niacin 2 to 4 g/day vs conventional therapy (88% single statin therapy)				P<0.001), on-therapy LDL-C (0.201; 0.069 to 0.332; P=0.003), and percent change in LDL-C (0.04; 0.005 to 0.091; P=0.03). As compared with the usual care group, the combination treated group had a significantly younger mean vascular age (74.4 ± 16.5 years vs 84.6 ± 13.5 years; P<0.05).
Bays et al.[149,150] (2015) ODYSSEY OPTIONS I Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 12 if LDL ≥70 mg/dL) vs ezetimibe 10 mg QD vs atorvastatin (at double baseline dose) vs	AC, DB, MC, PG, RCT Patients ≥18 years of age with LDL-C ≥70 mg/dL and established heart disease or LDL-C ≥ 100 mg/dL and risk factors for CVE	N=355 24 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Safety evaluations	Primary: Among atorvastatin 20 and 40 mg regimens respectively, there was a significantly greater decrease in LDL-C with alirocumab add-on from baseline at week 24 compared to add-on ezetimibe, double dose atorvastatin and switching to rosuvastatin (44.1% and 54.0% vs 20.5% and 22.6%, 5.0% and 4.8%, and 21.4%; P<0.001 vs all comparators). Most alirocumab-treated patients (86%) maintained their 75 mg every two weeks regimen. Secondary: Treatment-emergent adverse events occurred in 65.4% of alirocumab patients, compare to 64.4% ezetimibe and 63.8% double atorvastatin/switch to rosuvastatin (data pooled).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
rosuvastatin 40 mg QD (atorvastatin 40 mg baseline dose cohort only) Prior to randomization, patients were stabilized on atorvastatin 20 mg to 40 mg QD.				
Farnier et al.[151] (2016) ODYSSEY OPTIONS II Add-on alirocumab 75 mg every 2 weeks (1-mL subcutaneous injection via pre-filled pen) vs add-on ezetimibe 10 mg/day vs double-dose rosuvastatin All patients received baseline	DB, DD, MC, RCT Patients with cardiovascular disease and LDL–C ≥70 mg/dL or cardiovascular disease risk factors and LDL–C ≥100 mg/dL	N=305 24 weeks	Primary: Percent change in calculated LDL–C from baseline to 24 weeks Secondary: Percent change from baseline in calculated LDL–C on-treatment at Week 24 in the modified ITT (mITT) population (on-treatment analysis), percent change in LDL–C from baseline to Week 12 (ITT and on-	Primary: In the baseline rosuvastatin 10 mg regimen ITT analysis, alirocumab add-on treatment significantly reduced LDL–C levels at Week 24 versus the other comparators (P<0.0001). From baseline, add-on alirocumab reduced LDL–C by 50.6%, add-on ezetimibe reduced LDL–C by 14.4%, and double-dose (20 mg) rosuvastatin reduced LDL–C by 16.3%. In the baseline rosuvastatin 20 mg regimen ITT analysis, mean reductions from baseline in LDL–C at Week 24 were greater in the alirocumab add-on group versus the other comparators. LDL–C reductions were 36.3% in the add-on alirocumab group, compared with 11.0% in the add-on ezetimibe group (P=0.0136) and with 15.9% in the double-dose (40 mg) rosuvastatin group (P=0.0453). However, the pre-specified threshold P-value for these 4-way comparisons was 0.0125; therefore, both primary comparisons failed to reach statistical significance in the baseline rosuvastatin 20 mg regimen. Secondary: As a result of both primary comparisons failing to reach statistical significance, all key secondary efficacy endpoints were not tested for statistical significance with respect to the two comparisons in the baseline rosuvastatin 20 mg regimen. In the baseline rosuvastatin 10 mg regimen groups, the proportion of patients at very-high and high CV risk who reached a LDL–C level of <70 mg/dL or

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
rosuvastatin regimens (10 or 20 mg)			treatment), the percent change in other lipid parameters, and the proportion of very-high and high CV risk patients reaching LDL–C <70 mg/ or <100 mg/ at Week 24, respectively, in both ITT and on-treatment analyses; Safety	<100 mg/dL at Week 24, depending on risk status, was significantly greater in the alirocumab add-on group (84.9%) compared with the ezetimibe add-on group (57.2%; P=0.0007) and the rosuvastatin 20 mg group (45.0%; P<0.0001). The proportion of patients who reached the more stringent LDL–C level of <70 mg/dL at Week 24 was also significantly greater in the alirocumab add-on group (77.8%) compared with the ezetimibe add-on and rosuvastatin 20 mg groups (43.1%; P<0.0001 and 31.3%; P<0.0001), respectively. Treatment-emergent adverse events occurred in 56.3% of alirocumab patients versus 53.5% ezetimibe and 67.3% double-dose rosuvastatin (pooled data).
Moriarty et al.[152] (2015) ODYSSEY ALTERNATIVE Alirocumab 75 mg SC every 2 weeks vs ezetimibe 10 mg/ day vs atorvastatin 20 mg/ day	AC, DB, MC, PG, RCT Patients with primary hypercholesterolemia at moderate to high cardiovascular risk with statin intolerance (unable to tolerate ≥2 statins, including one at the lowest approved starting dose) due to muscle symptoms	N=314 24 weeks	Primary: Percent change in calculated LDL–C from baseline to 24 weeks Secondary: Change from baseline to 24 weeks using on-treatment (modified ITT) LDL-C values, and percent change from baseline to 12 and 24 weeks in LDL-C, apolipoprotein B, non–HDL-C,	Primary: For the primary ITT efficacy analysis, LS mean change in LDL-C concentrations from baseline to week 24 were −45.0% for alirocumab and −14.6% for ezetimibe, with a difference between groups of −30.4% (P<0.0001). Secondary: For the on-treatment analysis, the change from baseline was −52.2% for alirocumab and −17.1% for ezetimibe (LS mean difference of −35.1%; P<0.0001). A substantial reduction in LDL-C concentration occurred over the first four weeks, which was greater in the alirocumab arm and persisted throughout the 24-week treatment period. At week 24, 52 (41.9%) patients on alirocumab and 5 (4.4%) of those on ezetimibe (P<0.0001; ITT analysis) reached an LDL-C goal of <70 mg/dL in very high cardiovascular risk patients or <100 mg/dL in moderate-to-high-risk patients. Corresponding results in the on-treatment population were 51.2% and 5.6% (P<0.0001). The greater effect of alirocumab relative to ezetimibe on LDL-C-lowering from baseline to week 24 was consistent across most of the prespecified subgroups in the ITT population. In addition, reductions in apolipoprotein B, non–HDL-C, total cholesterol and lipoprotein(a) concentrations were greater for alirocumab vs ezetimibe (all P<0.0001). There were no statistically significant differences

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			total cholesterol, lipoprotein(a), HDL-C, apolipoprotein A1, and fasting triglyceride concentrations; adverse events	between the two groups in changes in triglyceride, HDL-C, and apolipoprotein A1 concentrations. Overall rates of treatment-emergent and serious AEs were generally similar between treatment arms, and there were no deaths in the study.
Primary Prevention of Coronary Heart Disease (Single Entity Agents)				
Knopp et al.[153] (2006) ASPEN Atorvastatin 10 mg QD vs placebo	DB, MC, PG, RCT Patients 40 to 75 years of age with type 2 diabetes for ≥3 years prior to screening, LDL-C ≤140 (if they had a history of an MI or an interventional procedure >3 months before screening) or ≤160 mg/dL, TG ≤600 mg/dL	N=2,410 4 years	Primary: Time to occurrence of the composite clinical endpoint including cardiovascular death, nonfatal MI, nonfatal stroke, recanalization, CABG surgery, resuscitated cardiac arrest or worsening or unstable angina requiring hospitalization Secondary: Time to occurrence of cardiovascular death, noncardiovascular death, TIA,	Primary: There was no significant difference between the two treatments in the time to first primary event (HR, 90; 95% CI, 0.73 to 1.12; P=0.034). Less patients receiving atorvastatin experienced the primary endpoints compared to patients receiving placebo (13.7 vs 15.0%; P=0.034). Secondary: Atorvastatin was associated with a significant decrease in LDL-C compared to placebo (29.0 vs 1.6%; P<0.0001). Among patients without a prior history of an MI or interventional procedure, 10.4 and 10.8% of atorvastatin- and placebo-treated patients experienced a primary endpoint (HR, 97; 95% CI, 0.74 to 1.18). Among patients with a prior history of an MI or interventional procedure, 26.2 and 30.8% of atorvastatin- and placebo-treated patients experienced a primary endpoint (HR, 82; 95% CI, 0.59 to 1.15). RR reductions in fatal and nonfatal MI were 27% overall (P=0.10), 19% for patients treated for primary protection (P=0.41) and 36% for patients treated for secondary protection (P=0.11). Adverse events were similar in both treatments for the total, primary and secondary prevention groups (P value not reported). Serious adverse events occurred in 37.7 and 35.4% of atorvastatin- and placebo-treated patients (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			worsening or unstable angina not requiring hospitalization, worsening or unstable angina requiring hospitalization, surgery for newly diagnosed PAD and acute ischemic heart failure requiring hospitalization; cholesterol level reduction; safety	
Colhoun et al.[154] (2004) CARDS Atorvastatin 10 mg/day vs placebo All patients were randomized after a 6 week placebo lead in period.	DB, MC, RCT Patients 40 to 75 years of age with type 2 diabetes without a history of CHD, LDL-C ≤160 mg/dL, TG ≤600 mg/dL and ≥1 other CHD risk factor	N=2,838 3.9 years	Primary: Incidence of major cardiovascular events (CHD death, nonfatal MI, including silent MI on annual ECG, fatal or nonfatal stroke, resuscitated cardiac arrest and coronary revascularization procedures) Secondary:	Primary: Atorvastatin led to a significant 37% reduction in the RR of the primary endpoint compared to placebo (95% CI, 17 to 52; P=0.001). Secondary: Atorvastatin led to a significant 27% reduction in the RR of all-cause mortality compared to placebo (95% CI, 1 to 48; P=0.059). Atorvastatin led to a significant 32% reduction in the RR of any cardiovascular endpoint compared to placebo (95% CI, 15 to 45; P=0.001). Atorvastatin was associated with a significant reduction in stroke compared to placebo (1.5 vs 2.8%; HR, 0.52; 95% CI, 0.31 to 0.89). Atorvastatin was not associated with a significant reduction in coronary revascularization compared to placebo (HR, 0.69; 95% CI, 0.41 to 1.16). Atorvastatin was associated with a significant 40% reduction in baseline LDL-

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			All-cause mortality, acute hospital-verified cardiovascular endpoint (major cardiovascular disease events, angina, TIA, peripheral vascular disease requiring hospitalization or surgery), reduction in coronary revascular-ization, lipid reduction	C compared to placebo (P<0.0001). Atorvastatin was associated with a significant 26% reduction in baseline TC levels compared to placebo (P<0.0001). Atorvastatin was associated with a significant one percent increase in baseline HDL-C compared to placebo (P=0.0002). Atorvastatin was associated with a significant 36% reduction in baseline non-HDL-C compared to placebo (P<0.0001). Atorvastatin was associated with a significant 19% reduction in baseline TG compared to placebo (P<0.0001). Atorvastatin was associated with a significant 23% reduction in baseline apo B compared to placebo (P<0.0001). The frequency of adverse events was similar between the two treatments (P value not reported).
Neil et al.[155] (2006) CARDS Atorvastatin 10 mg/day vs placebo All patients were randomized after a 6 week placebo lead in period.	Post hoc analysis of CARDS Adult patients with type 2 diabetes without a history of CHD, LDL-C ≤160 mg/dL, TG ≤600 mg/dL and ≥1 other CHD risk factor; stratified by age (≥65 years of age)	N=2,838 3.9 years	Primary: Major cardiovascular events (acute CHD death, nonfatal MI, including silent MI on annual ECG, fatal or nonfatal stroke, resuscitated cardiac arrest and coronary revascularizatio n procedures) among patients ≥65 and <65 years of age	Primary: Atorvastatin led to a significant 38% reduction in the RR of the primary endpoint in patients ≥65 years of age (95% CI, 8 to 58; ARR, 3.9%, P=0.017). Consequently, 21 patients would need to be treated for four years to prevent one major cardiovascular event. Atorvastatin led to a significant 37% reduction in the RR of the primary endpoint in patients <65 years of age (95% CI, 7 to 57; ARR, 2.7%; P=0.019). Consequently, 33 patients would need to be treated for four years to prevent one major cardiovascular event. Secondary: There was no significant effect on all-cause mortality in either the <65 (P=0.98) or the ≥65 year old population (P=0.245). Atorvastatin led to a significant reduction in LDL-C among both the younger and the older patients compared to placebo (38 and 41%, respectively; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			Secondary: All-cause mortality, acute hospital-verified cardiovascular endpoint (major cardiovascular disease events, angina, TIA, peripheral vascular disease requiring hospitalization or surgery) among patients ≥65 and <65 years of age	Atorvastatin led to a significant reduction in TC among both the younger and the older patients compared to placebo (26 and 27%, respectively; P<0.001). Atorvastatin led to a significant reduction in TG among both the younger and the older patients compared to placebo (P<0.001). The frequency of adverse events was similar between the two treatments (P value not reported).
Hitman et al.[156] (2007) CARDS Atorvastatin 10 mg/day vs placebo All patients were randomized after a 6 week placebo lead in period.	Subanalysis of CARDS Patients 40 to 75 years of age with type 2 diabetes without a history of CHD, LDL-C ≤160 mg/dL, TG ≤600 mg/dL and ≥1 other CHD risk factor	N=2,838 3.9 years	Primary: Fatal or nonfatal stroke, type of stroke, risk factors for stroke Secondary: Not reported	Primary: Atorvastatin was associated with a significant 48% reduction in stroke compared to placebo (1.5 vs 2.5%; HR, 0.52; 95% CI, 0.31 to 0.89; P=0.016). Atorvastatin was associated with a significant 50% reduction in non-hemorrhagic stroke compared to placebo (1.1 vs 2.2%; HR, 0.50; 95% CI, 0.27 to 0.91; P=0.024). Atorvastatin was associated with a significant 42% reduction in stroke or TIAs compared to placebo (2.1 vs 3.6%; HR, 0.58; 95% CI, 0.37 to 0.92; P=0.019). Independent risk factors predicting stroke were age (HR, 2.3; P<0.001), microalbuminuria (HR, 2.0; P=0.007) and glycemic control (HR, 2.7; P=0.007). Women were at a lower risk for stroke than men (HR, 0.3; P=0.004). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Sever et al.[157] (2003) ASCOT-LLA Atorvastatin 10 mg/day vs placebo All patients received antihypertensive treatment (amlodipine or atenolol with additional therapy as needed to reach SBP and DBP goals of <140 and 90 mm Hg, respectively).	DB, MC, RCT Patients 40 to 79 years of age with either untreated or treated HTN, TC ≤6.5 mmol/L and not currently taking a statin or a fibrate; patients were also required to have >3 of the following cardiovascular disease risk factors: left-ventricular hypertrophy, ECG abnormality, diabetes type 2, PAD, previous stroke or TIA, age >55 years, microalbuminuria or proteinuria, male sex, smoking, TC:HDL-C >6 or family history of CHD	N=10,305 3.3 years	Primary: Combined endpoint of nonfatal MI and fatal CHD Secondary: The primary outcome without silent events, all-cause mortality, total cardiovascular mortality, fatal and nonfatal heart failure, fatal and nonfatal stroke, total coronary endpoints, total cardiovascular events and procedures	Primary: Atorvastatin was associated with a significant 36% reduction in the primary endpoint compared to placebo (HR, 0.64; 95% CI, 0.50 to 0.83; P=0.0005). Secondary: Atorvastatin was associated with a significant 38% reduction in the primary endpoint, excluding silent MIs, compared to placebo (HR, 0.62; 95% CI, 0.47 to 0.81; P=0.0005). Atorvastatin was not associated with a significant reduction in all-cause mortality (P=0.1649), cardiovascular mortality (P=0.5066) or fatal and nonfatal heart failure (P=0.5794) compared to placebo. Atorvastatin was associated with a significant 27% reduction in the risk for fatal and nonfatal strokes compared to placebo (HR, 0.73; 95% CI, 0.56 to 0.96; P=0.0236). Atorvastatin was associated with a significant 29% reduction in the risk for total coronary events compared to placebo (HR, 0.71; 95% CI, 0.59 to 0.86; P=0.005). Atorvastatin was associated with a significant 21% reduction in the risk for total cardiovascular events and procedures compared to placebo (HR, 0.79; 95% CI, 0.69 to 0.90; P=0.0005).
Sever et al.[158] (2005) ASCOT-LLA Atorvastatin 10 mg/day	2 year extension of ASCOT-LLA Patients 40 to 79 years of age with either untreated or treated HTN, TC	N=10,305 5.5 years	Primary: Combined endpoint of nonfatal MI and fatal CHD Secondary:	Primary: Atorvastatin was associated with a significant 36% reduction in the primary endpoint compared to placebo (HR, 0.64; 95% CI, 0.53 to 0.78; P≤0.0001). Secondary: Atorvastatin was associated with a significant 37% reduction in the primary endpoint, excluding silent MIs, compared to placebo (HR, 0.63; 95% CI, 0.51

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs placebo All patients received antihypertensive treatment (amlodipine or atenolol with additional therapy as needed to reach SBP and DBP goals of <140 and 90 mm Hg, respectively).	≤6.5 mmol/L and not currently taking a statin or a fibrate; patients were also required to have >3 of the following cardio-vascular disease risk factors: left-ventricular hypertrophy, ECG abnormality, diabetes type 2, PAD, previous stroke or TIA, age >55 years, microalbuminuria or proteinuria, male sex, smoking, TC:HDL-C >6 or family history of CHD		The primary outcome without silent events, all-cause mortality, total cardiovascular mortality, fatal and nonfatal stroke, fatal and nonfatal heart failure, total coronary endpoints, total cardiovascular events	to 0.77; P≤0.0001). Atorvastatin was associated with a significant 15% reduction in the risk for all-cause mortality compared to placebo (HR, 0.85; 95% CI, 0.74 to 0.98; P=0.0219). Atorvastatin was not associated with a significant reduction in cardiovascular mortality (P=0.1281), or fatal and nonfatal heart failure (P=0.9809) compared to placebo. Atorvastatin was associated with a significant 23% reduction in the risk for fatal and nonfatal strokes compared to placebo (HR, 0.77; 95% CI, 0.63 to 0.95; P=0.0127). Atorvastatin was associated with a significant 27% reduction in the risk for total coronary events compared to placebo (HR, 0.73; 95% CI, 0.63 to 0.85; P≤0.0001). Atorvastatin was associated with a significant 19% reduction in the risk for total cardiovascular events and procedures compared to placebo (HR, 0.81; 95% CI, 0.73 to 0.89; P≤0.0001).
Downs et al.[159] (1998) AFCAPS/TexCAPS Lovastatin 20 to 40 mg QD vs placebo	DB, MC, PC, RCT Men 45 to 73 years of age and postmenopausal women 55 to 73 years of age on a low-saturated fat, low-cholesterol diet with TC 180 to 264 mg/dL, LDL-C 130 to 190 mg/dL, HDL	N=6,605 5.2 years	Primary First acute major coronary event (fatal or nonfatal MI, unstable angina or sudden cardiac death) Secondary Fatal or nonfatal coronary revascularizatio	Primary After an average follow up of 5.2 years, lovastatin was associated with a significant 37% lower incidence of the first acute major coronary event compared to placebo (95% CI, 0.50 to 0.79; P<0.001). Secondary Lovastatin was associated with a significant 33% reduction in revascularization (95% CI, 0.52 to 0.85; P=0.001), 32% reduction in unstable angina (95% CI, 0.49 to 0.95; P=0.02), 40% reduction in the incidence of fatal or nonfatal MI (95% CI, 0.43 to 0.83; P=0.002), 25% reduction in fatal or nonfatal cardiovascular events (95% CI, 0.62 to 0.91; P=0.003) and 25% reduction in fatal or nonfatal coronary events (95% CI, 0.61 to 0.92; P=0.006) compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	≤45 mg/dL for men or ≤47 mg/dL for women and TG ≤400 mg/dL, without a prior history of MI, angina, claudication, cerebrovascular accident or TIA; patients with LDL-C 125 to 129 mg/dL were included when TC:HDL-C >6		n procedure, unstable angina, fatal or nonfatal MI, fatal or nonfatal cardiovascular events, fatal or nonfatal coronary events, cardiovascular mortality and CHD mortality, total mortality, fatal and nonfatal cancer, safety, discontinuation rates	There were too few events to perform survival analysis on cardiovascular (1.0 vs 1.4%) and CHD mortality (0.6 vs 0.8%) events based on prespecified criteria. The overall mortality rate and fatal and nonfatal cancer rates were similar between the two treatments (P value not reported). Discontinuation rates due to adverse events were 13.6 and 13.8% with lovastatin and placebo (P value not reported). Both treatments had similar rates of serious adverse events (34.2 vs 34.1%; P value not reported).
Schouten et al.[160] (2009) DECREASE III Fluvastatin XL 80 mg QD prior to surgery vs placebo Patients in both groups also received beta-blocker therapy prior to surgery	RCT, DB, PC Patients ≥40 years of age who were scheduled for noncardiac vascular surgery (abdominal aortic aneurysm repair, distal aortoiliac reconstruction, lower-limb arterial reconstruction, or carotid-artery endarterectomy) who were statin	N=497 ≥30 days post-surgery	Primary: Occurrence of myocardial ischemia Secondary: Composite of death from cardiovascular causes and nonfatal MI	Primary: Myocardial ischemia occurred in 10.8% of patients in the fluvastatin XL group within 30 days after surgery compared to 19.0% of patients in the placebo group (HR, 0.55; 95% CI, 0.34 to 0.88; P=0.01). The number of patients who would need to be treated to prevent 1 patient from having myocardial ischemia was 12. Secondary: The composite of death from cardiovascular causes or nonfatal myocardial infarction occurred in 4.8% of patients receiving fluvastatin XL compared to 10.1% of patients receiving placebo (HR, 0.47; 95% CI, 0.24 to 0.94; P=0.03). The number of patients who would need to be treated to prevent the composite end point of death from cardiovascular causes or nonfatal MI in one patient was 19.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	naïve			
No authors listed.[161] (2002) ALLHAT-LLT Pravastatin 40 mg/day vs usual care Vigorous cholesterol-lowering therapy in the usual care group was discouraged.	MC, OL, RCT Patients ≥55 years of age, with Stage 1 or 2 HTN, ≥1 additional CHD risk factor, fasting LDL-C 120 to 189 mg/dL for patients with no known CHD or 100 to 129 mg/dL for patients with known CHD and fasting TG <350 mg/dL	N=10,355 Mean, 4.8 years (maximum 7.8 years)	Primary: All-cause mortality Secondary: Composite of fatal CHD or nonfatal MI, cause-specific mortality, total and site-specific cancers	Primary: All-cause mortality did not differ significantly between the two treatments (RR, 0.99; 95% CI, 0.89 to 1.11; P=0.88). Secondary: Rates of CHD (fatal CHD plus nonfatal MI) and stroke were slightly lower with pravastatin compared to usual care (RR, 0.91; 95% CI, 0.79 to 1.04; P=0.16). There were 209 total strokes with pravastatin and 231 total strokes with usual care (RR, 0.91; 95% CI, 0.75 to 1.09; P=0.31). Heart failure rates were similar between the two treatments (RR, 0.99; 95% CI, 0.83 to 1.18; P=0.89). The six year cancer rates were similar between the two treatments (RR, 1.03; 95% CI, 0.89 to 1.19; P=0.66).
Nakamura et al.[162] (2006) MEGA Pravastatin 10 to 20 mg/day plus NCEP step I diet vs NCEP step I diet	OL, PRO, RCT Patients 40 to 70 years of age weighing ≥40 kg, with hypercholesterolemia, without a history of CHD or FH	N=8,214 Mean 5.2 years	Primary: CHD incidence, sudden cardiac deaths, MIs, coronary re-vascularization Secondary: CHD and cerebral infarction, all cardiovascular events, strokes, all-cause mortality	Primary: Pravastatin plus diet was associated with a significant reduction in the incidence of CHD compared to diet (3.3 vs 5.0%; HR, 0.67; 95% CI, 0.49 to 0.91; P=0.01). There was no significant difference between the two treatments in the incidence of sudden cardiac deaths or anginal episodes (P>0.05 for both). Secondary: Pravastatin plus diet was associated with a significant reduction in the incidence of MIs compared to diet (0.9 vs 1.6%; HR, 0.52; 95% CI, 0.29 to 0.94; P=0.03). Pravastatin plus diet was associated with a significant reduction in the incidence of coronary revascularizations compared to diet (2.0 vs 3.2%; HR, 0.60; 95% CI, 0.41 to 0.89; P=0.01). Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Pravastatin plus diet was associated with a significant reduction in the incidence of CHD and cerebral infarctions compared to diet (5.0 vs 7.1%; HR, 0.70; 95% CI, 0.54 to 0.90; P=0.005). Pravastatin plus diet was associated with a significant reduction in the incidence of all cardiovascular events compared to diet (6.4 vs 8.5%; HR, 0.74; 95% CI, 0.59 to 0.94; P=0.01). There was no significant difference between the two treatments in all-cause mortality or the incidence of strokes (P>0.05 for both).
No authors listed.[163] (1993) PMS-CRP Pravastatin 20 to 40 mg/day vs placebo	DB, MC, PC, RCT Adult patients with hypercholesterolemia	N=1,062 26 weeks	Primary: Lipid levels at 13 and 26 weeks, occurrence of cardiovascular events Secondary: Not reported	Primary: After 13 weeks, pravastatin was associated with significant reductions in LDL-C (26%), TC (19%) and TG (12%) and significant elevations in HDL-C (7%) compared to placebo (P<0.001 for all). Throughout the 26 weeks, there were no differences in the total incidence of clinical adverse events between the two treatments. No MIs or cerebral infarctions occurred with pravastatin, and a total of six MIs and three cerebral infarctions occurred with placebo (P value not reported). Secondary: Not reported
Shepherd et al.[164] (1995) WOSCOPS Pravastatin 40 mg/day vs placebo	DB, PC Men 45 to 64 years of age with hypercholesterolemia and no history of MI	N=6,595 4.9 years	Primary: Incidence of nonfatal MI or death from CHD as a first event Secondary: Incidence of death from CHD and nonfatal MI	Primary: Pravastatin was associated with a significant 31% reduction in the risk of the combined primary endpoint of definite nonfatal MI and death from CHD (95% CI, 17 to 43; P<0.001) compared to placebo. The absolute difference in the risk at five-years was 2.4%. Secondary: The reduction in the risk of nonfatal MI with pravastatin was significant whether the definite cases of MI were considered alone or in combination with suspected cases (P≤0.001). In the analysis of both definite and suspected cases of death from CHD, there was a significant risk reduction of 33% with pravastatin (95% CI, 1 to 55; P=0.042), but not in the analysis of definite cases alone (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				When the effect of pravastatin on death from all cardiovascular causes was analyzed, a 32% risk reduction was observed (95% CI, 3 to 53; P=0.033). Additionally, pravastatin was associated with a significant 31% reduction in the frequency of coronary angiography (95% CI, 10 to 47; P=0.007) and a 37% reduction in the frequency of revascularization procedures (95% CI, 11 to 56; P=0.009) compared to placebo.
Ford et al.[165] (2007) WOSCOPS Pravastatin 40 mg/day vs placebo	ES of WOSCOPS Men 45 to 64 years of age with hypercholesterolemia and no history of MI	N=6,595 15 years of total follow-up	Primary: Mortality from CHD or nonfatal MI, CHD, cardiovascular causes, all-cause mortality Secondary: Not reported	Primary: Pravastatin was associated with a significant reduction in the risk of death from CHD or nonfatal MI compared to placebo over a 15 year period (11.8 vs 15.5%; HR, 0.73; 95% CI, 0.63 to 0.83; P<0.001). Pravastatin was associated with a significant reduction in the risk of death from all causes compared to placebo over a 15 year period (18.7 vs 20.5%; HR, 0.88; 95% CI, 0.79 to 0.99; P=0.03). Pravastatin was associated with a significant reduction in the risk of death from cardiovascular causes compared to placebo over a 15 year period (7.6 vs 9.0%; HR, 0.81; 95% CI, 0.68 to 0.96; P=0.01). Pravastatin was associated with a significant reduction in the risk of death from CHD compared to placebo over a 15 year period (5.1 vs 6.3%; HR, 0.78; 95% CI, 0.64 to 0.96; P=0.02). Pravastatin was associated with a small increase in the risk of death from stroke compared to placebo over a 15 year period (1.6 vs 1.1%; HR, 1.37; 95% CI, 0.90 to 2.09; P=0.14). Secondary: Not reported
Ridker et al.[166] (2008) JUPITER Rosuvastatin 20 mg/day	DB, MC, PC, RCT Men ≥50 years of age and women ≥60 years of age with no known	N=17,802 1.9 years	Primary: Incidence of a first major cardiovascular event (nonfatal MI, nonfatal stroke,	Primary: At the time of trial termination (median follow up, 1.9 years; maximal follow up, 5.0 years), 142 first major cardiovascular events had occurred with rosuvastatin compared to 251 first major cardiovascular events with placebo. The rates of the primary endpoint were 0.77 and 1.36 per 100 persons-years of follow up with rosuvastatin and placebo, respectively (HR for rosuvastatin, 0.56; 95% CI, 0.46 to 0.69; P<0.00001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs placebo	history of cardiovascular disease, LDL-C <130 mg/dL, hsCRP ≥2 mg/L and TG <500 mg/dL		hospitalization for unstable angina, arterial re-vascularization procedure or confirmed death from cardiovascular causes) Secondary: Individual components of the primary endpoint, all-cause mortality	The number of patients who would need to be treated with rosuvastatin for two years to prevent the incidence of one primary endpoint is 95, and the NNT for four years is 31. Secondary: Rosuvastatin was associated with significant reductions in rates of the individual components of the primary endpoint. The corresponding rates per 100 persons-years of follow up for the individual endpoints with rosuvastatin and placebo were: 0.17 and 0.37 for fatal or nonfatal MI (HR, 0.46; 95% CI, 0.30 to 0.70; P=0.0002); 0.18 and 0.34 for fatal or nonfatal stroke (HR, 0.52; 95% CI, 0.34 to 0.79; P=0.002); 0.41 and 0.77 for revascularization or unstable angina (HR, 0.53; 95% CI, 0.40 to 0.70; P<0.00001) 0.45 and 0.85 for the combined endpoint of MI, stroke or death from cardiovascular causes (HR, 0.53; 95% CI, 0.40 to 0.69; P<0.00001) and 1.00 and 1.25 for death from any cause (HR, 0.80; 95% CI, 0.67 to 0.97; P=0.02). In analyses limited to deaths for which the date of death was known with certainty, there was a similar reduction in the HR associated with rosuvastatin (0.81; 95% CI, 0.67 to 0.98; P=0.03). For patients with elevated hsCRP levels but no other major risk factor other than increased age, the benefit of rosuvastatin was similar to that for higher risk patients (HR, 0.63; 95% CI, 0.44 to 0.92; P=0.01).
Everett et al.[167] (2001) JUPITER Rosuvastatin 20 mg/day vs placebo	Post hoc analysis of JUPITER Men ≥50 years of age and women ≥60 years of age with no known history of cardiovascular disease, LDL-C <130 mg/dL, hsCRP ≥2 mg/L and TG <500 mg/dL	N=17,802 1.9 years (maximum, 5.0 years)	Primary: Incidence of stroke Secondary: Not reported	Primary: At the time of trial termination, 33 and 64 strokes occurred in patients receiving rosuvastatin and placebo. Rosuvastatin resulted in a 48% reduction in the HR of fatal and nonfatal stroke compared to placebo (incidence rate, 0.18 vs 0.34 per 100 person-years; HR, 0.52; 95% CI, 0.34 to 0.79; P=0.002), a finding that was consistent across all examined subgroups. This finding was due to a 51% reduction in the rate of ischemic stroke (HR, 0.49; 95% CI, 0.30 to 0.81; P=0.004), with no difference in the rates of hemorrhagic stroke (HR, 0.67; 95% CI, 0.24 to 1.88; P=0.44). TIAs were observed with similar frequency in the two treatments (HR, 0.93; 95% CI, 0.56 to 1.56; P=0.79). The projected NNT for five-years to prevent one stroke was 123. Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Not reported
Koenig et al.[168] (2001) JUPITER Rosuvastatin 20 mg/day vs placebo	Post hoc analysis of JUPITER Men ≥50 years of age and women ≥60 years of age with no known history of cardiovascular disease, LDL-C <130 mg/dL, hsCRP ≥2 mg/L and TG <500 mg/dL; patients with high global cardiovascular risk (10 year Framingham risk score >20% and 10 year European systematic coronary risk evaluation ≥5%)	N=17,802 (9 and 52% were considered to be high risk based on 10 year Framingham risk score and 10 year European systematic coronary risk evaluation) 1.9 years (maximum, 5.0 years)	Primary: Incidence of first MI, stroke or cardiovascular death; first incidence of a first major cardiovascular event (nonfatal MI, nonfatal stroke, hospitalization for unstable angina, arterial revascularization procedure or confirmed death from cardiovascular causes); all-cause mortality Secondary: Not reported	Primary: Patients with a 10 year Framingham risk score >20% the rate of the combined endpoint of MI, stroke or cardiovascular death was 9.4 and 18.2 per 1,000 person-years with rosuvastatin and placebo (HR, 0.50; 95% CI, 0.27 to 0.93; P=0.028). Rosuvastatin had no significant effect on the incidence of major cardiovascular events (P=0.155) and all-cause mortality (P=0.193). Among patients with a 10 year European systematic coronary risk evaluation ≥5%, the corresponding rates were 6.9 vs 12.0 using a model extrapolating risk for age ≥65 years (HR, 0.57; 95% CI, 0.43 to 0.78; P=0.0003) and rates were 5.9 vs 12.7 when risk for age was capped at 65 years of age (HR, 0.47; 95% CI, 0.32 to 0.68; P<0.0001). Rosuvastatin significantly reduced the incidence of major coronary events (P=0.0003) but not all-cause mortality (P=0.076) in patients with a 10 year European systematic coronary risk evaluation ≥5% extrapolating risk for age ≥65 years. When the risk for age was capped at 65 years of age, rosuvastatin had significant effect on the incidence of major cardiovascular events (P<0.0001) and all-cause mortality (P=0.022). Secondary: Not reported
Ridker et al.[169] (2010) JUPITER Rosuvastatin 20 mg/day vs placebo	Post hoc analysis of JUPITER Men ≥50 years of age and women ≥60 years of age with no known history of cardiovascular disease, LDL-C <130 mg/dL,	N=17,802 (n=3,267 with moderate CKD) 1.9 years (maximum, 5.0 years)	Primary: Incidence of a first major cardiovascular event (nonfatal MI, nonfatal stroke, hospitalization for unstable angina, arterial revascularizatio	Primary: Among patients with eGFR <60 mL/min, the incidence rate of the primary endpoint was significantly lower with rosuvastatin compared to placebo (incidence rate, 1.08 vs 1.95 per 100 person-years; HR, 0.55; 95% CI, 0.38 to 0.82; P=0.002). Irrespective of treatment, at trial end 111 and 282 patients with eGFR <60 and ≥60 mL/min suffered a primary endpoint (incidence rate, 1.51 vs 0.95 per 100 person-years; HR, 1.54; 95% CI, 1.23 to 1.92; P=0.0002). Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	hsCRP ≥2 mg/L and TG <500 mg/dL; stratified by kidney function (eGFR <60 mL/min and eGFR ≥60 mL/min)		n procedure or confirmed death from cardiovascular causes), all-cause mortality Secondary: Individual components of the primary endpoint, all-cause mortality	Among patients with eGFR <60 mL/min, rosuvastatin significantly reduced the rate of MI (incidence rate, 0.21 vs 0.54 per 100 person-years; HR, 0.40; 95% CI, 0.17 to 0.90; P=0.02), arterial revascularization (0.51 vs 1.07; HR, 0.48; 95% CI, 0.28 to 0.83; P=0.006), the combined MI, stoke or confirmed cardiovascular death (0.64 vs 1.09; HR, 0.59; 95% CI, 0.36 to 0.99; P=0.04), venous thromboembolism (0.16 vs 0.46; HR, 0.14 to 0.88; P=0.02), all-cause mortality (0.85 vs 1.53; HR, 0.56; 95% CI, 0.37 to 0.85; P=0.005), combined primary endpoint plus any death (1.72 vs 3.13; HR, 0.55; 95% CI, 0.41 to 0.75; P=0.0001) and the primary endpoint plus VTE plus any death (1.86 vs 3.51; HR, 0.53; 95% CI, 0.40 to 0.71; P<0.0001) compared to placebo. Among patients with eGFR <60 mL/min, rosuvastatin demonstrated no benefit compared to placebo in reducing the risk of stroke (incidence rate, 0.27 vs 0.38 per 100 person-years; HR, 0.71; 95% CI, 0.31 to 1.59; P=0.40).
Ridker et al.[170] (2009) JUPITER Rosuvastatin 20 mg/day vs placebo	Post hoc analysis of JUPITER Men ≥50 years of age and women ≥60 years of age with no known history of cardiovascular disease, LDL-C <130 mg/dL, hsCRP ≥2 mg/L and TG <500 mg/dL	N=17,802 1.9 years (maximum, 5 years)	Primary: Incidence of a first major cardiovascular event Secondary: Not reported	Primary: For the endpoint of MI, stroke, revascularization or death, the five-year NNT was 20 (95% CI, 14 to 34). All subgroups had five-year NNTs for this combined endpoint below 50 (men, 17; women, 31; whites, 21; nonwhites, 19; BMI ≤25 kg/m^2, 18; BMI >25 kg/m^2, 21; with or without a family history of coronary disease, 9 and 6; with or without metabolic syndrome, 19 and 22; estimated 10 years Framingham risk >10% and <10%, 14 and 37). For the combined primary endpoint plus VTE, the five-year NNT was 18 (95%; 13 to 29). For the endpoint of MI, stroke or death, the five-year NNT was 29 (95% CI, 19 to 56). In sensitivity analyses addressing the theoretical utility of alternative agents, five-year NNT values of 38 and 57 were estimated for statin regimens that deliver 75 and 50% of the relative benefit observed in JUPITER, respectively. Secondary: Not reported
Yusuf et al.[171] (2016) HOPE-3	DB, MC, RCT Men ≥55 years of	N=12,705 Median 5.6 years	Primary: Composite of death from	Primary: The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (haHR,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Rosuvastatin 10 mg/day vs placebo	age and women ≥65 years of age who did not have cardiovascular disease and were at intermediate risk (defined as an annual risk of major cardiovascular events of approximately 1%)		cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and second coprimary outcome of composite of revascularization, heart failure, and resuscitated cardiac arrest Secondary: Death from any cause, the components of the coprimary outcomes, new-onset diabetes	0.76; 95% CI, 0.64 to 0.91; P=0.002; NNT with rosuvastatin to prevent one coprimary outcome event, 91). The second coprimary outcome occurred in 277 participants (4.4%) in the rosuvastatin group and in 363 participants (5.7%) in the placebo group (HR, 0.75; 95% CI, 0.64 to 0.88; P<0.001; NNT, 73). Secondary: Significantly fewer participants in the rosuvastatin group than in the placebo group had strokes. Fewer ischemic strokes occurred in the rosuvastatin group than in the placebo group (41 vs 77), but slightly more hemorrhagic strokes occurred (11 vs 8), and the same number of cases of subarachnoid hemorrhage occurred in both groups (4). Significantly fewer myocardial infarctions and coronary revascularizations occurred in the rosuvastatin group than in the placebo group. There was no significant difference between the two groups in the number of participants who had new-onset diabetes. Death from cardiovascular causes occurred in 154 participants (2.4%) in the rosuvastatin group and in 171 (2.7%) in the placebo group, and death from noncardiovascular causes occurred in 180 participants (2.8%) in the rosuvastatin group and in 186 (2.9%) in the placebo group. The total number of deaths was 334 in the rosuvastatin group and 357 in the placebo group.
Taylor et al.[172] (2011) Statins vs placebo or usual care	SR (14 RCTs) Patients ≥18 years of age with no restrictions on TC, LDL-C or HDL-C levels, population had ≤10% of patients with a previous history of cardiovascular disease	N=34,272 ≥12 months	Primary: All-cause mortality; fatal and nonfatal CHD; cardiovascular disease and stroke events; combined endpoint of fatal and non fatal CHD, cardiovascular disease and stroke	Primary: None of the individual trials (eight) showed strong evidence of a reduction in all-cause mortality, but pooled analysis demonstrated that statins were associated with a significant 16% decrease in all-cause mortality (RR, 0.84; 95% CI, 0.79 to 0.96). Four trials demonstrated a significant reduction in the combined endpoint of fatal and nonfatal CHD in favor of statins (RR, 0.72; 95% CI, 0.65 to 0.79). Six trials demonstrated a significant reduction in combined endpoint of fatal and nonfatal cardiovascular disease in favor of statins (RR, 0.74; 95% CI, 0.66 to 0.85). Seven trials demonstrated a significant reduction in stroke events in favor of statins (RR, 0.78; 95% CI, 0.65 to 0.94).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			Secondary: Change from baseline in TC, revascularizatio n, adverse events, quality of life	Three trials demonstrated a significant reduction in the combined endpoint of fatal and nonfatal CHD, cardiovascular disease and stroke in favor or statins (RR, 0.70; 95% CI, 0.61 to 0.79). Secondary: Five trials demonstrated a significant reduction in revascularization in favor of statins (RR, 0.66; 95% CI, 0.53 to 0.83). Nine and 11 trials reported on TC and LDL-C, demonstrating significant reductions in both with a statin (0.89 mmol/L [95% CI, -1.20 to -0.57] and 0.92 [95% CI, -1.10 to -0.74]). In terms of adverse events, incidence rates indicated no difference between statins and control groups (RR, 0.99; 95% CI, 0.94 to 1.05). There was no reliable data on patient quality of life.
Mora et al.[173] (2010) Statin therapy vs placebo	MA (5 primary prevention statin RCTs) Women receiving statin therapy	N=not reported Duration not reported	Primary: Cardiovascular disease, all cause mortality Secondary: Not reported	Primary: Compared to placebo, statin therapy in women significantly reduced cardiovascular disease by about one third in exclusively primary prevention trials. The summary RR for the three trials was 0.63 (95% CI, 0.49 to 0.82; P<0.001). When trials that included predominately primary prevention were analyzed together with the exclusively primary prevention trials, the summary RR was similar but no significant (0.79; 95% CI, 0.59 to 1.05; P=0.11). When two additional trials were included that did not report sex specific outcomes for women, the summary RR was unchanged (0.82; 95% CI, 0.69 to 0.98; P=0.03). The summary RR for the three exclusively primary prevention trials (n=13,154 women; 216 deaths) that reported sex specific total mortality was 0.78 (95% CI, 0.53 to 1.15; P=0.21). When all trials that reported sex specific mortality outcomes in predominantly or exclusively primary prevention in women were included, the summary RR was similar. Secondary: Not reported
Baigent et al.[174] (2005)	MA (14 RCTs)	N=90,056	Primary: All-cause	Primary: Statin therapy was associated with a significant 12% reduction in all-cause

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Statins (pravastatin 40 mg/day, fluvastatin 40 to 80 mg/day, simvastatin 20 to 40 mg/day, atorvastatin 10 mg/day, lovastatin 20 to 80 mg/day) vs placebo	Demographics not reported	≥2 years	mortality, CHD mortality, non-CHD mortality Secondary: Effect on CHD death and on major coronary events (nonfatal MI or CHD death) in prespecified subgroups; effect on stroke, cancer, and vascular procedures, vascular events	mortality per 1 mmol/L reduction in LDL-C compared to placebo (RR, 0.88; 95% CI, 0.84 to 0.91; P<0.0001). Statin therapy was associated with a significant 19% reduction in CHD mortality compared to placebo (3.4 vs 4.4%; RR, 0.81; 95% CI, 0.76 to 0.85; P<0.0001). Statin therapy was associated with a nonsignificant 17% reduction in non-CHD mortality compared to placebo (1.2 vs 1.3%; RR, 0.93; 95% CI, 0.83 to 1.03; P value not reported). Secondary: Statin therapy was associated with a significant 17% reduction in vascular mortality compared to placebo (4.7 vs 5.7%; RR, 0.83; 95% CI, 0.79 to 0.87; P<0.0001). Statin therapy was associated with a significant 21% reduction in major vascular events compared to placebo (RR, 0.79; 95% CI, 0.77 to 0.81; P<0.0001). Statin therapy was associated with a significant 26% reduction in nonfatal MI compared to placebo (RR, 0.74; 99% CI, 0.70 to 0.79; P<0.0001). Statin therapy was associated with a significant 23% reduction in any major coronary event compared to placebo (RR, 0.77; 95% CI, 0.74 to 0.80; P<0.0001). Statin therapy was associated with a significant 24% reduction in any coronary revascularization compared to placebo (RR, 0.76; 95% CI, 0.73 to 0.80; P<0.0001). Statin therapy was associated with a significant 21% reduction in any stroke compared to placebo (RR, 0.79; 95% CI, 0.77 to 0.81; P<0.0001). Statin therapy was associated with a nonsignificant increase in the incidence of rhabdomyolysis compared to placebo (P=0.4).
No authors	MA, subanalysis	N=90,056	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
listed.[175] (2008) CTT Collaborators Statins (pravastatin 40 mg/day, fluvastatin 40 to 80 mg/day, simvastatin 20 to 40 mg/day, atorvastatin 10 mg/day, lovastatin 20 to 80 mg/day) vs placebo	(14 trials) Demographics not reported	≥2 years	All-cause mortality, CHD mortality, non-CHD mortality among diabetes and non-diabetes patients Secondary: Effect on CHD death and on major coronary events (nonfatal MI or CHD death), major vascular events among diabetic and non-diabetic patients	Among patients with diabetes, statins were associated with a significant nine percent reduction in all-cause mortality per each additional mmol/L reduction in LDL-C compared to placebo (RR, 0.91; 99% CI, 0.82 to 1.01; P=0.02). Among patients without diabetes, statins were associated with a significant 13% reduction in all-cause mortality per each additional mmol/L reduction in LDL-C compared to placebo (RR, 0.87; 99% CI, 0.82 to 0.92; P<0.0001). Secondary: Among patients with diabetes, statins were associated with a significant 13% reduction in vascular mortality per each additional mmol/L reduction in LDL-C compared to placebo (RR, 0.87; 99% CI, 0.76 to 1.00; P=0.008) and no effect on nonvascular mortality (RR, 0.97; 99% CI, 0.82 to 1.16; P=0.7). Among patients with diabetes, statins were associated with a significant 21% reduction in major vascular events per each additional mmol/L reduction in LDL-C compared to placebo (RR, 0.79; 99% CI, 0.72 to 0.86; P<0.0001). Among patients without diabetes, statins were associated with a significant 21% reduction in major vascular events per each additional mmol/L reduction in LDL-C compared to placebo (RR, 0.79; 99% CI, 0.76 to 0.82; P<0.0001). Among patients with diabetes, statins were associated with a significant 22% reduction in MI or coronary death (RR, 0.78; 99%CI, 0.69 to 0.87; P<0.0001), 25% reduction in coronary revascularization (RR, 0.75; 99% CI, 0.64 to 0.88; P<0.0001) and 21% reduction in stroke (RR, 0.79; 99% CI, 0.67 to 0.93; P=0.0002) compared to placebo. After five-years of treating 1,000 diabetic patients with statin therapy, 42 patients may be prevented from having a major vascular event (95% CI, 30 to 55; P value not reported). The benefit was greater among patients with diabetes and known vascular disease at baseline.
O'Regan et al.[176] (2008) Statins (atorvastatin 10 to	MA (41 primary prevention trials, 1 secondary prevention trial)	N=121,285 Up to 6 years	Primary: All-cause mortality, all-stroke incidence	Primary: Compared to placebo, statin therapy was associated with a significant reduction in the risk of all-cause mortality (RR, 0.88; 95% CI, 0.83 to 0.93). Compared to placebo, statin therapy was associated with a significant

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
80 mg/day, simvastatin 20 to 40 mg/day, fluvastatin 40 to 80 mg/day, pravastatin 10 to 40 mg/day, lovastatin 20 to 73 mg/day) vs placebo	Demographics not reported		Secondary: Incidence of cardiovascular deaths, non-hemorrhagic cerebrovascular events, hemorrhagic strokes, fatal strokes	reduction in the risk of strokes (RR, 0.84; 95% CI, 0.79 to 0.91). Secondary: Compared to placebo, statin therapy was associated with a significant reduction in the risk of cardiovascular death (RR, 0.81; 95% CI, 0.74 to 0.90). Compared to placebo, statin therapy was associated with a significant reduction in the risk of nonhemorrhagic cerebrovascular events (RR, 0.81; 95% CI, 0.69 to 0.94). Compared to placebo, statin therapy was associated with a nonsignificant reduction in the risk hemorrhagic strokes (RR, 0.94; 95% CI, 0.68 to 1.30). Compared to placebo, statin therapy was associated with a nonsignificant reduction in the risk of fatal strokes (RR, 0.99; 95% CI, 0.80 to 1.21). A meta-regression analysis determined that every unit increase in LDL-C was associated with a 0.3% increased risk of mortality (RR, 1.003; 95% CI, 1.0005 to 1.006; P=0.02).
Secondary Prevention of Coronary Heart Disease (Single-Entity Agents)				
Bushnell et al.[177] (2006) Statin therapy vs no statin therapy	MA Patients with CHD or vascular disease	N=22,943 90 days	Primary: Incidence of stroke at 90 days, stroke severity, mortality from strokes, differences between sexes Secondary: Not reported	Primary: Patients reporting statin therapy had lower rates of stroke at 90 days of follow up (HR, 0.72; 95% CI, 0.53 to 0.97; P value not reported). Statin therapy was not associated with a significant reduction in stroke mortality (P=0.8). Women had an increased risk of experiencing a severe stroke compared to men (P=0.035). Statin therapy was not associated with a significant reduction in stroke severity among women (P=0.096). Secondary: Not reported
LaRosa et al.[178] (2005)	DB, MC, PG, RCT	N=10,001	Primary: First major	Primary: Compared to 10 mg, 80 mg was associated with a significant 22% reduction in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease)	5 years	cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest or fatal or nonfatal stroke) Secondary: Individual components of a major coronary event, cerebrovascular event, hospitalization for heart failure, PAD, all-cause mortality, any cardiovascular event, and any coronary event, side effects	the incidence of the primary endpoint (10.9 vs 8.7%; HR, 0.78; 95% CI, 0.69 to 0.89; P=0.0002). Secondary: Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of strokes (3.1 vs 2.3%; HR, 0.75; 95% CI, 0.59 to 0.96; P=0.021). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of cerebrovascular events (5.0 vs 3.9%; HR, 0.77; 95% CI, 0.64 to 0.93; P=0.007). Each 1 mg/dL reduction in LDL-C was associated with a 0.6% RRR in cerebrovascular events (P=0.002) and a 0.5% RRR in stroke (P=0.041). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of nonfatal MIs (6.2 vs 4.9%; HR, 0.78; 95% CI, 0.66 to 0.93; P=0.004). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of major coronary events (8.3 vs 6.7%; HR, 0.80; 95% CI, 0.69 to 0.92; P=0.0019). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any coronary events (26.5 vs 21.6%; HR, 0.79; 95% CI, 0.73 to 0.86; P<0.0001). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any cardiovascular events (33.5 vs 28.1%; HR, 0.81; 95% CI, 0.75 to 0.87; P<0.0001). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of hospitalization for heart failure (33.5 vs 28.1%; HR, 0.81; 95% CI, 0.75 to 0.87; P<0.0001). There was no significant difference between the two treatments in the incidence of death from CHD (3.3 vs 2.4%; HR, 0.74; 95% CI, 0.59 to 0.94; P=0.01).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				There was no significant difference between the two treatments in the incidence of resuscitation after cardiac arrest (0.5%; HR, 0.96; 95% CI, 0.56 to 1.67; P=0.89). There was no significant difference between the two treatments in the incidence of PAD (5.6 vs 5.5%; HR, 0.97; 95% CI, 0.83 to1.15; P=0.76). There was no significant difference between the two treatments in the incidence of death from any cause (5.6 vs 5.7%; HR, 1.01; 95% CI, 0.85 to 1.19; P=0.92). Compared to 10 mg, 80 mg was associated with a significantly higher incidence of treatment-related adverse events (5.8 vs 8.1%; P<0.001). Compared to 10 mg, 80 mg was associated with a significantly higher incidence of ALT and AST elevations greater than three times the upper limit of normal (0.2 vs 1.2%; P<0.001).
Shah et al.[179] (2008) TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Subanalysis of TNT Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease) with a previous CABG	N=4,654 5 years	Primary: First major cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest or fatal or nonfatal stroke) Secondary: Safety	Primary: A first major cardiovascular event occurred in 11.4% (n=529) of patients with prior CABG and 8.5% (n=453) of those without prior CABG (HR, 1.38; 95% CI, 1.22 to 1.56; P<0.0001). Among post-CABG patients, a primary endpoint event occurred in 9.7 (n=224) vs 13.0% (n=305) of patients receiving 80 and 10 mg/day, resulting in a 27% RR reduction and a 3.3% ARR (HR, 0.73; 95% CI, 0.62 to 0.87; P=0.0004). During follow up, 11.3 (n=262) vs 15.9% (n=371) of patients receiving 80 and 10 mg/day underwent repeat coronary revascularization, either with CABG or percutaneous coronary intervention, resulting in a 30% RR reduction and a 4.6% ARR (HR, 0.70; 95% CI, 0.60 to 0.82; P<0.0001). The combined endpoint of a major cardiovascular event or coronary revascularization occurred in 18.0 (n=417) vs 24.2% (n=566) in patients receiving 80 and 10 mg/day, resulting in a 28% RR reduction and a 6.2% ARR (HR, 0.72; 95% CI, 0.64 to 0.82; P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Secondary: In the CABG cohort, discontinuations from therapy due to treatment-related adverse events during the five-years of follow up occurred in 3.8 (n=87) vs 2.7% (n=62) of patients receiving 80 and 10 mg/day (P=0.004). Treatment-related myalgias were reported in 1.3% of patients receiving both treatments, and no post-CABG patient experienced an elevation of CK >10 times the upper limit of normal on two consecutive measurements. Elevated AST and ALT greater than three times the upper limit of normal on consecutive measurements occurred in 1.1 and 0.3% of patients receiving 80 and 10 mg/day (P=0.0003).
Waters et al.[180] (2006) TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Subanalysis of TNT Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease)	N=10,001 5 years	Primary: First major cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest or fatal or nonfatal stroke) Secondary: Any occurrence of a major coronary event, cerebrovascular event, hospitalization for heart failure, PAD, all-cause mortality, any cardiovascular event, any coronary event	Primary: Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of the primary endpoint (10.9 vs 8.7%; HR, 0.78; 95% CI, 0.69 to 0.89; P=0.0002). Secondary: Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of strokes (3.1 vs 2.3%; HR, 0.75; 95% CI, 0.59 to 0.86; P=0.021). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of cerebrovascular events (5.0 vs 3.9%; HR, 0.77; 95% CI, 0.64 to 0.93; P=0.007). Each 1 mg/dL reduction in LDL-C was associated with a 0.6% RR reduction in cerebrovascular events (P=0.002) and a 0.5% RR reduction in stroke (P=0.041). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of nonfatal MIs (6.2 vs 4.9%; HR, 0.78; 95% CI, 0.66 to 0.93; P=0.004). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of major coronary events (8.3 vs 6.7%; HR, 0.80; 95% CI, 0.69 to 0.92; P=0.0019). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any coronary events (26.5 vs 21.6%; HR, 0.79; 95% CI, 0.73 to

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				0.86; P<0.0001). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any cardiovascular events (33.5 vs 28.1%; HR, 0.81; 95% CI, 0.75 to 0.87; P<0.0001). There was no significant difference between the two treatments in the incidence of TIAs (P=0.099). There was no significant difference between the two treatments in the incidence of death from CHD (P=0.087). Compared to 10 mg, 80 mg was associated with a significantly higher incidence of treatment-related adverse events (5.8 vs 8.1%; P<0.001). Compared to 10 mg, 80 mg was associated with a significantly higher incidence of ALT and AST elevations at least three times the upper limit of normal (0.2 vs 1.2%; P<0.001).
Deedwania et al.[181] (2006) TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Post hoc analysis of TNT Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease), stratified by metabolic syndrome	N=5,584 5 years	Primary: First major cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest or fatal or nonfatal stroke) among patients with metabolic syndrome Secondary: Any occurrence of a major coronary event, cerebrovascular	Primary: Compared to 10 mg, 80 mg was associated with a significant 29% reduction in the incidence of the primary endpoint among patient with metabolic syndrome (13.0 vs 9.5%; HR, 0.71; 95% CI, 0.61 to 0.84; P<0.0001). Secondary: Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of cerebrovascular events among patients with metabolic syndrome (HR, 0.74; 95% CI, 0.59 to 0.93; P=0.011). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of major coronary events among patients with metabolic syndrome (HR, 0.72; 95% CI, 0.60 to 0.86; P=0.0004). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any coronary events among patients with metabolic syndrome (HR, 0.75; 95% CI, 0.67 to 0.83; P<0.0001). Compared to 10 mg, 80 mg was associated with a significant reduction in the

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			event, hospitalization for heart failure, PAD, all-cause mortality, any cardiovascular event, any coronary event among patients with metabolic syndrome	incidence of any cardiovascular events among patients with metabolic syndrome (HR, 0.78; 95% CI, 0.71 to 0.85; P<0.0001). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of hospitalization for CHF among patients with metabolic syndrome (HR, 0.73; 95% CI, 0.55 to 0.96; P=0.027). There was no significant difference between the two treatments in the incidence of all-cause mortality among patients with metabolic syndrome (P value not reported).
Shepherd et al.[182] (2006) TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Post hoc analysis of TNT Patients 35 to 75 years of age with type 2 diabetes and CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease)	N=1,501 5 years	Primary: First major cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest or fatal or nonfatal stroke) among patients with type 2 diabetes Secondary: Any occurrence of a major coronary event, cerebrovascular event, hospitalization for heart failure, PAD, all-cause mortality, any	Primary: Compared to 10 mg, 80 mg was associated with a significant 25% reduction in the incidence of the primary endpoint among patients with diabetes (17.9 vs 13.8%; HR, 0.75; 95% CI, 0.58 to 0.97; P=0.026). Secondary: Significant differences between the treatments in favor of 80 mg/day were observed for the secondary outcomes of time to cerebrovascular event (HR, 0.69; 95% CI, 0.48 to 0.98; P=0.037) and time to cardiovascular event (HR, 0.85; 95% CI, 0.73 to 1.00; P=0.044) There was no significant difference between the two treatments in the incidence of cerebrovascular events among patients with diabetes (P=0.437). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of nonfatal MI among patients with diabetes (HR, 0.79; 95% CI, 0.55 to 1.14; P=0.202). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of fatal and nonfatal stroke among patients with diabetes (HR, 0.67; 95% CI, 0.43 to 1.04; P=0.075). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of death from CHD among patients with diabetes (HR, 0.74; 95% CI, 0.47 to 1.18; P=0.203).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			cardiovascular event, any coronary event among patients with type 2 diabetes	There was no significant difference between the two treatments in the incidence of major coronary events among patients with diabetes (P=0.922). There was no significant difference between the two treatments in the incidence of any coronary events among patients with diabetes (P=0.192). There was no significant difference between the two treatments in the incidence of any cardiovascular events among patients with diabetes (P=0.458). There was no significant difference between the two treatments in the incidence of major cardiovascular events among patients with diabetes (P=0.689). There was no significant difference between the two treatments in the incidence of hospitalization with heart failure among patients with diabetes (P=0.277). There was no significant difference between the two treatments in the incidence of all-cause mortality among patients with diabetes (P=0.521). There was no significant difference between the two treatments in the incidence of PAD among patients with diabetes (P=0.789). There was no significant difference between the two treatments in the incidence of treatment-related adverse effects or persistent elevations in liver enzymes (P values not reported).
Wenger et al.[183] (2007) TNT Atorvastatin 10 mg/day vs	Post hoc analysis of TNT Patients ≥65 years of age with CHD (either previous MI, coronary revascularization, angina with	N=3,809 5 years	Primary: First major cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest or fatal or	Primary: Compared to 10 mg, 80 mg was associated with a significant 19% reduction in the incidence of the primary endpoint among patients ≥65 years of age (12.6 vs 10.3%; HR, 0.81; 95% CI, 0.67 to 0.98; P=0.032). Consequently, in treating 35 patients with 80 mg vs 10 mg, one cardiovascular event could be prevented over a five-year period. Secondary: Compared to 10 mg, 80 mg was associated with a significant reduction in the

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
atorvastatin 80 mg/day	objective evidence of coronary disease)		nonfatal stroke) Secondary: Individual components of a major coronary event, cerebrovascular event, hospitalization for heart failure, PAD, all-cause mortality, any cardiovascular event, and any coronary event, side effects	incidence of cerebrovascular events among patients ≥65 years of age (P=0.010). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of nonfatal MI among patients ≥65 years of age (HR, 0.79; 95% CI, 0.60 to 1.03; P=0.084). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of fatal and nonfatal stroke among patients ≥65 years of age (HR, 0.79; 95% CI, 0.57 to 1.09; P=0.158). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of death from CHD among patients ≥65 years of age (HR, 0.91; 95% CI, 0.63 to 1.29; P=0.59). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of resuscitated cardiac arrests among patients ≥65 years of age (HR, 1.19; 95% CI, 0.49 to 2.87; P=0.70). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any cardiovascular events among patients ≥65 years of age (P<0.001). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of any coronary events among patients ≥65 years of age (P<0.001). Compared to 10 mg, 80 mg was associated with a significant reduction in incidence of hospitalization for heart failure among patients ≥65 years of age (P=0.008). There was no significant difference between the two treatments in the incidence of major coronary events among patients ≥65 years of age (P=0.128). Compared to 10 mg, 80 mg was associated with a nonsignificant reduction in the incidence of death from cardiovascular causes among patients ≥65 years of age (HR, 0.91; 95% CI, 0.67 to 1.24; P=0.55).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Compared to patients receiving 10 mg, more patients receiving 80 mg died from noncardiovascular causes among patients ≥65 years of age (HR, 1.26; 95% CI, 0.93 to 1.70; P=0.129). More patients ≥65 years of age receiving 80 mg experienced treatment-related adverse events compared to patients ≥65 years of age receiving 10 mg (P value not reported).
Khush et al.[184] (2007) TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Post hoc analysis of TNT Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease)	N=10,001 5 years	Primary: Hospitalization for heart failure among patients with and without a history of heart failure Secondary: Not reported	Primary: Prior history of heart failure is a significant risk factor for hospitalization from heart failure. While 14.1% of patients with heart failure at baseline were hospitalized for heart failure, only 1.9% of patients who did not have heart failure at baseline were hospitalized for heart failure during the trial period (P<0.001). Compared to 10 mg, 80 mg was associated with a significant reduction in the incidence of hospitalization from heart failure among patients with heart failure at baseline (17.3 vs 10.6%; HR, 0.59; 95% CI, 0.4 to 0.80; P=0.008). Mortality was significantly higher among patients with heart failure compared to patients without heart failure at baseline (15.0 vs 4.9%; P<0.001). Each reduction of 1 mg/dL in LDL-C was associated with a reduction in the risk of hospitalization for heart failure by 0.6% (P=0.007). Secondary: Not reported
LaRosa et al.[185] (2007) TNT Atorvastatin 10 mg/day vs atorvastatin 80	Post hoc analysis of TNT Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with	N=9,769 5 years	Primary: First major cardiovascular event (death from CHD, nonfatal MI, resuscitation after cardiac arrest, fatal or nonfatal stroke)	Primary: Patients in the lowest LDL-C Quintiles were associated with the most reduction in the primary endpoint (P<0.0001). Secondary: Patients in the lowest LDL-C Quintiles were associated with the most reduction in the risk of death from CHD (P<0.01). Patients in the lowest LDL-C Quintiles were associated with the most reduction in the risk of nonfatal MIs (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day	objective evidence of coronary disease), stratified by LDL-C level		among patients with LDL-C <64 mg/dL (Quintile 1), 64 to ≤77 mg/dL (Quintile 2), 77 to ≤90 mg/dL (Quintile 3), 90 to ≤106 mg/dL (Quintile 4), and ≥106 mg/dL (Quintile 5) Secondary: Any occurrence of a major coronary event, cerebrovascular event, hospitalization for heart failure, PAD, all-cause mortality, any cardiovascular event, and any coronary event among patients classified as Quintile 1, 2, 3, 4 or 5 (from above)	Patients in the lowest LDL-C Quintiles were associated with the most reduction in the risk of stroke (P<0.05). There were no differences in the incidence of all-cause mortality across LDL-C Quintiles (P=0.104). There were no differences in the incidence of cardiovascular mortality across quintiles (P=0.060). There were no differences in the incidence of all-cause mortality across LDL-C Quintiles (P=0.653). There were no differences in the incidence of treatment-related adverse effects across LDL-C Quintiles (P value not reported).
Barter et al.[186] (2007) TNT	Post hoc analysis of TNT Patients 35 to 75	N=9,770 5 years	Primary: First major cardiovascular event (death	Primary: Patients in the highest HDL-C Quintiles were associated with the greatest reduction in the primary endpoint (P=0.04).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease), stratified by HDL-C level		from CHD, nonfatal MI, resuscitation after cardiac arrest, fatal or nonfatal stroke) among patients with HDL-C <38 mg/dL (Quintile 1), 38 to 42 mg/dL (Quintile 2), 43 to 47 mg/dL (Quintile 3), 48 to 54 mg/dL (Quintile 4), and ≥55 mg/dL (Quintile 5) Secondary: Not reported	Compared to patients in HDL-C Quintile 1, patients classified as HDL-C Quintile 5 had a 25% reduction in risk of a major cardiovascular event (HR, 0.75; 95% CI, 0.60 to 0.95). An increase in 1 mg/dL in HDL-C reduces the risk of major cardiovascular events by 1.1% at three months (P=0.003). Patients with the lowest LDL-C:HDL-C were at a significantly lower risk for major cardiovascular events (P=0.006). Patients with the lowest TC:HDL-C were at a significantly lower risk for major cardiovascular events (P value not reported). Among patients whose LDL-C was <70 mg/dL, those in the highest HDL-C Quintile were at the lowest risk for a major cardiovascular event (P=0.03). Secondary: Not reported
Shepherd et al.[187] (2007) TNT Atorvastatin 10 mg/day vs atorvastatin 80 mg/day	Post hoc analysis of TNT Patients 35 to 75 years of age with CHD (either previous MI, coronary revascularization, angina with objective evidence of coronary disease)	N=9,770 5 years	Primary: GFR Secondary: Not reported	Primary: Eighty mg was associated with a significant increase in GFR from baseline over the five-year trial period compared to 10 mg (P<0.0001). Secondary: Not reported
Pitt et al.[188] (1999) AVERT	MC, OL, RCT Adult patients	N=341 18 months	Primary: Number of ischemic events	Primary: Atorvastatin was associated with a significantly lower incidence of ischemic events compared to revascularization procedure (21 vs 13%; P=0.048).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Atorvastatin 80 mg/day vs percutaneous coronary transluminal angioplasty	with stable CAD, LDL-C ≥115 mg/dL, TG ≤500 mg/dL, stenosis ≥50% in ≥1 coronary artery and had been recommended for treatment with percutaneous revascularization, asymptomatic or with Canadian Cardiovascular Society Class I or II angina, able to complete ≥4 minutes of a treadmill test or a bicycle exercise test without marked ECG changes indicative of ischemia		and/or need for re-vascularization, angina symptoms, adverse events Secondary: Not reported	Atorvastatin was associated with a significantly longer time to the first ischemic event compared to revascularization procedure (P=0.03). A significantly smaller proportion of patients receiving atorvastatin had an improvement in the Canadian Cardiovascular Society classification of angina symptoms compared to revascularization procedure (41 vs 54%; P=0.009). Adverse events were similar between the two treatments (P value not reported). Secondary: Not reported
Athyros et al.[189] (2002) GREACE Atorvastatin 10 mg/day, titrated up to 80 mg/day vs usual medical care (lifestyle	RCT Adult patients with established CHD not at LDL-C goal (<100 mg/dL) according to the NCEP criteria	N=1,600 3 years	Primary: Death, nonfatal MI, unstable angina, CHF, revascularization (coronary morbidity), stroke Secondary: Safety	Primary: Compared to usual care, atorvastatin was associated with a significant 51% reduction in the risk for CHD recurrent events or death (24.5 vs 12.0%; P<0.0001). Compared to usual care, atorvastatin was associated with a significant 43% reduction in all-cause mortality (5.0 vs 2.9%; P=0.0021). Compared to usual care, atorvastatin was associated with a significant 47% reduction in the risk of stroke (2.1 vs 1.1%; P=0.034). Compared to usual care, atorvastatin was associated with a significant 47%

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
modification and pharmacotherapy, including lipid lowering agents)				reduction in the risk of coronary mortality (4.8 vs 2.5%; P=0.0017). Compared to usual care, atorvastatin was associated with a significant 54% reduction in the risk of coronary morbidity (P<0.0001). Atorvastatin was associated with a reduction in TC by 36%, LDL-C by 46%, TG by 31% and non-HDL-C by 44% and an increase in HDL-C by seven percent (P value not reported). Compared to usual care, a greater proportion of patients receiving atorvastatin achieved the NCEP LDL-C goals (3 vs 95%, respectively; P value not reported). Compared to usual care, a greater proportion of patients receiving atorvastatin achieved the NCEP non-HDL-C goals (14 vs 97%, respectively; P value not reported). Secondary: Withdrawals due to adverse effects were similar between the two treatments (0.75 vs 0.40%; P value not reported).
Athyros et al.[190] (2007) GREACE Atorvastatin 10 mg/day, titrated up to 80 mg/day vs usual medical care (lifestyle modification and pharmacotherapy, including lipid lowering agents)	Post hoc analysis of GREACE Adult patients with established CHD not at LDL-C goal (<100 mg/dL) according to the NCEP criteria, stratified by the presence of metabolic syndrome	N=1,600 3 years	Primary: Vascular events, estimated GFR, serum uric acid level Secondary: Not reported	Primary: Among patients with metabolic syndrome, atorvastatin was associated with a significant 57% reduction in the incidence of vascular events compared to usual medical care (12.1 vs 28.0%; RR, 0.43; 95% CI, 0.20 to 0.64; P<0.0001). Among patients without metabolic syndrome, atorvastatin was associated with a significant 41% reduction in the incidence of vascular events compared to usual medical care (RR, 0.59; 95% CI, 0.41 to 0.79; P<0.0001). Atorvastatin was associated with a significant increase in GFR and a reduction in serum uric acid level from baseline (P<0.05), regardless of metabolic syndrome status. Usual medical care was associated with a significant reduction in GFR and an increase in serum uric acid level from baseline (P<0.05), regardless of metabolic syndrome status. Compared to patients without metabolic syndrome, patients with metabolic syndrome experienced a greater increase in GFR with atorvastatin (P=0.02).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Secondary: Not reported
Schwartz et al.[191] (2005) MIRACL Atorvastatin 80 mg/day vs placebo Treatment was administered within 96 hours of hospital admission with an ACS.	DB, MC, RCT Patients >18 years of age with unstable angina or non-Q-wave acute MI, with chest pain or discomfort ≥15 minutes that occurred at rest or with minimal exertion within the 24 hour period preceding hospitalization and representing a change from their usual anginal pattern	N=3,086 16 weeks	Primary: A composite endpoint of death, nonfatal acute MI, resuscitated cardiac arrest or recurrent symptomatic myocardial ischemia with objective evidence requiring hospitalization Secondary: Occurrence of the individual components of the primary endpoint, nonfatal stroke, new or worsening heart failure requiring hospitalization, worsening angina requiring hospitalization but without new objective evidence of	Primary: Compared to placebo, atorvastatin was associated with a 16% reduction in the risk of a composite endpoint of death, nonfatal acute MI, resuscitated cardiac arrest and recurrent symptomatic myocardial ischemia requiring hospitalization (17.4 vs 14.8%; P=0.048). Secondary: Compared to placebo, atorvastatin was associated with a significant 26% reduction in the risk of a recurrent ischemia requiring hospitalization (RR, 0.74; 95% CI, 0.57 to 0.95; P=0.02). Compared to placebo, atorvastatin was associated with a significant 50% reduction in the risk of a fatal and nonfatal stroke (RR, 0.50; 95% CI, 0.26 to 0.99; P=0.045). There were no significant differences between the two treatments in the incidence of coronary revascularization procedures, worsening heart failure, worsening angina, occurrence of at least one secondary endpoint or occurrence of at least one primary or secondary endpoint (P value not reported). Liver transaminase elevation was more common with atorvastatin (2.5 vs 0.6%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			ischemia and coronary revascu-larization; time to occurrence of any of the above; percent changes from baseline in lipid levels; safety	
Olsson et al.[192] (2007) MIRACL Atorvastatin 80 mg/day vs placebo Treatment was administered within 96 hours of hospital admission with an ACS.	Post hoc analysis of MIRACL Patients ≥65 years of age with unstable angina or non-Q-wave acute MI, with chest pain or discomfort ≥15 minutes duration that occurred at rest or with minimal exertion within the 24 hour period preceding hospitalization and representing a change from their usual anginal pattern	N=3,086 16 weeks	Primary: A composite endpoint of death, nonfatal acute MI, resuscitated cardiac arrest or recurrent symptomatic myocardial ischemia with objective evidence requiring hospitalization among patients ≥65 and <65 years of age Secondary: Occurrence of the individual components of the primary endpoint, nonfatal stroke, new or	Primary: Compared to placebo, atorvastatin was associated with a nonsignificant 14% reduction in the RR of the primary endpoint in patients ≥65 years of age (HR, 0.86; 95% CI, 0.70 to 1.07; ARR, 2.9%; P=0.18). Compared to placebo, atorvastatin was associated with a nonsignificant 22% reduction in the RR of the primary endpoint in patients <65 years of age (HR, 0.78; 95% CI, 0.56 to 1.06; ARR, 2.5%; P=0.11). Secondary: There was no significant difference in any of the secondary endpoints between patients ≥65 and <65 years of age (P>0.05). The frequency of adverse events was similar between the two treatments (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			worsening heart failure requiring hospitalization, worsening angina requiring hospitalization but without new objective evidence of ischemia, coronary revascu-larization, time to occurrence of any of the above; percent change from baseline in lipid levels among patients ≥65 and <65 years of age; safety	
Amarenco et al.[193] (2006) SPARCL Atorvastatin 80 mg/day vs placebo	DB, PC, RCT Patients ≥18 years of age who had an ischemic or hemorrhagic stroke or TIA 1 to 6 months before trial entry (patients with a prior hemorrhagic stroke could be included if they	N=4,731 4.9 years	Primary: Time to first occurrence of a nonfatal or fatal stroke Secondary: Occurrence of major cardiovascular events (stroke, cardiac death, nonfatal MI or	Primary: Patients with a reduction in LDL-C >16% had a significant reduction in stroke compared to those with a reduction <16% (11.0 vs 13.4%; HR, 0.792; 95% CI, 0.671 to 0.935; P=0.0058). Secondary: Patients with a reduction in LDL-C >16% had a significant reduction in major cardiovascular events compared to those with a reduction <16% (13.9 vs 17.3; HR, 0.761; 95% CI, 0.657 to 0.881; P=0.0003).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	were deemed to be at risk for ischemic stroke or CHD) and LDL-C ≥100 to ≤190 mg/dL		resuscitated cardiac arrest)	
Amerenco et al.[194] Atorvastatin 80 mg/day vs placebo	Subanalysis of SPARCL to evaluate stroke subtypes Patients ≥18 years of age who had an ischemic or hemorrhagic stroke or TIA 1 to 6 months before trial entry (patients with a prior hemorrhagic stroke could be included if they were deemed to be at risk for ischemic stroke or CHD) and LDL-C ≥100 to ≤190 mg/dL	N=4,731 4.9 years	Primary: Time to first occurrence of a nonfatal or fatal stroke Secondary: Occurrence of major cardiovascular events (stroke, cardiac death, nonfatal MI or resuscitated cardiac arrest), all-cause mortality	Primary: Atorvastatin was similarly effective in reducing the primary endpoint for all entry event stroke subtypes (large vessel, TIA, small vessel and unknown). Although there was no overall heterogeneity between subtypes, the patients with baseline hemorrhagic stroke receiving atorvastatin were qualitatively different and were more than three times more likely to have a recurrent stroke compared to placebo. Secondary: Atorvastatin was similarly effective in reducing the occurrence of major cardiovascular events for all entry event stroke subtypes (large vessel, TIA, small vessel and unknown). Mortality rates were similar across all entry event stroke subtypes. The analyses were also carried out with adjustment for BP, diabetes and ambulatory score at baseline and the results did not differ.
Sang et al.[195] (2009) Atorvastatin 10 mg/day vs atorvastatin 10	RCT Patients with clinical and angiographic criteria for coronary disease, with ≥50% stenosis of 1	N=108 12 months (plus a 12 month follow up)	Primary: All-cause mortality, MI, rehospitalization, revascularization with either PCI or CABG	Primary: At 12 months, clinical events included rehospitalization due to angina pectoris and heart failure attack, respectively, revascularization with PCI and sudden death (7.14%) with atorvastatin. With combination therapy, the clinical events included rehospitalization due to heart failure attack, revascularization after PCI or CABG (5.77%). No significant reduction was observed with combination therapy (OR, 0.78; P=0.052). Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day and niacin ER	coronary artery with high TC		Secondary: Mean percent changes from baseline lipid parameters, effects on glucose metabolism, safety	TC, TG, LDL-C and Lp(a) levels decreased significantly with both treatments (P<0.01), with no significant difference between the two during the course of follow up (P>0.05). Apo A increased significantly with both treatments (P<0.01), with a more favorable effect observed with combination therapy (24.5 vs 40.8%; P<0.01). During the follow up, apo B fell by 5.63 (P<0.05 and 7.35% (P<0.01) with atorvastatin and combination therapy; with no significant difference between the two (P>0.05). During the trial, HDL-C levels increased by 11.67 (P<0.05) and 29.36% (P<0.01) with atorvastatin and combination therapy, with a significant difference favoring combination therapy (P<0.01). Niacin resulted in no significant increase in glucose levels at six or 12 months compared to baseline levels (P>0.05). In the subgroup of diabetic patients (n=28), niacin resulted in a significant increase in glucose levels at six months (P<0.01), and glucose levels increased more significantly at 12 months (P<0.01), but the effect of niacin was not significant in nondiabetic patients (P>0.05). HbA_{1c} levels did not show a significant increase at six months in patient with diabetes, but levels increased significantly at 12 months (P<0.05). Both treatments were generally well tolerated. The most common side effect of niacin therapy was flushing which appeared in four patients receiving combination therapy; however, all patients continued the medication and the flushing disappeared.
Serruys et al.[196] (2002) LIPS Fluvastatin 40 mg BID vs placebo	DB, MC, PC, RCT Patients 18 to 80 years of age with angina or silent ischemia following successful completion of their first PCI, with baseline TC 135 to 270 mg/dL and fasting TG <400 mg/dL	N=1,677 3 to 4 years	Primary: Incidence of major adverse cardiac events (cardiac death, nonfatal MI or a reintervention procedure of CABG or repeat PCI) Secondary: Major adverse cardiac events excluding	Primary: Major adverse cardiac event-free survival time was significantly longer with fluvastatin compared to placebo (P=0.01). Major adverse cardiac events occurred significantly less frequently with fluvastatin compared to placebo (21.4 vs 26.7%; RR, 0.78; 95% CI, 0.64 to 0.95; P=0.01). During the follow up period, 13 patients (1.5%) receiving fluvastatin compared to 24 patients (2.9%) receiving placebo died from cardiac causes, 30 patients (3.6%) compared to 38 patients (4.6%) had a nonfatal MI and 167patients (19.8%) compared to193 patients (23.2%) underwent CABG or PCI (P values not reported). Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			reintervention procedures (surgical or PCI) occurring in the first six months of follow up for lesions treated at the index procedure, cardiac mortality, combined cardiac mortality and MI, combined all-cause mortality and MI, treatment effects on measured lipid levels, discontinuation rates, tolerability, safety	The risk of major adverse cardiac events, excluding reintervention procedures (surgical or PCI), occurring in the first six months of follow up for lesions treated at the index procedure was 33% lower (RR, 0.67; 95% CI, 0.54 to 0.8; P<0.001) with fluvastatin. There was no difference in the reduction of cardiac mortality, combined cardiac mortality and MI and combined all-cause mortality and MI between the two treatments (P=0.07, P=0.07 and P=0.08, respectively). After six weeks, fluvastatin significantly reduced LDL-C by 27% (95% CI, 25 to 29% compared to an 11% reduction with placebo (95% CI, 9 to 13; P<0.001). TG reductions were greater with fluvastatin compared to placebo (22 vs 14%; P value not reported). HDL-C increased by a median of 22% with both treatments (P value not reported). Discontinuation rates due to adverse events were 21.2 and 24.0% with fluvastatin and placebo. Death rates due to noncardiac causes were 2.7 and 3.0% with fluvastatin and placebo. There were three reported cases of elevations in CK ≥10 times the upper limit of normal with placebo. There were 10 patients receiving fluvastatin and three patients receiving placebo who had elevations of at least three times the upper limit of normal level in AST or ALT on two consecutive occasions. Cancers were reported in 46 and 49 patients receiving fluvastatin and placebo (P values not reported).
Liem et al.[197] (2002) FLORIDA Fluvastatin 80 mg/day vs placebo	DB, PC, PG, RCT Adult patients with an acute MI and TC <6.5 mmol/L, new or markedly increased chest pain lasting >30 minutes or a new	N=540 1 year	Primary: Presence of either ischemia on ambulatory ECG monitoring at 12 months or the occurrence of a major clinical event	Primary: After 12 months, fluvastatin did not significantly affect ischemia on ambulatory ECG (P=0.67), nor the occurrence of any major clinical event (P=0.24) when compared to placebo. Secondary: In patients with ischemia at baseline, 29 and 38% receiving fluvastatin and placebo were ischemic on the ambulatory ECG at six weeks and 27 and 21% were again positive for ischemia at 12 months (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	pathological Q wave ≥0.04 seconds duration, or ≥25% of the corresponding R wave amplitude, both in ≥2 contiguous leads		Secondary: Six week and 12 month incidence of ischemia on the ambulatory ECG, six week and 12 month change in ischemic burden, 12 month change in lipid profile, safety and tolerability	The six week and 12 month ischemic burden was lowered by 6.1 and 7.7%, respectively, with fluvastatin and by 10.5 and 13.0%, respectively, with placebo (P=0.81 and P=0.43, respectively between treatment groups). After 12 months, fluvastatin lowered LDL-C by 21% compared to an increase of nine percent with placebo (P<0.001). There were 62 and 68 patients receiving fluvastatin and placebo who had at least one major clinical event (P=0.764). All-cause mortality was 2.6 and 4.0% with fluvastatin and placebo (P value not reported).
Sacks et al.[198] (1996) CARE Pravastatin 40 mg QD vs placebo	DB, MC, RCT Adult post MI patients with TC <240 mg/dL, LDL-C 115 to 174 mg/dL, TG <350 mg/dL, glucose ≤220 mg/dL, left ventricular ejection fractions ≥25 percent and no symptomatic CHF	N=4,159 5 years	Primary: Death from CHD (including fatal MI, either definite or probable, sudden death, death during a coronary intervention and death from other coronary causes) or a symptomatic nonfatal MI confirmed by serum CK Secondary: Not reported	Primary: When compared to placebo, there was a significant 24% lower incidence of the primary endpoint with pravastatin (13.2 vs 10.2%; 95% CI, 9 to 36; P=0.003). Pravastatin was associated with a significant 23% risk reduction in nonfatal MIs compared to placebo (P=0.02). Pravastatin was associated with a nonsignificant 37% reduction in the rate of fatal MIs (95% CI, -5 to 62; P=0.07) and a nonsignificant 25% reduction in the rate of total MIs (95% CI, 8 to 39; P=0.06) compared to placebo. Secondary: Not reported
No authors	DB, MC, PC	N=9,014	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
listed.[199] (1998) LIPID Pravastatin 40 mg QD vs placebo	Patients 31 to 75 years of age who were post MI or who had a hospital discharge diagnosis of unstable angina between 3 and 36 months before trial entry	6.1 years	Death from CHD Secondary: Incidence of MI and stroke, rate of CABG surgery	Death from CHD occurred in 6.4 and 8.3% of patients receiving pravastatin and placebo (RRR, 24%; 95% CI, 12 to 35; P<0.001). Secondary: Pravastatin was associated with a significant 29% reduction in the incidence of MI compared to placebo (7.4 vs 10.3%; P<0.001). Pravastatin was associated with a significant 19% reduction in the incidence of stroke compared to placebo (3.7 vs 4.5%; P=0.048). Pravastatin was associated with a significant 22% reduction in the risk of CABG surgery compared to placebo (9.2 vs 11.6%; P<0.001). Pravastatin was associated with a significant 19% reduction in the risk of coronary angioplasty compared to placebo (4.7 vs 5.6%; P=0.024). Pravastatin was associated with a significant 12% reduction in the risk of unstable angina compared to placebo (22.3 vs 24.6%; P=0.005).
Shepherd et al.[200] (2002) PROSPER Pravastatin 40 mg QD vs placebo	DB, MC, PC, RCT Patients 70 to 82 years of age with pre-existing vascular disease (coronary, cerebral or peripheral) or at an increased risk of such disease due to risk factors (smoking, HTN, or diabetes) with TC 4 to 9 mmol/L and TG <6 mmol/L	N=5,804 Mean, 3.2 years (range, 2.8 to 4.0 years)	Primary: Combined endpoint of definite or suspect death from CHD, nonfatal MI and fatal or nonfatal stroke Secondary: Examination of coronary and cerebrovascular components separately, assessment of cognitive function,	Primary: Pravastatin was associated with a significant 15% reduction in the risk of the primary endpoint compared to placebo (14.1 vs 16.2%; HR, 0.85; 95% CI, 0.74 to 0.97; P=0.014). Secondary: When the primary endpoint was separated into coronary and cerebrovascular components, the authors noted a 19% reduction in coronary events with pravastatin, but no apparent effect on cerebrovascular events (P value not reported). Pravastatin was associated with a significant 19% reduction in the risk of CHD death or nonfatal MI compared to placebo (10.1 vs 12.2%; HR, 0.81; 95% CI, 0.69 to 0.94; P=0.006). When examining the rates of fatal or nonfatal stroke, there was no significant difference between the two treatments (HR, 1.03; 95% CI, 0.81 to 1.31; P=0.81).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			adverse events, cancer	There was no significant difference in cognitive function between the two treatments (P>0.05). The rate of serious adverse events reported was similar between the two treatments (56 vs 55%, respectively; P value not reported). There were no patients with either treatment reported rhabdomyolysis or CK concentrations >10 times the upper limit of normal (P value not reported). There were no significant differences in the rates of cancer development between the two treatments (P>0.05).
Lloyd et al.[201] (2013) PROSPER Pravastatin 40 mg QD vs placebo	FU Patients enrolled in the PROSPER trial	N=5,804 (5,188 were followed long-term) Mean follow-up of 8.2 years	Primary: All-cause mortality, coronary, stroke, cancer and non-CV mortality	Primary: There was no evidence of any effect on all-cause mortality or on non-CV or CV mortality. During the trial and post-trial there was a numerical excess of stroke deaths in the pravastatin arm; however, this difference did not reach statistical significance. There was a reduction in CHD mortality over the entire period of follow-up (HR 0.80, 95% CI, 0.68 to 0.95; P=0.0091). A suggestion of an increased risk of incident cancer during the trial period (HR, 1.23; 95% CI, 1.01 to 1.49; P=0.038) was not replicated in the post-trial period (HR, 1.08; 95% CI, 0.96 to 1.21; P=0.22).
Thompson et al.[202] (2004) PACT Pravastatin 20 to 40 mg/day vs placebo	DB, MC, PC, RCT Patients 18 to 85 years of age with <24 hours onset of symptoms and diagnosis of acute MI or unstable angina pectoris	N=3,408 4 weeks	Primary: Composite of death from any cause, acute MI or readmission to hospital with unstable angina pectoris during the first month following randomization Secondary: Incidence of individual causes of death, acute MI other	Primary: Pravastatin 40 mg was associated with a nonsignificant 6.4% reduction in the risk of the primary endpoint compared to placebo (P=0.48). Secondary: There were no significant differences in the frequency of individual components of the primary endpoint in the 30 days after randomization between the two treatments (P>0.05). The frequency of adverse events did not differ between the two treatments (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			than the index event, readmission for angina in the first month, urgent revascularization procedure, other nonfatal cardiovascular events; adverse events	
Asselbergs et al.[203] (2004) Pravastatin 40 mg QD and fosinopril 20 mg QD vs placebo	DB, PC, RCT Patients aged 28-75 years with persistent micro-albuminuria, BP <160/100 mm Hg (not on antihypertensive medications), TC level <8.0 mmol/L, or <5.0 mmol/L in case of previous MI, and no use of lipid-lowering medication	N=864 46 months	Primary: Combined incidence of cardiovascular mortality and hospitalization for cardiovascular morbidity (nonfatal or myocardial ischemia, heart failure, peripheral vascular disease and/or cerebrovascular accident) Secondary: Not reported	Primary: Pravastatin therapy was associated with a 13% reduction in the risk of the primary end point compared to placebo (4.8 vs 5.6%; P=0.649). The incidence of non-cardiovascular mortality was 2.1% in the pravastatin group compared to 1.9% in the placebo group. Secondary: Not reported
Sato et al.[204] (2008) OACIS-LIPID	MC, OL, RCT Patients with acute MI and mild	N=353 9 months	Primary: Composite end point of death, nonfatal MI,	Primary: The composite end point occurred in 17.9% of patients in the pravastatin group compared to 31.4% of patients in the non-pravastatin group (HR, 0.56; 95% CI, 0.36 to 0.87; P<0.006).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Pravastatin 10 mg QD vs no pravastatin	to moderate hyperlipidemia (TC 200 to 250 mg/dL and TG ≤300 mg/dL)		unstable angina, re-vascularization and non-fatal stroke, and rehospitalizatio n because of other cardiovascular diseases Secondary: Not reported	There were no significant differences in the risk of death (P=0.643), nonfatal MI (P=0.622), unstable angina (P=0.985), or nonfatal stroke (P=0.252) between the pravastatin group and non-pravastatin group. There was a lower risk of revascularization in the pravastatin group compared to the non-pravastatin group (12.7 vs 20.6%, P=0.049). Secondary: Not reported
Tavazzi et al.[205] (2008) GISSI-HF Rosuvastatin 10 mg QD vs placebo	RCT, DB, MC, PC Patients ≥18 years of age with symptomatic heart failure (NYHA class II to IV)	N=4,631 Median 3.9 years	Primary: Time to death, and time to death or admission to hospital for cardiovascular reasons Secondary: Cardiovascular mortality, cardiovascular mortality or admission for any reason, sudden cardiac death, admission for any reason, admission for cardiovascular reasons, admission for	Primary: At the end of the follow-up period, 29% of patients in the rosuvastatin group died from any cause compared to 28% of patients in the placebo group (HR, 1.00; 97% CI, 0.898 to 1.122; P=0.943). The composite of all-cause death or admission to hospital for cardiovascular reasons occurred in 57% of patients in the rosuvastatin group compared to 56% of patients in the placebo group (HR, 1.01; 99% CI, 0.908 to 1.112; P=0.903). Secondary: There was no difference in cardiovascular mortality (P=0.804), first hospital admission for any, cardiovascular, or heart failure cause (P=0.962, P=0.613, and P=0.987, respectively), or the combined outcome measure of cardiovascular death or admission to hospital for any cause (P=0.409) sudden cardiac death (P=0.221), MI (P=0.459), and stroke (P=0.174) with rosuvastatin compared to placebo.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			heart failure, MI, and stroke	
Rossebø et al.[206] (2008) SEAS Simvastatin 40 mg QD and ezetimibe 10 mg QD vs placebo Open-label lipid-lowering therapy, which included up to 40 mg of simvastatin or an equipotent dose of another lipid-lowering drug, could be administered in addition to the study drug at the discretion of each treating physician	DB, MC, RCT Patients 45 to 85 years of age who had asymptomatic, mild-to-moderate aortic valve stenosis with a peak aortic-jet velocity of 2.5 to 4 m per second	N=1,873 52.2 months (median duration)	Primary: Composite of major cardiovascular events (death from cardiovascular causes, aortic-valve replacement, CHF as a result of progression of aortic-valve stenosis, nonfatal MI, hospitalization for unstable angina, CABG, PCI, non-hemorrhagic stroke) Secondary: Aortic-valve events, progression of aortic stenosis, safety	Primary: The composite of major cardiovascular events occurred in 35.3% of patients in the simvastatin plus ezetimibe group and in 38.2% of patients in the placebo group (HR, 0.96; 95% CI, 0.83 to 1.12; P=0.59). Secondary: There was no significant difference between the treatments in aortic-valve-related events (HR, 0.97; 95% CI, 0.83 to 1.14; P=0.73). Aortic-valve replacement occurred in 28.3% of patients in the simvastatin plus ezetimibe group and in 29.9% of patients in the placebo group (HR, 1.00; 95% CI, 0.84 to 1.18; P=0.97). Ischemic cardiovascular events occurred in 15.7% of patients in the simvastatin plus ezetimibe group compared to 20.1% of patients in the placebo group (HR, 0.78; 95% CI, 0.63 to 0.97; P=0.02). A total of 7.3% of patients in the simvastatin plus ezetimibe group required CABG compared to 10.8% of patients in the placebo group (HR, 0.68; 95% CI, 0.50 to 0.93; P=0.02). There was no significant difference in the progression of aortic stenosis between the treatment groups. The mean peak aortic jet velocity was 3.71 m per second in the placebo group compared to 3.69 m per second in the simvastatin plus ezetimibe group at the end of the study (95% CI, -0.06 to 0.05; P=0.83). The mean pressure gradient increased to 34.4 mm Hg in the placebo group compared to 34.0±15.1 mm Hg in the simvastatin plus ezetimibe group at the end of the study. There was no significant difference in the aortic-valve area between the treatment groups. There was no significant difference in overall mortality among the treatment groups (P=0.80). The composite outcome of death from cardiovascular causes

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				and the individual components of this composite outcome did not differ significantly between the two groups (P=0.34). There was a significant increase in the number of patients with elevated liver enzyme levels in the simvastatin plus ezetimibe group. There was also a higher incidence of cancer in the simvastatin plus ezetimibe group (11.1%) compared to placebo (7.5%; P=0.01).
No authors listed.[207] (1994) 4S Simvastatin 10 mg/day, titrated up to 40 mg/day vs placebo	DB, PC, RCT Patients 35 to 70 years of age with CHD, a history of angina pectoris or previous MI, TC 212 to 309 mg/dL and TG <221 mg/dL on a lipid-lowering diet	N=4,444 5.4 years	Primary: All-cause mortality Secondary: Major coronary events (coronary deaths, definite or probable hospital-verified nonfatal acute MI, resuscitated cardiac arrest and definite silent MI)	Primary: Simvastatin was associated with a 30% reduction in all-cause mortality compared to placebo (8 vs 12%; RR, 0.70; 95% CI, 0.58 to 0.85; P=0.0003). Secondary: Overall, patients receiving placebo experienced at least one secondary event compared to patients receiving simvastatin (28 vs 19%, respectively; P value not reported). There were 189 (8.5%) coronary deaths with placebo compared to 111 (5.0%) coronary deaths with simvastatin (RR, 0.58; 95% CI, 0.46 to 0.73; P value not reported). There were 270 (12.1%) definite acute MI with placebo compared to 164 (7.4%) definite acute MI with simvastatin. There were 418 (18.8%) definite or probable acute MI with placebo compared to 279 (12.6%) definite or probable acute MI with simvastatin. There were 110 (4.9%) silent MIs with placebo compared to 88 (4.0%) silent MIs with simvastatin. There was one patient receiving simvastatin who experienced resuscitated cardiac arrest. (P values not reported). Additionally, a cerebrovascular event occurred in 95 (4.3%) patients with placebo compared to 61 (2.7%) patients with simvastatin (RR, 95% CI; P value not reported).
Chonchol et al.[208] 4S (2007) Simvastatin 10 mg/day, titrated up to 40 mg/day vs	Subanalysis of 4S Patients 35 to 70 years of age with CHD, a history of angina pectoris or previous MI, TC 212 to 309 mg/dL and TG <221 mg/dL on a lipid-	N=4,420 5.4 years	Primary: All-cause mortality Secondary: Major coronary events (coronary deaths, definite or probable	Primary: Simvastatin was associated with a significant reduction in all-cause mortality among patients with chronic renal insufficiency (HR, 0.70; 95% CI, 0.55 to 0.91; P value not reported). Secondary: Simvastatin was associated with a significant reduction in the incidence of major coronary events among patients with chronic renal insufficiency (HR, 0.68; 95% CI, 0.57 to 0.80; P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
placebo	lowering diet, stratified by estimated GFR of ≥75 or <75 mL/min/1.73 m^2		hospital-verified nonfatal acute MI, resuscitated cardiac arrest and definite silent MI)	Simvastatin was associated with a significant reduction in the incidence of CHD deaths or nonfatal MIs among patients with chronic renal insufficiency (HR, 0.66; 95% CI, 0.55 to 0.79; P value not reported). Simvastatin was associated with a significant reduction in the incidence of coronary revascularization among patients with chronic renal insufficiency (HR, 0.63; 95% CI, 0.51 to 0.79; P value not reported). Simvastatin was not associated with a significant reduction in the incidence of stroke among patients with chronic renal insufficiency (HR, 0.86; 95% CI, 0.54 to 1.36; P value not reported).
No authors listed.[209] (2003) MRC/BHF (HPS) Simvastatin 40 mg QD vs placebo	DB, MC, PC, RCT Patients 40 to 80 years of age with a history of CHD, PAD, cerebrovascular disease, diabetes or treated HTN (if also male and ≥65 years of age) with TC ≥135 mg/dL	N=20,536 5 years	Primary: All-cause mortality and CHD death events Secondary: Noncoronary causes of death, major coronary events (nonfatal MI or CHD death), stroke, revascularization, major vascular events (nonfatal MI, CHD death, stroke or revascular-ization), cancer	Primary: During the trial, 12.9 (1,328/10,269) vs 14.7% (1,507/10,267) of patients receiving simvastatin and placebo died (P=0.0003). The effect of simvastatin on all-cause mortality was mainly due to the definite 17% (SE, 4; 95% CI, 9 to 25) proportional reduction in the death rate from vascular causes (7.6 vs 9.1%; P<0.0001), which consists of a highly significant 18% (SE, 5) reduction in the coronary death rate (5.7 vs 6.9%; P=0.0005) and a nonsignificant 16% (SE, 9) reduction in the death rate from other vascular causes (1.9 vs 2.2%; P=0.07). There were no differences in all nonvascular deaths (5.3 vs 5.6%; P=0.4) or in any of the prespecified categories of nonvascular deaths (renal, hepatic and trauma). Secondary: Simvastatin was associated with a significant 38% (SE, 5; 95% CI, 30 to 46) proportional reduction in the incidence rate of first nonfatal MI (3.5 vs 5.6%; P<0.0001). For the endpoint of major coronary events, there was a significant 27% (SE, 4; 95% CI, 21 to 33) proportion reduction in the incidence rate of combined first nonfatal MI or coronary death (8.7 vs 11.8%; P<0.0001). Overall, simvastatin was associated with a significant 25% (SE, 5; 95% CI, 15 to 34) proportional reduction in the incidence rate of fist stroke (4.3 vs 5.7%; P<0.0001). This was due to mainly to a significant 30% (SE, 6; 95% CI, 19 to 40) proportional reduction in the incidence rate of strokes attributed to ischemia (2.8 vs 4.0%; P<0.0001), with no apparent difference in strokes attributed to hemorrhage (0.5 vs 0.5%; P=0.8).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Overall, simvastatin was associated with a significant 24% (SE, 4; 95% CI, 17 to 30) proportional reduction in the incidence rate of first revascularization procedure (9.1 vs 11.7%; P<0.0001). Specifically, simvastatin was associated with a significant 30% (SE, 5; 95% CI, 22 to 38) proportional reduction in the incidence rate of coronary revascularization (5.0 vs 7.1%; P<0.0001). Similar results were observed for noncoronary revascularization (4.4 vs 5.2%; P=0.006). When the data for major coronary events (first nonfatal MI or coronary death), stroke and revascularization are combined for the endpoint of major vascular events, simvastatin was associated with a significant 24% (SE, 3; 95% CI, 19 to 28) proportional reduction in the event rate (19.8 vs 25.2%; P<0.001). New primary cancers were diagnosed in 7.9 and 7.9% of patients receiving simvastatin and placebo (rate ratio, 1.00; 95% CI, 0.91 to 1.11). These cases were associated with death in 3.5 vs 3.4% of patients (rate ratio, 1.03; 95% CI, 0.89 to 1.19). There were also no differences in the incidence of cancers in any particular body system.
Collins et al.[210] (2007) MRC/BHF (HPS) Simvastatin 40 mg QD vs placebo	DB, MC, PC, RCT Patients 40 to 80 years of age with a history of CHD, PAD, cerebrovascular disease, diabetes or treated HTN (if also male and ≥65 years of age) with TC ≥135 mg/dL	N=20,536 (5,963 diabetics and 14,573 patients with occlusive arterial disease without diabetes) 5 years	Primary: Incidence of first nonfatal MI or coronary death; fatal or nonfatal stroke; revascular-ization procedures; first incidence of major coronary events, strokes and revascular-izations Secondary: Not reported	Primary: Simvastatin was associated with a significant 27% reduction in the incidence of first nonfatal MI or coronary death compared to placebo (95% CI, 21 to 33; P<0.0001). Among diabetic patients, simvastatin was associated with a significant 27% reduction in the incidence of first nonfatal MI or coronary death compared to placebo (95% CI, 19 to 34; P<0.0001). Simvastatin was associated with a significant 25% reduction in the incidence of first nonfatal or fatal strokes compared to placebo (95% CI, 15 to 34; P<0.0001). Simvastatin was associated with a significant 26% reduction in the incidence of fatal strokes compared to placebo (95% CI, 14 to 36; P=0.0002). Among diabetic patients, simvastatin was associated with a significant 24% reduction in the incidence of fatal strokes compared to placebo (95% CI, 6 to 39; P=0.01).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Simvastatin was associated with a significant 24% proportional reduction in the incidence of first revascularization compared to placebo (95% CI, 17 to 30; P<0.0001). Among diabetic patients, simvastatin was associated with a significant 17% reduction in the incidence of first revascularization procedure compared to placebo (95% CI, 3 to 30; P=0.02). Simvastatin was associated with a significant 24% reduction in the first incidence of major coronary events, strokes and revascularizations compared to placebo (95% CI, 19 to 28; P<0.0001). Among diabetic patients, simvastatin was associated with a significant 22% reduction in the incidence of first incidence of major coronary events, strokes and revascularizations compared to placebo (95% CI, 13 to 30; P<0.0001). Secondary: Not reported
de Lemos et al.[211] (2004) A to Z trial Simvastatin 40 mg/day for 1 month, titrated up to 80 mg/day (intensive therapy) vs placebo for 4 months, followed by simvastatin 20 mg/day (delayed initiation of a less	DB, MC, PC Adult patients with either non-ST-elevation ACS or STEMI	N=4,497 2 years	Primary: Composite of cardiovascular death, nonfatal MI, readmission for ACS (requiring new ECG changes or cardiac marker elevation) and stroke Secondary: Individual components of the primary endpoint, re-	Primary: Simvastatin 80 mg was associated with a nonsignificant reduction in the risk of the primary endpoint compared to simvastatin 20 mg (14.4 vs 16.7%; HR, 0.89; 95% CI, 0.76 to 1.04; P=0.14). Secondary: Simvastatin 80 mg was associated with a significant reduction in the risk of cardiovascular death compared to simvastatin 20 mg (HR, 0.75; 95% CI, 0.57 to 1.00; P=0.05). There was no significant difference between the two treatments in the secondary endpoints of MI, readmission for ACS, revascularization due to documented ischemia or stroke (P>0.05 for all). Simvastatin 80 mg was associated with a significant reduction in the risk of new onset CHF compared to simvastatin 20 mg (3.7 vs 5.0%; HR, 0.72; 95% CI, 0.53 to 0.98; P=0.04).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
intensive therapy)			vascularization due to documented ischemia, all-cause mortality, new-onset CHF (requiring admission or initiation of heart failure medications), cardiovascular Re-hospitalization	
No authors listed.[212] (2007) Simvastatin 40 mg QD vs placebo	DB, MC, RCT Patients 40 to 80 years of age with a history of CHD, PAD, cerebrovascular disease, diabetes or treated HTN (if also male and ≥65 years of age) with TC ≥135 mg/dL	N=20,536 5 years	Primary: The first major coronary event (nonfatal MI or coronary death), first major vascular event (major coronary event, stroke or revascular-ization) Secondary: Not reported	Primary: In the overall population, simvastatin was associated with a significant 24% reduction in the first incidence of a major vascular event compared to placebo (19.8 vs 25.2%; P<0.0001). Among patients with baseline PAD, simvastatin was associated with a significant 22% reduction in the first incidence of a major vascular event compared to placebo (26.4 vs 32.7%; P<0.0001). Among patients without baseline PAD, simvastatin was associated with a significant 25% reduction in the first occurrence of a major vascular event compared to placebo (16.5 vs 21.5%; P<0.0001). The difference in the reduction of the risk of major vascular events with statin therapy between the PAD and non-PAD groups was not significant (P=0.05). In the overall population, simvastatin was associated with a significant 27% reduction in the first incidence of a major coronary event compared to placebo (8.7 vs 11.8%; P<0.0001). Among patients with baseline PAD, simvastatin was associated with a significant reduction in the first incidence a major coronary event compared to placebo (10.9 vs 13.8%; P<0.0001). Among patients without baseline PAD, simvastatin was associated with a significant reduction in the first incidence of a major coronary event compared to placebo

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				(7.7 vs 10.8%; P<0.0001). The difference in the reduction of the risk of major coronary events with statin therapy between the PAD and non- PAD groups was not significant (P=0.03). In the overall population, simvastatin was associated with a significant 25% reduction in the first incidence of stroke compared to placebo (4.3 vs 5.7%; P<0.0001). Among patients with baseline PAD, simvastatin was associated with a significant reduction in the first incidence of stroke compared to placebo (5.3 vs 7.2%; P<0.0001). Among patients without baseline PAD, simvastatin was associated with a significant reduction in the first incidence of stroke compared to placebo (3.8 vs 5.0%; P<0.0001). The difference in the reduction of the risk of stroke with statin therapy between the PAD and non-PAD groups was not significant (P=0.07). In the overall population, simvastatin was associated with a significant 24% reduction in the first incidence of revascularization compared to placebo (9.1 vs 11.7%; P<0.0001). Among patients with baseline PAD, simvastatin was associated with a significant reduction in the first incidence of revascularization compared to placebo (13.8 vs 17.9%; P<0.0001). Among patients without baseline PAD, simvastatin was associated with a significant reduction in the first incidence of revascularization compared to placebo (6.9 vs 8.7%; P<0.0001). The difference in the reduction of the risk of revascularization with statin therapy between the PAD and non- PAD groups was not significant (P=0.07). In the overall population, simvastatin was associated with a significant 16% reduction in the risk of first incidence of a peripheral vascular event compared to placebo (4.7 vs 5.5%; P=0.006). This risk reduction was independent of baseline LDL-C, age, diabetes or coronary disease (P values not reported). Secondary: Not reported
Pauriah et al.[213] (2014)	OS, RETRO Patients who had	N=9,597 Mean follow-up	Primary: Mortality, lipid levels	Primary: The adjusted HR for the high-potency statin group was 0.72 (95% CI, 0.59 to 0.88; P<0.001), and for the ezetimibe/statin combination group, the adjusted

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Simvastatin monotherapy vs high-potency statin group (patients who started on simvastatin and switched to atorvastatin or rosuvastatin) vs ezetimibe/statin combination group	survived 30 days after their first acute MI, had not received prior statin or ezetimibe therapy, and were started on a statin within 30 days of acute MI	of 3.2 years	Secondary: Not reported	HR was 0.96 (95% CI, 0.64 to 1.43; P<0.85). In the subgroup analysis of 2787 patients with complete data for GFR, cholesterol, and blood pressure, the HR for ezetimibe use and high-potency statin use were 1.03 (95% CI, 0.47 to 2.23; P=0.943) and 0.79 (95% CI, 0.55 to 1.131; P=0.19), respectively. There was a decrease in total cholesterol and LDL-C in all three groups with significantly greater percentage decrease in these measures in the high-potency statin group and the ezetimibe/statin combination group compared with the simvastatin monotherapy group. Because of higher baseline total cholesterol levels, the best achieved total cholesterol levels were not lower in the high-potency statin and ezetimibe/statin combination groups. Secondary: Not reported
Briel et al.[214] (2006) Statins (pravastatin 10 to 40 mg, fluvastatin 80 mg, atorvastatin 20 to 80 mg, simvastatin 40 to 80 mg) vs placebo	MA (12 PC, RCTs) Patients with ACS (MI or unstable angina), started on statin therapy within 14 days of ACS and with a follow up ≥30 days	N=13,024 ≥30 days	Primary: Composite endpoint of nonfatal MI, nonfatal stroke and total death Secondary: Total death, total MI, total stroke, cardiovascular death, fatal and nonfatal MI, revascularization procedures (CABG surgery,	Primary: At either month one or four follow up, there was no significant difference in the primary endpoint between statin therapy and placebo (P=0.39 and P=0.30, respectively). Secondary: At either month one or four of follow up, there was no significant difference in any of the secondary endpoints (except for unstable angina) between statin therapy and placebo (P values not reported). After four months of therapy, statin therapy was associated with a significant moderate reduction in the incidence of unstable angina compared to placebo (P=0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			angioplasty) and unstable angina (recurrent myocardial ischemia requiring emergency hospitalization)	
Mood et al.[215] (2007) Statins (atorvastatin 20 to 40 mg/day, pravastatin 40 mg/day, fluvastatin 40 mg BID) vs placebo or usual care	MA (6 RCTs) Therapy was initiated around the time of a PCI	N=3,941 up to 45 months	Primary: Incidence of MI Secondary: All-cause mortality, cardiovascular mortality, surgical or percutaneous re-vascularization, stroke	Primary: Compared to placebo or usual care, statin therapy was associated with a significant 43% reduction in the risk for MI (5.2 vs 3.0%; OR, 0.57; 95% CI, 0.42 to 0.78; P<0.0001). Secondary: Compared to placebo or usual care, statin therapy was associated with a nonsignificant 26% reduction in all-cause mortality (3.0 vs 2.3%; OR, 0.74; 95% CI, 0.5 to 1.1; P=0.14). Compared to placebo or usual care, statin therapy was associated with a nonsignificant 42% reduction in cardiovascular mortality (1.20 vs 0.71%; OR, 0.58; 95% CI, 0.30 to 1.11; P=0.10). Compared to placebo or usual care, statin therapy was associated with a nonsignificant 11% reduction in the incidence of repeat surgical or percutaneous revascularization (21.9 vs 19.6%; OR, 0.89; 95% CI, 0.78 to 1.02; P=0.098). The incidence of stroke was nonsignificantly higher with statin therapy compared to placebo or usual care (0.40 vs 0.08%; OR, 3.00; 95% CI, 0.60 to 14.77; P=0.18).
Afilalo et al.[216] (2008) Moderate statin therapy (pravastatin 40	MA (9 RCTs) Patients ≥50 years of age with CHD	N=19,569 (9 studies) ≥6 months	Primary: All-cause mortality, CHD mortality, stroke, re-vascularization,	Primary: Statin therapy was associated with a lower rate of all-cause mortality compared to placebo (15.6 vs 18.7%; RR, 0.78; 95% CI, 0.65 to 0.89; P value not reported). Statin therapy was associated with a significant reduction in the risk of CHD

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day, fluvastatin 80 mg/day, simvastatin 20 to 40 mg/day) vs placebo			nonfatal MI Secondary: Not reported	mortality by 30% (RR, 0.70; 95% CI, 0.53 to 0.83), nonfatal MI by 26% (RR, 0.74; 95% CI, 0.60 to 0.89), revascularization by 30% (RR, 0.70; 95% CI, 0.53 to 0.83) and stroke by 25% (RR, 0.75; 95% CI, 0.56 to 0.94). The calculated NNT with statin therapy to save one life was 28 (95% CI, 15 to 56). Secondary: Not reported
Hulten et al.[217] (2006) Intensive statin therapy (pravastatin 40 mg/day, fluvastatin 80 mg/day, simvastatin 80 mg/day, atorvastatin 20 mg/day, atorvastatin 80 mg daily) vs placebo or lower dosed statin therapy	MA (13 RCTs) Adult patients initiated on intensive statin therapy or control within 14 days of hospitalization for ACS	N=17,963 Up to 2 years of follow up	Primary: Composite of death, recurrent ischemia and recurrent MI; death and cardiovascular events; cardiovascular death; ischemia; MI; LDL-C reduction; safety Secondary: Not reported	Primary: In patients with recent ACS, intensive statin therapy was associated with a significantly lower rate of mortality and cardiovascular events over 24 months of follow up (HR, 0.81; 95% CI, 0.77 to 0.87; P<0.001). In patients with recent ACS, intensive statin therapy was associated with a lower risk of overall cardiovascular events over 24 months of follow up (HR, 0.84; 95% CI, 0.76 to 0.94; P value not reported). In patients with recent ACS, intensive statin therapy was associated with lower cardiovascular mortality over 24 months of follow up (HR, 0.76; 95% CI, 0.66 to 0.87). In patients with recent ACS, intensive statin therapy was associated with lower ischemia over 24 months of follow up (HR, 0.68; 95% CI, 0.50 to 0.92). In patients with recent ACS, intensive statin therapy was not associated with a lower incidence of MIs over 24 months of follow up (HR, 0.89; 95% CI, 0.60 to 1.33). Intensive statin therapy was associated with a significantly greater reduction in LDL-C compared to controls (P<0.001). Adverse effects were similar between the two treatments (P value not reported). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Cannon et al.[218] (2004) PROVE IT-TIMI 22 Atorvastatin 80 mg/day (intensive regimen) vs pravastatin 40 mg/day (standard regimen)	DB, DD, MC, RCT Patients ≥18 years of age in stable condition after a hospitalization for an ACS with either an acute MI or high risk unstable angina in the preceding 10 days, with TC ≤240 mg/dL measured within the first 24 hours after the onset of the ACS or up to 6 months earlier if no sample had been obtained during the first 24 hours; patients who were receiving long-term lipid-lowering therapy at the time of the ACS had a TC ≤200 mg/dL	N=4,162 Up to 3 years (mean 2 years)	Primary: Rates of composite death from any cause, MI, documented unstable angina requiring hospitalization, revascularizatio n and stroke Secondary: Risk of death due to CHD, nonfatal MI or re-vascularization; risk of the individual components of the primary endpoint; discontinuation rates; safety	Primary: The rates of composite death from any cause, MI, unstable angina requiring hospitalization, revascularization and stroke at two years were 26.3 and 22.4% with pravastatin and atorvastatin, representing a 16% reduction in the HR favoring atorvastatin (95% CI, 5 to 26; P=0.005). Secondary: The risk of death due to CHD, nonfatal MI or revascularization was reduced by 14% with atorvastatin (P=0.029) with a two year event rate of 19.7% compared to a two year event rate of 22.3% with pravastatin. The risk of death, MI or urgent revascularization was reduced by 25% with atorvastatin (P<0.001). Among the individual components of the primary endpoint, atorvastatin was associated with a significant reduction of 14% for revascularization (P=0.04) and a 29% reduction in the risk of recurrent unstable angina (P=0.02) compared to pravastatin. There were nonsignificant reductions in the rates of death or MI (18%, P=0.06) and the rates of stroke (P value not reported) between the two treatments. The discontinuation rates due to adverse events or for other reasons were 21.4 and 22.8% with pravastatin and atorvastatin at one year (P=0.30) and 33.0 and 30.4%, respectively at two years (P=0.11). Discontinuation rates due to myalgias or muscle aches or elevations in CK levels were 2.7 and 3.3% with pravastatin and atorvastatin (P=0.23). There were 1.1 and 3.3% of patients receiving pravastatin and atorvastatin who had elevations in ALT levels that were at least three times the upper limit of normal (P<0.001).
Ray et al.[219] (2005) PROVE IT-TIMI 22 Atorvastatin 80 mg/day (intensive	Subanalysis of PROVE IT-TIMI 22 Patients ≥18 years of age in stable condition after a	N=4,162 Up to 3 years (mean, 2 years)	Primary: A composite of all-cause mortality, MI, unstable angina requiring hospitalization,	Primary: After 30 days, 3.0 and 4.2% of patients receiving atorvastatin and pravastatin experienced a primary endpoint (HR, 72; 95% CI, 0.52 to 0.99; P=0.046). From six months to the end of the trial, 15.1 and 17.7% of patients receiving atorvastatin and pravastatin experienced a primary endpoint (HR, 82; 95% CI, 0.69 to 0.99; P=0.037).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
regimen) vs pravastatin 40 mg/day (standard regimen)	hospitalization for an ACS with either an acute MI or high risk unstable angina in the preceding 10 days, with TC ≤240 mg/dL measured within the first 24 hours after the onset of the ACS or up to 6 months earlier if no sample had been obtained during the first 24 hours; patients who were receiving long-term lipid-lowering therapy at the time of the ACS had a TC ≤200 mg/dL		revascularization or stroke Secondary: A composite of death, MI or unstable angina requiring hospitalization	Secondary: Atorvastatin was associated with a significant reduction in the risk of the triple composite endpoint compared to pravastatin (15.7 vs 20.0%; HR, 76; 95% CI, 0.66 to 0.88; P=0.0002). After 30 days, patients receiving atorvastatin experienced a significantly greater reduction in LDL-C and hsCRP level compared to patients receiving pravastatin (P<0.001 for both).
Ahmed et al.[220] (2006) PROVE IT-TIMI 22 Atorvastatin 80 mg/day (intensive regimen) vs pravastatin 40 mg/day (standard	Subanalysis of PROVE IT-TIMI 22 Patients ≥18 years of age in stable condition after a hospitalization for an ACS with either an acute MI or high risk unstable angina in the preceding 10	N=4,162 Up to 3 years (mean, 2 years)	Primary: A composite of death, MI, unstable angina requiring hospitalization, revascularization with PCI or CABG surgery occurring within 30 days after randomization	Primary: There was no significant difference between the two treatments in terms of the primary endpoint among patients with diabetes (31.8 vs 28.4%; HR, 88; P=0.28). Secondary: Atorvastatin was associated with a significantly lower rate for the secondary composite endpoint compared to pravastatin among patients with diabetes (21.1 vs 26.6%; HR, 0.75; P=0.03) and patients without diabetes (14 vs 18%; HR, 0.76; P=0.002). Consequently, treating 1,000 diabetic and nondiabetic patients with atorvastatin would prevent 55 and 40 events, respectively (P value not

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
regimen)	days, with TC ≤240 mg/dL measured within the first 24 hours after the onset of the ACS or up to 6 months earlier if no sample had been obtained during the first 24 hours; patients who were receiving long-term lipid-lowering therapy at the time of the ACS had a TC ≤200 mg/dL, stratified by type 2 diabetes		or stroke within two years after trial onset Secondary: A composite of death, MI or unstable angina requiring hospitalization; LDL-C <70 mg/dL goal; hsCRP <2 mg/L goal; MI; unstable angina requiring hospitalization	reported). Compared to nondiabetic patients, fewer patients with diabetes receiving atorvastatin achieved the dual goal of LDL-C <70 mg/dL and hsCRP <2 mg/L (37.6 vs 45.4%; P=0.004). Out of diabetic patients receiving atorvastatin, 62% failed to reach the dual goal of LDL-C <70 mg/dL and hsCRP <2 mg/L. Diabetic patients who reached the dual LDL-C and CRP goals had significantly lower rates of the secondary endpoint compared to patients who failed to reach the goal (17.7 vs 24.7%; P=0.021). In the diabetic population, among the individual components of the primary and secondary composite endpoints, the only variable exhibiting a significant reduction with atorvastatin compared to pravastatin was unstable angina requiring hospitalization (3.1 vs 7.4%; P=0.003).
Scirica et al.[221] (2006) PROVE IT-TIMI 22 Atorvastatin 80 mg/day (intensive regimen) vs pravastatin 40 mg/day (standard regimen)	Subanalysis of PROVE IT-TIMI 22 Patients ≥18 years of age in stable condition after a hospitalization for an ACS with either an acute MI or high risk unstable angina in the preceding 10 days, with TC ≤240 mg/dL measured within the first 24 hours	N=4,162 Up to 3 years (mean, 2 years)	Primary: Hospitalization for heart failure occurring ≥30 days after randomization Secondary: Not reported	Primary: Atorvastatin was associated with a significant reduction in the rate of hospitalization for heart failure compared to pravastatin (1.6 vs 3.1%; HR, 0.55; 95% CI, 0.35 to 0.85; P=0.008). The benefit observed with atorvastatin was independent on recurrent MI or prior history of heart failure. Higher BNP was associated with an increased risk for heart failure (HR, 2.6; 95% CI, 1.2 to 5.5; P=0.016). Among patients with a high BNP level (>80 pg/mL), atorvastatin was associated with a lower incidence of heart failure compared to pravastatin (HR, 0.32; 95% CI, 0.13 to 0.8; P=0.014). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	after the onset of the ACS or up to 6 months earlier if no sample had been obtained during the first 24 hours; patients who were receiving long-term lipid-lowering therapy at the time of the ACS had a TC ≤200 mg/dL			
Ray et al.[222] (2006) PROVE IT-TIMI 22 Atorvastatin 80 mg/day (intensive regimen) vs pravastatin 40 mg/day (standard regimen)	Subanalysis of PROVE IT-TIMI 22 Patients ≥18 years of age in stable condition after a hospitalization for an ACS with either an acute MI or high risk unstable angina in the preceding 10 days, with TC ≤240 mg/dL measured within the first 24 hours after the onset of the ACS or up to 6 months earlier if no sample had been obtained during the first 24	N=4,162 Up to 3 years (mean, 2 years)	Primary: Cardiac mortality; MI; unstable angina requiring hospitalization; relationship between NCEP goal and a composite primary endpoint of all-cause mortality, MI, unstable angina requiring hospitalization, re-vascularization or stroke Secondary: A composite of	Primary: At 30 days, a greater proportion of patients in both age groups receiving atorvastatin achieved the NCEP goals compared to patients in both age groups receiving pravastatin (P<0.001). Among patients ≥75 years of age, the achievement of the NCEP LDL-C goal was associated with an eight percent reduction in the risk of primary endpoint from baseline (P=0.008). The younger age group achieving the NCEP LDL-C goal was associated with a 2.3% reduction in the risk of primary endpoint from baseline (P=0.013). Patients <75 years of age were associated with a lower risk of the primary composite endpoint compared to patients ≥75 years of age (23.0 vs 30.4%; P<0.0001). Patients <75 years of age were associated with a lower risk of all-cause mortality (P<0.0001), MIs (P<0.0001), unstable angina requiring hospitalization (P=0.01) or strokes (P=0.004) compared to patients ≥75 years of age. Secondary: The composite triple endpoint occurred more frequently in patients ≥75 years of age (20.1 vs 11.0%; HR, 1.93; 95% CI, 1.59 to 2.33; P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	hours; patients who were receiving long-term lipid-lowering therapy at the time of the ACS had a TC ≤200 mg/dL, stratified by age (<75 years of age and ≥75 years of age)		death, MI or unstable angina requiring hospitalization	
Deedwania et al.[223] (2007) SAGE Atorvastatin 80 mg/day (intensive regimen) vs pravastatin 40 mg/day (standard regimen)	DB, DD, MC, PG, RCT Ambulatory patients 65 to 85 years of age with CAD, ≥1 episode of myocardial ischemia that lasted ≥3 minutes during a 48 hour ambulatory ECG at screening and baseline LDL-C 100 to 250 mg/dL	N=893 12 months	Primary: Absolute change from baseline in the total duration of myocardial ischemia on 48 hour Holter monitor Secondary: Absolute change from baseline to month three in the total duration of myocardial ischemia on 48 hour Holter monitor; percent change from baseline to months three and 12 in the	Primary: After 12 months, the total duration of ischemia was significantly reduced from baseline with both treatments (P<0.001). There was no significant difference between the two treatments in terms of the primary endpoint (P=0.88). Secondary: There were no significant differences between the two treatments in any of the secondary endpoints assessing degree of ischemia at months three and 12 (P value not reported). Atorvastatin was associated with a significant 77% reduction in all-cause mortality compared to pravastatin (HR, 0.33; 95% CI, 0.13 to 0.83; P=0.014). Compared to pravastatin, atorvastatin was associated with significantly greater reductions in TC, LDL-C, TG and apo B at months three and 12 (P<0.001). Compared to atorvastatin, pravastatin was associated with a significantly greater increase in HDL-C at three (P<0.001) and 12 months (P=0.009). Atorvastatin was associated with a significantly higher incidence of liver test abnormalities (17.3 vs 13.9%; P<0.001). There were no significant differences between pravastatin and atorvastatin in treatment related adverse events (13.9 vs 17.3%; P=0.17).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			total duration of myocardial ischemia; absolute and percent changes from baseline to months three and 12 in the number of ischemic episodes; percent change in ischemic burden; proportion of patients free of ischemia at months three and 12; percent changes in the levels of TC, LDL-C, HDL-C, TG and apo B	
Pitt et al.[224] (2012) LUNAR Atorvastatin 80 mg/day vs rosuvastatin 20 mg/day vs	MC, OL, PG, PRO, RCT Patients 18 to 75 years of age with CAD who were hospitalized for ACS within 48 hours of ischemic symptoms with non-ST-segment elevation ACS or ST-segment	N=825 12 weeks	Primary: Averaged LDL reduction measurements at six and 12 weeks Secondary: Percentage reduction from baseline in LDL at two, six and 12 weeks,	Primary: The averaged week six and 12 LDL reduction from baseline was significantly greater with rosuvastatin 40 mg compared to atorvastatin 80 mg (46.8 vs 42.7%; P<0.05). The reduction from baseline with rosuvastatin 20 mg was -42.0%. Secondary: Compared to treatment with atorvastatin 80 mg, LDL was significantly reduced with rosuvastatin 20 mg at two weeks (P<0.01) and weeks six through 12 (P<0.05 for both). Similarly, rosuvastatin 40 mg significantly lowered LDL compared to atorvastatin 80 mg at weeks two, six and 12 (P<0.01 for all). The percent change in TC was significantly greater with rosuvastatin 20 mg

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
rosuvastatin 40 mg/day	elevation ACS who received optimal reperfusion therapy (successful treatment with a thrombolytic agent or primary catheter-based intervention initiated within 12 hours of symptom onset), LDL cholesterol level >70 mg/dL and a fasting TG level <500 mg/dL within 72 hours of symptom onset		percentage change in TC, HDL, apo AI, apo B, LDL:HDL cholesterol, TC/HDL, non-HDL:HDL-C, apo B:apo AI, change in CRP at six and 12 weeks and safety	compared to atorvastatin 80 mg (-28.6 vs 30.9%; P<0.05). Rosuvastatin 40 mg reduced TC from baseline by 32.2%. Both the 20 and 40 mg dose of rosuvastatin significantly increased HDL compared to atorvastatin 80 mg (9.7 and 11.9 vs 5.6%; P<0.01 for both rosuvastatin doses). Apo AI was significantly higher following treatment with rosuvastatin 20 and 40 mg compared to atorvastatin 80 mg (10.3 and 10.1 vs 4.2, respectively; P<0.01 for both rosuvastatin doses). There were no statistically significant differences between either dose of rosuvastatin and atorvastatin 80 mg with regard to decrease in Apo B over 12 weeks. The ratio of LDL:HDL decreased in all three groups, however, rosuvastatin 40 mg was associated with a greater percentage reduction compared to atorvastatin 80 mg (-51.5 vs 44.5%; P<0.001). Rosuvastatin 40 mg significantly reduced the ratio of TC:HDL compared to atorvastatin 80 mg (-38.2 vs 33.1%; P<0.001). Rosuvastatin 20 mg reduced the TC/HDL ratio by 34.0%. Rosuvastatin 40 mg also significantly improved the ratio of non-HDL:HDL compared to atorvastatin 80 mg (-47.3 vs -41.2%; P<0.001). Rosuvastatin 20 mg reduced the non-HDL:HDL ratio by -42.3%. The ratio of apo B:apo AI was significantly reduced with rosuvastatin 40 mg compared to atorvastatin 80 mg (P<0.001). The percent change in CRP at week 12 was >80% in all groups; however, there was no statistically significant difference between the treatments.
Pedersen et al.[225] (2005) IDEAL Atorvastatin 80	MC, OL, PG, RCT Patients ≤80 years of age with a	N=8,888 4.8 years	Primary: Incidence of a major coronary event (CHD death, nonfatal	Primary: Atorvastatin was associated with a nonsignificant reduction in the risk of a major coronary event compared to simvastatin (9.3 vs 10.4%; HR, 0.89; P=0.07).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day vs simvastatin 20 to 40 mg/day	history of an MI and qualifying for statin therapy based on NCEP ATP III guidelines		MI or cardiac arrest with resuscitation) Secondary: Major cardiovascular events (any primary event plus stroke), any CHD event (any primary event, any coronary revascularizatio n procedure or hospitalization for unstable angina), any cardiovascular events (any of the former plus hospitalization with a primary diagnosis of CHF and PAD), all individual endpoints, all-cause mortality	Secondary: Atorvastatin was associated with a significant reduction in the risk of a nonfatal MI compared to simvastatin (6.0 vs 7.2%; HR, 0.83; P=0.02). Atorvastatin was associated with a significant reduction in the risk of major cardiovascular events compared to simvastatin (12.0 vs 13.7%; HR, 0.87; P=0.02). Atorvastatin was associated with a significant reduction in the risk of any CHD event compared to simvastatin (20.2 vs 23.8%; HR, 0.84; P<0.001). Atorvastatin was associated with a significant reduction in the risk of any cardiovascular events compared to simvastatin (26.5 vs 30.8%; HR, 0.84; P<0.001). Atorvastatin was associated with a significant reduction in the risk of peripheral vascular disease compared to simvastatin (2.9 vs 3.8%; HR, 0.76; P=0.02). Atorvastatin was associated with a nonsignificant reduction in the risk of fatal or nonfatal stroke compared to simvastatin (3.4 vs 3.9%; HR, 0.87; P=0.20). Atorvastatin was associated with a nonsignificant reduction in the risk of hospitalization for nonfatal heart failure compared to simvastatin (2.2 vs 2.8%; HR, 0.81; P=0.11). Atorvastatin was associated with a nonsignificant reduction in the risk of death from cardiovascular or noncardiovascular cause compared to simvastatin (4.9 vs 5.0; HR, 1.03; 95% CI, 0.85 to 1.24; P=0.78 and 3.2 vs 3.5%; HR, 0.92; P=0.47). Atorvastatin was associated with a nonsignificant reduction in the risk of all-cause mortality compared to simvastatin (8.2 vs 8.4%; HR, 0.98; P=0.81). Atorvastatin was associated with a higher rate of drug discontinuations due to adverse effects compared to simvastatin (9.6 vs 4.2%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Atorvastatin was associated with a higher rate of liver transaminase elevations compared to simvastatin (P<0.001). There was no significant difference between the two treatments in the incidence of serious adverse events (P=0.42).
Tikkanen et al.[226] (2009) IDEAL Atorvastatin 80 mg/day vs simvastatin 20 to 40 mg/day	Post hoc analysis of IDEAL Adult patients with a history of an MI and qualifying for statin therapy based on NCEP ATP III guidelines; stratified by age (<65 years of age vs ≥65 years of age)	N=8,888 4.8 years	Primary: Incidence of a major coronary event (coronary death, confirmed nonfatal acute MI or cardiac arrest with resuscitation) Secondary: Major cardiovascular events (any primary event and stroke), any CHD event (any primary event, any coronary re-vascularization procedure, any hospitalization for unstable angina), any cardiovascular events	Primary: There was no significant heterogeneity of treatment effect by age for any composite endpoint, indicating that the benefit of atorvastatin was similar for younger and older patients. Nevertheless, the cardiovascular risk reductions associated with atorvastatin tended to be numerically lower in the older than younger age group. Atorvastatin was associated with a 20% decrease in risk of the primary endpoint of major coronary events in patients <65 years of age (HR, 0.80; 95% CI, 0.66 to 0.98), with similarly significant reductions in secondary composite endpoints. Secondary: There were similarly significant reductions in secondary composite endpoints, the corresponding reductions in the risk in patients ≥65 years of age were four to 12%, and significance was achieved for only the endpoint of any cardiovascular event in older patients (HR, 0.88; 95% CI, 0.79 to 0.99).
Strandberg et al.[227] (2009)	Post hoc analysis of IDEAL	N=8,888 4.8 years	Primary: Hospitalization for heart failure	At baseline, a history of heart failure (NYHA class I to IIIa) was reported by 537 patients, 5.5 (n=244) and 6.6% (n=293) of patients receiving simvastatin and atorvastatin, respectively.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
IDEAL Atorvastatin 80 mg/day vs simvastatin 20 mg/day	Patients ≤80 years of age with a history of an MI and qualifying for statin therapy based on NCEP ATP III guidelines		Secondary: Not reported	Primary: During the trial, there were 222 new hospitalizations for heart failure. Incidences of hospitalization for heart failure were 10.6 (57/537) vs 2.0% (165/8,351) in patients with and without a history of heart failure. Of the new cases, most were not preceded by an in-trial MI. Of the 222 patients with new hospitalization for heart failure during the trial, 71 (32.0%) patients subsequently died. Among the 222 new hospitalizations, 123 (2.8%) occurred with simvastatin compared to 99 (2.2%) with atorvastatin (HR, 0.81; 95% CI, 0.62 to 1.05; P=0.11). Of the 537 patients with heart failure at baseline, 104 died during the trial compared to 36 of the patients without a history of heart failure (HR, 2.66; 95% CI, 2.16 to 3.27; P<0.0001). After adjustments in the entire trial cohort, atorvastatin was associated with a 26% decrease (P=0.03) of new or recurrent heart failure events compared to simvastatin. Atorvastatin tended to be associated with fewer recurrent heart failure events in those with heart failure at baseline (n= 537; P=0.11) and in those without heart failure at baseline (n=8,351; P=0.15). Secondary: Not reported
Stoekenbroek et al.[228] (2015) IDEAL Atorvastatin 80 mg/day vs simvastatin 20 to 40 mg/day	MC, OL, PG, RCT Patients ≤80 years of age with a history of an MI and qualifying for statin therapy based on NCEP ATP III guidelines	N=8,888 4.8 years	Primary: PAD incidence Secondary: Posthoc analysis of the impact of baseline PAD on clinical outcomes: the rate of major coronary events (defined as coronary death,	Primary: During the study, incident PAD occurred in 94 patients (2.2%) receiving atorvastatin and 135 patients (3.2%) receiving simvastatin (HR, 0.70; 95% CI, 0.53 to 0.91; P=0.007). Secondary: For patients with PAD at baseline, the rate of major coronary events during the study was non-significantly lower in the atorvastatin group (14.4%) compared with the simvastatin group (20.1%) (HR, 0.68; 95% CI, 0.41 to 1.11; P=0.13). A significant treatment effect for atorvastatin was seen for reduction of overall cardiovascular (P=0.046) and coronary events (P=0.004) and coronary revascularisation (P=0.007) in these patients. Among participants without a history of PAD, treatment with atorvastatin

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			hospitalisation for non-fatal MI or cardiac arrest with resuscitation) with high-dose versus usual-dose statins	resulted in a non-significant reduction in major coronary events (HR, 0.91; 95% CI, 0.79 to 1.04; P=0.16), and significantly reduced the risk of major cardiovascular events (HR, 0.88; 95% CI, 0.78 to 1.00; P=0.046), any coronary event (HR, 0.86; 95% CI, 0.78 to 0.94; P=0.001), any cardiovascular event (HR, 0.85; 95% CI, 0.78 to 0.92; P<0.001), non-fatal MI (HR, 0.84; 95% CI, 0.71 to 1.00; P=0.046), coronary revascularisation (HR, 0.79; 95% CI, 0.70 to 0.88; P<0.001) and PAD (HR, 0.70; 95% CI, 0.53 to 0.91; P=0.007), compared with simvastatin treatment. Atorvastatin significantly reduced the incidence of any coronary heart event and coronary revascularisation in both patients with and without PAD at baseline. Compared with patients without PAD at baseline, the incremental benefit of atorvastatin appeared to be larger for patients with previous PAD. However, the only outcomes for which the interaction terms reached the prespecified level of significance were any coronary heart event and coronary revascularisation (P for interaction, 0.042 and 0.090, respectively). The incremental LDL-C reduction observed among patients treated with atorvastatin compared with simvastatin did not significantly differ between patients with or without PAD at baseline (P for interaction, 0.209).
Sakamoto et al.[229] (2007) MUSASHI-AMI Lipophilic statins (mean daily doses; atorvastatin 9.3 mg, fluvastatin 26.8 mg, pitavastatin 2 mg, simvastatin 5 mg) vs hydrophilic statin (mean daily dose; pravastatin 9.4	MC, RCT Adult patients randomized to statin or no statin therapy within 96 hours of an acute MI, with TC 190 to 240 mg/dL	N=486 416 days	Primary: Composite of ACS events (cardiovascular death, nonfatal MI, recurrent acute myocardial ischemia requiring emergency hospitalization) Secondary: Incidence of individual components of the primary	Primary: Hydrophilic statin therapy was associated with a nonsignificant lower incidence of ACS events compared to lipophilic statin therapy (3.6 vs 9.9%; P=0.053). Secondary: Hydrophilic statin therapy was associated with a significantly lower incidence of new Q-wave appearance on the ECG compared to lipophilic statin therapy (75% vs 89%; P=0.0056). There was no difference between the two treatments in any of the other secondary endpoints (P=0.339).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg) All medications were administered within 96 hours of hospital admission with an acute MI.			endpoint, nonfatal stroke, heart failure requiring emergent rehospitalization, new Q-wave appearance on the ECG	
Choi et al.[230] (2014) Nonstatin vs low-potency statin vs high-potency statin	OBS, RETRO Patients with first-ever cardioembolic stroke	N=535 Mean follow-up of 22.2 months	Primary: Time to mortality and time to recurrent stroke Secondary: Not reported	Primary: Among the 535 patients, 295 (55.1%) were not prescribed a statin, 125 (23.4%) were prescribed a low-potency statin, and 115 (21.5%) were prescribed a high-potency statin. Forty-two patients died (35 from the nonstatin group, 5 from the low-potency group, and 2 from the high-potency group): 11 from cardiac disease, 11 from recurrent stroke, 13 from other causes (including infection and cancer), and 7 from unknown causes. With regard to recurrent stroke, 40 patients had a recurrence (29 from the nonstatin group, 12 from the low-potency group, and 7 from the high-potency group). In patients with cardioembolic stroke, statin therapy was independently associated with reduced mortality. Kaplan–Meier estimation shows that either low- or high-potency statin therapy was associated with reduced mortality (log-rank test; P=0.006). Secondary: Not reported
Afilalo et al.[231] (2007) Moderate statin therapy (pravastatin ≤40 mg/day, lovastatin ≤40 mg/day, fluvastatin ≤40 mg/day, simvastatin ≤20	MA (6 RCTs) Patients with recent ACS or stable CHD randomized to an intensive statin therapy (intervention) or moderate statin therapy (control)	N=28,505 ≥6 months	Primary: All-cause mortality, CHD mortality, hospitalization for heart failure, major coronary event (cardiovascular death or ACS), stroke, adverse	Primary: In patients with recent ACS, intensive statin therapy was associated with lower all-cause mortality (OR, 0.75; 95% CI, 0.61 to 0.93). By treating 90 people with intensive statin therapy, one death could be prevented. All-cause mortality was not reduced by intensive statin therapy among patients with stable CHD (OR, 0.99; 95% CI, 0.89 to 1.11). In patients with recent ACS, intensive statin therapy was associated with a reduction in the incidence of major coronary events (OR, 0.86; 95% CI, 0.73 to 1.01).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day, atorvastatin ≤10 mg/day, rosuvastatin ≤5 mg/day) vs intensive statin therapy (simvastatin 80 mg/day, atorvastatin 80 mg/day, rosuvastatin 20 to 40 mg/day)			effects Secondary: Not reported	In patients with stable CHD, intensive statin therapy was associated with a reduction in the incidence of major coronary events (OR, 0.82; 95% CI, 0.75 to 0.91). Treating 46 patients with intensive statin therapy may prevent one major coronary event. In patients with recent ACS, intensive statin therapy was associated with a reduction in the incidence of heart failure hospitalizations (OR, 0.63; 95% CI, 0.46 to 0.86). In patients with stable CHD, intensive statin therapy was associated with a reduction in the incidence of heart failure hospitalizations (OR, 0.77; 95% CI, 0.64 to 0.92). Treating 112 patients with intensive statin therapy may prevent one hospitalization for heart failure. Intensive statin therapy was associated with a threefold increase in adverse hepatic (OR, 3.73; 95% CI, 2.11 to 6.58) and muscular events (OR, 1.96; 95% CI, 0.50 to 7.63). Consequently, 96 people would need to be treated, for one patient to experience an adverse hepatic event. Secondary: Not reported
Cannon et al.[232] (2006) Intensive statin therapy (simvastatin 40 to 80 mg/day, atorvastatin 80 mg/day) vs	MA (4 RCTs) Patients with recent ACS or stable CHD randomized to an intensive statin therapy (intervention) or moderate statin therapy (control)	N=27,548 (4 studies) Up to 5 years	Primary: Combined incidence of coronary death or nonfatal MI; the combined incidence of coronary death or any cardiovascular event (MI,	Primary: Intensive statin therapy was associated with a significant odds reduction of 16% for coronary death or MI compared to moderate statin therapy (9.4 vs 8.0%; OR, 0.84; 95% CI, 0.77 to 0.91; P<0.00001). Intensive statin therapy was associated with a significant odds reduction of 16% for coronary death or any cardiovascular event compared to moderate statin therapy (32.3 vs 28.8%; OR, 0.84; 95% CI, 0.80 to 0.89; P<0.0000001). Intensive statin therapy was associated with a nonsignificant reduction in cardiovascular mortality of 12% compared to moderate statin therapy (3.8 vs

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
moderate statin therapy (pravastatin 40 mg/day, simvastatin 20 mg/day, atorvastatin 10 mg/day)			stroke, hospitalization for unstable angina or re-vascularization); incidence of stroke; incidence of cardiovascular, noncardiovascular and all-cause mortality Secondary: Not reported	3.3%; OR, 0.88; 95% CI, 0.78 to 0.1.00; P=0.054). Intensive statin therapy was associated with a nonsignificant lower rate of noncardiovascular mortality compared to moderate statin therapy (P=0.73). Intensive statin therapy was associated with a nonsignificant significant reduction in all-cause mortality compared to moderate statin therapy (6.2 vs 5.9%; P=0.20). Intensive statin therapy was associated with a significant overall odds reduction of 18% for stroke compared to moderate statin therapy (2.8 vs 2.3%; OR, 0.82; 95% CI, 0.71 to 0.96; P=0.012). Intensive statin therapy was associated with a significant odds reduction of 16.5% for CHD death or MI compared to moderate statin therapy (OR, 0.835; 95% CI, 0.77 to 0.91; P<0.0001). Secondary: Not reported
Murphy et al.[233] (2007) Intensive statin therapy (simvastatin 40 to 80 mg/day, atorvastatin 80 mg/day) vs moderate statin therapy (pravastatin 40 mg/day, simvastatin 20 mg/day)	MA (2 RCTs) Patients with recent ACS, clinically stable for 12 to 24 hours, randomized to an intensive statin therapy (intervention) or moderate statin therapy (control)	N=8,658 Up to 2 years	Primary: Incidence of cardiovascular, non-cardiovascular and all-cause mortality Secondary: Not reported	Primary: Intensive statin therapy was associated with a significant 23% reduction in the risk of all-cause mortality compared to moderate statin therapy (3.6 vs 4.9%; HR, 0.77; 95% CI, 0.63 to 0.95; P=0.015). Intensive statin therapy was associated with a significant 24% reduction in the risk of cardiovascular mortality compared to moderate statin therapy (2.6 vs 3.5%; HR, 0.76; 95% CI, 0.59 to 0.97; P=0.025). Intensive statin therapy was associated with a nonsignificant reduction in the risk of noncardiovascular mortality compared to moderate statin therapy (1.0 vs 1.4%; HR, 0.82; 95% CI, 0.55 to 1.21; P=0.32). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Combination Products				
Hypercholesterolemia (Combination Products)				
Erdine et al.[234] (2009) Gemini-AALA Amlodipine-atorvastatin 5- or 10-10, 20, 40 or 80 mg/day All possible dosing combinations were evaluated. Patients were classified into 1 of 3 cardiovascular risk categories. Group 1: HTN and dyslipidemia with no additional cardiovascular risk factors (BP goal: <140/90 mm Hg, LDL-C goal: <4.1 mmol/L). Group 2: HTN and dyslipidemia with ≥1 additional cardiovascular risk factor,	OL, PRO Patients 18 to 80 years of age with concurrent HTN and dyslipidemia	N=1,649 14 weeks	Primary: Proportion of patients achieving both BP and LDL-C goals Secondary: Absolute and percentage change from baseline in BP and lipid levels, BP and LDL-C goal attainment stratified by prior anti-hypertensive and lipid lowering medications	Primary: More than half (55.2%) of patients achieved both their BP and LDL-C goals at the end of 14 weeks. A higher proportion of patients in Groups 1 and 2 achieved both goals compared to patients in Group 3 (81.3 and 78.8 vs 40.3%). When patients in Group 3 without diabetes (n=407) were further analyzed using a BP goal <140/90 mm Hg, goal achievement for both BP and LDL-C in nondiabetic patients rose to 70.0%. Secondary: All doses achieved significant improvements in LDL-C, TG, HDL-C, TC, SBP and DBP (P<0.001 for all). The proportions of patients with no prior treatment for HTN and dyslipidemia in the cardiovascular risk categories were 74.1 (95% CI, 53.7 to 88.9), 81.6 (95% CI, 72.7 to 88.5) and 39.8% (95% CI, 30.0 to 50.2) for Groups 1, 2 and 3. The corresponding proportions for patients with prior treatment for HTN and dyslipidemia were 82.0 (95% CI, 68.6 to 91.4), 80.7 (95% CI, 73.1 to 87.0) and 39.5% (95% CI, 35.3 to 43.8). The corresponding proportions for patients with no prior treatment for dyslipidemia were 80.2 (95% CI, 69.9 to 88.3), 77.8 (95% CI, 73.0 to 82.2) and 40.9% (95% CI, 36.1 to 45.7). The corresponding proportions for patients with prior treatment for dyslipidemia were 82.8 (95% CI, 70.6 to 91.4), 80.9 (95% CI, 73.8 to 86.8) and 39.8% (95% CI, 35.9 to 43.9). The corresponding proportions for patients with no prior treatment for HTN were 77.1 (95% CI, 59.9 to 89.6), 81.7 (95% CI, 73.6 to 88.1) and 41.1% (95% CI, 33.1 to 49.3). The corresponding proportions for patients with prior treatment for HTN were 82.7 (95% CI, 74.0 to 89.4), 77.9 (95% CI, 73.3 to 82.0) and 40.1% (95% CI, 36.8 to 43.5). The corresponding proportions for patients with prior treatment for HTN only were 83.3 (95% CI, 70.7 to 92.1), 76.2 (95% CI, 70.2 to 81.5) and 41.2% (95% CI, 35.8 to 46.8). The corresponding proportions of patients with prior treatment for dyslipidemia only were 87.5 (95% CI, 47.3 to 99.7), 82.4 (95% CI, 56.6 to 96.2) and 43.4% (95% CI, 29.8 to 57.7).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
excluding CHD and diabetes (BP goal: <140/90 mm Hg, LDL-C goal: <3.4 mmol/L). Group 3: HTN and dyslipidemia with CHD or CHD risk equivalent (diabetes or other atherosclerotic disease (BP goal: <130/80 mm Hg, LDL-C goal: <2.6 mmol/L).				
Flack et al.[235] (2008) CAPABLE Amlodipine-atorvastatin 5- or 10-10, 20, 40, or 80 mg/day All possible dosing combinations were evaluated.	MC, OL African American patients 18 to 80 years of age with uncontrolled HTN and dyslipidemia	N=489 20 weeks	Primary: Proportion of patients in three cardiovascular risk groups (Group 1: patients without additional risk factors; Group 2: patients with >1 additional risk factors, excluding CHD and diabetes and Group 3: patients with CHD or CHD risk equivalent) who achieved the JNC 7 and	Primary: More patients in Groups 1 and 2 achieved both goals compared to patients in Group 3 (69.7, 66.7 and 28.2%, respectively; P value not reported). Secondary: Combination therapy was associated with a 17.5 and 10.1 mm Hg decrease in the SBP and DBP, respectively (P value not reported). Combination therapy was associated with a 23.6% reduction in LDL-C (P value not reported). Combination therapy was associated with a 17% reduction in TC (P value not reported). Combination therapy was associated with a 2.2% increase in HDL-C (P value not reported). Combination therapy was associated with a 6.9% reduction in TG (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
			NCEP ATP III goals Secondary: Changes from baseline in SBP, DBP, LDL-C, TC, TG, HDL-C and apo B	Combination therapy was associated with a 19.3% reduction in apo B (P value not reported).
Hobbs et al.[236] (abstract) (2009) Amlodipine-atorvastatin 5- or 10-10, 20, 40 or 80 mg/day All possible dosing combinations were evaluated.	2 MC, OL Patients with uncontrolled BP and controlled/uncontrolled LDL-C qualifying for treatment according to local governing guidelines	N=2,245 16 weeks	Primary: Proportion of patients achieving country-specific BP and LDL-C goals, safety Secondary: Not reported	Primary: Within the two trials, 62.9 and 50.6% of patients achieved both country-specific BP and LDL-C goals. BP was reduced by 20.4/10.7 and 21.8/12.6 mm Hg in the two trials, respectively, and reductions in LDL-C were 34.8 and 42.2 mg/dL, respectively. The most common adverse events were peripheral edema (11.0%), joint swelling (2.9%) and headache (2.9%), of which, only edema was linked to trial medication. Secondary: Not reported
Neutel et al.[237] (2009) CUSP Amlodipine-atorvastatin 5-20 mg/day vs placebo All patients also received lifestyle	DB, MC, PC, RCT Patients ≥21 years of age with coexisting HTN (140 to 168/90 to 105 mm Hg) and dyslipidemia (LDL-C 110 to 160 mg/dL), without a history of cardiovascular disease who have	N=130 8 weeks	Primary: Proportion of patients who achieved both BP (<140/90 mm Hg) and LDL-C (<100 mg/dL) goals at week four Secondary: Proportion of patients who achieved both	Primary: After four weeks, the proportion of patients who achieved both BP and LDL-C goals was significantly greater with combination therapy compared to placebo (47.6 vs 1.7%; OR, 59.8; 95% CI, 7.4 to 486.0; P<0.001). Secondary: After eight weeks, the proportion of patients who achieved both BP and LDL-C goals was significantly greater with combination therapy compared to placebo (55.6 vs 5.0%; OR, 23.8; 95% CI, 6.7 to 85.0; P<0.001). After four and eight weeks, the proportion of patients who achieved the BP goal was significantly greater with combination therapy compared to placebo (P=0.001 and P=0.006).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
changes. After 4 weeks, add-on antihypertensive and/or lipid lowering therapy was permitted.	never received treatment in the 3 months prior to enrollment		BP and LDL-C goals at week eight; proportion of patients who achieved both BP and LDL-C goals at both weeks four and eight; proportion of patients who achieved the LDL-C goal at weeks four and eight; mean changes from baseline in SBP, DBP and LDL-C at weeks four and eight; 10 year Framingham risk of CHD at weeks four and eight	After four and eight weeks, the proportion of patients who achieved the LDL-C goal was significantly greater with combination therapy compared to placebo (P<0.001 for both). Mean reductions in SBP (13.3 vs 5.6 mm Hg) and DBP (9.4 vs 4.2 mm Hg) at week four was significantly greater with combination therapy (P<0.001). The mean percentage change in LDL-C (35.6 vs +3.3%) at week four was significantly greater with combination therapy (P<0.001). These benefits were maintained throughout eight weeks of treatment. With placebo, 10 year Framingham risk of CHD increased by 4.1% both at weeks four and eight relative to baseline. With combination therapy, the risk of future cardiac events over the next 10 years decreased by 33 and 38% at weeks four and eight, respectively, relative to baseline (P<0.001 vs placebo).
Grimm et al.[238] (2010) TOGETHER Amlodipine-atorvastatin 5- to 10-20 mg/day vs amlodipine 5 to	DB, DD, PRO, RCT Patients ≥21 years of age with HTN, no history of cardiovascular disease or diabetes and ≥2 of the following risk factors: age ≥45	N=245 6 weeks	Primary: Proportion of patients achieving both BP (<140/90 mm Hg) and LDL-C (<100 mg/dL) goals Secondary: Proportion of	Primary: The proportion of patients achieving both BP and LDL-C goals at six weeks was 67.8 vs 9.6% with combination therapy and amlodipine (risk difference, 58.2; 95% CI, 48.1 to 68.4; P<0.001; OR, 19.0; 95% CI, 9.1 to 39.6; P<0.001). Secondary: The proportion of patients achieving both BP and LDL-C goals at four weeks was 62.9 vs 5.2% (risk difference, 57.7; 95% CI, 47.9 to 67.5; P<0.001; OR, 31.4; 95% CI, 12.6 to 78.1; P<0.001). LDL-C goal was achieved by 82.8 and 7.0% (risk difference, 75.8; 95% CI,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
10 mg/day All patients received therapeutic lifestyle changes.	years if male and ≥55 years if female; current smoker; a family history of premature CHD in a first-degree relative; HDL-C <40 mg/dL; waist circumference 102 cm if male or 88 cm if female; all patients had been previously treated with amlodipine 5 or 10 mg with either controlled or Stage 1 HTN, fasting LDL-C ≥100 to ≤170 mg/dL		patients achieving both BP and LDL-C goals at four weeks; proportion of patients achieving the BP or LDL-C goal at weeks four and six; change from baseline in SBP, DBP, LDL-C, TC, TG and HDL-C at four and six weeks; predicted 10 year Framingham risk of CHD outcomes at four and six weeks; safety	67.4 to 84.2; P<0.001; OR, 65.5; 95% CI, 27.1 to 158.3; P<0.001) at four weeks and 83.9 and 11.3% (risk difference, 72.6; 95% CI, 63.7 to 81.5; P<0.001; OR, 42.0; 95% CI, 19.4 to 91.0; P<0.001) at six weeks. The difference in the proportions of patients achieving the BP goal at weeks four and six were not significantly different between the two treatments (four weeks; OR, 1.1; P=0.785 and six weeks; OR, 1.5; P=0.171). There were significant mean percentage reductions from baseline in LDL-C, TC and TG with combination therapy compared to amlodipine at four and six weeks (P<0.001 for all comparisons). There was no difference in DBP between the two treatments and no difference in SBP at week four; however, at week six improvements in SBP were significantly greater with combination therapy compared to amlodipine (P=0.02). In patients receiving combination therapy, the 10 year Framingham risk for CHD at baseline was 8.2% and was reduced to 5.5 and 5.4% at weeks four and six compared to amlodipine (remained unchanged, 8.1%) (P<0.001). After four weeks, the percentage relative reduction from baseline in the 10 year Framingham risk for CHD in patients receiving combination therapy was 39.6% compared to 0.6% with amlodipine. After six weeks, the corresponding numbers were 42.0 and 4.5% (P<0.001). There were no deaths or serious adverse events reported during the trial. Overall, treatment-related adverse events occurred in 9.0 and 14.8% in patients receiving combination therapy and amlodipine, respectively. The majority of events with both treatments were mild. Changes in liver function test and creatinine phosphokinase were mild to moderate.
Bays et al.[239] Ezetimibe-simvastatin 10-10, 10-20, 10-40 or 10-80 mg/day vs	DB, MC, RCT Patients 18 to 80 years of age with primary hypercholesterolemia with LDL-C >145 but ≤150 mg/dL and TG	N=1,528 24 weeks	Primary: Percent change from baseline in LDL-C Secondary: Mean and percent changes from baseline in	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to simvastatin (53 vs 39%; P<0.001) and ezetimibe (53 vs 18.9%; P<0.001). Secondary: At each corresponding dose of simvastatin, combination therapy was associated with a significant reduction in LDL-C at 12 weeks (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day vs placebo	≤350 mg/dL		TC, TG, HDL-C, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B, apo AI and hsCRP; proportion of patients reaching their NCEP ATP III LDL-C goal of <130, <100 or <70 mg/dL at 12 weeks	Combination therapy was associated with a significant reduction in LDL-C at 12 weeks compared to the next highest dose of simvastatin (P<0.001). Averaged across all doses, combination therapy resulted in a greater proportion of patients reaching their NCEP ATP III LDL-C goal <130, <100 or <70 mg/dL at 12 weeks compared to simvastatin (92.2, 78.6 and 38.7 vs 79.2, 45.9 and 7.0%, respectively; P<0.001 for al). Averaged across all doses, combination therapy was associated with a significant reduction in TC, TG, LDL-C:HDL-C, TC:HDL-C, non-HDL-C, apo B and hsCRP at 12 weeks compared to simvastatin (P<0.001 for all). Averaged across all doses, combination therapy was not associated with a significant change in HDL-C compared to simvastatin (P=0.607). Treatment-related adverse effects were similar in the pooled simvastatin, combination and ezetimibe groups, but were more frequent than placebo (14.8, 15.1, 12.8 and 8.1%, respectively; P values not reported).
Ose et al.[240] (2007) Simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe-simvastatin 10-10, 10-20, 10-40 or 10-80 mg/day vs ezetimibe 10 mg/day	DB, MC, RCT Patients 22 to 83 years of age with primary hyper-cholesterolemia (LDL-C 145 to 250 mg/dL and TG <350 mg/dL)	N=1,037 14 weeks	Primary: Change from baseline in LDL-C level, TG, TC, non-HDL, hsCRP, LDL-C:HDL-C and TC:HDL-C; proportion of patients reaching LDL-C target (<100 or <70 mg/dL) Secondary: Not reported	Primary: Across all doses, combination therapy was associated with a significant reduction in LDL-C compared to simvastatin (53.7 vs 38.8%; P<0.001). Across all doses, combination therapy was associated with a significant reduction in TG, TC, non-HDL, hsCRP, LDL-C:HDL-C and TC:HDL-C compared to simvastatin (P<0.001 for all). A significantly greater proportion of patients receiving combination therapy achieved LDL-C <100 mg/dL compared to simvastatin (79.2 vs 47.9%; P<0.001). Similar results were observed with a LDL-C goal <70 mg/dL (30.4 vs 7.0%; P<0.001). The incidence of drug-related adverse effects was similar with combination therapy and simvastatin (7.4 vs 5.5%, respectively; P value not reported). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs placebo				
Feldman et al.[241] (2006) Ezetimibe-simvastatin 10-10, 10-20, 10-40 or 10-80 mg/day vs simvastatin 10, 20, 40 or 80 mg/day vs ezetimibe 10 mg/day vs placebo	MA (3 DB, PC, RCTs) Patients with primary hypercholesterolemia	N=3,083 28 weeks	Primary: Percent change from baseline in LDL-C, TG, non-HDL-C, apo B and hsCRP; achievement of LDL-C <100 mg/dL at week-12 among patients <65 and ≥65 years of age Secondary: Not reported	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C, TG, non-HDL-C, apo B and hsCRP at 12 weeks compared to simvastatin (P<0.001 for all). These affects did not differ between the older and younger patients (P value not reported). Combination therapy and simvastatin produced comparable increases in HDL-C (8 vs 7%, respectively; P value not reported). Significantly more patients, in all age groups, receiving combination therapy, regardless of the dose, achieved an LDL-C level <100 mg/dL at week 12 compared to patients receiving simvastatin (79 vs 42%; P<0.001). Similar results were observed with a LDL-C goal <70 mg/dL (37 vs 6%; P<0.001). Treatment-related adverse effects were similar with simvastatin and combination therapy, regardless of dose used and age group (P values not reported). Secondary: Not reported
Farnier et al.[242] (2007) Fenofibrate 160 mg/day vs ezetimibe-simvastatin10-20 mg/day plus fenofibrate 160	DB, MC, PA, PC, RCT Patients 18 to 79 years of age with mixed hyperlipidemia and no CHD or CHD risk equivalent disease, or a 10 year CHD risk	N=611 12 weeks	Primary: Percent change from baseline in LDL-C Secondary: Changes from baseline in TC, TG, non-HDL-C, HDL-C, apo AI and apo B	Primary: LDL-C was significantly reduced with triple therapy (-45.8%) compared to fenofibrate (-15.7%; P<0.01) or placebo (-3.5%; P<0.01), but not when compared to combination therapy (-47.1%; P>0.2). Secondary: HDL-C and apo AI were significantly increased with triple therapy (18.7 and 11.1%) compared to combination therapy (9.3 and 6.6%; P<0.01) or placebo (1.1 and 1.6%; P<0.01), but not when compared to fenofibrate (18.2 and 10.8%; P>0.2). TG, non-HDL-C and apo B were significantly reduced with triple therapy

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
mg/day vs ezetimibe-simvastatin 10-20 mg/day vs placebo	>20% according to NCEP ATP III criteria			compared to all other active treatments (-50.0, -50.5 and -44.7%; P<0.01, respectively).
Farnier et al.[243] (2008) Fenofibrate 160 mg and ezetimibe-simvastatin 10-20 mg QD vs fenofibrate 160 mg QD vs ezetimibe-simvastatin 10-20 mg QD vs placebo	DB, MC, PC, RCT Patients 18 to 79 years of age with mixed hyperlipidemia and no CHD, CHD-equivalent disease (except for type 2 diabetes), or CHD risk score >20% (as defined by NCEP ATP III), LDL-C 130 to 220 mg/dL and TG 150 to 500 mg/dL	N=611 12 weeks	Primary: Percent change in cholesterol associated with lipoprotein subfractions (VLDL-C 1+2 and VLDL-C 3, IDL-C, LDL-C 1 to 4, Lp[a], HDL-C_2 and HDL-C_3, and changes in LDL particle size) Secondary: Not reported	Primary: The effects of ezetimibe-simvastatin, fenofibrate, and ezetimibe/simvastatin plus fenofibrate on VLDL subclasses were similar to those for VLDL-C overall. The maximal changes in IDL-C are achieved by ezetimibe-simvastatin with little additional effect of fenofibrate. Significant reductions were observed for all LDL-C subfractions with ezetimibe-simvastatin treatment. When coadministered with fenofibrate, the effects of both treatments were evident. Ezetimibe-simvastatin plus fenofibrate resulted in a pattern of changes that were similar to fenofibrate monotherapy indicating that the change in LDL-C pattern was primarily a function of fenofibrate. There was no significant difference in cholesterol associated with Lp(a) among the treatment groups. Fenofibrate and ezetimibe-simvastatin plus fenofibrate led to similar increases in median HDL-C_2 and HDL-C_3 compared to ezetimibe-simvastatin and placebo. Ezetimibe-simvastatin did not significantly affect LDL particle size. Fenofibrate and ezetimibe-simvastatin plus fenofibrate increased LDL particle size. At the end of the study, the percentages of patients exhibiting LDL size pattern B was 64, 49, 14, and 17% in the placebo, ezetimibe-simvastatin,

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				fenofibrate, and ezetimibe-simvastatin plus fenofibrate groups, respectively. Secondary: Not reported
Robinson et al.[244] (2009) VYMET Ezetimibe-simvastatin 10-20 to 10-40 mg QD vs atorvastatin 10 to 40 mg QD	DB, MC, PG, RCT Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia who were at moderately high or high risk for coronary heart disease	N=1,128 6 weeks	Primary: Percentage of change from baseline in LDL-C Secondary: Changes in other lipids, lipoprotein ratios, hsCRP, and attainment of prespecified lipid levels	Primary: After six weeks, the percent change in LDL-C was significantly greater with ezetimibe-simvastatin than with atorvastatin (all dose comparisons, P<0.001). Secondary: The percent of patients who achieved LDL-C <70 mg/dl and the non-HDL-C goal was significantly greater for ezetimibe-simvastatin than for atorvastatin (all dose comparisons, P<0.05). Treatment with ezetimibe-simvastatin led to a significantly greater reduction in TC, non-HDL-C, apo B, and all 4 lipid ratios compared to atorvastatin (all dose comparison, P<0.001). HDL-C cholesterol increased to a greater extent with ezetimibe/simvastatin 10/20 mg compared to atorvastatin 10 mg (P<0.05) and ezetimibe/simvastatin 10/40 mg compared to atorvastatin 40 mg (P<0.01). Changes in triglycerides, VLDL-C, apo AI, and hsCRP were comparable for both treatments, except that apo AI was significantly increased with ezetimibe-simvastatin 10-20 mg vs atorvastatin 10 mg (P<0.05). The rates of adverse events were similar for both treatments.
Ballantyne et al.[245] (2005) VYVA Ezetimibe-simvastatin 10-10, 10-20, 10-40 or 10-80 mg/day	DB, MC, PG, RCT Patients ≥18 years of age with a LDL-C at or above drug treatment thresholds established by NCEP ATP III	N=1,902 6 weeks	Primary: Mean percent change from baseline in LDL-C Secondary: Percent change from baseline in LDL-C at each mg-equivalent	Primary: Averaged across all doses, combination therapy was associated with a significant reduction in LDL-C compared to atorvastatin (53.4 vs 45.3%; P<0.001). Secondary: Combination therapy (10/20 mg) was associated with a significant reduction in LDL-C compared to atorvastatin 10 (50.6 vs 36.1%; P<0.001) and 20 mg (50.6 vs 43.7%; P<0.001). Combination therapy (10/40 mg) was associated with a significant reduction in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
vs atorvastatin 10, 20, 40 or 80 mg/day	guidelines, with CAD or CAD risk equivalent, or with ≥2 risk factors conferring a 10 year risk >20% for CHD; with LDL-C ≥130 mg/dL, no CHD or its risk equivalent, and with ≥2 risk factors conferring a 10 year risk of <20% for CHD; with LDL-C ≥160 mg/dL and no CHD or its risk equivalent with <2 risk factors; with LDL-C ≥190 mg/dL, TG ≤350 mg/dL, ALT or AST <1.5 times the upper limit of normal, serum creatinine ≤1.5 mg/dL, no active liver disease, CK <1.5 times the upper limit of normal and a HbA_{1c} <9.0% in patients with diabetes		statin dose comparison, percent change from baseline in HDL-C, proportion of patients achieving NCEP ATP III LDL-C goal (<100 mg/dL)	LDL-C compared to atorvastatin 40 mg (57.4 vs 48.3%; P<0.001). Combination therapy (10/80 mg) was associated with a significant reduction in LDL-C compared to atorvastatin 80 mg (58.6 vs 52.9%; P<0.001). Averaged across all doses, combination therapy was associated with a significant increase in HDL-C compared to atorvastatin (7.9 vs 4.3%; P<0.001). Averaged across all doses, a significantly greater proportion of patients receiving combination therapy achieved the NCEP ATP III LDL-C goal compared to atorvastatin (89.7 vs 81.1%; P<0.001). Averaged across all doses, a significantly greater proportion of patients with a CHD or a CHD risk equivalent receiving combination therapy achieved the NCEP ATP III LDL-C goals of <100 (85.4 vs 70.0%; P<0.001) and <70 mg/dL (45.3 vs 20.5%; P<0.001) compared to atorvastatin. Averaged across all doses, combination therapy was associated with a significant increase in the risk of ALT and AST elevation greater than three times the upper limit of normal compared to atorvastatin (P=0.006).
Ballantyne et al.[246]	DB, MC, RCT	N=788	Primary: Mean percent	Primary: Averaged across all doses, combination therapy was associated with a

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
(2004) Ezetimibe-simvastatin 10-20 mg/day for weeks 1 to 6, titrated to 10-40 mg for weeks 7 to 18, titrated to 10-80 mg for weeks 19 to 24 vs ezetimibe-simvastatin 10-10 mg/day for weeks 1 to 6, titrated to 10-20 mg/day for weeks 7 to 12, titrated to 10-40 mg/day for weeks 12 to 18, titrated to 10-80 mg/day for weeks 19 to 24 vs atorvastatin 10 mg/day for weeks 1 to 6, titrated to 20 mg/day for weeks 7 to 12, titrated to 40 mg/day for weeks 12 to 18, titrated	Patients ≥18 years of age with a LDL-C at or above drug treatment thresholds established by NCEP ATP III guidelines, with CAD or CAD risk equivalent, or with ≥2 risk factors conferring a 10 year risk >20% for CHD; with LDL-C ≥130 mg/dL, no CHD or its risk equivalent, and with ≥2 risk factors conferring a 10 year risk of <20% for CHD; with LDL-C ≥160 mg/dL and no CHD or its risk equivalent with <2 risk factors; with LDL-C ≥190 mg/dL, TG ≤350 mg/dL, ALT or AST <1.5 times the upper limit of normal, serum creatinine ≤1.5 mg/dL, no active liver disease, CK	24 weeks	change from baseline in LDL-C and HDL-C Secondary: Percent change from baseline to the ends of the second and fourth six week treatment periods in LDL-C and HDL-C, safety	significant reduction in LDL-C compared to atorvastatin (52.4 vs 45.1%; P<0.001). Averaged across all doses, combination therapy was associated with a significant increase in HDL-C compared to atorvastatin (12.3 vs 6.5%; P<0.001). Secondary: At the end of treatment period two, combination therapy was associated with a significant reduction in LDL-C compared to atorvastatin (50.2 and 54.3 vs 44.3%, respectively; P≤0.05). At the end of treatment period two, combination therapy (10/40 mg) was associated with a significant increase in HDL-C compared to atorvastatin (12.4 vs 6.9%; P≤0.05). At the end of treatment period four, combination therapy (10/40 mg) was associated with a significant reduction in LDL-C compared to atorvastatin (59.4 vs 52.5%, respectively; P≤0.05). At the end of treatment period four, combination therapy (10/40 mg) was associated with a significant increase in HDL-C compared to atorvastatin (12.3 vs 6.5%; P≤0.05). The safety of combination therapy was observed to be similar to that of atorvastatin (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
to 80 mg/day for weeks 19 to 24	<1.5 times the upper limit of normal and a HbA_{1c} <9.0% in patients with diabetes			
Foody et al.[247] (2010) VYTELD Ezetimibe-simvastatin 10-20 mg/day vs atorvastatin 10 or 20 mg/day AND Ezetimibe-simvastatin 10-40 mg/day vs atorvastatin 40 mg/day	DB, MC, PG, RCT Patients ≥65 years of age with hyperlipidemia at moderately high risk or high risk (with CHD or CHD risk equivalents) with or without atherosclerotic vascular disease with LDL-C ≥130 mg/dL, TC ≤350 mg/dL, liver transaminases ≤1.5 times the upper limit of normal with no active liver disease and creatinine kinase ≤2 times upper limit of normal	N=1,289 12 week	Primary: Percent change from baseline in LDL-C Secondary: Proportion of patients achieving an LDL-C <70 and <100 mg/dL; percent change from baseline in TC, TG, HDL-C, non-HDL-C, VLDL-C, apo B, apo AI, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, non-HDL-C:HDL-C and hsCRP; safety	Primary: Combination therapy achieved significantly greater percent decreases in LDL-C (-54.2 [10/20 mg] vs -39.5 [10 mg] and -46.6% [20 mg] and -59.1 [10/40 mg] vs -50.8% [40 mg]; P<0.001 for all). Secondary: A significantly greater proportion of combination therapy-treated patients achieved an LDL-C goal <70 mg/dL (51.3 [10/20 mg] and 68.2% [10/40mg]; P<0.05) and <100 mg/dL (83.6 and 90.3%; P<0.001). Analysis based on risk demonstrated that a significantly greater proportion of high risk patients reached target LDL-C levels <70 mg/dL with combination therapy compared to atorvastatin (P<0.001 for all comparisons). Combined analysis of LDL-C level attainment based on atherosclerotic vascular disease status (<100 mg/dL for patients without atherosclerotic vascular disease and <70 mg/dL for patients with atherosclerotic vascular disease) demonstrated that a significantly greater proportion of patients reached the specified target with combination therapy compared to atorvastatin (P<0.001 for ezetimibe/simvastatin 10/20 mg vs atorvastatin 10 mg, P<0.05 for ezetimibe/simvastatin 10/20 vs atorvastatin 20 mg and ezetimibe/simvastatin 10/40 mg vs atorvastatin 40 mg). Improvements in non-HDL-C, TC, apo B and lipoprotein ratios were significantly greater with combination therapy (P<0.01 to P<0.001). Only ezetimibe/simvastatin 10/20 mg significantly improved HDL-C (P<0.001) levels compared to atorvastatin 20 mg and TG (P<0.01) and VLDL-C (P<0.05) levels compared to atorvastatin 10 mg. Improvements in apo AI and hsCRP levels did not differ among the various treatments (P values not reported). All doses of ezetimibe/simvastatin and atorvastatin were generally safe and

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				well tolerated. The incidence of adverse events was similar between treatment groups. There were no serious drug-related adverse events observed during the trial.
Polis et al.[248] (2009) Ezetimibe-simvastatin 10-10, 10-20, 10-40 or 10-80 mg/day vs atorvastatin 10, 20, 40 or 80 mg/day or rosuvastatin 10, 20 or 40 mg/day	Post hoc analysis of 2 trials Patients with hypercholesterolemia not attaining NCEP ATP III LDL-C goals in patients with diabetes, metabolic syndrome or neither disease	N=4,861 6 weeks	Primary: Percent change from baseline in LDL-C, proportion of patients achieving individual LDL-C goals Secondary: Safety	Primary: Changes in LDL-C were generally similar regardless of diabetes/metabolic syndrome status or CHD risk strata in both trials. There was a significant effect by dose level in both trials in all condition and risk subgroups (P<0.001), with greater reductions observed with higher doses. NCEP ATP III LDL-C goal attainment was lowest in the high risk group with atherosclerotic vascular disease (12 to 64%) and greatest in the moderate and low risk groups (84 to 100%). Secondary: All treatments were generally well tolerated, with overall similar safety regardless of disease and risk level.
Bardini et al.[249] (2010) LEAD Ezetimibe-simvastatin 10-20 mg/day vs simvastatin 40 mg/day	DB, DD, MC, PG, RCT Patients 18 to 75 years of age with type 2 diabetes for ≥12 months and documented CHD, or symptomatic peripheral vascular disease, who were taking a stable dose of simvastatin 20 mg/day for 6 weeks with good compliance and LDL-C ≥100 to	N=93 6 weeks	Primary: Percent change from baseline in LDL-C Secondary: Proportion of patients achieving LDL-C <100 mg/dL; percent change from baseline in TC, HDL-C and TG	Primary: Combination therapy produced a significantly greater reduction in LDL-C compared to simvastatin 40 mg (-32.2 vs -20.8%; P<0.01). Secondary: A nonsignificantly greater proportion of patients receiving combination therapy achieved an LDL-C <100 mg/dL (78.4 vs 60.0%; OR, 2.81; P=0.052). Combination therapy produced a significantly greater change compared to simvastatin 40 mg in TC (-20.6 vs -13.2%; P<0.01). Changes in HDL-C (0.85 vs 0.80%) and TG (-8.5 vs -1.8%) were similar between treatments (P values not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	≤160 mg/dL			
Florentin et al.[250] (2011) Ezetimibe-simvastatin 10-10 mg/day vs simvastatin 40 mg/day	OL, RCT Patients with primary hypercholesterolemia with LDL-C levels above those recommended by the NCEP ATP III	N=100 3 months	Primary: Percent change from baseline in small density LDL-C Secondary: Percent change from baseline in lipid parameters, HOMA index and hsCRP	Primary: Both treatments decreased small density LDL-C (-42 vs -46%; P<0.000 vs baseline for both), with no significant difference between the two treatments (P value not reported). Secondary: Both treatments decreased TC (-31 vs -36%), LDL-C (-43 vs -49%), TG (-17 vs -19%), non-HDL-C (-40 vs -46%) and large LDL-C (-40 vs -44%) (P<0.000 vs baseline for all). Both treatments increased LDL particle size (0.5 vs 0.7%; P<0.05 vs baseline for both). Changes in TC, LDL-C and non-HDL-C were significantly greater with combination therapy (P<0.05 for all), while changes in TG, large LDL-C, and LDL particle size were similar (P values not reported). No significant changes were observed in HOMA index with either treatment, and hsCRP decreased by 23% (P<0.05 vs baseline) with both treatments.
Rotella et al.[251] (2010) Ezetimibe-simvastatin 10-20 mg/day vs simvastatin 40 mg/day	2 DB, MC, RCT Patients ≥18 to ≤75 years of age with documented CHD or symptomatic peripheral vascular disease, who were taking a stable dose of simvastatin 20 mg/day for 6 weeks with good compliance	N=93 6 weeks	Primary: Percentage change from baseline in LDL-C; proportion of patients who achieved an LDL-C goal <100 mg/dL Secondary: Safety	Primary: Combination therapy resulted in significantly greater reductions in LDL-C, TC and TC:HDL-C (P<0.01 for all); and significantly more patients treated with combination therapy achieved the LDL-C goal <100 mg/dL (P<0.01). Secondary: There was no significant difference in the proportion of patients who reported adverse events between the two treatments (P=0.606). No significant differences between groups were observed in the number and rate of drug related adverse events, which were reported in 9.8 and 6.3% of patients treated with combination therapy and simvastatin 40 mg (P=0.500). There were few discontinuations due to treatment-related adverse events.
Farnier et al.[252] (2009) IN-CROSS	AC, DB, MC, PG, RCT Patients 18 to 80	N=618 6 weeks	Primary: Percent change from baseline in LDL-C, HDL-	Primary: Combination therapy achieved greater reductions in LDL-C (27.7 vs 16.9%; P≤0.001), TC (17.5 vs 10.3%; P≤0.001), non-HDL-C (23.4 vs 14.0%; P≤0.001) and apo B (17.9 vs 9.8%; P≤0.001) compared to rosuvastatin. Both

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Ezetimibe-simvastatin 10-20 mg/day vs rosuvastatin 10 mg/day	years of age with hypercholesterolemia (LDL-C ≥100 and ≤190 mg/dL) and high cardiovascular risk who were taking a stable dose of none of the following statin medications for ≥6 weeks prior to trial randomization: atorvastatin (10 or 20 mg), fluvastatin (80 mg), pravastatin (40 mg), rosuvastatin (5 mg) or simvastatin (20 or 40 mg)		C, non-HDL-C, TC, TG and apo B; proportion of patients achieving LDL-C <100 and <70 mg/dL Secondary: Adverse events	treatments achieved similar increases in HDL-C (2.1 vs 3.0%; P=0.433) and decreases in TG (11.0 vs 5.3%; P=0.056). A significantly greater proportion of patients receiving combination therapy achieved an LDL-C <100 (73 vs 56%) and <70 mg/dL (25 vs 11%) (P≤0.001 for both). Secondary: There were no between-group differences in the incidences of adverse events or liver transaminase and CK elevations (P values not reported).
Viigimaa et al.[253] (2010) Ezetimibe-simvastatin 10-20 mg/day vs rosuvastatin 10 mg/day	Post hoc analysis Patients 18 to 80 years of age with hypercholesterolemia (LDL-C ≥100 and ≤190 mg/dL) and high cardiovascular risk who were taking a stable dose of none of the following statin medications	N=618 6 weeks	Primary: Changes from baseline in lipid parameters stratified by statin potency prior to randomization; proportion of patients achieving LDL-C <100, <77 or <70 mg/dL; non-HDL-C	Primary: Significant treatment-by-subgroup interaction occurred for LDL-C (P=0.013), TC (P=0.025), non-HDL-C (P=0.032) and apo B (P=0.016) with greater between-treatment differences in favor of combination therapy observed in patients who were previously treated with a high potency statin vs a low potency. Individual and triple target attainment was higher with combination therapy compared to rosuvastatin in patients previously treated with a high or low potency statin (P values not reported). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
	for ≥6 weeks prior to trial randomization: atorvastatin (10 or 20 mg), fluvastatin (80 mg), pravastatin (40 mg), rosuvastatin (5 mg) or simvastatin (20 or 40 mg)		<130 or <100 mg/dL; apo B <90 or <80 mg/dL and LDL-C <100 mg/dL, non-HDL-C <130 mg/dL and apo B <90 mg/dL Secondary: Not reported	
Catapano et al.[254] (2006) Ezetimibe-simvastatin 10-20, 10-40 or 10-80 mg/day vs rosuvastatin 10, 20 or 40 mg/day	DB, MC, PG, RCT Patients 18 to 81 years of age with LDL-C ≥145 and ≤250 mg/dL; TG ≤350 mg/dL; ALT, AST and CK level <1.5 times the upper limit of normal, serum creatinine ≤1.5 mg/dL and HbA_{1c} <9.0% in patients with diabetes	N=2,959 6 weeks	Primary: Percent change from baseline in LDL-C Secondary: Percent changes from baseline in LDL-C at various dose comparisons, HDL-C, TC, apo B, TG, non-HDL-C, LDL-C:HDL-C, TC:HDL-C and hsCRP; proportion of patients who achieved an LDL-C goal <100, <130 or <160 mg/dL; safety	Primary: At all doses, combination therapy significantly reduced LDL-C compared to rosuvastatin (52 to 61 vs 56 to 57%; P≤0.001). Secondary: Significantly greater reductions in LDL-C with combination therapy were achieved with the 10/20 (P<0.001), 10/40 (P=0.001) and 10/80 mg (P<0.001) compared to rosuvastatin. Combination therapy produced significantly greater reductions in TC (P<0.001), non-HDL-C (P<0.001), all lipid ratios (P≤0.003), TG (P<0.001) and apo B (P<0.05) compared to rosuvastatin. Increases in HDL-C and decreases in hsCRP were similar between the two treatments (P values not reported). Significantly greater proportions of all patients (P<0.001) and high risk patients (P≤0.005) attained an LDL-C goal <70 mg/dL with combination therapy compared to rosuvastatin across all doses. Safety profiles were comparable between the two treatments. The percent of patients with proteinuria was significantly higher with rosuvastatin compared to combination therapy at doses of 10 vs 10/20 mg (P=0.004) and 40 vs 10/80 mg (P<0.001).
Roeters van	RCT, OL	N=367	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Lennep et al.[255] (2008) EASEGO Ezetimibe-simvastatin (EZE/SIMVA) 10-20 mg QD vs doubling of statin dose (atorvastatin 20 mg or simvastatin 40 mg) QD Patients were randomized to continuation of statin monotherapy at a double dose or to EZE/SIMVA	Patients >18 years of age with controlled stable type 2 diabetes mellitus (>3 months) and/or established coronary heart disease who were on a stable daily statin dose of either atorvastatin 10 mg or simvastatin 20 mg for ≥4 weeks. Entry lipid values while on statin monotherapy were: LDL-C 97 to 193 mg/dL, TG ≤354 mg/dL and TC ≤270 mg/dL	15 weeks	Percentages of patients reaching the ESC goal LDL-C <97 mg/dl Secondary: TC, TG, HDL-C, apo-B, and TC/HDL-C	Overall, the LDL-C target of <97 mg/dl was achieved in 67% of the patients in the EZE/SIMVA group and 26% of the patients in the doubling statin group. After doubling the simvastatin dose from 20 to 40 mg, 24% of patients achieved LDL-C <97 mg/dl. After switching to EZE/SIMVA, 73% of patients reached LDL-C <97 mg/dl (P<0.0001). After doubling the atorvastatin dose from 10 to 20 mg, 28% of patients achieved LDL-C <97 mg/dl. After switching to EZE/SIMVA, 57% of patients achieved LDL-C 97 mg/dl (P<0.0004). After doubling the statin dose, LDL-C <77 mg/dl was achieved in 3% of patients and in 30% of the patients receiving EZE/SIMVA. Secondary: The mean percent change in TC, TC/HDL-C and apo-B were -6.6%, -6.1% and -7.2%, respectively after doubling the statin dose compared to -17.7%, -13.5%, and -19.7%, respectively in the EZE/SIMVA group (all, P<0.001). HDL-C increased 1.0% after doubling the statin dose compared to -2.6% in the EZE/SIMVA group (P=0.02). There was no significant difference in TG among the treatment groups. There were no significant differences between the treatment groups in adverse events.
Reckless et al.[256] (2008) Ezetimibe-simvastatin (EZE/SIMVA) 10-40 mg QD vs existing statin therapy (with the dose doubled)	AC, MC, OL, PG, RCT Patients ≥18 years of age hospitalized for an acute coronary event and taking a stable daily dose of one of the following statin medications for ≥6 weeks:	N=424 12 weeks	Primary: Absolute LDL-C value at study end point Secondary: TC, TG, HDL-C, non-HDL-C, LDL-C:HDL-C ratio, TC:HDL-C ratio, apo B, CRP, percentages of	Primary: Treatment with EZE/SIMVA lowered LDL-C by -25.5 mg/dL (27%) compared to -6.6 mg/dL (4.2%) in the statin group (P≤0.001). The absolute LDL-C value at study end point was 65.7 mg/dL in the EZE/SIMVA group and 85.8 mg/dL in the statin group. Secondary: A greater proportion of patients in the EZE/SIMVA group compared to placebo achieved LDL-C concentrations <100 mg/dL (85.8% vs 72.4%, respectively; P≤0.001), <77 mg/dL (70.1% vs 41.7%, respectively; P≤0.001) and <70 mg/dL (59.8 vs 30.7%, respectively; P≤0.001). Switching to EZE/SIMVA lowered TC by -24.0 mg/dL (14.6%) compared to -

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
administered QD	atorvastatin (10-40 mg), fluvastatin (20-40 mg), lovastatin (10-20 mg), pravastatin (10-20 mg), rosuvastatin (10-20 mg), or simvastatin (10-40 mg)		patients in each treatment group achieving LDL-C ≤100 mg/dL, <77 mg/dL and <70 mg/dL	5.4 mg/dL (1.7%) in the statin group (P≤0.001). Treatment with EZE/SIMVA produced greater reductions in non- HDL-C (P≤0.001), apo B (P≤0.001), LDL-C/HDL-C (P≤0.001) and TC/HDL-C (P≤0.001) compared to the statin group. Both treatments reduced TG and CRP, and increased HDL-C to a similar extent (P≥0.160 for all). There were no significant differences in adverse events between the two treatment groups.
Fazio et al.[257] (2010) Ezetimibe-simvastatin 10-20 mg/day plus niacin ER 2 g/day vs niacin ER 2 g/day vs ezetimibe-simvastatin 10-20 mg/day At the end of 24 weeks, patients receiving niacin ER were rerandomized to either one of the other 2 treatment regimens.	DB, MC, RCT Patients 18 to 79 years of age with hyperlipidemia (Types IIa and IIb) with LDL-C 130 to 190 mg/dL, TG ≤500 mg/dL, creatinine <2 mg/dL, creatine kinase ≤2 times the upper limit of normal, transaminases ≤1.5 times the upper limit of normal and HbA_{1c} ≤8%	N=942 64 weeks	Primary: Safety and tolerability of ezetimibe-simvastatin plus niacin ER Secondary: Changes in HDL-C, TG, non-HDL-C and LDL-C	Primary: The most frequent reason for discontinuation was clinical adverse events related to niacin-associated flushing with ezetimibe/simvastatin plus niacin (0.7% for ezetimibe-simvastatin vs 10.3% for ezetimibe/simvastatin plus niacin). A significant number of patients receiving ezetimibe/simvastatin plus niacin discontinued because of low LDL-C levels <50 mg/dL (1.5 vs 7.1%). The overall incidence of clinical adverse events was slightly greater for ezetimibe-simvastatin plus niacin compared to ezetimibe-simvastatin owing to the greater number of patients who experienced drug-related clinical adverse events and drug-related discontinuations with ezetimibe-simvastatin plus niacin, mainly attributed to niacin-associated flushing and pruritis. The percentage of patients with consecutive elevations in ALT or AST of at least three times or greater the upper limit of normal, and creatine kinase of at least ten times or greater the upper limit of normal were low and comparable between treatments. A total of 19 patients had adverse events of increased FPG levels, with eight receiving ezetimibe/simvastatin and 11 receiving ezetimibe-simvastatin plus niacin. Secondary: Ezetimibe-simvastatin plus niacin significantly improved baseline HDL-C, TG, non-HDL-C, LDL-C, apo B, apo AI and Lp ratios compared to ezetimibe-simvastatin at week 64 (P<0.004). The changes in TC were comparable between the two treatment groups and the reduction in hsCRP was numerically

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				greater with ezetimibe-simvastatin plus niacin (P value not reported). Ezetimibe-simvastatin plus niacin increased HDL-C considerably during the first 16 weeks of treatment, and at a lower, but significant, rate from 16 to 24 weeks, and then remained constant throughout 64 weeks. The HDL-C change was significantly greater with ezetimibe-simvastatin plus niacin vs ezetimibe/simvastatin throughout the 64 weeks (P<0.001). The reductions in LDL-C, non-HDL-C and TG observed after four weeks with ezetimibe-simvastatin plus niacin were maintained throughout the 64 weeks. In contrast, the levels remained relatively stable with ezetimibe-simvastatin throughout the 64 weeks (P<0.001) and became significant for non-HDL-C after eight weeks (P=0.002) and LDL-C after 12 weeks (P<0.001).
Fazio et al.[258] (2010) Ezetimibe-simvastatin 10-20 mg/day plus niacin ER 2 g/day vs niacin ER 2 g/day vs ezetimibe-simvastatin 10-20 mg/day At the end of 24 weeks, patients receiving niacin ER were rerandomized to either one of the other 2 treatment regimens.	Subgroup analysis Hyperlipidemic patients with diabetes mellitus, metabolic syndrome without diabetes mellitus or neither	N=765 at 24 weeks N=574 at 64 weeks	Primary: Changes in HDL-C, TG, non-HDL-C, LDL-C, fasting glucose and uric acid Secondary: Not reported	Primary: The effect of triple therapy on efficacy variables across patient subgroups was generally consistent with the significantly greater improvements observed in the total population compared to niacin and combination therapy. Triple therapy improved levels of LDL-C, other lipids and Lp ratios compared to niacin and combination therapy at 24 and 64 weeks. Triple therapy also increased HDL-C and Lp(a) comparably to niacin and more than combination therapy. Triple therapy also decreased hsCRP more effectively than niacin and comparably to combination therapy. Fasting glucose trended higher for niacin compared to combination therapy. Glucose elevations from baseline to 12 weeks were highest for patients with diabetes (niacin, 24.9 mg/dL; triple therapy, 21.2 mg/dL and combination therapy, 17.5 mg/dL). Fasting glucose levels then declined to pretreatment levels at 64 weeks in all subgroups. New onset diabetes was more frequent among patients with metabolic syndrome than those without for the first 24 weeks and trended higher among those receiving niacin (niacin, 5.1%; combination therapy, 1.7% and triple therapy, 8.8%). Between weeks 24 and 64, five and one additional patient(s) receiving combination (cumulative incidence, 5.9%) and triple therapy (cumulative incidence, 9.2%) were diagnosed with diabetes. Treatment-incident increases in uric acid were higher among patients receiving niacin, but there were no effects on symptomatic gout.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				Secondary: Not reported
Sharma et al.[259] (2006) Niacin ER-lovastatin 1,500-20 mg/day, combination entity, titrated up to LDL-C goal	MC, OL Patients with HTN and dyslipidemia	N=131 24 weeks	Primary: Percent change from baseline in LDL-C, HDL-C, TG, TC Secondary: Not reported	Primary: Niacin ER-lovastatin therapy was associated with a statistically significant reduction from baseline in LDL-C (38%), TG (21%), and TC (25.2%) at week 24 of therapy (P<0.01). Niacin ER-lovastatin therapy was associated with a statistically significant increase from baseline in HDL-C at week 24 of therapy (18.2%; P<0.01). Secondary: Not reported
Karas et al.[260] (2008) OCEANS <u>Group A:</u> Niacin ER-simvastatin 2,000-20 or 1,000-20 mg/day vs simvastatin 20 mg/day <u>Group B:</u> Niacin ER-simvastatin 1,000-40 or 2,000-40 mg/day vs simvastatin 80 mg/day	AC, MC, OL, PG, Phase III, RCT Patients ≥21 years of age with a diagnosis of primary type II hyperlipidemia or mixed dyslipidemia, proof of reasonable compliance with a standard cholesterol lowering diet for 4 weeks before screening and for the duration of the trial, and LDL and/or non-HDL levels above normal	N=641 24 weeks	Primary: Group A: mean percent change in non-HDL-C Group B: non-inferiority of niacin ER/simvastatin 2,000/40 mg to simvastatin 80 mg in mean percent change in non-HDL Secondary: Mean percent change in LDL-C, TG and HDL-C	Primary: In Group A, the mean percent changes in non-HDL-C at 24 weeks were significantly greater with niacin ER/simvastatin 1,000/20 and 2,000/20 mg than with simvastatin 20 mg (-13.6 and -19.5 vs -5.0%, respectively; P<0.05). In Group B, the mean percent change in non-HDL-C at 24 weeks with niacin ER/simvastatin 2,000/40 mg was non-inferior to that of simvastatin 80 mg (-7.6 vs -6.0%; 95% CI, -7.7 to 4.5). Similar results were obtained in non-inferiority comparisons between niacin ER/simvastatin 1,000/40 mg and simvastatin 80 mg (-6.7 vs -6.0%; 95% CI, -6.6 to 5.3). Secondary: In Group A, the mean percent change in LDL-C at 24 weeks with niacin ER/simvastatin 1,000/20 and 2,000/20 mg were non-superior to simvastatin 20 mg (-11.9 and -14.3 vs -6.7%, respectively) (P value not provided). However, mean percent reduction in TG and mean percent increase in HDL-C with niacin ER/simvastatin 1,000/20 and 2,000/20 mg were “superior” to simvastatin 20 mg (TG, -26.5 and -38 vs -15.3%, respectively, HDL, 20.7 and 29% vs 7.8%, respectively) (P values not provided).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
All simvastatin monotherapy patients received niacin IR 50 mg/day to prevent unblinding due to flushing. All patients were instructed to take aspirin or ibuprofen to minimize flushing.				
Ballantyne et al.[261] (2008) SEACOAST I Niacin ER-simvastatin 1,000-20 or 2,000-20 mg/day vs simvastatin 20 mg/day All simvastatin monotherapy patients received niacin IR 50 mg/day to prevent unblinding due to flushing.	AC, DB, MC, RCT High risk patients with primary or mixed dyslipidemia	N=319 24 weeks	Primary: Percentage change from baseline in non-HDL-C Secondary: Percent change from baseline in LDL-C, HDL-C, TC/HDL-C, TG, apo B and apo AI	Primary: Combination therapy achieved significant improvements in non-HDL-C. Median change from baseline at week 24 in non-HDL-C was -13.9, -22.5 (P<0.01) and -7.4% (P<0.001) for niacin ER-simvastatin 1,000-20 mg/day, niacin ER-simvastatin 2,000-20 mg/day and simvastatin. Secondary: Combination therapy was associated with nonsignificant additional decreases in LDL-C compared to simvastatin. Both combination therapy regimens had significantly greater decreases in TG, Lp(a), apo B and TC:HDL-C (P values not reported). Combination therapy also achieved significant increases in HDL-C and apo AI/apo B.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Ballantyne et al.[262] (2008) SEACOAST II Niacin ER-simvastatin (NER/S) 2,000-40 mg QD vs niacin ER-simvastatin (NER/S) 1,000-40 mg QD vs simvastatin 20 mg/day All simvastatin monotherapy patients received niacin IR 50 mg/day to prevent unblinding due to flushing.	AC, DB, MC, RCT Men and women ≥21 years of age, compliant with standard cholesterol-lowering diet for ≥4 weeks prior to screening; non-HDL cholesterol ≥130 mg/dL (CHD or CHD risk equivalent), ≥160 mg/dL (≥2 risk factors), ≥190 mg/dL (0 to 1 risk factors)	N=343 24 weeks	Primary: Percent change from baseline to week 24 in non-HDL-C Secondary: Percent change from baseline to week 24 in LDL-C, HDL-C, TC:HDL-C ratio, TG, Lp(a), apoB, and apoAI	Primary: Percent changes from baseline to week 24 in non-HDL-C in both NER/S groups were non-inferior to the simvastatin 80 mg/day group. Median changes in non-HDL-C were -10.1% for simvastatin 80 mg, -11.3% for NER/S 1,000-40 mg, and -17.1% for NER/S 2,000-40 mg. Secondary: Both NER/S treatment groups significantly reduced TG, Lp(a), and TC:HDL-C ratio, and significantly increased HDL-C and apoAI levels compared to patients receiving simvastatin 80 mg (P<0.01 and P<0.001). No significant differences in LDL-C or apoB were noted between the three treatment groups.
Charland et al.[263] (2010) High potency dyslipidemia pharmacotherapy (niacin ER-lovastatin, niacin	MA (120 unique reports) Patients with hyperlipidemia	N=43,974 Duration varied (≥4 weeks)	Primary: Percent change from baseline in lipid parameters, cardiovascular events	Primary: All of the high potency therapies lowered LDL-C by ≥45%, with the higher doses of ezetimibe/simvastatin and rosuvastatin achieving the greatest LDL-C reduction of -60 and -54%, respectively. In general, percent lipid changes for ezetimibe/simvastatin and rosuvastatin increased in a significant dose dependent manner for TC and LDL-C. With niacin-containing therapies, percent changes in these parameters were flat, and

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
ER-simvastatin, rosuvastatin and ezetimibe/simvastatin			Secondary: Not reported	no significant differences between moderate and high doses were observed. Ezetimibe/simvastatin and rosuvastatin did not demonstrate a significant difference in percent change in HDL-C throughout the doses evaluated. Non-niacin-containing therapies appeared to have a flat dose response curve, with weighted percent HDL-C changes between 5 and 9%. Niacin-containing therapies achieved a significant dose response effect. There was no significant difference in percent change in TG with any dose for ezetimibe/simvastatin or rosuvastatin (5, 20 and 40 mg/day). Niacin-containing therapies also demonstrated greater weighted percent changes in TG lowering (-40%) compared to ezetimibe/simvastatin or rosuvastatin (-31 and -24%). In evaluating percent changes in TC between the therapies there was no significant difference between rosuvastatin 40 mg, ezetimibe/simvastatin 10/80 mg and niacin ER/simvastatin. For LDL-C, there were significant differences between many of the therapies at various doses of rosuvastatin, ezetimibe/simvastatin, niacin ER/lovastatin and niacin ER/simvastatin; however, there was no significant difference in percent change in LDL-C between rosuvastatin 40 mg, ezetimibe/simvastatin 10/40 or 10/80 mg or niacin ER/simvastatin 2,000/40 mg. All of the high-potency therapies are predicted to reduce cardiovascular event rates by >50%, except for the lowest dose of ezetimibe/simvastatin (10/10 mg) and niacin ER/lovastatin (500/20 mg). There was no significant difference in predicted event risk reduction between the largest dose of niacin ER/lovastatin (2,000/40 mg) and niacin ER/simvastatin (2,000/40 mg); however, there was a significant difference in predicted event reduction between either of the highest doses of niacin ER/lovastatin (2,000/40 mg) and niacin ER/simvastatin (2,000/40 mg) compared to all of the doses of rosuvastatin or ezetimibe/simvastatin. The average percent cardiovascular event reduction for ezetimibe/simvastatin, rosuvastatin, niacin ER/lovastatin and niacin ER/simvastatin was 60, 58, 61 and 72%, respectively. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Prevention of Coronary Heart Disease (Combination Products)				
Murphy et al.[264] (2016) IMPROVE-IT Simvastatin 40 mg plus placebo vs combination of ezetimibe 10 mg, plus simvastatin, 40 mg once daily Given in addition to standard ACS therapy. Simvastatin dose was increased in each group to 80 mg if LDL-C was >79 mg/dL	DB, RCT Patients ≥50 years of age who were hospitalized for an ACS within the preceding 10 days, with either acute MI with or without electrocardiographic ST-segment elevation, or high-risk unstable angina; LDL-C concentration of ≥50 mg/dL, with a maximum of 125 mg/dl if not receiving chronic lipid-lowering therapy, or ≤100 mg/dL if chronically treated	N=18,144 Median of 6 years	Primary: Composite of time to first CV death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization (≥30 days post-randomization), or nonfatal stroke Secondary: Not reported	Primary: Among 18,144 patients, there were 9,545 total primary endpoint events (56% were first events and 44% subsequent events). Total primary endpoint events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (RR, 0.91; 95% CI, 0.85 to 0.97; P=0.007). The reduction in total events was driven by decreases in total nonfatal MI (RR, 0.87; 95% CI, 0.79 to 0.96; P=0.004) and total nonfatal stroke (RR, 0.77; 95% CI, 0.65 to 0.93; P=0.005). Secondary: Not reported
Adverse Events				
Newman et al.[265] (2006) Atorvastatin 10 or 80 mg QD vs placebo	MA (42 trials) Patients with various cardiovascular risks, LDL-C ≥130 mg/dL and TG ≤600 mg/dL	N=14,236 2 weeks to 52 months	Primary: Adverse effects Secondary: Not reported	Primary: Treatment-related side effects were similar between treatments (P value not reported). Treatment-associated myalgia was observed in 1.4, 1.5 and 0.7% of patients receiving atorvastatin 10 mg, 80 mg and placebo, respectively (P value not reported). No cases of rhabdomyolysis were reported with atorvastatin or placebo (P value not reported). Elevations in hepatic transaminases at least three times the upper limit of

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				normal were observed in 0.1, 0.6 and 0.2% of patients receiving atorvastatin 10 mg, 80 mg and placebo, respectively (P value not reported). Secondary: Not reported
Everett et al.[266] (2014) JUPITER Rosuvastatin 20 mg/day vs placebo	Post hoc analysis of JUPITER Men ≥50 years of age and women ≥60 years of age with no known history of cardiovascular disease, LDL-C <130 mg/dL, hsCRP ≥2 mg/L and TG <500 mg/dL treated to very low LDL-C levels (either an LDL-C <30 mg/dL or an LDL-C reduction of ≥70% from baseline)	N=17,802 (LDL-C <30 mg/dL (N=767) or ≥70% LDL-C reduction (N=718)) 1.9 years (maximum, 5 years)	Primary: Adverse events Secondary: Not reported	Primary: In the participants who achieved LDL-C <30 mg/dL, the adjusted risk of the composite outcome of any adverse event was higher than in those assigned to active therapy with LDL-C ≥30 mg/dL. No difference was seen by LDL-C reduction ≥70% or <70%. The rate of musculoskeletal disorders was similar for rosuvastatin-treated patients, regardless of achieved LDL-C <30 or ≥30 mg/dL. However, compared with the placebo-treated group, musculoskeletal disorders were more common in each of the rosuvastatin-treated groups. Although the incidence of hepatobiliary disorders was low in each of the achieved LDL-C groups, we observed a statistically significant increase in the risk for those with LDL-C <30 mg/dL compared with rosuvastatin-treated patients with LDL-C ≥30 mg/dL and compared with those allocated to placebo. We observed a statistically significant increase in the risk of type 2 diabetes for patients with LDL-C <30 mg/dL compared with either rosuvastatin-treated patients with LDL-C ≥30 mg/dL (HR, 1.56; 95% CI, 1.09 to 2.23; P=0.01) or placebo (HR, 1.90; 95% CI, 1.34 to 2.68; P=0.0003). In patients taking rosuvastatin, the rates of renal and urinary disorders were significantly higher in patients with LDL-C <30 vs ≥30 mg/dL (HR, 1.51; 95% CI, 1.21 to 1.90; P=0.0003). The patients on rosuvastatin who met the LDL-C goal of <30 mg/dL appeared to be at increased risk of both measures of hematuria compared with placebo.
Shepherd et al.[267] (2003) Rosuvastatin 5 to 40 mg QD vs	MA (33 RCTs) Patients with dyslipidemia	N=16,876 25,670 patient-years	Primary: Adverse events, elevation in transaminases, CK, myopathy, dipstick-positive proteinuria,	Primary: The incidence of adverse events was similar with rosuvastatin and placebo (52.1 vs 51.8%, respectively; P value not reported). The incidence of adverse events was similar across all the active treatments (P value not reported). The incidence of elevation in transaminases and CK, myopathy, dipstick-

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
atorvastatin 10 to 80 mg QD vs simvastatin 10 to 80 mg QD vs pravastatin 10 to 40 mg QD vs placebo			estimated glomerular rate Secondary: Not reported	positive proteinuria and estimated glomerular rate was similar across all the active treatment groups (P value not reported). Secondary: Not reported
Silva et al.[268] (2006) Statins (atorvastatin, pravastatin, simvastatin, lovastatin, fluvastatin, rosuvastatin) vs placebo	MA (18 PRO, RCTs) Patients receiving statin therapy or placebo	N=71,108 Up to 317 weeks	Primary: Adverse events, cardiovascular events Secondary: Not reported	Primary: Statin therapy significantly increased the risk of any adverse events by 39% compared to placebo (OR, 1.4; 95% CI, 1.09 to 1.80; P=0.008). Consequently, out of 197 statin-treated patients, one patient would experience an adverse event (95% CI, 24 to 37; P value not reported). Statin therapy was associated with a significant 26% reduction in the risk of a clinical cardiovascular event compared to placebo (OR, 0.74; 95% CI, 0.69 to 0.80; P<0.001). Consequently, the NNT to prevent one additional cardiovascular event was 27. Rosuvastatin trials were not included in the analysis of cardiovascular risk reduction due to inadequate data. The incidence of adverse effects during statin administration was observed in the following order, from highest to lowest: atorvastatin >pravastatin=simvastatin=lovastatin>fluvastatin. Secondary: Not reported
Kashani et al.[269] (2006)	MA (35 DB, RCTs)	N=74,102 Up to 65 months	Primary: Adverse events (myalgia, CK	Primary: Statin therapy was associated with a nonsignificant increase in the risk of myalgias (risk difference, 2.7; 95% CI, -3.2 to 8.7; P=0.37), CK elevation (risk

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Statins (atorvastatin 20 to 80 mg/day, fluvastatin 2.5 to 80 mg/day, lovastatin 10 to 80 mg/day, pravastatin 10 to 160 mg/day, rosuvastatin 1 to 80 mg/day, simvastatin 2.5 to 80 mg/day) vs placebo	Patients ≥18 years of age with hyperlipidemia		elevation, rhabdo-myolysis, transaminase elevation), discontinuation due to adverse event Secondary: Not reported	difference, 0.2; 95% CI, -0.6 to 0.9; P=0.64), rhabdomyolysis (risk difference, 0.4; 95% CI, -0.1 to 0.9; P=0.13) or discontinuation due to adverse events (risk difference, -0.5; 95% CI, -4.3 to 3.3; P=0.80) compared to placebo. Statin therapy was associated with a significant risk of transaminase elevations (risk difference, 4.2; 95% CI, 1.5 to 6.9; P<0.01) compared to placebo. When individual statins were compared to placebo, atorvastatin was the only statin with a significant increase in the risk of myalgias (P=0.04). When individual statins were compared to placebo, fluvastatin (P<0.01) and lovastatin (P=0.05) were the only statins with a significant increase in the risk of transaminase elevations. Secondary: Not reported
McClure et al.[270] (2007) Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin), stratified by ≤40 mg and >40 mg/day lovastatin equivalent dose vs placebo	MA (119 DB, RCTs) Patients ≥18 years of age with hyperlipidemia	N=86,000 Up to 65 months	Primary: Adverse events (myalgia, myositis, rhabdo-myolysis), discontinuation s due to adverse events Secondary: Not reported	Primary: Statin therapy was associated with a nonsignificant increase in the risk of myalgias (OR, 1.09; 95% CI, 0.97 to 1.23; P=0.471), rhabdomyolysis (OR, 1.59; 95% CI, 0.54 to 4.70; P=0.544) or myositis (OR, 2.56; 95% CI, 1.12 to 5.85; P=0.987) compared to placebo. Statin therapy was associated with a significantly lower incidence of discontinuations due to adverse events (OR, 0.88; 95% CI, 0.84 to 0.93; P<0.001) compared to placebo. Secondary: Not reported
Law et al.[271] (2006)	SR (2 cohort studies and 21	N=not reported	Primary: Incidence of	Primary: The incidence of rhabdomyolysis associated with the use of statins in two

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
Statins (lovastatin, atorvastatin, pravastatin, simvastatin, fluvastatin) vs placebo	PC, RCTs) Patients receiving statin therapy or placebo	Up to 6.1 years	rhabdomyolysis, myopathy, renal failure, elevated ALT, renal failure, proteinuria, and peripheral neuropathy Secondary: Not reported	cohort and RCTs was 3.4 (95% CI, 1.6 to 6.5) per 100,000 patient-years (P value not reported). The incidence of rhabdomyolysis associated with the use of statins in addition to gemfibrozil in two cohort studies was 35 (95% CI, 1 to 194) per 100,000 patient-years (P value not reported). The notification of rhabdomyolysis to the FDA adverse events reporting system was approximately four times higher in patients receiving lovastatin, simvastatin or atorvastatin compared to those receiving fluvastatin or pravastatin (P<0.001). The notification of rhabdomyolysis to the FDA adverse events reporting system was approximately 15 times higher in patients receiving statins in combination with gemfibrozil (21 per 100,000 patient-years; 95% CI, 17 to 25) compared to those receiving statin therapy (0.70 per 100,000 patient-years; 95% CI, 0.62 to 0.79; P<0.001). The incidence of myopathy associated with the statin therapy in RCTs was five (95% CI, -17 to 27) per 100,000 patient-years (P value not reported). The incidence of liver failure associated with statin therapy, reported to the FDA adverse events reporting system, was 0.1 per 100,000 patient-years of use (P value not reported). Statin therapy in patients with elevated ALT would lead to liver disease in less than one person (P value not reported). Statin therapy was not associated with a higher incidence of renal failure or proteinuria compared to placebo (P value not reported). Patients receiving statin therapy have 1.8 odds of experiencing peripheral neuropathy compared to placebo (95% CI, 1.1 to 3.0; P<0.001). Secondary: Not reported
Dale et al.[272] (2007) Intensive statin therapy;	MA (9 RCTs) Patients receiving statin therapy	N=21,765 Up to 5 years	Primary: Incidence of elevations in AST, ALT or CK	Primary: Intensive statin therapy was associated with a significant increased risk of AST or ALT elevation compared to the moderate statin therapy (1.5 vs 0.4%; RR, 3.10; 95% CI, 1.72 to 5.58; P=0.002).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
hydrophilic (atorvastatin 80 mg/day) and lipophilic statins (simvastatin 40 to 80 mg/day, lovastatin 76 mg/day) vs moderate statin therapy; hydrophilic (atorvastatin 10 mg/day, pravastatin 40 mg/day) and lipophilic statins (simvastatin 20 to 40 mg/day, lovastatin 4 mg/day)			Secondary: Not reported	Intensive statin therapy was associated with a nonsignificant risk of CK elevation compared to the moderate statin therapy (0.10 vs 0.02%; RR, 2.63; 95% CI, 0.88 to 7.85; P=0.89). In a subanalysis of hydrophilic and lipophilic statins, while no cases of CK elevation occurred in the hydrophilic intensive statin group, patients on lipophilic intensive statin therapy experienced a nonsignificant risk in CK elevation (RR, 6.09; 95% CI, 1.36 to 27.35; P≥0.11). Secondary: Not reported
Ko. et al.[273] (2013) Intensive statin therapy (atorvastatin ≥40 mg, rosuvastatin ≥20 mg, or simvastatin ≥60 mg) vs moderate statin	RETRO Patients with myocardial infarction aged >65 years old, hospitalized in Ontario, Canada, from 2004 to 2010, only the initial hospitalization in the study period was included in	N=17,080 5 years	Primary: New development of diabetes mellitus after hospital discharge Secondary: All-cause mortality and repeat hospitalization for ACS	Primary: At 5 years, after hospitalization with myocardial infarction, 13.6% of patients receiving intensive-dose statins and 13.0% of the patients receiving moderate-dose statins had a new diagnosis of diabetes mellitus (P=0.19). Secondary: At 5 years, the rate of ACS or death was significantly lower at 44.8% in the intensive-dose statin group compared with 46.5% in the moderate-dose statin group (P=0.044). At 5 years, the rate of ACS was significantly lower with intensive-dose statins at 22.2 vs 23.5% compared with moderate-dose statins (P=0.039). Rate of death was not significantly different in the treatment groups (34.8% in both groups) during the study period (P=0.89).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
therapy (atorvastatin <40 mg, rosuvastatin <20 mg, simvastatin <60 mg, and any dosage of fluvastatin, lovastatin, or pravastatin)	the cohort. Patients with diabetes mellitus and patients who were not prescribed statin medications were excluded			
Silva et al.[274] (2007) Intensive statin therapy (atorvastatin 80 mg/day, simvastatin 80 mg/day) vs moderate statin therapy (atorvastatin 10 mg/day, simvastatin 20 mg/day, pravastatin 40 mg/day)	MA (4 RCTs) Patients with ACS or stable CAD receiving statins for the reduction of secondary cardiovascular events	N=27,548 3.4 years	Primary: CK ≥10 times the upper limit of normal, with or without myalgia; ALT or AST ≥3 times the upper limit of normal; rhabdo-myolysis; drug-induced adverse effects requiring drug discontinuation; any drug-induced adverse event; all-cause mortality; cardiovascular death; nonfatal MI; and stroke Secondary: Not reported	Primary: Intensive statin therapy was associated with a significant increased risk of any adverse event compared to moderate statin therapy (OR, 1.44; 95% CI, 1.33 to 1.55; P<0.001). Consequently, out of 30 patients treated with intensive statin therapy, one patient would experience an adverse event (95% CI, 24 to 37; P value not reported). Intensive statin therapy was associated with a significant increased risk (absolute risk, 2.14%) of an adverse drug event requiring discontinuation of drug therapy (OR, 1.28; 95% CI, 1.18 to 1.39; P≤0.001). Intensive statin therapy was associated with a significant increased risk (absolute risk, 1.2%) of an elevation in AST and ALT at least three times the upper limit of normal (OR, 4.84; 95% CI, 3.27 to 6.16; P≤0.001). Consequently, out of 86 patients treated with intensive statin therapy, one patient would experience an elevation in AST and ALT at least three times the upper limit of normal (95% CI, 72 to 106; P value not reported). Intensive statin therapy was associated with a significant increased risk (absolute risk, 0.07%) of an elevation in CK ≥10 times the upper limit of normal (OR, 9.97; 95% CI, 1.28 to 77.92; P=0.028). Consequently, out of 1,534 patients treated with intensive statin therapy, one patient would experience an elevation in CK ≥10 times the upper limit of normal (P value not reported). There was no difference in the incidence of rhabdomyolysis between the treatments (P value not reported). Intensive statin therapy was associated with

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				a nonsignificant reduction in all-cause mortality compared to moderate-dose statin therapy (P=0.185). Intensive statin therapy was associated with a significant reduction in the risk for cardiovascular death (P=0.031), nonfatal MI (P<0.001) and stroke (P=0.004). Consequently, the NNT to prevent one additional cardiovascular death, MI or stroke was 229, 99 and 166, respectively. Secondary: Not reported
Strony et al.[275] (2008) Ezetimibe 10 mg QD coadministered with either pravastatin 10 to 40 mg QD or simvastatin 10 to 80 mg QD	Pooled analysis of 2 ES, MC, OL Patients with primary hypercholesterolemia	N=795 12 to 15 months	Primary: Tolerability Secondary: LDL-C, HDL-C, TG, TC, and proportion of patients achieving LDL-C goal	Primary: Treatment-emergent adverse events were reported in 81% of patients receiving ezetimibe plus pravastatin (15 months) and in 84% of patients receiving ezetimibe plus simvastatin (12 months). The most commonly reported treatment-emergent adverse events were upper respiratory tract infection (18%), headache (11%), musculoskeletal pain (10%), arthralgia (10%), sinusitis (10%), abdominal pain (8%), bronchitis (6%), coughing (6%), nausea (6%), back pain (5%), myalgia (5%), chest pain (5%), and fatigue (5%) with ezetimibe plus pravastatin. The most commonly reported treatment-emergent adverse events were upper respiratory tract infection (19%), arthralgia (11 %), musculoskeletal pain (10%), headache (9%), back pain (8%), myalgia (8%), abdominal pain (7%), nausea (7%), pharyngitis (6%), coughing (5%), fatigue (5%), and urinary tract infection (19%) with ezetimibe plus simvastatin. During the ezetimibe plus pravastatin extension study, 7% experienced serious adverse events. During the ezetimibe plus simvastatin extension study, serious adverse events were reported in 10% of patients. Life-threatening adverse events were reported in four patients in the ezetimibe plus simvastatin study. The incidence of newly reported adverse events did not increase over time in either study. In the ezetimibe plus pravastatin study, 1% of patients experienced increases in ALT/AST >3 X upper limit or normal, whereas this was not reported in the

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	Endpoints	Results
				patients receiving ezetimibe plus simvastatin. Secondary: The mean LDL-C was reduced by 36.5 and 40.4% in the ezetimibe plus pravastatin and ezetimibe plus simvastatin studies, respectively. Similar reductions in TC and TG, and an increase in HDL-C, were achieved and maintained throughout the study period in both studies. In the ezetimibe plus pravastatin study, 85% of patients achieved their NCEP ATP III LDL-C goal and 80% of patients in the ezetimibe plus simvastatin study achieved their recommended goal.

Drug regimen abbreviations: BID=twice daily, ER=extended-release, IR=immediate-release, QD=once daily, SR=sustained-release, TID=three times daily; XL=extended-release, XR=extended-release
Study abbreviations: AC=active comparator, DB=double blind, DD=double dummy, ES=extension study, FU=follow-up, MA=meta-analysis, MC=multicenter, NI=noninferiority, OL=open label, PA=parallel-arm, PC=placebo-controlled, PG=parallel group, PRO=prospective trial, RCT=randomized controlled trial, RETRO=retrospective, XO=cross-over
Miscellaneous abbreviations: ACS=acute coronary syndrome, ALT=alanine aminotransferase, apo=apolipoprotein, ARR=absolute risk reduction, AST=aspartate aminotransferase, BMI=body mass index, BNP=B-type natriuretic peptide, BP=blood pressure, CABG=coronary artery bypass graft, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, CIMT=carotid intima-media thickness, CK=creatine kinase, CKD=chronic kidney disease, CPK=creatinine phosphokinase, CRP=C-reactive protein, DBP=diastolic blood pressure, ECG=electrocardiogram, eGFR=estimated glomerular filtration rate, FBG=fasting blood glucose, FH=familial hypercholesterolemia, GFR=glomerular filtration rate, HAART=highly active anti-retroviral therapy, HbA_{1c}=glycosylated hemoglobin, HDL-C=high-density lipoprotein cholesterol, heFH=heterozygous familial hypercholesterolemia, HIV=human immunodeficiency virus, hoFH=homozygous familial hypercholesterolemia, HOMA=homeostasis model assessment, HR=hazard ratio, hsCRP=high-sensitivity C-reactive protein, HTN=hypertension, IMT=intima-medial thickness, IDL-C=intermediate-density lipoprotein cholesterol, JNC 7=Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, LDL-C=low-density lipoprotein cholesterol, Lp(a)=lipoprotein(a), MI=myocardial infarction, NCEP ATP=National Cholesterol Education Program, Adult Treatment Panel, NNT=number needed to treat, NYHA=New York Heart Association, OR=odds ratio, PAD=peripheral arterial disease, PAV=percent atheroma volume, PCI=percutaneous coronary intervention, RR=relative risk, SBP=systolic blood pressure, SE=standard error, STEMI=ST-segment myocardial infarction, TAV=total atheroma volume, TC=total cholesterol, TG=triglycerides, TIA=transient ischemic attack, TRL=triglyceride lipoprotein, VLDL-C=very low-density lipoprotein, VTE=venous thromboembolism

Additional Evidence

Dose Simplification

Wongwiwatthananukit et al evaluated the safety and efficacy with rosuvastatin 10 mg administered once-daily compared to every-other-day in patients with primary hypercholesterolemia. There was a significantly larger reduction in low-density lipoprotein cholesterol (LDL-C) with once daily therapy compared to every-other-day administration (48 vs 39%, respectively; P=0.011). Total cholesterol and triglycerides were significantly lower with once daily therapy (P<0.05). However, there was no difference in the percentage of patients achieving their National Cholesterol and Education Program Adult Treatment Panel III LDL-C goals (P=0.18).[276]

LaFleur et al evaluated the differences in adherence and persistence with (1) a fixed-dose combination product containing lovastatin and extended-release niacin, (2) statin monotherapy, (3) extended-release niacin monotherapy, and (4) extended-release niacin taken with lovastatin as separate formulations. A total of 2,389 patients met the eligibility criteria and were followed for one year. All groups exhibited an adherence rate >80%. Patients receiving extended-release niacin and lovastatin taken separately demonstrated higher adherence rates compared to those on the fixed-dose product (90 vs 88%; P=0.033). In addition, patients were less adherent to statin monotherapy than to either the fixed-dose combination product or niacin monotherapy (81, 90, and 89%, respectively; P<0.05). At 12 months, all treatment groups had a persistence rate of <20%. At nine months, patients randomized to niacin monotherapy exhibited a significantly lower rate of persistence compared to the rest of the groups (P<0.05). Since this was an adherence study only, based on an evaluation of pharmacy claims, the study did not measure the impact of adherence on LDL-C or other cholesterol goals.[277]

Balu et al retrospectively evaluated medication adherences rates in patients treated with the fixed-dose combination of niacin extended-release and lovastatin (NERL) compared to the multi-pill combination of niacin extended-release plus lovastatin (NER/L) or simvastatin (NER/S) using an integrated managed care database. Adherence rates were greater among patients initiating therapy with NERL compared to NER/S or NER/L P<0.0001). A higher percentage of patients initiating therapy with NERL (34.2%) exhibited optimal adherence (>80%) compared to those initiating therapy with NER/S (29.6%; P<0.0001) or NER/L (25.9%; P<0.0001). There were fewer cardiovascular disease-associated emergency room visits in patients with optimal adherence initiating therapy with NERL compared to those with optimal adherence initiating therapy with NER/S or NER/L (P=0.003), inpatient visits (P=0.018, outpatient visits (P<0.0001), and prescription fills (P<0.0001). Patients with optimal adherence had an 8% decrease (P=0.023) in annual cardiovascular disease-attributable total medical resource utilization compared to patients with suboptimal adherence (<80%).[278]

Patel et al evaluated adherence rates in patients newly initiated on dual therapy with a calcium channel blocker and a statin (as either a fixed-dose combination product or administration of each component separately). In this six month, retrospective, pharmacy claims database analysis, the authors found that the percentage of patients achieving adherence rates ≥80% were: 67.7% with amlodipine-atorvastatin; 49.9% with amlodipine plus atorvastatin; 40.4% with amlodipine plus other statins; 46.9% with other calcium channel blockers plus atorvastatin; 37.4% with other calcium channel blocker plus other statin (P<0.0001 amlodipine-atorvastatin vs all other cohorts).[279]

Stable Therapy

Cheetham et al evaluated the efficacy and safety of switching patients from Zocor® to generic lovastatin. Patients switching to lovastatin experienced a reduction in LDL-C, an increase in high-density lipoprotein cholesterol and a decrease in triglycerides. Rates of alanine aminotransferase and creatine kinase elevations were not found to be significantly different before or after conversion.[280]

Usher-Smith et al examined the effects of switching patients from atorvastatin to simvastatin in a two year retrospective analysis. Patients initially receiving atorvastatin 10 and 20 mg were converted to simvastatin 10, 20, or 40 mg, respectively. The change in therapy was not associated with a significant alteration in baseline total cholesterol levels (P=0.06).[281]

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 10. Relative Cost of the HMG-CoA Reductase Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Atorvastatin	tablet	Lipitor®*	$$$-$$$$	$
Fluvastatin	capsule, extended-release tablet	Lescol XL®*	$$$$$	$$$$$
Lovastatin	extended-release tablet, tablet	Altoprev®	$$$$$	$
Pitavastatin	tablet	Livalo®	$$$$$	N/A
Pravastatin	tablet	Pravachol®*	$$$-$$$$	$
Rosuvastatin	tablet	Crestor®*	$$$$$	$$
Simvastatin	tablet	Zocor®*	$$$$	$
Combination Products				
Amlodipine and atorvastatin	tablet	Caduet®*	$$$$-$$$$$	$$$$$
Ezetimibe and simvastatin	tablet	Vytorin®*	$$$$$	$$$$$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The HMG-CoA reductase inhibitors (statins) are approved for the treatment of a variety of lipid disorders, including primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceridemia (refer to Table 4 for specific indications). The fixed-dose combination products (amlodipine and atorvastatin, and ezetimibe and simvastatin) are indicated for use when dual therapy is appropriate.[1-10] Statins can decrease low-density lipoprotein cholesterol (LDL-C) by 18 to 60% and triglycerides (TG) by 7 to 30%, as well as increase high-density lipoprotein cholesterol (HDL-C) by 5 to 15% when administered as monotherapy.[11-13] Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and fixed-dose amlodipine-atorvastatin and ezetimibe-simvastatin are available in a generic formulation.

In general, therapeutic lifestyle changes, including diet, exercise, and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia. When LDL lowering is required, initial treatment with a statin, a bile acid sequestrant, or niacin is recommended. However, in general, the statins are considered first line therapy for decreasing LDL-C levels, and are recommended in patients with established

coronary heart disease (CHD) or coronary heart disease equivalents. If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or ezetimibe should be considered. Statins are also considered first line in the treatment of heterozygous familial hypercholesterolemia, but if required a bile acid sequestrant can be added to therapy. Choice of statin and dose should be based on cost and the amount of lipid lowering required for a specific patient. Patients with risk factors for CHD but no history of disease are likely to decrease their risk of CHD with lipid lowering therapy.[13] Guidelines do not give preference to statin over another.[13-27]

American College of Cardiology/American Heart Association (ACC/AHA) and Institute for Clinical Systems Improvement both released updated guidelines in 2013 which support initiating a statin in patients with established atherosclerotic cardiovascular disease (ASCVD). According to these recommendations, percent reduction in LDL-C is an indicator of response and adherence to therapy, but treating to a targeted level is not a primary goal.[18,19] Combination therapy can be considered on an individual basis, but studies of combination therapy have generally not shown benefit beyond statin monotherapy. Additionally, if patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available.[18,19] High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. When high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.[19] Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy with no 10-year ASCVD risk estimation required: use high-intensity statin therapy unless contraindicated and intensify statin therapy to achieve at least a 50% LDL-C reduction.[19] The ACC/AHA guidelines note that there is no differentiation between the specific statins and doses used in primary- and secondary-prevention trials and that statins reduce ASCVD risk similarly in both populations.[19]

Numerous clinical trials have demonstrated that the statins (single entity and combination products) can effectively lower LDL-C, non-HDL-C, total cholesterol, and TG, as well as positively impact other lipid/lipoprotein parameters. Many studies have compared active treatment to placebo or compared combination therapy to monotherapy. In these studies, the more aggressive treatment regimens often improved lipid parameters to a greater extent than the less-intensive treatment regimens.[28-134,234-264] The statins differ in their potency and their effects on LDL-C are dose-dependent. Atorvastatin and rosuvastatin are the most potent agents available and can lower LDL-C by ~60%.[11-15] The 2013 ACC/AHA guidelines recommend selecting statin product and dose based on intensity of LDL-C-lowering effect. Moderate-intensity statins lower LDL-C by 30 to <50% (e.g. atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 40 mg twice daily, and pitavastatin 2 to 4 mg) and high-intensity statins lower LDL-C by ≥50% and include atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg.[19] In general, the combination products do not offer any significant clinical advantage over coadministration of their individual components.

All of the statins, with the exception of pitavastatin, have been shown to have beneficial effects on CHD outcomes, while the majority of them (atorvastatin, pravastatin, rosuvastatin, and simvastatin) have also been shown to decrease the risk of stroke.[1-14,135-232] Atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin have been shown to reduce cardiovascular events in patients with clinically evident CHD (secondary prevention). In addition, fluvastatin, lovastatin, pravastatin, and rosuvastatin have been shown to slow progression of coronary atherosclerosis in patients with CHD. No incremental benefit of the combination statin products on cardiovascular morbidity and mortality has been established over and above that demonstrated for the single entity statin products.[1-10]

The statins are generally well-tolerated, and the most common side effects are gastrointestinal disturbances, headache, insomnia, myalgia, and rash. Muscle aches and weakness are reported by one to two percent of patients taking statins. The symptoms are usually mild and generally do not lead to discontinuation. All statins can increase hepatic transaminase levels and creatine kinase. Pravastatin and rosuvastatin do not undergo extensive first-pass metabolism; therefore, they are associated with a lower risk for drug interactions. Atorvastatin, lovastatin, and simvastatin are primarily metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme, while fluvastatin is metabolized by the CYP2C9 isoenzyme, which may result in differences in their drug interaction profiles.[11,12]

There is insufficient evidence to support that one brand HMG-CoA reductase inhibitor is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand HMG-CoA reductase inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand HMG-CoA reductase inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Altoprev® [package insert]. Florham Park (NJ): Shionogi, Inc.; 2014 Apr.
2. Caduet® [package insert]. New York (NY): Pfizer, Inc.; 2015 Mar.
3. Crestor® [package insert].Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2016 May.
4. Lescol® and Lescol XL® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2012 Oct.
5. Lipitor® [package insert]. New York (NY): Pfizer, Inc.; 2015 Mar.
6. Livalo® [package insert]. Montgomery (AL): Kowa Pharmaceuticals America, Inc.; 2016 Nov.
7. Pravachol® [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2016 Jul.
8. Vytorin® [package insert]. Whitehouse Station (NJ): Merck & Co, Inc.; 2015 Feb.
9. Zocor® [package insert]. Whitehouse Station (NJ): Merck & Co, Inc.; 2015 Feb.
10. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2017 [cited 2017 May]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
11. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited May 2017]. Available from: http://online.factsandcomparisons.com.
12. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 May]. Available from: http://www.thomsonhc.com/.
13. National Institutes of Health: National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
14. FDA Pulls Approval of Niacin, Fibrate in Combo with Statins. Medscape: Apr 15, 2016 [cited 2017 June 1]. Available from: http://www.medscape.com/viewarticle/862022.
15. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
16. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2017 Feb 3. doi: 10.4158/EP171764.GL.
17. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.
18. Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Institute for Clinical Systems Improvement. Lipid Management in Adults. Updated November 2013.
19. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000–000. DOI: 10.1161/01.cir.0000437738.63853.7a.
20. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519.
21. National Institute for Health and Clinical Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. National Institute for Health and Clinical Excellence; London (UK): 2014 [cited 2017 Jan 15]. Available from: https://www.nice.org.uk/Guidance/cg181.
22. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr;115(14):1948-67.
23. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular

Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106.
24. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
25. Lindor KD, Gershwin ME, Poupon R, et al. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
26. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 Executive Summary. Endocr Pract. 2016;22(1):84-113.
27. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. National Institute for Health and Clinical Excellence; London (UK): 2008 [cited 2017 Jan 6]. Available from: http://www.nice.org.uk/guidance/cg71.
28. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007 Aug 7;116(6):664-8.
29. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014 Sep;312(10):1055-1057.
30. Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Weigman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121-6.
31. Braamskamp MJ, Langslet G, McCrindle BW, et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study.
32. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1803-10.
33. Shafiq N, Bhasin B, Pattanaik S, Pandhi P, Venkateshan SP, Singh M, Malhotra S. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Ther. 2007 Oct; 45(10):548-55.
34. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar;197(1):400-6.
35. Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, et al. Comparison of atorvastatin vs fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism. 2007 Nov;56(11):1534-41.
36. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002 May 28;105(21):2469-75.
37. Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb. 2008;15:345:50.
38. Motomura T, Okamoto M, Kitamura T, Yamamoto H, Otsuki M, Asanuma N, et al. Effects of pitavastatin on serum lipids and high sensitivity c-reactive protein in Type 2 diabetic patients. J Atheroscler Thromb. 2009;16:546-52.
39. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210:202-8.
40. Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, Harats D, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol. 2007 Nov 1;100(9):1387-96.
41. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol. 2007 Dec;47(12):1555-69.

42. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20;107(19):2409-15.
43. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004 Sep;447-55.
44. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) vs uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008;102:1489-94.
45. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared to uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008;102:1495-501.
46. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin vs up titration of atorvastatin to 40 mg in patients >or = 65 years of age (ZETELD). Am J Cardiol 2010;105:656-63.
47. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, et al. Treatment with ezetimibe plus low-dose atorvastatin compared to higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007 Mar 13;49(10):1035-42.
48. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006 Dec;81(12):1579-88.
49. Winkler K, Ablethauser CB, Gimpelewicz C, Bortolini M, Isaacsohn JL. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. Clin Ther. 2007;29:1987-2000.
50. Stein E, Ballantyne C, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101:490-496.
51. Alvarez-Sala L, Cachofeiro V, Masana L, et al. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther 2008;30:84-97.
52. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug;8(8):571-81.
53. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 Oct;158(2):407-16.
54. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
55. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003 Feb 15;91(4):418-24.
56. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007 Nov;46(5):1453-63.
57. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003 Apr;24(8):717-28.
58. Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infection patients. AIDS. 2006 Aug;20(12):1675-7.
59. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med. 1994;154:1586-95.
60. Eriksson M, Hådell K, Holme I, Walldius G, Kjellström T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med. 1998 May;243(5):373-80.

61. Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, et al. Ezetimibe/simvastatin 10/40 mg vs atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis. 2012 Jan 31;11:18.
62. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin vs simvastatin vs atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15;99(12):1706-13.
63. Winkler K, Schewe T, Putz G, Odunc N, Schafer G, Siegel E, et al. Fluvastatin/fenofibrate vs simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009;39(6):463-70.
64. Becker DJ, Gordon RY, Morris PB, Yorko J, Gordon YJ, Li M, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83(7):758-64.
65. Meredith KG, Horne BD, Pearson RR, Maycock CA, Lappe DL, Anderson JL, et al. Comparison of effects of high (80 mg) vs low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. Am J Cardiol. 2007 Jan 15;99(2):149-53.
66. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 Apr;110(5):352-60.
67. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest. 2007 May;37(5):357-63.
68. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18;40(12):2125-34.
69. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004 May;79(5):620-9.
70. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov;345(22):1583-92.
71. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004 Feb;93:307-12.
72. Stalenhoef A, Ballantyne C, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: Results of The Comets Study. Eur Heart J. 2005;1093:822-9.
73. Constance C, Westphal S, Chung N, Lund M, McCrary Sisk C, Johnson-Levonas AO, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared to atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2007 Jul;9(4):575-84.
74. Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate vs atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 2009;8(56):1-8.
75. Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103:515-22.
76. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Vs Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003 Mar 15;91(6):667-72.
77. Sansanayudh N, Wongwiwatthananukit S, Putwai P, Dhumma-Upakorn R. Comparative efficacy and safety of low-dose pitavastatin vs atorvastatin in patients with hypercholesterolemia. Ann Pharmacother. 2010;44:415-23.
78. Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011 Nov;13(11):1047-55.
79. Yoshitomi Y, Ishii T, Kaneki M, Tsujibayashi T, Sakurai S, Nagakura C, et al. Efficacy of a low dose of pitavastatin compared to atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb. 2006;13(2):108-13.

80. Lee SH, Chung N, Kwan J, Kim D, Kim WH, Kim CJ, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29(11):2365-73.
81. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089-100.
82. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin vs pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162:373-9.
83. Stender S, Budinski D, Gosho M, and Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013 Feb;20(1):40-53.
84. Park A, Kang HJ, Rim SJ, Ha JW, Oh BH, Chung N, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared to simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27(7):1074-82.
85. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolemia or combined dyslipidemia. Curr Med Res Opin. 2009;25(11):2755-64.
86. Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther. 2011 Sep;28(9):811-23.
87. Rosenson RS, Otvos JD, Hsia J, et al. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009;32:1087-91.
88. Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med. 2010;25:27-35.
89. Mazza F, Stefanutti C, Di Giacomo S, et al. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs 2008;8:265-70.
90. Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007 May;24(5):541-9.
91. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin vs atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol. 2007 Oct 15;100(8):1245-8.
92. Clearfield MB, Amerena J, Bassand JP, Hernández García HR, Miller SS, Sosef FF, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006 Dec 21;7:35.
93. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin vs atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol. 2007 Jun 1;99(11):1538-43.
94. Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, et al. Comparison of efficacy and safety of rosuvastatin vs atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006 Jan 15;97(2):229-35.
95. Lloret R, Ycas J, Stein M, Haffner S; STARSHIP Study Group. Comparison of rosuvastatin vs atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006 Sep 15;98(6):768-73.
96. Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, et al. Treating to target patients with primary hyperlipidemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006 Jun;22(6):1123-31.
97. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, et al. Effects of maximal doses of atorvastatin vs rosuvastatin on small dense low-density lipoprotein cholesterol level. Am J Cardiol. 2008 Feb 1;101:315-8.
98. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al. Efficacy and safety of rosuvastatin 40 mg vs atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007 Oct;194(2):e154-64.

99. Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared to atorvastatin in patients with type 2 diabetes: the CORALL study. J Intern Med. 2005 Jun;257(6):531-9.
100. Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, et al. Effectiveness of rosuvastatin vs atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm. 2007 Feb 1;64(3):276-84.
101. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefit and risks of rosuvastatin vs atorvastatin for a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008;102:1654-62.
102. Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007 Dec;13(Suppl 10):S270-5.
103. Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, et al. Effect of rosuvastatin compared to other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006 Apr;26(4):469-78.
104. Nicholls S, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin vs rosuvastatin vs simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76.
105. Harley CR, Gandhi SK, Anoka N, Bullano MF, McKenney JM. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting. Am J Manag Care. 2007 Dec;13 Suppl 10:S276-81.
106. Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin. 2007 Sep;23(9):2125-33.
107. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar;99(5):673-80.
108. Jones P, Davidson M, Kashyap M, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 2009;204:208-215.
109. Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-a phase 3 study. Cardiovasc Drugs Ther. 2010;24:421-8.
110. Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia. Evaluation of dose response. Am J Cardiovasc Drugs. 2012;12(2):117-25.
111. Mohiuddin S, Pepine C, Kelly M, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009;157:195-203.
112. May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone vs fenofibrate alone vs simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008;101:486-9.
113. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83.
114. Rogers SL, Magliano DJ, Levison DB, Webb K, Clarke PJ, Grobler MP, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther. 2007 Feb;29(2):242-52.
115. Hall AS, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, et al. A randomized, controlled trial of simvastatin vs rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events—Reduction of Cholesterol to Key European Targets Trial (abstract). Eur J Cardiovasc Prev Rehabil. 2009 Dec;16(6):712-21.
116. Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration vs simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004 Jun 15;93(12):1481-6.
117. Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005 Jan;7(1):88-97.

118. Bays H, Sapre A, Taggart W, Liu J, Capece R, Tershakovec A. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008;24(10):2953-66.
119. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolemia in HIV-infected patients receiving protease inhibitors (abstract). Curr HIV Res. 2008 Nov;6(6):572-8.
120. Faergeman O, Hill L, Windler E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 2008;111:219-28.
121. Insull W Jr, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E, et al. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007 May;82(5):543-50.
122. Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May;151(5):975.e1-9.
123. Jones P, Davidson M, Stein E, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin vs atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-60.
124. Welty FK, Lewis SJ, Friday KE, Cain VA, Anzalone DA. A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study. J Womens Health (Larchmt). 2016 Jan;25(1):50-6.
125. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe vs a statin alone (the COMPELL study). Atherosclerosis. 2007 Jun;192(2):432-7.
126. Bays H, Jones P, Mohiuddin S, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidology 2008;2:426-35.
127. Kipnes MS, Roth EM, Rhyme JM, Setze CM, Lele A, Kelly MT, et al. Year two assessment of fenofibric acid and moderate-dose statin combination. A Phase 3, open-label, extension study. Clin Drug Investig. 2010;30(10):51-61.
128. Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) vs fenofibrate (200 mg) vs extended-release niacin (2 g). Am J Cardiol 2008;102:1341-7.
129. Jones P, Davidson M, Goldberg A, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidology 2009;3:125-37.
130. Bays HE, Maki KC, McKenney J, et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin 2010;26:907-15.
131. Rosen JB, Jimenez JG, Pirags V, et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab Vasc Dis Res. 2013 May;10(3):277-286.
132. Bays HE, Averna M, Majul C, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013 Dec;112(12):1885-1895.
133. Foody JM, Toth PP, Tomassini JE, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag. 2013;9:719-727.
134. Hogue JC, Lamarche B, Tremblay AJ, et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008;57:380-6.
135. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65.
136. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPS) research group. Circulation. 1994 Oct; 90(4):1679-87.

137. Byington RP, Furberg CD, Crouse JR, 3rd, Espeland MA, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995 Sep 28; 76:54C-9C.
138. Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intima-medial thickness in patients with coronary heart disease. Heart. 2007 Aug;93(8):933-9.
139. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, et al. Effect of intensive vs standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation. 2006 Jan 24;113(3):427-37.
140. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28; 297(12):1344-53.
141. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMERS Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTONOMER) trial. Circulation. 2010;121:306-14.
142. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared to moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial (REVERSAL). JAMA. 2004 Mar 3;291(9):1071-80.
143. Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K, Lin S, et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation. 2006 Jun 20;113(24):2826-34.
144. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Hazen SL, Ntanios F, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol. 2006 Jun 1;97(11):1553-7.
145. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005 Jan 6;352(1):29-38.
146. Ikeda K, Takahashi T, Yamada H, et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). Eur J Prev Cardiol. 2013 Dec;20(6):1069-1079.
147. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media Thickness and Overall arterial Rigidity study (VYCTOR). J Clin Pharmacol 2009;49:838-847.
148. Phan BA, Moore AB, Davis J, et al. Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol. 2014 Sep-Oct;8(5):489-493.
149. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF , Gouni-Berthold I et al. Alirocumab as Add-on To Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015 Jun 1:jc20151520.
150. Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct;37(10):597-604. doi: 10.1002/clc.22327.
151. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016 Jan;244:138-46.
152. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758-69.
153. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006 Jul;29(7):1478-85.
154. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685-96.

155. Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006 Nov;29(11):2378-84.
156. Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, Durrington PN, et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med. 2007 Dec;24(12):1313-21.
157. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58.
158. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005 May;28(5):1151-7.
159. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-22.
160. Schouten O, Boersma E, Hoeks S, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009;361:980-989.
161. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
162. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Nakaya N, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled study. Lancet. 2006;368:1155-63.
163. The Pravastatin Multinational Study Group for Cardiac Risk Patients (PMS-CRP). Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-7.
164. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West of Scotland Coronary Prevention Study (WOSCOPS). NEJM. 1995;333(20):1301-7.
165. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007 Oct 11;357(15):1477-86.
166. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
167. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121:143-50.
168. Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2001;32:75-83.
169. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein. J Am Coll Cardiol. 2010;55(12):1266-73.
170. Ridker PM, MacFadyen JG, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low-density lipoprotein cholesterol and elevated high-sensitivity c-reactive protein. Circ Cardiovasc Qual Outomes. 2009;2:616-23.
171. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31.
172. Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2011, Issue 1. Art. No.: CD004816. DOI:10.1002/14651858.CD004816.pub4.
173. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069-77.

174. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78.
175. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 Jan 12;371(9607):117-25.
176. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008 Jan;121(1):24-33.
177. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, et al. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun;37(6):1427-31.
178. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 7;352(14):1425-35.
179. Shah SJ, Waters DD, Barter P, Kastelein JJP, Shepherd J, Wenger NK, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008;51:1938-43.
180. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9.
181. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006 Sep 9;368(9539):919-28.
182. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006 Jun;29(6):1220-6.
183. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007 Jul;147(1):1-9.
184. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007 Feb 6;115(5):576-83.
185. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007 Sep 1;100(5):747-52.
186. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10.
187. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9.
188. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared to angioplasty in stable coronary artery disease. Atorvastatin vs Revascularization Treatment Investigators. N Engl J Med. 1999 Jul 8;341(2):70-6.
189. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal vs 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220-8.
190. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007 Jan;22(1):118-27.
191. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 Oct;28(10):2508-13.

192. Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol. 2007 Mar 1;99(5):632-5.
193. Amarenco P, Goldstein LB, Messig M, O'Neil BJ, Callahan III A, Sillesen H, et al. Relative and cumulative effects of lipids and blood pressure control in Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke. 2009;40:2486-92.
194. Amarenco P, Benavente O, Goldstein LB, Callahan III A, Sillesen H, Hennerici MG, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405-9.
195. Sang ZC, Wang F, Zhou Q, LI YH, LI Yg, Wang HP, et al. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chin Med J. 2009;122(14):1615-20.
196. Serruys PW, de Feyter P, Macaya C, Kokott N, Peul J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Lescol Intervention Prevention Study (LIPS). JAMA. 2002;287(24):3215-22.
197. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robels de Medina RM, Tijssen JG, et al. Effects of fluvastatin on ischemia following acute myocardial infarction: a randomized trial. Eur Heart J. 2002;23:1931-7.
198. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Trial (CARE). N Engl J Med.1996 Oct; 335(14):1001-9.
199. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57.
200. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-30.
201. Lloyd SM, Stott DJ, de Craen AJ, et al. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One. 2013 Sep;8(9):e72642.
202. Thompson P, Meredith I, Anerena J, Campbell TJ, Sloman JG, Harris PJ, et al. Effect of pravastatin compared to placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J. 2004 Jul;148(1):e2.
203. Asselbergs F., Diercks G., Hillege H., et al. Effects of fosinopril and pravastatin on cardiovascular events in patients with microalbuminuria. Circulation. 2004; Nov 2; 2809-16.
204. Sato H, Kinjo K, Ito H, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. Circ J 2008;72:17-22.
205. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
206. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (SEAS). N Engl J Med 2008;359:1343-56.
207. No authors listed. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383-9.
208. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis. 2007 Mar;49(3):373-82.
209. No authors listed. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 356 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
210. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-16.
211. de Lemos JA, Blazing MA, Wiviott SD, Lewis Ef, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 Sep 15;292(11):1307-16.
212. No authors listed. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007 Apr;45(4):645-54.
213. Pauriah M, Elder DH, Ogston S, et al. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart. 2014 Jun;100(11):867-872.

214. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006 May 3;295(17):2046-56.
215. Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol. 2007 Sep 15;100(6):919-23.
216. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008 Jan 1;51(1):37-45.
217. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006 Sep 25;166(17):1814-21.
218. Cannon C, Braunwald E, McCabe C, Rader DJ, Rouleau JL, Belder R, et al. Intensive vs moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr;350;15;1495-504.
219. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10.
220. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006 Oct;27(19):2323-9.
221. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 6;47(11):2326-31.
222. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct;27(19):2310-6.
223. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, et al. Effects of intensive vs moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007 Feb 13;115(6):700-7.
224. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin vs atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012 May 1;109(9):1239-46.
225. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437-45.
226. Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJP, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 vs ≥65 years with coronary heart disease (from the Incremental Decrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol. 2009;103:577-82.
227. Strandberg TE, Holme I, Faergeman O, Kastelein JJP, Lindahl C, Larsen ML, et al. Comparative effect of atorvastatin (80 mg) vs simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol. 2009;103:1381-5.
228. Stoekenbroek RM, Boekholdt SM, Fayyad R, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62.
229. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ J. 2007 Sep;71(9):1348-53.
230. Choi JY, Seo WK, Kang SH, et al. Statins improve survival in patients with cardioembolic stroke. Stroke. 2014 Jun;45(6):1849-1852.
231. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007 Aug;93(8):914-21.
232. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive vs moderate statin therapy. J Am Coll Cardiol. 2006 Aug 1;48(3):438-45.
233. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 1;100(7):1047-51.

234. Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Human Hypertens. 2009;23:196-210.
235. Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008 Jan;83(1):35-45.
236. Hobbs R, Gensini G, Mancini J, Manolis AJ, Bauer B, Genest J, et al. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme (abstract). Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):472-80.
237. Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2009;11:22-30.
238. Grimm R, Malik M, Yunis C, Surtradhar S, Kursun A; TOGETHER Investigators. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag. 2010;6:261-71.
239. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared to ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004 Nov;26(11):1758-73.
240. Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, et al. A multi-centre, randomized, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract. 2007 Sep;61(9):1469-80.
241. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older vs younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun;28(6):849-59.
242. Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007 Feb;153(2):335.e1-8.
243. Farnier M, Perevozskaya I, Taggart WV, et al. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008;49:2641-7.
244. Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin vs atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (VYMET). Am J Cardiol 2009;103:1694-702.
245. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) vs atorvastatin in patients with hypercholesterolemia: the Vytorin Vs Atorvastatin (VYVA) study. Am Heart J. 2005 Mar;149(3):464-73.
246. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared to atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15;93(12):1487-94.
247. Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, et al. Safety and efficacy of ezetimibe/simvastatin combination vs atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD Study). Am J Cardiol. 2010;106:1255-63.
248. Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, et al. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin vs atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by national cholesterol education program risk category. Metab Syndr Relat Disord. 2009;7(6):601-10.
249. Bardini G, Giorda CB, Pontiroli AE, Grazie CL, Rotella CM. Ezetimibe+simvastatin vs doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010;9(20):1-8.
250. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV. The effect of simvastatin alone vs simvastatin plus ezetimibe on the concentration of small density low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011;27(3):685-92.

251. Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids Health Dis. 2010;9(80):1-8.
252. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – the IN-CROSS study. Int J Clin Pract. 2009;63:534-5.
253. Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, et al. Ezetimibe/simvastatin 10/20 mg vs rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis. 2010 Nov 4;9:127.
254. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet vs rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22(10):2041-53.
255. Roeters van Lennep H, Liem A, Dunselman P, et al. The efficacy of statin monotherapy up-titration vs switching to ezetimibe/simvastatin (EASEGO). Curr Med Res Opin 2008;24:685-694.
256. Reckless J, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the statin dose in patients admitted to the hospital for a recent coronary event (INFORCE). Int J Clin Pract 2008;62:539-554.
257. Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010 Feb;105(4);487-94.
258. Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab. 2010;12:983-93.
259. Sharma M, Sharma DR, Singh V, Panwar RB, Hira HS, Mohan B, et al. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in Asian Indian dyslipidemic patients: a multicentric study. Vasc Health Risk Manag. 2006;2(1):87-93.
260. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;8(2):69-81.
261. Ballantyne CM, Davidson MH, McKenny J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101:1428-36.
262. Ballantyne CM, Davidson MH, McKenney JM, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high dose) study. J Clin Lipidology 2008;2:79-90.
263. Charland SL, Malone DC. Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Curr Med Res Opin. 2010 Feb;26(2):365-75.
264. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 2;67(4):353-61.
265. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg vs 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006 Jan 1;97(1):61-7.
266. Everett BM, Mora S, Glynn RJ, MacFadyen J, and Ridker PM. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol. 2014 Dec 1;114(11):1682-1689.
267. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol. 2003 Mar 6;91(5A):11C-7C.
268. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006 Jan;28(1):26-35.
269. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 Dec 19;114(25):2788-97.
270. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf. 2007 Feb;16(2):132-43.
271. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C.

272. Dale KM, White CM, Henyan NN, Kluger J, Coleman CI. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med. 2007 Aug;120(8):706-12.
273. Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, and Tu JV. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes. 2013 May;6(3):315-322.
274. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007 Feb;29(2):253-60.
275. Strony J, Hoffman R, Hanson M, et al. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin Ther 2008;30:2280-97.
276. Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared to once daily in patients with hypercholesterolemia. Ann Pharmacother. 2006 Nov;40(11):1917-23.
277. LaFleur J, Thompson CJ, Joish VN, Charland SL, Oderda GM, Brixner DI. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared to statins alone or in combination with extended-release niacin. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1274-9.
278. Balu S, Simko RJ, Quimbo RM, et al. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009;25:2765-75.
279. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673-81.
280. Cheetham C, Chan J, Benson V, et. al. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol lowering drug. Am J Manag Care.2005;11:546-52.
281. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract. 2007 Jan;61(1):15-23.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
AHFS Class 240624
August 9, 2017

I. Overview

Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease produced predominantly in the liver that leads to the degradation of hepatocyte low density lipoprotein (LDL) receptors and increased low density lipoprotein-cholesterol (LDL-C) levels. PCSK9 inhibitors work to inhibit the action of this enzyme leading to a decrease in LDL-C levels by as much as 60% in patients on statin therapy. This reduction in LDL-C may produce clinical benefits such as reductions in myocardial infarction or cardiac death. There are currently two Food and Drug Administration (FDA)-approved PCSK9 inhibitors commercially available. These agents include Praluent® (alirocumab) and Repatha® (evolucumab).[1]

Both Praluent® (alirocumab) and Repatha® (evolucumab) are FDA-approved as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C.[2,3] Repatha® (evolucumab) is also indicated as an adjunct to diet and other lipid lowering therapies (statins, ezetimibe, LDL-C apheresis) in patients with homozygous familial hypercholesterolemia (HoFH).[3]

In July 2016, the American College of Cardiology released the Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. In general, the use of PCSK9 inhibitors is only recommended for consideration after addressing statin intolerance, intensifying lifestyle modifications, increasing to high-intensity statin if not already taking, evaluating for statin intolerance if unable to tolerate moderate-intensity statin, controlling other risk factors, and adding ezetimibe or a bile acid sequestrant to therapy. In patients with ASCVD who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance and achieve a less-than-anticipated response, it is reasonable to consider the net benefit of a PCSK9 inhibitor to achieve further LDL-C reduction. Patient preference should be considered in the discussion to initiate PCSK9 inhibitor therapy, including considerations of the patient's perception of net benefit, convenience/burden of additional therapy, cost, quality of life, and the potential to jeopardize adherence to other evidence-based therapies.[5] The 2017 American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis recommend PCSK9 inhibitors be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH and individuals with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals.[6]

Although these agents have demonstrated a benefit in reducing various measures of cholesterol, data on the extent of benefit on cardiovascular morbidity and mortality is limited, or has not been determined. In addition, these agents are only approved as adjunctive therapy to maximally-dosed statin therapy and other lipid lowering therapies, not in statin intolerant patients.[2,3]

The PCSK9 inhibitor products that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. There are no generic products available. This is the first review of this class.

Table 1. PCSK9 Inhibitor Products Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Alirocumab	injection	Praluent®	none
Evolocumab	injection	Repatha®	none

PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the treatment of use of PCSK9 inhibitors are summarized in Table 2.

Table 2. Treatment Guidelines Using PCSK9 Inhibitors

Clinical Guideline	Recommendation(s)
American College of Cardiology/American Heart Association Task Force on Practice Guidelines: **Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)**[4]	Statin treatment • The panel makes no recommendations for or against specific LDL-C or non-HDL-C targets for the primary or secondary prevention of ASCVD. • High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. • In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated. • In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it. • Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy (ten-year ASCVD risk estimation is not required): use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity. • For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction. • For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions and consider patient preferences. • Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus. • High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a ≥7.5% estimated ten-year ASCVD risk unless contraindicated. • In adults with diabetes mellitus, who are <40 or >75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy. • Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated ten-year ASCVD risk ≥7.5% should be treated with moderate- to high-intensity statin therapy. • It is reasonable to offer treatment with a moderate intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated ten-year ASCVD risk of 5.0 to <7.5%. • Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 to 189 mg/dL without clinical ASCVD or diabetes it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions and patient preferences for treatment. • In adults with LDL-C <190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk based

Clinical Guideline	Recommendation(s)

	treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of patient preference.
	
	<u>Statin safety</u>
	• To maximize the safety of statins, selection of the appropriate statin and dose in men and non-pregnant/non-nursing women should be based on patient characteristics, level of ASCVD risk, and potential for adverse effects.
	• Moderate-intensity statin therapy should be used in individuals in whom high-intensity statin therapy would otherwise be recommended when characteristics predisposing them to statin associated adverse effects are present.
	• Characteristics predisposing individuals to statin adverse effects include, but are not limited to:
	  ○ Multiple or serious comorbidities, including impaired renal or hepatic function.
	  ○ History of previous statin intolerance or muscle disorders.
	  ○ Unexplained alanine transaminase elevations >3 times upper limit of normal.
	  ○ Patient characteristics or concomitant use of drugs affecting statin metabolism.
	  ○ >75 years of age.
	• Additional characteristics that may modify the decision to use higher statin intensities may include, but are not limited to:
	  ○ History of hemorrhagic stroke.
	  ○ Asian ancestry.
	• Creatinine kinase should not be routinely measured in individuals receiving statin therapy.
	• Baseline measurement of creatinine kinase is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy.
	• During statin therapy, it is reasonable to measure creatinine kinase in individuals with muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or generalized fatigue.
	• Baseline measurement of hepatic transaminase levels should be performed before initiating statin therapy.
	• During statin therapy, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine or yellowing of the skin or sclera).
	• Decreasing the statin dose may be considered when two consecutive values of LDL-C levels are <40 mg/dL.
	• It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.
	• Individuals receiving statin therapy should be evaluated for new-onset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during statin therapy should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce their risk of ASCVD events.
	• For individuals taking any dose of statins, it is reasonable to use caution in individuals >75 years of age, as well as in individuals that are taking concomitant medications that alter drug metabolism, taking multiple drugs, or taking drugs for conditions that require complex medication regimens (e.g.,

Clinical Guideline	Recommendation(s)

	those who have undergone solid organ transplantation or are receiving treatment for HIV) . A review of the manufacturer's prescribing information may be useful before initiating any cholesterol-lowering drug).
	• It is reasonable to evaluate and treat muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated patients according to the following management algorithm:
	  ○ To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline before initiating statin therapy.
	  ○ If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly discontinue the statin and address the possibility of rhabdomyolysis by evaluating creatinine kinase, creatinine, and a urinalysis for myoglobinuria.
	• If mild to moderate muscle symptoms develop during statin therapy:
	  ○ Discontinue the statin until the symptoms can be evaluated.
	  ○ Evaluate the patient for other conditions that might increase the risk for muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases).
	  ○ If muscle symptoms resolve, and if no contraindication exists, give the patient the original or a lower dose of the same statin to establish a causal relationship between the muscle symptoms and statin therapy.
	  ○ If a causal relationship exists, discontinue the original statin. Once muscle symptoms resolve, use a low dose of a different statin.
	  ○ Once a low dose of a statin is tolerated, gradually increase the dose as tolerated.
	  ○ If, after two months without statin treatment, muscle symptoms or elevated creatinine kinase levels do not resolve completely, consider other causes of muscle symptoms listed above.
	  ○ If persistent muscle symptoms are determined to arise from a condition unrelated to statin therapy, or if the predisposing condition has been treated, resume statin therapy at the original dose.
	• For individuals presenting with a confusional state or memory impairment while on statin therapy, it may be reasonable to evaluate the patient for non-statin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy.
	
	<u>Monitoring and optimizing statin therapy</u>
	• Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. This should also include a fasting lipid panel performed within four to 12 weeks after initiation or dose adjustment, and every three to 12 months thereafter. Other safety measurements should be measured as clinically indicated.
	• The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated.
	• Individuals who have a less-than anticipated therapeutic response or are intolerant of the recommended intensity of statin therapy, the following should be performed:
	  ○ Reinforce medication adherence.
	  ○ Reinforce adherence to intensive lifestyle changes.
	  ○ Exclude secondary causes of hyperlipidemia.
	• It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of statin therapy. Focus is on the intensity of the statin therapy. As an aid to monitoring:
	  ○ High-intensity statin therapy generally results in an average LDL-C

Clinical Guideline	Recommendation(s)
	reduction of ≥50% from the untreated baseline; ○ Moderate-intensity statin therapy generally results in an average LDL-C reduction of 30 to <50% from the untreated baseline; ○ LDL-C levels and percent reduction are to be used only to assess response to therapy and adherence. They are not to be used as performance standards. • Individuals at higher ASCVD risk receiving the maximum tolerated intensity of statin therapy who continue to have a less than-anticipated therapeutic response, addition of a non-statin cholesterol-lowering drug(s) may be considered if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. • Higher-risk individuals include: ○ Individuals with clinical ASCVD <75 years of age. ○ Individuals with baseline LDL-C ≥190 mg/dL. ○ Individuals 40 to 75 years of age with diabetes mellitus. ○ Preference should be given to non-statin cholesterol-lowering drugs shown to reduce ASCVD events in controlled trials. • In individuals who are candidates for statin treatment but are completely statin intolerant, it is reasonable to use non-statin cholesterol lowering drugs that have been shown to reduce ASCVD events in controlled trials if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. <u>Non statin safety</u> • Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric acid should be obtained before initiating niacin, and again during up-titration to a maintenance dose and every six months thereafter. • Niacin should not be used if: ○ Hepatic transaminase elevations are higher than two to three times upper limit of normal. ○ Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout or unexplained abdominal pain or gastrointestinal symptoms occur. ○ New-onset atrial fibrillation or weight loss occurs. • In individuals with adverse effects from niacin, the potential for ASCVD benefits and the potential for adverse effects should be reconsidered before reinitiating niacin therapy. • To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to: ○ Start niacin at a low dose and titrate to a higher dose over a period of weeks as tolerated. ○ Take niacin with food or premedicating with aspirin 325 mg 30 minutes before niacin dosing to alleviate flushing symptoms. ○ If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over four to eight weeks, with the dose of extended release niacin increasing not more than weekly. ○ If immediate-release niacin is chosen, start at a dose of 100 mg three times daily and up-titrate to 3 g/day, divided into two or three doses. • Bile acid sequestrants should not be used in individuals with baseline fasting triglyceride (TG) levels ≥300 mg/dL or type III hyperlipoproteinemia, because severe TG elevations might occur. • A fasting lipid panel should be obtained before bile acid sequestrants are initiated, three months after initiation, and every six to 12 months thereafter. • It is reasonable to use bile acid sequestrants with caution if baseline triglyceride levels are 250 to 299 mg/dL, and evaluate a fasting lipid panel in four to six weeks after initiation. Discontinue the bile acid sequestrants if triglycerides exceed 400 mg/dL.

Clinical Guideline	Recommendation(s)
	• It is reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase levels as clinically indicated, and discontinue ezetimibe if persistent alanine transaminase elevations >3 times upper limit of normal occur. • Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis. • Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, are judged to outweigh the potential risk for adverse effect. • Renal status should be evaluated before fenofibrate initiation, within three months after initiation, and every six months thereafter. Assess renal safety with both a serum creatinine level and an estimated glomerular filtration rate based on creatinine. • Fenofibrate should not be used if moderate or severe renal impairment, defined as estimated glomerular filtration rate <30 mL/min per 1.73 m^2, is present. • If estimated glomerular filtration rate is between 30 and 59 mL/min per 1.73 m^2, the dose of fenofibrate should not exceed 54 mg/day. • If, during follow-up, the estimated glomerular filtration rate decreases persistently to ≤30 mL/min per 1.73 m^2, fenofibrate should be discontinued. • If eicosapentaenoic acid and/or docosahexanoic acid are used for the management of severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal disturbances, skin changes, and bleeding.

American College of Cardiology: **2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016)**[5]	<u>Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention</u>
	• These patients should be treated first with maximally tolerated statin intensity. If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <100 mg/dL), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response (<50% reduction in LDL-C and may consider LDL-C ≥100 mg/dL):
	  ○ Assess statin adherence.
	  ○ If an adherent patient has not been tried on a high-intensity statin, the dose should be increased to a high-intensity dose at this time.
	  ○ Intensify lifestyle modifications.
	  ○ Consider adding ezetimibe 10 mg daily as the first non-statin agent.
	  ○ A bile acid sequestrant (BAS) may be considered as a second-line agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL, but there is no evidence for benefit of BAS in addition to statins in this population.
	• If ASCVD patients without comorbidities, who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response with <50% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL):
	  ○ It is reasonable to consider the net benefit of alirocumab or evolocumab (in addition to or in place of ezetimibe) as a second step to achieve further LDL-C reduction.
	  ○ If a PCSK9 inhibitor is prescribed, clinicians should continue maximally tolerated statin and monitoring for adherence to medications and lifestyle, side effects, and ongoing LDL-C response to therapy.
	
	<u>Clinical ASCVD with comorbidities, on statin for secondary prevention</u>
	• These patients should be treated first with maximally tolerated statin intensity.

Clinical Guideline	Recommendation(s)

	• If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <70 mg/dL or non–HDL-C <100 mg/dL for patients with diabetes), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response:
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	<u>Clinical ASCVD and baseline LDL-C ≥190 mg/dL not due to secondary causes, on statin for secondary prevention</u>
	• Patients with LDL-C ≥190 mg/dL are more likely to have heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia.
	• In patients who have a less-than-anticipated response on maximally tolerated statin therapy with <50% reduction in LDL-C (and may consider LDL-C ≥70 mg/dL):
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe (or BAS second line) first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	<u>Adults aged 40 to 75 years without ASCVD, but with diabetes</u>
	• In patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C despite adherence to lifestyle recommendations and moderate-intensity statin therapy, the recommended threshold for consideration of the net benefit of increasing to high-intensity statin therapy is failure to achieve 30 to <50% reduction in LDL-C (and may consider on -treatment LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL).
	• If a patient with diabetes and 10-year ASCVD risk <7.5% without high-risk features has a less-than-anticipated response, with <30% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL), additional clinical approaches may be warranted.
	• Ezetimibe is the preferred initial non-statin therapy due to tolerability, convenience, and single-tablet daily dose.
	• BAS may have a modest hypoglycemic effect that may be of benefit in some diabetic patients if fasting triglycerides are <300 mg/dL. BAS may also be considered if patients have an inadequate response to ezetimibe or if patients are ezetimibe intolerant.
	• In the absence of ASCVD or baseline LDL-C ≥190 mg/dL not due to secondary causes, the PCSK9 inhibitors do not have an established role for primary prevention of ASCVD in patients with diabetes.

American Association Of Clinical Endocrinologists And American College Of Endocrinology: **Guidelines For**	<u>Treatment recommendations in individuals with dyslipidemia and ASCVD risk:</u>
	• Treatment goals for dyslipidemia should be personalized according to risk.
	  ○ For individuals at low risk, an LDL-C goal <130 mg/dL is recommended.
	  ○ For individuals at moderate risk (i.e., with 2 or fewer risk factors and a calculated 10-year risk of less than 10%), an LDL-C goal <100 mg/dL is recommended.

Clinical Guideline	Recommendation(s)
Management Of Dyslipidemia And Prevention Of Cardiovascular Disease (2017)[6]	○ For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or stage 3 or 4 CKD with no other risk factors, or individuals with 2 or more risk factors and a 10-year risk of 10% to 20%), an LDL-C goal <100 mg/dL is recommended. ○ For individuals at very high risk (i.e., with established or recent hospitalization for ACS, coronary, carotid or peripheral vascular disease, diabetes or stage 3 or 4 chronic kidney disease (CKD) with 1or more risk factors, a calculated 10-year risk greater than 20%, or HeFH), an LDL-C goal <70 mg/dL is recommended. ○ For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dL, or established clinical ASCVD in individuals with diabetes, stage 3 or 4 CKD, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal <55 mg/dL is recommended. • A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended primarily using lifestyle changes and patient education with pharmacotherapy as needed. ○ In individuals at risk for ASCVD, aggressive lipid modifying therapy is recommended to achieve appropriate LDL-C goals. <u>Lipid Lowering Therapy Recommendations</u> • Statins ○ Statin therapy is recommended as the primary pharmacologic agent to achieve target LDL-C goals on the basis of morbidity and mortality outcome trials. ○ Mild elevations in blood glucose levels and/or an increased risk of new-onset type 2 diabetes mellitus associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction. ○ In individuals within high-risk and very high-risk categories, further lowering of LDL-C beyond established targets with statins results in additional ASCVD event reduction and may be considered. ○ Very high-risk individuals with established coronary, carotid, and peripheral vascular disease, or diabetes who also have at least one additional risk factor should be treated with statins to target a reduced LDL-C treatment goal of <70 mg/dL. ○ Extreme-risk individuals should be treated with statins to target an even lower LDL-C treatment goal of <55 mg/dL. • Fibrates ○ Fibrates should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). ○ Fibrates may improve ASCVD outcomes in primary and secondary prevention when TG concentrations are ≥200 mg/dL and HDL-C concentrations are <40 mg/dL. • Fish Oil ○ Prescription omega-3 oil, 2 to 4 g daily, should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). Dietary supplements are not FDA-approved for treatment of hypertriglyceridemia and generally are not recommended for this purpose. • Niacin ○ Niacin therapy is recommended principally as an adjunct for reducing TG. ○ Niacin therapy should not be used in individuals aggressively treated with statin due to absence of additional benefits with well-controlled LDL-C. • Bile Acid Sequestrants ○ Bile acid sequestrants may be considered for reducing LDL-C and apo B

Clinical Guideline	Recommendation(s)

	and modestly increasing HDL-C, but they may increase TG.
	• Cholesterol Absorption Inhibitors
	  ○ Ezetimibe may be considered as monotherapy in reducing LDL-C and apo B, especially in statin-intolerant individuals.
	  ○ Ezetimibe can be used in combination with statins to further reduce both LDL-C and ASCVD risk.
	• PCSK9 Inhibitors
	  ○ PCSK9 inhibitors should be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH.
	  ○ PCSK9 inhibitors should be considered in individuals with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals.
	• Combination therapy of lipid-lowering agents should be considered when the LDL-C/non-HDL-C level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal.

American Heart Association: **The Agenda for Familial Hypercholesterolemia A Scientific Statement From the American Heart Association (2015)**[7]	Treatment of Heterozygous Familial Hypercholesterolemia • For adult heterozygotes, the initial approach to treatment with an initial goal of reducing LDL-C by at least 50%, usually beginning with a statin. • This can be followed by achieving an LDL-C of <100 mg/dL (absence of coronary artery disease (CAD) or other major risk factors) or 70 mg/dL (presence of CAD or other major risk factors). • Ezetimibe or colesevelam is preferred as an additional LDL-C–lowering agent over niacin. • When the statin-induced side effects are disabling but a statin response is present, treatment with a lower dose of a statin given daily or on alternate days may be sufficient, together with other lipid-lowering medications, to reduce LDL-C to reasonably acceptable levels and to limit the disabling side effects. • A combination of ezetimibe, niacin, and bile acid sequestrants may also reduce LDL-C satisfactorily in patients with moderate elevations of LDL-C. • PCSK9 inhibitors have been shown to reduce LDL-C by an additional 50% to 60% on top of high-dose statin with or without ezetimibe in HeFH. • Alternatively, LDL apheresis or new forms of therapy, including microsomal transfer protein inhibitors and apoB antisense oligonucleotides. Treatment of Homozygous Familial Hypercholesterolemia • Lipid-lowering therapy, usually statins, should be instituted at diagnosis and as early as possible. • Statins reduce LDL-C levels modestly in HoFH, even in those who are receptor negative. • The addition of the cholesterol absorption inhibitor ezetimibe to statin therapy has been shown to reduce LDL-C by an additional 10% to 15%. • Other cholesterol-lowering medications such as bile acid sequestrants, niacin, fibrates, and probucol have also been used, but their LDL-C–reducing effects in HoFH are modest. • Mipomersen can reduce LDL-C by an additional 25% in HoFH patients when given subcutaneously in combination with maximum tolerated doses of lipid-lowering therapy, but even the addition of mipomersen does not achieve the recommended LDL-C target in the vast majority of HoFH patients. • Lomitapide can also reduce LDL-C levels by up to by 50% in HoFH patients; however, gastrointestinal side effects and elevation in liver enzymes are common. • PCSK9 inhibitor therapy has recently been shown to be partially effective in HoFH, at least in those subjects who are receptor defective. • Lipoprotein apheresis appears to improve cardiovascular outcomes and should

Clinical Guideline	Recommendation(s)
	be considered by five years of age or earlier in exceptional circumstances. • Liver transplantation has been described as a treatment for both children and young adults with HoFH in the form of case series.
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004)**[8]	• TLC remains an essential modality in clinical management. • When LDL-C lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard HMG-CoA reductase inhibitors (statins) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrants, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high TG and low HDL-C, especially in combination with statins. • In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of CHD risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u> • Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously). • Bile acid sequestrants (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrants and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u> • TLC indicated for all persons. • All LDL-C lowering drugs are effective. • If necessary to reach LDL-C goals, consider combined drug therapy.

III. Indications

The Food and Drug Administration (FDA)-approved indications for PCSK9 inhibitors are noted in Table 3.

Table 3. FDA-Approved Indications for PCSK9 Inhibitors [2,3,9]

Indication	Alirocumab	Evolocumab
Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol	✔	✔
Adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia who require additional lowering of LDL-cholesterol		✔

IV. Pharmacokinetics

The pharmacokinetic parameters of PCSK9 inhibitors are listed in Table 4.

Table 4. Pharmacokinetic Parameters of PCSK9 Inhibitors[9]

Generic Name	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (days)
Alirocumab	85	Not reported	Protein degradation	Proteolytic pathway	17 to 20
Evolocumab	72	Not reported	Immunoglobulin clearance pathways	Systemic clearance	11 to 17

V. Drug Interactions

There are no known clinically significant drug interactions with PCSK9 inhibitors. However, the median apparent half-life of alirocumab is reduced to 12 days when administered with a statin, and an approximately 20% decrease in the C_{max} and AUC of evolocumab was observed in patients co-administered with a high-intensity statin regimen. These differences are not clinically meaningful and do not impact dosing recommendations.[2,3,9]

VI. Adverse Drug Events

The most common adverse drug events reported with PCSK9 Inhibitors are listed in Table 5.

Table 5. Adverse Drug Events (%) Reported with PCSK9 Inhibitors[2,3]

Adverse Events	Alirocumab	Evolocumab
Nasopharyngitis	11.3	10.5
Upper respiratory infection	-	9.3
Injection site reactions	7.2	5.7
Back pain	-	6.2
Influenza	5.7	7.5
Urinary tract infection	4.8	4.5
Diarrhea	4.7	3.0
Bronchitis	4.3	-
Myalgia	4.2	4.0
Headache	-	4.0
Dizziness	-	3.7
Muscle spasms	3.1	-
Sinusitis	3.0	4.2

Adverse Events	Alirocumab	Evolocumab
Cough	2.5	4.5
Contusion	2.1	-
Musculoskeletal pain	2.1	3.3
Hypertension	-	3.2
Diarrhea	-	3.0
Gastroenteritis	-	3.0

- Event not reported.

VII. Dosing and Administration

The usual dosing regimens for PCSK9 Inhibitors are listed in Table 6.

Table 6. Usual Dosing Regimens for PCSK9 Inhibitors[2,3]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Alirocumab	HeFH or clinical atherosclerotic cardiovascular disease: Injection: initial, 75 mg SQ every two weeks; maintenance and maximum, 150 mg SQ every two weeks	Safety and efficacy in children have not been established.	Single-dose prefilled pen or syringe: 75 mg 150 mg
Evolocumab	HeFH or clinical atherosclerotic cardiovascular disease: Injection: initial, maintenance, and maximum: 140 mg SQ every 2 weeks, or 420 mg SQ once monthly in abdomen, thigh or upper arm HoFH: Injection: initial, maintenance, and maximum: 420 mg SQ once monthly	Safety and efficacy in children have not been established.	Single-dose prefilled auto-injector, syringe, or on-body infusor: 140 mg 420 mg

HeFH=heterozygous familial hypercholesterolemia, HoFH=homozygous familial hypercholesterolemia, SQ=subcutaneous

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of PCSK9 Inhibitors are summarized in Table 7.

Table 7. Comparative Clinical Trials with PCSK9 Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Kereiakes et al.[11,12] (2015) ODYSSEY COMBO I Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 12 if LDL ≥70 mg/dL) vs placebo Patients continued to take statin therapy with or without other lipid lowering therapy.	DB, MC, PG, RCT Patients ≥18 years of age with established heart disease or CHD equivalent, with LDL-C ≥70 mg/dL and established heart disease or LDL-C ≥100 mg/dL and no established heart disease but at a high risk for CVE and elevated LDL-C despite maximal doses of statins at maximum tolerated dosage for at least four weeks before screening	N=316 52 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Percentage of patients achieving LDL-C <70 mg/dL, other lipid parameters and safety evaluations	Primary: Alirocumab was associated with a significantly greater reduction in LDL-C from baseline to week 24 compared with placebo (48.2% vs 2.3%; P<0.0001). At week 12, 83.2% of evaluable alirocumab-treated patients remained on the 75 mg dose. In patients with a dose increase, LDL-C was reduced by an additional mean 22.8% at week 24 compared with week 12. These patients achieved similar reductions in LDL-C as those not requiring a dose increase (N=32). Secondary: LDL-C <70 mg/dL was achieved by 75% of the alirocumab group compared to 9% of the placebo group at week 24. Significant reductions from baseline to week 24 after therapy with alirocumab (P<0.0001 vs placebo) were observed in non–HDL-C (−39.1% vs −1.6%), apoB (−36.7% vs −0.9%), TC (−27.9% vs −2.9%), and lipoprotein(a) (−20.5% vs −5.9%). No significant change was observed in TG levels; whereas, a significant increase in HDL-C was observed in the alirocumab group (3.5% vs −3.8%; P<0.0001). The frequency of treatment-emergent adverse events and study medication discontinuations were generally comparable between treatment groups.
Cannon et al.[11,13] (2015) ODYSSEY COMBO II Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 12 if LDL ≥1.8 mmol/L)	AC, DB, DD, MC, PG, RCT Patients ≥18 years of age with established heart disease or CHD equivalent, LDL-C ≥70 mg/dL and	N=720 104 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Absolute	Primary: Alirocumab was associated with a significantly greater reduction in mean LDL-C from baseline at week 24 compared to ezetimibe (50.6 ± 1.4% vs 20.7 ± 1.9%; 29.8% ± 2.3% difference; P<0.0001). Secondary: Seventy seven percent of alirocumab and 45.6% of ezetimibe patients achieved LDL-C <1.8 mmol/L (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs ezetimibe 10 mg QD Patients continued to take statin therapy. Other lipid lowering therapy was not permitted. All patients were instructed to follow a stable Therapeutic Lifestyle Changes diet, as outlined by the ATP III or an equivalent diet for the duration of the study.	established heart disease or LDL-C ≥ 100 mg/dL and no established heart disease but at a high risk for CVE and elevated LDL-C despite maximal doses of statins at maximum tolerated dosage for at least four weeks before screening		cholesterol change, percent of patients achieving goal of LDL-C <70 mg/dL, other lipoprotein evaluations and safety evaluations	As compared with the ezetimibe group, the alirocumab group had greater reductions from baseline to week 24 in levels of non–HDL-C, apoB, TC, lipoprotein(a) and had a modest increase in levels of HDL-C (P<0.0001 for all comparisons). TG were reduced from baseline to week 24 by 13.0 ± 1.5% in the alirocumab group and by 12.8 ± 2.0% in the ezetimibe group, but the difference between treatment arms was not statistically significant. Alirocumab was generally well tolerated, with no evidence of an excess of treatment-emergent adverse events. Adjudicated cardiovascular events were infrequent, occurring in 4.8% (n=23) of the alirocumab group vs 3.7% (n=9) in the ezetimibe group. Treatment-emergent local injection site reactions occurred in 2.5% of patients in the alirocumab arm vs 0.8% for ezetimibe arm.
Robinson et al.[14] (2015) ODYSSEY LONG TERM Alirocumab 150 mg injected SC every two weeks vs placebo Patients continued to take statin therapy with or without other lipid lowering agents. All patients were instructed to follow a stable Therapeutic Lifestyle Changes diet, as outlined by the ATP III or an equivalent diet for the duration of the study.	DB, MC, PC, RCT Patients ≥18 years of age at a high risk for CVE (with HeFH or with established heart disease or CHD equivalent) with LDL ≥70 mg/dL receiving statins at maximum tolerated dosage for at least four weeks before screening	N=2,341 78 weeks	Primary: Percent change from baseline in LDL-C at week 24 Secondary: Absolute cholesterol change, percent of patients achieving goal of LDL-C <70 mg/dL, other lipoprotein evaluations, major cardiovascular events (death from CHD, nonfatal MI, fatal or nonfatal	Primary: There was a significantly greater decrease in LDL-C with alirocumab from baseline at week 24 compared to placebo (−61.0% vs 0.08%; −62% placebo-corrected difference; P<0.0001). This effect remained consistent over 78 weeks. Secondary: The mean absolute LDL-C level at week 24 was 48 mg/dL in the alirocumab group and 119 mg/dL in the placebo group, corresponding to a mean absolute change from baseline of −74 mg/dL and −4 mg/dL, respectively (P<0.0001). The goal of an LDL-C level of <70 mg/dL at week 24 was met by 79.3% of the patients in the alirocumab group compared to 8.0% of the patients in the placebo group (P<0.001). As compared with the placebo group, the alirocumab group had greater reductions from baseline to week 24 in levels of non–HDL-C, apoB, TC, lipoprotein(a) and triglycerides and had a modest increase in levels of HDL-C and apolipoprotein A1 (P<0.001 for all comparisons). In a post hoc analysis, the rate of major adverse cardiovascular events

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			ischemic stroke, or unstable angina requiring hospitalization), adherence rates and safety evaluations	was lower with alirocumab than with placebo (1.7% vs 3.3%; HR, 0.52; 95% CI, 0.31 to 0.90; P=0.02). Adherence was 98.0% and 97.6% in the alirocumab group and the placebo group, respectively. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs 4.2%), myalgia (5.4% vs 2.9%), neurocognitive events (1.2% vs 0.5%), and ophthalmologic events (2.9% vs 1.9%).
Roth et al.[15] (2015) ODYSSEY MONO Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 8 if LDL ≥70 mg/dL) vs ezetimibe 10 mg QD	DB, MC, PC, RCT Patients with primary hyper-cholesterolemia and moderate risk for CVE and LDL-C ≥100mg/ dL and ≤190mg/dL	N=103 34 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Safety evaluations	Primary: There was a significantly greater decrease in LDL-C with alirocumab from baseline at week 24 compared to ezetimibe (47.2% vs 15.6%; P<0.0001). Secondary: Safety parameters and adverse events were similar between the two groups. The most common class of adverse events was infections (39.2% with ezetimibe vs 42.3% with alirocumab), which included nasopharyngitis, influenza, and upper respiratory tract infection. Injection-site reactions occurred in less than 2% of patients in both groups. Muscle-related adverse events occurred in 3.9% of patients treated with ezetimibe and 3.8% of patients treated with alirocumab.
Bays et al.[16,17] (2015) ODYSSEY OPTIONS I Alirocumab 75 mg injected SC every two weeks (dose increased to 150 mg at week 12 if LDL ≥70 mg/dL) vs ezetimibe 10 mg QD	AC, DB, MC, PG, RCT Patients ≥18 years of age with LDL-C ≥70 mg/dL and established heart disease or LDL-C ≥ 100 mg/dL and risk factors for CVE	N=355 24 weeks	Primary: Percent change in calculated LDL-C from baseline to week 24 Secondary: Safety evaluations	Primary: Among atorvastatin 20 and 40 mg regimens respectively, there was a significantly greater decrease in LDL-C with alirocumab add-on from baseline at week 24 compared to add-on ezetimibe, double dose atorvastatin and switching to rosuvastatin (44.1% and 54.0% vs 20.5% and 22.6%, 5.0% and 4.8%, and 21.4%; P<0.001 vs all comparators). Most alirocumab-treated patients (86%) maintained their 75 mg every two weeks regimen. Secondary: Treatment-emergent adverse events occurred in 65.4% of alirocumab patients, compare to 64.4% ezetimibe and 63.8% double atorvastatin/switch to rosuvastatin (data pooled).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs atorvastatin (at double baseline dose) vs rosuvastatin 40 mg QD (atorvastatin 40 mg baseline dose cohort only) Prior to randomization, patients were stabilized on atorvastatin 20 mg to 40 mg QD.				
Farnier et al.[18] (2016) ODYSSEY OPTIONS II Add-on alirocumab 75 mg every 2 weeks (1-mL subcutaneous injection via pre-filled pen) vs add-on ezetimibe 10 mg/day vs double-dose rosuvastatin All patients received baseline rosuvastatin regimens (10 or 20 mg)	DB, DD, MC, RCT Patients with cardiovascular disease and LDL–C ≥70 mg/dL or cardiovascular disease risk factors and LDL–C ≥100 mg/dL	N=305 24 weeks	Primary: Percent change in calculated LDL–C from baseline to 24 weeks Secondary: Percent change from baseline in calculated LDL–C on-treatment at Week 24 in the modified ITT (mITT) population (on-treatment analysis), percent change in LDL–C from baseline to Week 12 (ITT and on-	Primary: In the baseline rosuvastatin 10 mg regimen ITT analysis, alirocumab add-on treatment significantly reduced LDL–C levels at Week 24 versus the other comparators (P<0.0001). From baseline, add-on alirocumab reduced LDL–C by 50.6%, add-on ezetimibe reduced LDL–C by 14.4%, and double-dose (20 mg) rosuvastatin reduced LDL–C by 16.3%. In the baseline rosuvastatin 20 mg regimen ITT analysis, mean reductions from baseline in LDL–C at Week 24 were greater in the alirocumab add-on group versus the other comparators. LDL–C reductions were 36.3% in the add-on alirocumab group, compared with 11.0% in the add-on ezetimibe group (P=0.0136) and with 15.9% in the double-dose (40 mg) rosuvastatin group (P=0.0453). However, the pre-specified threshold P-value for these 4-way comparisons was 0.0125; therefore, both primary comparisons failed to reach statistical significance in the baseline rosuvastatin 20 mg regimen. Secondary: As a result of both primary comparisons failing to reach statistical significance, all key secondary efficacy endpoints were not tested for statistical significance with respect to the two comparisons in the

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			treatment), the percent change in other lipid parameters, and the proportion of very-high and high CV risk patients reaching LDL–C <70 mg/ or <100 mg/ at Week 24, respectively, in both ITT and on-treatment analyses; Safety	baseline rosuvastatin 20 mg regimen. In the baseline rosuvastatin 10 mg regimen groups, the proportion of patients at very-high and high CV risk who reached a LDL–C level of <70 mg/dL or <100 mg/dL at Week 24, depending on risk status, was significantly greater in the alirocumab add-on group (84.9%) compared with the ezetimibe add-on group (57.2%; P=0.0007) and the rosuvastatin 20 mg group (45.0%; P<0.0001). The proportion of patients who reached the more stringent LDL–C level of <70 mg/dL at Week 24 was also significantly greater in the alirocumab add-on group (77.8%) compared with the ezetimibe add-on and rosuvastatin 20 mg groups (43.1%; P<0.0001 and 31.3%; P<0.0001), respectively. Treatment-emergent adverse events occurred in 56.3% of alirocumab patients versus 53.5% ezetimibe and 67.3% double-dose rosuvastatin (pooled data).
Moriarty et al.[19] (2015) ODYSSEY ALTERNATIVE Alirocumab 75 mg SC every 2 weeks vs ezetimibe 10 mg/ day vs atorvastatin 20 mg/ day	AC, DB, MC, PG, RCT Patients with primary hypercholesterolemia at moderate to high cardiovascular risk with statin intolerance (unable to tolerate ≥2 statins, including one at the lowest approved starting dose) due to muscle symptoms	N=314 24 weeks	Primary: Percent change in calculated LDL–C from baseline to 24 weeks Secondary: Change from baseline to 24 weeks using on-treatment (modified ITT) LDL-C values, and percent change from baseline to 12 and 24 weeks in LDL-C, apolipoprotein B, non–HDL-C,	Primary: For the primary ITT efficacy analysis, LS mean change in LDL-C concentrations from baseline to week 24 were −45.0% for alirocumab and −14.6% for ezetimibe, with a difference between groups of −30.4% (P<0.0001). Secondary: For the on-treatment analysis, the change from baseline was −52.2% for alirocumab and −17.1% for ezetimibe (LS mean difference of −35.1%:,P<0.0001). A substantial reduction in LDL-C concentration occurred over the first four weeks, which was greater in the alirocumab arm and persisted throughout the 24-week treatment period. At week 24, 52 (41.9%) patients on alirocumab and 5 (4.4%) of those on ezetimibe (P<0.0001; ITT analysis) reached an LDL-C goal of <70 mg/dL in very high cardiovascular risk patients or <100 mg/dL in moderate-to-high-risk patients. Corresponding results in the on-treatment population were 51.2% and 5.6% (P<0.0001). The greater effect of alirocumab relative to ezetimibe on LDL-C-lowering from baseline to week 24 was consistent across most of the prespecified subgroups in the ITT population. In addition, reductions in apolipoprotein B, non–HDL-C, total cholesterol and lipoprotein(a)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			total cholesterol, lipoprotein(a), HDL-C, apolipoprotein A1, and fasting triglyceride concentrations; adverse events	concentrations were greater for alirocumab vs ezetimibe (all P<0.0001). There were no statistically significant differences between the two groups in changes in triglyceride, HDL-C, and apolipoprotein A1 concentrations. Overall rates of treatment-emergent and serious AEs were generally similar between treatment arms, and there were no deaths in the study.
Blom et al.[20] (2014) DESCARTES Evolocumab 420 mg injected SC once monthly vs placebo Patients received 1) diet alone, 2) diet with atorvastatin 10 mg QD, 3) diet with atorvastatin 80 mg QD, 4) or diet with atorvastatin 80 mg QD plus 10 mg of ezetimibe QD An initial four week run-in patients with CHD or risk equivalent and LDL-C ≥100 mg/dL or without CHD or risk equivalent and LDL-C ≥130 mg/dL were randomized to background treatment noted above. Treatment	DB, MC, PC, RCT Patients 18 to 75 years of age with an LDL-C≥75 mg/dL and TG≤400 mg/dL	N=901 52 weeks	Primary: LDL-C at 52 weeks Secondary: LDL-C at week 12 and percentage of patients with LDL-C <70 mg/dL at week 52, TC, HDL-C, non-HDL-C, VLDL, apoB, apoB/ apolipoprotein A1, lipoprotein (a), TG and safety evaluations	Primary: At 52 weeks, the least-squares mean (±SE) reduction in LDL-C from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0 ± 2.1% at week 52. In the analysis according to background-therapy group, the least-squares mean reduction in LDL-C in the evolocumab group, taking into account the change in the placebo group, was 55.7 ± 4.2% in the diet-alone group, 61.6 ± 2.6% in the group receiving 10 mg of atorvastatin, 56.8 ± 5.3% in the group receiving 80 mg of atorvastatin and 48.5 ± 5.2% in the group receiving 80 mg of atorvastatin plus 10 mg of ezetimibe (P<0.001 for all comparisons). Secondary: The least-squares mean (±SE) reduction in LDL-C from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.5 ± 1.6% at week 12. The level of LDL-C was reduced below 70 mg/dL in 82.3% of patients in the evolocumab group, as compared with 6.4% of those in the placebo group. Evolocumab treatment, as compared with placebo, also resulted in significant least-squares mean percent reductions from baseline in levels of apoB, non-HDL-C, lipoprotein(a) and TG (P values not reported). Evolocumab treatment resulted in a least-squares mean increase of 5.4 ± 1.1% in the HDL-C (P<0.001) and of 3.0 ± 0.8% in the apolipoprotein A1 (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
was continued in four-week increments with increases in background intensity for patients not at CHD-based goal noted above. Patients were randomized to treatment once at or below CHD-based goal.				The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza and back pain.
Stroes et al.[21] (2014) GAUSS-2 Evolocumab 140 mg injected SC every two weeks vs evolocumab 420 mg injected SQ monthly vs ezetimibe 10 mg QD	AC, DB, MC, RCT Patients 18 to 80 years of age with an LDL-C above ATP III goal and a previous intolerance to ≥2 statins	N=307	Primary: LDL-C at week 12 and mean of weeks 10 and 12 Secondary: Percentage of patients with LDL-C <70 mg/dL, non HDL-C, apoB, apoB/apolipoprotein A1, lipoprotein (a), TG, TC/HDL-C, VLDL and safety evaluations.	Primary: Evolocumab reduced LDL-C from baseline by 53% (every two weeks) to 56% (monthly), corresponding to treatment differences versus ezetimibe of 37 to 39% (P<0.001). Mean percent reductions from baseline and treatment differences at week 12 were similar (P<0.001). Secondary: Evolocumab-treated patients were more likely to achieve LDL-C target levels than ezetimibe-treated patients. Compared with ezetimibe, evolocumab led to significant reductions in apoB, lipoprotein(a), non–HDL-C and the apoB/apolipoprotein A-I and TC/HDL-C ratios (P<0.001) Muscle adverse events occurred in 12% of evolocumab-treated patients and 23% of ezetimibe-treated patients. Treatment-emergent adverse events and laboratory abnormalities were comparable across treatment groups.
Nissen et al.[22] (2016) GAUSS-3 Evolocumab (420 mg monthly subcutaneously) vs ezetimibe (10 mg daily by	DB, DD, RCT Patients 18 to 80 years of age with elevated LDL-C levels who were unable to tolerate an effective dose of a statin because of muscle-related	N=491 24-week crossover procedure with atorvastatin or placebo to identify patients	Primary: Mean percent change in LDL-C level from baseline to the mean of weeks 22 and 24 levels and from baseline to week 24 levels	Primary: Mean percent change in LDL-C level from baseline to the mean of weeks 22 and 24 levels showed a least-squares mean change of −16.7% (95% CI, −20.5 to −12.9%) for ezetimibe and −54.5% (95% CI, −57.2 to −51.8%) for evolocumab: a mean difference of −37.8% (95% CI, −42.3 to −33.3%; P<0.001). Mean percent change in LDL-C level from baseline to the week 24 showed a least-squares mean change of −16.7% (95% CI, −20.8 to −12.5%) for ezetimibe and −52.8% (95% CI, −55.8 to −49.8%) for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mouth)	adverse effects	having symptoms only with atorvastatin but not placebo; followed by 2-week washout; followed by 24-week comparison	Secondary: Absolute change from baseline in LDL-C level; percent change from baseline in levels of total cholesterol, non–high-density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (ApoB); percent change from baseline in total cholesterol to HDL-C ratio and ApoB to apoliprotein A1 ratio; and the percentage of patients achieving an LDL-C level less than 70 mg/dL; safety	evolocumab: a mean difference of −36.1% (95% CI, −41.1 to −31.1%; P<0.001). Secondary: Secondary end points including percent changes in levels of total cholesterol, non–HDL-C, and ApoB; total cholesterol to HDL-C ratio; and ApoB to apolipoprotein A1 ratio showed similar results, with P<0.001 demonstrating greater cholesterol reductions in the evolocumab group. Muscle symptoms were reported in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treated patients (P=0.17). Active study drug was stopped for muscle symptoms in 5 of 73 ezetimibe-treated patients (6.8%) and 1 of 145 evolocumab-treated patients (0.7%).
Robinson et al.[23] (2014) LAPLACE-2 Evolocumab 140 mg injected SQ every two weeks	AC, DB, MC, PC, RCT Patients 18 to 80 years of age with LDL-C ≥150 mg/dL (not on statin), ≥100	N=2,067 12 weeks	Primary: LDL-C at week 12 and mean of weeks 10 and 12 Secondary: Mean at weeks 10 and 12	Primary: Evolocumab reduced LDL-C levels by 66% (95% CI, 58 to 73%) to 75% (95% CI, 65 to 84%) (every two weeks) and by 63% (95% CI, 54 to 71%) to 75% (95% CI, 67 to 83%) (monthly) compared to placebo at the mean of weeks 10 and 12 in the moderate- and high-intensity statin-treated groups. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs evolocumab 420 mg injected SQ once monthly ezetimibe 10 mg QD (atorvastatin group only) vs placebo During a four-week run in period, patients were initially randomized to a moderate-intensity (atorvastatin 10 mg QD, simvastatin 40 mg QD or rosuvastatin 5 mg QD) or high-intensity (atorvastatin 80 mg QD or rosuvastatin 40 mg QD) statin.	mg/dL (non-intensive statin) or ≥80 mg/dL (intensive statin [defined as daily atorvastatin (40mg or greater), rosuvastatin (20mg or greater), simvastatin (80 mg), or any statin plus ezetimibe]) and TG<400 mg/dL		and at week 12 for the change from baseline in LDL-C level, the percent change from baseline in additional lipid parameters, the proportion of patients achieving LDL-C levels less than 70mg/dL, and safety evaluations.	For moderate-intensity statin groups, evolocumab every two weeks reduced LDL-C from a baseline mean of 115 to 124 mg/dL to 39 to 49 mg/dL; monthly evolocumab reduced LDL-C from a baseline mean of 123 to 126 mg/dL to 43 to 48 mg/dL. For high-intensity statin groups, evolocumab every two weeks reduced LDL-C from a baseline mean of 89 to 94 mg/dL to 35 to 38 mg/dL; monthly evolocumab reduced LDL-C from a baseline mean of 89 to 94 mg/dL to 33 to 35 mg/dL. Evolocumab administered every two weeks and monthly resulted in significant reductions in non-HDL-C, apoB and lipoprotein(a) for all statin groups. Ninety four percent and 93 to 95% of patients receiving evolocumab every two weeks and monthly reached an LDL-C of <70 mg/dL, respectively. The most common adverse events in evolocumab-treated patients were back pain, arthralgia, headache, muscle spasms and pain in extremity (all <2%).
Koren et al.[24] (2014) MENDEL-2 Evolocumab 140 mg injected SC every two weeks vs evolocumab 420 mg injected SC once monthly vs	AC, DB, MC, PC, RCT Patients 18 to 80 years of age with LDL-C≥ 100 mg/dL, <190 mg/dL and Framingham risk scores ≤10%	N=614 12 weeks	Primary: LDL-C at week 12 and mean of weeks 10 and 12 Secondary: Proportion of patients achieving LDL-C <70 mg/dL, other lipid parameters and safety endpoints	Primary: Evolocumab treatment reduced LDL-C from baseline, on average, by 55 to 57% more than placebo and 38 to 40% more than ezetimibe (P<0.001 for all comparisons). At 12 weeks, LDL-C levels had decreased from baseline, on average, by 57.0% (95% CI, 59.5 to 54.6%) with biweekly evolocumab compared with 0.1% (95% CI, 3.2 to 3.4%) for placebo and 17.8% (95% CI, 21.0 to 14.5%) for ezetimibe (P<0.001). For patients administered monthly evolocumab, the mean 12-week LDL-C reduction was 56.1% (95% CI, 58.3% to 53.9%) compared to 1.3% (95% CI, 4.4%to 1.7%) for placebo and 18.6% (95%CI, 21.6% to 15.5%) for ezetimibe (P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
ezetimibe 10 mg QD vs placebo				LDL-C percent changes from baseline for the mean of weeks 10 and 12 and the absolute mean reductions in LDL-C levels were significant in all evolocumab groups compared with placebo and ezetimibe (P<0.001). Secondary: Patients in the evolocumab groups achieved a level of LDL-C <70 mg/dl at much higher rates (72% and 69%) than placebo (0% and 1%) or ezetimibe (2% and 1%) group patients for the mean of weeks 10 and 12 and at week 12, respectively. Evolocumab significantly decreased levels of apoB, lipoprotein (a), and non–HDL-C, TC/HDL-C and apoB/apolipoprotein A1. Significant HDL-C increases were observed with evolocumab (P<0.05). TG and VLDL were significantly lowered with monthly evolocumab vs placebo or ezetimibe and in some comparisons in the biweekly group. Evolocumab treatment also favorably altered other lipoprotein levels. Treatment-emergent adverse events, muscle-related adverse events and laboratory abnormalities were comparable across treatment groups.
Sabantine et al.[25] (2015) OSLER-1/2 Evolocumab 140 mg injected SC every two weeks (OSLER-2) or 420 mg once monthly (OSLER 1 or 2 [based upon patient preference]) vs standard therapy alone Evolocumab was administered in	ES, MC, OL, RCT (extension study of five phase II trials (OSLER-1) or seven phase III trials (OSLER-2) Patients with hyperlipidemia (trials included patients on monotherapy, combination with statin with or without ezetimibe, statin intolerant patients, patients	N=4,465 56 weeks randomized followed by ongoing non-randomized open-label evaluation (OSLER-1) 48 weeks by ongoing non-randomized open-label	Primary: Safety endpoints Secondary: LDL-C, non–HDL-C, HDL-C, TC, TG, apolipoprotein A1 and apoB, lipoprotein(a). and CVE	Primary: Most adverse events occurred with similar frequency in the two groups, although neurocognitive events were reported more frequently in the evolocumab group. The risk of adverse events, including neurocognitive events, did not vary significantly according to the achieved level of LDL-C. Secondary: As compared with standard therapy alone, evolocumab reduced the level of LDL-C by 61%, from a median of 120 mg/dL to 48 mg/dL at 12 weeks (P<0.001). At 12 weeks, the LDL-C was reduced to ≤100 mg/dL in 90.2% of patients and to ≤70 mg/dL in 73.6% of patients in the evolocumab group, as compared with 26.0% and 3.8%, respectively, in the standard-therapy group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
combination with other standard therapies based upon local guidelines for cholesterol treatment.	with HeFH)	evaluation (OSLER-2)		In the evolocumab group, as compared with the standard-therapy group, changes in related atherogenic lipid measures were similar to those observed for LDL-C, with reductions of 52.0% in non-HDL-C, 47.3% in apoB, 36.1% in TC, 12.6% in TG, and 25.5% in lipoprotein(a) (P<0.001 for all comparisons) Evolocumab also raised levels of HDL-C and apolipoprotein A1 by 7.0% and 4.2%, respectively (P<0.001 for both comparisons). The rate of CVE at one year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (HR in the evolocumab group, 0.47; 95% CI, 0.28 to 0.78; P=0.003).
Raal et al.[26] (2015) RUTHERFORD-2 Evolocumab 140 mg injected SC every two weeks vs evolocumab 420 mg injected SC once monthly vs placebo	DB, PC, MC, RCT Patients 18 to 80 years age who met clinical criteria for HeFH and were on stable lipid-lowering therapy for at least four weeks, with LDL-C≥ 100 mg/dL	N=331 12 weeks	Primary: LDL-C at week 12 and mean of weeks 10 and 12 Secondary: Other lipid parameters and safety endpoints	Primary: Compared with placebo, evolocumab at both dosing schedules led to a significant reduction in mean LDL-C at week 12 (biweekly dose: 59.2% reduction [95% CI, 53.4% to 65.1%], monthly dose: 61.3% reduction [53.6% to 69.0%]; both P<0.0001) and at the mean of weeks 10 and 12 (60.2% reduction [95% CI, 54.5% to 65.8%] and 65.6% reduction [59.8% to 71.3%]; both P<0.0001). Secondary: Mean reductions in lipoprotein(a) and apoB at week 12 were significantly greater in both evolocumab groups than in the placebo groups (P<0.05 for all comparisons). At week 12, evolocumab 140 mg every two weeks reduced TG concentrations compared with placebo, whereas the 420 mg monthly evolocumab dose resulted in a smaller, but still significant, decrease compared with placebo (P<0.05 for all comparisons). Both doses of evolocumab led to significant increases in HDL-C compared with placebo (P<0.05 for all comparisons). The most common adverse events occurring more frequently in the evolocumab-treated patients than in the placebo groups were nasopharyngitis (19 patients [9%] vs five [5%], respectively) and muscle-related adverse events (ten patients [5%] vs one [1%], respectively).
Raal et al.[27]	DB, MC, PC, RCT	N=50	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2015) TESLA-B Evolocumab 420 mg injected SC once monthly vs placebo Evolocumab was administered in combination with other standard therapies based upon local guidelines for cholesterol treatment.	Patients aged ≥12 years with HoFH diagnosed either by genetic analysis or clinical criteria and LDL-C >3.4 mmol/L (61.2 mg/dL) after at least four weeks of a stable, low-fat diet and baseline lipid-lowering therapies, fasting TG <81 mg/dL and body weight ≥40 kg	12 weeks	LDL-C at week 12 Secondary: Other lipid parameters and safety endpoints	Compared with placebo, evolocumab significantly reduced LDL-C at 12 weeks by 30.9% (95% CI, –43.9% to –18.0%; P<0.0001). The least-squares mean absolute reduction in LDL-C with evolocumab versus placebo at week 12 was 2.4 mmol/L (43.2 mg/dL; 95% CI, –3.7 to –1.1). Secondary: Evolocumab treatment led to a significant least-squares mean reduction in apoB at week 12 compared to placebo (P=0.0002). No differences between the two treatment groups were recorded in HDL-C or TG at week 12 (P values not reported). Treatment-emergent adverse events occurred in ten (63%) of 16 patients in the placebo group and 12 (36%) of 33 in the evolocumab group. No serious clinical or laboratory adverse events occurred, and no anti-evolocumab antibody development was detected during the study.
Sabatine et al.[28] (2017) FOURIER Evolocumab 140 mg injected SC every two weeks vs Evolocumab 240 mg injected SC once monthly vs placebo	DB, PC, RCT Patients (40 to 85 years of age) with LDL-C≥70 mg/dL or non-HDL 100mg/dl or higher and a history of MI, ischemic stroke, or symptomatic PAD who were on optimized statin therapy (atorvastatin 20 mg QD or equivalent statin) with or without ezetimibe	N=27,564 26 months	Primary: composite of cardiovascular death, MI, stroke, hospitalization for unstable angina or coronary revascularization Secondary: composite of cardiovascular death, MI or stroke, other lipid parameters	Primary: Compared to placebo, evolocumab significantly reduced the risk of the primary endpoint by 1.5% (11.3% vs 9.8%; HR, 0.85; 95% CI, 0.79 to 0.92; P<0.001). Secondary: Compared to placebo, evolocumab significantly reduced the risk of the secondary endpoint by 1.5% (7.4% vs 5.9%; HR, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL-C levels (median, 74 mg/dL). Although the aggregated results demonstrated a benefit in the primary and key secondary endpoint, individual components of the composite endpoint may not have shown a difference. For example, there was no difference in death from any cause in the evolocumab group compared to placebo (3.2% vs 3.1%; HR, 1.04; 95% CI, 0.91 to 1.19; P=0.54). There were no new significant safety concerns compared to earlier trials. There was a higher rate of injection site reactions in the evolocumab arm.

Drug regimen abbreviations: QD=once daily, SC=subcutaneously
Study abbreviations: AC=active-controlled, DB=double-blind, DD=double-dummy, ES=extension study, MC=multicenter, PC=placebo-controlled, PG=parallel-group, RCT=randomized controlled trial apoB=apolipoprotein B, ATP=Adult Treatment Program, CHD=coronary heart disease, CI=confidence interval, CVE=cardiovascular events, CRP= C-reactive protein, HDL-C=high density lipoprotein, HeFH=heterozygous familial hypercholesterolemia, HR=hazard ratio, LDL-C=low density lipoprotein cholesterol, SE=standard error, TC=total cholesterol, TG=triglyceride, VLDL=very low density lipoprotein

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 8. Relative Cost of the PCSK9 Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Alirocumab	injection	Praluent®	$$$$$	N/A
Evolocumab	injection	Repatha®	$$$$$	N/A

N/A=Not available

X. Conclusions

There are currently two Food and Drug Administration (FDA)-approved PCSK9 inhibitors commercially available. These agents include Praluent® (alirocumab) and Repatha® (evolucumab).[1] Both Praluent® (alirocumab) and Repatha® (evolucumab) are FDA-approved as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C.[2,3] Repatha® (evolucumab) is also indicated as an adjunct to diet and other lipid lowering therapies (statins, ezetimibe, LDL-C apheresis) in patients with homozygous familial hypercholesterolemia (HoFH).[3]

In July 2016, the American College of Cardiology released the Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular

Disease Risk. In general, the use of PCSK9 inhibitors is only recommended for consideration after addressing statin intolerance, intensifying lifestyle modifications, increasing to high-intensity statin if not already taking, evaluating for statin intolerance if unable to tolerate moderate-intensity statin, controlling other risk factors, and adding ezetimibe or a bile acid sequestrant to therapy. If patients with ASCVD who are on maximally tolerated statin and ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response, it is reasonable to consider the net benefit of a PCSK9 inhibitor to achieve further LDL-C reduction. Patient preference should be considered in the discussion to initiate PCSK9 inhibitor therapy, including considerations of the patient's perception of net benefit, convenience/burden of additional therapy, cost, quality of life, and the potential to jeopardize adherence to other evidence-based therapies.[5] The 2017 American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis recommend PCSK9 inhibitors be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH and individuals with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals.[6] Although these agents have demonstrated a benefit in reducing various measures of cholesterol, data on the extent of benefit on cardiovascular morbidity and mortality is limited, or has not been determined. In addition, these agents are only approved as adjunctive therapy to maximally-dosed statin therapy and other lipid lowering therapies, not in statin intolerant patients.[2,3]

The FDA-approval of alirocumab is based on data from twelve phase III ODYSSEY trials (N>5,000) including patients with HeFH, those with coronary heart disease (CHD) and those at risk for cardiovascular events (CVE).[2,11-16] Across the clinical trial program, alirocumab was associated with an approximate 40 to 60% decrease in LDL-C from baseline. In addition, other lipid measures generally decreased at higher levels than with placebo. The FDA-approval of evolocumab is based on data from ten phase III PROFICO trials (N~6,800). These trials included patients with elevated cholesterol on statins with or without other lipid-lowering therapies, patients who cannot tolerate statins, patients with HeFH, and patients with HoFH.[3,20-28] Across these clinical trials, evolocumab was evaluated at two dosing schedules, 120 mg every two weeks and 420 mg monthly. The agent was generally associated with a 40 to 60% reduction in LDL-C from baseline and a significant decrease in other lipid parameters compared to placebo. In addition, in an extension study of a phase II and III clinical trial (OSLER 1 and 2), the rate of cardiovascular events at one year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (HR, 0.47; 95% CI, 0.28 to 0.78; P=0.003).[25]

Recently, the results of the phase III FOURIER trial (N=27,564) assessing clinical benefits on cardiovascular morbidity and mortality were published. The double-blind, randomized, placebo-controlled trial compared evolocumab to placebo in patients with a history of myocardial infarction (MI), ischemic stroke, or symptomatic peripheral artery disease (PAD) who had an LDL of 70 mg/dL or higher, or a non-HDL of 100 mg/dL or higher despite optimized statin therapy defined as atorvastatin 20 mg or equivalent.[28] The trial was associated with an absolute reduction of approximately 2% in the risk of the primary cardiovascular composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) after a median follow-up of 26 months. Key secondary endpoints, including a more significant composite cardiovascular endpoint (e.g., removes less severe cardiac outcomes including elective revascularization) and lipid measures also supported efficacy.[28]

At this time, there is insufficient data to conclude that one PSCK9 inhibitor is safer or more efficacious than other brand or generic products within its class and that it offers a significant clinical advantage over other alternatives in general use. The drugs in this AHFS class are used in a specific patient population. Because these agents have narrow indications with limited usage, and very specific criteria must be met prior to initiating therapy, these agents should be made available through the medical justification portion of the prior authorization process.

Therefore, all brand products within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand PSCK9 inhibitor product is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Kastelein JJP, Stroes ESG, Stiekema LCA. PCSK9 inhibitors: Pharmacology, adverse effects, and use. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 Apr 20]. Available from: http://www.utdol.com/utd/index.
2. Praluent® [package insert]. Bridgewater (NJ): Sanofi-Aventis U.S.; 2015 Jul.
3. Repatha® [package insert]. Thousand Oaks (CA): Amgen Inc.; 2016 Jul.
4. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000–000. DOI: 10.1161/01.cir.0000437738.63853.7a.
5. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519.
6. American Association of Clinical Endocrinologists and American College of Endocrinology. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis [guideline on the internet]. Endocrine Practice. 2017 [2017 Apr 21];Rapid Electronic Article in Press. Available from: https://www.aace.com/files/lipid-guidelines.pdf.
7. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 1;132(22):2167-92.
8. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
9. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2016 [cited 2016 Jun]. Available from: http://www.thomsonhc.com/.
10. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2016 [cited Jun 2016]. Available from: http://online.factsandcomparisons.com.
11. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun;169(6):906-915.e13. doi: 10.1016/j.ahj.2015.03.004.
12. Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014 Sep 20;14:121. doi: 10.1186/1471-2261-14-121.
13. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015 Feb 16. pii: ehv028.
14. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 Mar 15.
15. Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37. doi: 10.2217/fca.14.82.
16. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF , Gouni-Berthold I et al. Alirocumab as Add-on To Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015 Jun 1:jc20151520.
17. Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct;37(10):597-604. doi: 10.1002/clc.22327.
18. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016 Jan;244:138-46.

19. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758-69.
20. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222.
21. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2541-8. doi: 10.1016/j.jacc.2014.03.019.
22. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90.
23. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030
24. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2531-40. doi: 10.1016/j.jacc.2014.03.018.
25. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858.
26. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4.
27. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):341-50. doi: 10.1016/S0140-6736(14)61374-X.
28. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 Mar 17; 1-10.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Antilipemic Agents, Miscellaneous
AHFS Class 240692
August 9, 2017

I. Overview

The antilipemic agents are categorized into six different American Hospital Formulary Service (AHFS) classes, including bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, HMG-CoA reductase inhibitors (statins), and miscellaneous antilipemic agents. The agents which make up these classes differ with regards to their Food and Drug Administration (FDA)-approved indications, mechanism of action, efficacy, safety profiles, tolerability, and ease of use.

Niacin favorably affects all lipids and lipoproteins when given in pharmacological doses; however, the mechanism of action is not completely understood.[1-5] Niacin has several effects on lipid metabolism including inhibition of hepatic production of very low-density lipoprotein cholesterol (VLDL-C), and consequently its metabolite low-density lipoprotein cholesterol (LDL-C). In addition, it decreases plasma concentrations of triglycerides (TGs) (20 to 50%), very low-density lipoprotein remnants, and intermediate density lipoprotein. Administration of niacin also causes a shift in low-density lipoprotein composition from small, dense particles to larger, more buoyant particles. Lastly, niacin increases high density lipoprotein cholesterol (HDL-C) (15 to 35%) both by reducing lipid transfer of cholesterol from HDL-C to VLDL-C, and by delaying HDL-C clearance. Niacin can decrease LDL-C by 5 to 25%.[1-3]

Modifications in lipids can also be effected by a number of dietary approaches or specific dietary supplements. Like medication classes, these modalities also differ with respect to their mechanism of action and to the degree and type of lipid modification.[1] Rich sources of omega-3-fatty acids include fatty fish, certain vegetables and nuts, and fish oil as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). When administered at high doses they can reduce levels of TGs by approximately 50%.[1] The mechanism by which this occurs is thought to be caused by the inhibition of VLDL-C.[6,7] In general, omega-3-fatty acids have no effect on LDL-C, but large doses have been shown to reciprocally increase LDL-C levels in patients with hypertriglyceridemia.[1] Each omega-3 acid ethyl esters capsule (Lovaza®) contains at least 900 mg of ethyl esters of omega-3 fatty acids sourced from fish oil, which are predominantly EPA (approximately 465 mg) and DHA (approximately 375 mg).[6] The total EPA and DHA dose recommended for TG-lowering is approximately 2 to 4 g per day.[1,2] Vascepa® is a new omega-3 fatty acid formulation. It also contains EPA obtained from fish oil; however, it contains at least 96% EPA and does not contain DHA. Studies suggest that this formulation does not cause significant increases in LDL-C, unlike the traditional mixtures of EPA and DHA.[7]

Two miscellaneous antilipemic agents are approved as adjuncts to diet and other lipid-lowering treatments to improve lipid parameters in patients with homozygous familial hypercholesterolemia (HoFH).[8,9] HoFH is a genetic condition usually leading to loss-of-function mutations in the LDL receptor and is associated with substantially elevated LDL-C (>400 mg/dL) and premature atherosclerotic cardiovascular disease.[10] Lomitapide is a microsomal triglyceride transfer protein inhibitor: This inhibition prevents the assembly of apolipoprotein (apo) B-containing lipoproteins, which inhibits the synthesis of VLDL, leading to reduced levels of plasma LDL-C.[8] Mipomersen is an oligonucleotide inhibitor of apo B-100 synthesis. Apo B-100 is an essential component of VLDL and LDL-C.[9,10]

There are over-the-counter (OTC) niacin products currently available, and these products are labeled as dietary supplements. While these supplements are "generally recognized as safe", the FDA does not examine the efficacy and safety of these products or regulate the manufacturing process.[11,12] The FDA has imposed statutory restrictions prohibiting manufacturers of dietary supplements from claiming that their products "treat, cure, or prevent any disease". Without FDA regulation, the content of nicotinic acid in niacin products is not guaranteed.[11] The American Heart Association states that "dietary supplement niacin must not be used as a substitute for prescription niacin" and "it should not be used for lowering cholesterol because of the potential for very serious side effects".[13]

The miscellaneous antilipemic agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Niacin and omega-3 acid ethyl esters are available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Antilipemic Agents, Miscellaneous Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Icosapent ethyl	capsule	Vascepa®	none
Lomitapide	capsule	Juxtapid®	none
Mipomersen	injection	Kynamro®	none
Niacin	extended-release tablet, tablet	Niacor®, Niaspan®*	Niacor®, niacin
Omega-3 acid ethyl esters	capsule	Lovaza®*	omega-3 acid ethyl esters

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.
N/A=Not available.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the miscellaneous antilipemic agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Antilipemic Agents, Miscellaneous

Clinical Guideline	Recommendation
National Cholesterol Education Program: **Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004)**[14]	• Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. • When low density lipoprotein cholesterol (LDL-C) lowering drug therapy is employed in high risk or moderately high risk patients, it is advised that intensity of therapy be sufficient to achieve ≥30 to 40% reduction in LDL-C levels. If drug therapy is a component of cholesterol management for a given patient, it is prudent to employ doses that will achieve at least a moderate risk reduction. • Standard HMG-CoA reductase inhibitors (statins) doses are defined as those that lower LDL-C levels by 30 to 40%. The same effect may be achieved by combining lower doses of statins with other drugs or products (e.g., bile acid sequestrants, ezetimibe, nicotinic acid, plant stanols/sterols). • When LDL-C level is well above 130 mg/dL (e.g., ≥160 mg/dL), the dose of statin may have to be increased or a second agent (e.g., a bile acid sequestrant, ezetimibe, nicotinic acid) may be required. Alternatively, maximizing dietary therapy (including use of plant stanols/sterols) combined with standard statin doses may be sufficient to attain goals. • Fibrates may have an adjunctive role in the treatment of patients with high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), especially in combination with statins. • In high risk patients with high TG or low HDL-C levels, consideration can be given to combination therapy with fibrates or nicotinic acid and a LDL lowering agent. • Several clinical trials support the efficacy of nicotinic acid, which raises HDL-C, for reduction of coronary heart disease (CHD) risk, both when used alone and in combination with statins. The combination of a statin with nicotinic acid produces a marked reduction of LDL-C and a striking rise in HDL-C. <u>Treatment of heterozygous familial hypercholesterolemia</u> • Begin LDL-C lowering drugs in young adulthood. • TLC indicated for all persons. • Statins, first line of therapy (start dietary therapy simultaneously).

Clinical Guideline	Recommendation
	• Bile acid sequestrants (if necessary in combination with statins). • If needed, consider triple drug therapy (statins and bile acid sequestrants and nicotinic acid). <u>Treatment of homozygous familial hypercholesterolemia</u> • Statins may be moderately effective in some persons. • LDL-pheresis currently employed therapy (in some persons, statin therapy may slow down rebound hypercholesterolemia). <u>Treatment of familial defective apolipoprotein B-100</u> • TLC indicated. • All LDL-C lowering drugs are effective. • Combined drug therapy required less often than in heterozygous familial hypercholesterolemia. <u>Treatment of polygenic hypercholesterolemia</u> • TLC indicated for all persons. • All LDL-C lowering drugs are effective. • If necessary to reach LDL-C goals, consider combined drug therapy.
National Cholesterol Education Program: **Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report (2002)[1]**	<u>General recommendations</u> • With regards to TLC, higher dietary intakes of omega-3 fatty acids in the form of fatty fish or vegetable oils are an option for reducing risk for CHD. This recommendation is optional because the strength of evidence is only moderate at present. National Cholesterol Education Program supports the American Heart Association's recommendation that fish be included as part of a CHD risk reduction diet. Fish in general is low in saturated fat and may contain some cardioprotective omega-3 fatty acids. However, a dietary recommendation for a specific amount of omega-3 fatty acids is not made. • Initiate LDL lowering drug therapy with a statin, bile acid sequestrant, or nicotinic acid. • Statins should be considered as first line drugs when LDL lowering drugs are indicated to achieve LDL-C treatment goals. • After six weeks if LDL-C goal is not achieved, intensify LDL lowering therapy. Consider a higher dose of a statin or add a bile acid sequestrant or nicotinic acid. <u>Statins</u> • Statins should be considered as first-line drugs when LDL-lowering drugs are indicated to achieve LDL treatment goals. <u>Bile acid sequestrants</u> • Bile acid sequestrants should be considered as LDL lowering therapy for patients with moderate elevations in LDL-C, for younger patients with elevated LDL-C, for women with elevated LDL-C who are considering pregnancy and for patients needing only modest reductions in LDL-C to achieve target goals. • Bile acid sequestrants should be considered in combination therapy with statins in patients with very high LDL-C levels. <u>Nicotinic acid</u> • Nicotinic acid should be considered as a therapeutic option for higher risk patients with atherogenic dyslipidemia. • Nicotinic acid should be considered as a single agent in higher risk patients with atherogenic dyslipidemia who do not have a substantial increase in LDL-C levels, and in combination therapy with other cholesterol lowering drugs in higher risk patients with atherogenic dyslipidemia combined with elevated

Clinical Guideline	Recommendation
	LDL-C levels. • Nicotinic acid should be used with caution in patients with active liver disease, recent peptic ulcer, hyperuricemia, gout, and type 2 diabetes. • High doses of nicotinic acid (>3 g/day) generally should be avoided in patients with type 2 diabetes, although lower doses may effectively treat diabetic dyslipidemia without significantly worsening hyperglycemia. <u>Fibric acid derivatives (fibrates)</u> • Fibrates can be recommended for patients with very high TG to reduce risk for acute pancreatitis. • They also can be recommended for patients with dysbetalipoproteinemia (elevated beta-very LDL). • Fibrate therapy should be considered an option for treatment of patients with established CHD who have low levels of LDL-C and atherogenic dyslipidemia. • They also should be considered in combination with statin therapy in patients who have elevated LDL-C and atherogenic dyslipidemia. <u>Omega-3 fatty acids</u> • Omega-3 fatty acids (e.g., linolenic acid, docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA]) have two potential uses. • In higher doses, DHA and EPA lower serum TGs by reducing hepatic secretion of TG-rich lipoproteins. They represent alternatives to fibrates or nicotinic acid for treatment of hypertriglyceridemia, particularly chylomicronemia. Doses of 3 to 12 g/day have been used depending on tolerance and severity of hypertriglyceridemia. • Recent trials also suggest that relatively high intakes of omega-3 fatty acids (1 to 2 g/day) in the form of fish, fish oils, or high-linolenic acid oils will reduce the risk for major coronary events in persons with established CHD. Omega-3 fatty acids can be a therapeutic option in secondary prevention (based on moderate evidence). The omega-3 fatty acids can be derived from either foods (omega-3 rich vegetable oils or fatty fish) or from fish-oil supplements. More definitive trials are required before strongly recommending relatively high intakes of omega-3 fatty acids (1 to 2 g/day) for either primary or secondary prevention.
American Association of Clinical Endocrinologists: **Guidelines for the management of dyslipidemia and prevention of atherosclerosis (2017)**[15]	<u>Cholesterol Goals</u> • For individuals at low risk (i.e., with no risk factors), an LDL-C goal of <130 mg/dL is recommended. • For individuals at moderate risk (i.e., with two or fewer risk factors and a calculated 10-year risk of <10%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or CKD stage 3 or 4 with no other risk factors, or individuals with two or more risk factors and a 10-year risk of 10 to 20%), an LDL-C goal of <100 mg/dL is recommended. • For individuals at very high risk (i.e., with established or recent hospitalization for ACS, coronary, carotid or peripheral vascular disease; diabetes or CKD stage 3 or 4 with one or more risk factors; a calculated 10-year risk >20%; or heterozygous familial hypercholesterolemia [HeFH]), an LDL-C goal of <70 mg/dL is recommended. • For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dL, or established clinical ASCVD in individuals with diabetes, CKD stage 3 or 4, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal of <55 mg/dL is recommended.

Clinical Guideline	Recommendation
	• An LDL-C goal of <100 mg/dL is considered "acceptable" for children and adolescents, with 100 to 129 mg/dL considered "borderline" and 130 mg/dL or greater considered "high" (based on recommendations from the American Academy of Pediatrics). • HDL-C should be >40 mg/dL, but also as high as possible, primarily through the use of lifestyle interventions (e.g., weight loss, physical activity, and tobacco cessation), and if risk factors are present (e.g., borderline elevated LDL-C levels, a family history of premature ASCVD, or a personal history of ASCVD), also through the use of pharmacotherapy primarily focused on reducing LDL-C. • For most individuals, a non–HDL-C goal (total cholesterol minus HDL-C) 30 mg/dL higher than the individual's specific LDL-C goal is recommended. • For individuals at extreme risk, a non-HDL-C goal 25 mg/dL higher than the individual specific LDL-C goal is recommended. • For individuals at increased risk of ASCVD, including those with diabetes, an optimal apo B goal is <90 mg/dL, while for individuals with established ASCVD or diabetes plus one or more additional risk factor(s), an optimal apo B goal is <80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is <70 mg/dL. • TG goals of <150 mg/dL are recommended. <u>General Recommendations</u> • A comprehensive strategy to control lipid levels and address associated metabolic abnormalities and modifiable risk factors is recommended primarily using lifestyle changes and patient education with pharmacotherapy as needed to achieve evidence based targets. • A reasonable and feasible approach to fitness therapy (i.e., exercise programs that include ≥30 minutes of moderate-intensity physical activity [consuming 4 to 7 kcal/min] four to six times weekly, with an expenditure of ≥200 kcal/day) is recommended; suggested activities include brisk walking, riding a stationary bike, water aerobics, cleaning/scrubbing, mowing the lawn, and sporting activities. • Daily physical activity goals can be met in a single session or in multiple sessions throughout the course of a day (10 minutes minimum per session); for some individuals, breaking activity up throughout the day may help improve adherence with physical activity programs. • In addition to aerobic activity, muscle-strengthening activity is recommended at least two days a week. • For adults, a reduced-calorie diet consisting of fruits and vegetables (combined ≥5 servings/day), grains (primarily whole grains), fish, and lean meats is recommended. • For adults, the intake of saturated fats, trans-fats, and cholesterol should be limited, while LDL-C-lowering macronutrient intake should include plant stanols/sterols (~2 g/ day) and soluble fiber (10 to 25 g/day). • Primary preventive nutrition consisting of healthy lifestyle habits is recommended in all healthy children. • Tobacco cessation should be strongly encouraged and facilitated. • In individuals at risk for ASCVD, aggressive lipid-modifying therapy is recommended to achieve appropriate LDL-C goals. <u>Statins</u> • Statin therapy is recommended as the primary pharmacologic agent to achieve target LDLC goals on the basis of morbidity and mortality outcome trials. • For clinical decision making, mild elevations in blood glucose levels and/or an increased risk of new-onset T2DM associated with intensive statin therapy do not outweigh the benefits of statin therapy for ASCVD risk reduction.

Clinical Guideline	Recommendation
	• In individuals within high-risk and very high-risk categories, further lowering of LDL-C beyond established targets with statins results in additional ASCVD event reduction and may be considered. • Very high-risk individuals with established coronary, carotid, and peripheral vascular disease, or diabetes, who also have at least one additional risk factor, should be treated with statins to target a reduced LDL-C treatment goal of <70 mg/dL. • Extreme risk individuals should be treated with statins to target an even lower LDL-C treatment goal of <55 mg/dL. Fibrates • Fibrates should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). • Fibrates may improve ASCVD outcomes in primary and secondary prevention when TG concentrations are ≥200 mg/dL and HDL-C concentrations <40 mg/dL. Omega-3 Fish Oil • Prescription omega-3 oil, 2 to 4 g daily, should be used to treat severe hypertriglyceridemia (TG >500 mg/dL). Dietary supplements are not FDA-approved for treatment of hypertriglyceridemia and generally are not recommended for this purpose. Niacin • Niacin therapy is recommended principally as an adjunct for reducing TG. • Niacin therapy should not be used in individuals aggressively treated with statin due to absence of additional benefits with well-controlled LDL-C. Bile Acid Sequestrants • Bile acid sequestrants may be considered for reducing LDL-C and apo B and modestly increasing HDL-C, but they may increase TG. Cholesterol Absorption Inhibitors • Ezetimibe may be considered as monotherapy in reducing LDL-C and apo B, especially in statin-intolerant individuals. • Ezetimibe can be used in combination with statins to further reduce both LDL-C and ASCVD risk. PCSK9 Inhibitors • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors should be considered for use in combination with statin therapy for LDL-C lowering in individuals with FH. • PCSK9 inhibitors should be considered in patients with clinical cardiovascular disease who are unable to reach LDL-C/non-HDL-C goals with maximally tolerated statin therapy. They should not be used as monotherapy except in statin-intolerant individuals. Combination Therapy • Combination therapy of lipid-lowering agents should be considered when the LDL-C/non-HDL-C level is markedly increased and monotherapy (usually with a statin) does not achieve the therapeutic goal. Special Considerations: Women • Women should be evaluated for their ASCVD risk and be treated with pharmacotherapy if lifestyle intervention is insufficient. • Hormone replacement therapy for the treatment of dyslipidemia in

Clinical Guideline	Recommendation

	postmenopausal women is not recommended.
	
	Special Considerations: Children and Adolescents
	• Pharmacotherapy is recommended for children and adolescents older than 10 years who do not respond sufficiently to lifestyle modification, and particularly for those satisfying the following criteria:
	  ○ LDL-C ≥190 mg/dL
	  ○ LDL-C ≥160 mg/dL and the presence of two or more cardiovascular risk factors, even after vigorous intervention
	  ○ Family history of premature ASCVD (before 55 years of age), or
	  ○ Having overweight, obesity, or other elements of the insulin resistance syndrome
	
	Follow-up and Monitoring
	• Reassess individuals' lipid status six weeks after therapy initiation and again at six-week intervals until the treatment goal is achieved.
	• While on stable lipid therapy, individuals should be tested at 6- to 12-month intervals.
	• While on stable lipid therapy, the specific interval of testing should depend on individual adherence to therapy and lipid profile consistency; if adherence is a concern or the lipid profile is unstable, the individual will probably benefit from more frequent assessment.
	• More frequent lipid status evaluation is recommended in situations such as deterioration of diabetes control, use of a new drug known to affect lipid levels, progression of atherothrombotic disease, considerable weight gain, unexpected adverse change in any lipid parameter, development of a new ASCVD risk factor, or convincing new clinical trial evidence or guidelines that suggest stricter lipid goals.
	• Liver transaminase levels should be measured before and three months after niacin or fibric acid treatment initiation because most liver abnormalities occur within 3 months of treatment initiation. Liver transaminase levels should be measured periodically thereafter (e.g., semiannually or annually).
	• Creatine kinase levels should be assessed and the statin discontinued, at least temporarily, when an individual reports clinically significant myalgias or muscle weakness on statin therapy.

American Heart Association/American College of Cardiology/National Heart, Lung, and Blood Institute: **American Heart Association/American College of Cardiology Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update (2011)[16]**	Lipid management • Goal: treatment with statin therapy; use statin therapy to achieve LDL-C of <100 mg/dL; for very high risk patients an LDL-C <70 mg/dL is reasonable; if TG are ≥200 mg/dL, non-HDL-C should be <130 mg/dL, whereas non-HDL-C <100 mg/dL for very high risk patients is reasonable. • Lifestyle modifications (daily physical activity and weight management) are strongly recommended for all patients. • In addition to lifestyle modifications, statin therapy should be prescribed in the absence of contraindications or documented adverse events. • An adequate dose of statin should be used that reduces LDL-C to <100 mg/dL and achieves ≥30% lowering of LDL-C. • Patients who have TG ≥200 mg/dL should be treated with statins to lower non-HDL-C to <130 mg/dL. • Patients who have TG >500 mg/dL should be started on fibrate therapy in addition to statin therapy to prevent acute pancreatitis. • If treatment with a statin does not achieve the goal selected for an individual patient, intensification of LDL-C-lowering drug therapy with a bile acid sequestrant or niacin is reasonable. • For patients who do not tolerate statins, LDL-C-lowering therapy with bile acid

Clinical Guideline	Recommendation
	sequestrants and/or niacin is reasonable. • It is reasonable to treat very high risk patients with statin therapy to lower LDL-C to <70 mg/dL. • In patients who are at very high risk and who have TG ≥200 mg/dL, a non-HDL-C goal of <100 mg/dL is reasonable. • The use of ezetimibe may be considered for patients who do not tolerate or achieve target LDL-C with statins, bile acid sequestrants, and/or niacin. • For patients who continue to have an elevated non-HDL-C while on adequate statin therapy, niacin or fibrate therapy or fish oil may be reasonable. • For all patients, it may be reasonable to recommend omega-3 fatty acids from fist or fish oil capsules (1 g/day) for cardiovascular disease risk reduction.
Institute for Clinical Systems Improvement: **Lipid Management in Adults (2013)**[17]	Clinical highlights • Initiate a statin with patients who have established atherosclerotic cardiovascular disease (ASCVD). • Establish lipid goals based on risk level. • Instruct patients on healthy lifestyle and adjunctive measures. • Patient adherence with recommended therapy should be reinforced during scheduled follow-up. Lifestyle modifications • Patients who are overweight should be advised to reduce their caloric intake to achieve weight loss. • Patients should follow a dietary pattern that emphasizes fruits, vegetables, planetoids, fish, nuts, and legumes. • A diet low saturated and trans fats, and added sugars; and high in soluble fiber, with consideration given to adding 2 grams of plant sterol/stanol is recommended. Statin treatment • Initiate a statin regardless of LDL in patients with established ASCVD. • Initiate statin therapy in patients whose LDL is >100 and have a 10-year CHD risk ≥10% or diabetes. • Combination therapy can be considered on an individual basis, as no studies have shown a benefit to use at this time, and some studies have shown an increased risk of harm over statin monotherapy. Monotherapy • Reducing LDL-cholesterol (LDL-C) levels is the primary approach to lowering risk of CHD in both primary and secondary prevention. • Patients with risk factors for coronary heart disease but no history of disease who receive lipid-lowering therapy are likely to experience a decreased risk of coronary heart disease. • Patients with a history of coronary disease (including unstable angina and acute myocardial infarction) often benefit from treatment with a statin. Studies have consistently shown a decrease in risk of death from coronary heart disease. • Statins are the drugs of choice for lowering LDL-C, and aggressive treatment with statins should be pursued. Statins also have a modest effect on reducing TG and increasing HDL-C. • Several trials with clinical endpoints support the use of statins in primary and secondary prevention. • If a patient is intolerant to a statin, patients should try another statin before ruling all of them out. • Provide patient education regarding recognition and reporting of symptoms of myopathy during statin therapy. • If patients are unable to take a statin, then bile acid sequestrants, niacin, fibric

Clinical Guideline	Recommendation

	acid derivatives or fibrates, and ezetimibe are available.
	• Many crystalline (immediate-release) and sustained-release preparations of niacin are available over-the-counter. The extended-release preparation of niacin is a prescription drug. Niacin exerts favorable effects on all lipids and lipoproteins, and is good for mixed hyperlipidemia.
	• Long-term use of niacin is usually limited for many patients due to side effects (e.g., flushing and pruritus, liver toxicity, gastrointestinal complaints, etc).
	• Niacin should not be used in combination therapy with a statin, as two major trials have shown increased side effects without any reduction in cardiovascular outcomes.
	• Prior to initiating a fibric acid (gemfibrozil, fenofibrate, and fenofibrate micronized), lifestyle therapies should be intensified for moderately elevated TG. These include reduction of liquid sugar, all refined starches and saturated fat; increased moderate-intensity exercise; and weight reduction.
	• With fibric acids, TG are reduced 30 to 50%, HDL-C is increased 10 to 20%, TC is reduced 5 to 20% in patients without elevated TG, and the effect on LDL-C is variable. Fibric acids are good for severe hypertriglyceridemia (>500 mg/dL) in patients at risk for pancreatitis and for prevention of CHD (not proven for fenofibrate).
	• Myositis, cholelithiasis, and cholecystitis can occur with fibric acid, and caution should be exercised with a history of liver disease.
	• The long-term effects of ezetimibe on cardiovascular morbidity and mortality are unknown. Ezetimibe is associated with a LDL-C lowering of about 18%, and additive LDL-C lowering occurs when used in combination with a statin.
	• The short-term tolerability of ezetimibe is similar to placebo, and the long-term safety is unknown.
	• Bile acid sequestrants reduce LDL-C by 15 to 30% and TG may increase 15%; therefore, are these agents are useful for patients with moderately elevated LDL-C. The effects of the bile acid sequestrants are apparent within one week and maximum at two to three weeks. Bile acid sequestrants are good for combination therapy and are most potent with a statin.
	• Bile acid sequestrants are not systemically absorbed; therefore, side effects are limited to the gastrointestinal tract. In addition, drug interactions are minimized by taking other medications one hour before the sequestrant or four hours after.
	
	<u>Combination therapy</u>
	• It has become common practice to adjust medication therapy, including using combinations of medications, to achieve LDL-C goals. Common combinations include statin/fibrate, statin/niacin, and statin/ezetimibe.
	  ○ A fibrate is commonly added to a statin, which results in enhanced lowering of LDL-C, as well as a higher incidence of myopathy.
	  ○ Recent clinical trials have not demonstrated improved outcomes by increasing HDL-cholesterol with niacin among individuals with CVD and optimally controlled LDL-cholesterol on statins.
	  ○ The addition of ezetimibe to a statin significantly improves LDL-C over either agent alone. To date no large clinical trials have been completed evaluating this combination therapy compared to statin monotherapy on clinical vascular endpoints.
	• Studies of combination therapy have failed to show any benefit beyond statin monotherapy.
	• Combination therapy can be considered on an individual basis, but the additional cost, complexity, and risk for side effects argue against routine use until further trials indicate what groups of patients might benefit.
	• There are negative trials of cholesterylester transfer protein inhibitors when used in combination with statins.

Clinical Guideline	Recommendation
	• No randomized-controlled trials looking at clinical vascular endpoints are available for other agents such as fish oils or bile-acid sequestrants used in combination therapy. • A systematic review of combination therapy for dyslipidemia concluded that the limited evidence available suggests that combinations of lipid-lowering agents do not improve clinical outcomes more than statin monotherapy.
American College of Cardiology/American Heart Association Task Force on Practice Guidelines: **Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013)[18]**	Statin treatment • The panel makes no recommendations for or against specific low density lipoprotein cholesterol (LDL-C) or non-high density lipoprotein cholesterol (HDL-C) targets for the primary or secondary prevention of arteriosclerotic cardiovascular disease (ASCVD). • High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age that have clinical ASCVD, unless contraindicated. • In individuals with clinical ASCVD in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated. • In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it. • Adults ≥21 years of age with primary LDL-C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity. • For individual's ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, it is reasonable to intensify statin therapy to achieve at least a 50% LDL-C reduction. • For individuals ≥21 years of age with an untreated primary LDL-C ≥190 mg/dL, after the maximum intensity of statin therapy has been achieved, addition of a non-statin drug may be considered to further lower LDL-C. Evaluate the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and consider patient preferences. • Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus. • High-intensity statin therapy is reasonable for adults 40 to 75 years of age with diabetes mellitus with a ≥7.5% estimated 10-year ASCVD risk unless contraindicated. • In adults with diabetes mellitus, who are <40 or >75 years of age, it is reasonable to evaluate the potential for ASCVD benefits and for adverse effects, for drug-drug interactions, and to consider patient preferences when deciding to initiate, continue, or intensify statin therapy. • Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, without clinical ASCVD or diabetes and an estimated 10-year ASCVD risk ≥7.5% should be treated with moderate- to high-intensity statin therapy. • It is reasonable to offer treatment with a moderate intensity statin to adults 40 to 75 years of age, with LDL-C 70 to 189 mg/dL, without clinica ASCVD or diabetes and an estimated 10-year ASCVD risk of 5.0 to <7.5%. • Before initiating statin therapy for the primary prevention of ASCVD in adults with LDL-C 70 to 189 mg/dL without clinical ASCVD or diabetes it is reasonable for clinicians and patients to engage in a discussion which considers

Clinical Guideline	Recommendation

	the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment.
	• In adults with LDL-C <190 mg/dL who are not otherwise identified in a statin benefit group, or for whom after quantitative risk assessment a risk based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. In these individuals, statin therapy for primary prevention may be considered after evaluating the potential for ASCVD risk reduction benefits, adverse effects, drug-drug interactions, and discussion of patient preference.
	
	<u>Statin safety</u>
	• To maximize the safety of statins, selection of the appropriate statin and dose in men and nonpregnant/non-nursing women should be based on patient characteristics, level of ASCVD risk, and potential for adverse effects.
	• Moderate-intensity statin therapy should be used in individuals in whom high-intensity statin therapy would otherwise be recommended when characteristics predisposing them to statin associated adverse effects are present.
	• Characteristics predisposing individuals to statin adverse effects include, but are not limited to:
	  o Multiple or serious comorbidities, including impaired renal or hepatic function.
	  o History of previous statin intolerance or muscle disorders.
	  o Unexplained alanine transaminase elevations >3 times upper limit of normal.
	  o Patient characteristics or concomitant use of drugs affecting statin metabolism.
	  o >75 years of age.
	• Additional characteristics that may modify the decision to use higher statin intensities may include, but are not limited to:
	  o History of hemorrhagic stroke.
	  o Asian ancestry.
	• Creatine kinase should not be routinely measured in individuals receiving statin therapy.
	• Baseline measurement of creatinine kinase is reasonable for individuals believed to be at increased risk for adverse muscle events based on a personal or family history of statin intolerance or muscle disease, clinical presentation, or concomitant drug therapy that might increase the risk for myopathy.
	• During statin therapy, it is reasonable to measure creatinine kinase in individuals with muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or generalized fatigue.
	• Baseline measurement of hepatic transaminase levels should be performed before initiating statin therapy.
	• During statin therapy, it is reasonable to measure hepatic function if symptoms suggesting hepatotoxicity arise (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine or yellowing of the skin or sclera).
	• Decreasing the statin dose may be considered when two consecutive values of LDL-C levels are <40 mg/dL.
	• It may be harmful to initiate simvastatin at 80 mg daily or increase the dose of simvastatin to 80 mg daily.
	• Individuals receiving statin therapy should be evaluated for new-onset diabetes mellitus according to the current diabetes screening guidelines. Those who develop diabetes mellitus during statin therapy should be encouraged to adhere to a heart healthy dietary pattern, engage in physical activity, achieve and maintain a healthy body weight, cease tobacco use, and continue statin therapy to reduce their risk of ASCVD events.

Clinical Guideline	Recommendation

	• For individuals taking any dose of statins, it is reasonable to use caution in individuals >75 years of age, as well as in individuals that are taking concomitant medications that alter drug metabolism, taking multiple drugs, or taking drugs for conditions that require complex medication regimens (e.g., those who have undergone solid organ transplantation or are receiving treatment for human immunodeficiency virus (HIV). A review of the manufacturer's prescribing information may be useful before initiating any cholesterol-lowering drug).
	• It is reasonable to evaluate and treat muscle symptoms, including pain, tenderness, stiffness, cramping, weakness, or fatigue, in statin-treated patients according to the following management algorithm:
	  o To avoid unnecessary discontinuation of statins, obtain a history of prior or current muscle symptoms to establish a baseline before initiating statin therapy.
	  o If unexplained severe muscle symptoms or fatigue develop during statin therapy, promptly discontinue the statin and address the possibility of rhabdomyolysis by evaluating creatinine kinase, creatinine, and a urinalysis for myoglobinuria.
	• If mild to moderate muscle symptoms develop during statin therapy:
	  o Discontinue the statin until the symptoms can be evaluated.
	  o Evaluate the patient for other conditions that might increase the risk for muscle symptoms (e.g., hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases).
	  o If muscle symptoms resolve, and if no contraindication exists, give the patient the original or a lower dose of the same statin to establish a causal relationship between the muscle symptoms and statin therapy.
	  o If a causal relationship exists, discontinue the original statin. Once muscle symptoms resolve, use a low dose of a different statin.
	  o Once a low dose of a statin is tolerated, gradually increase the dose as tolerated.
	  o If, after two months without statin treatment, muscle symptoms or elevated creatinine kinase levels do not resolve completely, consider other causes of muscle symptoms listed above.
	  o If persistent muscle symptoms are determined to arise from a condition unrelated to statin therapy, or if the predisposing condition has been treated, resume statin therapy at the original dose.
	• For individuals presenting with a confusional state or memory impairment while on statin therapy, it may be reasonable to evaluate the patient for non-statin causes, such as exposure to other drugs, as well as for systemic and neuropsychiatric causes, in addition to the possibility of adverse effects associated with statin drug therapy.
	
	<u>Monitoring and optimizing statin therapy</u>
	• Adherence to medication and lifestyle, therapeutic response to statin therapy, and safety should be regularly assessed. This should also include a fasting lipid panel performed within four to 12 weeks after initiation or dose adjustment, and every three to 12 months thereafter. Other safety measurements should be measured as clinically indicated.
	• The maximum tolerated intensity of statin should be used in individuals for whom a high- or moderate-intensity statin is recommended, but not tolerated.
	• Individuals who have a less-than anticipated therapeutic response or are intolerant of the recommended intensity of statin therapy, the following should be performed:
	  o Reinforce medication adherence.
	  o Reinforce adherence to intensive lifestyle changes.

Clinical Guideline	Recommendation
	○ Exclude secondary causes of hyperlipidemia. • It is reasonable to use the following as indicators of anticipated therapeutic response to the recommended intensity of statin therapy. Focus is on the intensity of the statin therapy. As an aid to monitoring: ○ High-intensity statin therapy generally results in an average LDL-C reduction of ≥50% from the untreated baseline; ○ Moderate-intensity statin therapy generally results in an average LDL-C reduction of 30 to <50% from the untreated baseline; ○ LDL-C levels and percent reduction are to be used only to assess response to therapy and adherence. They are not to be used as performance standards. • Individuals at higher ASCVD risk receiving the maximum tolerated intensity of statin therapy who continue to have a less than-anticipated therapeutic response, addition of a non-statin cholesterol-lowering drug(s) may be considered if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. • Higher-risk individuals include: ○ Individuals with clinical ASCVD <75 years of age. ○ Individuals with baseline LDL-C ≥190 mg/dL. ○ Individuals 40 to 75 years of age with diabetes mellitus. ○ Preference should be given to non-statin cholesterol-lowering drugs shown to reduce ASCVD events in controlled trials. • In individuals who are candidates for statin treatment but are completely statin intolerant, it is reasonable to use non-statin cholesterol lowering drugs that have been shown to reduce ASCVD events in controlled trials if the ASCVD risk-reduction benefits outweigh the potential for adverse effects. <u>Non statin safety</u> • Baseline hepatic transaminases, fasting blood glucose or hemoglobin A1c, and uric acid should be obtained before initiating niacin, and again during up-titration to a maintenance dose and every six months thereafter. • Niacin should not be used if: ○ Hepatic transaminase elevations are higher than two to three times upper limit of normal. ○ Persistent severe cutaneous symptoms, persistent hyperglycemia, acute gout or unexplained abdominal pain or gastrointestinal symptoms occur. ○ New-onset atrial fibrillation or weight loss occurs. • In individuals with adverse effects from niacin, the potential for ASCVD benefits and the potential for adverse effects should be reconsidered before reinitiating niacin therapy. • To reduce the frequency and severity of adverse cutaneous symptoms, it is reasonable to: ○ Start niacin at a low dose and titrate to a higher dose over a period of weeks as tolerated. ○ Take niacin with food or premedicating with aspirin 325 mg 30 minutes before niacin dosing to alleviate flushing symptoms. ○ If an extended-release preparation is used, increase the dose of extended-release niacin from 500 mg to a maximum of 2,000 mg/day over four to eight weeks, with the dose of extended release niacin increasing not more than weekly. ○ If immediate-release niacin is chosen, start at a dose of 100 mg three times daily and up-titrate to 3 g/day, divided into two or three doses. • Bile acid sequestrants should not be used in individuals with baseline fasting triglyceride levels ≥300 mg/dL or type III hyperlipoproteinemia, because severe triglyceride elevations might occur. • A fasting lipid panel should be obtained before bile acid sequestrants are

Clinical Guideline	Recommendation
	initiated, three months after initiation, and every six to 12 months thereafter. • It is reasonable to use bile acid sequestrants with caution if baseline triglyceride levels are 250 to 299 mg/dL, and evaluate a fasting lipid panel in four to six weeks after initiation. Discontinue the bile acid sequestrants if triglycerides exceed 400 mg/dL. • It is reasonable to obtain baseline hepatic transaminases before initiating ezetimibe. When ezetimibe is coadministered with a statin, monitor transaminase levels as clinically indicated, and discontinue ezetimibe if persistent alanine transaminase elevations >3 times upper limit of normal occur. • Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis. • Fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, are judged to outweigh the potential risk for adverse effect. • Renal status should be evaluated before fenofibrate initiation, within three months after initiation, and every six months thereafter. Assess renal safety with both a serum creatinine level and an estimated glomerular filtration rate based on creatinine. • Fenofibrate should not be used if moderate or severe renal impairment, defined as estimated glomerular filtration rate <30 mL/min per 1.73 m^2, is present. • If estimated glomerular filtration rate is between 30 and 59 mL/min per 1.73 m^2, the dose of fenofibrate should not exceed 54 mg/day. • If, during follow-up, the estimated glomerular filtration rate decreases persistently to ≤30 mL/min per 1.73 m^2, fenofibrate should be discontinued. • If eicosapentaenoic acid and/or docosahexanoic acid are used for the management of severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL, it is reasonable to evaluate the patient for gastrointestinal disturbances, skin changes, and bleeding.

American College of Cardiology:
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016)[19]
	Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention
	• These patients should be treated first with maximally tolerated statin intensity. If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <100 mg/dL), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response (<50% reduction in LDL-C and may consider LDL-C ≥100 mg/dL):
	  ○ Assess statin adherence.
	  ○ If an adherent patient has not been tried on a high-intensity statin, the dose should be increased to a high-intensity dose at this time.
	  ○ Intensify lifestyle modifications.
	  ○ Consider adding ezetimibe 10 mg daily as the first non-statin agent.
	  ○ A bile acid sequestrant (BAS) may be considered as a second-line agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL, but there is no evidence for benefit of BAS in addition to statins in this population.
	• If ASCVD patients without comorbidities, who are on maximally tolerated statin–ezetimibe or non-statin combination therapy in the setting of documented statin intolerance, achieve a less-than-anticipated response with <50% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL):
	  ○ It is reasonable to consider the net benefit of alirocumab or evolocumab (in addition to or in place of ezetimibe) as a second step to achieve further LDL-C reduction.
	  ○ If a PCSK9 inhibitor is prescribed, clinicians should continue

Clinical Guideline	Recommendation

	maximally tolerated statin and monitoring for adherence to medications and lifestyle, side effects, and ongoing LDL-C response to therapy.
	
	Clinical ASCVD with comorbidities, on statin for secondary prevention
	• These patients should be treated first with maximally tolerated statin intensity.
	• If patients have a ≥50% reduction in LDL-C from baseline (and may consider LDL-C <70 mg/dL or non–HDL-C <100 mg/dL for patients with diabetes), it is reasonable to continue the statin therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
	• If a patient has a less-than-anticipated response:
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	Clinical ASCVD and baseline LDL-C ≥190 mg/dL not due to secondary causes, on statin for secondary prevention
	• Patients with LDL-C ≥190 mg/dL are more likely to have heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia.
	• In patients who have a less-than-anticipated response on maximally tolerated statin therapy with <50% reduction in LDL-C (and may consider LDL-C ≥70 mg/dL):
	  ○ Address statin intolerance.
	  ○ Intensify lifestyle modifications (may consider phytosterols).
	  ○ Increase to high-intensity statin if not already taking.
	  ○ Evaluate for statin intolerance if unable to tolerate moderate-intensity statin. Consider referral to lipid specialist if statin intolerant.
	  ○ Control other risk factors.
	  ○ Consider ezetimibe (or BAS second line) first.
	  ○ Consider adding or replacing with PCSK9 inhibitor second.
	
	Adults Aged 40 to 75 Years Without ASCVD, but With Diabetes
	• In patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C despite adherence to lifestyle recommendations and moderate-intensity statin therapy, the recommended threshold for consideration of the net benefit of increasing to high-intensity statin therapy is failure to achieve 30 to <50% reduction in LDL-C (and may consider on -treatment LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL).
	• If a patient with diabetes and 10-year ASCVD risk <7.5% without high-risk features has a less-than-anticipated response, with <30% reduction in LDL-C (and may consider LDL-C ≥100 mg/dL or non-HDL-C ≥130 mg/dL), additional clinical approaches may be warranted.
	• Ezetimibe is the preferred initial non-statin therapy due to tolerability, convenience, and single-tablet daily dose.
	• BAS may have a modest hypoglycemic effect that may be of benefit in some diabetic patients if fasting triglycerides are <300 mg/dL. BAS may also be considered if patients have an inadequate response to ezetimibe or if patients are ezetimibe intolerant.
	In the absence of ASCVD or baseline LDL-C ≥190 mg/dL not due to secondary causes, the PCSK9 inhibitors do not have an established role for primary prevention of ASCVD in patients with diabetes.

National Institute for	• Be aware that when deciding on lipid modification therapy for the prevention of

Clinical Guideline	Recommendation

Health and Clinical Excellence: **Cardiovascular disease: risk assessment and reduction, including lipid modification (2014)**[20]
 	
Updated Sep 2016
	cardiovascular disease (CVD), drugs are preferred for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality.
	• When a decision is made to prescribe a statin use a statin of high intensity and low acquisition cost.
	
	Lipid Measurement and Referral:
	• Measure both total and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk.
	• Before starting lipid modification therapy for the primary prevention of CVD, take at least one lipid sample to measure a full lipid profile. This should include measurement of total cholesterol, HDL cholesterol, non-HDL cholesterol, and triglyceride concentrations. A fasting sample is not needed.
	• Use the clinical findings, lipid profile and family history to judge the likelihood of a familial lipid disorder rather than the use of strict lipid cut-off values alone.
	• Exclude possible common secondary causes of dyslipidemia (such as excess alcohol, uncontrolled diabetes, hypothyroidism, liver disease and nephrotic syndrome) before referring for specialist review.
	• Consider the possibility of familial hypercholesterolemia if they have a total cholesterol concentration >7.5 mmol/L and a family history of premature coronary heart disease.
	• Arrange for specialist assessment of people with a total cholesterol concentration of more than 9.0 mmol/L or a non-HDL cholesterol concentration of more than 7.5 mmol/L even in the absence of a first-degree family history of premature coronary heart disease.
	• Refer for urgent specialist review if a person has a triglyceride concentration of more than 20 mmol/L that is not a result of excess alcohol or poor glycemic control.
	• In people with a triglyceride concentration between 10 and 20 mmol/L:
	  ○ Repeat the triglyceride measurement with a fasting test (after an interval of five days, but within two weeks) and
	  ○ Review for potential secondary causes of hyperlipidemia and
	  ○ See specialist advice if the triglyceride concentration remains above 10 mmol/L
	• In people with a triglyceride concentration between 4.5 and 9.9 mmol/L:
	  ○ Be aware that the CVD risk may be underestimated by risk assessment tools and
	  ○ Optimize the management of other CVD risk factors present and
	  ○ Seek specialist advice if non-HDL cholesterol concentration is more than 7.5 mmol/litre.
	
	Statins for the prevention of CVD:
	• The decision whether to start statin therapy should be made after an informed discussion between the clinician and the person about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.
	• Before starting statin treatment perform baseline blood tests and clinical assessment, and treat comorbidities and secondary causes of dyslipidemia. Include smoking status, alcohol consumption, blood pressure, body mass index or other obesity measure, total cholesterol, non-HDL cholesterol, HDL cholesterol, triglyceride level, glycosylated hemoglobin (HbA_{1c}), renal function and estimated glomerular filtration rate (eGFR), transaminase levels, and thyroid stimulating hormone in the assessment.
	
	Statins for the Primary Prevention of CVD:

Clinical Guideline	Recommendation

	• Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimize the management of all other modifiable CVD risk factors if possible.
	• Recognize that people may need support to change their lifestyle. To help them do this, refer them to programs such as exercise referral schemes.
	• Offer people the opportunity to have their risk of CVD assessed again after they have tried to change their lifestyle.
	• If lifestyle modification is ineffective or inappropriate, offer statin treatment after risk assessment.
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	• For people 85 years or older consider atorvastatin 20 mg as statins may be of benefit in reducing the risk of non-fatal myocardial infarction. Be aware of factors that may make treatment inappropriate.
	
	<u>Statins for the Secondary Prevention of CVD</u>:
	• Start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower dose of atorvastatin if there are potential drug interactions, high risk of adverse effects, or patient preference.
	• Do not delay statin treatment in secondary prevention to manage modifiable risk factors.
	• If a person has acute coronary syndrome, do not delay statin treatment. Take a lipid sample on admission and about three months after the start of treatment.
	
	<u>Statins for the Primary Prevention of CVD for People with Type 1 Diabetes</u>:
	• Consider statin treatment for the primary prevention of CVD in all adults with type 1 diabetes.
	• Offer statin treatment for the primary prevention of CVD to adults with type 1 diabetes who are older than 40 years, have had diabetes for more than 10 years, have established nephropathy, or have other CVD risk factors.
	• Start treatment for adults with type 1 diabetes with atorvastatin 20 mg.
	
	<u>Statins for the Primary Prevention of CVD in People with Type 2 Diabetes</u>:
	• Offer atorvastatin 20 mg for the primary prevention of CVD to people with type 2 diabetes who have a 10% or greater 10-year risk of developing CVD. Estimate the level of risk using the QRISK2 assessment tool.
	
	<u>Statins for People with CKD</u>:
	• Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD
	  ○ Increase the dose if a greater than 40% reduction in non-HDL cholesterol is not achieved and eGFR is 30 mL/min/1.73 m^2 or more.
	  ○ Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73 m^2.
	
	<u>Follow-up of People Started on Statin Therapy</u>:
	• Measure total cholesterol, HDL cholesterol and non-HDL cholesterol in all people who have been started on high-intensity statin treatment at three months of treatment and aim for a greater than 40% reduction in non-HDL cholesterol.
	• If a greater than 40% reduction in non-HDL cholesterol is not achieved, discuss adherence to lifestyle modifications and drug therapy, timing of dose.
	  ○ Consider increasing the dose if started on less than atorvastatin 80 mg and the person is judged to be at higher risk because of comorbidities, risk score or using clinical judgement.

Clinical Guideline	Recommendation

	• Provide annual medication reviews for people taking statins.
	• Discuss with people who are stable on a low- or middle-intensity statin the likely benefits and potential risks of changing to a high-intensity statin when they have a medication review and agree with the person whether a change is needed.
	
	<u>Monitoring Statin Therapy for Adverse Effects</u>:
	• Advise people who are being treated with a statin that other drugs, some foods (e.g., grapefruit juice) and some supplements may interfere with statins and to always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements.
	• Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses.
	• Before offering a statin, ask the person if they have had persistent generalized unexplained muscle pain, whether associated or not with previous lipid-lowering therapy. If they have, measure creatine kinase levels.
	  o If creatine kinase levels are more than five times the upper limit of normal, re-measure creatine kinase after seven days. If creatine kinase levels are still five times the upper limit of normal, do not start statin treatment.
	  o If creatine kinase levels are raised but less than five times the upper limit of normal, start statin treatment at a lower dose.
	• Advise people who are being treated with a statin to seek medical advice if they develop muscle symptoms (pain, tenderness or weakness). If this occurs, measure creatine kinase.
	• If people report muscle pain or weakness while taking a statin, explore other possible causes of muscle pain or weakness and raised creatine kinase if they have previously tolerated statin therapy for more than three months.
	• Do not measure creatine kinase levels in asymptomatic people who are being treated with a statin.
	• Measure baseline liver transaminase before starting a statin. Measure liver transaminase within three months of starting treatment and at 12 months, but not again unless clinically indicated.
	• Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than three times the upper limit of normal.
	• Do not stop statins because of an increase in blood glucose level or HbA_{1c}.
	• Statins are contraindicated in pregnancy and women of childbearing potential should be advised of the potential teratogenic risk of statins and to stop taking them if pregnancy is a possibility.
	  o Advise women planning pregnancy to stop taking statins three months before they attempt to conceive and to not restart them until breastfeeding is finished.
	
	<u>Intolerance to Statin Therapy</u>:
	• If a person is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose.
	• Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statins discuss the following possible strategies with them:
	  o stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin and
	  o reducing the dose within the same intensity group and
	  o changing the statin to a lower intensity group.
	• Seek specialist advice about options for treating people at high risk of CVD

Clinical Guideline	Recommendation
	such as those with CKD, type 1 diabetes, type 2 diabetes or genetic dyslipidemias, and those with CVD, who are intolerant to three different statins. Fibrates for Preventing CVD: • Do not routinely offer fibrates for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Nicotinic Acid for Preventing CVD: • Do not offer nicotinic acid (niacin) for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Bile Acid Sequestrants (Anion Exchange Resins) for Preventing CVD: • Do not offer bile acid sequestrants for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer omega-3 fatty acid compounds for the prevention of CVD to people who are being treated for primary or secondary prevention, or people with CKD or diabetes type 1 or 2. • Tell people that there is no evidence that omega-3 fatty acid compounds help to prevent CVD. Omega-3 Fatty Acid Compounds for Preventing CVD: • Do not offer the combination of a bile acid sequestrant (anion exchange resin), fibrate, nicotinic acid or omega-3 fatty acid compound with a statin for the primary or secondary prevention of CVD. Ezetimibe for Preventing CVD: • People with primary hypercholesterolemia should be considered for ezetimibe treatment.
American Heart Association: **Drug Therapy of High Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association (2007)**[21]	• For children meeting criteria for lipid-lowering drug therapy, a statin is recommended as first line treatment. The choice of statin is dependent upon preference but should be initiated at the lowest dose once daily, usually at bedtime. • For patients with high risk lipid abnormalities, the presence of additional risk factors or high risk conditions may reduce the recommended LDL level for initiation of drug therapy and the desired target LDL levels. Therapy may also be considered for initiation in patients <10 years of age. • Additional research regarding drug therapy of high risk lipid abnormalities in children is needed to evaluate the long term efficacy and safety and impact on the atherosclerotic disease process. • Niacin is rarely used to treat the pediatric population. • Given the reported poor tolerance, the potential for very serious adverse effects, and the limited available data, niacin cannot be routinely recommended but may be considered for selected patients. • This guideline does not contain recommendations regarding the use of omega-3 acid ethyl esters.
European Society of Cardiology and Other Societies: **Guidelines on Cardiovascular**	Drugs • Currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g. ezetimibe) and, more recently, proprotein convertase

Clinical Guideline	Recommendation
Disease Prevention in Clinical Practice (2016)[22]	subtilisin/kexin type 9 (PCSK9) inhibitors. Response to all therapy varies widely among individuals and therefore monitoring the effect on LDL-C levels is recommended. • Statins, by reducing LDL-C, reduce cardiovascular morbidity and mortality as well as the need for coronary artery interventions. • Statins should be used as the drugs of first choice in patients with hypercholesterolemia or combined hyperlipidemia. • Selective cholesterol absorption inhibitors are not usually used as monotherapy to decrease LDL-C concentrations, unless patients are intolerant to statins. They are recommended as combination therapy with statins in selected patients when a specific goal is not reached with the maximal tolerated dose of a statin. • Bile acid sequestrants also decrease TC and LDL-C, but are poorly tolerated and tend to increase plasma triglyceride concentrations. They are therefore not recommended for routine use in CVD prevention. • Fibrates and niacin are used primarily for triglyceride lowering and increasing HDL-C, while fish oils (n-3 fatty acids) are used for triglyceride lowering. Evidence supporting the use of these drugs for CVD event reduction is limited and, given the strong evidence favouring statins, routine use of these drugs in CVD prevention is not recommended. In order to prevent pancreatitis, when triglycerides are >10 mmol/L (>900 mg/dL) they must be reduced not only by drugs but also by restriction of alcohol, treatment of DM, withdrawal of estrogen therapy, etc. In those rare patients with severe primary hypertriglyceridaemia, specialist referral must be considered. • Regarding new therapies, recent data from phase I–III trials show that PCSK9 inhibitors sharply decrease LDL-C by up to 60%, either as monotherapy or in addition to the maximal statin dose. Whether this approach results in the predicted reduction in CV events is being addressed in large outcome trials; preliminary evidence suggests that this is the case. <u>Drug combinations</u> • Patients with dyslipidemia, particularly those with established cardiovascular disease, diabetes, or asymptomatic high risk patients, may not always reach treatment targets; therefore, combination treatment may be needed. • The only combination that has evidence of clinical benefit (one large RCT) is that of a statin combined with ezetimibe. Based on the relatively limited body of evidence, clinicians may restrict the use of this combination to patients at high or very-high risk of CVD. • Combinations of niacin and a statin increase HDL-C and decrease TG better than either drug used as monotherapy, but flushing is the main adverse event with niacin, which may affect compliance. • Fibrates, particularly fenofibrate, may be useful, not only for decreasing TG and increasing HDL-C, but can further lower LDL-C when administered in combination with a statin. • If target levels cannot be reached with maximal doses of lipid-lowering therapy or combination therapy, patients will still benefit from treatment to the extent to which dyslipidemia has been improved. In these patients, increased attention to other risk factors may help to reduce total risk.
American Heart Association/ American Stroke Association: **Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack**	• Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or transient ischemic attack (TIA) presumed to be of atherosclerotic origin and an LDL-C level ≥100mg/dL with or without evidence for other clinical ASCVD. • Statin therapy with intensive lipid-lowering effects is recommended to reduce risk of stroke and cardiovascular events among patients with ischemic stroke or TIA presumed to be of atherosclerotic origin, and LDL-C level <100 mg/dL, and no evidence for other clinical ASCVD.

Clinical Guideline	Recommendation
(2014)[23]	• Patients with ischemic stroke or TIA and other comorbid ASCVD should be otherwise managed according to the 2013 ACC/AHA cholesterol guidelines, which include lifestyle modifications, dietary recommendations, and medication recommendations.
American Association of the Study of Liver Disease: **Primary Biliary Cirrhosis (2009)**[24] **Reaffirmed October 2014**	• Ursodeoxycholic acid therapy is the only Food and Drug Administration-approved agent for the treatment of primary biliary cirrhosis. It is currently supported by the most data and is recommended for use in appropriately selected patients who have abnormal liver chemistry. • Issues of patient compliance, development of superimposed liver disease, or coadministration with bile sequestrants (e.g., cholestyramine or colestipol) should be considered for patients with suboptimal response. • Pruritus is a complication of primary biliary cirrhosis and cholestyramine is the drug of choice for the treatment of this complication. Alternative treatments of pruritus include rifampin, opioid antagonists, and liver transplantation.

American Association of Clinical Endocrinologists: **Consensus Statement on the Comprehensive Type 2 Diabetes Management Algorithm 2016 (2016)**[25]	Principles underlying the algorithm
	• Lifestyle optimization is essential for all patients with diabetes; however, it should not delay needed pharmacotherapy, which can be initiated simultaneously and adjusted based on patient response to lifestyle efforts. The need for medical therapy should not be interpreted as a failure of lifestyle management, but as an adjunct to it.
	• Achieving an HbA_{1c} ≤6.5% is recommended as the primary goal if it can be achieved in a safe and affordable manner; however, higher targets may be appropriate for certain individuals and may change for a given individual over time.
	• Minimizing risk of hypoglycemia and weight gain is a priority. It is a matter of safety, adherence, and cost.
	• For optimal glycemic control, therapies with complementary mechanisms of action must typically be used in combination.
	• Therapeutic effectiveness must be evaluated frequently until stable (e.g., every three months).
	• Safety and efficacy should be given higher priority than the initial acquisition cost of medications, as medication cost is only a small part of the total cost of diabetes care. In assessing the cost of a medication, consideration should be given to monitoring requirements and risks of hypoglycemia and weight gain.
	• The therapeutic regimen should be as simple as possible to optimize adherence.
	
	Monotherapy
	• Patients with recent-onset diabetes and those with mild hyperglycemia (HbA_{1c} <7.5%), initial monotherapy with metformin (at doses of 1,500 to 2,000 mg/day) and life-style modifications will achieve their glycemic goals in a majority of patients.
	• In patients with intolerance or contraindications to metformin, acceptable therapeutic alternatives that reduce glucose without weight gain or hypoglycemia (in order based on suggested hierarchy of usage) include:
	  ○ GLP-1 receptor agonists.
	  ○ Sodium glucose cotransporter 2 (SGLT-2) inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZDs (use with caution).
	  ○ Alpha-glucosidase inhibitors.
	• sulfonylureas, and glinides (in order based on suggested hierarchy of usage) may be used but with caution due to possible weight gain and hypoglycemia.
	
	Combination therapy
	• Patients who present with an initial HbA_{1c} >7.5% or who do not reach their target HbA_{1c} with metformin in three months should be started on a second

Clinical Guideline	Recommendation

	agent to be used in combination with metformin.
	• Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy.
	• In metformin-intolerant patients, two drugs from other classes with complimentary mechanisms of action should be used.
	• Combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent) plus:
	  ○ GLP-1 receptor agonists.
	  ○ SGLT-2 inhibitors.
	  ○ DPP-4 inhibitors.
	  ○ TZD.
	  ○ Basal insulin.
	  ○ Colesevelam.
	  ○ Bromocriptine quick release.
	  ○ Alpha-glucosidase inhibitors.
	  ○ Sulfonylureas and glinides.
	
	<u>Three-drug combination therapy</u>
	• Generally, the efficacy of a third antidiabetic agent added to dual therapy is reduced compared to the efficacy of the same drug used as monotherapy or combination therapy with one other agent.
	• Patients who present with an initial HbA_{1c} >9.0% with no symptoms should be started on combination therapy or three-drug combination therapy.
	• Patients who present with an HbA_{1c} <8.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs after three months have a high likelihood of reaching target with a third agent.
	• Patients who present with an HbA_{1c} >9.0% or who do not reach their target HbA_{1c} with two antidiabetic drugs has are less likely of reaching target with a third agent or fourth agent and insulin should be considered.
	• Continuation with noninsulin therapies while starting basal insulin is common and does not increase cardiovascular risk, but may increase risk of hypoglycemia when sulfourea are used in conjunction with insulin.
	• Three-drug combination (in order based on suggested hierarchy of usage) include metformin (or other first-line agent), a second-line agent plus:
	  ○ GLP-1 receptor agonists.
	  ○ SGLT-2 inhibitors.
	  ○ TZD.
	  ○ Basal insulin.
	  ○ DPP-4 inhibitors.
	  ○ Colesevelam.
	  ○ Bromocriptine quick release.
	  ○ Alpha-glucosidase inhibitors.
	  ○ Sulfonylureas and glinides.
	
	<u>Insulin therapy algorithm</u>
	• Patients who present with an initial HbA_{1c} >9.0% and are symptomatic, should initiate therapy with insulin with or without other antidiabetic agents.
	• Start insulin if a patient has marked hyperglycemia despite treatment with several oral antidiabetic agents and is symptomatic with polyuria and weight loss.
	• Patients who are not at target HbA_{1c} despite the use of oral antidiabetic agents or GLP-1 therapy should be considered for insulin therapy.
	• Patients with an HbA_{1c} level >8.0% while receiving ≥2 antidiabetic agents, particularly individuals with long duration of diabetes, have significant impairment of beta cell insulin secretory capacity and are unlikely to reach the

Clinical Guideline	Recommendation
	recommended target by the addition of further oral antidiabetic drugs. Basal insulin • Patients with an HbA_{1c} level >8.0% while receiving ≥2 oral antidiabetic agents or GLP-1 therapy can be started on single daily dose of basal insulin as an add-on to the patient's existing regimen. • Titrate insulin dose every two to three days to reach glycemic goals. • Basal insulin analogues (glargine and detemir) are preferred over protamine Hagedorn insulin because they have been shown to provide a relatively flat serum insulin concentration for up to 24 hours from a single daily injection. • Patients who fail to achieve glucose control with basal insulin or premixed insulin formulations can also be considered for basal intensification with a DPP-4 inhibitor or GLP-1 receptor agonist if the glucose level is not markedly elevated, because this approach tends to not cause weight gain or additional hypoglycemia. Basal-bolus insulin regimens • Patients who fail to achieve glucose control with basal insulin or premixed insulin formulations and those with symptomatic hyperglycemia and HbA_{1c} >10% often respond better to combined basal and mealtime bolus insulin. • A full basal-bolus program with an insulin basal analogue once or twice daily and a rapid-acting analogue at each meal is most effective and provides flexibility for patients with variable mealtimes and meal carbohydrate content. • Doses of insulin may be titrated every two to three days to reach glycemic goals. Basal insulin and incretin therapy regimens • Use of the amylin analog pramlintide in conjunction with bolus insulin improves both glycemia and weight in patients with type 2 diabetes. • The incretin therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have similar properties, and also increase endogenous insulin secretion. Therefore, the combination of basal insulin and incretin therapy decreases basal and postprandial glucose and may minimize the weight gain and hypoglycemia risk observed with basal-bolus insulin replacement.
National Institute for Health and Clinical Excellence: **Identification and management of familial hypercholesterolaemia (2008)**[26] **Last updated July 2016**	Drug treatment in adults • When offering lipid-modifying drug therapy to adults with familial hypercholesterolemia (FH), inform the patient that this treatment should be life-long. • Statins should be the initial treatment for all adults with FH. • Consider prescribing a high-intensity statin to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline. • The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline. • Offer treatment with a statin with a low acquisition cost for adults with FH in whom the diagnosis is made after the age of 60 and who do not have coronary heart disease. • Ezetimibe monotherapy is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who would otherwise be initiated on statin therapy but who are unable to do so because of contraindications or intolerance to initial statin therapy. • Ezetimibe, coadministered with initial statin therapy, is recommended as an option for the treatment of adults with heterozygous-familial hypercholesterolemia who have been initiated on statin therapy when: ○ Serum total or LDL-C concentration is not appropriately controlled either

Clinical Guideline	Recommendation
	after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy AND ○ Consideration is being given to changing from initial statin therapy to an alternative statin. • Prescribing of drug therapy for adults with homozygous FH should be undertaken within a specialist center. • Adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration. • Exercise caution when adding a fibrate or nicotinic acid to a statin because of the risk of muscle-related side effects (including rhabdomyolysis). Gemfibrozil and statins should not be used together. <u>Drug treatment in children and young people</u> • All children and young people diagnosed with, or being investigated for, a diagnosis of FH should have a referral to a specialist with expertise in FH in children and young people. • Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-modifying drug therapy for a child or young person should take into account: ○ Their age. ○ The age of onset of coronary heart disease within the family. ○ And the presence of other cardiovascular risk factors, including LCL-C concentration. • When offering lipid-modifying drug therapy for children or young people, inform the child/young person and their parent/carer that this treatment should be life-long. • When the decision to initiate lipid-modifying drug therapy has been made in children and young people, statins should be the initial treatment. Healthcare professionals with expertise in FH in children and young people should choose a statin that is licensed for use in the appropriate age group. • In exceptional instances, for example, when there is a family history of coronary heart disease in early adulthood, healthcare professionals with expertise in FH in children and young people should consider offering: ○ A higher dose of statin than is licensed for use in the age group and/or ○ More than one lipid-modifying drug therapy, and/or ○ Lipid-modifying drug therapy before the age of 10 years. • In children and young people with homozygous FH, LDL-C concentration may be lowered by lipid-modifying drug therapy and this should be considered before LDL apheresis. • In children and young people with FH who are intolerant of statins, consider offering other lipid-modifying drug therapies capable of reducing LDL-C concentration (such as bile acid sequestrants [resins], fibrates or ezetimibe). • Routine monitoring of growth and pubertal development in children and young people with FH is recommended.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the miscellaneous antilipemic agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-

reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Antilipemic Agents, Miscellaneous[2,4-9]

Indication	Icosapent Ethyl	Lomit-apide	Mipom-ersen	Niacin Extended-Release*	Niacin Immediate-Release*	Omega-3 Acid Ethyl Esters*
Hypertriglyceridemia						
Adjunctive therapy for the treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them				✔	✔ †	
Adjunct to diet to reduce triglyceride (TG) levels in adults with severe (≥500 mg/dL) hypertriglyceridemia	✔					✔
Primary Hypercholesterolemia and Mixed Dyslipidemia						
Adjunct to diet, alone or in combination with a bile acid binding resin, for reduction of elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia					✔	
Adjunct to diet to reduce elevated TC, LDL-C, apolipoprotein B, and TG levels, and to increase high-density lipoprotein cholesterol in patients with primary hyperlipidemia and mixed dyslipidemia				✔		
Adjunct to diet and in combination with a bile acid binding resin to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia				✔		
Secondary Prevention of Cardiovascular Disease						
Adjunct to diet to reduce the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidemia				✔		
Adjunct to diet and in combination with a bile acid binding resin to slow progression or promote regression of atherosclerotic disease in patients with a history of coronary artery disease and hyperlipidemia				✔		
Homozygous Familial Hypercholesterolemia (HoFH)						
Adjunct to diet and other lipid-lowering treatments^, to reduce LDL-C, TC, apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with HoFH		✔	✔			

*Over-the-counter products are considered dietary supplements.
†Types IV and V hyperlipidemia.
^The safety and effectiveness of mipomersen as an adjunct to LDL apheresis have not been established; therefore, the use of mipomersen as an adjunct to LDL apheresis is not recommended.

IV. Pharmacokinetics

The pharmacokinetic parameters of the miscellaneous antilipemic agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Antilipemic Agents, Miscellaneous[3]

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life
Icosapent ethyl	Not reported	>99	Liver (% not reported)	Not reported	89 hours
Lomitapide	7	99.8	Liver (extensive)	Renal (53 to 60) Feces (33 to 35)	39.7 hours
Mipomersen	SQ: 54 to 78	≥90	Nucleases	Renal (<4)	1 to 2 months
Niacin	ER: 60 to 76	Not reported	Liver (rapid; % not reported)	Renal (60 to 88)	IR: 20 to 45 minutes
Omega-3 acid ethyl esters	Not reported	Not reported	Not reported	Not reported	Not reported

ER=extended-release, IR=immediate-release, SQ=subcutaneous

V. Drug Interactions

Major drug interactions with the miscellaneous antilipemic agents are listed in Table 5. There are no significant drug interactions reported with the icosapent ethyl, mipomersen, niacin, and omega-3 acid ethyl esters.[2] A strong CYP3A4 inhibitor has been shown to increase lomitapide exposure approximately 27-fold. Concomitant use of strong CYP3A4 inhibitors with lomitapide is contraindicated. Patients must avoid grapefruit juice. Do not exceed 30 mg daily of lomitapide when used concomitantly with weak CYP3A4 inhibitors, including atorvastatin and oral contraceptives.[8]

Table 5. Major Drug Interactions with the Oral Anticoagulants[3]

Generic Name(s)	Interaction	Mechanism
Lomitapide	Aprepitant	Aprepitant inhibits lomitapide CYP3A4 metabolism, which may increase lomitapide plasma concentrations and risk of adverse reactions (e.g., hepatotoxicity).
Lomitapide	Protease inhibitors	Concurrent use of strong or moderate CYP3A4 inhibitors, such protease inhibitors, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Azole antifungals	Concurrent use of strong or moderate CYP3A4 inhibitors, such as azole antifungals, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Macrolide antibiotics	Concurrent use of strong or moderate CYP3A4 inhibitors, such as macrolide antibiotics, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Conivaptan	Concurrent use of strong or moderate CYP3A4 inhibitors, such as conivaptan, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Diltiazem	Concurrent use of strong or moderate CYP3A4 inhibitors, such as diltiazem, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Grapefruit Juice	Grapefruit juice ingestion inhibits lomitapide CYP3A4 metabolism, which may increase lomitapide plasma concentrations and risk of adverse reactions (e.g., hepatotoxicity).
Lomitapide	Imatinib	Concurrent use of strong or moderate CYP3A4 inhibitors, such as imatinib, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Nefazodone	Concurrent use of moderate or strong CYP3A4 inhibitors, such as nefazodone, may elevate lomitapide plasma concentrations, increasing the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	Verapamil	Concurrent use of strong or moderate CYP3A4 inhibitors, such as verapamil, may elevate lomitapide plasma concentrations, increasing

Generic Name(s)	Interaction	Mechanism
		the risk of serious adverse reactions (e.g., hepatotoxicity).
Lomitapide	HMG-CoA Reductase Inhibitors (Atorvastatin, lovastatin, simvastatin)	Inhibition of metabolism (CYP3A4) of certain HMG-CoA reductase inhibitors by lomitapide. Plasma concentrations of certain HMG-CoA reductase inhibitors may be elevated, increasing the pharmacologic effects and risk of adverse reactions (e.g., myositis).
Lomitapide	Warfarin	Concurrent use of lomitapide and warfarin may result in increased warfarin exposure.

VI. Adverse Drug Events

The most common adverse drug events reported with the miscellaneous antilipemic agents are listed in Table 6. The boxed warnings for lomitapide and mipomersen are listed in Tables 7 and 8. Pooled data from randomized, placebo-controlled trials have shown that prescription omega-3 acid ethyl esters are safe and well tolerated.[11] At usual antilipemic dosages, niacin is generally well tolerated and side effects are mild and transient. The most common adverse effects with niacin are gastrointestinal upset, flushing and pruritus. Flushing is more common with the immediate-release formulation and may be diminished by starting with a low dose, taking niacin after meals, and by pretreating with aspirin or ibuprofen.[2,3] Sustained-release preparations have been shown to be hepatotoxic in doses ≥2 g per day. Cases of severe hepatic toxicity, including fulminant hepatic necrosis have occurred in patients who have substituted sustained-release niacin products for immediate-release products at equivalent doses.[4,5]

Table 6. Adverse Drug Events (%) Reported with the Antilipemic Agents, Miscellaneous[2,4-9]

Adverse Event	Icosapent Ethyl (Vascepa®)	Lomitapide (Juxtapid®)	Mipomersen (Kynamro®)	Niacin ER (Niaspan®)	Niacin IR (Niacor®)	Omega-3 Acid Ethyl Esters (Lovaza®)
Cardiovascular						
Angina pectoris	-	10	4	-	-	1
Arrhythmia	-	-	-	✔	✔	✔
Atrial fibrillation	-	-	-	✔	✔	-
Bypass surgery	-	-	-	-	-	✔
Cardiac arrest	-	-	-	-	-	✔
Chest pain	-	24	-	-	-	✔
Hypertension	-	-	7	-	-	✔
Hypotension	-	-	-	✔	✔	-
Migraine	-	-	-	✔	-	✔
Myocardial infarction	-	-	-	-	-	✔
Myocardial ischemia	-	-	-	-	-	✔
Occlusion	-	-	-	-	-	✔
Orthostasis	-	-	-	✔	✔	-
Palpitations	-	10	3	✔	-	-
Peripheral edema	-	-	-	✔	-	-
Peripheral vascular disorder	-	-	-	-	-	✔
Postural hypotension	-	-	-	✔	-	-
Syncope	-	-	-	✔	-	✔
Tachycardia	-	-	-	✔	-	✔
Central Nervous System						
Depression	-	-	-	-	-	✔
Dizziness	-	10	-	✔	-	✔
Emotional lability	-	-	-	-	-	✔
Facial paralysis	-	-	-	-	-	✔
Fatigue	-	17	15	-	-	-
Headache	-	10	12	-	✔	-

Adverse Event	Icosapent Ethyl (Vascepa®)	Lomitapide (Juxtapid®)	Mipomersen (Kynamro®)	Niacin ER (Niaspan®)	Niacin IR (Niacor®)	Omega-3 Acid Ethyl Esters (Lovaza®)
Insomnia	-	-	3	✔	-	✔
Migraine	-	-	-	✔	-	-
Nervousness	-	-	-	✔	-	-
Paresthesia	-	-	-	✔	-	-
Vasodilatation	-	-	-	-	-	✔
Vertigo	-	-	-	-	-	✔
Dermatologic						
Acanthosis nigricans	-	-	-	-	✔	-
Alopecia	-	-	-	-	-	✔
Dry skin	-	-	-	✔	✔	-
Eczema	-	-	-	-	-	✔
Flushing	-	-	-	63 to 69	✔	-
Hyperpigmentation	-	-	-	-	✔	-
Pruritus	-	-	-	3 to 8	✔	✔
Rash	-	-	-	0 to 5	-	2
Skin burning sensation	-	-	-	✔	-	-
Skin discoloration	-	-	-	✔	-	-
Sweating	-	-	-	✔	-	-
Urticaria	-	-	-	✔	-	✔
Endocrine and Metabolic						
Gout	-	-	-	✔	✔	-
Gastrointestinal						
Abdominal discomfort	-	21	-	-	-	-
Abdominal pain	-	34	3	-	-	-
Abdomen enlarged	-	21	-	-	-	✔
Anorexia	-	-	-	-	-	✔
Colitis	-	-	-	-	-	✔
Constipation	-	21	-	-	-	✔
Defecation urgency	-	10	-	-	-	-
Diarrhea	-	79	-	7 to 14	✔	-
Dry mouth	-	-	-	-	-	✔
Dyspepsia	-	38	-	-	✔	3
Dysphagia	-	-	-	-	-	✔
Eructation	-	-	-	✔	-	5
Fecal incontinence	-	-	-	-	-	✔
Flatulence	-	21	-	✔	-	-
Gastritis	-	-	-	-	-	✔
Gastroenteritis	-	14	-	-	-	✔
Gastroesophageal reflux disease	-	10	-	-	-	-
Increased appetite	-	-	-	-	-	✔
Intestinal obstruction	-	-	-	-	-	✔
Melena	-	-	-	-	-	✔
Nausea	-	65	14	4 to 11	-	-
Pancreatitis	-	-	-	-	-	✔
Peptic ulceration	-	-	-	✔	✔	-
Tenesmus	-	10	-	-	-	✔
Vomiting	-	34	4	0 to 9	✔	✔
Weight loss	-	24	-	-	-	-
Hematologic						
Prothrombin time increased	-	-	-	✔	-	-
Thrombocytopenia	-	-	-	✔	-	-
Hepatic						
Fulminant hepatic necrosis	-	-	-	-	✔	-
Hepatitis	-	-	-	✔	-	-
Hepatotoxicity	-	10	-	✔	✔	-

Adverse Event	Icosapent Ethyl (Vascepa®)	Lomitapide (Juxtapid®)	Mipomersen (Kynamro®)	Niacin ER (Niaspan®)	Niacin IR (Niacor®)	Omega-3 Acid Ethyl Esters (Lovaza®)
Jaundice	-	-	-	✔	✔	-
Laboratory Test Abnormalities						
Amylase increased	-	-	-	✔	-	-
Hepatic steatosis	-	-	7	-	-	-
Hyperglycemia	-	-	-	✔	✔	✔
Hyperlipidemia	-	-	-	-	-	✔
Hyperuricemia	-	-	-	✔	✔	-
Lactate dehydrogenase increased	-	-	-	✔	-	-
Liver function test abnormalities	-	34	10	✔	✔	✔
Phosphorus decreased	-	-	-	✔	-	-
Musculoskeletal						
Arthralgia	2.3	-	-	-	-	✔
Arthritis	-	-	-	-	-	✔
Asthenia	-	-	-	✔	-	✔
Back pain	-	14	-	-	-	2
Fracture	-	-	-	-	-	✔
Malaise	-	-	-	-	-	✔
Myalgia	-	-	-	✔	-	✔
Myasthenia	-	-	-	✔	-	-
Myopathy	-	-	-	✔	-	-
Neck pain	-	-	-	-	-	✔
Pain	-	-	4	-	-	2
Rhabdomyolysis	-	-	-	-	✔	-
Rheumatoid arthritis	-	-	-	-	-	✔
Tendon rupture	-	-	-	-	-	✔
Respiratory						
Asthma	-	-	-	-	-	✔
Bronchitis	-	-	-	-	-	✔
Cough	-	-	-	2 to 8	-	✔
Dyspnea	-	-	-	✔	-	✔
Epistaxis	-	-	-	-	-	✔
Laryngitis	-	-	-	-	-	✔
Nasal congestion	-	10	-	-	-	-
Pharyngitis	-	17	-	-	-	✔
Pneumonia	-	-	-	-	-	✔
Rhinitis	-	-	-	-	-	✔
Sinusitis	-	-	-	-	-	✔
Urogenital						
Cervix disorder	-	-	-	-	-	✔
Endometrial carcinoma	-	-	-	-	-	✔
Epididymitis	-	-	-	-	-	✔
Impotence	-	-	-	-	-	✔
Other						
Anaphylaxis	-	-	-	✔	-	✔
Angioedema	-	-	-	✔	-	-
Blurred vision	-	-	-	✔	-	-
Body odor	-	-	-	-	-	✔
Cataract	-	-	-	-	-	✔
Chills	-	-	6	-	-	✔
Edema	-	-	5	-	-	✔
Facial edema	-	-	-	✔	-	-
Fever	-	10	8	-	-	✔
Flu symptoms	-	21	13	-	-	4
Hemorrhagic diathesis	-	-	-	-	-	✔

Adverse Event	Icosapent Ethyl (Vascepa®)	Lomitapide (Juxtapid®)	Mipomersen (Kynamro®)	Niacin ER (Niaspan®)	Niacin IR (Niacor®)	Omega-3 Acid Ethyl Esters (Lovaza®)
Hypersensitivity reactions	-	-	✔	✔	-	-
Infection	-	-	-	-	-	4
Injection-site reaction	-	-	84	-	-	-
Laryngismus	-	-	-	✔	-	-
Larynx edema	-	-	-	✔	-	-
Lymphadenopathy	-	-	-	-	-	✔
Macular edema	-	-	-	✔	✔	-
Neoplasm	-	-	✔	-	-	✔
Psychiatric disorders	-	-	10	-	-	-
Sudden death	-	-	-	-	-	✔
Suicide	-	-	-	-	-	✔
Taste perversion	-	-	-	-	-	3
Tongue edema	-	-	-	✔	-	-
Toxoid amblyopia	-	-	-	-	✔	-
Vascular disorders	-	-	11	-	-	-

✔ Percent not specified.
-Event not reported.
ER=Extended-release, IR=Immediate-release.

Table 7. Boxed Warning for Lomitapide[8]

WARNING
Warning: Risk of Hepatotoxicity Lomitapide can cause elevations in transaminases. In the Juxtapid clinical trial, 10 (34%) of the 29 patients treated with lomitapide had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase. Lomitapide also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat was 6% after both 26 and 78 weeks of treatment, from 1% at baseline, measured by magnetic resonance spectroscopy. Hepatic steatosis associated with lomitapide treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment, adjust the dose of lomitapide if the ALT or AST are ≥3x ULN. Discontinue lomitapide for clinically significant liver toxicity. Because of the risk of hepatotoxicity, lomitapide is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the JUXTAPID REMS Program. Prescribe lomitapide only to patients with a clinical or laboratory diagnosis consistent with HoFH. The safety and effectiveness of lomitapide have not been established in patients with hypercholesterolemia who do not have HoFH.

Table 8. Boxed Warning for Mipomersen[9]

WARNING
Warning: Risk of Hepatotoxicity Mipomersen can cause elevations in transaminases. In the Kynamro clinical trial in patients with HoFH, four (12%) of the 34 patients treated with mipomersen compared with 0% of the 17 patients treated with placebo had at least one elevation in alanine aminotransferase (ALT) ≥3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR) or partial thromboplastin time (PTT).

Mipomersen also increases hepatic fat, with or without concomitant increases in transaminases. In the trials in patients with heterozygous familial hypercholesterolemia (HeFH) and hyperlipidemia, the median absolute increase in hepatic fat was 10% after 26 weeks of treatment, from 0% at baseline, measured by magnetic resonance imaging (MRI). Hepatic steatosis is a risk factor for advanced liver disease; including steatohepatitis and cirrhosis.

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT, AST regularly as recommended. During treatment, withhold the dose of mipomersen if the ALT or AST are ≥3 x ULN. Discontinue mipomersen for clinically significant liver toxicity.

Because of the risk of hepatotoxicity, mipomersen is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYNAMRO REMS. Prescribe mipomersen only to patients with a clinical or laboratory diagnosis consistent with HoFH. The safety and effectiveness of mipomersen have not been established in patients with hypercholesterolemia who do not have HoFH.

VII. Dosing and Administration

The usual dosing regimens for the miscellaneous antilipemic agents are listed in Table 9.

Table 9. Usual Dosing Regimens for the Antilipemic Agents, Miscellaneous[4-9]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Icosapent ethyl	Severe hypertriglyceridemia: Capsule: 4 g/day taken as four 0.5 gram capsules twice daily or two 1 gram capsules twice daily	Safety and effectiveness in children have not been established.	Capsule: 0.5 gram 1 gram
Lomitapide	Homozygous Familial Hypercholesterolemia*: Capsule: initial, 5 mg once daily; maximum, 60 mg once daily	Safety and effectiveness in children have not been established.	Capsule: 5 mg 10 mg 20 mg 30 mg 40 mg 60 mg
Mipomersen	Homozygous Familial Hypercholesterolemia*: Injection: 200 mg once weekly as a subcutaneous injection	Safety and effectiveness in children have not been established.	Injection: 200 mg/mL
Niacin	Hyperlipidemia: Extended-release capsule: 1 to 2 g two to three times daily; maximum, 6 g/day Extended-release tablet: initial, 500 mg at bedtime; maintenance, 1,000 to 2,000 mg once daily; maximum, doses >2,000 mg/day are not recommended Tablet: initial, 250 mg/day with evening meal; maintenance, 1 to 2 g two or three times daily Secondary prevention of	Safety and efficacy in children have not been established (extended-release capsule, immediate-release). Safety and effectiveness in children ≤16 years of age have not been established (extended-release tablet).	Extended-release tablet: 500 mg 750 mg 1,000 mg Tablet: 500 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	cardiovascular disease: Extended-release tablet: initial, 500 mg at bedtime; maintenance, 1,000 to 2,000 mg once daily; maximum, doses >2,000 mg/day are not recommended Severe hypertriglyceridemia: Extended-release capsule: 1to 2 g two to three times daily; maximum, 6 g/day Extended-release tablet: initial, 500 mg at bedtime; maintenance, 1,000 to 2,000 mg once daily; maximum, doses >2,000 mg/day are not recommended Tablet: initial, 250 mg/day with evening meal; maintenance, 1 to 2 g two or three times daily		
Omega-3 acid ethyl esters	Severe hypertriglyceridemia: Capsule: 4 g/day taken as a single 4 g dose or as two 2 g doses (2 capsules given twice daily)	Safety and effectiveness in children have not been established.	Capsule: 1 gram

*Before beginning treatment, measure alanine aminotransaminase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the miscellaneous antilipemic agents are summarized in Table 10.

Table 10. Comparative Clinical Trials with the Antilipemic Agents, Miscellaneous

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hypercholesterolemia				
Bays et al.[27] (2011) MARINE Icosapent ethyl 4 g/day (2 g twice daily) vs icosapent ethyl 2 g/day (1 g twice daily) vs placebo twice daily (Icosapent ethyl is referred to by the investigational name AMR101 in this trial)	DB, MC, PC, RCT Adults >18 years of age with TG levels of ≥500 and ≤2000 mg/dL	N=229 4 to 6 week wash-out (any lipid-altering drug therapy other than statins and ezetimibe were discontinued) 2 to 3 week qualifying period 12 weeks of treatment	Primary: Placebo-corrected median percentage of change in TG from baseline to week 12 Secondary: Percent change from baseline in VLDL-C, apo B, and lipoprotein-associated phospholipase A_2; safety	Primary: Icosapent ethyl 4 g/day reduced placebo-corrected median TG levels by 33.1% (P<0.0001); icosapent ethyl 2 g/day reduced placebo-corrected median TG levels by 19.7% (P=0.0051). Secondary: Neither icosapent ethyl 4 g/day nor 2 g/day significantly increased the LDL cholesterol levels. Icosapent ethyl 4 g/day significantly reduced non-HDL-C by 17.7% (P<0.0001), lipoprotein-associated phospholipase A_2 by 13.6% (P=0.0003), very low density lipoprotein–TG by 25.8% (P=0.0023), and apo B by 8.5% (P=0.0019). Icosapent ethyl 2 g/day significantly reduced non-HDL-C by 8.1% (P=0.0182). Both icosapent ethyl doses significantly reduced VLDL-C and TC, with no significant effect on HD-C. The incidence of treatment-emergent adverse events was generally similar across the three treatment groups.
Ballantyne et al.[28] (2012) ANCHOR Icosapent ethyl 4 g/day (2 g twice daily)	DB, MC, PC, RCT Patients >18 years of age and at high risk for CV disease with residually high TG levels (≥200 and <500 mg/dL) despite	N=702 4 to 6 week wash-out (any lipid-altering drug therapy other than statins	Primary: Median percent change in TG levels from baseline versus placebo at 12 weeks	Primary: Icosapent ethyl 4 and 2 g/day significantly decreased TG levels by 21.5% (P<0.0001) and 10.1% (P=0.0005), respectively. Secondary: Icosapent ethyl 4 and 2 g/day significantly decreased non-HDL-C by 13.6% (P<0.0001) and 5.5% (P=0.0054), respectively. Icosapent ethyl 4 g/day produced greater TG and non-HDL-C decreases in patients with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs icosapent ethyl 2 g/day (1 g twice daily) vs placebo twice daily (Icosapent ethyl is referred to by the investigational name AMR101 in this trial)	LDL-C control (≥40 and <100 mg/dL) with statin therapy	were discontinued) 2 to 3 week qualifying period 12 weeks of treatment	Secondary: Median placebo-adjusted percent change in non-HDL-C, LDL-C, apo B, VLDL, and lipoprotein-associated phospholipase A_2; safety	higher-efficacy statin regimens and greater TG decreases in patients with higher baseline TG levels. Icosapent ethyl 4 g/day decreased LDL-C by 6.2% (P=0.0067) and decreased apo B (9.3%), TC (12.0%), VLDL-C (24.4%), lipoprotein-associated phospholipase A_2 (19.0%), and hsCRP (22.0%) versus placebo (P<0.001 for all comparisons). Icosapent ethyl was generally well tolerated, with safety profiles similar to placebo.
Samaha et al.[29] (2008) Group 1: ezetimibe 10 daily plus placebo for 12 weeks vs group 2: lomitapide 5 mg for the first 4 weeks, 7.5 mg for the second 4 weeks, and 10 mg for the last 4 weeks, plus placebo for 12 weeks vs	DB, MC, RCT Hypercholesterolemic patients 18 to 70 years of age; Patients with 0 or 1 risk factors were required to have an LDL-C concentration between 160 and 250 mg/dL, and those with more than two risk factors were required to have an LDL-C concentration between 130 and 250 mg/dL	N=85 12 weeks	Primary: Percentage change in LDL-C from baseline Secondary: Percentage changes in other serum lipoproteins (TC, non-HDL, VLDL, TG, HDL-C, Lp(a), apoB and apoA-I), change in body weight and overall safety and tolerability	Primary: Patients assigned to the combination of ezetimibe plus lomitapide experienced dose-dependent reductions in LDL ranging from 35 to 46% (P<0.001 vs ezetimibe alone). Patients assigned ezetimibe monotherapy experienced a 20 to 22% decrease in LDL-C levels after 12 weeks of therapy. Patients assigned to lomitapide monotherapy experienced dose-dependent reductions in LDL-C concentrations ranging from 19 to 30% (P=0.013 for a greater LDL reduction with 10 mg lomitapide alone vs 10 mg ezetimibe alone). Secondary: Patients receiving lomitapide monotherapy experienced dose-dependent decreases in concentrations of TC (23% at 10 mg), non-HDL-C (27% at 10 mg) and apoB (24% at 10 mg); these reductions were all greater than those observed with ezetimibe monotherapy. Further reductions in TC, non-HD-C, and apoB levels were observed in the group receiving combination therapy. TG did not change significantly from baseline in any of the three groups. Patients receiving lomitapide either alone or in combination with ezetimibe experienced a significant decrease in Lp(a) compared with those receiving ezetimibe alone. After 12 weeks, patients assigned ezetimibe monotherapy experienced a

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
group 3: lomitapide (with the same dosing schedule as group 2) plus 10 mg ezetimibe daily for 12 weeks (Lomitapide is referred to by the investigational name AEGR-733 in this trial)				mean weight loss of 0.2 ±1.9 kg (0.1%); those assigned lomitapide monotherapy experienced a mean weight loss of 0.7 ±2.0 kg (1.0%); and those assigned combined lomitapide plus ezetimibe experienced a mean weight loss of 1.4 ±2.6 kg (1.4%); only the latter change was significant (P=0.013). However, the weight loss was not significantly different in the combination group vs the group receiving ezetimibe alone. Of the 85 patients enrolled, 18 (20%) either stopped or were taken off study medication before completion of the study, mainly owing to mildly elevated transaminase levels. This adverse event occurred in 9 of 56 (18%) patients who took lomitapide, either alone or in combination with ezetimibe, compared with none of the 29 patients assigned to ezetimibe alone. Transaminase levels returned to baseline in all these patients over the course of the protocol-specified, 2-week follow-up.
Cuchel et al.[30] (2013) Lomitapide at a starting dose of 5 mg/day for the first 2 weeks and then escalated to 10, 20, 40, and 60 mg a day at 4-week intervals or until an individually determined maximum dose was achieved Patients continued current lipid-lowering therapy	OL, single-arm Patients ≥18 years of age with HoFH	N=29 78 weeks	Primary: Mean percent change in levels of LDL-C from baseline to week 26 Secondary: Percent changes in other lipid parameters, long-term safety (78 weeks), and changes in hepatic-fat content	Primary: Mean LDL-C significantly decreased by 50% from baseline to the end of the efficacy phase (week 26). Secondary: Mean TC, LDL-C, VLDL-C, non-HDL-C, TG, and apo B all decreased between 45 and 50% from baseline (P<0.0001). Lp(a), HDL-C, and ApoA-I all also saw significant reductions at week 26. HDL-C, Lp(a), and ApoA-I returned to levels similar to those at baseline by week 78. The most commonly reported events during treatment with lomitapide were gastrointestinal (27 patients during the efficacy phase, and 17 during the safety phase). The three patients who discontinued the study because of gastrointestinal disorders permanently stopped lomitapide by week 12. No serious adverse events were reported between weeks 26 and 78. Ten patients had elevated levels of ALT, AST, or both of more than three times the upper limit of normal at least once during the study. Hepatic fat was measured non-invasively with nuclear magnetic resonance spectroscopy (NMRS). Mean hepatic fat in the 20 patients with evaluable NMRS scans was 1.0% (range 0 to 5.0) at baseline, 8.6% (0 to 33.6) at week 26, 5.8% (0 to 16.5%) at week 56, and 8.3% (0 to 19.0%) at week 78.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Stefanutti et al.[31] (2015) Lomitapide at a starting dose of 5 mg/day for the first two weeks and then escalated to 10, 20, 40, and 60 mg a day at 4-week intervals or until an individually determined maximum dose was achieved Patients continued current lipid-lowering therapy	Post-hoc analysis of Cuchel et al. Patients ≥18 years of age with HoFH, stratified by those who did or did not receive lipoprotein apheresis	N=29 78 weeks	Primary: Mean percent change in levels of LDL-C from baseline to week 26 Secondary: Percent changes in other lipid parameters	Primary: Of the 29 patients who entered the efficacy phase, 18 (62%) were receiving either lipoprotein apheresis or therapeutic plasma exchange at baseline. By the end of the efficacy phase (Week 26), during which apheresis schedules were to remain consistent, lomitapide was associated with a similar mean percent reduction in LDL-C from baseline irrespective of whether patients received apheresis or not. According to a mixed model repeated measures, overall percent reductions in LDL-C from baseline were −51.0% in all patients, −48.0% in those on apheresis and −55.1% in those not on apheresis (P=0.545). Secondary: Similarly, percent reductions in non-HDL-C (−48.3 vs −54.2%; P=0.613), TC (−43.8 vs −49.8%; P=0.575) and apoB (−47.9 vs −53.2%; P=0.625) were not significantly different between those on apheresis and those not. Changes in Lp(a) levels were modest and not different between groups (P=0.436).
Raal et al.[32] (2010) Mipomersen 200 mg subcutaneously every week vs placebo	DB, RCT Patients aged 12 years and older with clinical diagnosis or genetic confirmation of HoFH, who were already receiving the maximum tolerated dose of a lipid-lowering drug	N=51 26 weeks of treatment	Primary: Percentage change in LDL-C concentration from baseline Secondary: Percentage change from baseline in apo B, TC, and non-HDL-C concentrations	Primary: The reduction in LDL cholesterol concentration with mipomersen reflected an absolute mean decrease of 24.7 vs 3.3% in the placebo group (P=0.0003). Secondary: The percentage change from baseline in apo B concentration was significantly greater with mipomersen than with placebo. Reductions of a similar magnitude were also recorded for concentrations of TC, non-HDL-C, and VLD-C, and to a lesser extent for TG.
Visser et al.[33] (2012) Mipomersen 200 mg subcutaneously	DB, RCT Hypercholesterolem-ic subjects who were statin intolerant	N=33 26 weeks	Primary: Percentage change in LDL-C concentration from baseline	Primary: Treatment with mipomersen resulted in significant reductions in LDL-C of 47% (±18) (P<0.001 vs placebo) with a range of −19 to −77%. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
every week vs placebo	(unable to tolerate at least two different statins due to side effects of any kind) and at high risk for CV events		Secondary: Percentage change from baseline in apo B, TC, HDL-C, TG, VLDL-C, and non-HDL-C concentrations; safety	Mipomersen treatment significantly lowered apo B, TC, TG, and Lp(a) but did not affect HDL-C and apo A1. Increases in ALT above the upper limit of normal were more common in the mipomersen treatment group [N=17 (81%)] compared with the placebo treatment group [N=3 (25%)]. Persistent increases in ALT (≥3× upper limit of normal on two consecutive occasions at least seven days apart) were observed in seven subjects (33%) from the active treatment group.
Stein et al.[34] (2012) Mipomersen 200 mg subcutaneously every week vs placebo	DB, RCT Adults aged ≥18 years with HeFH by either genetic confirmation of a LDL receptor defect or clinical diagnosis of untreated LDL cholesterol >190 mg/dL and clinical criteria consistent with those of the Simon Broome Register plus documented and stable (>24 weeks) CAD. At screening, patients were required to have LDL-C ≥100 mg/dL and TG <200 mg/dL and to have received a stable maximally tolerated statin, with or without other lipid-lowering therapy for at least 12	N=124 26 weeks	Primary: Percentage change in LDL-C concentration from baseline Secondary: Percentage change from baseline in apo B, TC, and non-HDL-C concentrations; safety Tertiary: Percent change in lipoprotein(a), TG, VLDL-C, HDL-C, apo A1, and ratio of LDL to HDL ratio.	Primary: Mipomersen treatment resulted in a statistically significant mean percent reduction from baseline in LDL cholesterol (-28.0%) compared with a small increase with placebo (+5.2%) (P<0.001). Thirty-seven patients (45.1%) achieved LDL cholesterol <100 mg/dL compared with two patients (4.9%) on placebo. Secondary/Tertiary: Mipomersen significantly reduced apo B (-26.3%), TC (-19.4%), non-HDL-C (-25.0%), and Lp(a) (-21.1%) compared with placebo (all P<0.001). No significant differences in changes in HDL-C or hsCRP levels were observed. Common adverse events consisted primarily of injection site reactions (41.5% placebo, 92.8% mipomersen) and influenza-like symptoms (31.7% placebo, 49.4% mipomersen). Elevations in ALT ≥3 times the upper limit of normal occurred in one placebo patient (2.4%) and 12 mipomersen patients (14.5%). These elevations were confirmed ≥1 week later in five (6%) of the mipomersen and none of the placebo patients. Overall, increased ALT levels appear to be associated with reductions in apo B levels. Mipomersen did not have adverse effects on serum creatinine, creatine kinase, platelet count, fasting glucose, or blood pressure.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	weeks			
McGowan et al.[35] (2012) Mipomersen 200 mg subcutaneously every week vs placebo	DB, RCT Adults patients with severe hypercholesterolemia defined as an LDL-C ≥200 mg/dL with known CHD or an LDL-C ≥300 mg/dL in the absence of known CHD. Patients were on a stable low fat diet, at a stable weight, on maximally tolerated lipid-lowering therapy, met LDL-apheresis criteria but apheresis was prohibited	N=57 26 weeks	Primary: Percentage change in LDL-C concentration from baseline Secondary: Percentage change from baseline in apo B, TC, and non-HDL-C concentrations	Primary: The mean percent change in LDL-C of −36% (95% CI, –51.3 to −15.3) in mipomersen patients was statistically significant (P<0.001) compared to the mean percent change of 12.5% (95% CI, –10.8 to 35.8) in placebo patients. Secondary: Changes in apo B, TC, non-HDL-C, and Lp(a) mirrored the primary findings.
Thomas et al.[36] (2013) Mipomersen 200 mg subcutaneously every week vs placebo	DB, RCT Patients ≥18 years of age with baseline LDL-C levels ≥100 mg/dL with, or at high risk for, CHD who were receiving maximally tolerated lipid-lowering therapy	N=157 26 weeks	Primary: Percentage change in LDL-C concentration from baseline Secondary: Percentage change from baseline in apo B, TC, non-HDL-C, TG, Lp(a), VLDL-C, LDL/HDL ratio, apo A1, and HDL-C concentrations	Primary: Mipomersen-treated patients experienced significantly greater reductions from baseline in mean LDL cholesterol (−36.9%) than placebo-treated patients (−4.5%) (P<0.001). Moreover, 76% of mipomersen versus 38% of placebo patients attained LDL cholesterol <100 mg/dl at the primary efficacy timepoint, while 51% of mipomersen versus 8% of placebo attained LDL cholesterol <70 mg/dl. Secondary: Reductions from baseline in apo B, non-HDL-C, and LDL/HDL ratio were similar (about 37%) to those in LDL-C; reductions in TC, TG, and VLDL-C were slightly smaller (about 25%). Lp(a) was also reduced (26% with mipomersen, 0% with placebo). A small decrease in apo A1 was observed with mipomersen. No significant difference was noted between treatment groups in HDL-C or hsCRP.
Santos et al.[37] (2015)	ES, OL	N=141	Primary: Percent change in	Primary: The mean changes in LDL-C from baseline to weeks 26 (n = 130), 52 (n =

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Mipomersen 200 mg subcutaneously every week	Patients with HeFH or HoFH taking maximally tolerated lipid-lowering therapy who had successfully completed a phase III placebo-controlled mipomersen trial and had an acceptable safety profile (no significant liver blood test abnormalities that met stopping criteria or intolerable injections site reactions/flu-like symptoms), no new or worsening conditions that interfered with study completion, and were willing to limit alcohol consumption to moderate amounts	104 weeks	LDL-C, apoB, TC, non-HDL-C, LDL/HDL ratio, TG, VLDL-C, HDL-C, apo A-I, and Lp(a) Secondary: Safety	111), 76 (n = 66), and 104 (n = 53) were −28, −27, −27, and −28%, respectively. If treatment was stopped, LDL-C gradually returned to near baseline over 24 weeks. The mean changes in apoB from baseline to weeks 26, 52, 76, and 104 were −29, −28, −30, and −31%, respectively (P<0.001). Mean reductions in TC and non-HDL-C and median percent reductions in Lp(a) were observed throughout treatment, consistent with the mean reductions in LDL-C and apoB. Mean increases in HDL-C from baseline at weeks 26, 52, 76, and 104 were 6% (P<0.01), 6% (P<0.05), 3%, and 10% (P<0.01), respectively. Secondary: All patients had at least one treatment-emergent adverse event; 138 (98%) experienced at least one injection site reaction, and 92 (65%) had at least one episode of flu-like symptoms. Flu-like symptoms were the most frequent cause of drug discontinuation. The frequency of injection site reactions progressively decreased by two-thirds after 24 months of follow-up. Serious adverse events occurred in 33 (23%) patients; four were considered possibly drug related, which included membranous glomerulonephritis, atrial fibrillation, appendicitis, and biliary colic. The biliary colic resulted in treatment discontinuation. Of the 141 patients treated, 77 (55%) discontinued treatment within the first two years of treatment; 61 (43%) due to treatment-emergent adverse events and 16 (11%) for reasons that were not adverse events such as investigator drop-out, patient study fatigue, or starting LDL apheresis. Eighteen of 141 patients (13%) had an ALT ≥3xULN on two consecutive occasions at least seven days apart. The time to the first occurrence of persistent ALT elevations was predominantly six to 12 months. There were no notable changes in other biochemistry or hematology parameters. There was no change in renal function as determined by serum creatinine levels and calculated glomerular filtration rates.
Elam et al.[38] (2000) Niacin IR	MC, PC, RCT Patients with peripheral arterial	N=468 (N=125 patients with diabetes)	Primary: Change in lipid profile, glucose, HbA_{1c}, ALT, uric	Primary: Niacin use significantly increased HDL-C by 29 and 29% and decreased TG by 23 and 28% and LDL-C by 8 and 9%, respectively, in participants with and without diabetes compared to baseline (P<0.001 for niacin vs

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(Niacor®) 3,000 mg per day or maximum tolerated dosage vs placebo	disease with or without diabetes, mean age 67 years for patients with diabetes and 65 years for those without diabetes	Up to 60 weeks (12-week active run-in and 48-week double-blind)	acid; hypoglycemic drug use, compliance, adverse events Secondary: Not reported	placebo for all). Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL; P=0.04 and P<0.001) in participants with and without diabetes, respectively. HbA_{1c} levels were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA_{1c} decreased by 0.3% (P=0.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. Secondary: Not reported
Capuzzi et al.[39] (1998) Niacin ER (Niaspan®) titrated to 1 to 3 g per day Concomitant therapy with a statin, bile acid sequestrant or both was permitted if the patient did not achieve sufficient LDL-C reduction.	ES, MC, OL Patients with primary hypercholesterolemia who were previously enrolled in a randomized short-term study or in a placebo-only qualification clinical trial	N=517 Up to 96 weeks	Primary: Changes in LDL-C and apo B Secondary: Changes in TC, HDL-C, TC:HDL-C, Lp(a) and TG; adverse events	Primary: Patients receiving niacin experienced significant reductions in LDL-C by 18% at week 48 and 20% at week 96. Similar reductions were seen with apo B (16% at week 48 and 19% at week 96). The percent changes achieved by both 48 and 96 weeks of therapy were statistically significant (P<0.001). Secondary: HDL-C significantly increased by 26% at week 48 and 28% at week 96 in patients receiving niacin. TC modestly decreased (12 and 13%, respectively), whereas the TC:HDL-C ratio decreased by almost one third (P<0.001 for all). TG and Lp(a) levels were decreased by 27 and 30%, respectively, at week 48, and by 28 and 40%, respectively, at week 96 (P<0.001 for all). Niacin was generally well tolerated. Flushing was common (75%); however, there was a progressive decrease in flushing with time from 3.3 episodes in the first month to ≤1 episode by week 48. Aspirin was used by one third of patients before niacin dosing to minimize flushing episodes. Six percent of patients discontinued therapy due to flushing.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Serious adverse events occurred in about 10% of patients; however, none were considered probably or definitely related to niacin. No deaths or myopathy occurred. There were statistically significant increases in alkaline phosphatase, ALT, amylase, AST, direct bilirubin, glucose, and uric acid and a decrease in phosphorus (P<0.001 for all). Mean platelet counts decreased by 10.1% at week 48 and 14.8% at week 96, whereas leukocyte counts increased by 6.5% and 6.8%, respectively, at week 48 and week 96 of therapy (P<0.0001 for all).
Guyton et al.[40] (1998) Niacin ER (Niaspan®) titrated to 1 to 3 g per day Concomitant therapy with a statin, bile acid sequestrant or both was permitted if the patient did not achieve sufficient LDL-C reduction.	ES, MC, OL Patients with primary hyperlipidemia who were previously enrolled in an RCT or in a placebo-only qualification clinical trial	N=269 patients treated up to 96 weeks and a cohort of N=230 patients treated for 3 months (safety data)	Primary: Changes in TC, LDL-C, HCL-C, TG, apo B and Lp(a); safety Secondary: Not reported	Primary: The dosages of niacin attained by 269 patients were 1,000 mg (95% of patients), 1,500 mg (86%) and 2,000 mg (65%). After 96 weeks of treatment, niacin alone (median dose 2,000 mg) significantly reduced LDL-C (18%), TC (10%), and TG (26%), and increased HDL-C (32%). Apo B and Lp(a) were significantly reduced by 26 and 36%, respectively, at 48 weeks but values for these parameters were not available at 96 weeks (P<0.01 for all). At 96 weeks of the study, niacin plus a statin significantly lowered LDL-C (32%), TC (24%), and TG (32%) and increased HDL-C (25%) (P<0.01 for all values). Apo B (26%; P<0.01) and Lp(a) (19%; P value not significant) were also reduced at 48 weeks but values for these parameters were not available at 96 weeks. Niacin plus a bile acid sequestrant lowered LDL-C (28%) and TC (15%) and increased HDL-C (31%) (P<0.01 for all values). Niacin plus a bile acid sequestrant increased TG (5%; P value not significant). Apo B and Lp(a) were significantly reduced by 19 and 24% (P<0.01), respectively, at 48 weeks but values for these parameters were not available at 96 weeks. Intolerance to flushing led 4.8% of participants (13 of 269) to discontinue niacin. (Combining all of the data, 7.3% of patients discontinued niacin due to flushing.) Other medication-related adverse events leading to discontinuation from the 96-week study included nausea (3.3% of patients) sometimes with vomiting, other gastrointestinal symptoms

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(1.5%) and pruritus (2.6%). One case each of acanthosis nigricans, elevated glucose, gout, headache, palpitations and shoulder pain led to patient withdrawal. Overall, 9 of 499 (2.6%) patients experienced an ALT or AST elevation >2 times upper limit of normal. Five of these patients were on combination therapy, including four with a statin and one with a bile acid sequestrant. In five of the nine cases, the transaminase elevation resolved while niacin was continued without reduction in dose. Three cases led to niacin dosage reduction. One patient discontinued niacin because of transaminase elevations. Leg aches and myalgias with normal creatine kinase levels were described in one patient taking niacin with simvastatin. Secondary: Not reported
Gray et al.[41] (1994) Niacin SR (Slo-Niacin®) average maintenance dose of 1.67 g per day	RETRO Male veterans with dyslipoproteinemia who were treated with niacin	N=969 1 to 36 months	Primary: Changes in lipid profile, alterations in hepatic enzymes and blood chemistry tests, hepatotoxicity Secondary: Not reported	Primary: Lipoprotein responses were dose-related and favorable. Results included the following: TC -19.1%, LDL-C -24.0%, HDL-C 5.7%, and TG -32.5% (P≤0.0035 for all). Statistically but not clinically meaningful dose-related increases were seen in levels of liver enzymes and serum glucose (AST 29%, ALT 23%, alkaline phosphatase 25%, and glucose 7%; P=0.0001). Niacin was discontinued in 48.5% (435 of 896) of patients primarily because of adverse effects. The primary documented reasons for discontinuation included flushing and itching (8.9%), increased serum glucose (4.8%), gastrointestinal complaints (3.7%) and increased liver function tests (3.7%). Poor glycemic controlled to discontinuation in 40.6% (43 of 106) patients with diabetes mellitus. Twenty of 896 (2.2%) and 42 of 896 (4.7%) patients met biochemical criteria for “probable” and for “possible or probable” niacin-induced hepatotoxicity, respectively. Predisposing factors included high dose, alcohol use, preexisting liver disease and concurrent oral sulfonylurea therapy.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Grundy et al.[42] (2002) Niacin ER (Niaspan®) 1,000 mg per day vs niacin ER (Niaspan®) 1,500 mg per day vs placebo	DB, PC, RCT Patients with stable type 2 diabetes, 47% were receiving concomitant statin therapy	N=148 16 weeks	Primary: Change in HDL-C, TG, HbA_{1c} Secondary: TC, LDL-C, FBG, adverse effects	Primary: Dose-dependent increases in HDL-C (13 to 19% for the 1,000 mg dose and 22 to 24% for the 1,500 mg dose; both P<0.05 vs placebo) and reductions in TG levels (-15 to -20% for the 1,000 mg dose; P value not significant, and -28 to -36% for the 1,500 mg dose; P<0.05) were observed. Changes in HbA_{1c} levels from baseline to week 16 were no different for niacin 1,000 mg/day (7.28 and 7.35%; P=0.16) and placebo (7.13 and 7.11%) but were significantly different for niacin 1,500 mg/day (7.2 and 7.5%; P=0.048). Secondary: Mean LDL-C levels were not significantly different than baseline for the placebo and niacin 1,000 mg groups. In the niacin 1,500 mg group, LDL-C levels decreased at all time points and the difference vs placebo was statistically significant at weeks 12 and 16 (P<0.05). The mean changes from baseline at 16 weeks were 9, 5 and -7% in the placebo, niacin 1,000 mg and 1,500 mg groups, respectively. Similar trends were observed for TC with mean increases of 4% in both the placebo and niacin 1,000 mg groups and a decrease of -6% in the niacin ER 1,500 mg group. In both the niacin groups, an initial rise in FBG was observed between weeks 4 and 8 which returned to baseline by week 16. Four patients in the niacin group (3 patients were receiving 1,500 mg) discontinued participation because of inadequate glucose control. Rates of adverse events other than flushing were similar for the niacin and placebo groups. Flushing was reported by about 67% of patients receiving niacin ER and about 10% of patients receiving placebo. Four patients, including 1 patient in the placebo arm, withdrew from the study due to flushing. No hepatotoxic effects or myopathy was observed.
Kuvin et al.[43]	PC, RCT	N=60	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2006) Niacin ER (Niaspan®) initially 500 mg at bedtime for 2 weeks then 1,000 mg at bedtime vs placebo	Patients with stable CAD and LDL-C <100 mg/dL, all received concurrent statin therapy (>80% atorvastatin)	3 months	Changes in lipoproteins, HDL and LDL particle distribution and inflammatory markers Secondary: Not reported	Six patients did not complete the protocol, two discontinued treatment due to flushing, and four were lost to follow-up. Niacin significantly increased total HDL-C by 7.5% and decreased TG by 15% compared to baseline (P<0.005 for both), whereas TC and LDL-C remained unchanged. Compared to baseline values, the addition of niacin resulted in a 32% increase in large-particle HDL (P<0.001) and an 8% decrease in small-particle HDL (P=0.0032). Addition of niacin produced an 82% increase in large-particle LDL (P=0.09) and a 12% decrease in small-particle LDL (P=0.008). Niacin also favorably altered inflammatory markers with lipoprotein-associated phospholipase A2 and CRP levels decreasing by 20 and 15%, respectively, compared to baseline (P<0.05 for both). No significant changes from baseline were seen in any tested parameter in patients who received placebo. No major cardiovascular events were reported during the study in the treatment or placebo group. Secondary: Not reported
Knopp et al.[44] (1998) Niacin IR titrated to 3 g per day vs niacin ER (Niaspan®) titrated to 1.5 g per day	DB, MC, PG, RCT Patients with hypercholesterolemia , average age 54 years	N=223 25 weeks (9 week lead-in period)	Primary: Change in LDL-C, FPG, uric acid, drug tolerance Secondary: Change in TC, TG, HDL-C, HDL sub-fractions, apo B, apo AI, apo E, and Lp(a)	Primary: LDL-C was significantly reduced by 12, 12 and 22%, respectively, by niacin ER 1.5 g at bedtime, niacin IR 1.5 g/day, and niacin IR 3.0 g/day, respectively, compared to placebo (P≤0.05). At equal doses of 1.5 g/day of niacin ER vs niacin IR, AST increased 5.0% vs 4.8% (P value not significant), FPG increased 4.8 vs 4.5% (P value not reported), and uric acid concentration increased 6 vs 16% (P=0.0001), respectively. Flushing events were more frequent with niacin IR vs niacin ER (1,905 vs

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				575; P<0.001). Flushing severity was slightly greater with SR niacin, but still well tolerated. Secondary: Compared to placebo at eight weeks, niacin SR 1.5 g at bedtime vs niacin IR 1.5 g/day showed comparable efficacy in lowering TC, TG, apo B, apo E and Lp(a), and raising HDL-C, HDL2-C, HDL3-C and apo AI (P≤0.05 in all instances). Niacin IR 3.0 g/day produced significantly greater changes in the above lipid parameters compared to niacin IR 1.5 g/day and niacin ER 1.5 g at bedtime (P≤0.05).
McKenney et al.[45] (1994) Niacin IR BID, for a total daily dose of 500, 1,000, 1,500, 2,000 and 3,000 mg for 6 weeks each vs niacin ER BID, for a total daily dose of 500, 1,000, 1,500, 2,000 and 3,000 mg for 6 weeks each	DB, PG, RCT Patients with LDL-C >160 mg/dL after 1 month on a NCEP ATP III-Step 1 diet	N=46 36 weeks	Primary: Changes in LCL-C, HDL-C and TG; adverse events Secondary: Not reported	Primary: Niacin ER significantly decreased LDL-C more than niacin IR with doses of ≥1,500 mg/day (P<0.04 or P<0.001). Niacin IR significantly increased HDL-C more than niacin ER with all doses (P<0.04 or P<0.001). The reductions in TG levels were similar between niacin IR and ER with all doses, except for niacin IR 1,000 mg/day which led to significantly greater reductions (P=0.009). Nine of 23 patients (39%) receiving niacin IR withdrew before completing the 3,000 mg/day dose. Four patients withdrew at 1,000 mg/day, one at 1,500 mg/day, three at 2,000 mg/day and one at 3,000 mg/day. The most common reasons for withdrawal were vasodilatory symptoms, fatigue and acanthosis nigricans. Eighteen of 23 patients (78%) receiving niacin ER withdrew before completing the 3,000 mg/day dose. Two patients withdrew at 1,000 mg/day, two at 1,500 mg/day, seven at 2,000 mg/day and seven at 3,000 mg/day. The most common reasons for withdrawal were gastrointestinal tract symptoms, fatigue and increases in liver function tests, often with symptoms of hepatic dysfunction. None of the patients receiving niacin IR developed hepatotoxic effects,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				while 12 patients (52%) receiving niacin ER did. Secondary: Not reported
Superko et al.[46] (2004) Niacin IR 3,000 mg/day vs niacin ER (Niaspan®) 1,500 mg/day vs placebo Results of 38 patients receiving niacin ER 3,000 mg/day from a previous trial were utilized in this analysis.	PC, RCT Patients with hyper-cholesterolemia	N=218 14 weeks	Primary: Changes in lipid profile and Lp subclass distribution Secondary: Not reported	Primary: Niacin IR and ER significantly decreased TG, LDL-C, apo B and Lp(a), and significantly increased HDL-C (P≤0.0001 for all). Niacin IR and ER significantly increased mean LDL peak particle diameter and percent distribution of large LDL I and IIa, with a significant decrease in small LDL IIIa, IIIb, and IVb (P<0.05 for all, except for LDL I; P=0.12 for niacin ER). In general, the effects were greater in patients with LDL pattern B (predominance of dense LDL) compared to those with LDL pattern A (predominance of buoyant LDL). Compared to niacin IR, niacin ER 3,000 mg/day produced a smaller decrease in TG (-27 vs -47%; P<0.001), but had similar changes in LDL-C (-20 vs -22%; P value not reported), apo B (-22 vs -21%; P value not reported), HDL-C (27 vs 28%; P value not reported) and LDL peak particle diameter (0.90 vs 0.76 mm; P value not reported). Secondary: Not reported
Wi et al.[47] (2010) Niacin ER 500 mg/day for 5 weeks, followed by 1,000 mg/day for 4 weeks, followed by 1,500 mg/day	OL, RCT Patients 20 to 79 years of age with TG 150 to 499 mg/dL and HDL-C <45 mg/dL	N=201 24 weeks (includes 8 week dietary run in period)	Primary: Percent change from randomization to week 16 in apo B/apo AI Secondary: Percent changes in other lipid	Primary: Apo B/apo AI was reduced with both treatments with no difference between the two (P=0.47). The percent reduction in apo B was greater with niacin, whereas the percent elevation in apo AI was higher with fenofibrate. Secondary: TC significantly decreased with both treatments, and TG decreased and HDL-C increased. LDL-C increased with fenofibrate but decreased with niacin. The percent reduction in TC was greater with niacin (P=0.01). TG

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs fenofibrate 160 mg/day After discontinuation of any lipid modifying drug, patients entered an 8 week dietary run in period.			parameters, levels of glucose metabolism-related parameters, hsCRP	decreased significantly more with fenofibrate (P=0.045), whereas the percent elevation in HDL-C was not different between the two treatments (P=0.22). The percent change in LDL-C was significantly different with the two treatments (P<0.001). Lp(a) levels were reduced with niacin only, and the change was significantly different compared to fenofibrate (P<0.001). FPG levels decreased with fenofibrate and increased significantly with niacin. HbA_{1c} levels increased with both treatments; the increase was borderline with fenofibrate and significant with niacin. The percent changes in FPG (P<0.001) and HbA_{1c} (P<0.001) levels were significantly different between the two treatments. Fasting insulin levels showed a borderline reduction with fenofibrate and a significant increase with niacin. HOMA-IR was decreased with fenofibrate and was increased with niacin. Percent changes of insulin (P<0.001) and HOMA-IR (P<0.001) were significantly different between the two treatments. hsCRP levels were significantly lowered with both treatments, but the percent change was greater with niacin (P=0.03).
Balasubramanyam et al.[48] (2011) Usual care vs low saturated fat diet and exercise (D/E) vs D/E and fenofibrate 145 mg/day (Tricor®)	DB, PC, RCT Patients 21 to 65 years of age with hypertriglyceridemia (fasting TG >150 mg/dL) and receiving stable ART therapy for 6 months	N=191 24 weeks	Primary: Baseline changes in lipid parameters Secondary: Baseline changes in insulin sensitivity, glycemia, adiponectin, CRP, energy expenditure, and body composition	Primary: Patients receiving fenofibrate achieved significant improvements in TG (P=0.002), TC (P=0.02), and non-HDL-C (P=0.003), compared to patients receiving niacin who achieved significant improvements in HDL-C (P=0.03), and both groups of patients achieved significant improvements in TC:HDL-C (P=0.005 and P=0.01). The combination of D/E plus fenofibrate plus niacin provided maximal benefit, reducing TG (-52% vs usual care; P=0.003), increasing HDL-C (12% vs usual care; P<0.001), and decreasing non-HDL-C (-18.5% vs usual care; P=0.003) and TC:HDL-C (-24.5% vs usual care; P<0.001). Secondary: Of the secondary endpoints evaluated, there was an effect of niacin on FPG (P=0.0002), oral glucose tolerance test area under the curve for glucose (P=0.02), fasting insulin (P=0.03), HOMA-IR (P=0.008), insulin sensitivity index (P=0.007), and adiponectin (P<0.0001), and an effect of fenofibrate on creatinine (P=0.002).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs D/E and niacin SR 2,000 mg/day (Niaspan®) vs D/E and fenofibrate 145 mg/day and niacin SR 2,000 mg/day				
Guyton et al.[49] (2000) Niacin ER (Niaspan®) titrated up to 1,000 mg at bedtime for 4 weeks, followed by 1,500 mg at bedtime for 4 weeks, followed by 2,000 mg at bedtime for 8 weeks vs gemfibrozil 600 mg BID	DB, MC, PC, RCT Patients 21 to 75 years of age with HDL-C ≤40 mg/dL, LDL-C ≤160 mg/dL or <130 mg/dL with atherosclerotic disease and TG ≤400 mg/dL	N=173 8 weeks	Primary: Effect on HDL-C Secondary: Change in other lipoproteins, adverse effects	Primary: Niacin 1,500 and 2,000 mg/day significantly increased HDL-C by 21 and 26%, respectively, compared to 13% with gemfibrozil (P<0.02). Secondary: Compared to gemfibrozil, niacin 1,500 and 2,000 mg/day significantly increased apo AI (9 and 11 vs 4%), reduced TC:HDL-C ratio (-17 and -22 vs -12%), reduced Lp(a) (-7 and -20 vs no change) and had no adverse effect on LDL-C (2 and 0 vs 9%; P<0.001 to P<0.02.). TG decreased by 40% with gemfibrozil compared to 16 and 29% with niacin 1,000 (P<0.001) and 2,000 mg/day (P<0.06). Effects on plasma fibrinogen levels were significantly favorable for niacin compared to gemfibrozil (-1 to -6% vs 5 to 9%, respectively; P<0.02). Flushing was significantly more frequent with niacin compared to gemfibrozil at every point (78 vs 10%; P values not reported). Flu syndrome occurred more frequently with niacin (P=0.006). Dyspepsia was more frequent with gemfibrozil (P=0.009).
Alrasadi et al.[50] (2008) <u>Protocol 1</u> Fenofibrate 200	XO Men with HDL-C <5th percentile for age- and gender-	N=19 32 weeks	Primary: Percent changes in HDL-C and TC:HDL-C	Primary: <u>Protocol 1</u> The mean percent change in HDL-C was +6, -6, and +22% in patients receiving fenofibrate, atorvastatin, and niacin, respectively. Only niacin significantly raised HDL-C (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day for 8 weeks vs atorvastatin 20 mg/day for 8 weeks vs niacin SR 1 g BID for 8 weeks <u>Protocol 2</u> Fenofibrate 200 mg/day and atorvastatin 20 mg/day for 8 weeks vs niacin SR 1 g BID and atorvastatin 20 mg/day for 8 weeks Patients in whom a statin was required were switched or maintained on atorvastatin 20 mg throughout the study in Protocol 2.	matched patients and an identified genetic cause of HDL deficiency or ≥1 first degree relative affected with HDL deficiency		Secondary: Not reported	The mean percent change in TC/HDL-C ratio was +19, -26, and -22% in patients receiving fenofibrate, atorvastatin, and niacin, respectively. Both niacin and atorvastatin significantly lowered TC/HDL-C (P<0.05 and P<0.01, respectively). <u>Protocol 2</u> The mean percent change in HDL-C was -2 and +18% in patients receiving fenofibrate plus atorvastatin and niacin plus atorvastatin, respectively. Only the group receiving niacin experienced a significant increase in HDL-C (P<0.05). The mean percent change in TC:HDL-C was +32 and -32% in patients receiving fenofibrate plus atorvastatin and niacin plus atorvastatin, respectively. Only the group receiving niacin experienced a significant decrease in TC:HDL-C (P<0.01). Secondary: Not reported
Shearer et al.[51]	DB, PC, RCT	N=60	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2012) Extended-release niacin (ERN, Niaspan 2g/day) vs P-OM3 (Lovaza, 4g/day) vs combination ERN and P-OM3 vs dual placebo All patients took aspirin 81 mg prior to dinner	Patients age 40 to 69 years; BMI 25 to 40 kg/m^2; fasting TG, 150 to 750 mg/dL; HDL-C >10 mg/dL; and the ratio of TG/HDL-C >3.5	6-week, diet-stabilization, dual-placebo, run-in phase 16 weeks of treatment	Least squares mean changes, adjusted for baseline in non-HDL-C, HDL-C, TG, augmentation index, and reactive hyperemia index Secondary: Changes in TG:HDL, TC, LDL-C, VLDL-C, and lipoprotein subfractions	Significant improvements occurred in non-HDL-C, HDL-C, TG, and augmentation index with ERN treatment; TG with P-OM3 treatment; and HDL-C and TG with combination treatment. The TG reduction with combination treatment was greater than P-OM3 alone but was not greater than ERN (P=0.09). Secondary: No significant change from baseline in any group was observed for TC and LDL-C. Combination treatment had the greatest impact on lipoprotein subfractions, where improvements in particle density were observed. ERN significantly reduced the AI, a marker of vascular stiffness, by 3.5 units. No effect on this measure was observed in either P-OM3 or combination treatments. No significant effect of either agent (singly or combined) was observed on endothelial function measured by reactive hyperemia index or on blood pressure.
Guyton et al.[52] (2008) Niacin ER 2 g (titrated) per day and ezetimibe-simvastatin 10-20 mg QD vs niacin ER 2 g (titrated) per day	DB, MC, RCT Patients 18 to 79 years of age with type IIa and IIb hyperlipidemia (LDL-C 130 to 190 mg/dL and TG ≤500 mg/dL)	N=1,220 24 weeks	Primary: Percent change from baseline in LDL-C, non-HDL-C, HDL-C, TG, TC, apo B, apo AI, and hsCRP Secondary: Not reported	Primary: After 24 weeks of therapy, the percent change from baseline in LDL-C, non-HDL-C, TG, apoB, TC:HDL-C, LDL-C:HDL-C, apo B:apo AI, and non-HDL-C:HDL-C were greater with niacin + E/S compared to treatment with niacin or E/S (P<0.001 for all). The percent change in HDL-C from baseline was significantly greater with niacin plus E/S compared to E/S (P<0.001). There was no significant difference with niacin plus E/S and niacin monotherapy (P>0.05). The percent change in TC from baseline was significantly greater with niacin plus E/S compared to niacin (P<0.001). There was no significant difference with niacin plus E/S and E/S monotherapy.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs ezetimibe-simvastatin (E/S) 10-20 mg QD				The percent change in apoAI from baseline was significantly greater with niacin + E/S compared E/S (P<0.001). There was no significant difference with niacin + E/S and niacin monotherapy (P>0.05). Treatment with niacin + E/S led to a greater reduction in hsCRP compared to niacin monotherapy (P<0.005). Adverse events occurred more frequently in patients treated with niacin monotherapy and niacin + E/S compared to E/S monotherapy. This difference was due to flushing-related AEs in the niacin groups. Secondary: Not reported
Zhao et al.[53] (2004) Niacin 2.4±2.0 g/day (mean dose) plus simvastatin 13±6 mg/day (mean dose) vs antioxidants (vitamin E 800 IU/day, vitamin C 1,000 mg/day, beta carotene 25 mg/day and selenium 100 µg/day) vs niacin plus simvastatin plus	ES Patients with clinical coronary disease (defined as previous MI, coronary interventions or confirmed angina) including 25 with diabetes mellitus with mean LDL-C 128 mg/dL, HDL-C 31mg/dL and TG 217 mg/dL	N=160 38 months	Primary: Side effects, response to the question "Overall, how difficult is it to take the study medication?" Secondary: Not reported	Primary: Patients receiving niacin plus simvastatin experienced similar frequencies of clinical or laboratory side effects compared to placebo; any degree of flushing (30 vs 23%; P value not significant), symptoms of fatigue, nausea and/or muscle aches (9 vs 5%; P value not significant), AST at least three times the upper limit of normal (3 vs 1%; P value not significant), CPK at least two times the upper limit of normal (3 vs 4%; P value not significant), new onset of uric acid ≥7.5 mg/dL (18 vs 15%; P value not significant) and homocysteine ≥15 µmol/L (9 vs 4%; P value not significant). There were no side effects attributable to the antioxidant regimen. Glycemic control among diabetics declined mildly with niacin plus simvastatin, but returned to pre-treatment levels at month eight and remained stable for the rest of the trial. Niacin plus simvastatin was repeatedly described by 91% of treated patients vs 86% of placebo subjects as "very easy" or "fairly easy" to take. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
antioxidants vs placebo Patients whose HDL-C had not increased by prespecified amounts were switched to niacin IR (Niacor®) titrated to 4 g per day.				
McKenney et al.[54] (2007) COMPELL Rosuvastatin 10 mg/day for 4 weeks, followed by 20 mg/day for 4 weeks, followed by 40 mg/day vs atorvastatin 20 mg/day plus niacin SR 500 mg/day for 4 weeks, followed by atorvastatin 20 mg/day plus niacin SR 1,000 mg/day for 4 weeks, followed by	MC, OL, PG, RCT Patients ≥21 years of age with hyper-cholesterolemia, eligible for treatment based on the NCEP ATP III guidelines, with 2 consecutive LDL-C levels within 15% of each other and mean TG ≤300 mg/dL	N=292 12 weeks	Primary: Change from baseline in LDL-C Secondary: Change from baseline in HDL-C non-HDL-C, TG, Lp(a) and apo B; side effects	Primary: Atorvastatin plus niacin SR, rosuvastatin plus niacin SR, simvastatin plus ezetimibe and rosuvastatin were associated with similar reductions in LDL-C (56, 51, 57 and 53%, respectively; P=0.093). Secondary: Atorvastatin plus niacin SR was associated with a significant increase in HDL-C compared to simvastatin plus ezetimibe and rosuvastatin-containing therapy (22, 10 and 7%, respectively; P≤0.05). There was no significant differences in the reduction of non-HDL-C from baseline with any treatment (P=0.053). Atorvastatin plus niacin SR was associated with a significant reduction in TG compared to simvastatin plus ezetimibe and rosuvastatin-containing therapy (47, 33 and 25%, respectively; P≤0.05). Atorvastatin plus niacin SR was associated with a significant reduction in Lp(a) compared to simvastatin plus ezetimibe and rosuvastatin (20 mg)-containing therapy (-14, 7 and 18%, respectively; P≤0.05). Atorvastatin plus niacin SR was associated with a significant reduction in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
atorvastatin 40 mg/day plus niacin SR 2,000 mg/day vs simvastatin 20 mg/day plus ezetimibe 10 mg/day for 8 weeks, followed by simvastatin 40 mg/day plus ezetimibe 10 mg/day vs rosuvastatin 10 mg/day plus niacin SR 500 mg/day for 4 weeks, followed by rosuvastatin 10 mg/day plus niacin SR 1,000 mg/day for 4 weeks, followed by rosuvastatin 20 mg/day plus niacin SR 1,000 mg/day				apo B compared to rosuvastatin (43 vs 39%, respectively; P≤0.05). Side effects were similar across treatments (P values not reported). There were no cases of myopathy or hepatotoxicity reported.
Fazio et al.[55] (2010) Ezetimibe-simvastatin 10-20 mg/day plus niacin ER 2 g/day	DB, MC, RCT Patients 18 to 79 years of age with hyperlipidemia (Types IIa and IIb) with LDL-C 130 to	N=942 64 weeks	Primary: Safety and tolerability of ezetimibe/ simvastatin plus niacin ER	Primary: The most frequent reason for discontinuation was clinical adverse events related to niacin-associated flushing with ezetimibe/simvastatin plus niacin (0.7% for ezetimibe/simvastatin vs 10.3% for ezetimibe/simvastatin plus niacin). A significant number of patients receiving ezetimibe/simvastatin plus niacin discontinued because of low LDL-C levels <50 mg/dL (1.5 vs 7.1%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs niacin ER 2 g/day vs ezetimibe-simvastatin 10-20 mg/day At the end of 24 weeks, patients receiving niacin ER were rerandomized to either one of the other 2 treatment regimens.	190 mg/dL, TG ≤500 mg/dL, creatinine <2 mg/dL, creatine kinase ≤2 times the upper limit of normal, transaminases ≤1.5 times the upper limit of normal and HbA_{1c} ≤8%		Secondary: Changes in HDL-C, TG, non-HDL-C and LDL-C	The overall incidence of clinical adverse events was slightly greater for ezetimibe/simvastatin plus niacin compared to ezetimibe/simvastatin owing to the greater number of patients who experienced drug-related clinical adverse events and drug-related discontinuations with ezetimibe/simvastatin plus niacin, mainly attributed to niacin-associated flushing and pruritis. The percentage of patients with consecutive elevations in ALT or AST of at least three times or greater the upper limit of normal, and creatine kinase of at least ten times or greater the upper limit of normal were low and comparable between treatments. A total of 19 patients had adverse events of increased FPG levels, with eight receiving ezetimibe/simvastatin and 11 receiving ezetimibe/simvastatin plus niacin. Secondary: Ezetimibe/simvastatin plus niacin significantly improved baseline HDL-C, TG, non-HDL-C, LDL-C, apo B, apo AI and Lp ratios compared to ezetimibe/simvastatin at week 64 (P<0.004). The changes in TC were comparable between the two treatment groups and the reduction in hsCRP was numerically greater with ezetimibe/simvastatin plus niacin (P value not reported). Ezetimibe/simvastatin plus niacin increased HDL-C considerably during the first 16 weeks of treatment, and at a lower, but significant, rate from 16 to 24 weeks, and then remained constant throughout 64 weeks. The HDL-C change was significantly greater with ezetimibe/simvastatin plus niacin vs ezetimibe/simvastatin throughout the 64 weeks (P<0.001). The reductions in LDL-C, non-HDL-C and TG observed after four weeks with ezetimibe/simvastatin plus niacin were maintained throughout the 64 weeks. In contrast, the levels remained relatively stable with ezetimibe/simvastatin throughout the 64 weeks (P<0.001) and became significant for non-HDL-C after eight weeks (P=0.002) and LDL-C after 12 weeks (P<0.001).
Fazio et al.[56] (2010)	Subgroup analysis Hyperlipidemic	N=765 at 24 weeks	Primary: Changes in HDL-C, TG, non-HDL-	Primary: The effect of triple therapy on efficacy variables across patient subgroups was generally consistent with the significantly greater improvements

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ezetimibe-simvastatin 10-20 mg/day plus niacin ER 2 g/day vs niacin ER 2 g/day vs ezetimibe-simvastatin 10-20 mg/day At the end of 24 weeks, patients receiving niacin ER were rerandomized to either one of the other 2 treatment regimens.	patients with diabetes mellitus, metabolic syndrome without diabetes mellitus or neither	N=574 at 64 weeks	C, LDL-C, fasting glucose and uric acid Secondary: Not reported	observed in the total population compared to niacin and combination therapy. Triple therapy improved levels of LDL-C, other lipids and Lp ratios compared to niacin and combination therapy at 24 and 64 weeks. Triple therapy also increased HDL-C and Lp(a) comparably to niacin and more than combination therapy. Triple therapy also decreased hsCRP more effectively than niacin and comparably to combination therapy. Fasting glucose trended higher for niacin compared to combination therapy. Glucose elevations from baseline to 12 weeks were highest for patients with diabetes (niacin, 24.9 mg/dL; triple therapy, 21.2 mg/dL and combination therapy, 17.5 mg/dL). Fasting glucose levels then declined to pretreatment levels at 64 weeks in all subgroups. New onset diabetes was more frequent among patients with metabolic syndrome than those without for the first 24 weeks and trended higher among those receiving niacin (niacin, 5.1%; combination therapy, 1.7% and triple therapy, 8.8%). Between weeks 24 and 64, five and one additional patient(s) receiving combination (cumulative incidence, 5.9%) and triple therapy (cumulative incidence, 9.2%) were diagnosed with diabetes. Treatment-incident increases in uric acid were higher among patients receiving niacin, but there were no effects on symptomatic gout. Secondary: Not reported
Pownall et al.[57] (1999) Omega-3 acid ethyl esters (Omacor®*) 4 g per day vs placebo	DB, PC, PG, RCT Patients with severe hypertriglyceridemia (TG ≥500 mg/dL but <2,000 mg/dL)	N=40 12 weeks	Primary: Effect on TG, lipid profile, and lipid composition Secondary: Not reported	Primary: Median TG levels were reduced 38.9% from baseline in the omega-3 acid ethyl ester group compared to 7.8% with placebo (P=0.001). Omega-3 acid ethyl esters also significantly reduced TC (-9.9%; P=0.004) and VLDL-C (-29.2%; P=0.001) and significantly increased LDL-C (16.7%; P=0.007) from baseline. HDL-C increased in patients receiving omega-3 acid ethyl esters (5.9%; P=0.057 vs baseline and P=0.023 vs placebo) and decreased in patients receiving placebo (-5.9%; P value not significant vs baseline).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
McKeone et al.[58] (1997) Omega-3 acid ethyl esters (Omacor®*) 4 g per day vs placebo	DB, PC, RCT Patients with severe hypertriglyceridemia (TG ≥500 mg/dL but <2,000 mg/dL)	N=40 12 weeks	Primary: Effect on TG and serum phospha-tidylcholine Secondary: Changes in lipid profile	Primary: Treatment with omega-3 acid ethyl esters significantly reduced TG levels by 26% compared to a 7% increase for placebo. Incorporation of eicosapentaenoic and docosahexaenoic acid into the serum phosphatidylcholine occurred within 6 weeks and was usually accompanied by a reduction in plasma TG. Secondary: Omega-3 acid ethyl esters also significantly reduced VLDL-C (28%) and TC (11%), and increased HDL-C (14%). None of these parameters significantly changed in the placebo group.
Calabresi et al.[59] (2000) Omega-3 acid ethyl esters (Omacor®*) 4 g per day for 8 weeks vs placebo for 8 weeks	DB, RCT, XO Patients with familial combined hyperlipidemia	N=14 26 weeks	Primary: Changes in lipid profile and LDL-C subclass distribution Secondary: Safety	Primary: Omega-3 acid ethyl esters significantly lowered plasma TG and VLDL-C by 27 and 18%, respectively (both P<0.05) compared to baseline. TC and HDL-C did not change but LDL-C and apo B increased by 21% (P=0.05) and 6% compared to baseline (P<0.05). Omega-3 acid ethyl esters treatment caused a redistribution of LDL-C subclasses towards less dense lipoprotein particles (possibly indicative of a less atherogenic LDL-C profile); however, the average LDL-C size did not change. Secondary: Omega-3 acid ethyl esters were well tolerated with no reports of drug-related adverse events or negative safety parameters (e.g., glucose, uric acid, liver enzymes, kidney function, and platelet count).
Calabresi et al.[60](2004) Omega-3 acid ethyl esters (Omacor®*) 4 g per day for 8 weeks	DB, RCT, XO Patients with familial combined hyperlipidemia	N=14 20 weeks	Primary: Changes in lipid profile, LDL-C and HDL-C subclass distribution Secondary: Not reported	Primary: Plasma TG were 44% lower and LDL-C and apo B were 25 and 7% higher after omega-3 acid ethyl esters than placebo (P<0.05 for all). HDL-C was higher (8%) after omega-3 acid ethyl esters than placebo but this difference did not reach statistical significance (P>0.05). Omega-3 acid ethyl esters caused a selective increase of the more buoyant HDL_2-C subfraction; plasma HDL_2-C and total mass increased by 40%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo for 8 weeks				(P<0.05) and 26%, respectively, whereas HDL_3-C and total mass decreased by 4% (P>0.05) and 6%. The plasma concentration of the HDL-bound antioxidant enzyme paraoxonase increased by 10% after omega-3 acid ethyl esters (P<0.05). Secondary: Not reported
Bays et al.[61] (2010) Omega-3 acid ethyl ester (Lovaza®) 4 g/day vs placebo All patients received atorvastatin 10 mg/day for 8 weeks, 20 mg for 4 weeks, and 40 mg for 4 weeks.	DB, MC, PC, RCT Patients 18 to 79 years of age with hypercholesterolemia (non-HDL-C >160 mg/dL and TG 250 to 599 mg/dL)	N=245 16 weeks	Primary: Percent change in non-HDL-C level between baseline and week eight Secondary: Percent changes in non-HDL-C level between baseline and the end of treatment with atorvastatin at 20 mg and 40 mg, percent changes in TC, HDL-C, LDL-C, VLDL-C, TG, apo AI and apo B concentrations	Primary: After eight weeks of therapy, the median percent change in non-HDL-C was -40.2% in the omega-3 acid ethyl ester group and -33.7% in the placebo group (90% CI, -7.2 to -2.9; P<0.001). Secondary: Omega-3 acid ethyl ester significantly reduced non-HDL-C compared to placebo during the atorvastatin 20 mg phase (-7.9%; 90% CI, -9.1 to -4.9; P<0.001) and atorvastatin 40 mg phase (-4.1%, 90% Cl, -6.8 to -2.4; P<0.001). There was no significant difference in the percentage of patients who achieved LDL-C goals with omega-3 acid ethyl ester (85.7%) or placebo groups (91.5%; P=0.20). There was no significant difference in the percentage of patients who achieved non-HDL-C goals with omega-3 acid ethyl ester (88.7%) or placebo groups (87.8%; P>0.99). Treatment with omega-3-acid ethyl esters with all doses of atorvastatin significantly reduced TC (P<0.001), TC:HDL-C (P<0.001), TG (P<0.001), VLDL-C (P<0.001), RLP-C (P<0.001) and increased HDL-C (P<0.001) compared to treatment with placebo with all doses of atorvastatin. There was no significant difference in LDL-C, apo AI, or apo B between the treatment groups. There was no significant difference in adverse events among the treatment groups.
Durrington et al.[62] (2001)	DB, RCT Patients ≤75 years of	N=59 48 weeks	Primary: Percent change in TG and VLDL-C,	Primary: Serum TG and VLDL-C significantly decreased with omega-3 acid ethyl esters compared to baseline or placebo (20 to 30% reduction; P<0.0005

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Phase I Omega-3 acid ethyl esters (Omacor*) 2 g BID for 24 weeks vs placebo for 24 weeks All patients received simvastatin. Phase II Omega-3 acid ethyl esters (Omacor*) 2 g BID and simvastatin 10 to 40 mg QD for 24 weeks	age with established CHD who were already receiving treatment with simvastatin 10 to 40 mg daily and who had TG >203 mg/dl		as well as effects on other lipid parameters Secondary: Not reported	and 30 to 40% reduction; P<0.005, respectively). There were no adverse effects on other lipid parameters with omega-3 acid ethyl esters, including LDL-C and HDL-C. There were no significant adverse events with omega-3 acid ethyl esters. Secondary: Not reported
Nordoy et al.[63] (1998) Omega-3 acid ethyl esters (Omacor*) 4 g per/day vs placebo All patients received	DB, PC, RCT Patients 25 to 60 years of age with combined hyperlipidemia receiving simvastatin 20 mg for 5 to 10 weeks	N=41 5 weeks	Primary: Lipid and lipoprotein parameters Secondary: Not reported	Primary: The addition of omega-3 acid ethyl esters to simvastatin therapy led to an increase in EPA (P<0.0002) and DHA (P<0.0003) and reduction in linoleic acid (P=0.001). The addition of omega-3 acid ethyl esters to simvastatin led to a reduction in TC (P=0.052) and TG (P<0.001). There was no significant effect on HDL-C with omega-3 acid ethyl esters. There was no effect on apo A1 or apo B with the addition of omega-3 acid ethyl esters to simvastatin; however, there was a significant reduction in the concentration of apo E (P=0.035). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
simvastatin 20 mg QD.				Not reported
Davidson et al.[64] (2007) Omega-3-acid ethyl ester (Lovaza®) 4 g/day vs placebo All patients were receiving simvastatin 40 mg/day.	DB, MC, PC, PG, RCT Adult patients who have received ≥8 weeks of stable statin therapy and have a mean fasting TG ≥200 and <500 mg/dL and mean LDL-C below or within 10% NCEP ATP III goal	N=254 16 weeks (includes 8 weeks OL treatment with simvastatin)	Primary: Change in non-HDL-C Secondary: Changes in TG, VLDL-C, LDL-C, HDL-C, TC and apo B; adverse events	Primary: At the end of treatment, the median percent change in non-HDL-C was significantly greater with omega-3-acid ethyl esters compared to placebo (-9.0 vs -2.2%; P<0.001). Secondary: Treatment with omega-3-acid ethyl esters was associated with significant reductions in TG (2.9 vs 6.3%), VLDL-C (27.5 vs 7.2%) and TC:HDL-C ratio (9.6 vs 0.7%), and a significant increase in HDL-C (3.4 vs -1.2%) (*P*<0.001 for all). Adverse events reported by at least one percent of patients treated with omega-3-acid ethyl esters that occurred with a higher frequency than those receiving simvastatin monotherapy were nasopharyngitis (3.3%), upper respiratory tract infection (3.3%), diarrhea (2.5%) and dyspepsia (2.5%). There was no significant difference in the frequency of adverse events between treatment groups. No serious adverse events were considered treatment related.
Maki et al.[65] (2010) COMBOS Omega-3-acid ethyl esters (Lovaza®) 4 g/day vs placebo All patients received simvastatin 40 mg/day.	DB, PC, RCT Patients 18 to 79 years of age who had been receiving stable dose statin therapy for ≥8 weeks prior to trial enrollment	N=256 8 weeks	Primary: Non-HDL-C levels Secondary: TG, VLDL-C, LDL-C and HDL-C levels	Primary: Use of omega-3-acid ethyl esters and placebo in patients with a baseline LDL-C in the lowest (<80.4 mg/dL), middle (80.4 to <99.0 mg/dL) and highest (≥99.0 mg/dL) tertiles achieved a percent change from baseline in non-HDL-C of the following: -5 vs 0%, -13 vs -4% and -11 vs -2% (P values not reported). Secondary: Use of omega-3-acid ethyl esters and placebo in patients with a baseline LDL-C in the lowest, middle and highest tertiles achieved a percent change from baseline in TG of the following: -27 vs -8%, -32 vs -5% and -30 vs -6% (P values not reported). Use of omega-3-acid ethyl esters and placebo in patients with a baseline LDL-C in the lowest, middle and highest (≥99.0 mg/dL) tertiles achieved a percent change from baseline in VLDL-C of the following: -27 vs -7%, -28 vs -10% and -29 vs -7% (P values not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Use of omega-3-acid ethyl esters and placebo in patients with a baseline LDL-C in the lowest, middle and highest tertiles achieved a percent change from baseline in LDL-C of the following: 9.5 vs 1.1%, -0.9 vs -3.8% and -6.4 vs -4.5% (P values not reported). The baseline LDL-C tertile had a significant interaction with treatment for the LDL-C response (P=0.022). Use of omega-3-acid ethyl esters and placebo in patients with a baseline LDL-C in the lowest, middle and highest tertiles achieved a percent change from baseline in HDL-C of the following: 4 vs -1%, 2 vs -1% and 4 vs -1% (P values not reported).
Bays et al.[66] (2010) COMBOS Omega-3-acid ethyl esters (Lovaza®) 4 g/day plus simvastatin 40 mg/day Patients who received placebo in the COMBOS trial were switched to OL treatment with omega-3-acid ethyl esters plus simvastatin (Switchers). Those who received omega-3-acid ethyl esters plus simvastatin in the COMBOS trial	ES, OL of COMBOS Patients 18 to 79 years of age who had been receiving stable dose statin therapy for ≥8 weeks prior to trial enrollment	N=188 Up to 24 months	Primary: The difference between Nonswitchers and Switchers in median percent change in non-HDL-C from COMBOS end of treatment to month four Secondary: Difference in the median percent change in non-HDL-C from COMBOS end of treatment to month 12 and 24; the change in non-HDL-C from COMBOS baseline to months four, 12 and 24 and from	Primary: The percent change in non-HDL-C from COMBOS end of treatment to month four revealed a greater response among Switchers when compared to Nonswitchers. At month four, the median percent change in non-HDL-C from the end of DB treatment was -9.4% in Switchers and 0.9% in Nonswitchers (P<0.001). Secondary: After 12 and 24 months of treatment, the median percent change in non-HDL-C from COMBOS end of treatment in Nonswitchers vs Switchers was -0.2 vs -0.64% (P=0.027) and 1.6 vs -6.3% (P=0.004). Reductions in non-HDL-C were maintained throughout the trial. After four, 12 and 24 months of treatment, the median percent change in non-HDL-C from COMBOS baseline in the total population was -8.3, -7.3 and -8.9%, respectively (P<0.001 for all). After four, 12 and 24 months of treatment, the median percent change in non-HDL-C from COMBOS baseline in Nonswitchers vs Switchers was -5.4 vs -10.3% (P=0.062), -6.6 vs -8.1% (P=0.604) and -7.8 vs -9.0% (P=0.496). Consistent with the non-HDL-C response, comparisons of the changes from the COMBOS end of treatment to months four, 12 and 24 in TG and other lipoprotein lipid parameters generally revealed greater reductions in Switchers vs Nonswitchers. The comparisons of the change from COMBOS baseline to these same endpoints reveled generally

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
were maintained on current therapy (Nonswitchers) All patients continued therapeutic lifestyle changes diet.			COMBOS end of treatment to months four, 12 and 24; percent changes in TC, HDL-C, LDL-C, VLDL-C, TG and TC:HDL-C for the same time points; HbA_{1c} levels	nonsignificant differences between the two groups. Median percent reductions from COMBOS baseline in TG, TC and VLDL-C in the total population were maintained at months four, 12 and 24 of treatment (P<0.001 for all). Omega-3-acid ethyl esters produced small median percent increases from baseline LDL-C levels at months four, 12 and 24. Among the subset of patients who had HbA_{1c} measured at baseline (n=38), the median absolute change in HbA_{1c} after 24 months of treatment was 0.1% (P value not reported).
Maki et al.[67] (2008) Omega-3 acid ethyl esters (Lovaza®) 4 g/day vs placebo All patients received simvastatin 20 mg/day.	RCT, XO Patients 18 to 79 years of age with mixed dyslipidemia (TG 200 to 600 mg/dL and non-HDL-C above NCEP ATP III goal)	N=40 12 weeks	Primary: Lipid and lipoprotein parameters Secondary: Not reported	Primary: Treatment with omega-3 acid ethyl esters resulted in a -40% reduction in non-HDL-C compared to -34% with placebo (P<0.001). Treatment with omega-3 acid ethyl esters resulted in significantly greater changes in other lipid parameters compared to placebo, including VLDL-C (-42 vs -22%, respectively), TG (-44 vs -29%, respectively), TC (-31 vs -26%, respectively), and HDL-C (-16 vs -11%, respectively; P<0.05 for all). There was no significant difference in LDL-C with omega-3 acid ethyl esters (-37%) and placebo (-38%; P=0.433). Treatment with omega-3 acid ethyl esters resulted in significantly greater changes in other lipoprotein parameters compared to placebo, including apo B (-32 vs -28%, respectively), TC:HDL-C ratio (-39 vs -33%, respectively), and TG:HDL-C ratio (-51 vs -37%, respectively). There was no significant difference in apo AI levels with omega-3 acid ethyl esters (0.9) and placebo (4.3%; P=0.667). Secondary: Not reported
Peters et al.[68] (2012) Omega-3 PUFA vs	DB, MC, PC, RCT HIV-infected adult patients receiving HAART therapy and a fasting TG level 3.39 to 11.3 mmol/L	N=48 12 weeks	Primary: Change in baseline mean fasting TG, biochemical and virologic safety parameters	Primary: Omega-3 PUFA reduced TG by a mean of 1.75 mmol/L vs a 0.41 mmol/L increase with placebo (baseline-corrected percentage change related to placebo 95% CI, -69.48 to -6.53; P=0.019). No effect was observed on biochemical or virologic safety parameters.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo All patients were allowed to receive fenofibrate or niacin.			Secondary: Safety	Secondary: No severe treatment-emergent adverse events occurred. Mild to moderate treatment-emergent adverse events were reported in 20 and 19 patients receiving omega-3 PUFA and placebo. Most treatment-emergent adverse events were gastrointestinal-related and included diarrhea, nausea, and flatulence.
Roth et al.[69] (2009) <u>Phase I</u> Fenofibrate 130 mg (FENO) QD and omega-3 acid ethyl esters 4 g (P-OM3) QD for 8 weeks vs fenofibrate 130 mg (FENO) QD and placebo for 8 weeks <u>Phase II</u> Fenofibrate 130 mg (FENO) QD and omega-3 acid ethyl esters 4 g (P-OM3) QD for 8 weeks	DB, MC, PC, RCT Patients 18 to 79 years of age with Fredrickson type IV dyslipidemia, BMI 25 to 43 kg/m^2, and TG 500 to 1,300 mg/dL	N=167 16 weeks	Primary: Median percent change in TG Secondary: Additional lipid and cardiovascular risk factors	Primary: After eight weeks of therapy, median TG values were reduced from 649.5 to 267.5 mg/dL (-60.8%) with P-OM3 + FENO and from 669.3 to 310 mg/dL (-53.8%) with FENO monotherapy (P=0.059). There was no significant difference between the treatment groups (P=0.059). Secondary: LDL-C was significantly increased with P-OM3 + FENO compared to FENO monotherapy (48.2 vs 39.0%, respectively; P=0.030). There was no significant difference in non-HDL-C among the treatment groups (-8.2% for P-OM3 + FENO vs -7.1% for FENO; P=0.767). There was a greater reduction in VLDL-C with P-OM3 + FENO than with FENO monotherapy (-57.6 vs -47.6%, respectively; P=0.016). There was a greater reduction in RLP-C with P-OM3 + FENO than with FENO monotherapy (-72.0 vs -62.1%; P=0.029). In the first eight week ES, the addition of P-OM3 to FENO monotherapy significantly reduced TGs compared to the end of the DB treatment period (-17.5%; P=0.003). In the first eight week ES, the addition of P-OM3 to FENO monotherapy significantly increased LDL-C (+8.1%; P=0.001) compared to the group previously receiving P-OM3 + FENO (+0.4%). There was no significant change in non-HDL-C following the addition of P-OM3 to FENO. VLDL-C and RLP-C were significantly reduced by the addition of P-OM3 (-15.4%; P=0.030 and -25.8%; P=0.035, respectively). There was no significant difference in final lipid results for those who

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				received P-OM3 + FENO for 16 weeks and those in which P-OM3 was added to FENO monotherapy during the OL phase of the study. In the pooled analysis of all patients enrolled in the eight week OL extension phase, the overall reductions of TGs and VLDL-C were -60.0 and -56.5%, respectively (P<0.001 for both). Non-HDLC and TC were also significantly reduced (P<0.001) over the 16 week treatment period in the pooled analysis. LDL-C increased 52.2% (P<0.001). There was no significant change in apo B at the end of the 16 week treatment study (P=0.544). The treatments were generally well tolerated and there was no significant difference in the safety profiles. The most adverse events were upper respiratory infection, nausea, diarrhea, constipation, gastroenteritis, dyspepsia, and headache.
Koh et al.[70] (2012) Omega-3 fatty acids 2 g/day vs fenofibrate 160 mg/day vs placebo	PC, PG, RCT, SB Patients with primary hypertriglyceridemia (>150 mg/dL)	N=50 2 months	Primary: Change in baseline lipid profile; change in baseline vasomotor function, hsCRP, and fibrinogen; change in baseline adiponectin, HbA_{1c}, and insulin resistance Secondary: Not reported	Primary: Placebo treatment significant reduced TG and TG:HDL-C, but increased LDL-C from baseline. Omega-3 fatty acids significantly reduced TG and TG:HDL-C from baseline. Fenofibrate significantly reduced T C, TG, apo B, TG:HDL-C, and non-HDL-C, and increased HDL-C and apo AI from baseline. Effects of fenofibrate on TC and T G were both significant compared to placebo (P<0.05). The magnitude of change in HDL-C, apo AI, TG:HDL-C, and non-HDL-C were significantly different when omega-3 fatty acids and fenofibrate therapy were compared, but both treatments resulted in comparable improvements in TG (P<0.05). Placebo did not significantly improve flow-mediated dilator response to hyperemia, but omega-3 fatty acids and fenofibrate significantly improved flow-mediated dilator response to hyperemia after two months when compared to baseline (P<0.001), and when compared to placebo (P<0.001). Brachial artery dilator responses to nitroglycerin were not significantly different between any of the therapies. Placebo and omega-3 fatty acids did not significantly change hsCRP and fibrinogen levels relative to baseline measurements. Fenofibrate significantly reduced hsCRP and fibrinogen levels after two months compared to baseline (P<0.001) or when compared to placebo (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Omega-3 fatty acids did not significantly change insulin, plasma adiponectin levels, or insulin sensitivity compared to placebo. Compared omega-3 fatty acids, fenofibrate significantly decreased fasting insulin (P=0.023) and increased plasma adiponectin (P=0.002) and insulin sensitivity (P=0.015). Secondary: Not reported
Stalenhoef et al.[71] (2000) Omega-3 acid ethyl esters (Omacor*) 4 g per day vs gemfibrozil 1,200 mg per day	DB, DD, RCT Patients with primary hyper-triglyceridemia	N=28 12 weeks	Primary: Change in lipid profile, LDL-C subfraction profile Secondary: Not reported	Primary: Both omega-3-acid ethyl esters and gemfibrozil resulted in similar and significant decreases in serum TG, VLDL-TG and VLDL-C concentrations and increases in HDL-C and LDL-C (P=0.05 to P<0.001 from baseline and P=0.29 to P=1.00 between groups). Both therapies resulted in a more buoyant LDL-C subfraction profile (P=0.05 for omega-3-acid ethyl esters, P<0.01 for gemfibrozil and P=0.09 between groups in favor of gemfibrozil). Secondary: Not reported
van Dam et al.[72] (2001) Omega-3 acid ethyl esters (Omacor*) 4 g/day vs gemfibrozil 1,200 mg/day	DB, RCT Patients with hypertriglyceridemia (TG >400 mg/dL)	N=89 12 weeks	Primary: Percent change in TG Secondary: Percent change in TC, HDL-C, VLDL-C	Primary: The mean percent change in TG was -28.9% with omega-3 acid ethyl esters and -51.2% with gemfibrozil (P=0.007). Secondary: The mean percent change in HDL-C and TC were 1.2 and -10.2%, respectively, with omega-3 acid ethyl esters and 27.9 and -13.0%, respectively, with gemfibrozil (P=0.012 and P=0.513, respectively). The mean percent change in VLDL-C was -11.8% with omega-3 acid ethyl esters and -19.4% with gemfibrozil (P=0.494).
Trials Assessing Cardiovascular Outcomes				
Coronary Drug Project[73] (1975) Niacin IR 3,000	DB, MC, PC, RCT Men 30 to 64 years of age with previous MI	N=8,341 5 years	Primary: All-cause mortality Secondary: Cause-specific	Primary: The incidence of all-cause mortality was comparable between niacin (24.4%), clofibrate (25.5%) and placebo (25.4%) (P values not significant).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg per day vs clofibrate 1.8 g per day vs placebo			mortality (e.g., coronary mortality and sudden death), nonfatal cardiovascular events	Secondary: Five year rates of death due to cardiovascular disease were comparable between niacin (18.8%), clofibrate (17.3%) and placebo (18.9%) (P values not significant). Major cardiovascular events were reduced with niacin; CHD events by 13%, nonfatal MI by 27% and cerebrovascular events by 21%. Niacin significantly reduced the incidence of nonfatal MI compared to placebo (8.9 vs 12.2%; P<0.004). There was no evidence of significant efficacy of clofibrate with regard to all-cause and cause-specific mortality. Treatment with niacin for five years lowered TC by 10% and TG levels by 26% (P values not reported). Treatment with clofibrate lowered TC by 7% and TG levels by 22% (P values not reported).
Canner et al.[74] (1986) Coronary Drug Project Niacin IR 3,000 mg per day vs placebo	ES of the Coronary Drug Project Men 30 to 64 years of age with previous MI	N=8,341 9 years	Primary: All-cause mortality Secondary: Cause-specific mortality (e.g., coronary mortality and sudden death)	Primary: A follow-up of patients nine years after completion of the Coronary Drug Project trial (total mean follow up of 15 years) revealed that niacin reduced the risk of all-cause mortality by 11% (52.0 vs 58.2%; P=0.0004 vs placebo). Secondary: The survival benefit with niacin was primarily evident for death caused by CHD (36.5 vs 41.3%; P<0.05 vs placebo).
Lee et al.[75] (2009) Niacin ER (Niaspan®) 2,000 mg per day vs placebo	DB, PC, RCT Patients with pre-existing atherosclerosis and low HDL-C (<40 mg/dL) in whom LDL-C was treated with statins	N=71 1 year	Primary: Absolute change in carotid artery wall area and change in carotid plaque index Secondary: Not reported	Primary: Patients receiving niacin had a significantly greater change in carotid wall area at 12 months compared to placebo (difference -1.64 mm^2; 95% CI, -3.12 to -0.16; P=0.03). After 12 months of therapy, the change in carotid plaque index was significantly reduced by niacin compared to placebo (difference -0.016; 95% CI, -0.03 to -0.0022; P=0.02). Niacin increased HDL-C by 23% and decreased LDL-C by 19%. TG, apo

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				B, and Lp(a) were significantly decreased by niacin compared to placebo. CRP was decreased by niacin compared to placebo (P=0.03 at six months and P=0.1 at 12 months). Adiponectin was significantly increased at both six and at 12 months (P<0.01). Secondary: Not reported
Taylor et al.[76] (2004) Niacin ER (Niaspan®) 1,000 mg/day vs placebo All patients received background statin therapy.	DB, PC, RCT Adult patients with known CHD and low levels of HDL-C (<45 mg/dL)	N=167 1 year	Primary: Change in mean common CIMT after one year Secondary: Changes in lipid concentrations, composite of clinical cardiovascular events (including any hospitalization for an acute coronary syndrome, stroke, revascularization procedure or sudden cardiac death), adverse events	Primary: After one year, mean CIMT increased significantly with placebo (0.044±0.100 mm; P<0.001) and was unchanged with niacin (0.014±0.104 mm; P=0.23). The overall difference in CIMT progression between placebo and niacin was not significant (P=0.08); however, a post hoc analysis revealed that niacin significantly reduced the rate of CIMT progression in subjects without insulin resistance (P=0.026). Secondary: HDL-C increased by 21% with niacin and did not change with placebo (P<0.003). Clinical cardiovascular events occurred in three patients receiving niacin (3.8%) and seven receiving placebo (9.6%; P=0.20). Adherence to trial medication based on pill counts ranged from 90.3 to 94.5%, and was not different between the two treatments (P value not reported). No patient experienced significant (three times the upper limit of normal) elevations of liver enzymes or developed myositis. At the end of the trial, skin flushing was reported in 69.2 and 12.7% of patients receiving niacin and placebo (P<0.001).
Philpott et al.[77] (2013)	DB, PC, XO, RCT	N=66	Primary: Effect of niacin on	Primary: There was no significant difference between Niacin ER and placebo on

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Niacin ER vs placebo	Patients with stable coronary disease on high dose statin therapy	24 weeks (12 weeks of each treatment)	flow-mediated dilation Secondary: Effect of niacin on the microvascular responses of pulse arterial tonometry and hyperemic velocity	flow-mediated dilation. Secondary: Measures of microvascular function were not statistically different with niacin therapy.
AIM-HIGH Investigators[78] (2011) Niacin ER (Niaspan) 1500 to 2000 mg daily vs placebo Both groups received daily simvastatin adjusted to LDL-C and ezetimibe 10 mg could also be added on All patients underwent a 4 to 8 week open-label phase of simvastatin 40 mg plus niacin titration from 500	MC, RCT Patients were 45 years of age or older and had established CV disease, low baseline levels of HDL-C (<40 mg/dL for men; <50 mg/dL for women), elevated TG (150 to 400 mg/dL), and LDL-C <180 mg/dL if not taking a statin at entry Patients who were screened were required to discontinue lipid-modifying drugs, except for statins or ezetimibe, at least 4 weeks before enrollment	N=3414 3 years	Primary: Composite of the first event of death from CHD, nonfatal MI, ischemic stroke, hospitalization (for >23 hours) for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization Secondary: Composite end points included death from CHD, nonfatal MI, ischemic stroke, or hospitalization for a “high-risk” acute coronary syndrome; death from CHD, nonfatal MI, or	Primary: The primary end point occurred in 282 patients in the niacin group (16.4%) and 274 in the placebo group (16.2%) (HR with niacin, 1.02; 95% CI, 0.87 to 1.21; P=0.80 for the superiority of niacin therapy with the use of a Cox proportional-hazards model and P=0.79 by the log-rank test). Secondary: Niacin therapy had a similar lack of effect on the composite secondary end point of death from CHD, nonfatal MI, ischemic stroke, or hospitalization for a high-risk acute coronary syndrome (HR, 1.08; 95% CI, 0.87 to 1.34; P=0.49) and on the composite secondary end point of death from CHD, nonfatal MI, or ischemic stroke (HR, 1.13; 95% CI, 0.90 to 1.42; P=0.30). The number of patients who died from CV causes was low in both the niacin group and the placebo group (45 patients [2.6%] and 38 patients [2.2%], respectively; P=0.47).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg to 2000 mg daily. Patients tolerating ≥1500 mg niacin were randomized			ischemic stroke; and death from CV causes	
Teo et al.[79] (2013) AIM-HIGH Niacin ER (Niaspan) 1500 to 2000 mg daily vs placebo Both groups received daily simvastatin adjusted to LDL-C and ezetimibe 10 mg could also be added on All patients underwent a 4 to 8 week open-label phase of simvastatin 40 mg plus niacin titration from 500 mg to 2000 mg daily. Patients tolerating ≥1500 mg niacin were randomized	MC, RCT Patients enrolled in the AIM-HIGH trial	N=3414 3 years	Primary: Ischemic stroke risk Secondary: Not reported	Primary: Of the 50 fatal or nonfatal ischemic strokes, there were an excess number of events in the statin–niacin combination group (HR, 1.78; 95% CI, 1.00 to 3.17; P=0.050). There were seven hemorrhagic strokes and 30 transient ischemic attacks (TIAs) among participants. The HR for the composite ischemic strokes and TIA was 1.20 (95% CI, 0.77 to1.88; P=0.428). Multivariate stepwise regressions analyses showed independent associations between ischemic stroke risk and ≥65 years of age (HR, 3.58; 95% CI, 1.82 to 7.05; P=0.0002), a history of stroke/TIA/carotid disease (HR, 2.18; 95% CI, 1.23 to 3.88; P=0.0079), and elevated baseline Lp(a) (HR, 2.80; 95% CI, 1.25 to 6.27 comparing the middle with the lowest tertile and HR, 2.31; 95% CI, 1.00 to 5.30 comparing the highest with the lowest tertile; overall P=0.042) but a nonsignificant association between ischemic stroke and combination therapy (HR, 1.74; 95% CI, 0.97 to 3.11; P=0.063). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Phan et al.[80] (2014) FATS-OS Combination therapy (lovastatin 40 mg/day, niacin 2 to 3 g/day, and colestipol 20 gm/day for 11 years, then continued with simvastatin 10 to 80 mg/day or lovastatin 40 to 80 mg/day plus niacin 2 to 4 g/day vs conventional therapy (88% single statin therapy)	Case-control study Patients enrolled in the Familial Atherosclerosis Treatment Study (FATS), which randomized 176 men with elevated apo B levels and CAD	N=69 20 years	Primary: Mean common CIMT Secondary: Association between lipids levels and mean common CIMT	Primary: The mean CIMT measured in the combination group was significantly smaller as compared with the usual care group (0.902 ± 0.164 vs 1.056 ± 0.169 mm, P<0.001). Secondary: After 20 years, there were significant changes in lipoprotein levels observed in both groups. The combination therapy group had a greater percent decrease in TC (−42 ± 14 vs −31 ± 17%; P=0.008) and LDL-C (−57 ± 13 vs −38 ± 25%; P<0.001), greater percent increase in HDL-C (38 ± 43 vs 15 ± 23%, P=0.02), and greater decrease in TG (−28 ± 44 vs −1.0 ± 49%, P=0.03) as compared with usual care. CIMT was correlated with combination therapy (−0.154; −0.24 to −0.07; P<0.001), on-therapy LDL-C (0.201; 0.069 to 0.332; P=0.003), and percent change in LDL-C (0.04; 0.005 to 0.091; P=0.03). As compared with the usual care group, the combination treated group had a significantly younger mean vascular age (74.4 ± 16.5 years vs 84.6 ± 13.5 years; P<0.05).
Phan et al.[81] (2013) Treatment with niacin vs Treatment not including niacin	Combined analysis (4 RCTs) Patients with established vascular disease without a diagnosis of diabetes mellitus who had been treated with or without niacin and had a baseline fasting glucose level <100 mg/dL	N=407 3 years	Primary: Change in FPG, development of impaired fasting glucose. Frequency of new-onset diabetes, change in mean coronary stenosis and major CV events Secondary: Not reported	Primary: Patients treated with niacin had a significantly larger increase in glucose levels than those not taking niacin (9.88 vs 4.05 mg/dL, P=0.002). The glucose increase was not associated with the type or dosage of niacin used. Impaired fasting glucose was significantly more likely to be seen in subjects treated with niacin than in those without niacin treatment (38% [78 of 197] vs 21% [44 of 210], P=0.003). A non-significant greater number of incident diabetes was found in the niacin group (5.6% [11 of 197] vs 4.8% [10 of 210]; P=0.5). After three years of therapy, the niacin-treated patients had a mean change in the percentage of stenosis that was significantly less than that in the untreated subjects (0.1 ± 0.3% vs 2 ± 12%, P<0.0001). Of the niacin-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				treated patients, 8% had major CV events during follow-up, significantly less than the 21% of untreated patients experiencing major cardiac events (P=0.0001). Secondary: Not reported
Illingworth et al.[82] (1994) Lovastatin 10 to 80 mg/day vs niacin IR 0.25 mg to 1.5 g TID	MC, OL, RCT Patients 21 to 75 years of age with primary hyper-cholesterolemia and either an LDL-C >160 mg/dL and CHD or ≥2 CHD risk factors without CHD or LDL-C >190 mg/dL without CHD or ≥2 risk factors after rigorous diet	N=136 26 weeks	Primary: Change from baseline in lipid parameters Secondary: Safety	Primary: Lovastatin reduced TC, LDL-C and apo B significantly more than niacin (P<0.01 for all). At weeks 10, 18 and 26, LDL-C was reduced by 26, 28 and 32% with lovastatin compared to five, 16 and 21% with niacin, respectively. The target treatment goal of LDL-C <130 mg/day for patients with CHD or less than two risk factors was achieved in 14, 19 and 35% of patients receiving lovastatin compared to zero, 18 and 26% of patients receiving placebo at weeks 10, 18 and 26, respectively (P values not significant). For the majority of those patients with CHD or two or more risk factors in whom the LDL-C goal was <110 mg/dL, neither drug was effective in achieving this goal. In these patients only 13 and 11% achieved this goal at week 26, respectively (P value not reported). Niacin was more effective in decreasing TG at week 26 (P<0.01 vs lovastatin). Both treatments were effective in reducing VLDL-C, with no significant difference observed between the two treatments (P value not reported). Niacin produced reductions in Lp(a) of 14, 30 and 35% at weeks 10, 18 and 26, whereas lovastatin had no effect (P<0.05 or P<0.01 between drugs at each time point). Niacin was significantly more effective at increasing HDL-C and apo AI (P<0.01 vs lovastatin), except for the change in apo AI at week 10 (P value not reported). Niacin increased HDL-C by 20, 29 and 33% and apo AI by 11, 19 and 22% at weeks 10, 18 and 26. Lovastatin resulted in a modest increase in HDL-C and apo AI of 7 and 6%, respectively, at week

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				26. Secondary: Four deaths occurred in the trial, one with niacin and three with lovastatin. All were related to atherosclerosis, and none were deemed to be drug-related. Five and nine patients receiving lovastatin and niacin discontinued treatment because of adverse experiences (excluding deaths). For those who discontinued treatment, the reason was considered to be drug-related in four and eight patients receiving lovastatin and niacin (P value not significant). The major reasons for discontinuation of niacin were cutaneous complaints, including flushing, pruritis and rash. One patient discontinued lovastatin because of myalgias. Overall, patient tolerance to the treatments was better with lovastatin. Adverse events (in decreasing frequency) that occurred more frequently with niacin include flushing, paresthesia, pruritis, dry skin, nausea/vomiting, asthenia and diarrhea.
Sang et al.[83] (2009) Atorvastatin 10 mg/day vs atorvastatin 10 mg/day and niacin ER	RCT Patients with clinical and angiographic criteria for coronary disease, with ≥50% stenosis of 1 coronary artery with high TC	N=108 12 months (plus a 12 month follow up)	Primary: All-cause mortality, MI, rehospitalization, revascularization with either PCI or CABG Secondary: Mean percent changes from baseline lipid parameters, effects on glucose metabolism, safety	Primary: At 12 months, clinical events included rehospitalization due to angina pectoris and heart failure attack, respectively, revascularization with PCI and sudden death (7.14%) with atorvastatin. With combination therapy, the clinical events included rehospitalization due to heart failure attack, revascularization after PCI or CABG (5.77%). No significant reduction was observed with combination therapy (OR, 0.78; P=0.052). Secondary: TC, TG, LDL-C and Lp(a) levels decreased significantly with both treatments (P<0.01), with no significant difference between the two during the course of follow up (P>0.05). Apo A increased significantly with both treatments (P<0.01), with a more favorable effect observed with combination therapy (24.5 vs 40.8%; P<0.01). During the follow up, apo B fell by 5.63 (P<0.05 and 7.35% (P<0.01) with atorvastatin and combination therapy; with no significant difference between the two (P>0.05). During the trial, HDL-C levels increased by 11.67 (P<0.05) and 29.36% (P<0.01) with atorvastatin and combination therapy, with a

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				significant difference favoring combination therapy (P<0.01). Niacin resulted in no significant increase in glucose levels at six or 12 months compared to baseline levels (P>0.05). In the subgroup of diabetic patients (n=28), niacin resulted in a significant increase in glucose levels at six months (P<0.01), and glucose levels increased more significantly at 12 months (P<0.01), but the effect of niacin was not significant in nondiabetic patients (P>0.05). HbA_{1c} levels did not show a significant increase at six months in patient with diabetes, but levels increased significantly at 12 months (P<0.05). Both treatments were generally well tolerated. The most common side effect of niacin therapy was flushing which appeared in four patients receiving combination therapy; however, all patients continued the medication and the flushing disappeared.
Taylor et al.[84] (2009) Niacin ER (Niaspan®) 2 g (titrated) QD vs ezetimibe 10 mg QD	OL, PG, RCT Patients ≥30 years of age with atherosclerotic coronary or vascular disease or a CHD risk equivalent (diabetes mellitus, 10-year Framingham risk score ≥20%, coronary calcium score >200 for women or >400 for men who were receiving treatment with a statin (LDL-C <100 mg/dL and HDL-C <50 mg/dL for men or <55 mg/dL for women)	N=208 14 months	Primary: Change in CIMT after 14 months Secondary: Change in lipid values, composite of major adverse cardiovascular events (MI, myocardial revascularization, admission to the hospital for an acute coronary syndrome, and death from CHD), discontinuation of study drug due to adverse effects, health-related quality of life	Primary: Treatment with niacin led to a significant reduction in mean and maximal CIMT at eight months (P=0.001 and P=0.004, respectively) and 14 months (P=0.001 and P<0.001, respectively). There was no significant change in mean or maximal CIMT with ezetimibe at eight or 14 months compared to baseline. There was a significant difference between the niacin group and the ezetimibe group (P=0.003). Secondary: The change in LDL-C in the ezetimibe group was -17.6 mg/dL compared to -10.0 mg/dL in the niacin group (P=0.01). The change in HDL-C in the ezetimibe group was -2.8 mg/dL compared to 7.5 mg/dL in the niacin group (P<0.001). There were significant reductions in TG in both groups. Major adverse cardiovascular events occurred in 5% of patients receiving ezetimibe compared to 1% of patients receiving niacin (P=0.04). Adverse drug effects led to withdrawal from the study in three of nine patients receiving ezetimibe and 17 of 27 patients receiving niacin (P=0.12). There was no significant difference between the two groups in the quality

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				of life at baseline or at 14 months.
Brown et al.[85] (2001) HATS Niacin SR (Slo-Niacin®) titrated to 1 g BID and simvastatin vs antioxidants vs niacin SR (Slo-Niacin®) titrated to 1 g BID, simvastatin, and antioxidants vs placebo Patients whose HDL-C had not increased by prespecified amounts were switched to niacin IR (Niacor®) titrated to 4 g per day.	DB, PC Patients with clinical coronary disease (defined as previous MI, coronary interventions or confirmed angina) and with ≥3 stenoses of ≥30% of the luminal diameter or 1 stenosis of ≥50%, low HDL-C, normal LDL-C	N=160 3 years	Primary: Changes in lipid profile, arteriographic evidence of change in coronary stenosis (% stenosis caused by most severe lesion in each of nine proximal coronary segments), occurrence of first cardiovascular event (death from coronary causes, MI, stroke or revascularization) Secondary: Mean change in % stenosis in lesions of varying degrees of severity, mean change in luminal diameter in proximal lesions and all lesions	Primary: The mean levels of LDL-C, HDL-C, and TG were significantly changed by -42% (P<0.001), 26% (P<0.001) and -36% (P<0.001), respectively, in the niacin plus simvastatin group but were unaltered in the antioxidant only and placebo groups. Similar changes were observed when antioxidants were added to niacin plus simvastatin. The protective increase in HDL_2 (considered to be the most protective component of HDL-C) with niacin plus simvastatin (65%) was attenuated by concurrent therapy with antioxidants (28%; P=0.02). The average stenosis progressed by 3.9% with placebo, 1.8% with antioxidants (P=0.16 compared to placebo) and 0.7% with niacin plus simvastatin plus antioxidants (P=0.004), and regressed by 0.4% with niacin plus simvastatin (P<0.001). The frequency of the composite primary end point (death from coronary causes, MI, stroke or revascularization) was 24% with placebos, 3% with niacin plus simvastatin, 21% with antioxidants and 14% with niacin plus simvastatin plus antioxidants. The risk of the composite primary end point was 90% lower in the niacin plus simvastatin group than placebo (P=0.03). The risk in the other treatment groups did not differ significantly from that in the placebo group. Secondary: In general, the treatment effects observed with respect to the primary angiographic end point were confirmed for the various subcategories of stenoses and were supported by the results for the mean minimal luminal diameter.
Blankernhorn et al.[86]	DB, PC, RCT	N=188	Primary: Coronary global	Primary: Deterioration in overall coronary status was significantly less with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1987) Colestipol 30 g/day plus niacin 3 to 12 g/day vs placebo	Nonsmoking men 49 to 59 years of age with progressive atherosclerosis who had coronary bypass surgery not involving valve replacement performed ≥3 months prior and a fasting blood cholesterol level 185 to 350 mg/dL	2 years	change score Secondary: Change from baseline in lipid parameters	combination therapy compared to placebo (P<0.001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2 and 2.4% of patients receiving combination therapy and placebo (P=0.002). Combination therapy resulted in a significant reduction in the average number of lesions per patient that progressed (P<0.03) and the percentage of patients with new atheroma formation in native coronary arteries (P<0.03). The percentage of patients receiving combination therapy with new lesions (P<0.04) or any adverse change in bypass grafts (P<0.03) was significant reduced. Secondary: Large, significant decreases in TC (26 vs 4%), TG (22 vs 5%), LDL-C (43 vs 5%) and LDL-C/HDL-C (57 vs 6%), and a large, significant increase in HDL-C (37 vs 2%) were achieved with combination therapy compared to placebo (P<0.001 for all). Modifications in lipid parameters achieved with combination therapy were significant compared to baseline values (P values not reported).
Brown et al.[87] (1990) Colestipol 5 to 10 g TID plus niacin 125 mg BID titrated to 1 to 1.5 g TID vs Colestipol 5 to 10 g TID plus lovastatin 20 mg BID titrated to 40 mg BID	DB, RCT Men ≤62 years of age with elevated apo B and a family history of CAD	N=120 32 months	Primary: Average change in the percent stenosis for the worst lesion in each of the nine proximal segments Secondary: Average changes in all lesions measured in each patient and in proximal lesions causing ≥50% (severe) stenosis or <50% (mild)	Primary: On average, placebo (conventional therapy) increased the index of stenosis by 2.1 percentage points a baseline of 34%. By contrast, it decreased by 0.7 percentage points with colestipol plus lovastatin and by 0.9 percentage points with colestipol and niacin (P<0.003 for trend). At trial end, on average, these nine lesions were almost 3 percentage points less severe among patients treated intensively compared to conventionally. This difference represents almost 1/10 of the amount of disease present at baseline (34% stenosis). Secondary: Placebo (conventional therapy) resulted in consistent worsening of disease when looking at the effect of treatment on certain subsets of lesions (all lesions measured in each patient, lesions causing severe or mild stenosis and those that did not cause total occlusion at baseline). The results with both treatment groups were significantly difference from those receiving

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo (or colestipol if LDL-C was elevated)			stenosis at baseline	conventional therapy for each subset, demonstrating either a mean regression or no change in severity of disease.
Eritsland et al.[88] (1996) Omega-3 acid ethyl esters (Omacor®*) 4 g/day vs dietary therapy	RCT Patients admitted for coronary artery bypass grafting without concomitant cardiac surgery	N=610 1 year	Primary: Graft occlusion Secondary: Not reported	Primary: After one year of therapy, the vein graft occlusion rate per distal anastomoses was 27% in the group receiving omega-3 acid ethyl esters compared to 33% in the control group (OR, 0.77, 95% CI, 0.60 to 0.99; P=0.034). In the omega-3 acid ethyl esters group, 43% of the patients had 21 vein grafts occluded compared to 51% of the patients in the control group (OR, 0.72, 95% CI, 0.51 to 1.01; P=0.05). Secondary: Not reported
Johansen et al.[89] (1999) Omega-3 acid ethyl esters (Omacor*) 3 g BID vs placebo	DB, PC, RCT Patients who were scheduled for elective coronary angioplasty for one or more lesions in native coronary arteries who had not undergone prior angioplasty	N=500 6 months	Primary: Restenosis Secondary: Not reported	Primary: Restenosis occurred in 40.6% of the treated stenoses in the omega-3 acid ethyl esters group and in 35.4% of the treated stenoses in the placebo group (OR, 1.25; 95% CI, 0.87 to 1.80; P=0.21). One or more restenoses occurred in 45.9% of patients treated with omega-3 acid ethyl esters compared to 44.8% of patients receiving placebo (OR, 1.05; 95% CI 0.69 to 1.59; P=0.82). Secondary: Not reported
Nilsen et al.[90] (2001) Omega-3 acid ethyl esters (Omacor*) 3 g BID	PC, RCT Patients >18 years of age with acute MI	N=300 Up to 2 years	Primary: Cardiac events and revascularizations Secondary: Not reported	Primary: Of the patients receiving omega-3 acid ethyl esters, 28% experienced at least one cardiac event compared to 24% of patients in the placebo group (P=0.74). There was no significant difference between the groups with regards to the number, type, or severity of cardiac events. There was no significant difference in the number of revascularizations with omega-3 acid ethyl esters or placebo (HR, 0.92; 95% CI 0.61 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				1.38). Secondary: Not reported
GISSI-Prevenzione Investigators[91] (1999) Omega-3 acid ethyl esters 1 g/day vs vitamin E 300 mg/day vs omega-3 acid ethyl esters 1 g/day vitamin E 300 mg/day vs no treatment	MC, OL, RCT Patients surviving a recent (≤3 months) MI	N=11,324 3.5 years	Primary: Cumulative rate of all-cause death, nonfatal MI and nonfatal stroke; cumulative rate of cardiovascular death, nonfatal MI, nonfatal stroke Secondary: Analyses of components of primary end points and main causes of death, adverse events	Primary: Treatment with omega-3 PUFA, but not vitamin E, significantly lowered the risk of the composite of death, nonfatal MI and nonfatal stroke (RR, 10%; 95% CI, 1 to 18; P=0.048 by 2-way analysis and RR, 15%; 95% CI, 2 to 26; P=0.023 by 4-way analysis). Treatment with omega-3 PUFA decreased the risk of the composite of cardiovascular death, nonfatal MI and nonfatal stroke (RR, 11%; 95% CI, 1 to 20; P=0.053 by 2-way analysis and RR, 20%; 95% CI, 5 to 32; P=0.008 by 4-way analysis). The effect of the combined treatment with omega-3 PUFA and vitamin E was similar to that for omega-3 PUFA for the primary end point (RR, 14%; 95% CI, 1 to 26) and for fatal events (RR, 20%; 95% CI, 5 to 33). Secondary: Analyses of the individual components of the main end point showed that the decrease in mortality (20% for total deaths [P value not reported], 30% for cardiovascular deaths [P=0.0242] and 45% for sudden deaths [P=0.010]) which was obtained with omega-3 PUFA accounted for all of the benefit seen in the combined end point. There was no difference across the treatment groups for nonfatal cardiovascular events. At one year and at the end of the trial, 11.6 and 28.5% of patients receiving omega-3 PUFA and 7.3 and 26.2% of those receiving vitamin E, respectively, had permanently stopped taking the study drug. Side effects were reported as a reason for discontinuing therapy for 3.8% of patients in the omega-3 PUFA groups and 2.1% of those in the vitamin E groups. Overall, gastrointestinal disturbances and nausea were the most frequently reported side effects (4.9 and 1.4% with omega-3 PUFA and 2.9 and 0.4% with vitamin E, respectively; P values not reported.).

*Omacor was renamed to Lovaza in August 2007.
Drug regimen abbreviations: BID=twice daily, ER=extended-release, IR=immediate release, QD=once daily, SR=sustained release, TID=three times daily

Study abbreviations: DB=double-blind, ES=extension study, MC=multicenter, OL=open-label, PC=placebo-controlled, PG=parallel-group, RCT=randomized controlled trial, RETRO=retrospective, SB=single-blind, XO=crossover
Miscellaneous abbreviations: ALT=alanine aminotransferase, apo=apolipoprotein, AST=aspartate aminotransferase, BMI=body mass index, CABG=coronary artery bypass graft, CAD=coronary artery disease, CHD=coronary heart disease, CI=confidence interval, CIMT=carotid intima-media thickness, CPK=creatinine phosphokinase, CRP=C-reactive protein, CV=cardiovascular, DHA=docosahexaenoic acid, EPA=eicosapentaenoic acid, FBG=fasting blood glucose, HAART=high active antiretroviral therapy, HbA_{1c}=glycosylated hemoglobin, HDL-C=high-density lipoprotein cholesterol, HeFH=heterozygous familial hypercholesterolemia, HIV=human immunodeficiency virus, HoFH=homozygous familial hypercholesterolemia, HOMA-IR=homeostasis model assessment-insulin resistance, HR=hazard ratio, hsCRP=high sensitivity C reactive protein, LDL-C=low-density lipoprotein cholesterol, Lp(a)=lipoprotein(a), MI=myocardial infarction, NCEP ATP=National Cholesterol Education Program Adult Treatment Panel, OR=odds ratio, PCI=percutaneous coronary intervention, PUFA=polyunsaturated fatty acids, RLP-C=remnant like particle cholesterol, RR=relative risk, TC=total cholesterol, TG=triglycerides, VLDL-C=very low-density lipoprotein cholesterol

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 8. Relative Cost of the Antilipemic Agents, Miscellaneous

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Icosapent ethyl	capsule	Vascepa®	$$$$$	N/A
Lomitapide	capsule	Juxtapid®	$$$$$	N/A
Mipomersen	injection	Kynamro®	$$$$$	N/A
Niacin	extended-release capsule*, extended-release tablet*, tablet*	Niacor®, Niaspan®*	$	$$$
Omega-3 acid ethyl esters	capsule	Lovaza®*	$$$$	$$$

*Product is available over-the-counter.
N/A=Not available.

X. Conclusions

Prescription niacin, icosapent ethyl, and omega-3 acid ethyl esters are approved by the Food and Drug Administration (FDA) for the treatment of hypertriglyceridemia. Lomitapide and mipomersen are approved for adjunctive treatment of homozygous familial hypercholesterolemia (HoFH). Prescription niacin is also approved for the treatment of primary hypercholesterolemia and mixed dyslipidemia.[4-9] Niacin is available over-the-counter (OTC) in immediate-release and sustained-release formulations. Niacin is also available by prescription as immediate-release (Niacor®) and extended-release (Niaspan®) formulations. Niacin extended release and omega-3 acid ethyl esters are available in a generic formulation.

In general, therapeutic lifestyle changes, including diet, exercise, and smoking cessation, remain an essential modality in the management of patients with hypercholesterolemia. When LDL lowering is required, initial treatment with a statin, a bile acid sequestrant, or niacin is recommended. However, in general, the statins are considered first line therapy for decreasing LDL-C levels, and are recommended in patients with established coronary heart disease (CHD) or CHD equivalents. If after six weeks of therapy lipid goals are not achieved on a statin alone, a dosage increase or the addition of a bile acid sequestrant or ezetimibe should be considered.[15,16,22] More recent guidelines discourage use of niacin in combination with statins, as trials have shown increased side effects without any reduction in cardiovascular outcomes.[17] The FDA has withdrawn approval it had previously given for use of niacin with statins to treat high cholesterol, citing a lack of cardiovascular benefit.[5,92] In patients with an elevated triglyceride level (≥500 mg/dL) a fibric acid derivative or niacin should be initiated before LDL-C lowering therapy to prevent pancreatitis. Omega-3-acid ethyl esters represent an alternative to fibric acid derivatives and niacin for the treatment of hypertriglyceridemia. More recent clinical trials suggest that relatively high doses of omega-3-fatty acids, in the form of fish, fish oils, or high-linolenic acid oils, will reduce the risk for major coronary events in persons with established coronary heart disease. For all patients, it may be reasonable to recommend omega-3-acid ethyl esters for cardiovascular disease risk reduction.[1,15,16,22]

American College of Cardiology/American Heart Association (ACC/AHA) and Institute for Clinical Systems Improvement both released updated guidelines in 2013 which support initiating a statin in patients with established atherosclerotic cardiovascular disease (ASCVD). According to these recommendations, percent reduction in LDL-C is an indicator of response and adherence to therapy, but treating to a targeted level is not a primary goal.[17,18] Combination therapy can be considered on an individual basis, but studies of combination therapy have generally not shown benefit beyond statin monotherapy. Additionally, if patients are unable to take a statin, then bile acid sequestrants, niacin, fibric acid derivatives or fibrates, and ezetimibe are available.[17,18] The ACC/AHA guidelines state that randomized controlled trial evidence show that use of therapy (e.g., niacin) to additionally lower non-HDL–C, once an LDL–C target was achieved, did not further reduce ASCVD outcomes. Of note, this guideline solely looks at the treatment of cholesterol for the primary and secondary prevention of ASCVD, and future updates are expected to provide guidance on the management of complex lipid disorders.[18]

Clinical trials have demonstrated that niacin positively impacts a variety of lipid/lipoprotein parameters.[38-55] Niacin has been shown to reduce the risk of recurrent nonfatal myocardial infarction in patients with hypercholesterolemia, as well as slow the progression or promote regression of atherosclerotic disease (in combination with bile acid sequestrants) in patients with a history of coronary artery disease and hypercholesterolemia.[73,74,85] The 3-year AIM-HIGH trial found no difference in the primary composite cardiovascular outcome end point between the niacin group (16.4%) and placebo group (16.2%).[78] There are limited head-to-head studies comparing the efficacy and safety of the different niacin formulations.[44-46] While flushing may be more common with the immediate-release formulation, it still occurs with the sustained-release and extended-release products. Cases of severe hepatic toxicity have occurred in patients who have substituted sustained-release niacin products for immediate-release niacin at equivalent doses.[4,5] Due to significant safety concerns, the American Heart Association stresses that dietary supplement niacin must not be used as a substitute for prescription niacin, and should not be used for cholesterol lowering due to the potential for very serious side effects.[13]

Clinical trials have demonstrated that prescription omega-3 acid ethyl esters can effectively lower triglycerides, as well as positively impact other lipid/lipoprotein parameters when used as monotherapy or in combination with fenofibrate or statins.[57-72] The GISSI-Prevenzione trial demonstrated the beneficial effects of omega-3 acid ethyl esters in patients who have experienced a recent myocardial infarction; omega-3 acid ethyl esters significantly reduced the risk of death, nonfatal myocardial infarction, and nonfatal stroke compared to vitamin E.[91] Icosapent ethyl, lomitapide, and mipomersen are all recently approved medications which are not yet addressed in clinical guidelines. Two placebo-controlled icosapent ethyl trials (MARINE and ANCHOR) suggest that the drug significantly decreases triglyceride levels without increasing LDL-C levels.[27,28] Studies of lomitapide in combination with other lipid-lowering therapies have shown a reduction in LDL-C from baseline of 35 to 50%.[29,30] Mipomersen, which is administered as a weekly subcutaneous injection, has shown a mean percent change in LDL-C from baseline ranging from 25 to 47% in patients on maximally tolerated lipid-lowering therapy across five clinical trials.[32-36] Both lomitapide and mipomersen have boxed warnings regarding the risk of hepatotoxicity and are only available through Risk Evaluation and Mitigation Strategy (REMS) programs and are only used as adjunctive therapy in patients with HoFH.[8,9]

Therefore, prescription niacin products offer significant clinical advantages in general use over the other brand, generic, and OTC niacin products in the same class (if applicable), but are comparable to each other. Extended-release niacin is available in a generic formulation. Due to their limited FDA-approved indications, prescription omega-3 acid ethyl esters and icosapent ethyl should be available through the medical justification portion of the prior authorization process for adults with severe hypertriglyceridemia (≥500 mg/dL). Also due to their limited FDA-approved indications, lomitapide and mipomersen should be available through the medical justification portion of the prior authorization process for adjunctive use to diet and other lipid-lowering treatments in patients with HoFH.

XI. Recommendations

No brand miscellaneous antilipemic agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. National Institutes of Health: National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited June 2017]. Available from: http://online.factsandcomparisons.com.
3. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 June]. Available from: http://www.thomsonhc.com/.
4. Niacor® [package insert]. Minneapolis (MN): Upsher-Smith Laboratories, Inc; 2013 Mar.
5. Niaspan® [package insert]. Barceloneta, (PR): AbbVie; 2015 Apr.
6. Lovaza® [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2014 May.
7. Vascepa® [package insert]. Bedminster (NJ): Amarin Pharma Inc; 2017 Feb.
8. Juxtapid® [package insert]. Cambridge (MA): Aegerion Pharmaceuticals Inc; 2016 May.
9. Kynamro® [package insert]. Cambridge (MA): Genzyme Corporation; 2016 May.
10. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014 Mar;129(9):1022-1032.
11. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007 May;27(5):715-28.
12. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003;139:996-1002.
13. American Heart Association. Drug Therapy for Cholesterol [guideline on the Internet]. Dallas (TX); American Heart Association: 2017 [cited 2017 Jun]. Available from: http://www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Drug-Therapy-for-Cholesterol_UCM_305632_Article.jsp.
14. Grundy SM, Cleeman JI, Merz NB, Brewer Jr B, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
15. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2017 Feb 3. doi: 10.4158/EP171764.GL.
16. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.
17. Woolley T, Canoniero M, Conroy W, Fareed M, Groen S, Helmrick K, Kofron P, Kottke T, Leslie S, Myers C, Needham R, O'Connor P, Peters J, Reddan J, Sorge L, Zerr B. Institute for Clinical Systems Improvement. Lipid Management in Adults. Updated November 2013.
18. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;00:000–000. DOI: 10.1161/01.cir.0000437738.63853.7a.
19. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519.
20. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment: the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Institute for Health and Clinical Excellence; London (UK): 2014 [cited 2017 Jan 15]. Available from: https://www.nice.org.uk/Guidance/cg181.
21. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr;115(14):1948-67.

22. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106.
23. Kernan WN, Ovbiagele B, Black HR, Bravata DW, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45:2160-2236.
24. Lindor KD, Gershwin ME, Poupon R, et al. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308.
25. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 Executive Summary. Endocr Pract. 2016;22(1):84-113.
26. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. National Institute for Health and Clinical Excellence; London (UK): 2008 [cited 2015 Jan 6]. Available from: http://www.nice.org.uk/guidance/cg71.
27. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep;108(5):682-690.
28. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012 Oct;110(7):984-992.
29. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, and Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature Clinical Practice Cardiovascular Medicine.2008;5: 497-505.
30. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013 Jan;381(9860):40-46.
31. Stefanutti C, Blom DJ, Averna MR, et al. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis. 2015 Jun;240(2):408-14.
32. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar;375(9719):998-1006.
33. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012 May;33(9):1142-1149.
34. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012 Nov;126(19):2283-2292.
35. McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7(11):e49006.
36. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, and Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec;62(23):2178-2184.
37. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015 Mar 1;36(9):566-75.
38. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT

Study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000 Sep 13;284(10):1263-70.
39. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (Niaspan®): a long-term study. Am J Cardiol. 1998 Dec 17;82 Suppl 12A:74U-81U.
40. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998 Sep 15;82:737-43.
41. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994 Aug 15;121(4):252-8.
42. Grundy SM, Vega GL, McGovern ME, Tullock BR, Kendall DM, Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002 Jul 22;162:1568-76.
43. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelsteil CD, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743-5.
44. Knopp RH, Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Sashyap M, Sprecher D, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once a night vs plain niacin in the management of hyperlipidemia. Metabolism. 1998;47(9):1097-104.
45. McKenney JM, Proctor JD, Harris S et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:697-705.
46. Superko HR, McGovern ME, Raul E, Garrett B. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. Am J Cardiol. 2004 Sep 1;94(5):588-94.
47. Wi J, Kim JY, Park S, Kang SM, Jang Y, Chung N. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1,500 mg. Atherosclerosis. 2010;213:235-40.
48. Balasubramanyam A, Coraza I, O'Brian Smith E, Scott LW, Patel P, Iyer D, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96:2236-47.
49. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177-84.
50. Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) vs fenofibrate (200 mg) vs extended-release niacin (2 g). Am J Cardiol 2008;102:1341-7.
51. Shearer GC, Pottala JV, Hansen SN, Brandenburg V, and Harris WS. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res. 2012 Nov;53(11):2429-2435.
52. Guyton JR, Brown BG, Fazio S, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008;51:1564-72.
53. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004 Feb 1;93:307-12.
54. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe vs a statin alone (the COMPELL study). Atherosclerosis. 2007 Jun;192(2):432-7.
55. Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010 Feb;105(4);487-94.
56. Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab. 2010;12:983-93.

57. Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-97.
58. McKeone BJ, Osmundsen K, Brauchi D, Pao Q, Payton-Ross C, Kilinc C, et al. Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia. J Lipid Res. 1997;38:429-36.
59. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148:387-96.
60. Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, Franceschini G. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism. 2004 Feb;53(2):153-8.
61. Bays HE, McKenney J, Maki KC, et al. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010;85:122-8.
62. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 2001;85:544–548.
63. Nordoy A, Bonaa KH, Nilsen H, et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Intern Med 1998;243:163–170.
64. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Jul;29(7):1354-67.
65. Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM; COMBination of prescription omega-3 with simvastatin (COMBOS) Investigators. Am J Caridol. 2010 May;105(10):1409-12.
66. Bays HE, Maki KC, McKenney J, et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin 2010;26:907-15.
67. Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008;102:429-33.
68. Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Clin Ther. 2012;34:67-76.
69. Roth EM, Bays HE, Forker AD, et al. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic patients. J Cardiovasc Pharmacol 2009;54:196-203.
70. Koh KK, Quon MJ, Shin KC, Lim S, Lee Y, Sakuma I, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis. 2012;220:537-44.
71. Stalenhoef AFH, de Graaf J, Wittekoek ME, Bredie SJH, Demacker PNM, Kastelein JJP. The effect of concentrated n-3 fatty acids vs gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 2000;153:129-38.
72. Van Dam M, Stalenhoef AFH, Wittekoek J, et al. Efficacy of concentrated omega-3 fatty acids in hypertriglyceridemia: A comparison with gemfibrozil. Clin Drug Invest 2001;21:175–181.
73. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231:360-81.
74. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.
75. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94.
76. Taylor AJ, Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004 Dec 7;110:3512-7.
77. Philpott AC, Hubacek J, Sun YC, Hillard D, and Anderson TJ. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. Atherosclerosis. 2013 Feb;226(2):453-458.

78. The AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 2011; 365:2255-2267.
79. Teo KK, Goldstein LB, Chaitman BR, et al. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct;44(10):2688-2693.
80. Phan BA, Moore AB, Davis J, et al. Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol. 2014 Sep-Oct;8(5):489-493.
81. Phan BA, Muñoz L, Shadzi P, et al. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study. Am J Cardiol. 2013 Feb;111(3):352-355.
82. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med. 1994;154:1586-95.
83. Sang ZC, Wang F, Zhou Q, LI YH, LI Yg, Wang HP, et al. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chin Med J. 2009;122(14):1615-20.
84. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22.
85. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov 29;345(22):1583-92.
86. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-40.
87. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
88. Eritsland L, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996;77:31–36.
89. Johansen O, Brekke M, Seljeflot I, et al., Coronary Angioplasty Restenosis Trial. n-3 fatty acids do not prevent re stenosis after coronary angioplasty: Results from the CART study. J Am Coll Cardiol 1999; 33:1619-1626.
90. Nilsen DWT, Albrelasen G, Landmark K, et al. Effects of a high-dose concentration of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001;74:50–56.
91. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999 Aug 7;354(9177):447-55.
92. FDA Pulls Approval of Niacin, Fibrate in Combo with Statins. Medscape: Apr 15, 2016 [cited 2017 June 1]. Available from: http://www.medscape.com/viewarticle/862022.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Nitrates and Nitrites
AHFS Class 241208
August 9, 2017

I. Overview

Angina occurs when myocardial oxygen demand exceeds supply, which results in chest discomfort or pain. Common treatments for chronic angina include nitrates, β-blockers, and calcium channel blockers.[1] The nitrites and nitrates reduce oxygen demand by decreasing left ventricular pressure and systemic vascular resistance, as well as by dilating coronary arteries.[2-12] β-blockers reduce heart rate and contractility by competitively blocking the response to beta-adrenergic stimulation in the heart. Calcium channel blockers increase oxygen supply by producing coronary and peripheral vasodilatation, decreasing atrioventricular conduction, and reducing contractility. They also decrease oxygen demand by reducing systemic vascular resistance and arterial pressure.[13,14]

Tolerance develops after chronic exposure to nitrates, regardless of the route of administration or formulation used. This can be overcome by instituting short periods (10 to 12 hours) of withdrawal from nitrate therapy.[2-14] For example: administer the last dose of a short-acting product prior to 7:00 p.m., administer products twice daily instead of four times daily, or use sustained-release products once daily in the morning.[13,14]

The nitrates and nitrites that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the agents are available in a generic formulation. This class was last reviewed in May 2015.

Table 1. Nitrates and Nitrites Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Isosorbide dinitrate	extended-release capsule, extended-release tablet, tablet	Dilatrate-SR®, Isordil®*, Isordil Titradose®*	isosorbide dinitrate
Isosorbide mononitrate	extended-release tablet, tablet	N/A	isosorbide mononitrate
Nitroglycerin	injection, ointment, sublingual powder, sublingual tablet, transdermal patch, translingual spray	GoNitro®, Minitran®*, Nitro-Bid®, Nitro-Dur®*, Nitrolingual®*, Nitrostat®*, Nitromist®*	Nitro-Bid®, Nitrostat®*, nitroglycerin

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the nitrates and nitrites are summarized in Table 2.

Table 2. Treatment Guidelines Using the Nitrates and Nitrites

Clinical Guideline	Recommendation(s)
Institute for Clinical Systems Improvement: **Stable Coronary Artery Disease (2013)**[15]	• The use of one aspirin tablet daily (81 to 162 mg) is strongly recommended unless there are medical contraindications. • In patients with mild, stable coronary artery disease (CAD), drug therapy may be limited to short-acting sublingual nitrates on an as-needed basis. • β-blockers should be used in all status post-myocardial infarction (MI) patients, based on studies showing mortality reduction. • β-blockers are the preferred first-line therapy for reducing symptoms of angina in patients with stable CAD.

Clinical Guideline	Recommendation(s)
	• Drugs with intrinsic sympathomimetic activity should be avoided. • Abrupt withdrawal of all β-blockers should be avoided. • If β-blockers cannot be prescribed as first-line therapy, nitrates are the preferred alternative first-line therapy because of efficacy, low cost, and relatively few adverse events. • For patients who are unable to take β-blockers or long-acting nitrates, the use of calcium channel blockers has been shown to be clinically effective in decreasing symptoms of angina. Dihydropyridines as monotherapy may exacerbate angina. • Combination therapy may be necessary in selected patients, but it increases adverse events and medical costs. A combination of β-blockers and long-acting nitrates is preferred because of cost, efficacy, and reduced potential for adverse events. • If after several attempts at adjusting the medications, a therapeutic combination is not achieved for the patient, a cardiology consultation or referral may be appropriate. • Among patients with stable angina, angiotensin converting enzyme (ACE) inhibitors are most beneficial to patients with left ventricular dysfunction post-MI, persistent hypertension, and diabetes. If the patient cannot tolerate ACE inhibitors, a potential substitute would be an angiotensin II receptor blocker (ARB). • The decision to initiate daily drug therapy for CAD is based upon the symptom complex of the patient in combination with findings from the history, physical examination, laboratory studies and prognostic testing. • Ranolazine is not a first-line drug and should be used in conjunction with a cardiologist. Consider the use of ranolazine when β-blockers, calcium channel blockers, and nitrates are not adequately effective or are not tolerated.
American College of Cardiology /American Heart Association: **2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007)**[16]	• Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. • Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. • Patients with hypertension and established CAD should be treated with blood pressure medication(s) as tolerated, including ACE inhibitors and/or β-blockers with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes. • Long-acting calcium channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. • Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. • ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) of ≤40% and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. • ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. • ARBs are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction and have a LVEF of ≤40%. • ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. • Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF ≤40% and have either diabetes

Clinical Guideline	Recommendation(s)
	or heart failure. • It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a myocardial infarction, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. • Annual influenza vaccination is recommended in patients with cardiovascular disease.
American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons: **Management of Stable Ischemic Heart Disease (2012)**[17]	<u>Medical therapy to prevent MI and death in patients with stable IHD</u> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin in contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction ≤40%) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction ≤40%), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <u>Medical therapy for relief of symptoms in patients with stable IHD</u> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
European Society of Cardiology: **Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation (2012)**[18]	<u>Long-term therapies for ST-segment elevation myocardial infarction (STEMI)-nitrates</u> • The routine use of nitrates in STEMI has not been shown to be of value; therefore, is not recommended. • Intravenous nitrates may be useful during the acute phase in patients with hypertension or heart failure, with no hypotension, right ventricular infarction, or use of phosphodiesterase type 5 inhibitors in the previous 48 hours. • In the acute and stable phase, nitrates remain valuable to control symptoms of angina. <u>Periprocedural antithrombotic medication in primary PCI</u> • Aspirin oral or intravenous is recommended. • An adenosine diphosphate-receptor blocker is recommended in addition to aspirin. Options include: ○ Prasugrel (in clopidogrel-naïve patients, if no history of prior

Clinical Guideline	Recommendation(s)
	stroke/transient ischemic stroke, age <75 years) ○ Ticagrelor ○ Clopidogrel (preferably when prasugrel or ticagrelor are either not available or contraindicated) <u>Routine therapies in the acute, subacute, and long-term phase of STEMI</u> • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI. • Patients who are intolerant to aspirin, clopidogrel is indicated as an alternative to aspirin. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI. • Dual antiplatelet therapy with aspirin and an oral adenosine diphosphate receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of one month for patients receiving bare metal stent and six months for patients receiving drug eluting stent.
American College of Cardiology Foundation/American Heart Association: **2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes (2014)[19]**	<u>Early hospital care- standard medical therapies</u> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications ○ Nitrates ▪ Patients with NSTE-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTE-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTE-ACE if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use ○ Beta-adrenergic blockers ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTE-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. ○ Calcium channel blockers (CCBs)

Clinical Guideline	Recommendation(s)
	▪ In patients with NSTE-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTE-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-clockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTE-ACS in the absence of beta-blocker therapy. o Other anti-ischemic interventions ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTE-ACS patients due to a reduction in recurrent ischemia. o Cholesterol management ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTE-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTE-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system o ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. o ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. o Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS treated with an initial invasive or ischemia-guided strategy o Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTE-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. o In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. o A $P2Y_{12}$ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for $P2Y_{12}$ treatment in patients with NSTE-ACS who undergo an early invasive

Clinical Guideline	Recommendation(s)
	or ischemia-guided strategy. ▪ In patients with NSTE-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatide or tirofiban. <u>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</u> • Antiplatelet agents o Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI o Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. o After PCI, aspirin should be continued indefinitely. o A loading dose of a $P2Y_{12}$ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. o In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. o In patients receiving a stent (bare metal or drug eluting) during PCI, $P2Y_{12}$ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. • Anticoagulant therapy o An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. o Intravenous unfractionated heparin (UFH) is useful in patients with NSTE-ACS undergoing PCI. o Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. o An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTE-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. o If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). o Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. • Timing of CABG in relation to use of antiplatelet agents o Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. o In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. o In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. o In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion.

Clinical Guideline	Recommendation(s)

	Late hospital care, hospital discharge, and posthospital discharge care
	• Medications at discharge
	  ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required.
	  ○ All patients who are post–NSTE-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use.
	  ○ Before hospital discharge, patients with NSTE-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms.
	  ○ Before hospital discharge, patients who are post–NSTE-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use.
	  ○ For patients who are post–NSTE-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services.
	  ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing.
	  ○ Before discharge, patients should be educated about modification of cardiovascular risk factors.
	• Late hospital and post-hospital oral antiplatelet therapy
	  ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients.
	  ○ In addition to aspirin, a $P2Y_{12}$ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy.
	  ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given for at least 12 months.
	• Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTE-ACS
	  ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding.
	  ○ Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a $P2Y_{12}$ receptor inhibitor.

European Society of Cardiology: **Guideline for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2015)**[20]	Pharmacological treatment of ischemia • Early initiation of beta-blocker treatment is recommended in patients with ongoing ischaemic symptoms and without contraindications. • Sublingual or intravenous nitrates are recommended to relieve angina; intravenous treatment is recommended in patients with recurrent angina, uncontrolled hypertension, or signs of heart failure. • In patients with suspected/confirmed vasospastic angina, calcium channel blockers, and nitrates should be considered and beta-blockers avoided. Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes • Aspirin is recommended for all patients without contraindications at an initial

Clinical Guideline	Recommendation(s)

	oral loading dose of 150 to 300 mg (in aspirin-naïve patients) and a maintenance dose of 75 to 100 mg/day long-term regardless of treatment strategy.
	• A $P2Y_{12}$ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risks of bleeds.
	  ○ Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindication, for all patients at moderate-to-high risk of ischemic events (e.g., elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started).
	  ○ Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no contraindication.
	  ○ Clopidogrel (300 to 600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation.
	• $P2Y_{12}$ inhibitor administration for a shorter duration of three to six months after DES implantation may be considered in patients deemed at high bleeding risk.
	• It is not recommended to administer prasugrel in patients whom coronary anatomy is not known.
	• GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications.
	• Cangrelor may be considered in $P2Y_{12}$ inhibitor-naïve patients undergoing PCI.
	• It is not recommended to administer GPIIb/IIIa inhibitors in patients whom coronary anatomy is not known.
	• $P2Y_{12}$ inhibitor administration in addition to aspirin beyond one year may be considered after careful assessment of the ischemic and bleeding risks of the patient.
	
	<u>Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes</u>
	• Parenteral anticoagulation is recommended at the time of diagnosis according to both ischemic and bleeding risks.
	• Fondaparinux is recommended as having the most favorable efficacy-safety profile regardless of the management strategy.
	• Bivalirudin is recommended as an alternative to UFH plus GPIIb/IIIa inhibitors during PCI.
	• UFH is recommended in patients undergoing PCI who did not receive any anticoagulant.
	• In patients on fondaparinux undergoing PCI, a single intravenous bolus of UFH is recommended during the procedure.
	• Enoxaparin or UFH are recommended when fondaparinux is not available.
	• Enoxaparin should be considered as an anticoagulant for PCI in patients pretreated for PCI with subcutaneous enoxaparin.
	• Additional activated clotting time-guided intravenous boluses of UFH during PCI may be considered following initial UFH treatment.
	• Discontinuation of anticoagulation should be considered after PCI, unless otherwise indicated.
	• Crossover between UFH and LMWH is not recommended.
	• In NSTEMI patients with no prior stroke/TIA and at high ischemic risk as well as low bleeding risk receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily for approximately one year) may be considered after discontinuation of parenteral anticoagulation.
	
	<u>Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation</u>
	• In patients with a firm indication for oral anticoagulation (e.g., atrial fibrillation with a CHADS2-VASc score ≥2, recent VTE, mechanical valve prosthesis), oral

Clinical Guideline	Recommendation(s)
	anticoagulation is recommended in addition to antiplatelet therapy. • An early invasive coronary angiography (within 24 hours) should be considered in moderate- to high-risk patients, irrespective of oral anticoagulant exposure, to expedite treatment allocation (medical vs PCI vs CABG) and to determine optimal antithrombotic regimen. • Initial dual antiplatelet therapy with aspirin plus a $P2Y_{12}$ inhibitor in addition to oral anticoagulation before coronary angiography is not recommended. • During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all non-vitamin K antagonist oral anticoagulants (NOACs) and if INR is <2.5 in VKA-treated patients. • Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase. • Following coronary stenting, dual (oral) antiplatelet therapy (DAPT) including new $P2Y_{12}$ inhibitors should be considered as an alternative to triple therapy for patients with non-ST-elevation acute coronary syndromes and atrial fibrillation with a CHADS2-VASc score of 1 (in males) or 2 (in females). • If at low bleeding risk (HAS-BLED ≤2), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for six months, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months. • If at high bleeding risk (HAS-BLED ≥3), triple therapy with oral anticoagulant, aspirin, and clopidogrel should be considered for one month, followed by oral anticoagulant and aspirin or clopidogrel continued up to 12 months irrespective of the stent type. • Dual therapy with oral anticoagulant and clopidogrel may be considered as an alternative to triple antithrombotic therapy in selected patients (HAS-BLED ≥3 and low risk of stent thrombosis). • The use of ticagrelor or prasugrel as part of triple therapy is not recommended. • In medically managed patients, one antiplatelet agent in addition to oral anticoagulant should be considered for up to one year.
American College of Cardiology Foundation/American Heart Association: **Guideline for the Management of ST-Elevation Myocardial Infarction (2013)**[21]	<u>Antiplatelet therapy to support primary PCI for STEMI</u> • Aspirin 162 to 325 mg should be given before primary PCI. • After PCI, aspirin should be continued indefinitely. • A loading dose of a $P2Y_{12}$ receptor inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI. Options include clopidogrel 600 mg, prasugrel 60 mg or ticagrelor 180 mg. • $P2Y_{12}$ inhibitor therapy should be given for one year to patients with STEMI who receive a stent (bare-metal or drug-eluting) during primary PCI using clopidogrel 75 mg/day, prasugrel 10 mg/day or ticagrelor 90 mg twice daily. • It is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses after primary PCI. • It is reasonable to start treatment with an IV GP IIb/IIIa receptor antagonist such as abciximab, high bolus-dose tirofiban or double-bolus eptifibatide at the time of primary PCI (with or without stenting or clopidogrel pre-treatment) in selected patients with STEMI who are receiving UFH. • It may be reasonable to administer IV GP IIb/IIIa receptor antagonist in the precatheterization laboratory setting (e.g., ambulance, emergency department) to patients with STEMI for whom primary PCI is intended. • It may be reasonable to administer intracoronary abciximab to patients with STEMI undergoing primary PCI. • Continuation of a $P2Y_{12}$ inhibitor beyond one year may be considered in patients undergoing drug-eluting stent placement. • Prasugrel should not be administered to patients with a history of prior stroke or TIA. <u>Anticoagulant therapy to support primary PCI</u>

Clinical Guideline	Recommendation(s)
	• For patients with STEMI undergoing primary PCI, the following supportive anticoagulant regimens are recommended: UFH, with additional boluses administered as needed to maintain therapeutic activated clotting time levels, taking into account whether a GP IIb/IIIa receptor antagonist has been administered or bivalirudin with or without prior treatment with UFH. • In patients with STEMI undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist. • Fondaparinux should not be used as the sole anticoagulant to support primary PCI because of the risk of catheter thrombosis. <u>Adjunctive antiplatelet therapy with fibrinolysis</u> • Aspirin (162- to 325-mg loading dose) and clopidogrel (300 mg loading dose for ≤75 year of age, 75-mg dose for patients >75 years of age) should be administered to patients with STEMI who receive fibrinolytic therapy. • Aspirin should be continued indefinitely and clopidogrel (75 mg daily) should be continued for at least 14 days and up to one year in patients with STEMI who receive fibrinolytic therapy. • It is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses after fibrinolytic therapy. <u>Adjunctive anticoagulant therapy with fibrinolysis</u> • Patients with STEMI undergoing reperfusion with fibrinolytic therapy should receive anticoagulant therapy for a minimum of 48 hours, and preferably for the duration of the hospitalization, up to eight days or until revascularization if performed. • Recommended regimens include UFH administered as a weight-adjusted IV bolus and infusion to obtain an activated partial thromboplastin time of 1.5 to 2.0 times control, for 48 hours or until revascularization; enoxaparin administered according to age, weight, and creatinine clearance, given as an IV bolus, followed in 15 minutes by subcutaneous injection for the duration of the index hospitalization, up to eight days or until revascularization; or fondaparinux administered with initial IV dose, followed in 24 hours by daily subcutaneous injections if the estimated creatinine clearance is greater than 30 mL/min, for the duration of the index hospitalization, up to eight days or until revascularization. <u>Antiplatelet therapy to support PCI after fibrinolytic therapy</u> • After PCI, aspirin should be continued indefinitely. • Clopidogrel should be provided as a 300 mg loading dose given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI within 24 hours of receiving fibrinolytic therapy; a 600 mg loading dose given before or at the time of PCI to patients who did not receive a previous loading dose and who are undergoing PCI more than 24 hours after receiving fibrinolytic therapy; and a dose of 75 mg daily should be given after PCI. • After PCI, it is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses. • Prasugrel, in a 60 mg loading dose, is reasonable once the coronary anatomy is known in patients who did not receive a previous loading dose of clopidogrel at the time of administration of a fibrinolytic agent, but prasugrel should not be given sooner than 24 hours after administration of a fibrin-specific agent or 48 hours after administration of a non–fibrin-specific agent. • Prasugrel, in a 10 mg daily maintenance dose, is reasonable after PCI. • Prasugrel should not be administered to patients with a history of prior stroke or TIA.

Clinical Guideline	Recommendation(s)
	Anticoagulant therapy to support PCI after fibrinolytic therapy • For patients with STEMI undergoing PCI after receiving fibrinolytic therapy with IV UFH, additional boluses of IV UFH should be administered as needed to support the procedure, taking into account whether GP IIb/IIIa receptor antagonists have been administered. • For patients with STEMI undergoing PCI after receiving fibrinolytic therapy with enoxaparin, if the last subcutaneous dose was administered within the prior eight hours, no additional enoxaparin should be given; if the last subcutaneous dose was administered between eight and 12 hours earlier, enoxaparin 0.3 mg/kg IV should be given.
Institute for Clinical Systems Improvement: **Diagnosis and Treatment of Chest Pain and Acute Coronary Syndrome (2012)**[22]	Early therapy-NTG • ISIS-4 and GISSI-3 failed to show a benefit of NTG on reduction of mortality in acute MI. • NTG should be given sublingually to relieve ischemic symptoms. If symptoms are ongoing or recurrent despite the administration of intravenous β-blockers, intravenous NTG can be initiated. • NTG is contraindicated in patients who are hypotensive, have documented severe aortic stenosis, have hypertrophic cardiomyopathy, or who have received sildenafil or vardenafil within the previous 24 hours or tadalafil in the previous 48 hours. • Consider oral nitrates for outpatients with ongoing angina. • Oral nitrates may benefit selected patients with postinfarction mortality in all MIs.
American College of Cardiology Foundation/ American Heart Association: **ACCF/AHA Guideline for the Management of Heart Failure (2013)**[23]	ACCF/AHA Stages of Heart Failure (HF) • Stage A: At high risk for HF but without structural heart disease or symptoms of HF. • Stage B: Structural heart disease but without signs or symptoms of HF. • Stage C: Structural heart disease with prior or current symptoms of HF. • Stage D: Refractory HF requiring specialized interventions. Treatment of Stage A: Recommendations • Hypertension and lipid disorders should be controlled in accordance with contemporary guidelines to lower the risk of HF. • Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. Treatment of Stage B: Recommendations • In all patients with a recent or remote history of myocardial infarction (MI) or acute coronary syndrome (ACS) and reduced ejection fraction (EF), ACE inhibitors should be used to prevent symptomatic HF and reduce mortality. In patients intolerant of ACE inhibitors, ARBs are appropriate unless contraindicated. • In all patients with a recent or remote history of MI or ACS and reduced EF, evidence-based beta blockers should be used to reduce mortality. • In all patients with a recent or remote history of MI or ACS, statins should be used to prevent symptomatic HF and cardiovascular events. • In patients with structural cardiac abnormalities, including left ventricular (LV) hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic HF. • ACE inhibitors should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI.

Clinical Guideline	Recommendation(s)
	• Beta blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. • Nondihydropyridine calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of HF after MI. Treatment of Stage C HF with reduced EF (HFrEF): Recommendations • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. • ARBs are recommended in patients with HFrEF with current or prior symptoms who are ACE inhibitor intolerant, unless contraindicated, to reduce morbidity and mortality. • Use of one of the three beta blockers proven to reduce mortality (bisoprolol, carvedilol, and sustained-release metoprolol succinate) is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. • Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II-IV HF and who have LVEF of ≤35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤2.5 mg/dL in men or ≤2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2), and potassium should be less than 5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III to IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. Treatment of Stage C HF with preserved EF (HFpEF): Recommendations • Systolic and diastolic blood pressure should be controlled in patients with HFpEF in accordance with published clinical practice guidelines to prevent morbidity. • Diuretics should be used for relief of symptoms due to volume overload in patients with HFpEF. • Management of AF according to published clinical practice guidelines in patients with HFpEF is reasonable to improve symptomatic HF. • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF.
Institute for Clinical Systems Improvement: **Heart Failure in Adults (2013)**[24]	Pharmacologic management: • Carvedilol, metoprolol succinate (extended-release) and bisoprolol have demonstrated reductions in mortality for patients with all classes of heart failure. These agents should be used before using other generic β-blockers. • ACE inhibitors should be prescribed for all patients with left ventricular systolic dysfunction unless contraindications are present. • If non-African American, ACE inhibitors are recommended for decreasing heart failure mortality than isosorbide dinitrate/hydralazine. In contrast, combination hydralazine and nitrates is recommended for patients self-described as African Americans, with moderate to severe symptoms on optimal therapy with ACE

Clinical Guideline	Recommendation(s)

	inhibitors, β-blockers, and diuretics.
	• ARBs should be considered primarily for patients who are intolerant to ACE inhibitors or in patients receiving standard drug therapy (including ACE inhibitors) who continue to show clinical deterioration.
	• Routine use of ARBs and ACE inhibitors and aldosterone antagonists cannot be recommended.
	• Diuretics should not be the sole therapy for patients with signs of volume overload; vasoactive drugs should be considered.
	• In severe heart failure, loop diuretics should be used over thiazide diuretics and combination therapy with thiazide. Loop diuretics are also effective in refractory cases of volume overload.
	• Patients with NYHA class III-IV heart failure on stable doses of digoxin and ACE inhibitors can reduce mortality by administering aldosterone-blocking agents.
	• Nesiritide is recommended to be reserved for patients with decompensated heart failure who remain volume overloaded despite aggressive treatment with diuretics/vasodilators display tolerance and/or resistance to vasodilators or diuretics, or demonstrate significant side effects to other vasodilators.
	• When considering the use of calcium channel blockers, only dihydropyridine calcium channel blockers have been shown safe. Non-dihydropyridine calcium channel blockers can be used in patients with preserved systolic heart failure.
	
	<u>Pharmacologic management-digoxin</u>
	• In patients in normal sinus rhythm with preserved systolic function and mild to moderate heart failure symptoms on optimal therapy, digoxin had no effect on the endpoints of all-cause or cardiovascular mortality or hospitalization.
	• Serum levels less than 1.0 ng/mL are considered therapeutic. Levels greater than 1.2 have been associated with greater side effects. Serum levels do not always correlate to symptoms of digoxin toxicity.
	• Digoxin has been found useful:
	  o In heart failure patients with atrial fibrillation with a rapid ventricular response.
	  o In combination with ACE inhibitors in reducing hospitalizations in heart failure patients.
	• Digoxin should not:
	  o Be initiated in asymptomatic heart failure patients as it remains unsupported by clinical trials.
	  o Be "loaded" either orally or intravenously. Loading doses are generally not needed and steady state generally takes one week to reach.
	• Monitor for symptoms of toxicity, reduction of renal function or conduction abnormality.
	• To avoid digitalis toxicity, use lower doses in the elderly and those with renal impairment, check level in one to two weeks after start of therapy in elderly or renal-impaired patients, and be aware of drug interactions with new medications.
	• If continuing digoxin therapy in women, it may be reasonable to recommend that lower dosing (0.125 mg/day) should be used and lower serum levels (1.0 or less) should be maintained.

Heart Failure Society of America: **Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (2010)**[25]	• Combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE inhibitors for African Americans with heart failure and reduced LVEF. • In patients with reduced LVEF, combination hydralazine and an oral nitrate may be considered when ACE inhibitors are not tolerated due to hyperkalemia or renal insufficiency or ARBs are not tolerated due to cough or angioedema. • May be considered in non–African American patients with left ventricular dysfunction who remain symptomatic despite optimized standard therapy.

Clinical Guideline	Recommendation(s)
	• Addition of the combination of hydralazine and isosorbide dinitrate should be considered in African American patients with heart failure and reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with ACE inhibitors and β-blocker or unable to tolerate a β-blocker. • In patients admitted with acute decompensated heart failure, intravenous NTG, nitroprusside or nesiritide may be considered as an addition to diuretic therapy for rapid improvement of congestive symptoms in the absence of symptomatic hypotension. • Intravenous vasodilators (NTG or nitroprusside) and diuretics are recommended for rapid symptom relief in patients with acute pulmonary edema or severe hypertension. • Intravenous vasodilators (NTG, nesiritide, or nitroprusside) can be considered in patients with acute decompensated heart failure who have persistent symptoms despite aggressive treatment with diuretics and standard oral therapy. • Nitrates should be considered in patients with heart failure when additional medication is needed for anginal symptoms.
European Society of Cardiology: **Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2016)**[26]	Pharmacological treatments indicated in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction • An ACE inhibitor is recommended, in addition to a beat-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death. • A mineralocorticoid receptor antagonist is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker, to reduce the risk of HF hospitalization and death. • Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. • Sacubitril-valsartan is recommended as a replacement for an ACE inhibitor to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker, and a mineralocorticoid receptor antagonist. • Ivabradine should be considered to reduce the risk of HF hospitalization or cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm despite treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose below that), ACE inhibitor (or ARB), and a mineralocorticoid receptor antagonist (or ARB). • Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contraindications for a beta-blocker. Patients should also receive an ACE inhibitor (or ARB) and a mineralocorticoid receptor antagonist (or ARB). • An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to tolerate an ACE inhibitor (patients should also receive a beta-blocker and mineralocorticoid receptor antagonist). • An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate a mineralocorticoid receptor antagonist. • Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with LVEF ≤35% or with an LVEF <45% combined with a dilated LV in NYHA Class III–IV despite treatment with an ACE-I a beta-blocker and a mineralocorticoid receptor antagonist to reduce the risk of HF hospitalization and death. • Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE inhibitor nor an ARB (or they are contraindicated) to reduce the risk of death.

Clinical Guideline	Recommendation(s)
	• Digoxin is a treatment with less-certain benefits and may be considered in symptomatic patients in sinus rhythm despite treatment with an ACE inhibitor (or ARB), a beta-blocker and a mineralocorticoid receptor antagonist, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations). Recommendations for treatment of patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction • It is recommended to screen patients with HFpEF or HFmrEF (mid-range) for both cardiovascular and noncardiovascular comorbidities, which, if present, should be treated provided safe and effective interventions exist to improve symptoms, well-being and/or prognosis. • Diuretics are recommended in congested patients with HFpEF or HFmrEF in order to alleviate symptoms and signs. Recommendations for initial management of a rapid ventricular rate in patients with heart failure and atrial fibrillation in the acute or chronic setting • Urgent electrical cardioversion is recommended if AF is thought to be contributing to the patient's haemodynamic compromise in order to improve the patient clinical condition. • For patients in NYHA Class IV, in addition to treatment for acute HF, an intravenous bolus of amiodarone or, in digoxin-naïve patients, an intravenous bolus of digoxin should be considered to reduce the ventricular rate. • For patients in NYHA Class I–III, a beta-blocker, usually given orally, is safe and therefore is recommended as first-line treatment to control ventricular rate, provided the patient is euvolaemic. • For patients in NYHA Class I–III, digoxin should be considered when ventricular rate remains high despite beta-blockers or when beta-blockers are not tolerated or contraindicated. • Treatment with dronedarone to improve ventricular rate control is not recommended due to safety concerns. Recommendations for cardiac imaging in patients with suspected or established heart failure • Transthoracic Echocardiogram (TTE) is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of HFrEF, HFmrEF, or HFpEF. • TTE is recommended for the assessment of LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device treatment recommended for HFrEF. Recommendations aiming to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms • Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life. • ACE inhibitor is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to prevent or delay the onset of HF and prolong life. • Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order to prevent or delay the onset of HF and prolong life. Pharmacological treatments indicated in patients with symptomatic heart failure with reduced ejection fraction • An ACE inhibitor is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and

Clinical Guideline	Recommendation(s)
	death. • A beta-blocker is recommended, in addition to an ACE inhibitor, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. • A mineralocorticoid receptor antagonist is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker, to reduce the risk of HF hospitalization and death. Other pharmacological treatments recommended in selected patients with symptomatic heart failure with reduced ejection fraction • Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. • Sacubitril-valsartan is recommended as a replacement for an ACE inhibitor to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and a mineralocorticoid receptor antagonist. Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (New York Heart Association Class II–IV) heart failure with reduced ejection fraction • Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization. • The addition of an ARB (or a renin inhibitor) to the combination of an ACE inhibitor and a mineralocorticoid receptor antagonist is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalemia. Not-recommended treatments of co-morbidities in patients with heart failure • Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. • NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization. Recommendations for the management of patients with acute heart failure – pharmacotherapy • Intravenous loop diuretics are recommended for all patients with acute HF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of intravenous diuretics. • In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20 to 40 mg intravenous furosemide (or equivalent); for those on chronic diuretic therapy, initial intravenous dose should be at least equivalent to oral dose. • It is recommended to give diuretics either as intermittent boluses or a continuous infusion, and the dose and duration should be adjusted according to the patients' symptoms and clinical status. • Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.
National Institute for Health and Clinical Excellence: **Chronic heart failure in adults: management (2010)**[27]	Heart failure due to left ventricular systolic dysfunction • As first-line treatment, offer both ACE inhibitors and β-blockers licensed for heart failure to all patients. • As second-line treatment, seek advice from a specialist and consider adding one of the following if a patient remains symptomatic despite optimal therapy with ACE inhibitor or a β-blocker: ○ An aldosterone antagonist licensed for heart failure (especially moderate

Clinical Guideline	Recommendation(s)
(Reviewed Nov 2014)	or severe heart failure or previous MI within the past month). ○ An ARB licensed for heart failure (especially mild to moderate heart failure). ○ Hydralazine in combination with nitrate (especially if patient is of African or Caribbean origin and has moderate to severe heart failure). • Hydralazine in combination with nitrate may be used first-line in patients intolerant to ACE inhibitors and ARBs. • ARBs may be used first-line in patients intolerant to ACE inhibitors. • Digoxin is recommended for worsening or severe heart failure due to left ventricular systolic dysfunction despite first- and second-line treatment for heart failure. <u>Monitoring</u> • Routine monitoring of serum digoxin concentrations is not recommended. A digoxin concentration measured within eight to 12 hours of the last dose may be useful to confirm a clinical impression of toxicity or non-adherence. • The serum digoxin concentration should be interpreted in the clinical context as toxicity may occur even when the concentration is within the 'therapeutic' range.
European Society of Cardiology: **Guidelines for Pre-Operative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-Cardiac Surgery (2014)**[28]	• NTG has been shown to reverse myocardial ischemia. • The effect of perioperative intravenous nitroglycerin on perioperative ischaemia is a matter of debate and no effect has been demonstrated on the incidence of myocardial infarction or cardiac death. • Also perioperative use of nitroglycerin may pose a significant haemodynamic risk to patients, since decreased pre-load may lead to tachycardia and hypotension.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the nitrates and nitrites are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Nitrates and Nitrites[2-12]

Indication	Isosorbide Dinitrate*	Isosorbide Mononitrate*	Nitroglycerin		
			Lingual spray/ Sublingual tablet/ Sublingual powder	Injection	Topical/ Transdermal*
Angina Pectoris					
Acute relief of an attack of angina pectoris			✔		
Prevention of angina pectoris due to coronary artery disease	✔	✔	✔		✔
Treatment of angina pectoris due to coronary artery disease	✔ (sublingual tablet)	✔ (tablet)		✔ †	
Cardiovascular Uses					
Control of congestive heart failure in the setting of acute myocardial infarction				✔	
Induction of intraoperative hypotension				✔	
Treatment of perioperative hypertension				✔	

*The onset of action of this product is not sufficiently rapid for it to be useful in aborting an acute attack.
†In patients who have not responded to sublingual nitroglycerin and beta-blockers.

IV. Pharmacokinetics

The pharmacokinetic parameters of the nitrates and nitrites are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Nitrates and Nitrites[14]

Generic Name(s)	Bioavailability (%)	Onset (minutes)	Duration	Excretion (%)	Half-Life
Isosorbide dinitrate	ER: 22 IR: 58 SL: 19 to 93	SL: 2 to 10	IR: 8 hours SL: 1 to 2 hours	Renal (80 to 90) Feces (limited; % not reported)	ER: 4 hours IR: 4 hours SL: 1 hour
Isosorbide mononitrate	ER: 80 to 100 IR: 93 to 100	ER: 45 to 60 IR: 45 to 60	ER: 6 hours IR: 6 hours	Renal (78) Feces (1)	ER: 6 hours IR: 6 hours
Nitroglycerin	Patch: 75* SL: 38.5	Oint: 30 to 60 SL: 1 to 3	Oint: 7 hours Patch: 8 to 10 hours SL: up to 60 minutes	Renal (22)	1.5 to 7.5 minutes

*Compared to intravenous dosing.
ER=extended-release, IR=immediate-release, Oint=ointment, SL=sublingual

V. Drug Interactions

Major drug interactions with the nitrates and nitrites are listed in Table 5.

Table 5. Major Drug Interactions with the Nitrates and Nitrites[14]

Generic Name(s)	Interaction	Mechanism
Isosorbide dinitrate, Isosorbide mononitrate, Nitroglycerin	Avanafil	Avanafil potentiates the hypotensive effects of nitrates, resulting in severe hypotension.
Isosorbide dinitrate, Isosorbide mononitrate, Nitroglycerin	Sildenafil, tadalafil, vardenafil	Sildenafil may potentiate the hypotensive effects of nitrates. The use of these agents in combination is contraindicated.
Isosorbide dinitrate, Isosorbide mononitrate, Nitroglycerin	Riociguat	Riociguat potentiates the hypotensive effects of nitrates, resulting in severe hypotension.
Nitroglycerin	Alteplase	Concentrations of tissue-type plasminogen activator (tPA) are decreased, indicating impairment of the thrombolytic effect of alteplase. The enhanced hepatic blood flow as a result of the nitroglycerin facilitates the hepatic metabolism of tPA.
Nitroglycerin	Heparin	Concurrent use of heparin and nitroglycerin may result in a decrease in partial thromboplastin time.

VI. Adverse Drug Events

The most common adverse drug events reported with the nitrates and nitrites are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Nitrates and Nitrites[2-14]

Adverse Events	Isosorbide Dinitrate	Isosorbide Mononitrate SR	Isosorbide Mononitrate IR	Nitroglycerin
Cardiovascular				
Abnormal heart sound	-	≤5	-	-
Aggravated angina pectoris	-	≤5	-	-
Angina pectoris	-	-	≥1	-
Arrhythmia	-	≤5	<1	-
Atrial fibrillation	-	≤5	<1	-
Bradycardia	-	≤5	-	-

Adverse Events	Isosorbide Dinitrate	Isosorbide Mononitrate SR	Isosorbide Mononitrate IR	Nitroglycerin
Bundle branch block	-	≤5	-	-
Cardiac failure	-	≤5	-	-
Crescendo angina	✔	-	-	✔
Extrasystole	-	≤5	-	-
Flushing	-	≤5	-	✔
Heart murmur	-	≤5	-	-
Hypertension	-	≤5	-	-
Hypotension	✔	≤5	<1	4
Migraine	-	≤5	-	-
Myocardial infarction	-	≤5	✔	-
Palpitation	-	≤5	<1	✔
Postural hypotension	✔	-	<1	✔
Premature ventricular contraction	-	-	<1	-
Q wave abnormality	-	≤5	-	-
Rebound hypertension	✔	-	-	✔
Supraventricular tachycardia	-	-	<1	-
Syncope	✔	✔	<1	✔
Tachyarrhythmia	-	-	-	-
Tachycardia	-	≤5	-	-
Ventricular tachycardia	-	≤5	-	-
Central Nervous System				
Anxiety	-	≤5	<1	-
Confusion	-	≤5	<1	-
Decreased libido	-	≤5	-	-
Depression	-	≤5	-	-
Dizziness	✔	8 to 11	3 to 5	≥2
Headache	✔	≥5	19 to 38	50 to 63
Impotence	-	≤5	<1	-
Insomnia	-	≤5	<1	-
Lightheadedness	✔	-	-	6
Nervousness	-	≤5	<1	-
Neuritis	-	≤5	-	-
Paresis	-	≤5	-	-
Paresthesia	-	≤5	-	≥2
Purpura	-	≤5	-	-
Somnolence	-	≤5	-	-
Vertigo	-	≤5	-	✔
Dermatological				
Acne	-	≤5	-	-
Anaphylactoid reactions	-	-	-	✔
Contact dermatitis	-	-	-	✔ *
Exfoliative dermatitis	-	-	-	✔
Photophobia	-	≤5	-	-
Pruritus	-	≤5	<1	-
Rash	-	≤5	<1	✔
Skin nodule	-	≤5	-	-
Gastrointestinal				
Abdominal pain	-	≤5	<1	≤2
Constipation	-	≤5	-	-
Diarrhea	-	≤5	<1	-
Dyspepsia	-	≤5	<1	-
Flatulence	-	≤5	-	-
Gastric ulcer	-	≤5	-	-

Adverse Events	Isosorbide Dinitrate	Isosorbide Mononitrate SR	Isosorbide Mononitrate IR	Nitroglycerin
Gastritis	-	≤5	-	-
Hemorrhagic gastric ulcer	-	≤5	-	-
Loose stools	-	≤5	-	-
Nausea	-	≤5	2 to 4	✔
Vomiting	-	≤5	2 to 4	✔
Genitourinary				
Dysuria	-	-	<1	-
Polyuria	-	≤5	-	-
Renal calculus	-	≤5	-	-
Urinary tract infection	-	≤5	-	-
Hematologic				
Hemolytic anemia	-	-	-	-
Hypochromic anemia	-	≤5	-	-
Methemoglobinemia	✔	✔	✔	✔
Thrombocytopenia	-	≤5	-	-
Laboratory Test Abnormalities				
Elevated SGOT	-	≤5	-	-
Elevated SGPT	-	≤5	-	-
Musculoskeletal				
Arthralgia	-	≤5	<1	-
Asthenia	-	≤5	<1	-
Muscle weakness	-	≤5	-	-
Musculoskeletal pain	-	≤5	-	-
Myalgia	-	≤5	-	-
Respiratory				
Bronchitis	-	≤5	<1	-
Bronchospasm	-	≤5	-	-
Coughing	-	≤5	-	-
Dyspnea	-	≤5	-	≤2
Increased sputum	-	≤5	-	-
Nasal congestion	-	≤5	-	-
Pharyngitis	-	≤5	-	-
Pneumonia	-	≤5	<1	-
Pulmonary infiltration	-	≤5	-	-
Rales	-	≤5	-	-
Rhinitis	-	≤5	-	-
Sinusitis	-	≤5	-	-
Upper respiratory tract infection	-	-	<1	-
Other				
Abnormal hair texture	-	≤5	-	-
Abnormal vision	-	≤5	-	-
Agitation	-	-	<1	-
Atrophic vaginitis	-	≤5	-	-
Back pain	-	≤5	-	-
Bacterial infection	-	≤5	-	-
Blurred vision	✔	-	<1	-
Breast pain	-	≤5	-	-
Chest pain	-	≤5	-	-
Cold sweat	-	-	<1	-
Collapse	-	-	-	✔
Conjunctivitis	-	≤5	-	-
Diplopia	-	-	<1	-
Dry mouth	-	≤5	-	-

Adverse Events	Isosorbide Dinitrate	Isosorbide Mononitrate SR	Isosorbide Mononitrate IR	Nitroglycerin
Discoordination	-	-	<1	-
Earache	-	≤5	-	-
Edema	-	≤5	<1	-
Fatigue	-	≤5	-	-
Fever	-	≤5	-	-
Flu-like symptoms	-	≤5	-	-
Frozen shoulder	-	≤5	-	-
Glossitis	-	≤5	-	-
Hemorrhoids	-	≤5	-	-
Hot flashes	-	≤5	-	-
Hyperuricemia	-	≤5	-	-
Hypoesthesia	-	≤5	<1	-
Hypokalemia	-	≤5	-	-
Hypokinesia	-	-	<1	-
Impaired concentration	-	≤5	-	-
Increased appetite	-	-	<1	-
Increased sweating	-	≤5	-	-
Intermittent claudication	-	≤5	-	-
Leg ulcer	-	≤5	-	-
Malaise	-	≤5	<1	-
Melena	-	≤5	-	-
Moniliasis	-	≤5	-	-
Myositis	-	≤5	-	-
Nightmares	-	-	<1	-
Pallor	-	-	-	✔
Paroniria	-	≤5	-	-
Ptosis	-	≤5	-	-
Restlessness	-	-	-	✔
Rigors	-	≤5	<1	-
Tendon disorder	-	≤5	-	-
Tenesmus	-	-	<1	-
Tinnitus	-	≤5	-	-
Tooth disorder	-	-	<1	-
Tremor	-	≤5	-	-
Tympanic membrane perforation	-	≤5	-	-
Varicose veins	-	≤5	-	-
Viral infection	-	≤5	-	-
Weakness	-	-	-	✔

IR=immediate-release, SR=sustained-release
*Topical formulation only.
✔ Percent not specified.
- Event not reported.

VII. Dosing and Administration

The usual dosing regimens for the nitrates and nitrites are listed in Table 7.

Table 7. Usual Dosing Regimens for the Nitrates and Nitrites[2-12]

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Isosorbide dinitrate	Angina pectoris: Extended-release capsule, extended-release tablet: initial, 40 mg/day; maintenance, 40 to 80 mg every 8 to	Safety and efficacy in children have not been established.	Extended-release capsule: 40 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	12 hours; maximum, 160 mg/day Sublingual tablet (treatment): initial, 2.5 to 5 mg; maintenance, titrate upward until angina is relieved or side effects limit the dose Sublingual tablet (prophylaxis): 2.5 to 5 mg approximately 15 minutes before the anticipated activity likely to cause angina is expected to begin* Tablet: initial, 5 to 20 mg two or three times daily; maintenance, 10 to 40 mg two or three times daily		Extended-release tablet: 40 mg Sublingual tablet: 2.5 mg 5 mg Tablet: 5 mg 10 mg 20 mg 30 mg 40 mg
Isosorbide mononitrate	Angina pectoris: Extended-release tablet: initial, 30 or 60 mg once daily; maintenance, dosage may be increased to 120 mg once daily, 240 mg/day may be required Tablet: initial, 5 to 10 mg/day; maintenance, 20 mg twice daily, with the two doses administered seven hours apart	Safety and efficacy in children have not been established.	Extended-release tablet: 30 mg 60 mg 120 mg Tablet: 10 mg 20 mg
Nitroglycerin	Angina pectoris: Injection, ointment, sublingual tablet, transdermal patch, translingual spray: there is no fixed optimum dose Injection: 5 µg/min; increase 5 µg/min every 3 to 5 minutes until some response is noted; if no response at 20 µg/min, increase by 10 µg/min every 3 to 5 minutes, up to 200 µg/min; maximum, 400 µg/mL Ointment: ½ inch (1.3 cm, 7.5 mg) to 2 inches (5.1 cm, 30 mg) typically applied to 36 square inches of truncal skin Powder packet: one or two packets at the onset of an attack under the tongue, one additional packet may be administered every five minutes as needed, maximum of three packets are recommended within a 15-minute period Sublingual tablet: 1 tablet dissolved under the tongue or in the buccal pouch at the first sing of an acute attack; maintenance, the dose may be	Safety and efficacy in children have not been established.	Injection: 0.1 mg/mL 0.2 mg/mL 0.4 mg/mL 5 mg/mL Ointment: 2% Powder packet: 0.4 mg Sublingual tablet: 0.3 mg 0.4 mg 0.6 mg Transdermal patch: 0.1 mg/hr 0.2 mg/hr 0.3 mg/hr 0.4 mg/hr 0.6 mg/hr 0.8 mg/hr Translingual spray: 0.4 mg/dose

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	repeated approximately every 5 minutes until relief is obtained; maximum, 3 tablets within a 15 minute period Transdermal patch: initial, 0.2 and 0.4 mg/hr; maintenance, 0.4 and 0.8 mg/hr; the appropriate dosing schedule would include a daily patch-on period of 12 to 14 hours and a daily patch-off period of 10 to 12 hours Translingual spray: 1 or 2 metered sprays administered onto or under the tongue at the onset of an attack; maximum, no more than 2 sprays are recommended within a 15 minute period <u>Congestive heart failure:</u> Injection: 5 µg/min; increase 5 µg/min every 3 to 5 minutes until some response is noted; if no response at 20 µg/min, increase by 10 µg/min every 3 to 5 minutes, up to 200 µg/min; maximum, 400 µg/mL <u>Intraoperative hypotension and perioperative hypertension:</u> Injection: 5 µg/min; increase 5 µg/min every 3 to 5 minutes until some response is noted; if no response at 20 µg/min, increase by 10 µg/min every 3 to 5 minutes, up to 200 µg/min; maximum, 400 µg/mL		

*Isosorbide dinitrate sublingual tablet may be used to abort an acute anginal episode, but its use is recommended only in patients who fail to respond to sublingual nitroglycerin.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the nitrates and nitrites are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Nitrates and Nitrites

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Chronic Stable Angina				
Parker et al.[29] (1993) ISMN 5 mg BID vs ISMN 10 mg BID vs ISMN 20 mg BID vs placebo	DB, PC, PG Patients with stable angina underwent testing prior to exercise as well as 2 and 7 hours after each dose on days 1 and 14. Additionally, on days 7 and 21, testing was performed 2 hours after the first dose.	N=214 3 weeks	Primary: Total exercise duration and time to moderate angina Secondary: Not reported	Primary: ISMN, at all doses, showed improvement over placebo at two and seven hours after the morning dose and two hours after the second dose on day one. Active treatment prolonged exercise duration over placebo at two hours postdose for each of the two daily doses. ISMN 20 mg was the only strength which demonstrated increased exercise duration seven hours after administration, which occurred on day 14. Overall, there were fewer episodes of angina noted in the ISMN 20 mg group. Secondary: Not reported
Thadani et al.[30] (1994) ISMN 20 mg BID vs placebo Patients were allowed to continue β-blocker therapy.	DB, MC, PC, PG, RCT Patients with stable exertional angina who stopped treadmill exercise secondary to angina pectoris	N=116 2 weeks	Primary: Total exercise duration (time to moderately severe angina) Secondary: ST-segment depression, heart rate, DBP and SBP, number of anginal attacks, number of nitroglycerin doses	Primary: A statistically significant improvement in total exercise duration was observed at both the morning and afternoon dose compared to placebo ($P<0.01$). Secondary: The magnitude of ST-segment depression was comparable in both the isosorbide-5-mononitrate and placebo groups (1.2±0.1 vs 1.2±0.2 mm; $P>0.2$). Heart rate and SBP, during the period of exercise, was determined to be similar among the groups. Additionally, the number of anginal attacks and doses of nitroglycerin were no different per group.
Chrysant et al.[31]	DB, RCT	N=313	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1993) ISMN ER 30 mg in the morning vs ISMN ER 60 mg in the morning vs ISMN ER 120 mg in the morning vs ISMN ER 240 mg in the morning vs placebo	Patients with stable effort-induced angina	6 weeks	Mean change from baseline in total exercise time (serial exercise testing immediately prior to and four and two hours after administration, on days one, seven, 14, 28 and 42) Secondary: Adverse effect	A significant improvement in mean total exercise time of 30 to 50 seconds was shown in all active-treatment groups compared to placebo at four and 12 hours postdose (P<0.01). The mean changes from baseline in total exercise time in patients on ISMN ER 120 mg or 240 mg surpassed placebo by about 50 to 60 seconds at 4 hours postdose (P<0.01), and by 30 to 35 seconds 12 hours after dosing (P≤0.05). There was no meaningful difference in response found between active treatment and placebo at 24 hours after administration, thus no indication that ISMN ER induced rebound angina. Secondary: The most common adverse effect among active treatment groups was transient headache.
Bray et al.[32] (1991) NTG administered buccally vs NTG administered sublingually	DB, MC Patients with proven chronic stable exercise-induced angina	N=Not reported Duration not reported	Primary: Efficacy Secondary: Not reported	Primary: The two formulations had comparable effects on acute attacks of angina pectoris. Secondary: Not reported
Ryden et al.[33] (1987) NTG administered	MC, XO Patients with stable angina pectoris	N=126 2 weeks	Primary: Efficacy Secondary:	Primary: Buccal NTG resulted in 31% less acute anginal attacks compared to the sublingual formulation (P<0.001). Prophylaxis was effective in 74% of patients taking buccal NTG compared to 66% of sublingual-treated

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
buccally vs NTG administered sublingually			Ease of use, patient preference	patients (P<0.05). Secondary: There was no difference in ease of use reported in 67% of patients, whereas 19% indicated that sublingual NTG was easier and 14% buccal NTG. Overall, 65% of patients preferred buccal NTG and 19% preferred sublingual NTG (P<0.05). As far as prophylactic use, buccal administration was again preferred by more patients (81%) than sublingual use (4%; P<0.05).
Demots et al.[34] (1989) NTG 0.2 mg/hour or 0.4 mg/hour transdermal patch for 12 hours (Group A) vs NTG 0.6 mg/hour or 0.8mg/hour transdermal patch for 12 hours (Group B) vs placebo	DB, RCT Patients with chronic stable angina	N=206 4 weeks	Primary: Effectiveness in chronic stable angina (serial treadmill testing performed 0, four, eight and 12 hours after patch application at baseline and on days one, 15 and 29) Secondary: Adverse reaction	Primary: Improved walking times were observed in both Group A and Group B over placebo at all testing points after short-term administration. Results were statistically significant for Group A at 12 hours and for Group B at four, eight and 12 hours. At weeks two and four, walking times were again greater in Group B over placebo at all testing points with the four hour test time at week two and the eight hour test time at week two and four reaching statistical significance. Group A did not demonstrate increased duration in walking time long-term. Secondary: Active therapy was generally tolerated well. An increase in nonexertional angina during the patch-off interval was reported in nine patients.
Ninomiya et al.[35] (2008) ISDN ER 40 mg/day or ISMN ER 40 mg/day vs	RCT Patients suspected to have angina pectoris and with normal or mildly diseased coronary arteries underwent	N=42 Not specified	Primary: Coronary wall shear stress Secondary: Changes in coronary blood flow	Primary: The percent increase in coronary blood flow and coronary artery diameter induced by acetylcholine was significantly smaller in the ISDN/ISMN group than in the calcium channel blocker group (33±74 vs 83±77%; P<0.05, -3±16 vs 11±12%; P<0.01, respectively). Secondary: The percent diameter decrease in the region of greatest constrictive

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
amlodipine 5mg/day or nifedipine ER 20 mg/day	Doppler flow study of the left anterior descending coronary artery. All patients had been taking long acting nitrates or calcium channel blockers for ≥1 year			response to acetylcholine was significantly greater in the ISDN/ISMN group than in the calcium channel blocker group (44±39 vs 15±32%; P<0.02).
Unstable Angina				
Dellborg et al.[36] (1991) NTG IV for 24 hours vs NTG administered buccally every 4 hours	RCT Patients admitted to the coronary care unit due to UA	N=29 24 hours	Primary: Efficacy Secondary: Adverse effects	Primary: Efficacy was comparable in the two groups Secondary: Less adverse effects (headache, hemodynamic intolerance) were associated with buccal nitroglycerin than IV although the differences were not significant.
Kaplan et al.[37] (1983) NTG IV 10 µg/min increased by 10 µg/min every 5 minutes to 50 µg/min then increased by 50 µg/min per each episode of angina	OL, OS Patients with angina at rest unresponsive to standard therapy including oral or topical nitrates and β-blockers	N=35 24 hours	Primary: Clinical response Secondary: Not reported	Primary: NTG therapy reduced the number of episodes of angina at rest from 3.5±0.4 to 0.3±0.1, reduced doses of sublingual NTG from 1.9±0.3 to 0.4±0.1 mg/day and decreased morphine sulfate use from 5.5±1.3 to 0.4±0.2 mg/day (P<0.001 for all). Complete response, defined as no rest angina, was achieved in 25 patients, while eight patients experienced greater than a 50% reduction in episodes and two patients where nonresponders. Secondary: Not reported
Karlberg et al.[38] (1998) NTG IV titrated from 1.5 mL/hour	DB, PC, RCT Patients with recent onset of chest pain, suggestive of	N=143 48 hours	Primary: Reduction in ongoing signs of myocardial ischemia,	Primary: Treatment with NTG IV resulted in fewer patients (13) experiencing ongoing signs of ischemia (AP1 + AP2) than placebo (25; P<0.03). There were significantly less patients on active treatment that required >2 sublingual NTG tablets compared to placebo (12 vs 22; P<0.005).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
in <1 hour to a maximum of 12 mL/hour vs placebo	myocardial ischemia or worsening of previously stable angina pectoris and clinical evidence of underlying CAD		leukocyte activation, inhibition of platelet aggregation Secondary: Adverse effects	There was no significant difference found between groups in regards to leukocyte activation or inhibition of platelet aggregation. Secondary: Active treatment was stopped in seven patients compared to zero in the placebo group (P<0.001). Five patients terminated therapy prematurely because of headache while two patients stopped because of a decrease in BP and bradycardia.
Heart Failure				
Cohn et al.[39] (1986) V-HeFT I ISDN 160 mg/day and hydralazine 300 mg/day vs prazosin 20 mg/day vs placebo	AC, DB, PC, RCT Men with impaired cardiac function and reduced exercise tolerance on digoxin and a diuretic	N=642 3 years	Primary: Mortality Secondary: Effect on left ventricular function	Primary: There was a 34% risk reduction in mortality by two years in the ISDN plus hydralazine group compared to placebo (P<0.028). Cumulative mortality rates of 25.6 and 36.2% were observed in the ISDN plus hydralazine group at two and three years respectively, compared to 34.3 and 46.9% in the placebo group. The results found in the prazosin group were similar to placebo. Secondary: A significant increase in the LVEF was reported at eight weeks and one year in the ISDN plus hydralazine treatment group, but not in either the prazosin or placebo groups.
Cohn et al.[40] (1991) ISDN 40 mg QID and hydralazine 75 mg QID (individual agents, concurrent therapy) vs	AC, DB, RCT Men with heart failure (primarily NYHA class II and III), receiving digoxin and diuretics	N=804 2 years	Primary: All-cause mortality Secondary: Not reported	Primary: The results demonstrated significantly lower mortality after two years with enalapril (18%) vs ISDN and hydralazine (25%; P=0.016). In addition, overall mortality tended to be lower with enalapril vs ISDN and hydralazine (P=0.08). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
enalapril 10 mg BID				
Taylor et al.[41] (2004) A-HeFT ISDN 20 mg TID and hydralazine 37.5 mg TID, increased to ISDN 40 mg TID plus hydralazine 75 mg TID vs placebo	DB, MC, PC, RCT Patients ≥18 years of age, self-identified as of African descent, with NYHA class III or IV heart failure on standard therapy for ≥3 months and evidence of left ventricular dysfunction within the prior 6 months	N=1,050 Mean duration of follow-up was 10 months	Primary: A composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, quality of life changes Secondary: Not reported	Primary: Combination of vasodilators in addition to standard therapy had significant mortality benefit (mortality rate of 6.2 vs 10.2%; P=0.02). From a range of possible scores of -6 to 2, patients in the active treatment group achieved a significantly better score of -0.1±1.9 compared to -0.5±2.0 in the placebo group (P=0.01). Each separate value of the composite score was also significantly better in the active group when compared to placebo. There was a 43% decrease in the rate of death from any cause (HR, 0.57; P=0.01), and a 33% reduction in the rate of first hospitalizations (P=0.001). This led to the early termination of the trial. Additionally, there was a significant improvement in quality of life scores found with ISDN plus hydralazine when compared to placebo (-5.6±20.6 vs -2.7±21.2; P=0.02). Secondary: Not reported
Taylor et al.[42] (2007) A-HeFT ISDN 20 mg TID and hydralazine 37.5 mg TID, increased to ISDN 40 mg TID and hydralazine 75 mg TID vs placebo	Post-hoc analysis of A-HeFT Patients ≥18 years of age, self-identified as of African descent, with NYHA class III or IV heart failure on standard therapy for ≥3 months and evidence of left ventricular dysfunction within the prior 6 months	N=1,050 Mean duration of follow-up was 18 months	Primary: Cause specific mortality, event free survival (time to either death or first hospitalization and time to first hospitalization for heart failure Secondary: Subgroup analysis	Primary: Cardiovascular deaths were significantly reduced in the treatment group compared to the placebo group (5.0 vs 8.5%; P=0.027). Pump failure death was also significantly reduced (75%) compared to the placebo group (0.8 vs 3.0%; P=0.012). There were no significant differences between the groups for other causes of death. In the treatment group event-free survival (death or first hospitalization for heart failure) was significantly improved compared to the placebo group (HR, 0.63; 95% CI, 0.49 to 0.81; P<0.001). The time to first hospitalization for heart failure was also significantly reduced (HR, 0.61; 95% CI, 0.46 to 0.80; P<0.001). Secondary: A consistent beneficial effect was seen in the treatment sub groups (age,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				sex, baseline BP, history of chronic renal insufficiency, presence of diabetes, cause of heart failure, and baseline medication use) on primary composite score and event-free survival.
Yancy et al.[43] (2007) X-A-HeFT ISDN 20 mg TID and hydralazine 20 mg TID, titrated up to ISDN 40 mg TID and hydralazine 75 mg TID vs placebo	ES, OL Patients previously enrolled in A-HeFT with NYHA class I to IV heart failure symptoms while receiving background therapy and satisfying the A-HeFT inclusion criteria	N=158 12 months or until ISDN-hydralazine approved by the FDA	Primary: Compliance with study drug, safety, tolerability Secondary: Change in NYHA association class, death, hospitalization for heart failure	Primary: Compliance in the treatment group averaged 87±25%, with no significant difference when compared to the placebo group. There were no significant differences in adverse events between the groups. Secondary: No significant difference was seen in hospitalizations from heart failure according to randomization. The greatest improvement in heart failure symptoms occurred in NYHA class III (at baseline) compared to other classes ($P<0.001$). Overall most patients were unchanged with 24% showing improved NYHA class and 9% showing a worsening.

Drug regimen abbreviations: BID=twice daily, ER=extended-release, ISDN=isosorbide dinitrate, ISMN=isosorbide mononitrate, IV=intravenous, NTG=nitroglycerin, QID=four times daily, TID=three times daily
Study abbreviations: AC=active comparator, DB=double-blind, ES=extended study, MC=multicenter, OL=open-label, OS=observational, PC=placebo-controlled, PG=parallel-group, RCT=randomized-controlled trial, XO=cross-over
Miscellaneous abbreviations: BP=blood pressure, CAD=coronary artery disease, DBP=diastolic blood pressure, FDA=Food and Drug Administration, HR=hazard ratio, LVEF=left ventricular ejection fraction, NYHA=New York Heart Association, SBP=systolic blood pressure, UA=unstable angina

Additional Evidence

Dose Simplification
Kardas et al evaluated adherence rates with once daily isosorbide mononitrate compared to twice daily isosorbide mononitrate over the course of 10 weeks. Adherence rates were significantly better with the once daily regimen compared to the twice daily regimen (P<0.001). The once daily regimen also led to a significant reduction in the mean weekly number of chest pain episodes compared to the twice-daily regimen (P<0.0001).[44] Brun et al evaluated adherence with a once daily and twice daily formulation of isosorbide mononitrate in patients with stable angina. Adherence rates were better with the once daily regimen compared to the twice daily regimen. The improvement in adherence also resulted in fewer angina episodes and a reduction in the number of nitroglycerin tablets that were taken to treat acute angina attacks.[45]

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of the Nitrates and Nitrites

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Isosorbide dinitrate	extended-release capsule, extended-release tablet, tablet	Dilatrate-SR®, Isordil®, Isordil Titradose®*	$-$$$$$	$$$$
Isosorbide mononitrate	extended-release tablet, tablet	N/A	N/A	$
Nitroglycerin	injection, ointment, sublingual powder, sublingual tablet, transdermal patch, translingual spray	GoNitro®, Minitran®*, Nitro-Bid®, Nitro-Dur®*, Nitrolingual®*, Nitrostat®*, Nitromist®*	$$	$$

*Generic is available in at least one dosage form or strength.
N/A=Not available.

X. Conclusions

The nitrates and nitrites are approved for the acute, prophylactic and chronic treatment of angina. In addition, intravenous nitroglycerin is approved for the control of congestive heart failure in the setting of myocardial infarction, for the induction of intraoperative hypotension, and for the treatment of perioperative hypertension.[2-12] All of the nitrate and nitrite agents are available in a generic formulation.

There are several organizations that provide recommendations on the use of the nitrates and nitrites. Sublingual nitroglycerin tablets and nitroglycerin spray are recommended for the immediate relief of angina in all patients. For the treatment of chronic angina, β-blockers are recommended as first-line therapy. Long-acting calcium channel blockers or long-acting nitrates may be used if initial therapy is not successful, or if β-blockers are contraindicated. Combination therapy may be necessary in certain patients. The combination of β-blockers and long-acting nitrates are preferred due to their efficacy and safety.[15-17,19] Nitrates have not demonstrated a reduction in mortality in patients with coronary artery disease or following a myocardial infarction.[22] Sublingual and intravenous nitroglycerin are recommended for the acute treatment of unstable angina, myocardial infarction, and acute coronary syndrome in addition to standard therapy. For the treatment of heart failure, angiotensin converting enzyme (ACE) inhibitors, β-blockers, and diuretics are the cornerstone of therapy. The combination hydralazine and a nitrate is an alternative treatment option in patients with heart failure who have reduced left ventricular ejection function when ACE inhibitors or angiotensin II receptor blockers are not tolerated. Furthermore, the combination hydralazine and a nitrate is recommended to improve outcomes for patients self-described as African American who have moderate to severe symptoms on optimal therapy with ACE inhibitors, β-blockers, and diuretics. The addition of hydralazine and a nitrate is reasonable for patients with heart failure who are already taking an ACE inhibitor and β-blocker for symptomatic heart failure, but who have persistent symptoms.[16,17,19,23-27]

Since all nitrates have similar pharmacologic effects, product selection is based on the desired onset and duration of action. Tolerance develops after chronic exposure to nitrates, regardless of the route of administration or formulation used. This can be overcome by instituting short periods (10 to 12 hours) of withdrawal from nitrate therapy.[2-14]

There is insufficient evidence to support that one brand nitrate or nitrite product is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand nitrates or nitrites within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand nitrate or nitrite is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Kannam JP, Aroesty JM, Gersh B. Stable ischemic heart disease: Overview of care. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2017 [cited 2017 Jun 7]. Available from: http://www.utdol.com/utd/index.do.
2. Dilatrate-SR® [package insert]. Lake Forest (IL): Actient Pharmaceuticals, LLC; 2014 Oct.
3. Isordil® [package insert] Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2015 Jan.
4. Isordil Titradose® [package insert]. Columbus (OH): American Health Packing; 2011 Dec.
5. GoNitro® [package insert]. Jacksonville (FL): Espero Pharmaceuticals, Inc.; 2016 Jun.
6. Minitran® [package insert]. Northridge (CA): 3M Drug Delivery Systems; 2012 Jan.
7. Nitro-Bid® [package insert]. Melville (NY): Savage Laboratories; 2012 Jun.
8. Nitro-Dur® [package insert]. Whitehouse Station (NJ): Merck & CO., Inc.; 2014 Sep.
9. Nitrolingual® Pumpspray [package insert]. Raleigh (NC): Arbor Pharmaceuticals, Inc.; 2015 Jan.
10. Nitromist® [package insert]. Cranford (NJ): Mist Pharmaceuticals, LLC; 2016 Jun.
11. Nitrostat® [package insert]. New York (NY): Pfizer, Inc; 2017 Jan.
12. Daily Med [database on the internet]. Bethesda (MD): National Library of Medicine; 2017 [cited 2017 June]. Available at: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
13. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited June 2017]. Available from: http://online.factsandcomparisons.com.
14. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 June]. Available from: http://www.thomsonhc.com/.
15. Goblirsch G, Bershow S, Cummings K, Hayes R, Kokoszka M, Lu Y, Sanders D, Zarling K. Institute for Clinical Systems Improvement. Stable Coronary Artery Disease. Updated May 2013.
16. Fraker TD Jr, Fihn SD; 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007 Dec 4;50(23):2264-74.
17. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
18. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619.
19. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology (2014), doi: 10.1016/j.jacc.2014.09.017.
20. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2016) 37 (3): 267-315. DOI: https://doi.org/10.1093/eurheartj/ehv320.
21. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):485-510.
22. Institute for Clinical Systems Improvement (ISCI). Diagnosis and treatment of chest pain and acute coronary syndrome [guideline on the Internet]. ISCI; 2012 Nov [cited 2012 Dec]. Available from: http://www.icsi.org/acs_acute_coronary_syndrome/acute_coronary_syndrome_and_chest_pain__diagnosis_and_treatment_of_2.html.
23. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019.

24. Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Institute for Clinical Systems Improvement. Heart Failure in Adults. Updated July 2013.
25. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):475-539.
26. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.
27. National Institute for Health and Clinical Excellence (NICE). Chronic heart failure in adults: management [guideline on the Internet]. London (UK): National Institute for Health and Clinical Excellence, 2010 Aug [cited 2016 Dec]. Available at: https://www.nice.org.uk/guidance/cg108.
28. The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal 2014; 35: 2383–2431. doi:10.1093/eurheartj/ehu282.
29. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol. 1993;72:871-6.
30. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med. 1994; 120(5):353-9.
31. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993; 72(17):1249-56.
32. Bray CL, Jain S, Faragher EB, Myers A, Myers P, MacIntyre, P, et al. A comparison of buccal nitroglycerin and sublingual nitroglycerin in the prophylaxis and treatment of exertional (situation-provoked) angina pectoris. Eur Heart J. 1991 May; 12 Suppl A: 16-20.
33. Ryden L, Schaffrath R. Buccal vs sublingual nitroglycerin administration in the treatment of angina pectoris: a multicenter study. Eur Heart J. 1987; 8(7):995-1001.
34. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol.1989; 13(4):786-95.
35. Ninomiya Y, Hamasaki S, Saihara K, et al. Comparison of effect between nitrates and calcium channel antagonist on vascular function in patients with normal or mildly diseased coronary arteries. Heart Vessels 2008;23:83-90.
36. Dellborg M, Gustafsson G, Swedberg K. Buccal vs intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol. 1991; 41(1): 5-9.
37. Kaplan K, Davison R, Parker M, et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol. 1983; 51(5):694-8.
38. Karlberg KE, Saldeen T, Wallin R, Henriksson P, Nyquist O, Sylven C. Intravenous nitroglycerin reduces ischemia in unstable angina pectoris: a double-blind placebo-controlled study. J Intern Med. 1998; 243:25-31.
39. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study (VHEFT-I). N Engl J Med. 1986; 314:1547-52.
40. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril and hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325:303-10.
41. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in black with heart failure. N Engl J Med. 2004; 351:2049-57.
42. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al; African-American Heart Failure Trial Investigators. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007 Apr 3;115(13):1747-53.
43. Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, et al. Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). Am J Cardiol. 2007 Aug 15;100(4):684-9.
44. Kardas P; COMPASS investigators. Comparison of once daily vs twice daily oral nitrates in stable angina pectoris. Am J Cardiol. 2004 Jul 15; 94(2):213-6.
45. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-izosorbide mononitrate: a comparative study. J Int Med Res. 1994; 22:266-72.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of
Miscellaneous Renin-Angiotensin-Aldosterone System Inhibitors
AHFS Class 243292
August 9, 2017

I. Overview

Heart failure (HF) is a complex clinical syndrome that affects approximately 5.1 million Americans.[1,2] HF is characterized by fluid retention and/or poor systemic perfusion that results from structural or functional impairment of ventricular filling or ejection of blood from the heart.[2] Treatment of symptomatic HF typically consists of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB) and a β-blocker to reduce morbidity and mortality. In the case of volume overload, a diuretic agent may be added on to therapy to improve symptoms. The combination of hydralazine and isosorbide dinitrate may be considered for those who cannot receive treatment with an ACEI or ARB because of drug intolerance, hypotension or renal insufficiency. Aldosterone receptor antagonists may also be used to reduce morbidity and mortality following an acute myocardial infarction (MI) in patients with a left ventricular ejection fraction (LVEF) ≤40% who develop symptoms of HF or who have a history of diabetes mellitus.[2] The 2016 American College of Cardiology (ACC)/ American Heart Association (AHA)/ Heart Failure Society of America (HFSA) update of the 2013 American College of Cardiology Foundation (ACCF)/AHA guideline for the management of HF reaffirms the benefits of therapy with ACEI or ARB in patients with HF with reduced EF (HFrEF), but recommends replacement of ACEI or ARB with an angiotensin receptor neprilysin inhibitor (ARNI) in patients with chronic symptomatic HFrEF (New York Heart Association [NYHA] Class II-IV) who tolerate an ACEI or ARB to further reduce morbidity and mortality.[3]

Entresto® (sacubitril-valsartan) is a novel combination of sacubitril, a neprilysin inhibitor, and valsartan, an ARB, that is Food and Drug Administration (FDA)-approved to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic heart failure (NYHA Class II to IV) and reduced ejection fraction (EF). This agent provides cardiovascular and renal benefits through two distinct mechanisms. The first mechanism consists of the inhibition of neprilysin by LBQ657, the active metabolite of the prodrug sacubitril. Inhibition of neprilysin reduces the degradation of natriuretic peptides which promote natriuresis, diuresis, and vasodilation associated with inhibition of the renin-angiotensin-aldosterone and sympathetic nervous systems, as well as trophic effects that oppose cardiac hypertrophy and fibrosis. The second mechanism consists of the selective antagonism of the angiotensin II type-1 (AT1) receptor by valsartan. This blockade of the AT1 receptor inhibits the effects of angiotensin II, including angiotensin II-dependent aldosterone release.[4,5]

Sacubitril-valsartan was reviewed under the priority review program of the FDA, which provides for expedited review of drugs that are intended to treat a serious disease or condition and may provide a significant improvement over currently available therapies. It was also granted Fast Track designation, which supports the FDA's efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and fill an unmet medical need.[1]

The miscellaneous renin-angiotensin-aldosterone system (RAAS) inhibitor products included in this review are listed in Table 1. Sacubitril-valsartan is not available in a generic formulation. This is the first review of this class; although, Entresto® (sacubitril-valsartan) has been reviewed as a new drug.

Table 1. Products Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Sacubitril and valsartan	tablet	Entresto®	none

PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current clinical guidelines are summarized in Table 2.

Table 2. Treatment Guidelines for Using RAAS Inhibitors

Clinical Guideline	Recommendation(s)
American College of Cardiology Foundation/American Heart Association: **Guideline for the Management of Heart Failure (2013)**[2]	Pharmacologic treatment for Stage A HFrEF: • Hypertension and lipid disorders should be controlled in accordance with contemporary guidelines to lower the risk of HF. • Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use and known cardiotoxic agents, should be controlled or avoided. Pharmacologic treatment for Stage B HFrEF (NYHA Class I): • All patients with a recent or remote history of MI or ACS and reduced EF, ACEI should be used to prevent symptomatic HF and reduce mortality. In patients intolerant of ACEI, ARBs are appropriate unless contraindicated. • In all patients with a recent or remote history of MI or ACS and reduced EF, evidence–based β-blockers should be used to reduce mortality. • In all patients with a recent or remote history of MI or ACS, statins should be used to prevent symptomatic HF and cardiovascular events. • In patients with structural cardiac abnormalities, including LV hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic HF. • ACEIs should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. • β-blockers should be used in all patients with a reduce EF to prevent symptomatic HF, even if they do not have a history of MI. Pharmacologic treatment for Stage C HFrEF (NYHA Class I-IV): • It is recommended to provide treatment with an ACEI or ARB and a β-blocker, unless contraindicated, to reduce morbidity and mortality. • ACEI have shown benefits in patients with mild, moderate or severe symptoms of HF and in patients with or without CAD. • There are no differences between available ACEI in their effects on symptoms or survival. • Treatment with an ACEI should be initiated at low doses followed by gradual dose increments if lower doses have been well tolerated. Clinicians should attempt to use doses that have been shown to reduce the risk of cardiovascular events in clinical trials. If these target doses of an ACE inhibitor cannot be used or are poorly tolerated, intermediate doses should be used. • ARBs are recommended for individuals who are ACEI intolerant or can be considered as reasonable alternatives to ACEI for first-line therapy for patients with HFrEF. • ARBs may also be considered in persistently symptomatic patients with HFrEF who are already being treated with an ACEI and a β-blocker in whom an aldosterone antagonist is not indicated or tolerated. • Use of bisoprolol, carvedilol or sustained-release metoprolol succinate is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated. • For all volume overload, in NYHA Class II-IV patients: it is recommended to add a diuretic, unless contraindicated, to improve symptoms. The loop diuretics are currently the preferred diuretics. • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality in persistently symptomatic African Americans with NYHA Class III-IV HFrEF receiving optimal therapy with ACEI and β-blockers, unless contraindicated. • The combination of hydralazine and isosorbide dinitrate can be useful in

Clinical Guideline	Recommendation(s)
	patients with current or prior symptomatic HFrEF who cannot be given an ACEI or ARB because of drug intolerance, hypotension or renal insufficiency, unless contraindicated. • In patients with NYHA Class II-IV and who have LVEF ≤ 35% with an estimated creatinine clearance > 30 mL/min and potassium level < 5.0 mEq/dL: it is recommended to add an aldosterone antagonist. • Aldosterone receptor antagonists are also recommended to reduce morbidity and mortality following an acute MI in patients with a LVEF ≤ 40% who develop symptoms of HF or who have a history of diabetes mellitus, unless contraindicated. • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. • Digoxin can also be considered as an addition to the initial regimen in patients with severe symptoms who have not yet responded symptomatically to initial regimen. • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack or ≥ 75 years of age) should receive chronic anticoagulant therapy. • The selection of an anticoagulant agent for permanent/persistent/paroxysmal AF should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time in the international normalized ratio therapeutic range if the patient has been taking warfarin. • Chronic anticoagulation is reasonable for patients with chronic HF who have permanent/persistent/paroxysmal AF but are without additional risk factors for cardioembolic stroke. • Omega-3 polyunsaturated fatty acid (PUFA) supplementation is reasonable to use as adjunctive therapy in patients with NYHA Class II-IV symptoms and HFrEF or HFpEF, unless contraindicated, to reduce mortality and cardiovascular hospitalizations. • Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HFrEF are potentially harmful and should be avoided or withdrawn whenever possible (e.g., most antiarrhythmic drugs, most calcium channel-blocking drugs [except amlodipine], NSAIDS, or thiazolidinediones). <u>Pharmacologic treatment for Stage C HFpEF:</u> • Systolic and diastolic blood pressure should be controlled in patients in accordance with published clinical practice guidelines to prevent morbidity. • Coronary revascularization is reasonable in patients with CAD in whom symptoms (angina) or demonstrable MI is judged to be having an adverse effect on symptomatic HFpEF despite GDMT. • Management of AF according to published clinical practice guidelines in patients with HFpEF is reasonable to improve symptomatic HF. • The use of β-blockers, ACEI and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. • The use of ARBs might be considered to decrease hospitalizations for patients with HFpEF.
American College of Cariology/American Heart Association/Heart Failure Society of America: **2016 ACC/AHA/HFSA**	<u>Pharmacologic treatment for Stage C HFrEF</u> • It is recommended to provide treatment with ACEI or ARB or angiotensin receptor neprilysin inhibitors (ARNI), in conjunction with β-blockers, and aldosterone antagonists in selected patients, to reduce morbidity and mortality. • The use of ACEI is beneficial for patients with prior or current symptoms of chronic HFrEF to reduce morbidity and mortality. • The use of ARB is beneficial for patients with prior or current symptoms of

Clinical Guideline	Recommendation(s)
Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (2016)[3]	chronic HFrEF who are intolerant to ACE because of cough or angioedema to reduce morbidity and mortality. • In patients with chronic symptomatic HFrEF (NYHA Class II-III) who tolerate an ACEI or ARB, it is recommended to replace the ACEI or ARB with an ARNI to further reduce morbidity and mortality. • Ivabradine (Corlanor®) may be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA Class II-III) stable, chronic HFrEF (LVEF≤35%) who are receiving guideline-directed evaluation and management of their HF, including a β-blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate ≥70 bpm at rest.

ACEI=angiotensin-converting enzyme inhibitor, ACS=acute coronary syndrome, AF=atrial fibrillation, ARB=angiotensin-receptor blocker, CAD=coronary artery disease, EF=ejection fraction, GDMT=guideline-directed medical therapy, HF=heart failure, HFrEF=heart failure with reduced ejection fraction, HFpEF=heart failure with preserved ejection fraction, LV=left ventricular, LVEF=left ventricular ejection fraction, MI= myocardial infarction, NSAIDS=non-steroidal antiinflammatory drugs, NYHA=New York Heart Association

III. Indications

The FDA-approved indications for miscellaneous RAAS inhibitors are noted in Table 3.

Table 3. FDA-Approved Indications for Miscellaneous RAAS Inhibitors[4]

Indication	Entresto®
Reduction of risk of cardiovascular death and hospitalization for HF in patients with chronic HFrEF (NYHA Class II-IV)	✔

HFrEF=heart failure with reduced ejection fraction

IV. Pharmacokinetics

The pharmacokinetic parameters of the miscellaneous RAAS inhibitors are listed in Table 4.

Table 4. Pharmacokinetic Parameters for Miscellaneous RAAS Inhibitors[4]

Generic Name(s)	Bioavailability	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Sacubitril-valsartan	Sacubitril: ≥60 Valsartan: Not reported*	94 to 97	Converted by esterases to LBQ657 (sacubitril)/minimally metabolized (valsartan)	Renal: 52 to 68 (sacubitril)/~13 (valsartan) Fecal: 37 to 48 (sacubitril)/86 (valsartan)	Sacubitril: 1.4 Valsartan: 9.9 LBQ657: 11.5

* The valsartan component in Entresto® is more bioavailable than the valsartan in other marketed tablet formulations.

V. Drug Interactions

Major drug interactions with miscellaneous RAAS inhibitors are listed in Table 5.

Table 5. Major Drug Interactions with Miscellaneous RAAS Inhibitors[4,6]

Generic Name(s)	Interaction	Mechanism
ARB	Aliskiren	Direct renin inhibitor and ARB may have additive effects on the renin-angiotensin-aldosterone system. Concomitant use of aliskiren and an ARB, such as valsartan, is contraindicated in patients with diabetes due to increased risk of hyperkalemia, hypotension, and renal impairment. The combination of aliskiren with valsartan should also be avoided in patients with renal

Generic Name(s)	Interaction	Mechanism
		impairment (GFR < 60 mL/min).
Sacubitril-valsartan	ACEI	Dual blockade of the renin-angiotensin-aldosterone system by concomitant use of an ACEI and an ARB may increase the risk of adverse events, including angioedema, hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure).
ARB	Lithium	Concomitant use of lithium and an ARB may increase the risk of lithium toxicity.
OATP1B1/3 substrates	Simeprevir	Simeprevir inhibits OATP1B1/3-mediated efflux transport. Concomitant use of simeprevir and an OATP1B1/3 substrate may result in increased exposure to the OATP1B1/3 substrate.
Potassium-sparing agents	Trimethoprim	Trimethoprim and other potassium-sparing agents may have additive effects on serum potassium. Concomitant use of trimethoprim with drugs known to induce hyperkalemia, including ARBs, may result in increased risk of hyperkalemia.

ACEI=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, GFR=glomerular filtration rate, OATP=organic anion transporting polypeptide

VI. Adverse Drug Events

The most common adverse drug events reported with miscellaneous RAAS inhibitors are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with Miscellaneous RAAS Inhibitors[4,6]

Adverse Event	Entresto®
Angioedema	0.5*
Cough	9.0
Decrease in hemoglobin/hematocrit >20%	5.0
Dizziness	6.0
Falls	1.9
Hyperkalemia	12.0
Hypotension	18.0
Increase in serum creatinine >50%	16.0
Orthostasis	2.1
Renal failure/acute renal failure	5.0
Serum potassium >5.5 mEq/L	16.0

✓ Percent not specified.
- Event not reported.
* The rate of angioedema in the Black population was 2.4%

VII. Dosing and Administration

The usual dosing regimens for miscellaneous RAAS inhibitors are listed in Table 7.

Table 7. Usual Dosing Regimens for Miscellaneous RAAS Inhibitors[4]

Generic Name	Usual Adult Dose*	Usual Pediatric Dose	Availability
Sacubitril-valsartan	Patients with chronic HFrEF (NYHA Class II to IV): Tablet: initial, 49/51 mg BID; maintenance and maximum, 97/103 mg BID Dosage for patients NOT previously taking an ACEI or ARB or previously taking low doses of these agents: Tablet: initial, 24/26 mg BID; maintenance and	Safety and efficacy in children have not been established	Tablets: 24 mg/26 mg 49 mg/51 mg 97 mg/103 mg

Generic Name	Usual Adult Dose*	Usual Pediatric Dose	Availability
	maximum, 97/103 mg BID Dosage for severe renal impairment (eGFR < 30 mL/min/1.73 m^2): Tablet: initial, 24/26 mg BID; maintenance and maximum, 97/103 mg BID Dosage for hepatic impairment (Child-Pugh B): Tablet: initial, 24/26 mg BID; maintenance and maximum, 97/103 mg BID Do not use in patients with severe hepatic impairment.		

ACEI=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, NYHA=New York Heart Association
Drug regimen abbreviations: BID=twice daily
* If switching from an ACE inhibitor to sacubitril-valsartan allow a 36-hour washout period between the two drugs.

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of miscellaneous RAAS inhibitors are summarized in Table 8.

Table 8. Comparative Clinical Trials with Miscellaneous RAAS Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
McMurray et al.[7,8] (2014) PARADIGM-HF Sacubitril-valsartan (LCZ696) 200 mg BID vs enalapril 10 mg BID After discontinuing their existing ACEI/ARB therapy, patients entered sequential single-blind run-in periods during which they received enalapril 10 mg twice-daily for two weeks then held therapy with enalapril for one day, followed by sacubitril-valsartan 100 mg twice-daily, increasing to 200 mg twice daily for four to six weeks before being randomized in final	AC, DB, MC, PG, RCT Adults with chronic HF (NYHA Class II to IV) symptoms, an LVEF of ≤40% (changed to ≤35% later in study) and a BNP ≥150 pg/mL (or N terminal proBNP ≥600 pg/mL), or, if hospitalized for HF within previous 12 months, a BNP of ≥100 pg/mL (or NT-proBNP ≥400 pg/mL), stable dose of a β-blocker (unless contraindicated or not tolerated), and a ACE-I or ARB equivalent to enalapril 10 mg daily for at least four weeks before screening along with a mineralocorticoid antagonist (if	N=8,399 Median follow-up of 27 months (study terminated by data safety and monitoring board due to the boundary for an over-whelming benefit with sacubitril-valsartan had been reached)	Primary: Composite of death from cardiovascular causes or a first hospitalization for heart failure Secondary: Time to death from any cause, the change from baseline to eight months in the clinical summary score on the KCCQ, time to new onset AF, and time to first occurrence of decline in renal function (defined as ESRD, a decrease in eGFR of ≥50%, or a decrease of ≥30 mL/min/1.73 m^2)	Primary: Sacubitril-valsartan was associated with a greater risk reduction of the combined cardiovascular endpoint compared to enalapril (914 [21.8%] vs 1,117 [26.5%]; HR, 0.80; 95% CI, 0.73 to 0.87; P=0.0000004). This treatment effect reflected a greater reduction in risk of cardiovascular death (558 [13.3%] vs 693 [16.5%]; HR, 0.80; 95% CI, 0.71 to 0.89; P<0.001) and HF hospitalization (537 [12.8%] vs 658 [15.6%]; HR, 0.79; 95% CI, 0.71 to 0.89; P<0.001) with sacubitril-valsartan compared to enalapril. The NNT for the composite primary endpoint and for cardiovascular death were 21 and 32, respectively. Secondary: Sacubitril-valsartan was associated with a reduction in all-cause mortality compared to enalapril (711 [17.0%] vs 835 [19.8%]; HR, 0.84; 95% CI, 0.76 to 0.93; P <0.0001). The mean change from baseline to month eight in the KCCQ clinical summary score was a reduction in 2.99 points in the sacubitril-valsartan group and a reduction of 4.63 points in the enalapril group (between group difference, 1.64 points; 95% CI, 0.63 to 2.65; P=0.001). New onset atrial fibrillation was comparable for both groups (84 patients in the sacubitril-valsartan group and 83 in the enalapril group, P=0.84). Protocol-defined decline in renal function was seen in 94 patients in the sacubitril-valsartan group compared to 108 patients in the enalapril group (P=0.28). Among these patients, progression to ESRD was seen in eight patients in the sacubitril-valsartan group compared to 16 patients in the enalapril group (P=0.11).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
phase to sacubitril-valsartan or enalapril.	indicated)			

Drug regimen abbreviations: BID=twice daily
Study abbreviations: AC=active-controlled, CI=confidence interval, DB=double-blind, HR=hazard ratio, MC=multicenter, PG=parallel-group, RCT=randomized controlled trial
Miscellaneous abbreviations: ACEI=angiotensin converting enzyme inhibitor, AF=atrial fibrillation, ARB=angiotensin receptor blocker, BNP= B-type natriuretic peptide, CV=cardiovascular, ED=emergency department, ESRD=end-stage renal disease, eGFR=estimated glomerular filtration rate, GMP=guanosine monophosphate, HF=heart failure, KCCQ=Kansas City Cardiomyopathy Questionnaire, LVEF=left ventricular ejection fraction, NNT=number needed-to-treat, NT-proBNP=N-terminal pro-B-type natriuretic peptide, NYHA=New York Heart Association

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of Miscellaneous RAAS Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Sacubitril-valsartan	tablet	Entresto®	$$$$$	N/A

N/A=Not available

X. Conclusions

Treatment of symptomatic heart failure (HF) typically consists of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB) and a β-blocker to reduce morbidity and mortality. In the case of volume overload, a diuretic agent may be added on to therapy to improve symptoms. The combination of hydralazine and isosorbide dinitrate may be considered for those who cannot receive treatment with an ACEI or ARB because of drug intolerance, hypotension, or renal insufficiency. Aldosterone receptor antagonists may also be used to reduce morbidity and mortality following an acute MI in patients with a left ventricular ejection fraction (LVEF) ≤ 40% who develop symptoms of HF or who have a history of diabetes mellitus.[2] The 2016 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) update of the 2013 American College of Cardiology (ACCF)/AHA guideline for the management of HF reaffirms the benefits of therapy with an ACEI or ARB in patients with HFrEF, but also recommends replacement of ACEI or ARB with an angiotensin receptor neprilysin inhibitor (ARNI) in patients with chronic symptomatic HFrEF (NYHA class II-IV) who tolerate an ACEI or ARB to further reduce morbidity and mortality.[3]

Entresto® (sacubitril-valsartan) is a novel combination of sacubitril, a neprilysin inhibitor, and valsartan, an ARB, that is Food and Drug Administration (FDA)-approved to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic HF with reduced ejection fraction (HFrEF) (New York Heart Association [NYHA] Class II-IV).[4] It is the only agent currently available that targets both the natriuretic peptide and the renin-angiotensin-aldosterone system (RAAS). In the phase III PARADIGM-HF trial, this agent was shown to significantly reduce the rate of cardiovascular death, HF hospitalizations, and all-cause mortality compared to enalapril.[7]

The drugs in this American Hospital Formulary Service (AHFS) class are used in a specific patient population. Because very specific criteria must be met prior to initiating therapy, these agents should be available through the medical justification portion of the prior authorization process.

Therefore, all brand miscellaneous renin-angiotensin-aldosterone system inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand miscellaneous renin-angiotensin-aldosterone system inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. FDA approves new drug to treat heart failure [press release on the Internet]. Rockville (MD): Food and Drug Administration (US): 2015 Jul 7 [cited 2016 Nov 18]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm.
2. Yancy CW, Jessup M, Bozhurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the management of heart failure. Circulation. 2013; 128: e240-e327.
3. Yancy CQ, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2016; 68(13): 1476-88.
4. Entresto® [package insert]. East Hanover (NJ): Novartis 2015 Aug.
5. Bayes-Genis A, Morant-Talamante N, Lupon J. Neprilysin and Natriuretic Peptide Regulation in Heart Failure. Curr Heart Fail Rep. 2016; 13(4): 151-7.
6. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2016 Nov 18]. Available from: http://www.thomsonhc.com/.
7. McMurray JJ, Packer M, Desai A, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep11; 371(11): 993-1004.
8. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep; 15(9): 1062–1073.

Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
New Drug Pharmacotherapy Review of Adzenys XR-ODT™
Amphetamines: AHFS Class 282004
August 9, 2017

I. Overview

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that is often diagnosed during childhood; however, children with ADHD may continue to manifest symptoms into adulthood.[1-2] The key diagnostic feature is a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.[1] There are three subtypes of ADHD, including a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype in which both symptoms are displayed.[1] Untreated (or undertreated) ADHD is associated with adverse sequelae, including conduct disorder, antisocial personality traits, substance abuse, and other comorbidities.[1]

There are several central nervous system agents that are approved for the treatment of ADHD. This includes cerebral stimulants (amphetamines and methylphenidate derivatives), as well as atomoxetine, extended-release clonidine, and extended-release guanfacine.[3-5] The stimulants are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.[3-5] Due to their potential for abuse, the stimulants are classified as Schedule II controlled substances.

Adzenys XR-ODT™ (amphetamine) is the first extended-release orally disintegrating tablet Food and Drug Administration (FDA)-approved for the treatment of ADHD in children six years of age or older.[3] Adzenys XR-ODT™ tablets contain 50% immediate-release and 50% extended-release amphetamine for once daily dosing in a three to one ratio of d-amphetamine to l-amphetamine.[3]

The amphetamine products included in this review are listed in Table 1. Adzenys XR-ODT™ (amphetamine) is not available in a generic formulation.

Table 1. Products Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Amphetamine	extended-release orally disintegrating tablet	Adzenys XR-ODT™	none

PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current clinical guidelines are summarized in Table 2.

Table 2. Treatment Guidelines Using the Cerebral Stimulants/Agents Used for ADHD

Clinical Guideline	Recommendation(s)
American Academy of Pediatrics: **Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents (2011)**[6]	<u>Preschool-aged children (four to five years of age)</u> • The primary care clinician should prescribe evidence-based parent- and/or teacher-administered behavior therapy as the first-line of treatment. • Methylphenidate may be prescribed if the behavior interventions do not provide significant improvement and there is moderate-to-severe continuing disturbance in the child's function. <u>Elementary school-aged children (six to 11 years of age)</u> • The primary care clinician should prescribe Food and Drug Administration (FDA)-approved medications for attention deficit-hyperactivity disorder (ADHD) and/or evidence-based parent and/or teacher-administered behavior therapy as treatment for ADHD, preferably both.

Clinical Guideline	Recommendation(s)
	• The evidence is particularly strong for stimulant medications and sufficient but less strong for atomoxetine, extended-release guanfacine, and extended-release clonidine (in that order). Adolescents (12 to 18 years of age) • The primary care clinician should prescribe FDA-approved medications for ADHD with the assent of the adolescent and may prescribe behavior therapy as treatment for ADHD, preferably both. General considerations • Stimulant medications are highly effective for most children in reduction of core symptoms of ADHD. • Atomoxetine, extended-release guanfacine and extended-release clonidine reduce core symptoms; however, they have a smaller evidence base than stimulants. • Extended-release guanfacine and extended-release clonidine have evidence to support their use as adjunctive therapy with stimulant medications. • Before beginning medication treatment for adolescents with newly diagnosed ADHD, clinicians should assess these patients for symptoms of substance abuse. • Clinicians should monitor symptoms and prescription-refill requests for signs of misuse or diversion of ADHD medications and consider prescribing medications with no abuse potential, such as atomoxetine, extended-release guanfacine, or extended-release clonidine (which are not stimulants) or stimulant medications with less abuse potential, such as lisdexamfetamine, dermal methylphenidate, or osmotic-release oral system methylphenidate). • Primary care clinicians should titrate doses of medication for ADHD to achieve maximum benefit with minimum adverse effects.
Institute for Clinical Systems Improvement: **Diagnosis and Management of Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents (2012)**[7]	Medication trials • Prescribe FDA-approved treatments for ADHD in children, including psychostimulants and/or non-stimulants. • The decision to use medications should be made in conjunction with parents following a thorough discussion of expected benefits and potential risks. Factors such as the child's age, severity of symptoms and presence of comorbidity should also be considered and may involve decision-making regarding choice of medication. • Obtain cardiology consultation for patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of central nervous system stimulants and/or atomoxetine. • Review the personal and family cardiovascular history, and complete a physical examination of each patient prior to starting stimulant therapy and/or atomoxetine. Medication history or physical exam changes consistent with possible cardiac disease during treatment with stimulant medication and/or atomoxetine may require additional evaluation by a cardiologist. • Optimal medication management alone is superior to other modalities for the core symptoms of ADHD. • Response to one stimulant does not predict response to the others. If a child is a non-responder to one stimulant, it is advisable to attempt a second or third trial with other stimulants. • Treatment with psychostimulants is often safe and effective in managing many children with ADHD with mild to moderate tics. Nevertheless, frequency and severity of tics should be carefully monitored in these patients. No routine blood work is necessary before or during psychostimulant therapy.

Clinical Guideline	Recommendation(s)
	• Current evidence does not support a higher risk of sudden cardiac death with stimulant medication compared to the general population; however, certain conditions may place a patient at higher risk for such an outcome. • Atomoxetine is a good option for patients with comorbid anxiety, sleep initiation disorder, substance abuse, or tics, or if initially preferred by parents and/or physician. Atomoxetine is a non-controlled substance that may make it preferable in certain clinical situations. • Extended-release guanfacine and extended-release clonidine are the first ADHD medications to achieve FDA approval as adjunctive therapy with stimulant medications. • Extended-release guanfacine is the first ADHD medication to look for improvement of oppositional symptoms in addition to ADHD core symptoms. <u>Alternative medications</u> • When adequate stimulant, atomoxetine or alpha adrenergic trials are unsuccessful due to either poor response or adverse effects, or if associated comorbidity is present, alternative medication trials should be considered. Second-line medications for ADHD therapy include tricyclic antidepressants (imipramine, desipramine), alpha adrenergic agonist (clonidine) a non- tricyclic antidepressant (bupropion), or immediate-release guanfacine.

National Institute for Health and Clinical Excellence: **Attention Deficit Hyperactivity Disorder: Diagnosis and Management of Attention Deficit Hyperactivity Disorder in Children, Young People, and Adults (2008)**[8]	<u>Treatment for children and adolescents with ADHD</u>
	• Methylphenidate, atomoxetine and dexamphetamine are recommended as options for the management of ADHD in children and adolescents.
	• The decision regarding which product to use should be based on the following:
	  ○ The presence of comorbid conditions.
	  ○ The different adverse effects of the drugs.
	  ○ Specific issues regarding compliance identified for the individual child or adolescent.
	  ○ The potential for drug diversion.
	  ○ The preferences of the child/adolescent and/or his or her parent or guardian.
	• Healthcare professionals should consider the following treatment recommendations:
	  ○ Methylphenidate for patients with ADHD without significant comorbidities.
	  ○ Methylphenidate for patients with ADHD with comorbid conduct disorder.
	  ○ Methylphenidate or atomoxetine when tics, Tourette's syndrome, anxiety disorder, stimulant misuse or risk of stimulant diversion are present.
	  ○ Atomoxetine if methylphenidate has been tried and has been ineffective at the maximum tolerated dose, or the child or young person is intolerant to low or moderate doses of methylphenidate.
	• Modified-release preparations should be considered for the following reasons:
	  ○ Convenience.
	  ○ Improving adherence.
	  ○ Reducing stigma (because the child or young person does not need to take medication at school).
	  ○ Reducing problems schools have in storing and administering controlled drugs.
	  ○ Their pharmacokinetic profiles.
	• Immediate-release preparations may be considered if more flexible dosing regimens are required, or during initial titration to determine correct dosing levels.
	
	<u>Treatment of adults with ADHD</u>

Clinical Guideline	Recommendation(s)
	• Drug treatment is the first-line treatment for adults with ADHD with either moderate or severe levels of impairment. • Methylphenidate is recommended as the first-line drug. • If methylphenidate is ineffective or unacceptable, atomoxetine or dexamphetamine can be tried. • Caution should be exercised when prescribing dexamphetamine to those likely to be at risk of stimulant misuse or diversion.
British Association of Psychopharmacology: **Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology (2014)**[9]	Treatment recommendations for children and adolescents • All children with severe ADHD (conceptualized as hyperkinetic disorder) should be offered pharmacological treatment. In addition, consider pharmacological treatment for children with moderate symptoms of ADHD who have not responded to psychological interventions. • The treatment of choice for children with severe ADHD or moderate ADHD non-responsive to psychological treatments is psychostimulant medication. • Atomoxetine can be used instead when there is a risk of misuse of psychostimulants by children or the adults supporting the child. • Appropriate child and family-based psychological interventions should be available to all children with ADHD. These interventions should be tailored to the child's needs and not depend on the local availability of services. • Teachers should be given evidence-based information about ADHD. • Patient and parental preferences should be taken into account when designing a psychological intervention for ADHD. • Every effort should be made to facilitate the transition from adolescence to adulthood. This should include education of parents, children, and professionals involved in the care of these children and the development of appropriate services and shared care protocols to enable this transition. • Systems and protocols need to be implemented to allow early re-acces to services for young people who may have dropped out of treatment at an early age, but still have significant symptoms and impairment. Treatment recommendations for adults • Stimulant medications are the first-line drugs in adults with ADHD. • Although amphetamines, methylphenidate and atomoxetine are all effective in adults with ADHD, they cannot be considered equivalent because they have different mechanisms of actions and hazards. • Once methylphenidate, atomoxetine, and amphetamines have all been given a fair trial, third-line medications can be considered. These include bupropion, modafinil, tricyclic antidepressants, guanfacine and clonidine. • Co-administration of psychostimulant and other drugs (mainly atomoxetine) is an option for patients showing a limited or lack of clinical response. There is, however, limited evidence supporting either the efficacy or safety of combination therapy. • Psychological treatments are a complement to pharmacological treatment. • Different approaches have been used but the majority the evidence is for structured treatments employing a cognitive behavioral paradigm. • The use of different methods of delivery (group and individual therapy), different criteria for control groups and different outcome measures limit the generalization of results. Abuse potential • Abuse potential is related to drug action and formulation. Abuse is generally low among patients but it can occur with stimulants. Slow-release preparations of these agents or atomoxetine are preferred for patients with a history of substance abuse, or who are at risk for substance abuse.

III. Indications

The Food and Drug Administration (FDA)-approved indications for Adzenys XR-ODT™ are noted in Table 3.

Table 3. FDA-Approved Indications for Adzenys XR-ODT™[3]

Indication	Adzenys XR-ODT™
Treatment of Attention Deficit Hyperactivity Disorder	✔

IV. Pharmacokinetics

The pharmacokinetic parameters of Adzenys XR-ODT™ are listed in Table 4. A single dose of Adzenys XR-ODT™ 18.8 mg provided comparable plasma concentration profiles of both d-amphetamine and l-amphetamine to mixed salts of a single-entity amphetamine product extended-release 30 mg capsules. The mean elimination half-life for d-amphetamine is 11 hours in adults and nine to 10 hours in pediatric patients aged six to 12 years. For l-amphetamine, the mean elimination half-life in adults is 14 hours and 10 to11 hours in pediatric patients aged six to 12 years.[3]

Table 4. Pharmacokinetic Parameters of Adzenys XR-ODT™[4]

Generic Name(s)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Amphetamine extended-release orally disintegrating tablet	20	Hepatic	Renal (30 to 40 unchanged; 50 as metabolites)	7 to 34

V. Drug Interactions

Major drug interactions with amphetamines are listed in Table 5.

Table 5. Major Drug Interactions with Amphetamine[3,4]

Generic Name(s)	Interaction	Mechanism
Amphetamines	MAOIs	MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.
Amphetamines	CYP2D6 inhibitors	The concomitant use of amphetamines and CYP2D6 inhibitors may increase the exposure of amphetamines compared to the use of the drug alone and increase the risk of serotonin syndrome.
Amphetamines	Alkalinizing agents	The concomitant use of amphetamines and alkalinizing agents may increase blood levels and potentiate the action of amphetamine.
Amphetamines	Acidifying agents	The concomitant use of amphetamines and acidifying agents may lower blood levels and efficacy of amphetamines.
Amphetamines	Serotonergic drugs	The concomitant use of amphetamine and serotonergic drugs increases the risk of serotonin syndrome.
Amphetamines	Tricyclic antidepressants	The concomitant use of amphetamines and tricyclic antidepressants may enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.
Amphetamines	Thiazide diuretics	The concomitant use of amphetamines and thiazide diuretics may result in increased exposure to amphetamine.

MAOI=monoamine oxidase inhibitor

VI. Adverse Drug Events

The most common adverse drug events reported with amphetamines are listed in Table 6. The boxed warning for Adzenys XR-ODT™ is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with Amphetamine[5]

Adverse Events	Amphetamine
Cardiovascular	
Blood pressure increased	✔
Cardiomyopathy	✔
Palpitations	2 to 4
Peripheral vascular disease	-
Raynaud's disease	-
Tachycardia	6
Central Nervous System	
Aggressive behavior	-
Agitation	8
Anxiety	8
Depression	-
Dizziness	2 to 7
Drowsiness	2 to 4
Dyskinesia	✔
Dysphoria	✔
Euphoria	✔
Fever	5
Headache	26
Insomnia	12 to 27
Irritability	-
Labile affect	2 to 9
Mania	-
Nervousness	6
Overstimulation	✔
Psychotic episodes	-
Restlessness	✔
Seizures	-
Somnolence	-
Speech disorder	2 to 4
Stroke	-
Tic exacerbation	✔
Tourette's exacerbation	✔
Tremor	✔
Twitching	2 to 4
Dermatological	
Diaphoresis	-
Hyperhidrosis	2 to 4
Photosensitivity	2 to 4
Rash	-
Stevens-Johnson syndrome	-
Toxic epidermal necrolysis	-
Urticaria	✔
Gastrointestinal	
Abdominal pain	11 to 14
Anorexia	22 to 36
Appetite decreased	-
Constipation	2 to 4
Dental disease	2 to 4
Diarrhea	6
Dry mouth	-
Dyspepsia	2
Nausea	5 to 8

Adverse Events	Amphetamine
Other gastrointestinal disturbances	-
Unpleasant taste	-
Vomiting	7
Weight loss	4 to 10
Xerostomia	35
Genitourinary	
Changes in libido	2 to 4
Impotence	2 to 4
Prolonged erections	✔
Urinary tract infection	5
Other	
Accidental injury	3
Allergic rhinitis	4
Anaphylaxis	-
Angioedema	-
Blurred vision	-
Dysmenorrhea	2 to 4
Dyspnea	-
Epistaxis	4
Growth suppression	-
Hypersensitivity reactions	-
Infection	2 to 4
Tolerance	-
Weakness	2 to 6

✔ Percent not specified.
-Event not reported or incidence <1%.

Table 7. Boxed Warning for Adzenys XR-ODT™[3]

WARNING
WARNING: ABUSE AND DEPENDENCE • CNS stimulants, including Adzenys XR-ODT™, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

VII. Dosing and Administration

The usual dosing regimens for Adzenys XR-ODT™ are listed in Table 8. Adzenys XR-ODT™ may be taken with or without food. Dosing for Adzenys XR-ODT™ should not be substituted for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and pharmacokinetic profiles.[3]

Table 8. Usual Dosing Regimens for Adzenys XR-ODT™[3]

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
Amphetamine	Treatment of Attention Deficit Hyperactivity Disorder: The recommended dose is 12.5 mg daily. Individualize the dosage according to the therapeutic needs and response of the patient.	Treatment of Attention Deficit Hyperactivity Disorder: The recommended starting dose is 6.3 mg once daily in the morning. Increase in increments of 3.1 mg or 6.3 mg at weekly intervals. The maximum recommended dose is 18.8 mg daily for patients 6 to 12 years, and 12.5 mg daily for patients 13 to 17 years. Individualize the dosage according to the therapeutic needs and response of the patient.	Extended-release orally disintegrating tablet: 3.1 mg 6.3 mg 9.4 mg 12.5 mg 15.7 mg 18.8 mg

VIII. Effectiveness

The FDA-approval of Adzenys XR-ODT™ was based on the results of clinical trials demonstrating that Adzenys XR-ODT™ is bioequivalent to a previously approved mixed amphetamine salts extended-release capsule (Adderall XR®) (MAS ER). These trials, as referenced in the prescribing information, included double-blind, randomized, placebo-controlled, parallel-group trials in both adults (N=255) and pediatric patients (N=584 [6 to 12 years] and N=327 [13 to 17 years]) who met DSM-IV criteria for ADHD.[3] Endpoints, which included the Attention Deficit Hyperactivity Disorder-Rating Scale IV (ADHD-RS-IV), teacher-rated Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scale Attention and Deportment variables, and Permanent Product Measure of Performance (PERMP) Scales, favored active treatment compared to placebo. In pediatric patients, improvements in the primary cohort were statistically significantly greater in all four primary cohort active treatment groups (MAS ER 10 mg, 20 mg, 30 mg, and 40 mg) compared with the placebo group. There was not adequate evidence that doses greater than 20 mg per day conferred additional benefit. In adult patients, improvements, measured with the ADHD-RS were observed at endpoint for MAS ER 20, 40 and 60 mg, compared to patients who received placebo for all four weeks. However, there was not adequate evidence that doses greater than 20 mg per day conferred additional benefit.[3] No additional clinical studies for Adzenys XR-ODT™ were identified. Clinical trials evaluating other amphetamine formulations are included in Table 8.

Table 8. Comparative Clinical Trials with Amphetamines

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
McCracken et al.[10] (2003) AMP-IR (Adderall®) 10 mg daily vs AMP-XR (Adderall XR®) 10 to 30 mg daily vs placebo	DB, PC, RCT, XO Children six to 12 years of age diagnosed with ADHD (combined or hyperactive-impulsive subtype)	N=51 5 weeks	Primary: SKAMP scales Secondary: Examination of the time course of AMP-XR	Primary: AMP-IR and AMP-XR were judged to have similar efficacy, and both exceeded placebo on attention and deportment SKAMP scales (P<0.0001). Secondary: The AMP-XR group displayed continued efficacy (in SKAMP score improvements) at time points beyond that of the AMP-IR group (i.e., 12 hours post dose).
Pliszka et al.[11] (2000) AMP-IR (Adderall®) 12.5 mg daily	DB, PC, PG, RCT Children in grades one through five diagnosed with ADHD	N=58 3 weeks	Primary: CGI-S (parent and teacher) Secondary: Not reported	Primary: More responders were reported with AMP-IR than MPH-IR or placebo on both CGI-S scores (P<0.05). Behavioral effects of AMP-IR appeared to persist longer than with MPH-IR. Fourteen (70%) patients in the AMP-IR group required only a single

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs MPH-IR 25 mg daily vs placebo				morning dose, and 17 (85%) patients in the MPH-IR group received two or more doses per day (P=0.003). Secondary: Not reported
Pelham et al.[12] (1999) AMP-IR (Adderall®) 7.5 or 12.5 mg twice daily vs MPH-IR (Ritalin®) 10 or 17.5 mg twice daily vs placebo	DB, PC, RCT, XO Children five to 12 years of age diagnosed with ADHD	N=25 6 weeks	Primary: Time course and dose-dependent response information Secondary: Not reported	Primary: Both doses of AMP-IR were generally more efficacious in reducing negative behaviors and improving academic productivity than low-dose MPH-IR (10 mg BID) throughout the course of the entire day. The differences were more pronounced when the effects of MPH-IR were wearing off at midday and late afternoon/early evening (P<0.025). Conversely, AMP-IR 7.5 mg BID and MPH-IR 17.5 mg BID produced equivalent behavioral changes throughout the entire day. The doses of AMP-IR that were assessed produced greater improvement than did the assessed doses of MPH-IR, particularly the lower dose of MPH-IR (P<0.01). Both drugs produced low and comparable levels of clinically significant side effects. Secondary: Not reported
Faraone et al.[13] (2002) AMP-IR (Adderall®) vs MPH-IR	MA (4 trials) Patients diagnosed with ADHD	N=216 3 to 8 weeks	Primary: CGI-S (parent, teacher and investigator) Secondary: Not reported	Primary: Combined results showed slightly greater efficacy with AMP-IR vs MPH-IR in clinician and parent ratings (P<0.05). No statistically significant difference was found in CGI-S scores with teacher ratings (P≥0.26). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Biederman et al.[14] (2002) AMP-XR (Adderall XR®) 10 to 30 mg daily vs placebo	DB, MC, PC, RCT Children six to 12 years of age diagnosed with ADHD (hyperactive-impulsive or combined subtypes)	N=584 3 weeks	Primary: CGI-S (teachers and parents) Secondary: Variation in responses based on morning and afternoon assessments	Primary: Each AMP-XR treatment group had a statistically significant improvement in both CGI-S teacher and parent scales (P<0.001). Secondary: The CGI-S teacher scores calculated for the morning and afternoon assessments showed all doses of AMP-XR to be more effective than placebo (P<0.001) at each assessment. The CGI-S teacher scores in the AMP-XR group were statistically significantly improved at all time points compared to those in the placebo group (P<0.001).
Goodman et al.[15] (2005) AMP-XR (Adderall XR®) 10 to 60 mg daily	MC, OL, PRO Adults ≥18 years of age diagnosed with ADHD (any subtype)	N=725 10 weeks	Primary: ADHD-RS, CGI-I Secondary: SF-36	Primary: At the end of the study, the mean ADHD-RS scores significantly decreased in the AMP-XR group regardless of dose compared to baseline (P<0.0001). Statistical analysis comparing the individual AMP-XR doses was not performed. At the end of the study, most patients obtained CGI-I ratings of much/very much improved (522/702; 74.4%). Secondary: At the end of the study, the AMP-XR groups reported significant improvements in all quality of life measurements (P<0.0001 for all) measured by the SF-36, including physical functioning and mental health parameters.

Drug regimen abbreviations: AMP=mixed amphetamine salts, DEX=dextroamphetamine, DXM=dexmethylphenidate, ER=extended release, IR=immediate release, LDX=lisdexamfetamine, MPH=methylphenidate, OROS=osmotic-release oral system, SR=sustained release, XR=extended release
Study abbreviations: CI=confidence interval, DB=double blind, DR=dosing ranging, ES=extension study, FD=fixed dose, HR=hazard ratio, MA=meta-analysis, MC=multi-center, OL=open-label, OR=odds ratio, OS=observational study, PC=placebo-controlled, PG=parallel-group, PRO=prospective trial, RCT=randomized controlled trial, RETRO=retrospective, RR=relative risk, SA=single arm, SB=single blind, TB=triple blind, XO=crossover design
Other abbreviations: ADHD=attention deficit hyperactivity disorder, ADHD-RS=ADHD rating scale, CGI-S=clinical global impression of severity, SF-36=36-item Short Form Health Survey, SKAMP=Swanson, Kotkin, Agler, M-Flynn, and Pelham

Additional Evidence

Dose Simplification
A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy
A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits
A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
$	$0-$30 per Rx
$$	$31-$50 per Rx
$$$	$51-$100 per Rx
$$$$	$101-$200 per Rx
$$$$$	Over $200 per Rx

Rx=prescription

Table 9. Relative Cost of Adzenys XR-ODT™

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Amphetamine	extended-release orally disintegrating tablet	Adzenys XR-ODT™	$$$$$	N/A

N/A=Not available

X. Conclusions

Adzenys XR-ODT™ (amphetamine) is the first extended-release orally disintegrating tablet Food and Drug Administration (FDA)-approved for the treatment of ADHD in children six years of age or older.[3]

Guidelines recommend the use of an agent approved by the Food and Drug Administration (FDA) for the initial pharmacologic treatment of ADHD and they do not give preference to one agent over another.[6-9] The FDA-approval of Adzenys XR-ODT™ was based on the results of clinical trials demonstrating that Adzenys XR-ODT™ is bioequivalent to a previously approved mixed amphetamine salts extended-release capsule (Adderall XR®). These trials, as referenced in the prescribing information, included double-blind, randomized, placebo-controlled, parallel-group trials in both adults (N=255) and pediatric patients (N=584 [6 to 12 years] and N=327 [13 to 17 years]) who met DSM-IV criteria for ADHD. Endpoints, which included the Attention Deficit Hyperactivity Disorder-Rating Scale IV (ADHD-RS-IV), teacher-rated Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scale Attention and Deportment variables, and Permanent Product Measure of Performance (PERMP)

Scales, favored active treatment compared to placebo.[3] No additional clinical studies for Adzenys XR-ODT™ were identified.

There are several factors to take into consideration when selecting a pharmacologic agent for the treatment of children and adolescents with ADHD. This includes the presence of comorbid conditions, patient/family preference, storage/administration at school, history of substance abuse, drug diversion, pharmacokinetics, and adverse events.[1,2] The advantage of a once-daily formulation is that the medication does not need to be taken during school hours, as is the case with the immediate-release formulations. Administration of medications during school hours, especially Schedule II controlled substances, can be difficult since the medication must be administered by a licensed school nurse. An orally disintegrating tablet can be utilized for patients unable to swallow whole capsules or tablets or with a comorbid condition causing dysphagia.

There is insufficient evidence to support that one brand Adzenys XR-ODT™ (amphetamine) product is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand Adzenys XR-ODT™ (amphetamine) products within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand amphetamine extended-release orally disintegrating tablet product is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA. American Psychiatric Association, 2013.
2. Krull K. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. In: UpToDate, Torchia, M (Ed), UpToDate, Waltham, MA, 2016 [cited 2017 May 30]. Available from: http://www.utdol.com/utd/index.do.
3. Adzenys XR-ODT™ [package insert]. Grand Prairie (TX): Neos Therapeutics Brands LLC.; 2017 Jan.
4. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2017 [cited 2017 Mar]. Available from: http://www.thomsonhc.com/.
5. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2017 [cited Mar 2017]. Available from: http://online.factsandcomparisons.com.
6. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2011;128:1-16.
7. Institute for Clinical Systems Improvement. Health care guideline: diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents [guideline on the Internet]. 9th ed. Bloomington (MN): Institute for Clinical Systems Improvement; March 2012. Available at: http://www.icsi.org/adhd/adhd_2300.html. Accessed January 2016.
8. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people, and adults [guideline on the Internet]. London (UK). September 2008. Available at: http://guidance.nice.org.uk/CG72. Accessed January 2016.
9. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2014. 1-25. DOI: 10.1177/0269881113519509.
10. McCracken JT, Biederman J, Greenhill LL et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLL381 (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychology. 2003;426(6):673-83.
11. Pliszka SR, Browne RG, Olvera RL et al. A double-blind, placebo controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(5):619-26.
12. Pelham WE, Aronof HR, Midlam JL et al. A comparison of Ritalin and Adderall; efficacy and time course in children with attention hyperactivity deficit disorder. Pediatrics. 1999;103:e43.
13. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002;22(5):468-73.
14. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double blind, placebo controlled parallel group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-66.
15. Goodman DW, Ginsberg L, Weisler, RH, Cutler AJ, Hodgkins P. An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD. CNS Spectr. 2005;10(Suppl 20):26-34.